<html><head>
  <meta http-equiv="Content-Security-Policy" content="default-src 'none'; script-src http: https: 'unsafe-inline'; style-src http: https: 'unsafe-inline' ; img-src http: https: data:; font-src http: https:; connect-src http: https:; media-src http: https:; object-src 'none'; child-src 'none'; frame-src 'none'">
  <script type="text/javascript">
    

    // Initialize sandbox
    (function () {
      function blockMethod (name) {
        return () => console.error("Ignored call to '" + name + "()'.")
      }

      window['alert'] = blockMethod('alert'); window['confirm'] = blockMethod('confirm'); window['print'] = blockMethod('print'); window['prompt'] = blockMethod('prompt');
      delete window['Worker']; window['Worker'] = undefined; delete window['indexedDB']; window['indexedDB'] = undefined;

      let _navigator = {};
      for (let key in navigator) {
        const prop = navigator[key];
        if (typeof prop !== 'object' && typeof prop !== 'function') {
          _navigator[key] = prop;
        }
      }
      delete window.navigator;
      window.navigator = _navigator;
    })();
  </script>
  
</head>
<body>
  
<style type="text/css">
.tftable {font-size:14px;color:#333333;width:100%;border-width: 1px;border-color: #87ceeb;border-collapse: collapse;}
.tftable th {font-size:18px;background-color:#87ceeb;border-width: 1px;padding: 8px;border-style: solid;border-color: #87ceeb;text-align:left;}
.tftable tr {background-color:#ffffff;}
.tftable td {font-size:14px;border-width: 1px;padding: 8px;border-style: solid;border-color: #87ceeb;}
.tftable tr:hover {background-color:#e0ffff;}
</style>

<table class="tftable" border="1">
<tbody><tr>
<th>ID</th>
<th>Name</th>
</tr>

<tr>
<td>1</td>
<td>Congenital anomaly of aortic arch branch</td>
</tr>
<tr>
<td>2</td>
<td>Aberrant origin of right subclavian artery</td>
</tr>
<tr>
<td>3</td>
<td>aberrant right subclavian artery syndrome</td>
</tr>
<tr>
<td>4</td>
<td>ARSA - [aberrant right subclavian artery]</td>
</tr>
<tr>
<td>5</td>
<td>ARSCA - [aberrant right subclavian artery]</td>
</tr>
<tr>
<td>6</td>
<td>arteria lusoria</td>
</tr>
<tr>
<td>7</td>
<td>Aberrant origin of left subclavian artery</td>
</tr>
<tr>
<td>8</td>
<td>ALSA - [aberrant left subclavian artery]</td>
</tr>
<tr>
<td>9</td>
<td>ALSCA - [aberrant left subclavian artery]</td>
</tr>
<tr>
<td>10</td>
<td>aberrant left subclavian artery</td>
</tr>
<tr>
<td>11</td>
<td>retroesophageal left subclavian artery</td>
</tr>
<tr>
<td>12</td>
<td>RELSCA - [retroesophageal left subclavian artery]</td>
</tr>
<tr>
<td>13</td>
<td>Isolation of an aortic arch branch</td>
</tr>
<tr>
<td>14</td>
<td>Isolation of innominate artery</td>
</tr>
<tr>
<td>15</td>
<td>Aberrant innominate artery</td>
</tr>
<tr>
<td>16</td>
<td>aberrant origin of brachiocephalic artery</td>
</tr>
<tr>
<td>17</td>
<td>anomalous origin of innominate artery</td>
</tr>
<tr>
<td>18</td>
<td>aberrant origin of innominate artery</td>
</tr>
<tr>
<td>19</td>
<td>aberrant brachiocephalic artery</td>
</tr>
<tr>
<td>20</td>
<td>anomalous origin of the brachiocephalic artery</td>
</tr>
<tr>
<td>21</td>
<td>Common origin of the innominate artery and left common carotid artery</td>
</tr>
<tr>
<td>22</td>
<td>left common carotid artery arising from innominate artery</td>
</tr>
<tr>
<td>23</td>
<td>bovine arch</td>
</tr>
<tr>
<td>24</td>
<td>Separate origins of internal and external carotid arteries</td>
</tr>
<tr>
<td>25</td>
<td>Isolation of left common carotid artery</td>
</tr>
<tr>
<td>26</td>
<td>Isolation of common carotid artery (deprecated)</td>
</tr>
<tr>
<td>27</td>
<td>Isolation of right common carotid artery</td>
</tr>
<tr>
<td>28</td>
<td>Isolation of common carotid artery (deprecated)</td>
</tr>
<tr>
<td>29</td>
<td>Isolation of left subclavian artery</td>
</tr>
<tr>
<td>30</td>
<td>Isolation of subclavian artery (deprecated)</td>
</tr>
<tr>
<td>31</td>
<td>Isolation of right subclavian artery</td>
</tr>
<tr>
<td>32</td>
<td>Isolation of subclavian artery (deprecated)</td>
</tr>
<tr>
<td>33</td>
<td>Vitamin A deficiency, unspecified</td>
</tr>
<tr>
<td>34</td>
<td>Vitamin A deficiency</td>
</tr>
<tr>
<td>35</td>
<td>Hypovitaminosis A</td>
</tr>
<tr>
<td>36</td>
<td>Atrial fibrillation, unspecified</td>
</tr>
<tr>
<td>37</td>
<td>Atrial fibrillation</td>
</tr>
<tr>
<td>38</td>
<td>AF - [atrial fibrillation]</td>
</tr>
<tr>
<td>39</td>
<td>rapid atrial fibrillation</td>
</tr>
<tr>
<td>40</td>
<td>A Fib - [atrial fibrillation]</td>
</tr>
<tr>
<td>41</td>
<td>AFib - [atrial fibrillation]</td>
</tr>
<tr>
<td>42</td>
<td>Hypervitaminosis A</td>
</tr>
<tr>
<td>43</td>
<td>hyperalimentation of Vitamin A</td>
</tr>
<tr>
<td>44</td>
<td>Excess vitamin A administered as drug</td>
</tr>
<tr>
<td>45</td>
<td>Other specified adrenocortical insufficiency</td>
</tr>
<tr>
<td>46</td>
<td>Congenital adrenocortical insufficiency</td>
</tr>
<tr>
<td>47</td>
<td>Congenital isolated ACTH deficiency</td>
</tr>
<tr>
<td>48</td>
<td>Familial adrenal hypoplasia</td>
</tr>
<tr>
<td>49</td>
<td>Familial hypoadrenocorticism</td>
</tr>
<tr>
<td>50</td>
<td>Hereditary adrenal hypoplasia</td>
</tr>
<tr>
<td>51</td>
<td>Familial adrenal hypoplasia, miniature type</td>
</tr>
<tr>
<td>52</td>
<td>Familial glucocorticoid deficiency</td>
</tr>
<tr>
<td>53</td>
<td>Hereditary glucocorticoid deficiency</td>
</tr>
<tr>
<td>54</td>
<td>ACTH - [adrenocorticotropic hormone] resistance</td>
</tr>
<tr>
<td>55</td>
<td>Neonatal adrenoleukodystrophy</td>
</tr>
<tr>
<td>56</td>
<td>Autosomal recessive neonatal adrenoleukodystrophy</td>
</tr>
<tr>
<td>57</td>
<td>NALD - [neonatal adrenoleukodystrophy]</td>
</tr>
<tr>
<td>58</td>
<td>IMAGe syndrome</td>
</tr>
<tr>
<td>59</td>
<td>Intrauterine growth retardation - metaphyseal dysplasia - adrenal hypoplasia congenita - genital anomalies</td>
</tr>
<tr>
<td>60</td>
<td>Triple A syndrome</td>
</tr>
<tr>
<td>61</td>
<td>Achalasia - addisonianism - alacrima syndrome</td>
</tr>
<tr>
<td>62</td>
<td>Allgrove syndrome</td>
</tr>
<tr>
<td>63</td>
<td>Achalasia - alacrimia syndrome</td>
</tr>
<tr>
<td>64</td>
<td>Adrenal gland atrophy</td>
</tr>
<tr>
<td>65</td>
<td>adrenal atrophy</td>
</tr>
<tr>
<td>66</td>
<td>adrenal glandular atrophy</td>
</tr>
<tr>
<td>67</td>
<td>suprarenal atrophy</td>
</tr>
<tr>
<td>68</td>
<td>Adrenal gland calcification</td>
</tr>
<tr>
<td>69</td>
<td>adrenal calcification</td>
</tr>
<tr>
<td>70</td>
<td>adrenal glandular calcification</td>
</tr>
<tr>
<td>71</td>
<td>suprarenal calcification</td>
</tr>
<tr>
<td>72</td>
<td>suprarenal gland calcification</td>
</tr>
<tr>
<td>73</td>
<td>suprarenal glandular calcification</td>
</tr>
<tr>
<td>74</td>
<td>gl. suprarenalis calcification</td>
</tr>
<tr>
<td>75</td>
<td>Adrenal gland haemorrhage</td>
</tr>
<tr>
<td>76</td>
<td>adrenal glandular haemorrhage</td>
</tr>
<tr>
<td>77</td>
<td>suprarenal haemorrhage</td>
</tr>
<tr>
<td>78</td>
<td>suprarenal glandular haemorrhage</td>
</tr>
<tr>
<td>79</td>
<td>suprarenal gland haemorrhage</td>
</tr>
<tr>
<td>80</td>
<td>gl. suprarenalis haemorrhage</td>
</tr>
<tr>
<td>81</td>
<td>cortex adrenal haemorrhage</td>
</tr>
<tr>
<td>82</td>
<td>haemorrhage of adrenal medulla</td>
</tr>
<tr>
<td>83</td>
<td>adrenal haemorrhage</td>
</tr>
<tr>
<td>84</td>
<td>Adrenal gland necrosis</td>
</tr>
<tr>
<td>85</td>
<td>adrenal glandular necrosis</td>
</tr>
<tr>
<td>86</td>
<td>adrenal necrosis</td>
</tr>
<tr>
<td>87</td>
<td>ischaemic adrenal necrosis</td>
</tr>
<tr>
<td>88</td>
<td>suprarenal necrosis</td>
</tr>
<tr>
<td>89</td>
<td>suprarenal glandular necrosis</td>
</tr>
<tr>
<td>90</td>
<td>suprarenal gland necrosis</td>
</tr>
<tr>
<td>91</td>
<td>necrotic adrenal</td>
</tr>
<tr>
<td>92</td>
<td>gl. suprarenalis necrosis</td>
</tr>
<tr>
<td>93</td>
<td>fatty adrenal necrosis</td>
</tr>
<tr>
<td>94</td>
<td>Adrenomyodystrophy</td>
</tr>
<tr>
<td>95</td>
<td>Adrenal gland infarction</td>
</tr>
<tr>
<td>96</td>
<td>adrenal glandular infarct</td>
</tr>
<tr>
<td>97</td>
<td>adrenal infarct</td>
</tr>
<tr>
<td>98</td>
<td>suprarenal capsule infarction</td>
</tr>
<tr>
<td>99</td>
<td>suprarenal capsule infarct</td>
</tr>
<tr>
<td>100</td>
<td>suprarenal gland infarction</td>
</tr>
<tr>
<td>101</td>
<td>suprarenal infarction</td>
</tr>
<tr>
<td>102</td>
<td>suprarenal glandular infarct</td>
</tr>
<tr>
<td>103</td>
<td>suprarenal glandular infarction</td>
</tr>
<tr>
<td>104</td>
<td>suprarenal gland infarct</td>
</tr>
<tr>
<td>105</td>
<td>gl. suprarenalis infarction</td>
</tr>
<tr>
<td>106</td>
<td>Other specified hereditary sensory or autonomic neuropathy</td>
</tr>
<tr>
<td>107</td>
<td>Hereditary sensory and autonomic neuropathy type II</td>
</tr>
<tr>
<td>108</td>
<td>HSAN2 - [Hereditary sensory and autonomic neuropathy type 2]</td>
</tr>
<tr>
<td>109</td>
<td>Hereditary sensory and autonomic neuropathy type IIA</td>
</tr>
<tr>
<td>110</td>
<td>HSAN2A - [Hereditary sensory autonomic neuropathy type 2A]</td>
</tr>
<tr>
<td>111</td>
<td>Hereditary sensory and autonomic neuropathy type IIB</td>
</tr>
<tr>
<td>112</td>
<td>HSAN2B - [Hereditary sensory autonomic neuropathy type 2B]</td>
</tr>
<tr>
<td>113</td>
<td>Hereditary sensory and autonomic neuropathy type IIC</td>
</tr>
<tr>
<td>114</td>
<td>HSAN2C - [Hereditary sensory autonomic neuropathy type 2C]</td>
</tr>
<tr>
<td>115</td>
<td>Certain specified forms of hereditary sensory or autonomic neuropathy</td>
</tr>
<tr>
<td>116</td>
<td>Cold-induced sweating syndrome</td>
</tr>
<tr>
<td>117</td>
<td>Hereditary sensory and autonomic neuropathy with deafness or global delay</td>
</tr>
<tr>
<td>118</td>
<td>Hereditary sensory and autonomic neuropathy with spastic paraplegia</td>
</tr>
<tr>
<td>119</td>
<td>X-linked hereditary sensory and autonomic neuropathy with deafness</td>
</tr>
<tr>
<td>120</td>
<td>Duplications of the short arm of chromosome 17</td>
</tr>
<tr>
<td>121</td>
<td>17p duplication</td>
</tr>
<tr>
<td>122</td>
<td>17p duplication syndrome</td>
</tr>
<tr>
<td>123</td>
<td>17p13.3 duplication</td>
</tr>
<tr>
<td>124</td>
<td>17p13.3 duplication syndrome</td>
</tr>
<tr>
<td>125</td>
<td>Trisomy 17p13.3</td>
</tr>
<tr>
<td>126</td>
<td>Potocki-Lupski syndrome</td>
</tr>
<tr>
<td>127</td>
<td>Trisomy 17p11.2</td>
</tr>
<tr>
<td>128</td>
<td>17p11.2 duplication</td>
</tr>
<tr>
<td>129</td>
<td>Charcot-Marie-Tooth disease 1 autosomal dominant due to chromosome 17 duplication</td>
</tr>
<tr>
<td>130</td>
<td>Charcot-Marie-Tooth disease type 1A</td>
</tr>
<tr>
<td>131</td>
<td>Charcot Marie Tooth disease 1 autosomal dominant secondary to the chromosome 17 duplication</td>
</tr>
<tr>
<td>132</td>
<td>CMT1A - [Charcot-Marie-Tooth disease type 1A]</td>
</tr>
<tr>
<td>133</td>
<td>Oculocutaneous albinism</td>
</tr>
<tr>
<td>134</td>
<td>OCA - [Oculocutaneous albinism]</td>
</tr>
<tr>
<td>135</td>
<td>Oculocutaneous albinism type 1A</td>
</tr>
<tr>
<td>136</td>
<td>Tyrosinase-negative oculocutaneous albinism</td>
</tr>
<tr>
<td>137</td>
<td>Albino</td>
</tr>
<tr>
<td>138</td>
<td>OCA1A - [Oculocutaneous albinism type 1A]</td>
</tr>
<tr>
<td>139</td>
<td>Oculocutaneous albinism type 1B</td>
</tr>
<tr>
<td>140</td>
<td>OCA1B - [Oculocutaneous albinism type 1B]</td>
</tr>
<tr>
<td>141</td>
<td>Yellow oculocutaneous albinism</td>
</tr>
<tr>
<td>142</td>
<td>Oculocutaneous albinism, Amish type</td>
</tr>
<tr>
<td>143</td>
<td>Minimal pigment oculocutaneous albinism</td>
</tr>
<tr>
<td>144</td>
<td>Platinum oculocutaneous albinism</td>
</tr>
<tr>
<td>145</td>
<td>Temperature sensitive oculocutaneous albinism</td>
</tr>
<tr>
<td>146</td>
<td>OCA1-TS - [Temperature-sensitive oculocutaneous albinism]</td>
</tr>
<tr>
<td>147</td>
<td>Oculocutaneous albinism type 2</td>
</tr>
<tr>
<td>148</td>
<td>OCA2 - [Oculocutaneous albinism type 2]</td>
</tr>
<tr>
<td>149</td>
<td>Tyrosinase-positive oculocutaneous albinism</td>
</tr>
<tr>
<td>150</td>
<td>Brown oculocutaneous albinism</td>
</tr>
<tr>
<td>151</td>
<td>Oculocutaneous albinism type 3</td>
</tr>
<tr>
<td>152</td>
<td>Rufous oculocutaneous albinism</td>
</tr>
<tr>
<td>153</td>
<td>Red oculocutaneous albinism</td>
</tr>
<tr>
<td>154</td>
<td>Xanthous oculocutaneous albinism</td>
</tr>
<tr>
<td>155</td>
<td>Xanthism</td>
</tr>
<tr>
<td>156</td>
<td>OCA3 - [Oculocutaneous albinism type 3]</td>
</tr>
<tr>
<td>157</td>
<td>Oculocutaneous albinism type 4</td>
</tr>
<tr>
<td>158</td>
<td>OCA4 - [Oculocutaneous albinism type 4]</td>
</tr>
<tr>
<td>159</td>
<td>Hermansky-Pudlak syndrome</td>
</tr>
<tr>
<td>160</td>
<td>Albinism with haemorrhagic diathesis and pigmented reticuloendothelial cells</td>
</tr>
<tr>
<td>161</td>
<td>HPS - [Hermansky-Pudlak syndrome]</td>
</tr>
<tr>
<td>162</td>
<td>Hermansky-Pudlak syndrome type 7</td>
</tr>
<tr>
<td>163</td>
<td>HPS7 - [Hermansky-Pudlak syndrome type 7] (MIM 614076)</td>
</tr>
<tr>
<td>164</td>
<td>Hermansky-Pudlak syndrome type 8</td>
</tr>
<tr>
<td>165</td>
<td>HPS8 - [Hermansky-Pudlak syndrome type 8] (MIM 614077)</td>
</tr>
<tr>
<td>166</td>
<td>Hermansky-Pudlak syndrome type 9</td>
</tr>
<tr>
<td>167</td>
<td>Hermansky-Pudlak syndrome with neutropaenia</td>
</tr>
<tr>
<td>168</td>
<td>Hermansky-Pudlak syndrome type 2</td>
</tr>
<tr>
<td>169</td>
<td>HPS 2 - [Hermansky-Pudlak syndrome type 2] (MIM 608233)</td>
</tr>
<tr>
<td>170</td>
<td>Hermansky-Pudlak syndrome with pulmonary fibrosis</td>
</tr>
<tr>
<td>171</td>
<td>Hermansky-Pudlak syndrome without pulmonary fibrosis</td>
</tr>
<tr>
<td>172</td>
<td>HPS - [Hermansky-Pudlak syndrome] without pulmonary fibrosis</td>
</tr>
<tr>
<td>173</td>
<td>Chédiak-Higashi syndrome</td>
</tr>
<tr>
<td>174</td>
<td>Chediak-Higashi-Steinbrinck syndrome</td>
</tr>
<tr>
<td>175</td>
<td>Chediak-Steinbrinck syndrome</td>
</tr>
<tr>
<td>176</td>
<td>Béguez César syndrome</td>
</tr>
<tr>
<td>177</td>
<td>Steinbrinck anomaly</td>
</tr>
<tr>
<td>178</td>
<td>Oculocerebral syndrome with hypopigmentation</td>
</tr>
<tr>
<td>179</td>
<td>Cross syndrome</td>
</tr>
<tr>
<td>180</td>
<td>Gangliosidosis</td>
</tr>
<tr>
<td>181</td>
<td>GM1 gangliosidosis</td>
</tr>
<tr>
<td>182</td>
<td>Landing disease</td>
</tr>
<tr>
<td>183</td>
<td>GM1 gangliosidosis type 1</td>
</tr>
<tr>
<td>184</td>
<td>Generalised gangliosidosis</td>
</tr>
<tr>
<td>185</td>
<td>Infantile GM1 gangliosidosis</td>
</tr>
<tr>
<td>186</td>
<td>GM1 gangliosidosis type 2</td>
</tr>
<tr>
<td>187</td>
<td>Juvenile GM1 gangliosidosis</td>
</tr>
<tr>
<td>188</td>
<td>GM1 gangliosidosis type 3</td>
</tr>
<tr>
<td>189</td>
<td>Adult GM1 gangliosidosis</td>
</tr>
<tr>
<td>190</td>
<td>GM2 gangliosidosis</td>
</tr>
<tr>
<td>191</td>
<td>deficiency of beta-n-acetylhexosaminidase isoenzymes</td>
</tr>
<tr>
<td>192</td>
<td>GM&lt;sub&gt;2&lt;/sub&gt; gangliosidosis</td>
</tr>
<tr>
<td>193</td>
<td>GM 2 gangliosidosis NOS</td>
</tr>
<tr>
<td>194</td>
<td>Retinal dystrophy in GM2 gangliosidosis</td>
</tr>
<tr>
<td>195</td>
<td>Sandhoff disease</td>
</tr>
<tr>
<td>196</td>
<td>GM2 gangliosidosis type 2</td>
</tr>
<tr>
<td>197</td>
<td>GM2 gangliosidosis 0 variant</td>
</tr>
<tr>
<td>198</td>
<td>Hexosaminidase A and B deficiency</td>
</tr>
<tr>
<td>199</td>
<td>Total hexosaminidase deficiency</td>
</tr>
<tr>
<td>200</td>
<td>GM&gt;2&lt; gangliosidosis, type 2</td>
</tr>
<tr>
<td>201</td>
<td>GM&lt;sub&gt;2&lt;/sub&gt; gangliosidosis, type 2</td>
</tr>
<tr>
<td>202</td>
<td>Infantile Sandhoff disease</td>
</tr>
<tr>
<td>203</td>
<td>Total hexosaminidase deficiency, infantile form</td>
</tr>
<tr>
<td>204</td>
<td>infantile GM2 gangliosidosis</td>
</tr>
<tr>
<td>205</td>
<td>infantile GM&lt;sub&gt;2&lt;/sub&gt; gangliosidosis</td>
</tr>
<tr>
<td>206</td>
<td>infantile GM&gt;2&lt; gangliosidosis</td>
</tr>
<tr>
<td>207</td>
<td>Juvenile Sandhoff disease</td>
</tr>
<tr>
<td>208</td>
<td>Total hexosaminidase deficiency, juvenile form</td>
</tr>
<tr>
<td>209</td>
<td>juvenile GM2 gangliosidosis</td>
</tr>
<tr>
<td>210</td>
<td>juvenile GM&lt;sub&gt;2&lt;/sub&gt; gangliosidosis</td>
</tr>
<tr>
<td>211</td>
<td>juvenile GM&gt;2&lt; gangliosidosis</td>
</tr>
<tr>
<td>212</td>
<td>Adult Sandhoff disease</td>
</tr>
<tr>
<td>213</td>
<td>Total hexosaminidase deficiency, adult form</td>
</tr>
<tr>
<td>214</td>
<td>adult GM2 gangliosidosis</td>
</tr>
<tr>
<td>215</td>
<td>Tay-Sachs disease</td>
</tr>
<tr>
<td>216</td>
<td>GM2-gangliosidosis, B, B1, AB variant</td>
</tr>
<tr>
<td>217</td>
<td>Hexosaminidase A deficiency</td>
</tr>
<tr>
<td>218</td>
<td>severe hexosaminidase a deficiency</td>
</tr>
<tr>
<td>219</td>
<td>B variant of hexosaminidase A deficiency</td>
</tr>
<tr>
<td>220</td>
<td>B variant of hexosaminidase A deficiency, infantile form</td>
</tr>
<tr>
<td>221</td>
<td>Classic infantile acute Tay-Sachs disease</td>
</tr>
<tr>
<td>222</td>
<td>GM2 gangliosidosis type 1</td>
</tr>
<tr>
<td>223</td>
<td>GM&lt;sub&gt;2&lt;/sub&gt; gangliosidosis, type 1</td>
</tr>
<tr>
<td>224</td>
<td>GM&gt;2&lt; gangliosidosis, type 1</td>
</tr>
<tr>
<td>225</td>
<td>B variant of hexosaminidase A deficiency, juvenile form</td>
</tr>
<tr>
<td>226</td>
<td>Juvenile subacute Tay-Sachs disease</td>
</tr>
<tr>
<td>227</td>
<td>GM2 gangliosidosis type 3</td>
</tr>
<tr>
<td>228</td>
<td>GM&lt;sub&gt;2&lt;/sub&gt; gangliosidosis, type 3</td>
</tr>
<tr>
<td>229</td>
<td>GM&gt;2&lt; gangliosidosis, type 3</td>
</tr>
<tr>
<td>230</td>
<td>B variant of hexosaminidase A deficiency, adult form</td>
</tr>
<tr>
<td>231</td>
<td>Adult Tay-Sachs disease</td>
</tr>
<tr>
<td>232</td>
<td>Chronic GM2 gangliosidosis</td>
</tr>
<tr>
<td>233</td>
<td>B1 variant of hexosaminidase A deficiency</td>
</tr>
<tr>
<td>234</td>
<td>Late infantile Tay-Sachs disease</td>
</tr>
<tr>
<td>235</td>
<td>Pseudo-AB variant of hexosaminidase deficiency</td>
</tr>
<tr>
<td>236</td>
<td>Hexosaminidase activator deficiency</td>
</tr>
<tr>
<td>237</td>
<td>GM2 activator deficiency</td>
</tr>
<tr>
<td>238</td>
<td>AB variant of hexosaminidase deficiency</td>
</tr>
<tr>
<td>239</td>
<td>Primary hypercholesterolaemia</td>
</tr>
<tr>
<td>240</td>
<td>low-density-lipoid-type hyperlipoproteinemia</td>
</tr>
<tr>
<td>241</td>
<td>pure hypercholesterolaemia</td>
</tr>
<tr>
<td>242</td>
<td>LDL - [low density lipoprotein} hyperlipoproteinemia</td>
</tr>
<tr>
<td>243</td>
<td>group A hyperlipidaemia</td>
</tr>
<tr>
<td>244</td>
<td>pure hypercholesterinaemia</td>
</tr>
<tr>
<td>245</td>
<td>cholesterolaemia</td>
</tr>
<tr>
<td>246</td>
<td>essential cholesterolaemia</td>
</tr>
<tr>
<td>247</td>
<td>essential hypercholesterolaemia</td>
</tr>
<tr>
<td>248</td>
<td>group A hyperlipemia</td>
</tr>
<tr>
<td>249</td>
<td>increased low density lipoprotein</td>
</tr>
<tr>
<td>250</td>
<td>low-density-lipoprotein-type</td>
</tr>
<tr>
<td>251</td>
<td>low-density-lipoprotein-type hyperlipoproteinemia</td>
</tr>
<tr>
<td>252</td>
<td>Familial hypercholesterolaemia</td>
</tr>
<tr>
<td>253</td>
<td>Hypercholesterolaemia due to LDL receptor deficiency</td>
</tr>
<tr>
<td>254</td>
<td>low density lipoprotein catabolic defect</td>
</tr>
<tr>
<td>255</td>
<td>low density lipoprotein receptor disorder</td>
</tr>
<tr>
<td>256</td>
<td>familial hypercholesterinaemia</td>
</tr>
<tr>
<td>257</td>
<td>essential familial hypercholesterolaemia</td>
</tr>
<tr>
<td>258</td>
<td>hereditary cholesterolaemia</td>
</tr>
<tr>
<td>259</td>
<td>hereditary hypercholesterinaemia</td>
</tr>
<tr>
<td>260</td>
<td>hereditary hypercholesterolaemia</td>
</tr>
<tr>
<td>261</td>
<td>familial hyperbetalipoproteinaemia</td>
</tr>
<tr>
<td>262</td>
<td>Fredrickson 2A</td>
</tr>
<tr>
<td>263</td>
<td>Fredrickson type 2A hyperlipoproteinemia</td>
</tr>
<tr>
<td>264</td>
<td>familial cholesterolaemia</td>
</tr>
<tr>
<td>265</td>
<td>Familial hypercholesterolaemia - heterozygous</td>
</tr>
<tr>
<td>266</td>
<td>Familial hypercholesterolaemia - homozygous</td>
</tr>
<tr>
<td>267</td>
<td>Familial hypercholesterolemic xanthomatosis</td>
</tr>
<tr>
<td>268</td>
<td>Familial defective apolipoprotein B-100</td>
</tr>
<tr>
<td>269</td>
<td>Autosomal recessive hypercholesterolaemia</td>
</tr>
<tr>
<td>270</td>
<td>Autosomal dominant hypercholesterolaemia</td>
</tr>
<tr>
<td>271</td>
<td>Polygenic hypercholesterolaemia</td>
</tr>
<tr>
<td>272</td>
<td>Hyperbetalipoproteinaemia</td>
</tr>
<tr>
<td>273</td>
<td>Interrupted aortic arch</td>
</tr>
<tr>
<td>274</td>
<td>aorta atresia</td>
</tr>
<tr>
<td>275</td>
<td>aortic arch interruption</td>
</tr>
<tr>
<td>276</td>
<td>IAA - [interrupted aortic arch]</td>
</tr>
<tr>
<td>277</td>
<td>aorta arch atresia</td>
</tr>
<tr>
<td>278</td>
<td>aorta ring atresia</td>
</tr>
<tr>
<td>279</td>
<td>aortic arch atresia</td>
</tr>
<tr>
<td>280</td>
<td>aortic ring atresia</td>
</tr>
<tr>
<td>281</td>
<td>Interrupted aortic arch distal to subclavian artery, type A</td>
</tr>
<tr>
<td>282</td>
<td>aortic arch interruption, type A</td>
</tr>
<tr>
<td>283</td>
<td>IAA type A - [interrupted aortic arch type A]</td>
</tr>
<tr>
<td>284</td>
<td>Interrupted aortic arch between subclavian and common carotid arteries, type B</td>
</tr>
<tr>
<td>285</td>
<td>aortic arch interruption, type B</td>
</tr>
<tr>
<td>286</td>
<td>IAA type B - [interrupted aortic arch type B]</td>
</tr>
<tr>
<td>287</td>
<td>Aortic interruption, type B</td>
</tr>
<tr>
<td>288</td>
<td>Interruption of the aortic arch, type B</td>
</tr>
<tr>
<td>289</td>
<td>Interrupted aortic arch between carotid arteries, type C</td>
</tr>
<tr>
<td>290</td>
<td>aortic arch interruption, type C</td>
</tr>
<tr>
<td>291</td>
<td>IAA type C - [interrupted aortic arch type C]</td>
</tr>
<tr>
<td>292</td>
<td>Aortic interruption, type C</td>
</tr>
<tr>
<td>293</td>
<td>Interruption of the aortic arch, type C</td>
</tr>
<tr>
<td>294</td>
<td>Glycogen storage disease</td>
</tr>
<tr>
<td>295</td>
<td>Glycogenosis</td>
</tr>
<tr>
<td>296</td>
<td>GSD - [Glycogen storage disease]</td>
</tr>
<tr>
<td>297</td>
<td>glycogen thesaurismosis</td>
</tr>
<tr>
<td>298</td>
<td>diffuse glycogenosis</td>
</tr>
<tr>
<td>299</td>
<td>generalised glycogen storage disease</td>
</tr>
<tr>
<td>300</td>
<td>generalised glycogenosis</td>
</tr>
<tr>
<td>301</td>
<td>generalised glycogen storage disease of infants</td>
</tr>
<tr>
<td>302</td>
<td>glycogen synthase deficiency</td>
</tr>
<tr>
<td>303</td>
<td>Glycogen storage disease due to glycogen synthase deficiency</td>
</tr>
<tr>
<td>304</td>
<td>Glycogen storage disease type 0</td>
</tr>
<tr>
<td>305</td>
<td>Glycogenosis type 0</td>
</tr>
<tr>
<td>306</td>
<td>GSD type 0</td>
</tr>
<tr>
<td>307</td>
<td>deficiency of glycogen synthetase</td>
</tr>
<tr>
<td>308</td>
<td>Glycogen storage disease due to liver glycogen synthase deficiency</td>
</tr>
<tr>
<td>309</td>
<td>GSD type 0A</td>
</tr>
<tr>
<td>310</td>
<td>Glycogen storage disease type 0A</td>
</tr>
<tr>
<td>311</td>
<td>Glycogenosis type 0A</td>
</tr>
<tr>
<td>312</td>
<td>Glycogen storage disease due to muscle or heart glycogen synthase deficiency</td>
</tr>
<tr>
<td>313</td>
<td>Glycogen storage disease type 0B</td>
</tr>
<tr>
<td>314</td>
<td>Glycogenosis type 0B</td>
</tr>
<tr>
<td>315</td>
<td>GSD type 0B</td>
</tr>
<tr>
<td>316</td>
<td>Cardiomyopathy-exercise intolerance due to muscle and heart glycogen deficiency</td>
</tr>
<tr>
<td>317</td>
<td>Glycogen storage disease due to glucose-6-phosphate system deficiency</td>
</tr>
<tr>
<td>318</td>
<td>Glycogen storage disease type 1</td>
</tr>
<tr>
<td>319</td>
<td>Glycogenosis type 1</td>
</tr>
<tr>
<td>320</td>
<td>GSD type 1</td>
</tr>
<tr>
<td>321</td>
<td>Hepatorenal glycogenosis</td>
</tr>
<tr>
<td>322</td>
<td>Von Gierke disease</td>
</tr>
<tr>
<td>323</td>
<td>HERS - [hepatorenal glycogen storage disease]</td>
</tr>
<tr>
<td>324</td>
<td>glycogen storage disease of liver and kidney</td>
</tr>
<tr>
<td>325</td>
<td>hepatorenal glycogen storage disease</td>
</tr>
<tr>
<td>326</td>
<td>Glycogen storage disease due to glucose-6-phosphatase deficiency</td>
</tr>
<tr>
<td>327</td>
<td>Glycogen storage disease type 1A</td>
</tr>
<tr>
<td>328</td>
<td>Glycogenosis type 1A</td>
</tr>
<tr>
<td>329</td>
<td>GSD type 1A</td>
</tr>
<tr>
<td>330</td>
<td>g6pd - [glucose-6-phosphate dehydrogenase deficiency]</td>
</tr>
<tr>
<td>331</td>
<td>glucose-6-phosphatase deficiency</td>
</tr>
<tr>
<td>332</td>
<td>deficiency of g-6pd</td>
</tr>
<tr>
<td>333</td>
<td>Glycogen storage disease due to glucose-6-phosphate transport defect</td>
</tr>
<tr>
<td>334</td>
<td>Glycogen storage disease type 1B</td>
</tr>
<tr>
<td>335</td>
<td>Glycogenosis type 1B</td>
</tr>
<tr>
<td>336</td>
<td>GSD1B</td>
</tr>
<tr>
<td>337</td>
<td>Glycogen storage disease type non-1A</td>
</tr>
<tr>
<td>338</td>
<td>Glycogenosis type non-1A</td>
</tr>
<tr>
<td>339</td>
<td>Glycogen storage disease due to glucose-6-phosphate translocase deficiency</td>
</tr>
<tr>
<td>340</td>
<td>Glucose-6-phosphate dehydrogenase deficiency</td>
</tr>
<tr>
<td>341</td>
<td>Glycogen storage disease due to acid maltase deficiency</td>
</tr>
<tr>
<td>342</td>
<td>Glycogen storage disease type 2</td>
</tr>
<tr>
<td>343</td>
<td>Glycogenosis type 2</td>
</tr>
<tr>
<td>344</td>
<td>GSD type 2</td>
</tr>
<tr>
<td>345</td>
<td>Acid maltase deficiency</td>
</tr>
<tr>
<td>346</td>
<td>Pompe disease</td>
</tr>
<tr>
<td>347</td>
<td>Acid alpha-1,4-glucosidase deficiency</td>
</tr>
<tr>
<td>348</td>
<td>alpha-glucosidase deficiency</td>
</tr>
<tr>
<td>349</td>
<td>deficiency of amyloglucosidase</td>
</tr>
<tr>
<td>350</td>
<td>Glycogen storage disease due to acid maltase deficiency, infantile onset</td>
</tr>
<tr>
<td>351</td>
<td>Glycogen storage disease type 2, infantile onset</td>
</tr>
<tr>
<td>352</td>
<td>Glycogenosis type 2, infantile onset</td>
</tr>
<tr>
<td>353</td>
<td>GSD2, infantile onset</td>
</tr>
<tr>
<td>354</td>
<td>Glycogen storage disease due to acid alpha-1,4-glucosidase deficiency, infantile onset</td>
</tr>
<tr>
<td>355</td>
<td>Infantile Pompe disease</td>
</tr>
<tr>
<td>356</td>
<td>lysosomal alpha-1,4-glucosidase deficiency (disorder)</td>
</tr>
<tr>
<td>357</td>
<td>Glycogen storage disease due to acid maltase deficiency, juvenile onset</td>
</tr>
<tr>
<td>358</td>
<td>Glycogen storage disease due to acid maltase deficiency, adult onset</td>
</tr>
<tr>
<td>359</td>
<td>Deficiency of exo-1,4-alpha-glucosidase</td>
</tr>
<tr>
<td>360</td>
<td>Deficiency of glucan 1,4-alpha-glucosidase</td>
</tr>
<tr>
<td>361</td>
<td>Deficiency of gamma-amylase</td>
</tr>
<tr>
<td>362</td>
<td>Deficiency of glucoamylase</td>
</tr>
<tr>
<td>363</td>
<td>Deficiency of glucoinvertase</td>
</tr>
<tr>
<td>364</td>
<td>Deficiency of glucosidosucrase</td>
</tr>
<tr>
<td>365</td>
<td>Deficiency of maltase</td>
</tr>
<tr>
<td>366</td>
<td>Glycogen storage disease due to LAMP-2 deficiency</td>
</tr>
<tr>
<td>367</td>
<td>Glycogen storage disease type 2B</td>
</tr>
<tr>
<td>368</td>
<td>Glycogenosis type 2B</td>
</tr>
<tr>
<td>369</td>
<td>GSD type 2B</td>
</tr>
<tr>
<td>370</td>
<td>Lysosomal glycogen storage disease with normal acid maltase activity</td>
</tr>
<tr>
<td>371</td>
<td>Danon disease</td>
</tr>
<tr>
<td>372</td>
<td>Glycogen storage disease due to glycogen debranching enzyme deficiency</td>
</tr>
<tr>
<td>373</td>
<td>Glycogen storage disease type 3</td>
</tr>
<tr>
<td>374</td>
<td>Glycogenosis type 3</td>
</tr>
<tr>
<td>375</td>
<td>GSD type 3</td>
</tr>
<tr>
<td>376</td>
<td>Amylo-1,6-glucosidase deficiency</td>
</tr>
<tr>
<td>377</td>
<td>Glycogen debranching deficiency</td>
</tr>
<tr>
<td>378</td>
<td>Cori-Forbes disease</td>
</tr>
<tr>
<td>379</td>
<td>Cori disease</td>
</tr>
<tr>
<td>380</td>
<td>Forbes disease</td>
</tr>
<tr>
<td>381</td>
<td>Forbes glycogen storage disease</td>
</tr>
<tr>
<td>382</td>
<td>debrancher deficiency glycogen storage disease</td>
</tr>
<tr>
<td>383</td>
<td>debrancher enzyme deficiency</td>
</tr>
<tr>
<td>384</td>
<td>deficiency of 6-alpha-d-glucosidase</td>
</tr>
<tr>
<td>385</td>
<td>amylo-1,6-glucosidase deficiency disorder</td>
</tr>
<tr>
<td>386</td>
<td>Glycogen storage disease due to muscle glycogen phosphorylase deficiency</td>
</tr>
<tr>
<td>387</td>
<td>Glycogen storage disease type 5</td>
</tr>
<tr>
<td>388</td>
<td>Glycogenosis type 5</td>
</tr>
<tr>
<td>389</td>
<td>GSD type 5</td>
</tr>
<tr>
<td>390</td>
<td>Myophosphorylase deficiency</td>
</tr>
<tr>
<td>391</td>
<td>McArdle disease</td>
</tr>
<tr>
<td>392</td>
<td>myophosphorylase deficiency glycogenosis</td>
</tr>
<tr>
<td>393</td>
<td>Glycogen storage disease due to liver glycogen phosphorylase deficiency</td>
</tr>
<tr>
<td>394</td>
<td>Glycogenosis due to liver phosphorylase deficiency</td>
</tr>
<tr>
<td>395</td>
<td>Glycogen storage disease type 6</td>
</tr>
<tr>
<td>396</td>
<td>Glycogenosis type 6</td>
</tr>
<tr>
<td>397</td>
<td>GSD type 6</td>
</tr>
<tr>
<td>398</td>
<td>Glycogen storage disease type 6B</td>
</tr>
<tr>
<td>399</td>
<td>Glycogenosis type 6B</td>
</tr>
<tr>
<td>400</td>
<td>GSD type 6B</td>
</tr>
<tr>
<td>401</td>
<td>Hers disease</td>
</tr>
<tr>
<td>402</td>
<td>deficiency of hepatophosphorylase</td>
</tr>
<tr>
<td>403</td>
<td>Glycogen storage disease due to muscle phosphofructokinase deficiency</td>
</tr>
<tr>
<td>404</td>
<td>Glycogen storage disease type 7</td>
</tr>
<tr>
<td>405</td>
<td>Glycogenosis type 7</td>
</tr>
<tr>
<td>406</td>
<td>GSD type 7</td>
</tr>
<tr>
<td>407</td>
<td>Muscle phosphofructokinase deficiency</td>
</tr>
<tr>
<td>408</td>
<td>Tarui disease</td>
</tr>
<tr>
<td>409</td>
<td>anaemia due to phosphofructo-aldolase deficiency</td>
</tr>
<tr>
<td>410</td>
<td>Glycogen storage disease due to glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>411</td>
<td>Glycogenosis due to phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>412</td>
<td>GSD due to phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>413</td>
<td>Glycogen storage disease due to liver glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>414</td>
<td>Hepatic phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>415</td>
<td>Glycogen storage disease type 8</td>
</tr>
<tr>
<td>416</td>
<td>Glycogenosis type 8</td>
</tr>
<tr>
<td>417</td>
<td>GSD8 - [glycogen storage disease type 8]</td>
</tr>
<tr>
<td>418</td>
<td>Glycogen storage disease type 6A</td>
</tr>
<tr>
<td>419</td>
<td>Glycogen storage disease type 9A</td>
</tr>
<tr>
<td>420</td>
<td>Glycogen storage disease type 9C</td>
</tr>
<tr>
<td>421</td>
<td>Glycogenosis type 6A</td>
</tr>
<tr>
<td>422</td>
<td>Glycogenosis type 9A</td>
</tr>
<tr>
<td>423</td>
<td>Glycogenosis type 9C</td>
</tr>
<tr>
<td>424</td>
<td>GSD type 9C - [glycogen storage disease type 9C]</td>
</tr>
<tr>
<td>425</td>
<td>GSD6A - [glycogen storage disease type 6A]</td>
</tr>
<tr>
<td>426</td>
<td>GSD9A - [glycogen storage disease type 9A]</td>
</tr>
<tr>
<td>427</td>
<td>Glycogen storage disease due to liver or muscle glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>428</td>
<td>Glycogen storage disease type 9B</td>
</tr>
<tr>
<td>429</td>
<td>Glycogenosis type 9B</td>
</tr>
<tr>
<td>430</td>
<td>GSD type 9B</td>
</tr>
<tr>
<td>431</td>
<td>Glycogen storage disease type 9</td>
</tr>
<tr>
<td>432</td>
<td>Glycogenosis type 9</td>
</tr>
<tr>
<td>433</td>
<td>GSD9 - [glycogen storage disease type 9]</td>
</tr>
<tr>
<td>434</td>
<td>Glycogen storage disease due to heart glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>435</td>
<td>Glycogen storage disease of heart</td>
</tr>
<tr>
<td>436</td>
<td>Cardiac glycogenosis</td>
</tr>
<tr>
<td>437</td>
<td>Glycogen storage disease type 9F</td>
</tr>
<tr>
<td>438</td>
<td>Glycogenosis type 9F</td>
</tr>
<tr>
<td>439</td>
<td>GSD9F</td>
</tr>
<tr>
<td>440</td>
<td>glycogen heart disease</td>
</tr>
<tr>
<td>441</td>
<td>glycogenic myocardial infiltration</td>
</tr>
<tr>
<td>442</td>
<td>glycogenic myocardium infiltration</td>
</tr>
<tr>
<td>443</td>
<td>cardiomegalia glycogenica diffusa</td>
</tr>
<tr>
<td>444</td>
<td>Glycogen storage disease due to muscle glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>445</td>
<td>GSD9D - [glycogen storage disease type IXD]</td>
</tr>
<tr>
<td>446</td>
<td>Glycogen storage disease type 9D</td>
</tr>
<tr>
<td>447</td>
<td>Glycogen storage disease type 9E</td>
</tr>
<tr>
<td>448</td>
<td>Glycogenosis type 9D</td>
</tr>
<tr>
<td>449</td>
<td>Glycogenosis type 9E</td>
</tr>
<tr>
<td>450</td>
<td>GSD9E</td>
</tr>
<tr>
<td>451</td>
<td>muscle glycogen phosphorylase deficiency</td>
</tr>
<tr>
<td>452</td>
<td>glycogenosis type IXE</td>
</tr>
<tr>
<td>453</td>
<td>Glycogen storage disease due to muscle phosphoglycerate mutase deficiency</td>
</tr>
<tr>
<td>454</td>
<td>Glycogen storage disease type 10</td>
</tr>
<tr>
<td>455</td>
<td>Glycogenosis type 10</td>
</tr>
<tr>
<td>456</td>
<td>GSD type 10</td>
</tr>
<tr>
<td>457</td>
<td>Di Mauro disease</td>
</tr>
<tr>
<td>458</td>
<td>Glycogen storage disease due to GLUT2 deficiency</td>
</tr>
<tr>
<td>459</td>
<td>Glycogen storage disease type 11</td>
</tr>
<tr>
<td>460</td>
<td>Glycogenosis type 11</td>
</tr>
<tr>
<td>461</td>
<td>GSD type 11</td>
</tr>
<tr>
<td>462</td>
<td>Fanconi-Bickel glycogenosis</td>
</tr>
<tr>
<td>463</td>
<td>Bickel-Fanconi disease</td>
</tr>
<tr>
<td>464</td>
<td>Facilitated glucose transporter protein type 2 deficiency</td>
</tr>
<tr>
<td>465</td>
<td>Fanconi-Bickel syndrome</td>
</tr>
<tr>
<td>466</td>
<td>Glycogen storage disease due to aldolase A deficiency</td>
</tr>
<tr>
<td>467</td>
<td>Glycogen storage disease type 12</td>
</tr>
<tr>
<td>468</td>
<td>Glycogenosis type 12</td>
</tr>
<tr>
<td>469</td>
<td>GSD type 12</td>
</tr>
<tr>
<td>470</td>
<td>Glycogen storage disease due to muscle beta-enolase deficiency</td>
</tr>
<tr>
<td>471</td>
<td>Glycogen storage disease type 13</td>
</tr>
<tr>
<td>472</td>
<td>Glycogenosis type 13</td>
</tr>
<tr>
<td>473</td>
<td>GSD type 13</td>
</tr>
<tr>
<td>474</td>
<td>Glycogen storage disease due to phosphoglucomutase deficiency</td>
</tr>
<tr>
<td>475</td>
<td>Glycogen storage disease type 14</td>
</tr>
<tr>
<td>476</td>
<td>Glycogenosis type 14</td>
</tr>
<tr>
<td>477</td>
<td>GSD type 14</td>
</tr>
<tr>
<td>478</td>
<td>Glycogen storage disease due to glycogenin deficiency</td>
</tr>
<tr>
<td>479</td>
<td>Glycogen storage disease type 15</td>
</tr>
<tr>
<td>480</td>
<td>GSD type 15</td>
</tr>
<tr>
<td>481</td>
<td>Glocogenosis type 15</td>
</tr>
<tr>
<td>482</td>
<td>Glycogen storage disease due to phosphoglycerate kinase 1 deficiency</td>
</tr>
<tr>
<td>483</td>
<td>Glycogenosis due to phosphoglycerate kinase 1 deficiency</td>
</tr>
<tr>
<td>484</td>
<td>GSD due to phosphoglycerate kinase 1 deficiency</td>
</tr>
<tr>
<td>485</td>
<td>Glycogen storage disease due to lactate dehydrogenase deficiency</td>
</tr>
<tr>
<td>486</td>
<td>Glycogenosis due to lactate dehydrogenase deficiency</td>
</tr>
<tr>
<td>487</td>
<td>GSD due to lactate dehydrogenase deficiency</td>
</tr>
<tr>
<td>488</td>
<td>Glycogen storage disease due to muscle pyruvate kinase deficiency</td>
</tr>
<tr>
<td>489</td>
<td>Glycogenosis due to muscle pyruvate kinase deficiency</td>
</tr>
<tr>
<td>490</td>
<td>GSD due to muscle pyruvate kinase deficiency</td>
</tr>
<tr>
<td>491</td>
<td>Glycogen storage liver disease</td>
</tr>
<tr>
<td>492</td>
<td>hepatomegalia glycogenica diffusa</td>
</tr>
<tr>
<td>493</td>
<td>liver glycogen disease</td>
</tr>
<tr>
<td>494</td>
<td>liver phosphorylase deficiency</td>
</tr>
<tr>
<td>495</td>
<td>Glycogen storage disease due to branching-transferase deficiency</td>
</tr>
<tr>
<td>496</td>
<td>Andersen disease</td>
</tr>
<tr>
<td>497</td>
<td>brancher deficiency glycogen storage disease</td>
</tr>
<tr>
<td>498</td>
<td>branching enzyme deficiency</td>
</tr>
<tr>
<td>499</td>
<td>branching-transferase deficiency glycogenosis</td>
</tr>
<tr>
<td>500</td>
<td>deficiency of 1,4-alpha-glucan branching enzyme</td>
</tr>
<tr>
<td>501</td>
<td>deficiency of amylo-(1,4,6)-transglycosylase</td>
</tr>
<tr>
<td>502</td>
<td>Glycogen storage disease type 4</td>
</tr>
<tr>
<td>503</td>
<td>Glycogenosis type 4</td>
</tr>
<tr>
<td>504</td>
<td>GSD- [Glycogen storage disease] type 4</td>
</tr>
<tr>
<td>505</td>
<td>Dilated cardiomyopathy due to glycogen branching enzyme deficiency</td>
</tr>
<tr>
<td>506</td>
<td>Amylopectinosis</td>
</tr>
<tr>
<td>507</td>
<td>dilated cardiomyopathy due to Andersen's disease</td>
</tr>
<tr>
<td>508</td>
<td>dilated cardiomyopathy due to glycogen storage disease type 4 (GSD4)</td>
</tr>
<tr>
<td>509</td>
<td>Dystonia-plus</td>
</tr>
<tr>
<td>510</td>
<td>Myoclonus-dystonia</td>
</tr>
<tr>
<td>511</td>
<td>Dopa-responsive dystonia</td>
</tr>
<tr>
<td>512</td>
<td>Segawa syndrome</td>
</tr>
<tr>
<td>513</td>
<td>DYT5</td>
</tr>
<tr>
<td>514</td>
<td>DRD - [dopa-responsive dystonia]</td>
</tr>
<tr>
<td>515</td>
<td>Autosomal dominant dopa-responsive dystonia</td>
</tr>
<tr>
<td>516</td>
<td>Hereditary progressive dystonia with marked diurnal fluctuation</td>
</tr>
<tr>
<td>517</td>
<td>Autosomal dominant Segawa syndrome</td>
</tr>
<tr>
<td>518</td>
<td>DYT5a</td>
</tr>
<tr>
<td>519</td>
<td>HPD - [ hereditary progressive dystonia] with marked diurnal fluctuation</td>
</tr>
<tr>
<td>520</td>
<td>Autosomal dominant DRD - [dopa-responsive dystonia]</td>
</tr>
<tr>
<td>521</td>
<td>Autosomal recessive dopa-responsive dystonia</td>
</tr>
<tr>
<td>522</td>
<td>Autosomal recessive Segawa syndrome</td>
</tr>
<tr>
<td>523</td>
<td>Autosomal recessive DRD - [dopa-responsive dystonia]</td>
</tr>
<tr>
<td>524</td>
<td>Tyrosine hydroxylase deficiency</td>
</tr>
<tr>
<td>525</td>
<td>Mucopolysaccharidosis type 2</td>
</tr>
<tr>
<td>526</td>
<td>Iduronate 2-sulfatase deficiency</td>
</tr>
<tr>
<td>527</td>
<td>Hunter syndrome</td>
</tr>
<tr>
<td>528</td>
<td>iduronate 2-sulphatase deficiency</td>
</tr>
<tr>
<td>529</td>
<td>iduronate sulfatase deficiency</td>
</tr>
<tr>
<td>530</td>
<td>iduronate sulphatase deficiency</td>
</tr>
<tr>
<td>531</td>
<td>sulfo-iduronate sulfatase deficiency</td>
</tr>
<tr>
<td>532</td>
<td>sulfoiduronidate sulfatase deficiency</td>
</tr>
<tr>
<td>533</td>
<td>sulpho-iduronate sulphatase deficiency</td>
</tr>
<tr>
<td>534</td>
<td>sulphoiduronidate sulphatase deficiency</td>
</tr>
<tr>
<td>535</td>
<td>MPS2 - [mucopolysaccharidosis 2]</td>
</tr>
<tr>
<td>536</td>
<td>Mucopolysaccharidosis type 2A</td>
</tr>
<tr>
<td>537</td>
<td>Iduronate 2-sulfatase deficiency type A</td>
</tr>
<tr>
<td>538</td>
<td>Hunter syndrome type A</td>
</tr>
<tr>
<td>539</td>
<td>Mucopolysaccharidosis type 2, severe form</td>
</tr>
<tr>
<td>540</td>
<td>Mucopolysaccharidosis type 2B</td>
</tr>
<tr>
<td>541</td>
<td>Iduronate 2-sulfatase deficiency type B</td>
</tr>
<tr>
<td>542</td>
<td>Hunter syndrome type B</td>
</tr>
<tr>
<td>543</td>
<td>Mucopolysaccharidosis type 2, mild form</td>
</tr>
<tr>
<td>544</td>
<td>Mucopolysaccharidosis type 2, attenuated form</td>
</tr>
<tr>
<td>545</td>
<td>Other specified structural developmental anomaly of heart or great vessels</td>
</tr>
<tr>
<td>546</td>
<td>Congenital anomaly of position or spatial relationships of thoraco-abdominal organs</td>
</tr>
<tr>
<td>547</td>
<td>Usual atrial arrangement</td>
</tr>
<tr>
<td>548</td>
<td>atrial situs solitus</td>
</tr>
<tr>
<td>549</td>
<td>Abnormal atrial arrangement</td>
</tr>
<tr>
<td>550</td>
<td>Abnormal atrial situs</td>
</tr>
<tr>
<td>551</td>
<td>Atrial situs inversus</td>
</tr>
<tr>
<td>552</td>
<td>Mirror-image atrial arrangement</td>
</tr>
<tr>
<td>553</td>
<td>Isomerism of right atrial appendages</td>
</tr>
<tr>
<td>554</td>
<td>isomeric right atrial appendages</td>
</tr>
<tr>
<td>555</td>
<td>Isomerism of left atrial appendages</td>
</tr>
<tr>
<td>556</td>
<td>isomeric left atrial appendages</td>
</tr>
<tr>
<td>557</td>
<td>Abnormal relationship of great arterial roots</td>
</tr>
<tr>
<td>558</td>
<td>Abnormal relationships of great arteries</td>
</tr>
<tr>
<td>559</td>
<td>Abnormal relationships of great vessels</td>
</tr>
<tr>
<td>560</td>
<td>Aortic root directly anterior to pulmonary root</td>
</tr>
<tr>
<td>561</td>
<td>A-malposed aorta</td>
</tr>
<tr>
<td>562</td>
<td>A-malposed great arteries</td>
</tr>
<tr>
<td>563</td>
<td>Aorta directly anterior to pulmonary artery</td>
</tr>
<tr>
<td>564</td>
<td>A-transposed aorta</td>
</tr>
<tr>
<td>565</td>
<td>Aortic root anterior and rightward to pulmonary root</td>
</tr>
<tr>
<td>566</td>
<td>D-malposed great vessels with anterior aorta</td>
</tr>
<tr>
<td>567</td>
<td>Dextroposed great arteries with anterior aorta</td>
</tr>
<tr>
<td>568</td>
<td>Dextroposed great vessels with anterior aorta</td>
</tr>
<tr>
<td>569</td>
<td>D-malposed great arteries with anterior aorta</td>
</tr>
<tr>
<td>570</td>
<td>D-transposed great arteries</td>
</tr>
<tr>
<td>571</td>
<td>D-transposed great vessels</td>
</tr>
<tr>
<td>572</td>
<td>Aortic root anterior and leftward to pulmonary root</td>
</tr>
<tr>
<td>573</td>
<td>L-malposed great vessels with anterior aorta</td>
</tr>
<tr>
<td>574</td>
<td>L-malposed great arteries with anterior aorta</td>
</tr>
<tr>
<td>575</td>
<td>Levoposed great arteries with anterior aorta</td>
</tr>
<tr>
<td>576</td>
<td>Levoposed great vessels with anterior aorta</td>
</tr>
<tr>
<td>577</td>
<td>L-transposed great arteries with anterior aorta</td>
</tr>
<tr>
<td>578</td>
<td>L-transposed great vessels with anterior aorta</td>
</tr>
<tr>
<td>579</td>
<td>Aortic root side by side and directly rightward to pulmonary root</td>
</tr>
<tr>
<td>580</td>
<td>D-transposed side by side great arteries</td>
</tr>
<tr>
<td>581</td>
<td>D-transposed side by side great vessels</td>
</tr>
<tr>
<td>582</td>
<td>Dextroposed side by side great arteries</td>
</tr>
<tr>
<td>583</td>
<td>Dextroposed side by side great vessels</td>
</tr>
<tr>
<td>584</td>
<td>D-malposed side by side great arteries</td>
</tr>
<tr>
<td>585</td>
<td>Aortic root side by side and directly leftward to pulmonary root</td>
</tr>
<tr>
<td>586</td>
<td>L-transposed side by side great vessels</td>
</tr>
<tr>
<td>587</td>
<td>L-malposed side by side great vessels</td>
</tr>
<tr>
<td>588</td>
<td>L-malposed side by side great arteries</td>
</tr>
<tr>
<td>589</td>
<td>Levoposed side by side great vessels</td>
</tr>
<tr>
<td>590</td>
<td>Levoposed side by side great arteries</td>
</tr>
<tr>
<td>591</td>
<td>L-transposed side by side great arteries</td>
</tr>
<tr>
<td>592</td>
<td>Aortic root directly posterior to pulmonary root</td>
</tr>
<tr>
<td>593</td>
<td>Aortic root posterior and rightward to pulmonary root</td>
</tr>
<tr>
<td>594</td>
<td>d-malposed great arteries with posterior aorta</td>
</tr>
<tr>
<td>595</td>
<td>normally related great arteries</td>
</tr>
<tr>
<td>596</td>
<td>segmental analysis D with posterior aorta</td>
</tr>
<tr>
<td>597</td>
<td>Aortic root posterior and leftward to pulmonary root</td>
</tr>
<tr>
<td>598</td>
<td>L-malposed great arteries with posterior aorta</td>
</tr>
<tr>
<td>599</td>
<td>L-malposed great vessels with posterior aorta</td>
</tr>
<tr>
<td>600</td>
<td>Mirror imaged normally related great arteries</td>
</tr>
<tr>
<td>601</td>
<td>Levoposed great arteries with posterior aorta</td>
</tr>
<tr>
<td>602</td>
<td>Levoposed great vessels with posterior aorta</td>
</tr>
<tr>
<td>603</td>
<td>Mirror imaged normally related great vessels</td>
</tr>
<tr>
<td>604</td>
<td>Abnormal intrapericardial course of great arteries</td>
</tr>
<tr>
<td>605</td>
<td>Spiralling course of great arteries</td>
</tr>
<tr>
<td>606</td>
<td>Normal course of great arteries</td>
</tr>
<tr>
<td>607</td>
<td>Parallel course of great arteries</td>
</tr>
<tr>
<td>608</td>
<td>Visceral heterotaxy</td>
</tr>
<tr>
<td>609</td>
<td>Abnormal arrangement of thoraco-abdominal organs</td>
</tr>
<tr>
<td>610</td>
<td>Heterotaxy</td>
</tr>
<tr>
<td>611</td>
<td>Heterotaxia</td>
</tr>
<tr>
<td>612</td>
<td>Heterotaxia syndrome</td>
</tr>
<tr>
<td>613</td>
<td>Situs ambiguous</td>
</tr>
<tr>
<td>614</td>
<td>Splenic syndromes</td>
</tr>
<tr>
<td>615</td>
<td>Heterotaxy syndrome</td>
</tr>
<tr>
<td>616</td>
<td>Congenital anomaly of an atrium or atrial septum</td>
</tr>
<tr>
<td>617</td>
<td>congenital atrial malformation</td>
</tr>
<tr>
<td>618</td>
<td>cor triatriatum (deprecated)</td>
</tr>
<tr>
<td>619</td>
<td>Aortic aneurysm due to congenital heart disease</td>
</tr>
<tr>
<td>620</td>
<td>Aortic aneurysm secondary to congenital heart disease</td>
</tr>
<tr>
<td>621</td>
<td>Congenital heart block</td>
</tr>
<tr>
<td>622</td>
<td>Congenital complete heart block</td>
</tr>
<tr>
<td>623</td>
<td>Immune-mediated heart block</td>
</tr>
<tr>
<td>624</td>
<td>Accessory heart</td>
</tr>
<tr>
<td>625</td>
<td>Congenital cardiac dilatation</td>
</tr>
<tr>
<td>626</td>
<td>acute congenital heart dilatation</td>
</tr>
<tr>
<td>627</td>
<td>chronic congenital cardiac dilatation</td>
</tr>
<tr>
<td>628</td>
<td>chronic congenital heart dilatation</td>
</tr>
<tr>
<td>629</td>
<td>congenital cardiac valve dilatation</td>
</tr>
<tr>
<td>630</td>
<td>Anomalous bands of heart</td>
</tr>
<tr>
<td>631</td>
<td>anomaly of heart bands or folds</td>
</tr>
<tr>
<td>632</td>
<td>Bifid apex of heart</td>
</tr>
<tr>
<td>633</td>
<td>Congenital cardiomegaly</td>
</tr>
<tr>
<td>634</td>
<td>Congenital microcardia</td>
</tr>
<tr>
<td>635</td>
<td>Other specified mucopolysaccharidosis</td>
</tr>
<tr>
<td>636</td>
<td>Mucopolysaccharidosis type 3</td>
</tr>
<tr>
<td>637</td>
<td>Acetyl-CoA alpha-glucosaminide-N-acetyl transferase deficiency</td>
</tr>
<tr>
<td>638</td>
<td>N-acetyl-alpha-glucosaminidase sulfamidase deficiency</td>
</tr>
<tr>
<td>639</td>
<td>N-acetyl-glucosamine-6-sulfate sulfatase deficiency</td>
</tr>
<tr>
<td>640</td>
<td>Sanfilippo syndrome</td>
</tr>
<tr>
<td>641</td>
<td>Mucopolysaccharidosis type 3A</td>
</tr>
<tr>
<td>642</td>
<td>Sanfilippo syndrome type A</td>
</tr>
<tr>
<td>643</td>
<td>Heparan-N-sulfatase deficiency</td>
</tr>
<tr>
<td>644</td>
<td>Heparan sulfamidase deficiency</td>
</tr>
<tr>
<td>645</td>
<td>Heparan sulfate sulfatase deficiency</td>
</tr>
<tr>
<td>646</td>
<td>Mucopolysaccharidosis type 3B</td>
</tr>
<tr>
<td>647</td>
<td>Sanfilippo syndrome type B</td>
</tr>
<tr>
<td>648</td>
<td>Alpha-N-acetylglucosaminidase deficiency</td>
</tr>
<tr>
<td>649</td>
<td>N-acetyl-alpha-D-glucosaminidase deficiency</td>
</tr>
<tr>
<td>650</td>
<td>Mucopolysaccharidosis type 3C</td>
</tr>
<tr>
<td>651</td>
<td>Sanfilippo syndrome type C</td>
</tr>
<tr>
<td>652</td>
<td>Acetyl-CoA alpha-glucosaminide acetyltransferase deficiency</td>
</tr>
<tr>
<td>653</td>
<td>N-acetyl transferase deficiency</td>
</tr>
<tr>
<td>654</td>
<td>Mucopolysaccharidosis type 3D</td>
</tr>
<tr>
<td>655</td>
<td>Sanfilippo syndrome type D</td>
</tr>
<tr>
<td>656</td>
<td>N-acetylglucosamine-6-sulfate sulfatase deficiency</td>
</tr>
<tr>
<td>657</td>
<td>Mucopolysaccharidosis type 7</td>
</tr>
<tr>
<td>658</td>
<td>Beta-glucuronidase deficiency</td>
</tr>
<tr>
<td>659</td>
<td>Sly disease</td>
</tr>
<tr>
<td>660</td>
<td>Sly syndrome</td>
</tr>
<tr>
<td>661</td>
<td>Mucopolysaccharidosis type 9</td>
</tr>
<tr>
<td>662</td>
<td>Hyaluronidase deficiency</td>
</tr>
<tr>
<td>663</td>
<td>Natowicz syndrome</td>
</tr>
<tr>
<td>664</td>
<td>Vitamin A deficiency with other specified manifestations</td>
</tr>
<tr>
<td>665</td>
<td>Phrynoderma</td>
</tr>
<tr>
<td>666</td>
<td>Certain specified ocular manifestations of vitamin A deficiency</td>
</tr>
<tr>
<td>667</td>
<td>Vitamin A deficiency with xerophthalmia</td>
</tr>
<tr>
<td>668</td>
<td>xerophthalmia</td>
</tr>
<tr>
<td>669</td>
<td>Xerophthalmia NOS</td>
</tr>
<tr>
<td>670</td>
<td>Follicular keratosis due to vitamin A deficiency</td>
</tr>
<tr>
<td>671</td>
<td>Xeroderma due to vitamin A deficiency</td>
</tr>
<tr>
<td>672</td>
<td>Mucopolysaccharidosis type 4</td>
</tr>
<tr>
<td>673</td>
<td>Galactosamine-6-sulfatase deficiency</td>
</tr>
<tr>
<td>674</td>
<td>Morquio syndrome</td>
</tr>
<tr>
<td>675</td>
<td>Morquio-Brailsford disease</td>
</tr>
<tr>
<td>676</td>
<td>Mucopolysaccharidosis type 4A</td>
</tr>
<tr>
<td>677</td>
<td>Galactose-6-sulfatase deficiency</td>
</tr>
<tr>
<td>678</td>
<td>Galactosamide-6-sulfatase deficiency</td>
</tr>
<tr>
<td>679</td>
<td>Morquio syndrome type A</td>
</tr>
<tr>
<td>680</td>
<td>Mucopolysaccharidosis type 4B</td>
</tr>
<tr>
<td>681</td>
<td>Beta-D-galactosidase deficiency</td>
</tr>
<tr>
<td>682</td>
<td>Morquio syndrome type B</td>
</tr>
<tr>
<td>683</td>
<td>Disorders of protein N-glycosylation</td>
</tr>
<tr>
<td>684</td>
<td>Phosphomannomutase 2 deficiency</td>
</tr>
<tr>
<td>685</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1A</td>
</tr>
<tr>
<td>686</td>
<td>Congenital disorder of glycosylation type 1A</td>
</tr>
<tr>
<td>687</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1A</td>
</tr>
<tr>
<td>688</td>
<td>Phosphomannose isomerase deficiency</td>
</tr>
<tr>
<td>689</td>
<td>Saguenay-Lac-Saint-Jean syndrome</td>
</tr>
<tr>
<td>690</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1B</td>
</tr>
<tr>
<td>691</td>
<td>Congenital disorder of glycosylation type 1B</td>
</tr>
<tr>
<td>692</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1B</td>
</tr>
<tr>
<td>693</td>
<td>SLSJ - [Saguenay-Lac-Saint-Jean] syndrome</td>
</tr>
<tr>
<td>694</td>
<td>Glucosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>695</td>
<td>Dol-P-Glc: Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>696</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1C</td>
</tr>
<tr>
<td>697</td>
<td>Congenital disorder of glycosylation type 1C</td>
</tr>
<tr>
<td>698</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1C</td>
</tr>
<tr>
<td>699</td>
<td>Mannosyltransferase 6 deficiency</td>
</tr>
<tr>
<td>700</td>
<td>Dol-P-Man: Man5-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>701</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1D</td>
</tr>
<tr>
<td>702</td>
<td>Congenital disorder of glycosylation type 1D</td>
</tr>
<tr>
<td>703</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1D</td>
</tr>
<tr>
<td>704</td>
<td>Mannosyltransferase 8 deficiency</td>
</tr>
<tr>
<td>705</td>
<td>Dol-P-Man: Man7-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>706</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1G</td>
</tr>
<tr>
<td>707</td>
<td>Congenital disorder of glycosylation type 1G</td>
</tr>
<tr>
<td>708</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1G</td>
</tr>
<tr>
<td>709</td>
<td>Glucosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>710</td>
<td>Dol-P-Glc: Glc1-Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>711</td>
<td>Carbohydrate deficient glycoprotein syndrome 1H</td>
</tr>
<tr>
<td>712</td>
<td>Congenital disorder of glycosylation type 1H</td>
</tr>
<tr>
<td>713</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1H</td>
</tr>
<tr>
<td>714</td>
<td>Mannosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>715</td>
<td>Dol-P-Man: Man1-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>716</td>
<td>Carbohydrate deficient glycoprotein syndrome 1I</td>
</tr>
<tr>
<td>717</td>
<td>Congenital disorder of glycosylation 1I</td>
</tr>
<tr>
<td>718</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1I</td>
</tr>
<tr>
<td>719</td>
<td>Dolichyl-phosphate N-acetylgalactosamine phosphotransferase deficiency</td>
</tr>
<tr>
<td>720</td>
<td>UDP-GlcNAc: Dol-P-GlcNac-P transferase deficiency</td>
</tr>
<tr>
<td>721</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1J</td>
</tr>
<tr>
<td>722</td>
<td>Congenital disorder of glycosylation type 1J</td>
</tr>
<tr>
<td>723</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1J</td>
</tr>
<tr>
<td>724</td>
<td>Mannosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>725</td>
<td>Dol-P-Man: GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>726</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1K</td>
</tr>
<tr>
<td>727</td>
<td>Congenital disorder of glycosylation type 1K</td>
</tr>
<tr>
<td>728</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1K</td>
</tr>
<tr>
<td>729</td>
<td>Mannosyltransferase 7-9 deficiency</td>
</tr>
<tr>
<td>730</td>
<td>Congenital disorder of glycosylation type 1L</td>
</tr>
<tr>
<td>731</td>
<td>Dol-P-Man: Man6 and Man8-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>732</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1L</td>
</tr>
<tr>
<td>733</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1L</td>
</tr>
<tr>
<td>734</td>
<td>M5-DLO flippase deficiency</td>
</tr>
<tr>
<td>735</td>
<td>Man5GlcNAc2-PP-Dol flippase deficiency</td>
</tr>
<tr>
<td>736</td>
<td>RTF1-CDG</td>
</tr>
<tr>
<td>737</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1N</td>
</tr>
<tr>
<td>738</td>
<td>N-acetylglucosaminyltransferase deficiency</td>
</tr>
<tr>
<td>739</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2A</td>
</tr>
<tr>
<td>740</td>
<td>Congenital disorder of glycosylation type 2A</td>
</tr>
<tr>
<td>741</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2A</td>
</tr>
<tr>
<td>742</td>
<td>Glucosidase 1 deficiency</td>
</tr>
<tr>
<td>743</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2B</td>
</tr>
<tr>
<td>744</td>
<td>Congenital disorder of glycosylation type 2B</td>
</tr>
<tr>
<td>745</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2B</td>
</tr>
<tr>
<td>746</td>
<td>TUSC3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>747</td>
<td>TUSC3-CDG</td>
</tr>
<tr>
<td>748</td>
<td>SRD5A3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>749</td>
<td>SRD5A3-CDG</td>
</tr>
<tr>
<td>750</td>
<td>Congenital disorder of glycosylation due to steroid 5-alpha-reductase type 3 deficiency</td>
</tr>
<tr>
<td>751</td>
<td>Intellectual deficit - cataract - coloboma - kyphosis</td>
</tr>
<tr>
<td>752</td>
<td>Kahrizi syndrome</td>
</tr>
<tr>
<td>753</td>
<td>Intellectual deficit, Kahrizi type</td>
</tr>
<tr>
<td>754</td>
<td>DPM3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>755</td>
<td>Congenital disorder of glycosylation type 1O</td>
</tr>
<tr>
<td>756</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1O</td>
</tr>
<tr>
<td>757</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1O</td>
</tr>
<tr>
<td>758</td>
<td>ALG11 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>759</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1P</td>
</tr>
<tr>
<td>760</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1P</td>
</tr>
<tr>
<td>761</td>
<td>Congenital disorder of glycosylation type 1P</td>
</tr>
<tr>
<td>762</td>
<td>Phosphoglucomutase-1 deficiency</td>
</tr>
<tr>
<td>763</td>
<td>PGM1-CDG - [Phosphoglucomutase-1 deficiency]</td>
</tr>
<tr>
<td>764</td>
<td>Congenital disorder of glycosylation type 1t</td>
</tr>
<tr>
<td>765</td>
<td>Certain specified disorders of arteries or arterioles</td>
</tr>
<tr>
<td>766</td>
<td>Aortic dilatation - joint hypermobility - arterial tortuosity</td>
</tr>
<tr>
<td>767</td>
<td>Generalised arterial calcification of infancy</td>
</tr>
<tr>
<td>768</td>
<td>Median arcuate ligament syndrome</td>
</tr>
<tr>
<td>769</td>
<td>Aortic root abscess</td>
</tr>
<tr>
<td>770</td>
<td>Periaortic abscess</td>
</tr>
<tr>
<td>771</td>
<td>Acquired deformity of aorta</td>
</tr>
<tr>
<td>772</td>
<td>acquired aorta arch deformity</td>
</tr>
<tr>
<td>773</td>
<td>acquired aorta deformity</td>
</tr>
<tr>
<td>774</td>
<td>acquired aortic arch deformity</td>
</tr>
<tr>
<td>775</td>
<td>acquired aortic deformity</td>
</tr>
<tr>
<td>776</td>
<td>Acquired deformity of renal artery</td>
</tr>
<tr>
<td>777</td>
<td>acquired deformity of kidney artery</td>
</tr>
<tr>
<td>778</td>
<td>Arterial abscess</td>
</tr>
<tr>
<td>779</td>
<td>artery wall abscess</td>
</tr>
<tr>
<td>780</td>
<td>arterial wall abscess</td>
</tr>
<tr>
<td>781</td>
<td>artery abscess</td>
</tr>
<tr>
<td>782</td>
<td>Arterial hypertrophy</td>
</tr>
<tr>
<td>783</td>
<td>artery hypertrophy</td>
</tr>
<tr>
<td>784</td>
<td>Erosion of artery</td>
</tr>
<tr>
<td>785</td>
<td>artery erosion</td>
</tr>
<tr>
<td>786</td>
<td>erosion arterial</td>
</tr>
<tr>
<td>787</td>
<td>Fatty degeneration of aorta</td>
</tr>
<tr>
<td>788</td>
<td>fatty aorta degeneration</td>
</tr>
<tr>
<td>789</td>
<td>fatty aortic degeneration</td>
</tr>
<tr>
<td>790</td>
<td>Hyperplasia of renal artery</td>
</tr>
<tr>
<td>791</td>
<td>renal arterial hyperplasia</td>
</tr>
<tr>
<td>792</td>
<td>renal artery hyperplasia</td>
</tr>
<tr>
<td>793</td>
<td>FMH - [fibromuscular hyperplasia, of renal artery]</td>
</tr>
<tr>
<td>794</td>
<td>Fibromuscular hyperplasia of renal artery</td>
</tr>
<tr>
<td>795</td>
<td>a. renalis; hyperplasia</td>
</tr>
<tr>
<td>796</td>
<td>Renal vasculitis</td>
</tr>
<tr>
<td>797</td>
<td>vasculitis kidney</td>
</tr>
<tr>
<td>798</td>
<td>Ulcer of artery</td>
</tr>
<tr>
<td>799</td>
<td>arterial ulcer</td>
</tr>
<tr>
<td>800</td>
<td>artery ulcer</td>
</tr>
<tr>
<td>801</td>
<td>Obliterative arteriolar disease</td>
</tr>
<tr>
<td>802</td>
<td>Arteriovenous fistula, not elsewhere classified</td>
</tr>
<tr>
<td>803</td>
<td>arteriovenous fistula NOS</td>
</tr>
<tr>
<td>804</td>
<td>Disorders of nucleotide metabolism</td>
</tr>
<tr>
<td>805</td>
<td>Aicardi-Goutières syndrome</td>
</tr>
<tr>
<td>806</td>
<td>Encephalopathy with basal ganglia calcification</td>
</tr>
<tr>
<td>807</td>
<td>Encephalopathy with intracranial calcification and chronic lymphocytosis of cerebrospinal fluid</td>
</tr>
<tr>
<td>808</td>
<td>Aicardi-Goutières syndrome type 1</td>
</tr>
<tr>
<td>809</td>
<td>TREX deficiency</td>
</tr>
<tr>
<td>810</td>
<td>DNase III deficiency</td>
</tr>
<tr>
<td>811</td>
<td>Aicardi-Goutières syndrome type 2</td>
</tr>
<tr>
<td>812</td>
<td>RNASEH2B deficiency</td>
</tr>
<tr>
<td>813</td>
<td>Aicardi-Goutières syndrome type 3</td>
</tr>
<tr>
<td>814</td>
<td>RNASEH2C deficiency</td>
</tr>
<tr>
<td>815</td>
<td>Aicardi-Goutières syndrome type 4</td>
</tr>
<tr>
<td>816</td>
<td>RNASEH2A deficiency</td>
</tr>
<tr>
<td>817</td>
<td>Aicardi-Goutières syndrome type 5</td>
</tr>
<tr>
<td>818</td>
<td>SAMHD1deficiency</td>
</tr>
<tr>
<td>819</td>
<td>Cystic leukoencephalopathy without megalencephaly</td>
</tr>
<tr>
<td>820</td>
<td>RNASET2-deficient cystic leukoencephalopathy</td>
</tr>
<tr>
<td>821</td>
<td>Insulin-resistance syndromes</td>
</tr>
<tr>
<td>822</td>
<td>Insulin-resistance syndrome type A</td>
</tr>
<tr>
<td>823</td>
<td>Insulin-resistance syndrome type B</td>
</tr>
<tr>
<td>824</td>
<td>Rabson-Mendenhall syndrome</td>
</tr>
<tr>
<td>825</td>
<td>Laminopathy type Decaudain-Vigouroux</td>
</tr>
<tr>
<td>826</td>
<td>Laminopathy with severe metabolic syndrome and myopathy</td>
</tr>
<tr>
<td>827</td>
<td>Leprechaunism</td>
</tr>
<tr>
<td>828</td>
<td>Donohue syndrome</td>
</tr>
<tr>
<td>829</td>
<td>HAIR-AN syndrome</td>
</tr>
<tr>
<td>830</td>
<td>HAIR-AN - [hyperandrogenic-insulin resistance-acanthosis nigricans] syndrome</td>
</tr>
<tr>
<td>831</td>
<td>Insulin resistance - short fifth metacarpals</td>
</tr>
<tr>
<td>832</td>
<td>Berardinelli-Seip congenital lipodystrophy</td>
</tr>
<tr>
<td>833</td>
<td>Berardinelli-Seip syndrome</td>
</tr>
<tr>
<td>834</td>
<td>Lipoatrophic diabetes</td>
</tr>
<tr>
<td>835</td>
<td>Brunzell syndrome</td>
</tr>
<tr>
<td>836</td>
<td>Berardinelli type lipodystrophy</td>
</tr>
<tr>
<td>837</td>
<td>BSCL - [Berardinelli-Seip congenital lipodystrophy]</td>
</tr>
<tr>
<td>838</td>
<td>Familial partial lipodystrophy</td>
</tr>
<tr>
<td>839</td>
<td>Hereditary partial lipodystrophy</td>
</tr>
<tr>
<td>840</td>
<td>Familial partial lipodystrophy, Köbberling type</td>
</tr>
<tr>
<td>841</td>
<td>Familial partial lipodystrophy type 1</td>
</tr>
<tr>
<td>842</td>
<td>FPLD1 - [Familial partial lipodystrophy type 1]</td>
</tr>
<tr>
<td>843</td>
<td>Familial partial lipodystrophy, Dunnigan type</td>
</tr>
<tr>
<td>844</td>
<td>Familial partial lipodystrophy type 2</td>
</tr>
<tr>
<td>845</td>
<td>Dunnigan syndrome</td>
</tr>
<tr>
<td>846</td>
<td>FPLD2 - [Familial partial lipodystrophy type 2]</td>
</tr>
<tr>
<td>847</td>
<td>Familial partial lipodystrophy associated with PPARG mutations</td>
</tr>
<tr>
<td>848</td>
<td>Familial partial lipodystrophy type 3</td>
</tr>
<tr>
<td>849</td>
<td>FPLD3 - [Familial partial lipodystrophy type 3]</td>
</tr>
<tr>
<td>850</td>
<td>Familial partial lipodystrophy due to AKT2 mutations</td>
</tr>
<tr>
<td>851</td>
<td>Familial partial lipodystrophy due to lamin-A mutations</td>
</tr>
<tr>
<td>852</td>
<td>Severe lipodystrophic laminopathy</td>
</tr>
<tr>
<td>853</td>
<td>Familial partial lipodystrophy associated with PLIN1 mutations</td>
</tr>
<tr>
<td>854</td>
<td>Acquired generalised lipodystrophy</td>
</tr>
<tr>
<td>855</td>
<td>Metabolic syndrome</td>
</tr>
<tr>
<td>856</td>
<td>metabolic syndrome NOS</td>
</tr>
<tr>
<td>857</td>
<td>Testicular hypofunction</td>
</tr>
<tr>
<td>858</td>
<td>hypofunction testicle</td>
</tr>
<tr>
<td>859</td>
<td>gonadal insufficiency of testis</td>
</tr>
<tr>
<td>860</td>
<td>Testicular hypogonadism NOS</td>
</tr>
<tr>
<td>861</td>
<td>undeveloped testis</td>
</tr>
<tr>
<td>862</td>
<td>testicular hypogonadism</td>
</tr>
<tr>
<td>863</td>
<td>male hypogonadism</td>
</tr>
<tr>
<td>864</td>
<td>prepuberal castrate syndrome</td>
</tr>
<tr>
<td>865</td>
<td>eunuchoidism</td>
</tr>
<tr>
<td>866</td>
<td>deficiency of testicular hormone</td>
</tr>
<tr>
<td>867</td>
<td>androgen deficiency</td>
</tr>
<tr>
<td>868</td>
<td>5-alpha-reductase deficiency with male pseudohermaphroditism</td>
</tr>
<tr>
<td>869</td>
<td>defect of testicular androgen synthesis</td>
</tr>
<tr>
<td>870</td>
<td>5-alpha-reductase deficiency</td>
</tr>
<tr>
<td>871</td>
<td>Male infertility due to a systemic disease</td>
</tr>
<tr>
<td>872</td>
<td>Male infertility with normal virilization due to a systemic disease</td>
</tr>
<tr>
<td>873</td>
<td>Male infertility with normal virilization due to acquired testicular defects</td>
</tr>
<tr>
<td>874</td>
<td>Defective biosynthesis of testosterone in aged men</td>
</tr>
<tr>
<td>875</td>
<td>Testicular hypogonadism in aged men</td>
</tr>
<tr>
<td>876</td>
<td>defective biosynthesis of testicular androgen</td>
</tr>
<tr>
<td>877</td>
<td>Defective biosynthesis of testicular androgen NOS</td>
</tr>
<tr>
<td>878</td>
<td>deficiency of testosterone biosynthesis</td>
</tr>
<tr>
<td>879</td>
<td>Male infertility associated with autoimmunity</td>
</tr>
<tr>
<td>880</td>
<td>Male infertility with normal virilisation due to acquired testicular defect associated with autoimmunity</td>
</tr>
<tr>
<td>881</td>
<td>Male infertility associated with drug</td>
</tr>
<tr>
<td>882</td>
<td>Male infertility with normal virilisation due to acquired testicular defect associated with drug</td>
</tr>
<tr>
<td>883</td>
<td>Drug induced testicular hypofunction</td>
</tr>
<tr>
<td>884</td>
<td>Male infertility associated with environmental toxin</td>
</tr>
<tr>
<td>885</td>
<td>Male infertility with normal virilisation due to acquired testicular defect associated with environmental toxin</td>
</tr>
<tr>
<td>886</td>
<td>Male infertility associated with mycoplasma infection</td>
</tr>
<tr>
<td>887</td>
<td>Male infertility associated with radiation</td>
</tr>
<tr>
<td>888</td>
<td>Male infertility with normal virilisation due to acquired testicular defect associated with radiation</td>
</tr>
<tr>
<td>889</td>
<td>Male infertility associated with spinal cord injury</td>
</tr>
<tr>
<td>890</td>
<td>Male infertility with normal virilisation due to testicular defect associated with spinal cord injury</td>
</tr>
<tr>
<td>891</td>
<td>Male infertility with normal virilization due to developmental or structural testicular defects</td>
</tr>
<tr>
<td>892</td>
<td>Chromosome Y deletion</td>
</tr>
<tr>
<td>893</td>
<td>Male sterility due to chromosome Y deletion</td>
</tr>
<tr>
<td>894</td>
<td>Partial chromosome Y deletion</td>
</tr>
<tr>
<td>895</td>
<td>Male infertility associated with cryptorchidism</td>
</tr>
<tr>
<td>896</td>
<td>Male infertility with normal virilisation due to developmental or structural testicular defect associated with cryptorchidism</td>
</tr>
<tr>
<td>897</td>
<td>Male infertility associated with varicocele</td>
</tr>
<tr>
<td>898</td>
<td>Male infertility with normal virilisation due to a developmental or structural testicular defect associated with varicocele</td>
</tr>
<tr>
<td>899</td>
<td>Sertoli cell only syndrome</td>
</tr>
<tr>
<td>900</td>
<td>Secondary syphilis of skin or mucous membranes</td>
</tr>
<tr>
<td>901</td>
<td>Mucocutaneous secondary syphilis</td>
</tr>
<tr>
<td>902</td>
<td>Macular syphilide</td>
</tr>
<tr>
<td>903</td>
<td>Papular syphilide</td>
</tr>
<tr>
<td>904</td>
<td>Oral mucosal secondary syphilis</td>
</tr>
<tr>
<td>905</td>
<td>Secondary syphilis of mouth</td>
</tr>
<tr>
<td>906</td>
<td>Syphilitic snail-track ulcers</td>
</tr>
<tr>
<td>907</td>
<td>Syphilitic mucous patches</td>
</tr>
<tr>
<td>908</td>
<td>Condylomata lata</td>
</tr>
<tr>
<td>909</td>
<td>Condyloma latum</td>
</tr>
<tr>
<td>910</td>
<td>Secondary syphilis of anus</td>
</tr>
<tr>
<td>911</td>
<td>Secondary syphilis of vulva</td>
</tr>
<tr>
<td>912</td>
<td>Cutaneous complications of secondary syphilis</td>
</tr>
<tr>
<td>913</td>
<td>Lues maligna</td>
</tr>
<tr>
<td>914</td>
<td>Syphilitic leukoderma</td>
</tr>
<tr>
<td>915</td>
<td>Syphilitic alopecia</td>
</tr>
<tr>
<td>916</td>
<td>Chronic kidney disease, stage 3a</td>
</tr>
<tr>
<td>917</td>
<td>chronic renal failure, stage 3a</td>
</tr>
<tr>
<td>918</td>
<td>CKD - [chronic kidney disease] stage 3a</td>
</tr>
<tr>
<td>919</td>
<td>chronic kidney disease stage 3 NOS</td>
</tr>
<tr>
<td>920</td>
<td>eGFR - [estimated glomerular filtration rate] 45-59 ml/min/1.73m²</td>
</tr>
<tr>
<td>921</td>
<td>Other specified problems associated with upbringing</td>
</tr>
<tr>
<td>922</td>
<td>Lack of learning or play experience</td>
</tr>
<tr>
<td>923</td>
<td>Problem with a parenting situation</td>
</tr>
<tr>
<td>924</td>
<td>problem with atypical parenting situation</td>
</tr>
<tr>
<td>925</td>
<td>Extravasation of urine</td>
</tr>
<tr>
<td>926</td>
<td>leakage of urine</td>
</tr>
<tr>
<td>927</td>
<td>Rupture of a renal calyx</td>
</tr>
<tr>
<td>928</td>
<td>Rupture of a renal fornix</td>
</tr>
<tr>
<td>929</td>
<td>Fabry disease</td>
</tr>
<tr>
<td>930</td>
<td>Anderson-Fabry disease</td>
</tr>
<tr>
<td>931</td>
<td>Ceramide trihexosidase deficiency</td>
</tr>
<tr>
<td>932</td>
<td>Alpha-galactosidase A deficiency</td>
</tr>
<tr>
<td>933</td>
<td>Fabry disease X-linked</td>
</tr>
<tr>
<td>934</td>
<td>X-linked dominant Fabry disease</td>
</tr>
<tr>
<td>935</td>
<td>X-linked recessive Fabry disease</td>
</tr>
<tr>
<td>936</td>
<td>Angiokeratoma corporis diffusum</td>
</tr>
<tr>
<td>937</td>
<td>Lichen sclerosus, unspecified</td>
</tr>
<tr>
<td>938</td>
<td>Lichen sclerosus</td>
</tr>
<tr>
<td>939</td>
<td>LS et A - [Lichen sclerosus et atrophicus]</td>
</tr>
<tr>
<td>940</td>
<td>Lichen sclerosus et atrophicus</td>
</tr>
<tr>
<td>941</td>
<td>Lichen albus</td>
</tr>
<tr>
<td>942</td>
<td>Structural device failure, as mode of injury or harm</td>
</tr>
<tr>
<td>943</td>
<td>part failure of a structural device as a mode of injury</td>
</tr>
<tr>
<td>944</td>
<td>structural device component failure as a mode of injury</td>
</tr>
<tr>
<td>945</td>
<td>structural device design failure as a mode of injury</td>
</tr>
<tr>
<td>946</td>
<td>manufacturing fault of a structural device as a mode of injury</td>
</tr>
<tr>
<td>947</td>
<td>leakage of a device</td>
</tr>
<tr>
<td>948</td>
<td>defective component as mode of injury</td>
</tr>
<tr>
<td>949</td>
<td>defective device as mode of injury</td>
</tr>
<tr>
<td>950</td>
<td>crack in device</td>
</tr>
<tr>
<td>951</td>
<td>broken device</td>
</tr>
<tr>
<td>952</td>
<td>chip in device</td>
</tr>
<tr>
<td>953</td>
<td>Leakage from device, as mode of injury or harm</td>
</tr>
<tr>
<td>954</td>
<td>Wear, breakage or breakdown of device, as mode of injury or harm</td>
</tr>
<tr>
<td>955</td>
<td>Breakdown of intraocular lens</td>
</tr>
<tr>
<td>956</td>
<td>mechanical breakdown of intraocular lens as mode of injury</td>
</tr>
<tr>
<td>957</td>
<td>Dominant limb-girdle muscular dystrophy</td>
</tr>
<tr>
<td>958</td>
<td>LGMD1 - [limb-girdle muscular dystrophy] 1</td>
</tr>
<tr>
<td>959</td>
<td>Limb-girdle muscular dystrophy 1A, myotilin myopathy</td>
</tr>
<tr>
<td>960</td>
<td>LGMD 1A - [Limb-girdle muscular dystrophy 1A, myotilin myopathy]</td>
</tr>
<tr>
<td>961</td>
<td>Limb-girdle muscular dystrophy 1B, lamin myopathy</td>
</tr>
<tr>
<td>962</td>
<td>LGMD 1B - [Limb-girdle muscular dystrophy 1B, lamin myopathy]</td>
</tr>
<tr>
<td>963</td>
<td>Limb-girdle muscular dystrophy 1C, caveolin myopathy</td>
</tr>
<tr>
<td>964</td>
<td>LGMD 1C - [Limb-girdle muscular dystrophy 1C, caveolin myopathy]</td>
</tr>
<tr>
<td>965</td>
<td>Limb-girdle muscular dystrophy 1D, gene mapped to 6q23</td>
</tr>
<tr>
<td>966</td>
<td>Limb-girdle muscular dystrophy 1E, gene mapped to 7q</td>
</tr>
<tr>
<td>967</td>
<td>Limb-girdle muscular dystrophy 1F, gene mapped to 7q32.1-32.2</td>
</tr>
<tr>
<td>968</td>
<td>Limb-girdle muscular dystrophy 1G, gene mapped to 4q21</td>
</tr>
<tr>
<td>969</td>
<td>Limb-girdle muscular dystrophy 1H, gene mapped to 3p25.1p23</td>
</tr>
<tr>
<td>970</td>
<td>LGMD1H - [Limb-girdle muscular dystrophy] 1H</td>
</tr>
<tr>
<td>971</td>
<td>Problem of unspecified body part</td>
</tr>
<tr>
<td>972</td>
<td>Symptom or complaint of a body part</td>
</tr>
<tr>
<td>973</td>
<td>Hypersomnia associated with a mental disorder</td>
</tr>
<tr>
<td>974</td>
<td>hypersomnolence associated with a mental disorder</td>
</tr>
<tr>
<td>975</td>
<td>Female infertility without specification whether primary or secondary</td>
</tr>
<tr>
<td>976</td>
<td>Female infertility</td>
</tr>
<tr>
<td>977</td>
<td>female infertility of unspecified origin</td>
</tr>
<tr>
<td>978</td>
<td>female sterility NOS</td>
</tr>
<tr>
<td>979</td>
<td>inability to achieve a pregnancy</td>
</tr>
<tr>
<td>980</td>
<td>Female infertility associated with ovarian dysfunction</td>
</tr>
<tr>
<td>981</td>
<td>anovulatory infertility</td>
</tr>
<tr>
<td>982</td>
<td>female infertility associated with anovulation</td>
</tr>
<tr>
<td>983</td>
<td>female infertility associated with anovulatory cycle</td>
</tr>
<tr>
<td>984</td>
<td>female infertility of anovulatory origin</td>
</tr>
<tr>
<td>985</td>
<td>anovular cycle</td>
</tr>
<tr>
<td>986</td>
<td>anovulatory</td>
</tr>
<tr>
<td>987</td>
<td>anovulatory cycle</td>
</tr>
<tr>
<td>988</td>
<td>anovulatory period</td>
</tr>
<tr>
<td>989</td>
<td>failure or lack of ovulation</td>
</tr>
<tr>
<td>990</td>
<td>lack of ovulation</td>
</tr>
<tr>
<td>991</td>
<td>nonovulation</td>
</tr>
<tr>
<td>992</td>
<td>Female infertility associated with male factors</td>
</tr>
<tr>
<td>993</td>
<td>failure to conceive due to infertility of male partner</td>
</tr>
<tr>
<td>994</td>
<td>Female infertility associated with female sexual dysfunction</td>
</tr>
<tr>
<td>995</td>
<td>Female infertility associated with male sexual dysfunction</td>
</tr>
<tr>
<td>996</td>
<td>Female infertility of cervical origin</td>
</tr>
<tr>
<td>997</td>
<td>Female infertility associated with vaginal disease or anomaly</td>
</tr>
<tr>
<td>998</td>
<td>Female infertility of genetic origin</td>
</tr>
<tr>
<td>999</td>
<td>Unexplained female infertility</td>
</tr>
<tr>
<td>1000</td>
<td>Hereditary skin peeling</td>
</tr>
<tr>
<td>1001</td>
<td>Generalised non-inflammatory peeling skin syndrome</td>
</tr>
<tr>
<td>1002</td>
<td>Peeling skin syndrome, type A</td>
</tr>
<tr>
<td>1003</td>
<td>Generalised inflammatory peeling skin syndrome</td>
</tr>
<tr>
<td>1004</td>
<td>Peeling skin syndrome, type B</td>
</tr>
<tr>
<td>1005</td>
<td>Acral skin peeling syndrome</td>
</tr>
<tr>
<td>1006</td>
<td>APSS</td>
</tr>
<tr>
<td>1007</td>
<td>Other specified arthrogryposis syndromes</td>
</tr>
<tr>
<td>1008</td>
<td>Popliteal pterygium syndrome</td>
</tr>
<tr>
<td>1009</td>
<td>Popliteal web syndrome</td>
</tr>
<tr>
<td>1010</td>
<td>Bartsocas-Papas syndrome</td>
</tr>
<tr>
<td>1011</td>
<td>Autosomal dominant popliteal pterygium syndrome</td>
</tr>
<tr>
<td>1012</td>
<td>Lethal congenital contracture syndrome</td>
</tr>
<tr>
<td>1013</td>
<td>Lethal congenital contracture syndrome type 1</td>
</tr>
<tr>
<td>1014</td>
<td>Lethal congenital contracture syndrome type 2</td>
</tr>
<tr>
<td>1015</td>
<td>Lethal congenital contracture syndrome type 3</td>
</tr>
<tr>
<td>1016</td>
<td>Distal arthrogryposis</td>
</tr>
<tr>
<td>1017</td>
<td>Digitotalar dysmorphism</td>
</tr>
<tr>
<td>1018</td>
<td>Distal arthrogryposis type 1</td>
</tr>
<tr>
<td>1019</td>
<td>Freeman-Sheldon syndrome</td>
</tr>
<tr>
<td>1020</td>
<td>Distal arthrogryposis type 2A</td>
</tr>
<tr>
<td>1021</td>
<td>Craniocarpotarsal dysplasia</td>
</tr>
<tr>
<td>1022</td>
<td>Craniocarpotarsal dystrophy</td>
</tr>
<tr>
<td>1023</td>
<td>Whistling face syndrome</td>
</tr>
<tr>
<td>1024</td>
<td>Sheldon-Hall syndrome</td>
</tr>
<tr>
<td>1025</td>
<td>Distal arthrogryposis type 2B</td>
</tr>
<tr>
<td>1026</td>
<td>Distal arthrogryposis type 3</td>
</tr>
<tr>
<td>1027</td>
<td>Arthrogryposis - severe scoliosis</td>
</tr>
<tr>
<td>1028</td>
<td>Distal arthrogryposis type 4</td>
</tr>
<tr>
<td>1029</td>
<td>Arthrogryposis - ophthalmoplegia - retinopathy</td>
</tr>
<tr>
<td>1030</td>
<td>Distal arthrogryposis type 5</td>
</tr>
<tr>
<td>1031</td>
<td>Arthrogryposis-like hand anomaly - sensorineural deafness</td>
</tr>
<tr>
<td>1032</td>
<td>Distal arthrogryposis type 6</td>
</tr>
<tr>
<td>1033</td>
<td>Trismus - pseudocamptodactyly</td>
</tr>
<tr>
<td>1034</td>
<td>Distal arthrogryposis type 7</td>
</tr>
<tr>
<td>1035</td>
<td>Hecht syndrome</td>
</tr>
<tr>
<td>1036</td>
<td>Acute monoblastic or monocytic leukaemia</td>
</tr>
<tr>
<td>1037</td>
<td>FAB M5</td>
</tr>
<tr>
<td>1038</td>
<td>acute monocytic leukaemia</td>
</tr>
<tr>
<td>1039</td>
<td>acute monocytic/monoblastic leukaemia</td>
</tr>
<tr>
<td>1040</td>
<td>acute monoblastic/monocytic leukaemia without mention of remission</td>
</tr>
<tr>
<td>1041</td>
<td>acute monocytoid leukaemia</td>
</tr>
<tr>
<td>1042</td>
<td>monoblastic leukaemia</td>
</tr>
<tr>
<td>1043</td>
<td>FAB type M5a</td>
</tr>
<tr>
<td>1044</td>
<td>French-American-British (FAB) type M5a</td>
</tr>
<tr>
<td>1045</td>
<td>Acute monoblastic or monocytic leukaemia in complete remission</td>
</tr>
<tr>
<td>1046</td>
<td>AML M5a</td>
</tr>
<tr>
<td>1047</td>
<td>AML M5b</td>
</tr>
<tr>
<td>1048</td>
<td>Acute hepatitis A</td>
</tr>
<tr>
<td>1049</td>
<td>Acute hepatitis A virus infection</td>
</tr>
<tr>
<td>1050</td>
<td>Hyperprolactinaemia</td>
</tr>
<tr>
<td>1051</td>
<td>Drug-induced hyperprolactinaemia</td>
</tr>
<tr>
<td>1052</td>
<td>Hypothyroidism-associated hyperprolactinemia</td>
</tr>
<tr>
<td>1053</td>
<td>Functional hyperprolactinoma</td>
</tr>
<tr>
<td>1054</td>
<td>Chiari-Frommel Syndrome</td>
</tr>
<tr>
<td>1055</td>
<td>Argonz-del Castillo Syndrome</td>
</tr>
<tr>
<td>1056</td>
<td>Ahumada-Del Castillo syndrome</td>
</tr>
<tr>
<td>1057</td>
<td>amenorrhoea-galactorrhoea syndrome</td>
</tr>
<tr>
<td>1058</td>
<td>non-pregnancy related a-g syndrome</td>
</tr>
<tr>
<td>1059</td>
<td>Hyperprolactinemia caused by other hypothalamo-pituitary disorders</td>
</tr>
<tr>
<td>1060</td>
<td>Macroprolactinaemia</td>
</tr>
<tr>
<td>1061</td>
<td>Waardenburg-Shah syndrome</td>
</tr>
<tr>
<td>1062</td>
<td>Waardenburg syndrome type 4A</td>
</tr>
<tr>
<td>1063</td>
<td>Hirschsprung disease with pigmentary anomaly</td>
</tr>
<tr>
<td>1064</td>
<td>Waardenburg-Shah syndrome, neurologic variant</td>
</tr>
<tr>
<td>1065</td>
<td>Vertical gaze palsy</td>
</tr>
<tr>
<td>1066</td>
<td>Paralysis of downgaze</td>
</tr>
<tr>
<td>1067</td>
<td>Paralysis of upgaze</td>
</tr>
<tr>
<td>1068</td>
<td>Paralysis of combined upgaze and downgaze</td>
</tr>
<tr>
<td>1069</td>
<td>Vertical one-and-a-half syndrome</td>
</tr>
<tr>
<td>1070</td>
<td>Dorsal midbrain syndrome</td>
</tr>
<tr>
<td>1071</td>
<td>Parinaud’s syndrome</td>
</tr>
<tr>
<td>1072</td>
<td>pretectal syndrome</td>
</tr>
<tr>
<td>1073</td>
<td>Sylvian aqueduct syndrome</td>
</tr>
<tr>
<td>1074</td>
<td>Koerber-Salus-Elschnig syndrome</td>
</tr>
<tr>
<td>1075</td>
<td>Other specified sphingolipidosis</td>
</tr>
<tr>
<td>1076</td>
<td>Mucolipidosis type 4</td>
</tr>
<tr>
<td>1077</td>
<td>Sialolipidosis</td>
</tr>
<tr>
<td>1078</td>
<td>Gaucher disease</td>
</tr>
<tr>
<td>1079</td>
<td>Acid beta-glucosidase deficiency</td>
</tr>
<tr>
<td>1080</td>
<td>Glucocerebrosidase deficiency</td>
</tr>
<tr>
<td>1081</td>
<td>Glucosylceramide beta-glucosidase deficiency</td>
</tr>
<tr>
<td>1082</td>
<td>Glucocerebrosidosis</td>
</tr>
<tr>
<td>1083</td>
<td>Cerebroside lipidosis syndrome</td>
</tr>
<tr>
<td>1084</td>
<td>Gaucher disease type 1</td>
</tr>
<tr>
<td>1085</td>
<td>Noncerebral juvenile Gaucher disease</td>
</tr>
<tr>
<td>1086</td>
<td>Adult Gaucher disease</td>
</tr>
<tr>
<td>1087</td>
<td>Gaucher disease type 2</td>
</tr>
<tr>
<td>1088</td>
<td>Acute neuronopathic Gaucher disease</td>
</tr>
<tr>
<td>1089</td>
<td>Infantile cerebral Gaucher disease</td>
</tr>
<tr>
<td>1090</td>
<td>Infantile Gaucher disease</td>
</tr>
<tr>
<td>1091</td>
<td>Cerebral acute Gaucher disease</td>
</tr>
<tr>
<td>1092</td>
<td>Gaucher disease type 3</td>
</tr>
<tr>
<td>1093</td>
<td>Cerebral juvenile and adult form of Gaucher disease</td>
</tr>
<tr>
<td>1094</td>
<td>Chronic neuronopathic Gaucher disease</td>
</tr>
<tr>
<td>1095</td>
<td>Subacute neuronopathic Gaucher disease</td>
</tr>
<tr>
<td>1096</td>
<td>Juvenile Gaucher disease</td>
</tr>
<tr>
<td>1097</td>
<td>Norrbotnian Gaucher disease</td>
</tr>
<tr>
<td>1098</td>
<td>Gaucher disease - ophthalmoplegia - cardiovascular calcification</td>
</tr>
<tr>
<td>1099</td>
<td>Cardiovascular Gaucher disease</td>
</tr>
<tr>
<td>1100</td>
<td>Gaucher disease type 3C</td>
</tr>
<tr>
<td>1101</td>
<td>Gaucher-like disease</td>
</tr>
<tr>
<td>1102</td>
<td>Perinatal-lethal Gaucher disease</td>
</tr>
<tr>
<td>1103</td>
<td>Fetal Gaucher disease</td>
</tr>
<tr>
<td>1104</td>
<td>Collodion type Gaucher disease</td>
</tr>
<tr>
<td>1105</td>
<td>Atypical Gaucher disease due to saposin C deficiency</td>
</tr>
<tr>
<td>1106</td>
<td>Gaucher’s splenomegaly</td>
</tr>
<tr>
<td>1107</td>
<td>Mucosulfatidosis</td>
</tr>
<tr>
<td>1108</td>
<td>Multiple sulfatase deficiency</td>
</tr>
<tr>
<td>1109</td>
<td>Juvenile sulfatidose, Austin type</td>
</tr>
<tr>
<td>1110</td>
<td>Austin disease</td>
</tr>
<tr>
<td>1111</td>
<td>Niemann-Pick disease</td>
</tr>
<tr>
<td>1112</td>
<td>Sphingomyelinase deficiency</td>
</tr>
<tr>
<td>1113</td>
<td>Niemann-Pick disease type A</td>
</tr>
<tr>
<td>1114</td>
<td>Niemann-Pick disease type B</td>
</tr>
<tr>
<td>1115</td>
<td>Niemann-Pick disease type C</td>
</tr>
<tr>
<td>1116</td>
<td>cholesterol transporter deficiency</td>
</tr>
<tr>
<td>1117</td>
<td>Niemann-Pick disease type C, severe perinatal</td>
</tr>
<tr>
<td>1118</td>
<td>Niemann-Pick disease type C, severe early infantile neurologic onset</td>
</tr>
<tr>
<td>1119</td>
<td>Niemann-Pick disease type C, late infantile neurologic onset</td>
</tr>
<tr>
<td>1120</td>
<td>Niemann-Pick disease type C, juvenile neurologic onset</td>
</tr>
<tr>
<td>1121</td>
<td>Niemann-Pick disease type C, classic form</td>
</tr>
<tr>
<td>1122</td>
<td>Niemann-Pick disease type C, adult neurologic onset</td>
</tr>
<tr>
<td>1123</td>
<td>Farber disease</td>
</tr>
<tr>
<td>1124</td>
<td>Farber lipogranulomatosis</td>
</tr>
<tr>
<td>1125</td>
<td>Ceramidase deficiency</td>
</tr>
<tr>
<td>1126</td>
<td>Disseminated lipogranulomatosis</td>
</tr>
<tr>
<td>1127</td>
<td>Lysosomal acid lipase deficiency</td>
</tr>
<tr>
<td>1128</td>
<td>Acid esterase deficiency</td>
</tr>
<tr>
<td>1129</td>
<td>Wolman disease</td>
</tr>
<tr>
<td>1130</td>
<td>Cholesteryl ester storage disease</td>
</tr>
<tr>
<td>1131</td>
<td>CESD - [Cholesteryl ester storage disease]</td>
</tr>
<tr>
<td>1132</td>
<td>Encephalopathy due to prosaposin deficiency</td>
</tr>
<tr>
<td>1133</td>
<td>Combined prosaposin deficiency</td>
</tr>
<tr>
<td>1134</td>
<td>Congenital anomaly of a ventricle or the ventricular septum, unspecified</td>
</tr>
<tr>
<td>1135</td>
<td>Congenital anomaly of a ventricle or the ventricular septum</td>
</tr>
<tr>
<td>1136</td>
<td>Syndromes with lissencephaly as a major feature</td>
</tr>
<tr>
<td>1137</td>
<td>Pachygyria</td>
</tr>
<tr>
<td>1138</td>
<td>Agyria</td>
</tr>
<tr>
<td>1139</td>
<td>Classic lissencephaly</td>
</tr>
<tr>
<td>1140</td>
<td>Lissencephaly type 1</td>
</tr>
<tr>
<td>1141</td>
<td>Lissencephaly type 1 due to doublecortin gene mutation</td>
</tr>
<tr>
<td>1142</td>
<td>Subcortical band heterotopia</td>
</tr>
<tr>
<td>1143</td>
<td>Miller-Dieker syndrome</td>
</tr>
<tr>
<td>1144</td>
<td>Lissencephaly due to 17p13.3 deletion</td>
</tr>
<tr>
<td>1145</td>
<td>17p13.3 microdeletion syndrome</td>
</tr>
<tr>
<td>1146</td>
<td>Telomeric deletion 17p</td>
</tr>
<tr>
<td>1147</td>
<td>Monosomy 17p13.3</td>
</tr>
<tr>
<td>1148</td>
<td>17p13.3 deletion</td>
</tr>
<tr>
<td>1149</td>
<td>Lissencephaly type 1 due to LIS1 gene mutation</td>
</tr>
<tr>
<td>1150</td>
<td>Isolated lissencephaly type 1 without known genetic defects</td>
</tr>
<tr>
<td>1151</td>
<td>Lissencephaly type 2</td>
</tr>
<tr>
<td>1152</td>
<td>Lissencephaly type 3</td>
</tr>
<tr>
<td>1153</td>
<td>Neu-Laxova syndrome</td>
</tr>
<tr>
<td>1154</td>
<td>Lissencephaly type 3 - familial fetal akinesia sequence</td>
</tr>
<tr>
<td>1155</td>
<td>Lissencephaly type 3 - metacarpal bone dysplasia</td>
</tr>
<tr>
<td>1156</td>
<td>Lissencephaly with cerebellar hypoplasia</td>
</tr>
<tr>
<td>1157</td>
<td>Lissencephaly with cerebellar hypoplasia type A</td>
</tr>
<tr>
<td>1158</td>
<td>Lissencephaly with cerebellar hypoplasia type B</td>
</tr>
<tr>
<td>1159</td>
<td>Lissencephaly with cerebellar hypoplasia type C</td>
</tr>
<tr>
<td>1160</td>
<td>Lissencephaly with cerebellar hypoplasia type D</td>
</tr>
<tr>
<td>1161</td>
<td>Lissencephaly with cerebellar hypoplasia type E</td>
</tr>
<tr>
<td>1162</td>
<td>Lissencephaly with cerebellar hypoplasia type F</td>
</tr>
<tr>
<td>1163</td>
<td>Microlissencephaly</td>
</tr>
<tr>
<td>1164</td>
<td>Microlissencephaly type A</td>
</tr>
<tr>
<td>1165</td>
<td>Lissencephaly syndrome, Norman-Roberts type</td>
</tr>
<tr>
<td>1166</td>
<td>Microlissencephaly type B</td>
</tr>
<tr>
<td>1167</td>
<td>Lissencephaly due to TUBA1A gene mutation</td>
</tr>
<tr>
<td>1168</td>
<td>X-linked lissencephaly - agenesis of corpus callosum - genital anomalies</td>
</tr>
<tr>
<td>1169</td>
<td>Craniotelencephalic dysplasia</td>
</tr>
<tr>
<td>1170</td>
<td>Micro syndrome</td>
</tr>
<tr>
<td>1171</td>
<td>Warburg Micro syndrome</td>
</tr>
<tr>
<td>1172</td>
<td>WARBM1 - [Warburg Micro syndrome]</td>
</tr>
<tr>
<td>1173</td>
<td>Iris coloboma with ptosis - intellectual deficit</td>
</tr>
<tr>
<td>1174</td>
<td>Harmful effects of drugs, medicaments or biological substances, not elsewhere classified</td>
</tr>
<tr>
<td>1175</td>
<td>drugs, medicaments or biological substances, toxicity not elsewhere classified</td>
</tr>
<tr>
<td>1176</td>
<td>adverse drug effects</td>
</tr>
<tr>
<td>1177</td>
<td>drug reaction NOS</td>
</tr>
<tr>
<td>1178</td>
<td>drug allergy NOS</td>
</tr>
<tr>
<td>1179</td>
<td>drug toxicity NOS</td>
</tr>
<tr>
<td>1180</td>
<td>drug ingestion NOS</td>
</tr>
<tr>
<td>1181</td>
<td>toxic effects of drugs NOS</td>
</tr>
<tr>
<td>1182</td>
<td>acute drug intoxication</td>
</tr>
<tr>
<td>1183</td>
<td>toxic use of drugs</td>
</tr>
<tr>
<td>1184</td>
<td>intake of a toxic substance</td>
</tr>
<tr>
<td>1185</td>
<td>Harmful effects of opioids or related analgesics</td>
</tr>
<tr>
<td>1186</td>
<td>Harmful effects of opium</td>
</tr>
<tr>
<td>1187</td>
<td>Harmful effects of morphine</td>
</tr>
<tr>
<td>1188</td>
<td>Harmful effects of oxycodone</td>
</tr>
<tr>
<td>1189</td>
<td>oxycodone toxicity</td>
</tr>
<tr>
<td>1190</td>
<td>Harmful effects of codeine</td>
</tr>
<tr>
<td>1191</td>
<td>Harmful effects of heroin</td>
</tr>
<tr>
<td>1192</td>
<td>poisoning by diacetylmorphine</td>
</tr>
<tr>
<td>1193</td>
<td>poisoning by heroin</td>
</tr>
<tr>
<td>1194</td>
<td>poisoning by heroin NOS</td>
</tr>
<tr>
<td>1195</td>
<td>acute heroin intoxication</td>
</tr>
<tr>
<td>1196</td>
<td>acute heroin toxicity</td>
</tr>
<tr>
<td>1197</td>
<td>toxic effects of heroin</td>
</tr>
<tr>
<td>1198</td>
<td>Harmful effects of methadone</td>
</tr>
<tr>
<td>1199</td>
<td>poisoning by methadone</td>
</tr>
<tr>
<td>1200</td>
<td>poisoning by methadone NOS</td>
</tr>
<tr>
<td>1201</td>
<td>methadone toxicity</td>
</tr>
<tr>
<td>1202</td>
<td>Harmful effects of pethidine</td>
</tr>
<tr>
<td>1203</td>
<td>pethidine poisoning</td>
</tr>
<tr>
<td>1204</td>
<td>Harmful effects of fentanyl</td>
</tr>
<tr>
<td>1205</td>
<td>fentanyl poisoning</td>
</tr>
<tr>
<td>1206</td>
<td>fentanyl toxicity</td>
</tr>
<tr>
<td>1207</td>
<td>toxic effects of fentanyl</td>
</tr>
<tr>
<td>1208</td>
<td>fentanyl toxication</td>
</tr>
<tr>
<td>1209</td>
<td>acute fentanyl toxicity</td>
</tr>
<tr>
<td>1210</td>
<td>Harmful effects of phenoperidine</td>
</tr>
<tr>
<td>1211</td>
<td>phenoperidine poisoning</td>
</tr>
<tr>
<td>1212</td>
<td>Fentanyl and heroin toxicity</td>
</tr>
<tr>
<td>1213</td>
<td>Harmful effects of sedative hypnotic drugs or other CNS depressants</td>
</tr>
<tr>
<td>1214</td>
<td>Harmful effects of sedative-hypnotic drugs</td>
</tr>
<tr>
<td>1215</td>
<td>hypnotic poisoning</td>
</tr>
<tr>
<td>1216</td>
<td>sleeping draught NOS poisoning</td>
</tr>
<tr>
<td>1217</td>
<td>sleeping drug NOS poisoning</td>
</tr>
<tr>
<td>1218</td>
<td>sleeping tablet NOS poisoning</td>
</tr>
<tr>
<td>1219</td>
<td>Harmful effects of barbiturates</td>
</tr>
<tr>
<td>1220</td>
<td>Harmful effects of benzodiazepines</td>
</tr>
<tr>
<td>1221</td>
<td>Harmful effects of chlordiazepoxide</td>
</tr>
<tr>
<td>1222</td>
<td>chlordiazepoxide poisoning</td>
</tr>
<tr>
<td>1223</td>
<td>Harmful effects of clozapine</td>
</tr>
<tr>
<td>1224</td>
<td>clozapine poisoning</td>
</tr>
<tr>
<td>1225</td>
<td>Harmful effects of cloral derivatives</td>
</tr>
<tr>
<td>1226</td>
<td>Harmful effects of paraldehyde</td>
</tr>
<tr>
<td>1227</td>
<td>Harmful effects of bromine compounds</td>
</tr>
<tr>
<td>1228</td>
<td>Harmful effects of mixed sedatives or hypnotics, not elsewhere classified</td>
</tr>
<tr>
<td>1229</td>
<td>Harmful effects of anaesthetics or therapeutic gases</td>
</tr>
<tr>
<td>1230</td>
<td>Harmful effects of anaesthetics or therapeutic gases, nitrous oxide</td>
</tr>
<tr>
<td>1231</td>
<td>Harmful effects of anaesthetics or therapeutic gases, other inhaled anaesthetics</td>
</tr>
<tr>
<td>1232</td>
<td>Harmful effects of anaesthetics or therapeutic gases, intravenous anaesthetics</td>
</tr>
<tr>
<td>1233</td>
<td>Harmful effects of anaesthetics or therapeutic gases, unspecified general anaesthetics</td>
</tr>
<tr>
<td>1234</td>
<td>Harmful effects of anaesthetics or therapeutic gases, gamma hydroxybutyrate</td>
</tr>
<tr>
<td>1235</td>
<td>Harmful effects of anaesthetics or therapeutic gases, ketamine</td>
</tr>
<tr>
<td>1236</td>
<td>ketamine poisoning</td>
</tr>
<tr>
<td>1237</td>
<td>Harmful effects of anaesthetics or therapeutic gases, other specified general anaesthetic</td>
</tr>
<tr>
<td>1238</td>
<td>Harmful effects of anaesthetics or therapeutic gases, local anaesthetics</td>
</tr>
<tr>
<td>1239</td>
<td>Harmful effects of cinchocaine</td>
</tr>
<tr>
<td>1240</td>
<td>cinchocaine poisoning</td>
</tr>
<tr>
<td>1241</td>
<td>Harmful effects of oxybuprocaine</td>
</tr>
<tr>
<td>1242</td>
<td>oxybuprocaine poisoning</td>
</tr>
<tr>
<td>1243</td>
<td>Harmful effects of psychostimulants</td>
</tr>
<tr>
<td>1244</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Central nervous system stimulants, not elsewhere classified</td>
</tr>
<tr>
<td>1245</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Analeptics</td>
</tr>
<tr>
<td>1246</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Opioid receptor antagonists</td>
</tr>
<tr>
<td>1247</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Caffeine</td>
</tr>
<tr>
<td>1248</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Amphetamine</td>
</tr>
<tr>
<td>1249</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Methylamphetamine</td>
</tr>
<tr>
<td>1250</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Methylenedioxy methamphetamine</td>
</tr>
<tr>
<td>1251</td>
<td>methamphetamine toxicity</td>
</tr>
<tr>
<td>1252</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Other specified amphetamines</td>
</tr>
<tr>
<td>1253</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Cocaine</td>
</tr>
<tr>
<td>1254</td>
<td>poisoning by cocaine NOS</td>
</tr>
<tr>
<td>1255</td>
<td>cocaine toxicity</td>
</tr>
<tr>
<td>1256</td>
<td>acute cocaine toxicity</td>
</tr>
<tr>
<td>1257</td>
<td>toxic effects of cocaine</td>
</tr>
<tr>
<td>1258</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Methylphenidate</td>
</tr>
<tr>
<td>1259</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Cathinone</td>
</tr>
<tr>
<td>1260</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Cathinone derivatives</td>
</tr>
<tr>
<td>1261</td>
<td>Harmful effects of Cannabinoids or hallucinogens</td>
</tr>
<tr>
<td>1262</td>
<td>Harmful effects of Cannabis</td>
</tr>
<tr>
<td>1263</td>
<td>cannabis poisoning</td>
</tr>
<tr>
<td>1264</td>
<td>poisoning by cannabis derivative</td>
</tr>
<tr>
<td>1265</td>
<td>poisoning by marijuana</td>
</tr>
<tr>
<td>1266</td>
<td>poisoning by marijuana derivative</td>
</tr>
<tr>
<td>1267</td>
<td>Harmful effects of synthetic cannabinoids</td>
</tr>
<tr>
<td>1268</td>
<td>Harmful effects of Lysergide</td>
</tr>
<tr>
<td>1269</td>
<td>Harmful effects of unspecified psychodysleptics</td>
</tr>
<tr>
<td>1270</td>
<td>harmful effect of unspecified hallucinogens</td>
</tr>
<tr>
<td>1271</td>
<td>Harmful effects of other psychodysleptics</td>
</tr>
<tr>
<td>1272</td>
<td>Other hallucinogens</td>
</tr>
<tr>
<td>1273</td>
<td>Harmful effects of analgesics, antipyretics or anti-inflammatory drugs</td>
</tr>
<tr>
<td>1274</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, analgesics, antipyretics or anti-inflammatory drugs, Aspirin</td>
</tr>
<tr>
<td>1275</td>
<td>aspirin poisoning</td>
</tr>
<tr>
<td>1276</td>
<td>Harmful effects of other salicylates</td>
</tr>
<tr>
<td>1277</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, analgesics, antipyretics or anti-inflammatory drugs, Paracetamol</td>
</tr>
<tr>
<td>1278</td>
<td>paracetamol poisoning</td>
</tr>
<tr>
<td>1279</td>
<td>Harmful effects of 4-Aminophenol derivatives</td>
</tr>
<tr>
<td>1280</td>
<td>Harmful effects of Pyrazolone derivatives</td>
</tr>
<tr>
<td>1281</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, analgesics, antipyretics or anti-inflammatory drugs, Ibuprofen</td>
</tr>
<tr>
<td>1282</td>
<td>ibuprofen poisoning</td>
</tr>
<tr>
<td>1283</td>
<td>Harmful effects of other propionic acid derivatives</td>
</tr>
<tr>
<td>1284</td>
<td>Harmful effects of Indomethacin</td>
</tr>
<tr>
<td>1285</td>
<td>indometacin poisoning</td>
</tr>
<tr>
<td>1286</td>
<td>indomethacin poisoning</td>
</tr>
<tr>
<td>1287</td>
<td>Harmful effects of other nonsteroidal anti-inflammatory drugs</td>
</tr>
<tr>
<td>1288</td>
<td>poisoning by NSAID - [nonsteroidal anti-inflammatory drugs]</td>
</tr>
<tr>
<td>1289</td>
<td>Harmful effects of etodolac</td>
</tr>
<tr>
<td>1290</td>
<td>etodolac poisoning</td>
</tr>
<tr>
<td>1291</td>
<td>Harmful effects of antirheumatics, not elsewhere classified</td>
</tr>
<tr>
<td>1292</td>
<td>Harmful effects of antidepressants</td>
</tr>
<tr>
<td>1293</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Tricyclic antidepressants</td>
</tr>
<tr>
<td>1294</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Tetracyclic antidepressants</td>
</tr>
<tr>
<td>1295</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Monoamine-oxidase-inhibitor antidepressants</td>
</tr>
<tr>
<td>1296</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Selective serotonin or norepinephrine reuptake inhibitors</td>
</tr>
<tr>
<td>1297</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Selective serotonin reuptake inhibitors</td>
</tr>
<tr>
<td>1298</td>
<td>Harmful effects of antipsychotics</td>
</tr>
<tr>
<td>1299</td>
<td>Harmful effects of phenothiazine antipsychotics or neuroleptics</td>
</tr>
<tr>
<td>1300</td>
<td>Harmful effects of promazine</td>
</tr>
<tr>
<td>1301</td>
<td>promazine poisoning</td>
</tr>
<tr>
<td>1302</td>
<td>Harmful effects of butyrophenone or thiothixene neuroleptics</td>
</tr>
<tr>
<td>1303</td>
<td>Harmful effects of typical, second-generation antipsychotics</td>
</tr>
<tr>
<td>1304</td>
<td>Harmful effects of lithium carbonate</td>
</tr>
<tr>
<td>1305</td>
<td>Harmful effects of antiepileptics or antiparkinsonism drugs</td>
</tr>
<tr>
<td>1306</td>
<td>Harmful effects of hydantoin derivatives</td>
</tr>
<tr>
<td>1307</td>
<td>Harmful effects of iminostilbenes</td>
</tr>
<tr>
<td>1308</td>
<td>Harmful effects of deoxybarbiturates</td>
</tr>
<tr>
<td>1309</td>
<td>Harmful effects of succinimides</td>
</tr>
<tr>
<td>1310</td>
<td>Harmful effects of oxazolidinediones</td>
</tr>
<tr>
<td>1311</td>
<td>Harmful effects of mixed antiepileptics, not elsewhere classified</td>
</tr>
<tr>
<td>1312</td>
<td>Harmful effects of Amantadine</td>
</tr>
<tr>
<td>1313</td>
<td>Harmful effects of Valproic acid</td>
</tr>
<tr>
<td>1314</td>
<td>Harmful effects of L-DOPA</td>
</tr>
<tr>
<td>1315</td>
<td>Harmful effects of Antiparkinsonism drugs or other central muscle-tone depressants, not elsewhere classified</td>
</tr>
<tr>
<td>1316</td>
<td>Harmful effects of antispasticity drugs</td>
</tr>
<tr>
<td>1317</td>
<td>Harmful effects of substances, drugs, medicaments or biological substance, Other or unspecified drugs, medicaments or biological substances</td>
</tr>
<tr>
<td>1318</td>
<td>Harmful effects of systemic antibiotics</td>
</tr>
<tr>
<td>1319</td>
<td>Harmful effects of Penicillins</td>
</tr>
<tr>
<td>1320</td>
<td>poisoning by penicillin</td>
</tr>
<tr>
<td>1321</td>
<td>poisoning by penicillins nos</td>
</tr>
<tr>
<td>1322</td>
<td>Harmful effects of cephalosporins and other beta-lactam antibiotics</td>
</tr>
<tr>
<td>1323</td>
<td>Harmful effects of cefotaxime</td>
</tr>
<tr>
<td>1324</td>
<td>cefotaxime poisoning</td>
</tr>
<tr>
<td>1325</td>
<td>Harmful effects of chloramphenicol group</td>
</tr>
<tr>
<td>1326</td>
<td>chloramphenicol poisoning</td>
</tr>
<tr>
<td>1327</td>
<td>Harmful effects of macrolides</td>
</tr>
<tr>
<td>1328</td>
<td>Harmful effects of tetracyclines</td>
</tr>
<tr>
<td>1329</td>
<td>poisoning by tetracyclines</td>
</tr>
<tr>
<td>1330</td>
<td>poisoning by tetracyclines nos</td>
</tr>
<tr>
<td>1331</td>
<td>Harmful effects of aminoglycosides</td>
</tr>
<tr>
<td>1332</td>
<td>Harmful effects of rifampicin</td>
</tr>
<tr>
<td>1333</td>
<td>rifampicin poisoning</td>
</tr>
<tr>
<td>1334</td>
<td>Harmful effects of antifungal antibiotics, systemically used</td>
</tr>
<tr>
<td>1335</td>
<td>Harmful effects of co-trimoxazole</td>
</tr>
<tr>
<td>1336</td>
<td>co-trimoxazole poisoning</td>
</tr>
<tr>
<td>1337</td>
<td>Harmful effects of fusidic acid</td>
</tr>
<tr>
<td>1338</td>
<td>fusidic acid poisoning</td>
</tr>
<tr>
<td>1339</td>
<td>Harmful effects of sodium fusidate</td>
</tr>
<tr>
<td>1340</td>
<td>sodium fusidate poisoning</td>
</tr>
<tr>
<td>1341</td>
<td>Harmful effects of vancomycin</td>
</tr>
<tr>
<td>1342</td>
<td>vancomycin poisoning</td>
</tr>
<tr>
<td>1343</td>
<td>Harmful effects of other systemic anti-infectives or antiparasitics</td>
</tr>
<tr>
<td>1344</td>
<td>Harmful effects of Sulfonamides</td>
</tr>
<tr>
<td>1345</td>
<td>Harmful effects of antimycobacterial drugs</td>
</tr>
<tr>
<td>1346</td>
<td>Harmful effects of antimalarials or drugs acting on other blood protozoa</td>
</tr>
<tr>
<td>1347</td>
<td>Harmful effects of other antiprotozoal drugs</td>
</tr>
<tr>
<td>1348</td>
<td>Harmful effects of anthelminthics</td>
</tr>
<tr>
<td>1349</td>
<td>Harmful effects of antiviral drugs</td>
</tr>
<tr>
<td>1350</td>
<td>Harmful effects of chiniofon</td>
</tr>
<tr>
<td>1351</td>
<td>chiniofon poisoning</td>
</tr>
<tr>
<td>1352</td>
<td>Harmful effects of diiodohydroxyquinoline</td>
</tr>
<tr>
<td>1353</td>
<td>diiodohydroxyquinoline poisoning</td>
</tr>
<tr>
<td>1354</td>
<td>Harmful effects of flucytosine</td>
</tr>
<tr>
<td>1355</td>
<td>flucytosine poisoning</td>
</tr>
<tr>
<td>1356</td>
<td>Harmful effects of hydroxyquinoline derivatives</td>
</tr>
<tr>
<td>1357</td>
<td>hydroxyquinoline derivatives poisoning</td>
</tr>
<tr>
<td>1358</td>
<td>Harmful effects of trimethoprim</td>
</tr>
<tr>
<td>1359</td>
<td>trimethoprim poisoning</td>
</tr>
<tr>
<td>1360</td>
<td>Harmful effects of hormones or their synthetic substitutes or antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>1361</td>
<td>Harmful effects of Glucocorticoids or synthetic analogues</td>
</tr>
<tr>
<td>1362</td>
<td>Harmful effects of thyroid hormones or substitutes</td>
</tr>
<tr>
<td>1363</td>
<td>Harmful effects of antithyroid drugs</td>
</tr>
<tr>
<td>1364</td>
<td>Harmful effects of insulin or oral hypoglycaemic drugs</td>
</tr>
<tr>
<td>1365</td>
<td>Harmful effects of oral contraceptives</td>
</tr>
<tr>
<td>1366</td>
<td>poisoning by oral contraceptive</td>
</tr>
<tr>
<td>1367</td>
<td>poisoning by oral contraceptives nos</td>
</tr>
<tr>
<td>1368</td>
<td>Harmful effects of other estrogens or progestogens</td>
</tr>
<tr>
<td>1369</td>
<td>oestrogen poisoning</td>
</tr>
<tr>
<td>1370</td>
<td>Harmful effects of antigonadotropins, antiestrogens, antiandrogens, not elsewhere classified</td>
</tr>
<tr>
<td>1371</td>
<td>Harmful effects of androgens or anabolic congeners</td>
</tr>
<tr>
<td>1372</td>
<td>androgen poisoning</td>
</tr>
<tr>
<td>1373</td>
<td>Harmful effects of unspecified hormones or synthetic substitutes</td>
</tr>
<tr>
<td>1374</td>
<td>Harmful effects of anterior pituitary hormones</td>
</tr>
<tr>
<td>1375</td>
<td>Harmful effects of other hormones or synthetic substitutes</td>
</tr>
<tr>
<td>1376</td>
<td>Harmful effects of unspecified hormone antagonists</td>
</tr>
<tr>
<td>1377</td>
<td>Harmful effects of other hormone antagonists</td>
</tr>
<tr>
<td>1378</td>
<td>Harmful effects of trilostane</td>
</tr>
<tr>
<td>1379</td>
<td>Harmful effects of drugs primarily affecting the autonomic nervous system</td>
</tr>
<tr>
<td>1380</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Anticholinesterase agents</td>
</tr>
<tr>
<td>1381</td>
<td>anticholinesterase poisoning</td>
</tr>
<tr>
<td>1382</td>
<td>poisoning by anticholinesterase agents nos</td>
</tr>
<tr>
<td>1383</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Other parasympathomimetics</td>
</tr>
<tr>
<td>1384</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Ganglionic blocking drugs</td>
</tr>
<tr>
<td>1385</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Other parasympatholytics or spasmolytics</td>
</tr>
<tr>
<td>1386</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Predominantly alpha-adrenoreceptor agonists</td>
</tr>
<tr>
<td>1387</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Predominantly beta-adrenoreceptor agonists</td>
</tr>
<tr>
<td>1388</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Alpha-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>1389</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Beta-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>1390</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Centrally-acting or adrenergic-neuron-blocking agents</td>
</tr>
<tr>
<td>1391</td>
<td>Harmful effects of agents primarily affecting blood constituents</td>
</tr>
<tr>
<td>1392</td>
<td>haematological agent poisoning</td>
</tr>
<tr>
<td>1393</td>
<td>Harmful effects of Diphenhydramine</td>
</tr>
<tr>
<td>1394</td>
<td>diphenhydramine toxicity</td>
</tr>
<tr>
<td>1395</td>
<td>Harmful effects of other H1-receptor antagonists</td>
</tr>
<tr>
<td>1396</td>
<td>Harmful effects of antiallergic or antiemetic drugs</td>
</tr>
<tr>
<td>1397</td>
<td>Harmful effects of antineoplastic antimetabolites</td>
</tr>
<tr>
<td>1398</td>
<td>Harmful effects of antineoplastic natural products</td>
</tr>
<tr>
<td>1399</td>
<td>Harmful effects of other antineoplastic drugs</td>
</tr>
<tr>
<td>1400</td>
<td>Harmful effects of immunosuppressive agents</td>
</tr>
<tr>
<td>1401</td>
<td>Harmful effects of Vitamin B12, folic acid or other anti-megaloblastic-anaemia preparations</td>
</tr>
<tr>
<td>1402</td>
<td>Harmful effects of enzymes</td>
</tr>
<tr>
<td>1403</td>
<td>Harmful effects of iron or its compounds</td>
</tr>
<tr>
<td>1404</td>
<td>Harmful effects of anticoagulants</td>
</tr>
<tr>
<td>1405</td>
<td>Harmful effects of antithrombotic drugs</td>
</tr>
<tr>
<td>1406</td>
<td>harmful effect of platelet aggregation inhibitors</td>
</tr>
<tr>
<td>1407</td>
<td>Harmful effects of thrombolytic drug</td>
</tr>
<tr>
<td>1408</td>
<td>Harmful effects of anticoagulant antagonists, vitamin K or other coagulants</td>
</tr>
<tr>
<td>1409</td>
<td>Harmful effects of other fibrinolysis-affecting drugs</td>
</tr>
<tr>
<td>1410</td>
<td>fibrinolytic drug poisoning</td>
</tr>
<tr>
<td>1411</td>
<td>poisoning by fibrinolysis-affecting drug nos</td>
</tr>
<tr>
<td>1412</td>
<td>Harmful effects of natural blood or blood products</td>
</tr>
<tr>
<td>1413</td>
<td>Harmful effects of acidifying or alkalising agents</td>
</tr>
<tr>
<td>1414</td>
<td>Harmful effects of other primarily systemic agents, not elsewhere classified</td>
</tr>
<tr>
<td>1415</td>
<td>Blood poisoning, not elsewhere classified</td>
</tr>
<tr>
<td>1416</td>
<td>whole blood poisoning</td>
</tr>
<tr>
<td>1417</td>
<td>Harmful effects of heavy metal poisoning antidote</td>
</tr>
<tr>
<td>1418</td>
<td>Harmful effects of plasma substitutes</td>
</tr>
<tr>
<td>1419</td>
<td>Harmful effects of agents primarily affecting the cardiovascular system</td>
</tr>
<tr>
<td>1420</td>
<td>Harmful effects of cardiac-stimulant glycosides or drugs of similar action</td>
</tr>
<tr>
<td>1421</td>
<td>Harmful effects of calcium-channel blockers</td>
</tr>
<tr>
<td>1422</td>
<td>poisoning by calcium-channel blockers NOS</td>
</tr>
<tr>
<td>1423</td>
<td>Harmful effects of other antidysrhythmic drugs</td>
</tr>
<tr>
<td>1424</td>
<td>Harmful effects of Nitroglycerin, nitroglycerol, medicinal</td>
</tr>
<tr>
<td>1425</td>
<td>Harmful effects of other coronary vasodilators</td>
</tr>
<tr>
<td>1426</td>
<td>Harmful effects of Angiotensin-converting-enzyme inhibitors</td>
</tr>
<tr>
<td>1427</td>
<td>Harmful effects of other antihypertensive drugs</td>
</tr>
<tr>
<td>1428</td>
<td>Harmful effects of antihyperlipidemic or antiarteriosclerotic drugs</td>
</tr>
<tr>
<td>1429</td>
<td>Harmful effects of peripheral vasodilators</td>
</tr>
<tr>
<td>1430</td>
<td>Harmful effects of antivaricose drugs, including sclerosing agents</td>
</tr>
<tr>
<td>1431</td>
<td>antivaricose drug poisoning</td>
</tr>
<tr>
<td>1432</td>
<td>Harmful effects of agents primarily affecting the gastrointestinal system</td>
</tr>
<tr>
<td>1433</td>
<td>Harmful effects of Histamine H2-receptor blockers</td>
</tr>
<tr>
<td>1434</td>
<td>poisoning by histamine h 2 -receptor antagonists</td>
</tr>
<tr>
<td>1435</td>
<td>Harmful effects of other antacids or anti-gastric-secretion drugs</td>
</tr>
<tr>
<td>1436</td>
<td>Harmful effects of stimulant laxatives</td>
</tr>
<tr>
<td>1437</td>
<td>Harmful effects of saline or osmotic laxatives</td>
</tr>
<tr>
<td>1438</td>
<td>Harmful effects of other laxatives</td>
</tr>
<tr>
<td>1439</td>
<td>Harmful effects of digestants</td>
</tr>
<tr>
<td>1440</td>
<td>Harmful effects of antidiarrhoeal drugs</td>
</tr>
<tr>
<td>1441</td>
<td>Harmful effects of or exposure to emetics</td>
</tr>
<tr>
<td>1442</td>
<td>Harmful effects of agents primarily acting on smooth or skeletal muscles or the respiratory system</td>
</tr>
<tr>
<td>1443</td>
<td>Harmful effects of Oxytocic drugs</td>
</tr>
<tr>
<td>1444</td>
<td>oxytocin poisoning</td>
</tr>
<tr>
<td>1445</td>
<td>Harmful effects of skeletal muscle relaxants</td>
</tr>
<tr>
<td>1446</td>
<td>harmful effect of neuromuscular blocking agents</td>
</tr>
<tr>
<td>1447</td>
<td>Harmful effects of other drugs acting on muscles</td>
</tr>
<tr>
<td>1448</td>
<td>Harmful effects of unspecified drugs acting on muscles</td>
</tr>
<tr>
<td>1449</td>
<td>Harmful effects of antitussives</td>
</tr>
<tr>
<td>1450</td>
<td>Harmful effects of expectorants</td>
</tr>
<tr>
<td>1451</td>
<td>Harmful effects of other anti-common-cold drugs</td>
</tr>
<tr>
<td>1452</td>
<td>Harmful effects of Salbutamol</td>
</tr>
<tr>
<td>1453</td>
<td>salbutamol poisoning</td>
</tr>
<tr>
<td>1454</td>
<td>Harmful effects of Aminophylline, theophylline</td>
</tr>
<tr>
<td>1455</td>
<td>theophylline poisoning</td>
</tr>
<tr>
<td>1456</td>
<td>aminophylline poisoning</td>
</tr>
<tr>
<td>1457</td>
<td>Harmful effects of Terbutaline</td>
</tr>
<tr>
<td>1458</td>
<td>Harmful effects of antiasthmatics, not elsewhere classified</td>
</tr>
<tr>
<td>1459</td>
<td>Harmful effects of topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs</td>
</tr>
<tr>
<td>1460</td>
<td>Harmful effects of topical corticosteroid preparations</td>
</tr>
<tr>
<td>1461</td>
<td>Harmful effects of Iodine, antiseptic</td>
</tr>
<tr>
<td>1462</td>
<td>Harmful effects of silver nitrate</td>
</tr>
<tr>
<td>1463</td>
<td>Harmful effects of other local antifungal, anti-infective or anti-inflammatory drugs</td>
</tr>
<tr>
<td>1464</td>
<td>Harmful effects of antipruritics</td>
</tr>
<tr>
<td>1465</td>
<td>Harmful effects of Methyl salicylate</td>
</tr>
<tr>
<td>1466</td>
<td>Harmful effects of other local astringents or local detergents</td>
</tr>
<tr>
<td>1467</td>
<td>Tannic acid poisoning</td>
</tr>
<tr>
<td>1468</td>
<td>Harmful effects of emollients, demulcents or protectants</td>
</tr>
<tr>
<td>1469</td>
<td>Harmful effects of Podophyllin</td>
</tr>
<tr>
<td>1470</td>
<td>Harmful effects of keratolytics, keratoplastics, or other hair treatment drugs or preparations</td>
</tr>
<tr>
<td>1471</td>
<td>Harmful effects of ophthalmological drugs or preparations</td>
</tr>
<tr>
<td>1472</td>
<td>Harmful effects of otorhinolaryngological drugs or preparations</td>
</tr>
<tr>
<td>1473</td>
<td>Harmful effects of ear, nose or throat anti-infectives</td>
</tr>
<tr>
<td>1474</td>
<td>Harmful effects of fluoride preparations</td>
</tr>
<tr>
<td>1475</td>
<td>Harmful effects of other dental drugs, topically applied</td>
</tr>
<tr>
<td>1476</td>
<td>Harmful effects of Camphor</td>
</tr>
<tr>
<td>1477</td>
<td>Harmful effects of agents primarily affecting water-balance or mineral or uric acid metabolism</td>
</tr>
<tr>
<td>1478</td>
<td>Harmful effects of Mineralocorticoids</td>
</tr>
<tr>
<td>1479</td>
<td>Harmful effects of Mineralocorticoids antagonists</td>
</tr>
<tr>
<td>1480</td>
<td>Harmful effects of Loop diuretics</td>
</tr>
<tr>
<td>1481</td>
<td>Harmful effect of high-ceiling diuretics</td>
</tr>
<tr>
<td>1482</td>
<td>Frusemide poisoning</td>
</tr>
<tr>
<td>1483</td>
<td>furosemide poisoning</td>
</tr>
<tr>
<td>1484</td>
<td>Etacrynic acid poisoning</td>
</tr>
<tr>
<td>1485</td>
<td>ethacrynic acid poisoning</td>
</tr>
<tr>
<td>1486</td>
<td>Harmful effects of Carbonic-anhydrase inhibitors</td>
</tr>
<tr>
<td>1487</td>
<td>Acetazolamide poisoning</td>
</tr>
<tr>
<td>1488</td>
<td>Bendroflumethiazide poisoning</td>
</tr>
<tr>
<td>1489</td>
<td>Chlormerodrin poisoning</td>
</tr>
<tr>
<td>1490</td>
<td>Chlorothiazide poisoning</td>
</tr>
<tr>
<td>1491</td>
<td>Mercaptomerin poisoning</td>
</tr>
<tr>
<td>1492</td>
<td>Mersalyl poisoning</td>
</tr>
<tr>
<td>1493</td>
<td>Harmful effects of Benzothiadiazine derivatives</td>
</tr>
<tr>
<td>1494</td>
<td>harmful effect of thiazides</td>
</tr>
<tr>
<td>1495</td>
<td>Harmful effects of other diuretics</td>
</tr>
<tr>
<td>1496</td>
<td>Harmful effects of electrolytic, caloric or water-balance agents</td>
</tr>
<tr>
<td>1497</td>
<td>Harmful effect of oral rehydration salts</td>
</tr>
<tr>
<td>1498</td>
<td>Sodium chloride poisoning</td>
</tr>
<tr>
<td>1499</td>
<td>Harmful effects of mineral salts, not elsewhere classified</td>
</tr>
<tr>
<td>1500</td>
<td>Harmful effects of drugs affecting uric acid metabolism</td>
</tr>
<tr>
<td>1501</td>
<td>Allopurinol poisoning</td>
</tr>
<tr>
<td>1502</td>
<td>Colchicine poisoning</td>
</tr>
<tr>
<td>1503</td>
<td>Probenecid poisoning</td>
</tr>
<tr>
<td>1504</td>
<td>Harmful effects of agents primarily affecting water-balance and mineral or uric acid metabolism, Vitamin D and derivatives</td>
</tr>
<tr>
<td>1505</td>
<td>Harmful effects of Bisphosphonates</td>
</tr>
<tr>
<td>1506</td>
<td>Harmful effects of appetite depressants</td>
</tr>
<tr>
<td>1507</td>
<td>Harmful effects of antidotes or chelating agents, not elsewhere classified</td>
</tr>
<tr>
<td>1508</td>
<td>Harmful effects of Disulfiram</td>
</tr>
<tr>
<td>1509</td>
<td>disulfiram poisoning</td>
</tr>
<tr>
<td>1510</td>
<td>Harmful effects of alcohol deterrents, not elsewhere classified</td>
</tr>
<tr>
<td>1511</td>
<td>harmful effect of alcohol deterrents</td>
</tr>
<tr>
<td>1512</td>
<td>Toxic effect of alcohol deterrents</td>
</tr>
<tr>
<td>1513</td>
<td>Harmful effects of X-ray contrast media</td>
</tr>
<tr>
<td>1514</td>
<td>Harmful effects of MRI contrast agents</td>
</tr>
<tr>
<td>1515</td>
<td>Harmful effects of agents used for other scanning techniques</td>
</tr>
<tr>
<td>1516</td>
<td>Harmful effects of other diagnostic agents</td>
</tr>
<tr>
<td>1517</td>
<td>Harmful effects of Lipotropic drugs</td>
</tr>
<tr>
<td>1518</td>
<td>Harmful effects of vitamins, not elsewhere classified, Pharmaceutical excipients</td>
</tr>
<tr>
<td>1519</td>
<td>Harmful effects of herbal preparations or formulas</td>
</tr>
<tr>
<td>1520</td>
<td>Harmful effects of dietary supplements, vitamins or minerals</td>
</tr>
<tr>
<td>1521</td>
<td>Harmful effects of complementary or Traditional Medicines, not elsewhere classified</td>
</tr>
<tr>
<td>1522</td>
<td>Harmful effects of complementary or Traditional Medicines, unspecified</td>
</tr>
<tr>
<td>1523</td>
<td>Harmful effects of vaccines, immunoglobulins or other biological substances</td>
</tr>
<tr>
<td>1524</td>
<td>Harmful effects of BCG vaccine</td>
</tr>
<tr>
<td>1525</td>
<td>Harmful effects of Typhoid or paratyphoid vaccine</td>
</tr>
<tr>
<td>1526</td>
<td>Harmful effects of Cholera vaccine</td>
</tr>
<tr>
<td>1527</td>
<td>Harmful effects of Plague vaccine</td>
</tr>
<tr>
<td>1528</td>
<td>Harmful effects of Tetanus vaccine</td>
</tr>
<tr>
<td>1529</td>
<td>Harmful effects of Diphtheria vaccine</td>
</tr>
<tr>
<td>1530</td>
<td>Harmful effects of Haemophilus influenzae type B vaccines</td>
</tr>
<tr>
<td>1531</td>
<td>Harmful effects of Pertussis vaccine, including combinations with a pertussis component</td>
</tr>
<tr>
<td>1532</td>
<td>Harmful effects of mixed bacterial vaccines without a pertussis component</td>
</tr>
<tr>
<td>1533</td>
<td>Harmful effects of other or unspecified bacterial vaccines</td>
</tr>
<tr>
<td>1534</td>
<td>Harmful effects of Smallpox vaccines</td>
</tr>
<tr>
<td>1535</td>
<td>Harmful effects of Measles vaccines</td>
</tr>
<tr>
<td>1536</td>
<td>Harmful effects of Mumps vaccines</td>
</tr>
<tr>
<td>1537</td>
<td>Harmful effects of Rubella vaccines</td>
</tr>
<tr>
<td>1538</td>
<td>Harmful effects of Polio vaccines</td>
</tr>
<tr>
<td>1539</td>
<td>Harmful effects of Yellow fever vaccines</td>
</tr>
<tr>
<td>1540</td>
<td>Harmful effects of Hepatitis A vaccines</td>
</tr>
<tr>
<td>1541</td>
<td>Harmful effects of Hepatitis B vaccines</td>
</tr>
<tr>
<td>1542</td>
<td>Harmful effects of Influenza vaccines</td>
</tr>
<tr>
<td>1543</td>
<td>Harmful effects of Rotavirus vaccines</td>
</tr>
<tr>
<td>1544</td>
<td>Harmful effects of Human papillomavirus vaccines</td>
</tr>
<tr>
<td>1545</td>
<td>Harmful effects of other viral vaccines</td>
</tr>
<tr>
<td>1546</td>
<td>Harmful effects of Rickettsial vaccines</td>
</tr>
<tr>
<td>1547</td>
<td>Harmful effects of Protozoal vaccines</td>
</tr>
<tr>
<td>1548</td>
<td>Harmful effects of Hepatitis B immune globulin</td>
</tr>
<tr>
<td>1549</td>
<td>Harmful effects of antivenin, antivenom</td>
</tr>
<tr>
<td>1550</td>
<td>Harmful effects of immunoglobulin, not elsewhere classified</td>
</tr>
<tr>
<td>1551</td>
<td>Harmful effects of other specified vaccines</td>
</tr>
<tr>
<td>1552</td>
<td>Harmful effects of unspecified vaccines</td>
</tr>
<tr>
<td>1553</td>
<td>Multiple drug toxicity</td>
</tr>
<tr>
<td>1554</td>
<td>Catatonia due to medication or substance</td>
</tr>
<tr>
<td>1555</td>
<td>Overdose of drug, not otherwise specified</td>
</tr>
<tr>
<td>1556</td>
<td>overdose NOS</td>
</tr>
<tr>
<td>1557</td>
<td>Harmful effects of ketorolac</td>
</tr>
<tr>
<td>1558</td>
<td>ketorolac poisoning</td>
</tr>
<tr>
<td>1559</td>
<td>Harmful effects of meptazinol</td>
</tr>
<tr>
<td>1560</td>
<td>meptazinol poisoning</td>
</tr>
<tr>
<td>1561</td>
<td>Harmful effects of nefopam</td>
</tr>
<tr>
<td>1562</td>
<td>nefopam poisoning</td>
</tr>
<tr>
<td>1563</td>
<td>Harmful effects of oxygen</td>
</tr>
<tr>
<td>1564</td>
<td>oxygen poisoning</td>
</tr>
<tr>
<td>1565</td>
<td>Harmful effects of ethosuximide</td>
</tr>
<tr>
<td>1566</td>
<td>ethosuximide poisoning</td>
</tr>
<tr>
<td>1567</td>
<td>Harmful effects of paramethadione</td>
</tr>
<tr>
<td>1568</td>
<td>paramethadione poisoning</td>
</tr>
<tr>
<td>1569</td>
<td>Harmful effects of trimethadione</td>
</tr>
<tr>
<td>1570</td>
<td>trimethadione poisoning</td>
</tr>
<tr>
<td>1571</td>
<td>Harmful effects of phensuximide</td>
</tr>
<tr>
<td>1572</td>
<td>phensuximide poisoning</td>
</tr>
<tr>
<td>1573</td>
<td>Adverse effect medical agent</td>
</tr>
<tr>
<td>1574</td>
<td>side effect</td>
</tr>
<tr>
<td>1575</td>
<td>side effect of medical agent</td>
</tr>
<tr>
<td>1576</td>
<td>Cocaine and fentanyl toxicity</td>
</tr>
<tr>
<td>1577</td>
<td>Methamphetamine and fentanyl toxicity</td>
</tr>
<tr>
<td>1578</td>
<td>Metachromatic leukodystrophy</td>
</tr>
<tr>
<td>1579</td>
<td>Greenfield's disease (metachromatic leukodystrophy)</td>
</tr>
<tr>
<td>1580</td>
<td>Arylsulfatase A deficiency</td>
</tr>
<tr>
<td>1581</td>
<td>Cerebroside sulfatase deficiency</td>
</tr>
<tr>
<td>1582</td>
<td>Late infantile metachromatic leukodystrophy</td>
</tr>
<tr>
<td>1583</td>
<td>Juvenile metachromatic leukodystrophy</td>
</tr>
<tr>
<td>1584</td>
<td>Adult metachromatic leukodystrophy</td>
</tr>
<tr>
<td>1585</td>
<td>Metachromatic leukodystrophy due to sphingolipid activator protein I deficiency</td>
</tr>
<tr>
<td>1586</td>
<td>Metachromatic leukodystrophy due to saposin B deficiency</td>
</tr>
<tr>
<td>1587</td>
<td>Metachromatic leukodystrophy due to cerebroside sulfatase activator deficiency</td>
</tr>
<tr>
<td>1588</td>
<td>Syndromes with vascular anomalies as a major feature</td>
</tr>
<tr>
<td>1589</td>
<td>Primary intraosseous vascular malformation</td>
</tr>
<tr>
<td>1590</td>
<td>Retinal cavernous haemangioma</td>
</tr>
<tr>
<td>1591</td>
<td>Sturge-Weber syndrome</td>
</tr>
<tr>
<td>1592</td>
<td>encephalotrigeminal angiomatosis</td>
</tr>
<tr>
<td>1</td>
<td>Unspecified undernutrition</td>
</tr>
<tr>
<td>2</td>
<td>Malnutrition NOS</td>
</tr>
<tr>
<td>3</td>
<td>nutritional deficiency NOS</td>
</tr>
<tr>
<td>4</td>
<td>nutritional depletion NOS</td>
</tr>
<tr>
<td>5</td>
<td>severe malnutrition NOS</td>
</tr>
<tr>
<td>6</td>
<td>severe malnourished NOS</td>
</tr>
<tr>
<td>7</td>
<td>diminished nutrition NOS</td>
</tr>
<tr>
<td>8</td>
<td>inadequate nutrition NOS</td>
</tr>
<tr>
<td>9</td>
<td>nutritional imbalance NOS</td>
</tr>
<tr>
<td>10</td>
<td>poor nutritional intake</td>
</tr>
<tr>
<td>11</td>
<td>caloric protein malnutrition</td>
</tr>
<tr>
<td>12</td>
<td>calorie deficiency</td>
</tr>
<tr>
<td>13</td>
<td>calorie malnutrition NOS</td>
</tr>
<tr>
<td>14</td>
<td>deficiency of macronutrients</td>
</tr>
<tr>
<td>15</td>
<td>energy supply deficiency</td>
</tr>
<tr>
<td>16</td>
<td>malnourished</td>
</tr>
<tr>
<td>17</td>
<td>pcm - [protein-calorie malnutrition]</td>
</tr>
<tr>
<td>18</td>
<td>pem - [protein-energy malnutrition]</td>
</tr>
<tr>
<td>19</td>
<td>protein-energy imbalance NOS</td>
</tr>
<tr>
<td>20</td>
<td>protein- calorie malnutrition unspecified</td>
</tr>
<tr>
<td>21</td>
<td>undernourishment</td>
</tr>
<tr>
<td>22</td>
<td>Alimentary oedema</td>
</tr>
<tr>
<td>23</td>
<td>Oedematous inanition</td>
</tr>
<tr>
<td>24</td>
<td>inanition with oedema</td>
</tr>
<tr>
<td>25</td>
<td>Severe energy supply deficiency</td>
</tr>
<tr>
<td>26</td>
<td>Nutritional oedema</td>
</tr>
<tr>
<td>27</td>
<td>nutritional hydrops</td>
</tr>
<tr>
<td>28</td>
<td>starvation oedema</td>
</tr>
<tr>
<td>29</td>
<td>oedematous starvation</td>
</tr>
<tr>
<td>30</td>
<td>nutritional anasarca</td>
</tr>
<tr>
<td>31</td>
<td>Deficiency oedema</td>
</tr>
<tr>
<td>32</td>
<td>Severe protein calorie malnutrition</td>
</tr>
<tr>
<td>33</td>
<td>severe protein energy malnutrition</td>
</tr>
<tr>
<td>34</td>
<td>severe caloric protein malnutrition</td>
</tr>
<tr>
<td>35</td>
<td>severe protein deprivation</td>
</tr>
<tr>
<td>36</td>
<td>severe calorie deficiency</td>
</tr>
<tr>
<td>37</td>
<td>protein deficit</td>
</tr>
<tr>
<td>38</td>
<td>Third degree malnutrition</td>
</tr>
<tr>
<td>39</td>
<td>Nutritional inanition</td>
</tr>
<tr>
<td>40</td>
<td>Moderate protein-energy malnutrition</td>
</tr>
<tr>
<td>41</td>
<td>moderate protein caloric malnutrition</td>
</tr>
<tr>
<td>42</td>
<td>malnutrition of moderate degree</td>
</tr>
<tr>
<td>43</td>
<td>moderate protein-calorie malnutrition</td>
</tr>
<tr>
<td>44</td>
<td>malnutrition second degree</td>
</tr>
<tr>
<td>45</td>
<td>Mild protein-energy malnutrition</td>
</tr>
<tr>
<td>46</td>
<td>mild protein caloric malnutrition</td>
</tr>
<tr>
<td>47</td>
<td>malnutrition of mild degree</td>
</tr>
<tr>
<td>48</td>
<td>mild protein-calorie malnutrition</td>
</tr>
<tr>
<td>49</td>
<td>malnutrition first degree</td>
</tr>
<tr>
<td>50</td>
<td>Chronic hepatitis B, unspecified</td>
</tr>
<tr>
<td>51</td>
<td>Chronic hepatitis B</td>
</tr>
<tr>
<td>52</td>
<td>Chronic hepatitis B without delta agent</td>
</tr>
<tr>
<td>53</td>
<td>chronic HBV - [hepatitis B virus] infection</td>
</tr>
<tr>
<td>54</td>
<td>hepatitis B NOS</td>
</tr>
<tr>
<td>55</td>
<td>chronic type B viral hepatitis</td>
</tr>
<tr>
<td>56</td>
<td>hep B NOS</td>
</tr>
<tr>
<td>57</td>
<td>Chronic hepatitis B virus infection</td>
</tr>
<tr>
<td>58</td>
<td>Glycogen storage disease</td>
</tr>
<tr>
<td>59</td>
<td>Glycogenosis</td>
</tr>
<tr>
<td>60</td>
<td>GSD - [Glycogen storage disease]</td>
</tr>
<tr>
<td>61</td>
<td>glycogen thesaurismosis</td>
</tr>
<tr>
<td>62</td>
<td>diffuse glycogenosis</td>
</tr>
<tr>
<td>63</td>
<td>generalised glycogen storage disease</td>
</tr>
<tr>
<td>64</td>
<td>generalised glycogenosis</td>
</tr>
<tr>
<td>65</td>
<td>generalised glycogen storage disease of infants</td>
</tr>
<tr>
<td>66</td>
<td>glycogen synthase deficiency</td>
</tr>
<tr>
<td>67</td>
<td>Glycogen storage disease due to glycogen synthase deficiency</td>
</tr>
<tr>
<td>68</td>
<td>Glycogen storage disease type 0</td>
</tr>
<tr>
<td>69</td>
<td>Glycogenosis type 0</td>
</tr>
<tr>
<td>70</td>
<td>GSD type 0</td>
</tr>
<tr>
<td>71</td>
<td>deficiency of glycogen synthetase</td>
</tr>
<tr>
<td>72</td>
<td>Glycogen storage disease due to liver glycogen synthase deficiency</td>
</tr>
<tr>
<td>73</td>
<td>GSD type 0A</td>
</tr>
<tr>
<td>74</td>
<td>Glycogen storage disease type 0A</td>
</tr>
<tr>
<td>75</td>
<td>Glycogenosis type 0A</td>
</tr>
<tr>
<td>76</td>
<td>Glycogen storage disease due to muscle or heart glycogen synthase deficiency</td>
</tr>
<tr>
<td>77</td>
<td>Glycogen storage disease type 0B</td>
</tr>
<tr>
<td>78</td>
<td>Glycogenosis type 0B</td>
</tr>
<tr>
<td>79</td>
<td>GSD type 0B</td>
</tr>
<tr>
<td>80</td>
<td>Cardiomyopathy-exercise intolerance due to muscle and heart glycogen deficiency</td>
</tr>
<tr>
<td>81</td>
<td>Glycogen storage disease due to glucose-6-phosphate system deficiency</td>
</tr>
<tr>
<td>82</td>
<td>Glycogen storage disease type 1</td>
</tr>
<tr>
<td>83</td>
<td>Glycogenosis type 1</td>
</tr>
<tr>
<td>84</td>
<td>GSD type 1</td>
</tr>
<tr>
<td>85</td>
<td>Hepatorenal glycogenosis</td>
</tr>
<tr>
<td>86</td>
<td>Von Gierke disease</td>
</tr>
<tr>
<td>87</td>
<td>HERS - [hepatorenal glycogen storage disease]</td>
</tr>
<tr>
<td>88</td>
<td>glycogen storage disease of liver and kidney</td>
</tr>
<tr>
<td>89</td>
<td>hepatorenal glycogen storage disease</td>
</tr>
<tr>
<td>90</td>
<td>Glycogen storage disease due to glucose-6-phosphatase deficiency</td>
</tr>
<tr>
<td>91</td>
<td>Glycogen storage disease type 1A</td>
</tr>
<tr>
<td>92</td>
<td>Glycogenosis type 1A</td>
</tr>
<tr>
<td>93</td>
<td>GSD type 1A</td>
</tr>
<tr>
<td>94</td>
<td>g6pd - [glucose-6-phosphate dehydrogenase deficiency]</td>
</tr>
<tr>
<td>95</td>
<td>glucose-6-phosphatase deficiency</td>
</tr>
<tr>
<td>96</td>
<td>deficiency of g-6pd</td>
</tr>
<tr>
<td>97</td>
<td>Glycogen storage disease due to glucose-6-phosphate transport defect</td>
</tr>
<tr>
<td>98</td>
<td>Glycogen storage disease type 1B</td>
</tr>
<tr>
<td>99</td>
<td>Glycogenosis type 1B</td>
</tr>
<tr>
<td>100</td>
<td>GSD1B</td>
</tr>
<tr>
<td>101</td>
<td>Glycogen storage disease type non-1A</td>
</tr>
<tr>
<td>102</td>
<td>Glycogenosis type non-1A</td>
</tr>
<tr>
<td>103</td>
<td>Glycogen storage disease due to glucose-6-phosphate translocase deficiency</td>
</tr>
<tr>
<td>104</td>
<td>Glucose-6-phosphate dehydrogenase deficiency</td>
</tr>
<tr>
<td>105</td>
<td>Glycogen storage disease due to acid maltase deficiency</td>
</tr>
<tr>
<td>106</td>
<td>Glycogen storage disease type 2</td>
</tr>
<tr>
<td>107</td>
<td>Glycogenosis type 2</td>
</tr>
<tr>
<td>108</td>
<td>GSD type 2</td>
</tr>
<tr>
<td>109</td>
<td>Acid maltase deficiency</td>
</tr>
<tr>
<td>110</td>
<td>Pompe disease</td>
</tr>
<tr>
<td>111</td>
<td>Acid alpha-1,4-glucosidase deficiency</td>
</tr>
<tr>
<td>112</td>
<td>alpha-glucosidase deficiency</td>
</tr>
<tr>
<td>113</td>
<td>deficiency of amyloglucosidase</td>
</tr>
<tr>
<td>114</td>
<td>Glycogen storage disease due to acid maltase deficiency, infantile onset</td>
</tr>
<tr>
<td>115</td>
<td>Glycogen storage disease type 2, infantile onset</td>
</tr>
<tr>
<td>116</td>
<td>Glycogenosis type 2, infantile onset</td>
</tr>
<tr>
<td>117</td>
<td>GSD2, infantile onset</td>
</tr>
<tr>
<td>118</td>
<td>Glycogen storage disease due to acid alpha-1,4-glucosidase deficiency, infantile onset</td>
</tr>
<tr>
<td>119</td>
<td>Infantile Pompe disease</td>
</tr>
<tr>
<td>120</td>
<td>lysosomal alpha-1,4-glucosidase deficiency (disorder)</td>
</tr>
<tr>
<td>121</td>
<td>Glycogen storage disease due to acid maltase deficiency, juvenile onset</td>
</tr>
<tr>
<td>122</td>
<td>Glycogen storage disease due to acid maltase deficiency, adult onset</td>
</tr>
<tr>
<td>123</td>
<td>Deficiency of exo-1,4-alpha-glucosidase</td>
</tr>
<tr>
<td>124</td>
<td>Deficiency of glucan 1,4-alpha-glucosidase</td>
</tr>
<tr>
<td>125</td>
<td>Deficiency of gamma-amylase</td>
</tr>
<tr>
<td>126</td>
<td>Deficiency of glucoamylase</td>
</tr>
<tr>
<td>127</td>
<td>Deficiency of glucoinvertase</td>
</tr>
<tr>
<td>128</td>
<td>Deficiency of glucosidosucrase</td>
</tr>
<tr>
<td>129</td>
<td>Deficiency of maltase</td>
</tr>
<tr>
<td>130</td>
<td>Glycogen storage disease due to LAMP-2 deficiency</td>
</tr>
<tr>
<td>131</td>
<td>Glycogen storage disease type 2B</td>
</tr>
<tr>
<td>132</td>
<td>Glycogenosis type 2B</td>
</tr>
<tr>
<td>133</td>
<td>GSD type 2B</td>
</tr>
<tr>
<td>134</td>
<td>Lysosomal glycogen storage disease with normal acid maltase activity</td>
</tr>
<tr>
<td>135</td>
<td>Danon disease</td>
</tr>
<tr>
<td>136</td>
<td>Glycogen storage disease due to glycogen debranching enzyme deficiency</td>
</tr>
<tr>
<td>137</td>
<td>Glycogen storage disease type 3</td>
</tr>
<tr>
<td>138</td>
<td>Glycogenosis type 3</td>
</tr>
<tr>
<td>139</td>
<td>GSD type 3</td>
</tr>
<tr>
<td>140</td>
<td>Amylo-1,6-glucosidase deficiency</td>
</tr>
<tr>
<td>141</td>
<td>Glycogen debranching deficiency</td>
</tr>
<tr>
<td>142</td>
<td>Cori-Forbes disease</td>
</tr>
<tr>
<td>143</td>
<td>Cori disease</td>
</tr>
<tr>
<td>144</td>
<td>Forbes disease</td>
</tr>
<tr>
<td>145</td>
<td>Forbes glycogen storage disease</td>
</tr>
<tr>
<td>146</td>
<td>debrancher deficiency glycogen storage disease</td>
</tr>
<tr>
<td>147</td>
<td>debrancher enzyme deficiency</td>
</tr>
<tr>
<td>148</td>
<td>deficiency of 6-alpha-d-glucosidase</td>
</tr>
<tr>
<td>149</td>
<td>amylo-1,6-glucosidase deficiency disorder</td>
</tr>
<tr>
<td>150</td>
<td>Glycogen storage disease due to muscle glycogen phosphorylase deficiency</td>
</tr>
<tr>
<td>151</td>
<td>Glycogen storage disease type 5</td>
</tr>
<tr>
<td>152</td>
<td>Glycogenosis type 5</td>
</tr>
<tr>
<td>153</td>
<td>GSD type 5</td>
</tr>
<tr>
<td>154</td>
<td>Myophosphorylase deficiency</td>
</tr>
<tr>
<td>155</td>
<td>McArdle disease</td>
</tr>
<tr>
<td>156</td>
<td>myophosphorylase deficiency glycogenosis</td>
</tr>
<tr>
<td>157</td>
<td>Glycogen storage disease due to liver glycogen phosphorylase deficiency</td>
</tr>
<tr>
<td>158</td>
<td>Glycogenosis due to liver phosphorylase deficiency</td>
</tr>
<tr>
<td>159</td>
<td>Glycogen storage disease type 6</td>
</tr>
<tr>
<td>160</td>
<td>Glycogenosis type 6</td>
</tr>
<tr>
<td>161</td>
<td>GSD type 6</td>
</tr>
<tr>
<td>162</td>
<td>Glycogen storage disease type 6B</td>
</tr>
<tr>
<td>163</td>
<td>Glycogenosis type 6B</td>
</tr>
<tr>
<td>164</td>
<td>GSD type 6B</td>
</tr>
<tr>
<td>165</td>
<td>Hers disease</td>
</tr>
<tr>
<td>166</td>
<td>deficiency of hepatophosphorylase</td>
</tr>
<tr>
<td>167</td>
<td>Glycogen storage disease due to muscle phosphofructokinase deficiency</td>
</tr>
<tr>
<td>168</td>
<td>Glycogen storage disease type 7</td>
</tr>
<tr>
<td>169</td>
<td>Glycogenosis type 7</td>
</tr>
<tr>
<td>170</td>
<td>GSD type 7</td>
</tr>
<tr>
<td>171</td>
<td>Muscle phosphofructokinase deficiency</td>
</tr>
<tr>
<td>172</td>
<td>Tarui disease</td>
</tr>
<tr>
<td>173</td>
<td>anaemia due to phosphofructo-aldolase deficiency</td>
</tr>
<tr>
<td>174</td>
<td>Glycogen storage disease due to glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>175</td>
<td>Glycogenosis due to phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>176</td>
<td>GSD due to phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>177</td>
<td>Glycogen storage disease due to liver glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>178</td>
<td>Hepatic phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>179</td>
<td>Glycogen storage disease type 8</td>
</tr>
<tr>
<td>180</td>
<td>Glycogenosis type 8</td>
</tr>
<tr>
<td>181</td>
<td>GSD8 - [glycogen storage disease type 8]</td>
</tr>
<tr>
<td>182</td>
<td>Glycogen storage disease type 6A</td>
</tr>
<tr>
<td>183</td>
<td>Glycogen storage disease type 9A</td>
</tr>
<tr>
<td>184</td>
<td>Glycogen storage disease type 9C</td>
</tr>
<tr>
<td>185</td>
<td>Glycogenosis type 6A</td>
</tr>
<tr>
<td>186</td>
<td>Glycogenosis type 9A</td>
</tr>
<tr>
<td>187</td>
<td>Glycogenosis type 9C</td>
</tr>
<tr>
<td>188</td>
<td>GSD type 9C - [glycogen storage disease type 9C]</td>
</tr>
<tr>
<td>189</td>
<td>GSD6A - [glycogen storage disease type 6A]</td>
</tr>
<tr>
<td>190</td>
<td>GSD9A - [glycogen storage disease type 9A]</td>
</tr>
<tr>
<td>191</td>
<td>Glycogen storage disease due to liver or muscle glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>192</td>
<td>Glycogen storage disease type 9B</td>
</tr>
<tr>
<td>193</td>
<td>Glycogenosis type 9B</td>
</tr>
<tr>
<td>194</td>
<td>GSD type 9B</td>
</tr>
<tr>
<td>195</td>
<td>Glycogen storage disease type 9</td>
</tr>
<tr>
<td>196</td>
<td>Glycogenosis type 9</td>
</tr>
<tr>
<td>197</td>
<td>GSD9 - [glycogen storage disease type 9]</td>
</tr>
<tr>
<td>198</td>
<td>Glycogen storage disease due to heart glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>199</td>
<td>Glycogen storage disease of heart</td>
</tr>
<tr>
<td>200</td>
<td>Cardiac glycogenosis</td>
</tr>
<tr>
<td>201</td>
<td>Glycogen storage disease type 9F</td>
</tr>
<tr>
<td>202</td>
<td>Glycogenosis type 9F</td>
</tr>
<tr>
<td>203</td>
<td>GSD9F</td>
</tr>
<tr>
<td>204</td>
<td>glycogen heart disease</td>
</tr>
<tr>
<td>205</td>
<td>glycogenic myocardial infiltration</td>
</tr>
<tr>
<td>206</td>
<td>glycogenic myocardium infiltration</td>
</tr>
<tr>
<td>207</td>
<td>cardiomegalia glycogenica diffusa</td>
</tr>
<tr>
<td>208</td>
<td>Glycogen storage disease due to muscle glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>209</td>
<td>GSD9D - [glycogen storage disease type IXD]</td>
</tr>
<tr>
<td>210</td>
<td>Glycogen storage disease type 9D</td>
</tr>
<tr>
<td>211</td>
<td>Glycogen storage disease type 9E</td>
</tr>
<tr>
<td>212</td>
<td>Glycogenosis type 9D</td>
</tr>
<tr>
<td>213</td>
<td>Glycogenosis type 9E</td>
</tr>
<tr>
<td>214</td>
<td>GSD9E</td>
</tr>
<tr>
<td>215</td>
<td>muscle glycogen phosphorylase deficiency</td>
</tr>
<tr>
<td>216</td>
<td>glycogenosis type IXE</td>
</tr>
<tr>
<td>217</td>
<td>Glycogen storage disease due to muscle phosphoglycerate mutase deficiency</td>
</tr>
<tr>
<td>218</td>
<td>Glycogen storage disease type 10</td>
</tr>
<tr>
<td>219</td>
<td>Glycogenosis type 10</td>
</tr>
<tr>
<td>220</td>
<td>GSD type 10</td>
</tr>
<tr>
<td>221</td>
<td>Di Mauro disease</td>
</tr>
<tr>
<td>222</td>
<td>Glycogen storage disease due to GLUT2 deficiency</td>
</tr>
<tr>
<td>223</td>
<td>Glycogen storage disease type 11</td>
</tr>
<tr>
<td>224</td>
<td>Glycogenosis type 11</td>
</tr>
<tr>
<td>225</td>
<td>GSD type 11</td>
</tr>
<tr>
<td>226</td>
<td>Fanconi-Bickel glycogenosis</td>
</tr>
<tr>
<td>227</td>
<td>Bickel-Fanconi disease</td>
</tr>
<tr>
<td>228</td>
<td>Facilitated glucose transporter protein type 2 deficiency</td>
</tr>
<tr>
<td>229</td>
<td>Fanconi-Bickel syndrome</td>
</tr>
<tr>
<td>230</td>
<td>Glycogen storage disease due to aldolase A deficiency</td>
</tr>
<tr>
<td>231</td>
<td>Glycogen storage disease type 12</td>
</tr>
<tr>
<td>232</td>
<td>Glycogenosis type 12</td>
</tr>
<tr>
<td>233</td>
<td>GSD type 12</td>
</tr>
<tr>
<td>234</td>
<td>Glycogen storage disease due to muscle beta-enolase deficiency</td>
</tr>
<tr>
<td>235</td>
<td>Glycogen storage disease type 13</td>
</tr>
<tr>
<td>236</td>
<td>Glycogenosis type 13</td>
</tr>
<tr>
<td>237</td>
<td>GSD type 13</td>
</tr>
<tr>
<td>238</td>
<td>Glycogen storage disease due to phosphoglucomutase deficiency</td>
</tr>
<tr>
<td>239</td>
<td>Glycogen storage disease type 14</td>
</tr>
<tr>
<td>240</td>
<td>Glycogenosis type 14</td>
</tr>
<tr>
<td>241</td>
<td>GSD type 14</td>
</tr>
<tr>
<td>242</td>
<td>Glycogen storage disease due to glycogenin deficiency</td>
</tr>
<tr>
<td>243</td>
<td>Glycogen storage disease type 15</td>
</tr>
<tr>
<td>244</td>
<td>GSD type 15</td>
</tr>
<tr>
<td>245</td>
<td>Glocogenosis type 15</td>
</tr>
<tr>
<td>246</td>
<td>Glycogen storage disease due to phosphoglycerate kinase 1 deficiency</td>
</tr>
<tr>
<td>247</td>
<td>Glycogenosis due to phosphoglycerate kinase 1 deficiency</td>
</tr>
<tr>
<td>248</td>
<td>GSD due to phosphoglycerate kinase 1 deficiency</td>
</tr>
<tr>
<td>249</td>
<td>Glycogen storage disease due to lactate dehydrogenase deficiency</td>
</tr>
<tr>
<td>250</td>
<td>Glycogenosis due to lactate dehydrogenase deficiency</td>
</tr>
<tr>
<td>251</td>
<td>GSD due to lactate dehydrogenase deficiency</td>
</tr>
<tr>
<td>252</td>
<td>Glycogen storage disease due to muscle pyruvate kinase deficiency</td>
</tr>
<tr>
<td>253</td>
<td>Glycogenosis due to muscle pyruvate kinase deficiency</td>
</tr>
<tr>
<td>254</td>
<td>GSD due to muscle pyruvate kinase deficiency</td>
</tr>
<tr>
<td>255</td>
<td>Glycogen storage liver disease</td>
</tr>
<tr>
<td>256</td>
<td>hepatomegalia glycogenica diffusa</td>
</tr>
<tr>
<td>257</td>
<td>liver glycogen disease</td>
</tr>
<tr>
<td>258</td>
<td>liver phosphorylase deficiency</td>
</tr>
<tr>
<td>259</td>
<td>Glycogen storage disease due to branching-transferase deficiency</td>
</tr>
<tr>
<td>260</td>
<td>Andersen disease</td>
</tr>
<tr>
<td>261</td>
<td>brancher deficiency glycogen storage disease</td>
</tr>
<tr>
<td>262</td>
<td>branching enzyme deficiency</td>
</tr>
<tr>
<td>263</td>
<td>branching-transferase deficiency glycogenosis</td>
</tr>
<tr>
<td>264</td>
<td>deficiency of 1,4-alpha-glucan branching enzyme</td>
</tr>
<tr>
<td>265</td>
<td>deficiency of amylo-(1,4,6)-transglycosylase</td>
</tr>
<tr>
<td>266</td>
<td>Glycogen storage disease type 4</td>
</tr>
<tr>
<td>267</td>
<td>Glycogenosis type 4</td>
</tr>
<tr>
<td>268</td>
<td>GSD- [Glycogen storage disease] type 4</td>
</tr>
<tr>
<td>269</td>
<td>Dilated cardiomyopathy due to glycogen branching enzyme deficiency</td>
</tr>
<tr>
<td>270</td>
<td>Amylopectinosis</td>
</tr>
<tr>
<td>271</td>
<td>dilated cardiomyopathy due to Andersen's disease</td>
</tr>
<tr>
<td>272</td>
<td>dilated cardiomyopathy due to glycogen storage disease type 4 (GSD4)</td>
</tr>
<tr>
<td>273</td>
<td>Other specified hereditary sensory or autonomic neuropathy</td>
</tr>
<tr>
<td>274</td>
<td>Hereditary sensory and autonomic neuropathy type II</td>
</tr>
<tr>
<td>275</td>
<td>HSAN2 - [Hereditary sensory and autonomic neuropathy type 2]</td>
</tr>
<tr>
<td>276</td>
<td>Hereditary sensory and autonomic neuropathy type IIA</td>
</tr>
<tr>
<td>277</td>
<td>HSAN2A - [Hereditary sensory autonomic neuropathy type 2A]</td>
</tr>
<tr>
<td>278</td>
<td>Hereditary sensory and autonomic neuropathy type IIB</td>
</tr>
<tr>
<td>279</td>
<td>HSAN2B - [Hereditary sensory autonomic neuropathy type 2B]</td>
</tr>
<tr>
<td>280</td>
<td>Hereditary sensory and autonomic neuropathy type IIC</td>
</tr>
<tr>
<td>281</td>
<td>HSAN2C - [Hereditary sensory autonomic neuropathy type 2C]</td>
</tr>
<tr>
<td>282</td>
<td>Certain specified forms of hereditary sensory or autonomic neuropathy</td>
</tr>
<tr>
<td>283</td>
<td>Cold-induced sweating syndrome</td>
</tr>
<tr>
<td>284</td>
<td>Hereditary sensory and autonomic neuropathy with deafness or global delay</td>
</tr>
<tr>
<td>285</td>
<td>Hereditary sensory and autonomic neuropathy with spastic paraplegia</td>
</tr>
<tr>
<td>286</td>
<td>X-linked hereditary sensory and autonomic neuropathy with deafness</td>
</tr>
<tr>
<td>287</td>
<td>Encephalitis due to herpes simplex virus</td>
</tr>
<tr>
<td>288</td>
<td>herpes simplex neuroinvasion</td>
</tr>
<tr>
<td>289</td>
<td>herpetic encephalitis</td>
</tr>
<tr>
<td>290</td>
<td>herpetic encephalopathy</td>
</tr>
<tr>
<td>291</td>
<td>encephalitis due to herpesviridae</td>
</tr>
<tr>
<td>292</td>
<td>encephalitis due to herpesvirus</td>
</tr>
<tr>
<td>293</td>
<td>herpes encephalitis</td>
</tr>
<tr>
<td>294</td>
<td>herpesviral encephalitis</td>
</tr>
<tr>
<td>295</td>
<td>herpes simplex encephalitis</td>
</tr>
<tr>
<td>296</td>
<td>HSV - [herpes simplex virus] encephalitis</td>
</tr>
<tr>
<td>297</td>
<td>herpes virus encephalitis</td>
</tr>
<tr>
<td>298</td>
<td>Simian B disease</td>
</tr>
<tr>
<td>299</td>
<td>Simian B disorder</td>
</tr>
<tr>
<td>300</td>
<td>Encephalitis due to herpes simplex type 1</td>
</tr>
<tr>
<td>301</td>
<td>Encephalitis due to herpes simplex type 2</td>
</tr>
<tr>
<td>302</td>
<td>Herpesviral meningoencephalitis</td>
</tr>
<tr>
<td>303</td>
<td>Oculocutaneous albinism</td>
</tr>
<tr>
<td>304</td>
<td>OCA - [Oculocutaneous albinism]</td>
</tr>
<tr>
<td>305</td>
<td>Oculocutaneous albinism type 1A</td>
</tr>
<tr>
<td>306</td>
<td>Tyrosinase-negative oculocutaneous albinism</td>
</tr>
<tr>
<td>307</td>
<td>Albino</td>
</tr>
<tr>
<td>308</td>
<td>OCA1A - [Oculocutaneous albinism type 1A]</td>
</tr>
<tr>
<td>309</td>
<td>Oculocutaneous albinism type 1B</td>
</tr>
<tr>
<td>310</td>
<td>OCA1B - [Oculocutaneous albinism type 1B]</td>
</tr>
<tr>
<td>311</td>
<td>Yellow oculocutaneous albinism</td>
</tr>
<tr>
<td>312</td>
<td>Oculocutaneous albinism, Amish type</td>
</tr>
<tr>
<td>313</td>
<td>Minimal pigment oculocutaneous albinism</td>
</tr>
<tr>
<td>314</td>
<td>Platinum oculocutaneous albinism</td>
</tr>
<tr>
<td>315</td>
<td>Temperature sensitive oculocutaneous albinism</td>
</tr>
<tr>
<td>316</td>
<td>OCA1-TS - [Temperature-sensitive oculocutaneous albinism]</td>
</tr>
<tr>
<td>317</td>
<td>Oculocutaneous albinism type 2</td>
</tr>
<tr>
<td>318</td>
<td>OCA2 - [Oculocutaneous albinism type 2]</td>
</tr>
<tr>
<td>319</td>
<td>Tyrosinase-positive oculocutaneous albinism</td>
</tr>
<tr>
<td>320</td>
<td>Brown oculocutaneous albinism</td>
</tr>
<tr>
<td>321</td>
<td>Oculocutaneous albinism type 3</td>
</tr>
<tr>
<td>322</td>
<td>Rufous oculocutaneous albinism</td>
</tr>
<tr>
<td>323</td>
<td>Red oculocutaneous albinism</td>
</tr>
<tr>
<td>324</td>
<td>Xanthous oculocutaneous albinism</td>
</tr>
<tr>
<td>325</td>
<td>Xanthism</td>
</tr>
<tr>
<td>326</td>
<td>OCA3 - [Oculocutaneous albinism type 3]</td>
</tr>
<tr>
<td>327</td>
<td>Oculocutaneous albinism type 4</td>
</tr>
<tr>
<td>328</td>
<td>OCA4 - [Oculocutaneous albinism type 4]</td>
</tr>
<tr>
<td>329</td>
<td>Hermansky-Pudlak syndrome</td>
</tr>
<tr>
<td>330</td>
<td>Albinism with haemorrhagic diathesis and pigmented reticuloendothelial cells</td>
</tr>
<tr>
<td>331</td>
<td>HPS - [Hermansky-Pudlak syndrome]</td>
</tr>
<tr>
<td>332</td>
<td>Hermansky-Pudlak syndrome type 7</td>
</tr>
<tr>
<td>333</td>
<td>HPS7 - [Hermansky-Pudlak syndrome type 7] (MIM 614076)</td>
</tr>
<tr>
<td>334</td>
<td>Hermansky-Pudlak syndrome type 8</td>
</tr>
<tr>
<td>335</td>
<td>HPS8 - [Hermansky-Pudlak syndrome type 8] (MIM 614077)</td>
</tr>
<tr>
<td>336</td>
<td>Hermansky-Pudlak syndrome type 9</td>
</tr>
<tr>
<td>337</td>
<td>Hermansky-Pudlak syndrome with neutropaenia</td>
</tr>
<tr>
<td>338</td>
<td>Hermansky-Pudlak syndrome type 2</td>
</tr>
<tr>
<td>339</td>
<td>HPS 2 - [Hermansky-Pudlak syndrome type 2] (MIM 608233)</td>
</tr>
<tr>
<td>340</td>
<td>Hermansky-Pudlak syndrome with pulmonary fibrosis</td>
</tr>
<tr>
<td>341</td>
<td>Hermansky-Pudlak syndrome without pulmonary fibrosis</td>
</tr>
<tr>
<td>342</td>
<td>HPS - [Hermansky-Pudlak syndrome] without pulmonary fibrosis</td>
</tr>
<tr>
<td>343</td>
<td>Chédiak-Higashi syndrome</td>
</tr>
<tr>
<td>344</td>
<td>Chediak-Higashi-Steinbrinck syndrome</td>
</tr>
<tr>
<td>345</td>
<td>Chediak-Steinbrinck syndrome</td>
</tr>
<tr>
<td>346</td>
<td>Béguez César syndrome</td>
</tr>
<tr>
<td>347</td>
<td>Steinbrinck anomaly</td>
</tr>
<tr>
<td>348</td>
<td>Oculocerebral syndrome with hypopigmentation</td>
</tr>
<tr>
<td>349</td>
<td>Cross syndrome</td>
</tr>
<tr>
<td>350</td>
<td>Vitamin B2 deficiency</td>
</tr>
<tr>
<td>351</td>
<td>Ariboflavinosis</td>
</tr>
<tr>
<td>352</td>
<td>Riboflavin deficiency</td>
</tr>
<tr>
<td>353</td>
<td>Hyporiboflavinosis</td>
</tr>
<tr>
<td>354</td>
<td>B lymphoblastic leukaemia or lymphoma, not elsewhere classified</td>
</tr>
<tr>
<td>355</td>
<td>c-ALL</td>
</tr>
<tr>
<td>356</td>
<td>Lymphoblastic lymphoma, NOS</td>
</tr>
<tr>
<td>357</td>
<td>Common precursor B ALL</td>
</tr>
<tr>
<td>358</td>
<td>Lymphoblastic B-cell lymphoma</td>
</tr>
<tr>
<td>359</td>
<td>Pro-B ALL</td>
</tr>
<tr>
<td>360</td>
<td>B-precursor lymphoma</td>
</tr>
<tr>
<td>361</td>
<td>LBL - [lymphoblastic lymphoma]</td>
</tr>
<tr>
<td>362</td>
<td>Vitamin B1 deficiency, unspecified</td>
</tr>
<tr>
<td>363</td>
<td>Vitamin B1 deficiency</td>
</tr>
<tr>
<td>364</td>
<td>aneurin deficiency</td>
</tr>
<tr>
<td>365</td>
<td>thiamine vitamin deficiency</td>
</tr>
<tr>
<td>366</td>
<td>thiamine deficiency</td>
</tr>
<tr>
<td>367</td>
<td>Hereditary fructose intolerance</td>
</tr>
<tr>
<td>368</td>
<td>Hereditary fructose-1-phosphate aldolase deficiency</td>
</tr>
<tr>
<td>369</td>
<td>Hereditary fructosaemia</td>
</tr>
<tr>
<td>370</td>
<td>Fructose intolerance</td>
</tr>
<tr>
<td>371</td>
<td>Fructosaemia</td>
</tr>
<tr>
<td>372</td>
<td>Aldolase B deficiency</td>
</tr>
<tr>
<td>373</td>
<td>fructose-1,6-bisphosphate aldolase b deficiency (disorder)</td>
</tr>
<tr>
<td>374</td>
<td>fructose-biphosphate aldolase b deficiency</td>
</tr>
<tr>
<td>375</td>
<td>fructose-1-phosphate aldolase deficiency</td>
</tr>
<tr>
<td>376</td>
<td>fructose intolerance of newborn</td>
</tr>
<tr>
<td>377</td>
<td>ALDB - [aldolase B] deficiency</td>
</tr>
<tr>
<td>378</td>
<td>deficiency of fructose-bisphosphate aldolase</td>
</tr>
<tr>
<td>379</td>
<td>Interrupted aortic arch</td>
</tr>
<tr>
<td>380</td>
<td>aorta atresia</td>
</tr>
<tr>
<td>381</td>
<td>aortic arch interruption</td>
</tr>
<tr>
<td>382</td>
<td>IAA - [interrupted aortic arch]</td>
</tr>
<tr>
<td>383</td>
<td>aorta arch atresia</td>
</tr>
<tr>
<td>384</td>
<td>aorta ring atresia</td>
</tr>
<tr>
<td>385</td>
<td>aortic arch atresia</td>
</tr>
<tr>
<td>386</td>
<td>aortic ring atresia</td>
</tr>
<tr>
<td>387</td>
<td>Interrupted aortic arch distal to subclavian artery, type A</td>
</tr>
<tr>
<td>388</td>
<td>aortic arch interruption, type A</td>
</tr>
<tr>
<td>389</td>
<td>IAA type A - [interrupted aortic arch type A]</td>
</tr>
<tr>
<td>390</td>
<td>Interrupted aortic arch between subclavian and common carotid arteries, type B</td>
</tr>
<tr>
<td>391</td>
<td>aortic arch interruption, type B</td>
</tr>
<tr>
<td>392</td>
<td>IAA type B - [interrupted aortic arch type B]</td>
</tr>
<tr>
<td>393</td>
<td>Aortic interruption, type B</td>
</tr>
<tr>
<td>394</td>
<td>Interruption of the aortic arch, type B</td>
</tr>
<tr>
<td>395</td>
<td>Interrupted aortic arch between carotid arteries, type C</td>
</tr>
<tr>
<td>396</td>
<td>aortic arch interruption, type C</td>
</tr>
<tr>
<td>397</td>
<td>IAA type C - [interrupted aortic arch type C]</td>
</tr>
<tr>
<td>398</td>
<td>Aortic interruption, type C</td>
</tr>
<tr>
<td>399</td>
<td>Interruption of the aortic arch, type C</td>
</tr>
<tr>
<td>400</td>
<td>Vitamin B3 deficiency, unspecified</td>
</tr>
<tr>
<td>401</td>
<td>Vitamin B3 deficiency</td>
</tr>
<tr>
<td>402</td>
<td>nicotinic acid deficiency</td>
</tr>
<tr>
<td>403</td>
<td>vitamin B3 deficiency NOS</td>
</tr>
<tr>
<td>404</td>
<td>deficiency of niacin-tryptophan</td>
</tr>
<tr>
<td>405</td>
<td>nicotinamide deficiency</td>
</tr>
<tr>
<td>406</td>
<td>niacin deficiency NOS</td>
</tr>
<tr>
<td>407</td>
<td>amide nicotinic acid deficiency</td>
</tr>
<tr>
<td>408</td>
<td>Congenital muscular dystrophy</td>
</tr>
<tr>
<td>409</td>
<td>hereditary muscular dystrophy</td>
</tr>
<tr>
<td>410</td>
<td>congenital hereditary muscular dystrophy</td>
</tr>
<tr>
<td>411</td>
<td>congenital progressive muscular dystrophy</td>
</tr>
<tr>
<td>412</td>
<td>hereditary progressive muscular dystrophy</td>
</tr>
<tr>
<td>413</td>
<td>Congenital muscular dystrophy with central nervous system abnormalities</td>
</tr>
<tr>
<td>414</td>
<td>Congenital muscular dystrophy Fukuyama type</td>
</tr>
<tr>
<td>415</td>
<td>Congenital muscular dystrophy with central nervous system abnormalities, not elsewhere classified</td>
</tr>
<tr>
<td>416</td>
<td>Walker Warburg syndrome</td>
</tr>
<tr>
<td>417</td>
<td>Hydrocephalus - agyria - retinal dysplasia syndrome</td>
</tr>
<tr>
<td>418</td>
<td>WWS - [Walker Warburg syndrome]</td>
</tr>
<tr>
<td>419</td>
<td>HARD - [Hydrocephalus - agyria - retinal dysplasia syndrome]</td>
</tr>
<tr>
<td>420</td>
<td>Muscle Eye Brain disease</td>
</tr>
<tr>
<td>421</td>
<td>MEB - [Muscle Eye Brain disease]</td>
</tr>
<tr>
<td>422</td>
<td>Marinesco-Sjögren syndrome</td>
</tr>
<tr>
<td>423</td>
<td>Congenital muscular dystrophy type 1C, fukutin-related protein gene mutation</td>
</tr>
<tr>
<td>424</td>
<td>Congenital muscular dystrophy type 1D large gene mutation</td>
</tr>
<tr>
<td>425</td>
<td>MDC1D - [congenital muscular dystrophy 1D]</td>
</tr>
<tr>
<td>426</td>
<td>Congenital muscular dystrophy without central nervous system symptoms</td>
</tr>
<tr>
<td>427</td>
<td>Congenital muscular dystrophy without central nervous system abnormalities, not elsewhere classified</td>
</tr>
<tr>
<td>428</td>
<td>Merosin or laminin alpha 2 chain deficiency</td>
</tr>
<tr>
<td>429</td>
<td>Merosin-deficient congenital muscular dystrophy</td>
</tr>
<tr>
<td>430</td>
<td>Collagen VI deficiency</td>
</tr>
<tr>
<td>431</td>
<td>Bethlem myopathy</td>
</tr>
<tr>
<td>432</td>
<td>Ullrich congenital muscular dystrophy</td>
</tr>
<tr>
<td>433</td>
<td>UCMD - [Ullrich congenital muscular dystrophy</td>
</tr>
<tr>
<td>434</td>
<td>Congenital muscular dystrophy - infantile cataract - hypogonadism</td>
</tr>
<tr>
<td>435</td>
<td>Bassoe syndrome</td>
</tr>
<tr>
<td>436</td>
<td>Congenital muscular dystrophy due to lamin A/C deficiency</td>
</tr>
<tr>
<td>437</td>
<td>Congenital muscular dystrophy due to phosphatidylcholine biosynthesis defect</td>
</tr>
<tr>
<td>438</td>
<td>Congenital megaconial myopathy</td>
</tr>
<tr>
<td>439</td>
<td>Congenital muscular dystrophy with mitochondrial structural abnormalities</td>
</tr>
<tr>
<td>440</td>
<td>Congenital muscular dystrophy with integrin deficiency</td>
</tr>
<tr>
<td>441</td>
<td>Congenital muscular dystrophy, Paradas type</td>
</tr>
<tr>
<td>442</td>
<td>Rigid spine syndrome</td>
</tr>
<tr>
<td>443</td>
<td>Congenital muscular dystrophy type 1B</td>
</tr>
<tr>
<td>444</td>
<td>MDC1B - [Muscular Dystrophy Type 1B]</td>
</tr>
<tr>
<td>445</td>
<td>CMD1B - [Congenital muscular dystrophy type 1B]</td>
</tr>
<tr>
<td>446</td>
<td>Mature B-cell neoplasms, unspecified</td>
</tr>
<tr>
<td>447</td>
<td>Primary central nervous system lymphoma</td>
</tr>
<tr>
<td>448</td>
<td>Gangliosidosis</td>
</tr>
<tr>
<td>449</td>
<td>GM1 gangliosidosis</td>
</tr>
<tr>
<td>450</td>
<td>Landing disease</td>
</tr>
<tr>
<td>451</td>
<td>GM1 gangliosidosis type 1</td>
</tr>
<tr>
<td>452</td>
<td>Generalised gangliosidosis</td>
</tr>
<tr>
<td>453</td>
<td>Infantile GM1 gangliosidosis</td>
</tr>
<tr>
<td>454</td>
<td>GM1 gangliosidosis type 2</td>
</tr>
<tr>
<td>455</td>
<td>Juvenile GM1 gangliosidosis</td>
</tr>
<tr>
<td>456</td>
<td>GM1 gangliosidosis type 3</td>
</tr>
<tr>
<td>457</td>
<td>Adult GM1 gangliosidosis</td>
</tr>
<tr>
<td>458</td>
<td>GM2 gangliosidosis</td>
</tr>
<tr>
<td>459</td>
<td>deficiency of beta-n-acetylhexosaminidase isoenzymes</td>
</tr>
<tr>
<td>460</td>
<td>GM&lt;sub&gt;2&lt;/sub&gt; gangliosidosis</td>
</tr>
<tr>
<td>461</td>
<td>GM 2 gangliosidosis NOS</td>
</tr>
<tr>
<td>462</td>
<td>Retinal dystrophy in GM2 gangliosidosis</td>
</tr>
<tr>
<td>463</td>
<td>Sandhoff disease</td>
</tr>
<tr>
<td>464</td>
<td>GM2 gangliosidosis type 2</td>
</tr>
<tr>
<td>465</td>
<td>GM2 gangliosidosis 0 variant</td>
</tr>
<tr>
<td>466</td>
<td>Hexosaminidase A and B deficiency</td>
</tr>
<tr>
<td>467</td>
<td>Total hexosaminidase deficiency</td>
</tr>
<tr>
<td>468</td>
<td>GM&gt;2&lt; gangliosidosis, type 2</td>
</tr>
<tr>
<td>469</td>
<td>GM&lt;sub&gt;2&lt;/sub&gt; gangliosidosis, type 2</td>
</tr>
<tr>
<td>470</td>
<td>Infantile Sandhoff disease</td>
</tr>
<tr>
<td>471</td>
<td>Total hexosaminidase deficiency, infantile form</td>
</tr>
<tr>
<td>472</td>
<td>infantile GM2 gangliosidosis</td>
</tr>
<tr>
<td>473</td>
<td>infantile GM&lt;sub&gt;2&lt;/sub&gt; gangliosidosis</td>
</tr>
<tr>
<td>474</td>
<td>infantile GM&gt;2&lt; gangliosidosis</td>
</tr>
<tr>
<td>475</td>
<td>Juvenile Sandhoff disease</td>
</tr>
<tr>
<td>476</td>
<td>Total hexosaminidase deficiency, juvenile form</td>
</tr>
<tr>
<td>477</td>
<td>juvenile GM2 gangliosidosis</td>
</tr>
<tr>
<td>478</td>
<td>juvenile GM&lt;sub&gt;2&lt;/sub&gt; gangliosidosis</td>
</tr>
<tr>
<td>479</td>
<td>juvenile GM&gt;2&lt; gangliosidosis</td>
</tr>
<tr>
<td>480</td>
<td>Adult Sandhoff disease</td>
</tr>
<tr>
<td>481</td>
<td>Total hexosaminidase deficiency, adult form</td>
</tr>
<tr>
<td>482</td>
<td>adult GM2 gangliosidosis</td>
</tr>
<tr>
<td>483</td>
<td>Tay-Sachs disease</td>
</tr>
<tr>
<td>484</td>
<td>GM2-gangliosidosis, B, B1, AB variant</td>
</tr>
<tr>
<td>485</td>
<td>Hexosaminidase A deficiency</td>
</tr>
<tr>
<td>486</td>
<td>severe hexosaminidase a deficiency</td>
</tr>
<tr>
<td>487</td>
<td>B variant of hexosaminidase A deficiency</td>
</tr>
<tr>
<td>488</td>
<td>B variant of hexosaminidase A deficiency, infantile form</td>
</tr>
<tr>
<td>489</td>
<td>Classic infantile acute Tay-Sachs disease</td>
</tr>
<tr>
<td>490</td>
<td>GM2 gangliosidosis type 1</td>
</tr>
<tr>
<td>491</td>
<td>GM&lt;sub&gt;2&lt;/sub&gt; gangliosidosis, type 1</td>
</tr>
<tr>
<td>492</td>
<td>GM&gt;2&lt; gangliosidosis, type 1</td>
</tr>
<tr>
<td>493</td>
<td>B variant of hexosaminidase A deficiency, juvenile form</td>
</tr>
<tr>
<td>494</td>
<td>Juvenile subacute Tay-Sachs disease</td>
</tr>
<tr>
<td>495</td>
<td>GM2 gangliosidosis type 3</td>
</tr>
<tr>
<td>496</td>
<td>GM&lt;sub&gt;2&lt;/sub&gt; gangliosidosis, type 3</td>
</tr>
<tr>
<td>497</td>
<td>GM&gt;2&lt; gangliosidosis, type 3</td>
</tr>
<tr>
<td>498</td>
<td>B variant of hexosaminidase A deficiency, adult form</td>
</tr>
<tr>
<td>499</td>
<td>Adult Tay-Sachs disease</td>
</tr>
<tr>
<td>500</td>
<td>Chronic GM2 gangliosidosis</td>
</tr>
<tr>
<td>501</td>
<td>B1 variant of hexosaminidase A deficiency</td>
</tr>
<tr>
<td>502</td>
<td>Late infantile Tay-Sachs disease</td>
</tr>
<tr>
<td>503</td>
<td>Pseudo-AB variant of hexosaminidase deficiency</td>
</tr>
<tr>
<td>504</td>
<td>Hexosaminidase activator deficiency</td>
</tr>
<tr>
<td>505</td>
<td>GM2 activator deficiency</td>
</tr>
<tr>
<td>506</td>
<td>AB variant of hexosaminidase deficiency</td>
</tr>
<tr>
<td>507</td>
<td>Vitamin B6 deficiency</td>
</tr>
<tr>
<td>508</td>
<td>pyridoxal deficiency</td>
</tr>
<tr>
<td>509</td>
<td>pyridoxamine deficiency</td>
</tr>
<tr>
<td>510</td>
<td>pyridoxine deficiency</td>
</tr>
<tr>
<td>511</td>
<td>vitamin B6 deficiency syndrome</td>
</tr>
<tr>
<td>512</td>
<td>Peripheral neuropathy due to vitamin B6 deficiency</td>
</tr>
<tr>
<td>513</td>
<td>Peripheral neuropathy due to vitamin pyridoxine deficiency</td>
</tr>
<tr>
<td>514</td>
<td>Vitamin B12 deficiency</td>
</tr>
<tr>
<td>515</td>
<td>cobalamin deficiency</td>
</tr>
<tr>
<td>516</td>
<td>cyanocobalamin deficiency</td>
</tr>
<tr>
<td>517</td>
<td>deficiency of vitamin b12</td>
</tr>
<tr>
<td>518</td>
<td>Peripheral neuropathy due to vitamin B12 deficiency</td>
</tr>
<tr>
<td>519</td>
<td>Peripheral neuropathy due to cobalamin deficiency</td>
</tr>
<tr>
<td>520</td>
<td>Myelopathy due to vitamin B12 deficiency</td>
</tr>
<tr>
<td>521</td>
<td>myelopathy due to cobalamin deficiency</td>
</tr>
<tr>
<td>522</td>
<td>Encephalopathy due to vitamin B12 deficiency</td>
</tr>
<tr>
<td>523</td>
<td>Optic neuropathy due to vitamin B12 deficiency</td>
</tr>
<tr>
<td>524</td>
<td>Autosomal dominant hereditary spastic paraplegia</td>
</tr>
<tr>
<td>525</td>
<td>Autosomal dominant pure hereditary spastic paraplegia</td>
</tr>
<tr>
<td>526</td>
<td>Autosomal dominant pure hereditary spastic paraplegia due to mutations in Spastin gene</td>
</tr>
<tr>
<td>527</td>
<td>Autosomal dominant spastic paraplegia type 10</td>
</tr>
<tr>
<td>528</td>
<td>Autosomal dominant spastic paraplegia type 12</td>
</tr>
<tr>
<td>529</td>
<td>Autosomal dominant spastic paraplegia type 13</td>
</tr>
<tr>
<td>530</td>
<td>Autosomal dominant spastic paraplegia type 19</td>
</tr>
<tr>
<td>531</td>
<td>Autosomal dominant spastic paraplegia type 3</td>
</tr>
<tr>
<td>532</td>
<td>Autosomal dominant spastic paraplegia type 31</td>
</tr>
<tr>
<td>533</td>
<td>Autosomal dominant spastic paraplegia type 4</td>
</tr>
<tr>
<td>534</td>
<td>Autosomal dominant spastic paraplegia type 42</td>
</tr>
<tr>
<td>535</td>
<td>Autosomal dominant spastic paraplegia type 6</td>
</tr>
<tr>
<td>536</td>
<td>Autosomal dominant spastic paraplegia type 8</td>
</tr>
<tr>
<td>537</td>
<td>Autosomal dominant complex hereditary spastic paraplegia</td>
</tr>
<tr>
<td>538</td>
<td>Autosomal dominant complex hereditary spastic paraplegia due to mutations in Spastin gene</td>
</tr>
<tr>
<td>539</td>
<td>Autosomal dominant spastic paraplegia type 29</td>
</tr>
<tr>
<td>540</td>
<td>Autosomal dominant spastic paraplegia type 37</td>
</tr>
<tr>
<td>541</td>
<td>Autosomal dominant spastic paraplegia type 38</td>
</tr>
<tr>
<td>542</td>
<td>Autosomal dominant spastic paraplegia type 9</td>
</tr>
<tr>
<td>543</td>
<td>Autosomal dominant spastic paraplegia type 17</td>
</tr>
<tr>
<td>544</td>
<td>Distal hereditary motor neuropathy type 5B</td>
</tr>
<tr>
<td>545</td>
<td>HMN5B</td>
</tr>
<tr>
<td>546</td>
<td>SPG17</td>
</tr>
<tr>
<td>547</td>
<td>Spastic paraplegia-amyotrophy of hands and feet</td>
</tr>
<tr>
<td>548</td>
<td>Silver syndrome</td>
</tr>
<tr>
<td>549</td>
<td>Other specified vitamin B1 deficiency</td>
</tr>
<tr>
<td>550</td>
<td>Dementia due to thiamine deficiency</td>
</tr>
<tr>
<td>551</td>
<td>Peripheral neuropathy due to vitamin B1 deficiency</td>
</tr>
<tr>
<td>552</td>
<td>Peripheral neuropathy due to thiamine deficiency</td>
</tr>
<tr>
<td>553</td>
<td>Optic neuropathy due to vitamin B1 deficiency</td>
</tr>
<tr>
<td>554</td>
<td>Optic neuropathy due to thiamine deficiency</td>
</tr>
<tr>
<td>555</td>
<td>Mucopolysaccharidosis type 2</td>
</tr>
<tr>
<td>556</td>
<td>Iduronate 2-sulfatase deficiency</td>
</tr>
<tr>
<td>557</td>
<td>Hunter syndrome</td>
</tr>
<tr>
<td>558</td>
<td>iduronate 2-sulphatase deficiency</td>
</tr>
<tr>
<td>559</td>
<td>iduronate sulfatase deficiency</td>
</tr>
<tr>
<td>560</td>
<td>iduronate sulphatase deficiency</td>
</tr>
<tr>
<td>561</td>
<td>sulfo-iduronate sulfatase deficiency</td>
</tr>
<tr>
<td>562</td>
<td>sulfoiduronidate sulfatase deficiency</td>
</tr>
<tr>
<td>563</td>
<td>sulpho-iduronate sulphatase deficiency</td>
</tr>
<tr>
<td>564</td>
<td>sulphoiduronidate sulphatase deficiency</td>
</tr>
<tr>
<td>565</td>
<td>MPS2 - [mucopolysaccharidosis 2]</td>
</tr>
<tr>
<td>566</td>
<td>Mucopolysaccharidosis type 2A</td>
</tr>
<tr>
<td>567</td>
<td>Iduronate 2-sulfatase deficiency type A</td>
</tr>
<tr>
<td>568</td>
<td>Hunter syndrome type A</td>
</tr>
<tr>
<td>569</td>
<td>Mucopolysaccharidosis type 2, severe form</td>
</tr>
<tr>
<td>570</td>
<td>Mucopolysaccharidosis type 2B</td>
</tr>
<tr>
<td>571</td>
<td>Iduronate 2-sulfatase deficiency type B</td>
</tr>
<tr>
<td>572</td>
<td>Hunter syndrome type B</td>
</tr>
<tr>
<td>573</td>
<td>Mucopolysaccharidosis type 2, mild form</td>
</tr>
<tr>
<td>574</td>
<td>Mucopolysaccharidosis type 2, attenuated form</td>
</tr>
<tr>
<td>575</td>
<td>Other specified vitamin B3 deficiency</td>
</tr>
<tr>
<td>576</td>
<td>Other specified mucopolysaccharidosis</td>
</tr>
<tr>
<td>577</td>
<td>Mucopolysaccharidosis type 3</td>
</tr>
<tr>
<td>578</td>
<td>Acetyl-CoA alpha-glucosaminide-N-acetyl transferase deficiency</td>
</tr>
<tr>
<td>579</td>
<td>N-acetyl-alpha-glucosaminidase sulfamidase deficiency</td>
</tr>
<tr>
<td>580</td>
<td>N-acetyl-glucosamine-6-sulfate sulfatase deficiency</td>
</tr>
<tr>
<td>581</td>
<td>Sanfilippo syndrome</td>
</tr>
<tr>
<td>582</td>
<td>Mucopolysaccharidosis type 3A</td>
</tr>
<tr>
<td>583</td>
<td>Sanfilippo syndrome type A</td>
</tr>
<tr>
<td>584</td>
<td>Heparan-N-sulfatase deficiency</td>
</tr>
<tr>
<td>585</td>
<td>Heparan sulfamidase deficiency</td>
</tr>
<tr>
<td>586</td>
<td>Heparan sulfate sulfatase deficiency</td>
</tr>
<tr>
<td>587</td>
<td>Mucopolysaccharidosis type 3B</td>
</tr>
<tr>
<td>588</td>
<td>Sanfilippo syndrome type B</td>
</tr>
<tr>
<td>589</td>
<td>Alpha-N-acetylglucosaminidase deficiency</td>
</tr>
<tr>
<td>590</td>
<td>N-acetyl-alpha-D-glucosaminidase deficiency</td>
</tr>
<tr>
<td>591</td>
<td>Mucopolysaccharidosis type 3C</td>
</tr>
<tr>
<td>592</td>
<td>Sanfilippo syndrome type C</td>
</tr>
<tr>
<td>593</td>
<td>Acetyl-CoA alpha-glucosaminide acetyltransferase deficiency</td>
</tr>
<tr>
<td>594</td>
<td>N-acetyl transferase deficiency</td>
</tr>
<tr>
<td>595</td>
<td>Mucopolysaccharidosis type 3D</td>
</tr>
<tr>
<td>596</td>
<td>Sanfilippo syndrome type D</td>
</tr>
<tr>
<td>597</td>
<td>N-acetylglucosamine-6-sulfate sulfatase deficiency</td>
</tr>
<tr>
<td>598</td>
<td>Mucopolysaccharidosis type 7</td>
</tr>
<tr>
<td>599</td>
<td>Beta-glucuronidase deficiency</td>
</tr>
<tr>
<td>600</td>
<td>Sly disease</td>
</tr>
<tr>
<td>601</td>
<td>Sly syndrome</td>
</tr>
<tr>
<td>602</td>
<td>Mucopolysaccharidosis type 9</td>
</tr>
<tr>
<td>603</td>
<td>Hyaluronidase deficiency</td>
</tr>
<tr>
<td>604</td>
<td>Natowicz syndrome</td>
</tr>
<tr>
<td>605</td>
<td>Mucopolysaccharidosis type 4</td>
</tr>
<tr>
<td>606</td>
<td>Galactosamine-6-sulfatase deficiency</td>
</tr>
<tr>
<td>607</td>
<td>Morquio syndrome</td>
</tr>
<tr>
<td>608</td>
<td>Morquio-Brailsford disease</td>
</tr>
<tr>
<td>609</td>
<td>Mucopolysaccharidosis type 4A</td>
</tr>
<tr>
<td>610</td>
<td>Galactose-6-sulfatase deficiency</td>
</tr>
<tr>
<td>611</td>
<td>Galactosamide-6-sulfatase deficiency</td>
</tr>
<tr>
<td>612</td>
<td>Morquio syndrome type A</td>
</tr>
<tr>
<td>613</td>
<td>Mucopolysaccharidosis type 4B</td>
</tr>
<tr>
<td>614</td>
<td>Beta-D-galactosidase deficiency</td>
</tr>
<tr>
<td>615</td>
<td>Morquio syndrome type B</td>
</tr>
<tr>
<td>616</td>
<td>Human leukocyte antigen positive</td>
</tr>
<tr>
<td>617</td>
<td>HLA - [human leukocyte antigen] B27 positive</td>
</tr>
<tr>
<td>618</td>
<td>HLA B-27</td>
</tr>
<tr>
<td>619</td>
<td>Disorders of protein N-glycosylation</td>
</tr>
<tr>
<td>620</td>
<td>Phosphomannomutase 2 deficiency</td>
</tr>
<tr>
<td>621</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1A</td>
</tr>
<tr>
<td>622</td>
<td>Congenital disorder of glycosylation type 1A</td>
</tr>
<tr>
<td>623</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1A</td>
</tr>
<tr>
<td>624</td>
<td>Phosphomannose isomerase deficiency</td>
</tr>
<tr>
<td>625</td>
<td>Saguenay-Lac-Saint-Jean syndrome</td>
</tr>
<tr>
<td>626</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1B</td>
</tr>
<tr>
<td>627</td>
<td>Congenital disorder of glycosylation type 1B</td>
</tr>
<tr>
<td>628</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1B</td>
</tr>
<tr>
<td>629</td>
<td>SLSJ - [Saguenay-Lac-Saint-Jean] syndrome</td>
</tr>
<tr>
<td>630</td>
<td>Glucosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>631</td>
<td>Dol-P-Glc: Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>632</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1C</td>
</tr>
<tr>
<td>633</td>
<td>Congenital disorder of glycosylation type 1C</td>
</tr>
<tr>
<td>634</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1C</td>
</tr>
<tr>
<td>635</td>
<td>Mannosyltransferase 6 deficiency</td>
</tr>
<tr>
<td>636</td>
<td>Dol-P-Man: Man5-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>637</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1D</td>
</tr>
<tr>
<td>638</td>
<td>Congenital disorder of glycosylation type 1D</td>
</tr>
<tr>
<td>639</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1D</td>
</tr>
<tr>
<td>640</td>
<td>Mannosyltransferase 8 deficiency</td>
</tr>
<tr>
<td>641</td>
<td>Dol-P-Man: Man7-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>642</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1G</td>
</tr>
<tr>
<td>643</td>
<td>Congenital disorder of glycosylation type 1G</td>
</tr>
<tr>
<td>644</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1G</td>
</tr>
<tr>
<td>645</td>
<td>Glucosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>646</td>
<td>Dol-P-Glc: Glc1-Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>647</td>
<td>Carbohydrate deficient glycoprotein syndrome 1H</td>
</tr>
<tr>
<td>648</td>
<td>Congenital disorder of glycosylation type 1H</td>
</tr>
<tr>
<td>649</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1H</td>
</tr>
<tr>
<td>650</td>
<td>Mannosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>651</td>
<td>Dol-P-Man: Man1-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>652</td>
<td>Carbohydrate deficient glycoprotein syndrome 1I</td>
</tr>
<tr>
<td>653</td>
<td>Congenital disorder of glycosylation 1I</td>
</tr>
<tr>
<td>654</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1I</td>
</tr>
<tr>
<td>655</td>
<td>Dolichyl-phosphate N-acetylgalactosamine phosphotransferase deficiency</td>
</tr>
<tr>
<td>656</td>
<td>UDP-GlcNAc: Dol-P-GlcNac-P transferase deficiency</td>
</tr>
<tr>
<td>657</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1J</td>
</tr>
<tr>
<td>658</td>
<td>Congenital disorder of glycosylation type 1J</td>
</tr>
<tr>
<td>659</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1J</td>
</tr>
<tr>
<td>660</td>
<td>Mannosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>661</td>
<td>Dol-P-Man: GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>662</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1K</td>
</tr>
<tr>
<td>663</td>
<td>Congenital disorder of glycosylation type 1K</td>
</tr>
<tr>
<td>664</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1K</td>
</tr>
<tr>
<td>665</td>
<td>Mannosyltransferase 7-9 deficiency</td>
</tr>
<tr>
<td>666</td>
<td>Congenital disorder of glycosylation type 1L</td>
</tr>
<tr>
<td>667</td>
<td>Dol-P-Man: Man6 and Man8-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>668</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1L</td>
</tr>
<tr>
<td>669</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1L</td>
</tr>
<tr>
<td>670</td>
<td>M5-DLO flippase deficiency</td>
</tr>
<tr>
<td>671</td>
<td>Man5GlcNAc2-PP-Dol flippase deficiency</td>
</tr>
<tr>
<td>672</td>
<td>RTF1-CDG</td>
</tr>
<tr>
<td>673</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1N</td>
</tr>
<tr>
<td>674</td>
<td>N-acetylglucosaminyltransferase deficiency</td>
</tr>
<tr>
<td>675</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2A</td>
</tr>
<tr>
<td>676</td>
<td>Congenital disorder of glycosylation type 2A</td>
</tr>
<tr>
<td>677</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2A</td>
</tr>
<tr>
<td>678</td>
<td>Glucosidase 1 deficiency</td>
</tr>
<tr>
<td>679</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2B</td>
</tr>
<tr>
<td>680</td>
<td>Congenital disorder of glycosylation type 2B</td>
</tr>
<tr>
<td>681</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2B</td>
</tr>
<tr>
<td>682</td>
<td>TUSC3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>683</td>
<td>TUSC3-CDG</td>
</tr>
<tr>
<td>684</td>
<td>SRD5A3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>685</td>
<td>SRD5A3-CDG</td>
</tr>
<tr>
<td>686</td>
<td>Congenital disorder of glycosylation due to steroid 5-alpha-reductase type 3 deficiency</td>
</tr>
<tr>
<td>687</td>
<td>Intellectual deficit - cataract - coloboma - kyphosis</td>
</tr>
<tr>
<td>688</td>
<td>Kahrizi syndrome</td>
</tr>
<tr>
<td>689</td>
<td>Intellectual deficit, Kahrizi type</td>
</tr>
<tr>
<td>690</td>
<td>DPM3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>691</td>
<td>Congenital disorder of glycosylation type 1O</td>
</tr>
<tr>
<td>692</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1O</td>
</tr>
<tr>
<td>693</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1O</td>
</tr>
<tr>
<td>694</td>
<td>ALG11 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>695</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1P</td>
</tr>
<tr>
<td>696</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1P</td>
</tr>
<tr>
<td>697</td>
<td>Congenital disorder of glycosylation type 1P</td>
</tr>
<tr>
<td>698</td>
<td>Phosphoglucomutase-1 deficiency</td>
</tr>
<tr>
<td>699</td>
<td>PGM1-CDG - [Phosphoglucomutase-1 deficiency]</td>
</tr>
<tr>
<td>700</td>
<td>Congenital disorder of glycosylation type 1t</td>
</tr>
<tr>
<td>701</td>
<td>Disorders of nucleotide metabolism</td>
</tr>
<tr>
<td>702</td>
<td>Aicardi-Goutières syndrome</td>
</tr>
<tr>
<td>703</td>
<td>Encephalopathy with basal ganglia calcification</td>
</tr>
<tr>
<td>704</td>
<td>Encephalopathy with intracranial calcification and chronic lymphocytosis of cerebrospinal fluid</td>
</tr>
<tr>
<td>705</td>
<td>Aicardi-Goutières syndrome type 1</td>
</tr>
<tr>
<td>706</td>
<td>TREX deficiency</td>
</tr>
<tr>
<td>707</td>
<td>DNase III deficiency</td>
</tr>
<tr>
<td>708</td>
<td>Aicardi-Goutières syndrome type 2</td>
</tr>
<tr>
<td>709</td>
<td>RNASEH2B deficiency</td>
</tr>
<tr>
<td>710</td>
<td>Aicardi-Goutières syndrome type 3</td>
</tr>
<tr>
<td>711</td>
<td>RNASEH2C deficiency</td>
</tr>
<tr>
<td>712</td>
<td>Aicardi-Goutières syndrome type 4</td>
</tr>
<tr>
<td>713</td>
<td>RNASEH2A deficiency</td>
</tr>
<tr>
<td>714</td>
<td>Aicardi-Goutières syndrome type 5</td>
</tr>
<tr>
<td>715</td>
<td>SAMHD1deficiency</td>
</tr>
<tr>
<td>716</td>
<td>Cystic leukoencephalopathy without megalencephaly</td>
</tr>
<tr>
<td>717</td>
<td>RNASET2-deficient cystic leukoencephalopathy</td>
</tr>
<tr>
<td>718</td>
<td>Insulin-resistance syndromes</td>
</tr>
<tr>
<td>719</td>
<td>Insulin-resistance syndrome type A</td>
</tr>
<tr>
<td>720</td>
<td>Insulin-resistance syndrome type B</td>
</tr>
<tr>
<td>721</td>
<td>Rabson-Mendenhall syndrome</td>
</tr>
<tr>
<td>722</td>
<td>Laminopathy type Decaudain-Vigouroux</td>
</tr>
<tr>
<td>723</td>
<td>Laminopathy with severe metabolic syndrome and myopathy</td>
</tr>
<tr>
<td>724</td>
<td>Leprechaunism</td>
</tr>
<tr>
<td>725</td>
<td>Donohue syndrome</td>
</tr>
<tr>
<td>726</td>
<td>HAIR-AN syndrome</td>
</tr>
<tr>
<td>727</td>
<td>HAIR-AN - [hyperandrogenic-insulin resistance-acanthosis nigricans] syndrome</td>
</tr>
<tr>
<td>728</td>
<td>Insulin resistance - short fifth metacarpals</td>
</tr>
<tr>
<td>729</td>
<td>Berardinelli-Seip congenital lipodystrophy</td>
</tr>
<tr>
<td>730</td>
<td>Berardinelli-Seip syndrome</td>
</tr>
<tr>
<td>731</td>
<td>Lipoatrophic diabetes</td>
</tr>
<tr>
<td>732</td>
<td>Brunzell syndrome</td>
</tr>
<tr>
<td>733</td>
<td>Berardinelli type lipodystrophy</td>
</tr>
<tr>
<td>734</td>
<td>BSCL - [Berardinelli-Seip congenital lipodystrophy]</td>
</tr>
<tr>
<td>735</td>
<td>Familial partial lipodystrophy</td>
</tr>
<tr>
<td>736</td>
<td>Hereditary partial lipodystrophy</td>
</tr>
<tr>
<td>737</td>
<td>Familial partial lipodystrophy, Köbberling type</td>
</tr>
<tr>
<td>738</td>
<td>Familial partial lipodystrophy type 1</td>
</tr>
<tr>
<td>739</td>
<td>FPLD1 - [Familial partial lipodystrophy type 1]</td>
</tr>
<tr>
<td>740</td>
<td>Familial partial lipodystrophy, Dunnigan type</td>
</tr>
<tr>
<td>741</td>
<td>Familial partial lipodystrophy type 2</td>
</tr>
<tr>
<td>742</td>
<td>Dunnigan syndrome</td>
</tr>
<tr>
<td>743</td>
<td>FPLD2 - [Familial partial lipodystrophy type 2]</td>
</tr>
<tr>
<td>744</td>
<td>Familial partial lipodystrophy associated with PPARG mutations</td>
</tr>
<tr>
<td>745</td>
<td>Familial partial lipodystrophy type 3</td>
</tr>
<tr>
<td>746</td>
<td>FPLD3 - [Familial partial lipodystrophy type 3]</td>
</tr>
<tr>
<td>747</td>
<td>Familial partial lipodystrophy due to AKT2 mutations</td>
</tr>
<tr>
<td>748</td>
<td>Familial partial lipodystrophy due to lamin-A mutations</td>
</tr>
<tr>
<td>749</td>
<td>Severe lipodystrophic laminopathy</td>
</tr>
<tr>
<td>750</td>
<td>Familial partial lipodystrophy associated with PLIN1 mutations</td>
</tr>
<tr>
<td>751</td>
<td>Acquired generalised lipodystrophy</td>
</tr>
<tr>
<td>752</td>
<td>Metabolic syndrome</td>
</tr>
<tr>
<td>753</td>
<td>metabolic syndrome NOS</td>
</tr>
<tr>
<td>754</td>
<td>Hereditary agammaglobulinaemia with profoundly reduced or absent B cells</td>
</tr>
<tr>
<td>755</td>
<td>hereditary gamma globulin deficiency in blood</td>
</tr>
<tr>
<td>756</td>
<td>hereditary agammaglobulinaemia antibody deficiency syndrome</td>
</tr>
<tr>
<td>757</td>
<td>hereditary absence of gamma globulin in blood</td>
</tr>
<tr>
<td>758</td>
<td>hereditary agammaglobulinaemia</td>
</tr>
<tr>
<td>759</td>
<td>congenital sex-linked agammaglobulinaemia</td>
</tr>
<tr>
<td>760</td>
<td>Isolated agammaglobulinaemia</td>
</tr>
<tr>
<td>761</td>
<td>Autosomal recessive agammaglobulinaemia</td>
</tr>
<tr>
<td>762</td>
<td>Agammaglobulinaemia, non-Bruton type</td>
</tr>
<tr>
<td>763</td>
<td>Autosomal agammaglobulinaemia</td>
</tr>
<tr>
<td>764</td>
<td>Swiss type autosomal recessive agammaglobulinaemia</td>
</tr>
<tr>
<td>765</td>
<td>Swiss-type agammaglobulinaemia</td>
</tr>
<tr>
<td>766</td>
<td>Ig beta deficiency</td>
</tr>
<tr>
<td>767</td>
<td>Ig alpha deficiency</td>
</tr>
<tr>
<td>768</td>
<td>Lambda 5 deficiency</td>
</tr>
<tr>
<td>769</td>
<td>B-cell linker deficiency</td>
</tr>
<tr>
<td>770</td>
<td>BLNK - [B-cell linker] deficiency</td>
</tr>
<tr>
<td>771</td>
<td>X-linked agammaglobulinaemia</td>
</tr>
<tr>
<td>772</td>
<td>Bruton agammaglobulinaemia</td>
</tr>
<tr>
<td>773</td>
<td>Bruton type agammaglobulinaemia</td>
</tr>
<tr>
<td>774</td>
<td>Bruton x-linked agammaglobulinaemia</td>
</tr>
<tr>
<td>775</td>
<td>BTK - [Bruton tyrosine kinase] deficiency</td>
</tr>
<tr>
<td>776</td>
<td>Bruton hypogammaglobulinaemia</td>
</tr>
<tr>
<td>777</td>
<td>Syndromic agammaglobulinaemia</td>
</tr>
<tr>
<td>778</td>
<td>Agammaglobulinaemia - microcephaly - craniosynostosis - severe dermatitis</td>
</tr>
<tr>
<td>779</td>
<td>Immunodeficiency - centromeric region instability - facial anomalies syndrome</td>
</tr>
<tr>
<td>780</td>
<td>Immunodeficiency - centromeric instability - facial anomalies</td>
</tr>
<tr>
<td>781</td>
<td>Centromeric instability immunodeficiency syndrome</td>
</tr>
<tr>
<td>782</td>
<td>Malignant myelodysplasia with hypogammaglobulinaemia</td>
</tr>
<tr>
<td>783</td>
<td>Short stature due to growth hormone isolated deficiency with X-linked hypogammaglobulinaemia</td>
</tr>
<tr>
<td>784</td>
<td>Hereditary hypogammaglobulinaemia antibody deficiency syndrome</td>
</tr>
<tr>
<td>785</td>
<td>hereditary hypogammaglobulinaemia</td>
</tr>
<tr>
<td>786</td>
<td>Severe combined immunodeficiency due to absent lymphoid stem cells</td>
</tr>
<tr>
<td>787</td>
<td>SCID - [severe combined immunodeficiency] due to absent lymphoid stem cells</td>
</tr>
<tr>
<td>788</td>
<td>Malignant lymphoma of B cell type, not elsewhere classified</td>
</tr>
<tr>
<td>789</td>
<td>B-cell lymphoma NOS</td>
</tr>
<tr>
<td>790</td>
<td>Chronic kidney disease, stage 3b</td>
</tr>
<tr>
<td>791</td>
<td>chronic renal failure, stage 3b</td>
</tr>
<tr>
<td>792</td>
<td>CKD - [chronic kidney disease] stage 3b</td>
</tr>
<tr>
<td>793</td>
<td>eGFR - [estimated glomerular filtration rate] 30-44 ml/min/1.73m²</td>
</tr>
<tr>
<td>794</td>
<td>Dominant limb-girdle muscular dystrophy</td>
</tr>
<tr>
<td>795</td>
<td>LGMD1 - [limb-girdle muscular dystrophy] 1</td>
</tr>
<tr>
<td>796</td>
<td>Limb-girdle muscular dystrophy 1A, myotilin myopathy</td>
</tr>
<tr>
<td>797</td>
<td>LGMD 1A - [Limb-girdle muscular dystrophy 1A, myotilin myopathy]</td>
</tr>
<tr>
<td>798</td>
<td>Limb-girdle muscular dystrophy 1B, lamin myopathy</td>
</tr>
<tr>
<td>799</td>
<td>LGMD 1B - [Limb-girdle muscular dystrophy 1B, lamin myopathy]</td>
</tr>
<tr>
<td>800</td>
<td>Limb-girdle muscular dystrophy 1C, caveolin myopathy</td>
</tr>
<tr>
<td>801</td>
<td>LGMD 1C - [Limb-girdle muscular dystrophy 1C, caveolin myopathy]</td>
</tr>
<tr>
<td>802</td>
<td>Limb-girdle muscular dystrophy 1D, gene mapped to 6q23</td>
</tr>
<tr>
<td>803</td>
<td>Limb-girdle muscular dystrophy 1E, gene mapped to 7q</td>
</tr>
<tr>
<td>804</td>
<td>Limb-girdle muscular dystrophy 1F, gene mapped to 7q32.1-32.2</td>
</tr>
<tr>
<td>805</td>
<td>Limb-girdle muscular dystrophy 1G, gene mapped to 4q21</td>
</tr>
<tr>
<td>806</td>
<td>Limb-girdle muscular dystrophy 1H, gene mapped to 3p25.1p23</td>
</tr>
<tr>
<td>807</td>
<td>LGMD1H - [Limb-girdle muscular dystrophy] 1H</td>
</tr>
<tr>
<td>808</td>
<td>Japanese encephalitis</td>
</tr>
<tr>
<td>809</td>
<td>Russian autumnal encephalitis</td>
</tr>
<tr>
<td>810</td>
<td>JE - [Japanese encephalitis]</td>
</tr>
<tr>
<td>811</td>
<td>Japanese encephalitis virus disease</td>
</tr>
<tr>
<td>812</td>
<td>Japanese B encephalitis</td>
</tr>
<tr>
<td>813</td>
<td>JBE - [Japanese B encephalitis}</td>
</tr>
<tr>
<td>814</td>
<td>B type encephalitis</td>
</tr>
<tr>
<td>815</td>
<td>Hereditary skin peeling</td>
</tr>
<tr>
<td>816</td>
<td>Generalised non-inflammatory peeling skin syndrome</td>
</tr>
<tr>
<td>817</td>
<td>Peeling skin syndrome, type A</td>
</tr>
<tr>
<td>818</td>
<td>Generalised inflammatory peeling skin syndrome</td>
</tr>
<tr>
<td>819</td>
<td>Peeling skin syndrome, type B</td>
</tr>
<tr>
<td>820</td>
<td>Acral skin peeling syndrome</td>
</tr>
<tr>
<td>821</td>
<td>APSS</td>
</tr>
<tr>
<td>822</td>
<td>Other specified arthrogryposis syndromes</td>
</tr>
<tr>
<td>823</td>
<td>Popliteal pterygium syndrome</td>
</tr>
<tr>
<td>824</td>
<td>Popliteal web syndrome</td>
</tr>
<tr>
<td>825</td>
<td>Bartsocas-Papas syndrome</td>
</tr>
<tr>
<td>826</td>
<td>Autosomal dominant popliteal pterygium syndrome</td>
</tr>
<tr>
<td>827</td>
<td>Lethal congenital contracture syndrome</td>
</tr>
<tr>
<td>828</td>
<td>Lethal congenital contracture syndrome type 1</td>
</tr>
<tr>
<td>829</td>
<td>Lethal congenital contracture syndrome type 2</td>
</tr>
<tr>
<td>830</td>
<td>Lethal congenital contracture syndrome type 3</td>
</tr>
<tr>
<td>831</td>
<td>Distal arthrogryposis</td>
</tr>
<tr>
<td>832</td>
<td>Digitotalar dysmorphism</td>
</tr>
<tr>
<td>833</td>
<td>Distal arthrogryposis type 1</td>
</tr>
<tr>
<td>834</td>
<td>Freeman-Sheldon syndrome</td>
</tr>
<tr>
<td>835</td>
<td>Distal arthrogryposis type 2A</td>
</tr>
<tr>
<td>836</td>
<td>Craniocarpotarsal dysplasia</td>
</tr>
<tr>
<td>837</td>
<td>Craniocarpotarsal dystrophy</td>
</tr>
<tr>
<td>838</td>
<td>Whistling face syndrome</td>
</tr>
<tr>
<td>839</td>
<td>Sheldon-Hall syndrome</td>
</tr>
<tr>
<td>840</td>
<td>Distal arthrogryposis type 2B</td>
</tr>
<tr>
<td>841</td>
<td>Distal arthrogryposis type 3</td>
</tr>
<tr>
<td>842</td>
<td>Arthrogryposis - severe scoliosis</td>
</tr>
<tr>
<td>843</td>
<td>Distal arthrogryposis type 4</td>
</tr>
<tr>
<td>844</td>
<td>Arthrogryposis - ophthalmoplegia - retinopathy</td>
</tr>
<tr>
<td>845</td>
<td>Distal arthrogryposis type 5</td>
</tr>
<tr>
<td>846</td>
<td>Arthrogryposis-like hand anomaly - sensorineural deafness</td>
</tr>
<tr>
<td>847</td>
<td>Distal arthrogryposis type 6</td>
</tr>
<tr>
<td>848</td>
<td>Trismus - pseudocamptodactyly</td>
</tr>
<tr>
<td>849</td>
<td>Distal arthrogryposis type 7</td>
</tr>
<tr>
<td>850</td>
<td>Hecht syndrome</td>
</tr>
<tr>
<td>851</td>
<td>Acute monoblastic or monocytic leukaemia</td>
</tr>
<tr>
<td>852</td>
<td>FAB M5</td>
</tr>
<tr>
<td>853</td>
<td>acute monocytic leukaemia</td>
</tr>
<tr>
<td>854</td>
<td>acute monocytic/monoblastic leukaemia</td>
</tr>
<tr>
<td>855</td>
<td>acute monoblastic/monocytic leukaemia without mention of remission</td>
</tr>
<tr>
<td>856</td>
<td>acute monocytoid leukaemia</td>
</tr>
<tr>
<td>857</td>
<td>monoblastic leukaemia</td>
</tr>
<tr>
<td>858</td>
<td>FAB type M5a</td>
</tr>
<tr>
<td>859</td>
<td>French-American-British (FAB) type M5a</td>
</tr>
<tr>
<td>860</td>
<td>Acute monoblastic or monocytic leukaemia in complete remission</td>
</tr>
<tr>
<td>861</td>
<td>AML M5a</td>
</tr>
<tr>
<td>862</td>
<td>AML M5b</td>
</tr>
<tr>
<td>863</td>
<td>Acute hepatitis B</td>
</tr>
<tr>
<td>864</td>
<td>Acute hepatitis B virus infection</td>
</tr>
<tr>
<td>865</td>
<td>Acute hepatitis B with Hepatitis D virus co-infection</td>
</tr>
<tr>
<td>866</td>
<td>acute hepatitis B with delta-agent without hepatic coma</td>
</tr>
<tr>
<td>867</td>
<td>acute hepatitis type B, with delta-agent</td>
</tr>
<tr>
<td>868</td>
<td>Acute hepatitis B without Hepatitis D virus co-infection</td>
</tr>
<tr>
<td>869</td>
<td>acute hepatitis b without delta-agent and without hepatic coma</td>
</tr>
<tr>
<td>870</td>
<td>acute type B viral hepatitis</td>
</tr>
<tr>
<td>871</td>
<td>HAA - [hepatitis associated antigen]</td>
</tr>
<tr>
<td>872</td>
<td>hepatitis associated antigen</td>
</tr>
<tr>
<td>873</td>
<td>type B viral hepatitis</td>
</tr>
<tr>
<td>874</td>
<td>SH - [serum hepatitis]</td>
</tr>
<tr>
<td>875</td>
<td>serum hepatitis</td>
</tr>
<tr>
<td>876</td>
<td>homologous serum hepatitis</td>
</tr>
<tr>
<td>877</td>
<td>inoculation hepatitis b</td>
</tr>
<tr>
<td>878</td>
<td>post transfusion hepatitis b</td>
</tr>
<tr>
<td>879</td>
<td>postimmunization hepatitis b</td>
</tr>
<tr>
<td>880</td>
<td>posttransfusion viral hepatitis b</td>
</tr>
<tr>
<td>881</td>
<td>Australia antigen hepatitis</td>
</tr>
<tr>
<td>882</td>
<td>Transfusion hepatitis</td>
</tr>
<tr>
<td>883</td>
<td>Megavitamin-B6 syndrome</td>
</tr>
<tr>
<td>884</td>
<td>Other specified sphingolipidosis</td>
</tr>
<tr>
<td>885</td>
<td>Mucolipidosis type 4</td>
</tr>
<tr>
<td>886</td>
<td>Sialolipidosis</td>
</tr>
<tr>
<td>887</td>
<td>Gaucher disease</td>
</tr>
<tr>
<td>888</td>
<td>Acid beta-glucosidase deficiency</td>
</tr>
<tr>
<td>889</td>
<td>Glucocerebrosidase deficiency</td>
</tr>
<tr>
<td>890</td>
<td>Glucosylceramide beta-glucosidase deficiency</td>
</tr>
<tr>
<td>891</td>
<td>Glucocerebrosidosis</td>
</tr>
<tr>
<td>892</td>
<td>Cerebroside lipidosis syndrome</td>
</tr>
<tr>
<td>893</td>
<td>Gaucher disease type 1</td>
</tr>
<tr>
<td>894</td>
<td>Noncerebral juvenile Gaucher disease</td>
</tr>
<tr>
<td>895</td>
<td>Adult Gaucher disease</td>
</tr>
<tr>
<td>896</td>
<td>Gaucher disease type 2</td>
</tr>
<tr>
<td>897</td>
<td>Acute neuronopathic Gaucher disease</td>
</tr>
<tr>
<td>898</td>
<td>Infantile cerebral Gaucher disease</td>
</tr>
<tr>
<td>899</td>
<td>Infantile Gaucher disease</td>
</tr>
<tr>
<td>900</td>
<td>Cerebral acute Gaucher disease</td>
</tr>
<tr>
<td>901</td>
<td>Gaucher disease type 3</td>
</tr>
<tr>
<td>902</td>
<td>Cerebral juvenile and adult form of Gaucher disease</td>
</tr>
<tr>
<td>903</td>
<td>Chronic neuronopathic Gaucher disease</td>
</tr>
<tr>
<td>904</td>
<td>Subacute neuronopathic Gaucher disease</td>
</tr>
<tr>
<td>905</td>
<td>Juvenile Gaucher disease</td>
</tr>
<tr>
<td>906</td>
<td>Norrbotnian Gaucher disease</td>
</tr>
<tr>
<td>907</td>
<td>Gaucher disease - ophthalmoplegia - cardiovascular calcification</td>
</tr>
<tr>
<td>908</td>
<td>Cardiovascular Gaucher disease</td>
</tr>
<tr>
<td>909</td>
<td>Gaucher disease type 3C</td>
</tr>
<tr>
<td>910</td>
<td>Gaucher-like disease</td>
</tr>
<tr>
<td>911</td>
<td>Perinatal-lethal Gaucher disease</td>
</tr>
<tr>
<td>912</td>
<td>Fetal Gaucher disease</td>
</tr>
<tr>
<td>913</td>
<td>Collodion type Gaucher disease</td>
</tr>
<tr>
<td>914</td>
<td>Atypical Gaucher disease due to saposin C deficiency</td>
</tr>
<tr>
<td>915</td>
<td>Gaucher’s splenomegaly</td>
</tr>
<tr>
<td>916</td>
<td>Mucosulfatidosis</td>
</tr>
<tr>
<td>917</td>
<td>Multiple sulfatase deficiency</td>
</tr>
<tr>
<td>918</td>
<td>Juvenile sulfatidose, Austin type</td>
</tr>
<tr>
<td>919</td>
<td>Austin disease</td>
</tr>
<tr>
<td>920</td>
<td>Niemann-Pick disease</td>
</tr>
<tr>
<td>921</td>
<td>Sphingomyelinase deficiency</td>
</tr>
<tr>
<td>922</td>
<td>Niemann-Pick disease type A</td>
</tr>
<tr>
<td>923</td>
<td>Niemann-Pick disease type B</td>
</tr>
<tr>
<td>924</td>
<td>Niemann-Pick disease type C</td>
</tr>
<tr>
<td>925</td>
<td>cholesterol transporter deficiency</td>
</tr>
<tr>
<td>926</td>
<td>Niemann-Pick disease type C, severe perinatal</td>
</tr>
<tr>
<td>927</td>
<td>Niemann-Pick disease type C, severe early infantile neurologic onset</td>
</tr>
<tr>
<td>928</td>
<td>Niemann-Pick disease type C, late infantile neurologic onset</td>
</tr>
<tr>
<td>929</td>
<td>Niemann-Pick disease type C, juvenile neurologic onset</td>
</tr>
<tr>
<td>930</td>
<td>Niemann-Pick disease type C, classic form</td>
</tr>
<tr>
<td>931</td>
<td>Niemann-Pick disease type C, adult neurologic onset</td>
</tr>
<tr>
<td>932</td>
<td>Farber disease</td>
</tr>
<tr>
<td>933</td>
<td>Farber lipogranulomatosis</td>
</tr>
<tr>
<td>934</td>
<td>Ceramidase deficiency</td>
</tr>
<tr>
<td>935</td>
<td>Disseminated lipogranulomatosis</td>
</tr>
<tr>
<td>936</td>
<td>Lysosomal acid lipase deficiency</td>
</tr>
<tr>
<td>937</td>
<td>Acid esterase deficiency</td>
</tr>
<tr>
<td>938</td>
<td>Wolman disease</td>
</tr>
<tr>
<td>939</td>
<td>Cholesteryl ester storage disease</td>
</tr>
<tr>
<td>940</td>
<td>CESD - [Cholesteryl ester storage disease]</td>
</tr>
<tr>
<td>941</td>
<td>Encephalopathy due to prosaposin deficiency</td>
</tr>
<tr>
<td>942</td>
<td>Combined prosaposin deficiency</td>
</tr>
<tr>
<td>943</td>
<td>Genetic susceptibility to particular pathogens</td>
</tr>
<tr>
<td>944</td>
<td>Idiopathic CD4 lymphocytopenia</td>
</tr>
<tr>
<td>945</td>
<td>Immunodeficiency due to interleukin-1 receptor-associated kinase-4 deficiency</td>
</tr>
<tr>
<td>946</td>
<td>IRAK4 - [interleukin-1 receptor-associated kinase-4 deficiency]</td>
</tr>
<tr>
<td>947</td>
<td>Lung fibrosis - immunodeficiency - gonadal dysgenesis</td>
</tr>
<tr>
<td>948</td>
<td>Mendelian susceptibility to mycobacterial diseases</td>
</tr>
<tr>
<td>949</td>
<td>Idiopathic infection caused by BCG or atypical mycobacteria</td>
</tr>
<tr>
<td>950</td>
<td>MSMD - [Mendelian susceptibility to mycobacterial diseases]</td>
</tr>
<tr>
<td>951</td>
<td>Autosomal recessive mendelian susceptibility to mycobacterial diseases</td>
</tr>
<tr>
<td>952</td>
<td>AR MSMD - [autosomal recessive mendelian susceptibility to mycobacterial diseases]</td>
</tr>
<tr>
<td>953</td>
<td>Complete autosomal recessive interferon-gamma receptor 1 deficiency</td>
</tr>
<tr>
<td>954</td>
<td>Complete AR IFNGR1 - [autosomal recessive interferon-gamma receptor 1] deficiency</td>
</tr>
<tr>
<td>955</td>
<td>Partial autosomal recessive interferon-gamma receptor 1 deficiency</td>
</tr>
<tr>
<td>956</td>
<td>Partial AR IFNGR1- [autosomal recessive interferon-gamma receptor 1] deficiency</td>
</tr>
<tr>
<td>957</td>
<td>Complete autosomal recessive interferon-gamma receptor 2 deficiency</td>
</tr>
<tr>
<td>958</td>
<td>Complete AR IFNGR2 - [autosomal recessive interferon-gamma receptor 2] deficiency</td>
</tr>
<tr>
<td>959</td>
<td>Partial autosomal recessive interferon-gamma receptor 2 deficiency</td>
</tr>
<tr>
<td>960</td>
<td>Partial AR IFNGR2 - [autosomal recessive interferon-gamma receptor 2] deficiency</td>
</tr>
<tr>
<td>961</td>
<td>Autosomal recessive interleukin 12 receptor beta-1 chain deficiency</td>
</tr>
<tr>
<td>962</td>
<td>AR IL12RB1 - [Autosomal recessive interleukin 12 receptor beta-1 chain] deficiency</td>
</tr>
<tr>
<td>963</td>
<td>Autosomal recessive interleukin 12p40 deficiency</td>
</tr>
<tr>
<td>964</td>
<td>AR IL12B - [Autosomal recessive interleukin 12p40] deficiency</td>
</tr>
<tr>
<td>965</td>
<td>Autosomal recessive tyrosine kinase 2 deficiency</td>
</tr>
<tr>
<td>966</td>
<td>Autosomal recessive hyper-IgE syndrome with atypical mycobacteriosis</td>
</tr>
<tr>
<td>967</td>
<td>Autosomal dominant mendelian susceptibility to mycobacterial diseases</td>
</tr>
<tr>
<td>968</td>
<td>AD MSMD - [Autosomal dominant mendelian susceptibility to mycobacterial diseases]</td>
</tr>
<tr>
<td>969</td>
<td>Autosomal dominant interferon-gamma receptor 1 deficiency</td>
</tr>
<tr>
<td>970</td>
<td>AD IFNGR1 - [Autosomal dominant interferon-gamma receptor 1] deficiency</td>
</tr>
<tr>
<td>971</td>
<td>Autosomal dominant Stat1 deficiency</td>
</tr>
<tr>
<td>972</td>
<td>Mendelian susceptibility to mycobacterial diseases due to partial signal transducer and activator of transcription 1 deficiency</td>
</tr>
<tr>
<td>973</td>
<td>AD STAT1 - [Autosomal dominant Stat1] deficiency</td>
</tr>
<tr>
<td>974</td>
<td>X-linked recessive mendelian susceptibility to mycobacterial diseases</td>
</tr>
<tr>
<td>975</td>
<td>XR MSMD - [X-linked recessive mendelian susceptibility to mycobacterial diseases]</td>
</tr>
<tr>
<td>976</td>
<td>Monocytopenia with susceptibility to infections</td>
</tr>
<tr>
<td>977</td>
<td>MonoMAC syndrome</td>
</tr>
<tr>
<td>978</td>
<td>Pyogenic bacterial infections due to MyD88 deficiency</td>
</tr>
<tr>
<td>979</td>
<td>Mucopolysaccharidosis type 6</td>
</tr>
<tr>
<td>980</td>
<td>N-acetylgalactosamine 4-sulfatase deficiency</td>
</tr>
<tr>
<td>981</td>
<td>Arylsulfatase B deficiency</td>
</tr>
<tr>
<td>982</td>
<td>Maroteaux-Lamy syndrome</td>
</tr>
<tr>
<td>983</td>
<td>ARSB - [Arylsulfatase B] deficiency</td>
</tr>
<tr>
<td>984</td>
<td>Human leukocyte antigen negative</td>
</tr>
<tr>
<td>985</td>
<td>HLA - [human leukocyte antigen] B27 negative</td>
</tr>
<tr>
<td>986</td>
<td>Other specified immunodeficiencies with predominantly antibody defects</td>
</tr>
<tr>
<td>987</td>
<td>Common variable immunodeficiency</td>
</tr>
<tr>
<td>988</td>
<td>B-cell activating factor receptor deficiency</td>
</tr>
<tr>
<td>989</td>
<td>BAFF - [ B-cell activating factor] receptor deficiency</td>
</tr>
<tr>
<td>990</td>
<td>Cluster of differentiation 19 deficiency</td>
</tr>
<tr>
<td>991</td>
<td>CD19- [cluster of differentiation 19] deficiency</td>
</tr>
<tr>
<td>992</td>
<td>Cluster of differentiation 20 deficiency</td>
</tr>
<tr>
<td>993</td>
<td>CD20 - [cluster of differentiation 20] deficiency</td>
</tr>
<tr>
<td>994</td>
<td>Cluster of differentiation 81 deficiency</td>
</tr>
<tr>
<td>995</td>
<td>CD81 - [cluster of differentiation 81] deficiency</td>
</tr>
<tr>
<td>996</td>
<td>Inducible costimulator deficiency</td>
</tr>
<tr>
<td>997</td>
<td>ICOS - [inducible costimulator] deficiency</td>
</tr>
<tr>
<td>998</td>
<td>Transmembrane activator and calcium-modulating cyclophilin ligand interactor deficiency</td>
</tr>
<tr>
<td>999</td>
<td>TACI - [transmembrane activator and calcium-modulating cyclophilin ligand interactor] deficiency</td>
</tr>
<tr>
<td>1000</td>
<td>Certain specified immunodeficiencies with predominantly antibody defects</td>
</tr>
<tr>
<td>1001</td>
<td>Low birth weight - dwarfism - dysgammaglobulinaemia</td>
</tr>
<tr>
<td>1002</td>
<td>Christian-Rosenberg syndrome</td>
</tr>
<tr>
<td>1003</td>
<td>Osteopetrosis - hypogammaglobulinaemia</td>
</tr>
<tr>
<td>1004</td>
<td>Autosomal recessive osteoclast-poor osteopetrosis with hypogammaglobulinaemia</td>
</tr>
<tr>
<td>1005</td>
<td>Autosomal recessive osteopetrosis type 7</td>
</tr>
<tr>
<td>1006</td>
<td>Microcephaly - hypogammaglobulinaemia - abnormal immunity</td>
</tr>
<tr>
<td>1007</td>
<td>Say-Barber-Miller syndrome</td>
</tr>
<tr>
<td>1008</td>
<td>Kappa light chain deficiency</td>
</tr>
<tr>
<td>1009</td>
<td>Kappa light chain disease</td>
</tr>
<tr>
<td>1010</td>
<td>Kappa light chain immunodeficiency</td>
</tr>
<tr>
<td>1011</td>
<td>X-linked immunoneurologic disorder</td>
</tr>
<tr>
<td>1012</td>
<td>Other specified chronic hepatitis B</td>
</tr>
<tr>
<td>1013</td>
<td>Chronic hepatitis B, with cirrhosis</td>
</tr>
<tr>
<td>1014</td>
<td>hepatitis B-related cirrhosis</td>
</tr>
<tr>
<td>1015</td>
<td>Chronic hepatitis B, with cirrhosis, with cirrhosis-related complications</td>
</tr>
<tr>
<td>1016</td>
<td>Chronic hepatitis B, with cirrhosis, without cirrhosis-related complications</td>
</tr>
<tr>
<td>1017</td>
<td>Chronic hepatitis B, without cirrhosis</td>
</tr>
<tr>
<td>1018</td>
<td>Chronic hepatitis B, without mention of cirrhosis</td>
</tr>
<tr>
<td>1019</td>
<td>Chronic hepatitis B infection without liver disease</td>
</tr>
<tr>
<td>1020</td>
<td>Chronic hepatitis B infection with high viral load, immunotolerant</td>
</tr>
<tr>
<td>1021</td>
<td>Chronic hepatitis B infection with low viral load, immune control</td>
</tr>
<tr>
<td>1022</td>
<td>Chronic hepatitis B, co-infected with hepatitis C virus</td>
</tr>
<tr>
<td>1023</td>
<td>Chronic hepatitis B, co-infected with hepatitis C virus, with cirrhosis</td>
</tr>
<tr>
<td>1024</td>
<td>Chronic hepatitis B, co-infected with hepatitis C virus, with cirrhosis, with cirrhosis-related complications</td>
</tr>
<tr>
<td>1025</td>
<td>Chronic hepatitis B, co-infected with hepatitis C virus, with cirrhosis, without cirrhosis-related complications</td>
</tr>
<tr>
<td>1026</td>
<td>Chronic hepatitis B, co-infected with hepatitis C virus, without cirrhosis</td>
</tr>
<tr>
<td>1027</td>
<td>Chronic hepatitis B, co-infected with hepatitis C virus and hepatitis D virus</td>
</tr>
<tr>
<td>1028</td>
<td>Chronic hepatitis B, co-infected with hepatitis C virus and hepatitis D virus, with cirrhosis</td>
</tr>
<tr>
<td>1029</td>
<td>Chronic hepatitis B, co-infected with hepatitis C virus and hepatitis D virus, with cirrhosis with cirrhosis-related complications</td>
</tr>
<tr>
<td>1030</td>
<td>Chronic hepatitis B, co-infected with hepatitis C virus and hepatitis D virus, with cirrhosis, without cirrhosis-related complications</td>
</tr>
<tr>
<td>1031</td>
<td>Chronic hepatitis B, co-infected with hepatitis C virus and hepatitis D virus, without cirrhosis</td>
</tr>
<tr>
<td>1032</td>
<td>Chronic hepatitis B without human immunodeficiency virus co-infection</td>
</tr>
<tr>
<td>1033</td>
<td>Immunodeficiency with factor B deficiency</td>
</tr>
<tr>
<td>1034</td>
<td>Haemophilia B</td>
</tr>
<tr>
<td>1035</td>
<td>Christmas disease</td>
</tr>
<tr>
<td>1036</td>
<td>plasma thromboplastin component deficiency</td>
</tr>
<tr>
<td>1037</td>
<td>deficiency of functional factor ix</td>
</tr>
<tr>
<td>1038</td>
<td>sex-linked factor IX deficiency disease</td>
</tr>
<tr>
<td>1039</td>
<td>PTC - [plasma thromboplastin component] deficiency</td>
</tr>
<tr>
<td>1040</td>
<td>functional factor IX deficiency</td>
</tr>
<tr>
<td>1041</td>
<td>Severe haemophilia B</td>
</tr>
<tr>
<td>1042</td>
<td>Moderately severe haemophilia B</td>
</tr>
<tr>
<td>1043</td>
<td>Mild haemophilia B</td>
</tr>
<tr>
<td>1044</td>
<td>Symptomatic form of haemophilia B in female carriers</td>
</tr>
<tr>
<td>1045</td>
<td>Immune dysregulation syndromes presenting primarily with lymphoproliferation</td>
</tr>
<tr>
<td>1046</td>
<td>Autosomal recessive lymphoproliferative disease</td>
</tr>
<tr>
<td>1047</td>
<td>Autoimmune lymphoproliferative syndrome</td>
</tr>
<tr>
<td>1048</td>
<td>autoimmune lymphoproliferative syndrome with recurrent infections</td>
</tr>
<tr>
<td>1049</td>
<td>Canale-Smith syndrome</td>
</tr>
<tr>
<td>1050</td>
<td>FAS deficiency</td>
</tr>
<tr>
<td>1051</td>
<td>FAS deficiency (ALPS-FAS)(ALPS1a)</td>
</tr>
<tr>
<td>1052</td>
<td>Caspase 8 defect (ALPS2b)</td>
</tr>
<tr>
<td>1053</td>
<td>ALPS-NRAS</td>
</tr>
<tr>
<td>1054</td>
<td>ALPS-KRAS</td>
</tr>
<tr>
<td>1055</td>
<td>ALPS-FASLG (ALPS1b)</td>
</tr>
<tr>
<td>1056</td>
<td>ALPS-CASP10 (ALPS2a)</td>
</tr>
<tr>
<td>1057</td>
<td>X-linked lymphoproliferative disease</td>
</tr>
<tr>
<td>1058</td>
<td>Purtilo syndrome</td>
</tr>
<tr>
<td>1059</td>
<td>Immunodeficiency following hereditary defective response to Epstein-Barr virus</td>
</tr>
<tr>
<td>1060</td>
<td>immunodeficient hereditary defective response to Epstein Barr virus</td>
</tr>
<tr>
<td>1061</td>
<td>x-linked lymphoproliferation disease</td>
</tr>
<tr>
<td>1062</td>
<td>x-linked lymphoproliferative disease or disorder</td>
</tr>
<tr>
<td>1063</td>
<td>x-linked lymphoproliferative syndrome</td>
</tr>
<tr>
<td>1064</td>
<td>XLPS - [x-linked lymphoproliferative syndrome]</td>
</tr>
<tr>
<td>1065</td>
<td>Fatal Epstein Barr virus syndrome</td>
</tr>
<tr>
<td>1066</td>
<td>XIAP deficiency (XLP2)</td>
</tr>
<tr>
<td>1067</td>
<td>SH2D1A deficiency (XLP1)</td>
</tr>
<tr>
<td>1068</td>
<td>Diabetes mellitus due to other genetic syndromes</td>
</tr>
<tr>
<td>1069</td>
<td>MODY syndrome</td>
</tr>
<tr>
<td>1070</td>
<td>MODY 1 syndrome</td>
</tr>
<tr>
<td>1071</td>
<td>maturity onset diabetes of the young type 1</td>
</tr>
<tr>
<td>1072</td>
<td>MODY 2 syndrome</td>
</tr>
<tr>
<td>1073</td>
<td>Maturity Onset Diabetes of the Young type 2</td>
</tr>
<tr>
<td>1074</td>
<td>MODY 3 syndrome</td>
</tr>
<tr>
<td>1075</td>
<td>Maturity Onset Diabetes of the Young type 3</td>
</tr>
<tr>
<td>1076</td>
<td>MODY 4 syndrome</td>
</tr>
<tr>
<td>1077</td>
<td>Maturity Onset Diabetes of the Young type 4</td>
</tr>
<tr>
<td>1078</td>
<td>MODY 5 syndrome</td>
</tr>
<tr>
<td>1079</td>
<td>Maturity Onset Diabetes of the Young type 5</td>
</tr>
<tr>
<td>1080</td>
<td>Renal cysts - Maturity-Onset Diabetes of the Young type 5 syndrome</td>
</tr>
<tr>
<td>1081</td>
<td>Renal dysfunction - early-onset diabetes</td>
</tr>
<tr>
<td>1082</td>
<td>Microdeletion 17q11.2</td>
</tr>
<tr>
<td>1083</td>
<td>ADTKD - [Autosomal Dominant Tubulointerstitial Kidney Disease] -HNF1B</td>
</tr>
<tr>
<td>1084</td>
<td>Renal diabetes MODY 5 syndrome</td>
</tr>
<tr>
<td>1085</td>
<td>RCAD - [renal cyst and diabetes syndrome]</td>
</tr>
<tr>
<td>1086</td>
<td>MODY 6 syndrome</td>
</tr>
<tr>
<td>1087</td>
<td>Maturity Onset Diabetes of the Young type 6</td>
</tr>
<tr>
<td>1088</td>
<td>MODY 7 syndrome</td>
</tr>
<tr>
<td>1089</td>
<td>Maturity Onset Diabetes of the Young type 7</td>
</tr>
<tr>
<td>1090</td>
<td>MODY 8 syndrome</td>
</tr>
<tr>
<td>1091</td>
<td>Maturity Onset Diabetes of the Young type 8</td>
</tr>
<tr>
<td>1092</td>
<td>Wolcott-Rallison syndrome</td>
</tr>
<tr>
<td>1093</td>
<td>Multiple epiphyseal dysplasia with early-onset diabetes mellitus</td>
</tr>
<tr>
<td>1094</td>
<td>Female Genital Mutilation Type 2b</td>
</tr>
<tr>
<td>1</td>
<td>Other specified syndromic craniosynostoses</td>
</tr>
<tr>
<td>2</td>
<td>Crouzon syndrome - acanthosis nigricans</td>
</tr>
<tr>
<td>3</td>
<td>Carpenter syndrome</td>
</tr>
<tr>
<td>4</td>
<td>Saethre-Chotzen syndrome</td>
</tr>
<tr>
<td>5</td>
<td>Robinow-Sorauf syndrome</td>
</tr>
<tr>
<td>6</td>
<td>Muenke syndrome</td>
</tr>
<tr>
<td>7</td>
<td>Antley-Bixler syndrome</td>
</tr>
<tr>
<td>8</td>
<td>Baller-Gerold syndrome</td>
</tr>
<tr>
<td>9</td>
<td>Craniosynostosis, Boston type</td>
</tr>
<tr>
<td>10</td>
<td>Craniosynostosis, Philadelphia type</td>
</tr>
<tr>
<td>11</td>
<td>C syndrome</td>
</tr>
<tr>
<td>12</td>
<td>Opitz trigonocephaly syndrome</td>
</tr>
<tr>
<td>13</td>
<td>Aurocephalosyndactyly</td>
</tr>
<tr>
<td>14</td>
<td>Craniomicromelic syndrome</td>
</tr>
<tr>
<td>15</td>
<td>Cloverleaf skull - asphyxiating thoracic dysplasia</td>
</tr>
<tr>
<td>16</td>
<td>Hunter-McAlpine craniosynostosis</td>
</tr>
<tr>
<td>17</td>
<td>5q35.2 duplication</td>
</tr>
<tr>
<td>18</td>
<td>Familial scaphocephaly syndrome, McGillivray type</td>
</tr>
<tr>
<td>19</td>
<td>Craniosynostosis, Herrmann-Opitz type</td>
</tr>
<tr>
<td>20</td>
<td>Pseudoaminopterin syndrome</td>
</tr>
<tr>
<td>21</td>
<td>B lymphoblastic leukaemia or lymphoma, not elsewhere classified</td>
</tr>
<tr>
<td>22</td>
<td>c-ALL</td>
</tr>
<tr>
<td>23</td>
<td>Lymphoblastic lymphoma, NOS</td>
</tr>
<tr>
<td>24</td>
<td>Common precursor B ALL</td>
</tr>
<tr>
<td>25</td>
<td>Lymphoblastic B-cell lymphoma</td>
</tr>
<tr>
<td>26</td>
<td>Pro-B ALL</td>
</tr>
<tr>
<td>27</td>
<td>B-precursor lymphoma</td>
</tr>
<tr>
<td>28</td>
<td>LBL - [lymphoblastic lymphoma]</td>
</tr>
<tr>
<td>29</td>
<td>Cerebral vasoconstriction syndromes</td>
</tr>
<tr>
<td>30</td>
<td>Reversible cerebral vasoconstriction syndrome</td>
</tr>
<tr>
<td>31</td>
<td>isolated benign cerebral vasculitis</td>
</tr>
<tr>
<td>32</td>
<td>acute benign cerebral angiopathy</td>
</tr>
<tr>
<td>33</td>
<td>reversible cerebral segmental vasoconstriction</td>
</tr>
<tr>
<td>34</td>
<td>Call-Fleming syndrome</td>
</tr>
<tr>
<td>35</td>
<td>Call syndrome</td>
</tr>
<tr>
<td>36</td>
<td>CNS pseudovasculitis</td>
</tr>
<tr>
<td>37</td>
<td>Irritable bowel syndrome, constipation predominant</td>
</tr>
<tr>
<td>38</td>
<td>IBS-C - [Irritable bowel syndrome, constipation predominant]</td>
</tr>
<tr>
<td>39</td>
<td>Haemoglobin C disease</td>
</tr>
<tr>
<td>40</td>
<td>Homozygous HbC carriers</td>
</tr>
<tr>
<td>41</td>
<td>Homozygous (HbC/HbC, HbC/beta-thal and other)</td>
</tr>
<tr>
<td>42</td>
<td>Vitamin C deficiency, unspecified</td>
</tr>
<tr>
<td>43</td>
<td>Vitamin C deficiency</td>
</tr>
<tr>
<td>44</td>
<td>Ascorbic acid deficiency</td>
</tr>
<tr>
<td>45</td>
<td>Crimean-Congo haemorrhagic fever</td>
</tr>
<tr>
<td>46</td>
<td>CCHF - [Crimean-Congo haemorrhagic fever]</td>
</tr>
<tr>
<td>47</td>
<td>Kara mikh typhoid fever</td>
</tr>
<tr>
<td>48</td>
<td>Xīnjiāng haemorrhagic fever</td>
</tr>
<tr>
<td>49</td>
<td>Multiple system atrophy, Cerebellar type</td>
</tr>
<tr>
<td>50</td>
<td>Multiple system atrophy-C</td>
</tr>
<tr>
<td>51</td>
<td>MSA-C - [multiple system atrophy - cerebellar type]</td>
</tr>
<tr>
<td>52</td>
<td>Congenital pulmonary airway malformations</td>
</tr>
<tr>
<td>53</td>
<td>Congenital cystic disease of lung</td>
</tr>
<tr>
<td>54</td>
<td>Congenital lung cyst</td>
</tr>
<tr>
<td>55</td>
<td>Congenital cystic lung</td>
</tr>
<tr>
<td>56</td>
<td>Congenital cystic adenomatoid malformation</td>
</tr>
<tr>
<td>57</td>
<td>CCAM - [Congenital cystic adenomatoid malformation]</td>
</tr>
<tr>
<td>58</td>
<td>Congenital polycystic disease of lung</td>
</tr>
<tr>
<td>59</td>
<td>Congenital polycystic lung</td>
</tr>
<tr>
<td>60</td>
<td>Multiple congenital bronchogenic cysts</td>
</tr>
<tr>
<td>61</td>
<td>Congenital honeycomb lung</td>
</tr>
<tr>
<td>62</td>
<td>Congenital pulmonary airway malformation type 0</td>
</tr>
<tr>
<td>63</td>
<td>CPAM type 0 - [Congenital pulmonary airway malformation type 0]</td>
</tr>
<tr>
<td>64</td>
<td>Congenital pulmonary airway malformation type 1</td>
</tr>
<tr>
<td>65</td>
<td>CPAM type 1 - [Congenital pulmonary airway malformation type 1]</td>
</tr>
<tr>
<td>66</td>
<td>Congenital pulmonary airway malformation type 2</td>
</tr>
<tr>
<td>67</td>
<td>CPAM type 2 - [Congenital pulmonary airway malformation type 2]</td>
</tr>
<tr>
<td>68</td>
<td>Congenital pulmonary airway malformation type 3</td>
</tr>
<tr>
<td>69</td>
<td>CPAM type 3 - [Congenital pulmonary airway malformation type 3]</td>
</tr>
<tr>
<td>70</td>
<td>Congenital pulmonary airway malformation type 4</td>
</tr>
<tr>
<td>71</td>
<td>CPAM type 4 - [Congenital pulmonary airway malformation type 4]</td>
</tr>
<tr>
<td>72</td>
<td>Compound heterozygous sickling disorders without crisis</td>
</tr>
<tr>
<td>73</td>
<td>double heterozygous sickling disorder</td>
</tr>
<tr>
<td>74</td>
<td>Sickle cell Hb-C disease without crisis</td>
</tr>
<tr>
<td>75</td>
<td>Hb SC disease</td>
</tr>
<tr>
<td>76</td>
<td>Hb S Hb C disease</td>
</tr>
<tr>
<td>77</td>
<td>sickle-cell HbC disease</td>
</tr>
<tr>
<td>78</td>
<td>Sickle cell thalassaemia without crisis</td>
</tr>
<tr>
<td>79</td>
<td>sickle-cell thalassaemia</td>
</tr>
<tr>
<td>80</td>
<td>sickle-cell beta thalassaemia</td>
</tr>
<tr>
<td>81</td>
<td>haemoglobin s/beta thalassaemia</td>
</tr>
<tr>
<td>82</td>
<td>thalassaemia with haemoglobin S disease</td>
</tr>
<tr>
<td>83</td>
<td>microdrepanocytosis</td>
</tr>
<tr>
<td>84</td>
<td>double heterozygous for Hb S or beta thalassaemia</td>
</tr>
<tr>
<td>85</td>
<td>Compound HbS or HbC heterozygotes</td>
</tr>
<tr>
<td>86</td>
<td>Compound HbS, HbD-Punjab or Los Angeles heterozygotes</td>
</tr>
<tr>
<td>87</td>
<td>Hb-SD disease</td>
</tr>
<tr>
<td>88</td>
<td>Compound HbS or HbE heterozygotes</td>
</tr>
<tr>
<td>89</td>
<td>Hb SE disease</td>
</tr>
<tr>
<td>90</td>
<td>Compound HbS or O-Arab heterozygotes</td>
</tr>
<tr>
<td>91</td>
<td>Double heterozygous sickling disorders with retinopathy</td>
</tr>
<tr>
<td>92</td>
<td>Glomerular disorders in double heterozygous sickling disorders</td>
</tr>
<tr>
<td>93</td>
<td>Gouty arthropathy in double heterozygous sickling disorders</td>
</tr>
<tr>
<td>94</td>
<td>Compound HbS or beta thalassaemia heterozygotes</td>
</tr>
<tr>
<td>95</td>
<td>Compound HbS and beta thalassaemia heterozygotes including HbS/delta-beta-thal compounds</td>
</tr>
<tr>
<td>96</td>
<td>Hereditary persistence of fetal haemoglobin - sickle cell disease</td>
</tr>
<tr>
<td>97</td>
<td>Female Genital Mutilation, unspecified</td>
</tr>
<tr>
<td>98</td>
<td>Female Genital Mutilation</td>
</tr>
<tr>
<td>99</td>
<td>FGM - [female genital mutilation]</td>
</tr>
<tr>
<td>100</td>
<td>female circumcision</td>
</tr>
<tr>
<td>101</td>
<td>female genital cutting</td>
</tr>
<tr>
<td>102</td>
<td>FGC - [female genital cutting]</td>
</tr>
<tr>
<td>103</td>
<td>FGM/C - [female genital mutilation/cutting]</td>
</tr>
<tr>
<td>104</td>
<td>FGC/M - [female genital cutting/mutilation]</td>
</tr>
<tr>
<td>105</td>
<td>Chronic hepatitis C</td>
</tr>
<tr>
<td>106</td>
<td>chronic type C viral hepatitis</td>
</tr>
<tr>
<td>107</td>
<td>chronic HCV - [hepatitis C virus] infection</td>
</tr>
<tr>
<td>108</td>
<td>hepatitis C NOS</td>
</tr>
<tr>
<td>109</td>
<td>hepatitis C infection NOS</td>
</tr>
<tr>
<td>110</td>
<td>hepatitis C-related cirrhosis</td>
</tr>
<tr>
<td>111</td>
<td>type C viral hepatitis</td>
</tr>
<tr>
<td>112</td>
<td>hep C NOS</td>
</tr>
<tr>
<td>113</td>
<td>Chronic hepatitis C virus infection</td>
</tr>
<tr>
<td>114</td>
<td>Chronic hepatitis C, with cirrhosis</td>
</tr>
<tr>
<td>115</td>
<td>Chronic hepatitis C, with cirrhosis, with complications of cirrhosis</td>
</tr>
<tr>
<td>116</td>
<td>Chronic hepatitis C, with cirrhosis, without complications of cirrhosis</td>
</tr>
<tr>
<td>117</td>
<td>Chronic hepatitis C, without cirrhosis</td>
</tr>
<tr>
<td>118</td>
<td>Chronic hepatitis C, co-infected with human immunodeficiency virus</td>
</tr>
<tr>
<td>119</td>
<td>Chronic hepatitis C, co-infected with human immunodeficiency virus, with cirrhosis</td>
</tr>
<tr>
<td>120</td>
<td>Chronic hepatitis C, co-infected with human immunodeficiency virus, with cirrhosis, with complications of cirrhosis</td>
</tr>
<tr>
<td>121</td>
<td>Chronic hepatitis C, co-infected with human immunodeficiency virus, with cirrhosis, without complications of cirrhosis</td>
</tr>
<tr>
<td>122</td>
<td>Chronic hepatitis C, co-infected with human immunodeficiency virus, without cirrhosis</td>
</tr>
<tr>
<td>123</td>
<td>Other specified sickle cell disorders or other haemoglobinopathies</td>
</tr>
<tr>
<td>124</td>
<td>Other haemoglobinopathies</td>
</tr>
<tr>
<td>125</td>
<td>Abnormal haemoglobin NOS</td>
</tr>
<tr>
<td>126</td>
<td>haemoglobin dysfunction</td>
</tr>
<tr>
<td>127</td>
<td>Acquired haemoglobin H in myelodysplastic disorders</td>
</tr>
<tr>
<td>128</td>
<td>Compound HbC or beta thalassaemia heterozygotes</td>
</tr>
<tr>
<td>129</td>
<td>Haemoglobin C trait</td>
</tr>
<tr>
<td>130</td>
<td>haemoglobin C heterozygosity</td>
</tr>
<tr>
<td>131</td>
<td>heterozygous Hb C carriers</td>
</tr>
<tr>
<td>132</td>
<td>Haemoglobin E trait</td>
</tr>
<tr>
<td>133</td>
<td>haemoglobin E heterozygosity</td>
</tr>
<tr>
<td>134</td>
<td>heterozygous Hb E carriers</td>
</tr>
<tr>
<td>135</td>
<td>Compound HbE beta thalassaemia heterozygotes</td>
</tr>
<tr>
<td>136</td>
<td>Stransky-Regala type haemolytic anaemia</td>
</tr>
<tr>
<td>137</td>
<td>Unstable haemoglobin haemolytic disease</td>
</tr>
<tr>
<td>138</td>
<td>unstable haemoglobin disease</td>
</tr>
<tr>
<td>139</td>
<td>Haemoglobin C A disorder</td>
</tr>
<tr>
<td>140</td>
<td>Other specified hereditary sensory or autonomic neuropathy</td>
</tr>
<tr>
<td>141</td>
<td>Hereditary sensory and autonomic neuropathy type II</td>
</tr>
<tr>
<td>142</td>
<td>HSAN2 - [Hereditary sensory and autonomic neuropathy type 2]</td>
</tr>
<tr>
<td>143</td>
<td>Hereditary sensory and autonomic neuropathy type IIA</td>
</tr>
<tr>
<td>144</td>
<td>HSAN2A - [Hereditary sensory autonomic neuropathy type 2A]</td>
</tr>
<tr>
<td>145</td>
<td>Hereditary sensory and autonomic neuropathy type IIB</td>
</tr>
<tr>
<td>146</td>
<td>HSAN2B - [Hereditary sensory autonomic neuropathy type 2B]</td>
</tr>
<tr>
<td>147</td>
<td>Hereditary sensory and autonomic neuropathy type IIC</td>
</tr>
<tr>
<td>148</td>
<td>HSAN2C - [Hereditary sensory autonomic neuropathy type 2C]</td>
</tr>
<tr>
<td>149</td>
<td>Certain specified forms of hereditary sensory or autonomic neuropathy</td>
</tr>
<tr>
<td>150</td>
<td>Cold-induced sweating syndrome</td>
</tr>
<tr>
<td>151</td>
<td>Hereditary sensory and autonomic neuropathy with deafness or global delay</td>
</tr>
<tr>
<td>152</td>
<td>Hereditary sensory and autonomic neuropathy with spastic paraplegia</td>
</tr>
<tr>
<td>153</td>
<td>X-linked hereditary sensory and autonomic neuropathy with deafness</td>
</tr>
<tr>
<td>154</td>
<td>Other specified vitamin C deficiency</td>
</tr>
<tr>
<td>155</td>
<td>Hereditary sensory and autonomic neuropathy type I</td>
</tr>
<tr>
<td>156</td>
<td>HSAN1- [Hereditary sensory and autonomic neuropathy type I]</td>
</tr>
<tr>
<td>157</td>
<td>Hereditary sensory and autonomic neuropathy Type IA</td>
</tr>
<tr>
<td>158</td>
<td>HSAN1A - [Hereditary sensory autonomic neuropathy Type IA</td>
</tr>
<tr>
<td>159</td>
<td>Hereditary sensory and autonomic neuropathy Type IB</td>
</tr>
<tr>
<td>160</td>
<td>Hereditary sensory and autonomic neuropathy Type IC</td>
</tr>
<tr>
<td>161</td>
<td>HSAN1C - [Hereditary sensory autonomic neuropathy Type IC]</td>
</tr>
<tr>
<td>162</td>
<td>Hereditary sensory and autonomic neuropathy Type ID</td>
</tr>
<tr>
<td>163</td>
<td>HSAN1D - [Hereditary sensory autonomic neuropathy Type ID]</td>
</tr>
<tr>
<td>164</td>
<td>Hereditary sensory and autonomic neuropathy Type IE</td>
</tr>
<tr>
<td>165</td>
<td>HSAN1E - [Hereditary sensory autonomic neuropathy Type IE]</td>
</tr>
<tr>
<td>166</td>
<td>Interrupted aortic arch</td>
</tr>
<tr>
<td>167</td>
<td>aorta atresia</td>
</tr>
<tr>
<td>168</td>
<td>aortic arch interruption</td>
</tr>
<tr>
<td>169</td>
<td>IAA - [interrupted aortic arch]</td>
</tr>
<tr>
<td>170</td>
<td>aorta arch atresia</td>
</tr>
<tr>
<td>171</td>
<td>aorta ring atresia</td>
</tr>
<tr>
<td>172</td>
<td>aortic arch atresia</td>
</tr>
<tr>
<td>173</td>
<td>aortic ring atresia</td>
</tr>
<tr>
<td>174</td>
<td>Interrupted aortic arch distal to subclavian artery, type A</td>
</tr>
<tr>
<td>175</td>
<td>aortic arch interruption, type A</td>
</tr>
<tr>
<td>176</td>
<td>IAA type A - [interrupted aortic arch type A]</td>
</tr>
<tr>
<td>177</td>
<td>Interrupted aortic arch between subclavian and common carotid arteries, type B</td>
</tr>
<tr>
<td>178</td>
<td>aortic arch interruption, type B</td>
</tr>
<tr>
<td>179</td>
<td>IAA type B - [interrupted aortic arch type B]</td>
</tr>
<tr>
<td>180</td>
<td>Aortic interruption, type B</td>
</tr>
<tr>
<td>181</td>
<td>Interruption of the aortic arch, type B</td>
</tr>
<tr>
<td>182</td>
<td>Interrupted aortic arch between carotid arteries, type C</td>
</tr>
<tr>
<td>183</td>
<td>aortic arch interruption, type C</td>
</tr>
<tr>
<td>184</td>
<td>IAA type C - [interrupted aortic arch type C]</td>
</tr>
<tr>
<td>185</td>
<td>Aortic interruption, type C</td>
</tr>
<tr>
<td>186</td>
<td>Interruption of the aortic arch, type C</td>
</tr>
<tr>
<td>187</td>
<td>Congenital corneal opacity</td>
</tr>
<tr>
<td>188</td>
<td>Congenital corneal opacity, unilateral</td>
</tr>
<tr>
<td>189</td>
<td>Congenital corneal opacity, bilateral</td>
</tr>
<tr>
<td>190</td>
<td>Posterior polymorphous corneal dystrophy</td>
</tr>
<tr>
<td>191</td>
<td>PPCD - [Posterior polymorphous corneal dystrophy] C1 or C2</td>
</tr>
<tr>
<td>192</td>
<td>Congenital hereditary endothelial dystrophy type 1</td>
</tr>
<tr>
<td>193</td>
<td>CHED - [Congenital hereditary endothelial dystrophy] C1</td>
</tr>
<tr>
<td>194</td>
<td>Congenital leucoma</td>
</tr>
<tr>
<td>195</td>
<td>Diffuse palmoplantar keratodermas</td>
</tr>
<tr>
<td>196</td>
<td>Non-syndromic diffuse palmoplantar keratodermas</td>
</tr>
<tr>
<td>197</td>
<td>Diffuse epidermolytic palmoplantar keratoderma</td>
</tr>
<tr>
<td>198</td>
<td>Vörner-Thost palmoplantar keratoderma</td>
</tr>
<tr>
<td>199</td>
<td>Diffuse non-epidermolytic palmoplantar keratoderma</td>
</tr>
<tr>
<td>200</td>
<td>Unna palmoplantar keratoderma</td>
</tr>
<tr>
<td>201</td>
<td>Tylosis</td>
</tr>
<tr>
<td>202</td>
<td>Mal de Meleda</td>
</tr>
<tr>
<td>203</td>
<td>Keratosis palmoplantaris transgrediens of Siemens</td>
</tr>
<tr>
<td>204</td>
<td>Meleda disease</td>
</tr>
<tr>
<td>205</td>
<td>Nagashima-type palmoplantar keratoderma</td>
</tr>
<tr>
<td>206</td>
<td>Keratolytic winter erythema</td>
</tr>
<tr>
<td>207</td>
<td>Oudtshoorn disease</td>
</tr>
<tr>
<td>208</td>
<td>Syndromic diffuse palmoplantar keratodermas</td>
</tr>
<tr>
<td>209</td>
<td>Papillon-Lefèvre syndrome</td>
</tr>
<tr>
<td>210</td>
<td>Cathepsin C deficiency</td>
</tr>
<tr>
<td>211</td>
<td>Congenital palmoplantar or perioral keratoderma</td>
</tr>
<tr>
<td>212</td>
<td>Olmsted syndrome</td>
</tr>
<tr>
<td>213</td>
<td>Curly hair – acral keratoderma – caries syndrome</td>
</tr>
<tr>
<td>214</td>
<td>CHACS - [Curly hair – acral keratoderma – caries syndrome]</td>
</tr>
<tr>
<td>215</td>
<td>CHAC syndrome - [Curly hair - acral keratoderma - caries] syndrome</td>
</tr>
<tr>
<td>216</td>
<td>Palmoplantar keratoderma with scleroatrophy of the extremities</td>
</tr>
<tr>
<td>217</td>
<td>Huriez palmoplantar keratoderma</td>
</tr>
<tr>
<td>218</td>
<td>Palmoplantar keratoderma-sclerodactyly syndrome</td>
</tr>
<tr>
<td>219</td>
<td>Sclerotylosis</td>
</tr>
<tr>
<td>220</td>
<td>Connexin palmoplantar keratoderma with sensorineural deafness</td>
</tr>
<tr>
<td>221</td>
<td>Cicatrizing palmoplantar keratoderma with hearing loss (Vohwinkel)</td>
</tr>
<tr>
<td>222</td>
<td>Vohwinkel keratoderma (MIM 124500)</td>
</tr>
<tr>
<td>223</td>
<td>Congenital deafness with keratopachydermia or constrictions of fingers or toes</td>
</tr>
<tr>
<td>224</td>
<td>Loricrin palmoplantar keratoderma with ichthyosis</td>
</tr>
<tr>
<td>225</td>
<td>Vohwinkel syndrome - ichthyosis</td>
</tr>
<tr>
<td>226</td>
<td>Keratoderma hereditarium mutilans - ichthyosis</td>
</tr>
<tr>
<td>227</td>
<td>Mutilating keratoderma with ichthyosis</td>
</tr>
<tr>
<td>228</td>
<td>Palmoplantar keratoderma – digital clubbing – acro-osteolysis</td>
</tr>
<tr>
<td>229</td>
<td>Bureau-Barrière-Thomas palmoplantar keratoderma</td>
</tr>
<tr>
<td>230</td>
<td>Endothelial corneal dystrophy</td>
</tr>
<tr>
<td>231</td>
<td>dystrophy of corneal endothelium</td>
</tr>
<tr>
<td>232</td>
<td>Posterior corneal dystrophy</td>
</tr>
<tr>
<td>233</td>
<td>Congenital hereditary endothelial dystrophy type 2</td>
</tr>
<tr>
<td>234</td>
<td>Fuchs endothelial corneal dystrophy</td>
</tr>
<tr>
<td>235</td>
<td>Fuchs' corneal dystrophy</td>
</tr>
<tr>
<td>236</td>
<td>Fuchs' endothelial dystrophy</td>
</tr>
<tr>
<td>237</td>
<td>FECD - [Fuchs endothelial corneal dystrophy] C1, C2, or C3</td>
</tr>
<tr>
<td>238</td>
<td>X-linked endothelial corneal dystrophy</td>
</tr>
<tr>
<td>239</td>
<td>XECD - [X-linked endothelial corneal dystrophy] C2</td>
</tr>
<tr>
<td>240</td>
<td>Fracture of second cervical vertebra, unspecified</td>
</tr>
<tr>
<td>241</td>
<td>Fracture of second cervical vertebra</td>
</tr>
<tr>
<td>242</td>
<td>fracture of axis of spine</td>
</tr>
<tr>
<td>243</td>
<td>C2 fracture</td>
</tr>
<tr>
<td>244</td>
<td>axial fracture dislocation</td>
</tr>
<tr>
<td>245</td>
<td>axial fracture</td>
</tr>
<tr>
<td>246</td>
<td>second cervical vertebra fracture dislocation</td>
</tr>
<tr>
<td>247</td>
<td>fracture of C2 vertebra</td>
</tr>
<tr>
<td>248</td>
<td>fracture of cervical vertebra, C2</td>
</tr>
<tr>
<td>249</td>
<td>Fracture of first cervical vertebra, unspecified</td>
</tr>
<tr>
<td>250</td>
<td>Fracture of first cervical vertebra</td>
</tr>
<tr>
<td>251</td>
<td>fracture of atlas</td>
</tr>
<tr>
<td>252</td>
<td>fracture of atlas of spine</td>
</tr>
<tr>
<td>253</td>
<td>fracture of cervical vertebra, C1</td>
</tr>
<tr>
<td>254</td>
<td>C1 fracture</td>
</tr>
<tr>
<td>255</td>
<td>Other specified mucopolysaccharidosis</td>
</tr>
<tr>
<td>256</td>
<td>Mucopolysaccharidosis type 3</td>
</tr>
<tr>
<td>257</td>
<td>Acetyl-CoA alpha-glucosaminide-N-acetyl transferase deficiency</td>
</tr>
<tr>
<td>258</td>
<td>N-acetyl-alpha-glucosaminidase sulfamidase deficiency</td>
</tr>
<tr>
<td>259</td>
<td>N-acetyl-glucosamine-6-sulfate sulfatase deficiency</td>
</tr>
<tr>
<td>260</td>
<td>Sanfilippo syndrome</td>
</tr>
<tr>
<td>261</td>
<td>Mucopolysaccharidosis type 3A</td>
</tr>
<tr>
<td>262</td>
<td>Sanfilippo syndrome type A</td>
</tr>
<tr>
<td>263</td>
<td>Heparan-N-sulfatase deficiency</td>
</tr>
<tr>
<td>264</td>
<td>Heparan sulfamidase deficiency</td>
</tr>
<tr>
<td>265</td>
<td>Heparan sulfate sulfatase deficiency</td>
</tr>
<tr>
<td>266</td>
<td>Mucopolysaccharidosis type 3B</td>
</tr>
<tr>
<td>267</td>
<td>Sanfilippo syndrome type B</td>
</tr>
<tr>
<td>268</td>
<td>Alpha-N-acetylglucosaminidase deficiency</td>
</tr>
<tr>
<td>269</td>
<td>N-acetyl-alpha-D-glucosaminidase deficiency</td>
</tr>
<tr>
<td>270</td>
<td>Mucopolysaccharidosis type 3C</td>
</tr>
<tr>
<td>271</td>
<td>Sanfilippo syndrome type C</td>
</tr>
<tr>
<td>272</td>
<td>Acetyl-CoA alpha-glucosaminide acetyltransferase deficiency</td>
</tr>
<tr>
<td>273</td>
<td>N-acetyl transferase deficiency</td>
</tr>
<tr>
<td>274</td>
<td>Mucopolysaccharidosis type 3D</td>
</tr>
<tr>
<td>275</td>
<td>Sanfilippo syndrome type D</td>
</tr>
<tr>
<td>276</td>
<td>N-acetylglucosamine-6-sulfate sulfatase deficiency</td>
</tr>
<tr>
<td>277</td>
<td>Mucopolysaccharidosis type 7</td>
</tr>
<tr>
<td>278</td>
<td>Beta-glucuronidase deficiency</td>
</tr>
<tr>
<td>279</td>
<td>Sly disease</td>
</tr>
<tr>
<td>280</td>
<td>Sly syndrome</td>
</tr>
<tr>
<td>281</td>
<td>Mucopolysaccharidosis type 9</td>
</tr>
<tr>
<td>282</td>
<td>Hyaluronidase deficiency</td>
</tr>
<tr>
<td>283</td>
<td>Natowicz syndrome</td>
</tr>
<tr>
<td>284</td>
<td>Disorders of multiple glycosylation or other pathways</td>
</tr>
<tr>
<td>285</td>
<td>Dolichol-phosphate-mannose synthase 1 deficiency</td>
</tr>
<tr>
<td>286</td>
<td>GDP-Man: Dol-P-mannosyltransferase deficiency</td>
</tr>
<tr>
<td>287</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1E</td>
</tr>
<tr>
<td>288</td>
<td>Congenital disorder of glycosylation type 1E</td>
</tr>
<tr>
<td>289</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1E</td>
</tr>
<tr>
<td>290</td>
<td>Mannose-P-dolichol utilisation defect 1</td>
</tr>
<tr>
<td>291</td>
<td>Lec35 deficiency</td>
</tr>
<tr>
<td>292</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1F</td>
</tr>
<tr>
<td>293</td>
<td>Congenital disorder of glycosylation type 1F</td>
</tr>
<tr>
<td>294</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1F</td>
</tr>
<tr>
<td>295</td>
<td>Beta-1,4-galactosyltransferase deficiency</td>
</tr>
<tr>
<td>296</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2D</td>
</tr>
<tr>
<td>297</td>
<td>Congenital disorder of glycosylation type 2D</td>
</tr>
<tr>
<td>298</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2D</td>
</tr>
<tr>
<td>299</td>
<td>CMP-sialic acid transporter deficiency</td>
</tr>
<tr>
<td>300</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2F</td>
</tr>
<tr>
<td>301</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2F</td>
</tr>
<tr>
<td>302</td>
<td>Congenital disorder of glycosylation type 2F</td>
</tr>
<tr>
<td>303</td>
<td>Leukocyte adhesion deficiency type 2</td>
</tr>
<tr>
<td>304</td>
<td>Rambam-Hasharon syndrome</td>
</tr>
<tr>
<td>305</td>
<td>GDP-fucose transporter deficiency</td>
</tr>
<tr>
<td>306</td>
<td>LAD-II - [Leukocyte adhesion deficiency type 2]</td>
</tr>
<tr>
<td>307</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2C</td>
</tr>
<tr>
<td>308</td>
<td>Dolichol kinase deficiency</td>
</tr>
<tr>
<td>309</td>
<td>Hypotonia or ichthyosis due to dolichol phosphate deficiency</td>
</tr>
<tr>
<td>310</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1M</td>
</tr>
<tr>
<td>311</td>
<td>Congenital disorder of glycosylation type 1M</td>
</tr>
<tr>
<td>312</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1M</td>
</tr>
<tr>
<td>313</td>
<td>Conserved oligomeric Golgi complex deficiencies</td>
</tr>
<tr>
<td>314</td>
<td>Component of conserved oligomeric Golgi complex 1 deficiency</td>
</tr>
<tr>
<td>315</td>
<td>CDG syndrome type 2G</td>
</tr>
<tr>
<td>316</td>
<td>Component of conserved oligomeric Golgi complex 4 deficiency</td>
</tr>
<tr>
<td>317</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2J</td>
</tr>
<tr>
<td>318</td>
<td>Congenital disorder of glycosylation type 2J</td>
</tr>
<tr>
<td>319</td>
<td>Component of conserved oligomeric Golgi complex 5 deficiency</td>
</tr>
<tr>
<td>320</td>
<td>Component of conserved oligomeric Golgi complex 7 deficiency</td>
</tr>
<tr>
<td>321</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2E</td>
</tr>
<tr>
<td>322</td>
<td>Congenital disorder of glycosylation type 2E</td>
</tr>
<tr>
<td>323</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2E</td>
</tr>
<tr>
<td>324</td>
<td>Component of conserved oligomeric Golgi complex 8 deficiency</td>
</tr>
<tr>
<td>325</td>
<td>Congenital disorder of glycosylation type 2h</td>
</tr>
<tr>
<td>326</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2H</td>
</tr>
<tr>
<td>327</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2H</td>
</tr>
<tr>
<td>328</td>
<td>V-ATPase deficiencies</td>
</tr>
<tr>
<td>329</td>
<td>Disorders of protein N-glycosylation</td>
</tr>
<tr>
<td>330</td>
<td>Phosphomannomutase 2 deficiency</td>
</tr>
<tr>
<td>331</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1A</td>
</tr>
<tr>
<td>332</td>
<td>Congenital disorder of glycosylation type 1A</td>
</tr>
<tr>
<td>333</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1A</td>
</tr>
<tr>
<td>334</td>
<td>Phosphomannose isomerase deficiency</td>
</tr>
<tr>
<td>335</td>
<td>Saguenay-Lac-Saint-Jean syndrome</td>
</tr>
<tr>
<td>336</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1B</td>
</tr>
<tr>
<td>337</td>
<td>Congenital disorder of glycosylation type 1B</td>
</tr>
<tr>
<td>338</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1B</td>
</tr>
<tr>
<td>339</td>
<td>SLSJ - [Saguenay-Lac-Saint-Jean] syndrome</td>
</tr>
<tr>
<td>340</td>
<td>Glucosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>341</td>
<td>Dol-P-Glc: Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>342</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1C</td>
</tr>
<tr>
<td>343</td>
<td>Congenital disorder of glycosylation type 1C</td>
</tr>
<tr>
<td>344</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1C</td>
</tr>
<tr>
<td>345</td>
<td>Mannosyltransferase 6 deficiency</td>
</tr>
<tr>
<td>346</td>
<td>Dol-P-Man: Man5-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>347</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1D</td>
</tr>
<tr>
<td>348</td>
<td>Congenital disorder of glycosylation type 1D</td>
</tr>
<tr>
<td>349</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1D</td>
</tr>
<tr>
<td>350</td>
<td>Mannosyltransferase 8 deficiency</td>
</tr>
<tr>
<td>351</td>
<td>Dol-P-Man: Man7-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>352</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1G</td>
</tr>
<tr>
<td>353</td>
<td>Congenital disorder of glycosylation type 1G</td>
</tr>
<tr>
<td>354</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1G</td>
</tr>
<tr>
<td>355</td>
<td>Glucosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>356</td>
<td>Dol-P-Glc: Glc1-Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>357</td>
<td>Carbohydrate deficient glycoprotein syndrome 1H</td>
</tr>
<tr>
<td>358</td>
<td>Congenital disorder of glycosylation type 1H</td>
</tr>
<tr>
<td>359</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1H</td>
</tr>
<tr>
<td>360</td>
<td>Mannosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>361</td>
<td>Dol-P-Man: Man1-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>362</td>
<td>Carbohydrate deficient glycoprotein syndrome 1I</td>
</tr>
<tr>
<td>363</td>
<td>Congenital disorder of glycosylation 1I</td>
</tr>
<tr>
<td>364</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1I</td>
</tr>
<tr>
<td>365</td>
<td>Dolichyl-phosphate N-acetylgalactosamine phosphotransferase deficiency</td>
</tr>
<tr>
<td>366</td>
<td>UDP-GlcNAc: Dol-P-GlcNac-P transferase deficiency</td>
</tr>
<tr>
<td>367</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1J</td>
</tr>
<tr>
<td>368</td>
<td>Congenital disorder of glycosylation type 1J</td>
</tr>
<tr>
<td>369</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1J</td>
</tr>
<tr>
<td>370</td>
<td>Mannosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>371</td>
<td>Dol-P-Man: GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>372</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1K</td>
</tr>
<tr>
<td>373</td>
<td>Congenital disorder of glycosylation type 1K</td>
</tr>
<tr>
<td>374</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1K</td>
</tr>
<tr>
<td>375</td>
<td>Mannosyltransferase 7-9 deficiency</td>
</tr>
<tr>
<td>376</td>
<td>Congenital disorder of glycosylation type 1L</td>
</tr>
<tr>
<td>377</td>
<td>Dol-P-Man: Man6 and Man8-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>378</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1L</td>
</tr>
<tr>
<td>379</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1L</td>
</tr>
<tr>
<td>380</td>
<td>M5-DLO flippase deficiency</td>
</tr>
<tr>
<td>381</td>
<td>Man5GlcNAc2-PP-Dol flippase deficiency</td>
</tr>
<tr>
<td>382</td>
<td>RTF1-CDG</td>
</tr>
<tr>
<td>383</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1N</td>
</tr>
<tr>
<td>384</td>
<td>N-acetylglucosaminyltransferase deficiency</td>
</tr>
<tr>
<td>385</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2A</td>
</tr>
<tr>
<td>386</td>
<td>Congenital disorder of glycosylation type 2A</td>
</tr>
<tr>
<td>387</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2A</td>
</tr>
<tr>
<td>388</td>
<td>Glucosidase 1 deficiency</td>
</tr>
<tr>
<td>389</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2B</td>
</tr>
<tr>
<td>390</td>
<td>Congenital disorder of glycosylation type 2B</td>
</tr>
<tr>
<td>391</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2B</td>
</tr>
<tr>
<td>392</td>
<td>TUSC3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>393</td>
<td>TUSC3-CDG</td>
</tr>
<tr>
<td>394</td>
<td>SRD5A3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>395</td>
<td>SRD5A3-CDG</td>
</tr>
<tr>
<td>396</td>
<td>Congenital disorder of glycosylation due to steroid 5-alpha-reductase type 3 deficiency</td>
</tr>
<tr>
<td>397</td>
<td>Intellectual deficit - cataract - coloboma - kyphosis</td>
</tr>
<tr>
<td>398</td>
<td>Kahrizi syndrome</td>
</tr>
<tr>
<td>399</td>
<td>Intellectual deficit, Kahrizi type</td>
</tr>
<tr>
<td>400</td>
<td>DPM3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>401</td>
<td>Congenital disorder of glycosylation type 1O</td>
</tr>
<tr>
<td>402</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1O</td>
</tr>
<tr>
<td>403</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1O</td>
</tr>
<tr>
<td>404</td>
<td>ALG11 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>405</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1P</td>
</tr>
<tr>
<td>406</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1P</td>
</tr>
<tr>
<td>407</td>
<td>Congenital disorder of glycosylation type 1P</td>
</tr>
<tr>
<td>408</td>
<td>Phosphoglucomutase-1 deficiency</td>
</tr>
<tr>
<td>409</td>
<td>PGM1-CDG - [Phosphoglucomutase-1 deficiency]</td>
</tr>
<tr>
<td>410</td>
<td>Congenital disorder of glycosylation type 1t</td>
</tr>
<tr>
<td>411</td>
<td>Glycogen storage disease</td>
</tr>
<tr>
<td>412</td>
<td>Glycogenosis</td>
</tr>
<tr>
<td>413</td>
<td>GSD - [Glycogen storage disease]</td>
</tr>
<tr>
<td>414</td>
<td>glycogen thesaurismosis</td>
</tr>
<tr>
<td>415</td>
<td>diffuse glycogenosis</td>
</tr>
<tr>
<td>416</td>
<td>generalised glycogen storage disease</td>
</tr>
<tr>
<td>417</td>
<td>generalised glycogenosis</td>
</tr>
<tr>
<td>418</td>
<td>generalised glycogen storage disease of infants</td>
</tr>
<tr>
<td>419</td>
<td>glycogen synthase deficiency</td>
</tr>
<tr>
<td>420</td>
<td>Glycogen storage disease due to glycogen synthase deficiency</td>
</tr>
<tr>
<td>421</td>
<td>Glycogen storage disease type 0</td>
</tr>
<tr>
<td>422</td>
<td>Glycogenosis type 0</td>
</tr>
<tr>
<td>423</td>
<td>GSD type 0</td>
</tr>
<tr>
<td>424</td>
<td>deficiency of glycogen synthetase</td>
</tr>
<tr>
<td>425</td>
<td>Glycogen storage disease due to liver glycogen synthase deficiency</td>
</tr>
<tr>
<td>426</td>
<td>GSD type 0A</td>
</tr>
<tr>
<td>427</td>
<td>Glycogen storage disease type 0A</td>
</tr>
<tr>
<td>428</td>
<td>Glycogenosis type 0A</td>
</tr>
<tr>
<td>429</td>
<td>Glycogen storage disease due to muscle or heart glycogen synthase deficiency</td>
</tr>
<tr>
<td>430</td>
<td>Glycogen storage disease type 0B</td>
</tr>
<tr>
<td>431</td>
<td>Glycogenosis type 0B</td>
</tr>
<tr>
<td>432</td>
<td>GSD type 0B</td>
</tr>
<tr>
<td>433</td>
<td>Cardiomyopathy-exercise intolerance due to muscle and heart glycogen deficiency</td>
</tr>
<tr>
<td>434</td>
<td>Glycogen storage disease due to glucose-6-phosphate system deficiency</td>
</tr>
<tr>
<td>435</td>
<td>Glycogen storage disease type 1</td>
</tr>
<tr>
<td>436</td>
<td>Glycogenosis type 1</td>
</tr>
<tr>
<td>437</td>
<td>GSD type 1</td>
</tr>
<tr>
<td>438</td>
<td>Hepatorenal glycogenosis</td>
</tr>
<tr>
<td>439</td>
<td>Von Gierke disease</td>
</tr>
<tr>
<td>440</td>
<td>HERS - [hepatorenal glycogen storage disease]</td>
</tr>
<tr>
<td>441</td>
<td>glycogen storage disease of liver and kidney</td>
</tr>
<tr>
<td>442</td>
<td>hepatorenal glycogen storage disease</td>
</tr>
<tr>
<td>443</td>
<td>Glycogen storage disease due to glucose-6-phosphatase deficiency</td>
</tr>
<tr>
<td>444</td>
<td>Glycogen storage disease type 1A</td>
</tr>
<tr>
<td>445</td>
<td>Glycogenosis type 1A</td>
</tr>
<tr>
<td>446</td>
<td>GSD type 1A</td>
</tr>
<tr>
<td>447</td>
<td>g6pd - [glucose-6-phosphate dehydrogenase deficiency]</td>
</tr>
<tr>
<td>448</td>
<td>glucose-6-phosphatase deficiency</td>
</tr>
<tr>
<td>449</td>
<td>deficiency of g-6pd</td>
</tr>
<tr>
<td>450</td>
<td>Glycogen storage disease due to glucose-6-phosphate transport defect</td>
</tr>
<tr>
<td>451</td>
<td>Glycogen storage disease type 1B</td>
</tr>
<tr>
<td>452</td>
<td>Glycogenosis type 1B</td>
</tr>
<tr>
<td>453</td>
<td>GSD1B</td>
</tr>
<tr>
<td>454</td>
<td>Glycogen storage disease type non-1A</td>
</tr>
<tr>
<td>455</td>
<td>Glycogenosis type non-1A</td>
</tr>
<tr>
<td>456</td>
<td>Glycogen storage disease due to glucose-6-phosphate translocase deficiency</td>
</tr>
<tr>
<td>457</td>
<td>Glucose-6-phosphate dehydrogenase deficiency</td>
</tr>
<tr>
<td>458</td>
<td>Glycogen storage disease due to acid maltase deficiency</td>
</tr>
<tr>
<td>459</td>
<td>Glycogen storage disease type 2</td>
</tr>
<tr>
<td>460</td>
<td>Glycogenosis type 2</td>
</tr>
<tr>
<td>461</td>
<td>GSD type 2</td>
</tr>
<tr>
<td>462</td>
<td>Acid maltase deficiency</td>
</tr>
<tr>
<td>463</td>
<td>Pompe disease</td>
</tr>
<tr>
<td>464</td>
<td>Acid alpha-1,4-glucosidase deficiency</td>
</tr>
<tr>
<td>465</td>
<td>alpha-glucosidase deficiency</td>
</tr>
<tr>
<td>466</td>
<td>deficiency of amyloglucosidase</td>
</tr>
<tr>
<td>467</td>
<td>Glycogen storage disease due to acid maltase deficiency, infantile onset</td>
</tr>
<tr>
<td>468</td>
<td>Glycogen storage disease type 2, infantile onset</td>
</tr>
<tr>
<td>469</td>
<td>Glycogenosis type 2, infantile onset</td>
</tr>
<tr>
<td>470</td>
<td>GSD2, infantile onset</td>
</tr>
<tr>
<td>471</td>
<td>Glycogen storage disease due to acid alpha-1,4-glucosidase deficiency, infantile onset</td>
</tr>
<tr>
<td>472</td>
<td>Infantile Pompe disease</td>
</tr>
<tr>
<td>473</td>
<td>lysosomal alpha-1,4-glucosidase deficiency (disorder)</td>
</tr>
<tr>
<td>474</td>
<td>Glycogen storage disease due to acid maltase deficiency, juvenile onset</td>
</tr>
<tr>
<td>475</td>
<td>Glycogen storage disease due to acid maltase deficiency, adult onset</td>
</tr>
<tr>
<td>476</td>
<td>Deficiency of exo-1,4-alpha-glucosidase</td>
</tr>
<tr>
<td>477</td>
<td>Deficiency of glucan 1,4-alpha-glucosidase</td>
</tr>
<tr>
<td>478</td>
<td>Deficiency of gamma-amylase</td>
</tr>
<tr>
<td>479</td>
<td>Deficiency of glucoamylase</td>
</tr>
<tr>
<td>480</td>
<td>Deficiency of glucoinvertase</td>
</tr>
<tr>
<td>481</td>
<td>Deficiency of glucosidosucrase</td>
</tr>
<tr>
<td>482</td>
<td>Deficiency of maltase</td>
</tr>
<tr>
<td>483</td>
<td>Glycogen storage disease due to LAMP-2 deficiency</td>
</tr>
<tr>
<td>484</td>
<td>Glycogen storage disease type 2B</td>
</tr>
<tr>
<td>485</td>
<td>Glycogenosis type 2B</td>
</tr>
<tr>
<td>486</td>
<td>GSD type 2B</td>
</tr>
<tr>
<td>487</td>
<td>Lysosomal glycogen storage disease with normal acid maltase activity</td>
</tr>
<tr>
<td>488</td>
<td>Danon disease</td>
</tr>
<tr>
<td>489</td>
<td>Glycogen storage disease due to glycogen debranching enzyme deficiency</td>
</tr>
<tr>
<td>490</td>
<td>Glycogen storage disease type 3</td>
</tr>
<tr>
<td>491</td>
<td>Glycogenosis type 3</td>
</tr>
<tr>
<td>492</td>
<td>GSD type 3</td>
</tr>
<tr>
<td>493</td>
<td>Amylo-1,6-glucosidase deficiency</td>
</tr>
<tr>
<td>494</td>
<td>Glycogen debranching deficiency</td>
</tr>
<tr>
<td>495</td>
<td>Cori-Forbes disease</td>
</tr>
<tr>
<td>496</td>
<td>Cori disease</td>
</tr>
<tr>
<td>497</td>
<td>Forbes disease</td>
</tr>
<tr>
<td>498</td>
<td>Forbes glycogen storage disease</td>
</tr>
<tr>
<td>499</td>
<td>debrancher deficiency glycogen storage disease</td>
</tr>
<tr>
<td>500</td>
<td>debrancher enzyme deficiency</td>
</tr>
<tr>
<td>501</td>
<td>deficiency of 6-alpha-d-glucosidase</td>
</tr>
<tr>
<td>502</td>
<td>amylo-1,6-glucosidase deficiency disorder</td>
</tr>
<tr>
<td>503</td>
<td>Glycogen storage disease due to muscle glycogen phosphorylase deficiency</td>
</tr>
<tr>
<td>504</td>
<td>Glycogen storage disease type 5</td>
</tr>
<tr>
<td>505</td>
<td>Glycogenosis type 5</td>
</tr>
<tr>
<td>506</td>
<td>GSD type 5</td>
</tr>
<tr>
<td>507</td>
<td>Myophosphorylase deficiency</td>
</tr>
<tr>
<td>508</td>
<td>McArdle disease</td>
</tr>
<tr>
<td>509</td>
<td>myophosphorylase deficiency glycogenosis</td>
</tr>
<tr>
<td>510</td>
<td>Glycogen storage disease due to liver glycogen phosphorylase deficiency</td>
</tr>
<tr>
<td>511</td>
<td>Glycogenosis due to liver phosphorylase deficiency</td>
</tr>
<tr>
<td>512</td>
<td>Glycogen storage disease type 6</td>
</tr>
<tr>
<td>513</td>
<td>Glycogenosis type 6</td>
</tr>
<tr>
<td>514</td>
<td>GSD type 6</td>
</tr>
<tr>
<td>515</td>
<td>Glycogen storage disease type 6B</td>
</tr>
<tr>
<td>516</td>
<td>Glycogenosis type 6B</td>
</tr>
<tr>
<td>517</td>
<td>GSD type 6B</td>
</tr>
<tr>
<td>518</td>
<td>Hers disease</td>
</tr>
<tr>
<td>519</td>
<td>deficiency of hepatophosphorylase</td>
</tr>
<tr>
<td>520</td>
<td>Glycogen storage disease due to muscle phosphofructokinase deficiency</td>
</tr>
<tr>
<td>521</td>
<td>Glycogen storage disease type 7</td>
</tr>
<tr>
<td>522</td>
<td>Glycogenosis type 7</td>
</tr>
<tr>
<td>523</td>
<td>GSD type 7</td>
</tr>
<tr>
<td>524</td>
<td>Muscle phosphofructokinase deficiency</td>
</tr>
<tr>
<td>525</td>
<td>Tarui disease</td>
</tr>
<tr>
<td>526</td>
<td>anaemia due to phosphofructo-aldolase deficiency</td>
</tr>
<tr>
<td>527</td>
<td>Glycogen storage disease due to glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>528</td>
<td>Glycogenosis due to phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>529</td>
<td>GSD due to phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>530</td>
<td>Glycogen storage disease due to liver glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>531</td>
<td>Hepatic phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>532</td>
<td>Glycogen storage disease type 8</td>
</tr>
<tr>
<td>533</td>
<td>Glycogenosis type 8</td>
</tr>
<tr>
<td>534</td>
<td>GSD8 - [glycogen storage disease type 8]</td>
</tr>
<tr>
<td>535</td>
<td>Glycogen storage disease type 6A</td>
</tr>
<tr>
<td>536</td>
<td>Glycogen storage disease type 9A</td>
</tr>
<tr>
<td>537</td>
<td>Glycogen storage disease type 9C</td>
</tr>
<tr>
<td>538</td>
<td>Glycogenosis type 6A</td>
</tr>
<tr>
<td>539</td>
<td>Glycogenosis type 9A</td>
</tr>
<tr>
<td>540</td>
<td>Glycogenosis type 9C</td>
</tr>
<tr>
<td>541</td>
<td>GSD type 9C - [glycogen storage disease type 9C]</td>
</tr>
<tr>
<td>542</td>
<td>GSD6A - [glycogen storage disease type 6A]</td>
</tr>
<tr>
<td>543</td>
<td>GSD9A - [glycogen storage disease type 9A]</td>
</tr>
<tr>
<td>544</td>
<td>Glycogen storage disease due to liver or muscle glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>545</td>
<td>Glycogen storage disease type 9B</td>
</tr>
<tr>
<td>546</td>
<td>Glycogenosis type 9B</td>
</tr>
<tr>
<td>547</td>
<td>GSD type 9B</td>
</tr>
<tr>
<td>548</td>
<td>Glycogen storage disease type 9</td>
</tr>
<tr>
<td>549</td>
<td>Glycogenosis type 9</td>
</tr>
<tr>
<td>550</td>
<td>GSD9 - [glycogen storage disease type 9]</td>
</tr>
<tr>
<td>551</td>
<td>Glycogen storage disease due to heart glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>552</td>
<td>Glycogen storage disease of heart</td>
</tr>
<tr>
<td>553</td>
<td>Cardiac glycogenosis</td>
</tr>
<tr>
<td>554</td>
<td>Glycogen storage disease type 9F</td>
</tr>
<tr>
<td>555</td>
<td>Glycogenosis type 9F</td>
</tr>
<tr>
<td>556</td>
<td>GSD9F</td>
</tr>
<tr>
<td>557</td>
<td>glycogen heart disease</td>
</tr>
<tr>
<td>558</td>
<td>glycogenic myocardial infiltration</td>
</tr>
<tr>
<td>559</td>
<td>glycogenic myocardium infiltration</td>
</tr>
<tr>
<td>560</td>
<td>cardiomegalia glycogenica diffusa</td>
</tr>
<tr>
<td>561</td>
<td>Glycogen storage disease due to muscle glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>562</td>
<td>GSD9D - [glycogen storage disease type IXD]</td>
</tr>
<tr>
<td>563</td>
<td>Glycogen storage disease type 9D</td>
</tr>
<tr>
<td>564</td>
<td>Glycogen storage disease type 9E</td>
</tr>
<tr>
<td>565</td>
<td>Glycogenosis type 9D</td>
</tr>
<tr>
<td>566</td>
<td>Glycogenosis type 9E</td>
</tr>
<tr>
<td>567</td>
<td>GSD9E</td>
</tr>
<tr>
<td>568</td>
<td>muscle glycogen phosphorylase deficiency</td>
</tr>
<tr>
<td>569</td>
<td>glycogenosis type IXE</td>
</tr>
<tr>
<td>570</td>
<td>Glycogen storage disease due to muscle phosphoglycerate mutase deficiency</td>
</tr>
<tr>
<td>571</td>
<td>Glycogen storage disease type 10</td>
</tr>
<tr>
<td>572</td>
<td>Glycogenosis type 10</td>
</tr>
<tr>
<td>573</td>
<td>GSD type 10</td>
</tr>
<tr>
<td>574</td>
<td>Di Mauro disease</td>
</tr>
<tr>
<td>575</td>
<td>Glycogen storage disease due to GLUT2 deficiency</td>
</tr>
<tr>
<td>576</td>
<td>Glycogen storage disease type 11</td>
</tr>
<tr>
<td>577</td>
<td>Glycogenosis type 11</td>
</tr>
<tr>
<td>578</td>
<td>GSD type 11</td>
</tr>
<tr>
<td>579</td>
<td>Fanconi-Bickel glycogenosis</td>
</tr>
<tr>
<td>580</td>
<td>Bickel-Fanconi disease</td>
</tr>
<tr>
<td>581</td>
<td>Facilitated glucose transporter protein type 2 deficiency</td>
</tr>
<tr>
<td>582</td>
<td>Fanconi-Bickel syndrome</td>
</tr>
<tr>
<td>583</td>
<td>Glycogen storage disease due to aldolase A deficiency</td>
</tr>
<tr>
<td>584</td>
<td>Glycogen storage disease type 12</td>
</tr>
<tr>
<td>585</td>
<td>Glycogenosis type 12</td>
</tr>
<tr>
<td>586</td>
<td>GSD type 12</td>
</tr>
<tr>
<td>587</td>
<td>Glycogen storage disease due to muscle beta-enolase deficiency</td>
</tr>
<tr>
<td>588</td>
<td>Glycogen storage disease type 13</td>
</tr>
<tr>
<td>589</td>
<td>Glycogenosis type 13</td>
</tr>
<tr>
<td>590</td>
<td>GSD type 13</td>
</tr>
<tr>
<td>591</td>
<td>Glycogen storage disease due to phosphoglucomutase deficiency</td>
</tr>
<tr>
<td>592</td>
<td>Glycogen storage disease type 14</td>
</tr>
<tr>
<td>593</td>
<td>Glycogenosis type 14</td>
</tr>
<tr>
<td>594</td>
<td>GSD type 14</td>
</tr>
<tr>
<td>595</td>
<td>Glycogen storage disease due to glycogenin deficiency</td>
</tr>
<tr>
<td>596</td>
<td>Glycogen storage disease type 15</td>
</tr>
<tr>
<td>597</td>
<td>GSD type 15</td>
</tr>
<tr>
<td>598</td>
<td>Glocogenosis type 15</td>
</tr>
<tr>
<td>599</td>
<td>Glycogen storage disease due to phosphoglycerate kinase 1 deficiency</td>
</tr>
<tr>
<td>600</td>
<td>Glycogenosis due to phosphoglycerate kinase 1 deficiency</td>
</tr>
<tr>
<td>601</td>
<td>GSD due to phosphoglycerate kinase 1 deficiency</td>
</tr>
<tr>
<td>602</td>
<td>Glycogen storage disease due to lactate dehydrogenase deficiency</td>
</tr>
<tr>
<td>603</td>
<td>Glycogenosis due to lactate dehydrogenase deficiency</td>
</tr>
<tr>
<td>604</td>
<td>GSD due to lactate dehydrogenase deficiency</td>
</tr>
<tr>
<td>605</td>
<td>Glycogen storage disease due to muscle pyruvate kinase deficiency</td>
</tr>
<tr>
<td>606</td>
<td>Glycogenosis due to muscle pyruvate kinase deficiency</td>
</tr>
<tr>
<td>607</td>
<td>GSD due to muscle pyruvate kinase deficiency</td>
</tr>
<tr>
<td>608</td>
<td>Glycogen storage liver disease</td>
</tr>
<tr>
<td>609</td>
<td>hepatomegalia glycogenica diffusa</td>
</tr>
<tr>
<td>610</td>
<td>liver glycogen disease</td>
</tr>
<tr>
<td>611</td>
<td>liver phosphorylase deficiency</td>
</tr>
<tr>
<td>612</td>
<td>Glycogen storage disease due to branching-transferase deficiency</td>
</tr>
<tr>
<td>613</td>
<td>Andersen disease</td>
</tr>
<tr>
<td>614</td>
<td>brancher deficiency glycogen storage disease</td>
</tr>
<tr>
<td>615</td>
<td>branching enzyme deficiency</td>
</tr>
<tr>
<td>616</td>
<td>branching-transferase deficiency glycogenosis</td>
</tr>
<tr>
<td>617</td>
<td>deficiency of 1,4-alpha-glucan branching enzyme</td>
</tr>
<tr>
<td>618</td>
<td>deficiency of amylo-(1,4,6)-transglycosylase</td>
</tr>
<tr>
<td>619</td>
<td>Glycogen storage disease type 4</td>
</tr>
<tr>
<td>620</td>
<td>Glycogenosis type 4</td>
</tr>
<tr>
<td>621</td>
<td>GSD- [Glycogen storage disease] type 4</td>
</tr>
<tr>
<td>622</td>
<td>Dilated cardiomyopathy due to glycogen branching enzyme deficiency</td>
</tr>
<tr>
<td>623</td>
<td>Amylopectinosis</td>
</tr>
<tr>
<td>624</td>
<td>dilated cardiomyopathy due to Andersen's disease</td>
</tr>
<tr>
<td>625</td>
<td>dilated cardiomyopathy due to glycogen storage disease type 4 (GSD4)</td>
</tr>
<tr>
<td>626</td>
<td>Compound heterozygous sickling disorders with crisis</td>
</tr>
<tr>
<td>627</td>
<td>Sickle cell Hb-C disease with crisis</td>
</tr>
<tr>
<td>628</td>
<td>Hb SC disease with crisis</td>
</tr>
<tr>
<td>629</td>
<td>Hb S Hb C disease with crisis</td>
</tr>
<tr>
<td>630</td>
<td>Sickle cell Hb-C disease with crisis with acute chest syndrome</td>
</tr>
<tr>
<td>631</td>
<td>Sickle cell Hb-C disease with crisis with splenic sequestration</td>
</tr>
<tr>
<td>632</td>
<td>Sickle cell Hb-C disease with crisis with fever</td>
</tr>
<tr>
<td>633</td>
<td>Sickle cell thalassaemia with crisis</td>
</tr>
<tr>
<td>634</td>
<td>sickle-cell beta thalassaemia with crisis</td>
</tr>
<tr>
<td>635</td>
<td>thalassaemia Hb S disease</td>
</tr>
<tr>
<td>636</td>
<td>thalassaemia Hb S disease with crisis</td>
</tr>
<tr>
<td>637</td>
<td>Sickle cell thalassaemia with crisis with acute chest syndrome</td>
</tr>
<tr>
<td>638</td>
<td>Sickle cell thalassaemia with crisis with splenic sequestration</td>
</tr>
<tr>
<td>639</td>
<td>Sickle cell thalassaemia with crisis with fever</td>
</tr>
<tr>
<td>640</td>
<td>Sickle-cell thalassaemia with vaso-occlusive pain</td>
</tr>
<tr>
<td>641</td>
<td>Hereditary angioedema</td>
</tr>
<tr>
<td>642</td>
<td>Hereditary angioneurotic oedema</td>
</tr>
<tr>
<td>643</td>
<td>Familial angioedema</td>
</tr>
<tr>
<td>644</td>
<td>HAE - [hereditary angioneurotic oedema]</td>
</tr>
<tr>
<td>645</td>
<td>Bannister disease, hereditary</td>
</tr>
<tr>
<td>646</td>
<td>Quincke disease or oedema</td>
</tr>
<tr>
<td>647</td>
<td>hereditary Quincke oedema</td>
</tr>
<tr>
<td>648</td>
<td>Hereditary angioedema type I</td>
</tr>
<tr>
<td>649</td>
<td>Hereditary angioneurotic oedema type 1</td>
</tr>
<tr>
<td>650</td>
<td>C1 esterase inhibitor [C1-INH] quantitative deficiency</td>
</tr>
<tr>
<td>651</td>
<td>HAE-I - [Hereditary angioedema type I]</td>
</tr>
<tr>
<td>652</td>
<td>C1 esterase inhibitor deficiency - type 1</td>
</tr>
<tr>
<td>653</td>
<td>deficiency of c1 esterase inhibitor</td>
</tr>
<tr>
<td>654</td>
<td>Hereditary angioedema type II</td>
</tr>
<tr>
<td>655</td>
<td>Hereditary angioneurotic oedema type 2</td>
</tr>
<tr>
<td>656</td>
<td>C1 esterase inhibitor [C1-INH] qualitative deficiency</td>
</tr>
<tr>
<td>657</td>
<td>HAE-II - [Hereditary angioedema type II]</td>
</tr>
<tr>
<td>658</td>
<td>C1-INH - [C1 esterase inhibitor] deficiency</td>
</tr>
<tr>
<td>659</td>
<td>Hereditary angioedema type III</td>
</tr>
<tr>
<td>660</td>
<td>Hereditary angioneurotic oedema type 3</td>
</tr>
<tr>
<td>661</td>
<td>Inherited oestrogen-dependent angioedema</td>
</tr>
<tr>
<td>662</td>
<td>Inherited oestrogen-dependent angioneurotic oedema</td>
</tr>
<tr>
<td>663</td>
<td>Hereditary angioedema with FXII mutation</td>
</tr>
<tr>
<td>664</td>
<td>HAE-III - [Hereditary angioedema type III]</td>
</tr>
<tr>
<td>665</td>
<td>Acute hereditary circumscribed oedema</td>
</tr>
<tr>
<td>666</td>
<td>Acute hereditary essential oedema</td>
</tr>
<tr>
<td>667</td>
<td>Hereditary giant urticaria</td>
</tr>
<tr>
<td>668</td>
<td>Periodic hereditary oedema</td>
</tr>
<tr>
<td>669</td>
<td>Hereditary allergic angioedema</td>
</tr>
<tr>
<td>670</td>
<td>Hereditary angioneurotic oedema urticaria</td>
</tr>
<tr>
<td>671</td>
<td>Disorders of nucleotide metabolism</td>
</tr>
<tr>
<td>672</td>
<td>Aicardi-Goutières syndrome</td>
</tr>
<tr>
<td>673</td>
<td>Encephalopathy with basal ganglia calcification</td>
</tr>
<tr>
<td>674</td>
<td>Encephalopathy with intracranial calcification and chronic lymphocytosis of cerebrospinal fluid</td>
</tr>
<tr>
<td>675</td>
<td>Aicardi-Goutières syndrome type 1</td>
</tr>
<tr>
<td>676</td>
<td>TREX deficiency</td>
</tr>
<tr>
<td>677</td>
<td>DNase III deficiency</td>
</tr>
<tr>
<td>678</td>
<td>Aicardi-Goutières syndrome type 2</td>
</tr>
<tr>
<td>679</td>
<td>RNASEH2B deficiency</td>
</tr>
<tr>
<td>680</td>
<td>Aicardi-Goutières syndrome type 3</td>
</tr>
<tr>
<td>681</td>
<td>RNASEH2C deficiency</td>
</tr>
<tr>
<td>682</td>
<td>Aicardi-Goutières syndrome type 4</td>
</tr>
<tr>
<td>683</td>
<td>RNASEH2A deficiency</td>
</tr>
<tr>
<td>684</td>
<td>Aicardi-Goutières syndrome type 5</td>
</tr>
<tr>
<td>685</td>
<td>SAMHD1deficiency</td>
</tr>
<tr>
<td>686</td>
<td>Cystic leukoencephalopathy without megalencephaly</td>
</tr>
<tr>
<td>687</td>
<td>RNASET2-deficient cystic leukoencephalopathy</td>
</tr>
<tr>
<td>688</td>
<td>Other specified sphingolipidosis</td>
</tr>
<tr>
<td>689</td>
<td>Mucolipidosis type 4</td>
</tr>
<tr>
<td>690</td>
<td>Sialolipidosis</td>
</tr>
<tr>
<td>691</td>
<td>Gaucher disease</td>
</tr>
<tr>
<td>692</td>
<td>Acid beta-glucosidase deficiency</td>
</tr>
<tr>
<td>693</td>
<td>Glucocerebrosidase deficiency</td>
</tr>
<tr>
<td>694</td>
<td>Glucosylceramide beta-glucosidase deficiency</td>
</tr>
<tr>
<td>695</td>
<td>Glucocerebrosidosis</td>
</tr>
<tr>
<td>696</td>
<td>Cerebroside lipidosis syndrome</td>
</tr>
<tr>
<td>697</td>
<td>Gaucher disease type 1</td>
</tr>
<tr>
<td>698</td>
<td>Noncerebral juvenile Gaucher disease</td>
</tr>
<tr>
<td>699</td>
<td>Adult Gaucher disease</td>
</tr>
<tr>
<td>700</td>
<td>Gaucher disease type 2</td>
</tr>
<tr>
<td>701</td>
<td>Acute neuronopathic Gaucher disease</td>
</tr>
<tr>
<td>702</td>
<td>Infantile cerebral Gaucher disease</td>
</tr>
<tr>
<td>703</td>
<td>Infantile Gaucher disease</td>
</tr>
<tr>
<td>704</td>
<td>Cerebral acute Gaucher disease</td>
</tr>
<tr>
<td>705</td>
<td>Gaucher disease type 3</td>
</tr>
<tr>
<td>706</td>
<td>Cerebral juvenile and adult form of Gaucher disease</td>
</tr>
<tr>
<td>707</td>
<td>Chronic neuronopathic Gaucher disease</td>
</tr>
<tr>
<td>708</td>
<td>Subacute neuronopathic Gaucher disease</td>
</tr>
<tr>
<td>709</td>
<td>Juvenile Gaucher disease</td>
</tr>
<tr>
<td>710</td>
<td>Norrbotnian Gaucher disease</td>
</tr>
<tr>
<td>711</td>
<td>Gaucher disease - ophthalmoplegia - cardiovascular calcification</td>
</tr>
<tr>
<td>712</td>
<td>Cardiovascular Gaucher disease</td>
</tr>
<tr>
<td>713</td>
<td>Gaucher disease type 3C</td>
</tr>
<tr>
<td>714</td>
<td>Gaucher-like disease</td>
</tr>
<tr>
<td>715</td>
<td>Perinatal-lethal Gaucher disease</td>
</tr>
<tr>
<td>716</td>
<td>Fetal Gaucher disease</td>
</tr>
<tr>
<td>717</td>
<td>Collodion type Gaucher disease</td>
</tr>
<tr>
<td>718</td>
<td>Atypical Gaucher disease due to saposin C deficiency</td>
</tr>
<tr>
<td>719</td>
<td>Gaucher’s splenomegaly</td>
</tr>
<tr>
<td>720</td>
<td>Mucosulfatidosis</td>
</tr>
<tr>
<td>721</td>
<td>Multiple sulfatase deficiency</td>
</tr>
<tr>
<td>722</td>
<td>Juvenile sulfatidose, Austin type</td>
</tr>
<tr>
<td>723</td>
<td>Austin disease</td>
</tr>
<tr>
<td>724</td>
<td>Niemann-Pick disease</td>
</tr>
<tr>
<td>725</td>
<td>Sphingomyelinase deficiency</td>
</tr>
<tr>
<td>726</td>
<td>Niemann-Pick disease type A</td>
</tr>
<tr>
<td>727</td>
<td>Niemann-Pick disease type B</td>
</tr>
<tr>
<td>728</td>
<td>Niemann-Pick disease type C</td>
</tr>
<tr>
<td>729</td>
<td>cholesterol transporter deficiency</td>
</tr>
<tr>
<td>730</td>
<td>Niemann-Pick disease type C, severe perinatal</td>
</tr>
<tr>
<td>731</td>
<td>Niemann-Pick disease type C, severe early infantile neurologic onset</td>
</tr>
<tr>
<td>732</td>
<td>Niemann-Pick disease type C, late infantile neurologic onset</td>
</tr>
<tr>
<td>733</td>
<td>Niemann-Pick disease type C, juvenile neurologic onset</td>
</tr>
<tr>
<td>734</td>
<td>Niemann-Pick disease type C, classic form</td>
</tr>
<tr>
<td>735</td>
<td>Niemann-Pick disease type C, adult neurologic onset</td>
</tr>
<tr>
<td>736</td>
<td>Farber disease</td>
</tr>
<tr>
<td>737</td>
<td>Farber lipogranulomatosis</td>
</tr>
<tr>
<td>738</td>
<td>Ceramidase deficiency</td>
</tr>
<tr>
<td>739</td>
<td>Disseminated lipogranulomatosis</td>
</tr>
<tr>
<td>740</td>
<td>Lysosomal acid lipase deficiency</td>
</tr>
<tr>
<td>741</td>
<td>Acid esterase deficiency</td>
</tr>
<tr>
<td>742</td>
<td>Wolman disease</td>
</tr>
<tr>
<td>743</td>
<td>Cholesteryl ester storage disease</td>
</tr>
<tr>
<td>744</td>
<td>CESD - [Cholesteryl ester storage disease]</td>
</tr>
<tr>
<td>745</td>
<td>Encephalopathy due to prosaposin deficiency</td>
</tr>
<tr>
<td>746</td>
<td>Combined prosaposin deficiency</td>
</tr>
<tr>
<td>747</td>
<td>Other specified malignant neoplasms of thyroid gland</td>
</tr>
<tr>
<td>748</td>
<td>Follicular adenocarcinoma of thyroid gland</td>
</tr>
<tr>
<td>749</td>
<td>follicular adenocarcinoma of unspecified site</td>
</tr>
<tr>
<td>750</td>
<td>moderately differentiated follicular adenocarcinoma of thyroid gland</td>
</tr>
<tr>
<td>751</td>
<td>moderately differentiated follicular adenocarcinoma of unspecified site</td>
</tr>
<tr>
<td>752</td>
<td>trabecular follicular adenocarcinoma of thyroid gland</td>
</tr>
<tr>
<td>753</td>
<td>trabecular follicular adenocarcinoma of unspecified site</td>
</tr>
<tr>
<td>754</td>
<td>well differentiated follicular adenocarcinoma of thyroid gland</td>
</tr>
<tr>
<td>755</td>
<td>well differentiated follicular adenocarcinoma of unspecified site</td>
</tr>
<tr>
<td>756</td>
<td>C cell carcinoma of unspecified site</td>
</tr>
<tr>
<td>757</td>
<td>Follicular with papillary adenocarcinoma of unspecified site</td>
</tr>
<tr>
<td>758</td>
<td>Follicular variant papillary adenocarcinoma of unspecified site</td>
</tr>
<tr>
<td>759</td>
<td>Hurthle cell adenocarcinoma of unspecified site</td>
</tr>
<tr>
<td>760</td>
<td>malignant Hurthle cell tumour of unspecified site</td>
</tr>
<tr>
<td>761</td>
<td>Nonencapsulated sclerosing adenocarcinoma of unspecified site</td>
</tr>
<tr>
<td>762</td>
<td>Papillary and follicular adenocarcinoma of unspecified site</td>
</tr>
<tr>
<td>763</td>
<td>Parafollicular cell carcinoma of unspecified site</td>
</tr>
<tr>
<td>764</td>
<td>Wuchernde struma langhans of thyroid</td>
</tr>
<tr>
<td>765</td>
<td>Wuchernde struma langhans of unspecified site</td>
</tr>
<tr>
<td>766</td>
<td>Oxyphilic cell follicular carcinoma of thyroid gland</td>
</tr>
<tr>
<td>767</td>
<td>Dominant limb-girdle muscular dystrophy</td>
</tr>
<tr>
<td>768</td>
<td>LGMD1 - [limb-girdle muscular dystrophy] 1</td>
</tr>
<tr>
<td>769</td>
<td>Limb-girdle muscular dystrophy 1A, myotilin myopathy</td>
</tr>
<tr>
<td>770</td>
<td>LGMD 1A - [Limb-girdle muscular dystrophy 1A, myotilin myopathy]</td>
</tr>
<tr>
<td>771</td>
<td>Limb-girdle muscular dystrophy 1B, lamin myopathy</td>
</tr>
<tr>
<td>772</td>
<td>LGMD 1B - [Limb-girdle muscular dystrophy 1B, lamin myopathy]</td>
</tr>
<tr>
<td>773</td>
<td>Limb-girdle muscular dystrophy 1C, caveolin myopathy</td>
</tr>
<tr>
<td>774</td>
<td>LGMD 1C - [Limb-girdle muscular dystrophy 1C, caveolin myopathy]</td>
</tr>
<tr>
<td>775</td>
<td>Limb-girdle muscular dystrophy 1D, gene mapped to 6q23</td>
</tr>
<tr>
<td>776</td>
<td>Limb-girdle muscular dystrophy 1E, gene mapped to 7q</td>
</tr>
<tr>
<td>777</td>
<td>Limb-girdle muscular dystrophy 1F, gene mapped to 7q32.1-32.2</td>
</tr>
<tr>
<td>778</td>
<td>Limb-girdle muscular dystrophy 1G, gene mapped to 4q21</td>
</tr>
<tr>
<td>779</td>
<td>Limb-girdle muscular dystrophy 1H, gene mapped to 3p25.1p23</td>
</tr>
<tr>
<td>780</td>
<td>LGMD1H - [Limb-girdle muscular dystrophy] 1H</td>
</tr>
<tr>
<td>781</td>
<td>St Louis encephalitis</td>
</tr>
<tr>
<td>782</td>
<td>neuroinvasive Saint Louis encephalitis virus infection</td>
</tr>
<tr>
<td>783</td>
<td>neuroinvasive St. Louis encephalitis virus infection</td>
</tr>
<tr>
<td>784</td>
<td>Saint Louis encephalitis</td>
</tr>
<tr>
<td>785</td>
<td>St. Louis encephalitis virus infection</td>
</tr>
<tr>
<td>786</td>
<td>St. Louis encephalitis virus neuroinvasive disease</td>
</tr>
<tr>
<td>787</td>
<td>St. Louis viral disease</td>
</tr>
<tr>
<td>788</td>
<td>Type C lethargic encephalitis</td>
</tr>
<tr>
<td>789</td>
<td>encephalitis Type C</td>
</tr>
<tr>
<td>790</td>
<td>Immunodeficiency with an early component of complement deficiency</td>
</tr>
<tr>
<td>791</td>
<td>Deficiency of complement initial pathway</td>
</tr>
<tr>
<td>792</td>
<td>Complement component C1q deficiency</td>
</tr>
<tr>
<td>793</td>
<td>Complement component C1r/C1s deficiency</td>
</tr>
<tr>
<td>794</td>
<td>Complement component C2 deficiency</td>
</tr>
<tr>
<td>795</td>
<td>Complement component C4 deficiency</td>
</tr>
<tr>
<td>796</td>
<td>Acute hepatitis C</td>
</tr>
<tr>
<td>797</td>
<td>Acute hepatitis C virus infection</td>
</tr>
<tr>
<td>798</td>
<td>Other specified defects in the complement system</td>
</tr>
<tr>
<td>799</td>
<td>Complement component C3 deficiency</td>
</tr>
<tr>
<td>800</td>
<td>Recurrent Neisseria infections due to factor D deficiency</td>
</tr>
<tr>
<td>801</td>
<td>Complement component C4b-binding protein deficiency</td>
</tr>
<tr>
<td>802</td>
<td>Immunodeficiency with CD46 deficiency</td>
</tr>
<tr>
<td>803</td>
<td>Membrane cofactor protein deficiency</td>
</tr>
<tr>
<td>804</td>
<td>Immunodeficiency with decay accelerating factor deficiency</td>
</tr>
<tr>
<td>805</td>
<td>Immunodeficiency with CD55 deficiency</td>
</tr>
<tr>
<td>806</td>
<td>Immunodeficiency with DAF - [decay accelerating factor] deficiency</td>
</tr>
<tr>
<td>807</td>
<td>CHAPLE syndrome</td>
</tr>
<tr>
<td>808</td>
<td>Immunodeficiency with factor H anomaly</td>
</tr>
<tr>
<td>809</td>
<td>Immunodeficiency with factor I anomaly</td>
</tr>
<tr>
<td>810</td>
<td>Immunodeficiency with properdin deficiency</td>
</tr>
<tr>
<td>811</td>
<td>Immunodeficiency with CD59 deficiency</td>
</tr>
<tr>
<td>812</td>
<td>Immunodeficiency with MASP-2 deficiency</td>
</tr>
<tr>
<td>813</td>
<td>Mannan-binding lectin serine protease 2 deficiency</td>
</tr>
<tr>
<td>814</td>
<td>Immunodeficiency with MBL - [mannan-binding lectin] deficiency</td>
</tr>
<tr>
<td>815</td>
<td>Mannan-binding lectin deficiency</td>
</tr>
<tr>
<td>816</td>
<td>Mannose-binding protein deficiency</td>
</tr>
<tr>
<td>817</td>
<td>MBP - [mannan-binding lectin] deficiency</td>
</tr>
<tr>
<td>818</td>
<td>Immunodeficiency with ficolin-3 deficiency</td>
</tr>
<tr>
<td>819</td>
<td>Angioedema due to disordered complement activation or kinin metabolism</td>
</tr>
<tr>
<td>820</td>
<td>Immunodeficiency with a late component of complement deficiency</td>
</tr>
<tr>
<td>821</td>
<td>Deficiency of complement terminal pathway</td>
</tr>
<tr>
<td>822</td>
<td>Complement component C5 deficiency</td>
</tr>
<tr>
<td>823</td>
<td>Complement component C6 deficiency</td>
</tr>
<tr>
<td>824</td>
<td>Complement component C7 deficiency</td>
</tr>
<tr>
<td>825</td>
<td>Complement component 7 deficiency</td>
</tr>
<tr>
<td>826</td>
<td>Complement component C8 deficiency</td>
</tr>
<tr>
<td>827</td>
<td>Complement component C9 deficiency</td>
</tr>
<tr>
<td>828</td>
<td>Atlanto-axial dislocation</td>
</tr>
<tr>
<td>829</td>
<td>dislocation C1/C2</td>
</tr>
<tr>
<td>830</td>
<td>atlas dislocation</td>
</tr>
<tr>
<td>831</td>
<td>axis dislocation</td>
</tr>
<tr>
<td>832</td>
<td>dislocation of occiput from atlas</td>
</tr>
<tr>
<td>833</td>
<td>Partial dislocation of atlanto-axial joint</td>
</tr>
<tr>
<td>834</td>
<td>Ligamentous instability of atlanto-axial joint</td>
</tr>
<tr>
<td>835</td>
<td>Subluxation of atlanto-axial joint</td>
</tr>
<tr>
<td>836</td>
<td>Complete dislocation of atlanto-axial joint</td>
</tr>
<tr>
<td>837</td>
<td>Scorbutic anaemia</td>
</tr>
<tr>
<td>838</td>
<td>scorbutus anaemia</td>
</tr>
<tr>
<td>839</td>
<td>anaemia due to scurvy</td>
</tr>
<tr>
<td>840</td>
<td>anaemia due to ascorbic acid deficiency</td>
</tr>
<tr>
<td>841</td>
<td>anaemia due to vitamin c deficiency</td>
</tr>
<tr>
<td>842</td>
<td>Hypersecretion of calcitonin</td>
</tr>
<tr>
<td>843</td>
<td>Hypersecretion of thyrocalcitonin</td>
</tr>
<tr>
<td>844</td>
<td>C-cell hyperplasia of thyroid</td>
</tr>
<tr>
<td>845</td>
<td>Haemophilia C</td>
</tr>
<tr>
<td>846</td>
<td>Rosenthal factor deficiency</td>
</tr>
<tr>
<td>847</td>
<td>Rosenthal syndrome</td>
</tr>
<tr>
<td>848</td>
<td>plasma thromboplastin antecedent deficiency</td>
</tr>
<tr>
<td>849</td>
<td>thromboplastin antecedent deficiency</td>
</tr>
<tr>
<td>850</td>
<td>PTA - [plasma thromboplastin antecedent] deficiency</td>
</tr>
<tr>
<td>851</td>
<td>congenital factor XI deficiency</td>
</tr>
<tr>
<td>852</td>
<td>congenital factor XI deficiency disease</td>
</tr>
<tr>
<td>853</td>
<td>factor XI deficiency</td>
</tr>
<tr>
<td>854</td>
<td>hereditary factor XI deficiency disease</td>
</tr>
<tr>
<td>855</td>
<td>Rosenthal disease</td>
</tr>
<tr>
<td>856</td>
<td>Female Genital Mutilation Type 2c</td>
</tr>
<tr>
<td>857</td>
<td>Intestinal infections due to Clostridioides difficile</td>
</tr>
<tr>
<td>858</td>
<td>Clostridium difficile diarrhoea</td>
</tr>
<tr>
<td>859</td>
<td>colitis due to Clostridium difficile</td>
</tr>
<tr>
<td>860</td>
<td>Clostridium difficile gastroenteritis</td>
</tr>
<tr>
<td>861</td>
<td>C diff colitis</td>
</tr>
<tr>
<td>862</td>
<td>necrotizing enterocolitis due to clostridium difficile infection</td>
</tr>
<tr>
<td>863</td>
<td>foodborne clostridium difficile infection</td>
</tr>
<tr>
<td>864</td>
<td>enterocolitis due to Clostridium difficile</td>
</tr>
<tr>
<td>865</td>
<td>Clostridium difficile colitis</td>
</tr>
<tr>
<td>866</td>
<td>CDAD – [clostridium difficile associated diarrhoea]</td>
</tr>
<tr>
<td>867</td>
<td>C. difficile colitis</td>
</tr>
<tr>
<td>868</td>
<td>CDAD – [clostridioides difficile associated diarrhoea]</td>
</tr>
<tr>
<td>869</td>
<td>Pseudomembranous colitis</td>
</tr>
<tr>
<td>870</td>
<td>PMC - [pseudomembranous colitis]</td>
</tr>
<tr>
<td>871</td>
<td>Megacolon due to Clostridioides difficile</td>
</tr>
<tr>
<td>872</td>
<td>megacolon due to Clostridium difficile</td>
</tr>
<tr>
<td>1</td>
<td>Graft-versus-host disease, unspecified</td>
</tr>
<tr>
<td>2</td>
<td>Graft-versus-host disease</td>
</tr>
<tr>
<td>3</td>
<td>GVHD - [graft-versus-host disease]</td>
</tr>
<tr>
<td>4</td>
<td>graft-versus-host reaction or disease</td>
</tr>
<tr>
<td>5</td>
<td>GVH - [graft-versus-host] disease</td>
</tr>
<tr>
<td>6</td>
<td>GVH - [graft-versus-host] reaction</td>
</tr>
<tr>
<td>7</td>
<td>Irritable bowel syndrome, diarrhoea predominant</td>
</tr>
<tr>
<td>8</td>
<td>irritable bowel syndrome with diarrhoea</td>
</tr>
<tr>
<td>9</td>
<td>IBS-D - [Irritable bowel syndrome, diarrhoea predominant]</td>
</tr>
<tr>
<td>10</td>
<td>irritable bowel with diarrhoea</td>
</tr>
<tr>
<td>11</td>
<td>colon spasm with diarrhoea</td>
</tr>
<tr>
<td>12</td>
<td>irritable colon with diarrhoea</td>
</tr>
<tr>
<td>13</td>
<td>spastic colitis with diarrhoea</td>
</tr>
<tr>
<td>14</td>
<td>Haemoglobin D disease</td>
</tr>
<tr>
<td>15</td>
<td>Punjab disease</td>
</tr>
<tr>
<td>16</td>
<td>Los Angeles disease</td>
</tr>
<tr>
<td>17</td>
<td>Hb D Los Angeles disease</td>
</tr>
<tr>
<td>18</td>
<td>Hb D Punjab disease</td>
</tr>
<tr>
<td>19</td>
<td>Vitamin D deficiency, unspecified</td>
</tr>
<tr>
<td>20</td>
<td>Vitamin D deficiency</td>
</tr>
<tr>
<td>21</td>
<td>Avitaminosis D</td>
</tr>
<tr>
<td>22</td>
<td>Hypervitaminosis D</td>
</tr>
<tr>
<td>23</td>
<td>vitamin D hyperalimentation</td>
</tr>
<tr>
<td>24</td>
<td>Excess vitamin D administered as drug</td>
</tr>
<tr>
<td>25</td>
<td>Presence of cardiac resynchronization therapy defibrillator</td>
</tr>
<tr>
<td>26</td>
<td>CRT-D - [cardiac resynchronization therapy defibrillator]</td>
</tr>
<tr>
<td>27</td>
<td>Complete trisomy 13</td>
</tr>
<tr>
<td>28</td>
<td>Patau syndrome</td>
</tr>
<tr>
<td>29</td>
<td>complete trisomy 13 syndrome</td>
</tr>
<tr>
<td>30</td>
<td>d1 trisomy</td>
</tr>
<tr>
<td>31</td>
<td>d1 trisomy syndrome</td>
</tr>
<tr>
<td>32</td>
<td>d&gt;1&lt; trisomy syndrome</td>
</tr>
<tr>
<td>33</td>
<td>patau</td>
</tr>
<tr>
<td>34</td>
<td>trisomy 13</td>
</tr>
<tr>
<td>35</td>
<td>trisomy 13 syndrome</td>
</tr>
<tr>
<td>36</td>
<td>chromosome 13 trisomy</td>
</tr>
<tr>
<td>37</td>
<td>abnormal autosomes 13</td>
</tr>
<tr>
<td>38</td>
<td>Complete trisomy 13, meiotic non-disjunction</td>
</tr>
<tr>
<td>39</td>
<td>trisomy 13, meiotic nondisjunction</td>
</tr>
<tr>
<td>40</td>
<td>trisomy 13 syndrome, meiotic nondisjunction</td>
</tr>
<tr>
<td>41</td>
<td>Complete trisomy 13, translocation</td>
</tr>
<tr>
<td>42</td>
<td>partial trisomy 13 in patau syndrome</td>
</tr>
<tr>
<td>43</td>
<td>translocation trisomy 13</td>
</tr>
<tr>
<td>44</td>
<td>translocation trisomy 13 syndrome</td>
</tr>
<tr>
<td>45</td>
<td>translocation trisomy 13 chromosome</td>
</tr>
<tr>
<td>46</td>
<td>Other specified vitamin D deficiency</td>
</tr>
<tr>
<td>47</td>
<td>Ergocalciferol deficiency</td>
</tr>
<tr>
<td>48</td>
<td>viosterol deficiency</td>
</tr>
<tr>
<td>49</td>
<td>calciferol deficiency</td>
</tr>
<tr>
<td>50</td>
<td>deficiency of Vitamin D2</td>
</tr>
<tr>
<td>51</td>
<td>Ergosterol deficiency</td>
</tr>
<tr>
<td>52</td>
<td>Acute graft-versus-host disease</td>
</tr>
<tr>
<td>53</td>
<td>acute GVHD - [graft-versus-host disease]</td>
</tr>
<tr>
<td>54</td>
<td>Delayed acute graft-versus-host disease</td>
</tr>
<tr>
<td>55</td>
<td>delayed acute GVHD - [graft-versus-host disease]</td>
</tr>
<tr>
<td>56</td>
<td>Late acute graft-versus-host disease</td>
</tr>
<tr>
<td>57</td>
<td>late acute GVHD - [graft-versus-host disease]</td>
</tr>
<tr>
<td>58</td>
<td>Concurrent acute and chronic graft-versus-host disease</td>
</tr>
<tr>
<td>59</td>
<td>concurrent acute and chronic GVHD - [graft-versus-host disease]</td>
</tr>
<tr>
<td>60</td>
<td>Chronic graft-versus-host disease</td>
</tr>
<tr>
<td>61</td>
<td>chronic GVHD - [graft-versus-host disease]</td>
</tr>
<tr>
<td>62</td>
<td>chronic graft-versus-host-disease</td>
</tr>
<tr>
<td>63</td>
<td>Early chronic graft-versus-host disease</td>
</tr>
<tr>
<td>64</td>
<td>Chronic lichenoid graft-versus-host disease</td>
</tr>
<tr>
<td>65</td>
<td>early chronic GVHD - [graft-versus-host disease]</td>
</tr>
<tr>
<td>66</td>
<td>chronic lichenoid GVHD - [graft-versus-host disease]</td>
</tr>
<tr>
<td>67</td>
<td>Late chronic graft-versus-host disease</td>
</tr>
<tr>
<td>68</td>
<td>Sclerodermatous chronic graft-versus-host disease</td>
</tr>
<tr>
<td>69</td>
<td>sclerodermatous GVHD - [graft-versus-host disease]</td>
</tr>
<tr>
<td>70</td>
<td>late chronic GVHD - [graft-versus-host disease]</td>
</tr>
<tr>
<td>71</td>
<td>sclerodermatous graft-versus-host disease</td>
</tr>
<tr>
<td>72</td>
<td>Hereditary sensory and autonomic neuropathy type I</td>
</tr>
<tr>
<td>73</td>
<td>HSAN1- [Hereditary sensory and autonomic neuropathy type I]</td>
</tr>
<tr>
<td>74</td>
<td>Hereditary sensory and autonomic neuropathy Type IA</td>
</tr>
<tr>
<td>75</td>
<td>HSAN1A - [Hereditary sensory autonomic neuropathy Type IA</td>
</tr>
<tr>
<td>76</td>
<td>Hereditary sensory and autonomic neuropathy Type IB</td>
</tr>
<tr>
<td>77</td>
<td>Hereditary sensory and autonomic neuropathy Type IC</td>
</tr>
<tr>
<td>78</td>
<td>HSAN1C - [Hereditary sensory autonomic neuropathy Type IC]</td>
</tr>
<tr>
<td>79</td>
<td>Hereditary sensory and autonomic neuropathy Type ID</td>
</tr>
<tr>
<td>80</td>
<td>HSAN1D - [Hereditary sensory autonomic neuropathy Type ID]</td>
</tr>
<tr>
<td>81</td>
<td>Hereditary sensory and autonomic neuropathy Type IE</td>
</tr>
<tr>
<td>82</td>
<td>HSAN1E - [Hereditary sensory autonomic neuropathy Type IE]</td>
</tr>
<tr>
<td>83</td>
<td>Congenital muscular dystrophy</td>
</tr>
<tr>
<td>84</td>
<td>hereditary muscular dystrophy</td>
</tr>
<tr>
<td>85</td>
<td>congenital hereditary muscular dystrophy</td>
</tr>
<tr>
<td>86</td>
<td>congenital progressive muscular dystrophy</td>
</tr>
<tr>
<td>87</td>
<td>hereditary progressive muscular dystrophy</td>
</tr>
<tr>
<td>88</td>
<td>Congenital muscular dystrophy with central nervous system abnormalities</td>
</tr>
<tr>
<td>89</td>
<td>Congenital muscular dystrophy Fukuyama type</td>
</tr>
<tr>
<td>90</td>
<td>Congenital muscular dystrophy with central nervous system abnormalities, not elsewhere classified</td>
</tr>
<tr>
<td>91</td>
<td>Walker Warburg syndrome</td>
</tr>
<tr>
<td>92</td>
<td>Hydrocephalus - agyria - retinal dysplasia syndrome</td>
</tr>
<tr>
<td>93</td>
<td>WWS - [Walker Warburg syndrome]</td>
</tr>
<tr>
<td>94</td>
<td>HARD - [Hydrocephalus - agyria - retinal dysplasia syndrome]</td>
</tr>
<tr>
<td>95</td>
<td>Muscle Eye Brain disease</td>
</tr>
<tr>
<td>96</td>
<td>MEB - [Muscle Eye Brain disease]</td>
</tr>
<tr>
<td>97</td>
<td>Marinesco-Sjögren syndrome</td>
</tr>
<tr>
<td>98</td>
<td>Congenital muscular dystrophy type 1C, fukutin-related protein gene mutation</td>
</tr>
<tr>
<td>99</td>
<td>Congenital muscular dystrophy type 1D large gene mutation</td>
</tr>
<tr>
<td>100</td>
<td>MDC1D - [congenital muscular dystrophy 1D]</td>
</tr>
<tr>
<td>101</td>
<td>Congenital muscular dystrophy without central nervous system symptoms</td>
</tr>
<tr>
<td>102</td>
<td>Congenital muscular dystrophy without central nervous system abnormalities, not elsewhere classified</td>
</tr>
<tr>
<td>103</td>
<td>Merosin or laminin alpha 2 chain deficiency</td>
</tr>
<tr>
<td>104</td>
<td>Merosin-deficient congenital muscular dystrophy</td>
</tr>
<tr>
<td>105</td>
<td>Collagen VI deficiency</td>
</tr>
<tr>
<td>106</td>
<td>Bethlem myopathy</td>
</tr>
<tr>
<td>107</td>
<td>Ullrich congenital muscular dystrophy</td>
</tr>
<tr>
<td>108</td>
<td>UCMD - [Ullrich congenital muscular dystrophy</td>
</tr>
<tr>
<td>109</td>
<td>Congenital muscular dystrophy - infantile cataract - hypogonadism</td>
</tr>
<tr>
<td>110</td>
<td>Bassoe syndrome</td>
</tr>
<tr>
<td>111</td>
<td>Congenital muscular dystrophy due to lamin A/C deficiency</td>
</tr>
<tr>
<td>112</td>
<td>Congenital muscular dystrophy due to phosphatidylcholine biosynthesis defect</td>
</tr>
<tr>
<td>113</td>
<td>Congenital megaconial myopathy</td>
</tr>
<tr>
<td>114</td>
<td>Congenital muscular dystrophy with mitochondrial structural abnormalities</td>
</tr>
<tr>
<td>115</td>
<td>Congenital muscular dystrophy with integrin deficiency</td>
</tr>
<tr>
<td>116</td>
<td>Congenital muscular dystrophy, Paradas type</td>
</tr>
<tr>
<td>117</td>
<td>Rigid spine syndrome</td>
</tr>
<tr>
<td>118</td>
<td>Congenital muscular dystrophy type 1B</td>
</tr>
<tr>
<td>119</td>
<td>MDC1B - [Muscular Dystrophy Type 1B]</td>
</tr>
<tr>
<td>120</td>
<td>CMD1B - [Congenital muscular dystrophy type 1B]</td>
</tr>
<tr>
<td>121</td>
<td>Glycogen storage disease</td>
</tr>
<tr>
<td>122</td>
<td>Glycogenosis</td>
</tr>
<tr>
<td>123</td>
<td>GSD - [Glycogen storage disease]</td>
</tr>
<tr>
<td>124</td>
<td>glycogen thesaurismosis</td>
</tr>
<tr>
<td>125</td>
<td>diffuse glycogenosis</td>
</tr>
<tr>
<td>126</td>
<td>generalised glycogen storage disease</td>
</tr>
<tr>
<td>127</td>
<td>generalised glycogenosis</td>
</tr>
<tr>
<td>128</td>
<td>generalised glycogen storage disease of infants</td>
</tr>
<tr>
<td>129</td>
<td>glycogen synthase deficiency</td>
</tr>
<tr>
<td>130</td>
<td>Glycogen storage disease due to glycogen synthase deficiency</td>
</tr>
<tr>
<td>131</td>
<td>Glycogen storage disease type 0</td>
</tr>
<tr>
<td>132</td>
<td>Glycogenosis type 0</td>
</tr>
<tr>
<td>133</td>
<td>GSD type 0</td>
</tr>
<tr>
<td>134</td>
<td>deficiency of glycogen synthetase</td>
</tr>
<tr>
<td>135</td>
<td>Glycogen storage disease due to liver glycogen synthase deficiency</td>
</tr>
<tr>
<td>136</td>
<td>GSD type 0A</td>
</tr>
<tr>
<td>137</td>
<td>Glycogen storage disease type 0A</td>
</tr>
<tr>
<td>138</td>
<td>Glycogenosis type 0A</td>
</tr>
<tr>
<td>139</td>
<td>Glycogen storage disease due to muscle or heart glycogen synthase deficiency</td>
</tr>
<tr>
<td>140</td>
<td>Glycogen storage disease type 0B</td>
</tr>
<tr>
<td>141</td>
<td>Glycogenosis type 0B</td>
</tr>
<tr>
<td>142</td>
<td>GSD type 0B</td>
</tr>
<tr>
<td>143</td>
<td>Cardiomyopathy-exercise intolerance due to muscle and heart glycogen deficiency</td>
</tr>
<tr>
<td>144</td>
<td>Glycogen storage disease due to glucose-6-phosphate system deficiency</td>
</tr>
<tr>
<td>145</td>
<td>Glycogen storage disease type 1</td>
</tr>
<tr>
<td>146</td>
<td>Glycogenosis type 1</td>
</tr>
<tr>
<td>147</td>
<td>GSD type 1</td>
</tr>
<tr>
<td>148</td>
<td>Hepatorenal glycogenosis</td>
</tr>
<tr>
<td>149</td>
<td>Von Gierke disease</td>
</tr>
<tr>
<td>150</td>
<td>HERS - [hepatorenal glycogen storage disease]</td>
</tr>
<tr>
<td>151</td>
<td>glycogen storage disease of liver and kidney</td>
</tr>
<tr>
<td>152</td>
<td>hepatorenal glycogen storage disease</td>
</tr>
<tr>
<td>153</td>
<td>Glycogen storage disease due to glucose-6-phosphatase deficiency</td>
</tr>
<tr>
<td>154</td>
<td>Glycogen storage disease type 1A</td>
</tr>
<tr>
<td>155</td>
<td>Glycogenosis type 1A</td>
</tr>
<tr>
<td>156</td>
<td>GSD type 1A</td>
</tr>
<tr>
<td>157</td>
<td>g6pd - [glucose-6-phosphate dehydrogenase deficiency]</td>
</tr>
<tr>
<td>158</td>
<td>glucose-6-phosphatase deficiency</td>
</tr>
<tr>
<td>159</td>
<td>deficiency of g-6pd</td>
</tr>
<tr>
<td>160</td>
<td>Glycogen storage disease due to glucose-6-phosphate transport defect</td>
</tr>
<tr>
<td>161</td>
<td>Glycogen storage disease type 1B</td>
</tr>
<tr>
<td>162</td>
<td>Glycogenosis type 1B</td>
</tr>
<tr>
<td>163</td>
<td>GSD1B</td>
</tr>
<tr>
<td>164</td>
<td>Glycogen storage disease type non-1A</td>
</tr>
<tr>
<td>165</td>
<td>Glycogenosis type non-1A</td>
</tr>
<tr>
<td>166</td>
<td>Glycogen storage disease due to glucose-6-phosphate translocase deficiency</td>
</tr>
<tr>
<td>167</td>
<td>Glucose-6-phosphate dehydrogenase deficiency</td>
</tr>
<tr>
<td>168</td>
<td>Glycogen storage disease due to acid maltase deficiency</td>
</tr>
<tr>
<td>169</td>
<td>Glycogen storage disease type 2</td>
</tr>
<tr>
<td>170</td>
<td>Glycogenosis type 2</td>
</tr>
<tr>
<td>171</td>
<td>GSD type 2</td>
</tr>
<tr>
<td>172</td>
<td>Acid maltase deficiency</td>
</tr>
<tr>
<td>173</td>
<td>Pompe disease</td>
</tr>
<tr>
<td>174</td>
<td>Acid alpha-1,4-glucosidase deficiency</td>
</tr>
<tr>
<td>175</td>
<td>alpha-glucosidase deficiency</td>
</tr>
<tr>
<td>176</td>
<td>deficiency of amyloglucosidase</td>
</tr>
<tr>
<td>177</td>
<td>Glycogen storage disease due to acid maltase deficiency, infantile onset</td>
</tr>
<tr>
<td>178</td>
<td>Glycogen storage disease type 2, infantile onset</td>
</tr>
<tr>
<td>179</td>
<td>Glycogenosis type 2, infantile onset</td>
</tr>
<tr>
<td>180</td>
<td>GSD2, infantile onset</td>
</tr>
<tr>
<td>181</td>
<td>Glycogen storage disease due to acid alpha-1,4-glucosidase deficiency, infantile onset</td>
</tr>
<tr>
<td>182</td>
<td>Infantile Pompe disease</td>
</tr>
<tr>
<td>183</td>
<td>lysosomal alpha-1,4-glucosidase deficiency (disorder)</td>
</tr>
<tr>
<td>184</td>
<td>Glycogen storage disease due to acid maltase deficiency, juvenile onset</td>
</tr>
<tr>
<td>185</td>
<td>Glycogen storage disease due to acid maltase deficiency, adult onset</td>
</tr>
<tr>
<td>186</td>
<td>Deficiency of exo-1,4-alpha-glucosidase</td>
</tr>
<tr>
<td>187</td>
<td>Deficiency of glucan 1,4-alpha-glucosidase</td>
</tr>
<tr>
<td>188</td>
<td>Deficiency of gamma-amylase</td>
</tr>
<tr>
<td>189</td>
<td>Deficiency of glucoamylase</td>
</tr>
<tr>
<td>190</td>
<td>Deficiency of glucoinvertase</td>
</tr>
<tr>
<td>191</td>
<td>Deficiency of glucosidosucrase</td>
</tr>
<tr>
<td>192</td>
<td>Deficiency of maltase</td>
</tr>
<tr>
<td>193</td>
<td>Glycogen storage disease due to LAMP-2 deficiency</td>
</tr>
<tr>
<td>194</td>
<td>Glycogen storage disease type 2B</td>
</tr>
<tr>
<td>195</td>
<td>Glycogenosis type 2B</td>
</tr>
<tr>
<td>196</td>
<td>GSD type 2B</td>
</tr>
<tr>
<td>197</td>
<td>Lysosomal glycogen storage disease with normal acid maltase activity</td>
</tr>
<tr>
<td>198</td>
<td>Danon disease</td>
</tr>
<tr>
<td>199</td>
<td>Glycogen storage disease due to glycogen debranching enzyme deficiency</td>
</tr>
<tr>
<td>200</td>
<td>Glycogen storage disease type 3</td>
</tr>
<tr>
<td>201</td>
<td>Glycogenosis type 3</td>
</tr>
<tr>
<td>202</td>
<td>GSD type 3</td>
</tr>
<tr>
<td>203</td>
<td>Amylo-1,6-glucosidase deficiency</td>
</tr>
<tr>
<td>204</td>
<td>Glycogen debranching deficiency</td>
</tr>
<tr>
<td>205</td>
<td>Cori-Forbes disease</td>
</tr>
<tr>
<td>206</td>
<td>Cori disease</td>
</tr>
<tr>
<td>207</td>
<td>Forbes disease</td>
</tr>
<tr>
<td>208</td>
<td>Forbes glycogen storage disease</td>
</tr>
<tr>
<td>209</td>
<td>debrancher deficiency glycogen storage disease</td>
</tr>
<tr>
<td>210</td>
<td>debrancher enzyme deficiency</td>
</tr>
<tr>
<td>211</td>
<td>deficiency of 6-alpha-d-glucosidase</td>
</tr>
<tr>
<td>212</td>
<td>amylo-1,6-glucosidase deficiency disorder</td>
</tr>
<tr>
<td>213</td>
<td>Glycogen storage disease due to muscle glycogen phosphorylase deficiency</td>
</tr>
<tr>
<td>214</td>
<td>Glycogen storage disease type 5</td>
</tr>
<tr>
<td>215</td>
<td>Glycogenosis type 5</td>
</tr>
<tr>
<td>216</td>
<td>GSD type 5</td>
</tr>
<tr>
<td>217</td>
<td>Myophosphorylase deficiency</td>
</tr>
<tr>
<td>218</td>
<td>McArdle disease</td>
</tr>
<tr>
<td>219</td>
<td>myophosphorylase deficiency glycogenosis</td>
</tr>
<tr>
<td>220</td>
<td>Glycogen storage disease due to liver glycogen phosphorylase deficiency</td>
</tr>
<tr>
<td>221</td>
<td>Glycogenosis due to liver phosphorylase deficiency</td>
</tr>
<tr>
<td>222</td>
<td>Glycogen storage disease type 6</td>
</tr>
<tr>
<td>223</td>
<td>Glycogenosis type 6</td>
</tr>
<tr>
<td>224</td>
<td>GSD type 6</td>
</tr>
<tr>
<td>225</td>
<td>Glycogen storage disease type 6B</td>
</tr>
<tr>
<td>226</td>
<td>Glycogenosis type 6B</td>
</tr>
<tr>
<td>227</td>
<td>GSD type 6B</td>
</tr>
<tr>
<td>228</td>
<td>Hers disease</td>
</tr>
<tr>
<td>229</td>
<td>deficiency of hepatophosphorylase</td>
</tr>
<tr>
<td>230</td>
<td>Glycogen storage disease due to muscle phosphofructokinase deficiency</td>
</tr>
<tr>
<td>231</td>
<td>Glycogen storage disease type 7</td>
</tr>
<tr>
<td>232</td>
<td>Glycogenosis type 7</td>
</tr>
<tr>
<td>233</td>
<td>GSD type 7</td>
</tr>
<tr>
<td>234</td>
<td>Muscle phosphofructokinase deficiency</td>
</tr>
<tr>
<td>235</td>
<td>Tarui disease</td>
</tr>
<tr>
<td>236</td>
<td>anaemia due to phosphofructo-aldolase deficiency</td>
</tr>
<tr>
<td>237</td>
<td>Glycogen storage disease due to glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>238</td>
<td>Glycogenosis due to phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>239</td>
<td>GSD due to phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>240</td>
<td>Glycogen storage disease due to liver glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>241</td>
<td>Hepatic phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>242</td>
<td>Glycogen storage disease type 8</td>
</tr>
<tr>
<td>243</td>
<td>Glycogenosis type 8</td>
</tr>
<tr>
<td>244</td>
<td>GSD8 - [glycogen storage disease type 8]</td>
</tr>
<tr>
<td>245</td>
<td>Glycogen storage disease type 6A</td>
</tr>
<tr>
<td>246</td>
<td>Glycogen storage disease type 9A</td>
</tr>
<tr>
<td>247</td>
<td>Glycogen storage disease type 9C</td>
</tr>
<tr>
<td>248</td>
<td>Glycogenosis type 6A</td>
</tr>
<tr>
<td>249</td>
<td>Glycogenosis type 9A</td>
</tr>
<tr>
<td>250</td>
<td>Glycogenosis type 9C</td>
</tr>
<tr>
<td>251</td>
<td>GSD type 9C - [glycogen storage disease type 9C]</td>
</tr>
<tr>
<td>252</td>
<td>GSD6A - [glycogen storage disease type 6A]</td>
</tr>
<tr>
<td>253</td>
<td>GSD9A - [glycogen storage disease type 9A]</td>
</tr>
<tr>
<td>254</td>
<td>Glycogen storage disease due to liver or muscle glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>255</td>
<td>Glycogen storage disease type 9B</td>
</tr>
<tr>
<td>256</td>
<td>Glycogenosis type 9B</td>
</tr>
<tr>
<td>257</td>
<td>GSD type 9B</td>
</tr>
<tr>
<td>258</td>
<td>Glycogen storage disease type 9</td>
</tr>
<tr>
<td>259</td>
<td>Glycogenosis type 9</td>
</tr>
<tr>
<td>260</td>
<td>GSD9 - [glycogen storage disease type 9]</td>
</tr>
<tr>
<td>261</td>
<td>Glycogen storage disease due to heart glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>262</td>
<td>Glycogen storage disease of heart</td>
</tr>
<tr>
<td>263</td>
<td>Cardiac glycogenosis</td>
</tr>
<tr>
<td>264</td>
<td>Glycogen storage disease type 9F</td>
</tr>
<tr>
<td>265</td>
<td>Glycogenosis type 9F</td>
</tr>
<tr>
<td>266</td>
<td>GSD9F</td>
</tr>
<tr>
<td>267</td>
<td>glycogen heart disease</td>
</tr>
<tr>
<td>268</td>
<td>glycogenic myocardial infiltration</td>
</tr>
<tr>
<td>269</td>
<td>glycogenic myocardium infiltration</td>
</tr>
<tr>
<td>270</td>
<td>cardiomegalia glycogenica diffusa</td>
</tr>
<tr>
<td>271</td>
<td>Glycogen storage disease due to muscle glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>272</td>
<td>GSD9D - [glycogen storage disease type IXD]</td>
</tr>
<tr>
<td>273</td>
<td>Glycogen storage disease type 9D</td>
</tr>
<tr>
<td>274</td>
<td>Glycogen storage disease type 9E</td>
</tr>
<tr>
<td>275</td>
<td>Glycogenosis type 9D</td>
</tr>
<tr>
<td>276</td>
<td>Glycogenosis type 9E</td>
</tr>
<tr>
<td>277</td>
<td>GSD9E</td>
</tr>
<tr>
<td>278</td>
<td>muscle glycogen phosphorylase deficiency</td>
</tr>
<tr>
<td>279</td>
<td>glycogenosis type IXE</td>
</tr>
<tr>
<td>280</td>
<td>Glycogen storage disease due to muscle phosphoglycerate mutase deficiency</td>
</tr>
<tr>
<td>281</td>
<td>Glycogen storage disease type 10</td>
</tr>
<tr>
<td>282</td>
<td>Glycogenosis type 10</td>
</tr>
<tr>
<td>283</td>
<td>GSD type 10</td>
</tr>
<tr>
<td>284</td>
<td>Di Mauro disease</td>
</tr>
<tr>
<td>285</td>
<td>Glycogen storage disease due to GLUT2 deficiency</td>
</tr>
<tr>
<td>286</td>
<td>Glycogen storage disease type 11</td>
</tr>
<tr>
<td>287</td>
<td>Glycogenosis type 11</td>
</tr>
<tr>
<td>288</td>
<td>GSD type 11</td>
</tr>
<tr>
<td>289</td>
<td>Fanconi-Bickel glycogenosis</td>
</tr>
<tr>
<td>290</td>
<td>Bickel-Fanconi disease</td>
</tr>
<tr>
<td>291</td>
<td>Facilitated glucose transporter protein type 2 deficiency</td>
</tr>
<tr>
<td>292</td>
<td>Fanconi-Bickel syndrome</td>
</tr>
<tr>
<td>293</td>
<td>Glycogen storage disease due to aldolase A deficiency</td>
</tr>
<tr>
<td>294</td>
<td>Glycogen storage disease type 12</td>
</tr>
<tr>
<td>295</td>
<td>Glycogenosis type 12</td>
</tr>
<tr>
<td>296</td>
<td>GSD type 12</td>
</tr>
<tr>
<td>297</td>
<td>Glycogen storage disease due to muscle beta-enolase deficiency</td>
</tr>
<tr>
<td>298</td>
<td>Glycogen storage disease type 13</td>
</tr>
<tr>
<td>299</td>
<td>Glycogenosis type 13</td>
</tr>
<tr>
<td>300</td>
<td>GSD type 13</td>
</tr>
<tr>
<td>301</td>
<td>Glycogen storage disease due to phosphoglucomutase deficiency</td>
</tr>
<tr>
<td>302</td>
<td>Glycogen storage disease type 14</td>
</tr>
<tr>
<td>303</td>
<td>Glycogenosis type 14</td>
</tr>
<tr>
<td>304</td>
<td>GSD type 14</td>
</tr>
<tr>
<td>305</td>
<td>Glycogen storage disease due to glycogenin deficiency</td>
</tr>
<tr>
<td>306</td>
<td>Glycogen storage disease type 15</td>
</tr>
<tr>
<td>307</td>
<td>GSD type 15</td>
</tr>
<tr>
<td>308</td>
<td>Glocogenosis type 15</td>
</tr>
<tr>
<td>309</td>
<td>Glycogen storage disease due to phosphoglycerate kinase 1 deficiency</td>
</tr>
<tr>
<td>310</td>
<td>Glycogenosis due to phosphoglycerate kinase 1 deficiency</td>
</tr>
<tr>
<td>311</td>
<td>GSD due to phosphoglycerate kinase 1 deficiency</td>
</tr>
<tr>
<td>312</td>
<td>Glycogen storage disease due to lactate dehydrogenase deficiency</td>
</tr>
<tr>
<td>313</td>
<td>Glycogenosis due to lactate dehydrogenase deficiency</td>
</tr>
<tr>
<td>314</td>
<td>GSD due to lactate dehydrogenase deficiency</td>
</tr>
<tr>
<td>315</td>
<td>Glycogen storage disease due to muscle pyruvate kinase deficiency</td>
</tr>
<tr>
<td>316</td>
<td>Glycogenosis due to muscle pyruvate kinase deficiency</td>
</tr>
<tr>
<td>317</td>
<td>GSD due to muscle pyruvate kinase deficiency</td>
</tr>
<tr>
<td>318</td>
<td>Glycogen storage liver disease</td>
</tr>
<tr>
<td>319</td>
<td>hepatomegalia glycogenica diffusa</td>
</tr>
<tr>
<td>320</td>
<td>liver glycogen disease</td>
</tr>
<tr>
<td>321</td>
<td>liver phosphorylase deficiency</td>
</tr>
<tr>
<td>322</td>
<td>Glycogen storage disease due to branching-transferase deficiency</td>
</tr>
<tr>
<td>323</td>
<td>Andersen disease</td>
</tr>
<tr>
<td>324</td>
<td>brancher deficiency glycogen storage disease</td>
</tr>
<tr>
<td>325</td>
<td>branching enzyme deficiency</td>
</tr>
<tr>
<td>326</td>
<td>branching-transferase deficiency glycogenosis</td>
</tr>
<tr>
<td>327</td>
<td>deficiency of 1,4-alpha-glucan branching enzyme</td>
</tr>
<tr>
<td>328</td>
<td>deficiency of amylo-(1,4,6)-transglycosylase</td>
</tr>
<tr>
<td>329</td>
<td>Glycogen storage disease type 4</td>
</tr>
<tr>
<td>330</td>
<td>Glycogenosis type 4</td>
</tr>
<tr>
<td>331</td>
<td>GSD- [Glycogen storage disease] type 4</td>
</tr>
<tr>
<td>332</td>
<td>Dilated cardiomyopathy due to glycogen branching enzyme deficiency</td>
</tr>
<tr>
<td>333</td>
<td>Amylopectinosis</td>
</tr>
<tr>
<td>334</td>
<td>dilated cardiomyopathy due to Andersen's disease</td>
</tr>
<tr>
<td>335</td>
<td>dilated cardiomyopathy due to glycogen storage disease type 4 (GSD4)</td>
</tr>
<tr>
<td>336</td>
<td>Neuronal ceroid lipofuscinosis</td>
</tr>
<tr>
<td>337</td>
<td>cerebromacular dystrophy</td>
</tr>
<tr>
<td>338</td>
<td>cerebromacular degeneration</td>
</tr>
<tr>
<td>339</td>
<td>ceroid-lipofuscinosis</td>
</tr>
<tr>
<td>340</td>
<td>NCL - [neuronal ceroid lipofuscinosis]</td>
</tr>
<tr>
<td>341</td>
<td>amaurotic familial idiocy</td>
</tr>
<tr>
<td>342</td>
<td>amaurotic idiocy</td>
</tr>
<tr>
<td>343</td>
<td>amaurotic idiot</td>
</tr>
<tr>
<td>344</td>
<td>neuronal lipofuscinosis</td>
</tr>
<tr>
<td>345</td>
<td>Batten disease</td>
</tr>
<tr>
<td>346</td>
<td>pigmentary retinal lipoid neuronal heredodegeneration</td>
</tr>
<tr>
<td>347</td>
<td>Congenital neuronal ceroid lipofuscinosis</td>
</tr>
<tr>
<td>348</td>
<td>Congenital NCL - [neuronal ceroid lipofuscinosis]</td>
</tr>
<tr>
<td>349</td>
<td>Infantile neuronal ceroid lipofuscinosis</td>
</tr>
<tr>
<td>350</td>
<td>Hagberg-Santavuori disease</td>
</tr>
<tr>
<td>351</td>
<td>Santavuori-Haltia disease</td>
</tr>
<tr>
<td>352</td>
<td>Santavuori disease</td>
</tr>
<tr>
<td>353</td>
<td>Lysosomal palmitoyl protein thioesterase deficiency</td>
</tr>
<tr>
<td>354</td>
<td>Infantile NCL - [neuronal ceroid lipofuscinosis]</td>
</tr>
<tr>
<td>355</td>
<td>infantile amaurotic familial disease</td>
</tr>
<tr>
<td>356</td>
<td>infantile cerebral lipidosis</td>
</tr>
<tr>
<td>357</td>
<td>Late infantile neuronal ceroid lipofuscinosis</td>
</tr>
<tr>
<td>358</td>
<td>Jansky-Bielschowsky disease</td>
</tr>
<tr>
<td>359</td>
<td>Lysosomal pepstatin-insensitive peptidase deficiency</td>
</tr>
<tr>
<td>360</td>
<td>LINCL - [late infantile neuronal ceroid lipofuscinosis]</td>
</tr>
<tr>
<td>361</td>
<td>Dollinger-Bielschowsky syndrome</td>
</tr>
<tr>
<td>362</td>
<td>Dollinger-Bielschowsky type neuronal ceroid lipofuscinosis</td>
</tr>
<tr>
<td>363</td>
<td>amaurotic idiocy late infantile type</td>
</tr>
<tr>
<td>364</td>
<td>late familial amaurotic idiocy</td>
</tr>
<tr>
<td>365</td>
<td>Bielschowsky disease</td>
</tr>
<tr>
<td>366</td>
<td>Bielschowsky Jansky amaurotic idiocy</td>
</tr>
<tr>
<td>367</td>
<td>Bielschowsky Jansky amaurotic idiot</td>
</tr>
<tr>
<td>368</td>
<td>Bielschowsky Jansky type neuronal ceroid lipofuscinosis</td>
</tr>
<tr>
<td>369</td>
<td>infantile cerebrum lipidosis</td>
</tr>
<tr>
<td>370</td>
<td>Juvenile neuronal ceroid lipofuscinosis</td>
</tr>
<tr>
<td>371</td>
<td>Spielmeyer-Vogt disease</td>
</tr>
<tr>
<td>372</td>
<td>Lysosomal transmembrane CLN3 protein deficiency</td>
</tr>
<tr>
<td>373</td>
<td>Batten-Spielmeyer-Vogt disease</td>
</tr>
<tr>
<td>374</td>
<td>Juvenile NCL - [neuronal ceroid lipofuscinosis]</td>
</tr>
<tr>
<td>375</td>
<td>amaurotic idiocy early juvenile type</td>
</tr>
<tr>
<td>376</td>
<td>amaurotic idiocy juvenile type</td>
</tr>
<tr>
<td>377</td>
<td>Batten-Mayou disease</td>
</tr>
<tr>
<td>378</td>
<td>Batten-Mayou syndrome</td>
</tr>
<tr>
<td>379</td>
<td>Spielmeyer-Vogt type neuronal ceroid lipofuscinosis</td>
</tr>
<tr>
<td>380</td>
<td>Adult neuronal ceroid lipofuscinosis</td>
</tr>
<tr>
<td>381</td>
<td>Kufs disease</td>
</tr>
<tr>
<td>382</td>
<td>Adult NCL - [neuronal ceroid lipofuscinosis]</td>
</tr>
<tr>
<td>383</td>
<td>adult-type amaurotic idiocy</td>
</tr>
<tr>
<td>384</td>
<td>Kufs type neuronal ceroid lipofuscinosis</td>
</tr>
<tr>
<td>385</td>
<td>Finnish variant of late infantile neuronal ceroid lipofuscinosis</td>
</tr>
<tr>
<td>386</td>
<td>Progressive epilepsy-intellectual deficit, Finnish type</td>
</tr>
<tr>
<td>387</td>
<td>CLN8 disease, Northern epilepsy variant</td>
</tr>
<tr>
<td>388</td>
<td>Northern epilepsy</td>
</tr>
<tr>
<td>389</td>
<td>Variant late infantile neuronal ceroid lipofuscinosis</td>
</tr>
<tr>
<td>390</td>
<td>Neuronal ceroid lipofuscinosis type 10</td>
</tr>
<tr>
<td>391</td>
<td>CLN10 disease</td>
</tr>
<tr>
<td>392</td>
<td>Cathepsin D deficiency</td>
</tr>
<tr>
<td>393</td>
<td>Cerebral lipidoses</td>
</tr>
<tr>
<td>394</td>
<td>cerebral lipidosis</td>
</tr>
<tr>
<td>395</td>
<td>cerebrum lipidosis</td>
</tr>
<tr>
<td>396</td>
<td>Cerebral lipidosis myoclonic variant</td>
</tr>
<tr>
<td>397</td>
<td>Cerebroretinal lipidosis</td>
</tr>
<tr>
<td>398</td>
<td>Other specified porphyrias</td>
</tr>
<tr>
<td>399</td>
<td>Non-acute porphyrias</td>
</tr>
<tr>
<td>400</td>
<td>Hepatoerythropoietic porphyria</td>
</tr>
<tr>
<td>401</td>
<td>Homozygous porphyria cutanea tarda</td>
</tr>
<tr>
<td>402</td>
<td>Homozygous uroporphyrinogen decarboxylase deficiency</td>
</tr>
<tr>
<td>403</td>
<td>HEP - [Hepatoerythropoietic porphyria]</td>
</tr>
<tr>
<td>404</td>
<td>Acute porphyrias</td>
</tr>
<tr>
<td>405</td>
<td>Acute intermittent porphyria</td>
</tr>
<tr>
<td>406</td>
<td>Porphobilinogen deaminase deficiency</td>
</tr>
<tr>
<td>407</td>
<td>Hydroxymethylbilane synthase deficiency</td>
</tr>
<tr>
<td>408</td>
<td>Swedish porphyria</td>
</tr>
<tr>
<td>409</td>
<td>AIP - [acute intermittent porphyria]</td>
</tr>
<tr>
<td>410</td>
<td>PBGD - [Porphobilinogen deaminase] deficiency</td>
</tr>
<tr>
<td>411</td>
<td>Waldenström porphyria</td>
</tr>
<tr>
<td>412</td>
<td>Homozygous acute intermittent porphyria</td>
</tr>
<tr>
<td>413</td>
<td>Homozygous porphobilinogen deaminase deficiency</td>
</tr>
<tr>
<td>414</td>
<td>Homozygous hydroxymethylbilane synthase deficiency</td>
</tr>
<tr>
<td>415</td>
<td>Homozygous AIP - [acute intermittent porphyria]</td>
</tr>
<tr>
<td>416</td>
<td>Homozygous variegate porphyria</td>
</tr>
<tr>
<td>417</td>
<td>Homozygous VP - [variegate porphyria]</td>
</tr>
<tr>
<td>418</td>
<td>Hereditary coproporphyria</td>
</tr>
<tr>
<td>419</td>
<td>Coproporphyrinogen oxidase deficiency</td>
</tr>
<tr>
<td>420</td>
<td>Homozygous hereditary coproporphyria</td>
</tr>
<tr>
<td>421</td>
<td>Homozygous coproporphyrinogen oxidase deficiency</td>
</tr>
<tr>
<td>422</td>
<td>Homozygous HCP- [coproporphyrinogen oxidase deficiency]</td>
</tr>
<tr>
<td>423</td>
<td>Harderoporphyria</td>
</tr>
<tr>
<td>424</td>
<td>ALAD porphyria</td>
</tr>
<tr>
<td>425</td>
<td>Porphyria due to delta-aminolevulinate dehydratase deficiency</td>
</tr>
<tr>
<td>426</td>
<td>Porphyria due to ALA dehydratase deficiency</td>
</tr>
<tr>
<td>427</td>
<td>Porphyria of Doss</td>
</tr>
<tr>
<td>428</td>
<td>Aminolevulinic acid dehydratase deficiency porphyria</td>
</tr>
<tr>
<td>429</td>
<td>Aminolevulinate dehydratase deficiency porphyria</td>
</tr>
<tr>
<td>430</td>
<td>5-ALA dehydratase-deficient porphyria</td>
</tr>
<tr>
<td>431</td>
<td>ADP - [Aminolevulinate dehydratase deficiency porphyria]</td>
</tr>
<tr>
<td>432</td>
<td>Abnormal ventricular relationships</td>
</tr>
<tr>
<td>433</td>
<td>Right hand pattern ventricular topology</td>
</tr>
<tr>
<td>434</td>
<td>D-bulboventricular loop</td>
</tr>
<tr>
<td>435</td>
<td>D-loop ventricles</td>
</tr>
<tr>
<td>436</td>
<td>Dextro-ventricular looping</td>
</tr>
<tr>
<td>437</td>
<td>Left hand pattern ventricular topology</td>
</tr>
<tr>
<td>438</td>
<td>L-bulboventricular loop</td>
</tr>
<tr>
<td>439</td>
<td>L-loop ventricles</td>
</tr>
<tr>
<td>440</td>
<td>Levo-ventricular looping</td>
</tr>
<tr>
<td>441</td>
<td>Sinistro-ventricular looping</td>
</tr>
<tr>
<td>442</td>
<td>Crisscross heart</td>
</tr>
<tr>
<td>443</td>
<td>twisted atrioventricular connections</td>
</tr>
<tr>
<td>444</td>
<td>Criss-cross heart</td>
</tr>
<tr>
<td>445</td>
<td>Superior-inferior ventricular relationship</td>
</tr>
<tr>
<td>446</td>
<td>Upstairs-downstairs ventricular relationship</td>
</tr>
<tr>
<td>447</td>
<td>superior-inferior heart</td>
</tr>
<tr>
<td>448</td>
<td>Other specified mucopolysaccharidosis</td>
</tr>
<tr>
<td>449</td>
<td>Mucopolysaccharidosis type 3</td>
</tr>
<tr>
<td>450</td>
<td>Acetyl-CoA alpha-glucosaminide-N-acetyl transferase deficiency</td>
</tr>
<tr>
<td>451</td>
<td>N-acetyl-alpha-glucosaminidase sulfamidase deficiency</td>
</tr>
<tr>
<td>452</td>
<td>N-acetyl-glucosamine-6-sulfate sulfatase deficiency</td>
</tr>
<tr>
<td>453</td>
<td>Sanfilippo syndrome</td>
</tr>
<tr>
<td>454</td>
<td>Mucopolysaccharidosis type 3A</td>
</tr>
<tr>
<td>455</td>
<td>Sanfilippo syndrome type A</td>
</tr>
<tr>
<td>456</td>
<td>Heparan-N-sulfatase deficiency</td>
</tr>
<tr>
<td>457</td>
<td>Heparan sulfamidase deficiency</td>
</tr>
<tr>
<td>458</td>
<td>Heparan sulfate sulfatase deficiency</td>
</tr>
<tr>
<td>459</td>
<td>Mucopolysaccharidosis type 3B</td>
</tr>
<tr>
<td>460</td>
<td>Sanfilippo syndrome type B</td>
</tr>
<tr>
<td>461</td>
<td>Alpha-N-acetylglucosaminidase deficiency</td>
</tr>
<tr>
<td>462</td>
<td>N-acetyl-alpha-D-glucosaminidase deficiency</td>
</tr>
<tr>
<td>463</td>
<td>Mucopolysaccharidosis type 3C</td>
</tr>
<tr>
<td>464</td>
<td>Sanfilippo syndrome type C</td>
</tr>
<tr>
<td>465</td>
<td>Acetyl-CoA alpha-glucosaminide acetyltransferase deficiency</td>
</tr>
<tr>
<td>466</td>
<td>N-acetyl transferase deficiency</td>
</tr>
<tr>
<td>467</td>
<td>Mucopolysaccharidosis type 3D</td>
</tr>
<tr>
<td>468</td>
<td>Sanfilippo syndrome type D</td>
</tr>
<tr>
<td>469</td>
<td>N-acetylglucosamine-6-sulfate sulfatase deficiency</td>
</tr>
<tr>
<td>470</td>
<td>Mucopolysaccharidosis type 7</td>
</tr>
<tr>
<td>471</td>
<td>Beta-glucuronidase deficiency</td>
</tr>
<tr>
<td>472</td>
<td>Sly disease</td>
</tr>
<tr>
<td>473</td>
<td>Sly syndrome</td>
</tr>
<tr>
<td>474</td>
<td>Mucopolysaccharidosis type 9</td>
</tr>
<tr>
<td>475</td>
<td>Hyaluronidase deficiency</td>
</tr>
<tr>
<td>476</td>
<td>Natowicz syndrome</td>
</tr>
<tr>
<td>477</td>
<td>Chronic hepatitis D</td>
</tr>
<tr>
<td>478</td>
<td>hepatitis D NOS</td>
</tr>
<tr>
<td>479</td>
<td>Chronic hepatitis B, co-infected with hepatitis D virus</td>
</tr>
<tr>
<td>480</td>
<td>chronic delta hepatitis</td>
</tr>
<tr>
<td>481</td>
<td>chronic viral hepatitis B with delta-agent</td>
</tr>
<tr>
<td>482</td>
<td>chronic viral hepatitis B with hepatitis D</td>
</tr>
<tr>
<td>483</td>
<td>chronic HDV - [hepatitis D virus] infection</td>
</tr>
<tr>
<td>484</td>
<td>hepatitis D-related cirrhosis</td>
</tr>
<tr>
<td>485</td>
<td>Chronic hepatitis B, co-infected with hepatitis D virus, with cirrhosis</td>
</tr>
<tr>
<td>486</td>
<td>Chronic hepatitis B, co-infected with hepatitis D virus, with cirrhosis, with cirrhosis-related complications</td>
</tr>
<tr>
<td>487</td>
<td>Chronic hepatitis B, co-infected with hepatitis D virus, with cirrhosis, without cirrhosis-related complications</td>
</tr>
<tr>
<td>488</td>
<td>Chronic hepatitis B, co-infected with hepatitis D virus, without cirrhosis</td>
</tr>
<tr>
<td>489</td>
<td>Chronic hepatitis B, co-infected with hepatitis D virus, without mention of cirrhosis</td>
</tr>
<tr>
<td>490</td>
<td>Disorders of multiple glycosylation or other pathways</td>
</tr>
<tr>
<td>491</td>
<td>Dolichol-phosphate-mannose synthase 1 deficiency</td>
</tr>
<tr>
<td>492</td>
<td>GDP-Man: Dol-P-mannosyltransferase deficiency</td>
</tr>
<tr>
<td>493</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1E</td>
</tr>
<tr>
<td>494</td>
<td>Congenital disorder of glycosylation type 1E</td>
</tr>
<tr>
<td>495</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1E</td>
</tr>
<tr>
<td>496</td>
<td>Mannose-P-dolichol utilisation defect 1</td>
</tr>
<tr>
<td>497</td>
<td>Lec35 deficiency</td>
</tr>
<tr>
<td>498</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1F</td>
</tr>
<tr>
<td>499</td>
<td>Congenital disorder of glycosylation type 1F</td>
</tr>
<tr>
<td>500</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1F</td>
</tr>
<tr>
<td>501</td>
<td>Beta-1,4-galactosyltransferase deficiency</td>
</tr>
<tr>
<td>502</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2D</td>
</tr>
<tr>
<td>503</td>
<td>Congenital disorder of glycosylation type 2D</td>
</tr>
<tr>
<td>504</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2D</td>
</tr>
<tr>
<td>505</td>
<td>CMP-sialic acid transporter deficiency</td>
</tr>
<tr>
<td>506</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2F</td>
</tr>
<tr>
<td>507</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2F</td>
</tr>
<tr>
<td>508</td>
<td>Congenital disorder of glycosylation type 2F</td>
</tr>
<tr>
<td>509</td>
<td>Leukocyte adhesion deficiency type 2</td>
</tr>
<tr>
<td>510</td>
<td>Rambam-Hasharon syndrome</td>
</tr>
<tr>
<td>511</td>
<td>GDP-fucose transporter deficiency</td>
</tr>
<tr>
<td>512</td>
<td>LAD-II - [Leukocyte adhesion deficiency type 2]</td>
</tr>
<tr>
<td>513</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2C</td>
</tr>
<tr>
<td>514</td>
<td>Dolichol kinase deficiency</td>
</tr>
<tr>
<td>515</td>
<td>Hypotonia or ichthyosis due to dolichol phosphate deficiency</td>
</tr>
<tr>
<td>516</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1M</td>
</tr>
<tr>
<td>517</td>
<td>Congenital disorder of glycosylation type 1M</td>
</tr>
<tr>
<td>518</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1M</td>
</tr>
<tr>
<td>519</td>
<td>Conserved oligomeric Golgi complex deficiencies</td>
</tr>
<tr>
<td>520</td>
<td>Component of conserved oligomeric Golgi complex 1 deficiency</td>
</tr>
<tr>
<td>521</td>
<td>CDG syndrome type 2G</td>
</tr>
<tr>
<td>522</td>
<td>Component of conserved oligomeric Golgi complex 4 deficiency</td>
</tr>
<tr>
<td>523</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2J</td>
</tr>
<tr>
<td>524</td>
<td>Congenital disorder of glycosylation type 2J</td>
</tr>
<tr>
<td>525</td>
<td>Component of conserved oligomeric Golgi complex 5 deficiency</td>
</tr>
<tr>
<td>526</td>
<td>Component of conserved oligomeric Golgi complex 7 deficiency</td>
</tr>
<tr>
<td>527</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2E</td>
</tr>
<tr>
<td>528</td>
<td>Congenital disorder of glycosylation type 2E</td>
</tr>
<tr>
<td>529</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2E</td>
</tr>
<tr>
<td>530</td>
<td>Component of conserved oligomeric Golgi complex 8 deficiency</td>
</tr>
<tr>
<td>531</td>
<td>Congenital disorder of glycosylation type 2h</td>
</tr>
<tr>
<td>532</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2H</td>
</tr>
<tr>
<td>533</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2H</td>
</tr>
<tr>
<td>534</td>
<td>V-ATPase deficiencies</td>
</tr>
<tr>
<td>535</td>
<td>Disorders of protein N-glycosylation</td>
</tr>
<tr>
<td>536</td>
<td>Phosphomannomutase 2 deficiency</td>
</tr>
<tr>
<td>537</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1A</td>
</tr>
<tr>
<td>538</td>
<td>Congenital disorder of glycosylation type 1A</td>
</tr>
<tr>
<td>539</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1A</td>
</tr>
<tr>
<td>540</td>
<td>Phosphomannose isomerase deficiency</td>
</tr>
<tr>
<td>541</td>
<td>Saguenay-Lac-Saint-Jean syndrome</td>
</tr>
<tr>
<td>542</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1B</td>
</tr>
<tr>
<td>543</td>
<td>Congenital disorder of glycosylation type 1B</td>
</tr>
<tr>
<td>544</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1B</td>
</tr>
<tr>
<td>545</td>
<td>SLSJ - [Saguenay-Lac-Saint-Jean] syndrome</td>
</tr>
<tr>
<td>546</td>
<td>Glucosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>547</td>
<td>Dol-P-Glc: Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>548</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1C</td>
</tr>
<tr>
<td>549</td>
<td>Congenital disorder of glycosylation type 1C</td>
</tr>
<tr>
<td>550</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1C</td>
</tr>
<tr>
<td>551</td>
<td>Mannosyltransferase 6 deficiency</td>
</tr>
<tr>
<td>552</td>
<td>Dol-P-Man: Man5-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>553</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1D</td>
</tr>
<tr>
<td>554</td>
<td>Congenital disorder of glycosylation type 1D</td>
</tr>
<tr>
<td>555</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1D</td>
</tr>
<tr>
<td>556</td>
<td>Mannosyltransferase 8 deficiency</td>
</tr>
<tr>
<td>557</td>
<td>Dol-P-Man: Man7-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>558</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1G</td>
</tr>
<tr>
<td>559</td>
<td>Congenital disorder of glycosylation type 1G</td>
</tr>
<tr>
<td>560</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1G</td>
</tr>
<tr>
<td>561</td>
<td>Glucosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>562</td>
<td>Dol-P-Glc: Glc1-Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>563</td>
<td>Carbohydrate deficient glycoprotein syndrome 1H</td>
</tr>
<tr>
<td>564</td>
<td>Congenital disorder of glycosylation type 1H</td>
</tr>
<tr>
<td>565</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1H</td>
</tr>
<tr>
<td>566</td>
<td>Mannosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>567</td>
<td>Dol-P-Man: Man1-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>568</td>
<td>Carbohydrate deficient glycoprotein syndrome 1I</td>
</tr>
<tr>
<td>569</td>
<td>Congenital disorder of glycosylation 1I</td>
</tr>
<tr>
<td>570</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1I</td>
</tr>
<tr>
<td>571</td>
<td>Dolichyl-phosphate N-acetylgalactosamine phosphotransferase deficiency</td>
</tr>
<tr>
<td>572</td>
<td>UDP-GlcNAc: Dol-P-GlcNac-P transferase deficiency</td>
</tr>
<tr>
<td>573</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1J</td>
</tr>
<tr>
<td>574</td>
<td>Congenital disorder of glycosylation type 1J</td>
</tr>
<tr>
<td>575</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1J</td>
</tr>
<tr>
<td>576</td>
<td>Mannosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>577</td>
<td>Dol-P-Man: GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>578</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1K</td>
</tr>
<tr>
<td>579</td>
<td>Congenital disorder of glycosylation type 1K</td>
</tr>
<tr>
<td>580</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1K</td>
</tr>
<tr>
<td>581</td>
<td>Mannosyltransferase 7-9 deficiency</td>
</tr>
<tr>
<td>582</td>
<td>Congenital disorder of glycosylation type 1L</td>
</tr>
<tr>
<td>583</td>
<td>Dol-P-Man: Man6 and Man8-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>584</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1L</td>
</tr>
<tr>
<td>585</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1L</td>
</tr>
<tr>
<td>586</td>
<td>M5-DLO flippase deficiency</td>
</tr>
<tr>
<td>587</td>
<td>Man5GlcNAc2-PP-Dol flippase deficiency</td>
</tr>
<tr>
<td>588</td>
<td>RTF1-CDG</td>
</tr>
<tr>
<td>589</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1N</td>
</tr>
<tr>
<td>590</td>
<td>N-acetylglucosaminyltransferase deficiency</td>
</tr>
<tr>
<td>591</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2A</td>
</tr>
<tr>
<td>592</td>
<td>Congenital disorder of glycosylation type 2A</td>
</tr>
<tr>
<td>593</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2A</td>
</tr>
<tr>
<td>594</td>
<td>Glucosidase 1 deficiency</td>
</tr>
<tr>
<td>595</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2B</td>
</tr>
<tr>
<td>596</td>
<td>Congenital disorder of glycosylation type 2B</td>
</tr>
<tr>
<td>597</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2B</td>
</tr>
<tr>
<td>598</td>
<td>TUSC3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>599</td>
<td>TUSC3-CDG</td>
</tr>
<tr>
<td>600</td>
<td>SRD5A3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>601</td>
<td>SRD5A3-CDG</td>
</tr>
<tr>
<td>602</td>
<td>Congenital disorder of glycosylation due to steroid 5-alpha-reductase type 3 deficiency</td>
</tr>
<tr>
<td>603</td>
<td>Intellectual deficit - cataract - coloboma - kyphosis</td>
</tr>
<tr>
<td>604</td>
<td>Kahrizi syndrome</td>
</tr>
<tr>
<td>605</td>
<td>Intellectual deficit, Kahrizi type</td>
</tr>
<tr>
<td>606</td>
<td>DPM3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>607</td>
<td>Congenital disorder of glycosylation type 1O</td>
</tr>
<tr>
<td>608</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1O</td>
</tr>
<tr>
<td>609</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1O</td>
</tr>
<tr>
<td>610</td>
<td>ALG11 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>611</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1P</td>
</tr>
<tr>
<td>612</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1P</td>
</tr>
<tr>
<td>613</td>
<td>Congenital disorder of glycosylation type 1P</td>
</tr>
<tr>
<td>614</td>
<td>Phosphoglucomutase-1 deficiency</td>
</tr>
<tr>
<td>615</td>
<td>PGM1-CDG - [Phosphoglucomutase-1 deficiency]</td>
</tr>
<tr>
<td>616</td>
<td>Congenital disorder of glycosylation type 1t</td>
</tr>
<tr>
<td>617</td>
<td>Vitamin D deficiency rickets</td>
</tr>
<tr>
<td>618</td>
<td>infantile osteomalacia</td>
</tr>
<tr>
<td>619</td>
<td>juvenile osteomalacia</td>
</tr>
<tr>
<td>620</td>
<td>Other specified disorders of glycine metabolism</td>
</tr>
<tr>
<td>621</td>
<td>D-glyceric acidaemia</td>
</tr>
<tr>
<td>622</td>
<td>D-glyceric aciduria</td>
</tr>
<tr>
<td>623</td>
<td>D-glycerate kinase deficiency</td>
</tr>
<tr>
<td>624</td>
<td>Sarcosinuria</td>
</tr>
<tr>
<td>625</td>
<td>Demethylation defect of N-methylglycine</td>
</tr>
<tr>
<td>626</td>
<td>Glucoglycinuria</td>
</tr>
<tr>
<td>627</td>
<td>Glycinaemia</td>
</tr>
<tr>
<td>628</td>
<td>Hyperglycinaemia</td>
</tr>
<tr>
<td>629</td>
<td>Maternal care for red cell antibodies</td>
</tr>
<tr>
<td>630</td>
<td>Maternal care for rhesus isoimmunization</td>
</tr>
<tr>
<td>631</td>
<td>Rh factor immunization affecting management of pregnancy</td>
</tr>
<tr>
<td>632</td>
<td>Rh incompatibility</td>
</tr>
<tr>
<td>633</td>
<td>Rh incompatibility with hydrops fetalis</td>
</tr>
<tr>
<td>634</td>
<td>Anti-D [Rh] antibodies</td>
</tr>
<tr>
<td>635</td>
<td>Disorders of vitamin D metabolism or transport, unspecified</td>
</tr>
<tr>
<td>636</td>
<td>Disorders of vitamin D metabolism or transport</td>
</tr>
<tr>
<td>637</td>
<td>Hypocalcaemic vitamin D dependent rickets</td>
</tr>
<tr>
<td>638</td>
<td>Vitamin D-dependency type I</td>
</tr>
<tr>
<td>639</td>
<td>Mucopolysaccharidosis type 4</td>
</tr>
<tr>
<td>640</td>
<td>Galactosamine-6-sulfatase deficiency</td>
</tr>
<tr>
<td>641</td>
<td>Morquio syndrome</td>
</tr>
<tr>
<td>642</td>
<td>Morquio-Brailsford disease</td>
</tr>
<tr>
<td>643</td>
<td>Mucopolysaccharidosis type 4A</td>
</tr>
<tr>
<td>644</td>
<td>Galactose-6-sulfatase deficiency</td>
</tr>
<tr>
<td>645</td>
<td>Galactosamide-6-sulfatase deficiency</td>
</tr>
<tr>
<td>646</td>
<td>Morquio syndrome type A</td>
</tr>
<tr>
<td>647</td>
<td>Mucopolysaccharidosis type 4B</td>
</tr>
<tr>
<td>648</td>
<td>Beta-D-galactosidase deficiency</td>
</tr>
<tr>
<td>649</td>
<td>Morquio syndrome type B</td>
</tr>
<tr>
<td>650</td>
<td>Hypophosphataemic rickets</td>
</tr>
<tr>
<td>651</td>
<td>HPDR - [hypophosphatemic vitamin d-resistant rickets]</td>
</tr>
<tr>
<td>652</td>
<td>VDRR - [vitamin-D-resistant rickets]</td>
</tr>
<tr>
<td>653</td>
<td>Vitamin-D-resistant rickets</td>
</tr>
<tr>
<td>654</td>
<td>Autosomal dominant hypophosphataemic rickets</td>
</tr>
<tr>
<td>655</td>
<td>ADHR - [autosomal dominant hypophosphataemic rickets]</td>
</tr>
<tr>
<td>656</td>
<td>Autosomal dominant hypophosphataemia</td>
</tr>
<tr>
<td>657</td>
<td>Autosomal recessive hypophosphataemic rickets</td>
</tr>
<tr>
<td>658</td>
<td>Autosomal recessive hypophosphataemia</td>
</tr>
<tr>
<td>659</td>
<td>ARHR - [autosomal recessive hypophosphataemic rickets]</td>
</tr>
<tr>
<td>660</td>
<td>Hypophosphataemic rickets with hypercalciuria</td>
</tr>
<tr>
<td>661</td>
<td>X-linked hypophosphataemia</td>
</tr>
<tr>
<td>662</td>
<td>X-linked hypophosphatemic rickets</td>
</tr>
<tr>
<td>663</td>
<td>familial x-linked hypophosphatemic vitamin d refractory rickets</td>
</tr>
<tr>
<td>664</td>
<td>x-linked vitamin d-resistant rickets</td>
</tr>
<tr>
<td>665</td>
<td>X-linked hypophosphatemic osteomalacia</td>
</tr>
<tr>
<td>666</td>
<td>Familial hypophosphataemic rickets</td>
</tr>
<tr>
<td>667</td>
<td>familial vitamin d-resistant rickets</td>
</tr>
<tr>
<td>668</td>
<td>Acute hepatitis D</td>
</tr>
<tr>
<td>669</td>
<td>Acute hepatitis D, through super-infection of hepatitis B carrier</td>
</tr>
<tr>
<td>670</td>
<td>Cerebral organic aciduria</td>
</tr>
<tr>
<td>671</td>
<td>Glutaric aciduria type 1</td>
</tr>
<tr>
<td>672</td>
<td>Glutaric acidaemia type 1</td>
</tr>
<tr>
<td>673</td>
<td>Glutaryl-CoA dehydrogenase deficiency</td>
</tr>
<tr>
<td>674</td>
<td>2-hydroxyglutaric aciduria</td>
</tr>
<tr>
<td>675</td>
<td>L-2-hydroxyglutaric aciduria</td>
</tr>
<tr>
<td>676</td>
<td>D-2-hydroxyglutaric aciduria</td>
</tr>
<tr>
<td>677</td>
<td>D-2-hydroxyglutarate dehydrogenase deficiency</td>
</tr>
<tr>
<td>678</td>
<td>Mitochondrial isocitrate dehydrogenase deficiency</td>
</tr>
<tr>
<td>679</td>
<td>Aminoacylase deficiency</td>
</tr>
<tr>
<td>680</td>
<td>Neurological conditions associated with aminoacylase 1 deficiency</td>
</tr>
<tr>
<td>681</td>
<td>Canavan disease</td>
</tr>
<tr>
<td>682</td>
<td>Spongy degeneration of central nervous system</td>
</tr>
<tr>
<td>683</td>
<td>Aspartoacylase deficiency</td>
</tr>
<tr>
<td>684</td>
<td>Canavan-van Bogaert-Bertrand disease</td>
</tr>
<tr>
<td>685</td>
<td>Malonic aciduria</td>
</tr>
<tr>
<td>686</td>
<td>Malonyl-CoA decarboxylase deficiency</td>
</tr>
<tr>
<td>687</td>
<td>Ethylmalonic encephalopathy</td>
</tr>
<tr>
<td>688</td>
<td>4-hydroxybutyric aciduria</td>
</tr>
<tr>
<td>689</td>
<td>Succinic semialdehyde dehydrogenase deficiency</td>
</tr>
<tr>
<td>690</td>
<td>Gamma-hydroxybutyric acidaemia</td>
</tr>
<tr>
<td>691</td>
<td>Other specified disorders of vitamin D metabolism or transport</td>
</tr>
<tr>
<td>692</td>
<td>Hypocalcaemic rickets</td>
</tr>
<tr>
<td>693</td>
<td>Other specified disorders of glyoxylate metabolism</td>
</tr>
<tr>
<td>694</td>
<td>Primary hyperoxaluria type 2</td>
</tr>
<tr>
<td>695</td>
<td>D-glycerate dehydrogenase deficiency</td>
</tr>
<tr>
<td>696</td>
<td>Oxalosis type 2</td>
</tr>
<tr>
<td>697</td>
<td>Hydroxypyruvate reductase deficiency</td>
</tr>
<tr>
<td>698</td>
<td>Hyperoxaluria non1-non2 type</td>
</tr>
<tr>
<td>699</td>
<td>Other specified structural developmental anomaly of heart or great vessels</td>
</tr>
<tr>
<td>700</td>
<td>Congenital anomaly of position or spatial relationships of thoraco-abdominal organs</td>
</tr>
<tr>
<td>701</td>
<td>Usual atrial arrangement</td>
</tr>
<tr>
<td>702</td>
<td>atrial situs solitus</td>
</tr>
<tr>
<td>703</td>
<td>Abnormal atrial arrangement</td>
</tr>
<tr>
<td>704</td>
<td>Abnormal atrial situs</td>
</tr>
<tr>
<td>705</td>
<td>Atrial situs inversus</td>
</tr>
<tr>
<td>706</td>
<td>Mirror-image atrial arrangement</td>
</tr>
<tr>
<td>707</td>
<td>Isomerism of right atrial appendages</td>
</tr>
<tr>
<td>708</td>
<td>isomeric right atrial appendages</td>
</tr>
<tr>
<td>709</td>
<td>Isomerism of left atrial appendages</td>
</tr>
<tr>
<td>710</td>
<td>isomeric left atrial appendages</td>
</tr>
<tr>
<td>711</td>
<td>Abnormal relationship of great arterial roots</td>
</tr>
<tr>
<td>712</td>
<td>Abnormal relationships of great arteries</td>
</tr>
<tr>
<td>713</td>
<td>Abnormal relationships of great vessels</td>
</tr>
<tr>
<td>714</td>
<td>Aortic root directly anterior to pulmonary root</td>
</tr>
<tr>
<td>715</td>
<td>A-malposed aorta</td>
</tr>
<tr>
<td>716</td>
<td>A-malposed great arteries</td>
</tr>
<tr>
<td>717</td>
<td>Aorta directly anterior to pulmonary artery</td>
</tr>
<tr>
<td>718</td>
<td>A-transposed aorta</td>
</tr>
<tr>
<td>719</td>
<td>Aortic root anterior and rightward to pulmonary root</td>
</tr>
<tr>
<td>720</td>
<td>D-malposed great vessels with anterior aorta</td>
</tr>
<tr>
<td>721</td>
<td>Dextroposed great arteries with anterior aorta</td>
</tr>
<tr>
<td>722</td>
<td>Dextroposed great vessels with anterior aorta</td>
</tr>
<tr>
<td>723</td>
<td>D-malposed great arteries with anterior aorta</td>
</tr>
<tr>
<td>724</td>
<td>D-transposed great arteries</td>
</tr>
<tr>
<td>725</td>
<td>D-transposed great vessels</td>
</tr>
<tr>
<td>726</td>
<td>Aortic root anterior and leftward to pulmonary root</td>
</tr>
<tr>
<td>727</td>
<td>L-malposed great vessels with anterior aorta</td>
</tr>
<tr>
<td>728</td>
<td>L-malposed great arteries with anterior aorta</td>
</tr>
<tr>
<td>729</td>
<td>Levoposed great arteries with anterior aorta</td>
</tr>
<tr>
<td>730</td>
<td>Levoposed great vessels with anterior aorta</td>
</tr>
<tr>
<td>731</td>
<td>L-transposed great arteries with anterior aorta</td>
</tr>
<tr>
<td>732</td>
<td>L-transposed great vessels with anterior aorta</td>
</tr>
<tr>
<td>733</td>
<td>Aortic root side by side and directly rightward to pulmonary root</td>
</tr>
<tr>
<td>734</td>
<td>D-transposed side by side great arteries</td>
</tr>
<tr>
<td>735</td>
<td>D-transposed side by side great vessels</td>
</tr>
<tr>
<td>736</td>
<td>Dextroposed side by side great arteries</td>
</tr>
<tr>
<td>737</td>
<td>Dextroposed side by side great vessels</td>
</tr>
<tr>
<td>738</td>
<td>D-malposed side by side great arteries</td>
</tr>
<tr>
<td>739</td>
<td>Aortic root side by side and directly leftward to pulmonary root</td>
</tr>
<tr>
<td>740</td>
<td>L-transposed side by side great vessels</td>
</tr>
<tr>
<td>741</td>
<td>L-malposed side by side great vessels</td>
</tr>
<tr>
<td>742</td>
<td>L-malposed side by side great arteries</td>
</tr>
<tr>
<td>743</td>
<td>Levoposed side by side great vessels</td>
</tr>
<tr>
<td>744</td>
<td>Levoposed side by side great arteries</td>
</tr>
<tr>
<td>745</td>
<td>L-transposed side by side great arteries</td>
</tr>
<tr>
<td>746</td>
<td>Aortic root directly posterior to pulmonary root</td>
</tr>
<tr>
<td>747</td>
<td>Aortic root posterior and rightward to pulmonary root</td>
</tr>
<tr>
<td>748</td>
<td>d-malposed great arteries with posterior aorta</td>
</tr>
<tr>
<td>749</td>
<td>normally related great arteries</td>
</tr>
<tr>
<td>750</td>
<td>segmental analysis D with posterior aorta</td>
</tr>
<tr>
<td>751</td>
<td>Aortic root posterior and leftward to pulmonary root</td>
</tr>
<tr>
<td>752</td>
<td>L-malposed great arteries with posterior aorta</td>
</tr>
<tr>
<td>753</td>
<td>L-malposed great vessels with posterior aorta</td>
</tr>
<tr>
<td>754</td>
<td>Mirror imaged normally related great arteries</td>
</tr>
<tr>
<td>755</td>
<td>Levoposed great arteries with posterior aorta</td>
</tr>
<tr>
<td>756</td>
<td>Levoposed great vessels with posterior aorta</td>
</tr>
<tr>
<td>757</td>
<td>Mirror imaged normally related great vessels</td>
</tr>
<tr>
<td>758</td>
<td>Abnormal intrapericardial course of great arteries</td>
</tr>
<tr>
<td>759</td>
<td>Spiralling course of great arteries</td>
</tr>
<tr>
<td>760</td>
<td>Normal course of great arteries</td>
</tr>
<tr>
<td>761</td>
<td>Parallel course of great arteries</td>
</tr>
<tr>
<td>762</td>
<td>Visceral heterotaxy</td>
</tr>
<tr>
<td>763</td>
<td>Abnormal arrangement of thoraco-abdominal organs</td>
</tr>
<tr>
<td>764</td>
<td>Heterotaxy</td>
</tr>
<tr>
<td>765</td>
<td>Heterotaxia</td>
</tr>
<tr>
<td>766</td>
<td>Heterotaxia syndrome</td>
</tr>
<tr>
<td>767</td>
<td>Situs ambiguous</td>
</tr>
<tr>
<td>768</td>
<td>Splenic syndromes</td>
</tr>
<tr>
<td>769</td>
<td>Heterotaxy syndrome</td>
</tr>
<tr>
<td>770</td>
<td>Congenital anomaly of an atrium or atrial septum</td>
</tr>
<tr>
<td>771</td>
<td>congenital atrial malformation</td>
</tr>
<tr>
<td>772</td>
<td>cor triatriatum (deprecated)</td>
</tr>
<tr>
<td>773</td>
<td>Aortic aneurysm due to congenital heart disease</td>
</tr>
<tr>
<td>774</td>
<td>Aortic aneurysm secondary to congenital heart disease</td>
</tr>
<tr>
<td>775</td>
<td>Congenital heart block</td>
</tr>
<tr>
<td>776</td>
<td>Congenital complete heart block</td>
</tr>
<tr>
<td>777</td>
<td>Immune-mediated heart block</td>
</tr>
<tr>
<td>778</td>
<td>Accessory heart</td>
</tr>
<tr>
<td>779</td>
<td>Congenital cardiac dilatation</td>
</tr>
<tr>
<td>780</td>
<td>acute congenital heart dilatation</td>
</tr>
<tr>
<td>781</td>
<td>chronic congenital cardiac dilatation</td>
</tr>
<tr>
<td>782</td>
<td>chronic congenital heart dilatation</td>
</tr>
<tr>
<td>783</td>
<td>congenital cardiac valve dilatation</td>
</tr>
<tr>
<td>784</td>
<td>Anomalous bands of heart</td>
</tr>
<tr>
<td>785</td>
<td>anomaly of heart bands or folds</td>
</tr>
<tr>
<td>786</td>
<td>Bifid apex of heart</td>
</tr>
<tr>
<td>787</td>
<td>Congenital cardiomegaly</td>
</tr>
<tr>
<td>788</td>
<td>Congenital microcardia</td>
</tr>
<tr>
<td>789</td>
<td>Primary haemophagocytic lymphohistiocytosis</td>
</tr>
<tr>
<td>790</td>
<td>Haemophagocytic syndrome</td>
</tr>
<tr>
<td>791</td>
<td>Histiocytoses of mononuclear phagocytes</td>
</tr>
<tr>
<td>792</td>
<td>haemophagocytic lymphohistiocytosis NOS</td>
</tr>
<tr>
<td>793</td>
<td>Familial haemophagocytic lymphohistiocytosis</td>
</tr>
<tr>
<td>794</td>
<td>familial erythrophagocytic lymphohistiocytosis</td>
</tr>
<tr>
<td>795</td>
<td>FEL - [familial erythrophagocytic lymphohistiocytosis]</td>
</tr>
<tr>
<td>796</td>
<td>familial histiocytic reticulosis</td>
</tr>
<tr>
<td>797</td>
<td>familial haemophagocytic histiocytosis</td>
</tr>
<tr>
<td>798</td>
<td>FHL - [familial haemophagocytic lymphohistiocytosis]</td>
</tr>
<tr>
<td>799</td>
<td>Perforin deficiency</td>
</tr>
<tr>
<td>800</td>
<td>FHL1</td>
</tr>
<tr>
<td>801</td>
<td>FHL1 - [Familial haemophagocytic lymphohistiocytosis] 1</td>
</tr>
<tr>
<td>802</td>
<td>STXBP2 deficiency</td>
</tr>
<tr>
<td>803</td>
<td>FHL5</td>
</tr>
<tr>
<td>804</td>
<td>FHL5 - [Familial haemophagocytic lymphohistiocytosis] 5</td>
</tr>
<tr>
<td>805</td>
<td>Syntaxin deficiency</td>
</tr>
<tr>
<td>806</td>
<td>FHL4</td>
</tr>
<tr>
<td>807</td>
<td>FHL - [Familial haemophagocytic lymphohistiocytosis] 4</td>
</tr>
<tr>
<td>808</td>
<td>UNC13D deficiency</td>
</tr>
<tr>
<td>809</td>
<td>FHL3</td>
</tr>
<tr>
<td>810</td>
<td>FHL - [Familial haemophagocytic lymphohistiocytosis] 3</td>
</tr>
<tr>
<td>811</td>
<td>Griscelli syndrome type 2</td>
</tr>
<tr>
<td>812</td>
<td>Hypopigmentation - immunodeficiency, with or without neurological impairment</td>
</tr>
<tr>
<td>813</td>
<td>Partial albinism and immunodeficiency syndrome</td>
</tr>
<tr>
<td>814</td>
<td>GS2 (MIM 607624)</td>
</tr>
<tr>
<td>815</td>
<td>Syndromes with lissencephaly as a major feature</td>
</tr>
<tr>
<td>816</td>
<td>Pachygyria</td>
</tr>
<tr>
<td>817</td>
<td>Agyria</td>
</tr>
<tr>
<td>818</td>
<td>Classic lissencephaly</td>
</tr>
<tr>
<td>819</td>
<td>Lissencephaly type 1</td>
</tr>
<tr>
<td>820</td>
<td>Lissencephaly type 1 due to doublecortin gene mutation</td>
</tr>
<tr>
<td>821</td>
<td>Subcortical band heterotopia</td>
</tr>
<tr>
<td>822</td>
<td>Miller-Dieker syndrome</td>
</tr>
<tr>
<td>823</td>
<td>Lissencephaly due to 17p13.3 deletion</td>
</tr>
<tr>
<td>824</td>
<td>17p13.3 microdeletion syndrome</td>
</tr>
<tr>
<td>825</td>
<td>Telomeric deletion 17p</td>
</tr>
<tr>
<td>826</td>
<td>Monosomy 17p13.3</td>
</tr>
<tr>
<td>827</td>
<td>17p13.3 deletion</td>
</tr>
<tr>
<td>828</td>
<td>Lissencephaly type 1 due to LIS1 gene mutation</td>
</tr>
<tr>
<td>829</td>
<td>Isolated lissencephaly type 1 without known genetic defects</td>
</tr>
<tr>
<td>830</td>
<td>Lissencephaly type 2</td>
</tr>
<tr>
<td>831</td>
<td>Lissencephaly type 3</td>
</tr>
<tr>
<td>832</td>
<td>Neu-Laxova syndrome</td>
</tr>
<tr>
<td>833</td>
<td>Lissencephaly type 3 - familial fetal akinesia sequence</td>
</tr>
<tr>
<td>834</td>
<td>Lissencephaly type 3 - metacarpal bone dysplasia</td>
</tr>
<tr>
<td>835</td>
<td>Lissencephaly with cerebellar hypoplasia</td>
</tr>
<tr>
<td>836</td>
<td>Lissencephaly with cerebellar hypoplasia type A</td>
</tr>
<tr>
<td>837</td>
<td>Lissencephaly with cerebellar hypoplasia type B</td>
</tr>
<tr>
<td>838</td>
<td>Lissencephaly with cerebellar hypoplasia type C</td>
</tr>
<tr>
<td>839</td>
<td>Lissencephaly with cerebellar hypoplasia type D</td>
</tr>
<tr>
<td>840</td>
<td>Lissencephaly with cerebellar hypoplasia type E</td>
</tr>
<tr>
<td>841</td>
<td>Lissencephaly with cerebellar hypoplasia type F</td>
</tr>
<tr>
<td>842</td>
<td>Microlissencephaly</td>
</tr>
<tr>
<td>843</td>
<td>Microlissencephaly type A</td>
</tr>
<tr>
<td>844</td>
<td>Lissencephaly syndrome, Norman-Roberts type</td>
</tr>
<tr>
<td>845</td>
<td>Microlissencephaly type B</td>
</tr>
<tr>
<td>846</td>
<td>Lissencephaly due to TUBA1A gene mutation</td>
</tr>
<tr>
<td>847</td>
<td>X-linked lissencephaly - agenesis of corpus callosum - genital anomalies</td>
</tr>
<tr>
<td>848</td>
<td>Craniotelencephalic dysplasia</td>
</tr>
<tr>
<td>849</td>
<td>Micro syndrome</td>
</tr>
<tr>
<td>850</td>
<td>Warburg Micro syndrome</td>
</tr>
<tr>
<td>851</td>
<td>WARBM1 - [Warburg Micro syndrome]</td>
</tr>
<tr>
<td>852</td>
<td>Iris coloboma with ptosis - intellectual deficit</td>
</tr>
<tr>
<td>853</td>
<td>Complex brachydactylies</td>
</tr>
<tr>
<td>854</td>
<td>Brachydactyly type A1</td>
</tr>
<tr>
<td>855</td>
<td>Brachydactyly type A2</td>
</tr>
<tr>
<td>856</td>
<td>Brachydactyly type A3</td>
</tr>
<tr>
<td>857</td>
<td>Brachydactyly type A4</td>
</tr>
<tr>
<td>858</td>
<td>Brachydactyly type A5</td>
</tr>
<tr>
<td>859</td>
<td>Brachydactyly type A6</td>
</tr>
<tr>
<td>860</td>
<td>Brachydactyly type A7</td>
</tr>
<tr>
<td>861</td>
<td>Brachydactyly type B</td>
</tr>
<tr>
<td>862</td>
<td>Brachydactyly type B2</td>
</tr>
<tr>
<td>863</td>
<td>Brachydactyly type C</td>
</tr>
<tr>
<td>864</td>
<td>Brachydactyly type D</td>
</tr>
<tr>
<td>865</td>
<td>Brachydactyly type E</td>
</tr>
<tr>
<td>866</td>
<td>Ballard syndrome</td>
</tr>
<tr>
<td>867</td>
<td>Brachydactyly types B and E combined</td>
</tr>
<tr>
<td>868</td>
<td>Pitt-Williams brachydactyly</td>
</tr>
<tr>
<td>869</td>
<td>Brachydactyly-elbow wrist dysplasia</td>
</tr>
<tr>
<td>870</td>
<td>Disorders of peroxisomal alpha-, beta- or omega-oxidation</td>
</tr>
<tr>
<td>871</td>
<td>Refsum disease</td>
</tr>
<tr>
<td>872</td>
<td>Hereditary motor and sensory neuropathy type 4</td>
</tr>
<tr>
<td>873</td>
<td>Phytanic acid oxidase deficiency</td>
</tr>
<tr>
<td>874</td>
<td>Phytanic acid storage disease</td>
</tr>
<tr>
<td>875</td>
<td>Heredoataxia hemeralopica polyneuritiformis</td>
</tr>
<tr>
<td>876</td>
<td>Refsum-Thiebaut disease</td>
</tr>
<tr>
<td>877</td>
<td>HMSN 4 - [Hereditary motor and sensory neuropathy type 4]</td>
</tr>
<tr>
<td>878</td>
<td>Infantile Refsum disease</td>
</tr>
<tr>
<td>879</td>
<td>X-linked adrenoleukodystrophy</td>
</tr>
<tr>
<td>880</td>
<td>Schilder-Addison complex</td>
</tr>
<tr>
<td>881</td>
<td>X-linked cerebral adrenoleukodystrophy</td>
</tr>
<tr>
<td>882</td>
<td>X-linked childhood adrenoleukodystrophy</td>
</tr>
<tr>
<td>883</td>
<td>Adrenomyeloneuropathy</td>
</tr>
<tr>
<td>884</td>
<td>X-linked adult-onset adrenomyeloneuropathy</td>
</tr>
<tr>
<td>885</td>
<td>Peroxisomal D-bifunctional enzyme deficiency</td>
</tr>
<tr>
<td>886</td>
<td>Bifunctional enzyme deficiency</td>
</tr>
<tr>
<td>887</td>
<td>Peroxisomal acyl-CoA oxidase deficiency</td>
</tr>
<tr>
<td>888</td>
<td>Pseudo-neonatal adrenoleukodystrophy</td>
</tr>
<tr>
<td>889</td>
<td>Pseudoadrenoleukodystrophy</td>
</tr>
<tr>
<td>890</td>
<td>Sterol carrier protein deficiency</td>
</tr>
<tr>
<td>891</td>
<td>Vitamin D deficiency osteomalacia</td>
</tr>
<tr>
<td>892</td>
<td>Immunodeficiency with factor D anomaly</td>
</tr>
<tr>
<td>893</td>
<td>CFDD - [Complement factor D deficiency]</td>
</tr>
<tr>
<td>894</td>
<td>Oligosaccharidosis</td>
</tr>
<tr>
<td>895</td>
<td>Aspartylglucosaminuria</td>
</tr>
<tr>
<td>896</td>
<td>Aspartylglucosaminidase deficiency</td>
</tr>
<tr>
<td>897</td>
<td>Alpha-mannosidosis</td>
</tr>
<tr>
<td>898</td>
<td>Lysosomal alpha-D-mannosidase deficiency</td>
</tr>
<tr>
<td>899</td>
<td>Infantile alpha-mannosidosis</td>
</tr>
<tr>
<td>900</td>
<td>Adult alpha-mannosidosis</td>
</tr>
<tr>
<td>901</td>
<td>Beta-mannosidosis</td>
</tr>
<tr>
<td>902</td>
<td>Lysosomal beta-mannosidase deficiency</td>
</tr>
<tr>
<td>903</td>
<td>Mannosidosis, not otherwise specified</td>
</tr>
<tr>
<td>904</td>
<td>mannosidase deficiency</td>
</tr>
<tr>
<td>905</td>
<td>Fucosidosis</td>
</tr>
<tr>
<td>906</td>
<td>Alpha-L-fucosidase deficiency</td>
</tr>
<tr>
<td>907</td>
<td>Sialidosis</td>
</tr>
<tr>
<td>908</td>
<td>Mucolipidosis type 1</td>
</tr>
<tr>
<td>909</td>
<td>Sialidosis type 1</td>
</tr>
<tr>
<td>910</td>
<td>Cherry-red-spot-myoclonus syndrome</td>
</tr>
<tr>
<td>911</td>
<td>Lipomucopolysaccharidosis</td>
</tr>
<tr>
<td>912</td>
<td>Normomorphic sialidosis</td>
</tr>
<tr>
<td>913</td>
<td>Sialidosis type 2</td>
</tr>
<tr>
<td>914</td>
<td>Infantile dysmorphic sialidosis</td>
</tr>
<tr>
<td>915</td>
<td>Congenital sialidosis type 2</td>
</tr>
<tr>
<td>916</td>
<td>Juvenile sialidosis type 2</td>
</tr>
<tr>
<td>917</td>
<td>Alpha-N-acetylgalactosaminidase deficiency</td>
</tr>
<tr>
<td>918</td>
<td>N-acetyl-alpha-D-galactosaminidase deficiency</td>
</tr>
<tr>
<td>919</td>
<td>NAGA - [Alpha-N-acetylgalactosaminidase] deficiency</td>
</tr>
<tr>
<td>920</td>
<td>Alpha-N-acetylgalactosaminidase deficiency type 1</td>
</tr>
<tr>
<td>921</td>
<td>Schindler disease type 1</td>
</tr>
<tr>
<td>922</td>
<td>Schindler disease</td>
</tr>
<tr>
<td>923</td>
<td>NAGA deficiency type 1 - [Alpha-N-acetylgalactosaminidase deficiency type 1]</td>
</tr>
<tr>
<td>924</td>
<td>Alpha-N-acetylgalactosaminidase deficiency type 2</td>
</tr>
<tr>
<td>925</td>
<td>Adult-onset Alpha-N-acetylgalactosaminidase deficiency</td>
</tr>
<tr>
<td>926</td>
<td>Schindler disease type 2</td>
</tr>
<tr>
<td>927</td>
<td>Kanzaki disease</td>
</tr>
<tr>
<td>928</td>
<td>NAGA deficiency type 2 - [Alpha-N-acetylgalactosaminidase deficiency type 2]</td>
</tr>
<tr>
<td>929</td>
<td>Alpha-N-acetylgalactosaminidase deficiency type 3</td>
</tr>
<tr>
<td>930</td>
<td>Schindler disease type 3</td>
</tr>
<tr>
<td>931</td>
<td>NAGA deficiency type 3 - [Alpha-N-acetylgalactosaminidase deficiency type 3]</td>
</tr>
<tr>
<td>932</td>
<td>Galactosialidosis</td>
</tr>
<tr>
<td>933</td>
<td>Neuraminidase deficiency with beta-galactosidase deficiency</td>
</tr>
<tr>
<td>934</td>
<td>Goldberg syndrome</td>
</tr>
<tr>
<td>935</td>
<td>Combined deficiency of neuraminidase and beta-galactosidase</td>
</tr>
<tr>
<td>936</td>
<td>Protective protein deficiency</td>
</tr>
<tr>
<td>937</td>
<td>Spondyloepiphyseal or spondyloepimetaphyseal dysplasias</td>
</tr>
<tr>
<td>938</td>
<td>Congenital spondyloepiphyseal dysplasia</td>
</tr>
<tr>
<td>939</td>
<td>SEDC - [spondyloepiphyseal dysplasia congenita]</td>
</tr>
<tr>
<td>940</td>
<td>spondyloepiphyseal dysplasia</td>
</tr>
<tr>
<td>941</td>
<td>SED - [spondyloepiphyseal dysplasia]</td>
</tr>
<tr>
<td>942</td>
<td>spondyloepiphyseal dysplasia congenita</td>
</tr>
<tr>
<td>943</td>
<td>Mild spondyloepiphyseal dysplasia due to COL2A1 mutation with early-onset osteoarthritis</td>
</tr>
<tr>
<td>944</td>
<td>Kniest dysplasia</td>
</tr>
<tr>
<td>945</td>
<td>Spondyloepimetaphyseal dysplasia congenita, Strudwick type</td>
</tr>
<tr>
<td>946</td>
<td>spondyloepiphyseal dysplasia congenita group</td>
</tr>
<tr>
<td>947</td>
<td>spondyloepimetaphyseal dysplasia</td>
</tr>
<tr>
<td>948</td>
<td>Spondyloperipheral dysplasia - short ulna</td>
</tr>
<tr>
<td>949</td>
<td>Czech dysplasia, metatarsal type</td>
</tr>
<tr>
<td>950</td>
<td>Otospondylomegaepiphyseal dysplasia</td>
</tr>
<tr>
<td>951</td>
<td>Weissenbacher- Zweymuller syndrome</td>
</tr>
<tr>
<td>952</td>
<td>Fibrochondrogenesis</td>
</tr>
<tr>
<td>953</td>
<td>Dyssegmental dysplasia, Silverman-Handmaker type</td>
</tr>
<tr>
<td>954</td>
<td>Dyssegmental dysplasia, Rolland-Desbuquois type</td>
</tr>
<tr>
<td>955</td>
<td>Metatropic dysplasias</td>
</tr>
<tr>
<td>956</td>
<td>Metatropic dwarfism</td>
</tr>
<tr>
<td>957</td>
<td>Parastremmatic dwarfism</td>
</tr>
<tr>
<td>958</td>
<td>Schneckenbecken dysplasia</td>
</tr>
<tr>
<td>959</td>
<td>Solute carrier family 35 deficiency</td>
</tr>
<tr>
<td>960</td>
<td>SLC35D1-CDG</td>
</tr>
<tr>
<td>961</td>
<td>Spondyloepiphyseal dysplasia, Maroteaux type</td>
</tr>
<tr>
<td>962</td>
<td>Spondyloepimetaphyseal dysplasia - short limb - abnormal calcification</td>
</tr>
<tr>
<td>963</td>
<td>Spondyloepiphyseal dysplasia tarda, X-linked</td>
</tr>
<tr>
<td>964</td>
<td>Spondyloepiphyseal dysplasia, Kimberley type</td>
</tr>
<tr>
<td>965</td>
<td>Spondyloepiphyseal dysplasia, Omani type</td>
</tr>
<tr>
<td>966</td>
<td>Spondyloepiphyseal dysplasia tarda, Kohn type</td>
</tr>
<tr>
<td>967</td>
<td>Spondyloepiphyseal dysplasia, Nishimura type</td>
</tr>
<tr>
<td>968</td>
<td>Spondyloepiphyseal dysplasia, Reardon type</td>
</tr>
<tr>
<td>969</td>
<td>Spondyloepiphyseal dysplasia, MacDermot type</td>
</tr>
<tr>
<td>970</td>
<td>Spondyloepiphyseal dysplasia, Byers type</td>
</tr>
<tr>
<td>971</td>
<td>Spondyloepiphyseal dysplasia, Cantu type</td>
</tr>
<tr>
<td>972</td>
<td>Dyggve-Melchior-Clausen disease</td>
</tr>
<tr>
<td>973</td>
<td>Smith-McCort dysplasia</td>
</tr>
<tr>
<td>974</td>
<td>Spondylar and nasal alterations with striated metaphyses dysplasia</td>
</tr>
<tr>
<td>975</td>
<td>SPONASTRIME - [spondylar and nasal alterations with striated metaphyses] dysplasia</td>
</tr>
<tr>
<td>976</td>
<td>short limb dwarfism with saddle nose, spinal alterations and metaphyseal striation</td>
</tr>
<tr>
<td>977</td>
<td>Spondyloepimetaphyseal dysplasia, matrilin-3 type</td>
</tr>
<tr>
<td>978</td>
<td>Spondyloepimetaphyseal dysplasia - joint laxity</td>
</tr>
<tr>
<td>979</td>
<td>Spondyloepiphyseal dysplasia, Pakistani type</td>
</tr>
<tr>
<td>980</td>
<td>Spondyloepimetaphyseal dysplasia, aggrecan type</td>
</tr>
<tr>
<td>981</td>
<td>Spondyloepimetaphyseal dysplasia, X-linked</td>
</tr>
<tr>
<td>982</td>
<td>Spondyloepimetaphyseal dysplasia, Irapa type</td>
</tr>
<tr>
<td>983</td>
<td>Spondyloepimetaphyseal dysplasia, Shohat type</td>
</tr>
<tr>
<td>984</td>
<td>Spondyloepimetaphyseal dysplasia, Missouri type</td>
</tr>
<tr>
<td>985</td>
<td>Spondyloepimetaphyseal dysplasia - multiple dislocations</td>
</tr>
<tr>
<td>986</td>
<td>Spondyloepimetaphyseal dysplasia, Handigodu type</td>
</tr>
<tr>
<td>987</td>
<td>Spondyloepimetaphyseal dysplasia - hypotrichosis</td>
</tr>
<tr>
<td>988</td>
<td>Spondyloepimetaphyseal dysplasia, Bieganski type</td>
</tr>
<tr>
<td>989</td>
<td>Spondyloepimetaphyseal dysplasia - abnormal dentition</td>
</tr>
<tr>
<td>990</td>
<td>Spondyloepimetaphyseal dysplasia, Genevieve type</td>
</tr>
<tr>
<td>991</td>
<td>Spondyloenchondrodysplasia</td>
</tr>
<tr>
<td>992</td>
<td>Spondyloenchondromatosis</td>
</tr>
<tr>
<td>993</td>
<td>Progressive pseudorheumatoid arthropathy of childhood</td>
</tr>
<tr>
<td>994</td>
<td>Brachydactylous dwarfism, Mseleni type</td>
</tr>
<tr>
<td>995</td>
<td>Anauxetic dysplasia</td>
</tr>
<tr>
<td>996</td>
<td>Spondyloepimetaphyseal dysplasia, Menger type</td>
</tr>
<tr>
<td>997</td>
<td>Spondyloepimetaphyseal dysplasia, anauxetic type</td>
</tr>
<tr>
<td>998</td>
<td>CHST3-related skeletal dysplasia</td>
</tr>
<tr>
<td>999</td>
<td>Hypertriglyceridaemia</td>
</tr>
<tr>
<td>1000</td>
<td>Hyperlipidaemia, group B</td>
</tr>
<tr>
<td>1001</td>
<td>endogenous hyperlipemia</td>
</tr>
<tr>
<td>1002</td>
<td>endogenous hyperlipidaemia</td>
</tr>
<tr>
<td>1003</td>
<td>prebetalipoproteinemia</td>
</tr>
<tr>
<td>1004</td>
<td>very-low-density-lipoid-type hyperlipoproteinemia</td>
</tr>
<tr>
<td>1005</td>
<td>very-low-density-lipoprotein-type</td>
</tr>
<tr>
<td>1006</td>
<td>Fredrickson hyperlipoproteinaemia, type 4</td>
</tr>
<tr>
<td>1007</td>
<td>Fredrickson hyperlipoproteinemia, type 4</td>
</tr>
<tr>
<td>1008</td>
<td>very-low-density-lipoprotein-type hyperlipoproteinemia</td>
</tr>
<tr>
<td>1009</td>
<td>essential hypertriglyceridaemia</td>
</tr>
<tr>
<td>1010</td>
<td>familial hyperprebetalipoproteinaemia</td>
</tr>
<tr>
<td>1011</td>
<td>elevated fasting triglycerides dyslipidaemia</td>
</tr>
<tr>
<td>1012</td>
<td>Endogenous hyperglyceridaemia</td>
</tr>
<tr>
<td>1013</td>
<td>familial hyperglyceridaemia</td>
</tr>
<tr>
<td>1014</td>
<td>hereditary hyperglyceridaemia</td>
</tr>
<tr>
<td>1015</td>
<td>group B hyperlipemia</td>
</tr>
<tr>
<td>1016</td>
<td>hyperglyceridaemia</td>
</tr>
<tr>
<td>1017</td>
<td>essential hyperglyceridaemia</td>
</tr>
<tr>
<td>1018</td>
<td>Fredrickson type 4 lipidaemia</td>
</tr>
<tr>
<td>1019</td>
<td>Major hypertriglyceridaemia</td>
</tr>
<tr>
<td>1020</td>
<td>Hyperlipoproteinaemia type 1</td>
</tr>
<tr>
<td>1021</td>
<td>Hyperlipidaemia type 1</td>
</tr>
<tr>
<td>1022</td>
<td>endogenous hypertriglyceridaemia</td>
</tr>
<tr>
<td>1023</td>
<td>hepatosplenomegalic lipoidosis</td>
</tr>
<tr>
<td>1024</td>
<td>familial fat-induced hypertriglyceridaemia</td>
</tr>
<tr>
<td>1025</td>
<td>familial hyperchylomicronaemia</td>
</tr>
<tr>
<td>1026</td>
<td>familial lipoprotein lipase deficiency with type I phenotype</td>
</tr>
<tr>
<td>1027</td>
<td>primary hyperchylomicronaemia</td>
</tr>
<tr>
<td>1028</td>
<td>mixed hyperglyceridaemia</td>
</tr>
<tr>
<td>1029</td>
<td>hyperchylomicronaemia</td>
</tr>
<tr>
<td>1030</td>
<td>hypercholesterinaemic xanthomatosis</td>
</tr>
<tr>
<td>1031</td>
<td>Bürger-Grütz syndrome</td>
</tr>
<tr>
<td>1032</td>
<td>hyperlipoproteinaemia, type 1</td>
</tr>
<tr>
<td>1033</td>
<td>familial type 1 hyperlipoproteinaemia</td>
</tr>
<tr>
<td>1034</td>
<td>Fredrickson type 1 hyperlipoproteinaemia</td>
</tr>
<tr>
<td>1035</td>
<td>mixed familial hyperglyceridaemia</td>
</tr>
<tr>
<td>1036</td>
<td>mixed essential hyperglyceridaemia</td>
</tr>
<tr>
<td>1037</td>
<td>mixed endogenous hyperglyceridaemia</td>
</tr>
<tr>
<td>1038</td>
<td>mixed hereditary hyperglyceridaemia</td>
</tr>
<tr>
<td>1039</td>
<td>mixed pure hyperglyceridaemia</td>
</tr>
<tr>
<td>1040</td>
<td>Familial apolipoprotein C-II deficiency</td>
</tr>
<tr>
<td>1041</td>
<td>Familial lipoprotein lipase deficiency</td>
</tr>
<tr>
<td>1042</td>
<td>Fredrickson type 5 hyperlipoproteinaemia</td>
</tr>
<tr>
<td>1043</td>
<td>Hyperbetalipoproteinaemia hyperchylomicronaemia</td>
</tr>
<tr>
<td>1044</td>
<td>hyperchylomicronaemia with hyperbetalipoproteinaemia</td>
</tr>
<tr>
<td>1045</td>
<td>Hyperlipidaemia group D</td>
</tr>
<tr>
<td>1046</td>
<td>Hyperlipoproteinaemia type 4</td>
</tr>
<tr>
<td>1047</td>
<td>Familial hypertriglyceridaemia</td>
</tr>
<tr>
<td>1048</td>
<td>carbohydrate induced hyperlipemia</td>
</tr>
<tr>
<td>1049</td>
<td>Familial hyperlipoproteinaemia type 4</td>
</tr>
<tr>
<td>1050</td>
<td>Secondary hyperlipoproteinaemia type 4</td>
</tr>
<tr>
<td>1051</td>
<td>Hyperlipoproteinaemia type 5</td>
</tr>
<tr>
<td>1052</td>
<td>Major hyperlipidaemia</td>
</tr>
<tr>
<td>1053</td>
<td>Familial hyperlipoproteinaemia type 5</td>
</tr>
<tr>
<td>1054</td>
<td>Secondary hyperlipoproteinaemia type 5</td>
</tr>
<tr>
<td>1055</td>
<td>Xanthoma in association with primary hypertriglyceridaemia</td>
</tr>
<tr>
<td>1056</td>
<td>Xanthoma in association with primary chylomicronaemia</td>
</tr>
<tr>
<td>1057</td>
<td>Xanthoma in association with chylomicron retention disease</td>
</tr>
<tr>
<td>1058</td>
<td>Hyperprebetalipoproteinaemia</td>
</tr>
<tr>
<td>1059</td>
<td>VLDL - [very-low-density-lipoprotein-type] hyperlipoproteinaemia</td>
</tr>
<tr>
<td>1060</td>
<td>Hypocalcaemic vitamin D resistant rickets</td>
</tr>
<tr>
<td>1061</td>
<td>Disorders of calcium or phosphate excretion</td>
</tr>
<tr>
<td>1062</td>
<td>Phosphate losing hypophosphataemia</td>
</tr>
<tr>
<td>1063</td>
<td>hereditary hypophosphatemia</td>
</tr>
<tr>
<td>1064</td>
<td>Phosphate losing hypophosphataemia associated with familial or genetic disorders elsewhere classified</td>
</tr>
<tr>
<td>1065</td>
<td>Familial hypophosphataemia</td>
</tr>
<tr>
<td>1066</td>
<td>Familial hypophosphatemic bone disease</td>
</tr>
<tr>
<td>1067</td>
<td>Familial hypophosphatemic osteomalacia</td>
</tr>
<tr>
<td>1068</td>
<td>Vitamin-D-resistant osteomalacia</td>
</tr>
<tr>
<td>1069</td>
<td>Acquired hyperphosphaturia or hypophosphataemia</td>
</tr>
<tr>
<td>1070</td>
<td>Hypophosphatemia, not otherwise specified</td>
</tr>
<tr>
<td>1071</td>
<td>Hyperphosphaturia</td>
</tr>
<tr>
<td>1072</td>
<td>Renal hypophosphatemia</td>
</tr>
<tr>
<td>1073</td>
<td>Hyperphosphatemia</td>
</tr>
<tr>
<td>1074</td>
<td>Other specified defects in the complement system</td>
</tr>
<tr>
<td>1075</td>
<td>Complement component C3 deficiency</td>
</tr>
<tr>
<td>1076</td>
<td>Recurrent Neisseria infections due to factor D deficiency</td>
</tr>
<tr>
<td>1077</td>
<td>Complement component C4b-binding protein deficiency</td>
</tr>
<tr>
<td>1078</td>
<td>Immunodeficiency with CD46 deficiency</td>
</tr>
<tr>
<td>1079</td>
<td>Membrane cofactor protein deficiency</td>
</tr>
<tr>
<td>1080</td>
<td>Immunodeficiency with decay accelerating factor deficiency</td>
</tr>
<tr>
<td>1081</td>
<td>Immunodeficiency with CD55 deficiency</td>
</tr>
<tr>
<td>1082</td>
<td>Immunodeficiency with DAF - [decay accelerating factor] deficiency</td>
</tr>
<tr>
<td>1083</td>
<td>CHAPLE syndrome</td>
</tr>
<tr>
<td>1084</td>
<td>Immunodeficiency with factor H anomaly</td>
</tr>
<tr>
<td>1085</td>
<td>Immunodeficiency with factor I anomaly</td>
</tr>
<tr>
<td>1086</td>
<td>Immunodeficiency with properdin deficiency</td>
</tr>
<tr>
<td>1087</td>
<td>Immunodeficiency with CD59 deficiency</td>
</tr>
<tr>
<td>1088</td>
<td>Immunodeficiency with MASP-2 deficiency</td>
</tr>
<tr>
<td>1089</td>
<td>Mannan-binding lectin serine protease 2 deficiency</td>
</tr>
<tr>
<td>1090</td>
<td>Immunodeficiency with MBL - [mannan-binding lectin] deficiency</td>
</tr>
<tr>
<td>1091</td>
<td>Mannan-binding lectin deficiency</td>
</tr>
<tr>
<td>1092</td>
<td>Mannose-binding protein deficiency</td>
</tr>
<tr>
<td>1093</td>
<td>MBP - [mannan-binding lectin] deficiency</td>
</tr>
<tr>
<td>1094</td>
<td>Immunodeficiency with ficolin-3 deficiency</td>
</tr>
<tr>
<td>1095</td>
<td>Angioedema due to disordered complement activation or kinin metabolism</td>
</tr>
<tr>
<td>1096</td>
<td>Other specified monogenic autoinflammatory syndromes</td>
</tr>
<tr>
<td>1097</td>
<td>Autoinflammatory granulomatosis of childhood</td>
</tr>
<tr>
<td>1098</td>
<td>Granulomatous arthritis of childhood</td>
</tr>
<tr>
<td>1099</td>
<td>Early onset autoinflammatory granulomatosis</td>
</tr>
<tr>
<td>1100</td>
<td>Blau syndrome</td>
</tr>
<tr>
<td>1101</td>
<td>Caspase recruitment domain-containing protein 15 deficiency</td>
</tr>
<tr>
<td>1102</td>
<td>Paediatric granulomatous arthritis</td>
</tr>
<tr>
<td>1103</td>
<td>Familial juvenile sarcoidosis</td>
</tr>
<tr>
<td>1104</td>
<td>Jab syndrome</td>
</tr>
<tr>
<td>1105</td>
<td>CARD15 - [Caspase recruitment domain-containing protein 15] deficiency</td>
</tr>
<tr>
<td>1106</td>
<td>Early-onset sarcoidosis</td>
</tr>
<tr>
<td>1107</td>
<td>Sporadic Blau syndrome</td>
</tr>
<tr>
<td>1108</td>
<td>Sporadic autoinflammatory granulomatosis of childhood</td>
</tr>
<tr>
<td>1109</td>
<td>Pyogenic arthritis - pyoderma gangrenosum - acne</td>
</tr>
<tr>
<td>1110</td>
<td>PAPA- [pyogenic arthritis, pyoderma gangrenosum and acne] syndrome</td>
</tr>
<tr>
<td>1111</td>
<td>PAPA - predominantly arthritis</td>
</tr>
<tr>
<td>1112</td>
<td>PAPA – predominantly cutaneous</td>
</tr>
<tr>
<td>1113</td>
<td>Mevalonate kinase deficiency with recurrent fever</td>
</tr>
<tr>
<td>1114</td>
<td>Hyperimmunoglobulinaemia D with periodic fever</td>
</tr>
<tr>
<td>1115</td>
<td>Hyper-IgD syndrome</td>
</tr>
<tr>
<td>1116</td>
<td>Dutch-type periodic fever</td>
</tr>
<tr>
<td>1117</td>
<td>Hyperimmunoglobinaemia D with recurrent fever</td>
</tr>
<tr>
<td>1118</td>
<td>HIDS - [Hyper-IgD syndrome]</td>
</tr>
<tr>
<td>1119</td>
<td>MVK [mevalonate kinase deficiency] with recurrent fever</td>
</tr>
<tr>
<td>1120</td>
<td>NLRP12-associated hereditary periodic fever syndrome</td>
</tr>
<tr>
<td>1121</td>
<td>Drugs, medicaments or biological substances associated with injury or harm in therapeutic use</td>
</tr>
<tr>
<td>1122</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics</td>
</tr>
<tr>
<td>1123</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Penicillins</td>
</tr>
<tr>
<td>1124</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Cephalosporins or other beta-lactam antibiotics</td>
</tr>
<tr>
<td>1125</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Chloramphenicol group</td>
</tr>
<tr>
<td>1126</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Macrolides</td>
</tr>
<tr>
<td>1127</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Tetracyclines</td>
</tr>
<tr>
<td>1128</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Aminoglycosides</td>
</tr>
<tr>
<td>1129</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Rifamycins</td>
</tr>
<tr>
<td>1130</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Antifungal antibiotics, systemically used</td>
</tr>
<tr>
<td>1131</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics</td>
</tr>
<tr>
<td>1132</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics, Sulfonamides</td>
</tr>
<tr>
<td>1133</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics, Antimycobacterial drugs</td>
</tr>
<tr>
<td>1134</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics, Antimalarials or drugs acting on other blood protozoa</td>
</tr>
<tr>
<td>1135</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics, Other antiprotozoal drugs</td>
</tr>
<tr>
<td>1136</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics, Anthelminthics</td>
</tr>
<tr>
<td>1137</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics, Antiviral drugs</td>
</tr>
<tr>
<td>1138</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics, Other specified systemic anti-infectives or antiparasitics</td>
</tr>
<tr>
<td>1139</td>
<td>Injury or harm in therapeutic use by hydroxyquinoline derivatives</td>
</tr>
<tr>
<td>1140</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>1141</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Glucocorticoids or synthetic analogues</td>
</tr>
<tr>
<td>1142</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Thyroid hormones or substitutes</td>
</tr>
<tr>
<td>1143</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Antithyroid drugs</td>
</tr>
<tr>
<td>1144</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Insulin or oral hypoglycaemic drugs</td>
</tr>
<tr>
<td>1145</td>
<td>Injury or harm in therapeutic use by insulin and oral hypoglycaemic [antidiabetic] drugs, Antidiabetic drugs</td>
</tr>
<tr>
<td>1146</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Oral contraceptives</td>
</tr>
<tr>
<td>1147</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Other estrogens or progestogens</td>
</tr>
<tr>
<td>1148</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified</td>
</tr>
<tr>
<td>1149</td>
<td>Injury or harm in therapeutic use by tamoxifen</td>
</tr>
<tr>
<td>1150</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Androgens or anabolic congeners</td>
</tr>
<tr>
<td>1151</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents</td>
</tr>
<tr>
<td>1152</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents, Antiallergic or antiemetic drugs</td>
</tr>
<tr>
<td>1153</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents, Antineoplastic antimetabolites</td>
</tr>
<tr>
<td>1154</td>
<td>Injury or harm in therapeutic use by cytarabine</td>
</tr>
<tr>
<td>1155</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents, Antineoplastic natural products</td>
</tr>
<tr>
<td>1156</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents, Other antineoplastic drugs</td>
</tr>
<tr>
<td>1157</td>
<td>Injury or harm in therapeutic use by antineoplastic antibiotics</td>
</tr>
<tr>
<td>1158</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents, Immunosuppressive agents</td>
</tr>
<tr>
<td>1159</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents, Acidifying or alkalizing agents</td>
</tr>
<tr>
<td>1160</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents, Enzymes, not elsewhere classified</td>
</tr>
<tr>
<td>1161</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents</td>
</tr>
<tr>
<td>1162</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Iron preparations or other anti-hypochromic-anaemia preparations</td>
</tr>
<tr>
<td>1163</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Vitamin B, folic acid or other anti-megaloblastic-anaemia preparations</td>
</tr>
<tr>
<td>1164</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Anticoagulants</td>
</tr>
<tr>
<td>1165</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Anticoagulant antagonists, vitamin K or other coagulants</td>
</tr>
<tr>
<td>1166</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Antithrombotic drugs</td>
</tr>
<tr>
<td>1167</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Thrombolytic drugs</td>
</tr>
<tr>
<td>1168</td>
<td>Injury or harm caused by tissue‐type plasminogen activator in therapeutic use</td>
</tr>
<tr>
<td>1169</td>
<td>Injury or harm caused by tPA [tissue‐type plasminogen activator] in therapeutic use</td>
</tr>
<tr>
<td>1170</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Natural blood or blood products</td>
</tr>
<tr>
<td>1171</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Plasma substitutes</td>
</tr>
<tr>
<td>1172</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Analgesics, antipyretics or anti-inflammatory drugs</td>
</tr>
<tr>
<td>1173</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Analgesics, antipyretics or anti-inflammatory drugs, Opioids or related analgesics</td>
</tr>
<tr>
<td>1174</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Analgesics, antipyretics or anti-inflammatory drugs, Salicylates</td>
</tr>
<tr>
<td>1175</td>
<td>Injury or harm in therapeutic use of acetylsalicylic acid</td>
</tr>
<tr>
<td>1176</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Analgesics, antipyretics or anti-inflammatory drugs, Propionic acid derivatives</td>
</tr>
<tr>
<td>1177</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Analgesics, antipyretics or anti-inflammatory drugs, Other nonsteroidal anti-inflammatory drugs</td>
</tr>
<tr>
<td>1178</td>
<td>Other NSAID</td>
</tr>
<tr>
<td>1179</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Analgesics, antipyretics or anti-inflammatory drugs, Antirheumatics</td>
</tr>
<tr>
<td>1180</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Analgesics, antipyretics or anti-inflammatory drugs, 4-Aminophenol derivatives</td>
</tr>
<tr>
<td>1181</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs</td>
</tr>
<tr>
<td>1182</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Succinimides</td>
</tr>
<tr>
<td>1183</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Oxazolidinediones</td>
</tr>
<tr>
<td>1184</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Hydantoin derivatives</td>
</tr>
<tr>
<td>1185</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Deoxybarbiturates</td>
</tr>
<tr>
<td>1186</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Iminostilbenes</td>
</tr>
<tr>
<td>1187</td>
<td>Injury or harm in therapeutic use by carbamazepine</td>
</tr>
<tr>
<td>1188</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Valproic acid</td>
</tr>
<tr>
<td>1189</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Other or unspecified antiepileptics</td>
</tr>
<tr>
<td>1190</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Antiparkinsonism drugs</td>
</tr>
<tr>
<td>1191</td>
<td>Injury or harm in therapeutic use by amantadine</td>
</tr>
<tr>
<td>1192</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Antispasticity drugs</td>
</tr>
<tr>
<td>1193</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Sedatives, hypnotics or antianxiety drugs</td>
</tr>
<tr>
<td>1194</td>
<td>Injury or harm in therapeutic use by sleeping draught NOS</td>
</tr>
<tr>
<td>1195</td>
<td>Injury or harm in therapeutic use by sleeping drug NOS</td>
</tr>
<tr>
<td>1196</td>
<td>Injury or harm in therapeutic use by sleeping tablet NOS</td>
</tr>
<tr>
<td>1197</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Sedatives, hypnotics or antianxiety drugs, Barbiturates, not elsewhere classified</td>
</tr>
<tr>
<td>1198</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Sedatives, hypnotics or antianxiety drugs, Benzodiazepines</td>
</tr>
<tr>
<td>1199</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Sedatives, hypnotics or antianxiety drugs, Cloral derivatives</td>
</tr>
<tr>
<td>1200</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Sedatives, hypnotics or antianxiety drugs, Paraldehyde</td>
</tr>
<tr>
<td>1201</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Sedatives, hypnotics or antianxiety drugs, Bromine compounds</td>
</tr>
<tr>
<td>1202</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Sedatives, hypnotics or antianxiety drugs, Mixed sedatives or hypnotics, not elsewhere classified</td>
</tr>
<tr>
<td>1203</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Anaesthetics or therapeutic gases</td>
</tr>
<tr>
<td>1204</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Anaesthetics or therapeutic gases, Inhaled anaesthetics</td>
</tr>
<tr>
<td>1205</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Anaesthetics or therapeutic gases, Parenteral anaesthetics</td>
</tr>
<tr>
<td>1206</td>
<td>Injury or harm in therapeutic use of thiobarbiturates</td>
</tr>
<tr>
<td>1207</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Anaesthetics or therapeutic gases, Other or unspecified general anaesthetics</td>
</tr>
<tr>
<td>1208</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Anaesthetics or therapeutic gases, Local anaesthetics</td>
</tr>
<tr>
<td>1209</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Anaesthetics or therapeutic gases, Therapeutic gases</td>
</tr>
<tr>
<td>1210</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified</td>
</tr>
<tr>
<td>1211</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Tricyclic or tetracyclic antidepressants</td>
</tr>
<tr>
<td>1212</td>
<td>Drugs medicaments or biological, substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Monoamine-oxidase-inhibitor antidepressants</td>
</tr>
<tr>
<td>1213</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Other or unspecified antidepressants</td>
</tr>
<tr>
<td>1214</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Phenothiazine antipsychotics or neuroleptics</td>
</tr>
<tr>
<td>1215</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Butyrophenone or thioxanthene neuroleptics</td>
</tr>
<tr>
<td>1216</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Other antipsychotics or neuroleptics</td>
</tr>
<tr>
<td>1217</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Psychodysleptics</td>
</tr>
<tr>
<td>1218</td>
<td>Injury or harm in therapeutic use of hallucinogens</td>
</tr>
<tr>
<td>1219</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Psychostimulants with abuse potential</td>
</tr>
<tr>
<td>1220</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Central nervous system stimulants, not elsewhere classified</td>
</tr>
<tr>
<td>1221</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Central nervous system stimulants, not elsewhere classified, Analeptics</td>
</tr>
<tr>
<td>1222</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Central nervous system stimulants, not elsewhere classified, Opioid receptor antagonists</td>
</tr>
<tr>
<td>1223</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Central nervous system stimulants, not elsewhere classified, Methylxanthines, not elsewhere classified</td>
</tr>
<tr>
<td>1224</td>
<td>Injury or harm in therapeutic use of caffeine</td>
</tr>
<tr>
<td>1225</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system</td>
</tr>
<tr>
<td>1226</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Anticholinesterase agents</td>
</tr>
<tr>
<td>1227</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Other parasympathomimetics</td>
</tr>
<tr>
<td>1228</td>
<td>Injury or harm in therapeutic use of cholinergics</td>
</tr>
<tr>
<td>1229</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Ganglionic blocking drugs, not elsewhere classified</td>
</tr>
<tr>
<td>1230</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Other parasympatholytics or spasmolytics, not elsewhere classified</td>
</tr>
<tr>
<td>1231</td>
<td>Injury or harm in therapeutic use of anticholinergics or antimuscarinics</td>
</tr>
<tr>
<td>1232</td>
<td>Injury or harm in therapeutic use of papaverine</td>
</tr>
<tr>
<td>1233</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Predominantly alpha-adrenoreceptor agonists, not elsewhere classified</td>
</tr>
<tr>
<td>1234</td>
<td>Injury or harm in therapeutic use of metaraminol</td>
</tr>
<tr>
<td>1235</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Predominantly beta-adrenoreceptor agonists, not elsewhere classified</td>
</tr>
<tr>
<td>1236</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Alpha-adrenoreceptor antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>1237</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Beta-adrenoreceptor antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>1238</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Centrally acting or adrenergic-neuron-blocking agents, not elsewhere classified</td>
</tr>
<tr>
<td>1239</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system</td>
</tr>
<tr>
<td>1240</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Cardiac-stimulant glycosides or drugs of similar action</td>
</tr>
<tr>
<td>1241</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Calcium-channel blockers</td>
</tr>
<tr>
<td>1242</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Other antidysrhythmic drugs, not elsewhere classified</td>
</tr>
<tr>
<td>1243</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Coronary vasodilators, not elsewhere classified</td>
</tr>
<tr>
<td>1244</td>
<td>Injury or harm in therapeutic use of dipyridamole</td>
</tr>
<tr>
<td>1245</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Angiotensin-converting-enzyme inhibitors</td>
</tr>
<tr>
<td>1246</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Other antihypertensive drugs, not elsewhere classified</td>
</tr>
<tr>
<td>1247</td>
<td>Injury or harm in therapeutic use of clonidine</td>
</tr>
<tr>
<td>1248</td>
<td>Injury or harm in therapeutic use of guanethidine</td>
</tr>
<tr>
<td>1249</td>
<td>Injury or harm in therapeutic use of rauwolfia</td>
</tr>
<tr>
<td>1250</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Antihyperlipidaemic or antiarteriosclerotic drugs</td>
</tr>
<tr>
<td>1251</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Peripheral vasodilators</td>
</tr>
<tr>
<td>1252</td>
<td>Injury or harm in therapeutic use by nicotinic acid derivatives</td>
</tr>
<tr>
<td>1253</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Antivaricose drugs, including sclerosing agents</td>
</tr>
<tr>
<td>1254</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system</td>
</tr>
<tr>
<td>1255</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Histamine H-receptor antagonists</td>
</tr>
<tr>
<td>1256</td>
<td>histamine h 2 -receptor antagonists associated with injury or harm in therapeutic use</td>
</tr>
<tr>
<td>1257</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Other antacids or anti-gastric-secretion drugs</td>
</tr>
<tr>
<td>1258</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Stimulant laxatives</td>
</tr>
<tr>
<td>1259</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Saline or osmotic laxatives</td>
</tr>
<tr>
<td>1260</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Other laxatives</td>
</tr>
<tr>
<td>1261</td>
<td>injury or harm in therapeutic use of intestinal atonia drugs</td>
</tr>
<tr>
<td>1262</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Digestants</td>
</tr>
<tr>
<td>1263</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Antidiarrhoeal drugs</td>
</tr>
<tr>
<td>1264</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Emetics</td>
</tr>
<tr>
<td>1265</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism</td>
</tr>
<tr>
<td>1266</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Mineralocorticoids</td>
</tr>
<tr>
<td>1267</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Mineralocorticoid antagonists</td>
</tr>
<tr>
<td>1268</td>
<td>injury or harm in therapeutic use of aldosterone antagonists</td>
</tr>
<tr>
<td>1269</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Carbonic-anhydrase inhibitors</td>
</tr>
<tr>
<td>1270</td>
<td>Injury or harm in therapeutic use of acetazolamide</td>
</tr>
<tr>
<td>1271</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Benzothiadiazine derivatives</td>
</tr>
<tr>
<td>1272</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Loop diuretics</td>
</tr>
<tr>
<td>1273</td>
<td>injury or harm in therapeutic use of high-ceiling diuretics</td>
</tr>
<tr>
<td>1274</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Other diuretics</td>
</tr>
<tr>
<td>1275</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Electrolytic, caloric or water-balance agents</td>
</tr>
<tr>
<td>1276</td>
<td>Injury or harm in therapeutic use of oral rehydration salts</td>
</tr>
<tr>
<td>1277</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Agents affecting calcification</td>
</tr>
<tr>
<td>1278</td>
<td>Injury or harm in therapeutic use of parathyroid hormones or derivatives</td>
</tr>
<tr>
<td>1279</td>
<td>Injury or harm in therapeutic use of vitamin D group</td>
</tr>
<tr>
<td>1280</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Agents affecting uric acid metabolism</td>
</tr>
<tr>
<td>1281</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Mineral salts, not elsewhere classified</td>
</tr>
<tr>
<td>1282</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system</td>
</tr>
<tr>
<td>1283</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Oxytocic drugs</td>
</tr>
<tr>
<td>1284</td>
<td>Injury or harm in therapeutic use of ergot alkaloids</td>
</tr>
<tr>
<td>1285</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Skeletal muscle relaxants</td>
</tr>
<tr>
<td>1286</td>
<td>injury or harm in therapeutic use of neuromuscular blocking agents</td>
</tr>
<tr>
<td>1287</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Other or unspecified agents primarily acting on muscles</td>
</tr>
<tr>
<td>1288</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Antitussives</td>
</tr>
<tr>
<td>1289</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Expectorants</td>
</tr>
<tr>
<td>1290</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Anti-common-cold drugs</td>
</tr>
<tr>
<td>1291</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Antiasthmatics, not elsewhere classified</td>
</tr>
<tr>
<td>1292</td>
<td>Injury or harm in therapeutic use of aminophylline</td>
</tr>
<tr>
<td>1293</td>
<td>Injury or harm in therapeutic use of salbutamol</td>
</tr>
<tr>
<td>1294</td>
<td>Injury or harm in therapeutic use of theobromine</td>
</tr>
<tr>
<td>1295</td>
<td>Injury or harm in therapeutic use of theophylline</td>
</tr>
<tr>
<td>1296</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Other or unspecified agents primarily acting on the respiratory system</td>
</tr>
<tr>
<td>1297</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs</td>
</tr>
<tr>
<td>1298</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs, Local antifungal, anti-infective or anti-inflammatory drugs, not elsewhere classified</td>
</tr>
<tr>
<td>1299</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs, Antipruritics</td>
</tr>
<tr>
<td>1300</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs, Local astringents or local detergents</td>
</tr>
<tr>
<td>1301</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs, Emollients, demulcents or protectants</td>
</tr>
<tr>
<td>1302</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs, Keratolytics, keratoplastics or other hair treatment drugs or preparations</td>
</tr>
<tr>
<td>1303</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs, Ophthalmological drugs or preparations</td>
</tr>
<tr>
<td>1304</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological drugs or preparations or dental drugs</td>
</tr>
<tr>
<td>1305</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs, Dental drugs, topically applied</td>
</tr>
<tr>
<td>1306</td>
<td>Injury or harm in therapeutic use of glucocorticoids, topically used</td>
</tr>
<tr>
<td>1307</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments</td>
</tr>
<tr>
<td>1308</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, Appetite depressants</td>
</tr>
<tr>
<td>1309</td>
<td>injury or harm in therapeutic use of anorectics</td>
</tr>
<tr>
<td>1310</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, Lipotropic drugs</td>
</tr>
<tr>
<td>1311</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, Antidotes or chelating agents, not elsewhere classified</td>
</tr>
<tr>
<td>1312</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, Alcohol deterrents</td>
</tr>
<tr>
<td>1313</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, Pharmaceutical excipients</td>
</tr>
<tr>
<td>1314</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, X-ray contrast media</td>
</tr>
<tr>
<td>1315</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, Other diagnostic agents</td>
</tr>
<tr>
<td>1316</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, Vitamins, not elsewhere classified</td>
</tr>
<tr>
<td>1317</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines</td>
</tr>
<tr>
<td>1318</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, BCG vaccine</td>
</tr>
<tr>
<td>1319</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, Typhoid or paratyphoid vaccine</td>
</tr>
<tr>
<td>1320</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, Cholera vaccine</td>
</tr>
<tr>
<td>1321</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, Plague vaccine</td>
</tr>
<tr>
<td>1322</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, Tetanus vaccine</td>
</tr>
<tr>
<td>1323</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, Diphtheria vaccine</td>
</tr>
<tr>
<td>1324</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, Pertussis vaccine, including combinations with a pertussis component</td>
</tr>
<tr>
<td>1325</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, Mixed bacterial vaccines, except combinations with a pertussis component</td>
</tr>
<tr>
<td>1326</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified vaccines or biological substances</td>
</tr>
<tr>
<td>1327</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified vaccines or biological substances, Viral vaccines</td>
</tr>
<tr>
<td>1328</td>
<td>Drugs, medicaments or biological substances associated with injury or harm in therapeutic use, COVID-19 vaccine</td>
</tr>
<tr>
<td>1329</td>
<td>Correct administration of COVID-19 vaccine in prophylactic therapeutic use as the cause of any adverse effect</td>
</tr>
<tr>
<td>1330</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified vaccines or biological substances, Rickettsial vaccines</td>
</tr>
<tr>
<td>1331</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified vaccines or biological substances, Protozoal vaccines</td>
</tr>
<tr>
<td>1332</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified vaccines or biological substances, Immunoglobulin</td>
</tr>
<tr>
<td>1333</td>
<td>Other specified adult osteomalacia</td>
</tr>
<tr>
<td>1334</td>
<td>Osteomalacia due to malabsorption</td>
</tr>
<tr>
<td>1335</td>
<td>Adult osteomalacia due to malabsorption</td>
</tr>
<tr>
<td>1336</td>
<td>Osteomalacia due to malabsorption, multiple sites</td>
</tr>
<tr>
<td>1337</td>
<td>Adult osteomalacia due to malabsorption, multiple sites</td>
</tr>
<tr>
<td>1338</td>
<td>Osteomalacia due to malabsorption, shoulder region</td>
</tr>
<tr>
<td>1339</td>
<td>Adult osteomalacia due to malabsorption, shoulder region</td>
</tr>
<tr>
<td>1340</td>
<td>Osteomalacia due to malabsorption, clavicle</td>
</tr>
<tr>
<td>1341</td>
<td>Adult osteomalacia due to malabsorption, clavicle</td>
</tr>
<tr>
<td>1342</td>
<td>Osteomalacia due to malabsorption, scapula</td>
</tr>
<tr>
<td>1343</td>
<td>Adult osteomalacia due to malabsorption, scapula</td>
</tr>
<tr>
<td>1344</td>
<td>Osteomalacia due to malabsorption, acromioclavicular joint</td>
</tr>
<tr>
<td>1345</td>
<td>Adult osteomalacia due to malabsorption, acromioclavicular joint</td>
</tr>
<tr>
<td>1346</td>
<td>Osteomalacia due to malabsorption, glenohumeral joint</td>
</tr>
<tr>
<td>1347</td>
<td>Adult osteomalacia due to malabsorption, glenohumeral joint</td>
</tr>
<tr>
<td>1348</td>
<td>Osteomalacia due to malabsorption, sternoclavicular joint</td>
</tr>
<tr>
<td>1349</td>
<td>Adult osteomalacia due to malabsorption, sternoclavicular joint</td>
</tr>
<tr>
<td>1350</td>
<td>Osteomalacia due to malabsorption, upper arm</td>
</tr>
<tr>
<td>1351</td>
<td>Adult osteomalacia due to malabsorption, upper arm</td>
</tr>
<tr>
<td>1352</td>
<td>Osteomalacia due to malabsorption, humerus</td>
</tr>
<tr>
<td>1353</td>
<td>Adult osteomalacia due to malabsorption, humerus</td>
</tr>
<tr>
<td>1354</td>
<td>Osteomalacia due to malabsorption, elbow joint</td>
</tr>
<tr>
<td>1355</td>
<td>Adult osteomalacia due to malabsorption, elbow joint</td>
</tr>
<tr>
<td>1356</td>
<td>Osteomalacia due to malabsorption, forearm</td>
</tr>
<tr>
<td>1357</td>
<td>Adult osteomalacia due to malabsorption, forearm</td>
</tr>
<tr>
<td>1358</td>
<td>Osteomalacia due to malabsorption, radius</td>
</tr>
<tr>
<td>1359</td>
<td>Adult osteomalacia due to malabsorption, radius</td>
</tr>
<tr>
<td>1360</td>
<td>Osteomalacia due to malabsorption, ulna</td>
</tr>
<tr>
<td>1361</td>
<td>Adult osteomalacia due to malabsorption, ulna</td>
</tr>
<tr>
<td>1362</td>
<td>Osteomalacia due to malabsorption, wrist joint</td>
</tr>
<tr>
<td>1363</td>
<td>Adult osteomalacia due to malabsorption, wrist joint</td>
</tr>
<tr>
<td>1364</td>
<td>Osteomalacia due to malabsorption, hand</td>
</tr>
<tr>
<td>1365</td>
<td>Adult osteomalacia due to malabsorption, hand</td>
</tr>
<tr>
<td>1366</td>
<td>Osteomalacia due to malabsorption, carpus</td>
</tr>
<tr>
<td>1367</td>
<td>Adult osteomalacia due to malabsorption, carpus</td>
</tr>
<tr>
<td>1368</td>
<td>Osteomalacia due to malabsorption, fingers</td>
</tr>
<tr>
<td>1369</td>
<td>Adult osteomalacia due to malabsorption, fingers</td>
</tr>
<tr>
<td>1370</td>
<td>Osteomalacia due to malabsorption, metacarpus</td>
</tr>
<tr>
<td>1371</td>
<td>Adult osteomalacia due to malabsorption, metacarpus</td>
</tr>
<tr>
<td>1372</td>
<td>Osteomalacia due to malabsorption, pelvic region or thigh</td>
</tr>
<tr>
<td>1373</td>
<td>Adult osteomalacia due to malabsorption, pelvic region or thigh</td>
</tr>
<tr>
<td>1374</td>
<td>Osteomalacia due to malabsorption, femur</td>
</tr>
<tr>
<td>1375</td>
<td>Adult osteomalacia due to malabsorption, femur</td>
</tr>
<tr>
<td>1376</td>
<td>Osteomalacia due to malabsorption, pelvis</td>
</tr>
<tr>
<td>1377</td>
<td>Adult osteomalacia due to malabsorption, pelvis</td>
</tr>
<tr>
<td>1378</td>
<td>Osteomalacia due to malabsorption, hip joint</td>
</tr>
<tr>
<td>1379</td>
<td>Adult osteomalacia due to malabsorption, hip (joint)</td>
</tr>
<tr>
<td>1380</td>
<td>Osteomalacia due to malabsorption, lower leg</td>
</tr>
<tr>
<td>1381</td>
<td>Adult osteomalacia due to malabsorption, lower leg</td>
</tr>
<tr>
<td>1382</td>
<td>Osteomalacia due to malabsorption, fibula</td>
</tr>
<tr>
<td>1383</td>
<td>Adult osteomalacia due to malabsorption, fibula</td>
</tr>
<tr>
<td>1384</td>
<td>Osteomalacia due to malabsorption, knee joint</td>
</tr>
<tr>
<td>1385</td>
<td>Adult osteomalacia due to malabsorption, knee joint</td>
</tr>
<tr>
<td>1386</td>
<td>Osteomalacia due to malabsorption, tibia</td>
</tr>
<tr>
<td>1387</td>
<td>Adult osteomalacia due to malabsorption, tibia</td>
</tr>
<tr>
<td>1388</td>
<td>Osteomalacia due to malabsorption, ankle or foot</td>
</tr>
<tr>
<td>1389</td>
<td>Adult osteomalacia due to malabsorption, ankle or foot</td>
</tr>
<tr>
<td>1390</td>
<td>Osteomalacia due to malabsorption, metatarsus</td>
</tr>
<tr>
<td>1391</td>
<td>Adult osteomalacia due to malabsorption, metatarsus</td>
</tr>
<tr>
<td>1392</td>
<td>Osteomalacia due to malabsorption, tarsus</td>
</tr>
<tr>
<td>1393</td>
<td>Adult osteomalacia due to malabsorption, tarsus</td>
</tr>
<tr>
<td>1394</td>
<td>Osteomalacia due to malabsorption, toes</td>
</tr>
<tr>
<td>1395</td>
<td>Adult osteomalacia due to malabsorption, toes</td>
</tr>
<tr>
<td>1396</td>
<td>Osteomalacia due to malabsorption, ankle joint</td>
</tr>
<tr>
<td>1397</td>
<td>Adult osteomalacia due to malabsorption, ankle joint</td>
</tr>
<tr>
<td>1398</td>
<td>Osteomalacia due to malabsorption, other joints in foot</td>
</tr>
<tr>
<td>1399</td>
<td>Adult osteomalacia due to malabsorption, other joints in foot</td>
</tr>
<tr>
<td>1400</td>
<td>Osteomalacia due to malabsorption, head</td>
</tr>
<tr>
<td>1401</td>
<td>Adult osteomalacia due to malabsorption, head</td>
</tr>
<tr>
<td>1402</td>
<td>Osteomalacia due to malabsorption, neck</td>
</tr>
<tr>
<td>1403</td>
<td>Adult osteomalacia due to malabsorption, neck</td>
</tr>
<tr>
<td>1404</td>
<td>Osteomalacia due to malabsorption, ribs</td>
</tr>
<tr>
<td>1405</td>
<td>Adult osteomalacia due to malabsorption, ribs</td>
</tr>
<tr>
<td>1406</td>
<td>Osteomalacia due to malabsorption, skull</td>
</tr>
<tr>
<td>1407</td>
<td>Adult osteomalacia due to malabsorption, skull</td>
</tr>
<tr>
<td>1408</td>
<td>Osteomalacia due to malabsorption, trunk</td>
</tr>
<tr>
<td>1409</td>
<td>Adult osteomalacia due to malabsorption, trunk</td>
</tr>
<tr>
<td>1410</td>
<td>Osteomalacia due to malabsorption, vertebral column</td>
</tr>
<tr>
<td>1411</td>
<td>Adult osteomalacia due to malabsorption, vertebral column</td>
</tr>
<tr>
<td>1412</td>
<td>Postsurgical malabsorption osteomalacia in adults</td>
</tr>
<tr>
<td>1413</td>
<td>Adult osteomalacia in endocrine diseases</td>
</tr>
<tr>
<td>1414</td>
<td>Adult osteomalacia in liver disease</td>
</tr>
<tr>
<td>1415</td>
<td>Senile osteomalacia</td>
</tr>
<tr>
<td>1416</td>
<td>senile osteomalacia, site unspecified</td>
</tr>
<tr>
<td>1417</td>
<td>Inherited osteomalacia</td>
</tr>
<tr>
<td>1418</td>
<td>familial osteomalacia</td>
</tr>
<tr>
<td>1419</td>
<td>Adult osteomalacia, multiple sites</td>
</tr>
<tr>
<td>1420</td>
<td>Adult osteomalacia, shoulder region</td>
</tr>
<tr>
<td>1421</td>
<td>Adult osteomalacia, clavicle</td>
</tr>
<tr>
<td>1422</td>
<td>Adult osteomalacia, scapula</td>
</tr>
<tr>
<td>1423</td>
<td>Adult osteomalacia, acromioclavicular joint</td>
</tr>
<tr>
<td>1424</td>
<td>Adult osteomalacia, glenohumeral joint</td>
</tr>
<tr>
<td>1425</td>
<td>Adult osteomalacia, sternoclavicular joint</td>
</tr>
<tr>
<td>1426</td>
<td>Adult osteomalacia, upper arm</td>
</tr>
<tr>
<td>1427</td>
<td>Adult osteomalacia, humerus</td>
</tr>
<tr>
<td>1428</td>
<td>Adult osteomalacia, elbow joint</td>
</tr>
<tr>
<td>1429</td>
<td>Adult osteomalacia, forearm</td>
</tr>
<tr>
<td>1430</td>
<td>Adult osteomalacia, radius</td>
</tr>
<tr>
<td>1431</td>
<td>Adult osteomalacia, ulna</td>
</tr>
<tr>
<td>1432</td>
<td>Adult osteomalacia, wrist joint</td>
</tr>
<tr>
<td>1433</td>
<td>Adult osteomalacia, hand</td>
</tr>
<tr>
<td>1434</td>
<td>Adult osteomalacia, carpus</td>
</tr>
<tr>
<td>1435</td>
<td>Adult osteomalacia, fingers</td>
</tr>
<tr>
<td>1436</td>
<td>Adult osteomalacia, metacarpus</td>
</tr>
<tr>
<td>1437</td>
<td>Adult osteomalacia, pelvic region or thigh</td>
</tr>
<tr>
<td>1438</td>
<td>Adult osteomalacia, femur</td>
</tr>
<tr>
<td>1439</td>
<td>Adult osteomalacia, pelvis</td>
</tr>
<tr>
<td>1440</td>
<td>osteomalacic pelvis</td>
</tr>
<tr>
<td>1441</td>
<td>Adult osteomalacia, hip joint</td>
</tr>
<tr>
<td>1442</td>
<td>Adult osteomalacia, lower leg</td>
</tr>
<tr>
<td>1443</td>
<td>Adult osteomalacia, fibula</td>
</tr>
<tr>
<td>1444</td>
<td>Adult osteomalacia, knee joint</td>
</tr>
<tr>
<td>1445</td>
<td>Adult osteomalacia, tibia</td>
</tr>
<tr>
<td>1446</td>
<td>Adult osteomalacia, ankle or foot</td>
</tr>
<tr>
<td>1447</td>
<td>Adult osteomalacia, metatarsus</td>
</tr>
<tr>
<td>1448</td>
<td>Adult osteomalacia, tarsus</td>
</tr>
<tr>
<td>1449</td>
<td>Adult osteomalacia, toes</td>
</tr>
<tr>
<td>1450</td>
<td>Adult osteomalacia, ankle joint</td>
</tr>
<tr>
<td>1451</td>
<td>Adult osteomalacia, other joints in foot</td>
</tr>
<tr>
<td>1452</td>
<td>Adult osteomalacia, head</td>
</tr>
<tr>
<td>1453</td>
<td>Adult osteomalacia, neck</td>
</tr>
<tr>
<td>1454</td>
<td>Adult osteomalacia, ribs</td>
</tr>
<tr>
<td>1455</td>
<td>Adult osteomalacia, skull</td>
</tr>
<tr>
<td>1456</td>
<td>Adult osteomalacia, trunk</td>
</tr>
<tr>
<td>1457</td>
<td>Adult osteomalacia, vertebral column</td>
</tr>
<tr>
<td>1458</td>
<td>Milkman's syndrome</td>
</tr>
<tr>
<td>1459</td>
<td>Adult osteomalacia due to ergosterol deficiency</td>
</tr>
<tr>
<td>1460</td>
<td>Adult osteomalacia due to calciferol deficiency</td>
</tr>
<tr>
<td>1461</td>
<td>Adult osteomalacia due to Vitamin D deficiency</td>
</tr>
<tr>
<td>1462</td>
<td>Craniotabes, not elsewhere classified</td>
</tr>
<tr>
<td>1463</td>
<td>craniotabes NOS</td>
</tr>
<tr>
<td>1464</td>
<td>Immune dysregulation syndromes presenting primarily with lymphoproliferation</td>
</tr>
<tr>
<td>1465</td>
<td>Autosomal recessive lymphoproliferative disease</td>
</tr>
<tr>
<td>1466</td>
<td>Autoimmune lymphoproliferative syndrome</td>
</tr>
<tr>
<td>1467</td>
<td>autoimmune lymphoproliferative syndrome with recurrent infections</td>
</tr>
<tr>
<td>1468</td>
<td>Canale-Smith syndrome</td>
</tr>
<tr>
<td>1469</td>
<td>FAS deficiency</td>
</tr>
<tr>
<td>1470</td>
<td>FAS deficiency (ALPS-FAS)(ALPS1a)</td>
</tr>
<tr>
<td>1471</td>
<td>Caspase 8 defect (ALPS2b)</td>
</tr>
<tr>
<td>1472</td>
<td>ALPS-NRAS</td>
</tr>
<tr>
<td>1473</td>
<td>ALPS-KRAS</td>
</tr>
<tr>
<td>1474</td>
<td>ALPS-FASLG (ALPS1b)</td>
</tr>
<tr>
<td>1475</td>
<td>ALPS-CASP10 (ALPS2a)</td>
</tr>
<tr>
<td>1476</td>
<td>X-linked lymphoproliferative disease</td>
</tr>
<tr>
<td>1477</td>
<td>Purtilo syndrome</td>
</tr>
<tr>
<td>1478</td>
<td>Immunodeficiency following hereditary defective response to Epstein-Barr virus</td>
</tr>
<tr>
<td>1479</td>
<td>immunodeficient hereditary defective response to Epstein Barr virus</td>
</tr>
<tr>
<td>1480</td>
<td>x-linked lymphoproliferation disease</td>
</tr>
<tr>
<td>1481</td>
<td>x-linked lymphoproliferative disease or disorder</td>
</tr>
<tr>
<td>1482</td>
<td>x-linked lymphoproliferative syndrome</td>
</tr>
<tr>
<td>1483</td>
<td>XLPS - [x-linked lymphoproliferative syndrome]</td>
</tr>
<tr>
<td>1484</td>
<td>Fatal Epstein Barr virus syndrome</td>
</tr>
<tr>
<td>1485</td>
<td>XIAP deficiency (XLP2)</td>
</tr>
<tr>
<td>1486</td>
<td>SH2D1A deficiency (XLP1)</td>
</tr>
<tr>
<td>1</td>
<td>Haemoglobin E disease</td>
</tr>
<tr>
<td>2</td>
<td>Homozygous HbE carriers</td>
</tr>
<tr>
<td>3</td>
<td>Compound HbE or other Hb mutant heterozygotes</td>
</tr>
<tr>
<td>4</td>
<td>Vitamin E deficiency</td>
</tr>
<tr>
<td>5</td>
<td>tocopherol deficiency</td>
</tr>
<tr>
<td>6</td>
<td>Peripheral neuropathy due to vitamin E deficiency</td>
</tr>
<tr>
<td>7</td>
<td>Sensory polyneuropathy due to vitamin E deficiency</td>
</tr>
<tr>
<td>8</td>
<td>Spinocerebellar ataxia due to vitamin E deficiency</td>
</tr>
<tr>
<td>9</td>
<td>Complete trisomy 18</td>
</tr>
<tr>
<td>10</td>
<td>complete trisomy 18 syndrome</td>
</tr>
<tr>
<td>11</td>
<td>e3 trisomy</td>
</tr>
<tr>
<td>12</td>
<td>trisomy 18</td>
</tr>
<tr>
<td>13</td>
<td>trisomy 18 syndrome</td>
</tr>
<tr>
<td>14</td>
<td>trisomy 18 chromosome</td>
</tr>
<tr>
<td>15</td>
<td>Edwards syndrome</td>
</tr>
<tr>
<td>16</td>
<td>abnormal autosomes 18</td>
</tr>
<tr>
<td>17</td>
<td>Complete trisomy 18, meiotic non-disjunction</td>
</tr>
<tr>
<td>18</td>
<td>trisomy 18 syndrome, meiotic nondisjunction</td>
</tr>
<tr>
<td>19</td>
<td>trisomy 18, meiotic nondisjunction</td>
</tr>
<tr>
<td>20</td>
<td>Complete trisomy 18, translocation</td>
</tr>
<tr>
<td>21</td>
<td>trisomy 18 translocation</td>
</tr>
<tr>
<td>22</td>
<td>trisomy 18 chromosome translocation</td>
</tr>
<tr>
<td>23</td>
<td>trisomy 18 translocation syndrome</td>
</tr>
<tr>
<td>24</td>
<td>partial trisomy 18 in Edwards syndrome</td>
</tr>
<tr>
<td>25</td>
<td>Hereditary sensory and autonomic neuropathy type I</td>
</tr>
<tr>
<td>26</td>
<td>HSAN1- [Hereditary sensory and autonomic neuropathy type I]</td>
</tr>
<tr>
<td>27</td>
<td>Hereditary sensory and autonomic neuropathy Type IA</td>
</tr>
<tr>
<td>28</td>
<td>HSAN1A - [Hereditary sensory autonomic neuropathy Type IA</td>
</tr>
<tr>
<td>29</td>
<td>Hereditary sensory and autonomic neuropathy Type IB</td>
</tr>
<tr>
<td>30</td>
<td>Hereditary sensory and autonomic neuropathy Type IC</td>
</tr>
<tr>
<td>31</td>
<td>HSAN1C - [Hereditary sensory autonomic neuropathy Type IC]</td>
</tr>
<tr>
<td>32</td>
<td>Hereditary sensory and autonomic neuropathy Type ID</td>
</tr>
<tr>
<td>33</td>
<td>HSAN1D - [Hereditary sensory autonomic neuropathy Type ID]</td>
</tr>
<tr>
<td>34</td>
<td>Hereditary sensory and autonomic neuropathy Type IE</td>
</tr>
<tr>
<td>35</td>
<td>HSAN1E - [Hereditary sensory autonomic neuropathy Type IE]</td>
</tr>
<tr>
<td>36</td>
<td>Other specified hazardous substance use</td>
</tr>
<tr>
<td>37</td>
<td>Use of Vaping device</td>
</tr>
<tr>
<td>38</td>
<td>use of e-cigarette</td>
</tr>
<tr>
<td>39</td>
<td>Glycogen storage disease</td>
</tr>
<tr>
<td>40</td>
<td>Glycogenosis</td>
</tr>
<tr>
<td>41</td>
<td>GSD - [Glycogen storage disease]</td>
</tr>
<tr>
<td>42</td>
<td>glycogen thesaurismosis</td>
</tr>
<tr>
<td>43</td>
<td>diffuse glycogenosis</td>
</tr>
<tr>
<td>44</td>
<td>generalised glycogen storage disease</td>
</tr>
<tr>
<td>45</td>
<td>generalised glycogenosis</td>
</tr>
<tr>
<td>46</td>
<td>generalised glycogen storage disease of infants</td>
</tr>
<tr>
<td>47</td>
<td>glycogen synthase deficiency</td>
</tr>
<tr>
<td>48</td>
<td>Glycogen storage disease due to glycogen synthase deficiency</td>
</tr>
<tr>
<td>49</td>
<td>Glycogen storage disease type 0</td>
</tr>
<tr>
<td>50</td>
<td>Glycogenosis type 0</td>
</tr>
<tr>
<td>51</td>
<td>GSD type 0</td>
</tr>
<tr>
<td>52</td>
<td>deficiency of glycogen synthetase</td>
</tr>
<tr>
<td>53</td>
<td>Glycogen storage disease due to liver glycogen synthase deficiency</td>
</tr>
<tr>
<td>54</td>
<td>GSD type 0A</td>
</tr>
<tr>
<td>55</td>
<td>Glycogen storage disease type 0A</td>
</tr>
<tr>
<td>56</td>
<td>Glycogenosis type 0A</td>
</tr>
<tr>
<td>57</td>
<td>Glycogen storage disease due to muscle or heart glycogen synthase deficiency</td>
</tr>
<tr>
<td>58</td>
<td>Glycogen storage disease type 0B</td>
</tr>
<tr>
<td>59</td>
<td>Glycogenosis type 0B</td>
</tr>
<tr>
<td>60</td>
<td>GSD type 0B</td>
</tr>
<tr>
<td>61</td>
<td>Cardiomyopathy-exercise intolerance due to muscle and heart glycogen deficiency</td>
</tr>
<tr>
<td>62</td>
<td>Glycogen storage disease due to glucose-6-phosphate system deficiency</td>
</tr>
<tr>
<td>63</td>
<td>Glycogen storage disease type 1</td>
</tr>
<tr>
<td>64</td>
<td>Glycogenosis type 1</td>
</tr>
<tr>
<td>65</td>
<td>GSD type 1</td>
</tr>
<tr>
<td>66</td>
<td>Hepatorenal glycogenosis</td>
</tr>
<tr>
<td>67</td>
<td>Von Gierke disease</td>
</tr>
<tr>
<td>68</td>
<td>HERS - [hepatorenal glycogen storage disease]</td>
</tr>
<tr>
<td>69</td>
<td>glycogen storage disease of liver and kidney</td>
</tr>
<tr>
<td>70</td>
<td>hepatorenal glycogen storage disease</td>
</tr>
<tr>
<td>71</td>
<td>Glycogen storage disease due to glucose-6-phosphatase deficiency</td>
</tr>
<tr>
<td>72</td>
<td>Glycogen storage disease type 1A</td>
</tr>
<tr>
<td>73</td>
<td>Glycogenosis type 1A</td>
</tr>
<tr>
<td>74</td>
<td>GSD type 1A</td>
</tr>
<tr>
<td>75</td>
<td>g6pd - [glucose-6-phosphate dehydrogenase deficiency]</td>
</tr>
<tr>
<td>76</td>
<td>glucose-6-phosphatase deficiency</td>
</tr>
<tr>
<td>77</td>
<td>deficiency of g-6pd</td>
</tr>
<tr>
<td>78</td>
<td>Glycogen storage disease due to glucose-6-phosphate transport defect</td>
</tr>
<tr>
<td>79</td>
<td>Glycogen storage disease type 1B</td>
</tr>
<tr>
<td>80</td>
<td>Glycogenosis type 1B</td>
</tr>
<tr>
<td>81</td>
<td>GSD1B</td>
</tr>
<tr>
<td>82</td>
<td>Glycogen storage disease type non-1A</td>
</tr>
<tr>
<td>83</td>
<td>Glycogenosis type non-1A</td>
</tr>
<tr>
<td>84</td>
<td>Glycogen storage disease due to glucose-6-phosphate translocase deficiency</td>
</tr>
<tr>
<td>85</td>
<td>Glucose-6-phosphate dehydrogenase deficiency</td>
</tr>
<tr>
<td>86</td>
<td>Glycogen storage disease due to acid maltase deficiency</td>
</tr>
<tr>
<td>87</td>
<td>Glycogen storage disease type 2</td>
</tr>
<tr>
<td>88</td>
<td>Glycogenosis type 2</td>
</tr>
<tr>
<td>89</td>
<td>GSD type 2</td>
</tr>
<tr>
<td>90</td>
<td>Acid maltase deficiency</td>
</tr>
<tr>
<td>91</td>
<td>Pompe disease</td>
</tr>
<tr>
<td>92</td>
<td>Acid alpha-1,4-glucosidase deficiency</td>
</tr>
<tr>
<td>93</td>
<td>alpha-glucosidase deficiency</td>
</tr>
<tr>
<td>94</td>
<td>deficiency of amyloglucosidase</td>
</tr>
<tr>
<td>95</td>
<td>Glycogen storage disease due to acid maltase deficiency, infantile onset</td>
</tr>
<tr>
<td>96</td>
<td>Glycogen storage disease type 2, infantile onset</td>
</tr>
<tr>
<td>97</td>
<td>Glycogenosis type 2, infantile onset</td>
</tr>
<tr>
<td>98</td>
<td>GSD2, infantile onset</td>
</tr>
<tr>
<td>99</td>
<td>Glycogen storage disease due to acid alpha-1,4-glucosidase deficiency, infantile onset</td>
</tr>
<tr>
<td>100</td>
<td>Infantile Pompe disease</td>
</tr>
<tr>
<td>101</td>
<td>lysosomal alpha-1,4-glucosidase deficiency (disorder)</td>
</tr>
<tr>
<td>102</td>
<td>Glycogen storage disease due to acid maltase deficiency, juvenile onset</td>
</tr>
<tr>
<td>103</td>
<td>Glycogen storage disease due to acid maltase deficiency, adult onset</td>
</tr>
<tr>
<td>104</td>
<td>Deficiency of exo-1,4-alpha-glucosidase</td>
</tr>
<tr>
<td>105</td>
<td>Deficiency of glucan 1,4-alpha-glucosidase</td>
</tr>
<tr>
<td>106</td>
<td>Deficiency of gamma-amylase</td>
</tr>
<tr>
<td>107</td>
<td>Deficiency of glucoamylase</td>
</tr>
<tr>
<td>108</td>
<td>Deficiency of glucoinvertase</td>
</tr>
<tr>
<td>109</td>
<td>Deficiency of glucosidosucrase</td>
</tr>
<tr>
<td>110</td>
<td>Deficiency of maltase</td>
</tr>
<tr>
<td>111</td>
<td>Glycogen storage disease due to LAMP-2 deficiency</td>
</tr>
<tr>
<td>112</td>
<td>Glycogen storage disease type 2B</td>
</tr>
<tr>
<td>113</td>
<td>Glycogenosis type 2B</td>
</tr>
<tr>
<td>114</td>
<td>GSD type 2B</td>
</tr>
<tr>
<td>115</td>
<td>Lysosomal glycogen storage disease with normal acid maltase activity</td>
</tr>
<tr>
<td>116</td>
<td>Danon disease</td>
</tr>
<tr>
<td>117</td>
<td>Glycogen storage disease due to glycogen debranching enzyme deficiency</td>
</tr>
<tr>
<td>118</td>
<td>Glycogen storage disease type 3</td>
</tr>
<tr>
<td>119</td>
<td>Glycogenosis type 3</td>
</tr>
<tr>
<td>120</td>
<td>GSD type 3</td>
</tr>
<tr>
<td>121</td>
<td>Amylo-1,6-glucosidase deficiency</td>
</tr>
<tr>
<td>122</td>
<td>Glycogen debranching deficiency</td>
</tr>
<tr>
<td>123</td>
<td>Cori-Forbes disease</td>
</tr>
<tr>
<td>124</td>
<td>Cori disease</td>
</tr>
<tr>
<td>125</td>
<td>Forbes disease</td>
</tr>
<tr>
<td>126</td>
<td>Forbes glycogen storage disease</td>
</tr>
<tr>
<td>127</td>
<td>debrancher deficiency glycogen storage disease</td>
</tr>
<tr>
<td>128</td>
<td>debrancher enzyme deficiency</td>
</tr>
<tr>
<td>129</td>
<td>deficiency of 6-alpha-d-glucosidase</td>
</tr>
<tr>
<td>130</td>
<td>amylo-1,6-glucosidase deficiency disorder</td>
</tr>
<tr>
<td>131</td>
<td>Glycogen storage disease due to muscle glycogen phosphorylase deficiency</td>
</tr>
<tr>
<td>132</td>
<td>Glycogen storage disease type 5</td>
</tr>
<tr>
<td>133</td>
<td>Glycogenosis type 5</td>
</tr>
<tr>
<td>134</td>
<td>GSD type 5</td>
</tr>
<tr>
<td>135</td>
<td>Myophosphorylase deficiency</td>
</tr>
<tr>
<td>136</td>
<td>McArdle disease</td>
</tr>
<tr>
<td>137</td>
<td>myophosphorylase deficiency glycogenosis</td>
</tr>
<tr>
<td>138</td>
<td>Glycogen storage disease due to liver glycogen phosphorylase deficiency</td>
</tr>
<tr>
<td>139</td>
<td>Glycogenosis due to liver phosphorylase deficiency</td>
</tr>
<tr>
<td>140</td>
<td>Glycogen storage disease type 6</td>
</tr>
<tr>
<td>141</td>
<td>Glycogenosis type 6</td>
</tr>
<tr>
<td>142</td>
<td>GSD type 6</td>
</tr>
<tr>
<td>143</td>
<td>Glycogen storage disease type 6B</td>
</tr>
<tr>
<td>144</td>
<td>Glycogenosis type 6B</td>
</tr>
<tr>
<td>145</td>
<td>GSD type 6B</td>
</tr>
<tr>
<td>146</td>
<td>Hers disease</td>
</tr>
<tr>
<td>147</td>
<td>deficiency of hepatophosphorylase</td>
</tr>
<tr>
<td>148</td>
<td>Glycogen storage disease due to muscle phosphofructokinase deficiency</td>
</tr>
<tr>
<td>149</td>
<td>Glycogen storage disease type 7</td>
</tr>
<tr>
<td>150</td>
<td>Glycogenosis type 7</td>
</tr>
<tr>
<td>151</td>
<td>GSD type 7</td>
</tr>
<tr>
<td>152</td>
<td>Muscle phosphofructokinase deficiency</td>
</tr>
<tr>
<td>153</td>
<td>Tarui disease</td>
</tr>
<tr>
<td>154</td>
<td>anaemia due to phosphofructo-aldolase deficiency</td>
</tr>
<tr>
<td>155</td>
<td>Glycogen storage disease due to glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>156</td>
<td>Glycogenosis due to phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>157</td>
<td>GSD due to phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>158</td>
<td>Glycogen storage disease due to liver glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>159</td>
<td>Hepatic phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>160</td>
<td>Glycogen storage disease type 8</td>
</tr>
<tr>
<td>161</td>
<td>Glycogenosis type 8</td>
</tr>
<tr>
<td>162</td>
<td>GSD8 - [glycogen storage disease type 8]</td>
</tr>
<tr>
<td>163</td>
<td>Glycogen storage disease type 6A</td>
</tr>
<tr>
<td>164</td>
<td>Glycogen storage disease type 9A</td>
</tr>
<tr>
<td>165</td>
<td>Glycogen storage disease type 9C</td>
</tr>
<tr>
<td>166</td>
<td>Glycogenosis type 6A</td>
</tr>
<tr>
<td>167</td>
<td>Glycogenosis type 9A</td>
</tr>
<tr>
<td>168</td>
<td>Glycogenosis type 9C</td>
</tr>
<tr>
<td>169</td>
<td>GSD type 9C - [glycogen storage disease type 9C]</td>
</tr>
<tr>
<td>170</td>
<td>GSD6A - [glycogen storage disease type 6A]</td>
</tr>
<tr>
<td>171</td>
<td>GSD9A - [glycogen storage disease type 9A]</td>
</tr>
<tr>
<td>172</td>
<td>Glycogen storage disease due to liver or muscle glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>173</td>
<td>Glycogen storage disease type 9B</td>
</tr>
<tr>
<td>174</td>
<td>Glycogenosis type 9B</td>
</tr>
<tr>
<td>175</td>
<td>GSD type 9B</td>
</tr>
<tr>
<td>176</td>
<td>Glycogen storage disease type 9</td>
</tr>
<tr>
<td>177</td>
<td>Glycogenosis type 9</td>
</tr>
<tr>
<td>178</td>
<td>GSD9 - [glycogen storage disease type 9]</td>
</tr>
<tr>
<td>179</td>
<td>Glycogen storage disease due to heart glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>180</td>
<td>Glycogen storage disease of heart</td>
</tr>
<tr>
<td>181</td>
<td>Cardiac glycogenosis</td>
</tr>
<tr>
<td>182</td>
<td>Glycogen storage disease type 9F</td>
</tr>
<tr>
<td>183</td>
<td>Glycogenosis type 9F</td>
</tr>
<tr>
<td>184</td>
<td>GSD9F</td>
</tr>
<tr>
<td>185</td>
<td>glycogen heart disease</td>
</tr>
<tr>
<td>186</td>
<td>glycogenic myocardial infiltration</td>
</tr>
<tr>
<td>187</td>
<td>glycogenic myocardium infiltration</td>
</tr>
<tr>
<td>188</td>
<td>cardiomegalia glycogenica diffusa</td>
</tr>
<tr>
<td>189</td>
<td>Glycogen storage disease due to muscle glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>190</td>
<td>GSD9D - [glycogen storage disease type IXD]</td>
</tr>
<tr>
<td>191</td>
<td>Glycogen storage disease type 9D</td>
</tr>
<tr>
<td>192</td>
<td>Glycogen storage disease type 9E</td>
</tr>
<tr>
<td>193</td>
<td>Glycogenosis type 9D</td>
</tr>
<tr>
<td>194</td>
<td>Glycogenosis type 9E</td>
</tr>
<tr>
<td>195</td>
<td>GSD9E</td>
</tr>
<tr>
<td>196</td>
<td>muscle glycogen phosphorylase deficiency</td>
</tr>
<tr>
<td>197</td>
<td>glycogenosis type IXE</td>
</tr>
<tr>
<td>198</td>
<td>Glycogen storage disease due to muscle phosphoglycerate mutase deficiency</td>
</tr>
<tr>
<td>199</td>
<td>Glycogen storage disease type 10</td>
</tr>
<tr>
<td>200</td>
<td>Glycogenosis type 10</td>
</tr>
<tr>
<td>201</td>
<td>GSD type 10</td>
</tr>
<tr>
<td>202</td>
<td>Di Mauro disease</td>
</tr>
<tr>
<td>203</td>
<td>Glycogen storage disease due to GLUT2 deficiency</td>
</tr>
<tr>
<td>204</td>
<td>Glycogen storage disease type 11</td>
</tr>
<tr>
<td>205</td>
<td>Glycogenosis type 11</td>
</tr>
<tr>
<td>206</td>
<td>GSD type 11</td>
</tr>
<tr>
<td>207</td>
<td>Fanconi-Bickel glycogenosis</td>
</tr>
<tr>
<td>208</td>
<td>Bickel-Fanconi disease</td>
</tr>
<tr>
<td>209</td>
<td>Facilitated glucose transporter protein type 2 deficiency</td>
</tr>
<tr>
<td>210</td>
<td>Fanconi-Bickel syndrome</td>
</tr>
<tr>
<td>211</td>
<td>Glycogen storage disease due to aldolase A deficiency</td>
</tr>
<tr>
<td>212</td>
<td>Glycogen storage disease type 12</td>
</tr>
<tr>
<td>213</td>
<td>Glycogenosis type 12</td>
</tr>
<tr>
<td>214</td>
<td>GSD type 12</td>
</tr>
<tr>
<td>215</td>
<td>Glycogen storage disease due to muscle beta-enolase deficiency</td>
</tr>
<tr>
<td>216</td>
<td>Glycogen storage disease type 13</td>
</tr>
<tr>
<td>217</td>
<td>Glycogenosis type 13</td>
</tr>
<tr>
<td>218</td>
<td>GSD type 13</td>
</tr>
<tr>
<td>219</td>
<td>Glycogen storage disease due to phosphoglucomutase deficiency</td>
</tr>
<tr>
<td>220</td>
<td>Glycogen storage disease type 14</td>
</tr>
<tr>
<td>221</td>
<td>Glycogenosis type 14</td>
</tr>
<tr>
<td>222</td>
<td>GSD type 14</td>
</tr>
<tr>
<td>223</td>
<td>Glycogen storage disease due to glycogenin deficiency</td>
</tr>
<tr>
<td>224</td>
<td>Glycogen storage disease type 15</td>
</tr>
<tr>
<td>225</td>
<td>GSD type 15</td>
</tr>
<tr>
<td>226</td>
<td>Glocogenosis type 15</td>
</tr>
<tr>
<td>227</td>
<td>Glycogen storage disease due to phosphoglycerate kinase 1 deficiency</td>
</tr>
<tr>
<td>228</td>
<td>Glycogenosis due to phosphoglycerate kinase 1 deficiency</td>
</tr>
<tr>
<td>229</td>
<td>GSD due to phosphoglycerate kinase 1 deficiency</td>
</tr>
<tr>
<td>230</td>
<td>Glycogen storage disease due to lactate dehydrogenase deficiency</td>
</tr>
<tr>
<td>231</td>
<td>Glycogenosis due to lactate dehydrogenase deficiency</td>
</tr>
<tr>
<td>232</td>
<td>GSD due to lactate dehydrogenase deficiency</td>
</tr>
<tr>
<td>233</td>
<td>Glycogen storage disease due to muscle pyruvate kinase deficiency</td>
</tr>
<tr>
<td>234</td>
<td>Glycogenosis due to muscle pyruvate kinase deficiency</td>
</tr>
<tr>
<td>235</td>
<td>GSD due to muscle pyruvate kinase deficiency</td>
</tr>
<tr>
<td>236</td>
<td>Glycogen storage liver disease</td>
</tr>
<tr>
<td>237</td>
<td>hepatomegalia glycogenica diffusa</td>
</tr>
<tr>
<td>238</td>
<td>liver glycogen disease</td>
</tr>
<tr>
<td>239</td>
<td>liver phosphorylase deficiency</td>
</tr>
<tr>
<td>240</td>
<td>Glycogen storage disease due to branching-transferase deficiency</td>
</tr>
<tr>
<td>241</td>
<td>Andersen disease</td>
</tr>
<tr>
<td>242</td>
<td>brancher deficiency glycogen storage disease</td>
</tr>
<tr>
<td>243</td>
<td>branching enzyme deficiency</td>
</tr>
<tr>
<td>244</td>
<td>branching-transferase deficiency glycogenosis</td>
</tr>
<tr>
<td>245</td>
<td>deficiency of 1,4-alpha-glucan branching enzyme</td>
</tr>
<tr>
<td>246</td>
<td>deficiency of amylo-(1,4,6)-transglycosylase</td>
</tr>
<tr>
<td>247</td>
<td>Glycogen storage disease type 4</td>
</tr>
<tr>
<td>248</td>
<td>Glycogenosis type 4</td>
</tr>
<tr>
<td>249</td>
<td>GSD- [Glycogen storage disease] type 4</td>
</tr>
<tr>
<td>250</td>
<td>Dilated cardiomyopathy due to glycogen branching enzyme deficiency</td>
</tr>
<tr>
<td>251</td>
<td>Amylopectinosis</td>
</tr>
<tr>
<td>252</td>
<td>dilated cardiomyopathy due to Andersen's disease</td>
</tr>
<tr>
<td>253</td>
<td>dilated cardiomyopathy due to glycogen storage disease type 4 (GSD4)</td>
</tr>
<tr>
<td>254</td>
<td>Other specified sickle cell disorders or other haemoglobinopathies</td>
</tr>
<tr>
<td>255</td>
<td>Other haemoglobinopathies</td>
</tr>
<tr>
<td>256</td>
<td>Abnormal haemoglobin NOS</td>
</tr>
<tr>
<td>257</td>
<td>haemoglobin dysfunction</td>
</tr>
<tr>
<td>258</td>
<td>Acquired haemoglobin H in myelodysplastic disorders</td>
</tr>
<tr>
<td>259</td>
<td>Compound HbC or beta thalassaemia heterozygotes</td>
</tr>
<tr>
<td>260</td>
<td>Haemoglobin C trait</td>
</tr>
<tr>
<td>261</td>
<td>haemoglobin C heterozygosity</td>
</tr>
<tr>
<td>262</td>
<td>heterozygous Hb C carriers</td>
</tr>
<tr>
<td>263</td>
<td>Haemoglobin E trait</td>
</tr>
<tr>
<td>264</td>
<td>haemoglobin E heterozygosity</td>
</tr>
<tr>
<td>265</td>
<td>heterozygous Hb E carriers</td>
</tr>
<tr>
<td>266</td>
<td>Compound HbE beta thalassaemia heterozygotes</td>
</tr>
<tr>
<td>267</td>
<td>Stransky-Regala type haemolytic anaemia</td>
</tr>
<tr>
<td>268</td>
<td>Unstable haemoglobin haemolytic disease</td>
</tr>
<tr>
<td>269</td>
<td>unstable haemoglobin disease</td>
</tr>
<tr>
<td>270</td>
<td>Haemoglobin C A disorder</td>
</tr>
<tr>
<td>271</td>
<td>Vaping related disorder</td>
</tr>
<tr>
<td>272</td>
<td>dabbing related lung damage</td>
</tr>
<tr>
<td>273</td>
<td>dabbing related disorder</td>
</tr>
<tr>
<td>274</td>
<td>electronic cigarette related lung damage</td>
</tr>
<tr>
<td>275</td>
<td>electronic cigarette related lung injury</td>
</tr>
<tr>
<td>276</td>
<td>dabbing related lung injury</td>
</tr>
<tr>
<td>277</td>
<td>e-cigarette - [electronic] cigarette related disorder</td>
</tr>
<tr>
<td>278</td>
<td>EVALI - [e-cigarette, or vaping, product use associated lung injury]</td>
</tr>
<tr>
<td>279</td>
<td>Chronic hepatitis E</td>
</tr>
<tr>
<td>280</td>
<td>hepatitis E NOS</td>
</tr>
<tr>
<td>281</td>
<td>Disorders of multiple glycosylation or other pathways</td>
</tr>
<tr>
<td>282</td>
<td>Dolichol-phosphate-mannose synthase 1 deficiency</td>
</tr>
<tr>
<td>283</td>
<td>GDP-Man: Dol-P-mannosyltransferase deficiency</td>
</tr>
<tr>
<td>284</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1E</td>
</tr>
<tr>
<td>285</td>
<td>Congenital disorder of glycosylation type 1E</td>
</tr>
<tr>
<td>286</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1E</td>
</tr>
<tr>
<td>287</td>
<td>Mannose-P-dolichol utilisation defect 1</td>
</tr>
<tr>
<td>288</td>
<td>Lec35 deficiency</td>
</tr>
<tr>
<td>289</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1F</td>
</tr>
<tr>
<td>290</td>
<td>Congenital disorder of glycosylation type 1F</td>
</tr>
<tr>
<td>291</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1F</td>
</tr>
<tr>
<td>292</td>
<td>Beta-1,4-galactosyltransferase deficiency</td>
</tr>
<tr>
<td>293</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2D</td>
</tr>
<tr>
<td>294</td>
<td>Congenital disorder of glycosylation type 2D</td>
</tr>
<tr>
<td>295</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2D</td>
</tr>
<tr>
<td>296</td>
<td>CMP-sialic acid transporter deficiency</td>
</tr>
<tr>
<td>297</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2F</td>
</tr>
<tr>
<td>298</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2F</td>
</tr>
<tr>
<td>299</td>
<td>Congenital disorder of glycosylation type 2F</td>
</tr>
<tr>
<td>300</td>
<td>Leukocyte adhesion deficiency type 2</td>
</tr>
<tr>
<td>301</td>
<td>Rambam-Hasharon syndrome</td>
</tr>
<tr>
<td>302</td>
<td>GDP-fucose transporter deficiency</td>
</tr>
<tr>
<td>303</td>
<td>LAD-II - [Leukocyte adhesion deficiency type 2]</td>
</tr>
<tr>
<td>304</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2C</td>
</tr>
<tr>
<td>305</td>
<td>Dolichol kinase deficiency</td>
</tr>
<tr>
<td>306</td>
<td>Hypotonia or ichthyosis due to dolichol phosphate deficiency</td>
</tr>
<tr>
<td>307</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1M</td>
</tr>
<tr>
<td>308</td>
<td>Congenital disorder of glycosylation type 1M</td>
</tr>
<tr>
<td>309</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1M</td>
</tr>
<tr>
<td>310</td>
<td>Conserved oligomeric Golgi complex deficiencies</td>
</tr>
<tr>
<td>311</td>
<td>Component of conserved oligomeric Golgi complex 1 deficiency</td>
</tr>
<tr>
<td>312</td>
<td>CDG syndrome type 2G</td>
</tr>
<tr>
<td>313</td>
<td>Component of conserved oligomeric Golgi complex 4 deficiency</td>
</tr>
<tr>
<td>314</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2J</td>
</tr>
<tr>
<td>315</td>
<td>Congenital disorder of glycosylation type 2J</td>
</tr>
<tr>
<td>316</td>
<td>Component of conserved oligomeric Golgi complex 5 deficiency</td>
</tr>
<tr>
<td>317</td>
<td>Component of conserved oligomeric Golgi complex 7 deficiency</td>
</tr>
<tr>
<td>318</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2E</td>
</tr>
<tr>
<td>319</td>
<td>Congenital disorder of glycosylation type 2E</td>
</tr>
<tr>
<td>320</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2E</td>
</tr>
<tr>
<td>321</td>
<td>Component of conserved oligomeric Golgi complex 8 deficiency</td>
</tr>
<tr>
<td>322</td>
<td>Congenital disorder of glycosylation type 2h</td>
</tr>
<tr>
<td>323</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2H</td>
</tr>
<tr>
<td>324</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2H</td>
</tr>
<tr>
<td>325</td>
<td>V-ATPase deficiencies</td>
</tr>
<tr>
<td>326</td>
<td>Acute hepatitis E</td>
</tr>
<tr>
<td>327</td>
<td>hepatitis virus type E</td>
</tr>
<tr>
<td>328</td>
<td>Hyperimmunoglobulin E syndromes</td>
</tr>
<tr>
<td>329</td>
<td>recurring cold staphylococcal abscesses</td>
</tr>
<tr>
<td>330</td>
<td>IgE syndromes</td>
</tr>
<tr>
<td>331</td>
<td>Buckley syndrome</td>
</tr>
<tr>
<td>332</td>
<td>Job syndrome</td>
</tr>
<tr>
<td>333</td>
<td>HIE - [Hyperimmunoglobulin E] syndrome</td>
</tr>
<tr>
<td>334</td>
<td>Job-Buckley syndrome</td>
</tr>
<tr>
<td>335</td>
<td>Quie-Hill syndrome</td>
</tr>
<tr>
<td>336</td>
<td>Autosomal dominant hyperimmunoglobulin E syndrome</td>
</tr>
<tr>
<td>337</td>
<td>Autosomal dominant hyper-IgE syndrome</td>
</tr>
<tr>
<td>338</td>
<td>Hyperimmunoglobulin E-recurrent infection syndrome</td>
</tr>
<tr>
<td>339</td>
<td>Hyperimmunoglobulin E syndrome type 1</td>
</tr>
<tr>
<td>340</td>
<td>AD-HIES - [Autosomal dominant hyperimmunoglobulin E] syndrome</td>
</tr>
<tr>
<td>341</td>
<td>Autosomal recessive hyperimmunoglobulin E syndrome</td>
</tr>
<tr>
<td>342</td>
<td>Hyperimmunoglobulin E syndrome type 2</td>
</tr>
<tr>
<td>343</td>
<td>Nonskeletal hyper IgE syndrome</td>
</tr>
<tr>
<td>344</td>
<td>Autosomal recessive hyper-IgE syndrome</td>
</tr>
<tr>
<td>345</td>
<td>Autosomal recessive HIES - [Autosomal recessive hyperimmunoglobulin E] syndrome</td>
</tr>
<tr>
<td>346</td>
<td>SCID - [Severe combined immunodeficiency] due to dedicator of cytokinesis 8 protein deficiency</td>
</tr>
<tr>
<td>347</td>
<td>SCID - [Severe combined immunodeficiency] due to DOCK8 deficiency</td>
</tr>
<tr>
<td>348</td>
<td>Hyperimmunoglobulin E syndrome due to TYK2 deficiency</td>
</tr>
<tr>
<td>349</td>
<td>Syndromes with lissencephaly as a major feature</td>
</tr>
<tr>
<td>350</td>
<td>Pachygyria</td>
</tr>
<tr>
<td>351</td>
<td>Agyria</td>
</tr>
<tr>
<td>352</td>
<td>Classic lissencephaly</td>
</tr>
<tr>
<td>353</td>
<td>Lissencephaly type 1</td>
</tr>
<tr>
<td>354</td>
<td>Lissencephaly type 1 due to doublecortin gene mutation</td>
</tr>
<tr>
<td>355</td>
<td>Subcortical band heterotopia</td>
</tr>
<tr>
<td>356</td>
<td>Miller-Dieker syndrome</td>
</tr>
<tr>
<td>357</td>
<td>Lissencephaly due to 17p13.3 deletion</td>
</tr>
<tr>
<td>358</td>
<td>17p13.3 microdeletion syndrome</td>
</tr>
<tr>
<td>359</td>
<td>Telomeric deletion 17p</td>
</tr>
<tr>
<td>360</td>
<td>Monosomy 17p13.3</td>
</tr>
<tr>
<td>361</td>
<td>17p13.3 deletion</td>
</tr>
<tr>
<td>362</td>
<td>Lissencephaly type 1 due to LIS1 gene mutation</td>
</tr>
<tr>
<td>363</td>
<td>Isolated lissencephaly type 1 without known genetic defects</td>
</tr>
<tr>
<td>364</td>
<td>Lissencephaly type 2</td>
</tr>
<tr>
<td>365</td>
<td>Lissencephaly type 3</td>
</tr>
<tr>
<td>366</td>
<td>Neu-Laxova syndrome</td>
</tr>
<tr>
<td>367</td>
<td>Lissencephaly type 3 - familial fetal akinesia sequence</td>
</tr>
<tr>
<td>368</td>
<td>Lissencephaly type 3 - metacarpal bone dysplasia</td>
</tr>
<tr>
<td>369</td>
<td>Lissencephaly with cerebellar hypoplasia</td>
</tr>
<tr>
<td>370</td>
<td>Lissencephaly with cerebellar hypoplasia type A</td>
</tr>
<tr>
<td>371</td>
<td>Lissencephaly with cerebellar hypoplasia type B</td>
</tr>
<tr>
<td>372</td>
<td>Lissencephaly with cerebellar hypoplasia type C</td>
</tr>
<tr>
<td>373</td>
<td>Lissencephaly with cerebellar hypoplasia type D</td>
</tr>
<tr>
<td>374</td>
<td>Lissencephaly with cerebellar hypoplasia type E</td>
</tr>
<tr>
<td>375</td>
<td>Lissencephaly with cerebellar hypoplasia type F</td>
</tr>
<tr>
<td>376</td>
<td>Microlissencephaly</td>
</tr>
<tr>
<td>377</td>
<td>Microlissencephaly type A</td>
</tr>
<tr>
<td>378</td>
<td>Lissencephaly syndrome, Norman-Roberts type</td>
</tr>
<tr>
<td>379</td>
<td>Microlissencephaly type B</td>
</tr>
<tr>
<td>380</td>
<td>Lissencephaly due to TUBA1A gene mutation</td>
</tr>
<tr>
<td>381</td>
<td>X-linked lissencephaly - agenesis of corpus callosum - genital anomalies</td>
</tr>
<tr>
<td>382</td>
<td>Craniotelencephalic dysplasia</td>
</tr>
<tr>
<td>383</td>
<td>Micro syndrome</td>
</tr>
<tr>
<td>384</td>
<td>Warburg Micro syndrome</td>
</tr>
<tr>
<td>385</td>
<td>WARBM1 - [Warburg Micro syndrome]</td>
</tr>
<tr>
<td>386</td>
<td>Iris coloboma with ptosis - intellectual deficit</td>
</tr>
<tr>
<td>387</td>
<td>Complex brachydactylies</td>
</tr>
<tr>
<td>388</td>
<td>Brachydactyly type A1</td>
</tr>
<tr>
<td>389</td>
<td>Brachydactyly type A2</td>
</tr>
<tr>
<td>390</td>
<td>Brachydactyly type A3</td>
</tr>
<tr>
<td>391</td>
<td>Brachydactyly type A4</td>
</tr>
<tr>
<td>392</td>
<td>Brachydactyly type A5</td>
</tr>
<tr>
<td>393</td>
<td>Brachydactyly type A6</td>
</tr>
<tr>
<td>394</td>
<td>Brachydactyly type A7</td>
</tr>
<tr>
<td>395</td>
<td>Brachydactyly type B</td>
</tr>
<tr>
<td>396</td>
<td>Brachydactyly type B2</td>
</tr>
<tr>
<td>397</td>
<td>Brachydactyly type C</td>
</tr>
<tr>
<td>398</td>
<td>Brachydactyly type D</td>
</tr>
<tr>
<td>399</td>
<td>Brachydactyly type E</td>
</tr>
<tr>
<td>400</td>
<td>Ballard syndrome</td>
</tr>
<tr>
<td>401</td>
<td>Brachydactyly types B and E combined</td>
</tr>
<tr>
<td>402</td>
<td>Pitt-Williams brachydactyly</td>
</tr>
<tr>
<td>403</td>
<td>Brachydactyly-elbow wrist dysplasia</td>
</tr>
<tr>
<td>404</td>
<td>Dementia due to other specified diseases classified elsewhere</td>
</tr>
<tr>
<td>405</td>
<td>Dementia due to certain specified central nervous system degenerative diseases</td>
</tr>
<tr>
<td>406</td>
<td>Dementia due to corticobasal degeneration</td>
</tr>
<tr>
<td>407</td>
<td>Dementia due to progressive supranuclear palsy</td>
</tr>
<tr>
<td>408</td>
<td>Dementia due to neurofilament inclusion body disease</td>
</tr>
<tr>
<td>409</td>
<td>Dementia due to progressive subcortical gliosis</td>
</tr>
<tr>
<td>410</td>
<td>Dementia due to multiple system atrophy</td>
</tr>
<tr>
<td>411</td>
<td>Dementia due to spinocerebellar ataxia</td>
</tr>
<tr>
<td>412</td>
<td>Dementia due to neurodegeneration with brain iron accumulation</td>
</tr>
<tr>
<td>413</td>
<td>Dementia due to leukodystrophy</td>
</tr>
<tr>
<td>414</td>
<td>Dementia due to Parkinsonism-dementia complex of Guam</td>
</tr>
<tr>
<td>415</td>
<td>Dementia due to certain specified infectious diseases</td>
</tr>
<tr>
<td>416</td>
<td>Dementia due to neurosyphilis</td>
</tr>
<tr>
<td>417</td>
<td>syphilitic dementia paralytica</td>
</tr>
<tr>
<td>418</td>
<td>Dementia due to herpes encephalitis</td>
</tr>
<tr>
<td>419</td>
<td>Dementia due to trypanosomiasis</td>
</tr>
<tr>
<td>420</td>
<td>Dementia due to neurocysticercosis</td>
</tr>
<tr>
<td>421</td>
<td>Dementia due to Lyme disease</td>
</tr>
<tr>
<td>422</td>
<td>Dementia due to Whipple disease</td>
</tr>
<tr>
<td>423</td>
<td>Dementia due to progressive multifocal leukoencephalopathy</td>
</tr>
<tr>
<td>424</td>
<td>Certain specified primary degenerative dementias</td>
</tr>
<tr>
<td>425</td>
<td>Neurofibrillary tangle dementia</td>
</tr>
<tr>
<td>426</td>
<td>Familial multiple system tauopathy</td>
</tr>
<tr>
<td>427</td>
<td>Argyrophilic grain disease</td>
</tr>
<tr>
<td>428</td>
<td>Dementia due to certain specified disorders of the central nervous system</td>
</tr>
<tr>
<td>429</td>
<td>Dementia due to acute demyelinating encephalomyelitis</td>
</tr>
<tr>
<td>430</td>
<td>Dementia due to subacute sclerosing panencephalitis</td>
</tr>
<tr>
<td>431</td>
<td>Dementia due to Hashimoto encephalopathy</td>
</tr>
<tr>
<td>432</td>
<td>Dementia due to paraneoplastic encephalitis</td>
</tr>
<tr>
<td>433</td>
<td>Dementia due to autoimmune encephalitis</td>
</tr>
<tr>
<td>434</td>
<td>Dementia due to primary central nervous system neoplasm</td>
</tr>
<tr>
<td>435</td>
<td>Dementia due to metastatic brain tumour</td>
</tr>
<tr>
<td>436</td>
<td>Dementia due to epilepsy</td>
</tr>
<tr>
<td>437</td>
<td>Dementia due to metabolic disorders involving the brain</td>
</tr>
<tr>
<td>438</td>
<td>Dementia due to chronic subdural haematoma</td>
</tr>
<tr>
<td>439</td>
<td>Dementia due to obstructive hydrocephalus</td>
</tr>
<tr>
<td>440</td>
<td>Dementia due to nutritional deficiency</td>
</tr>
<tr>
<td>441</td>
<td>Dementia due to vitamin B12 deficiency</td>
</tr>
<tr>
<td>442</td>
<td>Dementia due to vitamin E deficiency</td>
</tr>
<tr>
<td>443</td>
<td>Dementia due to iron deficiency</td>
</tr>
<tr>
<td>444</td>
<td>Dementia due to other nutritional deficiency</td>
</tr>
<tr>
<td>445</td>
<td>Dementia due to metabolic abnormalities</td>
</tr>
<tr>
<td>446</td>
<td>Dementia due to hypercalcaemia</td>
</tr>
<tr>
<td>447</td>
<td>Dementia due to acquired hypothyroidism</td>
</tr>
<tr>
<td>448</td>
<td>Dementia due to Wilson disease</td>
</tr>
<tr>
<td>449</td>
<td>Dementia due to dialysis</td>
</tr>
<tr>
<td>450</td>
<td>Dementia due to hepatic failure</td>
</tr>
<tr>
<td>451</td>
<td>Dementia due to renal failure</td>
</tr>
<tr>
<td>452</td>
<td>Dementia due to chromosomal anomalies</td>
</tr>
<tr>
<td>453</td>
<td>Dementia due to Fragile X Syndrome</td>
</tr>
<tr>
<td>454</td>
<td>Dementia due to rheumatological diseases</td>
</tr>
<tr>
<td>455</td>
<td>Dementia due to polyarteritis nodosa</td>
</tr>
<tr>
<td>456</td>
<td>Dementia due to systemic lupus erythematosus</td>
</tr>
<tr>
<td>457</td>
<td>Dementia due to Behcet disease</td>
</tr>
<tr>
<td>458</td>
<td>Dementia due to certain specified cause</td>
</tr>
<tr>
<td>459</td>
<td>Acquired vitamin E deficiency anaemia</td>
</tr>
<tr>
<td>460</td>
<td>Haemolytic anaemia due to vitamin E deficiency</td>
</tr>
<tr>
<td>461</td>
<td>Urinary tract infection, site not specified, due to Escherichia coli</td>
</tr>
<tr>
<td>462</td>
<td>E coli UTI</td>
</tr>
<tr>
<td>463</td>
<td>E coli urinary tract infection</td>
</tr>
<tr>
<td>464</td>
<td>Escherichia coli UTI</td>
</tr>
<tr>
<td>465</td>
<td>Disorders of methionine cycle or sulphur amino acid metabolism</td>
</tr>
<tr>
<td>466</td>
<td>disorder of sulphur-bearing amino acid including those due to folate and b12 disturbance</td>
</tr>
<tr>
<td>467</td>
<td>disorder of sulphur-bearing amino acid metabolism</td>
</tr>
<tr>
<td>468</td>
<td>disorder of transsulfuration</td>
</tr>
<tr>
<td>469</td>
<td>disorder of transsulphuration</td>
</tr>
<tr>
<td>470</td>
<td>disturbances of sulphur-bearing amino-acid metabolism</td>
</tr>
<tr>
<td>471</td>
<td>sulphuraminoacidaemia</td>
</tr>
<tr>
<td>472</td>
<td>Disorders of sulphur-bearing amino-acid metabolism</td>
</tr>
<tr>
<td>473</td>
<td>Brain demyelination due to methionine adenosyltransferase deficiency</td>
</tr>
<tr>
<td>474</td>
<td>Methionine adenosyltransferase I/III deficiency</td>
</tr>
<tr>
<td>475</td>
<td>Isolated persistent hypermethioninaemia</td>
</tr>
<tr>
<td>476</td>
<td>MAT I/III - [Methionine adenosyltransferase I/III] deficiency</td>
</tr>
<tr>
<td>477</td>
<td>Glycine N-methyltransferase deficiency</td>
</tr>
<tr>
<td>478</td>
<td>GNMT - [Glycine N-methyltransferase] deficiency</td>
</tr>
<tr>
<td>479</td>
<td>Psychomotor retardation and myopathy due to S-adenosylhomocysteine hydrolase deficiency</td>
</tr>
<tr>
<td>480</td>
<td>Hypermethioninaemia due to S-adenosylhomocysteine hydrolase deficiency</td>
</tr>
<tr>
<td>481</td>
<td>Cystathioninuria</td>
</tr>
<tr>
<td>482</td>
<td>Gamma-cystathionase deficiency</td>
</tr>
<tr>
<td>483</td>
<td>Cystathione gamma-lyase deficiency</td>
</tr>
<tr>
<td>484</td>
<td>CTH - [cystathioninuria]</td>
</tr>
<tr>
<td>485</td>
<td>cystathionine metabolic disorder</td>
</tr>
<tr>
<td>486</td>
<td>Classical homocystinuria</td>
</tr>
<tr>
<td>487</td>
<td>Homocystinuria due to cystathionine beta-synthase deficiency</td>
</tr>
<tr>
<td>488</td>
<td>Cystathionine beta-synthase deficiency</td>
</tr>
<tr>
<td>489</td>
<td>CBS - [Cystathionine beta-synthase] deficiency</td>
</tr>
<tr>
<td>490</td>
<td>cystathionine synthase deficiency</td>
</tr>
<tr>
<td>491</td>
<td>homocystine metabolic disorder</td>
</tr>
<tr>
<td>492</td>
<td>Homocystinuria without methylmalonic aciduria</td>
</tr>
<tr>
<td>493</td>
<td>5-methyltetrahydrofolate-homocysteine s-methyltransferase deficiency</td>
</tr>
<tr>
<td>494</td>
<td>Methionine synthase deficiency</td>
</tr>
<tr>
<td>495</td>
<td>Methylcobalamin deficiency</td>
</tr>
<tr>
<td>496</td>
<td>N5-methylhomocysteine transferase deficiency</td>
</tr>
<tr>
<td>497</td>
<td>Methylcobalamin deficiency type cbl E</td>
</tr>
<tr>
<td>498</td>
<td>Homocystinuria due to defect in methylation type cbl E</td>
</tr>
<tr>
<td>499</td>
<td>Homocystinuria - megaloblastic anaemia due to defect in cobalamin metabolism, cbI E complementation type</td>
</tr>
<tr>
<td>500</td>
<td>Methylcobalamin deficiency type cbl G</td>
</tr>
<tr>
<td>501</td>
<td>Homocystinuria due to methionine synthase deficiency type Cbl G</td>
</tr>
<tr>
<td>502</td>
<td>Homocystinuria - megaloblastic anaemia due to defect in cobalamin metabolism, cbI G complementation type</td>
</tr>
<tr>
<td>503</td>
<td>Methylcobalamin deficiency type cbl Dv1</td>
</tr>
<tr>
<td>504</td>
<td>Encephalopathy due to sulfite oxidase deficiency</td>
</tr>
<tr>
<td>505</td>
<td>Isolated sulfite oxidase deficiency</td>
</tr>
<tr>
<td>506</td>
<td>ISOD - [Isolated sulfite oxidase deficiency]</td>
</tr>
<tr>
<td>507</td>
<td>Sulfite oxidase deficiency due to molybdenum cofactor deficiency</td>
</tr>
<tr>
<td>508</td>
<td>Combined deficiency of sulfite oxidase, xanthine dehydrogenase and aldehyde oxidase</td>
</tr>
<tr>
<td>509</td>
<td>Molybdenum cofactor deficiency, complementation group A</td>
</tr>
<tr>
<td>510</td>
<td>Molybdenum cofactor deficiency due to defects in MOCS1 gene</td>
</tr>
<tr>
<td>511</td>
<td>Molybdenum cofactor deficiency, complementation group B</td>
</tr>
<tr>
<td>512</td>
<td>Molybdenum cofactor deficiency due to defects in MOCS2 gene</td>
</tr>
<tr>
<td>513</td>
<td>Molybdenum cofactor deficiency, complementation group C</td>
</tr>
<tr>
<td>514</td>
<td>Hypermethioninaemia due to adenosine kinase deficiency</td>
</tr>
<tr>
<td>515</td>
<td>Other genetic defects of methionine cycle or sulfur amino acid metabolism</td>
</tr>
<tr>
<td>516</td>
<td>Secondary non-genetic disorders of methionine cycle or sulfur amino acid metabolism</td>
</tr>
<tr>
<td>517</td>
<td>Beery-baby syndrome</td>
</tr>
<tr>
<td>518</td>
<td>Cystathioninemia</td>
</tr>
<tr>
<td>519</td>
<td>Deficiency of cystathionase</td>
</tr>
<tr>
<td>520</td>
<td>Deficiency of cysteine desulfhydrase</td>
</tr>
<tr>
<td>521</td>
<td>deficiency of cysteine desulphydrase</td>
</tr>
<tr>
<td>522</td>
<td>deficiency of cystine desulfhydrase</td>
</tr>
<tr>
<td>523</td>
<td>deficiency of cystine desulphydrase</td>
</tr>
<tr>
<td>524</td>
<td>Deficiency of homoserine deaminase</td>
</tr>
<tr>
<td>525</td>
<td>Deficiency of methionine adenosyltransferase</td>
</tr>
<tr>
<td>526</td>
<td>Familial methionine malabsorption</td>
</tr>
<tr>
<td>527</td>
<td>Hepatic methionine adenosyltransferase deficiency</td>
</tr>
<tr>
<td>528</td>
<td>Homocystinaemia</td>
</tr>
<tr>
<td>529</td>
<td>Hypermethioninaemia</td>
</tr>
<tr>
<td>530</td>
<td>methionine metabolic disorder</td>
</tr>
<tr>
<td>531</td>
<td>Methionine malabsorption syndrome</td>
</tr>
<tr>
<td>532</td>
<td>oast-house disease</td>
</tr>
<tr>
<td>533</td>
<td>oast-house urine disease</td>
</tr>
<tr>
<td>534</td>
<td>oasthouse disease</td>
</tr>
<tr>
<td>535</td>
<td>oasthouse urine disease</td>
</tr>
<tr>
<td>536</td>
<td>Smith-Strang disease</td>
</tr>
<tr>
<td>537</td>
<td>Sulfite oxidase deficiency</td>
</tr>
<tr>
<td>538</td>
<td>sulfite oxidase deficiency syndrome</td>
</tr>
<tr>
<td>539</td>
<td>sulphite oxidase deficiency</td>
</tr>
<tr>
<td>540</td>
<td>sulfocysteinuria</td>
</tr>
<tr>
<td>541</td>
<td>sulphocysteinuria</td>
</tr>
<tr>
<td>542</td>
<td>Friedreich ataxia</td>
</tr>
<tr>
<td>543</td>
<td>Friedreich-like ataxia with selective vitamin E deficiency</td>
</tr>
<tr>
<td>544</td>
<td>Familial isolated vitamin E deficiency</td>
</tr>
<tr>
<td>545</td>
<td>AVED - [isolated vitamin E deficiency]</td>
</tr>
<tr>
<td>546</td>
<td>Xeroderma pigmentosum</td>
</tr>
<tr>
<td>547</td>
<td>XP - [xeroderma pigmentosum]</td>
</tr>
<tr>
<td>548</td>
<td>atrophoderma pigmentosum</td>
</tr>
<tr>
<td>549</td>
<td>Xeroderma pigmentosum A</td>
</tr>
<tr>
<td>550</td>
<td>XPA - [xeroderma pigmentosum A]</td>
</tr>
<tr>
<td>551</td>
<td>Xeroderma pigmentosum B</td>
</tr>
<tr>
<td>552</td>
<td>XPB - [xeroderma pigmentosum B]</td>
</tr>
<tr>
<td>553</td>
<td>Xeroderma pigmentosum C</td>
</tr>
<tr>
<td>554</td>
<td>XPC - [xeroderma pigmentosum C]</td>
</tr>
<tr>
<td>555</td>
<td>Xeroderma pigmentosum D</td>
</tr>
<tr>
<td>556</td>
<td>XPD - [xeroderma pigmentosum D]</td>
</tr>
<tr>
<td>557</td>
<td>Xeroderma pigmentosum E</td>
</tr>
<tr>
<td>558</td>
<td>XPE - [xeroderma pigmentosum E]</td>
</tr>
<tr>
<td>559</td>
<td>Xeroderma pigmentosum F</td>
</tr>
<tr>
<td>560</td>
<td>XPF - [xeroderma pigmentosum F]</td>
</tr>
<tr>
<td>561</td>
<td>Xeroderma pigmentosum G</td>
</tr>
<tr>
<td>562</td>
<td>XPG - [xeroderma pigmentosum G]</td>
</tr>
<tr>
<td>563</td>
<td>Beta thalassaemia</td>
</tr>
<tr>
<td>564</td>
<td>Mediterranean anaemia</td>
</tr>
<tr>
<td>565</td>
<td>beta thalassaemia syndrome</td>
</tr>
<tr>
<td>566</td>
<td>Mediterranean disease</td>
</tr>
<tr>
<td>567</td>
<td>beta thalassaemia disease</td>
</tr>
<tr>
<td>568</td>
<td>Beta thalassaemia minor</td>
</tr>
<tr>
<td>569</td>
<td>Heterozygous beta-thalassaemia</td>
</tr>
<tr>
<td>570</td>
<td>Beta thalassaemia carrier</td>
</tr>
<tr>
<td>571</td>
<td>Beta thalassaemia trait</td>
</tr>
<tr>
<td>572</td>
<td>Beta thalassaemia intermedia</td>
</tr>
<tr>
<td>573</td>
<td>Dominant beta thalassaemia</td>
</tr>
<tr>
<td>574</td>
<td>Beta thalassaemia major</td>
</tr>
<tr>
<td>575</td>
<td>Cooley anaemia</td>
</tr>
<tr>
<td>576</td>
<td>familial erythroblastic anaemia</td>
</tr>
<tr>
<td>577</td>
<td>Compound heterozygotes for beta zero or beta+ or delta-beta-thal genes</td>
</tr>
<tr>
<td>578</td>
<td>Homozygous beta thalassaemia</td>
</tr>
<tr>
<td>579</td>
<td>erythroblastic anaemia of childhood</td>
</tr>
<tr>
<td>580</td>
<td>Haemoglobin E beta thalassaemia</td>
</tr>
<tr>
<td>581</td>
<td>Hb E/beta thalassaemia</td>
</tr>
<tr>
<td>582</td>
<td>Beta-thalassemia-X-linked thrombocytopenia syndrome</td>
</tr>
<tr>
<td>583</td>
<td>Other specified ectodermal dysplasia syndromes</td>
</tr>
<tr>
<td>584</td>
<td>Absence of fingerprints-congenital milia syndrome</td>
</tr>
<tr>
<td>585</td>
<td>Ackerman syndrome</td>
</tr>
<tr>
<td>586</td>
<td>ADULT syndrome</td>
</tr>
<tr>
<td>587</td>
<td>Acro-dermato-ungual-lacrimal-tooth syndrome</td>
</tr>
<tr>
<td>588</td>
<td>Pigment anomaly - ectrodactyly - hypodontia</td>
</tr>
<tr>
<td>589</td>
<td>Propping Zerres syndrome</td>
</tr>
<tr>
<td>590</td>
<td>Amelo-cerebro-hypohidrotic syndrome</td>
</tr>
<tr>
<td>591</td>
<td>Epilepsy - dementia - amelogenesis imperfecta</td>
</tr>
<tr>
<td>592</td>
<td>Kohlschütter-Tönz syndrome</td>
</tr>
<tr>
<td>593</td>
<td>Ankyloblepharon - ectodermal defects - cleft lip or palate</td>
</tr>
<tr>
<td>594</td>
<td>AREDYLD syndrome</td>
</tr>
<tr>
<td>595</td>
<td>Acrorenal defect - ectodermal dysplasia - diabetes</td>
</tr>
<tr>
<td>596</td>
<td>Beare-Stevenson cutis gyrata syndrome</td>
</tr>
<tr>
<td>597</td>
<td>Blepharocheilodontic syndrome</td>
</tr>
<tr>
<td>598</td>
<td>Book syndrome</td>
</tr>
<tr>
<td>599</td>
<td>Cardio-facio-cutaneous syndrome</td>
</tr>
<tr>
<td>600</td>
<td>Cerebellar ataxia - ectodermal dysplasia</td>
</tr>
<tr>
<td>601</td>
<td>Curly hair – ankyloblepharon – nail dysplasia syndrome</td>
</tr>
<tr>
<td>602</td>
<td>Baughman syndrome</td>
</tr>
<tr>
<td>603</td>
<td>CHANDS - [Curly hair - ankyloblepharon - nail dysplasia syndrome]</td>
</tr>
<tr>
<td>604</td>
<td>Choroidal atrophy - alopecia</td>
</tr>
<tr>
<td>605</td>
<td>Coffin-Siris syndrome</td>
</tr>
<tr>
<td>606</td>
<td>Conductive deafness - ptosis - skeletal anomalies</td>
</tr>
<tr>
<td>607</td>
<td>Contractures - ectodermal dysplasia - cleft lip or palate</td>
</tr>
<tr>
<td>608</td>
<td>Cote-Katsantoni syndrome</td>
</tr>
<tr>
<td>609</td>
<td>Cranioectodermal dysplasia</td>
</tr>
<tr>
<td>610</td>
<td>Sensenbrenner syndrome</td>
</tr>
<tr>
<td>611</td>
<td>Dahlberg-Borer-Newcomer syndrome</td>
</tr>
<tr>
<td>612</td>
<td>Lymphoedema - hypoparathyroidism</td>
</tr>
<tr>
<td>613</td>
<td>Dermatoosteolysis, Kirghizian type</td>
</tr>
<tr>
<td>614</td>
<td>Dubowitz syndrome</td>
</tr>
<tr>
<td>615</td>
<td>Ectodermal dysplasia - absent dermatoglyphs</td>
</tr>
<tr>
<td>616</td>
<td>Ectodermal dysplasia - acanthosis nigricans</td>
</tr>
<tr>
<td>617</td>
<td>Lelis syndrome</td>
</tr>
<tr>
<td>618</td>
<td>Ectodermal dysplasia - arthrogryposis - diabetes mellitus</td>
</tr>
<tr>
<td>619</td>
<td>Ectodermal dysplasia - blindness</td>
</tr>
<tr>
<td>620</td>
<td>Ectodermal dysplasia - cutaneous syndactyly syndrome</td>
</tr>
<tr>
<td>621</td>
<td>Ectodermal dysplasia - ectrodactyly - macular dystrophy</td>
</tr>
<tr>
<td>622</td>
<td>EEM - [Ectodermal dysplasia - ectrodactyly - macular dystrophy] syndrome</td>
</tr>
<tr>
<td>623</td>
<td>Ectodermal dysplasia - intellectual deficit - central nervous system malformation</td>
</tr>
<tr>
<td>624</td>
<td>Ectodermal dysplasia - sensorineural deafness</td>
</tr>
<tr>
<td>625</td>
<td>Ectodermal dysplasia - syndactyly syndrome</td>
</tr>
<tr>
<td>626</td>
<td>Ectodermal dysplasia with natal teeth, Turnpenny type</td>
</tr>
<tr>
<td>627</td>
<td>Ectodermal dysplasia, pure hair-nail type</td>
</tr>
<tr>
<td>628</td>
<td>Ectodermal dysplasia, Berlin type</td>
</tr>
<tr>
<td>629</td>
<td>Ectrodactyly - ectodermal dysplasia - cleft lip or palate</td>
</tr>
<tr>
<td>630</td>
<td>EEC - [Ectrodactyly - ectodermal dysplasia - cleft lip or palate] syndrome</td>
</tr>
<tr>
<td>631</td>
<td>Ectrodactyly - ectodermal dysplasia without clefting</td>
</tr>
<tr>
<td>632</td>
<td>Facial ectodermal dysplasia</td>
</tr>
<tr>
<td>633</td>
<td>Focal facial dermal dysplasia</td>
</tr>
<tr>
<td>634</td>
<td>GAPO syndrome</td>
</tr>
<tr>
<td>635</td>
<td>Growth delay - alopecia - pseudoanodontia - optic atrophy</td>
</tr>
<tr>
<td>636</td>
<td>Gingival fibromatosis - hypertrichosis</td>
</tr>
<tr>
<td>637</td>
<td>Gingival fibromatosis-hypertrichosis syndrome</td>
</tr>
<tr>
<td>638</td>
<td>Gorlin-Chaudhry-Moss syndrome</td>
</tr>
<tr>
<td>639</td>
<td>Hidrotic ectodermal dysplasia, Christianson-Fourie type</td>
</tr>
<tr>
<td>640</td>
<td>Hidrotic ectodermal dysplasia, Halal type</td>
</tr>
<tr>
<td>641</td>
<td>Hypertrichosis cubiti - short stature</td>
</tr>
<tr>
<td>642</td>
<td>Hypoparathyroidism - deafness - renal disease</td>
</tr>
<tr>
<td>643</td>
<td>Barakat syndrome</td>
</tr>
<tr>
<td>644</td>
<td>HDR - [Hypoparathyroidism - deafness - renal disease] syndrome</td>
</tr>
<tr>
<td>645</td>
<td>Ichthyosis - alopecia - eclabion - ectropion - intellectual deficit</td>
</tr>
<tr>
<td>646</td>
<td>Johanson-Blizzard syndrome</td>
</tr>
<tr>
<td>647</td>
<td>Johnson neuroectodermal syndrome</td>
</tr>
<tr>
<td>648</td>
<td>Juvenile macular degeneration - hypotrichosis</td>
</tr>
<tr>
<td>649</td>
<td>Lacrimo-auriculo-dento-digital syndrome</td>
</tr>
<tr>
<td>650</td>
<td>Limb-mammary syndrome</td>
</tr>
<tr>
<td>651</td>
<td>Marshall syndrome</td>
</tr>
<tr>
<td>652</td>
<td>Naegeli-Franceschetti-Jadassohn syndrome</td>
</tr>
<tr>
<td>653</td>
<td>Oculo-dento-digital dysplasia</td>
</tr>
<tr>
<td>654</td>
<td>Oculo-osteo-cutaneous syndrome</td>
</tr>
<tr>
<td>655</td>
<td>Odonto-tricho-ungual-digito-palmar syndrome</td>
</tr>
<tr>
<td>656</td>
<td>Odontotrichomelic syndrome</td>
</tr>
<tr>
<td>657</td>
<td>OL-EDA-ID syndrome</td>
</tr>
<tr>
<td>658</td>
<td>Anhidrotic ectodermal dysplasia - immunodeficiency - osteopetrosis - lymphoedema</td>
</tr>
<tr>
<td>659</td>
<td>OLEDAID - [Anhidrotic ectodermal dysplasia - immunodeficiency - osteopetrosis - lymphoedema] syndrome</td>
</tr>
<tr>
<td>660</td>
<td>Anhidrotic ectodermal dysplasia - immunodeficiency - osteopetrosis - lymphoedema</td>
</tr>
<tr>
<td>661</td>
<td>Oligodontia - cancer predisposition syndrome</td>
</tr>
<tr>
<td>662</td>
<td>Autosomal dominant ectodermal dysplasia-neoplastic syndrome</td>
</tr>
<tr>
<td>663</td>
<td>Pilodental dysplasia - refractive errors</td>
</tr>
<tr>
<td>664</td>
<td>Rapp-Hodgkin syndrome</td>
</tr>
<tr>
<td>665</td>
<td>Scalp-ear-nipple syndrome</td>
</tr>
<tr>
<td>666</td>
<td>Schinzel-Giedion syndrome</td>
</tr>
<tr>
<td>667</td>
<td>Sparse hair - short stature - skin anomalies</td>
</tr>
<tr>
<td>668</td>
<td>Stern-Lubinsky-Durrie syndrome</td>
</tr>
<tr>
<td>669</td>
<td>Taurodontia - absent teeth - sparse hair</td>
</tr>
<tr>
<td>670</td>
<td>Toriello-Lacassie-Droste syndrome</td>
</tr>
<tr>
<td>671</td>
<td>Tricho-dento-osseous syndrome</td>
</tr>
<tr>
<td>672</td>
<td>Tricho-oculo-dermo-vertebral syndrome</td>
</tr>
<tr>
<td>673</td>
<td>Tricho-odonto-onychial dysplasia with bone deficiency in fronto-parietal region</td>
</tr>
<tr>
<td>674</td>
<td>Tricho-odonto-onychial ectodermal dysplasia</td>
</tr>
<tr>
<td>675</td>
<td>Tricho-retino-dento-digital syndrome</td>
</tr>
<tr>
<td>676</td>
<td>Trichodental syndrome</td>
</tr>
<tr>
<td>677</td>
<td>Trichodermodysplasia - dental alterations</td>
</tr>
<tr>
<td>678</td>
<td>Trichodysplasia - amelogenesis imperfecta</td>
</tr>
<tr>
<td>679</td>
<td>Trichomegaly - cataract - hereditary spherocytosis</td>
</tr>
<tr>
<td>680</td>
<td>Trichomegaly - retina pigmentary degeneration - dwarfism</td>
</tr>
<tr>
<td>681</td>
<td>Xeroderma - talipes - enamel defects</td>
</tr>
<tr>
<td>682</td>
<td>Zlotogora-Ogur syndrome</td>
</tr>
<tr>
<td>683</td>
<td>Margarita island ectodermal dysplasia</td>
</tr>
<tr>
<td>684</td>
<td>Rosselli-Gulienetti syndrome</td>
</tr>
<tr>
<td>685</td>
<td>Zlotogora-Martinez syndrome</td>
</tr>
<tr>
<td>686</td>
<td>Zunich-Kaye syndrome</td>
</tr>
<tr>
<td>687</td>
<td>Dermo-odontodysplasia</td>
</tr>
<tr>
<td>688</td>
<td>Dermoodontodysplasia</td>
</tr>
<tr>
<td>689</td>
<td>Oculotrichodysplasia</td>
</tr>
<tr>
<td>690</td>
<td>Cartilage-hair hypoplasia</td>
</tr>
<tr>
<td>691</td>
<td>Trichorhinophalangeal syndrome type 1 and 3</td>
</tr>
<tr>
<td>692</td>
<td>Chondroectodermal dysplasia</td>
</tr>
<tr>
<td>693</td>
<td>Ellis-van Creveld syndrome</td>
</tr>
<tr>
<td>694</td>
<td>Mesodermic dysplasia</td>
</tr>
<tr>
<td>695</td>
<td>EVC - [Ellis-van Creveld] syndrome</td>
</tr>
<tr>
<td>696</td>
<td>Odonto-onycho-dermal dysplasia</td>
</tr>
<tr>
<td>697</td>
<td>OODD (MIM 257980)</td>
</tr>
<tr>
<td>698</td>
<td>Woolly hair – hypotrichosis – everted lower lip – outstanding ears</td>
</tr>
<tr>
<td>699</td>
<td>Salamon syndrome</td>
</tr>
<tr>
<td>700</td>
<td>Autosomal dominant palmoplantar keratoderma and congenital alopecia</td>
</tr>
<tr>
<td>701</td>
<td>Stevanovic syndrome</td>
</tr>
<tr>
<td>702</td>
<td>BIDS syndrome</td>
</tr>
<tr>
<td>703</td>
<td>Amish brittle hair syndrome</td>
</tr>
<tr>
<td>704</td>
<td>Trichothiodystrophy type D</td>
</tr>
<tr>
<td>705</td>
<td>IBIDS syndrome</td>
</tr>
<tr>
<td>706</td>
<td>Tay syndrome</td>
</tr>
<tr>
<td>707</td>
<td>Trichothiodystrophy type E</td>
</tr>
<tr>
<td>708</td>
<td>Trichothiodystrophy with congenital ichthyosis</td>
</tr>
<tr>
<td>709</td>
<td>Sabinas brittle hair syndrome</td>
</tr>
<tr>
<td>710</td>
<td>Brittle hair - mental deficiency</td>
</tr>
<tr>
<td>711</td>
<td>Trichothiodystrophy type B</td>
</tr>
<tr>
<td>712</td>
<td>Onycho-tricho-dysplasia – neutropaenia syndrome</td>
</tr>
<tr>
<td>713</td>
<td>Trichothiodystrophy type G</td>
</tr>
<tr>
<td>714</td>
<td>ONMR (MIM 258360)</td>
</tr>
<tr>
<td>715</td>
<td>Itin syndrome</td>
</tr>
<tr>
<td>716</td>
<td>ONMR syndrome</td>
</tr>
<tr>
<td>717</td>
<td>Autosomal recessive palmoplantar keratoderma and congenital alopecia</td>
</tr>
<tr>
<td>718</td>
<td>Wallis syndrome</td>
</tr>
<tr>
<td>719</td>
<td>Alopecia - contractures - dwarfism - intellectual deficit</td>
</tr>
<tr>
<td>720</td>
<td>Cataract - alopecia - sclerodactyly</td>
</tr>
<tr>
<td>721</td>
<td>Odonto-onycho dysplasia - alopecia</td>
</tr>
<tr>
<td>722</td>
<td>Schöpf-Schulz-Passarge syndrome</td>
</tr>
<tr>
<td>723</td>
<td>Hypertrichosis lanuginosa congenita</td>
</tr>
<tr>
<td>724</td>
<td>Hypertrichosis universalis congenita</td>
</tr>
<tr>
<td>725</td>
<td>Congenital generalised hypertrichosis</td>
</tr>
<tr>
<td>726</td>
<td>Ambras syndrome</td>
</tr>
<tr>
<td>727</td>
<td>X-linked dominant congenital generalised hypertrichosis</td>
</tr>
<tr>
<td>728</td>
<td>Macias-Flores syndrome</td>
</tr>
<tr>
<td>729</td>
<td>Deafness – enamel hypoplasia – nail defects</td>
</tr>
<tr>
<td>730</td>
<td>Heimler syndrome</td>
</tr>
<tr>
<td>731</td>
<td>Sensorineural hearing loss with enamel hypoplasia and nail defects</td>
</tr>
<tr>
<td>732</td>
<td>Anonychia with bizarre flexural pigmentation</td>
</tr>
<tr>
<td>733</td>
<td>Anonychia with flexural pigmentation (MIM 106750)</td>
</tr>
<tr>
<td>734</td>
<td>Anonychia or onychodystrophy – hypoplasia or absence of distal phalanges</td>
</tr>
<tr>
<td>735</td>
<td>Cooks syndrome</td>
</tr>
<tr>
<td>736</td>
<td>Autosomal dominant hypodontia with nail dysplasia</td>
</tr>
<tr>
<td>737</td>
<td>Witkop syndrome (MIM 189500)</td>
</tr>
<tr>
<td>738</td>
<td>Tooth and nail syndrome</td>
</tr>
<tr>
<td>739</td>
<td>Amelo-onycho-hypohidrotic syndrome</td>
</tr>
<tr>
<td>740</td>
<td>Deafness – onychodystrophy</td>
</tr>
<tr>
<td>741</td>
<td>Deafness – onychodystrophy – osteodystrophy – intellectual deficit</td>
</tr>
<tr>
<td>742</td>
<td>Deafness – onychodystrophy, autosomal dominant</td>
</tr>
<tr>
<td>743</td>
<td>DOOR syndrome, autosomal dominant</td>
</tr>
<tr>
<td>744</td>
<td>Dominant deafness-onychodystrophy</td>
</tr>
<tr>
<td>745</td>
<td>DDOD syndrome (MIM 124480)</td>
</tr>
<tr>
<td>746</td>
<td>Deafness – onychodystrophy, autosomal recessive</td>
</tr>
<tr>
<td>747</td>
<td>DOOR syndrome, autosomal recessive</td>
</tr>
<tr>
<td>748</td>
<td>DOOR syndrome (MIM 220500)</td>
</tr>
<tr>
<td>749</td>
<td>Odonto-onycho-hypohidrotic dysplasia - midline scalp defects</td>
</tr>
<tr>
<td>750</td>
<td>Tricho-odonto-onycho-dermal syndrome</td>
</tr>
<tr>
<td>751</td>
<td>Tricho-odonto-onychodysplasia - dominant syndactyly</td>
</tr>
<tr>
<td>752</td>
<td>Pili torti - onychodysplasia</td>
</tr>
<tr>
<td>753</td>
<td>Focal dermal hypoplasia</td>
</tr>
<tr>
<td>754</td>
<td>Goltz syndrome</td>
</tr>
<tr>
<td>755</td>
<td>Goltz-Gorlin syndrome</td>
</tr>
<tr>
<td>756</td>
<td>Familial isolated trichomegaly</td>
</tr>
<tr>
<td>757</td>
<td>Familial isolated trichomegaly of the eyelashes</td>
</tr>
<tr>
<td>758</td>
<td>Pneumonia due to Escherichia coli</td>
</tr>
<tr>
<td>759</td>
<td>pneumonia due to E. coli</td>
</tr>
<tr>
<td>760</td>
<td>Escherichia coli lobar pneumonia</td>
</tr>
<tr>
<td>761</td>
<td>Early-onset pneumonia due to Escherichia coli</td>
</tr>
<tr>
<td>762</td>
<td>Late-onset pneumonia due to Escherichia coli</td>
</tr>
<tr>
<td>763</td>
<td>Charcot-Marie-Tooth disease 2 axonal</td>
</tr>
<tr>
<td>764</td>
<td>Charcot-Marie-Tooth disease 2 autosomal dominant</td>
</tr>
<tr>
<td>765</td>
<td>Recessive axonal Charcot-Marie-Tooth disease with acrodystrophy</td>
</tr>
<tr>
<td>766</td>
<td>Charcot-Marie-Tooth disease type 2A1</td>
</tr>
<tr>
<td>767</td>
<td>Charcot-Marie-Tooth disease type 2A2</td>
</tr>
<tr>
<td>768</td>
<td>Charcot-Marie-Tooth disease type 2B</td>
</tr>
<tr>
<td>769</td>
<td>Charcot-Marie-Tooth disease type 2C</td>
</tr>
<tr>
<td>770</td>
<td>Charcot-Marie-Tooth disease type 2D</td>
</tr>
<tr>
<td>771</td>
<td>Charcot-Marie-Tooth disease type 2E</td>
</tr>
<tr>
<td>772</td>
<td>Charcot-Marie-Tooth disease type 2F</td>
</tr>
<tr>
<td>773</td>
<td>Charcot-Marie-Tooth disease type 2G</td>
</tr>
<tr>
<td>774</td>
<td>Charcot-Marie-Tooth disease type 2I</td>
</tr>
<tr>
<td>775</td>
<td>Charcot-Marie-Tooth disease type 2J</td>
</tr>
<tr>
<td>776</td>
<td>Charcot-Marie-Tooth disease type 2K</td>
</tr>
<tr>
<td>777</td>
<td>Charcot-Marie-Tooth disease type 2L</td>
</tr>
<tr>
<td>778</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2M</td>
</tr>
<tr>
<td>779</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2N</td>
</tr>
<tr>
<td>780</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2O</td>
</tr>
<tr>
<td>781</td>
<td>Charcot-Marie-Tooth disease 2 autosomal recessive</td>
</tr>
<tr>
<td>782</td>
<td>Charcot-Marie-Tooth disease type 2B1</td>
</tr>
<tr>
<td>783</td>
<td>Charcot-Marie-Tooth disease type 2B2</td>
</tr>
<tr>
<td>784</td>
<td>Charcot-Marie-Tooth disease type 2B5</td>
</tr>
<tr>
<td>785</td>
<td>Charcot-Marie-Tooth disease type 2H</td>
</tr>
<tr>
<td>786</td>
<td>Autosomal recessive Charcot-Marie-Tooth disease with hoarseness</td>
</tr>
<tr>
<td>787</td>
<td>Hereditary motor and sensory neuropathy type 6</td>
</tr>
<tr>
<td>788</td>
<td>Charcot-Marie-Tooth type 6</td>
</tr>
<tr>
<td>789</td>
<td>HMSN6 - [Hereditary motor and sensory neuropathy type 6]</td>
</tr>
<tr>
<td>790</td>
<td>CMT6 - [Charcot-Marie-Tooth type 6]</td>
</tr>
<tr>
<td>791</td>
<td>Charcot-Marie-Tooth disease 1 demyelinating</td>
</tr>
<tr>
<td>792</td>
<td>Charcot-Marie-Tooth disease 1 autosomal dominant</td>
</tr>
<tr>
<td>793</td>
<td>Charcot-Marie-Tooth disease type 1E</td>
</tr>
<tr>
<td>794</td>
<td>Charcot-Marie-Tooth disease type 1B</td>
</tr>
<tr>
<td>795</td>
<td>Charcot-Marie-Tooth disease type 1C</td>
</tr>
<tr>
<td>796</td>
<td>Charcot-Marie-Tooth disease type 1D</td>
</tr>
<tr>
<td>797</td>
<td>Charcot-Marie-Tooth disease type 1F</td>
</tr>
<tr>
<td>798</td>
<td>Charcot-Marie-Tooth disease 1 autosomal recessive</td>
</tr>
<tr>
<td>799</td>
<td>Charcot-Marie-Tooth disease type 4</td>
</tr>
<tr>
<td>800</td>
<td>CMT4 - [Charcot-Marie-Tooth disease type 4]</td>
</tr>
<tr>
<td>801</td>
<td>Charcot-Marie-Tooth disease - deafness - intellectual deficit</td>
</tr>
<tr>
<td>802</td>
<td>Charcot-Marie-Tooth disease type 4A</td>
</tr>
<tr>
<td>803</td>
<td>Charcot-Marie-Tooth disease type 4C</td>
</tr>
<tr>
<td>804</td>
<td>Charcot-Marie-Tooth disease type 4D</td>
</tr>
<tr>
<td>805</td>
<td>Charcot-Marie-Tooth disease type 4E</td>
</tr>
<tr>
<td>806</td>
<td>Charcot-Marie-Tooth disease type 4F</td>
</tr>
<tr>
<td>807</td>
<td>Charcot-Marie-Tooth disease type 4G</td>
</tr>
<tr>
<td>808</td>
<td>Charcot-Marie-Tooth disease type 4H</td>
</tr>
<tr>
<td>809</td>
<td>Charcot-Marie-Tooth disease type 4B1</td>
</tr>
<tr>
<td>810</td>
<td>Charcot-Marie-Tooth disease type 4B2</td>
</tr>
<tr>
<td>811</td>
<td>Charcot-Marie-Tooth disease type 4J</td>
</tr>
<tr>
<td>812</td>
<td>X-linked Charcot-Marie-Tooth disease 1 due to mutations in gap junction protein beta 1</td>
</tr>
<tr>
<td>813</td>
<td>X-linked Charcot-Marie-Tooth disease 1 secondary to mutations in gap junction protein beta 1</td>
</tr>
<tr>
<td>814</td>
<td>Charcot-Marie-Tooth disease 1X, x-linked Charcot-Marie-Tooth disease 1 due to mutations in gap junction protein beta 1</td>
</tr>
<tr>
<td>815</td>
<td>Charcot-Marie-Tooth disease 1X, x-linked Charcot-Marie-Tooth disease 1 secondary to mutations in gap junction protein beta 1</td>
</tr>
<tr>
<td>816</td>
<td>Hereditary sensorimotor neuropathy with hyperelastic skin</td>
</tr>
<tr>
<td>817</td>
<td>Recessive limb-girdle muscular dystrophy</td>
</tr>
<tr>
<td>818</td>
<td>LGMD2 - [Limb-girdle muscular dystrophy] 2</td>
</tr>
<tr>
<td>819</td>
<td>Limb-girdle muscular dystrophy 2A, calpain-3 deficiency</td>
</tr>
<tr>
<td>820</td>
<td>Limb-girdle muscular dystrophy 2B, dysferlin deficiency</td>
</tr>
<tr>
<td>821</td>
<td>Limb-girdle muscular dystrophy 2C, gamma-sarcoglycan deficiency</td>
</tr>
<tr>
<td>822</td>
<td>Limb-girdle muscular dystrophy 2D, alpha-sarcoglycan deficiency</td>
</tr>
<tr>
<td>823</td>
<td>Limb-girdle muscular dystrophy 2E, beta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>824</td>
<td>Limb-girdle muscular dystrophy 2F, delta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>825</td>
<td>Limb-girdle muscular dystrophy 2G, telethonin gene mutation</td>
</tr>
<tr>
<td>826</td>
<td>Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation</td>
</tr>
<tr>
<td>827</td>
<td>LGMD 2H - [Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation]</td>
</tr>
<tr>
<td>828</td>
<td>Limb-girdle muscular dystrophy 2I, fukutin related protein gene mutation</td>
</tr>
<tr>
<td>829</td>
<td>FKRP - [fukutin related protein gene mutation]</td>
</tr>
<tr>
<td>830</td>
<td>LGMD 2I - [Limb-girdle muscular dystrophy 2I]</td>
</tr>
<tr>
<td>831</td>
<td>Limb-girdle muscular dystrophy 2J, Titin gene mutation</td>
</tr>
<tr>
<td>832</td>
<td>LGMD 2J - [Limb-girdle muscular dystrophy 2J, Titin gene mutation]</td>
</tr>
<tr>
<td>833</td>
<td>Limb-girdle muscular dystrophy 2K, protein-O-mannosyltransferase 1 transferase</td>
</tr>
<tr>
<td>834</td>
<td>POMT1 - [protein-O-mannosyltransferase 1 transferase]</td>
</tr>
<tr>
<td>835</td>
<td>LGMD 2K - [Limb-girdle muscular dystrophy 2K]</td>
</tr>
<tr>
<td>836</td>
<td>Limb-girdle muscular dystrophy 2L, AN05 gene mutation</td>
</tr>
<tr>
<td>837</td>
<td>LGMD 2L - [Limb-girdle muscular dystrophy 2L]</td>
</tr>
<tr>
<td>838</td>
<td>Limb-girdle muscular dystrophy 2M, POMGnT1 gene mutation</td>
</tr>
<tr>
<td>839</td>
<td>LGMD2M - [limb-girdle muscular dystrophy 2M]</td>
</tr>
<tr>
<td>840</td>
<td>Limb-girdle muscular dystrophy 2N, POMT2 gene mutation</td>
</tr>
<tr>
<td>841</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C2)</td>
</tr>
<tr>
<td>842</td>
<td>MDDGC2</td>
</tr>
<tr>
<td>843</td>
<td>LGMD2N - limb-girdle muscular dystrophy 2N]</td>
</tr>
<tr>
<td>844</td>
<td>Limb-girdle muscular dystrophy 2O, POMGNT1 gene mutation</td>
</tr>
<tr>
<td>845</td>
<td>LGMD2O - [limb-girdle muscular dystrophy 2O]</td>
</tr>
<tr>
<td>846</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C3)</td>
</tr>
<tr>
<td>847</td>
<td>MDDGC3</td>
</tr>
<tr>
<td>848</td>
<td>Limb-girdle muscular dystrophy 2Q, plectin deficiency</td>
</tr>
<tr>
<td>849</td>
<td>LGMD2Q - [limb-girdle muscular dystrophy 2Q]</td>
</tr>
<tr>
<td>850</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy C7</td>
</tr>
<tr>
<td>851</td>
<td>MDDGC7</td>
</tr>
<tr>
<td>852</td>
<td>Pyruvate dehydrogenase complex deficiency</td>
</tr>
<tr>
<td>853</td>
<td>Ataxia with lactic acidosis</td>
</tr>
<tr>
<td>854</td>
<td>PDC - [Pyruvate dehydrogenase complex] deficiency</td>
</tr>
<tr>
<td>855</td>
<td>pyruvate dehydrogenase deficiency</td>
</tr>
<tr>
<td>856</td>
<td>ataxia with lactic acidosis 1</td>
</tr>
<tr>
<td>857</td>
<td>ataxia with lactic acidosis 2</td>
</tr>
<tr>
<td>858</td>
<td>Pyruvate dehydrogenase complex E1-alpha subunit deficiency</td>
</tr>
<tr>
<td>859</td>
<td>Pyruvate dehydrogenase complex E1 subunit deficiency</td>
</tr>
<tr>
<td>860</td>
<td>Pyruvate decarboxylase deficiency</td>
</tr>
<tr>
<td>861</td>
<td>Pyruvate dehydrogenase complex E1-beta subunit deficiency</td>
</tr>
<tr>
<td>862</td>
<td>Pyruvate dehydrogenase complex E2 subunit deficiency</td>
</tr>
<tr>
<td>863</td>
<td>Dihydrolipoyl acetyltransferase deficiency</td>
</tr>
<tr>
<td>864</td>
<td>Dihydrolipoyl transacetylase deficiency</td>
</tr>
<tr>
<td>865</td>
<td>Dihydrolipoamide acetyltransferase deficiency</td>
</tr>
<tr>
<td>866</td>
<td>Dihydrolipolyllysine-residue acetyltransferase</td>
</tr>
<tr>
<td>867</td>
<td>Lipoate acetyltransferase deficiency</td>
</tr>
<tr>
<td>868</td>
<td>Lipoate transacetylase deficiency</td>
</tr>
<tr>
<td>869</td>
<td>Pyruvate dehydrogenase complex E3 subunit deficiency</td>
</tr>
<tr>
<td>870</td>
<td>Dihydrolipoyl dehydrogenase deficiency</td>
</tr>
<tr>
<td>871</td>
<td>Dihydrolipoamide dehydrogenase deficiency</td>
</tr>
<tr>
<td>872</td>
<td>Lipoamide dehydrogenase deficiency</td>
</tr>
<tr>
<td>873</td>
<td>Lipoamide oxidoreductase deficiency</td>
</tr>
<tr>
<td>874</td>
<td>Diaphorase deficiency</td>
</tr>
<tr>
<td>875</td>
<td>Lactic acidosis due to LAD deficiency</td>
</tr>
<tr>
<td>876</td>
<td>Pyruvate dehydrogenase complex E3-binding protein deficiency</td>
</tr>
<tr>
<td>877</td>
<td>Pyruvate dehydrogenase phosphatase deficiency</td>
</tr>
<tr>
<td>878</td>
<td>Phosphopyruvate dehydrogenase phosphatase deficiency</td>
</tr>
<tr>
<td>879</td>
<td>PDH - [Pyruvate dehydrogenase] phosphatase deficiency</td>
</tr>
<tr>
<td>880</td>
<td>Exostoses with anetodermia and brachydactyly type E</td>
</tr>
<tr>
<td>881</td>
<td>Mixed hyperlipidaemia</td>
</tr>
<tr>
<td>882</td>
<td>mixed hyperlipemia</td>
</tr>
<tr>
<td>883</td>
<td>Hyperlipidaemia, group C</td>
</tr>
<tr>
<td>884</td>
<td>familial hypercholesterolaemia with hyperlipaemia</td>
</tr>
<tr>
<td>885</td>
<td>familial hyperbetalipoproteinaemia and hyperprebetalipoproteinaemia</td>
</tr>
<tr>
<td>886</td>
<td>Hyperbetalipoproteinaemia with prebetalipoproteinaemia</td>
</tr>
<tr>
<td>887</td>
<td>Hypercholesterolaemia with endogenous hyperglyceridaemia</td>
</tr>
<tr>
<td>888</td>
<td>prebetalipoproteinemia hyperbetalipoproteinaemia</td>
</tr>
<tr>
<td>889</td>
<td>remnant hyperlipoproteinemia</td>
</tr>
<tr>
<td>890</td>
<td>Hyperlipidaemia type 3</td>
</tr>
<tr>
<td>891</td>
<td>Hyperlipoproteinaemia type 3</td>
</tr>
<tr>
<td>892</td>
<td>Broad-betalipoproteinaemia</td>
</tr>
<tr>
<td>893</td>
<td>Broad beta disease</td>
</tr>
<tr>
<td>894</td>
<td>Remnant hyperlipidaemia</td>
</tr>
<tr>
<td>895</td>
<td>Fredrickson type 3 hyperlipoproteinaemia</td>
</tr>
<tr>
<td>896</td>
<td>Familial type 3 hyperlipoproteinaemia</td>
</tr>
<tr>
<td>897</td>
<td>broad-beta lipoproteinemia</td>
</tr>
<tr>
<td>898</td>
<td>floating beta disease</td>
</tr>
<tr>
<td>899</td>
<td>Broad- or floating-betalipoproteinaemia</td>
</tr>
<tr>
<td>900</td>
<td>floating-beta lipoproteinemia</td>
</tr>
<tr>
<td>901</td>
<td>Hyperlipidaemia type 3 - Apolipoprotein E deficiency</td>
</tr>
<tr>
<td>902</td>
<td>apolipoprotein E deficiency</td>
</tr>
<tr>
<td>903</td>
<td>Hyperlipidaemia type 3 - familial defective apolipoprotein B</td>
</tr>
<tr>
<td>904</td>
<td>Hyperlipidaemia type 3 - familial dysbetalipoproteinaemia</td>
</tr>
<tr>
<td>905</td>
<td>Familial dysbetalipoproteinaemia</td>
</tr>
<tr>
<td>906</td>
<td>primary dysbetalipoproteinaemia</td>
</tr>
<tr>
<td>907</td>
<td>dysbetalipoproteinaemia</td>
</tr>
<tr>
<td>908</td>
<td>Hyperlipidaemia type 3 - familial dyslipoproteinaemia</td>
</tr>
<tr>
<td>909</td>
<td>Secondary hyperlipoproteinaemia type 3</td>
</tr>
<tr>
<td>910</td>
<td>Mixed hyperlipidaemia - type IIb hyperlipoproteinaemia</td>
</tr>
<tr>
<td>911</td>
<td>familial hyperlipoproteinemia type 2B</td>
</tr>
<tr>
<td>912</td>
<td>Fredrickson type 2B hyperlipoproteinemia</td>
</tr>
<tr>
<td>913</td>
<td>Familial combined hyperlipidaemia</td>
</tr>
<tr>
<td>914</td>
<td>FCH - [familial combined hyperlipidaemia]</td>
</tr>
<tr>
<td>915</td>
<td>hyperapobetalipoproteinaemia</td>
</tr>
<tr>
<td>916</td>
<td>Secondary combined hyperlipidaemia</td>
</tr>
<tr>
<td>917</td>
<td>Mixed hyperlipidaemia due to hepatic triglyceride lipase deficiency</td>
</tr>
<tr>
<td>918</td>
<td>Xanthoma in association with primary combined hyperlipidaemia</td>
</tr>
<tr>
<td>919</td>
<td>Xanthoma in association with secondary hyperlipidaemia</td>
</tr>
<tr>
<td>920</td>
<td>Bacteraemia</td>
</tr>
<tr>
<td>921</td>
<td>Bacteraemia NOS</td>
</tr>
<tr>
<td>922</td>
<td>Staphylococcus aureus bacteraemia</td>
</tr>
<tr>
<td>923</td>
<td>Septicaemia</td>
</tr>
<tr>
<td>924</td>
<td>group d streptococcal septicaemia (deprecated)</td>
</tr>
<tr>
<td>925</td>
<td>anaerobic septicaemia (deprecated)</td>
</tr>
<tr>
<td>926</td>
<td>Escherichia coli septicaemia (deprecated)</td>
</tr>
<tr>
<td>927</td>
<td>gangrenous septicaemia (deprecated)</td>
</tr>
<tr>
<td>928</td>
<td>gram-negative septicaemia NOS (deprecated)</td>
</tr>
<tr>
<td>929</td>
<td>pneumococcal septicaemia (deprecated)</td>
</tr>
<tr>
<td>930</td>
<td>salmonella septicaemia (deprecated)</td>
</tr>
<tr>
<td>931</td>
<td>septicaemia due to anaerobes (deprecated)</td>
</tr>
<tr>
<td>932</td>
<td>septicaemia due to coagulase-negative staphylococcus (deprecated)</td>
</tr>
<tr>
<td>933</td>
<td>septicaemia due to haemophilus influenzae [h. influenzae] (deprecated)</td>
</tr>
<tr>
<td>934</td>
<td>septicaemia due to streptococcus group A (deprecated)</td>
</tr>
<tr>
<td>935</td>
<td>septicaemia due to streptococcus group B (deprecated)</td>
</tr>
<tr>
<td>936</td>
<td>septicaemic colibacillosis (deprecated)</td>
</tr>
<tr>
<td>937</td>
<td>staphylococcal septicaemia NOS (deprecated)</td>
</tr>
<tr>
<td>938</td>
<td>staphylococcus aureus septicaemia NOS (deprecated)</td>
</tr>
<tr>
<td>939</td>
<td>streptococcal septicaemia (deprecated)</td>
</tr>
<tr>
<td>940</td>
<td>streptococcus pyogenes septicaemia (deprecated)</td>
</tr>
<tr>
<td>941</td>
<td>streptococcaemia (deprecated)</td>
</tr>
<tr>
<td>942</td>
<td>pyaemia (deprecated)</td>
</tr>
<tr>
<td>943</td>
<td>listerial septicaemia (deprecated)</td>
</tr>
<tr>
<td>944</td>
<td>Listeria monocytogenes septicaemia (deprecated)</td>
</tr>
<tr>
<td>945</td>
<td>Listeria monocytogenes septicaemia without mention of septic shock (deprecated)</td>
</tr>
<tr>
<td>946</td>
<td>actinomycotic septicaemia (deprecated)</td>
</tr>
<tr>
<td>947</td>
<td>anthrax septicaemia (deprecated)</td>
</tr>
<tr>
<td>948</td>
<td>Septicaemic plague NOS (deprecated)</td>
</tr>
<tr>
<td>949</td>
<td>septic plague (deprecated)</td>
</tr>
<tr>
<td>950</td>
<td>Septicaemic plague (deprecated)</td>
</tr>
<tr>
<td>951</td>
<td>septicaemic plague without mention of septic shock (deprecated)</td>
</tr>
<tr>
<td>952</td>
<td>E coli septicaemia (deprecated)</td>
</tr>
<tr>
<td>953</td>
<td>Pseudomonas aeruginosa septicaemia (deprecated)</td>
</tr>
<tr>
<td>954</td>
<td>Dystonia associated with heredodegenerative disorders</td>
</tr>
<tr>
<td>955</td>
<td>Dystonia due to autosomal dominant disorders</td>
</tr>
<tr>
<td>956</td>
<td>Rapid-onset dystonia-parkinsonism</td>
</tr>
<tr>
<td>957</td>
<td>Dystonia due to dentatorubropallidoluysian atrophy</td>
</tr>
<tr>
<td>958</td>
<td>Dystonia due to Huntington disease</td>
</tr>
<tr>
<td>959</td>
<td>Dystonia due to autosomal recessive disorders</td>
</tr>
<tr>
<td>960</td>
<td>Dystonia due to Wilson disease</td>
</tr>
<tr>
<td>961</td>
<td>Dystonia due to Niemann-Pick disease type C</td>
</tr>
<tr>
<td>962</td>
<td>Dystonia due to other autosomal recessive metabolic disorders</td>
</tr>
<tr>
<td>963</td>
<td>Dystonia due to GM2 gangliosidosis</td>
</tr>
<tr>
<td>964</td>
<td>Dystonia due to Metachromatic leukodystrophy</td>
</tr>
<tr>
<td>965</td>
<td>Dystonia due to homocystinuria</td>
</tr>
<tr>
<td>966</td>
<td>Dystonia due to glutaric acidaemia</td>
</tr>
<tr>
<td>967</td>
<td>Dystonia due to Hartnup disease</td>
</tr>
<tr>
<td>968</td>
<td>Dystonia due to ataxia-telangiectasia</td>
</tr>
<tr>
<td>969</td>
<td>Dystonia in neurodegeneration with brain iron accumulation type 1</td>
</tr>
<tr>
<td>970</td>
<td>NBIA 2 PLA2G6 mutation</td>
</tr>
<tr>
<td>971</td>
<td>PANK gene mutation</td>
</tr>
<tr>
<td>972</td>
<td>Dystonia due to Juvenile Parkinson Disease including Parkin mutation</td>
</tr>
<tr>
<td>973</td>
<td>Probable autosomal recessive dystonia</td>
</tr>
<tr>
<td>974</td>
<td>Progressive pallidal degeneration</td>
</tr>
<tr>
<td>975</td>
<td>Dystonia due to X-linked dominant disorders</td>
</tr>
<tr>
<td>976</td>
<td>Dystonia due to Rett syndrome</td>
</tr>
<tr>
<td>977</td>
<td>Dystonia due to X-linked recessive disorders</td>
</tr>
<tr>
<td>978</td>
<td>Deafness-dystonia optic atrophy syndrome</td>
</tr>
<tr>
<td>979</td>
<td>Mohr-Tranebjærg syndrome</td>
</tr>
<tr>
<td>980</td>
<td>Dystonia due to Pelizaeus-Merzbacher disease</td>
</tr>
<tr>
<td>981</td>
<td>Dystonia due to Lesch-Nyhan syndrome</td>
</tr>
<tr>
<td>982</td>
<td>Dystonia due to mitochondrial cytopathies</td>
</tr>
<tr>
<td>983</td>
<td>Dystonia due to Leber's disease</td>
</tr>
<tr>
<td>984</td>
<td>Dystonia due to other mitochondrial cytopathies</td>
</tr>
<tr>
<td>985</td>
<td>Dystonia of variable inheritance</td>
</tr>
<tr>
<td>986</td>
<td>Dystonia due to Familial basal ganglia calcifications</td>
</tr>
<tr>
<td>987</td>
<td>Dystonia due to certain specified inherited disorders</td>
</tr>
<tr>
<td>988</td>
<td>Dystonia associated with familial basal ganglia calcifications</td>
</tr>
<tr>
<td>989</td>
<td>Dystonia due to isolated hereditary vitamin E deficiency</td>
</tr>
<tr>
<td>990</td>
<td>Dystonia due to hereditary spastic paraplegia</td>
</tr>
<tr>
<td>991</td>
<td>Dystonia 16</td>
</tr>
<tr>
<td>992</td>
<td>Infantile dystonia-parkinsonism</td>
</tr>
<tr>
<td>993</td>
<td>Dominant limb-girdle muscular dystrophy</td>
</tr>
<tr>
<td>994</td>
<td>LGMD1 - [limb-girdle muscular dystrophy] 1</td>
</tr>
<tr>
<td>995</td>
<td>Limb-girdle muscular dystrophy 1A, myotilin myopathy</td>
</tr>
<tr>
<td>996</td>
<td>LGMD 1A - [Limb-girdle muscular dystrophy 1A, myotilin myopathy]</td>
</tr>
<tr>
<td>997</td>
<td>Limb-girdle muscular dystrophy 1B, lamin myopathy</td>
</tr>
<tr>
<td>998</td>
<td>LGMD 1B - [Limb-girdle muscular dystrophy 1B, lamin myopathy]</td>
</tr>
<tr>
<td>999</td>
<td>Limb-girdle muscular dystrophy 1C, caveolin myopathy</td>
</tr>
<tr>
<td>1000</td>
<td>LGMD 1C - [Limb-girdle muscular dystrophy 1C, caveolin myopathy]</td>
</tr>
<tr>
<td>1001</td>
<td>Limb-girdle muscular dystrophy 1D, gene mapped to 6q23</td>
</tr>
<tr>
<td>1002</td>
<td>Limb-girdle muscular dystrophy 1E, gene mapped to 7q</td>
</tr>
<tr>
<td>1003</td>
<td>Limb-girdle muscular dystrophy 1F, gene mapped to 7q32.1-32.2</td>
</tr>
<tr>
<td>1004</td>
<td>Limb-girdle muscular dystrophy 1G, gene mapped to 4q21</td>
</tr>
<tr>
<td>1005</td>
<td>Limb-girdle muscular dystrophy 1H, gene mapped to 3p25.1p23</td>
</tr>
<tr>
<td>1006</td>
<td>LGMD1H - [Limb-girdle muscular dystrophy] 1H</td>
</tr>
<tr>
<td>1007</td>
<td>Extended spectrum beta-lactamase producing Escherichia coli</td>
</tr>
<tr>
<td>1008</td>
<td>ESBL - [extended-spectrum beta-lactamase producing E.coli]</td>
</tr>
<tr>
<td>1009</td>
<td>beta-lactam resistant Escherichia Coli</td>
</tr>
<tr>
<td>1010</td>
<td>Laceration of liver, major</td>
</tr>
<tr>
<td>1011</td>
<td>Severe laceration of liver</td>
</tr>
<tr>
<td>1012</td>
<td>stellate laceration of liver</td>
</tr>
<tr>
<td>1013</td>
<td>multiple moderate lacerations of liver, with or without haematoma</td>
</tr>
<tr>
<td>1014</td>
<td>laceration of liver with significant disruption of hepatic parenchyma [i.e., greater than 10 cm long and 3 cm deep]</td>
</tr>
<tr>
<td>1015</td>
<td>Other specified secondary hypertension</td>
</tr>
<tr>
<td>1016</td>
<td>Secondary hypertension associated with renal parenchymal disease</td>
</tr>
<tr>
<td>1017</td>
<td>Secondary hypertension associated with renovascular disease</td>
</tr>
<tr>
<td>1018</td>
<td>hypertension due to renovascular disease</td>
</tr>
<tr>
<td>1019</td>
<td>renal vascular hypertension</td>
</tr>
<tr>
<td>1020</td>
<td>renal hypertension</td>
</tr>
<tr>
<td>1021</td>
<td>renovascular hypertension</td>
</tr>
<tr>
<td>1022</td>
<td>Renal artery stenosis due to fibromuscular hyperplasia</td>
</tr>
<tr>
<td>1023</td>
<td>Arterial hypertension due to renal artery stenosis secondary to vasculitis</td>
</tr>
<tr>
<td>1024</td>
<td>Renal artery stenosis due to congenital abnormality</td>
</tr>
<tr>
<td>1025</td>
<td>Autosomal dominant progressive nephropathy with hypertension</td>
</tr>
<tr>
<td>1026</td>
<td>Benign renovascular hypertension</td>
</tr>
<tr>
<td>1027</td>
<td>Malignant renovascular hypertension</td>
</tr>
<tr>
<td>1028</td>
<td>Malignant renal hypertension</td>
</tr>
<tr>
<td>1029</td>
<td>malignant secondary renovascular hypertension</td>
</tr>
<tr>
<td>1030</td>
<td>Secondary hypertension associated with renal tubular disorders</td>
</tr>
<tr>
<td>1031</td>
<td>Pseudohyperaldosteronism type 1</td>
</tr>
<tr>
<td>1032</td>
<td>Liddle syndrome</td>
</tr>
<tr>
<td>1033</td>
<td>Pseudohyperaldosteronism type 2</td>
</tr>
<tr>
<td>1034</td>
<td>Hypertension due to gain-of-function mutations in the mineralocorticoid receptor</td>
</tr>
<tr>
<td>1035</td>
<td>Early-onset hypertension with exacerbation in pregnancy</td>
</tr>
<tr>
<td>1036</td>
<td>Pseudohypoaldosteronism type 2</td>
</tr>
<tr>
<td>1037</td>
<td>Pseudohypoaldosteronism type 2A</td>
</tr>
<tr>
<td>1038</td>
<td>Pseudohypoaldosteronism type 2B</td>
</tr>
<tr>
<td>1039</td>
<td>Pseudohypoaldosteronism type 2C</td>
</tr>
<tr>
<td>1040</td>
<td>Pseudohypoaldosteronism type 2D</td>
</tr>
<tr>
<td>1041</td>
<td>Pseudohypoaldosteronism type 2E</td>
</tr>
<tr>
<td>1042</td>
<td>Secondary hypertension associated with congenital heart disorders</td>
</tr>
<tr>
<td>1043</td>
<td>Hypertension due to aortic arch obstruction</td>
</tr>
<tr>
<td>1044</td>
<td>Hypertension secondary to aortic arch obstruction</td>
</tr>
<tr>
<td>1045</td>
<td>Secondary hypertension associated with endocrine disorders</td>
</tr>
<tr>
<td>1046</td>
<td>Hypertension due to congenital adrenal hyperplasia</td>
</tr>
<tr>
<td>1047</td>
<td>Hypertension secondary to congenital adrenal hyperplasia</td>
</tr>
<tr>
<td>1048</td>
<td>Hypertension due to drug therapy</td>
</tr>
<tr>
<td>1049</td>
<td>Hypertension secondary to drug therapy</td>
</tr>
<tr>
<td>1050</td>
<td>Laceration of liver, moderate</td>
</tr>
<tr>
<td>1051</td>
<td>laceration of liver involving parenchyma but without major disruption of parenchyma [i.e., less than 10 cm long and less than 3 cm deep]</td>
</tr>
<tr>
<td>1052</td>
<td>Other specified congenital hypothyroidism</td>
</tr>
<tr>
<td>1053</td>
<td>Permanent congenital hypothyroidism</td>
</tr>
<tr>
<td>1054</td>
<td>Syndromic permanent congenital hypothyroidism</td>
</tr>
<tr>
<td>1055</td>
<td>Young-Simpson syndrome</td>
</tr>
<tr>
<td>1056</td>
<td>Hypothyroidism - dysmorphism - postaxial polydactyly - intellectual deficit</td>
</tr>
<tr>
<td>1057</td>
<td>Bamforth-Lazarus syndrome</td>
</tr>
<tr>
<td>1058</td>
<td>Hypothyroidism - cleft palate</td>
</tr>
<tr>
<td>1059</td>
<td>Bamforth syndrome</td>
</tr>
<tr>
<td>1060</td>
<td>Athydroidal hypothyroidism – spiky hair – cleft palate</td>
</tr>
<tr>
<td>1061</td>
<td>Bamforth-Lazarus syndrome due to Forkhead box protein E1 [FOXE1] mutations</td>
</tr>
<tr>
<td>1062</td>
<td>Kocher-Debre-Semelaigne syndrome</td>
</tr>
<tr>
<td>1063</td>
<td>Muscular pseudohypertrophy - hypothyroidism</td>
</tr>
<tr>
<td>1064</td>
<td>Choreoathetosis - hypothyroidism - neonatal respiratory distress</td>
</tr>
<tr>
<td>1065</td>
<td>Choreoathetosis - hypothyroidism - neonatal respiratory distress due to NKX 2-1 mutations</td>
</tr>
<tr>
<td>1066</td>
<td>Allan-Herndon-Dudley syndrome</td>
</tr>
<tr>
<td>1067</td>
<td>X-linked intellectual deficit - hypotonia</td>
</tr>
<tr>
<td>1068</td>
<td>AHDS - [Allan-Herndon-Dudley syndrome]</td>
</tr>
<tr>
<td>1069</td>
<td>Congenital hypothyroidism with chromosome abnormalities</td>
</tr>
<tr>
<td>1070</td>
<td>Benign chorea - hypothyroidism</td>
</tr>
<tr>
<td>1071</td>
<td>Congenital idiopathic hypothyroidism</td>
</tr>
<tr>
<td>1072</td>
<td>Laceration of liver, minor</td>
</tr>
<tr>
<td>1073</td>
<td>Mild laceration of liver</td>
</tr>
<tr>
<td>1074</td>
<td>laceration of liver involving capsule only, or, without significant involvement of hepatic parenchyma [i.e., less than 1 cm deep]</td>
</tr>
<tr>
<td>1075</td>
<td>Other B-lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities</td>
</tr>
<tr>
<td>1076</td>
<td>B lymphoblastic leukaemia or lymphoma with t(v;11q23); MLL rearranged</td>
</tr>
<tr>
<td>1077</td>
<td>B lymphoblastic leukaemia or lymphoma with t(12;21) (p13;q22); TEL/AML1 (ETV6-RUNX1)</td>
</tr>
<tr>
<td>1078</td>
<td>B lymphoblastic leukaemia or lymphoma with hyperdiploidy</td>
</tr>
<tr>
<td>1079</td>
<td>B lymphoblastic leukaemia or lymphoma with hypodiploidy</td>
</tr>
<tr>
<td>1080</td>
<td>Hypodiploid ALL</td>
</tr>
<tr>
<td>1081</td>
<td>B lymphoblastic leukaemia or lymphoma with t(5;14)(q31;q32)(IL3-IGH)</td>
</tr>
<tr>
<td>1082</td>
<td>B lymphoblastic leukaemia or lymphoma with t(1;19)(Q23;P13.3); (E2A-PBX1; TCF3/PBX1)</td>
</tr>
<tr>
<td>1</td>
<td>Hereditary persistence of fetal haemoglobin</td>
</tr>
<tr>
<td>2</td>
<td>HPFH - [Hereditary persistence of fetal haemoglobin]</td>
</tr>
<tr>
<td>3</td>
<td>fetal haemoglobin</td>
</tr>
<tr>
<td>4</td>
<td>persistence of fetal haemoglobin</td>
</tr>
<tr>
<td>5</td>
<td>persistent haemoglobin F</td>
</tr>
<tr>
<td>6</td>
<td>Hereditary persistence of fetal haemoglobin, deletional</td>
</tr>
<tr>
<td>7</td>
<td>Hereditary persistence of fetal haemoglobin, non-deletional</td>
</tr>
<tr>
<td>8</td>
<td>Glycogen storage disease</td>
</tr>
<tr>
<td>9</td>
<td>Glycogenosis</td>
</tr>
<tr>
<td>10</td>
<td>GSD - [Glycogen storage disease]</td>
</tr>
<tr>
<td>11</td>
<td>glycogen thesaurismosis</td>
</tr>
<tr>
<td>12</td>
<td>diffuse glycogenosis</td>
</tr>
<tr>
<td>13</td>
<td>generalised glycogen storage disease</td>
</tr>
<tr>
<td>14</td>
<td>generalised glycogenosis</td>
</tr>
<tr>
<td>15</td>
<td>generalised glycogen storage disease of infants</td>
</tr>
<tr>
<td>16</td>
<td>glycogen synthase deficiency</td>
</tr>
<tr>
<td>17</td>
<td>Glycogen storage disease due to glycogen synthase deficiency</td>
</tr>
<tr>
<td>18</td>
<td>Glycogen storage disease type 0</td>
</tr>
<tr>
<td>19</td>
<td>Glycogenosis type 0</td>
</tr>
<tr>
<td>20</td>
<td>GSD type 0</td>
</tr>
<tr>
<td>21</td>
<td>deficiency of glycogen synthetase</td>
</tr>
<tr>
<td>22</td>
<td>Glycogen storage disease due to liver glycogen synthase deficiency</td>
</tr>
<tr>
<td>23</td>
<td>GSD type 0A</td>
</tr>
<tr>
<td>24</td>
<td>Glycogen storage disease type 0A</td>
</tr>
<tr>
<td>25</td>
<td>Glycogenosis type 0A</td>
</tr>
<tr>
<td>26</td>
<td>Glycogen storage disease due to muscle or heart glycogen synthase deficiency</td>
</tr>
<tr>
<td>27</td>
<td>Glycogen storage disease type 0B</td>
</tr>
<tr>
<td>28</td>
<td>Glycogenosis type 0B</td>
</tr>
<tr>
<td>29</td>
<td>GSD type 0B</td>
</tr>
<tr>
<td>30</td>
<td>Cardiomyopathy-exercise intolerance due to muscle and heart glycogen deficiency</td>
</tr>
<tr>
<td>31</td>
<td>Glycogen storage disease due to glucose-6-phosphate system deficiency</td>
</tr>
<tr>
<td>32</td>
<td>Glycogen storage disease type 1</td>
</tr>
<tr>
<td>33</td>
<td>Glycogenosis type 1</td>
</tr>
<tr>
<td>34</td>
<td>GSD type 1</td>
</tr>
<tr>
<td>35</td>
<td>Hepatorenal glycogenosis</td>
</tr>
<tr>
<td>36</td>
<td>Von Gierke disease</td>
</tr>
<tr>
<td>37</td>
<td>HERS - [hepatorenal glycogen storage disease]</td>
</tr>
<tr>
<td>38</td>
<td>glycogen storage disease of liver and kidney</td>
</tr>
<tr>
<td>39</td>
<td>hepatorenal glycogen storage disease</td>
</tr>
<tr>
<td>40</td>
<td>Glycogen storage disease due to glucose-6-phosphatase deficiency</td>
</tr>
<tr>
<td>41</td>
<td>Glycogen storage disease type 1A</td>
</tr>
<tr>
<td>42</td>
<td>Glycogenosis type 1A</td>
</tr>
<tr>
<td>43</td>
<td>GSD type 1A</td>
</tr>
<tr>
<td>44</td>
<td>g6pd - [glucose-6-phosphate dehydrogenase deficiency]</td>
</tr>
<tr>
<td>45</td>
<td>glucose-6-phosphatase deficiency</td>
</tr>
<tr>
<td>46</td>
<td>deficiency of g-6pd</td>
</tr>
<tr>
<td>47</td>
<td>Glycogen storage disease due to glucose-6-phosphate transport defect</td>
</tr>
<tr>
<td>48</td>
<td>Glycogen storage disease type 1B</td>
</tr>
<tr>
<td>49</td>
<td>Glycogenosis type 1B</td>
</tr>
<tr>
<td>50</td>
<td>GSD1B</td>
</tr>
<tr>
<td>51</td>
<td>Glycogen storage disease type non-1A</td>
</tr>
<tr>
<td>52</td>
<td>Glycogenosis type non-1A</td>
</tr>
<tr>
<td>53</td>
<td>Glycogen storage disease due to glucose-6-phosphate translocase deficiency</td>
</tr>
<tr>
<td>54</td>
<td>Glucose-6-phosphate dehydrogenase deficiency</td>
</tr>
<tr>
<td>55</td>
<td>Glycogen storage disease due to acid maltase deficiency</td>
</tr>
<tr>
<td>56</td>
<td>Glycogen storage disease type 2</td>
</tr>
<tr>
<td>57</td>
<td>Glycogenosis type 2</td>
</tr>
<tr>
<td>58</td>
<td>GSD type 2</td>
</tr>
<tr>
<td>59</td>
<td>Acid maltase deficiency</td>
</tr>
<tr>
<td>60</td>
<td>Pompe disease</td>
</tr>
<tr>
<td>61</td>
<td>Acid alpha-1,4-glucosidase deficiency</td>
</tr>
<tr>
<td>62</td>
<td>alpha-glucosidase deficiency</td>
</tr>
<tr>
<td>63</td>
<td>deficiency of amyloglucosidase</td>
</tr>
<tr>
<td>64</td>
<td>Glycogen storage disease due to acid maltase deficiency, infantile onset</td>
</tr>
<tr>
<td>65</td>
<td>Glycogen storage disease type 2, infantile onset</td>
</tr>
<tr>
<td>66</td>
<td>Glycogenosis type 2, infantile onset</td>
</tr>
<tr>
<td>67</td>
<td>GSD2, infantile onset</td>
</tr>
<tr>
<td>68</td>
<td>Glycogen storage disease due to acid alpha-1,4-glucosidase deficiency, infantile onset</td>
</tr>
<tr>
<td>69</td>
<td>Infantile Pompe disease</td>
</tr>
<tr>
<td>70</td>
<td>lysosomal alpha-1,4-glucosidase deficiency (disorder)</td>
</tr>
<tr>
<td>71</td>
<td>Glycogen storage disease due to acid maltase deficiency, juvenile onset</td>
</tr>
<tr>
<td>72</td>
<td>Glycogen storage disease due to acid maltase deficiency, adult onset</td>
</tr>
<tr>
<td>73</td>
<td>Deficiency of exo-1,4-alpha-glucosidase</td>
</tr>
<tr>
<td>74</td>
<td>Deficiency of glucan 1,4-alpha-glucosidase</td>
</tr>
<tr>
<td>75</td>
<td>Deficiency of gamma-amylase</td>
</tr>
<tr>
<td>76</td>
<td>Deficiency of glucoamylase</td>
</tr>
<tr>
<td>77</td>
<td>Deficiency of glucoinvertase</td>
</tr>
<tr>
<td>78</td>
<td>Deficiency of glucosidosucrase</td>
</tr>
<tr>
<td>79</td>
<td>Deficiency of maltase</td>
</tr>
<tr>
<td>80</td>
<td>Glycogen storage disease due to LAMP-2 deficiency</td>
</tr>
<tr>
<td>81</td>
<td>Glycogen storage disease type 2B</td>
</tr>
<tr>
<td>82</td>
<td>Glycogenosis type 2B</td>
</tr>
<tr>
<td>83</td>
<td>GSD type 2B</td>
</tr>
<tr>
<td>84</td>
<td>Lysosomal glycogen storage disease with normal acid maltase activity</td>
</tr>
<tr>
<td>85</td>
<td>Danon disease</td>
</tr>
<tr>
<td>86</td>
<td>Glycogen storage disease due to glycogen debranching enzyme deficiency</td>
</tr>
<tr>
<td>87</td>
<td>Glycogen storage disease type 3</td>
</tr>
<tr>
<td>88</td>
<td>Glycogenosis type 3</td>
</tr>
<tr>
<td>89</td>
<td>GSD type 3</td>
</tr>
<tr>
<td>90</td>
<td>Amylo-1,6-glucosidase deficiency</td>
</tr>
<tr>
<td>91</td>
<td>Glycogen debranching deficiency</td>
</tr>
<tr>
<td>92</td>
<td>Cori-Forbes disease</td>
</tr>
<tr>
<td>93</td>
<td>Cori disease</td>
</tr>
<tr>
<td>94</td>
<td>Forbes disease</td>
</tr>
<tr>
<td>95</td>
<td>Forbes glycogen storage disease</td>
</tr>
<tr>
<td>96</td>
<td>debrancher deficiency glycogen storage disease</td>
</tr>
<tr>
<td>97</td>
<td>debrancher enzyme deficiency</td>
</tr>
<tr>
<td>98</td>
<td>deficiency of 6-alpha-d-glucosidase</td>
</tr>
<tr>
<td>99</td>
<td>amylo-1,6-glucosidase deficiency disorder</td>
</tr>
<tr>
<td>100</td>
<td>Glycogen storage disease due to muscle glycogen phosphorylase deficiency</td>
</tr>
<tr>
<td>101</td>
<td>Glycogen storage disease type 5</td>
</tr>
<tr>
<td>102</td>
<td>Glycogenosis type 5</td>
</tr>
<tr>
<td>103</td>
<td>GSD type 5</td>
</tr>
<tr>
<td>104</td>
<td>Myophosphorylase deficiency</td>
</tr>
<tr>
<td>105</td>
<td>McArdle disease</td>
</tr>
<tr>
<td>106</td>
<td>myophosphorylase deficiency glycogenosis</td>
</tr>
<tr>
<td>107</td>
<td>Glycogen storage disease due to liver glycogen phosphorylase deficiency</td>
</tr>
<tr>
<td>108</td>
<td>Glycogenosis due to liver phosphorylase deficiency</td>
</tr>
<tr>
<td>109</td>
<td>Glycogen storage disease type 6</td>
</tr>
<tr>
<td>110</td>
<td>Glycogenosis type 6</td>
</tr>
<tr>
<td>111</td>
<td>GSD type 6</td>
</tr>
<tr>
<td>112</td>
<td>Glycogen storage disease type 6B</td>
</tr>
<tr>
<td>113</td>
<td>Glycogenosis type 6B</td>
</tr>
<tr>
<td>114</td>
<td>GSD type 6B</td>
</tr>
<tr>
<td>115</td>
<td>Hers disease</td>
</tr>
<tr>
<td>116</td>
<td>deficiency of hepatophosphorylase</td>
</tr>
<tr>
<td>117</td>
<td>Glycogen storage disease due to muscle phosphofructokinase deficiency</td>
</tr>
<tr>
<td>118</td>
<td>Glycogen storage disease type 7</td>
</tr>
<tr>
<td>119</td>
<td>Glycogenosis type 7</td>
</tr>
<tr>
<td>120</td>
<td>GSD type 7</td>
</tr>
<tr>
<td>121</td>
<td>Muscle phosphofructokinase deficiency</td>
</tr>
<tr>
<td>122</td>
<td>Tarui disease</td>
</tr>
<tr>
<td>123</td>
<td>anaemia due to phosphofructo-aldolase deficiency</td>
</tr>
<tr>
<td>124</td>
<td>Glycogen storage disease due to glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>125</td>
<td>Glycogenosis due to phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>126</td>
<td>GSD due to phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>127</td>
<td>Glycogen storage disease due to liver glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>128</td>
<td>Hepatic phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>129</td>
<td>Glycogen storage disease type 8</td>
</tr>
<tr>
<td>130</td>
<td>Glycogenosis type 8</td>
</tr>
<tr>
<td>131</td>
<td>GSD8 - [glycogen storage disease type 8]</td>
</tr>
<tr>
<td>132</td>
<td>Glycogen storage disease type 6A</td>
</tr>
<tr>
<td>133</td>
<td>Glycogen storage disease type 9A</td>
</tr>
<tr>
<td>134</td>
<td>Glycogen storage disease type 9C</td>
</tr>
<tr>
<td>135</td>
<td>Glycogenosis type 6A</td>
</tr>
<tr>
<td>136</td>
<td>Glycogenosis type 9A</td>
</tr>
<tr>
<td>137</td>
<td>Glycogenosis type 9C</td>
</tr>
<tr>
<td>138</td>
<td>GSD type 9C - [glycogen storage disease type 9C]</td>
</tr>
<tr>
<td>139</td>
<td>GSD6A - [glycogen storage disease type 6A]</td>
</tr>
<tr>
<td>140</td>
<td>GSD9A - [glycogen storage disease type 9A]</td>
</tr>
<tr>
<td>141</td>
<td>Glycogen storage disease due to liver or muscle glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>142</td>
<td>Glycogen storage disease type 9B</td>
</tr>
<tr>
<td>143</td>
<td>Glycogenosis type 9B</td>
</tr>
<tr>
<td>144</td>
<td>GSD type 9B</td>
</tr>
<tr>
<td>145</td>
<td>Glycogen storage disease type 9</td>
</tr>
<tr>
<td>146</td>
<td>Glycogenosis type 9</td>
</tr>
<tr>
<td>147</td>
<td>GSD9 - [glycogen storage disease type 9]</td>
</tr>
<tr>
<td>148</td>
<td>Glycogen storage disease due to heart glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>149</td>
<td>Glycogen storage disease of heart</td>
</tr>
<tr>
<td>150</td>
<td>Cardiac glycogenosis</td>
</tr>
<tr>
<td>151</td>
<td>Glycogen storage disease type 9F</td>
</tr>
<tr>
<td>152</td>
<td>Glycogenosis type 9F</td>
</tr>
<tr>
<td>153</td>
<td>GSD9F</td>
</tr>
<tr>
<td>154</td>
<td>glycogen heart disease</td>
</tr>
<tr>
<td>155</td>
<td>glycogenic myocardial infiltration</td>
</tr>
<tr>
<td>156</td>
<td>glycogenic myocardium infiltration</td>
</tr>
<tr>
<td>157</td>
<td>cardiomegalia glycogenica diffusa</td>
</tr>
<tr>
<td>158</td>
<td>Glycogen storage disease due to muscle glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>159</td>
<td>GSD9D - [glycogen storage disease type IXD]</td>
</tr>
<tr>
<td>160</td>
<td>Glycogen storage disease type 9D</td>
</tr>
<tr>
<td>161</td>
<td>Glycogen storage disease type 9E</td>
</tr>
<tr>
<td>162</td>
<td>Glycogenosis type 9D</td>
</tr>
<tr>
<td>163</td>
<td>Glycogenosis type 9E</td>
</tr>
<tr>
<td>164</td>
<td>GSD9E</td>
</tr>
<tr>
<td>165</td>
<td>muscle glycogen phosphorylase deficiency</td>
</tr>
<tr>
<td>166</td>
<td>glycogenosis type IXE</td>
</tr>
<tr>
<td>167</td>
<td>Glycogen storage disease due to muscle phosphoglycerate mutase deficiency</td>
</tr>
<tr>
<td>168</td>
<td>Glycogen storage disease type 10</td>
</tr>
<tr>
<td>169</td>
<td>Glycogenosis type 10</td>
</tr>
<tr>
<td>170</td>
<td>GSD type 10</td>
</tr>
<tr>
<td>171</td>
<td>Di Mauro disease</td>
</tr>
<tr>
<td>172</td>
<td>Glycogen storage disease due to GLUT2 deficiency</td>
</tr>
<tr>
<td>173</td>
<td>Glycogen storage disease type 11</td>
</tr>
<tr>
<td>174</td>
<td>Glycogenosis type 11</td>
</tr>
<tr>
<td>175</td>
<td>GSD type 11</td>
</tr>
<tr>
<td>176</td>
<td>Fanconi-Bickel glycogenosis</td>
</tr>
<tr>
<td>177</td>
<td>Bickel-Fanconi disease</td>
</tr>
<tr>
<td>178</td>
<td>Facilitated glucose transporter protein type 2 deficiency</td>
</tr>
<tr>
<td>179</td>
<td>Fanconi-Bickel syndrome</td>
</tr>
<tr>
<td>180</td>
<td>Glycogen storage disease due to aldolase A deficiency</td>
</tr>
<tr>
<td>181</td>
<td>Glycogen storage disease type 12</td>
</tr>
<tr>
<td>182</td>
<td>Glycogenosis type 12</td>
</tr>
<tr>
<td>183</td>
<td>GSD type 12</td>
</tr>
<tr>
<td>184</td>
<td>Glycogen storage disease due to muscle beta-enolase deficiency</td>
</tr>
<tr>
<td>185</td>
<td>Glycogen storage disease type 13</td>
</tr>
<tr>
<td>186</td>
<td>Glycogenosis type 13</td>
</tr>
<tr>
<td>187</td>
<td>GSD type 13</td>
</tr>
<tr>
<td>188</td>
<td>Glycogen storage disease due to phosphoglucomutase deficiency</td>
</tr>
<tr>
<td>189</td>
<td>Glycogen storage disease type 14</td>
</tr>
<tr>
<td>190</td>
<td>Glycogenosis type 14</td>
</tr>
<tr>
<td>191</td>
<td>GSD type 14</td>
</tr>
<tr>
<td>192</td>
<td>Glycogen storage disease due to glycogenin deficiency</td>
</tr>
<tr>
<td>193</td>
<td>Glycogen storage disease type 15</td>
</tr>
<tr>
<td>194</td>
<td>GSD type 15</td>
</tr>
<tr>
<td>195</td>
<td>Glocogenosis type 15</td>
</tr>
<tr>
<td>196</td>
<td>Glycogen storage disease due to phosphoglycerate kinase 1 deficiency</td>
</tr>
<tr>
<td>197</td>
<td>Glycogenosis due to phosphoglycerate kinase 1 deficiency</td>
</tr>
<tr>
<td>198</td>
<td>GSD due to phosphoglycerate kinase 1 deficiency</td>
</tr>
<tr>
<td>199</td>
<td>Glycogen storage disease due to lactate dehydrogenase deficiency</td>
</tr>
<tr>
<td>200</td>
<td>Glycogenosis due to lactate dehydrogenase deficiency</td>
</tr>
<tr>
<td>201</td>
<td>GSD due to lactate dehydrogenase deficiency</td>
</tr>
<tr>
<td>202</td>
<td>Glycogen storage disease due to muscle pyruvate kinase deficiency</td>
</tr>
<tr>
<td>203</td>
<td>Glycogenosis due to muscle pyruvate kinase deficiency</td>
</tr>
<tr>
<td>204</td>
<td>GSD due to muscle pyruvate kinase deficiency</td>
</tr>
<tr>
<td>205</td>
<td>Glycogen storage liver disease</td>
</tr>
<tr>
<td>206</td>
<td>hepatomegalia glycogenica diffusa</td>
</tr>
<tr>
<td>207</td>
<td>liver glycogen disease</td>
</tr>
<tr>
<td>208</td>
<td>liver phosphorylase deficiency</td>
</tr>
<tr>
<td>209</td>
<td>Glycogen storage disease due to branching-transferase deficiency</td>
</tr>
<tr>
<td>210</td>
<td>Andersen disease</td>
</tr>
<tr>
<td>211</td>
<td>brancher deficiency glycogen storage disease</td>
</tr>
<tr>
<td>212</td>
<td>branching enzyme deficiency</td>
</tr>
<tr>
<td>213</td>
<td>branching-transferase deficiency glycogenosis</td>
</tr>
<tr>
<td>214</td>
<td>deficiency of 1,4-alpha-glucan branching enzyme</td>
</tr>
<tr>
<td>215</td>
<td>deficiency of amylo-(1,4,6)-transglycosylase</td>
</tr>
<tr>
<td>216</td>
<td>Glycogen storage disease type 4</td>
</tr>
<tr>
<td>217</td>
<td>Glycogenosis type 4</td>
</tr>
<tr>
<td>218</td>
<td>GSD- [Glycogen storage disease] type 4</td>
</tr>
<tr>
<td>219</td>
<td>Dilated cardiomyopathy due to glycogen branching enzyme deficiency</td>
</tr>
<tr>
<td>220</td>
<td>Amylopectinosis</td>
</tr>
<tr>
<td>221</td>
<td>dilated cardiomyopathy due to Andersen's disease</td>
</tr>
<tr>
<td>222</td>
<td>dilated cardiomyopathy due to glycogen storage disease type 4 (GSD4)</td>
</tr>
<tr>
<td>223</td>
<td>Disorders of multiple glycosylation or other pathways</td>
</tr>
<tr>
<td>224</td>
<td>Dolichol-phosphate-mannose synthase 1 deficiency</td>
</tr>
<tr>
<td>225</td>
<td>GDP-Man: Dol-P-mannosyltransferase deficiency</td>
</tr>
<tr>
<td>226</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1E</td>
</tr>
<tr>
<td>227</td>
<td>Congenital disorder of glycosylation type 1E</td>
</tr>
<tr>
<td>228</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1E</td>
</tr>
<tr>
<td>229</td>
<td>Mannose-P-dolichol utilisation defect 1</td>
</tr>
<tr>
<td>230</td>
<td>Lec35 deficiency</td>
</tr>
<tr>
<td>231</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1F</td>
</tr>
<tr>
<td>232</td>
<td>Congenital disorder of glycosylation type 1F</td>
</tr>
<tr>
<td>233</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1F</td>
</tr>
<tr>
<td>234</td>
<td>Beta-1,4-galactosyltransferase deficiency</td>
</tr>
<tr>
<td>235</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2D</td>
</tr>
<tr>
<td>236</td>
<td>Congenital disorder of glycosylation type 2D</td>
</tr>
<tr>
<td>237</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2D</td>
</tr>
<tr>
<td>238</td>
<td>CMP-sialic acid transporter deficiency</td>
</tr>
<tr>
<td>239</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2F</td>
</tr>
<tr>
<td>240</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2F</td>
</tr>
<tr>
<td>241</td>
<td>Congenital disorder of glycosylation type 2F</td>
</tr>
<tr>
<td>242</td>
<td>Leukocyte adhesion deficiency type 2</td>
</tr>
<tr>
<td>243</td>
<td>Rambam-Hasharon syndrome</td>
</tr>
<tr>
<td>244</td>
<td>GDP-fucose transporter deficiency</td>
</tr>
<tr>
<td>245</td>
<td>LAD-II - [Leukocyte adhesion deficiency type 2]</td>
</tr>
<tr>
<td>246</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2C</td>
</tr>
<tr>
<td>247</td>
<td>Dolichol kinase deficiency</td>
</tr>
<tr>
<td>248</td>
<td>Hypotonia or ichthyosis due to dolichol phosphate deficiency</td>
</tr>
<tr>
<td>249</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1M</td>
</tr>
<tr>
<td>250</td>
<td>Congenital disorder of glycosylation type 1M</td>
</tr>
<tr>
<td>251</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1M</td>
</tr>
<tr>
<td>252</td>
<td>Conserved oligomeric Golgi complex deficiencies</td>
</tr>
<tr>
<td>253</td>
<td>Component of conserved oligomeric Golgi complex 1 deficiency</td>
</tr>
<tr>
<td>254</td>
<td>CDG syndrome type 2G</td>
</tr>
<tr>
<td>255</td>
<td>Component of conserved oligomeric Golgi complex 4 deficiency</td>
</tr>
<tr>
<td>256</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2J</td>
</tr>
<tr>
<td>257</td>
<td>Congenital disorder of glycosylation type 2J</td>
</tr>
<tr>
<td>258</td>
<td>Component of conserved oligomeric Golgi complex 5 deficiency</td>
</tr>
<tr>
<td>259</td>
<td>Component of conserved oligomeric Golgi complex 7 deficiency</td>
</tr>
<tr>
<td>260</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2E</td>
</tr>
<tr>
<td>261</td>
<td>Congenital disorder of glycosylation type 2E</td>
</tr>
<tr>
<td>262</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2E</td>
</tr>
<tr>
<td>263</td>
<td>Component of conserved oligomeric Golgi complex 8 deficiency</td>
</tr>
<tr>
<td>264</td>
<td>Congenital disorder of glycosylation type 2h</td>
</tr>
<tr>
<td>265</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2H</td>
</tr>
<tr>
<td>266</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2H</td>
</tr>
<tr>
<td>267</td>
<td>V-ATPase deficiencies</td>
</tr>
<tr>
<td>268</td>
<td>Delta, delta-beta or gamma-delta-beta thalassaemia</td>
</tr>
<tr>
<td>269</td>
<td>Delta thalassaemia</td>
</tr>
<tr>
<td>270</td>
<td>Delta-beta thalassaemia</td>
</tr>
<tr>
<td>271</td>
<td>f thalassaemia</td>
</tr>
<tr>
<td>272</td>
<td>Gamma-delta-beta thalassaemia</td>
</tr>
<tr>
<td>273</td>
<td>Haemoglobin Lepore</td>
</tr>
<tr>
<td>274</td>
<td>Syndromes with lissencephaly as a major feature</td>
</tr>
<tr>
<td>275</td>
<td>Pachygyria</td>
</tr>
<tr>
<td>276</td>
<td>Agyria</td>
</tr>
<tr>
<td>277</td>
<td>Classic lissencephaly</td>
</tr>
<tr>
<td>278</td>
<td>Lissencephaly type 1</td>
</tr>
<tr>
<td>279</td>
<td>Lissencephaly type 1 due to doublecortin gene mutation</td>
</tr>
<tr>
<td>280</td>
<td>Subcortical band heterotopia</td>
</tr>
<tr>
<td>281</td>
<td>Miller-Dieker syndrome</td>
</tr>
<tr>
<td>282</td>
<td>Lissencephaly due to 17p13.3 deletion</td>
</tr>
<tr>
<td>283</td>
<td>17p13.3 microdeletion syndrome</td>
</tr>
<tr>
<td>284</td>
<td>Telomeric deletion 17p</td>
</tr>
<tr>
<td>285</td>
<td>Monosomy 17p13.3</td>
</tr>
<tr>
<td>286</td>
<td>17p13.3 deletion</td>
</tr>
<tr>
<td>287</td>
<td>Lissencephaly type 1 due to LIS1 gene mutation</td>
</tr>
<tr>
<td>288</td>
<td>Isolated lissencephaly type 1 without known genetic defects</td>
</tr>
<tr>
<td>289</td>
<td>Lissencephaly type 2</td>
</tr>
<tr>
<td>290</td>
<td>Lissencephaly type 3</td>
</tr>
<tr>
<td>291</td>
<td>Neu-Laxova syndrome</td>
</tr>
<tr>
<td>292</td>
<td>Lissencephaly type 3 - familial fetal akinesia sequence</td>
</tr>
<tr>
<td>293</td>
<td>Lissencephaly type 3 - metacarpal bone dysplasia</td>
</tr>
<tr>
<td>294</td>
<td>Lissencephaly with cerebellar hypoplasia</td>
</tr>
<tr>
<td>295</td>
<td>Lissencephaly with cerebellar hypoplasia type A</td>
</tr>
<tr>
<td>296</td>
<td>Lissencephaly with cerebellar hypoplasia type B</td>
</tr>
<tr>
<td>297</td>
<td>Lissencephaly with cerebellar hypoplasia type C</td>
</tr>
<tr>
<td>298</td>
<td>Lissencephaly with cerebellar hypoplasia type D</td>
</tr>
<tr>
<td>299</td>
<td>Lissencephaly with cerebellar hypoplasia type E</td>
</tr>
<tr>
<td>300</td>
<td>Lissencephaly with cerebellar hypoplasia type F</td>
</tr>
<tr>
<td>301</td>
<td>Microlissencephaly</td>
</tr>
<tr>
<td>302</td>
<td>Microlissencephaly type A</td>
</tr>
<tr>
<td>303</td>
<td>Lissencephaly syndrome, Norman-Roberts type</td>
</tr>
<tr>
<td>304</td>
<td>Microlissencephaly type B</td>
</tr>
<tr>
<td>305</td>
<td>Lissencephaly due to TUBA1A gene mutation</td>
</tr>
<tr>
<td>306</td>
<td>X-linked lissencephaly - agenesis of corpus callosum - genital anomalies</td>
</tr>
<tr>
<td>307</td>
<td>Craniotelencephalic dysplasia</td>
</tr>
<tr>
<td>308</td>
<td>Micro syndrome</td>
</tr>
<tr>
<td>309</td>
<td>Warburg Micro syndrome</td>
</tr>
<tr>
<td>310</td>
<td>WARBM1 - [Warburg Micro syndrome]</td>
</tr>
<tr>
<td>311</td>
<td>Iris coloboma with ptosis - intellectual deficit</td>
</tr>
<tr>
<td>312</td>
<td>Xeroderma pigmentosum</td>
</tr>
<tr>
<td>313</td>
<td>XP - [xeroderma pigmentosum]</td>
</tr>
<tr>
<td>314</td>
<td>atrophoderma pigmentosum</td>
</tr>
<tr>
<td>315</td>
<td>Xeroderma pigmentosum A</td>
</tr>
<tr>
<td>316</td>
<td>XPA - [xeroderma pigmentosum A]</td>
</tr>
<tr>
<td>317</td>
<td>Xeroderma pigmentosum B</td>
</tr>
<tr>
<td>318</td>
<td>XPB - [xeroderma pigmentosum B]</td>
</tr>
<tr>
<td>319</td>
<td>Xeroderma pigmentosum C</td>
</tr>
<tr>
<td>320</td>
<td>XPC - [xeroderma pigmentosum C]</td>
</tr>
<tr>
<td>321</td>
<td>Xeroderma pigmentosum D</td>
</tr>
<tr>
<td>322</td>
<td>XPD - [xeroderma pigmentosum D]</td>
</tr>
<tr>
<td>323</td>
<td>Xeroderma pigmentosum E</td>
</tr>
<tr>
<td>324</td>
<td>XPE - [xeroderma pigmentosum E]</td>
</tr>
<tr>
<td>325</td>
<td>Xeroderma pigmentosum F</td>
</tr>
<tr>
<td>326</td>
<td>XPF - [xeroderma pigmentosum F]</td>
</tr>
<tr>
<td>327</td>
<td>Xeroderma pigmentosum G</td>
</tr>
<tr>
<td>328</td>
<td>XPG - [xeroderma pigmentosum G]</td>
</tr>
<tr>
<td>329</td>
<td>Syndromic ichthyosis</td>
</tr>
<tr>
<td>330</td>
<td>X-linked ichthyosis syndromes</td>
</tr>
<tr>
<td>331</td>
<td>Ichthyosis follicularis – atrichia – photophobia</td>
</tr>
<tr>
<td>332</td>
<td>IFAP - [Ichthyosis follicularis – atrichia – photophobia] syndrome</td>
</tr>
<tr>
<td>333</td>
<td>ichthyosis follicularis - alopecia - photophobia</td>
</tr>
<tr>
<td>334</td>
<td>Autosomal ichthyosis syndromes with hair abnormalities</td>
</tr>
<tr>
<td>335</td>
<td>Netherton syndrome</td>
</tr>
<tr>
<td>336</td>
<td>Comèl-Netherton syndrome</td>
</tr>
<tr>
<td>337</td>
<td>Netherton disease</td>
</tr>
<tr>
<td>338</td>
<td>Trichorrhexis invaginata</td>
</tr>
<tr>
<td>339</td>
<td>Bamboo hair</td>
</tr>
<tr>
<td>340</td>
<td>Ichthyosis – hypotrichosis syndrome</td>
</tr>
<tr>
<td>341</td>
<td>PIBIDS syndrome</td>
</tr>
<tr>
<td>342</td>
<td>Trichothiodystrophy - sun sensitivity</td>
</tr>
<tr>
<td>343</td>
<td>Trichothiodystrophy type F</td>
</tr>
<tr>
<td>344</td>
<td>SIBIDS syndrome</td>
</tr>
<tr>
<td>345</td>
<td>Trichothiodystrophy - osteosclerosis</td>
</tr>
<tr>
<td>346</td>
<td>Autosomal ichthyosis syndromes with neurological manifestations</td>
</tr>
<tr>
<td>347</td>
<td>Autosomal ichthyoses with fatal disease course</td>
</tr>
<tr>
<td>348</td>
<td>Cerebral dysgenesis – neuropathy – ichthyosis – keratoderma syndrome</td>
</tr>
<tr>
<td>349</td>
<td>CEDNIK - [Cerebral dysgenesis – neuropathy – ichthyosis – keratoderma syndrome] syndrome</td>
</tr>
<tr>
<td>350</td>
<td>Other autosomal ichthyosis syndromes</td>
</tr>
<tr>
<td>351</td>
<td>Ichthyosis - oral and digital anomalies</td>
</tr>
<tr>
<td>352</td>
<td>Clayton Smith-Donnai syndrome</td>
</tr>
<tr>
<td>353</td>
<td>Keratitis – ichthyosis – deafness syndrome</td>
</tr>
<tr>
<td>354</td>
<td>Keratitis - ichthyosis - deafness/Hystrix-like ichthyosis - deafness</td>
</tr>
<tr>
<td>355</td>
<td>Senter syndrome</td>
</tr>
<tr>
<td>356</td>
<td>Hystrix-like ichthyosis - deafness</td>
</tr>
<tr>
<td>357</td>
<td>KID - [Keratitis – ichthyosis – deafness syndrome] syndrome</td>
</tr>
<tr>
<td>358</td>
<td>KID/HID - [Keratitis - ichthyosis - deafness/Hystrix-like ichthyosis - deafness] syndrome</td>
</tr>
<tr>
<td>359</td>
<td>Ichthyosis – prematurity syndrome</td>
</tr>
<tr>
<td>360</td>
<td>Ichthyosis as component of other specified genetic syndrome</td>
</tr>
<tr>
<td>361</td>
<td>Charcot-Marie-Tooth disease 2 axonal</td>
</tr>
<tr>
<td>362</td>
<td>Charcot-Marie-Tooth disease 2 autosomal dominant</td>
</tr>
<tr>
<td>363</td>
<td>Recessive axonal Charcot-Marie-Tooth disease with acrodystrophy</td>
</tr>
<tr>
<td>364</td>
<td>Charcot-Marie-Tooth disease type 2A1</td>
</tr>
<tr>
<td>365</td>
<td>Charcot-Marie-Tooth disease type 2A2</td>
</tr>
<tr>
<td>366</td>
<td>Charcot-Marie-Tooth disease type 2B</td>
</tr>
<tr>
<td>367</td>
<td>Charcot-Marie-Tooth disease type 2C</td>
</tr>
<tr>
<td>368</td>
<td>Charcot-Marie-Tooth disease type 2D</td>
</tr>
<tr>
<td>369</td>
<td>Charcot-Marie-Tooth disease type 2E</td>
</tr>
<tr>
<td>370</td>
<td>Charcot-Marie-Tooth disease type 2F</td>
</tr>
<tr>
<td>371</td>
<td>Charcot-Marie-Tooth disease type 2G</td>
</tr>
<tr>
<td>372</td>
<td>Charcot-Marie-Tooth disease type 2I</td>
</tr>
<tr>
<td>373</td>
<td>Charcot-Marie-Tooth disease type 2J</td>
</tr>
<tr>
<td>374</td>
<td>Charcot-Marie-Tooth disease type 2K</td>
</tr>
<tr>
<td>375</td>
<td>Charcot-Marie-Tooth disease type 2L</td>
</tr>
<tr>
<td>376</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2M</td>
</tr>
<tr>
<td>377</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2N</td>
</tr>
<tr>
<td>378</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2O</td>
</tr>
<tr>
<td>379</td>
<td>Charcot-Marie-Tooth disease 2 autosomal recessive</td>
</tr>
<tr>
<td>380</td>
<td>Charcot-Marie-Tooth disease type 2B1</td>
</tr>
<tr>
<td>381</td>
<td>Charcot-Marie-Tooth disease type 2B2</td>
</tr>
<tr>
<td>382</td>
<td>Charcot-Marie-Tooth disease type 2B5</td>
</tr>
<tr>
<td>383</td>
<td>Charcot-Marie-Tooth disease type 2H</td>
</tr>
<tr>
<td>384</td>
<td>Autosomal recessive Charcot-Marie-Tooth disease with hoarseness</td>
</tr>
<tr>
<td>385</td>
<td>Hereditary motor and sensory neuropathy type 6</td>
</tr>
<tr>
<td>386</td>
<td>Charcot-Marie-Tooth type 6</td>
</tr>
<tr>
<td>387</td>
<td>HMSN6 - [Hereditary motor and sensory neuropathy type 6]</td>
</tr>
<tr>
<td>388</td>
<td>CMT6 - [Charcot-Marie-Tooth type 6]</td>
</tr>
<tr>
<td>389</td>
<td>Charcot-Marie-Tooth disease 1 demyelinating</td>
</tr>
<tr>
<td>390</td>
<td>Charcot-Marie-Tooth disease 1 autosomal dominant</td>
</tr>
<tr>
<td>391</td>
<td>Charcot-Marie-Tooth disease type 1E</td>
</tr>
<tr>
<td>392</td>
<td>Charcot-Marie-Tooth disease type 1B</td>
</tr>
<tr>
<td>393</td>
<td>Charcot-Marie-Tooth disease type 1C</td>
</tr>
<tr>
<td>394</td>
<td>Charcot-Marie-Tooth disease type 1D</td>
</tr>
<tr>
<td>395</td>
<td>Charcot-Marie-Tooth disease type 1F</td>
</tr>
<tr>
<td>396</td>
<td>Charcot-Marie-Tooth disease 1 autosomal recessive</td>
</tr>
<tr>
<td>397</td>
<td>Charcot-Marie-Tooth disease type 4</td>
</tr>
<tr>
<td>398</td>
<td>CMT4 - [Charcot-Marie-Tooth disease type 4]</td>
</tr>
<tr>
<td>399</td>
<td>Charcot-Marie-Tooth disease - deafness - intellectual deficit</td>
</tr>
<tr>
<td>400</td>
<td>Charcot-Marie-Tooth disease type 4A</td>
</tr>
<tr>
<td>401</td>
<td>Charcot-Marie-Tooth disease type 4C</td>
</tr>
<tr>
<td>402</td>
<td>Charcot-Marie-Tooth disease type 4D</td>
</tr>
<tr>
<td>403</td>
<td>Charcot-Marie-Tooth disease type 4E</td>
</tr>
<tr>
<td>404</td>
<td>Charcot-Marie-Tooth disease type 4F</td>
</tr>
<tr>
<td>405</td>
<td>Charcot-Marie-Tooth disease type 4G</td>
</tr>
<tr>
<td>406</td>
<td>Charcot-Marie-Tooth disease type 4H</td>
</tr>
<tr>
<td>407</td>
<td>Charcot-Marie-Tooth disease type 4B1</td>
</tr>
<tr>
<td>408</td>
<td>Charcot-Marie-Tooth disease type 4B2</td>
</tr>
<tr>
<td>409</td>
<td>Charcot-Marie-Tooth disease type 4J</td>
</tr>
<tr>
<td>410</td>
<td>X-linked Charcot-Marie-Tooth disease 1 due to mutations in gap junction protein beta 1</td>
</tr>
<tr>
<td>411</td>
<td>X-linked Charcot-Marie-Tooth disease 1 secondary to mutations in gap junction protein beta 1</td>
</tr>
<tr>
<td>412</td>
<td>Charcot-Marie-Tooth disease 1X, x-linked Charcot-Marie-Tooth disease 1 due to mutations in gap junction protein beta 1</td>
</tr>
<tr>
<td>413</td>
<td>Charcot-Marie-Tooth disease 1X, x-linked Charcot-Marie-Tooth disease 1 secondary to mutations in gap junction protein beta 1</td>
</tr>
<tr>
<td>414</td>
<td>Hereditary sensorimotor neuropathy with hyperelastic skin</td>
</tr>
<tr>
<td>415</td>
<td>Classical organic aciduria</td>
</tr>
<tr>
<td>416</td>
<td>Methylmalonic aciduria - homocystinuria</td>
</tr>
<tr>
<td>417</td>
<td>Methylmalonic acidaemia - homocystinuria</td>
</tr>
<tr>
<td>418</td>
<td>Methylmalonic aciduria - homocystinuria type cbl C</td>
</tr>
<tr>
<td>419</td>
<td>Methylmalonic acidaemia - homocystinuria type cbl C</td>
</tr>
<tr>
<td>420</td>
<td>Methylmalonic aciduria - homocystinuria type cbl D</td>
</tr>
<tr>
<td>421</td>
<td>Methylmalonic acidaemia - homocystinuria type cbl D</td>
</tr>
<tr>
<td>422</td>
<td>Methylmalonic aciduria - homocystinuria type cbl F</td>
</tr>
<tr>
<td>423</td>
<td>Methylmalonic acidaemia - homocystinuria type cbl F</td>
</tr>
<tr>
<td>424</td>
<td>Methylmalonic aciduria</td>
</tr>
<tr>
<td>425</td>
<td>Methylmalonic acidaemia</td>
</tr>
<tr>
<td>426</td>
<td>Methylmalonic aciduria, vitamin B12 unresponsive</td>
</tr>
<tr>
<td>427</td>
<td>Complete deficiency of methylmalonyl-CoA mutase</td>
</tr>
<tr>
<td>428</td>
<td>Mutase0 methylmalonic acidaemia</td>
</tr>
<tr>
<td>429</td>
<td>Mutase0 methylmalonic aciduria</td>
</tr>
<tr>
<td>430</td>
<td>Partial deficiency of methylmalonyl-CoA mutase</td>
</tr>
<tr>
<td>431</td>
<td>Mutase methylmalonic acidaemia</td>
</tr>
<tr>
<td>432</td>
<td>Mutase methylmalonic aciduria</td>
</tr>
<tr>
<td>433</td>
<td>Methylmalonyl-CoA epimerase deficiency</td>
</tr>
<tr>
<td>434</td>
<td>Methylmalonyl-CoA racemase deficiency</td>
</tr>
<tr>
<td>435</td>
<td>Methylmalonyl-CoA epimerase deficiency with sepiapterin reductase deficiency</td>
</tr>
<tr>
<td>436</td>
<td>Methylmalonyl-CoA racemase deficiency with sepiapterin reductase deficiency</td>
</tr>
<tr>
<td>437</td>
<td>Methylmalonic aciduria, vitamin B12 responsive</td>
</tr>
<tr>
<td>438</td>
<td>Adenosylcobalamin deficiency</td>
</tr>
<tr>
<td>439</td>
<td>Vitamin B12 responsive methylmalonic aciduria type cbl A</td>
</tr>
<tr>
<td>440</td>
<td>Vitamin B12 responsive methylmalonic aciduria type cbl B</td>
</tr>
<tr>
<td>441</td>
<td>Vitamin B12 responsive methylmalonic aciduria type cbl mut-</td>
</tr>
<tr>
<td>442</td>
<td>Propionic aciduria</td>
</tr>
<tr>
<td>443</td>
<td>Propionic acidaemia</td>
</tr>
<tr>
<td>444</td>
<td>Propionyl-CoA carboxylase deficiency</td>
</tr>
<tr>
<td>445</td>
<td>Ketotic glycinaemia</td>
</tr>
<tr>
<td>446</td>
<td>Ketotic hyperglycinaemia</td>
</tr>
<tr>
<td>447</td>
<td>Hyperglycinaemia with ketosis and leucopaenia</td>
</tr>
<tr>
<td>448</td>
<td>Isovaleric aciduria</td>
</tr>
<tr>
<td>449</td>
<td>Isovaleric acidaemia</td>
</tr>
<tr>
<td>450</td>
<td>Isovaleric acid CoA dehydrogenase deficiency</td>
</tr>
<tr>
<td>451</td>
<td>Multiple carboxylase deficiency</td>
</tr>
<tr>
<td>452</td>
<td>Multiple carboxylase deficiency due to biotinidase deficiency</td>
</tr>
<tr>
<td>453</td>
<td>Multiple carboxylase deficiency due to holocarboxylase synthetase deficiency</td>
</tr>
<tr>
<td>454</td>
<td>Neurodegeneration due to 3-hydroxyisobutyryl-CoA hydrolase deficiency</td>
</tr>
<tr>
<td>455</td>
<td>Beta-hydroxyisobutyryl-CoA deacylase deficiency</td>
</tr>
<tr>
<td>456</td>
<td>Methacrylic aciduria</td>
</tr>
<tr>
<td>457</td>
<td>3-hydroxyisobutyric aciduria</td>
</tr>
<tr>
<td>458</td>
<td>3-hydroxyisobutyrate dehydrogenase deficiency</td>
</tr>
<tr>
<td>459</td>
<td>3-hydroxy-3-methylglutaric aciduria</td>
</tr>
<tr>
<td>460</td>
<td>3-methylcrotonylglycinuria</td>
</tr>
<tr>
<td>461</td>
<td>3-methylglutaconic aciduria</td>
</tr>
<tr>
<td>462</td>
<td>MGA - [3-methylglutaconic aciduria]</td>
</tr>
<tr>
<td>463</td>
<td>3-methylglutaconic aciduria type 1</td>
</tr>
<tr>
<td>464</td>
<td>3-methylglutaconyl-CoA hydratase deficiency</td>
</tr>
<tr>
<td>465</td>
<td>3MG-CoA hydratase deficiency</td>
</tr>
<tr>
<td>466</td>
<td>MGA1- [3-methylglutaconic aciduria type 1]</td>
</tr>
<tr>
<td>467</td>
<td>Barth syndrome</td>
</tr>
<tr>
<td>468</td>
<td>3-methylglutaconic aciduria type 2</td>
</tr>
<tr>
<td>469</td>
<td>Tafazzin gene defect</td>
</tr>
<tr>
<td>470</td>
<td>MGA2 - [3-methylglutaconic aciduria type 2]</td>
</tr>
<tr>
<td>471</td>
<td>Cardioskeletal myopathy-neutropaenia</td>
</tr>
<tr>
<td>472</td>
<td>3-methylglutaconic aciduria type 3</td>
</tr>
<tr>
<td>473</td>
<td>Infantile optic atrophy with chorea and spastic paraplegia</td>
</tr>
<tr>
<td>474</td>
<td>Autosomal recessive optic atrophy type 3</td>
</tr>
<tr>
<td>475</td>
<td>Costeff optic atrophy syndrome</td>
</tr>
<tr>
<td>476</td>
<td>Optic atrophy plus syndrome</td>
</tr>
<tr>
<td>477</td>
<td>Costeff syndrome</td>
</tr>
<tr>
<td>478</td>
<td>MGA3 - [3-methylglutaconic aciduria type 3]</td>
</tr>
<tr>
<td>479</td>
<td>3-methylglutaconic aciduria type 4</td>
</tr>
<tr>
<td>480</td>
<td>MGA4 - [3-methylglutaconic aciduria type 4]</td>
</tr>
<tr>
<td>481</td>
<td>3-methylglutaconic aciduria type 5</td>
</tr>
<tr>
<td>482</td>
<td>Dilated cardiomyopathy with ataxia</td>
</tr>
<tr>
<td>483</td>
<td>DCMA - [Dilated cardiomyopathy with ataxia] syndrome</td>
</tr>
<tr>
<td>484</td>
<td>3-methylglutaconic aciduria with normal3 -methylglutaconyl-Co A hydratase</td>
</tr>
<tr>
<td>485</td>
<td>2-methylbutyric aciduria</td>
</tr>
<tr>
<td>486</td>
<td>Short/branched-chain acyl-coA dehydrogenase deficiency</td>
</tr>
<tr>
<td>487</td>
<td>2-methylbutyryl glycinuria</td>
</tr>
<tr>
<td>488</td>
<td>Developmental delay due to 2-methylbutyryl-CoA dehydrogenase deficiency</td>
</tr>
<tr>
<td>489</td>
<td>SBCAD - [Short/branched-chain acyl-coA dehydrogenase] deficiency</td>
</tr>
<tr>
<td>490</td>
<td>Isobutyric aciduria</td>
</tr>
<tr>
<td>491</td>
<td>Isobutyric acidaemia</td>
</tr>
<tr>
<td>492</td>
<td>Isobutyryl-CoA dehydrogenase deficiency</td>
</tr>
<tr>
<td>493</td>
<td>Methylmalonate semialdehyde dehydrogenase deficiency</td>
</tr>
<tr>
<td>494</td>
<td>Glutaric aciduria type 3</td>
</tr>
<tr>
<td>495</td>
<td>Glutaric acidaemia type 3</td>
</tr>
<tr>
<td>496</td>
<td>Glutaryl-CoA oxidase deficiency</td>
</tr>
<tr>
<td>497</td>
<td>Recessive limb-girdle muscular dystrophy</td>
</tr>
<tr>
<td>498</td>
<td>LGMD2 - [Limb-girdle muscular dystrophy] 2</td>
</tr>
<tr>
<td>499</td>
<td>Limb-girdle muscular dystrophy 2A, calpain-3 deficiency</td>
</tr>
<tr>
<td>500</td>
<td>Limb-girdle muscular dystrophy 2B, dysferlin deficiency</td>
</tr>
<tr>
<td>501</td>
<td>Limb-girdle muscular dystrophy 2C, gamma-sarcoglycan deficiency</td>
</tr>
<tr>
<td>502</td>
<td>Limb-girdle muscular dystrophy 2D, alpha-sarcoglycan deficiency</td>
</tr>
<tr>
<td>503</td>
<td>Limb-girdle muscular dystrophy 2E, beta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>504</td>
<td>Limb-girdle muscular dystrophy 2F, delta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>505</td>
<td>Limb-girdle muscular dystrophy 2G, telethonin gene mutation</td>
</tr>
<tr>
<td>506</td>
<td>Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation</td>
</tr>
<tr>
<td>507</td>
<td>LGMD 2H - [Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation]</td>
</tr>
<tr>
<td>508</td>
<td>Limb-girdle muscular dystrophy 2I, fukutin related protein gene mutation</td>
</tr>
<tr>
<td>509</td>
<td>FKRP - [fukutin related protein gene mutation]</td>
</tr>
<tr>
<td>510</td>
<td>LGMD 2I - [Limb-girdle muscular dystrophy 2I]</td>
</tr>
<tr>
<td>511</td>
<td>Limb-girdle muscular dystrophy 2J, Titin gene mutation</td>
</tr>
<tr>
<td>512</td>
<td>LGMD 2J - [Limb-girdle muscular dystrophy 2J, Titin gene mutation]</td>
</tr>
<tr>
<td>513</td>
<td>Limb-girdle muscular dystrophy 2K, protein-O-mannosyltransferase 1 transferase</td>
</tr>
<tr>
<td>514</td>
<td>POMT1 - [protein-O-mannosyltransferase 1 transferase]</td>
</tr>
<tr>
<td>515</td>
<td>LGMD 2K - [Limb-girdle muscular dystrophy 2K]</td>
</tr>
<tr>
<td>516</td>
<td>Limb-girdle muscular dystrophy 2L, AN05 gene mutation</td>
</tr>
<tr>
<td>517</td>
<td>LGMD 2L - [Limb-girdle muscular dystrophy 2L]</td>
</tr>
<tr>
<td>518</td>
<td>Limb-girdle muscular dystrophy 2M, POMGnT1 gene mutation</td>
</tr>
<tr>
<td>519</td>
<td>LGMD2M - [limb-girdle muscular dystrophy 2M]</td>
</tr>
<tr>
<td>520</td>
<td>Limb-girdle muscular dystrophy 2N, POMT2 gene mutation</td>
</tr>
<tr>
<td>521</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C2)</td>
</tr>
<tr>
<td>522</td>
<td>MDDGC2</td>
</tr>
<tr>
<td>523</td>
<td>LGMD2N - limb-girdle muscular dystrophy 2N]</td>
</tr>
<tr>
<td>524</td>
<td>Limb-girdle muscular dystrophy 2O, POMGNT1 gene mutation</td>
</tr>
<tr>
<td>525</td>
<td>LGMD2O - [limb-girdle muscular dystrophy 2O]</td>
</tr>
<tr>
<td>526</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C3)</td>
</tr>
<tr>
<td>527</td>
<td>MDDGC3</td>
</tr>
<tr>
<td>528</td>
<td>Limb-girdle muscular dystrophy 2Q, plectin deficiency</td>
</tr>
<tr>
<td>529</td>
<td>LGMD2Q - [limb-girdle muscular dystrophy 2Q]</td>
</tr>
<tr>
<td>530</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy C7</td>
</tr>
<tr>
<td>531</td>
<td>MDDGC7</td>
</tr>
<tr>
<td>532</td>
<td>Other specified disorders of mitochondrial oxidative phosphorylation</td>
</tr>
<tr>
<td>533</td>
<td>Mitochondrial oxidative phosphorylation disorders due to mitochondrial DNA anomalies</td>
</tr>
<tr>
<td>534</td>
<td>Respiratory chain disorders caused by mutations of mtDNA</td>
</tr>
<tr>
<td>535</td>
<td>OXPHOS - [oxidative phosphorylation] diseases due to mtDNA anomalies</td>
</tr>
<tr>
<td>536</td>
<td>Proximal tubulopathy - diabetes mellitus - cerebellar ataxia</td>
</tr>
<tr>
<td>537</td>
<td>Large-scale single deletions of mitochondrial DNA</td>
</tr>
<tr>
<td>538</td>
<td>Duplications of mitochondrial DNA</td>
</tr>
<tr>
<td>539</td>
<td>Mitochondrial oxidative phosphorylation disorders due to nuclear DNA anomalies</td>
</tr>
<tr>
<td>540</td>
<td>Respiratory chain disorders caused by mutations of nuclear DNA</td>
</tr>
<tr>
<td>541</td>
<td>OXPHOS - [oxidative phosphorylation] diseases due to nDNA anomalies</td>
</tr>
<tr>
<td>542</td>
<td>GRACILE - [Growth delay - aminoaciduria - cholestasis - iron overload - lactic acidosis - early death] syndrome</td>
</tr>
<tr>
<td>543</td>
<td>Growth delay - aminoaciduria - cholestasis - iron overload - lactic acidosis - early death</td>
</tr>
<tr>
<td>544</td>
<td>Cardioencephalopathy with hyperammonaemia</td>
</tr>
<tr>
<td>545</td>
<td>Mitochondrial respiratory chain complex V deficiency</td>
</tr>
<tr>
<td>546</td>
<td>Mitochondrial encephalocardiomyopathy due to TMEM70 deficiency</td>
</tr>
<tr>
<td>547</td>
<td>ATP synthase deficiency caused by TMEM70 deficiency</td>
</tr>
<tr>
<td>548</td>
<td>F1Fo ATPase deficiency</td>
</tr>
<tr>
<td>549</td>
<td>ATP synthase deficiency, nuclear-encoded</td>
</tr>
<tr>
<td>550</td>
<td>Exercise intolerance with lactic acidosis</td>
</tr>
<tr>
<td>551</td>
<td>Isolated oxidative phosphorylation defects with variable phenotype, not elsewhere classified</td>
</tr>
<tr>
<td>552</td>
<td>Mitochondrial respiratory chain complex I structural subunit gene defect</td>
</tr>
<tr>
<td>553</td>
<td>Mitochondrial respiratory chain complex I assembly gene defect</td>
</tr>
<tr>
<td>554</td>
<td>Mitochondrial respiratory chain complex II structural subunit gene defect</td>
</tr>
<tr>
<td>555</td>
<td>Mitochondrial respiratory chain complex II assembly gene defect</td>
</tr>
<tr>
<td>556</td>
<td>Mitochondrial respiratory chain complex III structural subunit gene defect</td>
</tr>
<tr>
<td>557</td>
<td>Mitochondrial respiratory chain complex III assembly gene defect</td>
</tr>
<tr>
<td>558</td>
<td>Mitochondrial respiratory chain complex IV structural subunit gene defect</td>
</tr>
<tr>
<td>559</td>
<td>Mitochondrial respiratory chain complex IV assembly gene defect</td>
</tr>
<tr>
<td>560</td>
<td>ATP synthase structural subunit gene defect</td>
</tr>
<tr>
<td>561</td>
<td>Mitochondrial respiratory chain complex V structural subunit gene defect</td>
</tr>
<tr>
<td>562</td>
<td>ATP synthase assembly gene defect</td>
</tr>
<tr>
<td>563</td>
<td>Mitochondrial respiratory chain complex V assembly gene defect</td>
</tr>
<tr>
<td>564</td>
<td>Renal tubulopathy - encephalopathy - liver failure</td>
</tr>
<tr>
<td>565</td>
<td>Mitochondrial oxidative phosphorylation disorders with no known genetic basis</td>
</tr>
<tr>
<td>566</td>
<td>Respiratory chain deficiencies with no known genetic basis</td>
</tr>
<tr>
<td>567</td>
<td>OXPHOS - [oxidative phosphorylation] diseases due to unspecified DNA anomalies</td>
</tr>
<tr>
<td>568</td>
<td>Deafness - opticoacoustic nerve atrophy - dementia</td>
</tr>
<tr>
<td>569</td>
<td>Jensen syndrome</td>
</tr>
<tr>
<td>570</td>
<td>FASTKD2-related infantile mitochondrial encephalomyopathy</td>
</tr>
<tr>
<td>571</td>
<td>Succinic acidaemia</td>
</tr>
<tr>
<td>572</td>
<td>Zellweger-like syndrome without peroxisomal anomalies</td>
</tr>
<tr>
<td>573</td>
<td>Ahn-Lerman-Sagie syndrome</td>
</tr>
<tr>
<td>574</td>
<td>Isolated mitochondrial respiratory chain complex I deficiency</td>
</tr>
<tr>
<td>575</td>
<td>Nicotinamide-adenine-dinucleotide coenzyme Q reductase deficiency</td>
</tr>
<tr>
<td>576</td>
<td>Ubiquinone deficiency</td>
</tr>
<tr>
<td>577</td>
<td>NADH-CoQ - [Nicotinamide-adenine-dinucleotide coenzyme Q] reductase deficiency</td>
</tr>
<tr>
<td>578</td>
<td>Isolated mitochondrial respiratory chain complex II deficiency</td>
</tr>
<tr>
<td>579</td>
<td>Succinate coenzyme Q reductase deficiency</td>
</tr>
<tr>
<td>580</td>
<td>Succinate-CoQ reductase deficiency</td>
</tr>
<tr>
<td>581</td>
<td>Isolated mitochondrial respiratory chain complex III deficiency</td>
</tr>
<tr>
<td>582</td>
<td>Coenzyme Q cytochrome C reductase deficiency</td>
</tr>
<tr>
<td>583</td>
<td>Ubiquinone dehydrogenase deficiency</td>
</tr>
<tr>
<td>584</td>
<td>Isolated mitochondrial respiratory chain complex IV deficiency</td>
</tr>
<tr>
<td>585</td>
<td>Cytochrome C oxidase deficiency</td>
</tr>
<tr>
<td>586</td>
<td>Ataxia - leukodystrophy - tubulopathy, due to cytochrome C oxidase deficiency</td>
</tr>
<tr>
<td>587</td>
<td>Pancreatic insufficiency - anaemia - hyperostosis</td>
</tr>
<tr>
<td>588</td>
<td>Dominant limb-girdle muscular dystrophy</td>
</tr>
<tr>
<td>589</td>
<td>LGMD1 - [limb-girdle muscular dystrophy] 1</td>
</tr>
<tr>
<td>590</td>
<td>Limb-girdle muscular dystrophy 1A, myotilin myopathy</td>
</tr>
<tr>
<td>591</td>
<td>LGMD 1A - [Limb-girdle muscular dystrophy 1A, myotilin myopathy]</td>
</tr>
<tr>
<td>592</td>
<td>Limb-girdle muscular dystrophy 1B, lamin myopathy</td>
</tr>
<tr>
<td>593</td>
<td>LGMD 1B - [Limb-girdle muscular dystrophy 1B, lamin myopathy]</td>
</tr>
<tr>
<td>594</td>
<td>Limb-girdle muscular dystrophy 1C, caveolin myopathy</td>
</tr>
<tr>
<td>595</td>
<td>LGMD 1C - [Limb-girdle muscular dystrophy 1C, caveolin myopathy]</td>
</tr>
<tr>
<td>596</td>
<td>Limb-girdle muscular dystrophy 1D, gene mapped to 6q23</td>
</tr>
<tr>
<td>597</td>
<td>Limb-girdle muscular dystrophy 1E, gene mapped to 7q</td>
</tr>
<tr>
<td>598</td>
<td>Limb-girdle muscular dystrophy 1F, gene mapped to 7q32.1-32.2</td>
</tr>
<tr>
<td>599</td>
<td>Limb-girdle muscular dystrophy 1G, gene mapped to 4q21</td>
</tr>
<tr>
<td>600</td>
<td>Limb-girdle muscular dystrophy 1H, gene mapped to 3p25.1p23</td>
</tr>
<tr>
<td>601</td>
<td>LGMD1H - [Limb-girdle muscular dystrophy] 1H</td>
</tr>
<tr>
<td>1</td>
<td>Other specified effects of external causes</td>
</tr>
<tr>
<td>2</td>
<td>Adverse effect physical factor</td>
</tr>
<tr>
<td>3</td>
<td>Jet lag</td>
</tr>
<tr>
<td>4</td>
<td>Environmental exposure, not elsewhere classified</td>
</tr>
<tr>
<td>5</td>
<td>exposure NOS</td>
</tr>
<tr>
<td>6</td>
<td>weather exposure NOS</td>
</tr>
<tr>
<td>7</td>
<td>Effects of abnormal gravitation forces</td>
</tr>
<tr>
<td>8</td>
<td>effects of: abnormal G forces</td>
</tr>
<tr>
<td>9</td>
<td>Effects of weightlessness</td>
</tr>
<tr>
<td>10</td>
<td>Glycogen storage disease</td>
</tr>
<tr>
<td>11</td>
<td>Glycogenosis</td>
</tr>
<tr>
<td>12</td>
<td>GSD - [Glycogen storage disease]</td>
</tr>
<tr>
<td>13</td>
<td>glycogen thesaurismosis</td>
</tr>
<tr>
<td>14</td>
<td>diffuse glycogenosis</td>
</tr>
<tr>
<td>15</td>
<td>generalised glycogen storage disease</td>
</tr>
<tr>
<td>16</td>
<td>generalised glycogenosis</td>
</tr>
<tr>
<td>17</td>
<td>generalised glycogen storage disease of infants</td>
</tr>
<tr>
<td>18</td>
<td>glycogen synthase deficiency</td>
</tr>
<tr>
<td>19</td>
<td>Glycogen storage disease due to glycogen synthase deficiency</td>
</tr>
<tr>
<td>20</td>
<td>Glycogen storage disease type 0</td>
</tr>
<tr>
<td>21</td>
<td>Glycogenosis type 0</td>
</tr>
<tr>
<td>22</td>
<td>GSD type 0</td>
</tr>
<tr>
<td>23</td>
<td>deficiency of glycogen synthetase</td>
</tr>
<tr>
<td>24</td>
<td>Glycogen storage disease due to liver glycogen synthase deficiency</td>
</tr>
<tr>
<td>25</td>
<td>GSD type 0A</td>
</tr>
<tr>
<td>26</td>
<td>Glycogen storage disease type 0A</td>
</tr>
<tr>
<td>27</td>
<td>Glycogenosis type 0A</td>
</tr>
<tr>
<td>28</td>
<td>Glycogen storage disease due to muscle or heart glycogen synthase deficiency</td>
</tr>
<tr>
<td>29</td>
<td>Glycogen storage disease type 0B</td>
</tr>
<tr>
<td>30</td>
<td>Glycogenosis type 0B</td>
</tr>
<tr>
<td>31</td>
<td>GSD type 0B</td>
</tr>
<tr>
<td>32</td>
<td>Cardiomyopathy-exercise intolerance due to muscle and heart glycogen deficiency</td>
</tr>
<tr>
<td>33</td>
<td>Glycogen storage disease due to glucose-6-phosphate system deficiency</td>
</tr>
<tr>
<td>34</td>
<td>Glycogen storage disease type 1</td>
</tr>
<tr>
<td>35</td>
<td>Glycogenosis type 1</td>
</tr>
<tr>
<td>36</td>
<td>GSD type 1</td>
</tr>
<tr>
<td>37</td>
<td>Hepatorenal glycogenosis</td>
</tr>
<tr>
<td>38</td>
<td>Von Gierke disease</td>
</tr>
<tr>
<td>39</td>
<td>HERS - [hepatorenal glycogen storage disease]</td>
</tr>
<tr>
<td>40</td>
<td>glycogen storage disease of liver and kidney</td>
</tr>
<tr>
<td>41</td>
<td>hepatorenal glycogen storage disease</td>
</tr>
<tr>
<td>42</td>
<td>Glycogen storage disease due to glucose-6-phosphatase deficiency</td>
</tr>
<tr>
<td>43</td>
<td>Glycogen storage disease type 1A</td>
</tr>
<tr>
<td>44</td>
<td>Glycogenosis type 1A</td>
</tr>
<tr>
<td>45</td>
<td>GSD type 1A</td>
</tr>
<tr>
<td>46</td>
<td>g6pd - [glucose-6-phosphate dehydrogenase deficiency]</td>
</tr>
<tr>
<td>47</td>
<td>glucose-6-phosphatase deficiency</td>
</tr>
<tr>
<td>48</td>
<td>deficiency of g-6pd</td>
</tr>
<tr>
<td>49</td>
<td>Glycogen storage disease due to glucose-6-phosphate transport defect</td>
</tr>
<tr>
<td>50</td>
<td>Glycogen storage disease type 1B</td>
</tr>
<tr>
<td>51</td>
<td>Glycogenosis type 1B</td>
</tr>
<tr>
<td>52</td>
<td>GSD1B</td>
</tr>
<tr>
<td>53</td>
<td>Glycogen storage disease type non-1A</td>
</tr>
<tr>
<td>54</td>
<td>Glycogenosis type non-1A</td>
</tr>
<tr>
<td>55</td>
<td>Glycogen storage disease due to glucose-6-phosphate translocase deficiency</td>
</tr>
<tr>
<td>56</td>
<td>Glucose-6-phosphate dehydrogenase deficiency</td>
</tr>
<tr>
<td>57</td>
<td>Glycogen storage disease due to acid maltase deficiency</td>
</tr>
<tr>
<td>58</td>
<td>Glycogen storage disease type 2</td>
</tr>
<tr>
<td>59</td>
<td>Glycogenosis type 2</td>
</tr>
<tr>
<td>60</td>
<td>GSD type 2</td>
</tr>
<tr>
<td>61</td>
<td>Acid maltase deficiency</td>
</tr>
<tr>
<td>62</td>
<td>Pompe disease</td>
</tr>
<tr>
<td>63</td>
<td>Acid alpha-1,4-glucosidase deficiency</td>
</tr>
<tr>
<td>64</td>
<td>alpha-glucosidase deficiency</td>
</tr>
<tr>
<td>65</td>
<td>deficiency of amyloglucosidase</td>
</tr>
<tr>
<td>66</td>
<td>Glycogen storage disease due to acid maltase deficiency, infantile onset</td>
</tr>
<tr>
<td>67</td>
<td>Glycogen storage disease type 2, infantile onset</td>
</tr>
<tr>
<td>68</td>
<td>Glycogenosis type 2, infantile onset</td>
</tr>
<tr>
<td>69</td>
<td>GSD2, infantile onset</td>
</tr>
<tr>
<td>70</td>
<td>Glycogen storage disease due to acid alpha-1,4-glucosidase deficiency, infantile onset</td>
</tr>
<tr>
<td>71</td>
<td>Infantile Pompe disease</td>
</tr>
<tr>
<td>72</td>
<td>lysosomal alpha-1,4-glucosidase deficiency (disorder)</td>
</tr>
<tr>
<td>73</td>
<td>Glycogen storage disease due to acid maltase deficiency, juvenile onset</td>
</tr>
<tr>
<td>74</td>
<td>Glycogen storage disease due to acid maltase deficiency, adult onset</td>
</tr>
<tr>
<td>75</td>
<td>Deficiency of exo-1,4-alpha-glucosidase</td>
</tr>
<tr>
<td>76</td>
<td>Deficiency of glucan 1,4-alpha-glucosidase</td>
</tr>
<tr>
<td>77</td>
<td>Deficiency of gamma-amylase</td>
</tr>
<tr>
<td>78</td>
<td>Deficiency of glucoamylase</td>
</tr>
<tr>
<td>79</td>
<td>Deficiency of glucoinvertase</td>
</tr>
<tr>
<td>80</td>
<td>Deficiency of glucosidosucrase</td>
</tr>
<tr>
<td>81</td>
<td>Deficiency of maltase</td>
</tr>
<tr>
<td>82</td>
<td>Glycogen storage disease due to LAMP-2 deficiency</td>
</tr>
<tr>
<td>83</td>
<td>Glycogen storage disease type 2B</td>
</tr>
<tr>
<td>84</td>
<td>Glycogenosis type 2B</td>
</tr>
<tr>
<td>85</td>
<td>GSD type 2B</td>
</tr>
<tr>
<td>86</td>
<td>Lysosomal glycogen storage disease with normal acid maltase activity</td>
</tr>
<tr>
<td>87</td>
<td>Danon disease</td>
</tr>
<tr>
<td>88</td>
<td>Glycogen storage disease due to glycogen debranching enzyme deficiency</td>
</tr>
<tr>
<td>89</td>
<td>Glycogen storage disease type 3</td>
</tr>
<tr>
<td>90</td>
<td>Glycogenosis type 3</td>
</tr>
<tr>
<td>91</td>
<td>GSD type 3</td>
</tr>
<tr>
<td>92</td>
<td>Amylo-1,6-glucosidase deficiency</td>
</tr>
<tr>
<td>93</td>
<td>Glycogen debranching deficiency</td>
</tr>
<tr>
<td>94</td>
<td>Cori-Forbes disease</td>
</tr>
<tr>
<td>95</td>
<td>Cori disease</td>
</tr>
<tr>
<td>96</td>
<td>Forbes disease</td>
</tr>
<tr>
<td>97</td>
<td>Forbes glycogen storage disease</td>
</tr>
<tr>
<td>98</td>
<td>debrancher deficiency glycogen storage disease</td>
</tr>
<tr>
<td>99</td>
<td>debrancher enzyme deficiency</td>
</tr>
<tr>
<td>100</td>
<td>deficiency of 6-alpha-d-glucosidase</td>
</tr>
<tr>
<td>101</td>
<td>amylo-1,6-glucosidase deficiency disorder</td>
</tr>
<tr>
<td>102</td>
<td>Glycogen storage disease due to muscle glycogen phosphorylase deficiency</td>
</tr>
<tr>
<td>103</td>
<td>Glycogen storage disease type 5</td>
</tr>
<tr>
<td>104</td>
<td>Glycogenosis type 5</td>
</tr>
<tr>
<td>105</td>
<td>GSD type 5</td>
</tr>
<tr>
<td>106</td>
<td>Myophosphorylase deficiency</td>
</tr>
<tr>
<td>107</td>
<td>McArdle disease</td>
</tr>
<tr>
<td>108</td>
<td>myophosphorylase deficiency glycogenosis</td>
</tr>
<tr>
<td>109</td>
<td>Glycogen storage disease due to liver glycogen phosphorylase deficiency</td>
</tr>
<tr>
<td>110</td>
<td>Glycogenosis due to liver phosphorylase deficiency</td>
</tr>
<tr>
<td>111</td>
<td>Glycogen storage disease type 6</td>
</tr>
<tr>
<td>112</td>
<td>Glycogenosis type 6</td>
</tr>
<tr>
<td>113</td>
<td>GSD type 6</td>
</tr>
<tr>
<td>114</td>
<td>Glycogen storage disease type 6B</td>
</tr>
<tr>
<td>115</td>
<td>Glycogenosis type 6B</td>
</tr>
<tr>
<td>116</td>
<td>GSD type 6B</td>
</tr>
<tr>
<td>117</td>
<td>Hers disease</td>
</tr>
<tr>
<td>118</td>
<td>deficiency of hepatophosphorylase</td>
</tr>
<tr>
<td>119</td>
<td>Glycogen storage disease due to muscle phosphofructokinase deficiency</td>
</tr>
<tr>
<td>120</td>
<td>Glycogen storage disease type 7</td>
</tr>
<tr>
<td>121</td>
<td>Glycogenosis type 7</td>
</tr>
<tr>
<td>122</td>
<td>GSD type 7</td>
</tr>
<tr>
<td>123</td>
<td>Muscle phosphofructokinase deficiency</td>
</tr>
<tr>
<td>124</td>
<td>Tarui disease</td>
</tr>
<tr>
<td>125</td>
<td>anaemia due to phosphofructo-aldolase deficiency</td>
</tr>
<tr>
<td>126</td>
<td>Glycogen storage disease due to glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>127</td>
<td>Glycogenosis due to phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>128</td>
<td>GSD due to phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>129</td>
<td>Glycogen storage disease due to liver glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>130</td>
<td>Hepatic phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>131</td>
<td>Glycogen storage disease type 8</td>
</tr>
<tr>
<td>132</td>
<td>Glycogenosis type 8</td>
</tr>
<tr>
<td>133</td>
<td>GSD8 - [glycogen storage disease type 8]</td>
</tr>
<tr>
<td>134</td>
<td>Glycogen storage disease type 6A</td>
</tr>
<tr>
<td>135</td>
<td>Glycogen storage disease type 9A</td>
</tr>
<tr>
<td>136</td>
<td>Glycogen storage disease type 9C</td>
</tr>
<tr>
<td>137</td>
<td>Glycogenosis type 6A</td>
</tr>
<tr>
<td>138</td>
<td>Glycogenosis type 9A</td>
</tr>
<tr>
<td>139</td>
<td>Glycogenosis type 9C</td>
</tr>
<tr>
<td>140</td>
<td>GSD type 9C - [glycogen storage disease type 9C]</td>
</tr>
<tr>
<td>141</td>
<td>GSD6A - [glycogen storage disease type 6A]</td>
</tr>
<tr>
<td>142</td>
<td>GSD9A - [glycogen storage disease type 9A]</td>
</tr>
<tr>
<td>143</td>
<td>Glycogen storage disease due to liver or muscle glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>144</td>
<td>Glycogen storage disease type 9B</td>
</tr>
<tr>
<td>145</td>
<td>Glycogenosis type 9B</td>
</tr>
<tr>
<td>146</td>
<td>GSD type 9B</td>
</tr>
<tr>
<td>147</td>
<td>Glycogen storage disease type 9</td>
</tr>
<tr>
<td>148</td>
<td>Glycogenosis type 9</td>
</tr>
<tr>
<td>149</td>
<td>GSD9 - [glycogen storage disease type 9]</td>
</tr>
<tr>
<td>150</td>
<td>Glycogen storage disease due to heart glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>151</td>
<td>Glycogen storage disease of heart</td>
</tr>
<tr>
<td>152</td>
<td>Cardiac glycogenosis</td>
</tr>
<tr>
<td>153</td>
<td>Glycogen storage disease type 9F</td>
</tr>
<tr>
<td>154</td>
<td>Glycogenosis type 9F</td>
</tr>
<tr>
<td>155</td>
<td>GSD9F</td>
</tr>
<tr>
<td>156</td>
<td>glycogen heart disease</td>
</tr>
<tr>
<td>157</td>
<td>glycogenic myocardial infiltration</td>
</tr>
<tr>
<td>158</td>
<td>glycogenic myocardium infiltration</td>
</tr>
<tr>
<td>159</td>
<td>cardiomegalia glycogenica diffusa</td>
</tr>
<tr>
<td>160</td>
<td>Glycogen storage disease due to muscle glycogen phosphorylase kinase deficiency</td>
</tr>
<tr>
<td>161</td>
<td>GSD9D - [glycogen storage disease type IXD]</td>
</tr>
<tr>
<td>162</td>
<td>Glycogen storage disease type 9D</td>
</tr>
<tr>
<td>163</td>
<td>Glycogen storage disease type 9E</td>
</tr>
<tr>
<td>164</td>
<td>Glycogenosis type 9D</td>
</tr>
<tr>
<td>165</td>
<td>Glycogenosis type 9E</td>
</tr>
<tr>
<td>166</td>
<td>GSD9E</td>
</tr>
<tr>
<td>167</td>
<td>muscle glycogen phosphorylase deficiency</td>
</tr>
<tr>
<td>168</td>
<td>glycogenosis type IXE</td>
</tr>
<tr>
<td>169</td>
<td>Glycogen storage disease due to muscle phosphoglycerate mutase deficiency</td>
</tr>
<tr>
<td>170</td>
<td>Glycogen storage disease type 10</td>
</tr>
<tr>
<td>171</td>
<td>Glycogenosis type 10</td>
</tr>
<tr>
<td>172</td>
<td>GSD type 10</td>
</tr>
<tr>
<td>173</td>
<td>Di Mauro disease</td>
</tr>
<tr>
<td>174</td>
<td>Glycogen storage disease due to GLUT2 deficiency</td>
</tr>
<tr>
<td>175</td>
<td>Glycogen storage disease type 11</td>
</tr>
<tr>
<td>176</td>
<td>Glycogenosis type 11</td>
</tr>
<tr>
<td>177</td>
<td>GSD type 11</td>
</tr>
<tr>
<td>178</td>
<td>Fanconi-Bickel glycogenosis</td>
</tr>
<tr>
<td>179</td>
<td>Bickel-Fanconi disease</td>
</tr>
<tr>
<td>180</td>
<td>Facilitated glucose transporter protein type 2 deficiency</td>
</tr>
<tr>
<td>181</td>
<td>Fanconi-Bickel syndrome</td>
</tr>
<tr>
<td>182</td>
<td>Glycogen storage disease due to aldolase A deficiency</td>
</tr>
<tr>
<td>183</td>
<td>Glycogen storage disease type 12</td>
</tr>
<tr>
<td>184</td>
<td>Glycogenosis type 12</td>
</tr>
<tr>
<td>185</td>
<td>GSD type 12</td>
</tr>
<tr>
<td>186</td>
<td>Glycogen storage disease due to muscle beta-enolase deficiency</td>
</tr>
<tr>
<td>187</td>
<td>Glycogen storage disease type 13</td>
</tr>
<tr>
<td>188</td>
<td>Glycogenosis type 13</td>
</tr>
<tr>
<td>189</td>
<td>GSD type 13</td>
</tr>
<tr>
<td>190</td>
<td>Glycogen storage disease due to phosphoglucomutase deficiency</td>
</tr>
<tr>
<td>191</td>
<td>Glycogen storage disease type 14</td>
</tr>
<tr>
<td>192</td>
<td>Glycogenosis type 14</td>
</tr>
<tr>
<td>193</td>
<td>GSD type 14</td>
</tr>
<tr>
<td>194</td>
<td>Glycogen storage disease due to glycogenin deficiency</td>
</tr>
<tr>
<td>195</td>
<td>Glycogen storage disease type 15</td>
</tr>
<tr>
<td>196</td>
<td>GSD type 15</td>
</tr>
<tr>
<td>197</td>
<td>Glocogenosis type 15</td>
</tr>
<tr>
<td>198</td>
<td>Glycogen storage disease due to phosphoglycerate kinase 1 deficiency</td>
</tr>
<tr>
<td>199</td>
<td>Glycogenosis due to phosphoglycerate kinase 1 deficiency</td>
</tr>
<tr>
<td>200</td>
<td>GSD due to phosphoglycerate kinase 1 deficiency</td>
</tr>
<tr>
<td>201</td>
<td>Glycogen storage disease due to lactate dehydrogenase deficiency</td>
</tr>
<tr>
<td>202</td>
<td>Glycogenosis due to lactate dehydrogenase deficiency</td>
</tr>
<tr>
<td>203</td>
<td>GSD due to lactate dehydrogenase deficiency</td>
</tr>
<tr>
<td>204</td>
<td>Glycogen storage disease due to muscle pyruvate kinase deficiency</td>
</tr>
<tr>
<td>205</td>
<td>Glycogenosis due to muscle pyruvate kinase deficiency</td>
</tr>
<tr>
<td>206</td>
<td>GSD due to muscle pyruvate kinase deficiency</td>
</tr>
<tr>
<td>207</td>
<td>Glycogen storage liver disease</td>
</tr>
<tr>
<td>208</td>
<td>hepatomegalia glycogenica diffusa</td>
</tr>
<tr>
<td>209</td>
<td>liver glycogen disease</td>
</tr>
<tr>
<td>210</td>
<td>liver phosphorylase deficiency</td>
</tr>
<tr>
<td>211</td>
<td>Glycogen storage disease due to branching-transferase deficiency</td>
</tr>
<tr>
<td>212</td>
<td>Andersen disease</td>
</tr>
<tr>
<td>213</td>
<td>brancher deficiency glycogen storage disease</td>
</tr>
<tr>
<td>214</td>
<td>branching enzyme deficiency</td>
</tr>
<tr>
<td>215</td>
<td>branching-transferase deficiency glycogenosis</td>
</tr>
<tr>
<td>216</td>
<td>deficiency of 1,4-alpha-glucan branching enzyme</td>
</tr>
<tr>
<td>217</td>
<td>deficiency of amylo-(1,4,6)-transglycosylase</td>
</tr>
<tr>
<td>218</td>
<td>Glycogen storage disease type 4</td>
</tr>
<tr>
<td>219</td>
<td>Glycogenosis type 4</td>
</tr>
<tr>
<td>220</td>
<td>GSD- [Glycogen storage disease] type 4</td>
</tr>
<tr>
<td>221</td>
<td>Dilated cardiomyopathy due to glycogen branching enzyme deficiency</td>
</tr>
<tr>
<td>222</td>
<td>Amylopectinosis</td>
</tr>
<tr>
<td>223</td>
<td>dilated cardiomyopathy due to Andersen's disease</td>
</tr>
<tr>
<td>224</td>
<td>dilated cardiomyopathy due to glycogen storage disease type 4 (GSD4)</td>
</tr>
<tr>
<td>225</td>
<td>Disorders of multiple glycosylation or other pathways</td>
</tr>
<tr>
<td>226</td>
<td>Dolichol-phosphate-mannose synthase 1 deficiency</td>
</tr>
<tr>
<td>227</td>
<td>GDP-Man: Dol-P-mannosyltransferase deficiency</td>
</tr>
<tr>
<td>228</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1E</td>
</tr>
<tr>
<td>229</td>
<td>Congenital disorder of glycosylation type 1E</td>
</tr>
<tr>
<td>230</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1E</td>
</tr>
<tr>
<td>231</td>
<td>Mannose-P-dolichol utilisation defect 1</td>
</tr>
<tr>
<td>232</td>
<td>Lec35 deficiency</td>
</tr>
<tr>
<td>233</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1F</td>
</tr>
<tr>
<td>234</td>
<td>Congenital disorder of glycosylation type 1F</td>
</tr>
<tr>
<td>235</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1F</td>
</tr>
<tr>
<td>236</td>
<td>Beta-1,4-galactosyltransferase deficiency</td>
</tr>
<tr>
<td>237</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2D</td>
</tr>
<tr>
<td>238</td>
<td>Congenital disorder of glycosylation type 2D</td>
</tr>
<tr>
<td>239</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2D</td>
</tr>
<tr>
<td>240</td>
<td>CMP-sialic acid transporter deficiency</td>
</tr>
<tr>
<td>241</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2F</td>
</tr>
<tr>
<td>242</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2F</td>
</tr>
<tr>
<td>243</td>
<td>Congenital disorder of glycosylation type 2F</td>
</tr>
<tr>
<td>244</td>
<td>Leukocyte adhesion deficiency type 2</td>
</tr>
<tr>
<td>245</td>
<td>Rambam-Hasharon syndrome</td>
</tr>
<tr>
<td>246</td>
<td>GDP-fucose transporter deficiency</td>
</tr>
<tr>
<td>247</td>
<td>LAD-II - [Leukocyte adhesion deficiency type 2]</td>
</tr>
<tr>
<td>248</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2C</td>
</tr>
<tr>
<td>249</td>
<td>Dolichol kinase deficiency</td>
</tr>
<tr>
<td>250</td>
<td>Hypotonia or ichthyosis due to dolichol phosphate deficiency</td>
</tr>
<tr>
<td>251</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1M</td>
</tr>
<tr>
<td>252</td>
<td>Congenital disorder of glycosylation type 1M</td>
</tr>
<tr>
<td>253</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1M</td>
</tr>
<tr>
<td>254</td>
<td>Conserved oligomeric Golgi complex deficiencies</td>
</tr>
<tr>
<td>255</td>
<td>Component of conserved oligomeric Golgi complex 1 deficiency</td>
</tr>
<tr>
<td>256</td>
<td>CDG syndrome type 2G</td>
</tr>
<tr>
<td>257</td>
<td>Component of conserved oligomeric Golgi complex 4 deficiency</td>
</tr>
<tr>
<td>258</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2J</td>
</tr>
<tr>
<td>259</td>
<td>Congenital disorder of glycosylation type 2J</td>
</tr>
<tr>
<td>260</td>
<td>Component of conserved oligomeric Golgi complex 5 deficiency</td>
</tr>
<tr>
<td>261</td>
<td>Component of conserved oligomeric Golgi complex 7 deficiency</td>
</tr>
<tr>
<td>262</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2E</td>
</tr>
<tr>
<td>263</td>
<td>Congenital disorder of glycosylation type 2E</td>
</tr>
<tr>
<td>264</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2E</td>
</tr>
<tr>
<td>265</td>
<td>Component of conserved oligomeric Golgi complex 8 deficiency</td>
</tr>
<tr>
<td>266</td>
<td>Congenital disorder of glycosylation type 2h</td>
</tr>
<tr>
<td>267</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2H</td>
</tr>
<tr>
<td>268</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2H</td>
</tr>
<tr>
<td>269</td>
<td>V-ATPase deficiencies</td>
</tr>
<tr>
<td>270</td>
<td>Disorders of protein N-glycosylation</td>
</tr>
<tr>
<td>271</td>
<td>Phosphomannomutase 2 deficiency</td>
</tr>
<tr>
<td>272</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1A</td>
</tr>
<tr>
<td>273</td>
<td>Congenital disorder of glycosylation type 1A</td>
</tr>
<tr>
<td>274</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1A</td>
</tr>
<tr>
<td>275</td>
<td>Phosphomannose isomerase deficiency</td>
</tr>
<tr>
<td>276</td>
<td>Saguenay-Lac-Saint-Jean syndrome</td>
</tr>
<tr>
<td>277</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1B</td>
</tr>
<tr>
<td>278</td>
<td>Congenital disorder of glycosylation type 1B</td>
</tr>
<tr>
<td>279</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1B</td>
</tr>
<tr>
<td>280</td>
<td>SLSJ - [Saguenay-Lac-Saint-Jean] syndrome</td>
</tr>
<tr>
<td>281</td>
<td>Glucosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>282</td>
<td>Dol-P-Glc: Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>283</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1C</td>
</tr>
<tr>
<td>284</td>
<td>Congenital disorder of glycosylation type 1C</td>
</tr>
<tr>
<td>285</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1C</td>
</tr>
<tr>
<td>286</td>
<td>Mannosyltransferase 6 deficiency</td>
</tr>
<tr>
<td>287</td>
<td>Dol-P-Man: Man5-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>288</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1D</td>
</tr>
<tr>
<td>289</td>
<td>Congenital disorder of glycosylation type 1D</td>
</tr>
<tr>
<td>290</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1D</td>
</tr>
<tr>
<td>291</td>
<td>Mannosyltransferase 8 deficiency</td>
</tr>
<tr>
<td>292</td>
<td>Dol-P-Man: Man7-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>293</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1G</td>
</tr>
<tr>
<td>294</td>
<td>Congenital disorder of glycosylation type 1G</td>
</tr>
<tr>
<td>295</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1G</td>
</tr>
<tr>
<td>296</td>
<td>Glucosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>297</td>
<td>Dol-P-Glc: Glc1-Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>298</td>
<td>Carbohydrate deficient glycoprotein syndrome 1H</td>
</tr>
<tr>
<td>299</td>
<td>Congenital disorder of glycosylation type 1H</td>
</tr>
<tr>
<td>300</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1H</td>
</tr>
<tr>
<td>301</td>
<td>Mannosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>302</td>
<td>Dol-P-Man: Man1-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>303</td>
<td>Carbohydrate deficient glycoprotein syndrome 1I</td>
</tr>
<tr>
<td>304</td>
<td>Congenital disorder of glycosylation 1I</td>
</tr>
<tr>
<td>305</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1I</td>
</tr>
<tr>
<td>306</td>
<td>Dolichyl-phosphate N-acetylgalactosamine phosphotransferase deficiency</td>
</tr>
<tr>
<td>307</td>
<td>UDP-GlcNAc: Dol-P-GlcNac-P transferase deficiency</td>
</tr>
<tr>
<td>308</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1J</td>
</tr>
<tr>
<td>309</td>
<td>Congenital disorder of glycosylation type 1J</td>
</tr>
<tr>
<td>310</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1J</td>
</tr>
<tr>
<td>311</td>
<td>Mannosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>312</td>
<td>Dol-P-Man: GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>313</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1K</td>
</tr>
<tr>
<td>314</td>
<td>Congenital disorder of glycosylation type 1K</td>
</tr>
<tr>
<td>315</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1K</td>
</tr>
<tr>
<td>316</td>
<td>Mannosyltransferase 7-9 deficiency</td>
</tr>
<tr>
<td>317</td>
<td>Congenital disorder of glycosylation type 1L</td>
</tr>
<tr>
<td>318</td>
<td>Dol-P-Man: Man6 and Man8-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>319</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1L</td>
</tr>
<tr>
<td>320</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1L</td>
</tr>
<tr>
<td>321</td>
<td>M5-DLO flippase deficiency</td>
</tr>
<tr>
<td>322</td>
<td>Man5GlcNAc2-PP-Dol flippase deficiency</td>
</tr>
<tr>
<td>323</td>
<td>RTF1-CDG</td>
</tr>
<tr>
<td>324</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1N</td>
</tr>
<tr>
<td>325</td>
<td>N-acetylglucosaminyltransferase deficiency</td>
</tr>
<tr>
<td>326</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2A</td>
</tr>
<tr>
<td>327</td>
<td>Congenital disorder of glycosylation type 2A</td>
</tr>
<tr>
<td>328</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2A</td>
</tr>
<tr>
<td>329</td>
<td>Glucosidase 1 deficiency</td>
</tr>
<tr>
<td>330</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2B</td>
</tr>
<tr>
<td>331</td>
<td>Congenital disorder of glycosylation type 2B</td>
</tr>
<tr>
<td>332</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2B</td>
</tr>
<tr>
<td>333</td>
<td>TUSC3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>334</td>
<td>TUSC3-CDG</td>
</tr>
<tr>
<td>335</td>
<td>SRD5A3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>336</td>
<td>SRD5A3-CDG</td>
</tr>
<tr>
<td>337</td>
<td>Congenital disorder of glycosylation due to steroid 5-alpha-reductase type 3 deficiency</td>
</tr>
<tr>
<td>338</td>
<td>Intellectual deficit - cataract - coloboma - kyphosis</td>
</tr>
<tr>
<td>339</td>
<td>Kahrizi syndrome</td>
</tr>
<tr>
<td>340</td>
<td>Intellectual deficit, Kahrizi type</td>
</tr>
<tr>
<td>341</td>
<td>DPM3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>342</td>
<td>Congenital disorder of glycosylation type 1O</td>
</tr>
<tr>
<td>343</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1O</td>
</tr>
<tr>
<td>344</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1O</td>
</tr>
<tr>
<td>345</td>
<td>ALG11 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>346</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1P</td>
</tr>
<tr>
<td>347</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1P</td>
</tr>
<tr>
<td>348</td>
<td>Congenital disorder of glycosylation type 1P</td>
</tr>
<tr>
<td>349</td>
<td>Phosphoglucomutase-1 deficiency</td>
</tr>
<tr>
<td>350</td>
<td>PGM1-CDG - [Phosphoglucomutase-1 deficiency]</td>
</tr>
<tr>
<td>351</td>
<td>Congenital disorder of glycosylation type 1t</td>
</tr>
<tr>
<td>352</td>
<td>Hyperprolactinaemia</td>
</tr>
<tr>
<td>353</td>
<td>Drug-induced hyperprolactinaemia</td>
</tr>
<tr>
<td>354</td>
<td>Hypothyroidism-associated hyperprolactinemia</td>
</tr>
<tr>
<td>355</td>
<td>Functional hyperprolactinoma</td>
</tr>
<tr>
<td>356</td>
<td>Chiari-Frommel Syndrome</td>
</tr>
<tr>
<td>357</td>
<td>Argonz-del Castillo Syndrome</td>
</tr>
<tr>
<td>358</td>
<td>Ahumada-Del Castillo syndrome</td>
</tr>
<tr>
<td>359</td>
<td>amenorrhoea-galactorrhoea syndrome</td>
</tr>
<tr>
<td>360</td>
<td>non-pregnancy related a-g syndrome</td>
</tr>
<tr>
<td>361</td>
<td>Hyperprolactinemia caused by other hypothalamo-pituitary disorders</td>
</tr>
<tr>
<td>362</td>
<td>Macroprolactinaemia</td>
</tr>
<tr>
<td>363</td>
<td>Neuroendocrine neoplasm of duodenum</td>
</tr>
<tr>
<td>364</td>
<td>Neuroendocrine tumour of duodenum</td>
</tr>
<tr>
<td>365</td>
<td>Duodenal neuroendocrine tumour</td>
</tr>
<tr>
<td>366</td>
<td>NET - [neuroendocrine tumour] of duodenum</td>
</tr>
<tr>
<td>367</td>
<td>NET - [neuroendocrine tumour] of duodenum, G1 (carcinoid)</td>
</tr>
<tr>
<td>368</td>
<td>NET - [neuroendocrine tumour] of duodenum, G2</td>
</tr>
<tr>
<td>369</td>
<td>Neuroendocrine carcinoma of duodenum</td>
</tr>
<tr>
<td>370</td>
<td>NEC - [neuroendocrine carcinoma] of duodenum</td>
</tr>
<tr>
<td>371</td>
<td>Large cell neuroendocrine carcinoma of duodenum</td>
</tr>
<tr>
<td>372</td>
<td>Small cell neuroendocrine carcinoma of duodenum</td>
</tr>
<tr>
<td>373</td>
<td>Other specified neuroendocrine neoplasm of duodenum</td>
</tr>
<tr>
<td>374</td>
<td>EC cell serotonin-producing neuroendocrine tumour of duodenum</td>
</tr>
<tr>
<td>375</td>
<td>Gangliocytic paraganglioma of duodenum</td>
</tr>
<tr>
<td>376</td>
<td>CoGNET - [Composite gangliocytoma/neuroma and neuroendocrine tumour]</td>
</tr>
<tr>
<td>377</td>
<td>Composite gangliocytoma/neuroma and neuroendocrine tumour</td>
</tr>
<tr>
<td>378</td>
<td>gangliocytic NET - [neuroendocrine tumour]</td>
</tr>
<tr>
<td>379</td>
<td>gangliocytic neuroendocrine tumour</td>
</tr>
<tr>
<td>380</td>
<td>MiGNeN - [Mixed ganglioneuroma-neuroendocrine neoplasm]</td>
</tr>
<tr>
<td>381</td>
<td>Mixed ganglioneuroma-neuroendocrine neoplasm</td>
</tr>
<tr>
<td>382</td>
<td>neoplasm of paraganglion</td>
</tr>
<tr>
<td>383</td>
<td>Somatostatin-producing neuroendocrine tumour of duodenum</td>
</tr>
<tr>
<td>384</td>
<td>Neoplasms of unknown behaviour of oral cavity or digestive organs, unspecified site</td>
</tr>
<tr>
<td>385</td>
<td>Neoplasms of unknown behaviour of oral cavity or digestive organs</td>
</tr>
<tr>
<td>386</td>
<td>abdominal viscera growth</td>
</tr>
<tr>
<td>387</td>
<td>gastrointestinal neoplasm</td>
</tr>
<tr>
<td>388</td>
<td>oral cavity or digestive organ growth</td>
</tr>
<tr>
<td>389</td>
<td>oral cavity or digestive organ tumour</td>
</tr>
<tr>
<td>390</td>
<td>Cystic papillary tumour unknown behaviour of unspecified site</td>
</tr>
<tr>
<td>391</td>
<td>Solid and cystic tumour of unspecified site</td>
</tr>
<tr>
<td>392</td>
<td>Gastrin cell tumour of unspecified site</td>
</tr>
<tr>
<td>393</td>
<td>G cell tumour unknown behaviour of unspecified site</td>
</tr>
<tr>
<td>394</td>
<td>Solid and papillary epithelial neoplasm of unspecified site</td>
</tr>
<tr>
<td>395</td>
<td>Other specified syndromes with multiple structural anomalies, not of environmental origin</td>
</tr>
<tr>
<td>396</td>
<td>46,XX disorder of sex development - anorectal anomalies</td>
</tr>
<tr>
<td>397</td>
<td>46,XX DSD - anorectal anomalies</td>
</tr>
<tr>
<td>398</td>
<td>Aarskog-Scott syndrome</td>
</tr>
<tr>
<td>399</td>
<td>Aarskog syndrome</td>
</tr>
<tr>
<td>400</td>
<td>Faciodigitogenital syndrome</td>
</tr>
<tr>
<td>401</td>
<td>Faciogenital dysplasia</td>
</tr>
<tr>
<td>402</td>
<td>Ablepharon-macrostomia syndrome</td>
</tr>
<tr>
<td>403</td>
<td>Acro-renal-mandibular syndrome</td>
</tr>
<tr>
<td>404</td>
<td>Acrocallosal syndrome</td>
</tr>
<tr>
<td>405</td>
<td>Acrocardiofacial syndrome</td>
</tr>
<tr>
<td>406</td>
<td>Acrocephalopolydactyly</td>
</tr>
<tr>
<td>407</td>
<td>Acrocephalopolydactylous dysplasia</td>
</tr>
<tr>
<td>408</td>
<td>Elejalde syndrome</td>
</tr>
<tr>
<td>409</td>
<td>Acrorenal syndrome</td>
</tr>
<tr>
<td>410</td>
<td>Adams-Oliver syndrome</td>
</tr>
<tr>
<td>411</td>
<td>Agonadism - dextrocardia - diaphragmatic hernia</td>
</tr>
<tr>
<td>412</td>
<td>Ankyloblepharon filiforme adnatum - cleft palate</td>
</tr>
<tr>
<td>413</td>
<td>Arthrogryposis multiplex congenita - lissencephaly</td>
</tr>
<tr>
<td>414</td>
<td>Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis</td>
</tr>
<tr>
<td>415</td>
<td>Tuberous sclerosis/polycystic kidney disease contiguous gene syndrome</td>
</tr>
<tr>
<td>416</td>
<td>Bifid nose - anorectal and renal anomalies</td>
</tr>
<tr>
<td>417</td>
<td>BNAR - [Bifid nose - anorectal and renal anomalies] syndrome</td>
</tr>
<tr>
<td>418</td>
<td>Blepharophimosis-intellectual deficit syndrome, Ohdo type</td>
</tr>
<tr>
<td>419</td>
<td>Boissel lethal polymalformative syndrome</td>
</tr>
<tr>
<td>420</td>
<td>Branchio-oculo-facial syndrome</td>
</tr>
<tr>
<td>421</td>
<td>Branchio-otic syndrome</td>
</tr>
<tr>
<td>422</td>
<td>Branchio-oto-renal syndrome</td>
</tr>
<tr>
<td>423</td>
<td>BOR - [Branchio-oto-renal] syndrome</td>
</tr>
<tr>
<td>424</td>
<td>Branchio-skeleto-genital syndrome</td>
</tr>
<tr>
<td>425</td>
<td>CAMFAK syndrome</td>
</tr>
<tr>
<td>426</td>
<td>Cataract - microcephaly - arthrogryposis - kyphosis</td>
</tr>
<tr>
<td>427</td>
<td>CAMAK - [Cataract - microcephaly - arthrogryposis - kyphosis] syndrome</td>
</tr>
<tr>
<td>428</td>
<td>Cataract - microcephaly - failure to thrive - kyphoscoliosis</td>
</tr>
<tr>
<td>429</td>
<td>Camptodactyly - tall stature - scoliosis - hearing loss</td>
</tr>
<tr>
<td>430</td>
<td>Cantrell pentalogy</td>
</tr>
<tr>
<td>431</td>
<td>Cantrell syndrome</td>
</tr>
<tr>
<td>432</td>
<td>Pentalogy of Cantrell</td>
</tr>
<tr>
<td>433</td>
<td>Capra-DeMarco syndrome</td>
</tr>
<tr>
<td>434</td>
<td>Craniosynostosis - hydrocephalus - Chiari I malformation - radio-ulnar synostosis</td>
</tr>
<tr>
<td>435</td>
<td>Berant syndrome</td>
</tr>
<tr>
<td>436</td>
<td>Familial scaphocephaly - radioulnar synostosis</td>
</tr>
<tr>
<td>437</td>
<td>Cardiocranial syndrome, Pfeiffer type</td>
</tr>
<tr>
<td>438</td>
<td>Cardioskeletal syndromes</td>
</tr>
<tr>
<td>439</td>
<td>Heart-hand syndromes</td>
</tr>
<tr>
<td>440</td>
<td>Brachydactyly - long thumb</td>
</tr>
<tr>
<td>441</td>
<td>Heart-hand syndrome type 1</td>
</tr>
<tr>
<td>442</td>
<td>Holt-Oram syndrome</td>
</tr>
<tr>
<td>443</td>
<td>Heart-hand syndrome type 2</td>
</tr>
<tr>
<td>444</td>
<td>Heart-hand syndrome type 3</td>
</tr>
<tr>
<td>445</td>
<td>Heart-hand syndrome, Spanish type</td>
</tr>
<tr>
<td>446</td>
<td>Heart-hand syndrome, Slovenian type</td>
</tr>
<tr>
<td>447</td>
<td>Microcephaly - facio-cardio-skeletal syndrome, Hadziselimovic type</td>
</tr>
<tr>
<td>448</td>
<td>Carey-Fineman-Ziter syndrome</td>
</tr>
<tr>
<td>449</td>
<td>Catel-Manzke syndrome</td>
</tr>
<tr>
<td>450</td>
<td>Caudal duplication</td>
</tr>
<tr>
<td>451</td>
<td>Caudal regression sequence</td>
</tr>
<tr>
<td>452</td>
<td>Sacral agenesis</td>
</tr>
<tr>
<td>453</td>
<td>Cavernous haemangiomas of face - supraumbilical midline raphe</td>
</tr>
<tr>
<td>454</td>
<td>Cloverleaf skull - multiple congenital anomalies</td>
</tr>
<tr>
<td>455</td>
<td>Coffin-Lowry syndrome</td>
</tr>
<tr>
<td>456</td>
<td>Coloboma of macula - brachydactyly type B</td>
</tr>
<tr>
<td>457</td>
<td>Congenital cataracts - facial dysmorphism - neuropathy</td>
</tr>
<tr>
<td>458</td>
<td>Cornelia de Lange syndrome</td>
</tr>
<tr>
<td>459</td>
<td>Costello syndrome</td>
</tr>
<tr>
<td>460</td>
<td>Cranio-facio-cardio-skeletal syndrome</td>
</tr>
<tr>
<td>461</td>
<td>Cantu syndrome</td>
</tr>
<tr>
<td>462</td>
<td>Craniosynostosis - anal anomalies - porokeratosis</td>
</tr>
<tr>
<td>463</td>
<td>Craniosynostosis - cataract</td>
</tr>
<tr>
<td>464</td>
<td>Craniosynostosis - Dandy-Walker malformation - hydrocephalus</td>
</tr>
<tr>
<td>465</td>
<td>Craniosynostosis - synostoses - hypertensive nephropathy</td>
</tr>
<tr>
<td>466</td>
<td>Currarino triad</td>
</tr>
<tr>
<td>467</td>
<td>Dandy Walker malformation - facial haemangioma</td>
</tr>
<tr>
<td>468</td>
<td>Deafness - ear malformation - facial palsy</td>
</tr>
<tr>
<td>469</td>
<td>Double uterus - hemivagina - renal agenesis</td>
</tr>
<tr>
<td>470</td>
<td>Ectrodactyly - cleft palate</td>
</tr>
<tr>
<td>471</td>
<td>Endocrine-cerebro-osteodysplasia syndrome</td>
</tr>
<tr>
<td>472</td>
<td>Endosteal sclerosis - cerebellar hypoplasia</td>
</tr>
<tr>
<td>473</td>
<td>Familial intestinal malrotation - facial anomalies</td>
</tr>
<tr>
<td>474</td>
<td>Femoral-facial syndrome</td>
</tr>
<tr>
<td>475</td>
<td>fetal akinesia sequence</td>
</tr>
<tr>
<td>476</td>
<td>FG syndrome</td>
</tr>
<tr>
<td>477</td>
<td>Keller syndrome</td>
</tr>
<tr>
<td>478</td>
<td>Opitz-Kaveggia syndrome</td>
</tr>
<tr>
<td>479</td>
<td>Filippi syndrome</td>
</tr>
<tr>
<td>480</td>
<td>Floating-Harbor syndrome</td>
</tr>
<tr>
<td>481</td>
<td>Fryns syndrome</td>
</tr>
<tr>
<td>482</td>
<td>Fuhrmann-Rieger-de Sousa syndrome</td>
</tr>
<tr>
<td>483</td>
<td>Fibular hypoplasia or aplasia - femoral bowing - oligodactyly</td>
</tr>
<tr>
<td>484</td>
<td>Fuhrmann syndrome</td>
</tr>
<tr>
<td>485</td>
<td>Genito-palato-cardiac syndrome</td>
</tr>
<tr>
<td>486</td>
<td>Genito-patellar syndrome</td>
</tr>
<tr>
<td>487</td>
<td>Goldberg-Shprintzen megacolon syndrome</td>
</tr>
<tr>
<td>488</td>
<td>Haddad syndrome</td>
</tr>
<tr>
<td>489</td>
<td>Hand-foot-uterus syndrome</td>
</tr>
<tr>
<td>490</td>
<td>Hand-foot-genital syndrome</td>
</tr>
<tr>
<td>491</td>
<td>HERNS syndrome</td>
</tr>
<tr>
<td>492</td>
<td>Holmes-Schepens syndrome</td>
</tr>
<tr>
<td>493</td>
<td>Donnai-Barrow syndrome</td>
</tr>
<tr>
<td>494</td>
<td>Hypopituitarism - micropenis - cleft lip or palate</td>
</tr>
<tr>
<td>495</td>
<td>Hypotelorism - cleft palate - hypospadias</td>
</tr>
<tr>
<td>496</td>
<td>Juberg-Hayward syndrome</td>
</tr>
<tr>
<td>497</td>
<td>Kabuki syndrome</td>
</tr>
<tr>
<td>498</td>
<td>KBG syndrome</td>
</tr>
<tr>
<td>499</td>
<td>Keutel syndrome</td>
</tr>
<tr>
<td>500</td>
<td>Kleefstra syndrome</td>
</tr>
<tr>
<td>501</td>
<td>Knobloch syndrome</td>
</tr>
<tr>
<td>502</td>
<td>Limb body wall complex</td>
</tr>
<tr>
<td>503</td>
<td>Lethal arthrogryposis - anterior horn cell disease</td>
</tr>
<tr>
<td>504</td>
<td>Vuopala disease</td>
</tr>
<tr>
<td>505</td>
<td>LAAHD - [Lethal arthrogryposis - anterior horn cell disease]</td>
</tr>
<tr>
<td>506</td>
<td>Lowry-MacLean syndrome</td>
</tr>
<tr>
<td>507</td>
<td>Malpuech syndrome</td>
</tr>
<tr>
<td>508</td>
<td>Marfanoid habitus - intellectual deficit, autosomal recessive</td>
</tr>
<tr>
<td>509</td>
<td>McDonough syndrome</td>
</tr>
<tr>
<td>510</td>
<td>Meacham syndrome</td>
</tr>
<tr>
<td>511</td>
<td>Megacystis - microcolon - intestinal hypoperistalsis - hydronephrosis</td>
</tr>
<tr>
<td>512</td>
<td>Berdon syndrome</td>
</tr>
<tr>
<td>513</td>
<td>MMIHS - [Megacystis - microcolon - intestinal hypoperistalsis - hydronephrosis]</td>
</tr>
<tr>
<td>514</td>
<td>Microgastria - limb reduction defect</td>
</tr>
<tr>
<td>515</td>
<td>Moebius syndrome</td>
</tr>
<tr>
<td>516</td>
<td>Mowat-Wilson syndrome</td>
</tr>
<tr>
<td>517</td>
<td>MULIBREY nanism</td>
</tr>
<tr>
<td>518</td>
<td>Perheentupa syndrome</td>
</tr>
<tr>
<td>519</td>
<td>Pericardial constriction - growth failure</td>
</tr>
<tr>
<td>520</td>
<td>MULIBREY dwarfism</td>
</tr>
<tr>
<td>521</td>
<td>Muscle-liver-brain-eye nanism</td>
</tr>
<tr>
<td>522</td>
<td>Mullerian duct anomalies - limb anomalies</td>
</tr>
<tr>
<td>523</td>
<td>Nance-Horan syndrome</td>
</tr>
<tr>
<td>524</td>
<td>Noonan syndrome or related disorders</td>
</tr>
<tr>
<td>525</td>
<td>Noonan-like syndrome with loose anagen hair</td>
</tr>
<tr>
<td>526</td>
<td>LEOPARD syndrome</td>
</tr>
<tr>
<td>527</td>
<td>Noonan with multiple lentigines syndrome</td>
</tr>
<tr>
<td>528</td>
<td>Neurofibromatosis-Noonan syndrome</td>
</tr>
<tr>
<td>529</td>
<td>Ochoa syndrome</td>
</tr>
<tr>
<td>530</td>
<td>Oculo-digito-oesophageal-duodenal syndrome</td>
</tr>
<tr>
<td>531</td>
<td>ODOD - [Oculo-digito-oesophageal-duodenal syndrome]</td>
</tr>
<tr>
<td>532</td>
<td>Oculopalatocerebral syndrome</td>
</tr>
<tr>
<td>533</td>
<td>Okihiro syndrome</td>
</tr>
<tr>
<td>534</td>
<td>Opitz BBB/G syndrome</td>
</tr>
<tr>
<td>535</td>
<td>Osteopathia striata - pigmentary dermopathy - white forelock</td>
</tr>
<tr>
<td>536</td>
<td>Osteopoikilosis - short stature - intellectual deficit</td>
</tr>
<tr>
<td>537</td>
<td>12q14 deletion</td>
</tr>
<tr>
<td>538</td>
<td>Osteosclerosis - developmental delay - craniosynostosis</td>
</tr>
<tr>
<td>539</td>
<td>Osteosclerosis - ichthyosis - premature ovarian failure</td>
</tr>
<tr>
<td>540</td>
<td>Osteosclerosis abnormalities of nervous system or meninges</td>
</tr>
<tr>
<td>541</td>
<td>Overgrowth - craniosynostosis - arthrogryposis</td>
</tr>
<tr>
<td>542</td>
<td>Pai syndrome</td>
</tr>
<tr>
<td>543</td>
<td>Pallister-Hall syndrome</td>
</tr>
<tr>
<td>544</td>
<td>PELVIS syndrome</td>
</tr>
<tr>
<td>545</td>
<td>PHACE syndrome</td>
</tr>
<tr>
<td>546</td>
<td>PHACE - [posterior fossa malformations – haemangiomas – arterial anomalies – cardiac defects – eye abnormalities – sternal cleft – supraumbilical raphe] syndrome</td>
</tr>
<tr>
<td>547</td>
<td>Phocomelia, Schinzel type</td>
</tr>
<tr>
<td>548</td>
<td>Pitt-Hopkins syndrome</td>
</tr>
<tr>
<td>549</td>
<td>Pitt-Rogers-Danks syndrome</td>
</tr>
<tr>
<td>550</td>
<td>RAPADILINO syndrome</td>
</tr>
<tr>
<td>551</td>
<td>Retinitis pigmentosa - hypopituitarism - nephronophthisis - skeletal dysplasia</td>
</tr>
<tr>
<td>552</td>
<td>RHYNS - [Retinitis pigmentosa - hypopituitarism - nephronophthisis - skeletal dysplasia] syndrome</td>
</tr>
<tr>
<td>553</td>
<td>Richieri Costa-Pereira syndrome</td>
</tr>
<tr>
<td>554</td>
<td>Roberts syndrome</td>
</tr>
<tr>
<td>555</td>
<td>/SC phocomelia</td>
</tr>
<tr>
<td>556</td>
<td>Shprintzen-Goldberg omphalocele syndrome</td>
</tr>
<tr>
<td>557</td>
<td>Silver-Russell syndrome</td>
</tr>
<tr>
<td>558</td>
<td>Silver-Russell dwarfism</td>
</tr>
<tr>
<td>559</td>
<td>Russell-Silver syndrome</td>
</tr>
<tr>
<td>560</td>
<td>Spondylocostal dysostosis - anal and genitourinary malformations</td>
</tr>
<tr>
<td>561</td>
<td>Stapes ankylosis with broad thumbs and toes</td>
</tr>
<tr>
<td>562</td>
<td>Stickler syndrome</td>
</tr>
<tr>
<td>563</td>
<td>Stickler syndrome type 1</td>
</tr>
<tr>
<td>564</td>
<td>Stickler syndrome type 2</td>
</tr>
<tr>
<td>565</td>
<td>Stickler syndrome type 3</td>
</tr>
<tr>
<td>566</td>
<td>Stickler syndrome type 4</td>
</tr>
<tr>
<td>567</td>
<td>Autosomal recessive Stickler syndrome</td>
</tr>
<tr>
<td>568</td>
<td>Syndactyly - telecanthus - anogenital and renal malformations</td>
</tr>
<tr>
<td>569</td>
<td>TARP - [Talipes equinovarus - atrial septal defect - Robin sequence - persistent left superior vena cava] syndrome</td>
</tr>
<tr>
<td>570</td>
<td>Talipes equinovarus - atrial septal defect - Pierre Robin sequence - persistence of the left superior vena cava</td>
</tr>
<tr>
<td>571</td>
<td>Tetraamelia - multiple malformations</td>
</tr>
<tr>
<td>572</td>
<td>Thoraco-abdominal enteric duplication</td>
</tr>
<tr>
<td>573</td>
<td>Toriello-Carey syndrome</td>
</tr>
<tr>
<td>574</td>
<td>Townes-Brocks syndrome</td>
</tr>
<tr>
<td>575</td>
<td>Transverse limb deficiency - haemangioma</td>
</tr>
<tr>
<td>576</td>
<td>Ulnar-mammary syndrome</td>
</tr>
<tr>
<td>577</td>
<td>Schinzel syndrome</td>
</tr>
<tr>
<td>578</td>
<td>Umbilical cord ulceration - intestinal atresia</td>
</tr>
<tr>
<td>579</td>
<td>Uveal coloboma - cleft lip and palate - intellectual deficit</td>
</tr>
<tr>
<td>580</td>
<td>VACTERL with hydrocephalus</td>
</tr>
<tr>
<td>581</td>
<td>Van Der Woude syndrome</td>
</tr>
<tr>
<td>582</td>
<td>Warsaw breakage syndrome</td>
</tr>
<tr>
<td>583</td>
<td>WABS - [Warsaw breakage syndrome]</td>
</tr>
<tr>
<td>584</td>
<td>X-linked intellectual deficit with marfanoid habitus</td>
</tr>
<tr>
<td>585</td>
<td>Zimmermann-Laband syndrome</td>
</tr>
<tr>
<td>586</td>
<td>Hydrolethalus</td>
</tr>
<tr>
<td>587</td>
<td>Rieger syndrome</td>
</tr>
<tr>
<td>588</td>
<td>Axenfeld-Rieger syndrome</td>
</tr>
<tr>
<td>589</td>
<td>Thrombocytopaenia - absent radius</td>
</tr>
<tr>
<td>590</td>
<td>TAR - [Thrombocytopaenia - absent radius] syndrome</td>
</tr>
<tr>
<td>591</td>
<td>Thrombocytopenia with absent radius syndrome</td>
</tr>
<tr>
<td>592</td>
<td>Macrocephaly - capillary malformation</td>
</tr>
<tr>
<td>593</td>
<td>Macrocephaly - cutis marmorata telangiectatica congenita (MIM 602501)</td>
</tr>
<tr>
<td>594</td>
<td>Rubinstein-Taybi syndrome</td>
</tr>
<tr>
<td>595</td>
<td>RSTS - [Rubinstein-Taybi syndrome]</td>
</tr>
<tr>
<td>596</td>
<td>Broad thumb syndrome</td>
</tr>
<tr>
<td>597</td>
<td>Broad thumb-hallux syndrome</td>
</tr>
<tr>
<td>598</td>
<td>Ramon syndrome</td>
</tr>
<tr>
<td>599</td>
<td>Cherubism – gingival fibromatosis – epilepsy – mental deficiency – hypertrichosis – stunted growth (Ramon) syndrome</td>
</tr>
<tr>
<td>600</td>
<td>Maffucci syndrome</td>
</tr>
<tr>
<td>601</td>
<td>Chondrodysplasia with haemangiomata</td>
</tr>
<tr>
<td>602</td>
<td>Dyschondroplasia with cavernous haemangiomata</td>
</tr>
<tr>
<td>603</td>
<td>Amniotic bands</td>
</tr>
<tr>
<td>604</td>
<td>3MC syndrome</td>
</tr>
<tr>
<td>605</td>
<td>Haemolytic anaemia due to glucose-6-phosphate dehydrogenase deficiency</td>
</tr>
<tr>
<td>606</td>
<td>Chronic non spherocytic anaemia</td>
</tr>
<tr>
<td>607</td>
<td>G6PD - [glucose-6-phosphate dehydrogenase deficiency] anaemia</td>
</tr>
<tr>
<td>608</td>
<td>anaemia due to glucose-6-phosphate dehydrogenase deficiency</td>
</tr>
<tr>
<td>609</td>
<td>glucose-6-phosphate dehydrogenase deficiency with anaemia</td>
</tr>
<tr>
<td>610</td>
<td>glucose-6-phosphate dehydrogenase deficiency anaemia</td>
</tr>
<tr>
<td>611</td>
<td>favism anaemia</td>
</tr>
<tr>
<td>612</td>
<td>Haemolytic anaemia due toG6PD deficiency</td>
</tr>
<tr>
<td>613</td>
<td>Favism</td>
</tr>
<tr>
<td>614</td>
<td>pentose phosphate pathway disorder anaemia</td>
</tr>
<tr>
<td>615</td>
<td>anaemia due to pentose phosphate pathway defect</td>
</tr>
<tr>
<td>616</td>
<td>Baghdad spring anaemia</td>
</tr>
<tr>
<td>617</td>
<td>Hereditary haemolytic nonspherocytic type 1 anaemia</td>
</tr>
<tr>
<td>618</td>
<td>haemolytic nonspherocytic type 1 anaemia</td>
</tr>
<tr>
<td>619</td>
<td>anaemia due to haemolytic nonspherocytic (hereditary), type 1</td>
</tr>
<tr>
<td>620</td>
<td>Disorders of methionine cycle or sulphur amino acid metabolism</td>
</tr>
<tr>
<td>621</td>
<td>disorder of sulphur-bearing amino acid including those due to folate and b12 disturbance</td>
</tr>
<tr>
<td>622</td>
<td>disorder of sulphur-bearing amino acid metabolism</td>
</tr>
<tr>
<td>623</td>
<td>disorder of transsulfuration</td>
</tr>
<tr>
<td>624</td>
<td>disorder of transsulphuration</td>
</tr>
<tr>
<td>625</td>
<td>disturbances of sulphur-bearing amino-acid metabolism</td>
</tr>
<tr>
<td>626</td>
<td>sulphuraminoacidaemia</td>
</tr>
<tr>
<td>627</td>
<td>Disorders of sulphur-bearing amino-acid metabolism</td>
</tr>
<tr>
<td>628</td>
<td>Brain demyelination due to methionine adenosyltransferase deficiency</td>
</tr>
<tr>
<td>629</td>
<td>Methionine adenosyltransferase I/III deficiency</td>
</tr>
<tr>
<td>630</td>
<td>Isolated persistent hypermethioninaemia</td>
</tr>
<tr>
<td>631</td>
<td>MAT I/III - [Methionine adenosyltransferase I/III] deficiency</td>
</tr>
<tr>
<td>632</td>
<td>Glycine N-methyltransferase deficiency</td>
</tr>
<tr>
<td>633</td>
<td>GNMT - [Glycine N-methyltransferase] deficiency</td>
</tr>
<tr>
<td>634</td>
<td>Psychomotor retardation and myopathy due to S-adenosylhomocysteine hydrolase deficiency</td>
</tr>
<tr>
<td>635</td>
<td>Hypermethioninaemia due to S-adenosylhomocysteine hydrolase deficiency</td>
</tr>
<tr>
<td>636</td>
<td>Cystathioninuria</td>
</tr>
<tr>
<td>637</td>
<td>Gamma-cystathionase deficiency</td>
</tr>
<tr>
<td>638</td>
<td>Cystathione gamma-lyase deficiency</td>
</tr>
<tr>
<td>639</td>
<td>CTH - [cystathioninuria]</td>
</tr>
<tr>
<td>640</td>
<td>cystathionine metabolic disorder</td>
</tr>
<tr>
<td>641</td>
<td>Classical homocystinuria</td>
</tr>
<tr>
<td>642</td>
<td>Homocystinuria due to cystathionine beta-synthase deficiency</td>
</tr>
<tr>
<td>643</td>
<td>Cystathionine beta-synthase deficiency</td>
</tr>
<tr>
<td>644</td>
<td>CBS - [Cystathionine beta-synthase] deficiency</td>
</tr>
<tr>
<td>645</td>
<td>cystathionine synthase deficiency</td>
</tr>
<tr>
<td>646</td>
<td>homocystine metabolic disorder</td>
</tr>
<tr>
<td>647</td>
<td>Homocystinuria without methylmalonic aciduria</td>
</tr>
<tr>
<td>648</td>
<td>5-methyltetrahydrofolate-homocysteine s-methyltransferase deficiency</td>
</tr>
<tr>
<td>649</td>
<td>Methionine synthase deficiency</td>
</tr>
<tr>
<td>650</td>
<td>Methylcobalamin deficiency</td>
</tr>
<tr>
<td>651</td>
<td>N5-methylhomocysteine transferase deficiency</td>
</tr>
<tr>
<td>652</td>
<td>Methylcobalamin deficiency type cbl E</td>
</tr>
<tr>
<td>653</td>
<td>Homocystinuria due to defect in methylation type cbl E</td>
</tr>
<tr>
<td>654</td>
<td>Homocystinuria - megaloblastic anaemia due to defect in cobalamin metabolism, cbI E complementation type</td>
</tr>
<tr>
<td>655</td>
<td>Methylcobalamin deficiency type cbl G</td>
</tr>
<tr>
<td>656</td>
<td>Homocystinuria due to methionine synthase deficiency type Cbl G</td>
</tr>
<tr>
<td>657</td>
<td>Homocystinuria - megaloblastic anaemia due to defect in cobalamin metabolism, cbI G complementation type</td>
</tr>
<tr>
<td>658</td>
<td>Methylcobalamin deficiency type cbl Dv1</td>
</tr>
<tr>
<td>659</td>
<td>Encephalopathy due to sulfite oxidase deficiency</td>
</tr>
<tr>
<td>660</td>
<td>Isolated sulfite oxidase deficiency</td>
</tr>
<tr>
<td>661</td>
<td>ISOD - [Isolated sulfite oxidase deficiency]</td>
</tr>
<tr>
<td>662</td>
<td>Sulfite oxidase deficiency due to molybdenum cofactor deficiency</td>
</tr>
<tr>
<td>663</td>
<td>Combined deficiency of sulfite oxidase, xanthine dehydrogenase and aldehyde oxidase</td>
</tr>
<tr>
<td>664</td>
<td>Molybdenum cofactor deficiency, complementation group A</td>
</tr>
<tr>
<td>665</td>
<td>Molybdenum cofactor deficiency due to defects in MOCS1 gene</td>
</tr>
<tr>
<td>666</td>
<td>Molybdenum cofactor deficiency, complementation group B</td>
</tr>
<tr>
<td>667</td>
<td>Molybdenum cofactor deficiency due to defects in MOCS2 gene</td>
</tr>
<tr>
<td>668</td>
<td>Molybdenum cofactor deficiency, complementation group C</td>
</tr>
<tr>
<td>669</td>
<td>Hypermethioninaemia due to adenosine kinase deficiency</td>
</tr>
<tr>
<td>670</td>
<td>Other genetic defects of methionine cycle or sulfur amino acid metabolism</td>
</tr>
<tr>
<td>671</td>
<td>Secondary non-genetic disorders of methionine cycle or sulfur amino acid metabolism</td>
</tr>
<tr>
<td>672</td>
<td>Beery-baby syndrome</td>
</tr>
<tr>
<td>673</td>
<td>Cystathioninemia</td>
</tr>
<tr>
<td>674</td>
<td>Deficiency of cystathionase</td>
</tr>
<tr>
<td>675</td>
<td>Deficiency of cysteine desulfhydrase</td>
</tr>
<tr>
<td>676</td>
<td>deficiency of cysteine desulphydrase</td>
</tr>
<tr>
<td>677</td>
<td>deficiency of cystine desulfhydrase</td>
</tr>
<tr>
<td>678</td>
<td>deficiency of cystine desulphydrase</td>
</tr>
<tr>
<td>679</td>
<td>Deficiency of homoserine deaminase</td>
</tr>
<tr>
<td>680</td>
<td>Deficiency of methionine adenosyltransferase</td>
</tr>
<tr>
<td>681</td>
<td>Familial methionine malabsorption</td>
</tr>
<tr>
<td>682</td>
<td>Hepatic methionine adenosyltransferase deficiency</td>
</tr>
<tr>
<td>683</td>
<td>Homocystinaemia</td>
</tr>
<tr>
<td>684</td>
<td>Hypermethioninaemia</td>
</tr>
<tr>
<td>685</td>
<td>methionine metabolic disorder</td>
</tr>
<tr>
<td>686</td>
<td>Methionine malabsorption syndrome</td>
</tr>
<tr>
<td>687</td>
<td>oast-house disease</td>
</tr>
<tr>
<td>688</td>
<td>oast-house urine disease</td>
</tr>
<tr>
<td>689</td>
<td>oasthouse disease</td>
</tr>
<tr>
<td>690</td>
<td>oasthouse urine disease</td>
</tr>
<tr>
<td>691</td>
<td>Smith-Strang disease</td>
</tr>
<tr>
<td>692</td>
<td>Sulfite oxidase deficiency</td>
</tr>
<tr>
<td>693</td>
<td>sulfite oxidase deficiency syndrome</td>
</tr>
<tr>
<td>694</td>
<td>sulphite oxidase deficiency</td>
</tr>
<tr>
<td>695</td>
<td>sulfocysteinuria</td>
</tr>
<tr>
<td>696</td>
<td>sulphocysteinuria</td>
</tr>
<tr>
<td>697</td>
<td>Immunodeficiencies with isotype or light chain deficiencies with normal number of B cells</td>
</tr>
<tr>
<td>698</td>
<td>Recurrent infections associated with immunoglobulin isotypes deficiency</td>
</tr>
<tr>
<td>699</td>
<td>Recurrent infections associated with immunoglobulin isotypes</td>
</tr>
<tr>
<td>700</td>
<td>Deficiency of immunoglobulin A with immunoglobulin G subclasses deficiency</td>
</tr>
<tr>
<td>701</td>
<td>Deficiency of IgA with IgG subclasses deficiency</td>
</tr>
<tr>
<td>702</td>
<td>Immunoglobulin heavy chain deficiency</td>
</tr>
<tr>
<td>703</td>
<td>Deficiency of IgG and/or IgA subclasses and/or IgE</td>
</tr>
<tr>
<td>704</td>
<td>K chain deficiency</td>
</tr>
<tr>
<td>705</td>
<td>Selective deficiency of immunoglobulin A</td>
</tr>
<tr>
<td>706</td>
<td>Selective deficiency of IgA</td>
</tr>
<tr>
<td>707</td>
<td>selective immunodeficiency of immunoglobulin A (IgA)</td>
</tr>
<tr>
<td>708</td>
<td>Selective deficiency of immunoglobulin G subclasses</td>
</tr>
<tr>
<td>709</td>
<td>immunoglobin g subclass deficiency</td>
</tr>
<tr>
<td>710</td>
<td>immunoglobulin g subclass deficiency</td>
</tr>
<tr>
<td>711</td>
<td>selective deficiency of IgG</td>
</tr>
<tr>
<td>712</td>
<td>selective immunoglobulin g deficiency</td>
</tr>
<tr>
<td>713</td>
<td>Selective deficiency of IgG subclasses</td>
</tr>
<tr>
<td>714</td>
<td>IgG subclass deficiency</td>
</tr>
<tr>
<td>715</td>
<td>selective IgG immunodeficiency</td>
</tr>
<tr>
<td>716</td>
<td>Selective deficiency of immunoglobulin M</td>
</tr>
<tr>
<td>717</td>
<td>Selective deficiency of IgM</td>
</tr>
<tr>
<td>718</td>
<td>selective IgM immunodeficiency</td>
</tr>
<tr>
<td>719</td>
<td>selective immunodeficiency of immunoglobulin M (IgM)</td>
</tr>
<tr>
<td>720</td>
<td>Large newborn for gestational age</td>
</tr>
<tr>
<td>721</td>
<td>Birth weight 4000g to 4499g</td>
</tr>
<tr>
<td>722</td>
<td>Other fetus or infant heavy- or large-for-dates regardless of period of gestation</td>
</tr>
<tr>
<td>723</td>
<td>Xeroderma pigmentosum</td>
</tr>
<tr>
<td>724</td>
<td>XP - [xeroderma pigmentosum]</td>
</tr>
<tr>
<td>725</td>
<td>atrophoderma pigmentosum</td>
</tr>
<tr>
<td>726</td>
<td>Xeroderma pigmentosum A</td>
</tr>
<tr>
<td>727</td>
<td>XPA - [xeroderma pigmentosum A]</td>
</tr>
<tr>
<td>728</td>
<td>Xeroderma pigmentosum B</td>
</tr>
<tr>
<td>729</td>
<td>XPB - [xeroderma pigmentosum B]</td>
</tr>
<tr>
<td>730</td>
<td>Xeroderma pigmentosum C</td>
</tr>
<tr>
<td>731</td>
<td>XPC - [xeroderma pigmentosum C]</td>
</tr>
<tr>
<td>732</td>
<td>Xeroderma pigmentosum D</td>
</tr>
<tr>
<td>733</td>
<td>XPD - [xeroderma pigmentosum D]</td>
</tr>
<tr>
<td>734</td>
<td>Xeroderma pigmentosum E</td>
</tr>
<tr>
<td>735</td>
<td>XPE - [xeroderma pigmentosum E]</td>
</tr>
<tr>
<td>736</td>
<td>Xeroderma pigmentosum F</td>
</tr>
<tr>
<td>737</td>
<td>XPF - [xeroderma pigmentosum F]</td>
</tr>
<tr>
<td>738</td>
<td>Xeroderma pigmentosum G</td>
</tr>
<tr>
<td>739</td>
<td>XPG - [xeroderma pigmentosum G]</td>
</tr>
<tr>
<td>740</td>
<td>Dystonia associated with heredodegenerative disorders</td>
</tr>
<tr>
<td>741</td>
<td>Dystonia due to autosomal dominant disorders</td>
</tr>
<tr>
<td>742</td>
<td>Rapid-onset dystonia-parkinsonism</td>
</tr>
<tr>
<td>743</td>
<td>Dystonia due to dentatorubropallidoluysian atrophy</td>
</tr>
<tr>
<td>744</td>
<td>Dystonia due to Huntington disease</td>
</tr>
<tr>
<td>745</td>
<td>Dystonia due to autosomal recessive disorders</td>
</tr>
<tr>
<td>746</td>
<td>Dystonia due to Wilson disease</td>
</tr>
<tr>
<td>747</td>
<td>Dystonia due to Niemann-Pick disease type C</td>
</tr>
<tr>
<td>748</td>
<td>Dystonia due to other autosomal recessive metabolic disorders</td>
</tr>
<tr>
<td>749</td>
<td>Dystonia due to GM2 gangliosidosis</td>
</tr>
<tr>
<td>750</td>
<td>Dystonia due to Metachromatic leukodystrophy</td>
</tr>
<tr>
<td>751</td>
<td>Dystonia due to homocystinuria</td>
</tr>
<tr>
<td>752</td>
<td>Dystonia due to glutaric acidaemia</td>
</tr>
<tr>
<td>753</td>
<td>Dystonia due to Hartnup disease</td>
</tr>
<tr>
<td>754</td>
<td>Dystonia due to ataxia-telangiectasia</td>
</tr>
<tr>
<td>755</td>
<td>Dystonia in neurodegeneration with brain iron accumulation type 1</td>
</tr>
<tr>
<td>756</td>
<td>NBIA 2 PLA2G6 mutation</td>
</tr>
<tr>
<td>757</td>
<td>PANK gene mutation</td>
</tr>
<tr>
<td>758</td>
<td>Dystonia due to Juvenile Parkinson Disease including Parkin mutation</td>
</tr>
<tr>
<td>759</td>
<td>Probable autosomal recessive dystonia</td>
</tr>
<tr>
<td>760</td>
<td>Progressive pallidal degeneration</td>
</tr>
<tr>
<td>761</td>
<td>Dystonia due to X-linked dominant disorders</td>
</tr>
<tr>
<td>762</td>
<td>Dystonia due to Rett syndrome</td>
</tr>
<tr>
<td>763</td>
<td>Dystonia due to X-linked recessive disorders</td>
</tr>
<tr>
<td>764</td>
<td>Deafness-dystonia optic atrophy syndrome</td>
</tr>
<tr>
<td>765</td>
<td>Mohr-Tranebjærg syndrome</td>
</tr>
<tr>
<td>766</td>
<td>Dystonia due to Pelizaeus-Merzbacher disease</td>
</tr>
<tr>
<td>767</td>
<td>Dystonia due to Lesch-Nyhan syndrome</td>
</tr>
<tr>
<td>768</td>
<td>Dystonia due to mitochondrial cytopathies</td>
</tr>
<tr>
<td>769</td>
<td>Dystonia due to Leber's disease</td>
</tr>
<tr>
<td>770</td>
<td>Dystonia due to other mitochondrial cytopathies</td>
</tr>
<tr>
<td>771</td>
<td>Dystonia of variable inheritance</td>
</tr>
<tr>
<td>772</td>
<td>Dystonia due to Familial basal ganglia calcifications</td>
</tr>
<tr>
<td>773</td>
<td>Dystonia due to certain specified inherited disorders</td>
</tr>
<tr>
<td>774</td>
<td>Dystonia associated with familial basal ganglia calcifications</td>
</tr>
<tr>
<td>775</td>
<td>Dystonia due to isolated hereditary vitamin E deficiency</td>
</tr>
<tr>
<td>776</td>
<td>Dystonia due to hereditary spastic paraplegia</td>
</tr>
<tr>
<td>777</td>
<td>Dystonia 16</td>
</tr>
<tr>
<td>778</td>
<td>Infantile dystonia-parkinsonism</td>
</tr>
<tr>
<td>779</td>
<td>Other specified ectodermal dysplasia syndromes</td>
</tr>
<tr>
<td>780</td>
<td>Absence of fingerprints-congenital milia syndrome</td>
</tr>
<tr>
<td>781</td>
<td>Ackerman syndrome</td>
</tr>
<tr>
<td>782</td>
<td>ADULT syndrome</td>
</tr>
<tr>
<td>783</td>
<td>Acro-dermato-ungual-lacrimal-tooth syndrome</td>
</tr>
<tr>
<td>784</td>
<td>Pigment anomaly - ectrodactyly - hypodontia</td>
</tr>
<tr>
<td>785</td>
<td>Propping Zerres syndrome</td>
</tr>
<tr>
<td>786</td>
<td>Amelo-cerebro-hypohidrotic syndrome</td>
</tr>
<tr>
<td>787</td>
<td>Epilepsy - dementia - amelogenesis imperfecta</td>
</tr>
<tr>
<td>788</td>
<td>Kohlschütter-Tönz syndrome</td>
</tr>
<tr>
<td>789</td>
<td>Ankyloblepharon - ectodermal defects - cleft lip or palate</td>
</tr>
<tr>
<td>790</td>
<td>AREDYLD syndrome</td>
</tr>
<tr>
<td>791</td>
<td>Acrorenal defect - ectodermal dysplasia - diabetes</td>
</tr>
<tr>
<td>792</td>
<td>Beare-Stevenson cutis gyrata syndrome</td>
</tr>
<tr>
<td>793</td>
<td>Blepharocheilodontic syndrome</td>
</tr>
<tr>
<td>794</td>
<td>Book syndrome</td>
</tr>
<tr>
<td>795</td>
<td>Cardio-facio-cutaneous syndrome</td>
</tr>
<tr>
<td>796</td>
<td>Cerebellar ataxia - ectodermal dysplasia</td>
</tr>
<tr>
<td>797</td>
<td>Curly hair – ankyloblepharon – nail dysplasia syndrome</td>
</tr>
<tr>
<td>798</td>
<td>Baughman syndrome</td>
</tr>
<tr>
<td>799</td>
<td>CHANDS - [Curly hair - ankyloblepharon - nail dysplasia syndrome]</td>
</tr>
<tr>
<td>800</td>
<td>Choroidal atrophy - alopecia</td>
</tr>
<tr>
<td>801</td>
<td>Coffin-Siris syndrome</td>
</tr>
<tr>
<td>802</td>
<td>Conductive deafness - ptosis - skeletal anomalies</td>
</tr>
<tr>
<td>803</td>
<td>Contractures - ectodermal dysplasia - cleft lip or palate</td>
</tr>
<tr>
<td>804</td>
<td>Cote-Katsantoni syndrome</td>
</tr>
<tr>
<td>805</td>
<td>Cranioectodermal dysplasia</td>
</tr>
<tr>
<td>806</td>
<td>Sensenbrenner syndrome</td>
</tr>
<tr>
<td>807</td>
<td>Dahlberg-Borer-Newcomer syndrome</td>
</tr>
<tr>
<td>808</td>
<td>Lymphoedema - hypoparathyroidism</td>
</tr>
<tr>
<td>809</td>
<td>Dermatoosteolysis, Kirghizian type</td>
</tr>
<tr>
<td>810</td>
<td>Dubowitz syndrome</td>
</tr>
<tr>
<td>811</td>
<td>Ectodermal dysplasia - absent dermatoglyphs</td>
</tr>
<tr>
<td>812</td>
<td>Ectodermal dysplasia - acanthosis nigricans</td>
</tr>
<tr>
<td>813</td>
<td>Lelis syndrome</td>
</tr>
<tr>
<td>814</td>
<td>Ectodermal dysplasia - arthrogryposis - diabetes mellitus</td>
</tr>
<tr>
<td>815</td>
<td>Ectodermal dysplasia - blindness</td>
</tr>
<tr>
<td>816</td>
<td>Ectodermal dysplasia - cutaneous syndactyly syndrome</td>
</tr>
<tr>
<td>817</td>
<td>Ectodermal dysplasia - ectrodactyly - macular dystrophy</td>
</tr>
<tr>
<td>818</td>
<td>EEM - [Ectodermal dysplasia - ectrodactyly - macular dystrophy] syndrome</td>
</tr>
<tr>
<td>819</td>
<td>Ectodermal dysplasia - intellectual deficit - central nervous system malformation</td>
</tr>
<tr>
<td>820</td>
<td>Ectodermal dysplasia - sensorineural deafness</td>
</tr>
<tr>
<td>821</td>
<td>Ectodermal dysplasia - syndactyly syndrome</td>
</tr>
<tr>
<td>822</td>
<td>Ectodermal dysplasia with natal teeth, Turnpenny type</td>
</tr>
<tr>
<td>823</td>
<td>Ectodermal dysplasia, pure hair-nail type</td>
</tr>
<tr>
<td>824</td>
<td>Ectodermal dysplasia, Berlin type</td>
</tr>
<tr>
<td>825</td>
<td>Ectrodactyly - ectodermal dysplasia - cleft lip or palate</td>
</tr>
<tr>
<td>826</td>
<td>EEC - [Ectrodactyly - ectodermal dysplasia - cleft lip or palate] syndrome</td>
</tr>
<tr>
<td>827</td>
<td>Ectrodactyly - ectodermal dysplasia without clefting</td>
</tr>
<tr>
<td>828</td>
<td>Facial ectodermal dysplasia</td>
</tr>
<tr>
<td>829</td>
<td>Focal facial dermal dysplasia</td>
</tr>
<tr>
<td>830</td>
<td>GAPO syndrome</td>
</tr>
<tr>
<td>831</td>
<td>Growth delay - alopecia - pseudoanodontia - optic atrophy</td>
</tr>
<tr>
<td>832</td>
<td>Gingival fibromatosis - hypertrichosis</td>
</tr>
<tr>
<td>833</td>
<td>Gingival fibromatosis-hypertrichosis syndrome</td>
</tr>
<tr>
<td>834</td>
<td>Gorlin-Chaudhry-Moss syndrome</td>
</tr>
<tr>
<td>835</td>
<td>Hidrotic ectodermal dysplasia, Christianson-Fourie type</td>
</tr>
<tr>
<td>836</td>
<td>Hidrotic ectodermal dysplasia, Halal type</td>
</tr>
<tr>
<td>837</td>
<td>Hypertrichosis cubiti - short stature</td>
</tr>
<tr>
<td>838</td>
<td>Hypoparathyroidism - deafness - renal disease</td>
</tr>
<tr>
<td>839</td>
<td>Barakat syndrome</td>
</tr>
<tr>
<td>840</td>
<td>HDR - [Hypoparathyroidism - deafness - renal disease] syndrome</td>
</tr>
<tr>
<td>841</td>
<td>Ichthyosis - alopecia - eclabion - ectropion - intellectual deficit</td>
</tr>
<tr>
<td>842</td>
<td>Johanson-Blizzard syndrome</td>
</tr>
<tr>
<td>843</td>
<td>Johnson neuroectodermal syndrome</td>
</tr>
<tr>
<td>844</td>
<td>Juvenile macular degeneration - hypotrichosis</td>
</tr>
<tr>
<td>845</td>
<td>Lacrimo-auriculo-dento-digital syndrome</td>
</tr>
<tr>
<td>846</td>
<td>Limb-mammary syndrome</td>
</tr>
<tr>
<td>847</td>
<td>Marshall syndrome</td>
</tr>
<tr>
<td>848</td>
<td>Naegeli-Franceschetti-Jadassohn syndrome</td>
</tr>
<tr>
<td>849</td>
<td>Oculo-dento-digital dysplasia</td>
</tr>
<tr>
<td>850</td>
<td>Oculo-osteo-cutaneous syndrome</td>
</tr>
<tr>
<td>851</td>
<td>Odonto-tricho-ungual-digito-palmar syndrome</td>
</tr>
<tr>
<td>852</td>
<td>Odontotrichomelic syndrome</td>
</tr>
<tr>
<td>853</td>
<td>OL-EDA-ID syndrome</td>
</tr>
<tr>
<td>854</td>
<td>Anhidrotic ectodermal dysplasia - immunodeficiency - osteopetrosis - lymphoedema</td>
</tr>
<tr>
<td>855</td>
<td>OLEDAID - [Anhidrotic ectodermal dysplasia - immunodeficiency - osteopetrosis - lymphoedema] syndrome</td>
</tr>
<tr>
<td>856</td>
<td>Anhidrotic ectodermal dysplasia - immunodeficiency - osteopetrosis - lymphoedema</td>
</tr>
<tr>
<td>857</td>
<td>Oligodontia - cancer predisposition syndrome</td>
</tr>
<tr>
<td>858</td>
<td>Autosomal dominant ectodermal dysplasia-neoplastic syndrome</td>
</tr>
<tr>
<td>859</td>
<td>Pilodental dysplasia - refractive errors</td>
</tr>
<tr>
<td>860</td>
<td>Rapp-Hodgkin syndrome</td>
</tr>
<tr>
<td>861</td>
<td>Scalp-ear-nipple syndrome</td>
</tr>
<tr>
<td>862</td>
<td>Schinzel-Giedion syndrome</td>
</tr>
<tr>
<td>863</td>
<td>Sparse hair - short stature - skin anomalies</td>
</tr>
<tr>
<td>864</td>
<td>Stern-Lubinsky-Durrie syndrome</td>
</tr>
<tr>
<td>865</td>
<td>Taurodontia - absent teeth - sparse hair</td>
</tr>
<tr>
<td>866</td>
<td>Toriello-Lacassie-Droste syndrome</td>
</tr>
<tr>
<td>867</td>
<td>Tricho-dento-osseous syndrome</td>
</tr>
<tr>
<td>868</td>
<td>Tricho-oculo-dermo-vertebral syndrome</td>
</tr>
<tr>
<td>869</td>
<td>Tricho-odonto-onychial dysplasia with bone deficiency in fronto-parietal region</td>
</tr>
<tr>
<td>870</td>
<td>Tricho-odonto-onychial ectodermal dysplasia</td>
</tr>
<tr>
<td>871</td>
<td>Tricho-retino-dento-digital syndrome</td>
</tr>
<tr>
<td>872</td>
<td>Trichodental syndrome</td>
</tr>
<tr>
<td>873</td>
<td>Trichodermodysplasia - dental alterations</td>
</tr>
<tr>
<td>874</td>
<td>Trichodysplasia - amelogenesis imperfecta</td>
</tr>
<tr>
<td>875</td>
<td>Trichomegaly - cataract - hereditary spherocytosis</td>
</tr>
<tr>
<td>876</td>
<td>Trichomegaly - retina pigmentary degeneration - dwarfism</td>
</tr>
<tr>
<td>877</td>
<td>Xeroderma - talipes - enamel defects</td>
</tr>
<tr>
<td>878</td>
<td>Zlotogora-Ogur syndrome</td>
</tr>
<tr>
<td>879</td>
<td>Margarita island ectodermal dysplasia</td>
</tr>
<tr>
<td>880</td>
<td>Rosselli-Gulienetti syndrome</td>
</tr>
<tr>
<td>881</td>
<td>Zlotogora-Martinez syndrome</td>
</tr>
<tr>
<td>882</td>
<td>Zunich-Kaye syndrome</td>
</tr>
<tr>
<td>883</td>
<td>Dermo-odontodysplasia</td>
</tr>
<tr>
<td>884</td>
<td>Dermoodontodysplasia</td>
</tr>
<tr>
<td>885</td>
<td>Oculotrichodysplasia</td>
</tr>
<tr>
<td>886</td>
<td>Cartilage-hair hypoplasia</td>
</tr>
<tr>
<td>887</td>
<td>Trichorhinophalangeal syndrome type 1 and 3</td>
</tr>
<tr>
<td>888</td>
<td>Chondroectodermal dysplasia</td>
</tr>
<tr>
<td>889</td>
<td>Ellis-van Creveld syndrome</td>
</tr>
<tr>
<td>890</td>
<td>Mesodermic dysplasia</td>
</tr>
<tr>
<td>891</td>
<td>EVC - [Ellis-van Creveld] syndrome</td>
</tr>
<tr>
<td>892</td>
<td>Odonto-onycho-dermal dysplasia</td>
</tr>
<tr>
<td>893</td>
<td>OODD (MIM 257980)</td>
</tr>
<tr>
<td>894</td>
<td>Woolly hair – hypotrichosis – everted lower lip – outstanding ears</td>
</tr>
<tr>
<td>895</td>
<td>Salamon syndrome</td>
</tr>
<tr>
<td>896</td>
<td>Autosomal dominant palmoplantar keratoderma and congenital alopecia</td>
</tr>
<tr>
<td>897</td>
<td>Stevanovic syndrome</td>
</tr>
<tr>
<td>898</td>
<td>BIDS syndrome</td>
</tr>
<tr>
<td>899</td>
<td>Amish brittle hair syndrome</td>
</tr>
<tr>
<td>900</td>
<td>Trichothiodystrophy type D</td>
</tr>
<tr>
<td>901</td>
<td>IBIDS syndrome</td>
</tr>
<tr>
<td>902</td>
<td>Tay syndrome</td>
</tr>
<tr>
<td>903</td>
<td>Trichothiodystrophy type E</td>
</tr>
<tr>
<td>904</td>
<td>Trichothiodystrophy with congenital ichthyosis</td>
</tr>
<tr>
<td>905</td>
<td>Sabinas brittle hair syndrome</td>
</tr>
<tr>
<td>906</td>
<td>Brittle hair - mental deficiency</td>
</tr>
<tr>
<td>907</td>
<td>Trichothiodystrophy type B</td>
</tr>
<tr>
<td>908</td>
<td>Onycho-tricho-dysplasia – neutropaenia syndrome</td>
</tr>
<tr>
<td>909</td>
<td>Trichothiodystrophy type G</td>
</tr>
<tr>
<td>910</td>
<td>ONMR (MIM 258360)</td>
</tr>
<tr>
<td>911</td>
<td>Itin syndrome</td>
</tr>
<tr>
<td>912</td>
<td>ONMR syndrome</td>
</tr>
<tr>
<td>913</td>
<td>Autosomal recessive palmoplantar keratoderma and congenital alopecia</td>
</tr>
<tr>
<td>914</td>
<td>Wallis syndrome</td>
</tr>
<tr>
<td>915</td>
<td>Alopecia - contractures - dwarfism - intellectual deficit</td>
</tr>
<tr>
<td>916</td>
<td>Cataract - alopecia - sclerodactyly</td>
</tr>
<tr>
<td>917</td>
<td>Odonto-onycho dysplasia - alopecia</td>
</tr>
<tr>
<td>918</td>
<td>Schöpf-Schulz-Passarge syndrome</td>
</tr>
<tr>
<td>919</td>
<td>Hypertrichosis lanuginosa congenita</td>
</tr>
<tr>
<td>920</td>
<td>Hypertrichosis universalis congenita</td>
</tr>
<tr>
<td>921</td>
<td>Congenital generalised hypertrichosis</td>
</tr>
<tr>
<td>922</td>
<td>Ambras syndrome</td>
</tr>
<tr>
<td>923</td>
<td>X-linked dominant congenital generalised hypertrichosis</td>
</tr>
<tr>
<td>924</td>
<td>Macias-Flores syndrome</td>
</tr>
<tr>
<td>925</td>
<td>Deafness – enamel hypoplasia – nail defects</td>
</tr>
<tr>
<td>926</td>
<td>Heimler syndrome</td>
</tr>
<tr>
<td>927</td>
<td>Sensorineural hearing loss with enamel hypoplasia and nail defects</td>
</tr>
<tr>
<td>928</td>
<td>Anonychia with bizarre flexural pigmentation</td>
</tr>
<tr>
<td>929</td>
<td>Anonychia with flexural pigmentation (MIM 106750)</td>
</tr>
<tr>
<td>930</td>
<td>Anonychia or onychodystrophy – hypoplasia or absence of distal phalanges</td>
</tr>
<tr>
<td>931</td>
<td>Cooks syndrome</td>
</tr>
<tr>
<td>932</td>
<td>Autosomal dominant hypodontia with nail dysplasia</td>
</tr>
<tr>
<td>933</td>
<td>Witkop syndrome (MIM 189500)</td>
</tr>
<tr>
<td>934</td>
<td>Tooth and nail syndrome</td>
</tr>
<tr>
<td>935</td>
<td>Amelo-onycho-hypohidrotic syndrome</td>
</tr>
<tr>
<td>936</td>
<td>Deafness – onychodystrophy</td>
</tr>
<tr>
<td>937</td>
<td>Deafness – onychodystrophy – osteodystrophy – intellectual deficit</td>
</tr>
<tr>
<td>938</td>
<td>Deafness – onychodystrophy, autosomal dominant</td>
</tr>
<tr>
<td>939</td>
<td>DOOR syndrome, autosomal dominant</td>
</tr>
<tr>
<td>940</td>
<td>Dominant deafness-onychodystrophy</td>
</tr>
<tr>
<td>941</td>
<td>DDOD syndrome (MIM 124480)</td>
</tr>
<tr>
<td>942</td>
<td>Deafness – onychodystrophy, autosomal recessive</td>
</tr>
<tr>
<td>943</td>
<td>DOOR syndrome, autosomal recessive</td>
</tr>
<tr>
<td>944</td>
<td>DOOR syndrome (MIM 220500)</td>
</tr>
<tr>
<td>945</td>
<td>Odonto-onycho-hypohidrotic dysplasia - midline scalp defects</td>
</tr>
<tr>
<td>946</td>
<td>Tricho-odonto-onycho-dermal syndrome</td>
</tr>
<tr>
<td>947</td>
<td>Tricho-odonto-onychodysplasia - dominant syndactyly</td>
</tr>
<tr>
<td>948</td>
<td>Pili torti - onychodysplasia</td>
</tr>
<tr>
<td>949</td>
<td>Focal dermal hypoplasia</td>
</tr>
<tr>
<td>950</td>
<td>Goltz syndrome</td>
</tr>
<tr>
<td>951</td>
<td>Goltz-Gorlin syndrome</td>
</tr>
<tr>
<td>952</td>
<td>Familial isolated trichomegaly</td>
</tr>
<tr>
<td>953</td>
<td>Familial isolated trichomegaly of the eyelashes</td>
</tr>
<tr>
<td>954</td>
<td>Malignant neuroendocrine neoplasm of stomach</td>
</tr>
<tr>
<td>955</td>
<td>carcinoid and other malignant neuroendocrine neoplasms</td>
</tr>
<tr>
<td>956</td>
<td>Gastric endocrine tumour</td>
</tr>
<tr>
<td>957</td>
<td>Neuroendocrine tumour of stomach</td>
</tr>
<tr>
<td>958</td>
<td>NET - [neuroendocrine tumour] of stomach</td>
</tr>
<tr>
<td>959</td>
<td>Carcinoid or other neuroendocrine tumour of cardia of stomach</td>
</tr>
<tr>
<td>960</td>
<td>Carcinoid or other neuroendocrine tumour of body of stomach</td>
</tr>
<tr>
<td>961</td>
<td>Carcinoid or other neuroendocrine tumour of pyloric antrum of stomach</td>
</tr>
<tr>
<td>962</td>
<td>Carcinoid or other neuroendocrine tumour of overlapping lesion of stomach</td>
</tr>
<tr>
<td>963</td>
<td>Neuroendocrine tumour of stomach, G1 (carcinoid)</td>
</tr>
<tr>
<td>964</td>
<td>Neuroendocrine tumour of stomach, G2</td>
</tr>
<tr>
<td>965</td>
<td>Neuroendocrine carcinoma of stomach</td>
</tr>
<tr>
<td>966</td>
<td>NEC - [neuroendocrine carcinoma] of stomach</td>
</tr>
<tr>
<td>967</td>
<td>Neuroendocrine carcinoma of cardia of stomach</td>
</tr>
<tr>
<td>968</td>
<td>Neuroendocrine carcinoma of body of stomach</td>
</tr>
<tr>
<td>969</td>
<td>Neuroendocrine carcinoma of pyloric antrum of stomach</td>
</tr>
<tr>
<td>970</td>
<td>Neuroendocrine carcinoma involving overlapping sites of stomach</td>
</tr>
<tr>
<td>971</td>
<td>Large cell neuroendocrine carcinoma of stomach</td>
</tr>
<tr>
<td>972</td>
<td>Small cell neuroendocrine carcinoma of stomach</td>
</tr>
<tr>
<td>973</td>
<td>Other specified neuroendocrine neoplasm of stomach</td>
</tr>
<tr>
<td>974</td>
<td>ECL cell, serotonin-producing NET - [neuroendocrine tumour]</td>
</tr>
<tr>
<td>975</td>
<td>Gastrin-producing NET - [neuroendocrine tumour]</td>
</tr>
<tr>
<td>976</td>
<td>Gastrointestinal endocrine tumours</td>
</tr>
<tr>
<td>977</td>
<td>Gastrointestinal neuroendocrine tumours</td>
</tr>
<tr>
<td>978</td>
<td>Gastrointestinal APUDomas</td>
</tr>
<tr>
<td>979</td>
<td>Penicillin resistant Streptococcus pneumoniae</td>
</tr>
<tr>
<td>980</td>
<td>Oxacillin resistant Streptococcus pneumoniae</td>
</tr>
<tr>
<td>981</td>
<td>Penicillin G resistant Streptococcus pneumoniae</td>
</tr>
<tr>
<td>982</td>
<td>Other specified malignant neoplasms of colon</td>
</tr>
<tr>
<td>983</td>
<td>Neuroendocrine neoplasm of colon</td>
</tr>
<tr>
<td>984</td>
<td>Colon endocrine neoplasm</td>
</tr>
<tr>
<td>985</td>
<td>Neuroendocrine carcinoma of colon</td>
</tr>
<tr>
<td>986</td>
<td>NEC - [neuroendocrine carcinoma] of colon</td>
</tr>
<tr>
<td>987</td>
<td>Large cell neuroendocrine carcinoma of colon</td>
</tr>
<tr>
<td>988</td>
<td>large cell NEC of colon</td>
</tr>
<tr>
<td>989</td>
<td>Small cell neuroendocrine carcinoma of colon</td>
</tr>
<tr>
<td>990</td>
<td>Small cell NEC of colon</td>
</tr>
<tr>
<td>991</td>
<td>Neuroendocrine tumour of colon</td>
</tr>
<tr>
<td>992</td>
<td>NET - [neuroendocrine tumour] of colon</td>
</tr>
<tr>
<td>993</td>
<td>Neuroendocrine tumour, G1 of colon</td>
</tr>
<tr>
<td>994</td>
<td>Neuroendocrine tumour, G2 of colon</td>
</tr>
<tr>
<td>995</td>
<td>Other specified neuroendocrine neoplasm of colon</td>
</tr>
<tr>
<td>996</td>
<td>Mixed adenoneuroendocrine carcinoma of colon</td>
</tr>
<tr>
<td>997</td>
<td>Adenocarcinoma of colon</td>
</tr>
<tr>
<td>998</td>
<td>Carcinoma of large intestine</td>
</tr>
<tr>
<td>999</td>
<td>Adenocarcinomas involving overlapping sites of colon</td>
</tr>
<tr>
<td>1000</td>
<td>Familial nonpolyposis colorectal cancer</td>
</tr>
<tr>
<td>1001</td>
<td>Hereditary nonpolyposis colorectal cancer</td>
</tr>
<tr>
<td>1002</td>
<td>Familial adenomatous polyposis</td>
</tr>
<tr>
<td>1003</td>
<td>FAP - [familial adenomatous polyposis]</td>
</tr>
<tr>
<td>1004</td>
<td>Polyposis (hereditary) of colon</td>
</tr>
<tr>
<td>1005</td>
<td>FPC - [familial polyposis coli]</td>
</tr>
<tr>
<td>1006</td>
<td>familial polyposis coli</td>
</tr>
<tr>
<td>1007</td>
<td>familial multiple polyposis syndrome</td>
</tr>
<tr>
<td>1008</td>
<td>familial polyposis</td>
</tr>
<tr>
<td>1009</td>
<td>Attenuated familial adenomatous polyposis</td>
</tr>
<tr>
<td>1010</td>
<td>Familial adenomatous polyposis due to 5q22.2 microdeletion</td>
</tr>
<tr>
<td>1011</td>
<td>Familial adenomatous polyposis with intestinal malignancy</td>
</tr>
<tr>
<td>1012</td>
<td>Turcot syndrome with polyposis</td>
</tr>
<tr>
<td>1013</td>
<td>Juvenile gastrointestinal polyposis</td>
</tr>
<tr>
<td>1014</td>
<td>Juvenile polyposis of infancy</td>
</tr>
<tr>
<td>1015</td>
<td>Colon carcinoma</td>
</tr>
<tr>
<td>1016</td>
<td>colon carcinoma NOS</td>
</tr>
<tr>
<td>1017</td>
<td>Metastatic carcinoma of colon [primary colon carcinoma spreading elsewhere]</td>
</tr>
<tr>
<td>1018</td>
<td>Neuroendocrine neoplasms of appendix</td>
</tr>
<tr>
<td>1019</td>
<td>Neuroendocrine tumour of appendix</td>
</tr>
<tr>
<td>1020</td>
<td>NET- [neuroendocrine tumour] of appendix</td>
</tr>
<tr>
<td>1021</td>
<td>carcinoid tumour of appendix</td>
</tr>
<tr>
<td>1022</td>
<td>appendiceal carcinoid tumour</td>
</tr>
<tr>
<td>1023</td>
<td>Neuroendocrine tumour, G1 of appendix</td>
</tr>
<tr>
<td>1024</td>
<td>Neuroendocrine tumour, G2 of appendix</td>
</tr>
<tr>
<td>1025</td>
<td>Neuroendocrine carcinoma of appendix</td>
</tr>
<tr>
<td>1026</td>
<td>NEC - [neuroendocrine carcinoma] of appendix</td>
</tr>
<tr>
<td>1027</td>
<td>Large cell neuroendocrine carcinoma of appendix</td>
</tr>
<tr>
<td>1028</td>
<td>Small cell neuroendocrine carcinoma of appendix</td>
</tr>
<tr>
<td>1029</td>
<td>Other specified neuroendocrine neoplasms of appendix</td>
</tr>
<tr>
<td>1030</td>
<td>Mixed adenoneuroendocrine carcinoma of appendix</td>
</tr>
<tr>
<td>1031</td>
<td>Charcot-Marie-Tooth disease 2 axonal</td>
</tr>
<tr>
<td>1032</td>
<td>Charcot-Marie-Tooth disease 2 autosomal dominant</td>
</tr>
<tr>
<td>1033</td>
<td>Recessive axonal Charcot-Marie-Tooth disease with acrodystrophy</td>
</tr>
<tr>
<td>1034</td>
<td>Charcot-Marie-Tooth disease type 2A1</td>
</tr>
<tr>
<td>1035</td>
<td>Charcot-Marie-Tooth disease type 2A2</td>
</tr>
<tr>
<td>1036</td>
<td>Charcot-Marie-Tooth disease type 2B</td>
</tr>
<tr>
<td>1037</td>
<td>Charcot-Marie-Tooth disease type 2C</td>
</tr>
<tr>
<td>1038</td>
<td>Charcot-Marie-Tooth disease type 2D</td>
</tr>
<tr>
<td>1039</td>
<td>Charcot-Marie-Tooth disease type 2E</td>
</tr>
<tr>
<td>1040</td>
<td>Charcot-Marie-Tooth disease type 2F</td>
</tr>
<tr>
<td>1041</td>
<td>Charcot-Marie-Tooth disease type 2G</td>
</tr>
<tr>
<td>1042</td>
<td>Charcot-Marie-Tooth disease type 2I</td>
</tr>
<tr>
<td>1043</td>
<td>Charcot-Marie-Tooth disease type 2J</td>
</tr>
<tr>
<td>1044</td>
<td>Charcot-Marie-Tooth disease type 2K</td>
</tr>
<tr>
<td>1045</td>
<td>Charcot-Marie-Tooth disease type 2L</td>
</tr>
<tr>
<td>1046</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2M</td>
</tr>
<tr>
<td>1047</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2N</td>
</tr>
<tr>
<td>1048</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2O</td>
</tr>
<tr>
<td>1049</td>
<td>Charcot-Marie-Tooth disease 2 autosomal recessive</td>
</tr>
<tr>
<td>1050</td>
<td>Charcot-Marie-Tooth disease type 2B1</td>
</tr>
<tr>
<td>1051</td>
<td>Charcot-Marie-Tooth disease type 2B2</td>
</tr>
<tr>
<td>1052</td>
<td>Charcot-Marie-Tooth disease type 2B5</td>
</tr>
<tr>
<td>1053</td>
<td>Charcot-Marie-Tooth disease type 2H</td>
</tr>
<tr>
<td>1054</td>
<td>Autosomal recessive Charcot-Marie-Tooth disease with hoarseness</td>
</tr>
<tr>
<td>1055</td>
<td>Hereditary motor and sensory neuropathy type 6</td>
</tr>
<tr>
<td>1056</td>
<td>Charcot-Marie-Tooth type 6</td>
</tr>
<tr>
<td>1057</td>
<td>HMSN6 - [Hereditary motor and sensory neuropathy type 6]</td>
</tr>
<tr>
<td>1058</td>
<td>CMT6 - [Charcot-Marie-Tooth type 6]</td>
</tr>
<tr>
<td>1059</td>
<td>Charcot-Marie-Tooth disease 1 demyelinating</td>
</tr>
<tr>
<td>1060</td>
<td>Charcot-Marie-Tooth disease 1 autosomal dominant</td>
</tr>
<tr>
<td>1061</td>
<td>Charcot-Marie-Tooth disease type 1E</td>
</tr>
<tr>
<td>1062</td>
<td>Charcot-Marie-Tooth disease type 1B</td>
</tr>
<tr>
<td>1063</td>
<td>Charcot-Marie-Tooth disease type 1C</td>
</tr>
<tr>
<td>1064</td>
<td>Charcot-Marie-Tooth disease type 1D</td>
</tr>
<tr>
<td>1065</td>
<td>Charcot-Marie-Tooth disease type 1F</td>
</tr>
<tr>
<td>1066</td>
<td>Charcot-Marie-Tooth disease 1 autosomal recessive</td>
</tr>
<tr>
<td>1067</td>
<td>Charcot-Marie-Tooth disease type 4</td>
</tr>
<tr>
<td>1068</td>
<td>CMT4 - [Charcot-Marie-Tooth disease type 4]</td>
</tr>
<tr>
<td>1069</td>
<td>Charcot-Marie-Tooth disease - deafness - intellectual deficit</td>
</tr>
<tr>
<td>1070</td>
<td>Charcot-Marie-Tooth disease type 4A</td>
</tr>
<tr>
<td>1071</td>
<td>Charcot-Marie-Tooth disease type 4C</td>
</tr>
<tr>
<td>1072</td>
<td>Charcot-Marie-Tooth disease type 4D</td>
</tr>
<tr>
<td>1073</td>
<td>Charcot-Marie-Tooth disease type 4E</td>
</tr>
<tr>
<td>1074</td>
<td>Charcot-Marie-Tooth disease type 4F</td>
</tr>
<tr>
<td>1075</td>
<td>Charcot-Marie-Tooth disease type 4G</td>
</tr>
<tr>
<td>1076</td>
<td>Charcot-Marie-Tooth disease type 4H</td>
</tr>
<tr>
<td>1077</td>
<td>Charcot-Marie-Tooth disease type 4B1</td>
</tr>
<tr>
<td>1078</td>
<td>Charcot-Marie-Tooth disease type 4B2</td>
</tr>
<tr>
<td>1079</td>
<td>Charcot-Marie-Tooth disease type 4J</td>
</tr>
<tr>
<td>1080</td>
<td>X-linked Charcot-Marie-Tooth disease 1 due to mutations in gap junction protein beta 1</td>
</tr>
<tr>
<td>1081</td>
<td>X-linked Charcot-Marie-Tooth disease 1 secondary to mutations in gap junction protein beta 1</td>
</tr>
<tr>
<td>1082</td>
<td>Charcot-Marie-Tooth disease 1X, x-linked Charcot-Marie-Tooth disease 1 due to mutations in gap junction protein beta 1</td>
</tr>
<tr>
<td>1083</td>
<td>Charcot-Marie-Tooth disease 1X, x-linked Charcot-Marie-Tooth disease 1 secondary to mutations in gap junction protein beta 1</td>
</tr>
<tr>
<td>1084</td>
<td>Hereditary sensorimotor neuropathy with hyperelastic skin</td>
</tr>
<tr>
<td>1085</td>
<td>Other specified pemphigoid</td>
</tr>
<tr>
<td>1086</td>
<td>Bullous pemphigoid variants</td>
</tr>
<tr>
<td>1087</td>
<td>Lichen planus pemphigoides</td>
</tr>
<tr>
<td>1088</td>
<td>Localised bullous pemphigoid</td>
</tr>
<tr>
<td>1089</td>
<td>Localised vulval pemphigoid</td>
</tr>
<tr>
<td>1090</td>
<td>Pemphigoid nodularis</td>
</tr>
<tr>
<td>1091</td>
<td>Anti-laminin-g1 pemphigoid</td>
</tr>
<tr>
<td>1092</td>
<td>anti-p200 pemphigoid</td>
</tr>
<tr>
<td>1093</td>
<td>Miscellaneous pemphigoid variants</td>
</tr>
<tr>
<td>1094</td>
<td>Pretibial pemphigoid</td>
</tr>
<tr>
<td>1095</td>
<td>Cicatricial pemphigoid, Brunsting-Perry type</td>
</tr>
<tr>
<td>1096</td>
<td>Neuroendocrine neoplasms of small intestine, site unspecified</td>
</tr>
<tr>
<td>1097</td>
<td>Neuroendocrine tumour of small intestine, site unspecified</td>
</tr>
<tr>
<td>1098</td>
<td>NET - [neuroendocrine tumour] of small intestine</td>
</tr>
<tr>
<td>1099</td>
<td>small intestinal neuroendocrine tumour</td>
</tr>
<tr>
<td>1100</td>
<td>Neuroendocrine tumour of small intestine, G1</td>
</tr>
<tr>
<td>1101</td>
<td>Neuroendocrine tumour of small intestine, G2</td>
</tr>
<tr>
<td>1102</td>
<td>Neuroendocrine carcinoma of small intestine, site unspecified</td>
</tr>
<tr>
<td>1103</td>
<td>NEC - [neuroendocrine carcinoma] of small intestine</td>
</tr>
<tr>
<td>1104</td>
<td>Large cell neuroendocrine carcinoma of small intestine</td>
</tr>
<tr>
<td>1105</td>
<td>Small cell neuroendocrine carcinoma of small intestine</td>
</tr>
<tr>
<td>1106</td>
<td>Recessive limb-girdle muscular dystrophy</td>
</tr>
<tr>
<td>1107</td>
<td>LGMD2 - [Limb-girdle muscular dystrophy] 2</td>
</tr>
<tr>
<td>1108</td>
<td>Limb-girdle muscular dystrophy 2A, calpain-3 deficiency</td>
</tr>
<tr>
<td>1109</td>
<td>Limb-girdle muscular dystrophy 2B, dysferlin deficiency</td>
</tr>
<tr>
<td>1110</td>
<td>Limb-girdle muscular dystrophy 2C, gamma-sarcoglycan deficiency</td>
</tr>
<tr>
<td>1111</td>
<td>Limb-girdle muscular dystrophy 2D, alpha-sarcoglycan deficiency</td>
</tr>
<tr>
<td>1112</td>
<td>Limb-girdle muscular dystrophy 2E, beta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>1113</td>
<td>Limb-girdle muscular dystrophy 2F, delta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>1114</td>
<td>Limb-girdle muscular dystrophy 2G, telethonin gene mutation</td>
</tr>
<tr>
<td>1115</td>
<td>Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation</td>
</tr>
<tr>
<td>1116</td>
<td>LGMD 2H - [Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation]</td>
</tr>
<tr>
<td>1117</td>
<td>Limb-girdle muscular dystrophy 2I, fukutin related protein gene mutation</td>
</tr>
<tr>
<td>1118</td>
<td>FKRP - [fukutin related protein gene mutation]</td>
</tr>
<tr>
<td>1119</td>
<td>LGMD 2I - [Limb-girdle muscular dystrophy 2I]</td>
</tr>
<tr>
<td>1120</td>
<td>Limb-girdle muscular dystrophy 2J, Titin gene mutation</td>
</tr>
<tr>
<td>1121</td>
<td>LGMD 2J - [Limb-girdle muscular dystrophy 2J, Titin gene mutation]</td>
</tr>
<tr>
<td>1122</td>
<td>Limb-girdle muscular dystrophy 2K, protein-O-mannosyltransferase 1 transferase</td>
</tr>
<tr>
<td>1123</td>
<td>POMT1 - [protein-O-mannosyltransferase 1 transferase]</td>
</tr>
<tr>
<td>1124</td>
<td>LGMD 2K - [Limb-girdle muscular dystrophy 2K]</td>
</tr>
<tr>
<td>1125</td>
<td>Limb-girdle muscular dystrophy 2L, AN05 gene mutation</td>
</tr>
<tr>
<td>1126</td>
<td>LGMD 2L - [Limb-girdle muscular dystrophy 2L]</td>
</tr>
<tr>
<td>1127</td>
<td>Limb-girdle muscular dystrophy 2M, POMGnT1 gene mutation</td>
</tr>
<tr>
<td>1128</td>
<td>LGMD2M - [limb-girdle muscular dystrophy 2M]</td>
</tr>
<tr>
<td>1129</td>
<td>Limb-girdle muscular dystrophy 2N, POMT2 gene mutation</td>
</tr>
<tr>
<td>1130</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C2)</td>
</tr>
<tr>
<td>1131</td>
<td>MDDGC2</td>
</tr>
<tr>
<td>1132</td>
<td>LGMD2N - limb-girdle muscular dystrophy 2N]</td>
</tr>
<tr>
<td>1133</td>
<td>Limb-girdle muscular dystrophy 2O, POMGNT1 gene mutation</td>
</tr>
<tr>
<td>1134</td>
<td>LGMD2O - [limb-girdle muscular dystrophy 2O]</td>
</tr>
<tr>
<td>1135</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C3)</td>
</tr>
<tr>
<td>1136</td>
<td>MDDGC3</td>
</tr>
<tr>
<td>1137</td>
<td>Limb-girdle muscular dystrophy 2Q, plectin deficiency</td>
</tr>
<tr>
<td>1138</td>
<td>LGMD2Q - [limb-girdle muscular dystrophy 2Q]</td>
</tr>
<tr>
<td>1139</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy C7</td>
</tr>
<tr>
<td>1140</td>
<td>MDDGC7</td>
</tr>
<tr>
<td>1141</td>
<td>Neuroendocrine neoplasms of jejunum or ileum</td>
</tr>
<tr>
<td>1142</td>
<td>carcinoid tumour of jejunum or ileum</td>
</tr>
<tr>
<td>1143</td>
<td>NET - [neuroendocrine tumour] of jejunum or ileum</td>
</tr>
<tr>
<td>1144</td>
<td>Neuroendocrine tumour of jejunum or ileum</td>
</tr>
<tr>
<td>1145</td>
<td>Neuroendocrine carcinoma of jejunum or ileum</td>
</tr>
<tr>
<td>1146</td>
<td>Other specified neuroendocrine neoplasm of jejunum or ileum</td>
</tr>
<tr>
<td>1147</td>
<td>Neuroendocrine tumour of jejunum or ileum, G1 carcinoid</td>
</tr>
<tr>
<td>1148</td>
<td>Neuroendocrine tumour of jejunum or ileum, G2</td>
</tr>
<tr>
<td>1149</td>
<td>Low birth weight of newborn, 2000-2499g</td>
</tr>
<tr>
<td>1150</td>
<td>Low birth weight of newborn, 1500-1999g</td>
</tr>
<tr>
<td>1151</td>
<td>Extremely low birth weight of newborn, 499g or less</td>
</tr>
<tr>
<td>1152</td>
<td>Extremely low birth weight of newborn, 500-749g</td>
</tr>
<tr>
<td>1153</td>
<td>Very low birth weight of newborn, 1000-1249g</td>
</tr>
<tr>
<td>1154</td>
<td>Dominant limb-girdle muscular dystrophy</td>
</tr>
<tr>
<td>1155</td>
<td>LGMD1 - [limb-girdle muscular dystrophy] 1</td>
</tr>
<tr>
<td>1156</td>
<td>Limb-girdle muscular dystrophy 1A, myotilin myopathy</td>
</tr>
<tr>
<td>1157</td>
<td>LGMD 1A - [Limb-girdle muscular dystrophy 1A, myotilin myopathy]</td>
</tr>
<tr>
<td>1158</td>
<td>Limb-girdle muscular dystrophy 1B, lamin myopathy</td>
</tr>
<tr>
<td>1159</td>
<td>LGMD 1B - [Limb-girdle muscular dystrophy 1B, lamin myopathy]</td>
</tr>
<tr>
<td>1160</td>
<td>Limb-girdle muscular dystrophy 1C, caveolin myopathy</td>
</tr>
<tr>
<td>1161</td>
<td>LGMD 1C - [Limb-girdle muscular dystrophy 1C, caveolin myopathy]</td>
</tr>
<tr>
<td>1162</td>
<td>Limb-girdle muscular dystrophy 1D, gene mapped to 6q23</td>
</tr>
<tr>
<td>1163</td>
<td>Limb-girdle muscular dystrophy 1E, gene mapped to 7q</td>
</tr>
<tr>
<td>1164</td>
<td>Limb-girdle muscular dystrophy 1F, gene mapped to 7q32.1-32.2</td>
</tr>
<tr>
<td>1165</td>
<td>Limb-girdle muscular dystrophy 1G, gene mapped to 4q21</td>
</tr>
<tr>
<td>1166</td>
<td>Limb-girdle muscular dystrophy 1H, gene mapped to 3p25.1p23</td>
</tr>
<tr>
<td>1167</td>
<td>LGMD1H - [Limb-girdle muscular dystrophy] 1H</td>
</tr>
<tr>
<td>1168</td>
<td>Very low birth weight of newborn, 1250-1499g</td>
</tr>
<tr>
<td>1169</td>
<td>Extremely low birth weight of newborn, 750-999g</td>
</tr>
<tr>
<td>1170</td>
<td>Constitutional neutropaenia</td>
</tr>
<tr>
<td>1171</td>
<td>congenital agranulocytosis and neutropaenia</td>
</tr>
<tr>
<td>1172</td>
<td>congenital leukopaenia</td>
</tr>
<tr>
<td>1173</td>
<td>Congenital neutropaenias</td>
</tr>
<tr>
<td>1174</td>
<td>primary neutropaenia</td>
</tr>
<tr>
<td>1175</td>
<td>Benign ethnic neutropaenia</td>
</tr>
<tr>
<td>1176</td>
<td>Severe congenital neutropaenia</td>
</tr>
<tr>
<td>1177</td>
<td>severe infantile genetic neutropaenia</td>
</tr>
<tr>
<td>1178</td>
<td>Autosomal dominant severe congenital neutropaenia</td>
</tr>
<tr>
<td>1179</td>
<td>Autosomal recessive severe congenital neutropaenia due to G6PC3 deficiency</td>
</tr>
<tr>
<td>1180</td>
<td>Dursun syndrome</td>
</tr>
<tr>
<td>1181</td>
<td>Pulmonary arterial hypertension - leukopenia - atrial septal defect</td>
</tr>
<tr>
<td>1182</td>
<td>Autosomal recessive severe congenital neutropaenia due to JAGN1 deficiency</td>
</tr>
<tr>
<td>1183</td>
<td>CSF3R-related severe congenital neutropaenia</td>
</tr>
<tr>
<td>1184</td>
<td>Kostmann syndrome</td>
</tr>
<tr>
<td>1185</td>
<td>Kostmann disease</td>
</tr>
<tr>
<td>1186</td>
<td>X-linked severe congenital neutropaenia</td>
</tr>
<tr>
<td>1187</td>
<td>Congenital neutropaenia with myelokathexis</td>
</tr>
<tr>
<td>1188</td>
<td>Congenital neutropaenia with maturation arrest</td>
</tr>
<tr>
<td>1189</td>
<td>Congenital neutropaenia associated with syndromal features</td>
</tr>
<tr>
<td>1190</td>
<td>Cyclic neutropaenia</td>
</tr>
<tr>
<td>1191</td>
<td>cyclic agranulocytosis</td>
</tr>
<tr>
<td>1192</td>
<td>Cyclic haematopoiesis</td>
</tr>
<tr>
<td>1193</td>
<td>Constitutional neutropaenia with extra-haematopoietic manifestations</td>
</tr>
<tr>
<td>1194</td>
<td>Primary immunodeficiency syndrome due to p14 deficiency</td>
</tr>
<tr>
<td>1195</td>
<td>Primary immunodeficiency syndrome with short stature</td>
</tr>
<tr>
<td>1196</td>
<td>Infantile genetic agranulocytosis</td>
</tr>
<tr>
<td>1197</td>
<td>severe infantile genetic agranulocytosis</td>
</tr>
<tr>
<td>1198</td>
<td>Other specified hereditary thrombophilia</td>
</tr>
<tr>
<td>1199</td>
<td>Hereditary thrombophilia due to activated protein C resistance</td>
</tr>
<tr>
<td>1200</td>
<td>Hereditary thrombophilia due to activated protein C resistance, factor V Leiden</td>
</tr>
<tr>
<td>1201</td>
<td>Hereditary thrombophilia due to other inherited factor V defects</td>
</tr>
<tr>
<td>1202</td>
<td>Hereditary thrombophilia due to factor V Hong Kong defects</td>
</tr>
<tr>
<td>1203</td>
<td>Hereditary thrombophilia due to factor V Cambridge defects</td>
</tr>
<tr>
<td>1204</td>
<td>Hereditary thrombophilia due to congenital antithrombin deficiency</td>
</tr>
<tr>
<td>1205</td>
<td>hereditary thrombophilia due to congenital antithrombin 3 deficiency</td>
</tr>
<tr>
<td>1206</td>
<td>hereditary thrombophilia due to congenital antithrombin III deficiency</td>
</tr>
<tr>
<td>1207</td>
<td>antithrombin deficiency NOS</td>
</tr>
<tr>
<td>1208</td>
<td>Hereditary thrombophilia due to congenital protein S deficiency</td>
</tr>
<tr>
<td>1209</td>
<td>Hereditary thrombophilia due to congenital protein C deficiency</td>
</tr>
<tr>
<td>1210</td>
<td>Hereditary thrombophilia due to thrombomodulin deficiency</td>
</tr>
<tr>
<td>1211</td>
<td>Hereditary thrombophilia due to prothrombin gene</td>
</tr>
<tr>
<td>1212</td>
<td>hereditary thrombophilia due to prothrombin G20210A mutation</td>
</tr>
<tr>
<td>1213</td>
<td>hereditary thrombophilia due to prothrombin gene mutation</td>
</tr>
<tr>
<td>1214</td>
<td>Hereditary thrombophilia due to other prothrombotic prothrombin gene mutations</td>
</tr>
<tr>
<td>1215</td>
<td>Prothrombin gene mutation</td>
</tr>
<tr>
<td>1216</td>
<td>Hereditary thrombophilia due to congenital histidine-rich (poly-L) glycoprotein deficiency</td>
</tr>
<tr>
<td>1217</td>
<td>Hereditary thrombophilia due to congenital HRG - [histidine-rich (poly-L) glycoprotein] deficiency</td>
</tr>
<tr>
<td>1218</td>
<td>Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency</td>
</tr>
<tr>
<td>1219</td>
<td>Heparin co-factor II deficiency</td>
</tr>
<tr>
<td>1</td>
<td>Other specified syndromes with skin or mucosal anomalies as a major feature</td>
</tr>
<tr>
<td>2</td>
<td>Ascher syndrome</td>
</tr>
<tr>
<td>3</td>
<td>Blepharochalasia - double lip</td>
</tr>
<tr>
<td>4</td>
<td>Hereditary acrokeratotic poikiloderma, Weary type</td>
</tr>
<tr>
<td>5</td>
<td>H syndrome</td>
</tr>
<tr>
<td>6</td>
<td>Aplasia cutis congenita - intestinal lymphangiectasia</td>
</tr>
<tr>
<td>7</td>
<td>Bronspiegel-Zelnick syndrome</td>
</tr>
<tr>
<td>8</td>
<td>Autosomal recessive aplasia cutis</td>
</tr>
<tr>
<td>9</td>
<td>Aplasia cutis - myopia</td>
</tr>
<tr>
<td>10</td>
<td>Pachyonychia congenita</td>
</tr>
<tr>
<td>11</td>
<td>Neuroectodermal melanolysosomal disease</td>
</tr>
<tr>
<td>12</td>
<td>Elejalde disease</td>
</tr>
<tr>
<td>13</td>
<td>Xeroderma pigmentosum variant</td>
</tr>
<tr>
<td>14</td>
<td>Lipoid proteinosis</td>
</tr>
<tr>
<td>15</td>
<td>Urbach-Wiethe disease</td>
</tr>
<tr>
<td>16</td>
<td>Urbach lipoid proteinosis</td>
</tr>
<tr>
<td>17</td>
<td>Hyalinosis cutis et mucosae</td>
</tr>
<tr>
<td>18</td>
<td>lipid proteinosis</td>
</tr>
<tr>
<td>19</td>
<td>lipidosis cutis et mucosae</td>
</tr>
<tr>
<td>20</td>
<td>lipoid proteinosis of Urbach and Wiethe</td>
</tr>
<tr>
<td>21</td>
<td>Cutis verticis gyrata - intellectual deficit</td>
</tr>
<tr>
<td>22</td>
<td>Cutis verticis gyrata - retinitis pigmentosa - sensorineural deafness</td>
</tr>
<tr>
<td>23</td>
<td>Junctional epidermolysis bullosa</td>
</tr>
<tr>
<td>24</td>
<td>Junctional EB - [epidermolysis bullosa]</td>
</tr>
<tr>
<td>25</td>
<td>JEB - [junctional epidermolysis bullosa]</td>
</tr>
<tr>
<td>26</td>
<td>Lucidolytic epidermolysis bullosa</td>
</tr>
<tr>
<td>27</td>
<td>Junctional epidermolysis bullosa, generalised types</td>
</tr>
<tr>
<td>28</td>
<td>Junctional epidermolysis bullosa, generalised severe</td>
</tr>
<tr>
<td>29</td>
<td>Epidermolysis bullosa letalis</td>
</tr>
<tr>
<td>30</td>
<td>Herlitz syndrome</td>
</tr>
<tr>
<td>31</td>
<td>Herlitz junctional epidermolysis bullosa gravis</td>
</tr>
<tr>
<td>32</td>
<td>JEB-H - [junctional epidermolysis bullosa, Herlitz]</td>
</tr>
<tr>
<td>33</td>
<td>JEB-gen sev - [junctional epidermolysis bullosa, generalised severe]</td>
</tr>
<tr>
<td>34</td>
<td>Junctional epidermolysis bullosa, generalised intermediate type</td>
</tr>
<tr>
<td>35</td>
<td>GABEB - [generalised atrophic benign epidermolysis bullosa]</td>
</tr>
<tr>
<td>36</td>
<td>JEB-nH gen - [junctional epidermolysis bullosa, non-Herlitz, generalised]</td>
</tr>
<tr>
<td>37</td>
<td>JEB - [junctional epidermolysis bullosa] non-Herlitz, generalised</td>
</tr>
<tr>
<td>38</td>
<td>generalised atrophic benign epidermolysis bullosa</td>
</tr>
<tr>
<td>39</td>
<td>JEB-gen intermed - [junctional epidermolysis bullosa]</td>
</tr>
<tr>
<td>40</td>
<td>Junctional epidermolysis bullosa with pyloric atresia</td>
</tr>
<tr>
<td>41</td>
<td>JEB - [junctional epidermolysis bullosa] with pyloric atresia</td>
</tr>
<tr>
<td>42</td>
<td>JEB-PA - [junctional epidermolysis bullosa with pyloric atresia]</td>
</tr>
<tr>
<td>43</td>
<td>Junctional epidermolysis bullosa, late onset</td>
</tr>
<tr>
<td>44</td>
<td>Epidermolysis bullosa progressiva</td>
</tr>
<tr>
<td>45</td>
<td>JEB - [junctional epidermolysis bullosa] late onset</td>
</tr>
<tr>
<td>46</td>
<td>JEB-LO - [junctional epidermolysis bullosa late onset]</td>
</tr>
<tr>
<td>47</td>
<td>Junctional epidermolysis bullosa with respiratory and renal involvement</td>
</tr>
<tr>
<td>48</td>
<td>Junctional epidermolysis bullosa, localised types</td>
</tr>
<tr>
<td>49</td>
<td>Junctional epidermolysis bullosa, localised</td>
</tr>
<tr>
<td>50</td>
<td>JEB-nH loc - [junctional epidermolysis bullosa, non-Herlitz, localised]</td>
</tr>
<tr>
<td>51</td>
<td>JEB - [junctional epidermolysis bullosa] non-Herlitz, localised</td>
</tr>
<tr>
<td>52</td>
<td>JEB-loc - [junctional epidermolysis bullosa, localised</td>
</tr>
<tr>
<td>53</td>
<td>Junctional epidermolysis bullosa inversa</td>
</tr>
<tr>
<td>54</td>
<td>JEB - [junctional epidermolysis bullosa] inversa</td>
</tr>
<tr>
<td>55</td>
<td>JEB-inv - [junctional epidermolysis bullosa inversa]</td>
</tr>
<tr>
<td>56</td>
<td>Junctional epidermolysis bullosa, LOC</td>
</tr>
<tr>
<td>57</td>
<td>Laryngo-onycho-cutaneous syndrome</td>
</tr>
<tr>
<td>58</td>
<td>Shabbir syndrome</td>
</tr>
<tr>
<td>59</td>
<td>LOGIC</td>
</tr>
<tr>
<td>60</td>
<td>JEB-LOC - [junctional epidermolysis bullosa laryngo-onycho-cutaneous] syndrome</td>
</tr>
<tr>
<td>61</td>
<td>LOC - [laryngo-onycho-cutaneous] syndrome</td>
</tr>
<tr>
<td>62</td>
<td>Noninflammatory inclusion body myopathy</td>
</tr>
<tr>
<td>63</td>
<td>Hereditary inclusion body myopathy</td>
</tr>
<tr>
<td>64</td>
<td>HIBM - [hereditary inclusion body myositis]</td>
</tr>
<tr>
<td>65</td>
<td>Desmin-related myopathy with Mallory body-like inclusions</td>
</tr>
<tr>
<td>66</td>
<td>Hereditary inclusion body myopathy - joint contractures - ophthalmoplegia</td>
</tr>
<tr>
<td>67</td>
<td>Inclusion body myopathy with Paget disease of bone and frontotemporal dementia</td>
</tr>
<tr>
<td>68</td>
<td>IBMPFD - [inclusion body myopathy with Paget disease of bone and frontotemporal dementia]</td>
</tr>
<tr>
<td>69</td>
<td>X-linked myopathy with excess autophagy</td>
</tr>
<tr>
<td>70</td>
<td>XMEA - [x-linked myopathy with excess autophagy]</td>
</tr>
<tr>
<td>71</td>
<td>Sporadic inclusion body myopathy</td>
</tr>
<tr>
<td>72</td>
<td>Other specified disorders of urea cycle metabolism</td>
</tr>
<tr>
<td>73</td>
<td>Ornithine carbamoyltransferase deficiency</td>
</tr>
<tr>
<td>74</td>
<td>Ornithine carbamyltransferase deficiency</td>
</tr>
<tr>
<td>75</td>
<td>Ornithine transcarbamoylase deficiency</td>
</tr>
<tr>
<td>76</td>
<td>Ornithine transcarbamylase deficiency</td>
</tr>
<tr>
<td>77</td>
<td>OCT - [Ornithine carbamyltransferase] deficiency</td>
</tr>
<tr>
<td>78</td>
<td>Hyperammonaemia due to N-acetylglutamate synthetase deficiency</td>
</tr>
<tr>
<td>79</td>
<td>NAGS - [Hyperammonaemia due to N-acetylglutamate synthetase] deficiency</td>
</tr>
<tr>
<td>80</td>
<td>Transient hyperammonaemia of the newborn</td>
</tr>
<tr>
<td>81</td>
<td>Transient neonatal hyperammonaemia</td>
</tr>
<tr>
<td>82</td>
<td>Transient hyperammonaemia of infancy</td>
</tr>
<tr>
<td>83</td>
<td>THAN - [Transient hyperammonaemia of the newborn]</td>
</tr>
<tr>
<td>84</td>
<td>Hyperornithinaemia-hyperammonaemia-homocitrullinuria</td>
</tr>
<tr>
<td>85</td>
<td>Triple H syndrome</td>
</tr>
<tr>
<td>86</td>
<td>HHH - [Hyperornithinaemia-hyperammonaemia-homocitrullinuria] syndrome</td>
</tr>
<tr>
<td>87</td>
<td>Hyperinsulinism-hyperammonaemia syndrome</td>
</tr>
<tr>
<td>88</td>
<td>Other disorders of the urea cycle</td>
</tr>
<tr>
<td>89</td>
<td>Unspecified hyperammonaemia</td>
</tr>
<tr>
<td>90</td>
<td>Congenital hyperammonaemia</td>
</tr>
<tr>
<td>91</td>
<td>Mucopolysaccharidosis type 1</td>
</tr>
<tr>
<td>92</td>
<td>Alpha-L-iduronidase deficiency</td>
</tr>
<tr>
<td>93</td>
<td>l-iduronidase deficiency</td>
</tr>
<tr>
<td>94</td>
<td>Lipochondrodystrophy</td>
</tr>
<tr>
<td>95</td>
<td>dysostosis multiplex</td>
</tr>
<tr>
<td>96</td>
<td>dysostosis multiplex syndrome</td>
</tr>
<tr>
<td>97</td>
<td>Gargoylism</td>
</tr>
<tr>
<td>98</td>
<td>MPS1 - [Mucopolysaccharidosis type 1]</td>
</tr>
<tr>
<td>99</td>
<td>Mucopolysaccharidosis type 1H</td>
</tr>
<tr>
<td>100</td>
<td>Hurler syndrome</td>
</tr>
<tr>
<td>101</td>
<td>Mucopolysaccharidosis type 1, severe form</td>
</tr>
<tr>
<td>102</td>
<td>MPS1H - [Mucopolysaccharidosis type 1H]</td>
</tr>
<tr>
<td>103</td>
<td>Mucopolysaccharidosis type 1H/S</td>
</tr>
<tr>
<td>104</td>
<td>Hurler-Scheie syndrome</td>
</tr>
<tr>
<td>105</td>
<td>Mucopolysaccharidosis type 1, intermediate form</td>
</tr>
<tr>
<td>106</td>
<td>MPS1H/S - [Mucopolysaccharidosis type 1H/S]</td>
</tr>
<tr>
<td>107</td>
<td>Mucopolysaccharidosis type 1S</td>
</tr>
<tr>
<td>108</td>
<td>Scheie syndrome</td>
</tr>
<tr>
<td>109</td>
<td>Mucopolysaccharidosis type 1, mild form</td>
</tr>
<tr>
<td>110</td>
<td>MPS1S - [Mucopolysaccharidosis type 1S]</td>
</tr>
<tr>
<td>111</td>
<td>Disorders of multiple glycosylation or other pathways</td>
</tr>
<tr>
<td>112</td>
<td>Dolichol-phosphate-mannose synthase 1 deficiency</td>
</tr>
<tr>
<td>113</td>
<td>GDP-Man: Dol-P-mannosyltransferase deficiency</td>
</tr>
<tr>
<td>114</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1E</td>
</tr>
<tr>
<td>115</td>
<td>Congenital disorder of glycosylation type 1E</td>
</tr>
<tr>
<td>116</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1E</td>
</tr>
<tr>
<td>117</td>
<td>Mannose-P-dolichol utilisation defect 1</td>
</tr>
<tr>
<td>118</td>
<td>Lec35 deficiency</td>
</tr>
<tr>
<td>119</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1F</td>
</tr>
<tr>
<td>120</td>
<td>Congenital disorder of glycosylation type 1F</td>
</tr>
<tr>
<td>121</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1F</td>
</tr>
<tr>
<td>122</td>
<td>Beta-1,4-galactosyltransferase deficiency</td>
</tr>
<tr>
<td>123</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2D</td>
</tr>
<tr>
<td>124</td>
<td>Congenital disorder of glycosylation type 2D</td>
</tr>
<tr>
<td>125</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2D</td>
</tr>
<tr>
<td>126</td>
<td>CMP-sialic acid transporter deficiency</td>
</tr>
<tr>
<td>127</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2F</td>
</tr>
<tr>
<td>128</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2F</td>
</tr>
<tr>
<td>129</td>
<td>Congenital disorder of glycosylation type 2F</td>
</tr>
<tr>
<td>130</td>
<td>Leukocyte adhesion deficiency type 2</td>
</tr>
<tr>
<td>131</td>
<td>Rambam-Hasharon syndrome</td>
</tr>
<tr>
<td>132</td>
<td>GDP-fucose transporter deficiency</td>
</tr>
<tr>
<td>133</td>
<td>LAD-II - [Leukocyte adhesion deficiency type 2]</td>
</tr>
<tr>
<td>134</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2C</td>
</tr>
<tr>
<td>135</td>
<td>Dolichol kinase deficiency</td>
</tr>
<tr>
<td>136</td>
<td>Hypotonia or ichthyosis due to dolichol phosphate deficiency</td>
</tr>
<tr>
<td>137</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1M</td>
</tr>
<tr>
<td>138</td>
<td>Congenital disorder of glycosylation type 1M</td>
</tr>
<tr>
<td>139</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1M</td>
</tr>
<tr>
<td>140</td>
<td>Conserved oligomeric Golgi complex deficiencies</td>
</tr>
<tr>
<td>141</td>
<td>Component of conserved oligomeric Golgi complex 1 deficiency</td>
</tr>
<tr>
<td>142</td>
<td>CDG syndrome type 2G</td>
</tr>
<tr>
<td>143</td>
<td>Component of conserved oligomeric Golgi complex 4 deficiency</td>
</tr>
<tr>
<td>144</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2J</td>
</tr>
<tr>
<td>145</td>
<td>Congenital disorder of glycosylation type 2J</td>
</tr>
<tr>
<td>146</td>
<td>Component of conserved oligomeric Golgi complex 5 deficiency</td>
</tr>
<tr>
<td>147</td>
<td>Component of conserved oligomeric Golgi complex 7 deficiency</td>
</tr>
<tr>
<td>148</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2E</td>
</tr>
<tr>
<td>149</td>
<td>Congenital disorder of glycosylation type 2E</td>
</tr>
<tr>
<td>150</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2E</td>
</tr>
<tr>
<td>151</td>
<td>Component of conserved oligomeric Golgi complex 8 deficiency</td>
</tr>
<tr>
<td>152</td>
<td>Congenital disorder of glycosylation type 2h</td>
</tr>
<tr>
<td>153</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2H</td>
</tr>
<tr>
<td>154</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2H</td>
</tr>
<tr>
<td>155</td>
<td>V-ATPase deficiencies</td>
</tr>
<tr>
<td>156</td>
<td>Disorders of protein N-glycosylation</td>
</tr>
<tr>
<td>157</td>
<td>Phosphomannomutase 2 deficiency</td>
</tr>
<tr>
<td>158</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1A</td>
</tr>
<tr>
<td>159</td>
<td>Congenital disorder of glycosylation type 1A</td>
</tr>
<tr>
<td>160</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1A</td>
</tr>
<tr>
<td>161</td>
<td>Phosphomannose isomerase deficiency</td>
</tr>
<tr>
<td>162</td>
<td>Saguenay-Lac-Saint-Jean syndrome</td>
</tr>
<tr>
<td>163</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1B</td>
</tr>
<tr>
<td>164</td>
<td>Congenital disorder of glycosylation type 1B</td>
</tr>
<tr>
<td>165</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1B</td>
</tr>
<tr>
<td>166</td>
<td>SLSJ - [Saguenay-Lac-Saint-Jean] syndrome</td>
</tr>
<tr>
<td>167</td>
<td>Glucosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>168</td>
<td>Dol-P-Glc: Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>169</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1C</td>
</tr>
<tr>
<td>170</td>
<td>Congenital disorder of glycosylation type 1C</td>
</tr>
<tr>
<td>171</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1C</td>
</tr>
<tr>
<td>172</td>
<td>Mannosyltransferase 6 deficiency</td>
</tr>
<tr>
<td>173</td>
<td>Dol-P-Man: Man5-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>174</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1D</td>
</tr>
<tr>
<td>175</td>
<td>Congenital disorder of glycosylation type 1D</td>
</tr>
<tr>
<td>176</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1D</td>
</tr>
<tr>
<td>177</td>
<td>Mannosyltransferase 8 deficiency</td>
</tr>
<tr>
<td>178</td>
<td>Dol-P-Man: Man7-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>179</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1G</td>
</tr>
<tr>
<td>180</td>
<td>Congenital disorder of glycosylation type 1G</td>
</tr>
<tr>
<td>181</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1G</td>
</tr>
<tr>
<td>182</td>
<td>Glucosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>183</td>
<td>Dol-P-Glc: Glc1-Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>184</td>
<td>Carbohydrate deficient glycoprotein syndrome 1H</td>
</tr>
<tr>
<td>185</td>
<td>Congenital disorder of glycosylation type 1H</td>
</tr>
<tr>
<td>186</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1H</td>
</tr>
<tr>
<td>187</td>
<td>Mannosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>188</td>
<td>Dol-P-Man: Man1-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>189</td>
<td>Carbohydrate deficient glycoprotein syndrome 1I</td>
</tr>
<tr>
<td>190</td>
<td>Congenital disorder of glycosylation 1I</td>
</tr>
<tr>
<td>191</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1I</td>
</tr>
<tr>
<td>192</td>
<td>Dolichyl-phosphate N-acetylgalactosamine phosphotransferase deficiency</td>
</tr>
<tr>
<td>193</td>
<td>UDP-GlcNAc: Dol-P-GlcNac-P transferase deficiency</td>
</tr>
<tr>
<td>194</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1J</td>
</tr>
<tr>
<td>195</td>
<td>Congenital disorder of glycosylation type 1J</td>
</tr>
<tr>
<td>196</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1J</td>
</tr>
<tr>
<td>197</td>
<td>Mannosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>198</td>
<td>Dol-P-Man: GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>199</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1K</td>
</tr>
<tr>
<td>200</td>
<td>Congenital disorder of glycosylation type 1K</td>
</tr>
<tr>
<td>201</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1K</td>
</tr>
<tr>
<td>202</td>
<td>Mannosyltransferase 7-9 deficiency</td>
</tr>
<tr>
<td>203</td>
<td>Congenital disorder of glycosylation type 1L</td>
</tr>
<tr>
<td>204</td>
<td>Dol-P-Man: Man6 and Man8-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>205</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1L</td>
</tr>
<tr>
<td>206</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1L</td>
</tr>
<tr>
<td>207</td>
<td>M5-DLO flippase deficiency</td>
</tr>
<tr>
<td>208</td>
<td>Man5GlcNAc2-PP-Dol flippase deficiency</td>
</tr>
<tr>
<td>209</td>
<td>RTF1-CDG</td>
</tr>
<tr>
<td>210</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1N</td>
</tr>
<tr>
<td>211</td>
<td>N-acetylglucosaminyltransferase deficiency</td>
</tr>
<tr>
<td>212</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2A</td>
</tr>
<tr>
<td>213</td>
<td>Congenital disorder of glycosylation type 2A</td>
</tr>
<tr>
<td>214</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2A</td>
</tr>
<tr>
<td>215</td>
<td>Glucosidase 1 deficiency</td>
</tr>
<tr>
<td>216</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2B</td>
</tr>
<tr>
<td>217</td>
<td>Congenital disorder of glycosylation type 2B</td>
</tr>
<tr>
<td>218</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2B</td>
</tr>
<tr>
<td>219</td>
<td>TUSC3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>220</td>
<td>TUSC3-CDG</td>
</tr>
<tr>
<td>221</td>
<td>SRD5A3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>222</td>
<td>SRD5A3-CDG</td>
</tr>
<tr>
<td>223</td>
<td>Congenital disorder of glycosylation due to steroid 5-alpha-reductase type 3 deficiency</td>
</tr>
<tr>
<td>224</td>
<td>Intellectual deficit - cataract - coloboma - kyphosis</td>
</tr>
<tr>
<td>225</td>
<td>Kahrizi syndrome</td>
</tr>
<tr>
<td>226</td>
<td>Intellectual deficit, Kahrizi type</td>
</tr>
<tr>
<td>227</td>
<td>DPM3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>228</td>
<td>Congenital disorder of glycosylation type 1O</td>
</tr>
<tr>
<td>229</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1O</td>
</tr>
<tr>
<td>230</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1O</td>
</tr>
<tr>
<td>231</td>
<td>ALG11 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>232</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1P</td>
</tr>
<tr>
<td>233</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1P</td>
</tr>
<tr>
<td>234</td>
<td>Congenital disorder of glycosylation type 1P</td>
</tr>
<tr>
<td>235</td>
<td>Phosphoglucomutase-1 deficiency</td>
</tr>
<tr>
<td>236</td>
<td>PGM1-CDG - [Phosphoglucomutase-1 deficiency]</td>
</tr>
<tr>
<td>237</td>
<td>Congenital disorder of glycosylation type 1t</td>
</tr>
<tr>
<td>238</td>
<td>Recessive limb-girdle muscular dystrophy</td>
</tr>
<tr>
<td>239</td>
<td>LGMD2 - [Limb-girdle muscular dystrophy] 2</td>
</tr>
<tr>
<td>240</td>
<td>Limb-girdle muscular dystrophy 2A, calpain-3 deficiency</td>
</tr>
<tr>
<td>241</td>
<td>Limb-girdle muscular dystrophy 2B, dysferlin deficiency</td>
</tr>
<tr>
<td>242</td>
<td>Limb-girdle muscular dystrophy 2C, gamma-sarcoglycan deficiency</td>
</tr>
<tr>
<td>243</td>
<td>Limb-girdle muscular dystrophy 2D, alpha-sarcoglycan deficiency</td>
</tr>
<tr>
<td>244</td>
<td>Limb-girdle muscular dystrophy 2E, beta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>245</td>
<td>Limb-girdle muscular dystrophy 2F, delta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>246</td>
<td>Limb-girdle muscular dystrophy 2G, telethonin gene mutation</td>
</tr>
<tr>
<td>247</td>
<td>Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation</td>
</tr>
<tr>
<td>248</td>
<td>LGMD 2H - [Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation]</td>
</tr>
<tr>
<td>249</td>
<td>Limb-girdle muscular dystrophy 2I, fukutin related protein gene mutation</td>
</tr>
<tr>
<td>250</td>
<td>FKRP - [fukutin related protein gene mutation]</td>
</tr>
<tr>
<td>251</td>
<td>LGMD 2I - [Limb-girdle muscular dystrophy 2I]</td>
</tr>
<tr>
<td>252</td>
<td>Limb-girdle muscular dystrophy 2J, Titin gene mutation</td>
</tr>
<tr>
<td>253</td>
<td>LGMD 2J - [Limb-girdle muscular dystrophy 2J, Titin gene mutation]</td>
</tr>
<tr>
<td>254</td>
<td>Limb-girdle muscular dystrophy 2K, protein-O-mannosyltransferase 1 transferase</td>
</tr>
<tr>
<td>255</td>
<td>POMT1 - [protein-O-mannosyltransferase 1 transferase]</td>
</tr>
<tr>
<td>256</td>
<td>LGMD 2K - [Limb-girdle muscular dystrophy 2K]</td>
</tr>
<tr>
<td>257</td>
<td>Limb-girdle muscular dystrophy 2L, AN05 gene mutation</td>
</tr>
<tr>
<td>258</td>
<td>LGMD 2L - [Limb-girdle muscular dystrophy 2L]</td>
</tr>
<tr>
<td>259</td>
<td>Limb-girdle muscular dystrophy 2M, POMGnT1 gene mutation</td>
</tr>
<tr>
<td>260</td>
<td>LGMD2M - [limb-girdle muscular dystrophy 2M]</td>
</tr>
<tr>
<td>261</td>
<td>Limb-girdle muscular dystrophy 2N, POMT2 gene mutation</td>
</tr>
<tr>
<td>262</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C2)</td>
</tr>
<tr>
<td>263</td>
<td>MDDGC2</td>
</tr>
<tr>
<td>264</td>
<td>LGMD2N - limb-girdle muscular dystrophy 2N]</td>
</tr>
<tr>
<td>265</td>
<td>Limb-girdle muscular dystrophy 2O, POMGNT1 gene mutation</td>
</tr>
<tr>
<td>266</td>
<td>LGMD2O - [limb-girdle muscular dystrophy 2O]</td>
</tr>
<tr>
<td>267</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C3)</td>
</tr>
<tr>
<td>268</td>
<td>MDDGC3</td>
</tr>
<tr>
<td>269</td>
<td>Limb-girdle muscular dystrophy 2Q, plectin deficiency</td>
</tr>
<tr>
<td>270</td>
<td>LGMD2Q - [limb-girdle muscular dystrophy 2Q]</td>
</tr>
<tr>
<td>271</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy C7</td>
</tr>
<tr>
<td>272</td>
<td>MDDGC7</td>
</tr>
<tr>
<td>273</td>
<td>Dominant limb-girdle muscular dystrophy</td>
</tr>
<tr>
<td>274</td>
<td>LGMD1 - [limb-girdle muscular dystrophy] 1</td>
</tr>
<tr>
<td>275</td>
<td>Limb-girdle muscular dystrophy 1A, myotilin myopathy</td>
</tr>
<tr>
<td>276</td>
<td>LGMD 1A - [Limb-girdle muscular dystrophy 1A, myotilin myopathy]</td>
</tr>
<tr>
<td>277</td>
<td>Limb-girdle muscular dystrophy 1B, lamin myopathy</td>
</tr>
<tr>
<td>278</td>
<td>LGMD 1B - [Limb-girdle muscular dystrophy 1B, lamin myopathy]</td>
</tr>
<tr>
<td>279</td>
<td>Limb-girdle muscular dystrophy 1C, caveolin myopathy</td>
</tr>
<tr>
<td>280</td>
<td>LGMD 1C - [Limb-girdle muscular dystrophy 1C, caveolin myopathy]</td>
</tr>
<tr>
<td>281</td>
<td>Limb-girdle muscular dystrophy 1D, gene mapped to 6q23</td>
</tr>
<tr>
<td>282</td>
<td>Limb-girdle muscular dystrophy 1E, gene mapped to 7q</td>
</tr>
<tr>
<td>283</td>
<td>Limb-girdle muscular dystrophy 1F, gene mapped to 7q32.1-32.2</td>
</tr>
<tr>
<td>284</td>
<td>Limb-girdle muscular dystrophy 1G, gene mapped to 4q21</td>
</tr>
<tr>
<td>285</td>
<td>Limb-girdle muscular dystrophy 1H, gene mapped to 3p25.1p23</td>
</tr>
<tr>
<td>286</td>
<td>LGMD1H - [Limb-girdle muscular dystrophy] 1H</td>
</tr>
<tr>
<td>287</td>
<td>Haemoglobin H disease (– α/– – included)</td>
</tr>
<tr>
<td>288</td>
<td>alpha - /- - or mutational forms of alpha-thalassaemia</td>
</tr>
<tr>
<td>289</td>
<td>Alpha thalassaemia intermedia</td>
</tr>
<tr>
<td>290</td>
<td>Harmful effects of drugs, medicaments or biological substances, not elsewhere classified</td>
</tr>
<tr>
<td>291</td>
<td>drugs, medicaments or biological substances, toxicity not elsewhere classified</td>
</tr>
<tr>
<td>292</td>
<td>adverse drug effects</td>
</tr>
<tr>
<td>293</td>
<td>drug reaction NOS</td>
</tr>
<tr>
<td>294</td>
<td>drug allergy NOS</td>
</tr>
<tr>
<td>295</td>
<td>drug toxicity NOS</td>
</tr>
<tr>
<td>296</td>
<td>drug ingestion NOS</td>
</tr>
<tr>
<td>297</td>
<td>toxic effects of drugs NOS</td>
</tr>
<tr>
<td>298</td>
<td>acute drug intoxication</td>
</tr>
<tr>
<td>299</td>
<td>toxic use of drugs</td>
</tr>
<tr>
<td>300</td>
<td>intake of a toxic substance</td>
</tr>
<tr>
<td>301</td>
<td>Harmful effects of opioids or related analgesics</td>
</tr>
<tr>
<td>302</td>
<td>Harmful effects of opium</td>
</tr>
<tr>
<td>303</td>
<td>Harmful effects of morphine</td>
</tr>
<tr>
<td>304</td>
<td>Harmful effects of oxycodone</td>
</tr>
<tr>
<td>305</td>
<td>oxycodone toxicity</td>
</tr>
<tr>
<td>306</td>
<td>Harmful effects of codeine</td>
</tr>
<tr>
<td>307</td>
<td>Harmful effects of heroin</td>
</tr>
<tr>
<td>308</td>
<td>poisoning by diacetylmorphine</td>
</tr>
<tr>
<td>309</td>
<td>poisoning by heroin</td>
</tr>
<tr>
<td>310</td>
<td>poisoning by heroin NOS</td>
</tr>
<tr>
<td>311</td>
<td>acute heroin intoxication</td>
</tr>
<tr>
<td>312</td>
<td>acute heroin toxicity</td>
</tr>
<tr>
<td>313</td>
<td>toxic effects of heroin</td>
</tr>
<tr>
<td>314</td>
<td>Harmful effects of methadone</td>
</tr>
<tr>
<td>315</td>
<td>poisoning by methadone</td>
</tr>
<tr>
<td>316</td>
<td>poisoning by methadone NOS</td>
</tr>
<tr>
<td>317</td>
<td>methadone toxicity</td>
</tr>
<tr>
<td>318</td>
<td>Harmful effects of pethidine</td>
</tr>
<tr>
<td>319</td>
<td>pethidine poisoning</td>
</tr>
<tr>
<td>320</td>
<td>Harmful effects of fentanyl</td>
</tr>
<tr>
<td>321</td>
<td>fentanyl poisoning</td>
</tr>
<tr>
<td>322</td>
<td>fentanyl toxicity</td>
</tr>
<tr>
<td>323</td>
<td>toxic effects of fentanyl</td>
</tr>
<tr>
<td>324</td>
<td>fentanyl toxication</td>
</tr>
<tr>
<td>325</td>
<td>acute fentanyl toxicity</td>
</tr>
<tr>
<td>326</td>
<td>Harmful effects of phenoperidine</td>
</tr>
<tr>
<td>327</td>
<td>phenoperidine poisoning</td>
</tr>
<tr>
<td>328</td>
<td>Fentanyl and heroin toxicity</td>
</tr>
<tr>
<td>329</td>
<td>Harmful effects of sedative hypnotic drugs or other CNS depressants</td>
</tr>
<tr>
<td>330</td>
<td>Harmful effects of sedative-hypnotic drugs</td>
</tr>
<tr>
<td>331</td>
<td>hypnotic poisoning</td>
</tr>
<tr>
<td>332</td>
<td>sleeping draught NOS poisoning</td>
</tr>
<tr>
<td>333</td>
<td>sleeping drug NOS poisoning</td>
</tr>
<tr>
<td>334</td>
<td>sleeping tablet NOS poisoning</td>
</tr>
<tr>
<td>335</td>
<td>Harmful effects of barbiturates</td>
</tr>
<tr>
<td>336</td>
<td>Harmful effects of benzodiazepines</td>
</tr>
<tr>
<td>337</td>
<td>Harmful effects of chlordiazepoxide</td>
</tr>
<tr>
<td>338</td>
<td>chlordiazepoxide poisoning</td>
</tr>
<tr>
<td>339</td>
<td>Harmful effects of clozapine</td>
</tr>
<tr>
<td>340</td>
<td>clozapine poisoning</td>
</tr>
<tr>
<td>341</td>
<td>Harmful effects of cloral derivatives</td>
</tr>
<tr>
<td>342</td>
<td>Harmful effects of paraldehyde</td>
</tr>
<tr>
<td>343</td>
<td>Harmful effects of bromine compounds</td>
</tr>
<tr>
<td>344</td>
<td>Harmful effects of mixed sedatives or hypnotics, not elsewhere classified</td>
</tr>
<tr>
<td>345</td>
<td>Harmful effects of anaesthetics or therapeutic gases</td>
</tr>
<tr>
<td>346</td>
<td>Harmful effects of anaesthetics or therapeutic gases, nitrous oxide</td>
</tr>
<tr>
<td>347</td>
<td>Harmful effects of anaesthetics or therapeutic gases, other inhaled anaesthetics</td>
</tr>
<tr>
<td>348</td>
<td>Harmful effects of anaesthetics or therapeutic gases, intravenous anaesthetics</td>
</tr>
<tr>
<td>349</td>
<td>Harmful effects of anaesthetics or therapeutic gases, unspecified general anaesthetics</td>
</tr>
<tr>
<td>350</td>
<td>Harmful effects of anaesthetics or therapeutic gases, gamma hydroxybutyrate</td>
</tr>
<tr>
<td>351</td>
<td>Harmful effects of anaesthetics or therapeutic gases, ketamine</td>
</tr>
<tr>
<td>352</td>
<td>ketamine poisoning</td>
</tr>
<tr>
<td>353</td>
<td>Harmful effects of anaesthetics or therapeutic gases, other specified general anaesthetic</td>
</tr>
<tr>
<td>354</td>
<td>Harmful effects of anaesthetics or therapeutic gases, local anaesthetics</td>
</tr>
<tr>
<td>355</td>
<td>Harmful effects of cinchocaine</td>
</tr>
<tr>
<td>356</td>
<td>cinchocaine poisoning</td>
</tr>
<tr>
<td>357</td>
<td>Harmful effects of oxybuprocaine</td>
</tr>
<tr>
<td>358</td>
<td>oxybuprocaine poisoning</td>
</tr>
<tr>
<td>359</td>
<td>Harmful effects of psychostimulants</td>
</tr>
<tr>
<td>360</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Central nervous system stimulants, not elsewhere classified</td>
</tr>
<tr>
<td>361</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Analeptics</td>
</tr>
<tr>
<td>362</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Opioid receptor antagonists</td>
</tr>
<tr>
<td>363</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Caffeine</td>
</tr>
<tr>
<td>364</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Amphetamine</td>
</tr>
<tr>
<td>365</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Methylamphetamine</td>
</tr>
<tr>
<td>366</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Methylenedioxy methamphetamine</td>
</tr>
<tr>
<td>367</td>
<td>methamphetamine toxicity</td>
</tr>
<tr>
<td>368</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Other specified amphetamines</td>
</tr>
<tr>
<td>369</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Cocaine</td>
</tr>
<tr>
<td>370</td>
<td>poisoning by cocaine NOS</td>
</tr>
<tr>
<td>371</td>
<td>cocaine toxicity</td>
</tr>
<tr>
<td>372</td>
<td>acute cocaine toxicity</td>
</tr>
<tr>
<td>373</td>
<td>toxic effects of cocaine</td>
</tr>
<tr>
<td>374</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Methylphenidate</td>
</tr>
<tr>
<td>375</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Cathinone</td>
</tr>
<tr>
<td>376</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Cathinone derivatives</td>
</tr>
<tr>
<td>377</td>
<td>Harmful effects of Cannabinoids or hallucinogens</td>
</tr>
<tr>
<td>378</td>
<td>Harmful effects of Cannabis</td>
</tr>
<tr>
<td>379</td>
<td>cannabis poisoning</td>
</tr>
<tr>
<td>380</td>
<td>poisoning by cannabis derivative</td>
</tr>
<tr>
<td>381</td>
<td>poisoning by marijuana</td>
</tr>
<tr>
<td>382</td>
<td>poisoning by marijuana derivative</td>
</tr>
<tr>
<td>383</td>
<td>Harmful effects of synthetic cannabinoids</td>
</tr>
<tr>
<td>384</td>
<td>Harmful effects of Lysergide</td>
</tr>
<tr>
<td>385</td>
<td>Harmful effects of unspecified psychodysleptics</td>
</tr>
<tr>
<td>386</td>
<td>harmful effect of unspecified hallucinogens</td>
</tr>
<tr>
<td>387</td>
<td>Harmful effects of other psychodysleptics</td>
</tr>
<tr>
<td>388</td>
<td>Other hallucinogens</td>
</tr>
<tr>
<td>389</td>
<td>Harmful effects of analgesics, antipyretics or anti-inflammatory drugs</td>
</tr>
<tr>
<td>390</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, analgesics, antipyretics or anti-inflammatory drugs, Aspirin</td>
</tr>
<tr>
<td>391</td>
<td>aspirin poisoning</td>
</tr>
<tr>
<td>392</td>
<td>Harmful effects of other salicylates</td>
</tr>
<tr>
<td>393</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, analgesics, antipyretics or anti-inflammatory drugs, Paracetamol</td>
</tr>
<tr>
<td>394</td>
<td>paracetamol poisoning</td>
</tr>
<tr>
<td>395</td>
<td>Harmful effects of 4-Aminophenol derivatives</td>
</tr>
<tr>
<td>396</td>
<td>Harmful effects of Pyrazolone derivatives</td>
</tr>
<tr>
<td>397</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, analgesics, antipyretics or anti-inflammatory drugs, Ibuprofen</td>
</tr>
<tr>
<td>398</td>
<td>ibuprofen poisoning</td>
</tr>
<tr>
<td>399</td>
<td>Harmful effects of other propionic acid derivatives</td>
</tr>
<tr>
<td>400</td>
<td>Harmful effects of Indomethacin</td>
</tr>
<tr>
<td>401</td>
<td>indometacin poisoning</td>
</tr>
<tr>
<td>402</td>
<td>indomethacin poisoning</td>
</tr>
<tr>
<td>403</td>
<td>Harmful effects of other nonsteroidal anti-inflammatory drugs</td>
</tr>
<tr>
<td>404</td>
<td>poisoning by NSAID - [nonsteroidal anti-inflammatory drugs]</td>
</tr>
<tr>
<td>405</td>
<td>Harmful effects of etodolac</td>
</tr>
<tr>
<td>406</td>
<td>etodolac poisoning</td>
</tr>
<tr>
<td>407</td>
<td>Harmful effects of antirheumatics, not elsewhere classified</td>
</tr>
<tr>
<td>408</td>
<td>Harmful effects of antidepressants</td>
</tr>
<tr>
<td>409</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Tricyclic antidepressants</td>
</tr>
<tr>
<td>410</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Tetracyclic antidepressants</td>
</tr>
<tr>
<td>411</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Monoamine-oxidase-inhibitor antidepressants</td>
</tr>
<tr>
<td>412</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Selective serotonin or norepinephrine reuptake inhibitors</td>
</tr>
<tr>
<td>413</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Selective serotonin reuptake inhibitors</td>
</tr>
<tr>
<td>414</td>
<td>Harmful effects of antipsychotics</td>
</tr>
<tr>
<td>415</td>
<td>Harmful effects of phenothiazine antipsychotics or neuroleptics</td>
</tr>
<tr>
<td>416</td>
<td>Harmful effects of promazine</td>
</tr>
<tr>
<td>417</td>
<td>promazine poisoning</td>
</tr>
<tr>
<td>418</td>
<td>Harmful effects of butyrophenone or thiothixene neuroleptics</td>
</tr>
<tr>
<td>419</td>
<td>Harmful effects of typical, second-generation antipsychotics</td>
</tr>
<tr>
<td>420</td>
<td>Harmful effects of lithium carbonate</td>
</tr>
<tr>
<td>421</td>
<td>Harmful effects of antiepileptics or antiparkinsonism drugs</td>
</tr>
<tr>
<td>422</td>
<td>Harmful effects of hydantoin derivatives</td>
</tr>
<tr>
<td>423</td>
<td>Harmful effects of iminostilbenes</td>
</tr>
<tr>
<td>424</td>
<td>Harmful effects of deoxybarbiturates</td>
</tr>
<tr>
<td>425</td>
<td>Harmful effects of succinimides</td>
</tr>
<tr>
<td>426</td>
<td>Harmful effects of oxazolidinediones</td>
</tr>
<tr>
<td>427</td>
<td>Harmful effects of mixed antiepileptics, not elsewhere classified</td>
</tr>
<tr>
<td>428</td>
<td>Harmful effects of Amantadine</td>
</tr>
<tr>
<td>429</td>
<td>Harmful effects of Valproic acid</td>
</tr>
<tr>
<td>430</td>
<td>Harmful effects of L-DOPA</td>
</tr>
<tr>
<td>431</td>
<td>Harmful effects of Antiparkinsonism drugs or other central muscle-tone depressants, not elsewhere classified</td>
</tr>
<tr>
<td>432</td>
<td>Harmful effects of antispasticity drugs</td>
</tr>
<tr>
<td>433</td>
<td>Harmful effects of substances, drugs, medicaments or biological substance, Other or unspecified drugs, medicaments or biological substances</td>
</tr>
<tr>
<td>434</td>
<td>Harmful effects of systemic antibiotics</td>
</tr>
<tr>
<td>435</td>
<td>Harmful effects of Penicillins</td>
</tr>
<tr>
<td>436</td>
<td>poisoning by penicillin</td>
</tr>
<tr>
<td>437</td>
<td>poisoning by penicillins nos</td>
</tr>
<tr>
<td>438</td>
<td>Harmful effects of cephalosporins and other beta-lactam antibiotics</td>
</tr>
<tr>
<td>439</td>
<td>Harmful effects of cefotaxime</td>
</tr>
<tr>
<td>440</td>
<td>cefotaxime poisoning</td>
</tr>
<tr>
<td>441</td>
<td>Harmful effects of chloramphenicol group</td>
</tr>
<tr>
<td>442</td>
<td>chloramphenicol poisoning</td>
</tr>
<tr>
<td>443</td>
<td>Harmful effects of macrolides</td>
</tr>
<tr>
<td>444</td>
<td>Harmful effects of tetracyclines</td>
</tr>
<tr>
<td>445</td>
<td>poisoning by tetracyclines</td>
</tr>
<tr>
<td>446</td>
<td>poisoning by tetracyclines nos</td>
</tr>
<tr>
<td>447</td>
<td>Harmful effects of aminoglycosides</td>
</tr>
<tr>
<td>448</td>
<td>Harmful effects of rifampicin</td>
</tr>
<tr>
<td>449</td>
<td>rifampicin poisoning</td>
</tr>
<tr>
<td>450</td>
<td>Harmful effects of antifungal antibiotics, systemically used</td>
</tr>
<tr>
<td>451</td>
<td>Harmful effects of co-trimoxazole</td>
</tr>
<tr>
<td>452</td>
<td>co-trimoxazole poisoning</td>
</tr>
<tr>
<td>453</td>
<td>Harmful effects of fusidic acid</td>
</tr>
<tr>
<td>454</td>
<td>fusidic acid poisoning</td>
</tr>
<tr>
<td>455</td>
<td>Harmful effects of sodium fusidate</td>
</tr>
<tr>
<td>456</td>
<td>sodium fusidate poisoning</td>
</tr>
<tr>
<td>457</td>
<td>Harmful effects of vancomycin</td>
</tr>
<tr>
<td>458</td>
<td>vancomycin poisoning</td>
</tr>
<tr>
<td>459</td>
<td>Harmful effects of other systemic anti-infectives or antiparasitics</td>
</tr>
<tr>
<td>460</td>
<td>Harmful effects of Sulfonamides</td>
</tr>
<tr>
<td>461</td>
<td>Harmful effects of antimycobacterial drugs</td>
</tr>
<tr>
<td>462</td>
<td>Harmful effects of antimalarials or drugs acting on other blood protozoa</td>
</tr>
<tr>
<td>463</td>
<td>Harmful effects of other antiprotozoal drugs</td>
</tr>
<tr>
<td>464</td>
<td>Harmful effects of anthelminthics</td>
</tr>
<tr>
<td>465</td>
<td>Harmful effects of antiviral drugs</td>
</tr>
<tr>
<td>466</td>
<td>Harmful effects of chiniofon</td>
</tr>
<tr>
<td>467</td>
<td>chiniofon poisoning</td>
</tr>
<tr>
<td>468</td>
<td>Harmful effects of diiodohydroxyquinoline</td>
</tr>
<tr>
<td>469</td>
<td>diiodohydroxyquinoline poisoning</td>
</tr>
<tr>
<td>470</td>
<td>Harmful effects of flucytosine</td>
</tr>
<tr>
<td>471</td>
<td>flucytosine poisoning</td>
</tr>
<tr>
<td>472</td>
<td>Harmful effects of hydroxyquinoline derivatives</td>
</tr>
<tr>
<td>473</td>
<td>hydroxyquinoline derivatives poisoning</td>
</tr>
<tr>
<td>474</td>
<td>Harmful effects of trimethoprim</td>
</tr>
<tr>
<td>475</td>
<td>trimethoprim poisoning</td>
</tr>
<tr>
<td>476</td>
<td>Harmful effects of hormones or their synthetic substitutes or antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>477</td>
<td>Harmful effects of Glucocorticoids or synthetic analogues</td>
</tr>
<tr>
<td>478</td>
<td>Harmful effects of thyroid hormones or substitutes</td>
</tr>
<tr>
<td>479</td>
<td>Harmful effects of antithyroid drugs</td>
</tr>
<tr>
<td>480</td>
<td>Harmful effects of insulin or oral hypoglycaemic drugs</td>
</tr>
<tr>
<td>481</td>
<td>Harmful effects of oral contraceptives</td>
</tr>
<tr>
<td>482</td>
<td>poisoning by oral contraceptive</td>
</tr>
<tr>
<td>483</td>
<td>poisoning by oral contraceptives nos</td>
</tr>
<tr>
<td>484</td>
<td>Harmful effects of other estrogens or progestogens</td>
</tr>
<tr>
<td>485</td>
<td>oestrogen poisoning</td>
</tr>
<tr>
<td>486</td>
<td>Harmful effects of antigonadotropins, antiestrogens, antiandrogens, not elsewhere classified</td>
</tr>
<tr>
<td>487</td>
<td>Harmful effects of androgens or anabolic congeners</td>
</tr>
<tr>
<td>488</td>
<td>androgen poisoning</td>
</tr>
<tr>
<td>489</td>
<td>Harmful effects of unspecified hormones or synthetic substitutes</td>
</tr>
<tr>
<td>490</td>
<td>Harmful effects of anterior pituitary hormones</td>
</tr>
<tr>
<td>491</td>
<td>Harmful effects of other hormones or synthetic substitutes</td>
</tr>
<tr>
<td>492</td>
<td>Harmful effects of unspecified hormone antagonists</td>
</tr>
<tr>
<td>493</td>
<td>Harmful effects of other hormone antagonists</td>
</tr>
<tr>
<td>494</td>
<td>Harmful effects of trilostane</td>
</tr>
<tr>
<td>495</td>
<td>Harmful effects of drugs primarily affecting the autonomic nervous system</td>
</tr>
<tr>
<td>496</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Anticholinesterase agents</td>
</tr>
<tr>
<td>497</td>
<td>anticholinesterase poisoning</td>
</tr>
<tr>
<td>498</td>
<td>poisoning by anticholinesterase agents nos</td>
</tr>
<tr>
<td>499</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Other parasympathomimetics</td>
</tr>
<tr>
<td>500</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Ganglionic blocking drugs</td>
</tr>
<tr>
<td>501</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Other parasympatholytics or spasmolytics</td>
</tr>
<tr>
<td>502</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Predominantly alpha-adrenoreceptor agonists</td>
</tr>
<tr>
<td>503</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Predominantly beta-adrenoreceptor agonists</td>
</tr>
<tr>
<td>504</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Alpha-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>505</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Beta-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>506</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Centrally-acting or adrenergic-neuron-blocking agents</td>
</tr>
<tr>
<td>507</td>
<td>Harmful effects of agents primarily affecting blood constituents</td>
</tr>
<tr>
<td>508</td>
<td>haematological agent poisoning</td>
</tr>
<tr>
<td>509</td>
<td>Harmful effects of Diphenhydramine</td>
</tr>
<tr>
<td>510</td>
<td>diphenhydramine toxicity</td>
</tr>
<tr>
<td>511</td>
<td>Harmful effects of other H1-receptor antagonists</td>
</tr>
<tr>
<td>512</td>
<td>Harmful effects of antiallergic or antiemetic drugs</td>
</tr>
<tr>
<td>513</td>
<td>Harmful effects of antineoplastic antimetabolites</td>
</tr>
<tr>
<td>514</td>
<td>Harmful effects of antineoplastic natural products</td>
</tr>
<tr>
<td>515</td>
<td>Harmful effects of other antineoplastic drugs</td>
</tr>
<tr>
<td>516</td>
<td>Harmful effects of immunosuppressive agents</td>
</tr>
<tr>
<td>517</td>
<td>Harmful effects of Vitamin B12, folic acid or other anti-megaloblastic-anaemia preparations</td>
</tr>
<tr>
<td>518</td>
<td>Harmful effects of enzymes</td>
</tr>
<tr>
<td>519</td>
<td>Harmful effects of iron or its compounds</td>
</tr>
<tr>
<td>520</td>
<td>Harmful effects of anticoagulants</td>
</tr>
<tr>
<td>521</td>
<td>Harmful effects of antithrombotic drugs</td>
</tr>
<tr>
<td>522</td>
<td>harmful effect of platelet aggregation inhibitors</td>
</tr>
<tr>
<td>523</td>
<td>Harmful effects of thrombolytic drug</td>
</tr>
<tr>
<td>524</td>
<td>Harmful effects of anticoagulant antagonists, vitamin K or other coagulants</td>
</tr>
<tr>
<td>525</td>
<td>Harmful effects of other fibrinolysis-affecting drugs</td>
</tr>
<tr>
<td>526</td>
<td>fibrinolytic drug poisoning</td>
</tr>
<tr>
<td>527</td>
<td>poisoning by fibrinolysis-affecting drug nos</td>
</tr>
<tr>
<td>528</td>
<td>Harmful effects of natural blood or blood products</td>
</tr>
<tr>
<td>529</td>
<td>Harmful effects of acidifying or alkalising agents</td>
</tr>
<tr>
<td>530</td>
<td>Harmful effects of other primarily systemic agents, not elsewhere classified</td>
</tr>
<tr>
<td>531</td>
<td>Blood poisoning, not elsewhere classified</td>
</tr>
<tr>
<td>532</td>
<td>whole blood poisoning</td>
</tr>
<tr>
<td>533</td>
<td>Harmful effects of heavy metal poisoning antidote</td>
</tr>
<tr>
<td>534</td>
<td>Harmful effects of plasma substitutes</td>
</tr>
<tr>
<td>535</td>
<td>Harmful effects of agents primarily affecting the cardiovascular system</td>
</tr>
<tr>
<td>536</td>
<td>Harmful effects of cardiac-stimulant glycosides or drugs of similar action</td>
</tr>
<tr>
<td>537</td>
<td>Harmful effects of calcium-channel blockers</td>
</tr>
<tr>
<td>538</td>
<td>poisoning by calcium-channel blockers NOS</td>
</tr>
<tr>
<td>539</td>
<td>Harmful effects of other antidysrhythmic drugs</td>
</tr>
<tr>
<td>540</td>
<td>Harmful effects of Nitroglycerin, nitroglycerol, medicinal</td>
</tr>
<tr>
<td>541</td>
<td>Harmful effects of other coronary vasodilators</td>
</tr>
<tr>
<td>542</td>
<td>Harmful effects of Angiotensin-converting-enzyme inhibitors</td>
</tr>
<tr>
<td>543</td>
<td>Harmful effects of other antihypertensive drugs</td>
</tr>
<tr>
<td>544</td>
<td>Harmful effects of antihyperlipidemic or antiarteriosclerotic drugs</td>
</tr>
<tr>
<td>545</td>
<td>Harmful effects of peripheral vasodilators</td>
</tr>
<tr>
<td>546</td>
<td>Harmful effects of antivaricose drugs, including sclerosing agents</td>
</tr>
<tr>
<td>547</td>
<td>antivaricose drug poisoning</td>
</tr>
<tr>
<td>548</td>
<td>Harmful effects of agents primarily affecting the gastrointestinal system</td>
</tr>
<tr>
<td>549</td>
<td>Harmful effects of Histamine H2-receptor blockers</td>
</tr>
<tr>
<td>550</td>
<td>poisoning by histamine h 2 -receptor antagonists</td>
</tr>
<tr>
<td>551</td>
<td>Harmful effects of other antacids or anti-gastric-secretion drugs</td>
</tr>
<tr>
<td>552</td>
<td>Harmful effects of stimulant laxatives</td>
</tr>
<tr>
<td>553</td>
<td>Harmful effects of saline or osmotic laxatives</td>
</tr>
<tr>
<td>554</td>
<td>Harmful effects of other laxatives</td>
</tr>
<tr>
<td>555</td>
<td>Harmful effects of digestants</td>
</tr>
<tr>
<td>556</td>
<td>Harmful effects of antidiarrhoeal drugs</td>
</tr>
<tr>
<td>557</td>
<td>Harmful effects of or exposure to emetics</td>
</tr>
<tr>
<td>558</td>
<td>Harmful effects of agents primarily acting on smooth or skeletal muscles or the respiratory system</td>
</tr>
<tr>
<td>559</td>
<td>Harmful effects of Oxytocic drugs</td>
</tr>
<tr>
<td>560</td>
<td>oxytocin poisoning</td>
</tr>
<tr>
<td>561</td>
<td>Harmful effects of skeletal muscle relaxants</td>
</tr>
<tr>
<td>562</td>
<td>harmful effect of neuromuscular blocking agents</td>
</tr>
<tr>
<td>563</td>
<td>Harmful effects of other drugs acting on muscles</td>
</tr>
<tr>
<td>564</td>
<td>Harmful effects of unspecified drugs acting on muscles</td>
</tr>
<tr>
<td>565</td>
<td>Harmful effects of antitussives</td>
</tr>
<tr>
<td>566</td>
<td>Harmful effects of expectorants</td>
</tr>
<tr>
<td>567</td>
<td>Harmful effects of other anti-common-cold drugs</td>
</tr>
<tr>
<td>568</td>
<td>Harmful effects of Salbutamol</td>
</tr>
<tr>
<td>569</td>
<td>salbutamol poisoning</td>
</tr>
<tr>
<td>570</td>
<td>Harmful effects of Aminophylline, theophylline</td>
</tr>
<tr>
<td>571</td>
<td>theophylline poisoning</td>
</tr>
<tr>
<td>572</td>
<td>aminophylline poisoning</td>
</tr>
<tr>
<td>573</td>
<td>Harmful effects of Terbutaline</td>
</tr>
<tr>
<td>574</td>
<td>Harmful effects of antiasthmatics, not elsewhere classified</td>
</tr>
<tr>
<td>575</td>
<td>Harmful effects of topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs</td>
</tr>
<tr>
<td>576</td>
<td>Harmful effects of topical corticosteroid preparations</td>
</tr>
<tr>
<td>577</td>
<td>Harmful effects of Iodine, antiseptic</td>
</tr>
<tr>
<td>578</td>
<td>Harmful effects of silver nitrate</td>
</tr>
<tr>
<td>579</td>
<td>Harmful effects of other local antifungal, anti-infective or anti-inflammatory drugs</td>
</tr>
<tr>
<td>580</td>
<td>Harmful effects of antipruritics</td>
</tr>
<tr>
<td>581</td>
<td>Harmful effects of Methyl salicylate</td>
</tr>
<tr>
<td>582</td>
<td>Harmful effects of other local astringents or local detergents</td>
</tr>
<tr>
<td>583</td>
<td>Tannic acid poisoning</td>
</tr>
<tr>
<td>584</td>
<td>Harmful effects of emollients, demulcents or protectants</td>
</tr>
<tr>
<td>585</td>
<td>Harmful effects of Podophyllin</td>
</tr>
<tr>
<td>586</td>
<td>Harmful effects of keratolytics, keratoplastics, or other hair treatment drugs or preparations</td>
</tr>
<tr>
<td>587</td>
<td>Harmful effects of ophthalmological drugs or preparations</td>
</tr>
<tr>
<td>588</td>
<td>Harmful effects of otorhinolaryngological drugs or preparations</td>
</tr>
<tr>
<td>589</td>
<td>Harmful effects of ear, nose or throat anti-infectives</td>
</tr>
<tr>
<td>590</td>
<td>Harmful effects of fluoride preparations</td>
</tr>
<tr>
<td>591</td>
<td>Harmful effects of other dental drugs, topically applied</td>
</tr>
<tr>
<td>592</td>
<td>Harmful effects of Camphor</td>
</tr>
<tr>
<td>593</td>
<td>Harmful effects of agents primarily affecting water-balance or mineral or uric acid metabolism</td>
</tr>
<tr>
<td>594</td>
<td>Harmful effects of Mineralocorticoids</td>
</tr>
<tr>
<td>595</td>
<td>Harmful effects of Mineralocorticoids antagonists</td>
</tr>
<tr>
<td>596</td>
<td>Harmful effects of Loop diuretics</td>
</tr>
<tr>
<td>597</td>
<td>Harmful effect of high-ceiling diuretics</td>
</tr>
<tr>
<td>598</td>
<td>Frusemide poisoning</td>
</tr>
<tr>
<td>599</td>
<td>furosemide poisoning</td>
</tr>
<tr>
<td>600</td>
<td>Etacrynic acid poisoning</td>
</tr>
<tr>
<td>601</td>
<td>ethacrynic acid poisoning</td>
</tr>
<tr>
<td>602</td>
<td>Harmful effects of Carbonic-anhydrase inhibitors</td>
</tr>
<tr>
<td>603</td>
<td>Acetazolamide poisoning</td>
</tr>
<tr>
<td>604</td>
<td>Bendroflumethiazide poisoning</td>
</tr>
<tr>
<td>605</td>
<td>Chlormerodrin poisoning</td>
</tr>
<tr>
<td>606</td>
<td>Chlorothiazide poisoning</td>
</tr>
<tr>
<td>607</td>
<td>Mercaptomerin poisoning</td>
</tr>
<tr>
<td>608</td>
<td>Mersalyl poisoning</td>
</tr>
<tr>
<td>609</td>
<td>Harmful effects of Benzothiadiazine derivatives</td>
</tr>
<tr>
<td>610</td>
<td>harmful effect of thiazides</td>
</tr>
<tr>
<td>611</td>
<td>Harmful effects of other diuretics</td>
</tr>
<tr>
<td>612</td>
<td>Harmful effects of electrolytic, caloric or water-balance agents</td>
</tr>
<tr>
<td>613</td>
<td>Harmful effect of oral rehydration salts</td>
</tr>
<tr>
<td>614</td>
<td>Sodium chloride poisoning</td>
</tr>
<tr>
<td>615</td>
<td>Harmful effects of mineral salts, not elsewhere classified</td>
</tr>
<tr>
<td>616</td>
<td>Harmful effects of drugs affecting uric acid metabolism</td>
</tr>
<tr>
<td>617</td>
<td>Allopurinol poisoning</td>
</tr>
<tr>
<td>618</td>
<td>Colchicine poisoning</td>
</tr>
<tr>
<td>619</td>
<td>Probenecid poisoning</td>
</tr>
<tr>
<td>620</td>
<td>Harmful effects of agents primarily affecting water-balance and mineral or uric acid metabolism, Vitamin D and derivatives</td>
</tr>
<tr>
<td>621</td>
<td>Harmful effects of Bisphosphonates</td>
</tr>
<tr>
<td>622</td>
<td>Harmful effects of appetite depressants</td>
</tr>
<tr>
<td>623</td>
<td>Harmful effects of antidotes or chelating agents, not elsewhere classified</td>
</tr>
<tr>
<td>624</td>
<td>Harmful effects of Disulfiram</td>
</tr>
<tr>
<td>625</td>
<td>disulfiram poisoning</td>
</tr>
<tr>
<td>626</td>
<td>Harmful effects of alcohol deterrents, not elsewhere classified</td>
</tr>
<tr>
<td>627</td>
<td>harmful effect of alcohol deterrents</td>
</tr>
<tr>
<td>628</td>
<td>Toxic effect of alcohol deterrents</td>
</tr>
<tr>
<td>629</td>
<td>Harmful effects of X-ray contrast media</td>
</tr>
<tr>
<td>630</td>
<td>Harmful effects of MRI contrast agents</td>
</tr>
<tr>
<td>631</td>
<td>Harmful effects of agents used for other scanning techniques</td>
</tr>
<tr>
<td>632</td>
<td>Harmful effects of other diagnostic agents</td>
</tr>
<tr>
<td>633</td>
<td>Harmful effects of Lipotropic drugs</td>
</tr>
<tr>
<td>634</td>
<td>Harmful effects of vitamins, not elsewhere classified, Pharmaceutical excipients</td>
</tr>
<tr>
<td>635</td>
<td>Harmful effects of herbal preparations or formulas</td>
</tr>
<tr>
<td>636</td>
<td>Harmful effects of dietary supplements, vitamins or minerals</td>
</tr>
<tr>
<td>637</td>
<td>Harmful effects of complementary or Traditional Medicines, not elsewhere classified</td>
</tr>
<tr>
<td>638</td>
<td>Harmful effects of complementary or Traditional Medicines, unspecified</td>
</tr>
<tr>
<td>639</td>
<td>Harmful effects of vaccines, immunoglobulins or other biological substances</td>
</tr>
<tr>
<td>640</td>
<td>Harmful effects of BCG vaccine</td>
</tr>
<tr>
<td>641</td>
<td>Harmful effects of Typhoid or paratyphoid vaccine</td>
</tr>
<tr>
<td>642</td>
<td>Harmful effects of Cholera vaccine</td>
</tr>
<tr>
<td>643</td>
<td>Harmful effects of Plague vaccine</td>
</tr>
<tr>
<td>644</td>
<td>Harmful effects of Tetanus vaccine</td>
</tr>
<tr>
<td>645</td>
<td>Harmful effects of Diphtheria vaccine</td>
</tr>
<tr>
<td>646</td>
<td>Harmful effects of Haemophilus influenzae type B vaccines</td>
</tr>
<tr>
<td>647</td>
<td>Harmful effects of Pertussis vaccine, including combinations with a pertussis component</td>
</tr>
<tr>
<td>648</td>
<td>Harmful effects of mixed bacterial vaccines without a pertussis component</td>
</tr>
<tr>
<td>649</td>
<td>Harmful effects of other or unspecified bacterial vaccines</td>
</tr>
<tr>
<td>650</td>
<td>Harmful effects of Smallpox vaccines</td>
</tr>
<tr>
<td>651</td>
<td>Harmful effects of Measles vaccines</td>
</tr>
<tr>
<td>652</td>
<td>Harmful effects of Mumps vaccines</td>
</tr>
<tr>
<td>653</td>
<td>Harmful effects of Rubella vaccines</td>
</tr>
<tr>
<td>654</td>
<td>Harmful effects of Polio vaccines</td>
</tr>
<tr>
<td>655</td>
<td>Harmful effects of Yellow fever vaccines</td>
</tr>
<tr>
<td>656</td>
<td>Harmful effects of Hepatitis A vaccines</td>
</tr>
<tr>
<td>657</td>
<td>Harmful effects of Hepatitis B vaccines</td>
</tr>
<tr>
<td>658</td>
<td>Harmful effects of Influenza vaccines</td>
</tr>
<tr>
<td>659</td>
<td>Harmful effects of Rotavirus vaccines</td>
</tr>
<tr>
<td>660</td>
<td>Harmful effects of Human papillomavirus vaccines</td>
</tr>
<tr>
<td>661</td>
<td>Harmful effects of other viral vaccines</td>
</tr>
<tr>
<td>662</td>
<td>Harmful effects of Rickettsial vaccines</td>
</tr>
<tr>
<td>663</td>
<td>Harmful effects of Protozoal vaccines</td>
</tr>
<tr>
<td>664</td>
<td>Harmful effects of Hepatitis B immune globulin</td>
</tr>
<tr>
<td>665</td>
<td>Harmful effects of antivenin, antivenom</td>
</tr>
<tr>
<td>666</td>
<td>Harmful effects of immunoglobulin, not elsewhere classified</td>
</tr>
<tr>
<td>667</td>
<td>Harmful effects of other specified vaccines</td>
</tr>
<tr>
<td>668</td>
<td>Harmful effects of unspecified vaccines</td>
</tr>
<tr>
<td>669</td>
<td>Multiple drug toxicity</td>
</tr>
<tr>
<td>670</td>
<td>Catatonia due to medication or substance</td>
</tr>
<tr>
<td>671</td>
<td>Overdose of drug, not otherwise specified</td>
</tr>
<tr>
<td>672</td>
<td>overdose NOS</td>
</tr>
<tr>
<td>673</td>
<td>Harmful effects of ketorolac</td>
</tr>
<tr>
<td>674</td>
<td>ketorolac poisoning</td>
</tr>
<tr>
<td>675</td>
<td>Harmful effects of meptazinol</td>
</tr>
<tr>
<td>676</td>
<td>meptazinol poisoning</td>
</tr>
<tr>
<td>677</td>
<td>Harmful effects of nefopam</td>
</tr>
<tr>
<td>678</td>
<td>nefopam poisoning</td>
</tr>
<tr>
<td>679</td>
<td>Harmful effects of oxygen</td>
</tr>
<tr>
<td>680</td>
<td>oxygen poisoning</td>
</tr>
<tr>
<td>681</td>
<td>Harmful effects of ethosuximide</td>
</tr>
<tr>
<td>682</td>
<td>ethosuximide poisoning</td>
</tr>
<tr>
<td>683</td>
<td>Harmful effects of paramethadione</td>
</tr>
<tr>
<td>684</td>
<td>paramethadione poisoning</td>
</tr>
<tr>
<td>685</td>
<td>Harmful effects of trimethadione</td>
</tr>
<tr>
<td>686</td>
<td>trimethadione poisoning</td>
</tr>
<tr>
<td>687</td>
<td>Harmful effects of phensuximide</td>
</tr>
<tr>
<td>688</td>
<td>phensuximide poisoning</td>
</tr>
<tr>
<td>689</td>
<td>Adverse effect medical agent</td>
</tr>
<tr>
<td>690</td>
<td>side effect</td>
</tr>
<tr>
<td>691</td>
<td>side effect of medical agent</td>
</tr>
<tr>
<td>692</td>
<td>Cocaine and fentanyl toxicity</td>
</tr>
<tr>
<td>693</td>
<td>Methamphetamine and fentanyl toxicity</td>
</tr>
<tr>
<td>694</td>
<td>Other specified defects in the complement system</td>
</tr>
<tr>
<td>695</td>
<td>Complement component C3 deficiency</td>
</tr>
<tr>
<td>696</td>
<td>Recurrent Neisseria infections due to factor D deficiency</td>
</tr>
<tr>
<td>697</td>
<td>Complement component C4b-binding protein deficiency</td>
</tr>
<tr>
<td>698</td>
<td>Immunodeficiency with CD46 deficiency</td>
</tr>
<tr>
<td>699</td>
<td>Membrane cofactor protein deficiency</td>
</tr>
<tr>
<td>700</td>
<td>Immunodeficiency with decay accelerating factor deficiency</td>
</tr>
<tr>
<td>701</td>
<td>Immunodeficiency with CD55 deficiency</td>
</tr>
<tr>
<td>702</td>
<td>Immunodeficiency with DAF - [decay accelerating factor] deficiency</td>
</tr>
<tr>
<td>703</td>
<td>CHAPLE syndrome</td>
</tr>
<tr>
<td>704</td>
<td>Immunodeficiency with factor H anomaly</td>
</tr>
<tr>
<td>705</td>
<td>Immunodeficiency with factor I anomaly</td>
</tr>
<tr>
<td>706</td>
<td>Immunodeficiency with properdin deficiency</td>
</tr>
<tr>
<td>707</td>
<td>Immunodeficiency with CD59 deficiency</td>
</tr>
<tr>
<td>708</td>
<td>Immunodeficiency with MASP-2 deficiency</td>
</tr>
<tr>
<td>709</td>
<td>Mannan-binding lectin serine protease 2 deficiency</td>
</tr>
<tr>
<td>710</td>
<td>Immunodeficiency with MBL - [mannan-binding lectin] deficiency</td>
</tr>
<tr>
<td>711</td>
<td>Mannan-binding lectin deficiency</td>
</tr>
<tr>
<td>712</td>
<td>Mannose-binding protein deficiency</td>
</tr>
<tr>
<td>713</td>
<td>MBP - [mannan-binding lectin] deficiency</td>
</tr>
<tr>
<td>714</td>
<td>Immunodeficiency with ficolin-3 deficiency</td>
</tr>
<tr>
<td>715</td>
<td>Angioedema due to disordered complement activation or kinin metabolism</td>
</tr>
<tr>
<td>716</td>
<td>Leukodystrophies, unspecified</td>
</tr>
<tr>
<td>717</td>
<td>Leukodystrophies</td>
</tr>
<tr>
<td>718</td>
<td>Cerebral leukodystrophy</td>
</tr>
<tr>
<td>719</td>
<td>4H leukodystrophy</td>
</tr>
<tr>
<td>720</td>
<td>Hypomyelinating leukodystrophy-ataxia-hypodontia-hypomyelination syndrome</td>
</tr>
<tr>
<td>721</td>
<td>Meningitis due to Haemophilus influenzae</td>
</tr>
<tr>
<td>722</td>
<td>influenza meningitis</td>
</tr>
<tr>
<td>723</td>
<td>influenzal meningitis</td>
</tr>
<tr>
<td>724</td>
<td>meningitis due to h. influenzae</td>
</tr>
<tr>
<td>725</td>
<td>Haemophilus influenzae spinal meningitis</td>
</tr>
<tr>
<td>726</td>
<td>influenzal spinal meningitis</td>
</tr>
<tr>
<td>727</td>
<td>Pneumonia due to Haemophilus influenzae</td>
</tr>
<tr>
<td>728</td>
<td>pneumonia due to H. influenzae</td>
</tr>
<tr>
<td>729</td>
<td>pneumonia due to hemophilus influenzae</td>
</tr>
<tr>
<td>730</td>
<td>Bronchopneumonia due to H. influenzae</td>
</tr>
<tr>
<td>731</td>
<td>haemophilus influenzae lobar pneumonia</td>
</tr>
<tr>
<td>732</td>
<td>bronchopneumonia due to hemophilus influenzae</td>
</tr>
<tr>
<td>733</td>
<td>Early-onset pneumonia due to Haemophilus influenzae</td>
</tr>
<tr>
<td>734</td>
<td>Charcot-Marie-Tooth disease 2 axonal</td>
</tr>
<tr>
<td>735</td>
<td>Charcot-Marie-Tooth disease 2 autosomal dominant</td>
</tr>
<tr>
<td>736</td>
<td>Recessive axonal Charcot-Marie-Tooth disease with acrodystrophy</td>
</tr>
<tr>
<td>737</td>
<td>Charcot-Marie-Tooth disease type 2A1</td>
</tr>
<tr>
<td>738</td>
<td>Charcot-Marie-Tooth disease type 2A2</td>
</tr>
<tr>
<td>739</td>
<td>Charcot-Marie-Tooth disease type 2B</td>
</tr>
<tr>
<td>740</td>
<td>Charcot-Marie-Tooth disease type 2C</td>
</tr>
<tr>
<td>741</td>
<td>Charcot-Marie-Tooth disease type 2D</td>
</tr>
<tr>
<td>742</td>
<td>Charcot-Marie-Tooth disease type 2E</td>
</tr>
<tr>
<td>743</td>
<td>Charcot-Marie-Tooth disease type 2F</td>
</tr>
<tr>
<td>744</td>
<td>Charcot-Marie-Tooth disease type 2G</td>
</tr>
<tr>
<td>745</td>
<td>Charcot-Marie-Tooth disease type 2I</td>
</tr>
<tr>
<td>746</td>
<td>Charcot-Marie-Tooth disease type 2J</td>
</tr>
<tr>
<td>747</td>
<td>Charcot-Marie-Tooth disease type 2K</td>
</tr>
<tr>
<td>748</td>
<td>Charcot-Marie-Tooth disease type 2L</td>
</tr>
<tr>
<td>749</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2M</td>
</tr>
<tr>
<td>750</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2N</td>
</tr>
<tr>
<td>751</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2O</td>
</tr>
<tr>
<td>752</td>
<td>Charcot-Marie-Tooth disease 2 autosomal recessive</td>
</tr>
<tr>
<td>753</td>
<td>Charcot-Marie-Tooth disease type 2B1</td>
</tr>
<tr>
<td>754</td>
<td>Charcot-Marie-Tooth disease type 2B2</td>
</tr>
<tr>
<td>755</td>
<td>Charcot-Marie-Tooth disease type 2B5</td>
</tr>
<tr>
<td>756</td>
<td>Charcot-Marie-Tooth disease type 2H</td>
</tr>
<tr>
<td>757</td>
<td>Autosomal recessive Charcot-Marie-Tooth disease with hoarseness</td>
</tr>
<tr>
<td>758</td>
<td>Hereditary motor and sensory neuropathy type 6</td>
</tr>
<tr>
<td>759</td>
<td>Charcot-Marie-Tooth type 6</td>
</tr>
<tr>
<td>760</td>
<td>HMSN6 - [Hereditary motor and sensory neuropathy type 6]</td>
</tr>
<tr>
<td>761</td>
<td>CMT6 - [Charcot-Marie-Tooth type 6]</td>
</tr>
<tr>
<td>762</td>
<td>Other specified sickle cell disorders or other haemoglobinopathies</td>
</tr>
<tr>
<td>763</td>
<td>Other haemoglobinopathies</td>
</tr>
<tr>
<td>764</td>
<td>Abnormal haemoglobin NOS</td>
</tr>
<tr>
<td>765</td>
<td>haemoglobin dysfunction</td>
</tr>
<tr>
<td>766</td>
<td>Acquired haemoglobin H in myelodysplastic disorders</td>
</tr>
<tr>
<td>767</td>
<td>Compound HbC or beta thalassaemia heterozygotes</td>
</tr>
<tr>
<td>768</td>
<td>Haemoglobin C trait</td>
</tr>
<tr>
<td>769</td>
<td>haemoglobin C heterozygosity</td>
</tr>
<tr>
<td>770</td>
<td>heterozygous Hb C carriers</td>
</tr>
<tr>
<td>771</td>
<td>Haemoglobin E trait</td>
</tr>
<tr>
<td>772</td>
<td>haemoglobin E heterozygosity</td>
</tr>
<tr>
<td>773</td>
<td>heterozygous Hb E carriers</td>
</tr>
<tr>
<td>774</td>
<td>Compound HbE beta thalassaemia heterozygotes</td>
</tr>
<tr>
<td>775</td>
<td>Stransky-Regala type haemolytic anaemia</td>
</tr>
<tr>
<td>776</td>
<td>Unstable haemoglobin haemolytic disease</td>
</tr>
<tr>
<td>777</td>
<td>unstable haemoglobin disease</td>
</tr>
<tr>
<td>778</td>
<td>Haemoglobin C A disorder</td>
</tr>
<tr>
<td>779</td>
<td>Charcot-Marie-Tooth disease 1 demyelinating</td>
</tr>
<tr>
<td>780</td>
<td>Charcot-Marie-Tooth disease 1 autosomal dominant</td>
</tr>
<tr>
<td>781</td>
<td>Charcot-Marie-Tooth disease type 1E</td>
</tr>
<tr>
<td>782</td>
<td>Charcot-Marie-Tooth disease type 1B</td>
</tr>
<tr>
<td>783</td>
<td>Charcot-Marie-Tooth disease type 1C</td>
</tr>
<tr>
<td>784</td>
<td>Charcot-Marie-Tooth disease type 1D</td>
</tr>
<tr>
<td>785</td>
<td>Charcot-Marie-Tooth disease type 1F</td>
</tr>
<tr>
<td>786</td>
<td>Charcot-Marie-Tooth disease 1 autosomal recessive</td>
</tr>
<tr>
<td>787</td>
<td>Charcot-Marie-Tooth disease type 4</td>
</tr>
<tr>
<td>788</td>
<td>CMT4 - [Charcot-Marie-Tooth disease type 4]</td>
</tr>
<tr>
<td>789</td>
<td>Charcot-Marie-Tooth disease - deafness - intellectual deficit</td>
</tr>
<tr>
<td>790</td>
<td>Charcot-Marie-Tooth disease type 4A</td>
</tr>
<tr>
<td>791</td>
<td>Charcot-Marie-Tooth disease type 4C</td>
</tr>
<tr>
<td>792</td>
<td>Charcot-Marie-Tooth disease type 4D</td>
</tr>
<tr>
<td>793</td>
<td>Charcot-Marie-Tooth disease type 4E</td>
</tr>
<tr>
<td>794</td>
<td>Charcot-Marie-Tooth disease type 4F</td>
</tr>
<tr>
<td>795</td>
<td>Charcot-Marie-Tooth disease type 4G</td>
</tr>
<tr>
<td>796</td>
<td>Charcot-Marie-Tooth disease type 4H</td>
</tr>
<tr>
<td>797</td>
<td>Charcot-Marie-Tooth disease type 4B1</td>
</tr>
<tr>
<td>798</td>
<td>Charcot-Marie-Tooth disease type 4B2</td>
</tr>
<tr>
<td>799</td>
<td>Charcot-Marie-Tooth disease type 4J</td>
</tr>
<tr>
<td>800</td>
<td>X-linked Charcot-Marie-Tooth disease 1 due to mutations in gap junction protein beta 1</td>
</tr>
<tr>
<td>801</td>
<td>X-linked Charcot-Marie-Tooth disease 1 secondary to mutations in gap junction protein beta 1</td>
</tr>
<tr>
<td>802</td>
<td>Charcot-Marie-Tooth disease 1X, x-linked Charcot-Marie-Tooth disease 1 due to mutations in gap junction protein beta 1</td>
</tr>
<tr>
<td>803</td>
<td>Charcot-Marie-Tooth disease 1X, x-linked Charcot-Marie-Tooth disease 1 secondary to mutations in gap junction protein beta 1</td>
</tr>
<tr>
<td>804</td>
<td>Hereditary sensorimotor neuropathy with hyperelastic skin</td>
</tr>
<tr>
<td>805</td>
<td>Exposure to or harmful effects of undetermined intent of other or unspecified drugs, medicaments or biological substances</td>
</tr>
<tr>
<td>806</td>
<td>drug related harm</td>
</tr>
<tr>
<td>807</td>
<td>Exposure to or harmful effects of undetermined intent of systemic antibiotics</td>
</tr>
<tr>
<td>808</td>
<td>Exposure to or harmful effects of undetermined intent of penicillins</td>
</tr>
<tr>
<td>809</td>
<td>Exposure to or harmful effects of undetermined intent of cephalosporins or other beta-lactam antibiotics</td>
</tr>
<tr>
<td>810</td>
<td>Exposure to or harmful effects of undetermined intent of chloramphenicol group</td>
</tr>
<tr>
<td>811</td>
<td>Exposure to or harmful effects of undetermined intent of macrolides</td>
</tr>
<tr>
<td>812</td>
<td>Exposure to or harmful effects of undetermined intent of tetracyclines</td>
</tr>
<tr>
<td>813</td>
<td>Exposure to or harmful effects of undetermined intent of aminoglycosides</td>
</tr>
<tr>
<td>814</td>
<td>Exposure to or harmful effects of undetermined intent of rifampicins</td>
</tr>
<tr>
<td>815</td>
<td>Exposure to or harmful effects of undetermined intent of antifungal antibiotics, systemically used</td>
</tr>
<tr>
<td>816</td>
<td>Exposure to or harmful effects of undetermined intent of other systemic anti-infectives or antiparasitics</td>
</tr>
<tr>
<td>817</td>
<td>Exposure to or harmful effects of undetermined intent of sulfonamides</td>
</tr>
<tr>
<td>818</td>
<td>Exposure to or harmful effects of undetermined intent of antimycobacterial drugs</td>
</tr>
<tr>
<td>819</td>
<td>Exposure to or harmful effects of undetermined intent of antimalarials or drugs acting on other blood protozoa</td>
</tr>
<tr>
<td>820</td>
<td>Exposure to or harmful effects of undetermined intent of other antiprotozoal drugs</td>
</tr>
<tr>
<td>821</td>
<td>Exposure to or harmful effects of undetermined intent of anthelminthics</td>
</tr>
<tr>
<td>822</td>
<td>Exposure to or harmful effects of undetermined intent of antiviral drugs</td>
</tr>
<tr>
<td>823</td>
<td>Exposure to or harmful effects of undetermined intent of hormones or their synthetic substitutes or antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>824</td>
<td>Exposure to or harmful effects of undetermined intent of glucocorticoids or synthetic analogues</td>
</tr>
<tr>
<td>825</td>
<td>Exposure to or harmful effects of undetermined intent of thyroid hormones or substitutes</td>
</tr>
<tr>
<td>826</td>
<td>Exposure to or harmful effects of undetermined intent of antithyroid drugs</td>
</tr>
<tr>
<td>827</td>
<td>Exposure to or harmful effects of undetermined intent of insulin or oral hypoglycaemic drugs</td>
</tr>
<tr>
<td>828</td>
<td>harmful effect of antidiabetic drugs, undetermined intent</td>
</tr>
<tr>
<td>829</td>
<td>Exposure to or harmful effects of undetermined intent of oral contraceptives</td>
</tr>
<tr>
<td>830</td>
<td>Exposure to or harmful effects of undetermined intent of other estrogens or progestogens</td>
</tr>
<tr>
<td>831</td>
<td>Exposure to or harmful effects of undetermined intent of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified</td>
</tr>
<tr>
<td>832</td>
<td>Exposure to or harmful effects of undetermined intent of androgens or anabolic congeners</td>
</tr>
<tr>
<td>833</td>
<td>Exposure to or harmful effects of undetermined intent of unspecified hormones or synthetic substitutes</td>
</tr>
<tr>
<td>834</td>
<td>Exposure to or harmful effects of undetermined intent of anterior pituitary hormones</td>
</tr>
<tr>
<td>835</td>
<td>Harmful effect of adenohypophyseal hormones, undetermined intent</td>
</tr>
<tr>
<td>836</td>
<td>Exposure to or harmful effects of undetermined intent of other hormones or synthetic substitutes</td>
</tr>
<tr>
<td>837</td>
<td>Exposure to or harmful effects of undetermined intent of unspecified hormone antagonists</td>
</tr>
<tr>
<td>838</td>
<td>Exposure to or harmful effects of undetermined intent of other hormone antagonists</td>
</tr>
<tr>
<td>839</td>
<td>Exposure to or harmful effects of undetermined intent of drugs primarily affecting the autonomic nervous system</td>
</tr>
<tr>
<td>840</td>
<td>Exposure to or harmful effects of undetermined intent of anticholinesterase agents</td>
</tr>
<tr>
<td>841</td>
<td>Exposure to or harmful effects of undetermined intent of other parasympathomimetics</td>
</tr>
<tr>
<td>842</td>
<td>harmful effect of cholinergics, undetermined intent</td>
</tr>
<tr>
<td>843</td>
<td>Exposure to or harmful effects of undetermined intent of ganglionic blocking drugs</td>
</tr>
<tr>
<td>844</td>
<td>Exposure to or harmful effects of undetermined intent of other parasympatholytics or spasmolytics</td>
</tr>
<tr>
<td>845</td>
<td>harmful effect of anticholinergics or antimuscarinics, undetermined intent</td>
</tr>
<tr>
<td>846</td>
<td>Exposure to or harmful effects of undetermined intent of predominantly alpha-adrenoreceptor agonists</td>
</tr>
<tr>
<td>847</td>
<td>Exposure to or harmful effects of undetermined intent of predominantly beta-adrenoreceptor agonists</td>
</tr>
<tr>
<td>848</td>
<td>Exposure to or harmful effects of undetermined intent of alpha-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>849</td>
<td>Exposure to or harmful effects of undetermined intent of beta-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>850</td>
<td>Exposure to or harmful effects of undetermined intent of centrally-acting or adrenergic-neuron-blocking agents</td>
</tr>
<tr>
<td>851</td>
<td>Exposure to or harmful effects of undetermined intent of agents primarily affecting blood constituents</td>
</tr>
<tr>
<td>852</td>
<td>Exposure to or harmful effects of undetermined intent of diphenhydramine</td>
</tr>
<tr>
<td>853</td>
<td>Exposure to or harmful effects of undetermined intent of other H1-receptor antagonists</td>
</tr>
<tr>
<td>854</td>
<td>Exposure to or harmful effects of undetermined intent of antiallergic or antiemetic drugs</td>
</tr>
<tr>
<td>855</td>
<td>Exposure to or harmful effects of undetermined intent of antineoplastic antimetabolites</td>
</tr>
<tr>
<td>856</td>
<td>Exposure to or harmful effects of undetermined intent of antineoplastic natural products</td>
</tr>
<tr>
<td>857</td>
<td>Exposure to or harmful effects of undetermined intent of other antineoplastic drugs</td>
</tr>
<tr>
<td>858</td>
<td>Exposure to or harmful effects of undetermined intent of immunosuppressive agents</td>
</tr>
<tr>
<td>859</td>
<td>Exposure to or harmful effects of undetermined intent of vitamin B12, folic acid or other anti-megaloblastic-anaemia preparations</td>
</tr>
<tr>
<td>860</td>
<td>Exposure to or harmful effects of undetermined intent of enzymes</td>
</tr>
<tr>
<td>861</td>
<td>Exposure to or harmful effects of undetermined intent of iron or its compounds</td>
</tr>
<tr>
<td>862</td>
<td>Exposure to or harmful effects of undetermined intent of anticoagulants</td>
</tr>
<tr>
<td>863</td>
<td>Exposure to or harmful effects of undetermined intent of antithrombotic drugs</td>
</tr>
<tr>
<td>864</td>
<td>harmful effect of platelet aggregation inhibitors, undetermined intent</td>
</tr>
<tr>
<td>865</td>
<td>Exposure to or harmful effects of undetermined intent of thrombolytic drug</td>
</tr>
<tr>
<td>866</td>
<td>Exposure to or harmful effects of undetermined intent of anticoagulant antagonists, vitamin K or other coagulants</td>
</tr>
<tr>
<td>867</td>
<td>Exposure to or harmful effects of undetermined intent of other fibrinolysis-affecting drugs</td>
</tr>
<tr>
<td>868</td>
<td>Exposure to or harmful effects of undetermined intent of natural blood or blood products</td>
</tr>
<tr>
<td>869</td>
<td>Exposure to or harmful effects of undetermined intent of acidifying or alkalising agents</td>
</tr>
<tr>
<td>870</td>
<td>Exposure to or harmful effects of undetermined intent of other primarily systemic agents, not elsewhere classified</td>
</tr>
<tr>
<td>871</td>
<td>Exposure to or harmful effects of undetermined intent of plasma substitutes</td>
</tr>
<tr>
<td>872</td>
<td>Exposure to or harmful effects of undetermined intent of agents primarily affecting the cardiovascular system</td>
</tr>
<tr>
<td>873</td>
<td>Exposure to or harmful effects of undetermined intent of cardiac-stimulant glycosides or drugs of similar action</td>
</tr>
<tr>
<td>874</td>
<td>Exposure to or harmful effects of undetermined intent of calcium-channel blockers</td>
</tr>
<tr>
<td>875</td>
<td>Exposure to or harmful effects of undetermined intent of other antidysrhythmic drugs</td>
</tr>
<tr>
<td>876</td>
<td>Exposure to or harmful effects of undetermined intent of nitroglycerin, nitroglycerol, medicinal</td>
</tr>
<tr>
<td>877</td>
<td>Exposure to or harmful effects of undetermined intent of other coronary vasodilators</td>
</tr>
<tr>
<td>878</td>
<td>Exposure to or harmful effects of undetermined intent of angiotensin-converting-enzyme inhibitors</td>
</tr>
<tr>
<td>879</td>
<td>Exposure to or harmful effects of undetermined intent of other antihypertensive drugs</td>
</tr>
<tr>
<td>880</td>
<td>Exposure to or harmful effects of undetermined intent of antihyperlipidemic or antiarteriosclerotic drugs</td>
</tr>
<tr>
<td>881</td>
<td>Exposure to or harmful effects of undetermined intent of peripheral vasodilators</td>
</tr>
<tr>
<td>882</td>
<td>Exposure to or harmful effects of undetermined intent of antivaricose drugs, including sclerosing agents</td>
</tr>
<tr>
<td>883</td>
<td>Exposure to or harmful effects of undetermined intent of agents primarily affecting the gastrointestinal system</td>
</tr>
<tr>
<td>884</td>
<td>Exposure to or harmful effects of undetermined intent of histamine H2-receptor blockers</td>
</tr>
<tr>
<td>885</td>
<td>Exposure to or harmful effects of undetermined intent of other antacids or anti-gastric-secretion drugs</td>
</tr>
<tr>
<td>886</td>
<td>Exposure to or harmful effects of undetermined intent of stimulant laxatives</td>
</tr>
<tr>
<td>887</td>
<td>Exposure to or harmful effects of undetermined intent of saline or osmotic laxatives</td>
</tr>
<tr>
<td>888</td>
<td>Exposure to or harmful effects of undetermined intent of other laxatives</td>
</tr>
<tr>
<td>889</td>
<td>Exposure to or harmful effects of undetermined intent of digestants</td>
</tr>
<tr>
<td>890</td>
<td>Exposure to or harmful effects of undetermined intent of antidiarrhoeal drugs</td>
</tr>
<tr>
<td>891</td>
<td>Exposure to or harmful effects of undetermined intent of emetics</td>
</tr>
<tr>
<td>892</td>
<td>Exposure to or harmful effects of undetermined intent of agents primarily acting on smooth or skeletal muscles or the respiratory system</td>
</tr>
<tr>
<td>893</td>
<td>Exposure to or harmful effects of undetermined intent of oxytocic drugs</td>
</tr>
<tr>
<td>894</td>
<td>Exposure to or harmful effects of undetermined intent of skeletal muscle relaxants</td>
</tr>
<tr>
<td>895</td>
<td>harmful effect of neuromuscular blocking agents, undetermined intent</td>
</tr>
<tr>
<td>896</td>
<td>Exposure to or harmful effects of undetermined intent of other drugs acting on muscles</td>
</tr>
<tr>
<td>897</td>
<td>Exposure to or harmful effects of undetermined intent of unspecified drugs acting on muscles</td>
</tr>
<tr>
<td>898</td>
<td>Exposure to or harmful effects of undetermined intent of antitussives</td>
</tr>
<tr>
<td>899</td>
<td>Exposure to or harmful effects of undetermined intent of expectorants</td>
</tr>
<tr>
<td>900</td>
<td>Exposure to or harmful effects of undetermined intent of other anti-common-cold drugs</td>
</tr>
<tr>
<td>901</td>
<td>Exposure to or harmful effects of undetermined intent of salbutamol</td>
</tr>
<tr>
<td>902</td>
<td>Exposure to or harmful effects of undetermined intent of aminophylline, theophylline</td>
</tr>
<tr>
<td>903</td>
<td>Exposure to or harmful effects of undetermined intent of terbutaline</td>
</tr>
<tr>
<td>904</td>
<td>Exposure to or harmful effects of undetermined intent of antiasthmatics, not elsewhere classified</td>
</tr>
<tr>
<td>905</td>
<td>Exposure to or harmful effects of undetermined intent of topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs</td>
</tr>
<tr>
<td>906</td>
<td>Exposure to or harmful effects of undetermined intent of topical corticosteroid preparations</td>
</tr>
<tr>
<td>907</td>
<td>Exposure to or harmful effects of iodine, antiseptic, undetermined intent</td>
</tr>
<tr>
<td>908</td>
<td>Exposure to or harmful effects of undetermined intent of silver nitrate</td>
</tr>
<tr>
<td>909</td>
<td>Exposure to or harmful effects of undetermined intent of other local antifungal, anti-infective or anti-inflammatory drugs</td>
</tr>
<tr>
<td>910</td>
<td>Exposure to or harmful effects of undetermined intent of antipruritics</td>
</tr>
<tr>
<td>911</td>
<td>Exposure to or harmful effects of undetermined intent of methyl salicylate</td>
</tr>
<tr>
<td>912</td>
<td>Exposure to or harmful effects of undetermined intent of other local astringents or local detergents</td>
</tr>
<tr>
<td>913</td>
<td>Exposure to or harmful effects of undetermined intent of emollients, demulcents or protectants</td>
</tr>
<tr>
<td>914</td>
<td>Exposure to or harmful effects of undetermined intent of podophyllin</td>
</tr>
<tr>
<td>915</td>
<td>Exposure to or harmful effects of undetermined intent of keratolytics, keratoplastics, or other hair treatment drugs or preparations</td>
</tr>
<tr>
<td>916</td>
<td>Exposure to or harmful effects of undetermined intent of ophthalmological drugs or preparations</td>
</tr>
<tr>
<td>917</td>
<td>Exposure to or harmful effects of undetermined intent of otorhinolaryngological drugs or preparations</td>
</tr>
<tr>
<td>918</td>
<td>Exposure to or harmful effects of undetermined intent of fluoride preparations</td>
</tr>
<tr>
<td>919</td>
<td>Exposure to or harmful effects of undetermined intent of other dental drugs, topically applied</td>
</tr>
<tr>
<td>920</td>
<td>Exposure to or harmful effects of undetermined intent of camphor</td>
</tr>
<tr>
<td>921</td>
<td>Exposure to or harmful effects of undetermined intent of agents primarily affecting water-balance or mineral or uric acid metabolism</td>
</tr>
<tr>
<td>922</td>
<td>Exposure to or harmful effects of undetermined intent of mineralocorticoids</td>
</tr>
<tr>
<td>923</td>
<td>Exposure to or harmful effects of undetermined intent of mineralocorticoids antagonists</td>
</tr>
<tr>
<td>924</td>
<td>Exposure to or harmful effects of undetermined intent of loop diuretics</td>
</tr>
<tr>
<td>925</td>
<td>harmful effect of high-ceiling diuretics, undetermined intent</td>
</tr>
<tr>
<td>926</td>
<td>Exposure to or harmful effects of undetermined intent of carbonic-anhydrase inhibitors</td>
</tr>
<tr>
<td>927</td>
<td>Exposure to or harmful effects of undetermined intent of benzothiadiazine derivatives</td>
</tr>
<tr>
<td>928</td>
<td>harmful effect of thiazides, undetermined intent</td>
</tr>
<tr>
<td>929</td>
<td>Exposure to or harmful effects of undetermined intent of other diuretics</td>
</tr>
<tr>
<td>930</td>
<td>Exposure to or harmful effects of undetermined intent of electrolytic, caloric or water-balance agents</td>
</tr>
<tr>
<td>931</td>
<td>Exposure to or harmful effects of undetermined intent of mineral salts, not elsewhere classified</td>
</tr>
<tr>
<td>932</td>
<td>Exposure to or harmful effects of undetermined intent of drugs affecting uric acid metabolism</td>
</tr>
<tr>
<td>933</td>
<td>Exposure to or harmful effects of undetermined intent of vitamin D or derivatives</td>
</tr>
<tr>
<td>934</td>
<td>Exposure to or harmful effects of undetermined intent of bisphosphonates</td>
</tr>
<tr>
<td>935</td>
<td>Exposure to or harmful effects of undetermined intent of appetite depressants</td>
</tr>
<tr>
<td>936</td>
<td>Exposure to or harmful effects of undetermined intent of antidotes or chelating agents, not elsewhere classified</td>
</tr>
<tr>
<td>937</td>
<td>Exposure to or harmful effects of undetermined intent of disulfiram</td>
</tr>
<tr>
<td>938</td>
<td>Exposure to or harmful effects of undetermined intent of alcohol deterrents, not elsewhere classified</td>
</tr>
<tr>
<td>939</td>
<td>Exposure to or harmful effects of undetermined intent of X-ray contrast media</td>
</tr>
<tr>
<td>940</td>
<td>Exposure to or harmful effects of undetermined intent of MRI contrast agents</td>
</tr>
<tr>
<td>941</td>
<td>Exposure to or harmful effects of undetermined intent of agents used for other scanning techniques</td>
</tr>
<tr>
<td>942</td>
<td>Exposure to or harmful effects of undetermined intent of other diagnostic agents</td>
</tr>
<tr>
<td>943</td>
<td>Exposure to or harmful effects of undetermined intent of lipotropic drugs</td>
</tr>
<tr>
<td>944</td>
<td>Exposure to or harmful effects of undetermined intent of pharmaceutical excipients</td>
</tr>
<tr>
<td>945</td>
<td>Exposure to or harmful effects of undetermined intent of herbal preparations or formulas</td>
</tr>
<tr>
<td>946</td>
<td>Exposure to or harmful effects of undetermined intent of dietary supplements, vitamins or minerals</td>
</tr>
<tr>
<td>947</td>
<td>Exposure to or harmful effects of undetermined intent of complementary or traditional medicines, not elsewhere classified</td>
</tr>
<tr>
<td>948</td>
<td>Exposure to or harmful effects of undetermined intent of complementary or traditional medicines, unspecified</td>
</tr>
<tr>
<td>949</td>
<td>Exposure to or harmful effects of undetermined intent of vaccines immunoglobulins or other biological substances</td>
</tr>
<tr>
<td>950</td>
<td>Exposure to or harmful effects of undetermined intent of BCG vaccine</td>
</tr>
<tr>
<td>951</td>
<td>Exposure to or harmful effects of undetermined intent of typhoid or paratyphoid vaccine</td>
</tr>
<tr>
<td>952</td>
<td>Exposure to or harmful effects of undetermined intent of cholera vaccine</td>
</tr>
<tr>
<td>953</td>
<td>Exposure to or harmful effects of undetermined intent of plague vaccine</td>
</tr>
<tr>
<td>954</td>
<td>Exposure to or harmful effects of undetermined intent of tetanus vaccine</td>
</tr>
<tr>
<td>955</td>
<td>Exposure to or harmful effects of undetermined intent of diphtheria vaccine</td>
</tr>
<tr>
<td>956</td>
<td>Exposure to or harmful effects of undetermined intent of haemophilus influenzae type b vaccines</td>
</tr>
<tr>
<td>957</td>
<td>Exposure to or harmful effects of undetermined intent of pertussis vaccine, including combinations with a pertussis component</td>
</tr>
<tr>
<td>958</td>
<td>Exposure to or harmful effects of undetermined intent of mixed bacterial vaccines without a pertussis component</td>
</tr>
<tr>
<td>959</td>
<td>Exposure to or harmful effects of undetermined intent of other or unspecified bacterial vaccines</td>
</tr>
<tr>
<td>960</td>
<td>Exposure to or harmful effects of undetermined intent of smallpox vaccines</td>
</tr>
<tr>
<td>961</td>
<td>Exposure to or harmful effects of undetermined intent of measles vaccines</td>
</tr>
<tr>
<td>962</td>
<td>Exposure to or harmful effects of undetermined intent of mumps vaccines</td>
</tr>
<tr>
<td>963</td>
<td>Exposure to or harmful effects of undetermined intent of rubella vaccines</td>
</tr>
<tr>
<td>964</td>
<td>Exposure to or harmful effects of undetermined intent of polio vaccines</td>
</tr>
<tr>
<td>965</td>
<td>Exposure to or harmful effects of undetermined intent of yellow fever vaccines</td>
</tr>
<tr>
<td>966</td>
<td>Exposure to or harmful effects of undetermined intent of hepatitis A vaccines</td>
</tr>
<tr>
<td>967</td>
<td>Exposure to or harmful effects of undetermined intent of hepatitis B vaccines</td>
</tr>
<tr>
<td>968</td>
<td>Exposure to or harmful effects of undetermined intent of influenza vaccines</td>
</tr>
<tr>
<td>969</td>
<td>Exposure to or harmful effects of undetermined intent of rotavirus vaccines</td>
</tr>
<tr>
<td>970</td>
<td>Exposure to or harmful effects of undetermined intent of human papillomavirus vaccines</td>
</tr>
<tr>
<td>971</td>
<td>Exposure to or harmful effects of undetermined intent of other viral vaccines</td>
</tr>
<tr>
<td>972</td>
<td>Exposure to or harmful effects of undetermined intent of rickettsial vaccines</td>
</tr>
<tr>
<td>973</td>
<td>Exposure to or harmful effects of undetermined intent of protozoal vaccines</td>
</tr>
<tr>
<td>974</td>
<td>Exposure to or harmful effects of undetermined intent of hepatitis B immune globulin</td>
</tr>
<tr>
<td>975</td>
<td>Exposure to or harmful effects of undetermined intent of antivenin, antivenom</td>
</tr>
<tr>
<td>976</td>
<td>Exposure to or harmful effects of undetermined intent of immunoglobulin, not elsewhere classified</td>
</tr>
<tr>
<td>977</td>
<td>Exposure to or harmful effects of undetermined intent of other specified vaccines</td>
</tr>
<tr>
<td>978</td>
<td>Exposure to or harmful effects of undetermined intent of unspecified vaccines</td>
</tr>
<tr>
<td>979</td>
<td>Other specified hereditary haemolytic anaemia</td>
</tr>
<tr>
<td>980</td>
<td>Hereditary haemolytic anaemia due to enzyme deficiency</td>
</tr>
<tr>
<td>981</td>
<td>Constitutional haemolytic anaemia due to enzyme deficiency</td>
</tr>
<tr>
<td>982</td>
<td>anaemia due to enzyme disorders</td>
</tr>
<tr>
<td>983</td>
<td>Haemolytic anaemias due to disorders of glycolytic enzymes</td>
</tr>
<tr>
<td>984</td>
<td>anaemia due to disorders of glycolytic enzymes</td>
</tr>
<tr>
<td>985</td>
<td>anaemia due to anaerobic glycolysis disorder</td>
</tr>
<tr>
<td>986</td>
<td>anaemia due to glycolytic enzyme deficiency</td>
</tr>
<tr>
<td>987</td>
<td>glycolysis anaerobic disorder with anaemia</td>
</tr>
<tr>
<td>988</td>
<td>Haemolytic anaemia due to triose phosphate-isomerase deficiency</td>
</tr>
<tr>
<td>989</td>
<td>Haemolytic anaemia due to red cell pyruvate kinase deficiency</td>
</tr>
<tr>
<td>990</td>
<td>pyruvate kinase deficiency anaemia</td>
</tr>
<tr>
<td>991</td>
<td>hereditary nonspherocytic haemolytic anaemia due to pyruvate kinase deficiency</td>
</tr>
<tr>
<td>992</td>
<td>Haemolytic anaemia due to glucose-phosphate isomerase deficiency</td>
</tr>
<tr>
<td>993</td>
<td>Haemolytic anaemia due to glucophosphate isomerase deficiency</td>
</tr>
<tr>
<td>994</td>
<td>Haemolytic anaemia due to glyceraldehyde-3-phosphate dehydrogenase deficiency</td>
</tr>
<tr>
<td>995</td>
<td>anaemia due to glyceraldehyde phosphate dehydrogenase deficiency</td>
</tr>
<tr>
<td>996</td>
<td>Haemolytic anaemia due to red cell enolase deficiency</td>
</tr>
<tr>
<td>997</td>
<td>Erythrocyte enolase deficiency</td>
</tr>
<tr>
<td>998</td>
<td>Haemolytic anaemia due to red cell diphosphoglycerate mutase deficiency</td>
</tr>
<tr>
<td>999</td>
<td>Nonspherocytic haemolytic anaemia due to hexokinase deficiency</td>
</tr>
<tr>
<td>1000</td>
<td>anaemia due to hexokinase deficiency</td>
</tr>
<tr>
<td>1001</td>
<td>Haemolytic nonspherocytic hereditary anaemia, type 2</td>
</tr>
<tr>
<td>1002</td>
<td>haemolytic nonspherocytic anaemia, type 2</td>
</tr>
<tr>
<td>1003</td>
<td>Haemolytic anaemias due to disorders of nucleotide metabolism</td>
</tr>
<tr>
<td>1004</td>
<td>anaemia due to disorders of nucleotide metabolism</td>
</tr>
<tr>
<td>1005</td>
<td>Haemolytic anaemia due to adenosine triphosphatase deficiency</td>
</tr>
<tr>
<td>1006</td>
<td>Haemolytic anaemia due to pyrimidine 5' nucleotidase deficiency</td>
</tr>
<tr>
<td>1007</td>
<td>Uridine monophosphate hydrolase deficiency</td>
</tr>
<tr>
<td>1008</td>
<td>Haemolytic anaemia due to adenylate kinase deficiency</td>
</tr>
<tr>
<td>1009</td>
<td>Hereditary haemolytic anaemia due to red cell membrane defects</td>
</tr>
<tr>
<td>1010</td>
<td>Constitutional haemolytic anaemia due to red cell membrane defects</td>
</tr>
<tr>
<td>1011</td>
<td>Hereditary spherocytosis</td>
</tr>
<tr>
<td>1012</td>
<td>Minkowski-Chauffard disease</td>
</tr>
<tr>
<td>1013</td>
<td>Acholuric (familial) jaundice</td>
</tr>
<tr>
<td>1014</td>
<td>congenital spherocytosis</td>
</tr>
<tr>
<td>1015</td>
<td>familial spherocytosis</td>
</tr>
<tr>
<td>1016</td>
<td>Minkowski-Chauffard syndrome</td>
</tr>
<tr>
<td>1017</td>
<td>anaemia spherocytic</td>
</tr>
<tr>
<td>1018</td>
<td>acholuric icterus</td>
</tr>
<tr>
<td>1019</td>
<td>acholuric jaundice</td>
</tr>
<tr>
<td>1020</td>
<td>congenital haemolytic icterus</td>
</tr>
<tr>
<td>1021</td>
<td>Congenital (spherocytic) haemolytic icterus</td>
</tr>
<tr>
<td>1022</td>
<td>hereditary spherocytic anaemia</td>
</tr>
<tr>
<td>1023</td>
<td>spherocytosis</td>
</tr>
<tr>
<td>1024</td>
<td>congenital spherocytic haemolytic anaemia</td>
</tr>
<tr>
<td>1025</td>
<td>Southeast Asian ovalocytosis</td>
</tr>
<tr>
<td>1026</td>
<td>Hereditary stomatocytosis</td>
</tr>
<tr>
<td>1027</td>
<td>Dehydrated hereditary stomatocytosis</td>
</tr>
<tr>
<td>1028</td>
<td>Xerocytosis</td>
</tr>
<tr>
<td>1029</td>
<td>Hereditary cryohydrocytosis with reduced stomatin</td>
</tr>
<tr>
<td>1030</td>
<td>Hereditary cryohydrocytosis</td>
</tr>
<tr>
<td>1031</td>
<td>Intermediate stomatocytosis syndrome</td>
</tr>
<tr>
<td>1032</td>
<td>Overhydrated hereditary stomatocytosis</td>
</tr>
<tr>
<td>1033</td>
<td>Hydrocytosis</td>
</tr>
<tr>
<td>1034</td>
<td>Rh deficiency syndrome</td>
</tr>
<tr>
<td>1035</td>
<td>Rh-null syndrome</td>
</tr>
<tr>
<td>1036</td>
<td>Acanthocytosis</td>
</tr>
<tr>
<td>1037</td>
<td>Choreoacanthocytosis</td>
</tr>
<tr>
<td>1038</td>
<td>Neuroacanthocytosis</td>
</tr>
<tr>
<td>1039</td>
<td>McLeod neuroacanthocytosis syndrome</td>
</tr>
<tr>
<td>1040</td>
<td>Hereditary haemolytic uraemic syndrome</td>
</tr>
<tr>
<td>1041</td>
<td>Atypical haemolytic uraemic syndrome</td>
</tr>
<tr>
<td>1042</td>
<td>Constitutional haemolytic uraemic syndrome</td>
</tr>
<tr>
<td>1043</td>
<td>Haemolytic-uremic syndrome without diarrhoea</td>
</tr>
<tr>
<td>1044</td>
<td>Atypical haemolytic uraemic syndrome with C3 anomaly</td>
</tr>
<tr>
<td>1045</td>
<td>Atypical haemolytic uraemic syndrome with MCP or CD46 anomaly</td>
</tr>
<tr>
<td>1046</td>
<td>Atypical haemolytic uraemic syndrome with factor B anomaly</td>
</tr>
<tr>
<td>1047</td>
<td>Atypical haemolytic uraemic syndrome with factor H anomaly</td>
</tr>
<tr>
<td>1048</td>
<td>Atypical haemolytic uraemic syndrome with factor I anomaly</td>
</tr>
<tr>
<td>1049</td>
<td>Atypical haemolytic uraemic syndrome with thrombomodulin anomaly</td>
</tr>
<tr>
<td>1050</td>
<td>Drugs, medicaments or biological substances associated with injury or harm in therapeutic use</td>
</tr>
<tr>
<td>1051</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics</td>
</tr>
<tr>
<td>1052</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Penicillins</td>
</tr>
<tr>
<td>1053</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Cephalosporins or other beta-lactam antibiotics</td>
</tr>
<tr>
<td>1054</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Chloramphenicol group</td>
</tr>
<tr>
<td>1055</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Macrolides</td>
</tr>
<tr>
<td>1056</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Tetracyclines</td>
</tr>
<tr>
<td>1057</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Aminoglycosides</td>
</tr>
<tr>
<td>1058</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Rifamycins</td>
</tr>
<tr>
<td>1059</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Antifungal antibiotics, systemically used</td>
</tr>
<tr>
<td>1060</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics</td>
</tr>
<tr>
<td>1061</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics, Sulfonamides</td>
</tr>
<tr>
<td>1062</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics, Antimycobacterial drugs</td>
</tr>
<tr>
<td>1063</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics, Antimalarials or drugs acting on other blood protozoa</td>
</tr>
<tr>
<td>1064</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics, Other antiprotozoal drugs</td>
</tr>
<tr>
<td>1065</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics, Anthelminthics</td>
</tr>
<tr>
<td>1066</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics, Antiviral drugs</td>
</tr>
<tr>
<td>1067</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics, Other specified systemic anti-infectives or antiparasitics</td>
</tr>
<tr>
<td>1068</td>
<td>Injury or harm in therapeutic use by hydroxyquinoline derivatives</td>
</tr>
<tr>
<td>1069</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>1070</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Glucocorticoids or synthetic analogues</td>
</tr>
<tr>
<td>1071</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Thyroid hormones or substitutes</td>
</tr>
<tr>
<td>1072</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Antithyroid drugs</td>
</tr>
<tr>
<td>1073</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Insulin or oral hypoglycaemic drugs</td>
</tr>
<tr>
<td>1074</td>
<td>Injury or harm in therapeutic use by insulin and oral hypoglycaemic [antidiabetic] drugs, Antidiabetic drugs</td>
</tr>
<tr>
<td>1075</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Oral contraceptives</td>
</tr>
<tr>
<td>1076</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Other estrogens or progestogens</td>
</tr>
<tr>
<td>1077</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified</td>
</tr>
<tr>
<td>1078</td>
<td>Injury or harm in therapeutic use by tamoxifen</td>
</tr>
<tr>
<td>1079</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Androgens or anabolic congeners</td>
</tr>
<tr>
<td>1080</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents</td>
</tr>
<tr>
<td>1081</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents, Antiallergic or antiemetic drugs</td>
</tr>
<tr>
<td>1082</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents, Antineoplastic antimetabolites</td>
</tr>
<tr>
<td>1083</td>
<td>Injury or harm in therapeutic use by cytarabine</td>
</tr>
<tr>
<td>1084</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents, Antineoplastic natural products</td>
</tr>
<tr>
<td>1085</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents, Other antineoplastic drugs</td>
</tr>
<tr>
<td>1086</td>
<td>Injury or harm in therapeutic use by antineoplastic antibiotics</td>
</tr>
<tr>
<td>1087</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents, Immunosuppressive agents</td>
</tr>
<tr>
<td>1088</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents, Acidifying or alkalizing agents</td>
</tr>
<tr>
<td>1089</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents, Enzymes, not elsewhere classified</td>
</tr>
<tr>
<td>1090</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents</td>
</tr>
<tr>
<td>1091</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Iron preparations or other anti-hypochromic-anaemia preparations</td>
</tr>
<tr>
<td>1092</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Vitamin B, folic acid or other anti-megaloblastic-anaemia preparations</td>
</tr>
<tr>
<td>1093</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Anticoagulants</td>
</tr>
<tr>
<td>1094</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Anticoagulant antagonists, vitamin K or other coagulants</td>
</tr>
<tr>
<td>1095</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Antithrombotic drugs</td>
</tr>
<tr>
<td>1096</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Thrombolytic drugs</td>
</tr>
<tr>
<td>1097</td>
<td>Injury or harm caused by tissue‐type plasminogen activator in therapeutic use</td>
</tr>
<tr>
<td>1098</td>
<td>Injury or harm caused by tPA [tissue‐type plasminogen activator] in therapeutic use</td>
</tr>
<tr>
<td>1099</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Natural blood or blood products</td>
</tr>
<tr>
<td>1100</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Plasma substitutes</td>
</tr>
<tr>
<td>1101</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Analgesics, antipyretics or anti-inflammatory drugs</td>
</tr>
<tr>
<td>1102</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Analgesics, antipyretics or anti-inflammatory drugs, Opioids or related analgesics</td>
</tr>
<tr>
<td>1103</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Analgesics, antipyretics or anti-inflammatory drugs, Salicylates</td>
</tr>
<tr>
<td>1104</td>
<td>Injury or harm in therapeutic use of acetylsalicylic acid</td>
</tr>
<tr>
<td>1105</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Analgesics, antipyretics or anti-inflammatory drugs, Propionic acid derivatives</td>
</tr>
<tr>
<td>1106</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Analgesics, antipyretics or anti-inflammatory drugs, Other nonsteroidal anti-inflammatory drugs</td>
</tr>
<tr>
<td>1107</td>
<td>Other NSAID</td>
</tr>
<tr>
<td>1108</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Analgesics, antipyretics or anti-inflammatory drugs, Antirheumatics</td>
</tr>
<tr>
<td>1109</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Analgesics, antipyretics or anti-inflammatory drugs, 4-Aminophenol derivatives</td>
</tr>
<tr>
<td>1110</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs</td>
</tr>
<tr>
<td>1111</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Succinimides</td>
</tr>
<tr>
<td>1112</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Oxazolidinediones</td>
</tr>
<tr>
<td>1113</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Hydantoin derivatives</td>
</tr>
<tr>
<td>1114</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Deoxybarbiturates</td>
</tr>
<tr>
<td>1115</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Iminostilbenes</td>
</tr>
<tr>
<td>1116</td>
<td>Injury or harm in therapeutic use by carbamazepine</td>
</tr>
<tr>
<td>1117</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Valproic acid</td>
</tr>
<tr>
<td>1118</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Other or unspecified antiepileptics</td>
</tr>
<tr>
<td>1119</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Antiparkinsonism drugs</td>
</tr>
<tr>
<td>1120</td>
<td>Injury or harm in therapeutic use by amantadine</td>
</tr>
<tr>
<td>1121</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Antispasticity drugs</td>
</tr>
<tr>
<td>1122</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Sedatives, hypnotics or antianxiety drugs</td>
</tr>
<tr>
<td>1123</td>
<td>Injury or harm in therapeutic use by sleeping draught NOS</td>
</tr>
<tr>
<td>1124</td>
<td>Injury or harm in therapeutic use by sleeping drug NOS</td>
</tr>
<tr>
<td>1125</td>
<td>Injury or harm in therapeutic use by sleeping tablet NOS</td>
</tr>
<tr>
<td>1126</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Sedatives, hypnotics or antianxiety drugs, Barbiturates, not elsewhere classified</td>
</tr>
<tr>
<td>1127</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Sedatives, hypnotics or antianxiety drugs, Benzodiazepines</td>
</tr>
<tr>
<td>1128</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Sedatives, hypnotics or antianxiety drugs, Cloral derivatives</td>
</tr>
<tr>
<td>1129</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Sedatives, hypnotics or antianxiety drugs, Paraldehyde</td>
</tr>
<tr>
<td>1130</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Sedatives, hypnotics or antianxiety drugs, Bromine compounds</td>
</tr>
<tr>
<td>1131</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Sedatives, hypnotics or antianxiety drugs, Mixed sedatives or hypnotics, not elsewhere classified</td>
</tr>
<tr>
<td>1132</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Anaesthetics or therapeutic gases</td>
</tr>
<tr>
<td>1133</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Anaesthetics or therapeutic gases, Inhaled anaesthetics</td>
</tr>
<tr>
<td>1134</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Anaesthetics or therapeutic gases, Parenteral anaesthetics</td>
</tr>
<tr>
<td>1135</td>
<td>Injury or harm in therapeutic use of thiobarbiturates</td>
</tr>
<tr>
<td>1136</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Anaesthetics or therapeutic gases, Other or unspecified general anaesthetics</td>
</tr>
<tr>
<td>1137</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Anaesthetics or therapeutic gases, Local anaesthetics</td>
</tr>
<tr>
<td>1138</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Anaesthetics or therapeutic gases, Therapeutic gases</td>
</tr>
<tr>
<td>1139</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified</td>
</tr>
<tr>
<td>1140</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Tricyclic or tetracyclic antidepressants</td>
</tr>
<tr>
<td>1141</td>
<td>Drugs medicaments or biological, substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Monoamine-oxidase-inhibitor antidepressants</td>
</tr>
<tr>
<td>1142</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Other or unspecified antidepressants</td>
</tr>
<tr>
<td>1143</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Phenothiazine antipsychotics or neuroleptics</td>
</tr>
<tr>
<td>1144</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Butyrophenone or thioxanthene neuroleptics</td>
</tr>
<tr>
<td>1145</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Other antipsychotics or neuroleptics</td>
</tr>
<tr>
<td>1146</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Psychodysleptics</td>
</tr>
<tr>
<td>1147</td>
<td>Injury or harm in therapeutic use of hallucinogens</td>
</tr>
<tr>
<td>1148</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Psychostimulants with abuse potential</td>
</tr>
<tr>
<td>1149</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Central nervous system stimulants, not elsewhere classified</td>
</tr>
<tr>
<td>1150</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Central nervous system stimulants, not elsewhere classified, Analeptics</td>
</tr>
<tr>
<td>1151</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Central nervous system stimulants, not elsewhere classified, Opioid receptor antagonists</td>
</tr>
<tr>
<td>1152</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Central nervous system stimulants, not elsewhere classified, Methylxanthines, not elsewhere classified</td>
</tr>
<tr>
<td>1153</td>
<td>Injury or harm in therapeutic use of caffeine</td>
</tr>
<tr>
<td>1154</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system</td>
</tr>
<tr>
<td>1155</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Anticholinesterase agents</td>
</tr>
<tr>
<td>1156</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Other parasympathomimetics</td>
</tr>
<tr>
<td>1157</td>
<td>Injury or harm in therapeutic use of cholinergics</td>
</tr>
<tr>
<td>1158</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Ganglionic blocking drugs, not elsewhere classified</td>
</tr>
<tr>
<td>1159</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Other parasympatholytics or spasmolytics, not elsewhere classified</td>
</tr>
<tr>
<td>1160</td>
<td>Injury or harm in therapeutic use of anticholinergics or antimuscarinics</td>
</tr>
<tr>
<td>1161</td>
<td>Injury or harm in therapeutic use of papaverine</td>
</tr>
<tr>
<td>1162</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Predominantly alpha-adrenoreceptor agonists, not elsewhere classified</td>
</tr>
<tr>
<td>1163</td>
<td>Injury or harm in therapeutic use of metaraminol</td>
</tr>
<tr>
<td>1164</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Predominantly beta-adrenoreceptor agonists, not elsewhere classified</td>
</tr>
<tr>
<td>1165</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Alpha-adrenoreceptor antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>1166</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Beta-adrenoreceptor antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>1167</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Centrally acting or adrenergic-neuron-blocking agents, not elsewhere classified</td>
</tr>
<tr>
<td>1168</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system</td>
</tr>
<tr>
<td>1169</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Cardiac-stimulant glycosides or drugs of similar action</td>
</tr>
<tr>
<td>1170</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Calcium-channel blockers</td>
</tr>
<tr>
<td>1171</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Other antidysrhythmic drugs, not elsewhere classified</td>
</tr>
<tr>
<td>1172</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Coronary vasodilators, not elsewhere classified</td>
</tr>
<tr>
<td>1173</td>
<td>Injury or harm in therapeutic use of dipyridamole</td>
</tr>
<tr>
<td>1174</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Angiotensin-converting-enzyme inhibitors</td>
</tr>
<tr>
<td>1175</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Other antihypertensive drugs, not elsewhere classified</td>
</tr>
<tr>
<td>1176</td>
<td>Injury or harm in therapeutic use of clonidine</td>
</tr>
<tr>
<td>1177</td>
<td>Injury or harm in therapeutic use of guanethidine</td>
</tr>
<tr>
<td>1178</td>
<td>Injury or harm in therapeutic use of rauwolfia</td>
</tr>
<tr>
<td>1179</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Antihyperlipidaemic or antiarteriosclerotic drugs</td>
</tr>
<tr>
<td>1180</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Peripheral vasodilators</td>
</tr>
<tr>
<td>1181</td>
<td>Injury or harm in therapeutic use by nicotinic acid derivatives</td>
</tr>
<tr>
<td>1182</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Antivaricose drugs, including sclerosing agents</td>
</tr>
<tr>
<td>1183</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system</td>
</tr>
<tr>
<td>1184</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Histamine H-receptor antagonists</td>
</tr>
<tr>
<td>1185</td>
<td>histamine h 2 -receptor antagonists associated with injury or harm in therapeutic use</td>
</tr>
<tr>
<td>1186</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Other antacids or anti-gastric-secretion drugs</td>
</tr>
<tr>
<td>1187</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Stimulant laxatives</td>
</tr>
<tr>
<td>1188</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Saline or osmotic laxatives</td>
</tr>
<tr>
<td>1189</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Other laxatives</td>
</tr>
<tr>
<td>1190</td>
<td>injury or harm in therapeutic use of intestinal atonia drugs</td>
</tr>
<tr>
<td>1191</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Digestants</td>
</tr>
<tr>
<td>1192</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Antidiarrhoeal drugs</td>
</tr>
<tr>
<td>1193</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Emetics</td>
</tr>
<tr>
<td>1194</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism</td>
</tr>
<tr>
<td>1195</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Mineralocorticoids</td>
</tr>
<tr>
<td>1196</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Mineralocorticoid antagonists</td>
</tr>
<tr>
<td>1197</td>
<td>injury or harm in therapeutic use of aldosterone antagonists</td>
</tr>
<tr>
<td>1198</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Carbonic-anhydrase inhibitors</td>
</tr>
<tr>
<td>1199</td>
<td>Injury or harm in therapeutic use of acetazolamide</td>
</tr>
<tr>
<td>1200</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Benzothiadiazine derivatives</td>
</tr>
<tr>
<td>1201</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Loop diuretics</td>
</tr>
<tr>
<td>1202</td>
<td>injury or harm in therapeutic use of high-ceiling diuretics</td>
</tr>
<tr>
<td>1203</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Other diuretics</td>
</tr>
<tr>
<td>1204</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Electrolytic, caloric or water-balance agents</td>
</tr>
<tr>
<td>1205</td>
<td>Injury or harm in therapeutic use of oral rehydration salts</td>
</tr>
<tr>
<td>1206</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Agents affecting calcification</td>
</tr>
<tr>
<td>1207</td>
<td>Injury or harm in therapeutic use of parathyroid hormones or derivatives</td>
</tr>
<tr>
<td>1208</td>
<td>Injury or harm in therapeutic use of vitamin D group</td>
</tr>
<tr>
<td>1209</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Agents affecting uric acid metabolism</td>
</tr>
<tr>
<td>1210</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Mineral salts, not elsewhere classified</td>
</tr>
<tr>
<td>1211</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system</td>
</tr>
<tr>
<td>1212</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Oxytocic drugs</td>
</tr>
<tr>
<td>1213</td>
<td>Injury or harm in therapeutic use of ergot alkaloids</td>
</tr>
<tr>
<td>1214</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Skeletal muscle relaxants</td>
</tr>
<tr>
<td>1215</td>
<td>injury or harm in therapeutic use of neuromuscular blocking agents</td>
</tr>
<tr>
<td>1216</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Other or unspecified agents primarily acting on muscles</td>
</tr>
<tr>
<td>1217</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Antitussives</td>
</tr>
<tr>
<td>1218</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Expectorants</td>
</tr>
<tr>
<td>1219</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Anti-common-cold drugs</td>
</tr>
<tr>
<td>1220</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Antiasthmatics, not elsewhere classified</td>
</tr>
<tr>
<td>1221</td>
<td>Injury or harm in therapeutic use of aminophylline</td>
</tr>
<tr>
<td>1222</td>
<td>Injury or harm in therapeutic use of salbutamol</td>
</tr>
<tr>
<td>1223</td>
<td>Injury or harm in therapeutic use of theobromine</td>
</tr>
<tr>
<td>1224</td>
<td>Injury or harm in therapeutic use of theophylline</td>
</tr>
<tr>
<td>1225</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Other or unspecified agents primarily acting on the respiratory system</td>
</tr>
<tr>
<td>1226</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs</td>
</tr>
<tr>
<td>1227</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs, Local antifungal, anti-infective or anti-inflammatory drugs, not elsewhere classified</td>
</tr>
<tr>
<td>1228</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs, Antipruritics</td>
</tr>
<tr>
<td>1229</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs, Local astringents or local detergents</td>
</tr>
<tr>
<td>1230</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs, Emollients, demulcents or protectants</td>
</tr>
<tr>
<td>1231</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs, Keratolytics, keratoplastics or other hair treatment drugs or preparations</td>
</tr>
<tr>
<td>1232</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs, Ophthalmological drugs or preparations</td>
</tr>
<tr>
<td>1233</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological drugs or preparations or dental drugs</td>
</tr>
<tr>
<td>1234</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs, Dental drugs, topically applied</td>
</tr>
<tr>
<td>1235</td>
<td>Injury or harm in therapeutic use of glucocorticoids, topically used</td>
</tr>
<tr>
<td>1236</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments</td>
</tr>
<tr>
<td>1237</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, Appetite depressants</td>
</tr>
<tr>
<td>1238</td>
<td>injury or harm in therapeutic use of anorectics</td>
</tr>
<tr>
<td>1239</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, Lipotropic drugs</td>
</tr>
<tr>
<td>1240</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, Antidotes or chelating agents, not elsewhere classified</td>
</tr>
<tr>
<td>1241</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, Alcohol deterrents</td>
</tr>
<tr>
<td>1242</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, Pharmaceutical excipients</td>
</tr>
<tr>
<td>1243</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, X-ray contrast media</td>
</tr>
<tr>
<td>1244</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, Other diagnostic agents</td>
</tr>
<tr>
<td>1245</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, Vitamins, not elsewhere classified</td>
</tr>
<tr>
<td>1246</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines</td>
</tr>
<tr>
<td>1247</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, BCG vaccine</td>
</tr>
<tr>
<td>1248</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, Typhoid or paratyphoid vaccine</td>
</tr>
<tr>
<td>1249</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, Cholera vaccine</td>
</tr>
<tr>
<td>1250</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, Plague vaccine</td>
</tr>
<tr>
<td>1251</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, Tetanus vaccine</td>
</tr>
<tr>
<td>1252</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, Diphtheria vaccine</td>
</tr>
<tr>
<td>1253</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, Pertussis vaccine, including combinations with a pertussis component</td>
</tr>
<tr>
<td>1254</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, Mixed bacterial vaccines, except combinations with a pertussis component</td>
</tr>
<tr>
<td>1255</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified vaccines or biological substances</td>
</tr>
<tr>
<td>1256</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified vaccines or biological substances, Viral vaccines</td>
</tr>
<tr>
<td>1257</td>
<td>Drugs, medicaments or biological substances associated with injury or harm in therapeutic use, COVID-19 vaccine</td>
</tr>
<tr>
<td>1258</td>
<td>Correct administration of COVID-19 vaccine in prophylactic therapeutic use as the cause of any adverse effect</td>
</tr>
<tr>
<td>1259</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified vaccines or biological substances, Rickettsial vaccines</td>
</tr>
<tr>
<td>1260</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified vaccines or biological substances, Protozoal vaccines</td>
</tr>
<tr>
<td>1261</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified vaccines or biological substances, Immunoglobulin</td>
</tr>
<tr>
<td>1262</td>
<td>Unintentional exposure to or harmful effects of other or unspecified drug, medicament or biological substance</td>
</tr>
<tr>
<td>1263</td>
<td>accidental overdose of other or unspecified drug, medicament or biological substance</td>
</tr>
<tr>
<td>1264</td>
<td>accidental poisoning by other or unspecified drug, medicament or biological substance</td>
</tr>
<tr>
<td>1265</td>
<td>other or unspecified drug, medicament or biological substance taken in error</td>
</tr>
<tr>
<td>1266</td>
<td>accidental drug overdose</td>
</tr>
<tr>
<td>1267</td>
<td>accidental overdose</td>
</tr>
<tr>
<td>1268</td>
<td>Unintentional exposure to or harmful effects of systemic antibiotics</td>
</tr>
<tr>
<td>1269</td>
<td>Unintentional exposure to or harmful effects of penicillins</td>
</tr>
<tr>
<td>1270</td>
<td>Unintentional exposure to or harmful effects of cephalosporins or other beta-lactam antibiotics</td>
</tr>
<tr>
<td>1271</td>
<td>Unintentional exposure to or harmful effects of chloramphenicol group</td>
</tr>
<tr>
<td>1272</td>
<td>Unintentional exposure to or harmful effects of macrolides</td>
</tr>
<tr>
<td>1273</td>
<td>Unintentional exposure to or harmful effects of tetracyclines</td>
</tr>
<tr>
<td>1274</td>
<td>Unintentional exposure to or harmful effects of aminoglycosides</td>
</tr>
<tr>
<td>1275</td>
<td>Unintentional exposure to or harmful effects of rifampicin</td>
</tr>
<tr>
<td>1276</td>
<td>Unintentional exposure to or harmful effects of antifungal antibiotics, systemically used</td>
</tr>
<tr>
<td>1277</td>
<td>Unintentional exposure to or harmful effects of other systemic anti-infectives or antiparasitics</td>
</tr>
<tr>
<td>1278</td>
<td>Unintentional exposure to or harmful effects of sulfonamides</td>
</tr>
<tr>
<td>1279</td>
<td>Unintentional exposure to or harmful effects of antimycobacterial drugs</td>
</tr>
<tr>
<td>1280</td>
<td>Unintentional exposure to or harmful effects of antimalarials or drugs acting on other blood protozoa</td>
</tr>
<tr>
<td>1281</td>
<td>Unintentional exposure to or harmful effects of other antiprotozoal drugs</td>
</tr>
<tr>
<td>1282</td>
<td>Unintentional exposure to or harmful effects of anthelminthics</td>
</tr>
<tr>
<td>1283</td>
<td>Unintentional exposure to or harmful effects of antiviral drugs</td>
</tr>
<tr>
<td>1284</td>
<td>Unintentional exposure to or harmful effects of hormones or their synthetic substitutes or antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>1285</td>
<td>Unintentional exposure to or harmful effects of glucocorticoids or synthetic analogues</td>
</tr>
<tr>
<td>1286</td>
<td>Unintentional exposure to or harmful effects of thyroid hormones or substitutes</td>
</tr>
<tr>
<td>1287</td>
<td>Unintentional exposure to or harmful effects of antithyroid drugs</td>
</tr>
<tr>
<td>1288</td>
<td>Unintentional exposure to or harmful effects of insulin or oral hypoglycaemic drugs</td>
</tr>
<tr>
<td>1289</td>
<td>Unintentional harmful effect of antidiabetic drugs</td>
</tr>
<tr>
<td>1290</td>
<td>Unintentional exposure to or harmful effects of oral contraceptives</td>
</tr>
<tr>
<td>1291</td>
<td>Unintentional exposure to or harmful effects of other estrogens or progestogens</td>
</tr>
<tr>
<td>1292</td>
<td>Unintentional exposure to or harmful effects of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified</td>
</tr>
<tr>
<td>1293</td>
<td>Unintentional exposure to or harmful effects of androgens or anabolic congeners</td>
</tr>
<tr>
<td>1294</td>
<td>Unintentional exposure to or harmful effects of unspecified hormones or synthetic substitutes</td>
</tr>
<tr>
<td>1295</td>
<td>Unintentional exposure to or harmful effects of anterior pituitary hormones</td>
</tr>
<tr>
<td>1296</td>
<td>Unintentional harmful effect of adenohypophyseal hormones</td>
</tr>
<tr>
<td>1297</td>
<td>Unintentional exposure to or harmful effects of other hormones or synthetic substitutes</td>
</tr>
<tr>
<td>1298</td>
<td>Unintentional exposure to or harmful effects of other hormone antagonists</td>
</tr>
<tr>
<td>1299</td>
<td>Unintentional exposure to or harmful effects of unspecified hormone antagonists</td>
</tr>
<tr>
<td>1300</td>
<td>Unintentional exposure to or harmful effects of drugs primarily affecting the autonomic nervous system</td>
</tr>
<tr>
<td>1301</td>
<td>Unintentional exposure to or harmful effects of anticholinesterase agents</td>
</tr>
<tr>
<td>1302</td>
<td>Unintentional exposure to or harmful effects of other parasympathomimetics</td>
</tr>
<tr>
<td>1303</td>
<td>Unintentional harmful effect of cholinergics</td>
</tr>
<tr>
<td>1304</td>
<td>Unintentional exposure to or harmful effects of ganglionic blocking drugs</td>
</tr>
<tr>
<td>1305</td>
<td>Unintentional exposure to or harmful effects of other parasympatholytics or spasmolytics</td>
</tr>
<tr>
<td>1306</td>
<td>Unintentional harmful effect of anticholinergics or antimuscarinics</td>
</tr>
<tr>
<td>1307</td>
<td>Unintentional exposure to or harmful effects of predominantly alpha-adrenoreceptor agonists</td>
</tr>
<tr>
<td>1308</td>
<td>Unintentional exposure to or harmful effects of predominantly beta-adrenoreceptor agonists</td>
</tr>
<tr>
<td>1309</td>
<td>Unintentional exposure to or harmful effects of alpha-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>1310</td>
<td>Unintentional exposure to or harmful effects of beta-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>1311</td>
<td>Unintentional exposure to or harmful effects of centrally-acting or adrenergic-neuron-blocking agents</td>
</tr>
<tr>
<td>1312</td>
<td>Unintentional exposure to or harmful effects of agents primarily affecting blood constituents</td>
</tr>
<tr>
<td>1313</td>
<td>Unintentional exposure to or harmful effects of diphenhydramine</td>
</tr>
<tr>
<td>1314</td>
<td>Unintentional exposure to or harmful effects of other H1-receptor antagonists</td>
</tr>
<tr>
<td>1315</td>
<td>Unintentional exposure to or harmful effects of antiallergic or antiemetic drugs</td>
</tr>
<tr>
<td>1316</td>
<td>Unintentional exposure to or harmful effects of antineoplastic antimetabolites</td>
</tr>
<tr>
<td>1317</td>
<td>Unintentional exposure to or harmful effects of antineoplastic natural products</td>
</tr>
<tr>
<td>1318</td>
<td>Unintentional exposure to or harmful effects of other antineoplastic drugs</td>
</tr>
<tr>
<td>1319</td>
<td>Unintentional exposure to or harmful effects of immunosuppressive agents</td>
</tr>
<tr>
<td>1320</td>
<td>Unintentional exposure to or harmful effects of vitamin B12, folic acid or other anti-megaloblastic-anaemia preparations</td>
</tr>
<tr>
<td>1321</td>
<td>Unintentional exposure to or harmful effects of enzymes</td>
</tr>
<tr>
<td>1322</td>
<td>Unintentional exposure to or harmful effects of iron or its compounds</td>
</tr>
<tr>
<td>1323</td>
<td>Unintentional exposure to or harmful effects of anticoagulants</td>
</tr>
<tr>
<td>1324</td>
<td>Unintentional exposure to or harmful effects of antithrombotic drugs</td>
</tr>
<tr>
<td>1325</td>
<td>Unintentional harmful effect of platelet aggregation inhibitors</td>
</tr>
<tr>
<td>1326</td>
<td>Unintentional exposure to or harmful effects of thrombolytic drug</td>
</tr>
<tr>
<td>1327</td>
<td>Unintentional exposure to or harmful effects of anticoagulant antagonists, vitamin K or other coagulants</td>
</tr>
<tr>
<td>1328</td>
<td>Unintentional exposure to or harmful effects of other fibrinolysis-affecting drugs</td>
</tr>
<tr>
<td>1329</td>
<td>Unintentional exposure to or harmful effects of natural blood or blood products</td>
</tr>
<tr>
<td>1330</td>
<td>Unintentional exposure to or harmful effects of acidifying or alkalising agents</td>
</tr>
<tr>
<td>1331</td>
<td>Unintentional exposure to or harmful effects of other primarily systemic agents, not elsewhere classified</td>
</tr>
<tr>
<td>1332</td>
<td>Unintentional exposure to or harmful effects of plasma substitutes</td>
</tr>
<tr>
<td>1333</td>
<td>Unintentional exposure to or harmful effects of agents primarily affecting the cardiovascular system</td>
</tr>
<tr>
<td>1334</td>
<td>Unintentional exposure to or harmful effects of cardiac-stimulant glycosides or drugs of similar action</td>
</tr>
<tr>
<td>1335</td>
<td>Unintentional exposure to or harmful effects of calcium-channel blockers</td>
</tr>
<tr>
<td>1336</td>
<td>Unintentional exposure to or harmful effects of other antidysrhythmic drugs</td>
</tr>
<tr>
<td>1337</td>
<td>Unintentional exposure to or harmful effects of nitroglycerin, nitroglycerol, medicinal</td>
</tr>
<tr>
<td>1338</td>
<td>Unintentional exposure to or harmful effects of other coronary vasodilators</td>
</tr>
<tr>
<td>1339</td>
<td>Unintentional exposure to or harmful effects of angiotensin-converting-enzyme inhibitors</td>
</tr>
<tr>
<td>1340</td>
<td>Unintentional exposure to or harmful effects of other antihypertensive drugs</td>
</tr>
<tr>
<td>1341</td>
<td>Unintentional exposure to or harmful effects of antihyperlipidemic or antiarteriosclerotic drugs</td>
</tr>
<tr>
<td>1342</td>
<td>Unintentional exposure to or harmful effects of peripheral vasodilators</td>
</tr>
<tr>
<td>1343</td>
<td>Unintentional exposure to or harmful effects of antivaricose drugs, including sclerosing agents</td>
</tr>
<tr>
<td>1344</td>
<td>Unintentional exposure to or harmful effects of agents primarily affecting the gastrointestinal system</td>
</tr>
<tr>
<td>1345</td>
<td>Unintentional exposure to or harmful effects of histamine H2-receptor blockers</td>
</tr>
<tr>
<td>1346</td>
<td>Unintentional exposure to or harmful effects of other antacids or anti-gastric-secretion drugs</td>
</tr>
<tr>
<td>1347</td>
<td>Unintentional exposure to or harmful effects of stimulant laxatives</td>
</tr>
<tr>
<td>1348</td>
<td>Unintentional exposure to or harmful effects of saline or osmotic laxatives</td>
</tr>
<tr>
<td>1349</td>
<td>Unintentional exposure to or harmful effects of other laxatives</td>
</tr>
<tr>
<td>1350</td>
<td>Unintentional exposure to or harmful effects of digestants</td>
</tr>
<tr>
<td>1351</td>
<td>Unintentional exposure to or harmful effects of antidiarrhoeal drugs</td>
</tr>
<tr>
<td>1352</td>
<td>Unintentional exposure to or harmful effects of emetics</td>
</tr>
<tr>
<td>1353</td>
<td>Unintentional exposure to or harmful effects of agents primarily acting on smooth or skeletal muscles or the respiratory system</td>
</tr>
<tr>
<td>1354</td>
<td>Unintentional exposure to or harmful effects of oxytocic drugs</td>
</tr>
<tr>
<td>1355</td>
<td>Unintentional exposure to or harmful effects of skeletal muscle relaxants</td>
</tr>
<tr>
<td>1356</td>
<td>Unintentional harmful effect of neuromuscular blocking agents</td>
</tr>
<tr>
<td>1357</td>
<td>Unintentional exposure to or harmful effects of other drugs acting on muscles</td>
</tr>
<tr>
<td>1358</td>
<td>Unintentional exposure to or harmful effects of unspecified drugs acting on muscles</td>
</tr>
<tr>
<td>1359</td>
<td>Unintentional exposure to or harmful effects of antitussives</td>
</tr>
<tr>
<td>1360</td>
<td>Unintentional exposure to or harmful effects of expectorants</td>
</tr>
<tr>
<td>1361</td>
<td>Unintentional exposure to or harmful effects of other anti-common-cold drugs</td>
</tr>
<tr>
<td>1362</td>
<td>Unintentional exposure to or harmful effects of salbutamol</td>
</tr>
<tr>
<td>1363</td>
<td>Unintentional exposure to or harmful effects of aminophylline, theophylline</td>
</tr>
<tr>
<td>1364</td>
<td>Unintentional exposure to or harmful effects of terbutaline</td>
</tr>
<tr>
<td>1365</td>
<td>Unintentional exposure to or harmful effects of antiasthmatics, not elsewhere classified</td>
</tr>
<tr>
<td>1366</td>
<td>Unintentional exposure to or harmful effects of topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs</td>
</tr>
<tr>
<td>1367</td>
<td>Unintentional exposure to or harmful effects of topical corticosteroid preparations</td>
</tr>
<tr>
<td>1368</td>
<td>Unintentional exposure to or harmful effects of iodine, antiseptic</td>
</tr>
<tr>
<td>1369</td>
<td>Unintentional exposure to or harmful effects of silver nitrate</td>
</tr>
<tr>
<td>1370</td>
<td>Unintentional exposure to or harmful effects of other local antifungal, anti-infective or anti-inflammatory drugs</td>
</tr>
<tr>
<td>1371</td>
<td>Unintentional exposure to or harmful effects of antipruritics</td>
</tr>
<tr>
<td>1372</td>
<td>Unintentional exposure to or harmful effects of methyl salicylate</td>
</tr>
<tr>
<td>1373</td>
<td>Unintentional exposure to or harmful effects of other local astringents or local detergents</td>
</tr>
<tr>
<td>1374</td>
<td>Unintentional exposure to or harmful effects of emollients, demulcents or protectants</td>
</tr>
<tr>
<td>1375</td>
<td>Unintentional exposure to or harmful effects of podophyllin</td>
</tr>
<tr>
<td>1376</td>
<td>Unintentional exposure to or harmful effects of keratolytics, keratoplastics, or other hair treatment drugs or preparations</td>
</tr>
<tr>
<td>1377</td>
<td>Unintentional exposure to or harmful effects of ophthalmological drugs or preparations</td>
</tr>
<tr>
<td>1378</td>
<td>Unintentional exposure to or harmful effects of otorhinolaryngological drugs or preparations</td>
</tr>
<tr>
<td>1379</td>
<td>Unintentional exposure to or harmful effects of fluoride preparations</td>
</tr>
<tr>
<td>1380</td>
<td>Unintentional exposure to or harmful effects of other dental drugs, topically applied</td>
</tr>
<tr>
<td>1381</td>
<td>Unintentional exposure to or harmful effects of camphor</td>
</tr>
<tr>
<td>1382</td>
<td>Unintentional exposure to or harmful effects of agents primarily affecting water-balance or mineral or uric acid metabolism</td>
</tr>
<tr>
<td>1383</td>
<td>Unintentional exposure to or harmful effects of mineralocorticoids</td>
</tr>
<tr>
<td>1384</td>
<td>Unintentional exposure to or harmful effects of mineralocorticoids antagonists</td>
</tr>
<tr>
<td>1385</td>
<td>Unintentional exposure to or harmful effects of loop diuretics</td>
</tr>
<tr>
<td>1386</td>
<td>Unintentional harmful effect of high-ceiling diuretics</td>
</tr>
<tr>
<td>1387</td>
<td>Unintentional exposure to or harmful effects of carbonic-anhydrase inhibitors</td>
</tr>
<tr>
<td>1388</td>
<td>Unintentional exposure to or harmful effects of benzothiadiazine derivatives</td>
</tr>
<tr>
<td>1389</td>
<td>Unintentional harmful effect of thiazides</td>
</tr>
<tr>
<td>1390</td>
<td>Unintentional exposure to or harmful effects of other diuretics</td>
</tr>
<tr>
<td>1391</td>
<td>Unintentional exposure to or harmful effects of electrolytic, caloric or water-balance agents</td>
</tr>
<tr>
<td>1392</td>
<td>Unintentional exposure to or harmful effects of mineral salts, not elsewhere classified</td>
</tr>
<tr>
<td>1393</td>
<td>Unintentional exposure to or harmful effects of drugs affecting uric acid metabolism</td>
</tr>
<tr>
<td>1394</td>
<td>Unintentional exposure to or harmful effects of vitamin D or derivatives</td>
</tr>
<tr>
<td>1395</td>
<td>Unintentional exposure to or harmful effects of bisphosphonates</td>
</tr>
<tr>
<td>1396</td>
<td>Unintentional exposure to or harmful effects of appetite depressants</td>
</tr>
<tr>
<td>1397</td>
<td>Unintentional exposure to or harmful effects of antidotes or chelating agents, not elsewhere classified</td>
</tr>
<tr>
<td>1398</td>
<td>Unintentional exposure to or harmful effects of disulfiram</td>
</tr>
<tr>
<td>1399</td>
<td>Unintentional exposure to or harmful effects of alcohol deterrents, not elsewhere classified</td>
</tr>
<tr>
<td>1400</td>
<td>Unintentional exposure to or harmful effects of X-ray contrast media</td>
</tr>
<tr>
<td>1401</td>
<td>Unintentional exposure to or harmful effects of MRI contrast agents</td>
</tr>
<tr>
<td>1402</td>
<td>Unintentional exposure to or harmful effects of agents used for other scanning techniques</td>
</tr>
<tr>
<td>1403</td>
<td>Unintentional exposure to or harmful effects of other diagnostic agents</td>
</tr>
<tr>
<td>1404</td>
<td>Unintentional exposure to or harmful effects of lipotropic drugs</td>
</tr>
<tr>
<td>1405</td>
<td>Unintentional exposure to or harmful effects of vitamins, not elsewhere classified, Pharmaceutical excipients</td>
</tr>
<tr>
<td>1406</td>
<td>Unintentional exposure to or harmful effects of herbal preparations or formulas</td>
</tr>
<tr>
<td>1407</td>
<td>Unintentional exposure to or harmful effects of dietary supplements, vitamins or minerals</td>
</tr>
<tr>
<td>1408</td>
<td>Unintentional exposure to or harmful effects of complementary or traditional medicines, not elsewhere classified</td>
</tr>
<tr>
<td>1409</td>
<td>Unintentional exposure to or harmful effects of complementary or traditional medicines, unspecified</td>
</tr>
<tr>
<td>1410</td>
<td>Unintentional exposure to or harmful effects of vaccines immunoglobulins or other biological substances</td>
</tr>
<tr>
<td>1411</td>
<td>Unintentional exposure to or harmful effects of BCG vaccine</td>
</tr>
<tr>
<td>1412</td>
<td>Unintentional exposure to or harmful effects of typhoid or paratyphoid vaccine</td>
</tr>
<tr>
<td>1413</td>
<td>Unintentional exposure to or harmful effects of cholera vaccine</td>
</tr>
<tr>
<td>1414</td>
<td>Unintentional exposure to or harmful effects of plague vaccine</td>
</tr>
<tr>
<td>1415</td>
<td>Unintentional exposure to or harmful effects of tetanus vaccine</td>
</tr>
<tr>
<td>1416</td>
<td>Unintentional exposure to or harmful effects of diphtheria vaccine</td>
</tr>
<tr>
<td>1417</td>
<td>Unintentional exposure to or harmful effects of Haemophilus influenzae type B vaccines</td>
</tr>
<tr>
<td>1418</td>
<td>Unintentional exposure to or harmful effects of pertussis vaccine, including combinations with a pertussis component</td>
</tr>
<tr>
<td>1419</td>
<td>Unintentional exposure to or harmful effects of mixed bacterial vaccines without a pertussis component</td>
</tr>
<tr>
<td>1420</td>
<td>Unintentional exposure to or harmful effects of other or unspecified bacterial vaccines</td>
</tr>
<tr>
<td>1421</td>
<td>Unintentional exposure to or harmful effects of smallpox vaccines</td>
</tr>
<tr>
<td>1422</td>
<td>Unintentional exposure to or harmful effects of measles vaccines</td>
</tr>
<tr>
<td>1423</td>
<td>Unintentional exposure to or harmful effects of mumps vaccines</td>
</tr>
<tr>
<td>1424</td>
<td>Unintentional exposure to or harmful effects of rubella vaccines</td>
</tr>
<tr>
<td>1425</td>
<td>Unintentional exposure to or harmful effects of polio vaccines</td>
</tr>
<tr>
<td>1426</td>
<td>Unintentional exposure to or harmful effects of yellow fever vaccines</td>
</tr>
<tr>
<td>1427</td>
<td>Unintentional exposure to or harmful effects of hepatitis A vaccines</td>
</tr>
<tr>
<td>1428</td>
<td>Unintentional exposure to or harmful effects of hepatitis B vaccines</td>
</tr>
<tr>
<td>1429</td>
<td>Unintentional exposure to or harmful effects of influenza vaccines</td>
</tr>
<tr>
<td>1430</td>
<td>Unintentional exposure to or harmful effects of rotavirus vaccines</td>
</tr>
<tr>
<td>1431</td>
<td>Unintentional exposure to or harmful effects of human papillomavirus vaccines</td>
</tr>
<tr>
<td>1432</td>
<td>Unintentional exposure to or harmful effects of other viral vaccines</td>
</tr>
<tr>
<td>1433</td>
<td>Unintentional exposure to or harmful effects of rickettsial vaccines</td>
</tr>
<tr>
<td>1434</td>
<td>Unintentional exposure to or harmful effects of protozoal vaccines</td>
</tr>
<tr>
<td>1435</td>
<td>Unintentional exposure to or harmful effects of hepatitis B immune globulin</td>
</tr>
<tr>
<td>1436</td>
<td>Unintentional exposure to or harmful effects of antivenin, antivenom</td>
</tr>
<tr>
<td>1437</td>
<td>Unintentional exposure to or harmful effects of immunoglobulin, not elsewhere classified</td>
</tr>
<tr>
<td>1438</td>
<td>Unintentional exposure to or harmful effects of other specified vaccines</td>
</tr>
<tr>
<td>1439</td>
<td>Unintentional exposure to or harmful effects of unspecified vaccines</td>
</tr>
<tr>
<td>1440</td>
<td>Toxic effects of methamphetamine</td>
</tr>
<tr>
<td>1441</td>
<td>Other specified acquired haemolytic anaemia, non-immune</td>
</tr>
<tr>
<td>1442</td>
<td>Infectious non-immune haemolytic anaemia</td>
</tr>
<tr>
<td>1443</td>
<td>Drug-induced nonautoimmune haemolytic anaemia</td>
</tr>
<tr>
<td>1444</td>
<td>nonautoimmune haemolytic anaemia due to drugs</td>
</tr>
<tr>
<td>1445</td>
<td>acquired nonautoimmune haemolytic anaemia due to drugs</td>
</tr>
<tr>
<td>1446</td>
<td>drug-induced enzyme deficiency anaemia</td>
</tr>
<tr>
<td>1447</td>
<td>Certain nonautoimmune haemolytic anaemias</td>
</tr>
<tr>
<td>1448</td>
<td>nonautoimmune haemolytic anaemia</td>
</tr>
<tr>
<td>1449</td>
<td>acquired nonautoimmune haemolytic anaemia</td>
</tr>
<tr>
<td>1450</td>
<td>symptomatic haemolytic anaemia</td>
</tr>
<tr>
<td>1451</td>
<td>secondary haemolytic anaemia</td>
</tr>
<tr>
<td>1452</td>
<td>Mechanical haemolytic anaemia</td>
</tr>
<tr>
<td>1453</td>
<td>Haemoglobinuria from exertion</td>
</tr>
<tr>
<td>1454</td>
<td>Haemoglobinuria from marching</td>
</tr>
<tr>
<td>1455</td>
<td>march haemoglobulinuria</td>
</tr>
<tr>
<td>1456</td>
<td>Toxic haemolytic anaemia</td>
</tr>
<tr>
<td>1457</td>
<td>acquired toxic haemolytic anaemia</td>
</tr>
<tr>
<td>1458</td>
<td>Acquired infectious haemolytic anaemia</td>
</tr>
<tr>
<td>1459</td>
<td>Shunt hyperbilirubinemia</td>
</tr>
<tr>
<td>1460</td>
<td>Israel shunt hyperbilirubinemia</td>
</tr>
<tr>
<td>1461</td>
<td>Erythrocyte fragmentation syndrome</td>
</tr>
<tr>
<td>1462</td>
<td>Atypical haemolytic uraemic syndrome with anti-factor H antibodies</td>
</tr>
<tr>
<td>1463</td>
<td>Bacteraemia</td>
</tr>
<tr>
<td>1464</td>
<td>Bacteraemia NOS</td>
</tr>
<tr>
<td>1465</td>
<td>Staphylococcus aureus bacteraemia</td>
</tr>
<tr>
<td>1466</td>
<td>Septicaemia</td>
</tr>
<tr>
<td>1467</td>
<td>group d streptococcal septicaemia (deprecated)</td>
</tr>
<tr>
<td>1468</td>
<td>anaerobic septicaemia (deprecated)</td>
</tr>
<tr>
<td>1469</td>
<td>Escherichia coli septicaemia (deprecated)</td>
</tr>
<tr>
<td>1470</td>
<td>gangrenous septicaemia (deprecated)</td>
</tr>
<tr>
<td>1471</td>
<td>gram-negative septicaemia NOS (deprecated)</td>
</tr>
<tr>
<td>1472</td>
<td>pneumococcal septicaemia (deprecated)</td>
</tr>
<tr>
<td>1473</td>
<td>salmonella septicaemia (deprecated)</td>
</tr>
<tr>
<td>1474</td>
<td>septicaemia due to anaerobes (deprecated)</td>
</tr>
<tr>
<td>1475</td>
<td>septicaemia due to coagulase-negative staphylococcus (deprecated)</td>
</tr>
<tr>
<td>1476</td>
<td>septicaemia due to haemophilus influenzae [h. influenzae] (deprecated)</td>
</tr>
<tr>
<td>1477</td>
<td>septicaemia due to streptococcus group A (deprecated)</td>
</tr>
<tr>
<td>1478</td>
<td>septicaemia due to streptococcus group B (deprecated)</td>
</tr>
<tr>
<td>1479</td>
<td>septicaemic colibacillosis (deprecated)</td>
</tr>
<tr>
<td>1480</td>
<td>staphylococcal septicaemia NOS (deprecated)</td>
</tr>
<tr>
<td>1481</td>
<td>staphylococcus aureus septicaemia NOS (deprecated)</td>
</tr>
<tr>
<td>1482</td>
<td>streptococcal septicaemia (deprecated)</td>
</tr>
<tr>
<td>1483</td>
<td>streptococcus pyogenes septicaemia (deprecated)</td>
</tr>
<tr>
<td>1484</td>
<td>streptococcaemia (deprecated)</td>
</tr>
<tr>
<td>1485</td>
<td>pyaemia (deprecated)</td>
</tr>
<tr>
<td>1486</td>
<td>listerial septicaemia (deprecated)</td>
</tr>
<tr>
<td>1487</td>
<td>Listeria monocytogenes septicaemia (deprecated)</td>
</tr>
<tr>
<td>1488</td>
<td>Listeria monocytogenes septicaemia without mention of septic shock (deprecated)</td>
</tr>
<tr>
<td>1489</td>
<td>actinomycotic septicaemia (deprecated)</td>
</tr>
<tr>
<td>1490</td>
<td>anthrax septicaemia (deprecated)</td>
</tr>
<tr>
<td>1491</td>
<td>Septicaemic plague NOS (deprecated)</td>
</tr>
<tr>
<td>1492</td>
<td>septic plague (deprecated)</td>
</tr>
<tr>
<td>1493</td>
<td>Septicaemic plague (deprecated)</td>
</tr>
<tr>
<td>1494</td>
<td>septicaemic plague without mention of septic shock (deprecated)</td>
</tr>
<tr>
<td>1495</td>
<td>E coli septicaemia (deprecated)</td>
</tr>
<tr>
<td>1496</td>
<td>Pseudomonas aeruginosa septicaemia (deprecated)</td>
</tr>
<tr>
<td>1497</td>
<td>Intentional self-harm by exposure to other or unspecified drug, medicament or biological substance</td>
</tr>
<tr>
<td>1498</td>
<td>Intentional self-poisoning by and exposure to other or unspecified drug, medicament or biological substance</td>
</tr>
<tr>
<td>1499</td>
<td>Intentional overdose of other or unspecified drug, medicament or biological substance</td>
</tr>
<tr>
<td>1500</td>
<td>self-administered overdose by drugs</td>
</tr>
<tr>
<td>1501</td>
<td>Intentional self-harm by exposure to or harmful effects of systemic antibiotics</td>
</tr>
<tr>
<td>1502</td>
<td>Intentional overdose of systemic antibiotics</td>
</tr>
<tr>
<td>1503</td>
<td>Intentional self-poisoning by exposure to or harmful effects of systemic antibiotics</td>
</tr>
<tr>
<td>1504</td>
<td>Intentional self-harm by exposure to or harmful effects of penicillins</td>
</tr>
<tr>
<td>1505</td>
<td>Intentional overdose of penicillins</td>
</tr>
<tr>
<td>1506</td>
<td>Intentional self-poisoning by exposure to or harmful effects of penicillins</td>
</tr>
<tr>
<td>1507</td>
<td>Intentional self-harm by exposure to or harmful effects of cephalosporins or other beta-lactam antibiotics</td>
</tr>
<tr>
<td>1508</td>
<td>Intentional overdose of cephalosporins or other beta-lactam antibiotics</td>
</tr>
<tr>
<td>1509</td>
<td>Intentional self-poisoning by exposure to or harmful effects of cephalosporins or other beta-lactam antibiotics</td>
</tr>
<tr>
<td>1510</td>
<td>Intentional self-harm by exposure to or harmful effects of chloramphenicol group</td>
</tr>
<tr>
<td>1511</td>
<td>Intentional overdose of chloramphenicol group</td>
</tr>
<tr>
<td>1512</td>
<td>Intentional self-poisoning by exposure to or harmful effects of chloramphenicol group</td>
</tr>
<tr>
<td>1513</td>
<td>Intentional self-harm by exposure to or harmful effects of macrolides</td>
</tr>
<tr>
<td>1514</td>
<td>Intentional overdose of macrolides</td>
</tr>
<tr>
<td>1515</td>
<td>Intentional self-poisoning by exposure to or harmful effects of macrolides</td>
</tr>
<tr>
<td>1516</td>
<td>Intentional self-harm by exposure to or harmful effects of tetracyclines</td>
</tr>
<tr>
<td>1517</td>
<td>Intentional overdose of tetracyclines</td>
</tr>
<tr>
<td>1518</td>
<td>Intentional self-poisoning by exposure to or harmful effects of tetracyclines</td>
</tr>
<tr>
<td>1519</td>
<td>Intentional self-harm by exposure to or harmful effects of aminoglycosides</td>
</tr>
<tr>
<td>1520</td>
<td>Intentional overdose of aminoglycosides</td>
</tr>
<tr>
<td>1521</td>
<td>Intentional self-poisoning by exposure to or harmful effects of aminoglycosides</td>
</tr>
<tr>
<td>1522</td>
<td>Intentional self-harm by exposure to or harmful effects of rifampicin</td>
</tr>
<tr>
<td>1523</td>
<td>Intentional overdose of rifampicins</td>
</tr>
<tr>
<td>1524</td>
<td>Intentional self-poisoning by exposure to or harmful effects of rifampicins</td>
</tr>
<tr>
<td>1525</td>
<td>Intentional self-harm by exposure to or harmful effects of antifungal antibiotics, systemically used</td>
</tr>
<tr>
<td>1526</td>
<td>Intentional overdose of antifungal antibiotics, systemically used</td>
</tr>
<tr>
<td>1527</td>
<td>Intentional self-poisoning by exposure to or harmful effects of antifungal antibiotics, systemically used</td>
</tr>
<tr>
<td>1528</td>
<td>Intentional self-harm by exposure to or harmful effects of other systemic anti-infectives or antiparasitics</td>
</tr>
<tr>
<td>1529</td>
<td>Intentional overdose of other systemic anti-infectives or antiparasitics</td>
</tr>
<tr>
<td>1530</td>
<td>Intentional self-poisoning by exposure to or harmful effects of other systemic anti-infectives or antiparasitics</td>
</tr>
<tr>
<td>1531</td>
<td>Intentional self-harm by exposure to or harmful effects of sulfonamides</td>
</tr>
<tr>
<td>1532</td>
<td>Intentional overdose of sulfonamides</td>
</tr>
<tr>
<td>1533</td>
<td>Intentional self-poisoning by exposure to or harmful effects of sulfonamides</td>
</tr>
<tr>
<td>1534</td>
<td>Intentional self-harm by exposure to or harmful effects of antimycobacterial drugs</td>
</tr>
<tr>
<td>1535</td>
<td>Intentional overdose of antimycobacterial drugs</td>
</tr>
<tr>
<td>1536</td>
<td>Intentional self-poisoning by exposure to or harmful effects of antimycobacterial drugs</td>
</tr>
<tr>
<td>1537</td>
<td>Intentional self-harm by exposure to or harmful effects of antimalarials or drugs acting on other blood protozoa</td>
</tr>
<tr>
<td>1538</td>
<td>Intentional overdose of antimalarials or drugs acting on other blood protozoa</td>
</tr>
<tr>
<td>1539</td>
<td>Intentional self-poisoning by exposure to or harmful effects of antimalarials or drugs acting on other blood protozoa</td>
</tr>
<tr>
<td>1540</td>
<td>Intentional self-harm by exposure to or harmful effects of other antiprotozoal drugs</td>
</tr>
<tr>
<td>1541</td>
<td>Intentional overdose of other antiprotozoal drugs</td>
</tr>
<tr>
<td>1542</td>
<td>Intentional self-poisoning by exposure to or harmful effects of other antiprotozoal drugs</td>
</tr>
<tr>
<td>1543</td>
<td>Intentional self-harm by exposure to or harmful effects of anthelminthics</td>
</tr>
<tr>
<td>1544</td>
<td>Intentional overdose of anthelminthics</td>
</tr>
<tr>
<td>1545</td>
<td>Intentional self-poisoning by exposure to or harmful effects of anthelminthics</td>
</tr>
<tr>
<td>1546</td>
<td>Intentional self-harm by exposure to or harmful effects of antiviral drugs</td>
</tr>
<tr>
<td>1547</td>
<td>Intentional overdose of antiviral drugs</td>
</tr>
<tr>
<td>1548</td>
<td>Intentional self-poisoning by exposure to or harmful effects of antiviral drugs</td>
</tr>
<tr>
<td>1549</td>
<td>Intentional self-harm by exposure to or harmful effects of hormones or their synthetic substitutes or antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>1550</td>
<td>hormones and synthetic substitutes</td>
</tr>
<tr>
<td>1551</td>
<td>Intentional overdose of hormones or their synthetic substitutes or antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>1552</td>
<td>Intentional self-poisoning by exposure to or harmful effects of hormones or their synthetic substitutes or antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>1553</td>
<td>Intentional self-harm by exposure to or harmful effects of glucocorticoids or synthetic analogues</td>
</tr>
<tr>
<td>1554</td>
<td>Intentional overdose of glucocorticoids or synthetic analogues</td>
</tr>
<tr>
<td>1555</td>
<td>Intentional self-poisoning by exposure to or harmful effects of glucocorticoids or synthetic analogues</td>
</tr>
<tr>
<td>1556</td>
<td>Intentional self-harm by exposure to or harmful effects of thyroid hormones or substitutes</td>
</tr>
<tr>
<td>1557</td>
<td>Intentional overdose of thyroid hormones or substitutes</td>
</tr>
<tr>
<td>1558</td>
<td>Intentional self-poisoning by exposure to or harmful effects of thyroid hormones or substitutes</td>
</tr>
<tr>
<td>1559</td>
<td>Intentional self-harm by exposure to or harmful effects of antithyroid drugs</td>
</tr>
<tr>
<td>1560</td>
<td>Intentional overdose of antithyroid drugs</td>
</tr>
<tr>
<td>1561</td>
<td>Intentional self-poisoning by exposure to or harmful effects of antithyroid drugs</td>
</tr>
<tr>
<td>1562</td>
<td>Intentional self-harm by exposure to or harmful effects of insulin or oral hypoglycaemic drugs</td>
</tr>
<tr>
<td>1563</td>
<td>Intentional overdose of insulin or oral hypoglycaemic drugs</td>
</tr>
<tr>
<td>1564</td>
<td>Intentional harmful effect of antidiabetic drugs</td>
</tr>
<tr>
<td>1565</td>
<td>Intentional self-poisoning by exposure to or harmful effects of insulin or oral hypoglycaemic drugs</td>
</tr>
<tr>
<td>1566</td>
<td>Intentional self-harm by exposure to or harmful effects of oral contraceptives</td>
</tr>
<tr>
<td>1567</td>
<td>Intentional overdose of oral contraceptives</td>
</tr>
<tr>
<td>1568</td>
<td>Intentional self-poisoning by exposure to or harmful effects of oral contraceptives</td>
</tr>
<tr>
<td>1569</td>
<td>Intentional self-harm by exposure to or harmful effects of other estrogens or progestogens</td>
</tr>
<tr>
<td>1570</td>
<td>Intentional overdose of other estrogens or progestogens</td>
</tr>
<tr>
<td>1571</td>
<td>Intentional self-poisoning by exposure to or harmful effects of other estrogens or progestogens</td>
</tr>
<tr>
<td>1572</td>
<td>Intentional self-harm by exposure to or harmful effects of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified</td>
</tr>
<tr>
<td>1573</td>
<td>Intentional overdose of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified</td>
</tr>
<tr>
<td>1574</td>
<td>Intentional self-poisoning by exposure to or harmful effects of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified</td>
</tr>
<tr>
<td>1575</td>
<td>Intentional self-harm by exposure to or harmful effects of androgens or anabolic congeners</td>
</tr>
<tr>
<td>1576</td>
<td>Intentional overdose of androgens or anabolic congeners</td>
</tr>
<tr>
<td>1577</td>
<td>Intentional self-poisoning by exposure to or harmful effects of androgens or anabolic congeners</td>
</tr>
<tr>
<td>1578</td>
<td>Intentional self-harm by exposure to or harmful effects of unspecified hormones or synthetic substitutes</td>
</tr>
<tr>
<td>1579</td>
<td>Intentional overdose of unspecified hormones or synthetic substitutes</td>
</tr>
<tr>
<td>1580</td>
<td>Intentional self-poisoning by exposure to or harmful effects of unspecified hormones or synthetic substitutes</td>
</tr>
<tr>
<td>1581</td>
<td>Intentional self-harm by exposure to or harmful effects of anterior pituitary hormones</td>
</tr>
<tr>
<td>1582</td>
<td>Intentional self harm by adenohypophyseal hormones</td>
</tr>
<tr>
<td>1583</td>
<td>Intentional overdose of anterior pituitary hormones</td>
</tr>
<tr>
<td>1584</td>
<td>Intentional self-harm by exposure to or harmful effects of other hormones or synthetic substitutes</td>
</tr>
<tr>
<td>1585</td>
<td>Intentional overdose of other hormones or synthetic substitutes</td>
</tr>
<tr>
<td>1586</td>
<td>Intentional self-poisoning by exposure to or harmful effects of other hormones or synthetic substitutes</td>
</tr>
<tr>
<td>1587</td>
<td>Intentional self-harm by exposure to or harmful effects of unspecified hormone antagonists</td>
</tr>
<tr>
<td>1588</td>
<td>Intentional overdose of unspecified hormone antagonists</td>
</tr>
<tr>
<td>1589</td>
<td>Intentional self-poisoning by exposure to or harmful effects of unspecified hormone antagonists</td>
</tr>
<tr>
<td>1590</td>
<td>Intentional self-harm by exposure to or harmful effects of other hormone antagonists</td>
</tr>
<tr>
<td>1591</td>
<td>Intentional overdose of other hormone antagonists</td>
</tr>
<tr>
<td>1592</td>
<td>Intentional self-poisoning by exposure to or harmful effects of other hormone antagonists</td>
</tr>
<tr>
<td>1593</td>
<td>Intentional self-harm by exposure to or harmful effects of drugs primarily affecting the autonomic nervous system</td>
</tr>
<tr>
<td>1594</td>
<td>Intentional self-poisoning by exposure to or harmful effects of drugs primarily affecting the autonomic nervous system</td>
</tr>
<tr>
<td>1595</td>
<td>Intentional overdose of drugs primarily affecting the autonomic nervous system</td>
</tr>
<tr>
<td>1596</td>
<td>Intentional self-harm by exposure to or harmful effects of anticholinesterase agents</td>
</tr>
<tr>
<td>1597</td>
<td>Intentional overdose of anticholinesterase agents</td>
</tr>
<tr>
<td>1598</td>
<td>Intentional self-poisoning by exposure to or harmful effects of anticholinesterase agents</td>
</tr>
<tr>
<td>1599</td>
<td>Intentional self-harm by exposure to or harmful effects of other parasympathomimetics</td>
</tr>
<tr>
<td>1600</td>
<td>Intentional overdose of other parasympathomimetics</td>
</tr>
<tr>
<td>1601</td>
<td>Intentional self-poisoning by exposure to or harmful effects of other parasympathomimetics</td>
</tr>
<tr>
<td>1602</td>
<td>Intentional self harm of cholinergics</td>
</tr>
<tr>
<td>1603</td>
<td>Intentional self-harm by exposure to or harmful effects of ganglionic blocking drugs</td>
</tr>
<tr>
<td>1604</td>
<td>Intentional overdose of ganglionic blocking drugs</td>
</tr>
<tr>
<td>1605</td>
<td>Intentional self-poisoning by exposure to or harmful effects of ganglionic blocking drugs</td>
</tr>
<tr>
<td>1606</td>
<td>Intentional self-harm by exposure to or harmful effects of other parasympatholytics or spasmolytics</td>
</tr>
<tr>
<td>1607</td>
<td>Intentional overdose of other parasympatholytics or spasmolytics</td>
</tr>
<tr>
<td>1608</td>
<td>Intentional self-poisoning by exposure to or harmful effects of other parasympatholytics or spasmolytics</td>
</tr>
<tr>
<td>1609</td>
<td>Intentional self harm by anticholinergics or antimuscarinics</td>
</tr>
<tr>
<td>1610</td>
<td>Intentional self-harm by exposure to or harmful effects of predominantly alpha-adrenoreceptor agonists</td>
</tr>
<tr>
<td>1611</td>
<td>Intentional overdose of predominantly alpha-adrenoreceptor agonists</td>
</tr>
<tr>
<td>1612</td>
<td>Intentional self-poisoning by exposure to or harmful effects of predominantly alpha-adrenoreceptor agonists</td>
</tr>
<tr>
<td>1613</td>
<td>Intentional self-harm by exposure to or harmful effects of predominantly beta-adrenoreceptor agonists</td>
</tr>
<tr>
<td>1614</td>
<td>Intentional overdose of predominantly beta-adrenoreceptor agonists</td>
</tr>
<tr>
<td>1615</td>
<td>Intentional self-harm by exposure to or harmful effects of alpha-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>1616</td>
<td>Intentional overdose of alpha-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>1617</td>
<td>Intentional self-poisoning by exposure to or harmful effects of alpha-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>1618</td>
<td>Intentional self-harm by exposure to or harmful effects of beta-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>1619</td>
<td>Intentional overdose of beta-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>1620</td>
<td>Intentional self-poisoning by exposure to or harmful effects of beta-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>1621</td>
<td>Intentional self-harm by exposure to or harmful effects of centrally-acting or adrenergic-neuron-blocking agents</td>
</tr>
<tr>
<td>1622</td>
<td>Intentional overdose of centrally-acting or adrenergic-neuron-blocking agents</td>
</tr>
<tr>
<td>1623</td>
<td>Intentional self-poisoning by exposure to or harmful effects of centrally-acting or adrenergic-neuron-blocking agents</td>
</tr>
<tr>
<td>1624</td>
<td>Intentional self-poisoning by and exposure to other drugs acting on the autonomic nervous system</td>
</tr>
<tr>
<td>1625</td>
<td>Intentional self poisoning with or exposure to agents primarily affecting blood constituents</td>
</tr>
<tr>
<td>1626</td>
<td>Intentional self-harm by exposure to or harmful effects of diphenhydramine</td>
</tr>
<tr>
<td>1627</td>
<td>Intentional overdose of diphenhydramine</td>
</tr>
<tr>
<td>1628</td>
<td>Intentional self-poisoning by exposure to or harmful effects of diphenhydramine</td>
</tr>
<tr>
<td>1629</td>
<td>Intentional self-harm by exposure to or harmful effects of other H1-receptor antagonists</td>
</tr>
<tr>
<td>1630</td>
<td>Intentional self-poisoning by exposure to or harmful effects of other H1-receptor antagonists</td>
</tr>
<tr>
<td>1631</td>
<td>Intentional overdose of other H1-receptor antagonists</td>
</tr>
<tr>
<td>1632</td>
<td>Intentional self-harm by exposure to or harmful effects of antiallergic or antiemetic drugs</td>
</tr>
<tr>
<td>1633</td>
<td>Intentional overdose of antiallergic or antiemetic drugs</td>
</tr>
<tr>
<td>1634</td>
<td>Intentional self-poisoning by exposure to or harmful effects of antiallergic or antiemetic drugs</td>
</tr>
<tr>
<td>1635</td>
<td>Intentional self-harm by exposure to or harmful effects of antineoplastic antimetabolites</td>
</tr>
<tr>
<td>1636</td>
<td>Intentional overdose of antineoplastic antimetabolites</td>
</tr>
<tr>
<td>1637</td>
<td>Intentional self-poisoning by exposure to or harmful effects of antineoplastic antimetabolites</td>
</tr>
<tr>
<td>1638</td>
<td>Intentional self-harm by exposure to or harmful effects of antineoplastic natural products</td>
</tr>
<tr>
<td>1639</td>
<td>Intentional overdose of antineoplastic natural products</td>
</tr>
<tr>
<td>1640</td>
<td>Intentional self-poisoning by exposure to or harmful effects of antineoplastic natural products</td>
</tr>
<tr>
<td>1641</td>
<td>Intentional self-harm by exposure to or harmful effects of other antineoplastic drugs</td>
</tr>
<tr>
<td>1642</td>
<td>Intentional overdose of other antineoplastic drugs</td>
</tr>
<tr>
<td>1643</td>
<td>Intentional self-poisoning by exposure to or harmful effects of other antineoplastic drugs</td>
</tr>
<tr>
<td>1644</td>
<td>Intentional self-harm by exposure to or harmful effects of immunosuppressive agents</td>
</tr>
<tr>
<td>1645</td>
<td>Intentional overdose of immunosuppressive agents</td>
</tr>
<tr>
<td>1646</td>
<td>Intentional self-poisoning by exposure to or harmful effects of immunosuppressive agents</td>
</tr>
<tr>
<td>1647</td>
<td>Intentional self-harm by exposure to or harmful effects of vitamin B12, folic acid or other anti-megaloblastic-anaemia preparations</td>
</tr>
<tr>
<td>1648</td>
<td>Intentional overdose of vitamin B12, folic acid or other anti-megaloblastic-anaemia preparations</td>
</tr>
<tr>
<td>1649</td>
<td>Intentional self-poisoning by exposure to or harmful effects of vitamin B12, folic acid or other anti-megaloblastic-anaemia preparations</td>
</tr>
<tr>
<td>1650</td>
<td>Intentional self-harm by exposure to or harmful effects of enzymes</td>
</tr>
<tr>
<td>1651</td>
<td>Intentional overdose of enzymes</td>
</tr>
<tr>
<td>1652</td>
<td>Intentional self-poisoning by exposure to or harmful effects of enzymes</td>
</tr>
<tr>
<td>1653</td>
<td>Intentional self-harm by exposure to or harmful effects of iron or its compounds</td>
</tr>
<tr>
<td>1654</td>
<td>Intentional self-harm by exposure to or harmful effects of anticoagulants</td>
</tr>
<tr>
<td>1655</td>
<td>Intentional self-harm by exposure to or harmful effects of antithrombotic drugs</td>
</tr>
<tr>
<td>1656</td>
<td>Intentional self harm by platelet aggregation inhibitors</td>
</tr>
<tr>
<td>1657</td>
<td>Intentional self-harm by exposure to or harmful effects of thrombolytic drug</td>
</tr>
<tr>
<td>1658</td>
<td>Intentional self-harm by exposure to or harmful effects of anticoagulant antagonists, vitamin K or other coagulants</td>
</tr>
<tr>
<td>1659</td>
<td>Intentional self-harm by exposure to or harmful effects of other fibrinolysis-affecting drugs</td>
</tr>
<tr>
<td>1660</td>
<td>Intentional self-harm by exposure to or harmful effects of natural blood or blood products</td>
</tr>
<tr>
<td>1661</td>
<td>Intentional self-harm by exposure to or harmful effects of acidifying or alkalising agents</td>
</tr>
<tr>
<td>1662</td>
<td>Intentional self-harm by exposure to or harmful effects of other primarily systemic agents, not elsewhere classified</td>
</tr>
<tr>
<td>1663</td>
<td>Intentional self-harm by exposure to or harmful effects of plasma substitutes</td>
</tr>
<tr>
<td>1664</td>
<td>Intentional self-harm by exposure to or harmful effects of agents primarily affecting the cardiovascular system</td>
</tr>
<tr>
<td>1665</td>
<td>drugs affecting the cardiovascular system</td>
</tr>
<tr>
<td>1666</td>
<td>Intentional self-harm by exposure to or harmful effects of cardiac-stimulant glycosides or drugs of similar action</td>
</tr>
<tr>
<td>1667</td>
<td>Intentional self-harm by exposure to or harmful effects of calcium-channel blockers</td>
</tr>
<tr>
<td>1668</td>
<td>Intentional self-harm by exposure to or harmful effects of other antidysrhythmic drugs</td>
</tr>
<tr>
<td>1669</td>
<td>Intentional self-harm by exposure to or harmful effects of nitroglycerin, nitroglycerol, medicinal</td>
</tr>
<tr>
<td>1670</td>
<td>Intentional self-harm by exposure to or harmful effects of other coronary vasodilators</td>
</tr>
<tr>
<td>1671</td>
<td>Intentional self-harm by exposure to or harmful effects of angiotensin-converting-enzyme inhibitors</td>
</tr>
<tr>
<td>1672</td>
<td>Intentional self-harm by exposure to or harmful effects of other antihypertensive drugs</td>
</tr>
<tr>
<td>1673</td>
<td>Intentional self-harm by exposure to or harmful effects of antihyperlipidemic or antiarteriosclerotic drugs</td>
</tr>
<tr>
<td>1674</td>
<td>Intentional self-harm by exposure to or harmful effects of peripheral vasodilators</td>
</tr>
<tr>
<td>1675</td>
<td>Intentional self-harm by exposure to or harmful effects of antivaricose drugs, including sclerosing agents</td>
</tr>
<tr>
<td>1676</td>
<td>Intentional self-harm by exposure to or harmful effects of agents primarily affecting the gastrointestinal system</td>
</tr>
<tr>
<td>1677</td>
<td>drugs affecting the: gastrointestinal system</td>
</tr>
<tr>
<td>1678</td>
<td>Intentional self-harm by exposure to or harmful effects of histamine H2-receptor blockers</td>
</tr>
<tr>
<td>1679</td>
<td>Intentional self-harm by exposure to or harmful effects of other antacids or anti-gastric-secretion drugs</td>
</tr>
<tr>
<td>1680</td>
<td>Intentional self-harm by exposure to or harmful effects of stimulant laxatives</td>
</tr>
<tr>
<td>1681</td>
<td>Intentional self-harm by exposure to or harmful effects of saline or osmotic laxatives</td>
</tr>
<tr>
<td>1682</td>
<td>Intentional self-harm by exposure to or harmful effects of other laxatives</td>
</tr>
<tr>
<td>1683</td>
<td>Intentional self-harm by exposure to or harmful effects of digestants</td>
</tr>
<tr>
<td>1684</td>
<td>Intentional self-harm by exposure to or harmful effects of antidiarrhoeal drugs</td>
</tr>
<tr>
<td>1685</td>
<td>Intentional self-harm by exposure to or harmful effects of emetics</td>
</tr>
<tr>
<td>1686</td>
<td>Intentional self-harm by exposure to or harmful effects of topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs</td>
</tr>
<tr>
<td>1687</td>
<td>Intentional self-harm by exposure to or harmful effects of topical corticosteroid preparations</td>
</tr>
<tr>
<td>1688</td>
<td>Intentional self-harm by exposure to or harmful effects of iodine, antiseptic</td>
</tr>
<tr>
<td>1689</td>
<td>Intentional self-harm by exposure to or harmful effects of silver nitrate</td>
</tr>
<tr>
<td>1690</td>
<td>Intentional self-harm by exposure to or harmful effects of other local antifungal, anti-infective or anti-inflammatory drugs</td>
</tr>
<tr>
<td>1691</td>
<td>Intentional self-harm by exposure to or harmful effects of antipruritics</td>
</tr>
<tr>
<td>1692</td>
<td>Intentional self-harm by exposure to or harmful effects of methyl salicylate</td>
</tr>
<tr>
<td>1693</td>
<td>Intentional self-harm by exposure to or harmful effects of other local astringents or local detergents</td>
</tr>
<tr>
<td>1694</td>
<td>Intentional self-harm by exposure to or harmful effects of emollients, demulcents or protectants</td>
</tr>
<tr>
<td>1695</td>
<td>Intentional self-harm by exposure to or harmful effects of podophyllin</td>
</tr>
<tr>
<td>1696</td>
<td>Intentional self-harm by exposure to or harmful effects of keratolytics, keratoplastics, or other hair treatment drugs or preparations</td>
</tr>
<tr>
<td>1697</td>
<td>Intentional self-harm by exposure to or harmful effects of ophthalmological drugs or preparations</td>
</tr>
<tr>
<td>1698</td>
<td>Intentional self-harm by exposure to or harmful effects of otorhinolaryngological drugs or preparations</td>
</tr>
<tr>
<td>1699</td>
<td>Intentional self-harm by exposure to or harmful effects of fluoride preparations</td>
</tr>
<tr>
<td>1700</td>
<td>Intentional self-harm by exposure to or harmful effects of other dental drugs, topically applied</td>
</tr>
<tr>
<td>1701</td>
<td>Intentional self-harm by exposure to or harmful effects of camphor</td>
</tr>
<tr>
<td>1702</td>
<td>Intentional self-harm by exposure to or harmful effects of agents primarily acting on smooth or skeletal muscles or the respiratory system</td>
</tr>
<tr>
<td>1703</td>
<td>Intentional self-harm by exposure to or harmful effects of oxytocic drugs</td>
</tr>
<tr>
<td>1704</td>
<td>Intentional self-harm by exposure to or harmful effects of skeletal muscle relaxants</td>
</tr>
<tr>
<td>1705</td>
<td>Intentional self harm by neuromuscular blocking agents</td>
</tr>
<tr>
<td>1706</td>
<td>Intentional self-harm by exposure to or harmful effects of other drugs acting on muscles</td>
</tr>
<tr>
<td>1707</td>
<td>Intentional self-harm by exposure to or harmful effects of unspecified drugs acting on muscles</td>
</tr>
<tr>
<td>1708</td>
<td>Intentional self-harm by exposure to or harmful effects of antitussives</td>
</tr>
<tr>
<td>1709</td>
<td>Intentional self-harm by exposure to or harmful effects of expectorants</td>
</tr>
<tr>
<td>1710</td>
<td>Intentional self-harm by exposure to or harmful effects of other anti-common-cold drugs</td>
</tr>
<tr>
<td>1711</td>
<td>Intentional self-harm by exposure to or harmful effects of salbutamol</td>
</tr>
<tr>
<td>1712</td>
<td>Intentional self-harm by exposure to or harmful effects of aminophylline, theophylline</td>
</tr>
<tr>
<td>1713</td>
<td>Intentional self-harm by exposure to or harmful effects of terbutaline</td>
</tr>
<tr>
<td>1714</td>
<td>Intentional self-harm by exposure to or harmful effects of antiasthmatics, not elsewhere classified</td>
</tr>
<tr>
<td>1715</td>
<td>Intentional self-harm by exposure to or harmful effects of agents primarily affecting water-balance or mineral or uric acid metabolism</td>
</tr>
<tr>
<td>1716</td>
<td>Intentional self-harm by exposure to or harmful effects of mineralocorticoids</td>
</tr>
<tr>
<td>1717</td>
<td>Intentional self-harm by exposure to or harmful effects of mineralocorticoids antagonists</td>
</tr>
<tr>
<td>1718</td>
<td>Intentional self-harm by exposure to or harmful effects of Loop diuretics</td>
</tr>
<tr>
<td>1719</td>
<td>Intentional self harm by high-ceiling diuretics</td>
</tr>
<tr>
<td>1720</td>
<td>Intentional self-harm by exposure to or harmful effects of carbonic-anhydrase inhibitors</td>
</tr>
<tr>
<td>1721</td>
<td>Intentional self-harm by exposure to or harmful effects of benzothiadiazine derivatives</td>
</tr>
<tr>
<td>1722</td>
<td>Intentional self harm by thiazides</td>
</tr>
<tr>
<td>1723</td>
<td>Intentional self-harm by exposure to or harmful effects of other diuretics</td>
</tr>
<tr>
<td>1724</td>
<td>Intentional self-harm by exposure to or harmful effects of electrolytic, caloric or water-balance agents</td>
</tr>
<tr>
<td>1725</td>
<td>Intentional self-harm by exposure to or harmful effects of mineral salts, not elsewhere classified</td>
</tr>
<tr>
<td>1726</td>
<td>Intentional self-harm by exposure to or harmful effects of drugs affecting uric acid metabolism</td>
</tr>
<tr>
<td>1727</td>
<td>Intentional self-harm by exposure to or harmful effects of vitamin D or derivatives</td>
</tr>
<tr>
<td>1728</td>
<td>Intentional self-harm by exposure to or harmful effects of bisphosphonates</td>
</tr>
<tr>
<td>1729</td>
<td>Intentional self-harm by exposure to or harmful effects of appetite depressants</td>
</tr>
<tr>
<td>1730</td>
<td>Intentional self-harm by exposure to or harmful effects of antidotes or chelating agents, not elsewhere classified</td>
</tr>
<tr>
<td>1731</td>
<td>Intentional self-harm by exposure to or harmful effects of disulfiram</td>
</tr>
<tr>
<td>1732</td>
<td>Intentional self-harm by exposure to or harmful effects of alcohol deterrents, not elsewhere classified</td>
</tr>
<tr>
<td>1733</td>
<td>Intentional self-harm by exposure to or harmful effects of X-ray contrast media</td>
</tr>
<tr>
<td>1734</td>
<td>Intentional self-harm by exposure to or harmful effects of MRI contrast agents</td>
</tr>
<tr>
<td>1735</td>
<td>Intentional self-harm by exposure to or harmful effects of agents used for other scanning techniques</td>
</tr>
<tr>
<td>1736</td>
<td>Intentional self-harm by exposure to or harmful effects of other diagnostic agents</td>
</tr>
<tr>
<td>1737</td>
<td>Intentional self-harm by exposure to or harmful effects of lipotropic drugs</td>
</tr>
<tr>
<td>1738</td>
<td>Intentional self-harm by exposure to or harmful effects of vitamins, not elsewhere classified, Pharmaceutical excipients</td>
</tr>
<tr>
<td>1739</td>
<td>Intentional self-harm by exposure to or harmful effects of herbal preparations or formulas</td>
</tr>
<tr>
<td>1740</td>
<td>Intentional self-harm by exposure to or harmful effects of dietary supplements, vitamins or minerals</td>
</tr>
<tr>
<td>1741</td>
<td>Intentional self-harm by exposure to or harmful effects of complementary or traditional medicines, not elsewhere classified</td>
</tr>
<tr>
<td>1742</td>
<td>Intentional self-harm by exposure to or harmful effects of complementary or traditional medicines, unspecified</td>
</tr>
<tr>
<td>1743</td>
<td>Intentional self-harm by exposure to or harmful effects of vaccines immunoglobulins or other biological substances</td>
</tr>
<tr>
<td>1744</td>
<td>Intentional self-harm by exposure to or harmful effects of BCG vaccine</td>
</tr>
<tr>
<td>1745</td>
<td>Intentional self-harm by exposure to or harmful effects of typhoid or paratyphoid vaccine</td>
</tr>
<tr>
<td>1746</td>
<td>Intentional self-harm by exposure to or harmful effects of cholera vaccine</td>
</tr>
<tr>
<td>1747</td>
<td>Intentional self-harm by exposure to or harmful effects of plague vaccine</td>
</tr>
<tr>
<td>1748</td>
<td>Intentional self-harm by exposure to or harmful effects of tetanus vaccine</td>
</tr>
<tr>
<td>1749</td>
<td>Intentional self-harm by exposure to or harmful effects of diphtheria vaccine</td>
</tr>
<tr>
<td>1750</td>
<td>Intentional self-harm by exposure to or harmful effects of Haemophilus influenzae type B vaccines</td>
</tr>
<tr>
<td>1751</td>
<td>Intentional self-harm by exposure to or harmful effects of pertussis vaccine, including combinations with a pertussis component</td>
</tr>
<tr>
<td>1752</td>
<td>Intentional self-harm by exposure to or harmful effects of mixed bacterial vaccines without a pertussis component</td>
</tr>
<tr>
<td>1753</td>
<td>Intentional self-harm by exposure to or harmful effects of other or unspecified bacterial vaccines</td>
</tr>
<tr>
<td>1754</td>
<td>Intentional self-harm by exposure to or harmful effects of smallpox vaccines</td>
</tr>
<tr>
<td>1755</td>
<td>Intentional self-harm by exposure to or harmful effects of measles vaccines</td>
</tr>
<tr>
<td>1756</td>
<td>Intentional self-harm by exposure to or harmful effects of mumps vaccines</td>
</tr>
<tr>
<td>1757</td>
<td>Intentional self-harm by exposure to or harmful effects of rubella vaccines</td>
</tr>
<tr>
<td>1758</td>
<td>Intentional self-harm by exposure to or harmful effects of polio vaccines</td>
</tr>
<tr>
<td>1759</td>
<td>Intentional self-harm by exposure to or harmful effects of yellow fever vaccines</td>
</tr>
<tr>
<td>1760</td>
<td>Intentional self-harm by exposure to or harmful effects of hepatitis A vaccines</td>
</tr>
<tr>
<td>1761</td>
<td>Intentional self-harm by exposure to or harmful effects of hepatitis B vaccines</td>
</tr>
<tr>
<td>1762</td>
<td>Intentional self-harm by exposure to or harmful effects of influenza vaccines</td>
</tr>
<tr>
<td>1763</td>
<td>Intentional self-harm by exposure to or harmful effects of rotavirus vaccines</td>
</tr>
<tr>
<td>1764</td>
<td>Intentional self-harm by exposure to or harmful effects of human papillomavirus vaccines</td>
</tr>
<tr>
<td>1765</td>
<td>Intentional self-harm by exposure to or harmful effects of other viral vaccines</td>
</tr>
<tr>
<td>1766</td>
<td>Intentional self-harm by exposure to or harmful effects of rickettsial vaccines</td>
</tr>
<tr>
<td>1767</td>
<td>Intentional self-harm by exposure to or harmful effects of protozoal vaccines</td>
</tr>
<tr>
<td>1768</td>
<td>Intentional self-harm by exposure to or harmful effects of hepatitis B immune globulin</td>
</tr>
<tr>
<td>1769</td>
<td>Intentional self-harm by exposure to or harmful effects of antivenin, antivenom</td>
</tr>
<tr>
<td>1770</td>
<td>Intentional self-harm by exposure to or harmful effects of immunoglobulin, not elsewhere classified</td>
</tr>
<tr>
<td>1771</td>
<td>Intentional self-harm by exposure to or harmful effects of other specified vaccines</td>
</tr>
<tr>
<td>1772</td>
<td>Intentional self-harm by exposure to or harmful effects of unspecified vaccines</td>
</tr>
<tr>
<td>1773</td>
<td>Assault by exposure to or harmful effects of other or unspecified drug, medicament or biological substance</td>
</tr>
<tr>
<td>1774</td>
<td>homicidal poisoning by exposure to or harmful effects of other or unspecified drug, medicament or biological substance</td>
</tr>
<tr>
<td>1775</td>
<td>Assault by exposure to or harmful effects of systemic antibiotics</td>
</tr>
<tr>
<td>1776</td>
<td>Assault by exposure to or harmful effects of penicillins</td>
</tr>
<tr>
<td>1777</td>
<td>Assault by exposure to or harmful effects of cephalosporins or other beta-lactam antibiotics</td>
</tr>
<tr>
<td>1778</td>
<td>Assault by exposure to or harmful effects of chloramphenicol group</td>
</tr>
<tr>
<td>1779</td>
<td>Assault by exposure to or harmful effects of macrolides</td>
</tr>
<tr>
<td>1780</td>
<td>Assault by exposure to or harmful effects of tetracyclines</td>
</tr>
<tr>
<td>1781</td>
<td>Assault by exposure to or harmful effects of aminoglycosides</td>
</tr>
<tr>
<td>1782</td>
<td>Assault by exposure to or harmful effects of rifampicin</td>
</tr>
<tr>
<td>1783</td>
<td>Assault by exposure to or harmful effects of antifungal antibiotics, systemically used</td>
</tr>
<tr>
<td>1784</td>
<td>Assault by exposure to or harmful effects of other systemic anti-infectives or antiparasitics</td>
</tr>
<tr>
<td>1785</td>
<td>Assault by exposure to or harmful effects of sulfonamides</td>
</tr>
<tr>
<td>1786</td>
<td>Assault by exposure to or harmful effects of antimycobacterial drugs</td>
</tr>
<tr>
<td>1787</td>
<td>Assault by exposure to or harmful effects of antimalarials or drugs acting on other blood protozoa</td>
</tr>
<tr>
<td>1788</td>
<td>Assault by exposure to or harmful effects of other antiprotozoal drugs</td>
</tr>
<tr>
<td>1789</td>
<td>Assault by exposure to or harmful effects of anthelminthics</td>
</tr>
<tr>
<td>1790</td>
<td>Assault by exposure to or harmful effects of antiviral drugs</td>
</tr>
<tr>
<td>1791</td>
<td>Assault by exposure to or harmful effects of hormones or their synthetic substitutes or antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>1792</td>
<td>Assault by exposure to or harmful effects of glucocorticoids or synthetic analogues</td>
</tr>
<tr>
<td>1793</td>
<td>Assault by exposure to or harmful effects of thyroid hormones or substitutes</td>
</tr>
<tr>
<td>1794</td>
<td>Assault by exposure to or harmful effects of antithyroid drugs</td>
</tr>
<tr>
<td>1795</td>
<td>Assault by exposure to or harmful effects of insulin or oral hypoglycaemic drugs</td>
</tr>
<tr>
<td>1796</td>
<td>Assault by exposure to or harmful effects of antidiabetic drugs</td>
</tr>
<tr>
<td>1797</td>
<td>Assault by exposure to or harmful effects of oral contraceptives</td>
</tr>
<tr>
<td>1798</td>
<td>Assault by exposure to or harmful effects of other estrogens or progestogens</td>
</tr>
<tr>
<td>1799</td>
<td>Assault by exposure to or harmful effects of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified</td>
</tr>
<tr>
<td>1800</td>
<td>Assault by exposure to or harmful effects of androgens or anabolic congeners</td>
</tr>
<tr>
<td>1801</td>
<td>Assault by exposure to or harmful effects of unspecified hormones or synthetic substitutes</td>
</tr>
<tr>
<td>1802</td>
<td>Assault by exposure to or harmful effects of anterior pituitary hormones</td>
</tr>
<tr>
<td>1803</td>
<td>Assault by exposure to or harmful effects of adenohypophyseal hormones</td>
</tr>
<tr>
<td>1804</td>
<td>Assault by exposure to or harmful effects of other hormones or synthetic substitutes</td>
</tr>
<tr>
<td>1805</td>
<td>Assault by exposure to or harmful effects of unspecified hormone antagonists</td>
</tr>
<tr>
<td>1806</td>
<td>Assault by exposure to or harmful effects of other hormone antagonists</td>
</tr>
<tr>
<td>1807</td>
<td>Assault by exposure to or harmful effects of drugs primarily affecting the autonomic nervous system</td>
</tr>
<tr>
<td>1808</td>
<td>Assault by exposure to or harmful effects of anticholinesterase agents</td>
</tr>
<tr>
<td>1809</td>
<td>Assault by exposure to or harmful effects of other parasympathomimetics</td>
</tr>
<tr>
<td>1810</td>
<td>Assault by exposure to or harmful effects of cholinergics</td>
</tr>
<tr>
<td>1811</td>
<td>Assault by exposure to or harmful effects of ganglionic blocking drugs</td>
</tr>
<tr>
<td>1812</td>
<td>Assault by exposure to or harmful effects of other parasympatholytics or spasmolytics</td>
</tr>
<tr>
<td>1813</td>
<td>Assault by exposure to or harmful effects of anticholinergics or antimuscarinics</td>
</tr>
<tr>
<td>1814</td>
<td>Assault by exposure to or harmful effects of predominantly alpha-adrenoreceptor agonists</td>
</tr>
<tr>
<td>1815</td>
<td>Assault by exposure to or harmful effects of predominantly beta-adrenoreceptor agonists</td>
</tr>
<tr>
<td>1816</td>
<td>Assault by exposure to or harmful effects of alpha-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>1817</td>
<td>Assault by exposure to or harmful effects of beta-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>1818</td>
<td>Assault by exposure to or harmful effects of centrally-acting or adrenergic-neuron-blocking agents</td>
</tr>
<tr>
<td>1819</td>
<td>Assault by exposure to or harmful effects of agents primarily affecting blood constituents</td>
</tr>
<tr>
<td>1820</td>
<td>Assault by exposure to or harmful effects of diphenhydramine</td>
</tr>
<tr>
<td>1821</td>
<td>Assault by exposure to or harmful effects of other H1-receptor antagonists</td>
</tr>
<tr>
<td>1822</td>
<td>Assault by exposure to or harmful effects of antiallergic or antiemetic drugs</td>
</tr>
<tr>
<td>1823</td>
<td>Assault by exposure to or harmful effects of antineoplastic antimetabolites</td>
</tr>
<tr>
<td>1824</td>
<td>Assault by exposure to or harmful effects of antineoplastic natural products</td>
</tr>
<tr>
<td>1825</td>
<td>Assault by exposure to or harmful effects of other antineoplastic drugs</td>
</tr>
<tr>
<td>1826</td>
<td>Assault by exposure to or harmful effects of immunosuppressive agents</td>
</tr>
<tr>
<td>1827</td>
<td>Assault by exposure to or harmful effects of vitamin B12, folic acid or other anti-megaloblastic-anaemia preparations</td>
</tr>
<tr>
<td>1828</td>
<td>Assault by exposure to or harmful effects of enzymes</td>
</tr>
<tr>
<td>1829</td>
<td>Assault by exposure to or harmful effects of iron or its compounds</td>
</tr>
<tr>
<td>1830</td>
<td>Assault by exposure to or harmful effects of anticoagulants</td>
</tr>
<tr>
<td>1831</td>
<td>Assault by exposure to or harmful effects of antithrombotic drugs</td>
</tr>
<tr>
<td>1832</td>
<td>Assault by exposure to or harmful effects of platelet aggregation inhibitors</td>
</tr>
<tr>
<td>1833</td>
<td>Assault by exposure to or harmful effects of thrombolytic drug</td>
</tr>
<tr>
<td>1834</td>
<td>Assault by exposure to or harmful effects of anticoagulant antagonists, vitamin K or other coagulants</td>
</tr>
<tr>
<td>1835</td>
<td>Assault by exposure to or harmful effects of other fibrinolysis-affecting drugs</td>
</tr>
<tr>
<td>1836</td>
<td>Assault by exposure to or harmful effects of natural blood or blood products</td>
</tr>
<tr>
<td>1837</td>
<td>Assault by exposure to or harmful effects of acidifying or alkalising agents</td>
</tr>
<tr>
<td>1838</td>
<td>Assault by exposure to or harmful effects of other primarily systemic agents, not elsewhere classified</td>
</tr>
<tr>
<td>1839</td>
<td>Assault by exposure to or harmful effects of plasma substitutes</td>
</tr>
<tr>
<td>1840</td>
<td>Assault by exposure to or harmful effects of agents primarily affecting the cardiovascular system</td>
</tr>
<tr>
<td>1841</td>
<td>Assault by exposure to or harmful effects of cardiac-stimulant glycosides or drugs of similar action</td>
</tr>
<tr>
<td>1842</td>
<td>Assault by exposure to or harmful effects of calcium-channel blockers</td>
</tr>
<tr>
<td>1843</td>
<td>Assault by exposure to or harmful effects of other antidysrhythmic drugs</td>
</tr>
<tr>
<td>1844</td>
<td>Assault by exposure to or harmful effects of nitroglycerin, nitroglycerol, medicinal</td>
</tr>
<tr>
<td>1845</td>
<td>Assault by exposure to or harmful effects of other coronary vasodilators</td>
</tr>
<tr>
<td>1846</td>
<td>Assault by exposure to or harmful effects of angiotensin-converting-enzyme inhibitors</td>
</tr>
<tr>
<td>1847</td>
<td>Assault by exposure to or harmful effects of other antihypertensive drugs</td>
</tr>
<tr>
<td>1848</td>
<td>Assault by exposure to or harmful effects of antihyperlipidemic or antiarteriosclerotic drugs</td>
</tr>
<tr>
<td>1849</td>
<td>Assault by exposure to or harmful effects of peripheral vasodilators</td>
</tr>
<tr>
<td>1850</td>
<td>Assault by exposure to or harmful effects of antivaricose drugs, including sclerosing agents</td>
</tr>
<tr>
<td>1851</td>
<td>Assault by exposure to or harmful effects of agents primarily affecting the gastrointestinal system</td>
</tr>
<tr>
<td>1852</td>
<td>Assault by exposure to or harmful effects of histamine H2-receptor blockers</td>
</tr>
<tr>
<td>1853</td>
<td>Assault by exposure to or harmful effects of other antacids or anti-gastric-secretion drugs</td>
</tr>
<tr>
<td>1854</td>
<td>Assault by exposure to or harmful effects of stimulant laxatives</td>
</tr>
<tr>
<td>1855</td>
<td>Assault by exposure to or harmful effects of saline or osmotic laxatives</td>
</tr>
<tr>
<td>1856</td>
<td>Assault by exposure to or harmful effects of other laxatives</td>
</tr>
<tr>
<td>1857</td>
<td>Assault by exposure to or harmful effects of digestants</td>
</tr>
<tr>
<td>1858</td>
<td>Assault by exposure to or harmful effects of antidiarrhoeal drugs</td>
</tr>
<tr>
<td>1859</td>
<td>Assault by exposure to or harmful effects of emetics</td>
</tr>
<tr>
<td>1860</td>
<td>Assault by exposure to or harmful effects of agents primarily acting on smooth or skeletal muscles or the respiratory system</td>
</tr>
<tr>
<td>1861</td>
<td>Assault by exposure to or harmful effects of oxytocic drugs</td>
</tr>
<tr>
<td>1862</td>
<td>Assault by exposure to or harmful effects of skeletal muscle relaxants</td>
</tr>
<tr>
<td>1863</td>
<td>Assault by exposure to or harmful effects of neuromuscular blocking agents</td>
</tr>
<tr>
<td>1864</td>
<td>Assault by exposure to or harmful effects of unspecified drugs acting on muscles</td>
</tr>
<tr>
<td>1865</td>
<td>Assault by exposure to or harmful effects of other drugs acting on muscles</td>
</tr>
<tr>
<td>1866</td>
<td>Assault by exposure to or harmful effects of antitussives</td>
</tr>
<tr>
<td>1867</td>
<td>Assault by exposure to or harmful effects of expectorants</td>
</tr>
<tr>
<td>1868</td>
<td>Assault by exposure to or harmful effects of other anti-common-cold drugs</td>
</tr>
<tr>
<td>1869</td>
<td>Assault by exposure to or harmful effects of salbutamol</td>
</tr>
<tr>
<td>1870</td>
<td>Assault by exposure to or harmful effects of aminophylline, theophylline</td>
</tr>
<tr>
<td>1871</td>
<td>Assault by exposure to or harmful effects of terbutaline</td>
</tr>
<tr>
<td>1872</td>
<td>Assault by exposure to or harmful effects of antiasthmatics, not elsewhere classified</td>
</tr>
<tr>
<td>1873</td>
<td>Assault by exposure to or harmful effects of topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs</td>
</tr>
<tr>
<td>1874</td>
<td>Assault by exposure to or harmful effects of topical corticosteroid preparations</td>
</tr>
<tr>
<td>1875</td>
<td>Assault by exposure to or harmful effects of iodine, antiseptic</td>
</tr>
<tr>
<td>1876</td>
<td>Assault by exposure to or harmful effects of silver nitrate</td>
</tr>
<tr>
<td>1877</td>
<td>Assault by exposure to or harmful effects of other local antifungal, anti-infective or anti-inflammatory drugs</td>
</tr>
<tr>
<td>1878</td>
<td>Assault by exposure to or harmful effects of antipruritics</td>
</tr>
<tr>
<td>1879</td>
<td>Assault by exposure to or harmful effects of methyl salicylate</td>
</tr>
<tr>
<td>1880</td>
<td>Assault by exposure to or harmful effects of other local astringents or local detergents</td>
</tr>
<tr>
<td>1881</td>
<td>Assault by exposure to or harmful effects of emollients, demulcents or protectants</td>
</tr>
<tr>
<td>1882</td>
<td>Assault by exposure to or harmful effects of podophyllin</td>
</tr>
<tr>
<td>1883</td>
<td>Assault by exposure to or harmful effects of keratolytics, keratoplastics, or other hair treatment drugs or preparations</td>
</tr>
<tr>
<td>1884</td>
<td>Assault by exposure to or harmful effects of ophthalmological drugs or preparations</td>
</tr>
<tr>
<td>1885</td>
<td>Assault by exposure to or harmful effects of otorhinolaryngological drugs or preparations</td>
</tr>
<tr>
<td>1886</td>
<td>Assault by exposure to or harmful effects of fluoride preparations</td>
</tr>
<tr>
<td>1887</td>
<td>Assault by exposure to or harmful effects of other dental drugs, topically applied</td>
</tr>
<tr>
<td>1888</td>
<td>Assault by exposure to or harmful effects of camphor</td>
</tr>
<tr>
<td>1889</td>
<td>Assault by exposure to or harmful effects of agents primarily affecting water-balance or mineral or uric acid metabolism</td>
</tr>
<tr>
<td>1890</td>
<td>Assault by exposure to or harmful effects of mineralocorticoids</td>
</tr>
<tr>
<td>1891</td>
<td>Assault by exposure to or harmful effects of mineralocorticoids antagonists</td>
</tr>
<tr>
<td>1892</td>
<td>Assault by exposure to or harmful effects of loop diuretics</td>
</tr>
<tr>
<td>1893</td>
<td>Assault by exposure to or harmful effects of high-ceiling diuretics</td>
</tr>
<tr>
<td>1894</td>
<td>Assault by exposure to or harmful effects of carbonic-anhydrase inhibitors</td>
</tr>
<tr>
<td>1895</td>
<td>Assault by exposure to or harmful effects of benzothiadiazine derivatives</td>
</tr>
<tr>
<td>1896</td>
<td>Assault by exposure to or harmful effects of thiazides</td>
</tr>
<tr>
<td>1897</td>
<td>Assault by exposure to or harmful effects of other diuretics</td>
</tr>
<tr>
<td>1898</td>
<td>Assault by exposure to or harmful effects of electrolytic, caloric or water-balance agents</td>
</tr>
<tr>
<td>1899</td>
<td>Assault by exposure to or harmful effects of mineral salts, not elsewhere classified</td>
</tr>
<tr>
<td>1900</td>
<td>Assault by exposure to or harmful effects of drugs affecting uric acid metabolism</td>
</tr>
<tr>
<td>1901</td>
<td>Assault by exposure to or harmful effects of vitamin D or derivatives</td>
</tr>
<tr>
<td>1902</td>
<td>Assault by exposure to or harmful effects of bisphosphonates</td>
</tr>
<tr>
<td>1903</td>
<td>Assault by exposure to or harmful effects of appetite depressants</td>
</tr>
<tr>
<td>1904</td>
<td>Assault by exposure to or harmful effects of antidotes or chelating agents, not elsewhere classified</td>
</tr>
<tr>
<td>1905</td>
<td>Assault by exposure to or harmful effects of disulfiram</td>
</tr>
<tr>
<td>1906</td>
<td>Assault by exposure to or harmful effects of alcohol deterrents, not elsewhere classified</td>
</tr>
<tr>
<td>1907</td>
<td>Assault by exposure to or harmful effects of X-ray contrast media</td>
</tr>
<tr>
<td>1908</td>
<td>Assault by exposure to or harmful effects of MRI contrast agents</td>
</tr>
<tr>
<td>1909</td>
<td>Assault by exposure to or harmful effects of agents used for other scanning techniques</td>
</tr>
<tr>
<td>1910</td>
<td>Assault by exposure to or harmful effects of other diagnostic agents</td>
</tr>
<tr>
<td>1911</td>
<td>Assault by exposure to or harmful effects of lipotropic drugs</td>
</tr>
<tr>
<td>1912</td>
<td>Assault by or harmful exposure to harmful effects of vitamins or pharmaceutical excipients, not elsewhere classified</td>
</tr>
<tr>
<td>1913</td>
<td>Assault by or harmful exposure to herbal preparations or formulas</td>
</tr>
<tr>
<td>1914</td>
<td>Assault by or harmful exposure to dietary supplements, vitamins or minerals</td>
</tr>
<tr>
<td>1915</td>
<td>Assault by or harmful exposure to complementary or traditional medicines, not elsewhere classified</td>
</tr>
<tr>
<td>1916</td>
<td>Assault by or harmful exposure to complementary or traditional medicines, unspecified</td>
</tr>
<tr>
<td>1917</td>
<td>Assault by or harmful exposure to vaccines, immunoglobulins or other biological substances</td>
</tr>
<tr>
<td>1918</td>
<td>Assault by or harmful exposure to BCG vaccine</td>
</tr>
<tr>
<td>1919</td>
<td>Assault by or harmful exposure to typhoid or paratyphoid vaccine</td>
</tr>
<tr>
<td>1920</td>
<td>Assault by or harmful exposure to cholera vaccine</td>
</tr>
<tr>
<td>1921</td>
<td>Assault by or harmful exposure to plague vaccine</td>
</tr>
<tr>
<td>1922</td>
<td>Assault by or harmful exposure to tetanus vaccine</td>
</tr>
<tr>
<td>1923</td>
<td>Assault by or harmful exposure to diphtheria vaccine</td>
</tr>
<tr>
<td>1924</td>
<td>Assault by or harmful exposure to haemophilus influenzae type B vaccines</td>
</tr>
<tr>
<td>1925</td>
<td>Assault by or harmful exposure to pertussis vaccine, including combinations with a pertussis component</td>
</tr>
<tr>
<td>1926</td>
<td>Assault by or harmful exposure to mixed bacterial vaccines without a pertussis component</td>
</tr>
<tr>
<td>1927</td>
<td>Assault by or harmful exposure to other or unspecified bacterial vaccines</td>
</tr>
<tr>
<td>1928</td>
<td>Assault by or harmful exposure to smallpox vaccines</td>
</tr>
<tr>
<td>1929</td>
<td>Assault by or harmful exposure to measles vaccines</td>
</tr>
<tr>
<td>1930</td>
<td>Assault by or harmful exposure to mumps vaccines</td>
</tr>
<tr>
<td>1931</td>
<td>Assault by or harmful exposure to rubella vaccines</td>
</tr>
<tr>
<td>1932</td>
<td>Assault by or harmful exposure to polio vaccines</td>
</tr>
<tr>
<td>1933</td>
<td>Assault by or harmful exposure to yellow fever vaccines</td>
</tr>
<tr>
<td>1934</td>
<td>Assault by or harmful exposure to hepatitis A vaccines</td>
</tr>
<tr>
<td>1935</td>
<td>Assault by or harmful exposure to hepatitis B vaccines</td>
</tr>
<tr>
<td>1936</td>
<td>Assault by or harmful exposure to influenza vaccines</td>
</tr>
<tr>
<td>1937</td>
<td>Assault by or harmful exposure to rotavirus vaccines</td>
</tr>
<tr>
<td>1938</td>
<td>Assault by or harmful exposure to human papillomavirus vaccines</td>
</tr>
<tr>
<td>1939</td>
<td>Assault by or harmful exposure to other viral vaccines</td>
</tr>
<tr>
<td>1940</td>
<td>Assault by or harmful exposure to rickettsial vaccines</td>
</tr>
<tr>
<td>1941</td>
<td>Assault by or harmful exposure to protozoal vaccines</td>
</tr>
<tr>
<td>1942</td>
<td>Assault by or harmful exposure to hepatitis B immune globulin</td>
</tr>
<tr>
<td>1943</td>
<td>Assault by or harmful exposure to antivenin or antivenom</td>
</tr>
<tr>
<td>1944</td>
<td>Assault by or harmful exposure to immunoglobulin, not elsewhere classified</td>
</tr>
<tr>
<td>1945</td>
<td>Assault by or harmful exposure to other specified vaccines</td>
</tr>
<tr>
<td>1946</td>
<td>Assault by or harmful exposure to unspecified vaccines</td>
</tr>
<tr>
<td>1947</td>
<td>Bacterial pneumonia, unspecified</td>
</tr>
<tr>
<td>1948</td>
<td>Bacterial pneumonia</td>
</tr>
<tr>
<td>1949</td>
<td>acute bacillus pneumonia</td>
</tr>
<tr>
<td>1950</td>
<td>acute bacterial pneumonia</td>
</tr>
<tr>
<td>1951</td>
<td>bacillus double pneumonia</td>
</tr>
<tr>
<td>1952</td>
<td>bacillus pneumonia</td>
</tr>
<tr>
<td>1953</td>
<td>bacteria pneumonia</td>
</tr>
<tr>
<td>1954</td>
<td>bacterial double pneumonia</td>
</tr>
<tr>
<td>1955</td>
<td>bacterial lobar pneumonia</td>
</tr>
<tr>
<td>1956</td>
<td>bacterial purulent pneumonia</td>
</tr>
<tr>
<td>1957</td>
<td>bronchopneumonia due to bacteria other than S. pneumoniae and H. influenzae</td>
</tr>
<tr>
<td>1</td>
<td>Other specified nonstructural developmental anomalies of small intestine</td>
</tr>
<tr>
<td>2</td>
<td>Congenital enteropathy involving intestinal mucosa development</td>
</tr>
<tr>
<td>3</td>
<td>Congenital enterocyte heparan sulphate deficiency</td>
</tr>
<tr>
<td>4</td>
<td>Congenital malabsorptive diarrhoea due to paucity of enteroendocrine cells</td>
</tr>
<tr>
<td>5</td>
<td>Endocrine cell dysgenesis</td>
</tr>
<tr>
<td>6</td>
<td>Enteric anendocrinosis</td>
</tr>
<tr>
<td>7</td>
<td>Intestinal epithelial dysplasia</td>
</tr>
<tr>
<td>8</td>
<td>IED - [Intestinal epithelial dysplasia]</td>
</tr>
<tr>
<td>9</td>
<td>Tufting enteropathy</td>
</tr>
<tr>
<td>10</td>
<td>Intractable diarrhoea - choanal atresia - eye anomalies</td>
</tr>
<tr>
<td>11</td>
<td>Microvillous inclusion disease</td>
</tr>
<tr>
<td>12</td>
<td>congenital microvillous atrophy</td>
</tr>
<tr>
<td>13</td>
<td>inclusion disease NOS</td>
</tr>
<tr>
<td>14</td>
<td>Chronic diarrhoea with villous atrophy</td>
</tr>
<tr>
<td>15</td>
<td>Other specified congenital enteropathy involving intestinal mucosa development</td>
</tr>
<tr>
<td>16</td>
<td>Congenital intestinal disease due to an enzymatic defect</td>
</tr>
<tr>
<td>17</td>
<td>Congenital enteropeptidase deficiency</td>
</tr>
<tr>
<td>18</td>
<td>Mucolipidosis</td>
</tr>
<tr>
<td>19</td>
<td>Mucolipidosis type 3</td>
</tr>
<tr>
<td>20</td>
<td>Pseudo-Hurler polydystrophy</td>
</tr>
<tr>
<td>21</td>
<td>Pseudo-Hurler disease</td>
</tr>
<tr>
<td>22</td>
<td>Mucolipidosis type 2</td>
</tr>
<tr>
<td>23</td>
<td>N-acetyl-glucosamine 1-phosphotransferase deficiency</td>
</tr>
<tr>
<td>24</td>
<td>I-cell disease</td>
</tr>
<tr>
<td>25</td>
<td>Inclusion cell disease</td>
</tr>
<tr>
<td>26</td>
<td>Dystrophic epidermolysis bullosa</td>
</tr>
<tr>
<td>27</td>
<td>Epidermolysis bullosa dystrophica</td>
</tr>
<tr>
<td>28</td>
<td>Dystrophic EB - [epidermolysis bullosa]</td>
</tr>
<tr>
<td>29</td>
<td>Autosomal dominant dystrophic epidermolysis bullosa</td>
</tr>
<tr>
<td>30</td>
<td>Dominant dystrophic epidermolysis bullosa, generalised</td>
</tr>
<tr>
<td>31</td>
<td>DDEB-gen - [dominant dystrophic epidermolysis bullosa, generalised]</td>
</tr>
<tr>
<td>32</td>
<td>DDEB, generalised - [dominant dystrophic epidermolysis bullosa, generalised]</td>
</tr>
<tr>
<td>33</td>
<td>Dominant dystrophic epidermolysis bullosa, acral</td>
</tr>
<tr>
<td>34</td>
<td>Acral dystrophic epidermolysis bullosa</td>
</tr>
<tr>
<td>35</td>
<td>DDEB-acral - [dominant dystrophic epidermolysis bullosa, acral]</td>
</tr>
<tr>
<td>36</td>
<td>DDEB-ac - [dominant dystrophic epidermolysis bullosa, acral]</td>
</tr>
<tr>
<td>37</td>
<td>Dominant dystrophic epidermolysis bullosa, pretibial</td>
</tr>
<tr>
<td>38</td>
<td>DDEB-pretibial - [dominant dystrophic epidermolysis bullosa, pretibial]</td>
</tr>
<tr>
<td>39</td>
<td>DDEB-Pt - [dominant dystrophic epidermolysis bullosa, pretibial]</td>
</tr>
<tr>
<td>40</td>
<td>Dominant dystrophic epidermolysis bullosa pruriginosa</td>
</tr>
<tr>
<td>41</td>
<td>DDEB pruriginosa - [dominant dystrophic epidermolysis bullosa pruriginosa]</td>
</tr>
<tr>
<td>42</td>
<td>DDEB-Pr - [dominant dystrophic epidermolysis bullosa pruriginosa]</td>
</tr>
<tr>
<td>43</td>
<td>Dominant dystrophic epidermolysis bullosa, nails only</td>
</tr>
<tr>
<td>44</td>
<td>Dystrophic epidermolysis bullosa, nails only</td>
</tr>
<tr>
<td>45</td>
<td>DDEB, nails only - [dominant dystrophic epidermolysis bullosa, nails only]</td>
</tr>
<tr>
<td>46</td>
<td>DDEB-na - [dominant dystrophic epidermolysis bullosa, nails only]</td>
</tr>
<tr>
<td>47</td>
<td>Dominant bullous dermolysis of the newborn</td>
</tr>
<tr>
<td>48</td>
<td>DDEB-BDN - [dominant bullous dermolysis of the newborn]</td>
</tr>
<tr>
<td>49</td>
<td>Autosomal recessive dystrophic epidermolysis bullosa</td>
</tr>
<tr>
<td>50</td>
<td>Recessive dystrophic epidermolysis bullosa, generalised severe</td>
</tr>
<tr>
<td>51</td>
<td>RDEB Hallopeau-Siemens</td>
</tr>
<tr>
<td>52</td>
<td>RDEB-GS - [recessive dystrophic epidermolysis bullosa, generalised severe]</td>
</tr>
<tr>
<td>53</td>
<td>RDEB-gen sev - [recessive dystrophic epidermolysis bullosa, generalised severe]</td>
</tr>
<tr>
<td>54</td>
<td>Recessive dystrophic epidermolysis bullosa, generalised intermediate</td>
</tr>
<tr>
<td>55</td>
<td>RDEB-O - [recessive dystrophic epidermolysis bullosa, generalised other]</td>
</tr>
<tr>
<td>56</td>
<td>RDEB-gen intermed - [recessive dystrophic epidermolysis, generalised intermediate]</td>
</tr>
<tr>
<td>57</td>
<td>Recessive dystrophic epidermolysis bullosa inversa</td>
</tr>
<tr>
<td>58</td>
<td>RDEB - [recessive dystrophic epidermolysis bullosa] inversa</td>
</tr>
<tr>
<td>59</td>
<td>RDEB-I - [recessive dystrophic epidermolysis bullosa inversa]</td>
</tr>
<tr>
<td>60</td>
<td>RDEB-inv - [recessive dystrophic epidermolysis bullosa inversa]</td>
</tr>
<tr>
<td>61</td>
<td>Recessive dystrophic epidermolysis bullosa, pretibial</td>
</tr>
<tr>
<td>62</td>
<td>RDEB - [recessive dystrophic epidermolysis bullosa] pretibial</td>
</tr>
<tr>
<td>63</td>
<td>RDEB-Pt - [recessive dystrophic epidermolysis bullosa, pretibial]</td>
</tr>
<tr>
<td>64</td>
<td>Recessive dystrophic epidermolysis bullosa pruriginosa</td>
</tr>
<tr>
<td>65</td>
<td>RDEB - [recessive dystrophic epidermolysis bullosa] pruriginosa</td>
</tr>
<tr>
<td>66</td>
<td>RDEB-Pr - [recessive dystrophic epidermolysis bullosa pruriginosa]</td>
</tr>
<tr>
<td>67</td>
<td>Recessive dystrophic epidermolysis bullosa centripetalis</td>
</tr>
<tr>
<td>68</td>
<td>RDEB - [recessive dystrophic epidermolysis bullosa centripetalis] centripetalis</td>
</tr>
<tr>
<td>69</td>
<td>RDEB-Ce - [recessive dystrophic epidermolysis bullosa centripetalis]</td>
</tr>
<tr>
<td>70</td>
<td>Recessive bullous dermolysis of the newborn</td>
</tr>
<tr>
<td>71</td>
<td>Bullous dermolysis of the newborn (recessive)</td>
</tr>
<tr>
<td>72</td>
<td>Recessive transient bullous dermolysis of the newborn</td>
</tr>
<tr>
<td>73</td>
<td>RDEB-BDN - [recessive bullous dermolysis of the newborn]</td>
</tr>
<tr>
<td>74</td>
<td>Low grade squamous intraepithelial lesion of vagina</td>
</tr>
<tr>
<td>75</td>
<td>Vaginal intraepithelial neoplasia grade I</td>
</tr>
<tr>
<td>76</td>
<td>LSIL of vagina –[ Low grade squamous intraepithelial lesion] of vagina</td>
</tr>
<tr>
<td>77</td>
<td>mild vaginal dysplasia</td>
</tr>
<tr>
<td>78</td>
<td>VaIN I - [vaginal intraepithelial neoplasia grade 1] NOS</td>
</tr>
<tr>
<td>79</td>
<td>mild vaginal dysplasia and human papillomavirus</td>
</tr>
<tr>
<td>80</td>
<td>mild squamous dysplasia of vagina</td>
</tr>
<tr>
<td>81</td>
<td>koilocytosis of vagina</td>
</tr>
<tr>
<td>82</td>
<td>koilocytic atypia of vagina</td>
</tr>
<tr>
<td>83</td>
<td>Low grade squamous intraepithelial lesion of cervix uteri</td>
</tr>
<tr>
<td>84</td>
<td>cervical dysplasia</td>
</tr>
<tr>
<td>85</td>
<td>cervical dysplasia nos</td>
</tr>
<tr>
<td>86</td>
<td>intraepithelial neoplasia of cervix</td>
</tr>
<tr>
<td>87</td>
<td>intraepithelial neoplasia of the cervix uteri</td>
</tr>
<tr>
<td>88</td>
<td>cervical intraepithelial neoplasia</td>
</tr>
<tr>
<td>89</td>
<td>CIN - [cervical intraepithelial neoplasia]</td>
</tr>
<tr>
<td>90</td>
<td>cervix dysplasia</td>
</tr>
<tr>
<td>91</td>
<td>dysplasia of cervix</td>
</tr>
<tr>
<td>92</td>
<td>Cervical intraepithelial neoplasia grade I</td>
</tr>
<tr>
<td>93</td>
<td>mild cervical dysplasia</td>
</tr>
<tr>
<td>94</td>
<td>mild dysplasia of cervix</td>
</tr>
<tr>
<td>95</td>
<td>CIN I - [cervical intraepithelial neoplasia grade 1]</td>
</tr>
<tr>
<td>96</td>
<td>Mild cervical dysplasia or human papillomavirus</td>
</tr>
<tr>
<td>97</td>
<td>LSIL – [low grade squamous intraepithelial lesion] of cervix uteri</td>
</tr>
<tr>
<td>98</td>
<td>Anaplasia of cervix</td>
</tr>
<tr>
<td>99</td>
<td>Cervical hyperplasia</td>
</tr>
<tr>
<td>100</td>
<td>hyperplasia of cervix</td>
</tr>
<tr>
<td>101</td>
<td>Cervix dyskeratosis</td>
</tr>
<tr>
<td>102</td>
<td>Cervix hyperkeratosis</td>
</tr>
<tr>
<td>103</td>
<td>Displacement of columnar epithelial of cervix</td>
</tr>
<tr>
<td>104</td>
<td>Epithelial hyperactivity of cervix</td>
</tr>
<tr>
<td>105</td>
<td>Low grade squamous intraepithelial lesion of vulva</td>
</tr>
<tr>
<td>106</td>
<td>dysplasia of vulva NOS</td>
</tr>
<tr>
<td>107</td>
<td>intraepithelial neoplasia of vulva NOS</td>
</tr>
<tr>
<td>108</td>
<td>epithelial hyperplasia of vulva</td>
</tr>
<tr>
<td>109</td>
<td>mild vulvar dysplasia</td>
</tr>
<tr>
<td>110</td>
<td>VIN I- [vulvar intraepithelial neoplasia grade I]</td>
</tr>
<tr>
<td>111</td>
<td>LSIL – [low grade squamous intraepithelial lesion of vulva]</td>
</tr>
<tr>
<td>112</td>
<td>epithelial hyperplasia of labia (deprecated)</td>
</tr>
<tr>
<td>113</td>
<td>VIN [vulvar intraepithelial neoplasia] NOS</td>
</tr>
<tr>
<td>114</td>
<td>Hereditary angioedema</td>
</tr>
<tr>
<td>115</td>
<td>Hereditary angioneurotic oedema</td>
</tr>
<tr>
<td>116</td>
<td>Familial angioedema</td>
</tr>
<tr>
<td>117</td>
<td>HAE - [hereditary angioneurotic oedema]</td>
</tr>
<tr>
<td>118</td>
<td>Bannister disease, hereditary</td>
</tr>
<tr>
<td>119</td>
<td>Quincke disease or oedema</td>
</tr>
<tr>
<td>120</td>
<td>hereditary Quincke oedema</td>
</tr>
<tr>
<td>121</td>
<td>Hereditary angioedema type I</td>
</tr>
<tr>
<td>122</td>
<td>Hereditary angioneurotic oedema type 1</td>
</tr>
<tr>
<td>123</td>
<td>C1 esterase inhibitor [C1-INH] quantitative deficiency</td>
</tr>
<tr>
<td>124</td>
<td>HAE-I - [Hereditary angioedema type I]</td>
</tr>
<tr>
<td>125</td>
<td>C1 esterase inhibitor deficiency - type 1</td>
</tr>
<tr>
<td>126</td>
<td>deficiency of c1 esterase inhibitor</td>
</tr>
<tr>
<td>127</td>
<td>Hereditary angioedema type II</td>
</tr>
<tr>
<td>128</td>
<td>Hereditary angioneurotic oedema type 2</td>
</tr>
<tr>
<td>129</td>
<td>C1 esterase inhibitor [C1-INH] qualitative deficiency</td>
</tr>
<tr>
<td>130</td>
<td>HAE-II - [Hereditary angioedema type II]</td>
</tr>
<tr>
<td>131</td>
<td>C1-INH - [C1 esterase inhibitor] deficiency</td>
</tr>
<tr>
<td>132</td>
<td>Hereditary angioedema type III</td>
</tr>
<tr>
<td>133</td>
<td>Hereditary angioneurotic oedema type 3</td>
</tr>
<tr>
<td>134</td>
<td>Inherited oestrogen-dependent angioedema</td>
</tr>
<tr>
<td>135</td>
<td>Inherited oestrogen-dependent angioneurotic oedema</td>
</tr>
<tr>
<td>136</td>
<td>Hereditary angioedema with FXII mutation</td>
</tr>
<tr>
<td>137</td>
<td>HAE-III - [Hereditary angioedema type III]</td>
</tr>
<tr>
<td>138</td>
<td>Acute hereditary circumscribed oedema</td>
</tr>
<tr>
<td>139</td>
<td>Acute hereditary essential oedema</td>
</tr>
<tr>
<td>140</td>
<td>Hereditary giant urticaria</td>
</tr>
<tr>
<td>141</td>
<td>Periodic hereditary oedema</td>
</tr>
<tr>
<td>142</td>
<td>Hereditary allergic angioedema</td>
</tr>
<tr>
<td>143</td>
<td>Hereditary angioneurotic oedema urticaria</td>
</tr>
<tr>
<td>144</td>
<td>Respiratory failure, unspecified, Type I</td>
</tr>
<tr>
<td>145</td>
<td>Hypoxic respiratory failure, Type I, unspecified</td>
</tr>
<tr>
<td>146</td>
<td>type 1 respiratory failure, unspecified</td>
</tr>
<tr>
<td>147</td>
<td>hypoxaemic respiratory failure</td>
</tr>
<tr>
<td>148</td>
<td>hypoxic respiratory failure, unspecified</td>
</tr>
<tr>
<td>149</td>
<td>Complex regional pain syndrome</td>
</tr>
<tr>
<td>150</td>
<td>CRPS - [complex regional pain syndrome]</td>
</tr>
<tr>
<td>151</td>
<td>algoneurodystrophy (deprecated)</td>
</tr>
<tr>
<td>152</td>
<td>Complex regional pain syndrome type I</td>
</tr>
<tr>
<td>153</td>
<td>shoulder-hand syndrome</td>
</tr>
<tr>
<td>154</td>
<td>Reflex sympathetic dystrophy</td>
</tr>
<tr>
<td>155</td>
<td>reflex dystrophy</td>
</tr>
<tr>
<td>156</td>
<td>sympathetic dystrophy</td>
</tr>
<tr>
<td>157</td>
<td>sympathetic reflex dystrophia</td>
</tr>
<tr>
<td>158</td>
<td>steinbrocker syndrome</td>
</tr>
<tr>
<td>159</td>
<td>Sudeck atrophy</td>
</tr>
<tr>
<td>160</td>
<td>CRPS Type I - [complex regional pain syndrome type 1]</td>
</tr>
<tr>
<td>161</td>
<td>arm-shoulder syndrome</td>
</tr>
<tr>
<td>162</td>
<td>Complex regional pain syndrome type II</td>
</tr>
<tr>
<td>163</td>
<td>CRPS Type II - [complex regional pain syndrome type 2]</td>
</tr>
<tr>
<td>164</td>
<td>Causalgia</td>
</tr>
<tr>
<td>165</td>
<td>causalgia NOS</td>
</tr>
<tr>
<td>166</td>
<td>deafferentation pain</td>
</tr>
<tr>
<td>167</td>
<td>causalgia syndrome</td>
</tr>
<tr>
<td>168</td>
<td>Total anomalous pulmonary venous connection</td>
</tr>
<tr>
<td>169</td>
<td>total anomalous pulmonary venous drainage</td>
</tr>
<tr>
<td>170</td>
<td>TAPVC - [total anomalous pulmonary venous connection]</td>
</tr>
<tr>
<td>171</td>
<td>total anomalous pulmonary vein connection</td>
</tr>
<tr>
<td>172</td>
<td>total anomalous pulmonary venous return</td>
</tr>
<tr>
<td>173</td>
<td>total pulmonary vein connection anomaly</td>
</tr>
<tr>
<td>174</td>
<td>totally anomalous pulmonary venous connection</td>
</tr>
<tr>
<td>175</td>
<td>Total anomalous pulmonary venous connection of the supracardiac type</td>
</tr>
<tr>
<td>176</td>
<td>total anomalous pulmonary venous connection Type 1</td>
</tr>
<tr>
<td>177</td>
<td>TAPVC Type I - [total anomalous pulmonary venous connection Type 1]</td>
</tr>
<tr>
<td>178</td>
<td>Total anomalous pulmonary venous connection of the cardiac type</td>
</tr>
<tr>
<td>179</td>
<td>total anomalous pulmonary venous connection Type 2</td>
</tr>
<tr>
<td>180</td>
<td>TAPVC Type 2 - [total anomalous pulmonary venous connection Type 2]</td>
</tr>
<tr>
<td>181</td>
<td>total anomalous pulmonary venous connection, intracardiac</td>
</tr>
<tr>
<td>182</td>
<td>Total anomalous pulmonary venous connection of the infracardiac type</td>
</tr>
<tr>
<td>183</td>
<td>Total anomalous pulmonary venous connection Type 3</td>
</tr>
<tr>
<td>184</td>
<td>TAPVC Type 3 - [Total anomalous pulmonary venous connection Type 3]</td>
</tr>
<tr>
<td>185</td>
<td>Total anomalous pulmonary venous connection of the mixed type</td>
</tr>
<tr>
<td>186</td>
<td>Total anomalous pulmonary venous connection Type 4</td>
</tr>
<tr>
<td>187</td>
<td>TAPVC Type 4 - [Total anomalous pulmonary venous connection Type 4]</td>
</tr>
<tr>
<td>188</td>
<td>Disorders of cobalamin metabolism or transport</td>
</tr>
<tr>
<td>189</td>
<td>Haptocorrin deficiency</td>
</tr>
<tr>
<td>190</td>
<td>Transcobalamin I deficiency</td>
</tr>
<tr>
<td>191</td>
<td>Vitamin B12-binding protein 1 deficiency</td>
</tr>
<tr>
<td>192</td>
<td>Vitamin B12-binding alpha-globulin deficiency</td>
</tr>
<tr>
<td>193</td>
<td>Cobalophilin deficiency</td>
</tr>
<tr>
<td>194</td>
<td>Protein R deficiency</td>
</tr>
<tr>
<td>195</td>
<td>TCN1 - [Transcobalamin I] deficiency</td>
</tr>
<tr>
<td>196</td>
<td>Other genetic defects of cobalamine transport or metabolism</td>
</tr>
<tr>
<td>197</td>
<td>Secondary non-genetic disorders of cobalamin absorption, transport or metabolism</td>
</tr>
<tr>
<td>198</td>
<td>Unspecified disorders of cobalamin absorption, transport or metabolism</td>
</tr>
<tr>
<td>199</td>
<td>Hereditary deficiency of factor I</td>
</tr>
<tr>
<td>200</td>
<td>Deficiency of factor 1</td>
</tr>
<tr>
<td>201</td>
<td>Hereditary fibrinogen deficiency</td>
</tr>
<tr>
<td>202</td>
<td>Deficiency of fibrinogen</td>
</tr>
<tr>
<td>203</td>
<td>congenital fibrinogenopenia</td>
</tr>
<tr>
<td>204</td>
<td>Hereditary afibrinogenaemia</td>
</tr>
<tr>
<td>205</td>
<td>Congenital afibrinogenaemia</td>
</tr>
<tr>
<td>206</td>
<td>Hereditary dysfibrinogenaemia</td>
</tr>
<tr>
<td>207</td>
<td>congenital dysfibrinogenaemia</td>
</tr>
<tr>
<td>208</td>
<td>dysfibrinogenaemia NOS</td>
</tr>
<tr>
<td>209</td>
<td>Hereditary hypofibrinogenaemia</td>
</tr>
<tr>
<td>210</td>
<td>congenital hypofibrinogenaemia</td>
</tr>
<tr>
<td>211</td>
<td>Hereditary hypodysfibrinogenaemia</td>
</tr>
<tr>
<td>212</td>
<td>Bone dysplasias with multiple joint dislocations</td>
</tr>
<tr>
<td>213</td>
<td>Desbuquois syndrome</td>
</tr>
<tr>
<td>214</td>
<td>Pseudodiastrophic dysplasia</td>
</tr>
<tr>
<td>215</td>
<td>Larsen syndrome</td>
</tr>
<tr>
<td>216</td>
<td>Atelosteogenesis type I</td>
</tr>
<tr>
<td>217</td>
<td>Atelosteogenesis type III</td>
</tr>
<tr>
<td>218</td>
<td>Boomerang dysplasia</td>
</tr>
<tr>
<td>219</td>
<td>Auriculo-osteodysplasia</td>
</tr>
<tr>
<td>220</td>
<td>Auriculoosteodysplasia</td>
</tr>
<tr>
<td>221</td>
<td>Coxoauricular syndrome</td>
</tr>
<tr>
<td>222</td>
<td>Lethal Larsen-like syndrome</td>
</tr>
<tr>
<td>223</td>
<td>Larsen-like osseous dysplasia - short stature</td>
</tr>
<tr>
<td>224</td>
<td>Other specified functional neutrophil defects</td>
</tr>
<tr>
<td>225</td>
<td>Chronic granulomatous disease</td>
</tr>
<tr>
<td>226</td>
<td>Chronic septic granulomatosis</td>
</tr>
<tr>
<td>227</td>
<td>CGD - [chronic granulomatous disease]</td>
</tr>
<tr>
<td>228</td>
<td>chronic granulomatous disorder</td>
</tr>
<tr>
<td>229</td>
<td>Childhood granulomatous disorder</td>
</tr>
<tr>
<td>230</td>
<td>Chronic childhood granulomatous disease</td>
</tr>
<tr>
<td>231</td>
<td>Progressive septic granulomatosis</td>
</tr>
<tr>
<td>232</td>
<td>Leukocyte adhesion deficiency</td>
</tr>
<tr>
<td>233</td>
<td>LAD - [leukocyte adhesion deficiency]</td>
</tr>
<tr>
<td>234</td>
<td>Leukocyte adhesion deficiency type 1</td>
</tr>
<tr>
<td>235</td>
<td>LAD-1 - [leukocyte adhesion deficiency type 1]</td>
</tr>
<tr>
<td>236</td>
<td>Leukocyte adhesion deficiency type 3</td>
</tr>
<tr>
<td>237</td>
<td>Leukocyte adhesion deficiency-1 variant</td>
</tr>
<tr>
<td>238</td>
<td>LAD - [leukocyte adhesion deficiency] type 3</td>
</tr>
<tr>
<td>239</td>
<td>LAD - [leukocyte adhesion deficiency] I variant</td>
</tr>
<tr>
<td>240</td>
<td>Myeloperoxidase deficiency</td>
</tr>
<tr>
<td>241</td>
<td>Recurrent infection due to specific granule deficiency</td>
</tr>
<tr>
<td>242</td>
<td>Neutrophil-specific granule deficiency</td>
</tr>
<tr>
<td>243</td>
<td>Acute respiratory failure, Type I</td>
</tr>
<tr>
<td>244</td>
<td>Hypoxic acute respiratory failure</td>
</tr>
<tr>
<td>245</td>
<td>Acute Type I respiratory failure</td>
</tr>
<tr>
<td>246</td>
<td>Bipolar type I disorder, unspecified</td>
</tr>
<tr>
<td>247</td>
<td>Bipolar type I disorder</td>
</tr>
<tr>
<td>248</td>
<td>manic depression NOS</td>
</tr>
<tr>
<td>249</td>
<td>manic-depressive illness</td>
</tr>
<tr>
<td>250</td>
<td>Bipolar disorder NOS</td>
</tr>
<tr>
<td>251</td>
<td>Chronic respiratory failure, Type I</td>
</tr>
<tr>
<td>252</td>
<td>Hypoxic chronic respiratory failure</td>
</tr>
<tr>
<td>253</td>
<td>Arnold-Chiari malformation type I</td>
</tr>
<tr>
<td>254</td>
<td>Chiari malformation type I</td>
</tr>
<tr>
<td>255</td>
<td>Arnold-Chiari obstruction type I</td>
</tr>
<tr>
<td>256</td>
<td>Disorders of protein N-glycosylation</td>
</tr>
<tr>
<td>257</td>
<td>Phosphomannomutase 2 deficiency</td>
</tr>
<tr>
<td>258</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1A</td>
</tr>
<tr>
<td>259</td>
<td>Congenital disorder of glycosylation type 1A</td>
</tr>
<tr>
<td>260</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1A</td>
</tr>
<tr>
<td>261</td>
<td>Phosphomannose isomerase deficiency</td>
</tr>
<tr>
<td>262</td>
<td>Saguenay-Lac-Saint-Jean syndrome</td>
</tr>
<tr>
<td>263</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1B</td>
</tr>
<tr>
<td>264</td>
<td>Congenital disorder of glycosylation type 1B</td>
</tr>
<tr>
<td>265</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1B</td>
</tr>
<tr>
<td>266</td>
<td>SLSJ - [Saguenay-Lac-Saint-Jean] syndrome</td>
</tr>
<tr>
<td>267</td>
<td>Glucosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>268</td>
<td>Dol-P-Glc: Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>269</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1C</td>
</tr>
<tr>
<td>270</td>
<td>Congenital disorder of glycosylation type 1C</td>
</tr>
<tr>
<td>271</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1C</td>
</tr>
<tr>
<td>272</td>
<td>Mannosyltransferase 6 deficiency</td>
</tr>
<tr>
<td>273</td>
<td>Dol-P-Man: Man5-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>274</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1D</td>
</tr>
<tr>
<td>275</td>
<td>Congenital disorder of glycosylation type 1D</td>
</tr>
<tr>
<td>276</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1D</td>
</tr>
<tr>
<td>277</td>
<td>Mannosyltransferase 8 deficiency</td>
</tr>
<tr>
<td>278</td>
<td>Dol-P-Man: Man7-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>279</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1G</td>
</tr>
<tr>
<td>280</td>
<td>Congenital disorder of glycosylation type 1G</td>
</tr>
<tr>
<td>281</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1G</td>
</tr>
<tr>
<td>282</td>
<td>Glucosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>283</td>
<td>Dol-P-Glc: Glc1-Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>284</td>
<td>Carbohydrate deficient glycoprotein syndrome 1H</td>
</tr>
<tr>
<td>285</td>
<td>Congenital disorder of glycosylation type 1H</td>
</tr>
<tr>
<td>286</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1H</td>
</tr>
<tr>
<td>287</td>
<td>Mannosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>288</td>
<td>Dol-P-Man: Man1-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>289</td>
<td>Carbohydrate deficient glycoprotein syndrome 1I</td>
</tr>
<tr>
<td>290</td>
<td>Congenital disorder of glycosylation 1I</td>
</tr>
<tr>
<td>291</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1I</td>
</tr>
<tr>
<td>292</td>
<td>Dolichyl-phosphate N-acetylgalactosamine phosphotransferase deficiency</td>
</tr>
<tr>
<td>293</td>
<td>UDP-GlcNAc: Dol-P-GlcNac-P transferase deficiency</td>
</tr>
<tr>
<td>294</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1J</td>
</tr>
<tr>
<td>295</td>
<td>Congenital disorder of glycosylation type 1J</td>
</tr>
<tr>
<td>296</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1J</td>
</tr>
<tr>
<td>297</td>
<td>Mannosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>298</td>
<td>Dol-P-Man: GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>299</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1K</td>
</tr>
<tr>
<td>300</td>
<td>Congenital disorder of glycosylation type 1K</td>
</tr>
<tr>
<td>301</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1K</td>
</tr>
<tr>
<td>302</td>
<td>Mannosyltransferase 7-9 deficiency</td>
</tr>
<tr>
<td>303</td>
<td>Congenital disorder of glycosylation type 1L</td>
</tr>
<tr>
<td>304</td>
<td>Dol-P-Man: Man6 and Man8-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>305</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1L</td>
</tr>
<tr>
<td>306</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1L</td>
</tr>
<tr>
<td>307</td>
<td>M5-DLO flippase deficiency</td>
</tr>
<tr>
<td>308</td>
<td>Man5GlcNAc2-PP-Dol flippase deficiency</td>
</tr>
<tr>
<td>309</td>
<td>RTF1-CDG</td>
</tr>
<tr>
<td>310</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1N</td>
</tr>
<tr>
<td>311</td>
<td>N-acetylglucosaminyltransferase deficiency</td>
</tr>
<tr>
<td>312</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2A</td>
</tr>
<tr>
<td>313</td>
<td>Congenital disorder of glycosylation type 2A</td>
</tr>
<tr>
<td>314</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2A</td>
</tr>
<tr>
<td>315</td>
<td>Glucosidase 1 deficiency</td>
</tr>
<tr>
<td>316</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2B</td>
</tr>
<tr>
<td>317</td>
<td>Congenital disorder of glycosylation type 2B</td>
</tr>
<tr>
<td>318</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2B</td>
</tr>
<tr>
<td>319</td>
<td>TUSC3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>320</td>
<td>TUSC3-CDG</td>
</tr>
<tr>
<td>321</td>
<td>SRD5A3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>322</td>
<td>SRD5A3-CDG</td>
</tr>
<tr>
<td>323</td>
<td>Congenital disorder of glycosylation due to steroid 5-alpha-reductase type 3 deficiency</td>
</tr>
<tr>
<td>324</td>
<td>Intellectual deficit - cataract - coloboma - kyphosis</td>
</tr>
<tr>
<td>325</td>
<td>Kahrizi syndrome</td>
</tr>
<tr>
<td>326</td>
<td>Intellectual deficit, Kahrizi type</td>
</tr>
<tr>
<td>327</td>
<td>DPM3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>328</td>
<td>Congenital disorder of glycosylation type 1O</td>
</tr>
<tr>
<td>329</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1O</td>
</tr>
<tr>
<td>330</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1O</td>
</tr>
<tr>
<td>331</td>
<td>ALG11 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>332</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1P</td>
</tr>
<tr>
<td>333</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1P</td>
</tr>
<tr>
<td>334</td>
<td>Congenital disorder of glycosylation type 1P</td>
</tr>
<tr>
<td>335</td>
<td>Phosphoglucomutase-1 deficiency</td>
</tr>
<tr>
<td>336</td>
<td>PGM1-CDG - [Phosphoglucomutase-1 deficiency]</td>
</tr>
<tr>
<td>337</td>
<td>Congenital disorder of glycosylation type 1t</td>
</tr>
<tr>
<td>338</td>
<td>Thanatophoric dysplasia</td>
</tr>
<tr>
<td>339</td>
<td>Thanatophoric short stature</td>
</tr>
<tr>
<td>340</td>
<td>Thanatophoric dwarfism</td>
</tr>
<tr>
<td>341</td>
<td>thanatophoric dwarf</td>
</tr>
<tr>
<td>342</td>
<td>thanatophoric dwarfism or short stature</td>
</tr>
<tr>
<td>343</td>
<td>thanatophoric dwarfism syndrome</td>
</tr>
<tr>
<td>344</td>
<td>TD - [thanatophoric dwarfism]</td>
</tr>
<tr>
<td>345</td>
<td>Thanatophoric dysplasia type I</td>
</tr>
<tr>
<td>346</td>
<td>Thanatophoric dysplasia type 1</td>
</tr>
<tr>
<td>347</td>
<td>Thanatophoric dwarfism type 1</td>
</tr>
<tr>
<td>348</td>
<td>Thanatophoric short stature type 1</td>
</tr>
<tr>
<td>349</td>
<td>Thanatophoric dysplasia type II</td>
</tr>
<tr>
<td>350</td>
<td>Thanatophoric dysplasia type 2</td>
</tr>
<tr>
<td>351</td>
<td>Thanatophoric dwarfism type 2</td>
</tr>
<tr>
<td>352</td>
<td>Thanatophoric short stature type 2</td>
</tr>
<tr>
<td>353</td>
<td>Infantile spinal muscular atrophy, Type I</td>
</tr>
<tr>
<td>354</td>
<td>Werdnig-Hoffmann Disease</td>
</tr>
<tr>
<td>355</td>
<td>Werdnig-Hoffman muscular atrophy</td>
</tr>
<tr>
<td>356</td>
<td>infantile SMA - [spinal muscular atrophy], Type I</td>
</tr>
<tr>
<td>357</td>
<td>Infantile spinal muscular atrophy with respiratory distress type 1</td>
</tr>
<tr>
<td>358</td>
<td>SMARD 1 - [Infantile spinal muscular atrophy with respiratory distress type 1]</td>
</tr>
<tr>
<td>359</td>
<td>Pressure ulceration grade 1</td>
</tr>
<tr>
<td>360</td>
<td>pressure injury stage 1</td>
</tr>
<tr>
<td>361</td>
<td>pressure injury stage 1 with nonblanchable erythema</td>
</tr>
<tr>
<td>362</td>
<td>pressure ulcer category 1</td>
</tr>
<tr>
<td>363</td>
<td>stage I pressure injury</td>
</tr>
<tr>
<td>364</td>
<td>bedsore stage 1</td>
</tr>
<tr>
<td>365</td>
<td>decubitus ulcer grade I</td>
</tr>
<tr>
<td>366</td>
<td>pressure sore grade 1</td>
</tr>
<tr>
<td>367</td>
<td>stage 1 pressure ulcer</td>
</tr>
<tr>
<td>368</td>
<td>Pressure ulceration grade 1 of head</td>
</tr>
<tr>
<td>369</td>
<td>stage 1 decubitus ulcer of head</td>
</tr>
<tr>
<td>370</td>
<td>Pressure ulceration grade 1 of upper limb</td>
</tr>
<tr>
<td>371</td>
<td>stage 1 decubitus ulcer of upper limb</td>
</tr>
<tr>
<td>372</td>
<td>Pressure ulceration grade 1 of spinous processes</td>
</tr>
<tr>
<td>373</td>
<td>stage 1 decubitus ulcer of spinous processes</td>
</tr>
<tr>
<td>374</td>
<td>Pressure ulceration grade 1 of iliac crest</td>
</tr>
<tr>
<td>375</td>
<td>stage 1 decubitus ulcer of iliac crest</td>
</tr>
<tr>
<td>376</td>
<td>Pressure ulceration grade 1 of sacrum</td>
</tr>
<tr>
<td>377</td>
<td>stage 1 decubitus ulcer of sacrum</td>
</tr>
<tr>
<td>378</td>
<td>Pressure ulceration grade 1 of ischium</td>
</tr>
<tr>
<td>379</td>
<td>stage 1 decubitus ulcer of ischium</td>
</tr>
<tr>
<td>380</td>
<td>Pressure ulceration grade 1 of lower limb</td>
</tr>
<tr>
<td>381</td>
<td>stage 1 decubitus ulcer of other sites of lower limb</td>
</tr>
<tr>
<td>382</td>
<td>Pressure ulceration grade 1 of trochanter</td>
</tr>
<tr>
<td>383</td>
<td>stage 1 decubitus ulcer of trochanter</td>
</tr>
<tr>
<td>384</td>
<td>Pressure ulceration grade 1 of heel</td>
</tr>
<tr>
<td>385</td>
<td>stage 1 decubitus ulcer of heel</td>
</tr>
<tr>
<td>386</td>
<td>Pressure ulceration grade 1 of toe</td>
</tr>
<tr>
<td>387</td>
<td>Pressure ulceration grade 1 of upper back</td>
</tr>
<tr>
<td>388</td>
<td>Pressure ulceration grade 1 of lower back</td>
</tr>
<tr>
<td>389</td>
<td>Laryngotracheooesophageal cleft</td>
</tr>
<tr>
<td>390</td>
<td>LTEC - Laryngo-tracheo-oesophageal diastema]</td>
</tr>
<tr>
<td>391</td>
<td>Laryngo-tracheo-oesophageal diastema</td>
</tr>
<tr>
<td>392</td>
<td>Laryngotracheooesophageal cleft type 0</td>
</tr>
<tr>
<td>393</td>
<td>LTEC0 - [laryngo-tracheo-oesophageal cleft type 0]</td>
</tr>
<tr>
<td>394</td>
<td>Laryngotracheooesophageal cleft type I</td>
</tr>
<tr>
<td>395</td>
<td>LTEC1 - [Laryngo-tracheo-oesophageal cleft type I]</td>
</tr>
<tr>
<td>396</td>
<td>Laryngeal cleft type I</td>
</tr>
<tr>
<td>397</td>
<td>Laryngotracheooesophageal cleft type II</td>
</tr>
<tr>
<td>398</td>
<td>LTEC2 - [Laryngo-tracheo-oesophageal cleft type II]</td>
</tr>
<tr>
<td>399</td>
<td>Laryngeal cleft type II</td>
</tr>
<tr>
<td>400</td>
<td>Laryngotracheooesophageal cleft type III</td>
</tr>
<tr>
<td>401</td>
<td>LTEC3 - [Laryngo-tracheo-oesophageal cleft type III]</td>
</tr>
<tr>
<td>402</td>
<td>Laryngeal cleft type III</td>
</tr>
<tr>
<td>403</td>
<td>Laryngotracheooesophageal cleft type IV</td>
</tr>
<tr>
<td>404</td>
<td>LTEC4 - [Laryngo-tracheo-oesophageal cleft type IV]</td>
</tr>
<tr>
<td>405</td>
<td>Laryngeal cleft type IV</td>
</tr>
<tr>
<td>406</td>
<td>Other specified bipolar type I disorder</td>
</tr>
<tr>
<td>407</td>
<td>Congenital portosystemic shunt</td>
</tr>
<tr>
<td>408</td>
<td>anomalous pulmonary venous drainage to hepatic veins</td>
</tr>
<tr>
<td>409</td>
<td>anomaly of portal vein connection</td>
</tr>
<tr>
<td>410</td>
<td>portal vein deformity</td>
</tr>
<tr>
<td>411</td>
<td>portal vein anomaly</td>
</tr>
<tr>
<td>412</td>
<td>anomalous portal venous connection</td>
</tr>
<tr>
<td>413</td>
<td>Portal vein atresia</td>
</tr>
<tr>
<td>414</td>
<td>Portal vein distortion</td>
</tr>
<tr>
<td>415</td>
<td>Portal vein hypoplasia</td>
</tr>
<tr>
<td>416</td>
<td>Congenital intrahepatic portosystemic shunt</td>
</tr>
<tr>
<td>417</td>
<td>Congenital extrahepatic portosystemic shunt</td>
</tr>
<tr>
<td>418</td>
<td>Abernethy malformation</td>
</tr>
<tr>
<td>419</td>
<td>CEPS - [congenital extrahepatic portosystemic shunt]</td>
</tr>
<tr>
<td>420</td>
<td>congenital extrahepatic portosystemic venous shunt</td>
</tr>
<tr>
<td>421</td>
<td>Congenital absence of portal vein</td>
</tr>
<tr>
<td>422</td>
<td>portal vein agenesis</td>
</tr>
<tr>
<td>423</td>
<td>abernethy malformation type I</td>
</tr>
<tr>
<td>424</td>
<td>congenital extrahepatic portosystemic shunt type I</td>
</tr>
<tr>
<td>425</td>
<td>Congenital extrahepatic portosystemic shunt with hypoplastic intrahepatic portal venous system</td>
</tr>
<tr>
<td>426</td>
<td>congenital extrahepatic portosystemic shunt type II</td>
</tr>
<tr>
<td>427</td>
<td>abernethy malformation type II</td>
</tr>
<tr>
<td>428</td>
<td>Recessive limb-girdle muscular dystrophy</td>
</tr>
<tr>
<td>429</td>
<td>LGMD2 - [Limb-girdle muscular dystrophy] 2</td>
</tr>
<tr>
<td>430</td>
<td>Limb-girdle muscular dystrophy 2A, calpain-3 deficiency</td>
</tr>
<tr>
<td>431</td>
<td>Limb-girdle muscular dystrophy 2B, dysferlin deficiency</td>
</tr>
<tr>
<td>432</td>
<td>Limb-girdle muscular dystrophy 2C, gamma-sarcoglycan deficiency</td>
</tr>
<tr>
<td>433</td>
<td>Limb-girdle muscular dystrophy 2D, alpha-sarcoglycan deficiency</td>
</tr>
<tr>
<td>434</td>
<td>Limb-girdle muscular dystrophy 2E, beta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>435</td>
<td>Limb-girdle muscular dystrophy 2F, delta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>436</td>
<td>Limb-girdle muscular dystrophy 2G, telethonin gene mutation</td>
</tr>
<tr>
<td>437</td>
<td>Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation</td>
</tr>
<tr>
<td>438</td>
<td>LGMD 2H - [Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation]</td>
</tr>
<tr>
<td>439</td>
<td>Limb-girdle muscular dystrophy 2I, fukutin related protein gene mutation</td>
</tr>
<tr>
<td>440</td>
<td>FKRP - [fukutin related protein gene mutation]</td>
</tr>
<tr>
<td>441</td>
<td>LGMD 2I - [Limb-girdle muscular dystrophy 2I]</td>
</tr>
<tr>
<td>442</td>
<td>Limb-girdle muscular dystrophy 2J, Titin gene mutation</td>
</tr>
<tr>
<td>443</td>
<td>LGMD 2J - [Limb-girdle muscular dystrophy 2J, Titin gene mutation]</td>
</tr>
<tr>
<td>444</td>
<td>Limb-girdle muscular dystrophy 2K, protein-O-mannosyltransferase 1 transferase</td>
</tr>
<tr>
<td>445</td>
<td>POMT1 - [protein-O-mannosyltransferase 1 transferase]</td>
</tr>
<tr>
<td>446</td>
<td>LGMD 2K - [Limb-girdle muscular dystrophy 2K]</td>
</tr>
<tr>
<td>447</td>
<td>Limb-girdle muscular dystrophy 2L, AN05 gene mutation</td>
</tr>
<tr>
<td>448</td>
<td>LGMD 2L - [Limb-girdle muscular dystrophy 2L]</td>
</tr>
<tr>
<td>449</td>
<td>Limb-girdle muscular dystrophy 2M, POMGnT1 gene mutation</td>
</tr>
<tr>
<td>450</td>
<td>LGMD2M - [limb-girdle muscular dystrophy 2M]</td>
</tr>
<tr>
<td>451</td>
<td>Limb-girdle muscular dystrophy 2N, POMT2 gene mutation</td>
</tr>
<tr>
<td>452</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C2)</td>
</tr>
<tr>
<td>453</td>
<td>MDDGC2</td>
</tr>
<tr>
<td>454</td>
<td>LGMD2N - limb-girdle muscular dystrophy 2N]</td>
</tr>
<tr>
<td>455</td>
<td>Limb-girdle muscular dystrophy 2O, POMGNT1 gene mutation</td>
</tr>
<tr>
<td>456</td>
<td>LGMD2O - [limb-girdle muscular dystrophy 2O]</td>
</tr>
<tr>
<td>457</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C3)</td>
</tr>
<tr>
<td>458</td>
<td>MDDGC3</td>
</tr>
<tr>
<td>459</td>
<td>Limb-girdle muscular dystrophy 2Q, plectin deficiency</td>
</tr>
<tr>
<td>460</td>
<td>LGMD2Q - [limb-girdle muscular dystrophy 2Q]</td>
</tr>
<tr>
<td>461</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy C7</td>
</tr>
<tr>
<td>462</td>
<td>MDDGC7</td>
</tr>
<tr>
<td>463</td>
<td>Atresia of small intestine</td>
</tr>
<tr>
<td>464</td>
<td>Congenital stenosis of small intestine</td>
</tr>
<tr>
<td>465</td>
<td>Congenital absence of small intestine</td>
</tr>
<tr>
<td>466</td>
<td>congenital small intestinal stricture NOS</td>
</tr>
<tr>
<td>467</td>
<td>Multiple-level intestinal atresia</td>
</tr>
<tr>
<td>468</td>
<td>Small intestine atresia type IV</td>
</tr>
<tr>
<td>469</td>
<td>Congenital absence, atresia or stenosis of jejunum</td>
</tr>
<tr>
<td>470</td>
<td>Atresia of jejunum type I</td>
</tr>
<tr>
<td>471</td>
<td>Atresia of jejunum type II</td>
</tr>
<tr>
<td>472</td>
<td>Atresia of jejunum type IIIa</td>
</tr>
<tr>
<td>473</td>
<td>Apple-peel deformity</td>
</tr>
<tr>
<td>474</td>
<td>Christmas tree syndrome</td>
</tr>
<tr>
<td>475</td>
<td>Apple-peel syndrome</td>
</tr>
<tr>
<td>476</td>
<td>Christmas-tree deformity</td>
</tr>
<tr>
<td>477</td>
<td>Multiple atresias of jejunum type IV</td>
</tr>
<tr>
<td>478</td>
<td>Congenital stenosis of jejunum</td>
</tr>
<tr>
<td>479</td>
<td>stenosis of jejunum</td>
</tr>
<tr>
<td>480</td>
<td>congenital jejunal stenosis</td>
</tr>
<tr>
<td>481</td>
<td>Congenital absence of jejunum</td>
</tr>
<tr>
<td>482</td>
<td>jejunal agenesis</td>
</tr>
<tr>
<td>483</td>
<td>jejunum agenesis</td>
</tr>
<tr>
<td>484</td>
<td>Congenital atresia of jejunum</td>
</tr>
<tr>
<td>485</td>
<td>atresia of jejunum</td>
</tr>
<tr>
<td>486</td>
<td>jejunal atresia</td>
</tr>
<tr>
<td>487</td>
<td>jejunum atresia</td>
</tr>
<tr>
<td>488</td>
<td>Congenital imperforate of jejunum</td>
</tr>
<tr>
<td>489</td>
<td>Imperforate jejunum</td>
</tr>
<tr>
<td>490</td>
<td>jejunal imperforate</td>
</tr>
<tr>
<td>491</td>
<td>Congenital stricture of jejunum</td>
</tr>
<tr>
<td>492</td>
<td>Congenital absence, atresia or stenosis of ileum</td>
</tr>
<tr>
<td>493</td>
<td>Atresia of ileum type I</td>
</tr>
<tr>
<td>494</td>
<td>Atresia of ileum type II</td>
</tr>
<tr>
<td>495</td>
<td>Atresia of ileum type IIIa</td>
</tr>
<tr>
<td>496</td>
<td>Congenital stenosis of ileum</td>
</tr>
<tr>
<td>497</td>
<td>congenital ileum obstruction</td>
</tr>
<tr>
<td>498</td>
<td>Congenital absence of ileum</td>
</tr>
<tr>
<td>499</td>
<td>ileum agenesis</td>
</tr>
<tr>
<td>500</td>
<td>Congenital atresia of ileum</td>
</tr>
<tr>
<td>501</td>
<td>ileal atresia</td>
</tr>
<tr>
<td>502</td>
<td>atresia of ileum NOS</td>
</tr>
<tr>
<td>503</td>
<td>ileum atresia</td>
</tr>
<tr>
<td>504</td>
<td>Congenital stricture of ileum</td>
</tr>
<tr>
<td>505</td>
<td>Cortical dysplasia</td>
</tr>
<tr>
<td>506</td>
<td>Focal cortical dysplasia</td>
</tr>
<tr>
<td>507</td>
<td>Focal cortical dysplasia type I</td>
</tr>
<tr>
<td>508</td>
<td>Focal cortical dysplasia type Ia</td>
</tr>
<tr>
<td>509</td>
<td>Focal cortical dysplasia type Ib</td>
</tr>
<tr>
<td>510</td>
<td>Focal cortical dysplasia type Ic</td>
</tr>
<tr>
<td>511</td>
<td>Focal cortical dysplasia type II</td>
</tr>
<tr>
<td>512</td>
<td>Focal cortical dysplasia type IIa</td>
</tr>
<tr>
<td>513</td>
<td>Focal cortical dysplasia type IIb</td>
</tr>
<tr>
<td>514</td>
<td>Central bilateral macrogyria</td>
</tr>
<tr>
<td>515</td>
<td>Rolandic and perisylvian dysplasia</td>
</tr>
<tr>
<td>516</td>
<td>Disorders of methionine cycle or sulphur amino acid metabolism</td>
</tr>
<tr>
<td>517</td>
<td>disorder of sulphur-bearing amino acid including those due to folate and b12 disturbance</td>
</tr>
<tr>
<td>518</td>
<td>disorder of sulphur-bearing amino acid metabolism</td>
</tr>
<tr>
<td>519</td>
<td>disorder of transsulfuration</td>
</tr>
<tr>
<td>520</td>
<td>disorder of transsulphuration</td>
</tr>
<tr>
<td>521</td>
<td>disturbances of sulphur-bearing amino-acid metabolism</td>
</tr>
<tr>
<td>522</td>
<td>sulphuraminoacidaemia</td>
</tr>
<tr>
<td>523</td>
<td>Disorders of sulphur-bearing amino-acid metabolism</td>
</tr>
<tr>
<td>524</td>
<td>Brain demyelination due to methionine adenosyltransferase deficiency</td>
</tr>
<tr>
<td>525</td>
<td>Methionine adenosyltransferase I/III deficiency</td>
</tr>
<tr>
<td>526</td>
<td>Isolated persistent hypermethioninaemia</td>
</tr>
<tr>
<td>527</td>
<td>MAT I/III - [Methionine adenosyltransferase I/III] deficiency</td>
</tr>
<tr>
<td>528</td>
<td>Glycine N-methyltransferase deficiency</td>
</tr>
<tr>
<td>529</td>
<td>GNMT - [Glycine N-methyltransferase] deficiency</td>
</tr>
<tr>
<td>530</td>
<td>Psychomotor retardation and myopathy due to S-adenosylhomocysteine hydrolase deficiency</td>
</tr>
<tr>
<td>531</td>
<td>Hypermethioninaemia due to S-adenosylhomocysteine hydrolase deficiency</td>
</tr>
<tr>
<td>532</td>
<td>Cystathioninuria</td>
</tr>
<tr>
<td>533</td>
<td>Gamma-cystathionase deficiency</td>
</tr>
<tr>
<td>534</td>
<td>Cystathione gamma-lyase deficiency</td>
</tr>
<tr>
<td>535</td>
<td>CTH - [cystathioninuria]</td>
</tr>
<tr>
<td>536</td>
<td>cystathionine metabolic disorder</td>
</tr>
<tr>
<td>537</td>
<td>Classical homocystinuria</td>
</tr>
<tr>
<td>538</td>
<td>Homocystinuria due to cystathionine beta-synthase deficiency</td>
</tr>
<tr>
<td>539</td>
<td>Cystathionine beta-synthase deficiency</td>
</tr>
<tr>
<td>540</td>
<td>CBS - [Cystathionine beta-synthase] deficiency</td>
</tr>
<tr>
<td>541</td>
<td>cystathionine synthase deficiency</td>
</tr>
<tr>
<td>542</td>
<td>homocystine metabolic disorder</td>
</tr>
<tr>
<td>543</td>
<td>Homocystinuria without methylmalonic aciduria</td>
</tr>
<tr>
<td>544</td>
<td>5-methyltetrahydrofolate-homocysteine s-methyltransferase deficiency</td>
</tr>
<tr>
<td>545</td>
<td>Methionine synthase deficiency</td>
</tr>
<tr>
<td>546</td>
<td>Methylcobalamin deficiency</td>
</tr>
<tr>
<td>547</td>
<td>N5-methylhomocysteine transferase deficiency</td>
</tr>
<tr>
<td>548</td>
<td>Methylcobalamin deficiency type cbl E</td>
</tr>
<tr>
<td>549</td>
<td>Homocystinuria due to defect in methylation type cbl E</td>
</tr>
<tr>
<td>550</td>
<td>Homocystinuria - megaloblastic anaemia due to defect in cobalamin metabolism, cbI E complementation type</td>
</tr>
<tr>
<td>551</td>
<td>Methylcobalamin deficiency type cbl G</td>
</tr>
<tr>
<td>552</td>
<td>Homocystinuria due to methionine synthase deficiency type Cbl G</td>
</tr>
<tr>
<td>553</td>
<td>Homocystinuria - megaloblastic anaemia due to defect in cobalamin metabolism, cbI G complementation type</td>
</tr>
<tr>
<td>554</td>
<td>Methylcobalamin deficiency type cbl Dv1</td>
</tr>
<tr>
<td>555</td>
<td>Encephalopathy due to sulfite oxidase deficiency</td>
</tr>
<tr>
<td>556</td>
<td>Isolated sulfite oxidase deficiency</td>
</tr>
<tr>
<td>557</td>
<td>ISOD - [Isolated sulfite oxidase deficiency]</td>
</tr>
<tr>
<td>558</td>
<td>Sulfite oxidase deficiency due to molybdenum cofactor deficiency</td>
</tr>
<tr>
<td>559</td>
<td>Combined deficiency of sulfite oxidase, xanthine dehydrogenase and aldehyde oxidase</td>
</tr>
<tr>
<td>560</td>
<td>Molybdenum cofactor deficiency, complementation group A</td>
</tr>
<tr>
<td>561</td>
<td>Molybdenum cofactor deficiency due to defects in MOCS1 gene</td>
</tr>
<tr>
<td>562</td>
<td>Molybdenum cofactor deficiency, complementation group B</td>
</tr>
<tr>
<td>563</td>
<td>Molybdenum cofactor deficiency due to defects in MOCS2 gene</td>
</tr>
<tr>
<td>564</td>
<td>Molybdenum cofactor deficiency, complementation group C</td>
</tr>
<tr>
<td>565</td>
<td>Hypermethioninaemia due to adenosine kinase deficiency</td>
</tr>
<tr>
<td>566</td>
<td>Other genetic defects of methionine cycle or sulfur amino acid metabolism</td>
</tr>
<tr>
<td>567</td>
<td>Secondary non-genetic disorders of methionine cycle or sulfur amino acid metabolism</td>
</tr>
<tr>
<td>568</td>
<td>Beery-baby syndrome</td>
</tr>
<tr>
<td>569</td>
<td>Cystathioninemia</td>
</tr>
<tr>
<td>570</td>
<td>Deficiency of cystathionase</td>
</tr>
<tr>
<td>571</td>
<td>Deficiency of cysteine desulfhydrase</td>
</tr>
<tr>
<td>572</td>
<td>deficiency of cysteine desulphydrase</td>
</tr>
<tr>
<td>573</td>
<td>deficiency of cystine desulfhydrase</td>
</tr>
<tr>
<td>574</td>
<td>deficiency of cystine desulphydrase</td>
</tr>
<tr>
<td>575</td>
<td>Deficiency of homoserine deaminase</td>
</tr>
<tr>
<td>576</td>
<td>Deficiency of methionine adenosyltransferase</td>
</tr>
<tr>
<td>577</td>
<td>Familial methionine malabsorption</td>
</tr>
<tr>
<td>578</td>
<td>Hepatic methionine adenosyltransferase deficiency</td>
</tr>
<tr>
<td>579</td>
<td>Homocystinaemia</td>
</tr>
<tr>
<td>580</td>
<td>Hypermethioninaemia</td>
</tr>
<tr>
<td>581</td>
<td>methionine metabolic disorder</td>
</tr>
<tr>
<td>582</td>
<td>Methionine malabsorption syndrome</td>
</tr>
<tr>
<td>583</td>
<td>oast-house disease</td>
</tr>
<tr>
<td>584</td>
<td>oast-house urine disease</td>
</tr>
<tr>
<td>585</td>
<td>oasthouse disease</td>
</tr>
<tr>
<td>586</td>
<td>oasthouse urine disease</td>
</tr>
<tr>
<td>587</td>
<td>Smith-Strang disease</td>
</tr>
<tr>
<td>588</td>
<td>Sulfite oxidase deficiency</td>
</tr>
<tr>
<td>589</td>
<td>sulfite oxidase deficiency syndrome</td>
</tr>
<tr>
<td>590</td>
<td>sulphite oxidase deficiency</td>
</tr>
<tr>
<td>591</td>
<td>sulfocysteinuria</td>
</tr>
<tr>
<td>592</td>
<td>sulphocysteinuria</td>
</tr>
<tr>
<td>593</td>
<td>Hypocalcaemic vitamin D dependent rickets</td>
</tr>
<tr>
<td>594</td>
<td>Vitamin D-dependency type I</td>
</tr>
<tr>
<td>595</td>
<td>Other specified types of Ehlers-Danlos syndrome</td>
</tr>
<tr>
<td>596</td>
<td>Ehlers-Danlos syndrome, hypermobile type</td>
</tr>
<tr>
<td>597</td>
<td>Familial ligamentous laxity</td>
</tr>
<tr>
<td>598</td>
<td>Benign joint hypermobility syndrome</td>
</tr>
<tr>
<td>599</td>
<td>Ehlers-Danlos syndrome type 3</td>
</tr>
<tr>
<td>600</td>
<td>Ehlers-Danlos syndrome, vascular type</td>
</tr>
<tr>
<td>601</td>
<td>Sack-Barabas syndrome</td>
</tr>
<tr>
<td>602</td>
<td>Ehlers-Danlos syndrome type 4</td>
</tr>
<tr>
<td>603</td>
<td>Ehlers-Danlos syndrome, rare variants</td>
</tr>
<tr>
<td>604</td>
<td>Ehlers-Danlos syndrome, X-linked</td>
</tr>
<tr>
<td>605</td>
<td>Ehlers-Danlos syndrome type 5</td>
</tr>
<tr>
<td>606</td>
<td>Ehlers-Danlos syndrome, kyphoscoliotic type</td>
</tr>
<tr>
<td>607</td>
<td>Ehlers-Danlos syndrome type 6</td>
</tr>
<tr>
<td>608</td>
<td>Ehlers-Danlos syndrome type 6A</td>
</tr>
<tr>
<td>609</td>
<td>Ehlers-Danlos syndrome type 6B</td>
</tr>
<tr>
<td>610</td>
<td>Brittle cornea syndrome</td>
</tr>
<tr>
<td>611</td>
<td>Ehlers-Danlos syndrome, arthrochalasic type</td>
</tr>
<tr>
<td>612</td>
<td>Ehlers-Danlos syndrome type 7</td>
</tr>
<tr>
<td>613</td>
<td>Ehlers-Danlos syndrome type 7A</td>
</tr>
<tr>
<td>614</td>
<td>Ehlers-Danlos syndrome type 7B</td>
</tr>
<tr>
<td>615</td>
<td>Ehlers-Danlos syndrome, dermatosparaxis type</td>
</tr>
<tr>
<td>616</td>
<td>Ehlers-Danlos syndrome type 7C</td>
</tr>
<tr>
<td>617</td>
<td>Ehlers-Danlos syndrome, progeroid type</td>
</tr>
<tr>
<td>618</td>
<td>Galactosyltransferase I deficiency</td>
</tr>
<tr>
<td>619</td>
<td>Xylosylprotein 4-beta-galactosyltransferase deficiency</td>
</tr>
<tr>
<td>620</td>
<td>Defective biosynthesis of proteodermatan sulphate</td>
</tr>
<tr>
<td>621</td>
<td>Ehlers-Danlos syndrome, cardiac valvular type</td>
</tr>
<tr>
<td>622</td>
<td>Ehlers-Danlos syndrome, classic-like type</td>
</tr>
<tr>
<td>623</td>
<td>Ehlers-Danlos syndrome with periventricular heterotopia</td>
</tr>
<tr>
<td>624</td>
<td>Ehlers-Danlos-osteogenesis imperfecta syndrome</td>
</tr>
<tr>
<td>625</td>
<td>Ehlers-Danlos syndrome, spondylocheirodysplastic type</td>
</tr>
<tr>
<td>626</td>
<td>Ehlers-Danlos syndrome due to tenascin-X deficiency</td>
</tr>
<tr>
<td>627</td>
<td>Ehlers-Danlos syndrome, periodontitis type</td>
</tr>
<tr>
<td>628</td>
<td>Ehlers-Danlos syndrome type 8</td>
</tr>
<tr>
<td>629</td>
<td>Ehlers-Danlos syndrome, vascular-like type</td>
</tr>
<tr>
<td>630</td>
<td>Ehlers-Danlos syndrome, dysfibronectinaemic type</td>
</tr>
<tr>
<td>631</td>
<td>Ehlers-Danlos syndrome with platelet dysfunction from fibronectin abnormality</td>
</tr>
<tr>
<td>632</td>
<td>Ehlers-Danlos syndrome, fibronectin-deficient</td>
</tr>
<tr>
<td>633</td>
<td>Ehlers-Danlos syndrome type 10</td>
</tr>
<tr>
<td>634</td>
<td>Female Genital Mutilation Type 1, unspecified</td>
</tr>
<tr>
<td>635</td>
<td>Female Genital Mutilation Type 1</td>
</tr>
<tr>
<td>636</td>
<td>Female Genital Mutilation Type I</td>
</tr>
<tr>
<td>637</td>
<td>Other specified inflammatory or other diseases of prostate</td>
</tr>
<tr>
<td>638</td>
<td>Acute bacterial prostatitis</td>
</tr>
<tr>
<td>639</td>
<td>acute prostatitis</td>
</tr>
<tr>
<td>640</td>
<td>Prostatitis category I (NIH classification)</td>
</tr>
<tr>
<td>641</td>
<td>Prostatitis category I</td>
</tr>
<tr>
<td>642</td>
<td>Asymptomatic inflammatory prostatitis</td>
</tr>
<tr>
<td>643</td>
<td>Prostatitis category IV (NIH classification)</td>
</tr>
<tr>
<td>644</td>
<td>Prostatitis category IV</td>
</tr>
<tr>
<td>645</td>
<td>Granulomatous prostatitis</td>
</tr>
<tr>
<td>646</td>
<td>granuloma of prostate</td>
</tr>
<tr>
<td>647</td>
<td>Cyst of prostate</td>
</tr>
<tr>
<td>648</td>
<td>utriculus cyst</td>
</tr>
<tr>
<td>649</td>
<td>prostatic cyst</td>
</tr>
<tr>
<td>650</td>
<td>Stricture of prostate</td>
</tr>
<tr>
<td>651</td>
<td>Fistula of prostate</td>
</tr>
<tr>
<td>652</td>
<td>prostate fistula</td>
</tr>
<tr>
<td>653</td>
<td>prostatic fistula</td>
</tr>
<tr>
<td>654</td>
<td>Infarction of prostate</td>
</tr>
<tr>
<td>655</td>
<td>infarct of prostate</td>
</tr>
<tr>
<td>656</td>
<td>Periprostatic adhesions</td>
</tr>
<tr>
<td>657</td>
<td>Prostatorrhoea</td>
</tr>
<tr>
<td>658</td>
<td>accumulation of secretion of prostate</td>
</tr>
<tr>
<td>659</td>
<td>Acquired deformity of prostate, not elsewhere classified</td>
</tr>
<tr>
<td>660</td>
<td>acquired deformity of prostate NOS</td>
</tr>
<tr>
<td>661</td>
<td>Prostate cicatrix</td>
</tr>
<tr>
<td>662</td>
<td>Prostate contraction</td>
</tr>
<tr>
<td>663</td>
<td>Dilatation of prostate</td>
</tr>
<tr>
<td>664</td>
<td>Periprostatitis</td>
</tr>
<tr>
<td>665</td>
<td>Prostate infection</td>
</tr>
<tr>
<td>666</td>
<td>Langerhans cell histiocytosis involving the skin</td>
</tr>
<tr>
<td>667</td>
<td>Class I histiocytosis involving the skin</td>
</tr>
<tr>
<td>668</td>
<td>Histiocytosis X involving the skin</td>
</tr>
<tr>
<td>669</td>
<td>Classical phenylketonuria</td>
</tr>
<tr>
<td>670</td>
<td>phenylpyruvic oligophrenia</td>
</tr>
<tr>
<td>671</td>
<td>oligophrenia phenylpyruvica</td>
</tr>
<tr>
<td>672</td>
<td>imbecilitus phenylpyruvica</td>
</tr>
<tr>
<td>673</td>
<td>Typical phenylketonuria</td>
</tr>
<tr>
<td>674</td>
<td>phenylpyruvic aciduria</td>
</tr>
<tr>
<td>675</td>
<td>PAH - [phenylalanine hydroxylase] deficiency</td>
</tr>
<tr>
<td>676</td>
<td>hyperphenylalaninaemia Type I</td>
</tr>
<tr>
<td>677</td>
<td>Typical PKU - [phenylketonuria]</td>
</tr>
<tr>
<td>678</td>
<td>Folling disease</td>
</tr>
<tr>
<td>679</td>
<td>Classical phenylketonuria, phenylalanine hydroxylase partial deficiency</td>
</tr>
<tr>
<td>680</td>
<td>Classical phenylketonuria, phenylalanine hydroxylase total deficiency</td>
</tr>
<tr>
<td>681</td>
<td>Congenital sucrase-isomaltase deficiency</td>
</tr>
<tr>
<td>682</td>
<td>Congenital sucrose-isomaltose malabsorption</td>
</tr>
<tr>
<td>683</td>
<td>Disaccharidase deficiency</td>
</tr>
<tr>
<td>684</td>
<td>Invertase deficiency</td>
</tr>
<tr>
<td>685</td>
<td>Sucrase-alpha-dextrinase deficiency</td>
</tr>
<tr>
<td>686</td>
<td>Congenital sucrose intolerance</td>
</tr>
<tr>
<td>687</td>
<td>Disaccharide intolerance type I</td>
</tr>
<tr>
<td>688</td>
<td>CSID - [Congenital sucrase-isomaltase deficiency]</td>
</tr>
<tr>
<td>689</td>
<td>sucrose intolerance of newborn</td>
</tr>
<tr>
<td>690</td>
<td>sucrose intolerance</td>
</tr>
<tr>
<td>691</td>
<td>sucrase deficiency</td>
</tr>
<tr>
<td>692</td>
<td>disaccharide malabsorption</td>
</tr>
<tr>
<td>693</td>
<td>intestinal disaccharidase deficiency</td>
</tr>
<tr>
<td>694</td>
<td>Single umbilical cord artery</td>
</tr>
<tr>
<td>695</td>
<td>Congenital absence and hypoplasia of umbilical artery</td>
</tr>
<tr>
<td>696</td>
<td>congenital absence of umbilical artery</td>
</tr>
<tr>
<td>697</td>
<td>congenital hypoplasia of umbilical artery</td>
</tr>
<tr>
<td>698</td>
<td>umbilical artery hypoplasia</td>
</tr>
<tr>
<td>699</td>
<td>SUA - [Single umbilical cord artery]</td>
</tr>
<tr>
<td>700</td>
<td>absence of umbilical artery</td>
</tr>
<tr>
<td>701</td>
<td>agenesis of umbilical artery</td>
</tr>
<tr>
<td>702</td>
<td>single umbilical artery</td>
</tr>
<tr>
<td>703</td>
<td>Single umbilical cord artery type I</td>
</tr>
<tr>
<td>704</td>
<td>Single umbilical cord artery type II</td>
</tr>
<tr>
<td>705</td>
<td>Single umbilical cord artery type III</td>
</tr>
<tr>
<td>706</td>
<td>Single umbilical cord artery type IV</td>
</tr>
<tr>
<td>707</td>
<td>First degree haemorrhoids</td>
</tr>
<tr>
<td>708</td>
<td>Haemorrhoids (bleeding) without prolapse outside of anal canal</td>
</tr>
<tr>
<td>709</td>
<td>Grade 1 haemorrhoids</td>
</tr>
<tr>
<td>710</td>
<td>stage I haemorrhoids</td>
</tr>
<tr>
<td>711</td>
<td>Thoracic aortic dissection, ascending aorta dissection and propagation beyond arch, without mention of perforation or rupture</td>
</tr>
<tr>
<td>712</td>
<td>Thoracic aortic dissection, ascending aorta dissection and propagation beyond arch</td>
</tr>
<tr>
<td>713</td>
<td>DeBakey type I aortic dissection</td>
</tr>
<tr>
<td>714</td>
<td>Disorders of carnitine transport or the carnitine cycle</td>
</tr>
<tr>
<td>715</td>
<td>Carnitine transporter deficiency</td>
</tr>
<tr>
<td>716</td>
<td>Carnitine brain transporter deficiency</td>
</tr>
<tr>
<td>717</td>
<td>Carnitine uptake deficiency</td>
</tr>
<tr>
<td>718</td>
<td>Primary carnitine deficiency</td>
</tr>
<tr>
<td>719</td>
<td>Carnitine palmitoyltransferase I deficiency</td>
</tr>
<tr>
<td>720</td>
<td>Liver form of carnitine palmitoyltransferase deficiency</td>
</tr>
<tr>
<td>721</td>
<td>CPT1 - [Carnitine palmitoyltransferase I] deficiency</td>
</tr>
<tr>
<td>722</td>
<td>Carnitine palmitoyltransferase II deficiency</td>
</tr>
<tr>
<td>723</td>
<td>CPT2 - [Carnitine palmitoyltransferase II] deficiency</td>
</tr>
<tr>
<td>724</td>
<td>Carnitine palmitoyltransferase II deficiency, myopathic form</td>
</tr>
<tr>
<td>725</td>
<td>Carnitine palmitoyltransferase II deficiency, severe infantile form</td>
</tr>
<tr>
<td>726</td>
<td>Carnitine palmitoyltransferase II deficiency, neonatal form</td>
</tr>
<tr>
<td>727</td>
<td>Carnitine-acylcarnitine translocase deficiency</td>
</tr>
<tr>
<td>728</td>
<td>Muscle carnitine deficiency</td>
</tr>
<tr>
<td>729</td>
<td>Muscle carnitine palmityltransferase deficiency</td>
</tr>
<tr>
<td>730</td>
<td>Other specified structural developmental anomalies of umbilical cord</td>
</tr>
<tr>
<td>731</td>
<td>Umbilical cord calcifications</td>
</tr>
<tr>
<td>732</td>
<td>Omphalomesenteric duct remnants or cysts</td>
</tr>
<tr>
<td>733</td>
<td>Vitelline duct remnants and cysts</td>
</tr>
<tr>
<td>734</td>
<td>Persistent omphalomesenteric duct</td>
</tr>
<tr>
<td>735</td>
<td>Persistent vitelline duct</td>
</tr>
<tr>
<td>736</td>
<td>Patent vitelline duct</td>
</tr>
<tr>
<td>737</td>
<td>Persistent intestinal end of vitelline duct</td>
</tr>
<tr>
<td>738</td>
<td>Umbilical-enteric fistula</td>
</tr>
<tr>
<td>739</td>
<td>Omphaloileal fistula</td>
</tr>
<tr>
<td>740</td>
<td>Patent omphalomesenteric duct</td>
</tr>
<tr>
<td>741</td>
<td>Umbilical sinus</td>
</tr>
<tr>
<td>742</td>
<td>Umbilical cord polyps</td>
</tr>
<tr>
<td>743</td>
<td>Vitelline cyst or remnants</td>
</tr>
<tr>
<td>744</td>
<td>Intraabdominal vitelline cyst or remnants</td>
</tr>
<tr>
<td>745</td>
<td>Umbilical vitelline cyst or remnants</td>
</tr>
<tr>
<td>746</td>
<td>Subcutaneous vitelline cyst or remnants</td>
</tr>
<tr>
<td>747</td>
<td>Congenital vitelline band</td>
</tr>
<tr>
<td>748</td>
<td>Umbilical cord hernia</td>
</tr>
<tr>
<td>749</td>
<td>Umbilical cord pseudocyst</td>
</tr>
<tr>
<td>750</td>
<td>Cystic mucoid degeneration of the umbilical cord</td>
</tr>
<tr>
<td>751</td>
<td>Linear umbilical cord disruption</td>
</tr>
<tr>
<td>752</td>
<td>Umbilical cord agenesis</td>
</tr>
<tr>
<td>753</td>
<td>Acordia</td>
</tr>
<tr>
<td>754</td>
<td>Small-calibre umbilical cord</td>
</tr>
<tr>
<td>755</td>
<td>Large-calibre umbilical cord</td>
</tr>
<tr>
<td>756</td>
<td>Umbilical cord haematoma</td>
</tr>
<tr>
<td>757</td>
<td>Anomalies of umbilical cord insertion</td>
</tr>
<tr>
<td>758</td>
<td>Antenatal separation of umbilical cord</td>
</tr>
<tr>
<td>759</td>
<td>Complete antenatal separation of umbilical cord</td>
</tr>
<tr>
<td>760</td>
<td>Partial antenatal separation of umbilical cord</td>
</tr>
<tr>
<td>761</td>
<td>Umbilical cord torsion</td>
</tr>
<tr>
<td>762</td>
<td>Umbilical cord twist</td>
</tr>
<tr>
<td>763</td>
<td>Umbilical cord helical ulcerations</td>
</tr>
<tr>
<td>764</td>
<td>Umbilical cord neoplasms</td>
</tr>
<tr>
<td>765</td>
<td>Umbilical cord teratoma</td>
</tr>
<tr>
<td>766</td>
<td>Vascular anomalies of umbilical cord</td>
</tr>
<tr>
<td>767</td>
<td>Umbilical cord vein anomalies</td>
</tr>
<tr>
<td>768</td>
<td>Umbilical venous system anomalies</td>
</tr>
<tr>
<td>769</td>
<td>Umbilical cord vein anomalies, group I</td>
</tr>
<tr>
<td>770</td>
<td>Umbilical cord vein anomalies, group II</td>
</tr>
<tr>
<td>771</td>
<td>Umbilical cord vein anomalies, group III</td>
</tr>
<tr>
<td>772</td>
<td>Umbilical cord vein anomalies, group IV</td>
</tr>
<tr>
<td>773</td>
<td>Remnants of vitelline arteries or veins</td>
</tr>
<tr>
<td>774</td>
<td>Vitelline artery disruption</td>
</tr>
<tr>
<td>775</td>
<td>Omphalomesenteric artery disruption</td>
</tr>
<tr>
<td>776</td>
<td>Umbilical arteriovenous fistula</td>
</tr>
<tr>
<td>777</td>
<td>Umbilical aneurysms or varicosities</td>
</tr>
<tr>
<td>778</td>
<td>Fetus or newborn affected by umbilical cord-to-cord entanglements in monoamniotic twins</td>
</tr>
<tr>
<td>779</td>
<td>Fetus or newborn affected by umbilical cord knot</td>
</tr>
<tr>
<td>780</td>
<td>fetus or newborn affected by knot in cord</td>
</tr>
<tr>
<td>781</td>
<td>knot in umbilical cord affecting fetus or newborn</td>
</tr>
<tr>
<td>782</td>
<td>Fetus or newborn affected by umbilical cord loop</td>
</tr>
<tr>
<td>783</td>
<td>Other specified defects in the complement system</td>
</tr>
<tr>
<td>784</td>
<td>Complement component C3 deficiency</td>
</tr>
<tr>
<td>785</td>
<td>Recurrent Neisseria infections due to factor D deficiency</td>
</tr>
<tr>
<td>786</td>
<td>Complement component C4b-binding protein deficiency</td>
</tr>
<tr>
<td>787</td>
<td>Immunodeficiency with CD46 deficiency</td>
</tr>
<tr>
<td>788</td>
<td>Membrane cofactor protein deficiency</td>
</tr>
<tr>
<td>789</td>
<td>Immunodeficiency with decay accelerating factor deficiency</td>
</tr>
<tr>
<td>790</td>
<td>Immunodeficiency with CD55 deficiency</td>
</tr>
<tr>
<td>791</td>
<td>Immunodeficiency with DAF - [decay accelerating factor] deficiency</td>
</tr>
<tr>
<td>792</td>
<td>CHAPLE syndrome</td>
</tr>
<tr>
<td>793</td>
<td>Immunodeficiency with factor H anomaly</td>
</tr>
<tr>
<td>794</td>
<td>Immunodeficiency with factor I anomaly</td>
</tr>
<tr>
<td>795</td>
<td>Immunodeficiency with properdin deficiency</td>
</tr>
<tr>
<td>796</td>
<td>Immunodeficiency with CD59 deficiency</td>
</tr>
<tr>
<td>797</td>
<td>Immunodeficiency with MASP-2 deficiency</td>
</tr>
<tr>
<td>798</td>
<td>Mannan-binding lectin serine protease 2 deficiency</td>
</tr>
<tr>
<td>799</td>
<td>Immunodeficiency with MBL - [mannan-binding lectin] deficiency</td>
</tr>
<tr>
<td>800</td>
<td>Mannan-binding lectin deficiency</td>
</tr>
<tr>
<td>801</td>
<td>Mannose-binding protein deficiency</td>
</tr>
<tr>
<td>802</td>
<td>MBP - [mannan-binding lectin] deficiency</td>
</tr>
<tr>
<td>803</td>
<td>Immunodeficiency with ficolin-3 deficiency</td>
</tr>
<tr>
<td>804</td>
<td>Angioedema due to disordered complement activation or kinin metabolism</td>
</tr>
<tr>
<td>805</td>
<td>Primary lymphoedema</td>
</tr>
<tr>
<td>806</td>
<td>Congenital lymphoedema</td>
</tr>
<tr>
<td>807</td>
<td>Simple primary lymphoedema</td>
</tr>
<tr>
<td>808</td>
<td>Congenital primary lymphoedema</td>
</tr>
<tr>
<td>809</td>
<td>Milroy disease</td>
</tr>
<tr>
<td>810</td>
<td>Hereditary lymphoedema type I</td>
</tr>
<tr>
<td>811</td>
<td>Peripubertal primary lymphoedema</td>
</tr>
<tr>
<td>812</td>
<td>Meige disease</td>
</tr>
<tr>
<td>813</td>
<td>Hereditary lymphoedema type II</td>
</tr>
<tr>
<td>814</td>
<td>Lymphoedema praecox</td>
</tr>
<tr>
<td>815</td>
<td>Sporadic late-onset primary lymphoedema</td>
</tr>
<tr>
<td>816</td>
<td>Complex primary lymphoedema</td>
</tr>
<tr>
<td>817</td>
<td>Lymphoedema with atrial septal defects and facial changes</td>
</tr>
<tr>
<td>818</td>
<td>Lymphoedema-distichiasis syndrome</td>
</tr>
<tr>
<td>819</td>
<td>LDS - [lymphoedema distichiasis syndrome]</td>
</tr>
<tr>
<td>820</td>
<td>Hennekam lymphangiectasia-lymphoedema syndrome</td>
</tr>
<tr>
<td>821</td>
<td>Hennekam syndrome</td>
</tr>
<tr>
<td>822</td>
<td>Lymphoedema, microcephaly and chorioretinopathy syndrome</td>
</tr>
<tr>
<td>823</td>
<td>Deafness, lymphoedema and leukaemia syndrome</td>
</tr>
<tr>
<td>824</td>
<td>Emberger syndrome</td>
</tr>
<tr>
<td>825</td>
<td>Fracture of odontoid process</td>
</tr>
<tr>
<td>826</td>
<td>Fracture of dens</td>
</tr>
<tr>
<td>827</td>
<td>Fracture of dens, Type I</td>
</tr>
<tr>
<td>828</td>
<td>Fracture of dens, Type II</td>
</tr>
<tr>
<td>829</td>
<td>Fracture of dens, Type III</td>
</tr>
<tr>
<td>830</td>
<td>Congenital dyserythropoietic anaemia</td>
</tr>
<tr>
<td>831</td>
<td>congenital dyshaematopoietic anaemia</td>
</tr>
<tr>
<td>832</td>
<td>CDA - [congenital dyserythropoietic anaemia]</td>
</tr>
<tr>
<td>833</td>
<td>dyserythropoietic dyshaematopoietic congenital anaemia</td>
</tr>
<tr>
<td>834</td>
<td>dyshaematopoietic anaemia</td>
</tr>
<tr>
<td>835</td>
<td>dyserythropoietic anaemia</td>
</tr>
<tr>
<td>836</td>
<td>Congenital dyserythropoietic anaemia type I</td>
</tr>
<tr>
<td>837</td>
<td>CDA type 1 -[Congenital dyserythropoietic anaemia type 1]</td>
</tr>
<tr>
<td>838</td>
<td>Congenital dyserythropoietic anaemia type II</td>
</tr>
<tr>
<td>839</td>
<td>CDA type 2 - [Congenital dyserythropoietic anaemia type 2]</td>
</tr>
<tr>
<td>840</td>
<td>Congenital dyserythropoietic anaemia type III</td>
</tr>
<tr>
<td>841</td>
<td>CDA type 3 - [Congenital dyserythropoietic anaemia type 3]</td>
</tr>
<tr>
<td>842</td>
<td>Dyserythropoietic anaemia with thrombocytopenia</td>
</tr>
<tr>
<td>843</td>
<td>X-linked dyserythropoietic anaemia and thrombocytopenia</td>
</tr>
<tr>
<td>844</td>
<td>Other specified mitochondrial myopathies</td>
</tr>
<tr>
<td>845</td>
<td>Mitochondrial myopathy with cytochrome C oxidase deficiency</td>
</tr>
<tr>
<td>846</td>
<td>Mitochondrial myopathy with cytochrome C oxidase deficiency, severe infantile form</td>
</tr>
<tr>
<td>847</td>
<td>Mitochondrial myopathy with coenzyme Q deficiency</td>
</tr>
<tr>
<td>848</td>
<td>CoQ - [Mitochondrial myopathy with coenzyme Q deficiency]</td>
</tr>
<tr>
<td>849</td>
<td>CoQ deficiency</td>
</tr>
<tr>
<td>850</td>
<td>Mitochondrial myopathy with complex I deficiency</td>
</tr>
<tr>
<td>851</td>
<td>Luft disease</td>
</tr>
<tr>
<td>852</td>
<td>Mitochondrial neurogastrointestinal encephalopathy</td>
</tr>
<tr>
<td>853</td>
<td>MNGIE - [Mitochondrial neurogastrointestinal encephalopathy]</td>
</tr>
<tr>
<td>854</td>
<td>Point mutations of mitochondrial DNA</td>
</tr>
<tr>
<td>855</td>
<td>Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes</td>
</tr>
<tr>
<td>856</td>
<td>MELAS - [Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes] syndrome</td>
</tr>
<tr>
<td>857</td>
<td>MELAS - [Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes]</td>
</tr>
<tr>
<td>858</td>
<td>Myoclonic epilepsy, ragged red fibres</td>
</tr>
<tr>
<td>859</td>
<td>Fukuhara syndrome</td>
</tr>
<tr>
<td>860</td>
<td>MERRF - [Myoclonic epilepsy - ragged red fibres] syndrome</td>
</tr>
<tr>
<td>861</td>
<td>MERRF - [Myoclonic epilepsy - ragged red fibres]</td>
</tr>
<tr>
<td>862</td>
<td>Leber hereditary optic neuropathy</td>
</tr>
<tr>
<td>863</td>
<td>LHON - [Leber hereditary optic neuropathy]</td>
</tr>
<tr>
<td>864</td>
<td>Leber optic neuropathy</td>
</tr>
<tr>
<td>865</td>
<td>Leber atrophy</td>
</tr>
<tr>
<td>866</td>
<td>Leber hereditary optic atrophy</td>
</tr>
<tr>
<td>867</td>
<td>Leber optic atrophy</td>
</tr>
<tr>
<td>868</td>
<td>Leber 'plus' disease</td>
</tr>
<tr>
<td>869</td>
<td>Maternally inherited Leigh syndrome</td>
</tr>
<tr>
<td>870</td>
<td>MILS - [Maternally inherited Leigh syndrome]</td>
</tr>
<tr>
<td>871</td>
<td>Maternally inherited mitochondrial dystonia</td>
</tr>
<tr>
<td>872</td>
<td>Maternally inherited mitochondrial cardiomyopathy</td>
</tr>
<tr>
<td>873</td>
<td>Maternally inherited mitochondrial myopathy</td>
</tr>
<tr>
<td>874</td>
<td>Pure mitochondrial myopathy</td>
</tr>
<tr>
<td>875</td>
<td>Lethal infantile mitochondrial myopathy</td>
</tr>
<tr>
<td>876</td>
<td>Mitochondrial myopathy with diabetes mellitus</td>
</tr>
<tr>
<td>877</td>
<td>Mitochondrial myopathy with reversible cytochrome C oxidase deficiency</td>
</tr>
<tr>
<td>878</td>
<td>Mitochondrial myopathy with reversible COX - [cytochrome C oxidase] deficiency</td>
</tr>
<tr>
<td>879</td>
<td>Non-syndromic mitochondrial sensorineural deafness</td>
</tr>
<tr>
<td>880</td>
<td>Isolated mitochondrial neurosensory deafness</td>
</tr>
<tr>
<td>881</td>
<td>Isolated mitochondrial sensorineural deafness</td>
</tr>
<tr>
<td>882</td>
<td>Nonsyndromic mitochondrial neurosensory deafness</td>
</tr>
<tr>
<td>883</td>
<td>Cryoglobulinaemia</td>
</tr>
<tr>
<td>884</td>
<td>Cryoglobulinaemia Type I</td>
</tr>
<tr>
<td>885</td>
<td>monoclonal cryoglobulin</td>
</tr>
<tr>
<td>886</td>
<td>monoclonal cryoglobulinaemia</td>
</tr>
<tr>
<td>887</td>
<td>simple cryoglobulinaemia</td>
</tr>
<tr>
<td>888</td>
<td>Cryoglobulinaemia Type II</td>
</tr>
<tr>
<td>889</td>
<td>mixed, monoclonal immunoglobulin with antibody activity against immunoglobulin</td>
</tr>
<tr>
<td>890</td>
<td>Cryoglobulinaemia Type III</td>
</tr>
<tr>
<td>891</td>
<td>mixed, polyclonal immunoglobulin with antibody activity against immunoglobulin</td>
</tr>
<tr>
<td>892</td>
<td>Renal tubulo-interstitial disorders in simple cryoglobulinaemia</td>
</tr>
<tr>
<td>893</td>
<td>Respiratory disorders in simple cryoglobulinaemia</td>
</tr>
<tr>
<td>894</td>
<td>Cryoglobulinaemic purpura</td>
</tr>
<tr>
<td>1</td>
<td>Disorders of multiple glycosylation or other pathways</td>
</tr>
<tr>
<td>2</td>
<td>Dolichol-phosphate-mannose synthase 1 deficiency</td>
</tr>
<tr>
<td>3</td>
<td>GDP-Man: Dol-P-mannosyltransferase deficiency</td>
</tr>
<tr>
<td>4</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1E</td>
</tr>
<tr>
<td>5</td>
<td>Congenital disorder of glycosylation type 1E</td>
</tr>
<tr>
<td>6</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1E</td>
</tr>
<tr>
<td>7</td>
<td>Mannose-P-dolichol utilisation defect 1</td>
</tr>
<tr>
<td>8</td>
<td>Lec35 deficiency</td>
</tr>
<tr>
<td>9</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1F</td>
</tr>
<tr>
<td>10</td>
<td>Congenital disorder of glycosylation type 1F</td>
</tr>
<tr>
<td>11</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1F</td>
</tr>
<tr>
<td>12</td>
<td>Beta-1,4-galactosyltransferase deficiency</td>
</tr>
<tr>
<td>13</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2D</td>
</tr>
<tr>
<td>14</td>
<td>Congenital disorder of glycosylation type 2D</td>
</tr>
<tr>
<td>15</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2D</td>
</tr>
<tr>
<td>16</td>
<td>CMP-sialic acid transporter deficiency</td>
</tr>
<tr>
<td>17</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2F</td>
</tr>
<tr>
<td>18</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2F</td>
</tr>
<tr>
<td>19</td>
<td>Congenital disorder of glycosylation type 2F</td>
</tr>
<tr>
<td>20</td>
<td>Leukocyte adhesion deficiency type 2</td>
</tr>
<tr>
<td>21</td>
<td>Rambam-Hasharon syndrome</td>
</tr>
<tr>
<td>22</td>
<td>GDP-fucose transporter deficiency</td>
</tr>
<tr>
<td>23</td>
<td>LAD-II - [Leukocyte adhesion deficiency type 2]</td>
</tr>
<tr>
<td>24</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2C</td>
</tr>
<tr>
<td>25</td>
<td>Dolichol kinase deficiency</td>
</tr>
<tr>
<td>26</td>
<td>Hypotonia or ichthyosis due to dolichol phosphate deficiency</td>
</tr>
<tr>
<td>27</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1M</td>
</tr>
<tr>
<td>28</td>
<td>Congenital disorder of glycosylation type 1M</td>
</tr>
<tr>
<td>29</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1M</td>
</tr>
<tr>
<td>30</td>
<td>Conserved oligomeric Golgi complex deficiencies</td>
</tr>
<tr>
<td>31</td>
<td>Component of conserved oligomeric Golgi complex 1 deficiency</td>
</tr>
<tr>
<td>32</td>
<td>CDG syndrome type 2G</td>
</tr>
<tr>
<td>33</td>
<td>Component of conserved oligomeric Golgi complex 4 deficiency</td>
</tr>
<tr>
<td>34</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2J</td>
</tr>
<tr>
<td>35</td>
<td>Congenital disorder of glycosylation type 2J</td>
</tr>
<tr>
<td>36</td>
<td>Component of conserved oligomeric Golgi complex 5 deficiency</td>
</tr>
<tr>
<td>37</td>
<td>Component of conserved oligomeric Golgi complex 7 deficiency</td>
</tr>
<tr>
<td>38</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2E</td>
</tr>
<tr>
<td>39</td>
<td>Congenital disorder of glycosylation type 2E</td>
</tr>
<tr>
<td>40</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2E</td>
</tr>
<tr>
<td>41</td>
<td>Component of conserved oligomeric Golgi complex 8 deficiency</td>
</tr>
<tr>
<td>42</td>
<td>Congenital disorder of glycosylation type 2h</td>
</tr>
<tr>
<td>43</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2H</td>
</tr>
<tr>
<td>44</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2H</td>
</tr>
<tr>
<td>45</td>
<td>V-ATPase deficiencies</td>
</tr>
<tr>
<td>46</td>
<td>Disorders of protein N-glycosylation</td>
</tr>
<tr>
<td>47</td>
<td>Phosphomannomutase 2 deficiency</td>
</tr>
<tr>
<td>48</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1A</td>
</tr>
<tr>
<td>49</td>
<td>Congenital disorder of glycosylation type 1A</td>
</tr>
<tr>
<td>50</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1A</td>
</tr>
<tr>
<td>51</td>
<td>Phosphomannose isomerase deficiency</td>
</tr>
<tr>
<td>52</td>
<td>Saguenay-Lac-Saint-Jean syndrome</td>
</tr>
<tr>
<td>53</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1B</td>
</tr>
<tr>
<td>54</td>
<td>Congenital disorder of glycosylation type 1B</td>
</tr>
<tr>
<td>55</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1B</td>
</tr>
<tr>
<td>56</td>
<td>SLSJ - [Saguenay-Lac-Saint-Jean] syndrome</td>
</tr>
<tr>
<td>57</td>
<td>Glucosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>58</td>
<td>Dol-P-Glc: Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>59</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1C</td>
</tr>
<tr>
<td>60</td>
<td>Congenital disorder of glycosylation type 1C</td>
</tr>
<tr>
<td>61</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1C</td>
</tr>
<tr>
<td>62</td>
<td>Mannosyltransferase 6 deficiency</td>
</tr>
<tr>
<td>63</td>
<td>Dol-P-Man: Man5-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>64</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1D</td>
</tr>
<tr>
<td>65</td>
<td>Congenital disorder of glycosylation type 1D</td>
</tr>
<tr>
<td>66</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1D</td>
</tr>
<tr>
<td>67</td>
<td>Mannosyltransferase 8 deficiency</td>
</tr>
<tr>
<td>68</td>
<td>Dol-P-Man: Man7-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>69</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1G</td>
</tr>
<tr>
<td>70</td>
<td>Congenital disorder of glycosylation type 1G</td>
</tr>
<tr>
<td>71</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1G</td>
</tr>
<tr>
<td>72</td>
<td>Glucosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>73</td>
<td>Dol-P-Glc: Glc1-Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>74</td>
<td>Carbohydrate deficient glycoprotein syndrome 1H</td>
</tr>
<tr>
<td>75</td>
<td>Congenital disorder of glycosylation type 1H</td>
</tr>
<tr>
<td>76</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1H</td>
</tr>
<tr>
<td>77</td>
<td>Mannosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>78</td>
<td>Dol-P-Man: Man1-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>79</td>
<td>Carbohydrate deficient glycoprotein syndrome 1I</td>
</tr>
<tr>
<td>80</td>
<td>Congenital disorder of glycosylation 1I</td>
</tr>
<tr>
<td>81</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1I</td>
</tr>
<tr>
<td>82</td>
<td>Dolichyl-phosphate N-acetylgalactosamine phosphotransferase deficiency</td>
</tr>
<tr>
<td>83</td>
<td>UDP-GlcNAc: Dol-P-GlcNac-P transferase deficiency</td>
</tr>
<tr>
<td>84</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1J</td>
</tr>
<tr>
<td>85</td>
<td>Congenital disorder of glycosylation type 1J</td>
</tr>
<tr>
<td>86</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1J</td>
</tr>
<tr>
<td>87</td>
<td>Mannosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>88</td>
<td>Dol-P-Man: GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>89</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1K</td>
</tr>
<tr>
<td>90</td>
<td>Congenital disorder of glycosylation type 1K</td>
</tr>
<tr>
<td>91</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1K</td>
</tr>
<tr>
<td>92</td>
<td>Mannosyltransferase 7-9 deficiency</td>
</tr>
<tr>
<td>93</td>
<td>Congenital disorder of glycosylation type 1L</td>
</tr>
<tr>
<td>94</td>
<td>Dol-P-Man: Man6 and Man8-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>95</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1L</td>
</tr>
<tr>
<td>96</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1L</td>
</tr>
<tr>
<td>97</td>
<td>M5-DLO flippase deficiency</td>
</tr>
<tr>
<td>98</td>
<td>Man5GlcNAc2-PP-Dol flippase deficiency</td>
</tr>
<tr>
<td>99</td>
<td>RTF1-CDG</td>
</tr>
<tr>
<td>100</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1N</td>
</tr>
<tr>
<td>101</td>
<td>N-acetylglucosaminyltransferase deficiency</td>
</tr>
<tr>
<td>102</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2A</td>
</tr>
<tr>
<td>103</td>
<td>Congenital disorder of glycosylation type 2A</td>
</tr>
<tr>
<td>104</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2A</td>
</tr>
<tr>
<td>105</td>
<td>Glucosidase 1 deficiency</td>
</tr>
<tr>
<td>106</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2B</td>
</tr>
<tr>
<td>107</td>
<td>Congenital disorder of glycosylation type 2B</td>
</tr>
<tr>
<td>108</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2B</td>
</tr>
<tr>
<td>109</td>
<td>TUSC3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>110</td>
<td>TUSC3-CDG</td>
</tr>
<tr>
<td>111</td>
<td>SRD5A3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>112</td>
<td>SRD5A3-CDG</td>
</tr>
<tr>
<td>113</td>
<td>Congenital disorder of glycosylation due to steroid 5-alpha-reductase type 3 deficiency</td>
</tr>
<tr>
<td>114</td>
<td>Intellectual deficit - cataract - coloboma - kyphosis</td>
</tr>
<tr>
<td>115</td>
<td>Kahrizi syndrome</td>
</tr>
<tr>
<td>116</td>
<td>Intellectual deficit, Kahrizi type</td>
</tr>
<tr>
<td>117</td>
<td>DPM3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>118</td>
<td>Congenital disorder of glycosylation type 1O</td>
</tr>
<tr>
<td>119</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1O</td>
</tr>
<tr>
<td>120</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1O</td>
</tr>
<tr>
<td>121</td>
<td>ALG11 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>122</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1P</td>
</tr>
<tr>
<td>123</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1P</td>
</tr>
<tr>
<td>124</td>
<td>Congenital disorder of glycosylation type 1P</td>
</tr>
<tr>
<td>125</td>
<td>Phosphoglucomutase-1 deficiency</td>
</tr>
<tr>
<td>126</td>
<td>PGM1-CDG - [Phosphoglucomutase-1 deficiency]</td>
</tr>
<tr>
<td>127</td>
<td>Congenital disorder of glycosylation type 1t</td>
</tr>
<tr>
<td>128</td>
<td>Recessive limb-girdle muscular dystrophy</td>
</tr>
<tr>
<td>129</td>
<td>LGMD2 - [Limb-girdle muscular dystrophy] 2</td>
</tr>
<tr>
<td>130</td>
<td>Limb-girdle muscular dystrophy 2A, calpain-3 deficiency</td>
</tr>
<tr>
<td>131</td>
<td>Limb-girdle muscular dystrophy 2B, dysferlin deficiency</td>
</tr>
<tr>
<td>132</td>
<td>Limb-girdle muscular dystrophy 2C, gamma-sarcoglycan deficiency</td>
</tr>
<tr>
<td>133</td>
<td>Limb-girdle muscular dystrophy 2D, alpha-sarcoglycan deficiency</td>
</tr>
<tr>
<td>134</td>
<td>Limb-girdle muscular dystrophy 2E, beta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>135</td>
<td>Limb-girdle muscular dystrophy 2F, delta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>136</td>
<td>Limb-girdle muscular dystrophy 2G, telethonin gene mutation</td>
</tr>
<tr>
<td>137</td>
<td>Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation</td>
</tr>
<tr>
<td>138</td>
<td>LGMD 2H - [Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation]</td>
</tr>
<tr>
<td>139</td>
<td>Limb-girdle muscular dystrophy 2I, fukutin related protein gene mutation</td>
</tr>
<tr>
<td>140</td>
<td>FKRP - [fukutin related protein gene mutation]</td>
</tr>
<tr>
<td>141</td>
<td>LGMD 2I - [Limb-girdle muscular dystrophy 2I]</td>
</tr>
<tr>
<td>142</td>
<td>Limb-girdle muscular dystrophy 2J, Titin gene mutation</td>
</tr>
<tr>
<td>143</td>
<td>LGMD 2J - [Limb-girdle muscular dystrophy 2J, Titin gene mutation]</td>
</tr>
<tr>
<td>144</td>
<td>Limb-girdle muscular dystrophy 2K, protein-O-mannosyltransferase 1 transferase</td>
</tr>
<tr>
<td>145</td>
<td>POMT1 - [protein-O-mannosyltransferase 1 transferase]</td>
</tr>
<tr>
<td>146</td>
<td>LGMD 2K - [Limb-girdle muscular dystrophy 2K]</td>
</tr>
<tr>
<td>147</td>
<td>Limb-girdle muscular dystrophy 2L, AN05 gene mutation</td>
</tr>
<tr>
<td>148</td>
<td>LGMD 2L - [Limb-girdle muscular dystrophy 2L]</td>
</tr>
<tr>
<td>149</td>
<td>Limb-girdle muscular dystrophy 2M, POMGnT1 gene mutation</td>
</tr>
<tr>
<td>150</td>
<td>LGMD2M - [limb-girdle muscular dystrophy 2M]</td>
</tr>
<tr>
<td>151</td>
<td>Limb-girdle muscular dystrophy 2N, POMT2 gene mutation</td>
</tr>
<tr>
<td>152</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C2)</td>
</tr>
<tr>
<td>153</td>
<td>MDDGC2</td>
</tr>
<tr>
<td>154</td>
<td>LGMD2N - limb-girdle muscular dystrophy 2N]</td>
</tr>
<tr>
<td>155</td>
<td>Limb-girdle muscular dystrophy 2O, POMGNT1 gene mutation</td>
</tr>
<tr>
<td>156</td>
<td>LGMD2O - [limb-girdle muscular dystrophy 2O]</td>
</tr>
<tr>
<td>157</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C3)</td>
</tr>
<tr>
<td>158</td>
<td>MDDGC3</td>
</tr>
<tr>
<td>159</td>
<td>Limb-girdle muscular dystrophy 2Q, plectin deficiency</td>
</tr>
<tr>
<td>160</td>
<td>LGMD2Q - [limb-girdle muscular dystrophy 2Q]</td>
</tr>
<tr>
<td>161</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy C7</td>
</tr>
<tr>
<td>162</td>
<td>MDDGC7</td>
</tr>
<tr>
<td>163</td>
<td>J-shaped sella turcica</td>
</tr>
<tr>
<td>164</td>
<td>Early repolarisation syndrome</td>
</tr>
<tr>
<td>165</td>
<td>inferolateral J wave elevation syndrome</td>
</tr>
<tr>
<td>166</td>
<td>Charcot-Marie-Tooth disease 2 axonal</td>
</tr>
<tr>
<td>167</td>
<td>Charcot-Marie-Tooth disease 2 autosomal dominant</td>
</tr>
<tr>
<td>168</td>
<td>Recessive axonal Charcot-Marie-Tooth disease with acrodystrophy</td>
</tr>
<tr>
<td>169</td>
<td>Charcot-Marie-Tooth disease type 2A1</td>
</tr>
<tr>
<td>170</td>
<td>Charcot-Marie-Tooth disease type 2A2</td>
</tr>
<tr>
<td>171</td>
<td>Charcot-Marie-Tooth disease type 2B</td>
</tr>
<tr>
<td>172</td>
<td>Charcot-Marie-Tooth disease type 2C</td>
</tr>
<tr>
<td>173</td>
<td>Charcot-Marie-Tooth disease type 2D</td>
</tr>
<tr>
<td>174</td>
<td>Charcot-Marie-Tooth disease type 2E</td>
</tr>
<tr>
<td>175</td>
<td>Charcot-Marie-Tooth disease type 2F</td>
</tr>
<tr>
<td>176</td>
<td>Charcot-Marie-Tooth disease type 2G</td>
</tr>
<tr>
<td>177</td>
<td>Charcot-Marie-Tooth disease type 2I</td>
</tr>
<tr>
<td>178</td>
<td>Charcot-Marie-Tooth disease type 2J</td>
</tr>
<tr>
<td>179</td>
<td>Charcot-Marie-Tooth disease type 2K</td>
</tr>
<tr>
<td>180</td>
<td>Charcot-Marie-Tooth disease type 2L</td>
</tr>
<tr>
<td>181</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2M</td>
</tr>
<tr>
<td>182</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2N</td>
</tr>
<tr>
<td>183</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2O</td>
</tr>
<tr>
<td>184</td>
<td>Charcot-Marie-Tooth disease 2 autosomal recessive</td>
</tr>
<tr>
<td>185</td>
<td>Charcot-Marie-Tooth disease type 2B1</td>
</tr>
<tr>
<td>186</td>
<td>Charcot-Marie-Tooth disease type 2B2</td>
</tr>
<tr>
<td>187</td>
<td>Charcot-Marie-Tooth disease type 2B5</td>
</tr>
<tr>
<td>188</td>
<td>Charcot-Marie-Tooth disease type 2H</td>
</tr>
<tr>
<td>189</td>
<td>Autosomal recessive Charcot-Marie-Tooth disease with hoarseness</td>
</tr>
<tr>
<td>190</td>
<td>Hereditary motor and sensory neuropathy type 6</td>
</tr>
<tr>
<td>191</td>
<td>Charcot-Marie-Tooth type 6</td>
</tr>
<tr>
<td>192</td>
<td>HMSN6 - [Hereditary motor and sensory neuropathy type 6]</td>
</tr>
<tr>
<td>193</td>
<td>CMT6 - [Charcot-Marie-Tooth type 6]</td>
</tr>
<tr>
<td>194</td>
<td>Charcot-Marie-Tooth disease 1 demyelinating</td>
</tr>
<tr>
<td>195</td>
<td>Charcot-Marie-Tooth disease 1 autosomal dominant</td>
</tr>
<tr>
<td>196</td>
<td>Charcot-Marie-Tooth disease type 1E</td>
</tr>
<tr>
<td>197</td>
<td>Charcot-Marie-Tooth disease type 1B</td>
</tr>
<tr>
<td>198</td>
<td>Charcot-Marie-Tooth disease type 1C</td>
</tr>
<tr>
<td>199</td>
<td>Charcot-Marie-Tooth disease type 1D</td>
</tr>
<tr>
<td>200</td>
<td>Charcot-Marie-Tooth disease type 1F</td>
</tr>
<tr>
<td>201</td>
<td>Charcot-Marie-Tooth disease 1 autosomal recessive</td>
</tr>
<tr>
<td>202</td>
<td>Charcot-Marie-Tooth disease type 4</td>
</tr>
<tr>
<td>203</td>
<td>CMT4 - [Charcot-Marie-Tooth disease type 4]</td>
</tr>
<tr>
<td>204</td>
<td>Charcot-Marie-Tooth disease - deafness - intellectual deficit</td>
</tr>
<tr>
<td>205</td>
<td>Charcot-Marie-Tooth disease type 4A</td>
</tr>
<tr>
<td>206</td>
<td>Charcot-Marie-Tooth disease type 4C</td>
</tr>
<tr>
<td>207</td>
<td>Charcot-Marie-Tooth disease type 4D</td>
</tr>
<tr>
<td>208</td>
<td>Charcot-Marie-Tooth disease type 4E</td>
</tr>
<tr>
<td>209</td>
<td>Charcot-Marie-Tooth disease type 4F</td>
</tr>
<tr>
<td>210</td>
<td>Charcot-Marie-Tooth disease type 4G</td>
</tr>
<tr>
<td>211</td>
<td>Charcot-Marie-Tooth disease type 4H</td>
</tr>
<tr>
<td>212</td>
<td>Charcot-Marie-Tooth disease type 4B1</td>
</tr>
<tr>
<td>213</td>
<td>Charcot-Marie-Tooth disease type 4B2</td>
</tr>
<tr>
<td>214</td>
<td>Charcot-Marie-Tooth disease type 4J</td>
</tr>
<tr>
<td>215</td>
<td>X-linked Charcot-Marie-Tooth disease 1 due to mutations in gap junction protein beta 1</td>
</tr>
<tr>
<td>216</td>
<td>X-linked Charcot-Marie-Tooth disease 1 secondary to mutations in gap junction protein beta 1</td>
</tr>
<tr>
<td>217</td>
<td>Charcot-Marie-Tooth disease 1X, x-linked Charcot-Marie-Tooth disease 1 due to mutations in gap junction protein beta 1</td>
</tr>
<tr>
<td>218</td>
<td>Charcot-Marie-Tooth disease 1X, x-linked Charcot-Marie-Tooth disease 1 secondary to mutations in gap junction protein beta 1</td>
</tr>
<tr>
<td>219</td>
<td>Hereditary sensorimotor neuropathy with hyperelastic skin</td>
</tr>
<tr>
<td>1</td>
<td>Vitamin K deficiency</td>
</tr>
<tr>
<td>2</td>
<td>Immunodeficiencies with isotype or light chain deficiencies with normal number of B cells</td>
</tr>
<tr>
<td>3</td>
<td>Recurrent infections associated with immunoglobulin isotypes deficiency</td>
</tr>
<tr>
<td>4</td>
<td>Recurrent infections associated with immunoglobulin isotypes</td>
</tr>
<tr>
<td>5</td>
<td>Deficiency of immunoglobulin A with immunoglobulin G subclasses deficiency</td>
</tr>
<tr>
<td>6</td>
<td>Deficiency of IgA with IgG subclasses deficiency</td>
</tr>
<tr>
<td>7</td>
<td>Immunoglobulin heavy chain deficiency</td>
</tr>
<tr>
<td>8</td>
<td>Deficiency of IgG and/or IgA subclasses and/or IgE</td>
</tr>
<tr>
<td>9</td>
<td>K chain deficiency</td>
</tr>
<tr>
<td>10</td>
<td>Selective deficiency of immunoglobulin A</td>
</tr>
<tr>
<td>11</td>
<td>Selective deficiency of IgA</td>
</tr>
<tr>
<td>12</td>
<td>selective immunodeficiency of immunoglobulin A (IgA)</td>
</tr>
<tr>
<td>13</td>
<td>Selective deficiency of immunoglobulin G subclasses</td>
</tr>
<tr>
<td>14</td>
<td>immunoglobin g subclass deficiency</td>
</tr>
<tr>
<td>15</td>
<td>immunoglobulin g subclass deficiency</td>
</tr>
<tr>
<td>16</td>
<td>selective deficiency of IgG</td>
</tr>
<tr>
<td>17</td>
<td>selective immunoglobulin g deficiency</td>
</tr>
<tr>
<td>18</td>
<td>Selective deficiency of IgG subclasses</td>
</tr>
<tr>
<td>19</td>
<td>IgG subclass deficiency</td>
</tr>
<tr>
<td>20</td>
<td>selective IgG immunodeficiency</td>
</tr>
<tr>
<td>21</td>
<td>Selective deficiency of immunoglobulin M</td>
</tr>
<tr>
<td>22</td>
<td>Selective deficiency of IgM</td>
</tr>
<tr>
<td>23</td>
<td>selective IgM immunodeficiency</td>
</tr>
<tr>
<td>24</td>
<td>selective immunodeficiency of immunoglobulin M (IgM)</td>
</tr>
<tr>
<td>25</td>
<td>Hypokalaemia</td>
</tr>
<tr>
<td>26</td>
<td>Potassium [K] deficiency</td>
</tr>
<tr>
<td>27</td>
<td>Potassium deficiency</td>
</tr>
<tr>
<td>28</td>
<td>hypokalaemic syndrome</td>
</tr>
<tr>
<td>29</td>
<td>hypopotassaemia</td>
</tr>
<tr>
<td>30</td>
<td>hypopotassaemia syndrome</td>
</tr>
<tr>
<td>31</td>
<td>hypokalaemic</td>
</tr>
<tr>
<td>32</td>
<td>potassium depletion</td>
</tr>
<tr>
<td>33</td>
<td>Hyperkalaemia</td>
</tr>
<tr>
<td>34</td>
<td>Potassium [K] excess</td>
</tr>
<tr>
<td>35</td>
<td>Potassium [K] overload</td>
</tr>
<tr>
<td>36</td>
<td>hyperaemic syndrome</td>
</tr>
<tr>
<td>37</td>
<td>hyperpotassaemia</td>
</tr>
<tr>
<td>38</td>
<td>potassium intoxication syndrome</td>
</tr>
<tr>
<td>39</td>
<td>hyperkalaemic syndrome</td>
</tr>
<tr>
<td>40</td>
<td>Other specified lysosomal diseases</td>
</tr>
<tr>
<td>41</td>
<td>Pycnodysostosis</td>
</tr>
<tr>
<td>42</td>
<td>Cathepsin K deficiency</td>
</tr>
<tr>
<td>43</td>
<td>Follow-up care involving removal of fracture plate or other internal fixation device</td>
</tr>
<tr>
<td>44</td>
<td>Change of internal fixation device</td>
</tr>
<tr>
<td>45</td>
<td>change of fixation device</td>
</tr>
<tr>
<td>46</td>
<td>change of Kirschner wire</td>
</tr>
<tr>
<td>47</td>
<td>Checking of internal fixation device</td>
</tr>
<tr>
<td>48</td>
<td>checking of Kirschner wire</td>
</tr>
<tr>
<td>49</td>
<td>Removal of internal fixation device</td>
</tr>
<tr>
<td>50</td>
<td>removal of k-wire</td>
</tr>
<tr>
<td>51</td>
<td>removal of Kirschner wire internal bone fixator</td>
</tr>
<tr>
<td>52</td>
<td>removal of pin</td>
</tr>
<tr>
<td>53</td>
<td>removal of plate</td>
</tr>
<tr>
<td>54</td>
<td>removal of rod</td>
</tr>
<tr>
<td>55</td>
<td>removal of screw</td>
</tr>
<tr>
<td>56</td>
<td>Disorders of protein N-glycosylation</td>
</tr>
<tr>
<td>57</td>
<td>Phosphomannomutase 2 deficiency</td>
</tr>
<tr>
<td>58</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1A</td>
</tr>
<tr>
<td>59</td>
<td>Congenital disorder of glycosylation type 1A</td>
</tr>
<tr>
<td>60</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1A</td>
</tr>
<tr>
<td>61</td>
<td>Phosphomannose isomerase deficiency</td>
</tr>
<tr>
<td>62</td>
<td>Saguenay-Lac-Saint-Jean syndrome</td>
</tr>
<tr>
<td>63</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1B</td>
</tr>
<tr>
<td>64</td>
<td>Congenital disorder of glycosylation type 1B</td>
</tr>
<tr>
<td>65</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1B</td>
</tr>
<tr>
<td>66</td>
<td>SLSJ - [Saguenay-Lac-Saint-Jean] syndrome</td>
</tr>
<tr>
<td>67</td>
<td>Glucosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>68</td>
<td>Dol-P-Glc: Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>69</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1C</td>
</tr>
<tr>
<td>70</td>
<td>Congenital disorder of glycosylation type 1C</td>
</tr>
<tr>
<td>71</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1C</td>
</tr>
<tr>
<td>72</td>
<td>Mannosyltransferase 6 deficiency</td>
</tr>
<tr>
<td>73</td>
<td>Dol-P-Man: Man5-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>74</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1D</td>
</tr>
<tr>
<td>75</td>
<td>Congenital disorder of glycosylation type 1D</td>
</tr>
<tr>
<td>76</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1D</td>
</tr>
<tr>
<td>77</td>
<td>Mannosyltransferase 8 deficiency</td>
</tr>
<tr>
<td>78</td>
<td>Dol-P-Man: Man7-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>79</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1G</td>
</tr>
<tr>
<td>80</td>
<td>Congenital disorder of glycosylation type 1G</td>
</tr>
<tr>
<td>81</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1G</td>
</tr>
<tr>
<td>82</td>
<td>Glucosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>83</td>
<td>Dol-P-Glc: Glc1-Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>84</td>
<td>Carbohydrate deficient glycoprotein syndrome 1H</td>
</tr>
<tr>
<td>85</td>
<td>Congenital disorder of glycosylation type 1H</td>
</tr>
<tr>
<td>86</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1H</td>
</tr>
<tr>
<td>87</td>
<td>Mannosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>88</td>
<td>Dol-P-Man: Man1-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>89</td>
<td>Carbohydrate deficient glycoprotein syndrome 1I</td>
</tr>
<tr>
<td>90</td>
<td>Congenital disorder of glycosylation 1I</td>
</tr>
<tr>
<td>91</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1I</td>
</tr>
<tr>
<td>92</td>
<td>Dolichyl-phosphate N-acetylgalactosamine phosphotransferase deficiency</td>
</tr>
<tr>
<td>93</td>
<td>UDP-GlcNAc: Dol-P-GlcNac-P transferase deficiency</td>
</tr>
<tr>
<td>94</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1J</td>
</tr>
<tr>
<td>95</td>
<td>Congenital disorder of glycosylation type 1J</td>
</tr>
<tr>
<td>96</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1J</td>
</tr>
<tr>
<td>97</td>
<td>Mannosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>98</td>
<td>Dol-P-Man: GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>99</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1K</td>
</tr>
<tr>
<td>100</td>
<td>Congenital disorder of glycosylation type 1K</td>
</tr>
<tr>
<td>101</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1K</td>
</tr>
<tr>
<td>102</td>
<td>Mannosyltransferase 7-9 deficiency</td>
</tr>
<tr>
<td>103</td>
<td>Congenital disorder of glycosylation type 1L</td>
</tr>
<tr>
<td>104</td>
<td>Dol-P-Man: Man6 and Man8-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>105</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1L</td>
</tr>
<tr>
<td>106</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1L</td>
</tr>
<tr>
<td>107</td>
<td>M5-DLO flippase deficiency</td>
</tr>
<tr>
<td>108</td>
<td>Man5GlcNAc2-PP-Dol flippase deficiency</td>
</tr>
<tr>
<td>109</td>
<td>RTF1-CDG</td>
</tr>
<tr>
<td>110</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1N</td>
</tr>
<tr>
<td>111</td>
<td>N-acetylglucosaminyltransferase deficiency</td>
</tr>
<tr>
<td>112</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2A</td>
</tr>
<tr>
<td>113</td>
<td>Congenital disorder of glycosylation type 2A</td>
</tr>
<tr>
<td>114</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2A</td>
</tr>
<tr>
<td>115</td>
<td>Glucosidase 1 deficiency</td>
</tr>
<tr>
<td>116</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2B</td>
</tr>
<tr>
<td>117</td>
<td>Congenital disorder of glycosylation type 2B</td>
</tr>
<tr>
<td>118</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2B</td>
</tr>
<tr>
<td>119</td>
<td>TUSC3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>120</td>
<td>TUSC3-CDG</td>
</tr>
<tr>
<td>121</td>
<td>SRD5A3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>122</td>
<td>SRD5A3-CDG</td>
</tr>
<tr>
<td>123</td>
<td>Congenital disorder of glycosylation due to steroid 5-alpha-reductase type 3 deficiency</td>
</tr>
<tr>
<td>124</td>
<td>Intellectual deficit - cataract - coloboma - kyphosis</td>
</tr>
<tr>
<td>125</td>
<td>Kahrizi syndrome</td>
</tr>
<tr>
<td>126</td>
<td>Intellectual deficit, Kahrizi type</td>
</tr>
<tr>
<td>127</td>
<td>DPM3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>128</td>
<td>Congenital disorder of glycosylation type 1O</td>
</tr>
<tr>
<td>129</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1O</td>
</tr>
<tr>
<td>130</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1O</td>
</tr>
<tr>
<td>131</td>
<td>ALG11 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>132</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1P</td>
</tr>
<tr>
<td>133</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1P</td>
</tr>
<tr>
<td>134</td>
<td>Congenital disorder of glycosylation type 1P</td>
</tr>
<tr>
<td>135</td>
<td>Phosphoglucomutase-1 deficiency</td>
</tr>
<tr>
<td>136</td>
<td>PGM1-CDG - [Phosphoglucomutase-1 deficiency]</td>
</tr>
<tr>
<td>137</td>
<td>Congenital disorder of glycosylation type 1t</td>
</tr>
<tr>
<td>138</td>
<td>Neonatal vitamin K deficiency, unspecified</td>
</tr>
<tr>
<td>139</td>
<td>Neonatal vitamin K deficiency</td>
</tr>
<tr>
<td>140</td>
<td>Epidermolysis bullosa simplex</td>
</tr>
<tr>
<td>141</td>
<td>Epidermolytic epidermolysis bullosa</td>
</tr>
<tr>
<td>142</td>
<td>Suprabasal epidermolysis bullosa simplex</td>
</tr>
<tr>
<td>143</td>
<td>Suprabasal EBS</td>
</tr>
<tr>
<td>144</td>
<td>Acantholytic epidermolysis bullosa</td>
</tr>
<tr>
<td>145</td>
<td>LAEB - [lethal acantholytic epidermolysis bullosa] due to desmoplakin deficiency (MIM 609638)</td>
</tr>
<tr>
<td>146</td>
<td>EBS-acanth</td>
</tr>
<tr>
<td>147</td>
<td>LAEB</td>
</tr>
<tr>
<td>148</td>
<td>Lethal acantholytic epidermolysis bullosa</td>
</tr>
<tr>
<td>149</td>
<td>Epidermolysis bullosa simplex superficialis</td>
</tr>
<tr>
<td>150</td>
<td>EBS - [epidermolysis bullosa simplex] superficialis</td>
</tr>
<tr>
<td>151</td>
<td>EBSS - [epidermolysis bullosa simplex superficialis]</td>
</tr>
<tr>
<td>152</td>
<td>Ectodermal dysplasia – skin fragility syndrome</td>
</tr>
<tr>
<td>153</td>
<td>Plakophilin 1 deficiency</td>
</tr>
<tr>
<td>154</td>
<td>ED – SF - [Ectodermal dysplasia – skin fragility] syndrome (MIM 604536)</td>
</tr>
<tr>
<td>155</td>
<td>EBS-plakophilin</td>
</tr>
<tr>
<td>156</td>
<td>Skin fragility - ectodermal dysplasia syndrome</td>
</tr>
<tr>
<td>157</td>
<td>Skin fragility - plakoglobin deficiency</td>
</tr>
<tr>
<td>158</td>
<td>EBS-plakoglobin</td>
</tr>
<tr>
<td>159</td>
<td>Basal epidermolysis bullosa simplex</td>
</tr>
<tr>
<td>160</td>
<td>Basal EBS - [basal epidermolysis bullosa simplex]</td>
</tr>
<tr>
<td>161</td>
<td>Autosomal dominant basal epidermolysis bullosa simplex</td>
</tr>
<tr>
<td>162</td>
<td>Epidermolysis bullosa simplex, localised</td>
</tr>
<tr>
<td>163</td>
<td>Epidermolysis bullosa simplex, Weber-Cockayne</td>
</tr>
<tr>
<td>164</td>
<td>localised EBS- [epidermolysis bullosa simplex]</td>
</tr>
<tr>
<td>165</td>
<td>Epidermolysis bullosa simplex with mottled pigmentation</td>
</tr>
<tr>
<td>166</td>
<td>EBS - [epidermolysis bullosa simplex] with mottled pigmentation</td>
</tr>
<tr>
<td>167</td>
<td>EBS-MP - [epidermolysis bullosa simplex with mottled pigmentation]</td>
</tr>
<tr>
<td>168</td>
<td>Epidermolysis bullosa simplex, Ogna</td>
</tr>
<tr>
<td>169</td>
<td>EBS, Ogna - [epidermolysis bullosa simplex, Ogna]</td>
</tr>
<tr>
<td>170</td>
<td>EBS-Og - [epidermolysis bullosa simplex, Ogna]</td>
</tr>
<tr>
<td>171</td>
<td>Epidermolysis bullosa simplex, generalised severe</td>
</tr>
<tr>
<td>172</td>
<td>Epidermolysis bullosa herpetiformis</td>
</tr>
<tr>
<td>173</td>
<td>EBS-DM - [generalised epidermolysis bullosa simplex, Dowling-Meara]</td>
</tr>
<tr>
<td>174</td>
<td>EBS - [epidermolysis bullosa simplex] Dowling-Meara</td>
</tr>
<tr>
<td>175</td>
<td>EBS-gen sev - [epidermolysis bullosa simplex generalised type]</td>
</tr>
<tr>
<td>176</td>
<td>Epidermolysis bullosa simplex, generalised intermediate</td>
</tr>
<tr>
<td>177</td>
<td>EBS, gen-nDM - [generalised epidermolysis bullosa simplex, non-Dowling-Meara]</td>
</tr>
<tr>
<td>178</td>
<td>EBS - [epidermolysis bullosa simplex] non-Dowling-Meara</td>
</tr>
<tr>
<td>179</td>
<td>EBS-gen intermed</td>
</tr>
<tr>
<td>180</td>
<td>Autosomal recessive basal epidermolysis bullosa simplex</td>
</tr>
<tr>
<td>181</td>
<td>Epidermolysis bullosa simplex, migratory circinate</td>
</tr>
<tr>
<td>182</td>
<td>EBS - [epidermolysis bullosa simplex] migratory circinate</td>
</tr>
<tr>
<td>183</td>
<td>Epidermolysis bullosa simplex with muscular dystrophy</td>
</tr>
<tr>
<td>184</td>
<td>EBS - [epidermolysis bullosa simplex] with muscular dystrophy</td>
</tr>
<tr>
<td>185</td>
<td>Epidermolysis bullosa simplex with limb-girdle muscular dystrophy</td>
</tr>
<tr>
<td>186</td>
<td>EBS-MD - [epidermolysis bullosa simplex with muscular dystrophy]</td>
</tr>
<tr>
<td>187</td>
<td>Epidermolysis bullosa simplex with pyloric atresia</td>
</tr>
<tr>
<td>188</td>
<td>EBS-PA - [epidermolysis bullosa simplex with pyloric atresia]</td>
</tr>
<tr>
<td>189</td>
<td>EBS - [epidermolysis bullosa simplex] with pyloric atresia</td>
</tr>
<tr>
<td>190</td>
<td>Autosomal recessive epidermolysis bullosa simplex due to BP230 deficiency</td>
</tr>
<tr>
<td>191</td>
<td>EBS - [epidermolysis bullosa simplex] new subtype</td>
</tr>
<tr>
<td>192</td>
<td>EBS - [epidermolysis bullosa simplex] other specified autosomal recessive</td>
</tr>
<tr>
<td>193</td>
<td>EBS-AR BP230</td>
</tr>
<tr>
<td>194</td>
<td>Epidermolysis bullosa simplex, autosomal recessive due to exophilin 5 deficiency</td>
</tr>
<tr>
<td>195</td>
<td>EBS-AR - [epidermolysis bullosa simplex, autosomal recessive]</td>
</tr>
<tr>
<td>196</td>
<td>EBS - [epidermolysis bullosa simplex] autosomal recessive</td>
</tr>
<tr>
<td>197</td>
<td>EBS-AR exophilin 5</td>
</tr>
<tr>
<td>198</td>
<td>Epidermolysis bullosa simplex, autosomal recessive keratin 14 deficiency</td>
</tr>
<tr>
<td>199</td>
<td>EBS-AR K14 - [epidermolysis bullosa simplex - autosomal recessive keratin 14]</td>
</tr>
<tr>
<td>200</td>
<td>Recessive limb-girdle muscular dystrophy</td>
</tr>
<tr>
<td>201</td>
<td>LGMD2 - [Limb-girdle muscular dystrophy] 2</td>
</tr>
<tr>
<td>202</td>
<td>Limb-girdle muscular dystrophy 2A, calpain-3 deficiency</td>
</tr>
<tr>
<td>203</td>
<td>Limb-girdle muscular dystrophy 2B, dysferlin deficiency</td>
</tr>
<tr>
<td>204</td>
<td>Limb-girdle muscular dystrophy 2C, gamma-sarcoglycan deficiency</td>
</tr>
<tr>
<td>205</td>
<td>Limb-girdle muscular dystrophy 2D, alpha-sarcoglycan deficiency</td>
</tr>
<tr>
<td>206</td>
<td>Limb-girdle muscular dystrophy 2E, beta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>207</td>
<td>Limb-girdle muscular dystrophy 2F, delta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>208</td>
<td>Limb-girdle muscular dystrophy 2G, telethonin gene mutation</td>
</tr>
<tr>
<td>209</td>
<td>Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation</td>
</tr>
<tr>
<td>210</td>
<td>LGMD 2H - [Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation]</td>
</tr>
<tr>
<td>211</td>
<td>Limb-girdle muscular dystrophy 2I, fukutin related protein gene mutation</td>
</tr>
<tr>
<td>212</td>
<td>FKRP - [fukutin related protein gene mutation]</td>
</tr>
<tr>
<td>213</td>
<td>LGMD 2I - [Limb-girdle muscular dystrophy 2I]</td>
</tr>
<tr>
<td>214</td>
<td>Limb-girdle muscular dystrophy 2J, Titin gene mutation</td>
</tr>
<tr>
<td>215</td>
<td>LGMD 2J - [Limb-girdle muscular dystrophy 2J, Titin gene mutation]</td>
</tr>
<tr>
<td>216</td>
<td>Limb-girdle muscular dystrophy 2K, protein-O-mannosyltransferase 1 transferase</td>
</tr>
<tr>
<td>217</td>
<td>POMT1 - [protein-O-mannosyltransferase 1 transferase]</td>
</tr>
<tr>
<td>218</td>
<td>LGMD 2K - [Limb-girdle muscular dystrophy 2K]</td>
</tr>
<tr>
<td>219</td>
<td>Limb-girdle muscular dystrophy 2L, AN05 gene mutation</td>
</tr>
<tr>
<td>220</td>
<td>LGMD 2L - [Limb-girdle muscular dystrophy 2L]</td>
</tr>
<tr>
<td>221</td>
<td>Limb-girdle muscular dystrophy 2M, POMGnT1 gene mutation</td>
</tr>
<tr>
<td>222</td>
<td>LGMD2M - [limb-girdle muscular dystrophy 2M]</td>
</tr>
<tr>
<td>223</td>
<td>Limb-girdle muscular dystrophy 2N, POMT2 gene mutation</td>
</tr>
<tr>
<td>224</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C2)</td>
</tr>
<tr>
<td>225</td>
<td>MDDGC2</td>
</tr>
<tr>
<td>226</td>
<td>LGMD2N - limb-girdle muscular dystrophy 2N]</td>
</tr>
<tr>
<td>227</td>
<td>Limb-girdle muscular dystrophy 2O, POMGNT1 gene mutation</td>
</tr>
<tr>
<td>228</td>
<td>LGMD2O - [limb-girdle muscular dystrophy 2O]</td>
</tr>
<tr>
<td>229</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C3)</td>
</tr>
<tr>
<td>230</td>
<td>MDDGC3</td>
</tr>
<tr>
<td>231</td>
<td>Limb-girdle muscular dystrophy 2Q, plectin deficiency</td>
</tr>
<tr>
<td>232</td>
<td>LGMD2Q - [limb-girdle muscular dystrophy 2Q]</td>
</tr>
<tr>
<td>233</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy C7</td>
</tr>
<tr>
<td>234</td>
<td>MDDGC7</td>
</tr>
<tr>
<td>235</td>
<td>Other specified haemorrhagic diseases due to acquired coagulation factor defects</td>
</tr>
<tr>
<td>236</td>
<td>Deficiency of coagulation factor due to vitamin K deficiency</td>
</tr>
<tr>
<td>237</td>
<td>Deficiency of coagulation factor due to nutritional vitamin K deficiency</td>
</tr>
<tr>
<td>238</td>
<td>Deficiency of coagulation factor due to other cause of vitamin K deficiency</td>
</tr>
<tr>
<td>239</td>
<td>Deficiency of coagulation factor due to other cause of vitamin K deficiency, coeliac disease included</td>
</tr>
<tr>
<td>240</td>
<td>Deficiency of coagulation factor due to vitamin K malabsorption in intestinal disease</td>
</tr>
<tr>
<td>241</td>
<td>Deficiency of coagulation factor due to vitamin K malabsorption in obstructive biliary disease</td>
</tr>
<tr>
<td>242</td>
<td>Deficiency of coagulation factor due to vitamin K malabsorption in obstructive biliary disease, congenital biliary atresia included</td>
</tr>
<tr>
<td>243</td>
<td>Other non-autoimmune acquired coagulation factor deficiencies</td>
</tr>
<tr>
<td>244</td>
<td>Acquired von Willebrand disease</td>
</tr>
<tr>
<td>245</td>
<td>Acquired von Willebrand syndrome</td>
</tr>
<tr>
<td>246</td>
<td>Acquired Von Willebrand disease due to myeloproliferative neoplasm or reactive thrombocytosis</td>
</tr>
<tr>
<td>247</td>
<td>Acquired Von Willebrand disease due to stenotic aortic valve or cardiac malformation</td>
</tr>
<tr>
<td>248</td>
<td>Heyde syndrome</td>
</tr>
<tr>
<td>249</td>
<td>Factor X deficiency associated with systemic amyloidosis</td>
</tr>
<tr>
<td>250</td>
<td>Acquired prothrombin complex deficiency</td>
</tr>
<tr>
<td>251</td>
<td>Acquired hypoprothrombinaemia</td>
</tr>
<tr>
<td>252</td>
<td>Deficiency of coagulation factor due to liver disease</td>
</tr>
<tr>
<td>253</td>
<td>Acquired factor II deficiency</td>
</tr>
<tr>
<td>254</td>
<td>Acquired factor V deficiency disease</td>
</tr>
<tr>
<td>255</td>
<td>acquired hypoproaccelerinaemia</td>
</tr>
<tr>
<td>256</td>
<td>acquired labile factor deficiency</td>
</tr>
<tr>
<td>257</td>
<td>acquired proaccelerin deficiency</td>
</tr>
<tr>
<td>258</td>
<td>Acquired factor VII deficiency disease</td>
</tr>
<tr>
<td>259</td>
<td>acquired hypoproconvertinaemia</td>
</tr>
<tr>
<td>260</td>
<td>Acquired fibrin stabilizing factor deficiency</td>
</tr>
<tr>
<td>261</td>
<td>acquired fibrinopenia</td>
</tr>
<tr>
<td>262</td>
<td>Acquired idiopathic hypoprothrombinaemia</td>
</tr>
<tr>
<td>263</td>
<td>Acquired stable factor deficiency</td>
</tr>
<tr>
<td>264</td>
<td>Other specified neonatal vitamin K deficiency</td>
</tr>
<tr>
<td>265</td>
<td>Embryofetopathy due to oral anticoagulant therapy</td>
</tr>
<tr>
<td>266</td>
<td>Fetal warfarin syndrome</td>
</tr>
<tr>
<td>267</td>
<td>Coumarin embryopathy</td>
</tr>
<tr>
<td>268</td>
<td>Vitamin K antagonists embryofetopathy</td>
</tr>
<tr>
<td>269</td>
<td>Dysmorphism due to warfarin</td>
</tr>
<tr>
<td>270</td>
<td>Haemorrhagic disorder due to other specified circulating anticoagulants or coagulation factors</td>
</tr>
<tr>
<td>271</td>
<td>Haemorrhagic disorders due to circulating anticoagulants, drug-induced</td>
</tr>
<tr>
<td>272</td>
<td>haemorrhagic disorder due to overwarfarinisation</td>
</tr>
<tr>
<td>273</td>
<td>Haemorrhage due to low molecular weight heparin</td>
</tr>
<tr>
<td>274</td>
<td>Haemorrhage due to unfractionated heparin</td>
</tr>
<tr>
<td>275</td>
<td>Haemorrhage due to vitamin K antagonist</td>
</tr>
<tr>
<td>276</td>
<td>Haemorrhage due to vitamin K antagonist including superwarfarins</td>
</tr>
<tr>
<td>277</td>
<td>Haemorrhage during long-term use of anticoagulants</td>
</tr>
<tr>
<td>278</td>
<td>Hyperheparinaemia</td>
</tr>
<tr>
<td>279</td>
<td>Haemorrhagic disorder due to increase of antithrombin</td>
</tr>
<tr>
<td>280</td>
<td>Haemorrhagic disorder due to increase of anti-VIII</td>
</tr>
<tr>
<td>281</td>
<td>Haemorrhagic disorder due to increase in anti-VIIIa</td>
</tr>
<tr>
<td>282</td>
<td>Haemorrhagic disorder due to increase in anti-IXa</td>
</tr>
<tr>
<td>283</td>
<td>Haemorrhagic disorder due to increase in anti-Xa</td>
</tr>
<tr>
<td>284</td>
<td>Haemorrhagic disorder due to increase in anti-XIa</td>
</tr>
<tr>
<td>285</td>
<td>Diffuse bleeding diathesis due to vitamin K deficient haemorrhagic disease of fetus or newborn</td>
</tr>
<tr>
<td>286</td>
<td>Diffuse bleeding diathesis secondary to vitamin K deficient haemorrhagic disease of fetus and newborn</td>
</tr>
<tr>
<td>287</td>
<td>newborn vitamin K deficiency</td>
</tr>
<tr>
<td>288</td>
<td>newborn haemorrhagic disorder</td>
</tr>
<tr>
<td>289</td>
<td>Diffuse bleeding diathesis due to vitamin K deficient haemorrhagic disease of fetus or newborn, early</td>
</tr>
<tr>
<td>290</td>
<td>Diffuse bleeding diathesis secondary to vitamin K deficient haemorrhagic disease of fetus and newborn, early</td>
</tr>
<tr>
<td>291</td>
<td>Diffuse bleeding diathesis due to vitamin K deficient haemorrhagic disease of fetus or newborn, classic</td>
</tr>
<tr>
<td>292</td>
<td>Diffuse bleeding diathesis secondary to vitamin K deficient haemorrhagic disease of fetus and newborn, classic</td>
</tr>
<tr>
<td>293</td>
<td>Diffuse bleeding diathesis due to vitamin K deficient haemorrhagic disease of fetus or newborn, late</td>
</tr>
<tr>
<td>294</td>
<td>Diffuse bleeding diathesis secondary to vitamin K deficient haemorrhagic disease of fetus and newborn, late</td>
</tr>
<tr>
<td>295</td>
<td>Combined deficiency of vitamin K-dependent clotting factors</td>
</tr>
<tr>
<td>296</td>
<td>Combined deficiency of factors II,VII,IX and X</td>
</tr>
<tr>
<td>297</td>
<td>Vitamin K epoxide reductase deficiency</td>
</tr>
<tr>
<td>298</td>
<td>Other inherited coagulation factor deficiency with bleeding tendency, unspecified</td>
</tr>
<tr>
<td>299</td>
<td>Other inherited coagulation factor deficiency with bleeding tendency</td>
</tr>
<tr>
<td>300</td>
<td>Hereditary factor V deficiency</td>
</tr>
<tr>
<td>301</td>
<td>Proaccelerin deficiency</td>
</tr>
<tr>
<td>302</td>
<td>Owren disease</td>
</tr>
<tr>
<td>303</td>
<td>congenital factor V deficiency</td>
</tr>
<tr>
<td>304</td>
<td>Deficiency of factor V</td>
</tr>
<tr>
<td>305</td>
<td>Deficiency of factor V, labile</td>
</tr>
<tr>
<td>306</td>
<td>hereditary factor V deficiency disease</td>
</tr>
<tr>
<td>307</td>
<td>Parahaemophilia</td>
</tr>
<tr>
<td>308</td>
<td>Hereditary factor XIII deficiency</td>
</tr>
<tr>
<td>309</td>
<td>hereditary factor XIII deficiency disease</td>
</tr>
<tr>
<td>310</td>
<td>factor XIII deficiency disease</td>
</tr>
<tr>
<td>311</td>
<td>congenital factor XIII deficiency</td>
</tr>
<tr>
<td>312</td>
<td>deficiency of factor XIII</td>
</tr>
<tr>
<td>313</td>
<td>deficiency of stable factor</td>
</tr>
<tr>
<td>314</td>
<td>Combined deficiency of factor V and factor VIII</td>
</tr>
<tr>
<td>315</td>
<td>Familial multiple coagulation factor deficiency</td>
</tr>
<tr>
<td>316</td>
<td>FV - [factor 5] and FVIII - [factor 8] combined deficiency</td>
</tr>
<tr>
<td>317</td>
<td>Hereditary vitamin K-dependent coagulation factors deficiency</td>
</tr>
<tr>
<td>318</td>
<td>Hereditary factor II deficiency</td>
</tr>
<tr>
<td>319</td>
<td>Prothrombin deficiency</td>
</tr>
<tr>
<td>320</td>
<td>congenital factor II deficiency</td>
</tr>
<tr>
<td>321</td>
<td>deficiency of factor 2</td>
</tr>
<tr>
<td>322</td>
<td>hereditary factor II deficiency disease</td>
</tr>
<tr>
<td>323</td>
<td>Dysprothrombinaemia</td>
</tr>
<tr>
<td>324</td>
<td>constitutional dysprothrombinaemia</td>
</tr>
<tr>
<td>325</td>
<td>Hypoprothrombinaemia</td>
</tr>
<tr>
<td>326</td>
<td>idiopathic hypoprothrombinaemia</td>
</tr>
<tr>
<td>327</td>
<td>congenital hypoprothrombinaemia</td>
</tr>
<tr>
<td>328</td>
<td>Hereditary factor VII deficiency</td>
</tr>
<tr>
<td>329</td>
<td>Congenital proconvertin deficiency</td>
</tr>
<tr>
<td>330</td>
<td>proconvertin deficiency</td>
</tr>
<tr>
<td>331</td>
<td>Hypoproconvertinaemia</td>
</tr>
<tr>
<td>332</td>
<td>congenital factor VII deficiency</td>
</tr>
<tr>
<td>333</td>
<td>Deficiency of factor VII</td>
</tr>
<tr>
<td>334</td>
<td>factor VII deficiency</td>
</tr>
<tr>
<td>335</td>
<td>hereditary factor VII deficiency disease</td>
</tr>
<tr>
<td>336</td>
<td>hereditary factor VII deficiency syndrome</td>
</tr>
<tr>
<td>337</td>
<td>hereditary hypoproconvertinaemia</td>
</tr>
<tr>
<td>338</td>
<td>acquired deficiency of proconvertin</td>
</tr>
<tr>
<td>339</td>
<td>Acquired factor V deficiency</td>
</tr>
<tr>
<td>340</td>
<td>Harmful effects of drugs, medicaments or biological substances, not elsewhere classified</td>
</tr>
<tr>
<td>341</td>
<td>drugs, medicaments or biological substances, toxicity not elsewhere classified</td>
</tr>
<tr>
<td>342</td>
<td>adverse drug effects</td>
</tr>
<tr>
<td>343</td>
<td>drug reaction NOS</td>
</tr>
<tr>
<td>344</td>
<td>drug allergy NOS</td>
</tr>
<tr>
<td>345</td>
<td>drug toxicity NOS</td>
</tr>
<tr>
<td>346</td>
<td>drug ingestion NOS</td>
</tr>
<tr>
<td>347</td>
<td>toxic effects of drugs NOS</td>
</tr>
<tr>
<td>348</td>
<td>acute drug intoxication</td>
</tr>
<tr>
<td>349</td>
<td>toxic use of drugs</td>
</tr>
<tr>
<td>350</td>
<td>intake of a toxic substance</td>
</tr>
<tr>
<td>351</td>
<td>Harmful effects of opioids or related analgesics</td>
</tr>
<tr>
<td>352</td>
<td>Harmful effects of opium</td>
</tr>
<tr>
<td>353</td>
<td>Harmful effects of morphine</td>
</tr>
<tr>
<td>354</td>
<td>Harmful effects of oxycodone</td>
</tr>
<tr>
<td>355</td>
<td>oxycodone toxicity</td>
</tr>
<tr>
<td>356</td>
<td>Harmful effects of codeine</td>
</tr>
<tr>
<td>357</td>
<td>Harmful effects of heroin</td>
</tr>
<tr>
<td>358</td>
<td>poisoning by diacetylmorphine</td>
</tr>
<tr>
<td>359</td>
<td>poisoning by heroin</td>
</tr>
<tr>
<td>360</td>
<td>poisoning by heroin NOS</td>
</tr>
<tr>
<td>361</td>
<td>acute heroin intoxication</td>
</tr>
<tr>
<td>362</td>
<td>acute heroin toxicity</td>
</tr>
<tr>
<td>363</td>
<td>toxic effects of heroin</td>
</tr>
<tr>
<td>364</td>
<td>Harmful effects of methadone</td>
</tr>
<tr>
<td>365</td>
<td>poisoning by methadone</td>
</tr>
<tr>
<td>366</td>
<td>poisoning by methadone NOS</td>
</tr>
<tr>
<td>367</td>
<td>methadone toxicity</td>
</tr>
<tr>
<td>368</td>
<td>Harmful effects of pethidine</td>
</tr>
<tr>
<td>369</td>
<td>pethidine poisoning</td>
</tr>
<tr>
<td>370</td>
<td>Harmful effects of fentanyl</td>
</tr>
<tr>
<td>371</td>
<td>fentanyl poisoning</td>
</tr>
<tr>
<td>372</td>
<td>fentanyl toxicity</td>
</tr>
<tr>
<td>373</td>
<td>toxic effects of fentanyl</td>
</tr>
<tr>
<td>374</td>
<td>fentanyl toxication</td>
</tr>
<tr>
<td>375</td>
<td>acute fentanyl toxicity</td>
</tr>
<tr>
<td>376</td>
<td>Harmful effects of phenoperidine</td>
</tr>
<tr>
<td>377</td>
<td>phenoperidine poisoning</td>
</tr>
<tr>
<td>378</td>
<td>Fentanyl and heroin toxicity</td>
</tr>
<tr>
<td>379</td>
<td>Harmful effects of sedative hypnotic drugs or other CNS depressants</td>
</tr>
<tr>
<td>380</td>
<td>Harmful effects of sedative-hypnotic drugs</td>
</tr>
<tr>
<td>381</td>
<td>hypnotic poisoning</td>
</tr>
<tr>
<td>382</td>
<td>sleeping draught NOS poisoning</td>
</tr>
<tr>
<td>383</td>
<td>sleeping drug NOS poisoning</td>
</tr>
<tr>
<td>384</td>
<td>sleeping tablet NOS poisoning</td>
</tr>
<tr>
<td>385</td>
<td>Harmful effects of barbiturates</td>
</tr>
<tr>
<td>386</td>
<td>Harmful effects of benzodiazepines</td>
</tr>
<tr>
<td>387</td>
<td>Harmful effects of chlordiazepoxide</td>
</tr>
<tr>
<td>388</td>
<td>chlordiazepoxide poisoning</td>
</tr>
<tr>
<td>389</td>
<td>Harmful effects of clozapine</td>
</tr>
<tr>
<td>390</td>
<td>clozapine poisoning</td>
</tr>
<tr>
<td>391</td>
<td>Harmful effects of cloral derivatives</td>
</tr>
<tr>
<td>392</td>
<td>Harmful effects of paraldehyde</td>
</tr>
<tr>
<td>393</td>
<td>Harmful effects of bromine compounds</td>
</tr>
<tr>
<td>394</td>
<td>Harmful effects of mixed sedatives or hypnotics, not elsewhere classified</td>
</tr>
<tr>
<td>395</td>
<td>Harmful effects of anaesthetics or therapeutic gases</td>
</tr>
<tr>
<td>396</td>
<td>Harmful effects of anaesthetics or therapeutic gases, nitrous oxide</td>
</tr>
<tr>
<td>397</td>
<td>Harmful effects of anaesthetics or therapeutic gases, other inhaled anaesthetics</td>
</tr>
<tr>
<td>398</td>
<td>Harmful effects of anaesthetics or therapeutic gases, intravenous anaesthetics</td>
</tr>
<tr>
<td>399</td>
<td>Harmful effects of anaesthetics or therapeutic gases, unspecified general anaesthetics</td>
</tr>
<tr>
<td>400</td>
<td>Harmful effects of anaesthetics or therapeutic gases, gamma hydroxybutyrate</td>
</tr>
<tr>
<td>401</td>
<td>Harmful effects of anaesthetics or therapeutic gases, ketamine</td>
</tr>
<tr>
<td>402</td>
<td>ketamine poisoning</td>
</tr>
<tr>
<td>403</td>
<td>Harmful effects of anaesthetics or therapeutic gases, other specified general anaesthetic</td>
</tr>
<tr>
<td>404</td>
<td>Harmful effects of anaesthetics or therapeutic gases, local anaesthetics</td>
</tr>
<tr>
<td>405</td>
<td>Harmful effects of cinchocaine</td>
</tr>
<tr>
<td>406</td>
<td>cinchocaine poisoning</td>
</tr>
<tr>
<td>407</td>
<td>Harmful effects of oxybuprocaine</td>
</tr>
<tr>
<td>408</td>
<td>oxybuprocaine poisoning</td>
</tr>
<tr>
<td>409</td>
<td>Harmful effects of psychostimulants</td>
</tr>
<tr>
<td>410</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Central nervous system stimulants, not elsewhere classified</td>
</tr>
<tr>
<td>411</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Analeptics</td>
</tr>
<tr>
<td>412</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Opioid receptor antagonists</td>
</tr>
<tr>
<td>413</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Caffeine</td>
</tr>
<tr>
<td>414</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Amphetamine</td>
</tr>
<tr>
<td>415</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Methylamphetamine</td>
</tr>
<tr>
<td>416</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Methylenedioxy methamphetamine</td>
</tr>
<tr>
<td>417</td>
<td>methamphetamine toxicity</td>
</tr>
<tr>
<td>418</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Other specified amphetamines</td>
</tr>
<tr>
<td>419</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Cocaine</td>
</tr>
<tr>
<td>420</td>
<td>poisoning by cocaine NOS</td>
</tr>
<tr>
<td>421</td>
<td>cocaine toxicity</td>
</tr>
<tr>
<td>422</td>
<td>acute cocaine toxicity</td>
</tr>
<tr>
<td>423</td>
<td>toxic effects of cocaine</td>
</tr>
<tr>
<td>424</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Methylphenidate</td>
</tr>
<tr>
<td>425</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Cathinone</td>
</tr>
<tr>
<td>426</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Cathinone derivatives</td>
</tr>
<tr>
<td>427</td>
<td>Harmful effects of Cannabinoids or hallucinogens</td>
</tr>
<tr>
<td>428</td>
<td>Harmful effects of Cannabis</td>
</tr>
<tr>
<td>429</td>
<td>cannabis poisoning</td>
</tr>
<tr>
<td>430</td>
<td>poisoning by cannabis derivative</td>
</tr>
<tr>
<td>431</td>
<td>poisoning by marijuana</td>
</tr>
<tr>
<td>432</td>
<td>poisoning by marijuana derivative</td>
</tr>
<tr>
<td>433</td>
<td>Harmful effects of synthetic cannabinoids</td>
</tr>
<tr>
<td>434</td>
<td>Harmful effects of Lysergide</td>
</tr>
<tr>
<td>435</td>
<td>Harmful effects of unspecified psychodysleptics</td>
</tr>
<tr>
<td>436</td>
<td>harmful effect of unspecified hallucinogens</td>
</tr>
<tr>
<td>437</td>
<td>Harmful effects of other psychodysleptics</td>
</tr>
<tr>
<td>438</td>
<td>Other hallucinogens</td>
</tr>
<tr>
<td>439</td>
<td>Harmful effects of analgesics, antipyretics or anti-inflammatory drugs</td>
</tr>
<tr>
<td>440</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, analgesics, antipyretics or anti-inflammatory drugs, Aspirin</td>
</tr>
<tr>
<td>441</td>
<td>aspirin poisoning</td>
</tr>
<tr>
<td>442</td>
<td>Harmful effects of other salicylates</td>
</tr>
<tr>
<td>443</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, analgesics, antipyretics or anti-inflammatory drugs, Paracetamol</td>
</tr>
<tr>
<td>444</td>
<td>paracetamol poisoning</td>
</tr>
<tr>
<td>445</td>
<td>Harmful effects of 4-Aminophenol derivatives</td>
</tr>
<tr>
<td>446</td>
<td>Harmful effects of Pyrazolone derivatives</td>
</tr>
<tr>
<td>447</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, analgesics, antipyretics or anti-inflammatory drugs, Ibuprofen</td>
</tr>
<tr>
<td>448</td>
<td>ibuprofen poisoning</td>
</tr>
<tr>
<td>449</td>
<td>Harmful effects of other propionic acid derivatives</td>
</tr>
<tr>
<td>450</td>
<td>Harmful effects of Indomethacin</td>
</tr>
<tr>
<td>451</td>
<td>indometacin poisoning</td>
</tr>
<tr>
<td>452</td>
<td>indomethacin poisoning</td>
</tr>
<tr>
<td>453</td>
<td>Harmful effects of other nonsteroidal anti-inflammatory drugs</td>
</tr>
<tr>
<td>454</td>
<td>poisoning by NSAID - [nonsteroidal anti-inflammatory drugs]</td>
</tr>
<tr>
<td>455</td>
<td>Harmful effects of etodolac</td>
</tr>
<tr>
<td>456</td>
<td>etodolac poisoning</td>
</tr>
<tr>
<td>457</td>
<td>Harmful effects of antirheumatics, not elsewhere classified</td>
</tr>
<tr>
<td>458</td>
<td>Harmful effects of antidepressants</td>
</tr>
<tr>
<td>459</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Tricyclic antidepressants</td>
</tr>
<tr>
<td>460</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Tetracyclic antidepressants</td>
</tr>
<tr>
<td>461</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Monoamine-oxidase-inhibitor antidepressants</td>
</tr>
<tr>
<td>462</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Selective serotonin or norepinephrine reuptake inhibitors</td>
</tr>
<tr>
<td>463</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Selective serotonin reuptake inhibitors</td>
</tr>
<tr>
<td>464</td>
<td>Harmful effects of antipsychotics</td>
</tr>
<tr>
<td>465</td>
<td>Harmful effects of phenothiazine antipsychotics or neuroleptics</td>
</tr>
<tr>
<td>466</td>
<td>Harmful effects of promazine</td>
</tr>
<tr>
<td>467</td>
<td>promazine poisoning</td>
</tr>
<tr>
<td>468</td>
<td>Harmful effects of butyrophenone or thiothixene neuroleptics</td>
</tr>
<tr>
<td>469</td>
<td>Harmful effects of typical, second-generation antipsychotics</td>
</tr>
<tr>
<td>470</td>
<td>Harmful effects of lithium carbonate</td>
</tr>
<tr>
<td>471</td>
<td>Harmful effects of antiepileptics or antiparkinsonism drugs</td>
</tr>
<tr>
<td>472</td>
<td>Harmful effects of hydantoin derivatives</td>
</tr>
<tr>
<td>473</td>
<td>Harmful effects of iminostilbenes</td>
</tr>
<tr>
<td>474</td>
<td>Harmful effects of deoxybarbiturates</td>
</tr>
<tr>
<td>475</td>
<td>Harmful effects of succinimides</td>
</tr>
<tr>
<td>476</td>
<td>Harmful effects of oxazolidinediones</td>
</tr>
<tr>
<td>477</td>
<td>Harmful effects of mixed antiepileptics, not elsewhere classified</td>
</tr>
<tr>
<td>478</td>
<td>Harmful effects of Amantadine</td>
</tr>
<tr>
<td>479</td>
<td>Harmful effects of Valproic acid</td>
</tr>
<tr>
<td>480</td>
<td>Harmful effects of L-DOPA</td>
</tr>
<tr>
<td>481</td>
<td>Harmful effects of Antiparkinsonism drugs or other central muscle-tone depressants, not elsewhere classified</td>
</tr>
<tr>
<td>482</td>
<td>Harmful effects of antispasticity drugs</td>
</tr>
<tr>
<td>483</td>
<td>Harmful effects of substances, drugs, medicaments or biological substance, Other or unspecified drugs, medicaments or biological substances</td>
</tr>
<tr>
<td>484</td>
<td>Harmful effects of systemic antibiotics</td>
</tr>
<tr>
<td>485</td>
<td>Harmful effects of Penicillins</td>
</tr>
<tr>
<td>486</td>
<td>poisoning by penicillin</td>
</tr>
<tr>
<td>487</td>
<td>poisoning by penicillins nos</td>
</tr>
<tr>
<td>488</td>
<td>Harmful effects of cephalosporins and other beta-lactam antibiotics</td>
</tr>
<tr>
<td>489</td>
<td>Harmful effects of cefotaxime</td>
</tr>
<tr>
<td>490</td>
<td>cefotaxime poisoning</td>
</tr>
<tr>
<td>491</td>
<td>Harmful effects of chloramphenicol group</td>
</tr>
<tr>
<td>492</td>
<td>chloramphenicol poisoning</td>
</tr>
<tr>
<td>493</td>
<td>Harmful effects of macrolides</td>
</tr>
<tr>
<td>494</td>
<td>Harmful effects of tetracyclines</td>
</tr>
<tr>
<td>495</td>
<td>poisoning by tetracyclines</td>
</tr>
<tr>
<td>496</td>
<td>poisoning by tetracyclines nos</td>
</tr>
<tr>
<td>497</td>
<td>Harmful effects of aminoglycosides</td>
</tr>
<tr>
<td>498</td>
<td>Harmful effects of rifampicin</td>
</tr>
<tr>
<td>499</td>
<td>rifampicin poisoning</td>
</tr>
<tr>
<td>500</td>
<td>Harmful effects of antifungal antibiotics, systemically used</td>
</tr>
<tr>
<td>501</td>
<td>Harmful effects of co-trimoxazole</td>
</tr>
<tr>
<td>502</td>
<td>co-trimoxazole poisoning</td>
</tr>
<tr>
<td>503</td>
<td>Harmful effects of fusidic acid</td>
</tr>
<tr>
<td>504</td>
<td>fusidic acid poisoning</td>
</tr>
<tr>
<td>505</td>
<td>Harmful effects of sodium fusidate</td>
</tr>
<tr>
<td>506</td>
<td>sodium fusidate poisoning</td>
</tr>
<tr>
<td>507</td>
<td>Harmful effects of vancomycin</td>
</tr>
<tr>
<td>508</td>
<td>vancomycin poisoning</td>
</tr>
<tr>
<td>509</td>
<td>Harmful effects of other systemic anti-infectives or antiparasitics</td>
</tr>
<tr>
<td>510</td>
<td>Harmful effects of Sulfonamides</td>
</tr>
<tr>
<td>511</td>
<td>Harmful effects of antimycobacterial drugs</td>
</tr>
<tr>
<td>512</td>
<td>Harmful effects of antimalarials or drugs acting on other blood protozoa</td>
</tr>
<tr>
<td>513</td>
<td>Harmful effects of other antiprotozoal drugs</td>
</tr>
<tr>
<td>514</td>
<td>Harmful effects of anthelminthics</td>
</tr>
<tr>
<td>515</td>
<td>Harmful effects of antiviral drugs</td>
</tr>
<tr>
<td>516</td>
<td>Harmful effects of chiniofon</td>
</tr>
<tr>
<td>517</td>
<td>chiniofon poisoning</td>
</tr>
<tr>
<td>518</td>
<td>Harmful effects of diiodohydroxyquinoline</td>
</tr>
<tr>
<td>519</td>
<td>diiodohydroxyquinoline poisoning</td>
</tr>
<tr>
<td>520</td>
<td>Harmful effects of flucytosine</td>
</tr>
<tr>
<td>521</td>
<td>flucytosine poisoning</td>
</tr>
<tr>
<td>522</td>
<td>Harmful effects of hydroxyquinoline derivatives</td>
</tr>
<tr>
<td>523</td>
<td>hydroxyquinoline derivatives poisoning</td>
</tr>
<tr>
<td>524</td>
<td>Harmful effects of trimethoprim</td>
</tr>
<tr>
<td>525</td>
<td>trimethoprim poisoning</td>
</tr>
<tr>
<td>526</td>
<td>Harmful effects of hormones or their synthetic substitutes or antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>527</td>
<td>Harmful effects of Glucocorticoids or synthetic analogues</td>
</tr>
<tr>
<td>528</td>
<td>Harmful effects of thyroid hormones or substitutes</td>
</tr>
<tr>
<td>529</td>
<td>Harmful effects of antithyroid drugs</td>
</tr>
<tr>
<td>530</td>
<td>Harmful effects of insulin or oral hypoglycaemic drugs</td>
</tr>
<tr>
<td>531</td>
<td>Harmful effects of oral contraceptives</td>
</tr>
<tr>
<td>532</td>
<td>poisoning by oral contraceptive</td>
</tr>
<tr>
<td>533</td>
<td>poisoning by oral contraceptives nos</td>
</tr>
<tr>
<td>534</td>
<td>Harmful effects of other estrogens or progestogens</td>
</tr>
<tr>
<td>535</td>
<td>oestrogen poisoning</td>
</tr>
<tr>
<td>536</td>
<td>Harmful effects of antigonadotropins, antiestrogens, antiandrogens, not elsewhere classified</td>
</tr>
<tr>
<td>537</td>
<td>Harmful effects of androgens or anabolic congeners</td>
</tr>
<tr>
<td>538</td>
<td>androgen poisoning</td>
</tr>
<tr>
<td>539</td>
<td>Harmful effects of unspecified hormones or synthetic substitutes</td>
</tr>
<tr>
<td>540</td>
<td>Harmful effects of anterior pituitary hormones</td>
</tr>
<tr>
<td>541</td>
<td>Harmful effects of other hormones or synthetic substitutes</td>
</tr>
<tr>
<td>542</td>
<td>Harmful effects of unspecified hormone antagonists</td>
</tr>
<tr>
<td>543</td>
<td>Harmful effects of other hormone antagonists</td>
</tr>
<tr>
<td>544</td>
<td>Harmful effects of trilostane</td>
</tr>
<tr>
<td>545</td>
<td>Harmful effects of drugs primarily affecting the autonomic nervous system</td>
</tr>
<tr>
<td>546</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Anticholinesterase agents</td>
</tr>
<tr>
<td>547</td>
<td>anticholinesterase poisoning</td>
</tr>
<tr>
<td>548</td>
<td>poisoning by anticholinesterase agents nos</td>
</tr>
<tr>
<td>549</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Other parasympathomimetics</td>
</tr>
<tr>
<td>550</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Ganglionic blocking drugs</td>
</tr>
<tr>
<td>551</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Other parasympatholytics or spasmolytics</td>
</tr>
<tr>
<td>552</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Predominantly alpha-adrenoreceptor agonists</td>
</tr>
<tr>
<td>553</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Predominantly beta-adrenoreceptor agonists</td>
</tr>
<tr>
<td>554</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Alpha-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>555</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Beta-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>556</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Centrally-acting or adrenergic-neuron-blocking agents</td>
</tr>
<tr>
<td>557</td>
<td>Harmful effects of agents primarily affecting blood constituents</td>
</tr>
<tr>
<td>558</td>
<td>haematological agent poisoning</td>
</tr>
<tr>
<td>559</td>
<td>Harmful effects of Diphenhydramine</td>
</tr>
<tr>
<td>560</td>
<td>diphenhydramine toxicity</td>
</tr>
<tr>
<td>561</td>
<td>Harmful effects of other H1-receptor antagonists</td>
</tr>
<tr>
<td>562</td>
<td>Harmful effects of antiallergic or antiemetic drugs</td>
</tr>
<tr>
<td>563</td>
<td>Harmful effects of antineoplastic antimetabolites</td>
</tr>
<tr>
<td>564</td>
<td>Harmful effects of antineoplastic natural products</td>
</tr>
<tr>
<td>565</td>
<td>Harmful effects of other antineoplastic drugs</td>
</tr>
<tr>
<td>566</td>
<td>Harmful effects of immunosuppressive agents</td>
</tr>
<tr>
<td>567</td>
<td>Harmful effects of Vitamin B12, folic acid or other anti-megaloblastic-anaemia preparations</td>
</tr>
<tr>
<td>568</td>
<td>Harmful effects of enzymes</td>
</tr>
<tr>
<td>569</td>
<td>Harmful effects of iron or its compounds</td>
</tr>
<tr>
<td>570</td>
<td>Harmful effects of anticoagulants</td>
</tr>
<tr>
<td>571</td>
<td>Harmful effects of antithrombotic drugs</td>
</tr>
<tr>
<td>572</td>
<td>harmful effect of platelet aggregation inhibitors</td>
</tr>
<tr>
<td>573</td>
<td>Harmful effects of thrombolytic drug</td>
</tr>
<tr>
<td>574</td>
<td>Harmful effects of anticoagulant antagonists, vitamin K or other coagulants</td>
</tr>
<tr>
<td>575</td>
<td>Harmful effects of other fibrinolysis-affecting drugs</td>
</tr>
<tr>
<td>576</td>
<td>fibrinolytic drug poisoning</td>
</tr>
<tr>
<td>577</td>
<td>poisoning by fibrinolysis-affecting drug nos</td>
</tr>
<tr>
<td>578</td>
<td>Harmful effects of natural blood or blood products</td>
</tr>
<tr>
<td>579</td>
<td>Harmful effects of acidifying or alkalising agents</td>
</tr>
<tr>
<td>580</td>
<td>Harmful effects of other primarily systemic agents, not elsewhere classified</td>
</tr>
<tr>
<td>581</td>
<td>Blood poisoning, not elsewhere classified</td>
</tr>
<tr>
<td>582</td>
<td>whole blood poisoning</td>
</tr>
<tr>
<td>583</td>
<td>Harmful effects of heavy metal poisoning antidote</td>
</tr>
<tr>
<td>584</td>
<td>Harmful effects of plasma substitutes</td>
</tr>
<tr>
<td>585</td>
<td>Harmful effects of agents primarily affecting the cardiovascular system</td>
</tr>
<tr>
<td>586</td>
<td>Harmful effects of cardiac-stimulant glycosides or drugs of similar action</td>
</tr>
<tr>
<td>587</td>
<td>Harmful effects of calcium-channel blockers</td>
</tr>
<tr>
<td>588</td>
<td>poisoning by calcium-channel blockers NOS</td>
</tr>
<tr>
<td>589</td>
<td>Harmful effects of other antidysrhythmic drugs</td>
</tr>
<tr>
<td>590</td>
<td>Harmful effects of Nitroglycerin, nitroglycerol, medicinal</td>
</tr>
<tr>
<td>591</td>
<td>Harmful effects of other coronary vasodilators</td>
</tr>
<tr>
<td>592</td>
<td>Harmful effects of Angiotensin-converting-enzyme inhibitors</td>
</tr>
<tr>
<td>593</td>
<td>Harmful effects of other antihypertensive drugs</td>
</tr>
<tr>
<td>594</td>
<td>Harmful effects of antihyperlipidemic or antiarteriosclerotic drugs</td>
</tr>
<tr>
<td>595</td>
<td>Harmful effects of peripheral vasodilators</td>
</tr>
<tr>
<td>596</td>
<td>Harmful effects of antivaricose drugs, including sclerosing agents</td>
</tr>
<tr>
<td>597</td>
<td>antivaricose drug poisoning</td>
</tr>
<tr>
<td>598</td>
<td>Harmful effects of agents primarily affecting the gastrointestinal system</td>
</tr>
<tr>
<td>599</td>
<td>Harmful effects of Histamine H2-receptor blockers</td>
</tr>
<tr>
<td>600</td>
<td>poisoning by histamine h 2 -receptor antagonists</td>
</tr>
<tr>
<td>601</td>
<td>Harmful effects of other antacids or anti-gastric-secretion drugs</td>
</tr>
<tr>
<td>602</td>
<td>Harmful effects of stimulant laxatives</td>
</tr>
<tr>
<td>603</td>
<td>Harmful effects of saline or osmotic laxatives</td>
</tr>
<tr>
<td>604</td>
<td>Harmful effects of other laxatives</td>
</tr>
<tr>
<td>605</td>
<td>Harmful effects of digestants</td>
</tr>
<tr>
<td>606</td>
<td>Harmful effects of antidiarrhoeal drugs</td>
</tr>
<tr>
<td>607</td>
<td>Harmful effects of or exposure to emetics</td>
</tr>
<tr>
<td>608</td>
<td>Harmful effects of agents primarily acting on smooth or skeletal muscles or the respiratory system</td>
</tr>
<tr>
<td>609</td>
<td>Harmful effects of Oxytocic drugs</td>
</tr>
<tr>
<td>610</td>
<td>oxytocin poisoning</td>
</tr>
<tr>
<td>611</td>
<td>Harmful effects of skeletal muscle relaxants</td>
</tr>
<tr>
<td>612</td>
<td>harmful effect of neuromuscular blocking agents</td>
</tr>
<tr>
<td>613</td>
<td>Harmful effects of other drugs acting on muscles</td>
</tr>
<tr>
<td>614</td>
<td>Harmful effects of unspecified drugs acting on muscles</td>
</tr>
<tr>
<td>615</td>
<td>Harmful effects of antitussives</td>
</tr>
<tr>
<td>616</td>
<td>Harmful effects of expectorants</td>
</tr>
<tr>
<td>617</td>
<td>Harmful effects of other anti-common-cold drugs</td>
</tr>
<tr>
<td>618</td>
<td>Harmful effects of Salbutamol</td>
</tr>
<tr>
<td>619</td>
<td>salbutamol poisoning</td>
</tr>
<tr>
<td>620</td>
<td>Harmful effects of Aminophylline, theophylline</td>
</tr>
<tr>
<td>621</td>
<td>theophylline poisoning</td>
</tr>
<tr>
<td>622</td>
<td>aminophylline poisoning</td>
</tr>
<tr>
<td>623</td>
<td>Harmful effects of Terbutaline</td>
</tr>
<tr>
<td>624</td>
<td>Harmful effects of antiasthmatics, not elsewhere classified</td>
</tr>
<tr>
<td>625</td>
<td>Harmful effects of topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs</td>
</tr>
<tr>
<td>626</td>
<td>Harmful effects of topical corticosteroid preparations</td>
</tr>
<tr>
<td>627</td>
<td>Harmful effects of Iodine, antiseptic</td>
</tr>
<tr>
<td>628</td>
<td>Harmful effects of silver nitrate</td>
</tr>
<tr>
<td>629</td>
<td>Harmful effects of other local antifungal, anti-infective or anti-inflammatory drugs</td>
</tr>
<tr>
<td>630</td>
<td>Harmful effects of antipruritics</td>
</tr>
<tr>
<td>631</td>
<td>Harmful effects of Methyl salicylate</td>
</tr>
<tr>
<td>632</td>
<td>Harmful effects of other local astringents or local detergents</td>
</tr>
<tr>
<td>633</td>
<td>Tannic acid poisoning</td>
</tr>
<tr>
<td>634</td>
<td>Harmful effects of emollients, demulcents or protectants</td>
</tr>
<tr>
<td>635</td>
<td>Harmful effects of Podophyllin</td>
</tr>
<tr>
<td>636</td>
<td>Harmful effects of keratolytics, keratoplastics, or other hair treatment drugs or preparations</td>
</tr>
<tr>
<td>637</td>
<td>Harmful effects of ophthalmological drugs or preparations</td>
</tr>
<tr>
<td>638</td>
<td>Harmful effects of otorhinolaryngological drugs or preparations</td>
</tr>
<tr>
<td>639</td>
<td>Harmful effects of ear, nose or throat anti-infectives</td>
</tr>
<tr>
<td>640</td>
<td>Harmful effects of fluoride preparations</td>
</tr>
<tr>
<td>641</td>
<td>Harmful effects of other dental drugs, topically applied</td>
</tr>
<tr>
<td>642</td>
<td>Harmful effects of Camphor</td>
</tr>
<tr>
<td>643</td>
<td>Harmful effects of agents primarily affecting water-balance or mineral or uric acid metabolism</td>
</tr>
<tr>
<td>644</td>
<td>Harmful effects of Mineralocorticoids</td>
</tr>
<tr>
<td>645</td>
<td>Harmful effects of Mineralocorticoids antagonists</td>
</tr>
<tr>
<td>646</td>
<td>Harmful effects of Loop diuretics</td>
</tr>
<tr>
<td>647</td>
<td>Harmful effect of high-ceiling diuretics</td>
</tr>
<tr>
<td>648</td>
<td>Frusemide poisoning</td>
</tr>
<tr>
<td>649</td>
<td>furosemide poisoning</td>
</tr>
<tr>
<td>650</td>
<td>Etacrynic acid poisoning</td>
</tr>
<tr>
<td>651</td>
<td>ethacrynic acid poisoning</td>
</tr>
<tr>
<td>652</td>
<td>Harmful effects of Carbonic-anhydrase inhibitors</td>
</tr>
<tr>
<td>653</td>
<td>Acetazolamide poisoning</td>
</tr>
<tr>
<td>654</td>
<td>Bendroflumethiazide poisoning</td>
</tr>
<tr>
<td>655</td>
<td>Chlormerodrin poisoning</td>
</tr>
<tr>
<td>656</td>
<td>Chlorothiazide poisoning</td>
</tr>
<tr>
<td>657</td>
<td>Mercaptomerin poisoning</td>
</tr>
<tr>
<td>658</td>
<td>Mersalyl poisoning</td>
</tr>
<tr>
<td>659</td>
<td>Harmful effects of Benzothiadiazine derivatives</td>
</tr>
<tr>
<td>660</td>
<td>harmful effect of thiazides</td>
</tr>
<tr>
<td>661</td>
<td>Harmful effects of other diuretics</td>
</tr>
<tr>
<td>662</td>
<td>Harmful effects of electrolytic, caloric or water-balance agents</td>
</tr>
<tr>
<td>663</td>
<td>Harmful effect of oral rehydration salts</td>
</tr>
<tr>
<td>664</td>
<td>Sodium chloride poisoning</td>
</tr>
<tr>
<td>665</td>
<td>Harmful effects of mineral salts, not elsewhere classified</td>
</tr>
<tr>
<td>666</td>
<td>Harmful effects of drugs affecting uric acid metabolism</td>
</tr>
<tr>
<td>667</td>
<td>Allopurinol poisoning</td>
</tr>
<tr>
<td>668</td>
<td>Colchicine poisoning</td>
</tr>
<tr>
<td>669</td>
<td>Probenecid poisoning</td>
</tr>
<tr>
<td>670</td>
<td>Harmful effects of agents primarily affecting water-balance and mineral or uric acid metabolism, Vitamin D and derivatives</td>
</tr>
<tr>
<td>671</td>
<td>Harmful effects of Bisphosphonates</td>
</tr>
<tr>
<td>672</td>
<td>Harmful effects of appetite depressants</td>
</tr>
<tr>
<td>673</td>
<td>Harmful effects of antidotes or chelating agents, not elsewhere classified</td>
</tr>
<tr>
<td>674</td>
<td>Harmful effects of Disulfiram</td>
</tr>
<tr>
<td>675</td>
<td>disulfiram poisoning</td>
</tr>
<tr>
<td>676</td>
<td>Harmful effects of alcohol deterrents, not elsewhere classified</td>
</tr>
<tr>
<td>677</td>
<td>harmful effect of alcohol deterrents</td>
</tr>
<tr>
<td>678</td>
<td>Toxic effect of alcohol deterrents</td>
</tr>
<tr>
<td>679</td>
<td>Harmful effects of X-ray contrast media</td>
</tr>
<tr>
<td>680</td>
<td>Harmful effects of MRI contrast agents</td>
</tr>
<tr>
<td>681</td>
<td>Harmful effects of agents used for other scanning techniques</td>
</tr>
<tr>
<td>682</td>
<td>Harmful effects of other diagnostic agents</td>
</tr>
<tr>
<td>683</td>
<td>Harmful effects of Lipotropic drugs</td>
</tr>
<tr>
<td>684</td>
<td>Harmful effects of vitamins, not elsewhere classified, Pharmaceutical excipients</td>
</tr>
<tr>
<td>685</td>
<td>Harmful effects of herbal preparations or formulas</td>
</tr>
<tr>
<td>686</td>
<td>Harmful effects of dietary supplements, vitamins or minerals</td>
</tr>
<tr>
<td>687</td>
<td>Harmful effects of complementary or Traditional Medicines, not elsewhere classified</td>
</tr>
<tr>
<td>688</td>
<td>Harmful effects of complementary or Traditional Medicines, unspecified</td>
</tr>
<tr>
<td>689</td>
<td>Harmful effects of vaccines, immunoglobulins or other biological substances</td>
</tr>
<tr>
<td>690</td>
<td>Harmful effects of BCG vaccine</td>
</tr>
<tr>
<td>691</td>
<td>Harmful effects of Typhoid or paratyphoid vaccine</td>
</tr>
<tr>
<td>692</td>
<td>Harmful effects of Cholera vaccine</td>
</tr>
<tr>
<td>693</td>
<td>Harmful effects of Plague vaccine</td>
</tr>
<tr>
<td>694</td>
<td>Harmful effects of Tetanus vaccine</td>
</tr>
<tr>
<td>695</td>
<td>Harmful effects of Diphtheria vaccine</td>
</tr>
<tr>
<td>696</td>
<td>Harmful effects of Haemophilus influenzae type B vaccines</td>
</tr>
<tr>
<td>697</td>
<td>Harmful effects of Pertussis vaccine, including combinations with a pertussis component</td>
</tr>
<tr>
<td>698</td>
<td>Harmful effects of mixed bacterial vaccines without a pertussis component</td>
</tr>
<tr>
<td>699</td>
<td>Harmful effects of other or unspecified bacterial vaccines</td>
</tr>
<tr>
<td>700</td>
<td>Harmful effects of Smallpox vaccines</td>
</tr>
<tr>
<td>701</td>
<td>Harmful effects of Measles vaccines</td>
</tr>
<tr>
<td>702</td>
<td>Harmful effects of Mumps vaccines</td>
</tr>
<tr>
<td>703</td>
<td>Harmful effects of Rubella vaccines</td>
</tr>
<tr>
<td>704</td>
<td>Harmful effects of Polio vaccines</td>
</tr>
<tr>
<td>705</td>
<td>Harmful effects of Yellow fever vaccines</td>
</tr>
<tr>
<td>706</td>
<td>Harmful effects of Hepatitis A vaccines</td>
</tr>
<tr>
<td>707</td>
<td>Harmful effects of Hepatitis B vaccines</td>
</tr>
<tr>
<td>708</td>
<td>Harmful effects of Influenza vaccines</td>
</tr>
<tr>
<td>709</td>
<td>Harmful effects of Rotavirus vaccines</td>
</tr>
<tr>
<td>710</td>
<td>Harmful effects of Human papillomavirus vaccines</td>
</tr>
<tr>
<td>711</td>
<td>Harmful effects of other viral vaccines</td>
</tr>
<tr>
<td>712</td>
<td>Harmful effects of Rickettsial vaccines</td>
</tr>
<tr>
<td>713</td>
<td>Harmful effects of Protozoal vaccines</td>
</tr>
<tr>
<td>714</td>
<td>Harmful effects of Hepatitis B immune globulin</td>
</tr>
<tr>
<td>715</td>
<td>Harmful effects of antivenin, antivenom</td>
</tr>
<tr>
<td>716</td>
<td>Harmful effects of immunoglobulin, not elsewhere classified</td>
</tr>
<tr>
<td>717</td>
<td>Harmful effects of other specified vaccines</td>
</tr>
<tr>
<td>718</td>
<td>Harmful effects of unspecified vaccines</td>
</tr>
<tr>
<td>719</td>
<td>Multiple drug toxicity</td>
</tr>
<tr>
<td>720</td>
<td>Catatonia due to medication or substance</td>
</tr>
<tr>
<td>721</td>
<td>Overdose of drug, not otherwise specified</td>
</tr>
<tr>
<td>722</td>
<td>overdose NOS</td>
</tr>
<tr>
<td>723</td>
<td>Harmful effects of ketorolac</td>
</tr>
<tr>
<td>724</td>
<td>ketorolac poisoning</td>
</tr>
<tr>
<td>725</td>
<td>Harmful effects of meptazinol</td>
</tr>
<tr>
<td>726</td>
<td>meptazinol poisoning</td>
</tr>
<tr>
<td>727</td>
<td>Harmful effects of nefopam</td>
</tr>
<tr>
<td>728</td>
<td>nefopam poisoning</td>
</tr>
<tr>
<td>729</td>
<td>Harmful effects of oxygen</td>
</tr>
<tr>
<td>730</td>
<td>oxygen poisoning</td>
</tr>
<tr>
<td>731</td>
<td>Harmful effects of ethosuximide</td>
</tr>
<tr>
<td>732</td>
<td>ethosuximide poisoning</td>
</tr>
<tr>
<td>733</td>
<td>Harmful effects of paramethadione</td>
</tr>
<tr>
<td>734</td>
<td>paramethadione poisoning</td>
</tr>
<tr>
<td>735</td>
<td>Harmful effects of trimethadione</td>
</tr>
<tr>
<td>736</td>
<td>trimethadione poisoning</td>
</tr>
<tr>
<td>737</td>
<td>Harmful effects of phensuximide</td>
</tr>
<tr>
<td>738</td>
<td>phensuximide poisoning</td>
</tr>
<tr>
<td>739</td>
<td>Adverse effect medical agent</td>
</tr>
<tr>
<td>740</td>
<td>side effect</td>
</tr>
<tr>
<td>741</td>
<td>side effect of medical agent</td>
</tr>
<tr>
<td>742</td>
<td>Cocaine and fentanyl toxicity</td>
</tr>
<tr>
<td>743</td>
<td>Methamphetamine and fentanyl toxicity</td>
</tr>
<tr>
<td>744</td>
<td>Charcot-Marie-Tooth disease 2 axonal</td>
</tr>
<tr>
<td>745</td>
<td>Charcot-Marie-Tooth disease 2 autosomal dominant</td>
</tr>
<tr>
<td>746</td>
<td>Recessive axonal Charcot-Marie-Tooth disease with acrodystrophy</td>
</tr>
<tr>
<td>747</td>
<td>Charcot-Marie-Tooth disease type 2A1</td>
</tr>
<tr>
<td>748</td>
<td>Charcot-Marie-Tooth disease type 2A2</td>
</tr>
<tr>
<td>749</td>
<td>Charcot-Marie-Tooth disease type 2B</td>
</tr>
<tr>
<td>750</td>
<td>Charcot-Marie-Tooth disease type 2C</td>
</tr>
<tr>
<td>751</td>
<td>Charcot-Marie-Tooth disease type 2D</td>
</tr>
<tr>
<td>752</td>
<td>Charcot-Marie-Tooth disease type 2E</td>
</tr>
<tr>
<td>753</td>
<td>Charcot-Marie-Tooth disease type 2F</td>
</tr>
<tr>
<td>754</td>
<td>Charcot-Marie-Tooth disease type 2G</td>
</tr>
<tr>
<td>755</td>
<td>Charcot-Marie-Tooth disease type 2I</td>
</tr>
<tr>
<td>756</td>
<td>Charcot-Marie-Tooth disease type 2J</td>
</tr>
<tr>
<td>757</td>
<td>Charcot-Marie-Tooth disease type 2K</td>
</tr>
<tr>
<td>758</td>
<td>Charcot-Marie-Tooth disease type 2L</td>
</tr>
<tr>
<td>759</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2M</td>
</tr>
<tr>
<td>760</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2N</td>
</tr>
<tr>
<td>761</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2O</td>
</tr>
<tr>
<td>762</td>
<td>Charcot-Marie-Tooth disease 2 autosomal recessive</td>
</tr>
<tr>
<td>763</td>
<td>Charcot-Marie-Tooth disease type 2B1</td>
</tr>
<tr>
<td>764</td>
<td>Charcot-Marie-Tooth disease type 2B2</td>
</tr>
<tr>
<td>765</td>
<td>Charcot-Marie-Tooth disease type 2B5</td>
</tr>
<tr>
<td>766</td>
<td>Charcot-Marie-Tooth disease type 2H</td>
</tr>
<tr>
<td>767</td>
<td>Autosomal recessive Charcot-Marie-Tooth disease with hoarseness</td>
</tr>
<tr>
<td>768</td>
<td>Hereditary motor and sensory neuropathy type 6</td>
</tr>
<tr>
<td>769</td>
<td>Charcot-Marie-Tooth type 6</td>
</tr>
<tr>
<td>770</td>
<td>HMSN6 - [Hereditary motor and sensory neuropathy type 6]</td>
</tr>
<tr>
<td>771</td>
<td>CMT6 - [Charcot-Marie-Tooth type 6]</td>
</tr>
<tr>
<td>772</td>
<td>Unintentional exposure to or harmful effects of other or unspecified drug, medicament or biological substance</td>
</tr>
<tr>
<td>773</td>
<td>accidental overdose of other or unspecified drug, medicament or biological substance</td>
</tr>
<tr>
<td>774</td>
<td>accidental poisoning by other or unspecified drug, medicament or biological substance</td>
</tr>
<tr>
<td>775</td>
<td>other or unspecified drug, medicament or biological substance taken in error</td>
</tr>
<tr>
<td>776</td>
<td>accidental drug overdose</td>
</tr>
<tr>
<td>777</td>
<td>accidental overdose</td>
</tr>
<tr>
<td>778</td>
<td>Unintentional exposure to or harmful effects of systemic antibiotics</td>
</tr>
<tr>
<td>779</td>
<td>Unintentional exposure to or harmful effects of penicillins</td>
</tr>
<tr>
<td>780</td>
<td>Unintentional exposure to or harmful effects of cephalosporins or other beta-lactam antibiotics</td>
</tr>
<tr>
<td>781</td>
<td>Unintentional exposure to or harmful effects of chloramphenicol group</td>
</tr>
<tr>
<td>782</td>
<td>Unintentional exposure to or harmful effects of macrolides</td>
</tr>
<tr>
<td>783</td>
<td>Unintentional exposure to or harmful effects of tetracyclines</td>
</tr>
<tr>
<td>784</td>
<td>Unintentional exposure to or harmful effects of aminoglycosides</td>
</tr>
<tr>
<td>785</td>
<td>Unintentional exposure to or harmful effects of rifampicin</td>
</tr>
<tr>
<td>786</td>
<td>Unintentional exposure to or harmful effects of antifungal antibiotics, systemically used</td>
</tr>
<tr>
<td>787</td>
<td>Unintentional exposure to or harmful effects of other systemic anti-infectives or antiparasitics</td>
</tr>
<tr>
<td>788</td>
<td>Unintentional exposure to or harmful effects of sulfonamides</td>
</tr>
<tr>
<td>789</td>
<td>Unintentional exposure to or harmful effects of antimycobacterial drugs</td>
</tr>
<tr>
<td>790</td>
<td>Unintentional exposure to or harmful effects of antimalarials or drugs acting on other blood protozoa</td>
</tr>
<tr>
<td>791</td>
<td>Unintentional exposure to or harmful effects of other antiprotozoal drugs</td>
</tr>
<tr>
<td>792</td>
<td>Unintentional exposure to or harmful effects of anthelminthics</td>
</tr>
<tr>
<td>793</td>
<td>Unintentional exposure to or harmful effects of antiviral drugs</td>
</tr>
<tr>
<td>794</td>
<td>Unintentional exposure to or harmful effects of hormones or their synthetic substitutes or antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>795</td>
<td>Unintentional exposure to or harmful effects of glucocorticoids or synthetic analogues</td>
</tr>
<tr>
<td>796</td>
<td>Unintentional exposure to or harmful effects of thyroid hormones or substitutes</td>
</tr>
<tr>
<td>797</td>
<td>Unintentional exposure to or harmful effects of antithyroid drugs</td>
</tr>
<tr>
<td>798</td>
<td>Unintentional exposure to or harmful effects of insulin or oral hypoglycaemic drugs</td>
</tr>
<tr>
<td>799</td>
<td>Unintentional harmful effect of antidiabetic drugs</td>
</tr>
<tr>
<td>800</td>
<td>Unintentional exposure to or harmful effects of oral contraceptives</td>
</tr>
<tr>
<td>801</td>
<td>Unintentional exposure to or harmful effects of other estrogens or progestogens</td>
</tr>
<tr>
<td>802</td>
<td>Unintentional exposure to or harmful effects of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified</td>
</tr>
<tr>
<td>803</td>
<td>Unintentional exposure to or harmful effects of androgens or anabolic congeners</td>
</tr>
<tr>
<td>804</td>
<td>Unintentional exposure to or harmful effects of unspecified hormones or synthetic substitutes</td>
</tr>
<tr>
<td>805</td>
<td>Unintentional exposure to or harmful effects of anterior pituitary hormones</td>
</tr>
<tr>
<td>806</td>
<td>Unintentional harmful effect of adenohypophyseal hormones</td>
</tr>
<tr>
<td>807</td>
<td>Unintentional exposure to or harmful effects of other hormones or synthetic substitutes</td>
</tr>
<tr>
<td>808</td>
<td>Unintentional exposure to or harmful effects of other hormone antagonists</td>
</tr>
<tr>
<td>809</td>
<td>Unintentional exposure to or harmful effects of unspecified hormone antagonists</td>
</tr>
<tr>
<td>810</td>
<td>Unintentional exposure to or harmful effects of drugs primarily affecting the autonomic nervous system</td>
</tr>
<tr>
<td>811</td>
<td>Unintentional exposure to or harmful effects of anticholinesterase agents</td>
</tr>
<tr>
<td>812</td>
<td>Unintentional exposure to or harmful effects of other parasympathomimetics</td>
</tr>
<tr>
<td>813</td>
<td>Unintentional harmful effect of cholinergics</td>
</tr>
<tr>
<td>814</td>
<td>Unintentional exposure to or harmful effects of ganglionic blocking drugs</td>
</tr>
<tr>
<td>815</td>
<td>Unintentional exposure to or harmful effects of other parasympatholytics or spasmolytics</td>
</tr>
<tr>
<td>816</td>
<td>Unintentional harmful effect of anticholinergics or antimuscarinics</td>
</tr>
<tr>
<td>817</td>
<td>Unintentional exposure to or harmful effects of predominantly alpha-adrenoreceptor agonists</td>
</tr>
<tr>
<td>818</td>
<td>Unintentional exposure to or harmful effects of predominantly beta-adrenoreceptor agonists</td>
</tr>
<tr>
<td>819</td>
<td>Unintentional exposure to or harmful effects of alpha-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>820</td>
<td>Unintentional exposure to or harmful effects of beta-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>821</td>
<td>Unintentional exposure to or harmful effects of centrally-acting or adrenergic-neuron-blocking agents</td>
</tr>
<tr>
<td>822</td>
<td>Unintentional exposure to or harmful effects of agents primarily affecting blood constituents</td>
</tr>
<tr>
<td>823</td>
<td>Unintentional exposure to or harmful effects of diphenhydramine</td>
</tr>
<tr>
<td>824</td>
<td>Unintentional exposure to or harmful effects of other H1-receptor antagonists</td>
</tr>
<tr>
<td>825</td>
<td>Unintentional exposure to or harmful effects of antiallergic or antiemetic drugs</td>
</tr>
<tr>
<td>826</td>
<td>Unintentional exposure to or harmful effects of antineoplastic antimetabolites</td>
</tr>
<tr>
<td>827</td>
<td>Unintentional exposure to or harmful effects of antineoplastic natural products</td>
</tr>
<tr>
<td>828</td>
<td>Unintentional exposure to or harmful effects of other antineoplastic drugs</td>
</tr>
<tr>
<td>829</td>
<td>Unintentional exposure to or harmful effects of immunosuppressive agents</td>
</tr>
<tr>
<td>830</td>
<td>Unintentional exposure to or harmful effects of vitamin B12, folic acid or other anti-megaloblastic-anaemia preparations</td>
</tr>
<tr>
<td>831</td>
<td>Unintentional exposure to or harmful effects of enzymes</td>
</tr>
<tr>
<td>832</td>
<td>Unintentional exposure to or harmful effects of iron or its compounds</td>
</tr>
<tr>
<td>833</td>
<td>Unintentional exposure to or harmful effects of anticoagulants</td>
</tr>
<tr>
<td>834</td>
<td>Unintentional exposure to or harmful effects of antithrombotic drugs</td>
</tr>
<tr>
<td>835</td>
<td>Unintentional harmful effect of platelet aggregation inhibitors</td>
</tr>
<tr>
<td>836</td>
<td>Unintentional exposure to or harmful effects of thrombolytic drug</td>
</tr>
<tr>
<td>837</td>
<td>Unintentional exposure to or harmful effects of anticoagulant antagonists, vitamin K or other coagulants</td>
</tr>
<tr>
<td>838</td>
<td>Unintentional exposure to or harmful effects of other fibrinolysis-affecting drugs</td>
</tr>
<tr>
<td>839</td>
<td>Unintentional exposure to or harmful effects of natural blood or blood products</td>
</tr>
<tr>
<td>840</td>
<td>Unintentional exposure to or harmful effects of acidifying or alkalising agents</td>
</tr>
<tr>
<td>841</td>
<td>Unintentional exposure to or harmful effects of other primarily systemic agents, not elsewhere classified</td>
</tr>
<tr>
<td>842</td>
<td>Unintentional exposure to or harmful effects of plasma substitutes</td>
</tr>
<tr>
<td>843</td>
<td>Unintentional exposure to or harmful effects of agents primarily affecting the cardiovascular system</td>
</tr>
<tr>
<td>844</td>
<td>Unintentional exposure to or harmful effects of cardiac-stimulant glycosides or drugs of similar action</td>
</tr>
<tr>
<td>845</td>
<td>Unintentional exposure to or harmful effects of calcium-channel blockers</td>
</tr>
<tr>
<td>846</td>
<td>Unintentional exposure to or harmful effects of other antidysrhythmic drugs</td>
</tr>
<tr>
<td>847</td>
<td>Unintentional exposure to or harmful effects of nitroglycerin, nitroglycerol, medicinal</td>
</tr>
<tr>
<td>848</td>
<td>Unintentional exposure to or harmful effects of other coronary vasodilators</td>
</tr>
<tr>
<td>849</td>
<td>Unintentional exposure to or harmful effects of angiotensin-converting-enzyme inhibitors</td>
</tr>
<tr>
<td>850</td>
<td>Unintentional exposure to or harmful effects of other antihypertensive drugs</td>
</tr>
<tr>
<td>851</td>
<td>Unintentional exposure to or harmful effects of antihyperlipidemic or antiarteriosclerotic drugs</td>
</tr>
<tr>
<td>852</td>
<td>Unintentional exposure to or harmful effects of peripheral vasodilators</td>
</tr>
<tr>
<td>853</td>
<td>Unintentional exposure to or harmful effects of antivaricose drugs, including sclerosing agents</td>
</tr>
<tr>
<td>854</td>
<td>Unintentional exposure to or harmful effects of agents primarily affecting the gastrointestinal system</td>
</tr>
<tr>
<td>855</td>
<td>Unintentional exposure to or harmful effects of histamine H2-receptor blockers</td>
</tr>
<tr>
<td>856</td>
<td>Unintentional exposure to or harmful effects of other antacids or anti-gastric-secretion drugs</td>
</tr>
<tr>
<td>857</td>
<td>Unintentional exposure to or harmful effects of stimulant laxatives</td>
</tr>
<tr>
<td>858</td>
<td>Unintentional exposure to or harmful effects of saline or osmotic laxatives</td>
</tr>
<tr>
<td>859</td>
<td>Unintentional exposure to or harmful effects of other laxatives</td>
</tr>
<tr>
<td>860</td>
<td>Unintentional exposure to or harmful effects of digestants</td>
</tr>
<tr>
<td>861</td>
<td>Unintentional exposure to or harmful effects of antidiarrhoeal drugs</td>
</tr>
<tr>
<td>862</td>
<td>Unintentional exposure to or harmful effects of emetics</td>
</tr>
<tr>
<td>863</td>
<td>Unintentional exposure to or harmful effects of agents primarily acting on smooth or skeletal muscles or the respiratory system</td>
</tr>
<tr>
<td>864</td>
<td>Unintentional exposure to or harmful effects of oxytocic drugs</td>
</tr>
<tr>
<td>865</td>
<td>Unintentional exposure to or harmful effects of skeletal muscle relaxants</td>
</tr>
<tr>
<td>866</td>
<td>Unintentional harmful effect of neuromuscular blocking agents</td>
</tr>
<tr>
<td>867</td>
<td>Unintentional exposure to or harmful effects of other drugs acting on muscles</td>
</tr>
<tr>
<td>868</td>
<td>Unintentional exposure to or harmful effects of unspecified drugs acting on muscles</td>
</tr>
<tr>
<td>869</td>
<td>Unintentional exposure to or harmful effects of antitussives</td>
</tr>
<tr>
<td>870</td>
<td>Unintentional exposure to or harmful effects of expectorants</td>
</tr>
<tr>
<td>871</td>
<td>Unintentional exposure to or harmful effects of other anti-common-cold drugs</td>
</tr>
<tr>
<td>872</td>
<td>Unintentional exposure to or harmful effects of salbutamol</td>
</tr>
<tr>
<td>873</td>
<td>Unintentional exposure to or harmful effects of aminophylline, theophylline</td>
</tr>
<tr>
<td>874</td>
<td>Unintentional exposure to or harmful effects of terbutaline</td>
</tr>
<tr>
<td>875</td>
<td>Unintentional exposure to or harmful effects of antiasthmatics, not elsewhere classified</td>
</tr>
<tr>
<td>876</td>
<td>Unintentional exposure to or harmful effects of topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs</td>
</tr>
<tr>
<td>877</td>
<td>Unintentional exposure to or harmful effects of topical corticosteroid preparations</td>
</tr>
<tr>
<td>878</td>
<td>Unintentional exposure to or harmful effects of iodine, antiseptic</td>
</tr>
<tr>
<td>879</td>
<td>Unintentional exposure to or harmful effects of silver nitrate</td>
</tr>
<tr>
<td>880</td>
<td>Unintentional exposure to or harmful effects of other local antifungal, anti-infective or anti-inflammatory drugs</td>
</tr>
<tr>
<td>881</td>
<td>Unintentional exposure to or harmful effects of antipruritics</td>
</tr>
<tr>
<td>882</td>
<td>Unintentional exposure to or harmful effects of methyl salicylate</td>
</tr>
<tr>
<td>883</td>
<td>Unintentional exposure to or harmful effects of other local astringents or local detergents</td>
</tr>
<tr>
<td>884</td>
<td>Unintentional exposure to or harmful effects of emollients, demulcents or protectants</td>
</tr>
<tr>
<td>885</td>
<td>Unintentional exposure to or harmful effects of podophyllin</td>
</tr>
<tr>
<td>886</td>
<td>Unintentional exposure to or harmful effects of keratolytics, keratoplastics, or other hair treatment drugs or preparations</td>
</tr>
<tr>
<td>887</td>
<td>Unintentional exposure to or harmful effects of ophthalmological drugs or preparations</td>
</tr>
<tr>
<td>888</td>
<td>Unintentional exposure to or harmful effects of otorhinolaryngological drugs or preparations</td>
</tr>
<tr>
<td>889</td>
<td>Unintentional exposure to or harmful effects of fluoride preparations</td>
</tr>
<tr>
<td>890</td>
<td>Unintentional exposure to or harmful effects of other dental drugs, topically applied</td>
</tr>
<tr>
<td>891</td>
<td>Unintentional exposure to or harmful effects of camphor</td>
</tr>
<tr>
<td>892</td>
<td>Unintentional exposure to or harmful effects of agents primarily affecting water-balance or mineral or uric acid metabolism</td>
</tr>
<tr>
<td>893</td>
<td>Unintentional exposure to or harmful effects of mineralocorticoids</td>
</tr>
<tr>
<td>894</td>
<td>Unintentional exposure to or harmful effects of mineralocorticoids antagonists</td>
</tr>
<tr>
<td>895</td>
<td>Unintentional exposure to or harmful effects of loop diuretics</td>
</tr>
<tr>
<td>896</td>
<td>Unintentional harmful effect of high-ceiling diuretics</td>
</tr>
<tr>
<td>897</td>
<td>Unintentional exposure to or harmful effects of carbonic-anhydrase inhibitors</td>
</tr>
<tr>
<td>898</td>
<td>Unintentional exposure to or harmful effects of benzothiadiazine derivatives</td>
</tr>
<tr>
<td>899</td>
<td>Unintentional harmful effect of thiazides</td>
</tr>
<tr>
<td>900</td>
<td>Unintentional exposure to or harmful effects of other diuretics</td>
</tr>
<tr>
<td>901</td>
<td>Unintentional exposure to or harmful effects of electrolytic, caloric or water-balance agents</td>
</tr>
<tr>
<td>902</td>
<td>Unintentional exposure to or harmful effects of mineral salts, not elsewhere classified</td>
</tr>
<tr>
<td>903</td>
<td>Unintentional exposure to or harmful effects of drugs affecting uric acid metabolism</td>
</tr>
<tr>
<td>904</td>
<td>Unintentional exposure to or harmful effects of vitamin D or derivatives</td>
</tr>
<tr>
<td>905</td>
<td>Unintentional exposure to or harmful effects of bisphosphonates</td>
</tr>
<tr>
<td>906</td>
<td>Unintentional exposure to or harmful effects of appetite depressants</td>
</tr>
<tr>
<td>907</td>
<td>Unintentional exposure to or harmful effects of antidotes or chelating agents, not elsewhere classified</td>
</tr>
<tr>
<td>908</td>
<td>Unintentional exposure to or harmful effects of disulfiram</td>
</tr>
<tr>
<td>909</td>
<td>Unintentional exposure to or harmful effects of alcohol deterrents, not elsewhere classified</td>
</tr>
<tr>
<td>910</td>
<td>Unintentional exposure to or harmful effects of X-ray contrast media</td>
</tr>
<tr>
<td>911</td>
<td>Unintentional exposure to or harmful effects of MRI contrast agents</td>
</tr>
<tr>
<td>912</td>
<td>Unintentional exposure to or harmful effects of agents used for other scanning techniques</td>
</tr>
<tr>
<td>913</td>
<td>Unintentional exposure to or harmful effects of other diagnostic agents</td>
</tr>
<tr>
<td>914</td>
<td>Unintentional exposure to or harmful effects of lipotropic drugs</td>
</tr>
<tr>
<td>915</td>
<td>Unintentional exposure to or harmful effects of vitamins, not elsewhere classified, Pharmaceutical excipients</td>
</tr>
<tr>
<td>916</td>
<td>Unintentional exposure to or harmful effects of herbal preparations or formulas</td>
</tr>
<tr>
<td>917</td>
<td>Unintentional exposure to or harmful effects of dietary supplements, vitamins or minerals</td>
</tr>
<tr>
<td>918</td>
<td>Unintentional exposure to or harmful effects of complementary or traditional medicines, not elsewhere classified</td>
</tr>
<tr>
<td>919</td>
<td>Unintentional exposure to or harmful effects of complementary or traditional medicines, unspecified</td>
</tr>
<tr>
<td>920</td>
<td>Unintentional exposure to or harmful effects of vaccines immunoglobulins or other biological substances</td>
</tr>
<tr>
<td>921</td>
<td>Unintentional exposure to or harmful effects of BCG vaccine</td>
</tr>
<tr>
<td>922</td>
<td>Unintentional exposure to or harmful effects of typhoid or paratyphoid vaccine</td>
</tr>
<tr>
<td>923</td>
<td>Unintentional exposure to or harmful effects of cholera vaccine</td>
</tr>
<tr>
<td>924</td>
<td>Unintentional exposure to or harmful effects of plague vaccine</td>
</tr>
<tr>
<td>925</td>
<td>Unintentional exposure to or harmful effects of tetanus vaccine</td>
</tr>
<tr>
<td>926</td>
<td>Unintentional exposure to or harmful effects of diphtheria vaccine</td>
</tr>
<tr>
<td>927</td>
<td>Unintentional exposure to or harmful effects of Haemophilus influenzae type B vaccines</td>
</tr>
<tr>
<td>928</td>
<td>Unintentional exposure to or harmful effects of pertussis vaccine, including combinations with a pertussis component</td>
</tr>
<tr>
<td>929</td>
<td>Unintentional exposure to or harmful effects of mixed bacterial vaccines without a pertussis component</td>
</tr>
<tr>
<td>930</td>
<td>Unintentional exposure to or harmful effects of other or unspecified bacterial vaccines</td>
</tr>
<tr>
<td>931</td>
<td>Unintentional exposure to or harmful effects of smallpox vaccines</td>
</tr>
<tr>
<td>932</td>
<td>Unintentional exposure to or harmful effects of measles vaccines</td>
</tr>
<tr>
<td>933</td>
<td>Unintentional exposure to or harmful effects of mumps vaccines</td>
</tr>
<tr>
<td>934</td>
<td>Unintentional exposure to or harmful effects of rubella vaccines</td>
</tr>
<tr>
<td>935</td>
<td>Unintentional exposure to or harmful effects of polio vaccines</td>
</tr>
<tr>
<td>936</td>
<td>Unintentional exposure to or harmful effects of yellow fever vaccines</td>
</tr>
<tr>
<td>937</td>
<td>Unintentional exposure to or harmful effects of hepatitis A vaccines</td>
</tr>
<tr>
<td>938</td>
<td>Unintentional exposure to or harmful effects of hepatitis B vaccines</td>
</tr>
<tr>
<td>939</td>
<td>Unintentional exposure to or harmful effects of influenza vaccines</td>
</tr>
<tr>
<td>940</td>
<td>Unintentional exposure to or harmful effects of rotavirus vaccines</td>
</tr>
<tr>
<td>941</td>
<td>Unintentional exposure to or harmful effects of human papillomavirus vaccines</td>
</tr>
<tr>
<td>942</td>
<td>Unintentional exposure to or harmful effects of other viral vaccines</td>
</tr>
<tr>
<td>943</td>
<td>Unintentional exposure to or harmful effects of rickettsial vaccines</td>
</tr>
<tr>
<td>944</td>
<td>Unintentional exposure to or harmful effects of protozoal vaccines</td>
</tr>
<tr>
<td>945</td>
<td>Unintentional exposure to or harmful effects of hepatitis B immune globulin</td>
</tr>
<tr>
<td>946</td>
<td>Unintentional exposure to or harmful effects of antivenin, antivenom</td>
</tr>
<tr>
<td>947</td>
<td>Unintentional exposure to or harmful effects of immunoglobulin, not elsewhere classified</td>
</tr>
<tr>
<td>948</td>
<td>Unintentional exposure to or harmful effects of other specified vaccines</td>
</tr>
<tr>
<td>949</td>
<td>Unintentional exposure to or harmful effects of unspecified vaccines</td>
</tr>
<tr>
<td>950</td>
<td>Toxic effects of methamphetamine</td>
</tr>
<tr>
<td>951</td>
<td>Exposure to or harmful effects of undetermined intent of other or unspecified drugs, medicaments or biological substances</td>
</tr>
<tr>
<td>952</td>
<td>drug related harm</td>
</tr>
<tr>
<td>953</td>
<td>Exposure to or harmful effects of undetermined intent of systemic antibiotics</td>
</tr>
<tr>
<td>954</td>
<td>Exposure to or harmful effects of undetermined intent of penicillins</td>
</tr>
<tr>
<td>955</td>
<td>Exposure to or harmful effects of undetermined intent of cephalosporins or other beta-lactam antibiotics</td>
</tr>
<tr>
<td>956</td>
<td>Exposure to or harmful effects of undetermined intent of chloramphenicol group</td>
</tr>
<tr>
<td>957</td>
<td>Exposure to or harmful effects of undetermined intent of macrolides</td>
</tr>
<tr>
<td>958</td>
<td>Exposure to or harmful effects of undetermined intent of tetracyclines</td>
</tr>
<tr>
<td>959</td>
<td>Exposure to or harmful effects of undetermined intent of aminoglycosides</td>
</tr>
<tr>
<td>960</td>
<td>Exposure to or harmful effects of undetermined intent of rifampicins</td>
</tr>
<tr>
<td>961</td>
<td>Exposure to or harmful effects of undetermined intent of antifungal antibiotics, systemically used</td>
</tr>
<tr>
<td>962</td>
<td>Exposure to or harmful effects of undetermined intent of other systemic anti-infectives or antiparasitics</td>
</tr>
<tr>
<td>963</td>
<td>Exposure to or harmful effects of undetermined intent of sulfonamides</td>
</tr>
<tr>
<td>964</td>
<td>Exposure to or harmful effects of undetermined intent of antimycobacterial drugs</td>
</tr>
<tr>
<td>965</td>
<td>Exposure to or harmful effects of undetermined intent of antimalarials or drugs acting on other blood protozoa</td>
</tr>
<tr>
<td>966</td>
<td>Exposure to or harmful effects of undetermined intent of other antiprotozoal drugs</td>
</tr>
<tr>
<td>967</td>
<td>Exposure to or harmful effects of undetermined intent of anthelminthics</td>
</tr>
<tr>
<td>968</td>
<td>Exposure to or harmful effects of undetermined intent of antiviral drugs</td>
</tr>
<tr>
<td>969</td>
<td>Exposure to or harmful effects of undetermined intent of hormones or their synthetic substitutes or antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>970</td>
<td>Exposure to or harmful effects of undetermined intent of glucocorticoids or synthetic analogues</td>
</tr>
<tr>
<td>971</td>
<td>Exposure to or harmful effects of undetermined intent of thyroid hormones or substitutes</td>
</tr>
<tr>
<td>972</td>
<td>Exposure to or harmful effects of undetermined intent of antithyroid drugs</td>
</tr>
<tr>
<td>973</td>
<td>Exposure to or harmful effects of undetermined intent of insulin or oral hypoglycaemic drugs</td>
</tr>
<tr>
<td>974</td>
<td>harmful effect of antidiabetic drugs, undetermined intent</td>
</tr>
<tr>
<td>975</td>
<td>Exposure to or harmful effects of undetermined intent of oral contraceptives</td>
</tr>
<tr>
<td>976</td>
<td>Exposure to or harmful effects of undetermined intent of other estrogens or progestogens</td>
</tr>
<tr>
<td>977</td>
<td>Exposure to or harmful effects of undetermined intent of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified</td>
</tr>
<tr>
<td>978</td>
<td>Exposure to or harmful effects of undetermined intent of androgens or anabolic congeners</td>
</tr>
<tr>
<td>979</td>
<td>Exposure to or harmful effects of undetermined intent of unspecified hormones or synthetic substitutes</td>
</tr>
<tr>
<td>980</td>
<td>Exposure to or harmful effects of undetermined intent of anterior pituitary hormones</td>
</tr>
<tr>
<td>981</td>
<td>Harmful effect of adenohypophyseal hormones, undetermined intent</td>
</tr>
<tr>
<td>982</td>
<td>Exposure to or harmful effects of undetermined intent of other hormones or synthetic substitutes</td>
</tr>
<tr>
<td>983</td>
<td>Exposure to or harmful effects of undetermined intent of unspecified hormone antagonists</td>
</tr>
<tr>
<td>984</td>
<td>Exposure to or harmful effects of undetermined intent of other hormone antagonists</td>
</tr>
<tr>
<td>985</td>
<td>Exposure to or harmful effects of undetermined intent of drugs primarily affecting the autonomic nervous system</td>
</tr>
<tr>
<td>986</td>
<td>Exposure to or harmful effects of undetermined intent of anticholinesterase agents</td>
</tr>
<tr>
<td>987</td>
<td>Exposure to or harmful effects of undetermined intent of other parasympathomimetics</td>
</tr>
<tr>
<td>988</td>
<td>harmful effect of cholinergics, undetermined intent</td>
</tr>
<tr>
<td>989</td>
<td>Exposure to or harmful effects of undetermined intent of ganglionic blocking drugs</td>
</tr>
<tr>
<td>990</td>
<td>Exposure to or harmful effects of undetermined intent of other parasympatholytics or spasmolytics</td>
</tr>
<tr>
<td>991</td>
<td>harmful effect of anticholinergics or antimuscarinics, undetermined intent</td>
</tr>
<tr>
<td>992</td>
<td>Exposure to or harmful effects of undetermined intent of predominantly alpha-adrenoreceptor agonists</td>
</tr>
<tr>
<td>993</td>
<td>Exposure to or harmful effects of undetermined intent of predominantly beta-adrenoreceptor agonists</td>
</tr>
<tr>
<td>994</td>
<td>Exposure to or harmful effects of undetermined intent of alpha-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>995</td>
<td>Exposure to or harmful effects of undetermined intent of beta-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>996</td>
<td>Exposure to or harmful effects of undetermined intent of centrally-acting or adrenergic-neuron-blocking agents</td>
</tr>
<tr>
<td>997</td>
<td>Exposure to or harmful effects of undetermined intent of agents primarily affecting blood constituents</td>
</tr>
<tr>
<td>998</td>
<td>Exposure to or harmful effects of undetermined intent of diphenhydramine</td>
</tr>
<tr>
<td>999</td>
<td>Exposure to or harmful effects of undetermined intent of other H1-receptor antagonists</td>
</tr>
<tr>
<td>1000</td>
<td>Exposure to or harmful effects of undetermined intent of antiallergic or antiemetic drugs</td>
</tr>
<tr>
<td>1001</td>
<td>Exposure to or harmful effects of undetermined intent of antineoplastic antimetabolites</td>
</tr>
<tr>
<td>1002</td>
<td>Exposure to or harmful effects of undetermined intent of antineoplastic natural products</td>
</tr>
<tr>
<td>1003</td>
<td>Exposure to or harmful effects of undetermined intent of other antineoplastic drugs</td>
</tr>
<tr>
<td>1004</td>
<td>Exposure to or harmful effects of undetermined intent of immunosuppressive agents</td>
</tr>
<tr>
<td>1005</td>
<td>Exposure to or harmful effects of undetermined intent of vitamin B12, folic acid or other anti-megaloblastic-anaemia preparations</td>
</tr>
<tr>
<td>1006</td>
<td>Exposure to or harmful effects of undetermined intent of enzymes</td>
</tr>
<tr>
<td>1007</td>
<td>Exposure to or harmful effects of undetermined intent of iron or its compounds</td>
</tr>
<tr>
<td>1008</td>
<td>Exposure to or harmful effects of undetermined intent of anticoagulants</td>
</tr>
<tr>
<td>1009</td>
<td>Exposure to or harmful effects of undetermined intent of antithrombotic drugs</td>
</tr>
<tr>
<td>1010</td>
<td>harmful effect of platelet aggregation inhibitors, undetermined intent</td>
</tr>
<tr>
<td>1011</td>
<td>Exposure to or harmful effects of undetermined intent of thrombolytic drug</td>
</tr>
<tr>
<td>1012</td>
<td>Exposure to or harmful effects of undetermined intent of anticoagulant antagonists, vitamin K or other coagulants</td>
</tr>
<tr>
<td>1013</td>
<td>Exposure to or harmful effects of undetermined intent of other fibrinolysis-affecting drugs</td>
</tr>
<tr>
<td>1014</td>
<td>Exposure to or harmful effects of undetermined intent of natural blood or blood products</td>
</tr>
<tr>
<td>1015</td>
<td>Exposure to or harmful effects of undetermined intent of acidifying or alkalising agents</td>
</tr>
<tr>
<td>1016</td>
<td>Exposure to or harmful effects of undetermined intent of other primarily systemic agents, not elsewhere classified</td>
</tr>
<tr>
<td>1017</td>
<td>Exposure to or harmful effects of undetermined intent of plasma substitutes</td>
</tr>
<tr>
<td>1018</td>
<td>Exposure to or harmful effects of undetermined intent of agents primarily affecting the cardiovascular system</td>
</tr>
<tr>
<td>1019</td>
<td>Exposure to or harmful effects of undetermined intent of cardiac-stimulant glycosides or drugs of similar action</td>
</tr>
<tr>
<td>1020</td>
<td>Exposure to or harmful effects of undetermined intent of calcium-channel blockers</td>
</tr>
<tr>
<td>1021</td>
<td>Exposure to or harmful effects of undetermined intent of other antidysrhythmic drugs</td>
</tr>
<tr>
<td>1022</td>
<td>Exposure to or harmful effects of undetermined intent of nitroglycerin, nitroglycerol, medicinal</td>
</tr>
<tr>
<td>1023</td>
<td>Exposure to or harmful effects of undetermined intent of other coronary vasodilators</td>
</tr>
<tr>
<td>1024</td>
<td>Exposure to or harmful effects of undetermined intent of angiotensin-converting-enzyme inhibitors</td>
</tr>
<tr>
<td>1025</td>
<td>Exposure to or harmful effects of undetermined intent of other antihypertensive drugs</td>
</tr>
<tr>
<td>1026</td>
<td>Exposure to or harmful effects of undetermined intent of antihyperlipidemic or antiarteriosclerotic drugs</td>
</tr>
<tr>
<td>1027</td>
<td>Exposure to or harmful effects of undetermined intent of peripheral vasodilators</td>
</tr>
<tr>
<td>1028</td>
<td>Exposure to or harmful effects of undetermined intent of antivaricose drugs, including sclerosing agents</td>
</tr>
<tr>
<td>1029</td>
<td>Exposure to or harmful effects of undetermined intent of agents primarily affecting the gastrointestinal system</td>
</tr>
<tr>
<td>1030</td>
<td>Exposure to or harmful effects of undetermined intent of histamine H2-receptor blockers</td>
</tr>
<tr>
<td>1031</td>
<td>Exposure to or harmful effects of undetermined intent of other antacids or anti-gastric-secretion drugs</td>
</tr>
<tr>
<td>1032</td>
<td>Exposure to or harmful effects of undetermined intent of stimulant laxatives</td>
</tr>
<tr>
<td>1033</td>
<td>Exposure to or harmful effects of undetermined intent of saline or osmotic laxatives</td>
</tr>
<tr>
<td>1034</td>
<td>Exposure to or harmful effects of undetermined intent of other laxatives</td>
</tr>
<tr>
<td>1035</td>
<td>Exposure to or harmful effects of undetermined intent of digestants</td>
</tr>
<tr>
<td>1036</td>
<td>Exposure to or harmful effects of undetermined intent of antidiarrhoeal drugs</td>
</tr>
<tr>
<td>1037</td>
<td>Exposure to or harmful effects of undetermined intent of emetics</td>
</tr>
<tr>
<td>1038</td>
<td>Exposure to or harmful effects of undetermined intent of agents primarily acting on smooth or skeletal muscles or the respiratory system</td>
</tr>
<tr>
<td>1039</td>
<td>Exposure to or harmful effects of undetermined intent of oxytocic drugs</td>
</tr>
<tr>
<td>1040</td>
<td>Exposure to or harmful effects of undetermined intent of skeletal muscle relaxants</td>
</tr>
<tr>
<td>1041</td>
<td>harmful effect of neuromuscular blocking agents, undetermined intent</td>
</tr>
<tr>
<td>1042</td>
<td>Exposure to or harmful effects of undetermined intent of other drugs acting on muscles</td>
</tr>
<tr>
<td>1043</td>
<td>Exposure to or harmful effects of undetermined intent of unspecified drugs acting on muscles</td>
</tr>
<tr>
<td>1044</td>
<td>Exposure to or harmful effects of undetermined intent of antitussives</td>
</tr>
<tr>
<td>1045</td>
<td>Exposure to or harmful effects of undetermined intent of expectorants</td>
</tr>
<tr>
<td>1046</td>
<td>Exposure to or harmful effects of undetermined intent of other anti-common-cold drugs</td>
</tr>
<tr>
<td>1047</td>
<td>Exposure to or harmful effects of undetermined intent of salbutamol</td>
</tr>
<tr>
<td>1048</td>
<td>Exposure to or harmful effects of undetermined intent of aminophylline, theophylline</td>
</tr>
<tr>
<td>1049</td>
<td>Exposure to or harmful effects of undetermined intent of terbutaline</td>
</tr>
<tr>
<td>1050</td>
<td>Exposure to or harmful effects of undetermined intent of antiasthmatics, not elsewhere classified</td>
</tr>
<tr>
<td>1051</td>
<td>Exposure to or harmful effects of undetermined intent of topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs</td>
</tr>
<tr>
<td>1052</td>
<td>Exposure to or harmful effects of undetermined intent of topical corticosteroid preparations</td>
</tr>
<tr>
<td>1053</td>
<td>Exposure to or harmful effects of iodine, antiseptic, undetermined intent</td>
</tr>
<tr>
<td>1054</td>
<td>Exposure to or harmful effects of undetermined intent of silver nitrate</td>
</tr>
<tr>
<td>1055</td>
<td>Exposure to or harmful effects of undetermined intent of other local antifungal, anti-infective or anti-inflammatory drugs</td>
</tr>
<tr>
<td>1056</td>
<td>Exposure to or harmful effects of undetermined intent of antipruritics</td>
</tr>
<tr>
<td>1057</td>
<td>Exposure to or harmful effects of undetermined intent of methyl salicylate</td>
</tr>
<tr>
<td>1058</td>
<td>Exposure to or harmful effects of undetermined intent of other local astringents or local detergents</td>
</tr>
<tr>
<td>1059</td>
<td>Exposure to or harmful effects of undetermined intent of emollients, demulcents or protectants</td>
</tr>
<tr>
<td>1060</td>
<td>Exposure to or harmful effects of undetermined intent of podophyllin</td>
</tr>
<tr>
<td>1061</td>
<td>Exposure to or harmful effects of undetermined intent of keratolytics, keratoplastics, or other hair treatment drugs or preparations</td>
</tr>
<tr>
<td>1062</td>
<td>Exposure to or harmful effects of undetermined intent of ophthalmological drugs or preparations</td>
</tr>
<tr>
<td>1063</td>
<td>Exposure to or harmful effects of undetermined intent of otorhinolaryngological drugs or preparations</td>
</tr>
<tr>
<td>1064</td>
<td>Exposure to or harmful effects of undetermined intent of fluoride preparations</td>
</tr>
<tr>
<td>1065</td>
<td>Exposure to or harmful effects of undetermined intent of other dental drugs, topically applied</td>
</tr>
<tr>
<td>1066</td>
<td>Exposure to or harmful effects of undetermined intent of camphor</td>
</tr>
<tr>
<td>1067</td>
<td>Exposure to or harmful effects of undetermined intent of agents primarily affecting water-balance or mineral or uric acid metabolism</td>
</tr>
<tr>
<td>1068</td>
<td>Exposure to or harmful effects of undetermined intent of mineralocorticoids</td>
</tr>
<tr>
<td>1069</td>
<td>Exposure to or harmful effects of undetermined intent of mineralocorticoids antagonists</td>
</tr>
<tr>
<td>1070</td>
<td>Exposure to or harmful effects of undetermined intent of loop diuretics</td>
</tr>
<tr>
<td>1071</td>
<td>harmful effect of high-ceiling diuretics, undetermined intent</td>
</tr>
<tr>
<td>1072</td>
<td>Exposure to or harmful effects of undetermined intent of carbonic-anhydrase inhibitors</td>
</tr>
<tr>
<td>1073</td>
<td>Exposure to or harmful effects of undetermined intent of benzothiadiazine derivatives</td>
</tr>
<tr>
<td>1074</td>
<td>harmful effect of thiazides, undetermined intent</td>
</tr>
<tr>
<td>1075</td>
<td>Exposure to or harmful effects of undetermined intent of other diuretics</td>
</tr>
<tr>
<td>1076</td>
<td>Exposure to or harmful effects of undetermined intent of electrolytic, caloric or water-balance agents</td>
</tr>
<tr>
<td>1077</td>
<td>Exposure to or harmful effects of undetermined intent of mineral salts, not elsewhere classified</td>
</tr>
<tr>
<td>1078</td>
<td>Exposure to or harmful effects of undetermined intent of drugs affecting uric acid metabolism</td>
</tr>
<tr>
<td>1079</td>
<td>Exposure to or harmful effects of undetermined intent of vitamin D or derivatives</td>
</tr>
<tr>
<td>1080</td>
<td>Exposure to or harmful effects of undetermined intent of bisphosphonates</td>
</tr>
<tr>
<td>1081</td>
<td>Exposure to or harmful effects of undetermined intent of appetite depressants</td>
</tr>
<tr>
<td>1082</td>
<td>Exposure to or harmful effects of undetermined intent of antidotes or chelating agents, not elsewhere classified</td>
</tr>
<tr>
<td>1083</td>
<td>Exposure to or harmful effects of undetermined intent of disulfiram</td>
</tr>
<tr>
<td>1084</td>
<td>Exposure to or harmful effects of undetermined intent of alcohol deterrents, not elsewhere classified</td>
</tr>
<tr>
<td>1085</td>
<td>Exposure to or harmful effects of undetermined intent of X-ray contrast media</td>
</tr>
<tr>
<td>1086</td>
<td>Exposure to or harmful effects of undetermined intent of MRI contrast agents</td>
</tr>
<tr>
<td>1087</td>
<td>Exposure to or harmful effects of undetermined intent of agents used for other scanning techniques</td>
</tr>
<tr>
<td>1088</td>
<td>Exposure to or harmful effects of undetermined intent of other diagnostic agents</td>
</tr>
<tr>
<td>1089</td>
<td>Exposure to or harmful effects of undetermined intent of lipotropic drugs</td>
</tr>
<tr>
<td>1090</td>
<td>Exposure to or harmful effects of undetermined intent of pharmaceutical excipients</td>
</tr>
<tr>
<td>1091</td>
<td>Exposure to or harmful effects of undetermined intent of herbal preparations or formulas</td>
</tr>
<tr>
<td>1092</td>
<td>Exposure to or harmful effects of undetermined intent of dietary supplements, vitamins or minerals</td>
</tr>
<tr>
<td>1093</td>
<td>Exposure to or harmful effects of undetermined intent of complementary or traditional medicines, not elsewhere classified</td>
</tr>
<tr>
<td>1094</td>
<td>Exposure to or harmful effects of undetermined intent of complementary or traditional medicines, unspecified</td>
</tr>
<tr>
<td>1095</td>
<td>Exposure to or harmful effects of undetermined intent of vaccines immunoglobulins or other biological substances</td>
</tr>
<tr>
<td>1096</td>
<td>Exposure to or harmful effects of undetermined intent of BCG vaccine</td>
</tr>
<tr>
<td>1097</td>
<td>Exposure to or harmful effects of undetermined intent of typhoid or paratyphoid vaccine</td>
</tr>
<tr>
<td>1098</td>
<td>Exposure to or harmful effects of undetermined intent of cholera vaccine</td>
</tr>
<tr>
<td>1099</td>
<td>Exposure to or harmful effects of undetermined intent of plague vaccine</td>
</tr>
<tr>
<td>1100</td>
<td>Exposure to or harmful effects of undetermined intent of tetanus vaccine</td>
</tr>
<tr>
<td>1101</td>
<td>Exposure to or harmful effects of undetermined intent of diphtheria vaccine</td>
</tr>
<tr>
<td>1102</td>
<td>Exposure to or harmful effects of undetermined intent of haemophilus influenzae type b vaccines</td>
</tr>
<tr>
<td>1103</td>
<td>Exposure to or harmful effects of undetermined intent of pertussis vaccine, including combinations with a pertussis component</td>
</tr>
<tr>
<td>1104</td>
<td>Exposure to or harmful effects of undetermined intent of mixed bacterial vaccines without a pertussis component</td>
</tr>
<tr>
<td>1105</td>
<td>Exposure to or harmful effects of undetermined intent of other or unspecified bacterial vaccines</td>
</tr>
<tr>
<td>1106</td>
<td>Exposure to or harmful effects of undetermined intent of smallpox vaccines</td>
</tr>
<tr>
<td>1107</td>
<td>Exposure to or harmful effects of undetermined intent of measles vaccines</td>
</tr>
<tr>
<td>1108</td>
<td>Exposure to or harmful effects of undetermined intent of mumps vaccines</td>
</tr>
<tr>
<td>1109</td>
<td>Exposure to or harmful effects of undetermined intent of rubella vaccines</td>
</tr>
<tr>
<td>1110</td>
<td>Exposure to or harmful effects of undetermined intent of polio vaccines</td>
</tr>
<tr>
<td>1111</td>
<td>Exposure to or harmful effects of undetermined intent of yellow fever vaccines</td>
</tr>
<tr>
<td>1112</td>
<td>Exposure to or harmful effects of undetermined intent of hepatitis A vaccines</td>
</tr>
<tr>
<td>1113</td>
<td>Exposure to or harmful effects of undetermined intent of hepatitis B vaccines</td>
</tr>
<tr>
<td>1114</td>
<td>Exposure to or harmful effects of undetermined intent of influenza vaccines</td>
</tr>
<tr>
<td>1115</td>
<td>Exposure to or harmful effects of undetermined intent of rotavirus vaccines</td>
</tr>
<tr>
<td>1116</td>
<td>Exposure to or harmful effects of undetermined intent of human papillomavirus vaccines</td>
</tr>
<tr>
<td>1117</td>
<td>Exposure to or harmful effects of undetermined intent of other viral vaccines</td>
</tr>
<tr>
<td>1118</td>
<td>Exposure to or harmful effects of undetermined intent of rickettsial vaccines</td>
</tr>
<tr>
<td>1119</td>
<td>Exposure to or harmful effects of undetermined intent of protozoal vaccines</td>
</tr>
<tr>
<td>1120</td>
<td>Exposure to or harmful effects of undetermined intent of hepatitis B immune globulin</td>
</tr>
<tr>
<td>1121</td>
<td>Exposure to or harmful effects of undetermined intent of antivenin, antivenom</td>
</tr>
<tr>
<td>1122</td>
<td>Exposure to or harmful effects of undetermined intent of immunoglobulin, not elsewhere classified</td>
</tr>
<tr>
<td>1123</td>
<td>Exposure to or harmful effects of undetermined intent of other specified vaccines</td>
</tr>
<tr>
<td>1124</td>
<td>Exposure to or harmful effects of undetermined intent of unspecified vaccines</td>
</tr>
<tr>
<td>1125</td>
<td>Assault by exposure to or harmful effects of other or unspecified drug, medicament or biological substance</td>
</tr>
<tr>
<td>1126</td>
<td>homicidal poisoning by exposure to or harmful effects of other or unspecified drug, medicament or biological substance</td>
</tr>
<tr>
<td>1127</td>
<td>Assault by exposure to or harmful effects of systemic antibiotics</td>
</tr>
<tr>
<td>1128</td>
<td>Assault by exposure to or harmful effects of penicillins</td>
</tr>
<tr>
<td>1129</td>
<td>Assault by exposure to or harmful effects of cephalosporins or other beta-lactam antibiotics</td>
</tr>
<tr>
<td>1130</td>
<td>Assault by exposure to or harmful effects of chloramphenicol group</td>
</tr>
<tr>
<td>1131</td>
<td>Assault by exposure to or harmful effects of macrolides</td>
</tr>
<tr>
<td>1132</td>
<td>Assault by exposure to or harmful effects of tetracyclines</td>
</tr>
<tr>
<td>1133</td>
<td>Assault by exposure to or harmful effects of aminoglycosides</td>
</tr>
<tr>
<td>1134</td>
<td>Assault by exposure to or harmful effects of rifampicin</td>
</tr>
<tr>
<td>1135</td>
<td>Assault by exposure to or harmful effects of antifungal antibiotics, systemically used</td>
</tr>
<tr>
<td>1136</td>
<td>Assault by exposure to or harmful effects of other systemic anti-infectives or antiparasitics</td>
</tr>
<tr>
<td>1137</td>
<td>Assault by exposure to or harmful effects of sulfonamides</td>
</tr>
<tr>
<td>1138</td>
<td>Assault by exposure to or harmful effects of antimycobacterial drugs</td>
</tr>
<tr>
<td>1139</td>
<td>Assault by exposure to or harmful effects of antimalarials or drugs acting on other blood protozoa</td>
</tr>
<tr>
<td>1140</td>
<td>Assault by exposure to or harmful effects of other antiprotozoal drugs</td>
</tr>
<tr>
<td>1141</td>
<td>Assault by exposure to or harmful effects of anthelminthics</td>
</tr>
<tr>
<td>1142</td>
<td>Assault by exposure to or harmful effects of antiviral drugs</td>
</tr>
<tr>
<td>1143</td>
<td>Assault by exposure to or harmful effects of hormones or their synthetic substitutes or antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>1144</td>
<td>Assault by exposure to or harmful effects of glucocorticoids or synthetic analogues</td>
</tr>
<tr>
<td>1145</td>
<td>Assault by exposure to or harmful effects of thyroid hormones or substitutes</td>
</tr>
<tr>
<td>1146</td>
<td>Assault by exposure to or harmful effects of antithyroid drugs</td>
</tr>
<tr>
<td>1147</td>
<td>Assault by exposure to or harmful effects of insulin or oral hypoglycaemic drugs</td>
</tr>
<tr>
<td>1148</td>
<td>Assault by exposure to or harmful effects of antidiabetic drugs</td>
</tr>
<tr>
<td>1149</td>
<td>Assault by exposure to or harmful effects of oral contraceptives</td>
</tr>
<tr>
<td>1150</td>
<td>Assault by exposure to or harmful effects of other estrogens or progestogens</td>
</tr>
<tr>
<td>1151</td>
<td>Assault by exposure to or harmful effects of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified</td>
</tr>
<tr>
<td>1152</td>
<td>Assault by exposure to or harmful effects of androgens or anabolic congeners</td>
</tr>
<tr>
<td>1153</td>
<td>Assault by exposure to or harmful effects of unspecified hormones or synthetic substitutes</td>
</tr>
<tr>
<td>1154</td>
<td>Assault by exposure to or harmful effects of anterior pituitary hormones</td>
</tr>
<tr>
<td>1155</td>
<td>Assault by exposure to or harmful effects of adenohypophyseal hormones</td>
</tr>
<tr>
<td>1156</td>
<td>Assault by exposure to or harmful effects of other hormones or synthetic substitutes</td>
</tr>
<tr>
<td>1157</td>
<td>Assault by exposure to or harmful effects of unspecified hormone antagonists</td>
</tr>
<tr>
<td>1158</td>
<td>Assault by exposure to or harmful effects of other hormone antagonists</td>
</tr>
<tr>
<td>1159</td>
<td>Assault by exposure to or harmful effects of drugs primarily affecting the autonomic nervous system</td>
</tr>
<tr>
<td>1160</td>
<td>Assault by exposure to or harmful effects of anticholinesterase agents</td>
</tr>
<tr>
<td>1161</td>
<td>Assault by exposure to or harmful effects of other parasympathomimetics</td>
</tr>
<tr>
<td>1162</td>
<td>Assault by exposure to or harmful effects of cholinergics</td>
</tr>
<tr>
<td>1163</td>
<td>Assault by exposure to or harmful effects of ganglionic blocking drugs</td>
</tr>
<tr>
<td>1164</td>
<td>Assault by exposure to or harmful effects of other parasympatholytics or spasmolytics</td>
</tr>
<tr>
<td>1165</td>
<td>Assault by exposure to or harmful effects of anticholinergics or antimuscarinics</td>
</tr>
<tr>
<td>1166</td>
<td>Assault by exposure to or harmful effects of predominantly alpha-adrenoreceptor agonists</td>
</tr>
<tr>
<td>1167</td>
<td>Assault by exposure to or harmful effects of predominantly beta-adrenoreceptor agonists</td>
</tr>
<tr>
<td>1168</td>
<td>Assault by exposure to or harmful effects of alpha-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>1169</td>
<td>Assault by exposure to or harmful effects of beta-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>1170</td>
<td>Assault by exposure to or harmful effects of centrally-acting or adrenergic-neuron-blocking agents</td>
</tr>
<tr>
<td>1171</td>
<td>Assault by exposure to or harmful effects of agents primarily affecting blood constituents</td>
</tr>
<tr>
<td>1172</td>
<td>Assault by exposure to or harmful effects of diphenhydramine</td>
</tr>
<tr>
<td>1173</td>
<td>Assault by exposure to or harmful effects of other H1-receptor antagonists</td>
</tr>
<tr>
<td>1174</td>
<td>Assault by exposure to or harmful effects of antiallergic or antiemetic drugs</td>
</tr>
<tr>
<td>1175</td>
<td>Assault by exposure to or harmful effects of antineoplastic antimetabolites</td>
</tr>
<tr>
<td>1176</td>
<td>Assault by exposure to or harmful effects of antineoplastic natural products</td>
</tr>
<tr>
<td>1177</td>
<td>Assault by exposure to or harmful effects of other antineoplastic drugs</td>
</tr>
<tr>
<td>1178</td>
<td>Assault by exposure to or harmful effects of immunosuppressive agents</td>
</tr>
<tr>
<td>1179</td>
<td>Assault by exposure to or harmful effects of vitamin B12, folic acid or other anti-megaloblastic-anaemia preparations</td>
</tr>
<tr>
<td>1180</td>
<td>Assault by exposure to or harmful effects of enzymes</td>
</tr>
<tr>
<td>1181</td>
<td>Assault by exposure to or harmful effects of iron or its compounds</td>
</tr>
<tr>
<td>1182</td>
<td>Assault by exposure to or harmful effects of anticoagulants</td>
</tr>
<tr>
<td>1183</td>
<td>Assault by exposure to or harmful effects of antithrombotic drugs</td>
</tr>
<tr>
<td>1184</td>
<td>Assault by exposure to or harmful effects of platelet aggregation inhibitors</td>
</tr>
<tr>
<td>1185</td>
<td>Assault by exposure to or harmful effects of thrombolytic drug</td>
</tr>
<tr>
<td>1186</td>
<td>Assault by exposure to or harmful effects of anticoagulant antagonists, vitamin K or other coagulants</td>
</tr>
<tr>
<td>1187</td>
<td>Assault by exposure to or harmful effects of other fibrinolysis-affecting drugs</td>
</tr>
<tr>
<td>1188</td>
<td>Assault by exposure to or harmful effects of natural blood or blood products</td>
</tr>
<tr>
<td>1189</td>
<td>Assault by exposure to or harmful effects of acidifying or alkalising agents</td>
</tr>
<tr>
<td>1190</td>
<td>Assault by exposure to or harmful effects of other primarily systemic agents, not elsewhere classified</td>
</tr>
<tr>
<td>1191</td>
<td>Assault by exposure to or harmful effects of plasma substitutes</td>
</tr>
<tr>
<td>1192</td>
<td>Assault by exposure to or harmful effects of agents primarily affecting the cardiovascular system</td>
</tr>
<tr>
<td>1193</td>
<td>Assault by exposure to or harmful effects of cardiac-stimulant glycosides or drugs of similar action</td>
</tr>
<tr>
<td>1194</td>
<td>Assault by exposure to or harmful effects of calcium-channel blockers</td>
</tr>
<tr>
<td>1195</td>
<td>Assault by exposure to or harmful effects of other antidysrhythmic drugs</td>
</tr>
<tr>
<td>1196</td>
<td>Assault by exposure to or harmful effects of nitroglycerin, nitroglycerol, medicinal</td>
</tr>
<tr>
<td>1197</td>
<td>Assault by exposure to or harmful effects of other coronary vasodilators</td>
</tr>
<tr>
<td>1198</td>
<td>Assault by exposure to or harmful effects of angiotensin-converting-enzyme inhibitors</td>
</tr>
<tr>
<td>1199</td>
<td>Assault by exposure to or harmful effects of other antihypertensive drugs</td>
</tr>
<tr>
<td>1200</td>
<td>Assault by exposure to or harmful effects of antihyperlipidemic or antiarteriosclerotic drugs</td>
</tr>
<tr>
<td>1201</td>
<td>Assault by exposure to or harmful effects of peripheral vasodilators</td>
</tr>
<tr>
<td>1202</td>
<td>Assault by exposure to or harmful effects of antivaricose drugs, including sclerosing agents</td>
</tr>
<tr>
<td>1203</td>
<td>Assault by exposure to or harmful effects of agents primarily affecting the gastrointestinal system</td>
</tr>
<tr>
<td>1204</td>
<td>Assault by exposure to or harmful effects of histamine H2-receptor blockers</td>
</tr>
<tr>
<td>1205</td>
<td>Assault by exposure to or harmful effects of other antacids or anti-gastric-secretion drugs</td>
</tr>
<tr>
<td>1206</td>
<td>Assault by exposure to or harmful effects of stimulant laxatives</td>
</tr>
<tr>
<td>1207</td>
<td>Assault by exposure to or harmful effects of saline or osmotic laxatives</td>
</tr>
<tr>
<td>1208</td>
<td>Assault by exposure to or harmful effects of other laxatives</td>
</tr>
<tr>
<td>1209</td>
<td>Assault by exposure to or harmful effects of digestants</td>
</tr>
<tr>
<td>1210</td>
<td>Assault by exposure to or harmful effects of antidiarrhoeal drugs</td>
</tr>
<tr>
<td>1211</td>
<td>Assault by exposure to or harmful effects of emetics</td>
</tr>
<tr>
<td>1212</td>
<td>Assault by exposure to or harmful effects of agents primarily acting on smooth or skeletal muscles or the respiratory system</td>
</tr>
<tr>
<td>1213</td>
<td>Assault by exposure to or harmful effects of oxytocic drugs</td>
</tr>
<tr>
<td>1214</td>
<td>Assault by exposure to or harmful effects of skeletal muscle relaxants</td>
</tr>
<tr>
<td>1215</td>
<td>Assault by exposure to or harmful effects of neuromuscular blocking agents</td>
</tr>
<tr>
<td>1216</td>
<td>Assault by exposure to or harmful effects of unspecified drugs acting on muscles</td>
</tr>
<tr>
<td>1217</td>
<td>Assault by exposure to or harmful effects of other drugs acting on muscles</td>
</tr>
<tr>
<td>1218</td>
<td>Assault by exposure to or harmful effects of antitussives</td>
</tr>
<tr>
<td>1219</td>
<td>Assault by exposure to or harmful effects of expectorants</td>
</tr>
<tr>
<td>1220</td>
<td>Assault by exposure to or harmful effects of other anti-common-cold drugs</td>
</tr>
<tr>
<td>1221</td>
<td>Assault by exposure to or harmful effects of salbutamol</td>
</tr>
<tr>
<td>1222</td>
<td>Assault by exposure to or harmful effects of aminophylline, theophylline</td>
</tr>
<tr>
<td>1223</td>
<td>Assault by exposure to or harmful effects of terbutaline</td>
</tr>
<tr>
<td>1224</td>
<td>Assault by exposure to or harmful effects of antiasthmatics, not elsewhere classified</td>
</tr>
<tr>
<td>1225</td>
<td>Assault by exposure to or harmful effects of topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs</td>
</tr>
<tr>
<td>1226</td>
<td>Assault by exposure to or harmful effects of topical corticosteroid preparations</td>
</tr>
<tr>
<td>1227</td>
<td>Assault by exposure to or harmful effects of iodine, antiseptic</td>
</tr>
<tr>
<td>1228</td>
<td>Assault by exposure to or harmful effects of silver nitrate</td>
</tr>
<tr>
<td>1229</td>
<td>Assault by exposure to or harmful effects of other local antifungal, anti-infective or anti-inflammatory drugs</td>
</tr>
<tr>
<td>1230</td>
<td>Assault by exposure to or harmful effects of antipruritics</td>
</tr>
<tr>
<td>1231</td>
<td>Assault by exposure to or harmful effects of methyl salicylate</td>
</tr>
<tr>
<td>1232</td>
<td>Assault by exposure to or harmful effects of other local astringents or local detergents</td>
</tr>
<tr>
<td>1233</td>
<td>Assault by exposure to or harmful effects of emollients, demulcents or protectants</td>
</tr>
<tr>
<td>1234</td>
<td>Assault by exposure to or harmful effects of podophyllin</td>
</tr>
<tr>
<td>1235</td>
<td>Assault by exposure to or harmful effects of keratolytics, keratoplastics, or other hair treatment drugs or preparations</td>
</tr>
<tr>
<td>1236</td>
<td>Assault by exposure to or harmful effects of ophthalmological drugs or preparations</td>
</tr>
<tr>
<td>1237</td>
<td>Assault by exposure to or harmful effects of otorhinolaryngological drugs or preparations</td>
</tr>
<tr>
<td>1238</td>
<td>Assault by exposure to or harmful effects of fluoride preparations</td>
</tr>
<tr>
<td>1239</td>
<td>Assault by exposure to or harmful effects of other dental drugs, topically applied</td>
</tr>
<tr>
<td>1240</td>
<td>Assault by exposure to or harmful effects of camphor</td>
</tr>
<tr>
<td>1241</td>
<td>Assault by exposure to or harmful effects of agents primarily affecting water-balance or mineral or uric acid metabolism</td>
</tr>
<tr>
<td>1242</td>
<td>Assault by exposure to or harmful effects of mineralocorticoids</td>
</tr>
<tr>
<td>1243</td>
<td>Assault by exposure to or harmful effects of mineralocorticoids antagonists</td>
</tr>
<tr>
<td>1244</td>
<td>Assault by exposure to or harmful effects of loop diuretics</td>
</tr>
<tr>
<td>1245</td>
<td>Assault by exposure to or harmful effects of high-ceiling diuretics</td>
</tr>
<tr>
<td>1246</td>
<td>Assault by exposure to or harmful effects of carbonic-anhydrase inhibitors</td>
</tr>
<tr>
<td>1247</td>
<td>Assault by exposure to or harmful effects of benzothiadiazine derivatives</td>
</tr>
<tr>
<td>1248</td>
<td>Assault by exposure to or harmful effects of thiazides</td>
</tr>
<tr>
<td>1249</td>
<td>Assault by exposure to or harmful effects of other diuretics</td>
</tr>
<tr>
<td>1250</td>
<td>Assault by exposure to or harmful effects of electrolytic, caloric or water-balance agents</td>
</tr>
<tr>
<td>1251</td>
<td>Assault by exposure to or harmful effects of mineral salts, not elsewhere classified</td>
</tr>
<tr>
<td>1252</td>
<td>Assault by exposure to or harmful effects of drugs affecting uric acid metabolism</td>
</tr>
<tr>
<td>1253</td>
<td>Assault by exposure to or harmful effects of vitamin D or derivatives</td>
</tr>
<tr>
<td>1254</td>
<td>Assault by exposure to or harmful effects of bisphosphonates</td>
</tr>
<tr>
<td>1255</td>
<td>Assault by exposure to or harmful effects of appetite depressants</td>
</tr>
<tr>
<td>1256</td>
<td>Assault by exposure to or harmful effects of antidotes or chelating agents, not elsewhere classified</td>
</tr>
<tr>
<td>1257</td>
<td>Assault by exposure to or harmful effects of disulfiram</td>
</tr>
<tr>
<td>1258</td>
<td>Assault by exposure to or harmful effects of alcohol deterrents, not elsewhere classified</td>
</tr>
<tr>
<td>1259</td>
<td>Assault by exposure to or harmful effects of X-ray contrast media</td>
</tr>
<tr>
<td>1260</td>
<td>Assault by exposure to or harmful effects of MRI contrast agents</td>
</tr>
<tr>
<td>1261</td>
<td>Assault by exposure to or harmful effects of agents used for other scanning techniques</td>
</tr>
<tr>
<td>1262</td>
<td>Assault by exposure to or harmful effects of other diagnostic agents</td>
</tr>
<tr>
<td>1263</td>
<td>Assault by exposure to or harmful effects of lipotropic drugs</td>
</tr>
<tr>
<td>1264</td>
<td>Assault by or harmful exposure to harmful effects of vitamins or pharmaceutical excipients, not elsewhere classified</td>
</tr>
<tr>
<td>1265</td>
<td>Assault by or harmful exposure to herbal preparations or formulas</td>
</tr>
<tr>
<td>1266</td>
<td>Assault by or harmful exposure to dietary supplements, vitamins or minerals</td>
</tr>
<tr>
<td>1267</td>
<td>Assault by or harmful exposure to complementary or traditional medicines, not elsewhere classified</td>
</tr>
<tr>
<td>1268</td>
<td>Assault by or harmful exposure to complementary or traditional medicines, unspecified</td>
</tr>
<tr>
<td>1269</td>
<td>Assault by or harmful exposure to vaccines, immunoglobulins or other biological substances</td>
</tr>
<tr>
<td>1270</td>
<td>Assault by or harmful exposure to BCG vaccine</td>
</tr>
<tr>
<td>1271</td>
<td>Assault by or harmful exposure to typhoid or paratyphoid vaccine</td>
</tr>
<tr>
<td>1272</td>
<td>Assault by or harmful exposure to cholera vaccine</td>
</tr>
<tr>
<td>1273</td>
<td>Assault by or harmful exposure to plague vaccine</td>
</tr>
<tr>
<td>1274</td>
<td>Assault by or harmful exposure to tetanus vaccine</td>
</tr>
<tr>
<td>1275</td>
<td>Assault by or harmful exposure to diphtheria vaccine</td>
</tr>
<tr>
<td>1276</td>
<td>Assault by or harmful exposure to haemophilus influenzae type B vaccines</td>
</tr>
<tr>
<td>1277</td>
<td>Assault by or harmful exposure to pertussis vaccine, including combinations with a pertussis component</td>
</tr>
<tr>
<td>1278</td>
<td>Assault by or harmful exposure to mixed bacterial vaccines without a pertussis component</td>
</tr>
<tr>
<td>1279</td>
<td>Assault by or harmful exposure to other or unspecified bacterial vaccines</td>
</tr>
<tr>
<td>1280</td>
<td>Assault by or harmful exposure to smallpox vaccines</td>
</tr>
<tr>
<td>1281</td>
<td>Assault by or harmful exposure to measles vaccines</td>
</tr>
<tr>
<td>1282</td>
<td>Assault by or harmful exposure to mumps vaccines</td>
</tr>
<tr>
<td>1283</td>
<td>Assault by or harmful exposure to rubella vaccines</td>
</tr>
<tr>
<td>1284</td>
<td>Assault by or harmful exposure to polio vaccines</td>
</tr>
<tr>
<td>1285</td>
<td>Assault by or harmful exposure to yellow fever vaccines</td>
</tr>
<tr>
<td>1286</td>
<td>Assault by or harmful exposure to hepatitis A vaccines</td>
</tr>
<tr>
<td>1287</td>
<td>Assault by or harmful exposure to hepatitis B vaccines</td>
</tr>
<tr>
<td>1288</td>
<td>Assault by or harmful exposure to influenza vaccines</td>
</tr>
<tr>
<td>1289</td>
<td>Assault by or harmful exposure to rotavirus vaccines</td>
</tr>
<tr>
<td>1290</td>
<td>Assault by or harmful exposure to human papillomavirus vaccines</td>
</tr>
<tr>
<td>1291</td>
<td>Assault by or harmful exposure to other viral vaccines</td>
</tr>
<tr>
<td>1292</td>
<td>Assault by or harmful exposure to rickettsial vaccines</td>
</tr>
<tr>
<td>1293</td>
<td>Assault by or harmful exposure to protozoal vaccines</td>
</tr>
<tr>
<td>1294</td>
<td>Assault by or harmful exposure to hepatitis B immune globulin</td>
</tr>
<tr>
<td>1295</td>
<td>Assault by or harmful exposure to antivenin or antivenom</td>
</tr>
<tr>
<td>1296</td>
<td>Assault by or harmful exposure to immunoglobulin, not elsewhere classified</td>
</tr>
<tr>
<td>1297</td>
<td>Assault by or harmful exposure to other specified vaccines</td>
</tr>
<tr>
<td>1298</td>
<td>Assault by or harmful exposure to unspecified vaccines</td>
</tr>
<tr>
<td>1299</td>
<td>Drugs, medicaments or biological substances associated with injury or harm in therapeutic use</td>
</tr>
<tr>
<td>1300</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics</td>
</tr>
<tr>
<td>1301</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Penicillins</td>
</tr>
<tr>
<td>1302</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Cephalosporins or other beta-lactam antibiotics</td>
</tr>
<tr>
<td>1303</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Chloramphenicol group</td>
</tr>
<tr>
<td>1304</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Macrolides</td>
</tr>
<tr>
<td>1305</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Tetracyclines</td>
</tr>
<tr>
<td>1306</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Aminoglycosides</td>
</tr>
<tr>
<td>1307</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Rifamycins</td>
</tr>
<tr>
<td>1308</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Systemic antibiotics, Antifungal antibiotics, systemically used</td>
</tr>
<tr>
<td>1309</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics</td>
</tr>
<tr>
<td>1310</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics, Sulfonamides</td>
</tr>
<tr>
<td>1311</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics, Antimycobacterial drugs</td>
</tr>
<tr>
<td>1312</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics, Antimalarials or drugs acting on other blood protozoa</td>
</tr>
<tr>
<td>1313</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics, Other antiprotozoal drugs</td>
</tr>
<tr>
<td>1314</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics, Anthelminthics</td>
</tr>
<tr>
<td>1315</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics, Antiviral drugs</td>
</tr>
<tr>
<td>1316</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other systemic anti-infectives or antiparasitics, Other specified systemic anti-infectives or antiparasitics</td>
</tr>
<tr>
<td>1317</td>
<td>Injury or harm in therapeutic use by hydroxyquinoline derivatives</td>
</tr>
<tr>
<td>1318</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>1319</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Glucocorticoids or synthetic analogues</td>
</tr>
<tr>
<td>1320</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Thyroid hormones or substitutes</td>
</tr>
<tr>
<td>1321</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Antithyroid drugs</td>
</tr>
<tr>
<td>1322</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Insulin or oral hypoglycaemic drugs</td>
</tr>
<tr>
<td>1323</td>
<td>Injury or harm in therapeutic use by insulin and oral hypoglycaemic [antidiabetic] drugs, Antidiabetic drugs</td>
</tr>
<tr>
<td>1324</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Oral contraceptives</td>
</tr>
<tr>
<td>1325</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Other estrogens or progestogens</td>
</tr>
<tr>
<td>1326</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified</td>
</tr>
<tr>
<td>1327</td>
<td>Injury or harm in therapeutic use by tamoxifen</td>
</tr>
<tr>
<td>1328</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Hormones or their synthetic substitutes or antagonists, not elsewhere classified, Androgens or anabolic congeners</td>
</tr>
<tr>
<td>1329</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents</td>
</tr>
<tr>
<td>1330</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents, Antiallergic or antiemetic drugs</td>
</tr>
<tr>
<td>1331</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents, Antineoplastic antimetabolites</td>
</tr>
<tr>
<td>1332</td>
<td>Injury or harm in therapeutic use by cytarabine</td>
</tr>
<tr>
<td>1333</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents, Antineoplastic natural products</td>
</tr>
<tr>
<td>1334</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents, Other antineoplastic drugs</td>
</tr>
<tr>
<td>1335</td>
<td>Injury or harm in therapeutic use by antineoplastic antibiotics</td>
</tr>
<tr>
<td>1336</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents, Immunosuppressive agents</td>
</tr>
<tr>
<td>1337</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents, Acidifying or alkalizing agents</td>
</tr>
<tr>
<td>1338</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Primarily systemic agents, Enzymes, not elsewhere classified</td>
</tr>
<tr>
<td>1339</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents</td>
</tr>
<tr>
<td>1340</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Iron preparations or other anti-hypochromic-anaemia preparations</td>
</tr>
<tr>
<td>1341</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Vitamin B, folic acid or other anti-megaloblastic-anaemia preparations</td>
</tr>
<tr>
<td>1342</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Anticoagulants</td>
</tr>
<tr>
<td>1343</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Anticoagulant antagonists, vitamin K or other coagulants</td>
</tr>
<tr>
<td>1344</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Antithrombotic drugs</td>
</tr>
<tr>
<td>1345</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Thrombolytic drugs</td>
</tr>
<tr>
<td>1346</td>
<td>Injury or harm caused by tissue‐type plasminogen activator in therapeutic use</td>
</tr>
<tr>
<td>1347</td>
<td>Injury or harm caused by tPA [tissue‐type plasminogen activator] in therapeutic use</td>
</tr>
<tr>
<td>1348</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Natural blood or blood products</td>
</tr>
<tr>
<td>1349</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting blood constituents, Plasma substitutes</td>
</tr>
<tr>
<td>1350</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Analgesics, antipyretics or anti-inflammatory drugs</td>
</tr>
<tr>
<td>1351</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Analgesics, antipyretics or anti-inflammatory drugs, Opioids or related analgesics</td>
</tr>
<tr>
<td>1352</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Analgesics, antipyretics or anti-inflammatory drugs, Salicylates</td>
</tr>
<tr>
<td>1353</td>
<td>Injury or harm in therapeutic use of acetylsalicylic acid</td>
</tr>
<tr>
<td>1354</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Analgesics, antipyretics or anti-inflammatory drugs, Propionic acid derivatives</td>
</tr>
<tr>
<td>1355</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Analgesics, antipyretics or anti-inflammatory drugs, Other nonsteroidal anti-inflammatory drugs</td>
</tr>
<tr>
<td>1356</td>
<td>Other NSAID</td>
</tr>
<tr>
<td>1357</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Analgesics, antipyretics or anti-inflammatory drugs, Antirheumatics</td>
</tr>
<tr>
<td>1358</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Analgesics, antipyretics or anti-inflammatory drugs, 4-Aminophenol derivatives</td>
</tr>
<tr>
<td>1359</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs</td>
</tr>
<tr>
<td>1360</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Succinimides</td>
</tr>
<tr>
<td>1361</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Oxazolidinediones</td>
</tr>
<tr>
<td>1362</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Hydantoin derivatives</td>
</tr>
<tr>
<td>1363</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Deoxybarbiturates</td>
</tr>
<tr>
<td>1364</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Iminostilbenes</td>
</tr>
<tr>
<td>1365</td>
<td>Injury or harm in therapeutic use by carbamazepine</td>
</tr>
<tr>
<td>1366</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Valproic acid</td>
</tr>
<tr>
<td>1367</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Other or unspecified antiepileptics</td>
</tr>
<tr>
<td>1368</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Antiparkinsonism drugs</td>
</tr>
<tr>
<td>1369</td>
<td>Injury or harm in therapeutic use by amantadine</td>
</tr>
<tr>
<td>1370</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Antiepileptics or antiparkinsonism drugs, Antispasticity drugs</td>
</tr>
<tr>
<td>1371</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Sedatives, hypnotics or antianxiety drugs</td>
</tr>
<tr>
<td>1372</td>
<td>Injury or harm in therapeutic use by sleeping draught NOS</td>
</tr>
<tr>
<td>1373</td>
<td>Injury or harm in therapeutic use by sleeping drug NOS</td>
</tr>
<tr>
<td>1374</td>
<td>Injury or harm in therapeutic use by sleeping tablet NOS</td>
</tr>
<tr>
<td>1375</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Sedatives, hypnotics or antianxiety drugs, Barbiturates, not elsewhere classified</td>
</tr>
<tr>
<td>1376</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Sedatives, hypnotics or antianxiety drugs, Benzodiazepines</td>
</tr>
<tr>
<td>1377</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Sedatives, hypnotics or antianxiety drugs, Cloral derivatives</td>
</tr>
<tr>
<td>1378</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Sedatives, hypnotics or antianxiety drugs, Paraldehyde</td>
</tr>
<tr>
<td>1379</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Sedatives, hypnotics or antianxiety drugs, Bromine compounds</td>
</tr>
<tr>
<td>1380</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Sedatives, hypnotics or antianxiety drugs, Mixed sedatives or hypnotics, not elsewhere classified</td>
</tr>
<tr>
<td>1381</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Anaesthetics or therapeutic gases</td>
</tr>
<tr>
<td>1382</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Anaesthetics or therapeutic gases, Inhaled anaesthetics</td>
</tr>
<tr>
<td>1383</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Anaesthetics or therapeutic gases, Parenteral anaesthetics</td>
</tr>
<tr>
<td>1384</td>
<td>Injury or harm in therapeutic use of thiobarbiturates</td>
</tr>
<tr>
<td>1385</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Anaesthetics or therapeutic gases, Other or unspecified general anaesthetics</td>
</tr>
<tr>
<td>1386</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Anaesthetics or therapeutic gases, Local anaesthetics</td>
</tr>
<tr>
<td>1387</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Anaesthetics or therapeutic gases, Therapeutic gases</td>
</tr>
<tr>
<td>1388</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified</td>
</tr>
<tr>
<td>1389</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Tricyclic or tetracyclic antidepressants</td>
</tr>
<tr>
<td>1390</td>
<td>Drugs medicaments or biological, substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Monoamine-oxidase-inhibitor antidepressants</td>
</tr>
<tr>
<td>1391</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Other or unspecified antidepressants</td>
</tr>
<tr>
<td>1392</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Phenothiazine antipsychotics or neuroleptics</td>
</tr>
<tr>
<td>1393</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Butyrophenone or thioxanthene neuroleptics</td>
</tr>
<tr>
<td>1394</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Other antipsychotics or neuroleptics</td>
</tr>
<tr>
<td>1395</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Psychodysleptics</td>
</tr>
<tr>
<td>1396</td>
<td>Injury or harm in therapeutic use of hallucinogens</td>
</tr>
<tr>
<td>1397</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Psychotropic drugs, not elsewhere classified, Psychostimulants with abuse potential</td>
</tr>
<tr>
<td>1398</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Central nervous system stimulants, not elsewhere classified</td>
</tr>
<tr>
<td>1399</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Central nervous system stimulants, not elsewhere classified, Analeptics</td>
</tr>
<tr>
<td>1400</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Central nervous system stimulants, not elsewhere classified, Opioid receptor antagonists</td>
</tr>
<tr>
<td>1401</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Central nervous system stimulants, not elsewhere classified, Methylxanthines, not elsewhere classified</td>
</tr>
<tr>
<td>1402</td>
<td>Injury or harm in therapeutic use of caffeine</td>
</tr>
<tr>
<td>1403</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system</td>
</tr>
<tr>
<td>1404</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Anticholinesterase agents</td>
</tr>
<tr>
<td>1405</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Other parasympathomimetics</td>
</tr>
<tr>
<td>1406</td>
<td>Injury or harm in therapeutic use of cholinergics</td>
</tr>
<tr>
<td>1407</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Ganglionic blocking drugs, not elsewhere classified</td>
</tr>
<tr>
<td>1408</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Other parasympatholytics or spasmolytics, not elsewhere classified</td>
</tr>
<tr>
<td>1409</td>
<td>Injury or harm in therapeutic use of anticholinergics or antimuscarinics</td>
</tr>
<tr>
<td>1410</td>
<td>Injury or harm in therapeutic use of papaverine</td>
</tr>
<tr>
<td>1411</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Predominantly alpha-adrenoreceptor agonists, not elsewhere classified</td>
</tr>
<tr>
<td>1412</td>
<td>Injury or harm in therapeutic use of metaraminol</td>
</tr>
<tr>
<td>1413</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Predominantly beta-adrenoreceptor agonists, not elsewhere classified</td>
</tr>
<tr>
<td>1414</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Alpha-adrenoreceptor antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>1415</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Beta-adrenoreceptor antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>1416</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Drugs primarily affecting the autonomic nervous system, Centrally acting or adrenergic-neuron-blocking agents, not elsewhere classified</td>
</tr>
<tr>
<td>1417</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system</td>
</tr>
<tr>
<td>1418</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Cardiac-stimulant glycosides or drugs of similar action</td>
</tr>
<tr>
<td>1419</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Calcium-channel blockers</td>
</tr>
<tr>
<td>1420</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Other antidysrhythmic drugs, not elsewhere classified</td>
</tr>
<tr>
<td>1421</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Coronary vasodilators, not elsewhere classified</td>
</tr>
<tr>
<td>1422</td>
<td>Injury or harm in therapeutic use of dipyridamole</td>
</tr>
<tr>
<td>1423</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Angiotensin-converting-enzyme inhibitors</td>
</tr>
<tr>
<td>1424</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Other antihypertensive drugs, not elsewhere classified</td>
</tr>
<tr>
<td>1425</td>
<td>Injury or harm in therapeutic use of clonidine</td>
</tr>
<tr>
<td>1426</td>
<td>Injury or harm in therapeutic use of guanethidine</td>
</tr>
<tr>
<td>1427</td>
<td>Injury or harm in therapeutic use of rauwolfia</td>
</tr>
<tr>
<td>1428</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Antihyperlipidaemic or antiarteriosclerotic drugs</td>
</tr>
<tr>
<td>1429</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Peripheral vasodilators</td>
</tr>
<tr>
<td>1430</td>
<td>Injury or harm in therapeutic use by nicotinic acid derivatives</td>
</tr>
<tr>
<td>1431</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the cardiovascular system, Antivaricose drugs, including sclerosing agents</td>
</tr>
<tr>
<td>1432</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system</td>
</tr>
<tr>
<td>1433</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Histamine H-receptor antagonists</td>
</tr>
<tr>
<td>1434</td>
<td>histamine h 2 -receptor antagonists associated with injury or harm in therapeutic use</td>
</tr>
<tr>
<td>1435</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Other antacids or anti-gastric-secretion drugs</td>
</tr>
<tr>
<td>1436</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Stimulant laxatives</td>
</tr>
<tr>
<td>1437</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Saline or osmotic laxatives</td>
</tr>
<tr>
<td>1438</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Other laxatives</td>
</tr>
<tr>
<td>1439</td>
<td>injury or harm in therapeutic use of intestinal atonia drugs</td>
</tr>
<tr>
<td>1440</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Digestants</td>
</tr>
<tr>
<td>1441</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Antidiarrhoeal drugs</td>
</tr>
<tr>
<td>1442</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting the gastrointestinal system, Emetics</td>
</tr>
<tr>
<td>1443</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism</td>
</tr>
<tr>
<td>1444</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Mineralocorticoids</td>
</tr>
<tr>
<td>1445</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Mineralocorticoid antagonists</td>
</tr>
<tr>
<td>1446</td>
<td>injury or harm in therapeutic use of aldosterone antagonists</td>
</tr>
<tr>
<td>1447</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Carbonic-anhydrase inhibitors</td>
</tr>
<tr>
<td>1448</td>
<td>Injury or harm in therapeutic use of acetazolamide</td>
</tr>
<tr>
<td>1449</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Benzothiadiazine derivatives</td>
</tr>
<tr>
<td>1450</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Loop diuretics</td>
</tr>
<tr>
<td>1451</td>
<td>injury or harm in therapeutic use of high-ceiling diuretics</td>
</tr>
<tr>
<td>1452</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Other diuretics</td>
</tr>
<tr>
<td>1453</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Electrolytic, caloric or water-balance agents</td>
</tr>
<tr>
<td>1454</td>
<td>Injury or harm in therapeutic use of oral rehydration salts</td>
</tr>
<tr>
<td>1455</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Agents affecting calcification</td>
</tr>
<tr>
<td>1456</td>
<td>Injury or harm in therapeutic use of parathyroid hormones or derivatives</td>
</tr>
<tr>
<td>1457</td>
<td>Injury or harm in therapeutic use of vitamin D group</td>
</tr>
<tr>
<td>1458</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Agents affecting uric acid metabolism</td>
</tr>
<tr>
<td>1459</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily affecting water-balance or mineral or uric acid metabolism, Mineral salts, not elsewhere classified</td>
</tr>
<tr>
<td>1460</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system</td>
</tr>
<tr>
<td>1461</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Oxytocic drugs</td>
</tr>
<tr>
<td>1462</td>
<td>Injury or harm in therapeutic use of ergot alkaloids</td>
</tr>
<tr>
<td>1463</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Skeletal muscle relaxants</td>
</tr>
<tr>
<td>1464</td>
<td>injury or harm in therapeutic use of neuromuscular blocking agents</td>
</tr>
<tr>
<td>1465</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Other or unspecified agents primarily acting on muscles</td>
</tr>
<tr>
<td>1466</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Antitussives</td>
</tr>
<tr>
<td>1467</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Expectorants</td>
</tr>
<tr>
<td>1468</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Anti-common-cold drugs</td>
</tr>
<tr>
<td>1469</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Antiasthmatics, not elsewhere classified</td>
</tr>
<tr>
<td>1470</td>
<td>Injury or harm in therapeutic use of aminophylline</td>
</tr>
<tr>
<td>1471</td>
<td>Injury or harm in therapeutic use of salbutamol</td>
</tr>
<tr>
<td>1472</td>
<td>Injury or harm in therapeutic use of theobromine</td>
</tr>
<tr>
<td>1473</td>
<td>Injury or harm in therapeutic use of theophylline</td>
</tr>
<tr>
<td>1474</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Agents primarily acting on smooth or skeletal muscles or the respiratory system, Other or unspecified agents primarily acting on the respiratory system</td>
</tr>
<tr>
<td>1475</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs</td>
</tr>
<tr>
<td>1476</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs, Local antifungal, anti-infective or anti-inflammatory drugs, not elsewhere classified</td>
</tr>
<tr>
<td>1477</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs, Antipruritics</td>
</tr>
<tr>
<td>1478</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs, Local astringents or local detergents</td>
</tr>
<tr>
<td>1479</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs, Emollients, demulcents or protectants</td>
</tr>
<tr>
<td>1480</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs, Keratolytics, keratoplastics or other hair treatment drugs or preparations</td>
</tr>
<tr>
<td>1481</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs, Ophthalmological drugs or preparations</td>
</tr>
<tr>
<td>1482</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological drugs or preparations or dental drugs</td>
</tr>
<tr>
<td>1483</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs, Dental drugs, topically applied</td>
</tr>
<tr>
<td>1484</td>
<td>Injury or harm in therapeutic use of glucocorticoids, topically used</td>
</tr>
<tr>
<td>1485</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments</td>
</tr>
<tr>
<td>1486</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, Appetite depressants</td>
</tr>
<tr>
<td>1487</td>
<td>injury or harm in therapeutic use of anorectics</td>
</tr>
<tr>
<td>1488</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, Lipotropic drugs</td>
</tr>
<tr>
<td>1489</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, Antidotes or chelating agents, not elsewhere classified</td>
</tr>
<tr>
<td>1490</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, Alcohol deterrents</td>
</tr>
<tr>
<td>1491</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, Pharmaceutical excipients</td>
</tr>
<tr>
<td>1492</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, X-ray contrast media</td>
</tr>
<tr>
<td>1493</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, Other diagnostic agents</td>
</tr>
<tr>
<td>1494</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified drugs or medicaments, Vitamins, not elsewhere classified</td>
</tr>
<tr>
<td>1495</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines</td>
</tr>
<tr>
<td>1496</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, BCG vaccine</td>
</tr>
<tr>
<td>1497</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, Typhoid or paratyphoid vaccine</td>
</tr>
<tr>
<td>1498</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, Cholera vaccine</td>
</tr>
<tr>
<td>1499</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, Plague vaccine</td>
</tr>
<tr>
<td>1500</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, Tetanus vaccine</td>
</tr>
<tr>
<td>1501</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, Diphtheria vaccine</td>
</tr>
<tr>
<td>1502</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, Pertussis vaccine, including combinations with a pertussis component</td>
</tr>
<tr>
<td>1503</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Bacterial vaccines, Mixed bacterial vaccines, except combinations with a pertussis component</td>
</tr>
<tr>
<td>1504</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified vaccines or biological substances</td>
</tr>
<tr>
<td>1505</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified vaccines or biological substances, Viral vaccines</td>
</tr>
<tr>
<td>1506</td>
<td>Drugs, medicaments or biological substances associated with injury or harm in therapeutic use, COVID-19 vaccine</td>
</tr>
<tr>
<td>1507</td>
<td>Correct administration of COVID-19 vaccine in prophylactic therapeutic use as the cause of any adverse effect</td>
</tr>
<tr>
<td>1508</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified vaccines or biological substances, Rickettsial vaccines</td>
</tr>
<tr>
<td>1509</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified vaccines or biological substances, Protozoal vaccines</td>
</tr>
<tr>
<td>1510</td>
<td>Drugs medicaments or biological substances associated with injury or harm in therapeutic use, Other or unspecified vaccines or biological substances, Immunoglobulin</td>
</tr>
<tr>
<td>1</td>
<td>Other specified conditions with disorders of intellectual development as a relevant clinical feature</td>
</tr>
<tr>
<td>2</td>
<td>Non-syndromic conditions with disorders of intellectual development as a relevant clinical feature</td>
</tr>
<tr>
<td>3</td>
<td>Autosomal dominant non-syndromic intellectual deficit</td>
</tr>
<tr>
<td>4</td>
<td>Autosomal recessive non-syndromic intellectual deficit</td>
</tr>
<tr>
<td>5</td>
<td>X-linked non-syndromic intellectual deficit</td>
</tr>
<tr>
<td>6</td>
<td>Syndromic conditions with disorders of intellectual development as a relevant clinical feature</td>
</tr>
<tr>
<td>7</td>
<td>ATR-X-related syndromes</td>
</tr>
<tr>
<td>8</td>
<td>X-linked intellectual deficit - hypotonic face</td>
</tr>
<tr>
<td>9</td>
<td>Carpenter-Waziri syndrome</td>
</tr>
<tr>
<td>10</td>
<td>Chudley-Lowry-Hoar syndrome</td>
</tr>
<tr>
<td>11</td>
<td>Holmes-Gang syndrome</td>
</tr>
<tr>
<td>12</td>
<td>Juberg-Marsidi syndrome</td>
</tr>
<tr>
<td>13</td>
<td>Renier-Gabreels-Jasper syndrome</td>
</tr>
<tr>
<td>14</td>
<td>Smith-Fineman-Myers syndrome</td>
</tr>
<tr>
<td>15</td>
<td>Axonal hereditary motor and sensory neuropathy, X-linked</td>
</tr>
<tr>
<td>16</td>
<td>X-linked Charcot-Marie-Tooth disease type 2</td>
</tr>
<tr>
<td>17</td>
<td>X-linked Charcot-Marie-Tooth disease type 3</td>
</tr>
<tr>
<td>18</td>
<td>X-linked Charcot-Marie-Tooth disease type 4</td>
</tr>
<tr>
<td>19</td>
<td>X-linked Charcot-Marie-Tooth disease type 5</td>
</tr>
<tr>
<td>20</td>
<td>Cohen syndrome</td>
</tr>
<tr>
<td>21</td>
<td>FRAXE intellectual deficit</td>
</tr>
<tr>
<td>22</td>
<td>Hereditary hyperekplexia</td>
</tr>
<tr>
<td>23</td>
<td>Congenital stiff man syndrome</td>
</tr>
<tr>
<td>24</td>
<td>Hereditary hyperexplexia</td>
</tr>
<tr>
<td>25</td>
<td>Familial Startle disease</td>
</tr>
<tr>
<td>26</td>
<td>Stiff baby syndrome</td>
</tr>
<tr>
<td>27</td>
<td>Hyperekplexia</td>
</tr>
<tr>
<td>28</td>
<td>Kok disease</td>
</tr>
<tr>
<td>29</td>
<td>Infantile bilateral striatal necrosis</td>
</tr>
<tr>
<td>30</td>
<td>Familial infantile bilateral striatal necrosis</td>
</tr>
<tr>
<td>31</td>
<td>Sporadic infantile bilateral striatal necrosis</td>
</tr>
<tr>
<td>32</td>
<td>Infantile onset spinocerebellar ataxia</td>
</tr>
<tr>
<td>33</td>
<td>Ophthalmoplegia - hypotonia - ataxia - hypoacusis - athetosis</td>
</tr>
<tr>
<td>34</td>
<td>IOSCA - [infantile onset spinocerebellar ataxia]</td>
</tr>
<tr>
<td>35</td>
<td>Ohaha - [Ophthalmoplegia - hypotonia - ataxia - hypoacusis - athetosis] syndrome</td>
</tr>
<tr>
<td>36</td>
<td>L1 syndrome</td>
</tr>
<tr>
<td>37</td>
<td>Laurence-Moon syndrome</td>
</tr>
<tr>
<td>38</td>
<td>PEHO syndrome</td>
</tr>
<tr>
<td>39</td>
<td>Progressive encephalopathy with oedema, hypsarrhythmia and optic atrophy</td>
</tr>
<tr>
<td>40</td>
<td>Renpenning syndrome</td>
</tr>
<tr>
<td>41</td>
<td>X-linked intellectual deficit, Renpenning type</td>
</tr>
<tr>
<td>42</td>
<td>Hamel cerebro-palato-cardiac syndrome</td>
</tr>
<tr>
<td>43</td>
<td>X-linked intellectual deficit, Fichera type</td>
</tr>
<tr>
<td>44</td>
<td>X-linked intellectual deficit, Golabi-Ito-Hall type</td>
</tr>
<tr>
<td>45</td>
<td>X-linked intellectual deficit, Porteous type</td>
</tr>
<tr>
<td>46</td>
<td>X-linked intellectual deficit, Sutherland-Haan type</td>
</tr>
<tr>
<td>47</td>
<td>X-linked intellectual deficit, Najm type</td>
</tr>
<tr>
<td>48</td>
<td>X-linked intellectual disability, Najm type</td>
</tr>
<tr>
<td>49</td>
<td>X-linked spastic paraplegia type 2</td>
</tr>
<tr>
<td>50</td>
<td>Demyelinating hereditary motor and sensory neuropathy, X-linked</td>
</tr>
<tr>
<td>51</td>
<td>X-linked Charcot-Marie-Tooth disease 1</td>
</tr>
<tr>
<td>52</td>
<td>CMT X - [X-linked Charcot-Marie-Tooth disease 1]</td>
</tr>
<tr>
<td>53</td>
<td>Cerebellar atrophy - ataxia - seizures</td>
</tr>
<tr>
<td>54</td>
<td>Autosomal recessive ataxia due to ubiquinone deficiency</td>
</tr>
<tr>
<td>55</td>
<td>Autosomal recessive ataxia due to coenzyme Q10 deficiency</td>
</tr>
<tr>
<td>56</td>
<td>Atypical Rett syndrome</td>
</tr>
<tr>
<td>57</td>
<td>De Sanctis-Cacchione syndrome</td>
</tr>
<tr>
<td>58</td>
<td>SYNGAP1 syndrome</td>
</tr>
<tr>
<td>59</td>
<td>synaptic Ras-GTPase-activating protein 1 syndrome</td>
</tr>
<tr>
<td>60</td>
<td>Alopecia – psychomotor epilepsy – periodontal pyorrhoea – intellectual disability syndrome</td>
</tr>
<tr>
<td>61</td>
<td>Shokeir syndrome</td>
</tr>
<tr>
<td>62</td>
<td>Disorders of the pentose phosphate pathway</td>
</tr>
<tr>
<td>63</td>
<td>Essential pentosuria</td>
</tr>
<tr>
<td>64</td>
<td>L-xylulose reductase deficiency</td>
</tr>
<tr>
<td>65</td>
<td>L-xylulosuria</td>
</tr>
<tr>
<td>66</td>
<td>Xylitol dehydrogenase deficiency</td>
</tr>
<tr>
<td>67</td>
<td>Ribose-5-phosphate isomerase deficiency</td>
</tr>
<tr>
<td>68</td>
<td>Transaldolase deficiency</td>
</tr>
<tr>
<td>69</td>
<td>Mucopolysaccharidosis type 1</td>
</tr>
<tr>
<td>70</td>
<td>Alpha-L-iduronidase deficiency</td>
</tr>
<tr>
<td>71</td>
<td>l-iduronidase deficiency</td>
</tr>
<tr>
<td>72</td>
<td>Lipochondrodystrophy</td>
</tr>
<tr>
<td>73</td>
<td>dysostosis multiplex</td>
</tr>
<tr>
<td>74</td>
<td>dysostosis multiplex syndrome</td>
</tr>
<tr>
<td>75</td>
<td>Gargoylism</td>
</tr>
<tr>
<td>76</td>
<td>MPS1 - [Mucopolysaccharidosis type 1]</td>
</tr>
<tr>
<td>77</td>
<td>Mucopolysaccharidosis type 1H</td>
</tr>
<tr>
<td>78</td>
<td>Hurler syndrome</td>
</tr>
<tr>
<td>79</td>
<td>Mucopolysaccharidosis type 1, severe form</td>
</tr>
<tr>
<td>80</td>
<td>MPS1H - [Mucopolysaccharidosis type 1H]</td>
</tr>
<tr>
<td>81</td>
<td>Mucopolysaccharidosis type 1H/S</td>
</tr>
<tr>
<td>82</td>
<td>Hurler-Scheie syndrome</td>
</tr>
<tr>
<td>83</td>
<td>Mucopolysaccharidosis type 1, intermediate form</td>
</tr>
<tr>
<td>84</td>
<td>MPS1H/S - [Mucopolysaccharidosis type 1H/S]</td>
</tr>
<tr>
<td>85</td>
<td>Mucopolysaccharidosis type 1S</td>
</tr>
<tr>
<td>86</td>
<td>Scheie syndrome</td>
</tr>
<tr>
<td>87</td>
<td>Mucopolysaccharidosis type 1, mild form</td>
</tr>
<tr>
<td>88</td>
<td>MPS1S - [Mucopolysaccharidosis type 1S]</td>
</tr>
<tr>
<td>89</td>
<td>Harmful effects of drugs, medicaments or biological substances, not elsewhere classified</td>
</tr>
<tr>
<td>90</td>
<td>drugs, medicaments or biological substances, toxicity not elsewhere classified</td>
</tr>
<tr>
<td>91</td>
<td>adverse drug effects</td>
</tr>
<tr>
<td>92</td>
<td>drug reaction NOS</td>
</tr>
<tr>
<td>93</td>
<td>drug allergy NOS</td>
</tr>
<tr>
<td>94</td>
<td>drug toxicity NOS</td>
</tr>
<tr>
<td>95</td>
<td>drug ingestion NOS</td>
</tr>
<tr>
<td>96</td>
<td>toxic effects of drugs NOS</td>
</tr>
<tr>
<td>97</td>
<td>acute drug intoxication</td>
</tr>
<tr>
<td>98</td>
<td>toxic use of drugs</td>
</tr>
<tr>
<td>99</td>
<td>intake of a toxic substance</td>
</tr>
<tr>
<td>100</td>
<td>Harmful effects of opioids or related analgesics</td>
</tr>
<tr>
<td>101</td>
<td>Harmful effects of opium</td>
</tr>
<tr>
<td>102</td>
<td>Harmful effects of morphine</td>
</tr>
<tr>
<td>103</td>
<td>Harmful effects of oxycodone</td>
</tr>
<tr>
<td>104</td>
<td>oxycodone toxicity</td>
</tr>
<tr>
<td>105</td>
<td>Harmful effects of codeine</td>
</tr>
<tr>
<td>106</td>
<td>Harmful effects of heroin</td>
</tr>
<tr>
<td>107</td>
<td>poisoning by diacetylmorphine</td>
</tr>
<tr>
<td>108</td>
<td>poisoning by heroin</td>
</tr>
<tr>
<td>109</td>
<td>poisoning by heroin NOS</td>
</tr>
<tr>
<td>110</td>
<td>acute heroin intoxication</td>
</tr>
<tr>
<td>111</td>
<td>acute heroin toxicity</td>
</tr>
<tr>
<td>112</td>
<td>toxic effects of heroin</td>
</tr>
<tr>
<td>113</td>
<td>Harmful effects of methadone</td>
</tr>
<tr>
<td>114</td>
<td>poisoning by methadone</td>
</tr>
<tr>
<td>115</td>
<td>poisoning by methadone NOS</td>
</tr>
<tr>
<td>116</td>
<td>methadone toxicity</td>
</tr>
<tr>
<td>117</td>
<td>Harmful effects of pethidine</td>
</tr>
<tr>
<td>118</td>
<td>pethidine poisoning</td>
</tr>
<tr>
<td>119</td>
<td>Harmful effects of fentanyl</td>
</tr>
<tr>
<td>120</td>
<td>fentanyl poisoning</td>
</tr>
<tr>
<td>121</td>
<td>fentanyl toxicity</td>
</tr>
<tr>
<td>122</td>
<td>toxic effects of fentanyl</td>
</tr>
<tr>
<td>123</td>
<td>fentanyl toxication</td>
</tr>
<tr>
<td>124</td>
<td>acute fentanyl toxicity</td>
</tr>
<tr>
<td>125</td>
<td>Harmful effects of phenoperidine</td>
</tr>
<tr>
<td>126</td>
<td>phenoperidine poisoning</td>
</tr>
<tr>
<td>127</td>
<td>Fentanyl and heroin toxicity</td>
</tr>
<tr>
<td>128</td>
<td>Harmful effects of sedative hypnotic drugs or other CNS depressants</td>
</tr>
<tr>
<td>129</td>
<td>Harmful effects of sedative-hypnotic drugs</td>
</tr>
<tr>
<td>130</td>
<td>hypnotic poisoning</td>
</tr>
<tr>
<td>131</td>
<td>sleeping draught NOS poisoning</td>
</tr>
<tr>
<td>132</td>
<td>sleeping drug NOS poisoning</td>
</tr>
<tr>
<td>133</td>
<td>sleeping tablet NOS poisoning</td>
</tr>
<tr>
<td>134</td>
<td>Harmful effects of barbiturates</td>
</tr>
<tr>
<td>135</td>
<td>Harmful effects of benzodiazepines</td>
</tr>
<tr>
<td>136</td>
<td>Harmful effects of chlordiazepoxide</td>
</tr>
<tr>
<td>137</td>
<td>chlordiazepoxide poisoning</td>
</tr>
<tr>
<td>138</td>
<td>Harmful effects of clozapine</td>
</tr>
<tr>
<td>139</td>
<td>clozapine poisoning</td>
</tr>
<tr>
<td>140</td>
<td>Harmful effects of cloral derivatives</td>
</tr>
<tr>
<td>141</td>
<td>Harmful effects of paraldehyde</td>
</tr>
<tr>
<td>142</td>
<td>Harmful effects of bromine compounds</td>
</tr>
<tr>
<td>143</td>
<td>Harmful effects of mixed sedatives or hypnotics, not elsewhere classified</td>
</tr>
<tr>
<td>144</td>
<td>Harmful effects of anaesthetics or therapeutic gases</td>
</tr>
<tr>
<td>145</td>
<td>Harmful effects of anaesthetics or therapeutic gases, nitrous oxide</td>
</tr>
<tr>
<td>146</td>
<td>Harmful effects of anaesthetics or therapeutic gases, other inhaled anaesthetics</td>
</tr>
<tr>
<td>147</td>
<td>Harmful effects of anaesthetics or therapeutic gases, intravenous anaesthetics</td>
</tr>
<tr>
<td>148</td>
<td>Harmful effects of anaesthetics or therapeutic gases, unspecified general anaesthetics</td>
</tr>
<tr>
<td>149</td>
<td>Harmful effects of anaesthetics or therapeutic gases, gamma hydroxybutyrate</td>
</tr>
<tr>
<td>150</td>
<td>Harmful effects of anaesthetics or therapeutic gases, ketamine</td>
</tr>
<tr>
<td>151</td>
<td>ketamine poisoning</td>
</tr>
<tr>
<td>152</td>
<td>Harmful effects of anaesthetics or therapeutic gases, other specified general anaesthetic</td>
</tr>
<tr>
<td>153</td>
<td>Harmful effects of anaesthetics or therapeutic gases, local anaesthetics</td>
</tr>
<tr>
<td>154</td>
<td>Harmful effects of cinchocaine</td>
</tr>
<tr>
<td>155</td>
<td>cinchocaine poisoning</td>
</tr>
<tr>
<td>156</td>
<td>Harmful effects of oxybuprocaine</td>
</tr>
<tr>
<td>157</td>
<td>oxybuprocaine poisoning</td>
</tr>
<tr>
<td>158</td>
<td>Harmful effects of psychostimulants</td>
</tr>
<tr>
<td>159</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Central nervous system stimulants, not elsewhere classified</td>
</tr>
<tr>
<td>160</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Analeptics</td>
</tr>
<tr>
<td>161</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Opioid receptor antagonists</td>
</tr>
<tr>
<td>162</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Caffeine</td>
</tr>
<tr>
<td>163</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Amphetamine</td>
</tr>
<tr>
<td>164</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Methylamphetamine</td>
</tr>
<tr>
<td>165</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Methylenedioxy methamphetamine</td>
</tr>
<tr>
<td>166</td>
<td>methamphetamine toxicity</td>
</tr>
<tr>
<td>167</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Other specified amphetamines</td>
</tr>
<tr>
<td>168</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Cocaine</td>
</tr>
<tr>
<td>169</td>
<td>poisoning by cocaine NOS</td>
</tr>
<tr>
<td>170</td>
<td>cocaine toxicity</td>
</tr>
<tr>
<td>171</td>
<td>acute cocaine toxicity</td>
</tr>
<tr>
<td>172</td>
<td>toxic effects of cocaine</td>
</tr>
<tr>
<td>173</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Methylphenidate</td>
</tr>
<tr>
<td>174</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Cathinone</td>
</tr>
<tr>
<td>175</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Cathinone derivatives</td>
</tr>
<tr>
<td>176</td>
<td>Harmful effects of Cannabinoids or hallucinogens</td>
</tr>
<tr>
<td>177</td>
<td>Harmful effects of Cannabis</td>
</tr>
<tr>
<td>178</td>
<td>cannabis poisoning</td>
</tr>
<tr>
<td>179</td>
<td>poisoning by cannabis derivative</td>
</tr>
<tr>
<td>180</td>
<td>poisoning by marijuana</td>
</tr>
<tr>
<td>181</td>
<td>poisoning by marijuana derivative</td>
</tr>
<tr>
<td>182</td>
<td>Harmful effects of synthetic cannabinoids</td>
</tr>
<tr>
<td>183</td>
<td>Harmful effects of Lysergide</td>
</tr>
<tr>
<td>184</td>
<td>Harmful effects of unspecified psychodysleptics</td>
</tr>
<tr>
<td>185</td>
<td>harmful effect of unspecified hallucinogens</td>
</tr>
<tr>
<td>186</td>
<td>Harmful effects of other psychodysleptics</td>
</tr>
<tr>
<td>187</td>
<td>Other hallucinogens</td>
</tr>
<tr>
<td>188</td>
<td>Harmful effects of analgesics, antipyretics or anti-inflammatory drugs</td>
</tr>
<tr>
<td>189</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, analgesics, antipyretics or anti-inflammatory drugs, Aspirin</td>
</tr>
<tr>
<td>190</td>
<td>aspirin poisoning</td>
</tr>
<tr>
<td>191</td>
<td>Harmful effects of other salicylates</td>
</tr>
<tr>
<td>192</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, analgesics, antipyretics or anti-inflammatory drugs, Paracetamol</td>
</tr>
<tr>
<td>193</td>
<td>paracetamol poisoning</td>
</tr>
<tr>
<td>194</td>
<td>Harmful effects of 4-Aminophenol derivatives</td>
</tr>
<tr>
<td>195</td>
<td>Harmful effects of Pyrazolone derivatives</td>
</tr>
<tr>
<td>196</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, analgesics, antipyretics or anti-inflammatory drugs, Ibuprofen</td>
</tr>
<tr>
<td>197</td>
<td>ibuprofen poisoning</td>
</tr>
<tr>
<td>198</td>
<td>Harmful effects of other propionic acid derivatives</td>
</tr>
<tr>
<td>199</td>
<td>Harmful effects of Indomethacin</td>
</tr>
<tr>
<td>200</td>
<td>indometacin poisoning</td>
</tr>
<tr>
<td>201</td>
<td>indomethacin poisoning</td>
</tr>
<tr>
<td>202</td>
<td>Harmful effects of other nonsteroidal anti-inflammatory drugs</td>
</tr>
<tr>
<td>203</td>
<td>poisoning by NSAID - [nonsteroidal anti-inflammatory drugs]</td>
</tr>
<tr>
<td>204</td>
<td>Harmful effects of etodolac</td>
</tr>
<tr>
<td>205</td>
<td>etodolac poisoning</td>
</tr>
<tr>
<td>206</td>
<td>Harmful effects of antirheumatics, not elsewhere classified</td>
</tr>
<tr>
<td>207</td>
<td>Harmful effects of antidepressants</td>
</tr>
<tr>
<td>208</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Tricyclic antidepressants</td>
</tr>
<tr>
<td>209</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Tetracyclic antidepressants</td>
</tr>
<tr>
<td>210</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Monoamine-oxidase-inhibitor antidepressants</td>
</tr>
<tr>
<td>211</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Selective serotonin or norepinephrine reuptake inhibitors</td>
</tr>
<tr>
<td>212</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Selective serotonin reuptake inhibitors</td>
</tr>
<tr>
<td>213</td>
<td>Harmful effects of antipsychotics</td>
</tr>
<tr>
<td>214</td>
<td>Harmful effects of phenothiazine antipsychotics or neuroleptics</td>
</tr>
<tr>
<td>215</td>
<td>Harmful effects of promazine</td>
</tr>
<tr>
<td>216</td>
<td>promazine poisoning</td>
</tr>
<tr>
<td>217</td>
<td>Harmful effects of butyrophenone or thiothixene neuroleptics</td>
</tr>
<tr>
<td>218</td>
<td>Harmful effects of typical, second-generation antipsychotics</td>
</tr>
<tr>
<td>219</td>
<td>Harmful effects of lithium carbonate</td>
</tr>
<tr>
<td>220</td>
<td>Harmful effects of antiepileptics or antiparkinsonism drugs</td>
</tr>
<tr>
<td>221</td>
<td>Harmful effects of hydantoin derivatives</td>
</tr>
<tr>
<td>222</td>
<td>Harmful effects of iminostilbenes</td>
</tr>
<tr>
<td>223</td>
<td>Harmful effects of deoxybarbiturates</td>
</tr>
<tr>
<td>224</td>
<td>Harmful effects of succinimides</td>
</tr>
<tr>
<td>225</td>
<td>Harmful effects of oxazolidinediones</td>
</tr>
<tr>
<td>226</td>
<td>Harmful effects of mixed antiepileptics, not elsewhere classified</td>
</tr>
<tr>
<td>227</td>
<td>Harmful effects of Amantadine</td>
</tr>
<tr>
<td>228</td>
<td>Harmful effects of Valproic acid</td>
</tr>
<tr>
<td>229</td>
<td>Harmful effects of L-DOPA</td>
</tr>
<tr>
<td>230</td>
<td>Harmful effects of Antiparkinsonism drugs or other central muscle-tone depressants, not elsewhere classified</td>
</tr>
<tr>
<td>231</td>
<td>Harmful effects of antispasticity drugs</td>
</tr>
<tr>
<td>232</td>
<td>Harmful effects of substances, drugs, medicaments or biological substance, Other or unspecified drugs, medicaments or biological substances</td>
</tr>
<tr>
<td>233</td>
<td>Harmful effects of systemic antibiotics</td>
</tr>
<tr>
<td>234</td>
<td>Harmful effects of Penicillins</td>
</tr>
<tr>
<td>235</td>
<td>poisoning by penicillin</td>
</tr>
<tr>
<td>236</td>
<td>poisoning by penicillins nos</td>
</tr>
<tr>
<td>237</td>
<td>Harmful effects of cephalosporins and other beta-lactam antibiotics</td>
</tr>
<tr>
<td>238</td>
<td>Harmful effects of cefotaxime</td>
</tr>
<tr>
<td>239</td>
<td>cefotaxime poisoning</td>
</tr>
<tr>
<td>240</td>
<td>Harmful effects of chloramphenicol group</td>
</tr>
<tr>
<td>241</td>
<td>chloramphenicol poisoning</td>
</tr>
<tr>
<td>242</td>
<td>Harmful effects of macrolides</td>
</tr>
<tr>
<td>243</td>
<td>Harmful effects of tetracyclines</td>
</tr>
<tr>
<td>244</td>
<td>poisoning by tetracyclines</td>
</tr>
<tr>
<td>245</td>
<td>poisoning by tetracyclines nos</td>
</tr>
<tr>
<td>246</td>
<td>Harmful effects of aminoglycosides</td>
</tr>
<tr>
<td>247</td>
<td>Harmful effects of rifampicin</td>
</tr>
<tr>
<td>248</td>
<td>rifampicin poisoning</td>
</tr>
<tr>
<td>249</td>
<td>Harmful effects of antifungal antibiotics, systemically used</td>
</tr>
<tr>
<td>250</td>
<td>Harmful effects of co-trimoxazole</td>
</tr>
<tr>
<td>251</td>
<td>co-trimoxazole poisoning</td>
</tr>
<tr>
<td>252</td>
<td>Harmful effects of fusidic acid</td>
</tr>
<tr>
<td>253</td>
<td>fusidic acid poisoning</td>
</tr>
<tr>
<td>254</td>
<td>Harmful effects of sodium fusidate</td>
</tr>
<tr>
<td>255</td>
<td>sodium fusidate poisoning</td>
</tr>
<tr>
<td>256</td>
<td>Harmful effects of vancomycin</td>
</tr>
<tr>
<td>257</td>
<td>vancomycin poisoning</td>
</tr>
<tr>
<td>258</td>
<td>Harmful effects of other systemic anti-infectives or antiparasitics</td>
</tr>
<tr>
<td>259</td>
<td>Harmful effects of Sulfonamides</td>
</tr>
<tr>
<td>260</td>
<td>Harmful effects of antimycobacterial drugs</td>
</tr>
<tr>
<td>261</td>
<td>Harmful effects of antimalarials or drugs acting on other blood protozoa</td>
</tr>
<tr>
<td>262</td>
<td>Harmful effects of other antiprotozoal drugs</td>
</tr>
<tr>
<td>263</td>
<td>Harmful effects of anthelminthics</td>
</tr>
<tr>
<td>264</td>
<td>Harmful effects of antiviral drugs</td>
</tr>
<tr>
<td>265</td>
<td>Harmful effects of chiniofon</td>
</tr>
<tr>
<td>266</td>
<td>chiniofon poisoning</td>
</tr>
<tr>
<td>267</td>
<td>Harmful effects of diiodohydroxyquinoline</td>
</tr>
<tr>
<td>268</td>
<td>diiodohydroxyquinoline poisoning</td>
</tr>
<tr>
<td>269</td>
<td>Harmful effects of flucytosine</td>
</tr>
<tr>
<td>270</td>
<td>flucytosine poisoning</td>
</tr>
<tr>
<td>271</td>
<td>Harmful effects of hydroxyquinoline derivatives</td>
</tr>
<tr>
<td>272</td>
<td>hydroxyquinoline derivatives poisoning</td>
</tr>
<tr>
<td>273</td>
<td>Harmful effects of trimethoprim</td>
</tr>
<tr>
<td>274</td>
<td>trimethoprim poisoning</td>
</tr>
<tr>
<td>275</td>
<td>Harmful effects of hormones or their synthetic substitutes or antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>276</td>
<td>Harmful effects of Glucocorticoids or synthetic analogues</td>
</tr>
<tr>
<td>277</td>
<td>Harmful effects of thyroid hormones or substitutes</td>
</tr>
<tr>
<td>278</td>
<td>Harmful effects of antithyroid drugs</td>
</tr>
<tr>
<td>279</td>
<td>Harmful effects of insulin or oral hypoglycaemic drugs</td>
</tr>
<tr>
<td>280</td>
<td>Harmful effects of oral contraceptives</td>
</tr>
<tr>
<td>281</td>
<td>poisoning by oral contraceptive</td>
</tr>
<tr>
<td>282</td>
<td>poisoning by oral contraceptives nos</td>
</tr>
<tr>
<td>283</td>
<td>Harmful effects of other estrogens or progestogens</td>
</tr>
<tr>
<td>284</td>
<td>oestrogen poisoning</td>
</tr>
<tr>
<td>285</td>
<td>Harmful effects of antigonadotropins, antiestrogens, antiandrogens, not elsewhere classified</td>
</tr>
<tr>
<td>286</td>
<td>Harmful effects of androgens or anabolic congeners</td>
</tr>
<tr>
<td>287</td>
<td>androgen poisoning</td>
</tr>
<tr>
<td>288</td>
<td>Harmful effects of unspecified hormones or synthetic substitutes</td>
</tr>
<tr>
<td>289</td>
<td>Harmful effects of anterior pituitary hormones</td>
</tr>
<tr>
<td>290</td>
<td>Harmful effects of other hormones or synthetic substitutes</td>
</tr>
<tr>
<td>291</td>
<td>Harmful effects of unspecified hormone antagonists</td>
</tr>
<tr>
<td>292</td>
<td>Harmful effects of other hormone antagonists</td>
</tr>
<tr>
<td>293</td>
<td>Harmful effects of trilostane</td>
</tr>
<tr>
<td>294</td>
<td>Harmful effects of drugs primarily affecting the autonomic nervous system</td>
</tr>
<tr>
<td>295</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Anticholinesterase agents</td>
</tr>
<tr>
<td>296</td>
<td>anticholinesterase poisoning</td>
</tr>
<tr>
<td>297</td>
<td>poisoning by anticholinesterase agents nos</td>
</tr>
<tr>
<td>298</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Other parasympathomimetics</td>
</tr>
<tr>
<td>299</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Ganglionic blocking drugs</td>
</tr>
<tr>
<td>300</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Other parasympatholytics or spasmolytics</td>
</tr>
<tr>
<td>301</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Predominantly alpha-adrenoreceptor agonists</td>
</tr>
<tr>
<td>302</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Predominantly beta-adrenoreceptor agonists</td>
</tr>
<tr>
<td>303</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Alpha-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>304</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Beta-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>305</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Centrally-acting or adrenergic-neuron-blocking agents</td>
</tr>
<tr>
<td>306</td>
<td>Harmful effects of agents primarily affecting blood constituents</td>
</tr>
<tr>
<td>307</td>
<td>haematological agent poisoning</td>
</tr>
<tr>
<td>308</td>
<td>Harmful effects of Diphenhydramine</td>
</tr>
<tr>
<td>309</td>
<td>diphenhydramine toxicity</td>
</tr>
<tr>
<td>310</td>
<td>Harmful effects of other H1-receptor antagonists</td>
</tr>
<tr>
<td>311</td>
<td>Harmful effects of antiallergic or antiemetic drugs</td>
</tr>
<tr>
<td>312</td>
<td>Harmful effects of antineoplastic antimetabolites</td>
</tr>
<tr>
<td>313</td>
<td>Harmful effects of antineoplastic natural products</td>
</tr>
<tr>
<td>314</td>
<td>Harmful effects of other antineoplastic drugs</td>
</tr>
<tr>
<td>315</td>
<td>Harmful effects of immunosuppressive agents</td>
</tr>
<tr>
<td>316</td>
<td>Harmful effects of Vitamin B12, folic acid or other anti-megaloblastic-anaemia preparations</td>
</tr>
<tr>
<td>317</td>
<td>Harmful effects of enzymes</td>
</tr>
<tr>
<td>318</td>
<td>Harmful effects of iron or its compounds</td>
</tr>
<tr>
<td>319</td>
<td>Harmful effects of anticoagulants</td>
</tr>
<tr>
<td>320</td>
<td>Harmful effects of antithrombotic drugs</td>
</tr>
<tr>
<td>321</td>
<td>harmful effect of platelet aggregation inhibitors</td>
</tr>
<tr>
<td>322</td>
<td>Harmful effects of thrombolytic drug</td>
</tr>
<tr>
<td>323</td>
<td>Harmful effects of anticoagulant antagonists, vitamin K or other coagulants</td>
</tr>
<tr>
<td>324</td>
<td>Harmful effects of other fibrinolysis-affecting drugs</td>
</tr>
<tr>
<td>325</td>
<td>fibrinolytic drug poisoning</td>
</tr>
<tr>
<td>326</td>
<td>poisoning by fibrinolysis-affecting drug nos</td>
</tr>
<tr>
<td>327</td>
<td>Harmful effects of natural blood or blood products</td>
</tr>
<tr>
<td>328</td>
<td>Harmful effects of acidifying or alkalising agents</td>
</tr>
<tr>
<td>329</td>
<td>Harmful effects of other primarily systemic agents, not elsewhere classified</td>
</tr>
<tr>
<td>330</td>
<td>Blood poisoning, not elsewhere classified</td>
</tr>
<tr>
<td>331</td>
<td>whole blood poisoning</td>
</tr>
<tr>
<td>332</td>
<td>Harmful effects of heavy metal poisoning antidote</td>
</tr>
<tr>
<td>333</td>
<td>Harmful effects of plasma substitutes</td>
</tr>
<tr>
<td>334</td>
<td>Harmful effects of agents primarily affecting the cardiovascular system</td>
</tr>
<tr>
<td>335</td>
<td>Harmful effects of cardiac-stimulant glycosides or drugs of similar action</td>
</tr>
<tr>
<td>336</td>
<td>Harmful effects of calcium-channel blockers</td>
</tr>
<tr>
<td>337</td>
<td>poisoning by calcium-channel blockers NOS</td>
</tr>
<tr>
<td>338</td>
<td>Harmful effects of other antidysrhythmic drugs</td>
</tr>
<tr>
<td>339</td>
<td>Harmful effects of Nitroglycerin, nitroglycerol, medicinal</td>
</tr>
<tr>
<td>340</td>
<td>Harmful effects of other coronary vasodilators</td>
</tr>
<tr>
<td>341</td>
<td>Harmful effects of Angiotensin-converting-enzyme inhibitors</td>
</tr>
<tr>
<td>342</td>
<td>Harmful effects of other antihypertensive drugs</td>
</tr>
<tr>
<td>343</td>
<td>Harmful effects of antihyperlipidemic or antiarteriosclerotic drugs</td>
</tr>
<tr>
<td>344</td>
<td>Harmful effects of peripheral vasodilators</td>
</tr>
<tr>
<td>345</td>
<td>Harmful effects of antivaricose drugs, including sclerosing agents</td>
</tr>
<tr>
<td>346</td>
<td>antivaricose drug poisoning</td>
</tr>
<tr>
<td>347</td>
<td>Harmful effects of agents primarily affecting the gastrointestinal system</td>
</tr>
<tr>
<td>348</td>
<td>Harmful effects of Histamine H2-receptor blockers</td>
</tr>
<tr>
<td>349</td>
<td>poisoning by histamine h 2 -receptor antagonists</td>
</tr>
<tr>
<td>350</td>
<td>Harmful effects of other antacids or anti-gastric-secretion drugs</td>
</tr>
<tr>
<td>351</td>
<td>Harmful effects of stimulant laxatives</td>
</tr>
<tr>
<td>352</td>
<td>Harmful effects of saline or osmotic laxatives</td>
</tr>
<tr>
<td>353</td>
<td>Harmful effects of other laxatives</td>
</tr>
<tr>
<td>354</td>
<td>Harmful effects of digestants</td>
</tr>
<tr>
<td>355</td>
<td>Harmful effects of antidiarrhoeal drugs</td>
</tr>
<tr>
<td>356</td>
<td>Harmful effects of or exposure to emetics</td>
</tr>
<tr>
<td>357</td>
<td>Harmful effects of agents primarily acting on smooth or skeletal muscles or the respiratory system</td>
</tr>
<tr>
<td>358</td>
<td>Harmful effects of Oxytocic drugs</td>
</tr>
<tr>
<td>359</td>
<td>oxytocin poisoning</td>
</tr>
<tr>
<td>360</td>
<td>Harmful effects of skeletal muscle relaxants</td>
</tr>
<tr>
<td>361</td>
<td>harmful effect of neuromuscular blocking agents</td>
</tr>
<tr>
<td>362</td>
<td>Harmful effects of other drugs acting on muscles</td>
</tr>
<tr>
<td>363</td>
<td>Harmful effects of unspecified drugs acting on muscles</td>
</tr>
<tr>
<td>364</td>
<td>Harmful effects of antitussives</td>
</tr>
<tr>
<td>365</td>
<td>Harmful effects of expectorants</td>
</tr>
<tr>
<td>366</td>
<td>Harmful effects of other anti-common-cold drugs</td>
</tr>
<tr>
<td>367</td>
<td>Harmful effects of Salbutamol</td>
</tr>
<tr>
<td>368</td>
<td>salbutamol poisoning</td>
</tr>
<tr>
<td>369</td>
<td>Harmful effects of Aminophylline, theophylline</td>
</tr>
<tr>
<td>370</td>
<td>theophylline poisoning</td>
</tr>
<tr>
<td>371</td>
<td>aminophylline poisoning</td>
</tr>
<tr>
<td>372</td>
<td>Harmful effects of Terbutaline</td>
</tr>
<tr>
<td>373</td>
<td>Harmful effects of antiasthmatics, not elsewhere classified</td>
</tr>
<tr>
<td>374</td>
<td>Harmful effects of topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs</td>
</tr>
<tr>
<td>375</td>
<td>Harmful effects of topical corticosteroid preparations</td>
</tr>
<tr>
<td>376</td>
<td>Harmful effects of Iodine, antiseptic</td>
</tr>
<tr>
<td>377</td>
<td>Harmful effects of silver nitrate</td>
</tr>
<tr>
<td>378</td>
<td>Harmful effects of other local antifungal, anti-infective or anti-inflammatory drugs</td>
</tr>
<tr>
<td>379</td>
<td>Harmful effects of antipruritics</td>
</tr>
<tr>
<td>380</td>
<td>Harmful effects of Methyl salicylate</td>
</tr>
<tr>
<td>381</td>
<td>Harmful effects of other local astringents or local detergents</td>
</tr>
<tr>
<td>382</td>
<td>Tannic acid poisoning</td>
</tr>
<tr>
<td>383</td>
<td>Harmful effects of emollients, demulcents or protectants</td>
</tr>
<tr>
<td>384</td>
<td>Harmful effects of Podophyllin</td>
</tr>
<tr>
<td>385</td>
<td>Harmful effects of keratolytics, keratoplastics, or other hair treatment drugs or preparations</td>
</tr>
<tr>
<td>386</td>
<td>Harmful effects of ophthalmological drugs or preparations</td>
</tr>
<tr>
<td>387</td>
<td>Harmful effects of otorhinolaryngological drugs or preparations</td>
</tr>
<tr>
<td>388</td>
<td>Harmful effects of ear, nose or throat anti-infectives</td>
</tr>
<tr>
<td>389</td>
<td>Harmful effects of fluoride preparations</td>
</tr>
<tr>
<td>390</td>
<td>Harmful effects of other dental drugs, topically applied</td>
</tr>
<tr>
<td>391</td>
<td>Harmful effects of Camphor</td>
</tr>
<tr>
<td>392</td>
<td>Harmful effects of agents primarily affecting water-balance or mineral or uric acid metabolism</td>
</tr>
<tr>
<td>393</td>
<td>Harmful effects of Mineralocorticoids</td>
</tr>
<tr>
<td>394</td>
<td>Harmful effects of Mineralocorticoids antagonists</td>
</tr>
<tr>
<td>395</td>
<td>Harmful effects of Loop diuretics</td>
</tr>
<tr>
<td>396</td>
<td>Harmful effect of high-ceiling diuretics</td>
</tr>
<tr>
<td>397</td>
<td>Frusemide poisoning</td>
</tr>
<tr>
<td>398</td>
<td>furosemide poisoning</td>
</tr>
<tr>
<td>399</td>
<td>Etacrynic acid poisoning</td>
</tr>
<tr>
<td>400</td>
<td>ethacrynic acid poisoning</td>
</tr>
<tr>
<td>401</td>
<td>Harmful effects of Carbonic-anhydrase inhibitors</td>
</tr>
<tr>
<td>402</td>
<td>Acetazolamide poisoning</td>
</tr>
<tr>
<td>403</td>
<td>Bendroflumethiazide poisoning</td>
</tr>
<tr>
<td>404</td>
<td>Chlormerodrin poisoning</td>
</tr>
<tr>
<td>405</td>
<td>Chlorothiazide poisoning</td>
</tr>
<tr>
<td>406</td>
<td>Mercaptomerin poisoning</td>
</tr>
<tr>
<td>407</td>
<td>Mersalyl poisoning</td>
</tr>
<tr>
<td>408</td>
<td>Harmful effects of Benzothiadiazine derivatives</td>
</tr>
<tr>
<td>409</td>
<td>harmful effect of thiazides</td>
</tr>
<tr>
<td>410</td>
<td>Harmful effects of other diuretics</td>
</tr>
<tr>
<td>411</td>
<td>Harmful effects of electrolytic, caloric or water-balance agents</td>
</tr>
<tr>
<td>412</td>
<td>Harmful effect of oral rehydration salts</td>
</tr>
<tr>
<td>413</td>
<td>Sodium chloride poisoning</td>
</tr>
<tr>
<td>414</td>
<td>Harmful effects of mineral salts, not elsewhere classified</td>
</tr>
<tr>
<td>415</td>
<td>Harmful effects of drugs affecting uric acid metabolism</td>
</tr>
<tr>
<td>416</td>
<td>Allopurinol poisoning</td>
</tr>
<tr>
<td>417</td>
<td>Colchicine poisoning</td>
</tr>
<tr>
<td>418</td>
<td>Probenecid poisoning</td>
</tr>
<tr>
<td>419</td>
<td>Harmful effects of agents primarily affecting water-balance and mineral or uric acid metabolism, Vitamin D and derivatives</td>
</tr>
<tr>
<td>420</td>
<td>Harmful effects of Bisphosphonates</td>
</tr>
<tr>
<td>421</td>
<td>Harmful effects of appetite depressants</td>
</tr>
<tr>
<td>422</td>
<td>Harmful effects of antidotes or chelating agents, not elsewhere classified</td>
</tr>
<tr>
<td>423</td>
<td>Harmful effects of Disulfiram</td>
</tr>
<tr>
<td>424</td>
<td>disulfiram poisoning</td>
</tr>
<tr>
<td>425</td>
<td>Harmful effects of alcohol deterrents, not elsewhere classified</td>
</tr>
<tr>
<td>426</td>
<td>harmful effect of alcohol deterrents</td>
</tr>
<tr>
<td>427</td>
<td>Toxic effect of alcohol deterrents</td>
</tr>
<tr>
<td>428</td>
<td>Harmful effects of X-ray contrast media</td>
</tr>
<tr>
<td>429</td>
<td>Harmful effects of MRI contrast agents</td>
</tr>
<tr>
<td>430</td>
<td>Harmful effects of agents used for other scanning techniques</td>
</tr>
<tr>
<td>431</td>
<td>Harmful effects of other diagnostic agents</td>
</tr>
<tr>
<td>432</td>
<td>Harmful effects of Lipotropic drugs</td>
</tr>
<tr>
<td>433</td>
<td>Harmful effects of vitamins, not elsewhere classified, Pharmaceutical excipients</td>
</tr>
<tr>
<td>434</td>
<td>Harmful effects of herbal preparations or formulas</td>
</tr>
<tr>
<td>435</td>
<td>Harmful effects of dietary supplements, vitamins or minerals</td>
</tr>
<tr>
<td>436</td>
<td>Harmful effects of complementary or Traditional Medicines, not elsewhere classified</td>
</tr>
<tr>
<td>437</td>
<td>Harmful effects of complementary or Traditional Medicines, unspecified</td>
</tr>
<tr>
<td>438</td>
<td>Harmful effects of vaccines, immunoglobulins or other biological substances</td>
</tr>
<tr>
<td>439</td>
<td>Harmful effects of BCG vaccine</td>
</tr>
<tr>
<td>440</td>
<td>Harmful effects of Typhoid or paratyphoid vaccine</td>
</tr>
<tr>
<td>441</td>
<td>Harmful effects of Cholera vaccine</td>
</tr>
<tr>
<td>442</td>
<td>Harmful effects of Plague vaccine</td>
</tr>
<tr>
<td>443</td>
<td>Harmful effects of Tetanus vaccine</td>
</tr>
<tr>
<td>444</td>
<td>Harmful effects of Diphtheria vaccine</td>
</tr>
<tr>
<td>445</td>
<td>Harmful effects of Haemophilus influenzae type B vaccines</td>
</tr>
<tr>
<td>446</td>
<td>Harmful effects of Pertussis vaccine, including combinations with a pertussis component</td>
</tr>
<tr>
<td>447</td>
<td>Harmful effects of mixed bacterial vaccines without a pertussis component</td>
</tr>
<tr>
<td>448</td>
<td>Harmful effects of other or unspecified bacterial vaccines</td>
</tr>
<tr>
<td>449</td>
<td>Harmful effects of Smallpox vaccines</td>
</tr>
<tr>
<td>450</td>
<td>Harmful effects of Measles vaccines</td>
</tr>
<tr>
<td>451</td>
<td>Harmful effects of Mumps vaccines</td>
</tr>
<tr>
<td>452</td>
<td>Harmful effects of Rubella vaccines</td>
</tr>
<tr>
<td>453</td>
<td>Harmful effects of Polio vaccines</td>
</tr>
<tr>
<td>454</td>
<td>Harmful effects of Yellow fever vaccines</td>
</tr>
<tr>
<td>455</td>
<td>Harmful effects of Hepatitis A vaccines</td>
</tr>
<tr>
<td>456</td>
<td>Harmful effects of Hepatitis B vaccines</td>
</tr>
<tr>
<td>457</td>
<td>Harmful effects of Influenza vaccines</td>
</tr>
<tr>
<td>458</td>
<td>Harmful effects of Rotavirus vaccines</td>
</tr>
<tr>
<td>459</td>
<td>Harmful effects of Human papillomavirus vaccines</td>
</tr>
<tr>
<td>460</td>
<td>Harmful effects of other viral vaccines</td>
</tr>
<tr>
<td>461</td>
<td>Harmful effects of Rickettsial vaccines</td>
</tr>
<tr>
<td>462</td>
<td>Harmful effects of Protozoal vaccines</td>
</tr>
<tr>
<td>463</td>
<td>Harmful effects of Hepatitis B immune globulin</td>
</tr>
<tr>
<td>464</td>
<td>Harmful effects of antivenin, antivenom</td>
</tr>
<tr>
<td>465</td>
<td>Harmful effects of immunoglobulin, not elsewhere classified</td>
</tr>
<tr>
<td>466</td>
<td>Harmful effects of other specified vaccines</td>
</tr>
<tr>
<td>467</td>
<td>Harmful effects of unspecified vaccines</td>
</tr>
<tr>
<td>468</td>
<td>Multiple drug toxicity</td>
</tr>
<tr>
<td>469</td>
<td>Catatonia due to medication or substance</td>
</tr>
<tr>
<td>470</td>
<td>Overdose of drug, not otherwise specified</td>
</tr>
<tr>
<td>471</td>
<td>overdose NOS</td>
</tr>
<tr>
<td>472</td>
<td>Harmful effects of ketorolac</td>
</tr>
<tr>
<td>473</td>
<td>ketorolac poisoning</td>
</tr>
<tr>
<td>474</td>
<td>Harmful effects of meptazinol</td>
</tr>
<tr>
<td>475</td>
<td>meptazinol poisoning</td>
</tr>
<tr>
<td>476</td>
<td>Harmful effects of nefopam</td>
</tr>
<tr>
<td>477</td>
<td>nefopam poisoning</td>
</tr>
<tr>
<td>478</td>
<td>Harmful effects of oxygen</td>
</tr>
<tr>
<td>479</td>
<td>oxygen poisoning</td>
</tr>
<tr>
<td>480</td>
<td>Harmful effects of ethosuximide</td>
</tr>
<tr>
<td>481</td>
<td>ethosuximide poisoning</td>
</tr>
<tr>
<td>482</td>
<td>Harmful effects of paramethadione</td>
</tr>
<tr>
<td>483</td>
<td>paramethadione poisoning</td>
</tr>
<tr>
<td>484</td>
<td>Harmful effects of trimethadione</td>
</tr>
<tr>
<td>485</td>
<td>trimethadione poisoning</td>
</tr>
<tr>
<td>486</td>
<td>Harmful effects of phensuximide</td>
</tr>
<tr>
<td>487</td>
<td>phensuximide poisoning</td>
</tr>
<tr>
<td>488</td>
<td>Adverse effect medical agent</td>
</tr>
<tr>
<td>489</td>
<td>side effect</td>
</tr>
<tr>
<td>490</td>
<td>side effect of medical agent</td>
</tr>
<tr>
<td>491</td>
<td>Cocaine and fentanyl toxicity</td>
</tr>
<tr>
<td>492</td>
<td>Methamphetamine and fentanyl toxicity</td>
</tr>
<tr>
<td>493</td>
<td>Abnormal ventricular relationships</td>
</tr>
<tr>
<td>494</td>
<td>Right hand pattern ventricular topology</td>
</tr>
<tr>
<td>495</td>
<td>D-bulboventricular loop</td>
</tr>
<tr>
<td>496</td>
<td>D-loop ventricles</td>
</tr>
<tr>
<td>497</td>
<td>Dextro-ventricular looping</td>
</tr>
<tr>
<td>498</td>
<td>Left hand pattern ventricular topology</td>
</tr>
<tr>
<td>499</td>
<td>L-bulboventricular loop</td>
</tr>
<tr>
<td>500</td>
<td>L-loop ventricles</td>
</tr>
<tr>
<td>501</td>
<td>Levo-ventricular looping</td>
</tr>
<tr>
<td>502</td>
<td>Sinistro-ventricular looping</td>
</tr>
<tr>
<td>503</td>
<td>Crisscross heart</td>
</tr>
<tr>
<td>504</td>
<td>twisted atrioventricular connections</td>
</tr>
<tr>
<td>505</td>
<td>Criss-cross heart</td>
</tr>
<tr>
<td>506</td>
<td>Superior-inferior ventricular relationship</td>
</tr>
<tr>
<td>507</td>
<td>Upstairs-downstairs ventricular relationship</td>
</tr>
<tr>
<td>508</td>
<td>superior-inferior heart</td>
</tr>
<tr>
<td>509</td>
<td>Disorders of protein N-glycosylation</td>
</tr>
<tr>
<td>510</td>
<td>Phosphomannomutase 2 deficiency</td>
</tr>
<tr>
<td>511</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1A</td>
</tr>
<tr>
<td>512</td>
<td>Congenital disorder of glycosylation type 1A</td>
</tr>
<tr>
<td>513</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1A</td>
</tr>
<tr>
<td>514</td>
<td>Phosphomannose isomerase deficiency</td>
</tr>
<tr>
<td>515</td>
<td>Saguenay-Lac-Saint-Jean syndrome</td>
</tr>
<tr>
<td>516</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1B</td>
</tr>
<tr>
<td>517</td>
<td>Congenital disorder of glycosylation type 1B</td>
</tr>
<tr>
<td>518</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1B</td>
</tr>
<tr>
<td>519</td>
<td>SLSJ - [Saguenay-Lac-Saint-Jean] syndrome</td>
</tr>
<tr>
<td>520</td>
<td>Glucosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>521</td>
<td>Dol-P-Glc: Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>522</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1C</td>
</tr>
<tr>
<td>523</td>
<td>Congenital disorder of glycosylation type 1C</td>
</tr>
<tr>
<td>524</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1C</td>
</tr>
<tr>
<td>525</td>
<td>Mannosyltransferase 6 deficiency</td>
</tr>
<tr>
<td>526</td>
<td>Dol-P-Man: Man5-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>527</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1D</td>
</tr>
<tr>
<td>528</td>
<td>Congenital disorder of glycosylation type 1D</td>
</tr>
<tr>
<td>529</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1D</td>
</tr>
<tr>
<td>530</td>
<td>Mannosyltransferase 8 deficiency</td>
</tr>
<tr>
<td>531</td>
<td>Dol-P-Man: Man7-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>532</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1G</td>
</tr>
<tr>
<td>533</td>
<td>Congenital disorder of glycosylation type 1G</td>
</tr>
<tr>
<td>534</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1G</td>
</tr>
<tr>
<td>535</td>
<td>Glucosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>536</td>
<td>Dol-P-Glc: Glc1-Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>537</td>
<td>Carbohydrate deficient glycoprotein syndrome 1H</td>
</tr>
<tr>
<td>538</td>
<td>Congenital disorder of glycosylation type 1H</td>
</tr>
<tr>
<td>539</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1H</td>
</tr>
<tr>
<td>540</td>
<td>Mannosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>541</td>
<td>Dol-P-Man: Man1-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>542</td>
<td>Carbohydrate deficient glycoprotein syndrome 1I</td>
</tr>
<tr>
<td>543</td>
<td>Congenital disorder of glycosylation 1I</td>
</tr>
<tr>
<td>544</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1I</td>
</tr>
<tr>
<td>545</td>
<td>Dolichyl-phosphate N-acetylgalactosamine phosphotransferase deficiency</td>
</tr>
<tr>
<td>546</td>
<td>UDP-GlcNAc: Dol-P-GlcNac-P transferase deficiency</td>
</tr>
<tr>
<td>547</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1J</td>
</tr>
<tr>
<td>548</td>
<td>Congenital disorder of glycosylation type 1J</td>
</tr>
<tr>
<td>549</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1J</td>
</tr>
<tr>
<td>550</td>
<td>Mannosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>551</td>
<td>Dol-P-Man: GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>552</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1K</td>
</tr>
<tr>
<td>553</td>
<td>Congenital disorder of glycosylation type 1K</td>
</tr>
<tr>
<td>554</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1K</td>
</tr>
<tr>
<td>555</td>
<td>Mannosyltransferase 7-9 deficiency</td>
</tr>
<tr>
<td>556</td>
<td>Congenital disorder of glycosylation type 1L</td>
</tr>
<tr>
<td>557</td>
<td>Dol-P-Man: Man6 and Man8-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>558</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1L</td>
</tr>
<tr>
<td>559</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1L</td>
</tr>
<tr>
<td>560</td>
<td>M5-DLO flippase deficiency</td>
</tr>
<tr>
<td>561</td>
<td>Man5GlcNAc2-PP-Dol flippase deficiency</td>
</tr>
<tr>
<td>562</td>
<td>RTF1-CDG</td>
</tr>
<tr>
<td>563</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1N</td>
</tr>
<tr>
<td>564</td>
<td>N-acetylglucosaminyltransferase deficiency</td>
</tr>
<tr>
<td>565</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2A</td>
</tr>
<tr>
<td>566</td>
<td>Congenital disorder of glycosylation type 2A</td>
</tr>
<tr>
<td>567</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2A</td>
</tr>
<tr>
<td>568</td>
<td>Glucosidase 1 deficiency</td>
</tr>
<tr>
<td>569</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2B</td>
</tr>
<tr>
<td>570</td>
<td>Congenital disorder of glycosylation type 2B</td>
</tr>
<tr>
<td>571</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2B</td>
</tr>
<tr>
<td>572</td>
<td>TUSC3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>573</td>
<td>TUSC3-CDG</td>
</tr>
<tr>
<td>574</td>
<td>SRD5A3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>575</td>
<td>SRD5A3-CDG</td>
</tr>
<tr>
<td>576</td>
<td>Congenital disorder of glycosylation due to steroid 5-alpha-reductase type 3 deficiency</td>
</tr>
<tr>
<td>577</td>
<td>Intellectual deficit - cataract - coloboma - kyphosis</td>
</tr>
<tr>
<td>578</td>
<td>Kahrizi syndrome</td>
</tr>
<tr>
<td>579</td>
<td>Intellectual deficit, Kahrizi type</td>
</tr>
<tr>
<td>580</td>
<td>DPM3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>581</td>
<td>Congenital disorder of glycosylation type 1O</td>
</tr>
<tr>
<td>582</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1O</td>
</tr>
<tr>
<td>583</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1O</td>
</tr>
<tr>
<td>584</td>
<td>ALG11 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>585</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1P</td>
</tr>
<tr>
<td>586</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1P</td>
</tr>
<tr>
<td>587</td>
<td>Congenital disorder of glycosylation type 1P</td>
</tr>
<tr>
<td>588</td>
<td>Phosphoglucomutase-1 deficiency</td>
</tr>
<tr>
<td>589</td>
<td>PGM1-CDG - [Phosphoglucomutase-1 deficiency]</td>
</tr>
<tr>
<td>590</td>
<td>Congenital disorder of glycosylation type 1t</td>
</tr>
<tr>
<td>591</td>
<td>Recessive limb-girdle muscular dystrophy</td>
</tr>
<tr>
<td>592</td>
<td>LGMD2 - [Limb-girdle muscular dystrophy] 2</td>
</tr>
<tr>
<td>593</td>
<td>Limb-girdle muscular dystrophy 2A, calpain-3 deficiency</td>
</tr>
<tr>
<td>594</td>
<td>Limb-girdle muscular dystrophy 2B, dysferlin deficiency</td>
</tr>
<tr>
<td>595</td>
<td>Limb-girdle muscular dystrophy 2C, gamma-sarcoglycan deficiency</td>
</tr>
<tr>
<td>596</td>
<td>Limb-girdle muscular dystrophy 2D, alpha-sarcoglycan deficiency</td>
</tr>
<tr>
<td>597</td>
<td>Limb-girdle muscular dystrophy 2E, beta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>598</td>
<td>Limb-girdle muscular dystrophy 2F, delta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>599</td>
<td>Limb-girdle muscular dystrophy 2G, telethonin gene mutation</td>
</tr>
<tr>
<td>600</td>
<td>Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation</td>
</tr>
<tr>
<td>601</td>
<td>LGMD 2H - [Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation]</td>
</tr>
<tr>
<td>602</td>
<td>Limb-girdle muscular dystrophy 2I, fukutin related protein gene mutation</td>
</tr>
<tr>
<td>603</td>
<td>FKRP - [fukutin related protein gene mutation]</td>
</tr>
<tr>
<td>604</td>
<td>LGMD 2I - [Limb-girdle muscular dystrophy 2I]</td>
</tr>
<tr>
<td>605</td>
<td>Limb-girdle muscular dystrophy 2J, Titin gene mutation</td>
</tr>
<tr>
<td>606</td>
<td>LGMD 2J - [Limb-girdle muscular dystrophy 2J, Titin gene mutation]</td>
</tr>
<tr>
<td>607</td>
<td>Limb-girdle muscular dystrophy 2K, protein-O-mannosyltransferase 1 transferase</td>
</tr>
<tr>
<td>608</td>
<td>POMT1 - [protein-O-mannosyltransferase 1 transferase]</td>
</tr>
<tr>
<td>609</td>
<td>LGMD 2K - [Limb-girdle muscular dystrophy 2K]</td>
</tr>
<tr>
<td>610</td>
<td>Limb-girdle muscular dystrophy 2L, AN05 gene mutation</td>
</tr>
<tr>
<td>611</td>
<td>LGMD 2L - [Limb-girdle muscular dystrophy 2L]</td>
</tr>
<tr>
<td>612</td>
<td>Limb-girdle muscular dystrophy 2M, POMGnT1 gene mutation</td>
</tr>
<tr>
<td>613</td>
<td>LGMD2M - [limb-girdle muscular dystrophy 2M]</td>
</tr>
<tr>
<td>614</td>
<td>Limb-girdle muscular dystrophy 2N, POMT2 gene mutation</td>
</tr>
<tr>
<td>615</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C2)</td>
</tr>
<tr>
<td>616</td>
<td>MDDGC2</td>
</tr>
<tr>
<td>617</td>
<td>LGMD2N - limb-girdle muscular dystrophy 2N]</td>
</tr>
<tr>
<td>618</td>
<td>Limb-girdle muscular dystrophy 2O, POMGNT1 gene mutation</td>
</tr>
<tr>
<td>619</td>
<td>LGMD2O - [limb-girdle muscular dystrophy 2O]</td>
</tr>
<tr>
<td>620</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C3)</td>
</tr>
<tr>
<td>621</td>
<td>MDDGC3</td>
</tr>
<tr>
<td>622</td>
<td>Limb-girdle muscular dystrophy 2Q, plectin deficiency</td>
</tr>
<tr>
<td>623</td>
<td>LGMD2Q - [limb-girdle muscular dystrophy 2Q]</td>
</tr>
<tr>
<td>624</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy C7</td>
</tr>
<tr>
<td>625</td>
<td>MDDGC7</td>
</tr>
<tr>
<td>626</td>
<td>Cerebral organic aciduria</td>
</tr>
<tr>
<td>627</td>
<td>Glutaric aciduria type 1</td>
</tr>
<tr>
<td>628</td>
<td>Glutaric acidaemia type 1</td>
</tr>
<tr>
<td>629</td>
<td>Glutaryl-CoA dehydrogenase deficiency</td>
</tr>
<tr>
<td>630</td>
<td>2-hydroxyglutaric aciduria</td>
</tr>
<tr>
<td>631</td>
<td>L-2-hydroxyglutaric aciduria</td>
</tr>
<tr>
<td>632</td>
<td>D-2-hydroxyglutaric aciduria</td>
</tr>
<tr>
<td>633</td>
<td>D-2-hydroxyglutarate dehydrogenase deficiency</td>
</tr>
<tr>
<td>634</td>
<td>Mitochondrial isocitrate dehydrogenase deficiency</td>
</tr>
<tr>
<td>635</td>
<td>Aminoacylase deficiency</td>
</tr>
<tr>
<td>636</td>
<td>Neurological conditions associated with aminoacylase 1 deficiency</td>
</tr>
<tr>
<td>637</td>
<td>Canavan disease</td>
</tr>
<tr>
<td>638</td>
<td>Spongy degeneration of central nervous system</td>
</tr>
<tr>
<td>639</td>
<td>Aspartoacylase deficiency</td>
</tr>
<tr>
<td>640</td>
<td>Canavan-van Bogaert-Bertrand disease</td>
</tr>
<tr>
<td>641</td>
<td>Malonic aciduria</td>
</tr>
<tr>
<td>642</td>
<td>Malonyl-CoA decarboxylase deficiency</td>
</tr>
<tr>
<td>643</td>
<td>Ethylmalonic encephalopathy</td>
</tr>
<tr>
<td>644</td>
<td>4-hydroxybutyric aciduria</td>
</tr>
<tr>
<td>645</td>
<td>Succinic semialdehyde dehydrogenase deficiency</td>
</tr>
<tr>
<td>646</td>
<td>Gamma-hydroxybutyric acidaemia</td>
</tr>
<tr>
<td>647</td>
<td>Oligosaccharidosis</td>
</tr>
<tr>
<td>648</td>
<td>Aspartylglucosaminuria</td>
</tr>
<tr>
<td>649</td>
<td>Aspartylglucosaminidase deficiency</td>
</tr>
<tr>
<td>650</td>
<td>Alpha-mannosidosis</td>
</tr>
<tr>
<td>651</td>
<td>Lysosomal alpha-D-mannosidase deficiency</td>
</tr>
<tr>
<td>652</td>
<td>Infantile alpha-mannosidosis</td>
</tr>
<tr>
<td>653</td>
<td>Adult alpha-mannosidosis</td>
</tr>
<tr>
<td>654</td>
<td>Beta-mannosidosis</td>
</tr>
<tr>
<td>655</td>
<td>Lysosomal beta-mannosidase deficiency</td>
</tr>
<tr>
<td>656</td>
<td>Mannosidosis, not otherwise specified</td>
</tr>
<tr>
<td>657</td>
<td>mannosidase deficiency</td>
</tr>
<tr>
<td>658</td>
<td>Fucosidosis</td>
</tr>
<tr>
<td>659</td>
<td>Alpha-L-fucosidase deficiency</td>
</tr>
<tr>
<td>660</td>
<td>Sialidosis</td>
</tr>
<tr>
<td>661</td>
<td>Mucolipidosis type 1</td>
</tr>
<tr>
<td>662</td>
<td>Sialidosis type 1</td>
</tr>
<tr>
<td>663</td>
<td>Cherry-red-spot-myoclonus syndrome</td>
</tr>
<tr>
<td>664</td>
<td>Lipomucopolysaccharidosis</td>
</tr>
<tr>
<td>665</td>
<td>Normomorphic sialidosis</td>
</tr>
<tr>
<td>666</td>
<td>Sialidosis type 2</td>
</tr>
<tr>
<td>667</td>
<td>Infantile dysmorphic sialidosis</td>
</tr>
<tr>
<td>668</td>
<td>Congenital sialidosis type 2</td>
</tr>
<tr>
<td>669</td>
<td>Juvenile sialidosis type 2</td>
</tr>
<tr>
<td>670</td>
<td>Alpha-N-acetylgalactosaminidase deficiency</td>
</tr>
<tr>
<td>671</td>
<td>N-acetyl-alpha-D-galactosaminidase deficiency</td>
</tr>
<tr>
<td>672</td>
<td>NAGA - [Alpha-N-acetylgalactosaminidase] deficiency</td>
</tr>
<tr>
<td>673</td>
<td>Alpha-N-acetylgalactosaminidase deficiency type 1</td>
</tr>
<tr>
<td>674</td>
<td>Schindler disease type 1</td>
</tr>
<tr>
<td>675</td>
<td>Schindler disease</td>
</tr>
<tr>
<td>676</td>
<td>NAGA deficiency type 1 - [Alpha-N-acetylgalactosaminidase deficiency type 1]</td>
</tr>
<tr>
<td>677</td>
<td>Alpha-N-acetylgalactosaminidase deficiency type 2</td>
</tr>
<tr>
<td>678</td>
<td>Adult-onset Alpha-N-acetylgalactosaminidase deficiency</td>
</tr>
<tr>
<td>679</td>
<td>Schindler disease type 2</td>
</tr>
<tr>
<td>680</td>
<td>Kanzaki disease</td>
</tr>
<tr>
<td>681</td>
<td>NAGA deficiency type 2 - [Alpha-N-acetylgalactosaminidase deficiency type 2]</td>
</tr>
<tr>
<td>682</td>
<td>Alpha-N-acetylgalactosaminidase deficiency type 3</td>
</tr>
<tr>
<td>683</td>
<td>Schindler disease type 3</td>
</tr>
<tr>
<td>684</td>
<td>NAGA deficiency type 3 - [Alpha-N-acetylgalactosaminidase deficiency type 3]</td>
</tr>
<tr>
<td>685</td>
<td>Galactosialidosis</td>
</tr>
<tr>
<td>686</td>
<td>Neuraminidase deficiency with beta-galactosidase deficiency</td>
</tr>
<tr>
<td>687</td>
<td>Goldberg syndrome</td>
</tr>
<tr>
<td>688</td>
<td>Combined deficiency of neuraminidase and beta-galactosidase</td>
</tr>
<tr>
<td>689</td>
<td>Protective protein deficiency</td>
</tr>
<tr>
<td>690</td>
<td>Other specified structural developmental anomaly of heart or great vessels</td>
</tr>
<tr>
<td>691</td>
<td>Congenital anomaly of position or spatial relationships of thoraco-abdominal organs</td>
</tr>
<tr>
<td>692</td>
<td>Usual atrial arrangement</td>
</tr>
<tr>
<td>693</td>
<td>atrial situs solitus</td>
</tr>
<tr>
<td>694</td>
<td>Abnormal atrial arrangement</td>
</tr>
<tr>
<td>695</td>
<td>Abnormal atrial situs</td>
</tr>
<tr>
<td>696</td>
<td>Atrial situs inversus</td>
</tr>
<tr>
<td>697</td>
<td>Mirror-image atrial arrangement</td>
</tr>
<tr>
<td>698</td>
<td>Isomerism of right atrial appendages</td>
</tr>
<tr>
<td>699</td>
<td>isomeric right atrial appendages</td>
</tr>
<tr>
<td>700</td>
<td>Isomerism of left atrial appendages</td>
</tr>
<tr>
<td>701</td>
<td>isomeric left atrial appendages</td>
</tr>
<tr>
<td>702</td>
<td>Abnormal relationship of great arterial roots</td>
</tr>
<tr>
<td>703</td>
<td>Abnormal relationships of great arteries</td>
</tr>
<tr>
<td>704</td>
<td>Abnormal relationships of great vessels</td>
</tr>
<tr>
<td>705</td>
<td>Aortic root directly anterior to pulmonary root</td>
</tr>
<tr>
<td>706</td>
<td>A-malposed aorta</td>
</tr>
<tr>
<td>707</td>
<td>A-malposed great arteries</td>
</tr>
<tr>
<td>708</td>
<td>Aorta directly anterior to pulmonary artery</td>
</tr>
<tr>
<td>709</td>
<td>A-transposed aorta</td>
</tr>
<tr>
<td>710</td>
<td>Aortic root anterior and rightward to pulmonary root</td>
</tr>
<tr>
<td>711</td>
<td>D-malposed great vessels with anterior aorta</td>
</tr>
<tr>
<td>712</td>
<td>Dextroposed great arteries with anterior aorta</td>
</tr>
<tr>
<td>713</td>
<td>Dextroposed great vessels with anterior aorta</td>
</tr>
<tr>
<td>714</td>
<td>D-malposed great arteries with anterior aorta</td>
</tr>
<tr>
<td>715</td>
<td>D-transposed great arteries</td>
</tr>
<tr>
<td>716</td>
<td>D-transposed great vessels</td>
</tr>
<tr>
<td>717</td>
<td>Aortic root anterior and leftward to pulmonary root</td>
</tr>
<tr>
<td>718</td>
<td>L-malposed great vessels with anterior aorta</td>
</tr>
<tr>
<td>719</td>
<td>L-malposed great arteries with anterior aorta</td>
</tr>
<tr>
<td>720</td>
<td>Levoposed great arteries with anterior aorta</td>
</tr>
<tr>
<td>721</td>
<td>Levoposed great vessels with anterior aorta</td>
</tr>
<tr>
<td>722</td>
<td>L-transposed great arteries with anterior aorta</td>
</tr>
<tr>
<td>723</td>
<td>L-transposed great vessels with anterior aorta</td>
</tr>
<tr>
<td>724</td>
<td>Aortic root side by side and directly rightward to pulmonary root</td>
</tr>
<tr>
<td>725</td>
<td>D-transposed side by side great arteries</td>
</tr>
<tr>
<td>726</td>
<td>D-transposed side by side great vessels</td>
</tr>
<tr>
<td>727</td>
<td>Dextroposed side by side great arteries</td>
</tr>
<tr>
<td>728</td>
<td>Dextroposed side by side great vessels</td>
</tr>
<tr>
<td>729</td>
<td>D-malposed side by side great arteries</td>
</tr>
<tr>
<td>730</td>
<td>Aortic root side by side and directly leftward to pulmonary root</td>
</tr>
<tr>
<td>731</td>
<td>L-transposed side by side great vessels</td>
</tr>
<tr>
<td>732</td>
<td>L-malposed side by side great vessels</td>
</tr>
<tr>
<td>733</td>
<td>L-malposed side by side great arteries</td>
</tr>
<tr>
<td>734</td>
<td>Levoposed side by side great vessels</td>
</tr>
<tr>
<td>735</td>
<td>Levoposed side by side great arteries</td>
</tr>
<tr>
<td>736</td>
<td>L-transposed side by side great arteries</td>
</tr>
<tr>
<td>737</td>
<td>Aortic root directly posterior to pulmonary root</td>
</tr>
<tr>
<td>738</td>
<td>Aortic root posterior and rightward to pulmonary root</td>
</tr>
<tr>
<td>739</td>
<td>d-malposed great arteries with posterior aorta</td>
</tr>
<tr>
<td>740</td>
<td>normally related great arteries</td>
</tr>
<tr>
<td>741</td>
<td>segmental analysis D with posterior aorta</td>
</tr>
<tr>
<td>742</td>
<td>Aortic root posterior and leftward to pulmonary root</td>
</tr>
<tr>
<td>743</td>
<td>L-malposed great arteries with posterior aorta</td>
</tr>
<tr>
<td>744</td>
<td>L-malposed great vessels with posterior aorta</td>
</tr>
<tr>
<td>745</td>
<td>Mirror imaged normally related great arteries</td>
</tr>
<tr>
<td>746</td>
<td>Levoposed great arteries with posterior aorta</td>
</tr>
<tr>
<td>747</td>
<td>Levoposed great vessels with posterior aorta</td>
</tr>
<tr>
<td>748</td>
<td>Mirror imaged normally related great vessels</td>
</tr>
<tr>
<td>749</td>
<td>Abnormal intrapericardial course of great arteries</td>
</tr>
<tr>
<td>750</td>
<td>Spiralling course of great arteries</td>
</tr>
<tr>
<td>751</td>
<td>Normal course of great arteries</td>
</tr>
<tr>
<td>752</td>
<td>Parallel course of great arteries</td>
</tr>
<tr>
<td>753</td>
<td>Visceral heterotaxy</td>
</tr>
<tr>
<td>754</td>
<td>Abnormal arrangement of thoraco-abdominal organs</td>
</tr>
<tr>
<td>755</td>
<td>Heterotaxy</td>
</tr>
<tr>
<td>756</td>
<td>Heterotaxia</td>
</tr>
<tr>
<td>757</td>
<td>Heterotaxia syndrome</td>
</tr>
<tr>
<td>758</td>
<td>Situs ambiguous</td>
</tr>
<tr>
<td>759</td>
<td>Splenic syndromes</td>
</tr>
<tr>
<td>760</td>
<td>Heterotaxy syndrome</td>
</tr>
<tr>
<td>761</td>
<td>Congenital anomaly of an atrium or atrial septum</td>
</tr>
<tr>
<td>762</td>
<td>congenital atrial malformation</td>
</tr>
<tr>
<td>763</td>
<td>cor triatriatum (deprecated)</td>
</tr>
<tr>
<td>764</td>
<td>Aortic aneurysm due to congenital heart disease</td>
</tr>
<tr>
<td>765</td>
<td>Aortic aneurysm secondary to congenital heart disease</td>
</tr>
<tr>
<td>766</td>
<td>Congenital heart block</td>
</tr>
<tr>
<td>767</td>
<td>Congenital complete heart block</td>
</tr>
<tr>
<td>768</td>
<td>Immune-mediated heart block</td>
</tr>
<tr>
<td>769</td>
<td>Accessory heart</td>
</tr>
<tr>
<td>770</td>
<td>Congenital cardiac dilatation</td>
</tr>
<tr>
<td>771</td>
<td>acute congenital heart dilatation</td>
</tr>
<tr>
<td>772</td>
<td>chronic congenital cardiac dilatation</td>
</tr>
<tr>
<td>773</td>
<td>chronic congenital heart dilatation</td>
</tr>
<tr>
<td>774</td>
<td>congenital cardiac valve dilatation</td>
</tr>
<tr>
<td>775</td>
<td>Anomalous bands of heart</td>
</tr>
<tr>
<td>776</td>
<td>anomaly of heart bands or folds</td>
</tr>
<tr>
<td>777</td>
<td>Bifid apex of heart</td>
</tr>
<tr>
<td>778</td>
<td>Congenital cardiomegaly</td>
</tr>
<tr>
<td>779</td>
<td>Congenital microcardia</td>
</tr>
<tr>
<td>780</td>
<td>Dislocation of lumbar vertebra</td>
</tr>
<tr>
<td>781</td>
<td>dislocation of joint of lumbar spine</td>
</tr>
<tr>
<td>782</td>
<td>traumatic dislocation of joint of lumbar vertebra</td>
</tr>
<tr>
<td>783</td>
<td>acute traumatic lumbar spondylolisthesis</td>
</tr>
<tr>
<td>784</td>
<td>lumbar dislocation</td>
</tr>
<tr>
<td>785</td>
<td>Dislocation of lumbar spine NOS</td>
</tr>
<tr>
<td>786</td>
<td>Dislocation of L1-L2 lumbar vertebrae</td>
</tr>
<tr>
<td>787</td>
<td>Dislocation of L2-L3 lumbar vertebrae</td>
</tr>
<tr>
<td>788</td>
<td>Dislocation of L3-L4 lumbar vertebrae</td>
</tr>
<tr>
<td>789</td>
<td>Dislocation of L4-L5 lumbar vertebrae</td>
</tr>
<tr>
<td>790</td>
<td>Dislocation of L5-S1 lumbosacral vertebrae</td>
</tr>
<tr>
<td>791</td>
<td>dislocation of lumbosacral vertebra</td>
</tr>
<tr>
<td>792</td>
<td>lumbosacral dislocation</td>
</tr>
<tr>
<td>793</td>
<td>acute traumatic lumbosacral spondylolisthesis</td>
</tr>
<tr>
<td>794</td>
<td>Disorders of catecholamine synthesis</td>
</tr>
<tr>
<td>795</td>
<td>Aromatic L-amino acid decarboxylase deficiency</td>
</tr>
<tr>
<td>796</td>
<td>DOPA decarboxylase deficiency</td>
</tr>
<tr>
<td>797</td>
<td>Dopamine beta-hydroxylase deficiency</td>
</tr>
<tr>
<td>798</td>
<td>Norepinephrine deficiency</td>
</tr>
<tr>
<td>799</td>
<td>Noradrenaline deficiency</td>
</tr>
<tr>
<td>800</td>
<td>Charcot-Marie-Tooth disease 2 axonal</td>
</tr>
<tr>
<td>801</td>
<td>Charcot-Marie-Tooth disease 2 autosomal dominant</td>
</tr>
<tr>
<td>802</td>
<td>Recessive axonal Charcot-Marie-Tooth disease with acrodystrophy</td>
</tr>
<tr>
<td>803</td>
<td>Charcot-Marie-Tooth disease type 2A1</td>
</tr>
<tr>
<td>804</td>
<td>Charcot-Marie-Tooth disease type 2A2</td>
</tr>
<tr>
<td>805</td>
<td>Charcot-Marie-Tooth disease type 2B</td>
</tr>
<tr>
<td>806</td>
<td>Charcot-Marie-Tooth disease type 2C</td>
</tr>
<tr>
<td>807</td>
<td>Charcot-Marie-Tooth disease type 2D</td>
</tr>
<tr>
<td>808</td>
<td>Charcot-Marie-Tooth disease type 2E</td>
</tr>
<tr>
<td>809</td>
<td>Charcot-Marie-Tooth disease type 2F</td>
</tr>
<tr>
<td>810</td>
<td>Charcot-Marie-Tooth disease type 2G</td>
</tr>
<tr>
<td>811</td>
<td>Charcot-Marie-Tooth disease type 2I</td>
</tr>
<tr>
<td>812</td>
<td>Charcot-Marie-Tooth disease type 2J</td>
</tr>
<tr>
<td>813</td>
<td>Charcot-Marie-Tooth disease type 2K</td>
</tr>
<tr>
<td>814</td>
<td>Charcot-Marie-Tooth disease type 2L</td>
</tr>
<tr>
<td>815</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2M</td>
</tr>
<tr>
<td>816</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2N</td>
</tr>
<tr>
<td>817</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2O</td>
</tr>
<tr>
<td>818</td>
<td>Charcot-Marie-Tooth disease 2 autosomal recessive</td>
</tr>
<tr>
<td>819</td>
<td>Charcot-Marie-Tooth disease type 2B1</td>
</tr>
<tr>
<td>820</td>
<td>Charcot-Marie-Tooth disease type 2B2</td>
</tr>
<tr>
<td>821</td>
<td>Charcot-Marie-Tooth disease type 2B5</td>
</tr>
<tr>
<td>822</td>
<td>Charcot-Marie-Tooth disease type 2H</td>
</tr>
<tr>
<td>823</td>
<td>Autosomal recessive Charcot-Marie-Tooth disease with hoarseness</td>
</tr>
<tr>
<td>824</td>
<td>Hereditary motor and sensory neuropathy type 6</td>
</tr>
<tr>
<td>825</td>
<td>Charcot-Marie-Tooth type 6</td>
</tr>
<tr>
<td>826</td>
<td>HMSN6 - [Hereditary motor and sensory neuropathy type 6]</td>
</tr>
<tr>
<td>827</td>
<td>CMT6 - [Charcot-Marie-Tooth type 6]</td>
</tr>
<tr>
<td>828</td>
<td>Other specified combined immunodeficiencies</td>
</tr>
<tr>
<td>829</td>
<td>Combined immunodeficiency due to ORAI1 deficiency</td>
</tr>
<tr>
<td>830</td>
<td>Combined immunodeficiency due to STIM1 deficiency</td>
</tr>
<tr>
<td>831</td>
<td>Combined immunodeficiency T+ B+ due to partial RAG1 deficiency</td>
</tr>
<tr>
<td>832</td>
<td>Immunodeficiency due to purine nucleoside phosphorylase deficiency</td>
</tr>
<tr>
<td>833</td>
<td>Nucleoside phosphorylase deficiency</td>
</tr>
<tr>
<td>834</td>
<td>deficiency of inosine phosphorylase</td>
</tr>
<tr>
<td>835</td>
<td>deficiency of purine-nucleoside phosphorylase</td>
</tr>
<tr>
<td>836</td>
<td>NP - [nucleoside phosphorylase] deficiency</td>
</tr>
<tr>
<td>837</td>
<td>PNP - [purine nucleoside phosphorylase] deficiency</td>
</tr>
<tr>
<td>838</td>
<td>Severe combined immunodeficiency - microcephaly - growth retardation - sensitivity to ionizing radiation</td>
</tr>
<tr>
<td>839</td>
<td>Combined immunodeficiency due to Cernunnos protein deficiency</td>
</tr>
<tr>
<td>840</td>
<td>NHEJ1 - [non-homologous end joining factor] syndrome</td>
</tr>
<tr>
<td>841</td>
<td>DNA-ligase IV deficiency</td>
</tr>
<tr>
<td>842</td>
<td>Ligase 4 syndrome</td>
</tr>
<tr>
<td>843</td>
<td>LIG4 deficiency</td>
</tr>
<tr>
<td>844</td>
<td>Combined immunodeficiency due to CRAC channel dysfunction</td>
</tr>
<tr>
<td>845</td>
<td>Immune dysfunction due to T-cell inactivation due to calcium entry defect</td>
</tr>
<tr>
<td>846</td>
<td>Combined immunodeficiency due to ZAP70 deficiency</td>
</tr>
<tr>
<td>847</td>
<td>Zeta-associated-protein 70 deficiency</td>
</tr>
<tr>
<td>848</td>
<td>Severe T-cell immunodeficiency - congenital alopecia - nail dystrophy</td>
</tr>
<tr>
<td>849</td>
<td>SCID - [Severe combined immunodeficiency] due to winged helix deficiency</td>
</tr>
<tr>
<td>850</td>
<td>Combined immunodeficiency due to CD3 gamma deficiency</td>
</tr>
<tr>
<td>851</td>
<td>Familial CD8 deficiency</td>
</tr>
<tr>
<td>852</td>
<td>Susceptibility to respiratory infections associated with CD8 alpha chain mutation</td>
</tr>
<tr>
<td>853</td>
<td>Primary immunodeficiency with skin granulomas</td>
</tr>
<tr>
<td>854</td>
<td>Combined cellular and humoral deficiencies and multiple granulomas</td>
</tr>
<tr>
<td>855</td>
<td>Combined immunodeficiency due to DOCK8 deficiency</td>
</tr>
<tr>
<td>856</td>
<td>CID - [combined immunodeficiency] due to DOCK8 - [dedicator of cytokinesis 8 protein] deficiency</td>
</tr>
<tr>
<td>857</td>
<td>Pancytopenia due to IKZF1 mutations</td>
</tr>
<tr>
<td>858</td>
<td>CID - [combined immunodeficiency] due to Ikaros deficiency</td>
</tr>
<tr>
<td>859</td>
<td>X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection or neoplasia</td>
</tr>
<tr>
<td>860</td>
<td>Combined immunodeficiency due to MAGT1 deficiency</td>
</tr>
<tr>
<td>861</td>
<td>CID - [combined immunodeficiency] due to MAGT1 deficiency</td>
</tr>
<tr>
<td>862</td>
<td>Hyper-IgM syndrome due to CD40 ligand deficiency</td>
</tr>
<tr>
<td>863</td>
<td>Hyper-IgM syndrome type 1</td>
</tr>
<tr>
<td>864</td>
<td>Hyper-IgM syndrome due to CD40L deficiency</td>
</tr>
<tr>
<td>865</td>
<td>X-linked hyper-IgM syndrome</td>
</tr>
<tr>
<td>866</td>
<td>HIGM1 - [hyper-IgM syndrome type 1]</td>
</tr>
<tr>
<td>867</td>
<td>Hyper-IgM syndrome due to CD40 deficiency</td>
</tr>
<tr>
<td>868</td>
<td>Hyper-IgM syndrome type 3</td>
</tr>
<tr>
<td>869</td>
<td>HIGM3 - [hyper-IgM syndrome type 3]</td>
</tr>
<tr>
<td>870</td>
<td>Combined immunodeficiency with facio-oculo-skeletal anomalies</td>
</tr>
<tr>
<td>871</td>
<td>Corpus callosum agenesis – cataract – immunodeficiency</td>
</tr>
<tr>
<td>872</td>
<td>Dionisi-Vici-Sabetta-Gambarara syndrome</td>
</tr>
<tr>
<td>873</td>
<td>Vici syndrome</td>
</tr>
<tr>
<td>874</td>
<td>Absent thumb - short stature - immune deficiency</td>
</tr>
<tr>
<td>875</td>
<td>Hyper-IgM syndrome with susceptibility to opportunistic infections</td>
</tr>
<tr>
<td>876</td>
<td>Hyper-IgM syndrome without susceptibility to opportunistic infections</td>
</tr>
<tr>
<td>1</td>
<td>Other specified white matter disorders due to vascular abnormality or ischemia</td>
</tr>
<tr>
<td>2</td>
<td>White matter disorder due to central nervous system vasculopathy</td>
</tr>
<tr>
<td>3</td>
<td>Susac syndrome</td>
</tr>
<tr>
<td>4</td>
<td>Small infarctions of cochlear, retinal and encephalic tissue</td>
</tr>
<tr>
<td>5</td>
<td>Retinopathy, encephalopathy, deafness associated microangiopathy</td>
</tr>
<tr>
<td>6</td>
<td>Retinocochleocerebral vasculopathy</td>
</tr>
<tr>
<td>7</td>
<td>SICRET - [Small infarctions of cochlear, retinal and encephalic tissue]</td>
</tr>
<tr>
<td>8</td>
<td>RED-M - [Retinopathy, encephalopathy, deafness associated microangiopathy]</td>
</tr>
<tr>
<td>9</td>
<td>Progressive subcortical ischemic demyelination</td>
</tr>
<tr>
<td>10</td>
<td>Certain specified syndrome of delayed hypoxic cerebral demyelination</td>
</tr>
<tr>
<td>11</td>
<td>Slender bone dysplasias</td>
</tr>
<tr>
<td>12</td>
<td>3M syndrome</td>
</tr>
<tr>
<td>13</td>
<td>Kenny-Caffey syndrome, autosomal dominant</td>
</tr>
<tr>
<td>14</td>
<td>Kenny-Caffey syndrome, autosomal recessive</td>
</tr>
<tr>
<td>15</td>
<td>Sanjad-Sakati syndrome</td>
</tr>
<tr>
<td>16</td>
<td>Hypoparathyroidism - short stature - intellectual deficit - seizures</td>
</tr>
<tr>
<td>17</td>
<td>Hypoparathyroidism - intellectual deficit - dysmorphism</td>
</tr>
<tr>
<td>18</td>
<td>Osteocraniostenosis</td>
</tr>
<tr>
<td>19</td>
<td>Seckel syndrome</td>
</tr>
<tr>
<td>20</td>
<td>Dwarfism - thin bones - multiple fractures</td>
</tr>
<tr>
<td>21</td>
<td>Microcephalic primordial dwarfism, Toriello type</td>
</tr>
<tr>
<td>22</td>
<td>Microcephalic osteodysplastic dysplasia, Saul-Wilson type</td>
</tr>
<tr>
<td>23</td>
<td>Hereditary methaemoglobinaemia</td>
</tr>
<tr>
<td>24</td>
<td>Hereditary congenital methaemoglobinaemia</td>
</tr>
<tr>
<td>25</td>
<td>Haemoglobin-M disease</td>
</tr>
<tr>
<td>26</td>
<td>hereditary m haemoglobinopathy</td>
</tr>
<tr>
<td>27</td>
<td>hereditary Methemoglobinemia</td>
</tr>
<tr>
<td>28</td>
<td>chronic familial methaemoglobin reductase deficiency</td>
</tr>
<tr>
<td>29</td>
<td>cytochrome b&lt;sub&gt;5&lt;/sub&gt; reductase deficiency</td>
</tr>
<tr>
<td>30</td>
<td>cytochrome b5 reductase deficiency</td>
</tr>
<tr>
<td>31</td>
<td>Congenital NADH - [nicotinamide adenine dinucleotide] methaemoglobin reductase deficiency</td>
</tr>
<tr>
<td>32</td>
<td>cytochrome-b reductase deficiency</td>
</tr>
<tr>
<td>33</td>
<td>cytochrome b&gt;5&lt; reductase deficiency</td>
</tr>
<tr>
<td>34</td>
<td>deficiency of NADH - [nicotinamide adenine dinucleotide] cytochrome b5 reductase</td>
</tr>
<tr>
<td>35</td>
<td>deficiency of lipoamide reductase (NADH)</td>
</tr>
<tr>
<td>36</td>
<td>enzymatic methaemoglobinaemia</td>
</tr>
<tr>
<td>37</td>
<td>haemoglobin M disease</td>
</tr>
<tr>
<td>38</td>
<td>DPNH - [diphosphopyridine nucleotide] methaemoglobin reductase deficiency</td>
</tr>
<tr>
<td>39</td>
<td>congenital DPNH-methaemoglobin-reductase deficiency</td>
</tr>
<tr>
<td>40</td>
<td>congenital infantile lactic acidosis due to lad deficiency</td>
</tr>
<tr>
<td>41</td>
<td>Hb M - [haemoglobin-m disease]</td>
</tr>
<tr>
<td>42</td>
<td>maple syrup urine disease with lactic acidosis</td>
</tr>
<tr>
<td>43</td>
<td>NADH - [nicotinamide adenine dinucleotide] diaphorase or reductase deficiency</td>
</tr>
<tr>
<td>44</td>
<td>maple syrup urine disease, type 3</td>
</tr>
<tr>
<td>45</td>
<td>Recessive hereditary methaemoglobinaemia</td>
</tr>
<tr>
<td>46</td>
<td>hereditary methaemoglobinemia due to globin chain mutation</td>
</tr>
<tr>
<td>47</td>
<td>Hb M methaemoglobinaemia</td>
</tr>
<tr>
<td>48</td>
<td>Recessive hereditary methaemoglobinaemia type 1</td>
</tr>
<tr>
<td>49</td>
<td>NADH - [nicotinamide adenine dinucleotide] cytochrome b5 reductase deficiency type 1</td>
</tr>
<tr>
<td>50</td>
<td>NADH - [nicotinamide adenine dinucleotide] diaphorase deficiency type 1</td>
</tr>
<tr>
<td>51</td>
<td>Partial NADH - [nicotinamide adenine dinucleotide] cytochrome b5 reductase deficiency</td>
</tr>
<tr>
<td>52</td>
<td>Partial NADH - [nicotinamide adenine dinucleotide] diaphorase deficiency</td>
</tr>
<tr>
<td>53</td>
<td>Recessive congenital methaemoglobinaemia type 1</td>
</tr>
<tr>
<td>54</td>
<td>Recessive hereditary methaemoglobinaemia type 2</td>
</tr>
<tr>
<td>55</td>
<td>NADH - [nicotinamide adenine dinucleotide] cytochrome b5reductase deficiency type 2</td>
</tr>
<tr>
<td>56</td>
<td>NADH - [nicotinamide adenine dinucleotide] diaphorase deficiency type 2</td>
</tr>
<tr>
<td>57</td>
<td>Total NADH - [nicotinamide adenine dinucleotide] cytochrome b5 reductase deficiency</td>
</tr>
<tr>
<td>58</td>
<td>Total NADH - [nicotinamide adenine dinucleotide] diaphorase deficiency</td>
</tr>
<tr>
<td>59</td>
<td>Recessive congenital methaemoglobinaemia type 2</td>
</tr>
<tr>
<td>60</td>
<td>Methaemoglobin reductase deficiency haemoglobinopathy</td>
</tr>
<tr>
<td>61</td>
<td>NADPH - [Methaemoglobin reductase deficiency haemoglobinopathy]</td>
</tr>
<tr>
<td>62</td>
<td>Irritable bowel syndrome, mixed type</td>
</tr>
<tr>
<td>63</td>
<td>IBS-M - [Irritable bowel syndrome, mixed type]</td>
</tr>
<tr>
<td>64</td>
<td>Alternating bowel habit</td>
</tr>
<tr>
<td>65</td>
<td>Female Genital Mutilation, unspecified</td>
</tr>
<tr>
<td>66</td>
<td>Female Genital Mutilation</td>
</tr>
<tr>
<td>67</td>
<td>FGM - [female genital mutilation]</td>
</tr>
<tr>
<td>68</td>
<td>female circumcision</td>
</tr>
<tr>
<td>69</td>
<td>female genital cutting</td>
</tr>
<tr>
<td>70</td>
<td>FGC - [female genital cutting]</td>
</tr>
<tr>
<td>71</td>
<td>FGM/C - [female genital mutilation/cutting]</td>
</tr>
<tr>
<td>72</td>
<td>FGC/M - [female genital cutting/mutilation]</td>
</tr>
<tr>
<td>73</td>
<td>Multi organ failure</td>
</tr>
<tr>
<td>74</td>
<td>MODS - [multi organ dysfunction syndrome]</td>
</tr>
<tr>
<td>75</td>
<td>multiple organ failure</td>
</tr>
<tr>
<td>76</td>
<td>multisystem organ failure</td>
</tr>
<tr>
<td>77</td>
<td>multiorgan failure syndrome</td>
</tr>
<tr>
<td>78</td>
<td>multi system failure</td>
</tr>
<tr>
<td>79</td>
<td>MSOF - [multi system organ failure]</td>
</tr>
<tr>
<td>80</td>
<td>multiple system failure</td>
</tr>
<tr>
<td>81</td>
<td>multiple organ system failure</td>
</tr>
<tr>
<td>82</td>
<td>multiple system organ failure</td>
</tr>
<tr>
<td>83</td>
<td>organ failure NOS</td>
</tr>
<tr>
<td>84</td>
<td>Other specified oromandibular-limb anomaly syndrome</td>
</tr>
<tr>
<td>85</td>
<td>Oromandibular-limb hypogenesis syndrome</td>
</tr>
<tr>
<td>86</td>
<td>Charlie M syndrome</td>
</tr>
<tr>
<td>87</td>
<td>Hypoglossia - hypodactyly</td>
</tr>
<tr>
<td>88</td>
<td>Glossopalatine ankylosis</td>
</tr>
<tr>
<td>89</td>
<td>Acute monoblastic or monocytic leukaemia</td>
</tr>
<tr>
<td>90</td>
<td>FAB M5</td>
</tr>
<tr>
<td>91</td>
<td>acute monocytic leukaemia</td>
</tr>
<tr>
<td>92</td>
<td>acute monocytic/monoblastic leukaemia</td>
</tr>
<tr>
<td>93</td>
<td>acute monoblastic/monocytic leukaemia without mention of remission</td>
</tr>
<tr>
<td>94</td>
<td>acute monocytoid leukaemia</td>
</tr>
<tr>
<td>95</td>
<td>monoblastic leukaemia</td>
</tr>
<tr>
<td>96</td>
<td>FAB type M5a</td>
</tr>
<tr>
<td>97</td>
<td>French-American-British (FAB) type M5a</td>
</tr>
<tr>
<td>98</td>
<td>Acute monoblastic or monocytic leukaemia in complete remission</td>
</tr>
<tr>
<td>99</td>
<td>AML M5a</td>
</tr>
<tr>
<td>100</td>
<td>AML M5b</td>
</tr>
<tr>
<td>101</td>
<td>Disorders of mitochondrial fatty acid oxidation</td>
</tr>
<tr>
<td>102</td>
<td>Acyl-CoA dehydrogenase deficiencies</td>
</tr>
<tr>
<td>103</td>
<td>Short chain acyl-CoA dehydrogenase deficiency</td>
</tr>
<tr>
<td>104</td>
<td>Butyryl-CoA dehydrogenase deficiency</td>
</tr>
<tr>
<td>105</td>
<td>SCAD - [Short chain acyl-CoA dehydrogenase] deficiency</td>
</tr>
<tr>
<td>106</td>
<td>Medium chain acyl-CoA dehydrogenase deficiency</td>
</tr>
<tr>
<td>107</td>
<td>MCAD - [Medium chain acyl-CoA dehydrogenase] deficiency</td>
</tr>
<tr>
<td>108</td>
<td>Long chain acyl-CoA dehydrogenase deficiency</td>
</tr>
<tr>
<td>109</td>
<td>LCAD - [Long chain acyl-CoA dehydrogenase] deficiency</td>
</tr>
<tr>
<td>110</td>
<td>Very long chain acyl-CoA dehydrogenase deficiency</td>
</tr>
<tr>
<td>111</td>
<td>VLCAD - [Very long chain acyl-CoA dehydrogenase] deficiency</td>
</tr>
<tr>
<td>112</td>
<td>Multiple acyl-CoA dehydrogenase deficiency</td>
</tr>
<tr>
<td>113</td>
<td>Electron transfer flavoprotein ubiquinone oxydoreductase deficiency</td>
</tr>
<tr>
<td>114</td>
<td>Electron transfer flavoprotein deficiency</td>
</tr>
<tr>
<td>115</td>
<td>Multiple FAD dehydrogenase deficiency</td>
</tr>
<tr>
<td>116</td>
<td>Glutaric acidaemia type 2</td>
</tr>
<tr>
<td>117</td>
<td>Glutaric aciduria type 2</td>
</tr>
<tr>
<td>118</td>
<td>Ethylmalonic-adipicaciduria</td>
</tr>
<tr>
<td>119</td>
<td>ETFDH - [Electron transfer flavoprotein ubiquinone oxydoreductase] deficiency</td>
</tr>
<tr>
<td>120</td>
<td>MADD - [Multiple acyl-CoA dehydrogenase deficiency]</td>
</tr>
<tr>
<td>121</td>
<td>Electron transfer flavoprotein deficiency, alpha chain</td>
</tr>
<tr>
<td>122</td>
<td>ETF - [Electron transfer flavoprotein] alpha chain deficiency</td>
</tr>
<tr>
<td>123</td>
<td>Electron transfer flavoprotein deficiency, beta chain</td>
</tr>
<tr>
<td>124</td>
<td>ETF - [Electron transfer flavoprotein] beta chain deficiency</td>
</tr>
<tr>
<td>125</td>
<td>Electron transfer flavoprotein-ubiquinone oxidoreductase deficiency</td>
</tr>
<tr>
<td>126</td>
<td>Electron transfer flavoprotein dehydrogenase deficiency</td>
</tr>
<tr>
<td>127</td>
<td>ETF-QO - [Electron transfer flavoprotein-ubiquinone oxidoreductase] deficiency</td>
</tr>
<tr>
<td>128</td>
<td>3-hydroxyacyl-CoA dehydrogenase deficiencies</td>
</tr>
<tr>
<td>129</td>
<td>3-hydroxyacyl-CoA dehydrogenase deficiency, not otherwise specified</td>
</tr>
<tr>
<td>130</td>
<td>Short chain 3-hydroxyacyl-CoA dehydrogenase deficiency</td>
</tr>
<tr>
<td>131</td>
<td>3-hydroxy-2-methylbutyryl-CoA dehydrogenase deficiency</td>
</tr>
<tr>
<td>132</td>
<td>2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency</td>
</tr>
<tr>
<td>133</td>
<td>17b-hydroxysteroid dehydrogenase deficiency type 10</td>
</tr>
<tr>
<td>134</td>
<td>SCHAD - [Short chain 3-hydroxyacyl-CoA dehydrogenase] deficiency</td>
</tr>
<tr>
<td>135</td>
<td>MHBD - [2-methyl-3-hydroxybutyryl-CoA dehydrogenase] deficiency</td>
</tr>
<tr>
<td>136</td>
<td>Medium or short chain 3-hydroxyacyl-CoA dehydrogenase deficiency</td>
</tr>
<tr>
<td>137</td>
<td>M/SCHAD - [Medium and short chain 3-hydroxyacyl-CoA dehydrogenase] deficiency</td>
</tr>
<tr>
<td>138</td>
<td>Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency</td>
</tr>
<tr>
<td>139</td>
<td>LCHAD - [Long chain 3-hydroxyacyl-CoA dehydrogenase] deficiency</td>
</tr>
<tr>
<td>140</td>
<td>Mitochondrial trifunctional protein deficiency</td>
</tr>
<tr>
<td>141</td>
<td>Mitochondrial trifunctional enzyme deficiency</td>
</tr>
<tr>
<td>142</td>
<td>Acute megakaryoblastic leukaemia</td>
</tr>
<tr>
<td>143</td>
<td>Acute myeloid leukaemia, M7</td>
</tr>
<tr>
<td>144</td>
<td>Acute megakaryocytic leukaemia</td>
</tr>
<tr>
<td>145</td>
<td>acute megakaryoblastic leukaemia, fab m7</td>
</tr>
<tr>
<td>146</td>
<td>fab m7</td>
</tr>
<tr>
<td>147</td>
<td>malignant megakaryocytosis</td>
</tr>
<tr>
<td>148</td>
<td>megakaryocytic myelosis</td>
</tr>
<tr>
<td>149</td>
<td>m7 - acute megakaryoblastic leukaemia</td>
</tr>
<tr>
<td>150</td>
<td>megakaryoblastic leukaemia</td>
</tr>
<tr>
<td>151</td>
<td>megakaryocytic leukaemia</td>
</tr>
<tr>
<td>152</td>
<td>thrombocytic leukaemia</td>
</tr>
<tr>
<td>153</td>
<td>acute megakaryoblastic leukaemia, NOS</td>
</tr>
<tr>
<td>154</td>
<td>acute megakaryoblastic leukaemia without mention of remission</td>
</tr>
<tr>
<td>155</td>
<td>Acute megakaryoblastic leukaemia in complete remission</td>
</tr>
<tr>
<td>156</td>
<td>Disorders of multiple glycosylation or other pathways</td>
</tr>
<tr>
<td>157</td>
<td>Dolichol-phosphate-mannose synthase 1 deficiency</td>
</tr>
<tr>
<td>158</td>
<td>GDP-Man: Dol-P-mannosyltransferase deficiency</td>
</tr>
<tr>
<td>159</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1E</td>
</tr>
<tr>
<td>160</td>
<td>Congenital disorder of glycosylation type 1E</td>
</tr>
<tr>
<td>161</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1E</td>
</tr>
<tr>
<td>162</td>
<td>Mannose-P-dolichol utilisation defect 1</td>
</tr>
<tr>
<td>163</td>
<td>Lec35 deficiency</td>
</tr>
<tr>
<td>164</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1F</td>
</tr>
<tr>
<td>165</td>
<td>Congenital disorder of glycosylation type 1F</td>
</tr>
<tr>
<td>166</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1F</td>
</tr>
<tr>
<td>167</td>
<td>Beta-1,4-galactosyltransferase deficiency</td>
</tr>
<tr>
<td>168</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2D</td>
</tr>
<tr>
<td>169</td>
<td>Congenital disorder of glycosylation type 2D</td>
</tr>
<tr>
<td>170</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2D</td>
</tr>
<tr>
<td>171</td>
<td>CMP-sialic acid transporter deficiency</td>
</tr>
<tr>
<td>172</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2F</td>
</tr>
<tr>
<td>173</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2F</td>
</tr>
<tr>
<td>174</td>
<td>Congenital disorder of glycosylation type 2F</td>
</tr>
<tr>
<td>175</td>
<td>Leukocyte adhesion deficiency type 2</td>
</tr>
<tr>
<td>176</td>
<td>Rambam-Hasharon syndrome</td>
</tr>
<tr>
<td>177</td>
<td>GDP-fucose transporter deficiency</td>
</tr>
<tr>
<td>178</td>
<td>LAD-II - [Leukocyte adhesion deficiency type 2]</td>
</tr>
<tr>
<td>179</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2C</td>
</tr>
<tr>
<td>180</td>
<td>Dolichol kinase deficiency</td>
</tr>
<tr>
<td>181</td>
<td>Hypotonia or ichthyosis due to dolichol phosphate deficiency</td>
</tr>
<tr>
<td>182</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1M</td>
</tr>
<tr>
<td>183</td>
<td>Congenital disorder of glycosylation type 1M</td>
</tr>
<tr>
<td>184</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1M</td>
</tr>
<tr>
<td>185</td>
<td>Conserved oligomeric Golgi complex deficiencies</td>
</tr>
<tr>
<td>186</td>
<td>Component of conserved oligomeric Golgi complex 1 deficiency</td>
</tr>
<tr>
<td>187</td>
<td>CDG syndrome type 2G</td>
</tr>
<tr>
<td>188</td>
<td>Component of conserved oligomeric Golgi complex 4 deficiency</td>
</tr>
<tr>
<td>189</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2J</td>
</tr>
<tr>
<td>190</td>
<td>Congenital disorder of glycosylation type 2J</td>
</tr>
<tr>
<td>191</td>
<td>Component of conserved oligomeric Golgi complex 5 deficiency</td>
</tr>
<tr>
<td>192</td>
<td>Component of conserved oligomeric Golgi complex 7 deficiency</td>
</tr>
<tr>
<td>193</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2E</td>
</tr>
<tr>
<td>194</td>
<td>Congenital disorder of glycosylation type 2E</td>
</tr>
<tr>
<td>195</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2E</td>
</tr>
<tr>
<td>196</td>
<td>Component of conserved oligomeric Golgi complex 8 deficiency</td>
</tr>
<tr>
<td>197</td>
<td>Congenital disorder of glycosylation type 2h</td>
</tr>
<tr>
<td>198</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2H</td>
</tr>
<tr>
<td>199</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2H</td>
</tr>
<tr>
<td>200</td>
<td>V-ATPase deficiencies</td>
</tr>
<tr>
<td>201</td>
<td>Extreme prematurity of newborn, unspecified</td>
</tr>
<tr>
<td>202</td>
<td>Extreme prematurity of newborn</td>
</tr>
<tr>
<td>203</td>
<td>very premature baby</td>
</tr>
<tr>
<td>204</td>
<td>extreme prematurity</td>
</tr>
<tr>
<td>205</td>
<td>severe prem NOS</td>
</tr>
<tr>
<td>206</td>
<td>extreme immature birth</td>
</tr>
<tr>
<td>207</td>
<td>Recessive limb-girdle muscular dystrophy</td>
</tr>
<tr>
<td>208</td>
<td>LGMD2 - [Limb-girdle muscular dystrophy] 2</td>
</tr>
<tr>
<td>209</td>
<td>Limb-girdle muscular dystrophy 2A, calpain-3 deficiency</td>
</tr>
<tr>
<td>210</td>
<td>Limb-girdle muscular dystrophy 2B, dysferlin deficiency</td>
</tr>
<tr>
<td>211</td>
<td>Limb-girdle muscular dystrophy 2C, gamma-sarcoglycan deficiency</td>
</tr>
<tr>
<td>212</td>
<td>Limb-girdle muscular dystrophy 2D, alpha-sarcoglycan deficiency</td>
</tr>
<tr>
<td>213</td>
<td>Limb-girdle muscular dystrophy 2E, beta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>214</td>
<td>Limb-girdle muscular dystrophy 2F, delta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>215</td>
<td>Limb-girdle muscular dystrophy 2G, telethonin gene mutation</td>
</tr>
<tr>
<td>216</td>
<td>Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation</td>
</tr>
<tr>
<td>217</td>
<td>LGMD 2H - [Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation]</td>
</tr>
<tr>
<td>218</td>
<td>Limb-girdle muscular dystrophy 2I, fukutin related protein gene mutation</td>
</tr>
<tr>
<td>219</td>
<td>FKRP - [fukutin related protein gene mutation]</td>
</tr>
<tr>
<td>220</td>
<td>LGMD 2I - [Limb-girdle muscular dystrophy 2I]</td>
</tr>
<tr>
<td>221</td>
<td>Limb-girdle muscular dystrophy 2J, Titin gene mutation</td>
</tr>
<tr>
<td>222</td>
<td>LGMD 2J - [Limb-girdle muscular dystrophy 2J, Titin gene mutation]</td>
</tr>
<tr>
<td>223</td>
<td>Limb-girdle muscular dystrophy 2K, protein-O-mannosyltransferase 1 transferase</td>
</tr>
<tr>
<td>224</td>
<td>POMT1 - [protein-O-mannosyltransferase 1 transferase]</td>
</tr>
<tr>
<td>225</td>
<td>LGMD 2K - [Limb-girdle muscular dystrophy 2K]</td>
</tr>
<tr>
<td>226</td>
<td>Limb-girdle muscular dystrophy 2L, AN05 gene mutation</td>
</tr>
<tr>
<td>227</td>
<td>LGMD 2L - [Limb-girdle muscular dystrophy 2L]</td>
</tr>
<tr>
<td>228</td>
<td>Limb-girdle muscular dystrophy 2M, POMGnT1 gene mutation</td>
</tr>
<tr>
<td>229</td>
<td>LGMD2M - [limb-girdle muscular dystrophy 2M]</td>
</tr>
<tr>
<td>230</td>
<td>Limb-girdle muscular dystrophy 2N, POMT2 gene mutation</td>
</tr>
<tr>
<td>231</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C2)</td>
</tr>
<tr>
<td>232</td>
<td>MDDGC2</td>
</tr>
<tr>
<td>233</td>
<td>LGMD2N - limb-girdle muscular dystrophy 2N]</td>
</tr>
<tr>
<td>234</td>
<td>Limb-girdle muscular dystrophy 2O, POMGNT1 gene mutation</td>
</tr>
<tr>
<td>235</td>
<td>LGMD2O - [limb-girdle muscular dystrophy 2O]</td>
</tr>
<tr>
<td>236</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C3)</td>
</tr>
<tr>
<td>237</td>
<td>MDDGC3</td>
</tr>
<tr>
<td>238</td>
<td>Limb-girdle muscular dystrophy 2Q, plectin deficiency</td>
</tr>
<tr>
<td>239</td>
<td>LGMD2Q - [limb-girdle muscular dystrophy 2Q]</td>
</tr>
<tr>
<td>240</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy C7</td>
</tr>
<tr>
<td>241</td>
<td>MDDGC7</td>
</tr>
<tr>
<td>242</td>
<td>Other specified congenital disorders of glycosylation and protein modification</td>
</tr>
<tr>
<td>243</td>
<td>Disorders of glycosphingolipid or glycosylphosphatidylinositol anchor glycosylation</td>
</tr>
<tr>
<td>244</td>
<td>Lactosylceramide alpha-2,3-sialyltransferase deficiency</td>
</tr>
<tr>
<td>245</td>
<td>Infantile-onset symptomatic epilepsy syndrome - developmental stagnation - blindness</td>
</tr>
<tr>
<td>246</td>
<td>GM3 synthase deficiency</td>
</tr>
<tr>
<td>247</td>
<td>Amish infantile epilepsy</td>
</tr>
<tr>
<td>248</td>
<td>Phosphatidylinositolglycan, class M deficiency</td>
</tr>
<tr>
<td>249</td>
<td>PIGM deficiency</td>
</tr>
<tr>
<td>250</td>
<td>Disorders of protein ubiquitinylation</td>
</tr>
<tr>
<td>251</td>
<td>Other specified disorders of protein modification</td>
</tr>
<tr>
<td>252</td>
<td>Von Willebrand disease</td>
</tr>
<tr>
<td>253</td>
<td>Factor VIII deficiency with vascular defect</td>
</tr>
<tr>
<td>254</td>
<td>Vascular haemophilia</td>
</tr>
<tr>
<td>255</td>
<td>Willebrand Jurgen thrombopathy</td>
</tr>
<tr>
<td>256</td>
<td>pseudohaemophilia</td>
</tr>
<tr>
<td>257</td>
<td>Minot-von Willebrand-Jurgen disease</td>
</tr>
<tr>
<td>258</td>
<td>Angiohaemophilia</td>
</tr>
<tr>
<td>259</td>
<td>angiohaemophilia A</td>
</tr>
<tr>
<td>260</td>
<td>angiohaemophilia B</td>
</tr>
<tr>
<td>261</td>
<td>Von Willebrand disease type 1</td>
</tr>
<tr>
<td>262</td>
<td>Von Willebrand disease type 2</td>
</tr>
<tr>
<td>263</td>
<td>Von Willebrand disease type 2A</td>
</tr>
<tr>
<td>264</td>
<td>Von Willebrand disease type 2B</td>
</tr>
<tr>
<td>265</td>
<td>Von Willebrand disease type 2M</td>
</tr>
<tr>
<td>266</td>
<td>Von Willebrand disease type 2N</td>
</tr>
<tr>
<td>267</td>
<td>Von Willebrand disease type 3</td>
</tr>
<tr>
<td>268</td>
<td>Immunodeficiencies with isotype or light chain deficiencies with normal number of B cells</td>
</tr>
<tr>
<td>269</td>
<td>Recurrent infections associated with immunoglobulin isotypes deficiency</td>
</tr>
<tr>
<td>270</td>
<td>Recurrent infections associated with immunoglobulin isotypes</td>
</tr>
<tr>
<td>271</td>
<td>Deficiency of immunoglobulin A with immunoglobulin G subclasses deficiency</td>
</tr>
<tr>
<td>272</td>
<td>Deficiency of IgA with IgG subclasses deficiency</td>
</tr>
<tr>
<td>273</td>
<td>Immunoglobulin heavy chain deficiency</td>
</tr>
<tr>
<td>274</td>
<td>Deficiency of IgG and/or IgA subclasses and/or IgE</td>
</tr>
<tr>
<td>275</td>
<td>K chain deficiency</td>
</tr>
<tr>
<td>276</td>
<td>Selective deficiency of immunoglobulin A</td>
</tr>
<tr>
<td>277</td>
<td>Selective deficiency of IgA</td>
</tr>
<tr>
<td>278</td>
<td>selective immunodeficiency of immunoglobulin A (IgA)</td>
</tr>
<tr>
<td>279</td>
<td>Selective deficiency of immunoglobulin G subclasses</td>
</tr>
<tr>
<td>280</td>
<td>immunoglobin g subclass deficiency</td>
</tr>
<tr>
<td>281</td>
<td>immunoglobulin g subclass deficiency</td>
</tr>
<tr>
<td>282</td>
<td>selective deficiency of IgG</td>
</tr>
<tr>
<td>283</td>
<td>selective immunoglobulin g deficiency</td>
</tr>
<tr>
<td>284</td>
<td>Selective deficiency of IgG subclasses</td>
</tr>
<tr>
<td>285</td>
<td>IgG subclass deficiency</td>
</tr>
<tr>
<td>286</td>
<td>selective IgG immunodeficiency</td>
</tr>
<tr>
<td>287</td>
<td>Selective deficiency of immunoglobulin M</td>
</tr>
<tr>
<td>288</td>
<td>Selective deficiency of IgM</td>
</tr>
<tr>
<td>289</td>
<td>selective IgM immunodeficiency</td>
</tr>
<tr>
<td>290</td>
<td>selective immunodeficiency of immunoglobulin M (IgM)</td>
</tr>
<tr>
<td>291</td>
<td>Disorders of protein N-glycosylation</td>
</tr>
<tr>
<td>292</td>
<td>Phosphomannomutase 2 deficiency</td>
</tr>
<tr>
<td>293</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1A</td>
</tr>
<tr>
<td>294</td>
<td>Congenital disorder of glycosylation type 1A</td>
</tr>
<tr>
<td>295</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1A</td>
</tr>
<tr>
<td>296</td>
<td>Phosphomannose isomerase deficiency</td>
</tr>
<tr>
<td>297</td>
<td>Saguenay-Lac-Saint-Jean syndrome</td>
</tr>
<tr>
<td>298</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1B</td>
</tr>
<tr>
<td>299</td>
<td>Congenital disorder of glycosylation type 1B</td>
</tr>
<tr>
<td>300</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1B</td>
</tr>
<tr>
<td>301</td>
<td>SLSJ - [Saguenay-Lac-Saint-Jean] syndrome</td>
</tr>
<tr>
<td>302</td>
<td>Glucosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>303</td>
<td>Dol-P-Glc: Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>304</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1C</td>
</tr>
<tr>
<td>305</td>
<td>Congenital disorder of glycosylation type 1C</td>
</tr>
<tr>
<td>306</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1C</td>
</tr>
<tr>
<td>307</td>
<td>Mannosyltransferase 6 deficiency</td>
</tr>
<tr>
<td>308</td>
<td>Dol-P-Man: Man5-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>309</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1D</td>
</tr>
<tr>
<td>310</td>
<td>Congenital disorder of glycosylation type 1D</td>
</tr>
<tr>
<td>311</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1D</td>
</tr>
<tr>
<td>312</td>
<td>Mannosyltransferase 8 deficiency</td>
</tr>
<tr>
<td>313</td>
<td>Dol-P-Man: Man7-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>314</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1G</td>
</tr>
<tr>
<td>315</td>
<td>Congenital disorder of glycosylation type 1G</td>
</tr>
<tr>
<td>316</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1G</td>
</tr>
<tr>
<td>317</td>
<td>Glucosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>318</td>
<td>Dol-P-Glc: Glc1-Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>319</td>
<td>Carbohydrate deficient glycoprotein syndrome 1H</td>
</tr>
<tr>
<td>320</td>
<td>Congenital disorder of glycosylation type 1H</td>
</tr>
<tr>
<td>321</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1H</td>
</tr>
<tr>
<td>322</td>
<td>Mannosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>323</td>
<td>Dol-P-Man: Man1-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>324</td>
<td>Carbohydrate deficient glycoprotein syndrome 1I</td>
</tr>
<tr>
<td>325</td>
<td>Congenital disorder of glycosylation 1I</td>
</tr>
<tr>
<td>326</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1I</td>
</tr>
<tr>
<td>327</td>
<td>Dolichyl-phosphate N-acetylgalactosamine phosphotransferase deficiency</td>
</tr>
<tr>
<td>328</td>
<td>UDP-GlcNAc: Dol-P-GlcNac-P transferase deficiency</td>
</tr>
<tr>
<td>329</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1J</td>
</tr>
<tr>
<td>330</td>
<td>Congenital disorder of glycosylation type 1J</td>
</tr>
<tr>
<td>331</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1J</td>
</tr>
<tr>
<td>332</td>
<td>Mannosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>333</td>
<td>Dol-P-Man: GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>334</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1K</td>
</tr>
<tr>
<td>335</td>
<td>Congenital disorder of glycosylation type 1K</td>
</tr>
<tr>
<td>336</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1K</td>
</tr>
<tr>
<td>337</td>
<td>Mannosyltransferase 7-9 deficiency</td>
</tr>
<tr>
<td>338</td>
<td>Congenital disorder of glycosylation type 1L</td>
</tr>
<tr>
<td>339</td>
<td>Dol-P-Man: Man6 and Man8-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>340</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1L</td>
</tr>
<tr>
<td>341</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1L</td>
</tr>
<tr>
<td>342</td>
<td>M5-DLO flippase deficiency</td>
</tr>
<tr>
<td>343</td>
<td>Man5GlcNAc2-PP-Dol flippase deficiency</td>
</tr>
<tr>
<td>344</td>
<td>RTF1-CDG</td>
</tr>
<tr>
<td>345</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1N</td>
</tr>
<tr>
<td>346</td>
<td>N-acetylglucosaminyltransferase deficiency</td>
</tr>
<tr>
<td>347</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2A</td>
</tr>
<tr>
<td>348</td>
<td>Congenital disorder of glycosylation type 2A</td>
</tr>
<tr>
<td>349</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2A</td>
</tr>
<tr>
<td>350</td>
<td>Glucosidase 1 deficiency</td>
</tr>
<tr>
<td>351</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2B</td>
</tr>
<tr>
<td>352</td>
<td>Congenital disorder of glycosylation type 2B</td>
</tr>
<tr>
<td>353</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2B</td>
</tr>
<tr>
<td>354</td>
<td>TUSC3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>355</td>
<td>TUSC3-CDG</td>
</tr>
<tr>
<td>356</td>
<td>SRD5A3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>357</td>
<td>SRD5A3-CDG</td>
</tr>
<tr>
<td>358</td>
<td>Congenital disorder of glycosylation due to steroid 5-alpha-reductase type 3 deficiency</td>
</tr>
<tr>
<td>359</td>
<td>Intellectual deficit - cataract - coloboma - kyphosis</td>
</tr>
<tr>
<td>360</td>
<td>Kahrizi syndrome</td>
</tr>
<tr>
<td>361</td>
<td>Intellectual deficit, Kahrizi type</td>
</tr>
<tr>
<td>362</td>
<td>DPM3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>363</td>
<td>Congenital disorder of glycosylation type 1O</td>
</tr>
<tr>
<td>364</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1O</td>
</tr>
<tr>
<td>365</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1O</td>
</tr>
<tr>
<td>366</td>
<td>ALG11 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>367</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1P</td>
</tr>
<tr>
<td>368</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1P</td>
</tr>
<tr>
<td>369</td>
<td>Congenital disorder of glycosylation type 1P</td>
</tr>
<tr>
<td>370</td>
<td>Phosphoglucomutase-1 deficiency</td>
</tr>
<tr>
<td>371</td>
<td>PGM1-CDG - [Phosphoglucomutase-1 deficiency]</td>
</tr>
<tr>
<td>372</td>
<td>Congenital disorder of glycosylation type 1t</td>
</tr>
<tr>
<td>373</td>
<td>Dialysis-associated amyloidosis</td>
</tr>
<tr>
<td>374</td>
<td>beta-2-microglobulin amyloidosis</td>
</tr>
<tr>
<td>375</td>
<td>Haemodialysis-associated amyloidosis</td>
</tr>
<tr>
<td>376</td>
<td>Dialysis-related amyloidosis</td>
</tr>
<tr>
<td>377</td>
<td>ABeta2M amyloidosis</td>
</tr>
<tr>
<td>378</td>
<td>Wild type ABeta2M amyloidosis</td>
</tr>
<tr>
<td>379</td>
<td>Variant ABeta2M amyloidosis</td>
</tr>
<tr>
<td>380</td>
<td>Hereditary ATTR amyloidosis</td>
</tr>
<tr>
<td>381</td>
<td>familial neuropathic amyloidosis</td>
</tr>
<tr>
<td>382</td>
<td>familial polyneuropathic amyloidosis</td>
</tr>
<tr>
<td>383</td>
<td>AF type amyloidosis</td>
</tr>
<tr>
<td>384</td>
<td>Neuropathic heredofamilial amyloidosis</td>
</tr>
<tr>
<td>385</td>
<td>Transthyretin-related amyloidosis</td>
</tr>
<tr>
<td>386</td>
<td>Familial amyloid polyneuropathy</td>
</tr>
<tr>
<td>387</td>
<td>Portuguese amyloidosis</td>
</tr>
<tr>
<td>388</td>
<td>Corino de Andrade paramyloidosis</td>
</tr>
<tr>
<td>389</td>
<td>FAP - [familial amyloid polyneuropathy]</td>
</tr>
<tr>
<td>390</td>
<td>Andrade type amyloid polyneuropathy</td>
</tr>
<tr>
<td>391</td>
<td>Andrade syndrome</td>
</tr>
<tr>
<td>392</td>
<td>familial amyloid neuropathy, Andrade type</td>
</tr>
<tr>
<td>393</td>
<td>familial amyloid neuropathy, Portuguese type</td>
</tr>
<tr>
<td>394</td>
<td>hereditary amyloid polyneuropathy Portuguese type</td>
</tr>
<tr>
<td>395</td>
<td>hereditary neuropathic amyloidosis Type 1</td>
</tr>
<tr>
<td>396</td>
<td>Japanese type amyloid polyneuropathy</td>
</tr>
<tr>
<td>397</td>
<td>amyloid polyneuropathy type 1</td>
</tr>
<tr>
<td>398</td>
<td>amyloid polyneuropathy</td>
</tr>
<tr>
<td>399</td>
<td>amyloidosis Type 1</td>
</tr>
<tr>
<td>400</td>
<td>polyneuropathy in amyloidosis</td>
</tr>
<tr>
<td>401</td>
<td>Portuguese amyloid polyneuropathy</td>
</tr>
<tr>
<td>402</td>
<td>Portuguese polyneuritic amyloidosis</td>
</tr>
<tr>
<td>403</td>
<td>Portuguese type familial amyloid neuropathy</td>
</tr>
<tr>
<td>404</td>
<td>Swiss type amyloid polyneuropathy</td>
</tr>
<tr>
<td>405</td>
<td>Swedish type amyloid polyneuropathy</td>
</tr>
<tr>
<td>406</td>
<td>type I familial amyloid polyneuropathy</td>
</tr>
<tr>
<td>407</td>
<td>Wohlwill-Corino Andrade syndrome</td>
</tr>
<tr>
<td>408</td>
<td>type II familial amyloid polyneuropathy</td>
</tr>
<tr>
<td>409</td>
<td>Paramyloidosis</td>
</tr>
<tr>
<td>410</td>
<td>familial amyloid polyneuropathy, 30 met-for-val</td>
</tr>
<tr>
<td>411</td>
<td>Portuguese type amyloid polyneuropathy</td>
</tr>
<tr>
<td>412</td>
<td>Cerebral neuropathic heredofamilial amyloidosis angiopathy</td>
</tr>
<tr>
<td>413</td>
<td>Glomerular disorders in neuropathic heredofamilial amyloidosis</td>
</tr>
<tr>
<td>414</td>
<td>Transthyretin-related familial amyloid cardiomyopathy</td>
</tr>
<tr>
<td>415</td>
<td>Cardiac neuropathic heredofamilial amyloidosis</td>
</tr>
<tr>
<td>416</td>
<td>ATTRV30M amyloidosis</td>
</tr>
<tr>
<td>417</td>
<td>ATTRV122I amyloidosis</td>
</tr>
<tr>
<td>418</td>
<td>Chronic kidney disease, stage 5</td>
</tr>
<tr>
<td>419</td>
<td>chronic renal failure, stage 5</td>
</tr>
<tr>
<td>420</td>
<td>CKD - [chronic kidney disease] stage 5</td>
</tr>
<tr>
<td>421</td>
<td>end stage kidney failure</td>
</tr>
<tr>
<td>422</td>
<td>end stage renal failure</td>
</tr>
<tr>
<td>423</td>
<td>end stage kidney disease</td>
</tr>
<tr>
<td>424</td>
<td>end stage renal disease</td>
</tr>
<tr>
<td>425</td>
<td>end stage chronic renal failure</td>
</tr>
<tr>
<td>426</td>
<td>ESRF - [end stage renal failure]</td>
</tr>
<tr>
<td>427</td>
<td>ESRD - [end stage renal diseases]</td>
</tr>
<tr>
<td>428</td>
<td>eGFR - [estimated glomerular filtration rate] &lt; 15 ml/min/1.73m²</td>
</tr>
<tr>
<td>429</td>
<td>chronic renal disease, stage V</td>
</tr>
<tr>
<td>430</td>
<td>renal disease, stage 5</td>
</tr>
<tr>
<td>431</td>
<td>renal disease, stage V</td>
</tr>
<tr>
<td>432</td>
<td>kidney disease, stage 5</td>
</tr>
<tr>
<td>433</td>
<td>kidney disease, stage V</td>
</tr>
<tr>
<td>434</td>
<td>Chronic kidney disease, stage 5, not on dialysis</td>
</tr>
<tr>
<td>435</td>
<td>chronic renal failure, stage 5 not on dialysis</td>
</tr>
<tr>
<td>436</td>
<td>CKD- [chronic kidney disease] stage 5 not on dialysis</td>
</tr>
<tr>
<td>437</td>
<td>Chronic kidney disease, stage 5, on dialysis</td>
</tr>
<tr>
<td>438</td>
<td>chronic renal failure, stage 5 on dialysis</td>
</tr>
<tr>
<td>439</td>
<td>CKD - [chronic kidney disease] stage 5 on dialysis</td>
</tr>
<tr>
<td>440</td>
<td>end stage renal failure of dialysis</td>
</tr>
<tr>
<td>441</td>
<td>end stage renal failure on haemodialysis</td>
</tr>
<tr>
<td>442</td>
<td>Renal retinitis in chronic kidney disease, stage 5</td>
</tr>
<tr>
<td>443</td>
<td>Charcot-Marie-Tooth disease 2 axonal</td>
</tr>
<tr>
<td>444</td>
<td>Charcot-Marie-Tooth disease 2 autosomal dominant</td>
</tr>
<tr>
<td>445</td>
<td>Recessive axonal Charcot-Marie-Tooth disease with acrodystrophy</td>
</tr>
<tr>
<td>446</td>
<td>Charcot-Marie-Tooth disease type 2A1</td>
</tr>
<tr>
<td>447</td>
<td>Charcot-Marie-Tooth disease type 2A2</td>
</tr>
<tr>
<td>448</td>
<td>Charcot-Marie-Tooth disease type 2B</td>
</tr>
<tr>
<td>449</td>
<td>Charcot-Marie-Tooth disease type 2C</td>
</tr>
<tr>
<td>450</td>
<td>Charcot-Marie-Tooth disease type 2D</td>
</tr>
<tr>
<td>451</td>
<td>Charcot-Marie-Tooth disease type 2E</td>
</tr>
<tr>
<td>452</td>
<td>Charcot-Marie-Tooth disease type 2F</td>
</tr>
<tr>
<td>453</td>
<td>Charcot-Marie-Tooth disease type 2G</td>
</tr>
<tr>
<td>454</td>
<td>Charcot-Marie-Tooth disease type 2I</td>
</tr>
<tr>
<td>455</td>
<td>Charcot-Marie-Tooth disease type 2J</td>
</tr>
<tr>
<td>456</td>
<td>Charcot-Marie-Tooth disease type 2K</td>
</tr>
<tr>
<td>457</td>
<td>Charcot-Marie-Tooth disease type 2L</td>
</tr>
<tr>
<td>458</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2M</td>
</tr>
<tr>
<td>459</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2N</td>
</tr>
<tr>
<td>460</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2O</td>
</tr>
<tr>
<td>461</td>
<td>Charcot-Marie-Tooth disease 2 autosomal recessive</td>
</tr>
<tr>
<td>462</td>
<td>Charcot-Marie-Tooth disease type 2B1</td>
</tr>
<tr>
<td>463</td>
<td>Charcot-Marie-Tooth disease type 2B2</td>
</tr>
<tr>
<td>464</td>
<td>Charcot-Marie-Tooth disease type 2B5</td>
</tr>
<tr>
<td>465</td>
<td>Charcot-Marie-Tooth disease type 2H</td>
</tr>
<tr>
<td>466</td>
<td>Autosomal recessive Charcot-Marie-Tooth disease with hoarseness</td>
</tr>
<tr>
<td>467</td>
<td>Hereditary motor and sensory neuropathy type 6</td>
</tr>
<tr>
<td>468</td>
<td>Charcot-Marie-Tooth type 6</td>
</tr>
<tr>
<td>469</td>
<td>HMSN6 - [Hereditary motor and sensory neuropathy type 6]</td>
</tr>
<tr>
<td>470</td>
<td>CMT6 - [Charcot-Marie-Tooth type 6]</td>
</tr>
<tr>
<td>471</td>
<td>Chronic kidney disease, stage 4</td>
</tr>
<tr>
<td>472</td>
<td>severe decrease in GFR</td>
</tr>
<tr>
<td>473</td>
<td>chronic renal failure, stage 4</td>
</tr>
<tr>
<td>474</td>
<td>CKD - [chronic kidney disease] stage 4</td>
</tr>
<tr>
<td>475</td>
<td>eGFR - [estimated glomerular filtration rate] 15-29 ml/min/1.73m²</td>
</tr>
<tr>
<td>476</td>
<td>Chronic kidney disease, stage 3b</td>
</tr>
<tr>
<td>477</td>
<td>chronic renal failure, stage 3b</td>
</tr>
<tr>
<td>478</td>
<td>CKD - [chronic kidney disease] stage 3b</td>
</tr>
<tr>
<td>479</td>
<td>eGFR - [estimated glomerular filtration rate] 30-44 ml/min/1.73m²</td>
</tr>
<tr>
<td>480</td>
<td>Chronic kidney disease, stage 1</td>
</tr>
<tr>
<td>481</td>
<td>chronic renal failure, stage 1</td>
</tr>
<tr>
<td>482</td>
<td>CKD - [chronic kidney disease] stage 1</td>
</tr>
<tr>
<td>483</td>
<td>normal or increased eGFR (&gt;90 ml/min/1.73m²)</td>
</tr>
<tr>
<td>484</td>
<td>Chronic kidney disease, stage 2</td>
</tr>
<tr>
<td>485</td>
<td>kidney damage and mild decrease in GFR</td>
</tr>
<tr>
<td>486</td>
<td>chronic renal failure, stage 2</td>
</tr>
<tr>
<td>487</td>
<td>CKD - [chronic kidney disease] stage 2</td>
</tr>
<tr>
<td>488</td>
<td>kidney damage and mild decrease in eGFR - [estimated glomerular filtration rate]</td>
</tr>
<tr>
<td>489</td>
<td>eGFR - [estimated glomerular filtration rate] 60-89 ml/min/1.73m²</td>
</tr>
<tr>
<td>490</td>
<td>Chronic kidney disease, stage 3a</td>
</tr>
<tr>
<td>491</td>
<td>chronic renal failure, stage 3a</td>
</tr>
<tr>
<td>492</td>
<td>CKD - [chronic kidney disease] stage 3a</td>
</tr>
<tr>
<td>493</td>
<td>chronic kidney disease stage 3 NOS</td>
</tr>
<tr>
<td>494</td>
<td>eGFR - [estimated glomerular filtration rate] 45-59 ml/min/1.73m²</td>
</tr>
<tr>
<td>495</td>
<td>Albuminuria, Grade A3</td>
</tr>
<tr>
<td>496</td>
<td>albuminuria &gt;30 mg/mmol creatinine</td>
</tr>
<tr>
<td>497</td>
<td>macroalbuminuria</td>
</tr>
<tr>
<td>498</td>
<td>overt albuminuria</td>
</tr>
<tr>
<td>499</td>
<td>overt nephropathy</td>
</tr>
<tr>
<td>500</td>
<td>overt proteinuria</td>
</tr>
<tr>
<td>501</td>
<td>Albuminuria, Grade A2</td>
</tr>
<tr>
<td>502</td>
<td>microalbuminuria</td>
</tr>
<tr>
<td>503</td>
<td>incipient nephropathy</td>
</tr>
<tr>
<td>504</td>
<td>mild to moderate albuminuria</td>
</tr>
<tr>
<td>505</td>
<td>albuminuria 3-30 mg/mmol creatinine</td>
</tr>
<tr>
<td>506</td>
<td>Obesity hypoventilation syndrome</td>
</tr>
<tr>
<td>507</td>
<td>Pickwickian syndrome</td>
</tr>
<tr>
<td>508</td>
<td>cardiopulmonary obesity syndrome</td>
</tr>
<tr>
<td>509</td>
<td>alveolar hypoventilation syndrome</td>
</tr>
<tr>
<td>510</td>
<td>alveolus hypoventilation syndrome</td>
</tr>
<tr>
<td>511</td>
<td>OHS - [obesity hypoventilation syndrome]</td>
</tr>
<tr>
<td>512</td>
<td>Obesity hypoventilation syndrome with BMI 30.00-34.99 kg/m²</td>
</tr>
<tr>
<td>513</td>
<td>Obesity with alveolar hypoventilation with Body-Mass-Index of 30 kg/m² but less than 35 kg/m²</td>
</tr>
<tr>
<td>514</td>
<td>Obesity with alveolar hypoventilation with Body-Mass-Index of 30 but less than 35</td>
</tr>
<tr>
<td>515</td>
<td>Obesity hypoventilation syndrome with BMI 35.00-39.99 kg/m²</td>
</tr>
<tr>
<td>516</td>
<td>Obesity with alveolar hypoventilation with Body-Mass-Index of 35 but less than 40</td>
</tr>
<tr>
<td>517</td>
<td>Obesity with alveolar hypoventilation with Body-Mass-Index of 35 kg/m² but less than 40 kg/m²</td>
</tr>
<tr>
<td>518</td>
<td>Obesity hypoventilation syndrome with BMI greater than or equal to 40.00 kg/m²</td>
</tr>
<tr>
<td>519</td>
<td>Extreme obesity with alveolar hypoventilation with Body-Mass-Index of 40 and more</td>
</tr>
<tr>
<td>520</td>
<td>Extreme obesity with alveolar hypoventilation with Body-Mass-Index of 40 kg/m² and more</td>
</tr>
<tr>
<td>521</td>
<td>Extreme obesity with alveolar hypoventilation with BMI unspecified</td>
</tr>
<tr>
<td>522</td>
<td>Extreme obesity with alveolar hypoventilation with Body-Mass-Index unspecified</td>
</tr>
<tr>
<td>523</td>
<td>Other specified elevated blood glucose level</td>
</tr>
<tr>
<td>524</td>
<td>Blood glucose between 8.0 - 11.9 mmol/L pre-meal or fasting</td>
</tr>
<tr>
<td>525</td>
<td>Blood glucose between 12.0 - 13.9 mmol/L pre-meal or fasting</td>
</tr>
<tr>
<td>526</td>
<td>Blood glucose greater than or equal to 14.0 mmol/L pre-meal or fasting</td>
</tr>
<tr>
<td>527</td>
<td>Blood glucose between 12.0 - 13.9 mmol/L post-meal or not otherwise specified</td>
</tr>
<tr>
<td>528</td>
<td>Blood glucose greater than or equal to 14.0 mmol/L post-meal or not otherwise specified</td>
</tr>
<tr>
<td>529</td>
<td>Paraneoplastic or autoimmune disorders of the peripheral or autonomic nervous system</td>
</tr>
<tr>
<td>530</td>
<td>Paraneoplastic sensory ganglionopathy</td>
</tr>
<tr>
<td>531</td>
<td>Paraneoplastic sensory neuronopathy</td>
</tr>
<tr>
<td>532</td>
<td>Paraneoplastic sensory ganglionopathy, neural autoantibody negative</td>
</tr>
<tr>
<td>533</td>
<td>Autoimmune sensory ganglionopathy</td>
</tr>
<tr>
<td>534</td>
<td>Autoimmune sensory ganglionopathy, neural autoantibody negative</td>
</tr>
<tr>
<td>535</td>
<td>Autoimmune sensory ganglionopathy, neural autoantibody positive</td>
</tr>
<tr>
<td>536</td>
<td>Autoimmune neuritis</td>
</tr>
<tr>
<td>537</td>
<td>Autoimmune brachial neuritis</td>
</tr>
<tr>
<td>538</td>
<td>Autoimmune radiculoplexoneuropathy</td>
</tr>
<tr>
<td>539</td>
<td>Radiculoplexoneuropathy</td>
</tr>
<tr>
<td>540</td>
<td>Nondiabetic radiculoplexoneuropathy</td>
</tr>
<tr>
<td>541</td>
<td>Chronic immune demyelinating polyradiculoneuropathy</td>
</tr>
<tr>
<td>542</td>
<td>Brachial variant of chronic immune demyelinating polyradiculoneuropathy</td>
</tr>
<tr>
<td>543</td>
<td>Post surgical plexitis</td>
</tr>
<tr>
<td>544</td>
<td>Postsurgical plexitis</td>
</tr>
<tr>
<td>545</td>
<td>Post surgical brachial plexitis</td>
</tr>
<tr>
<td>546</td>
<td>Post surgical lumbosacral plexitis</td>
</tr>
<tr>
<td>547</td>
<td>Paraneoplastic sensorimotor neuropathy</td>
</tr>
<tr>
<td>548</td>
<td>Paraneoplastic sensorimotor neuropathy, neural autoantibody negative</td>
</tr>
<tr>
<td>549</td>
<td>Paraneoplastic sensorimotor neuropathy, neural autoantibody positive</td>
</tr>
<tr>
<td>550</td>
<td>Vasculitis or vasculitic neuropathy</td>
</tr>
<tr>
<td>551</td>
<td>Systemic multiple mononeuropathy vasculitis</td>
</tr>
<tr>
<td>552</td>
<td>Multiple mononeuropathy vasculitis with mixed cryoglobulinemia</td>
</tr>
<tr>
<td>553</td>
<td>Multiple mononeuropathy vasculitis with perinuclear antineutrophil cytoplasmic antibody-associated vasculitis</td>
</tr>
<tr>
<td>554</td>
<td>Multiple mononeuropathy vasculitis with Churg-Strauss syndrome</td>
</tr>
<tr>
<td>555</td>
<td>Multiple mononeuropathy vasculitis with Wegener granulomatosis</td>
</tr>
<tr>
<td>556</td>
<td>Non-systemic multiple mononeuropathy vasculitis</td>
</tr>
<tr>
<td>557</td>
<td>Nerve restricted multiple mononeuropathy vasculitis</td>
</tr>
<tr>
<td>558</td>
<td>Autoimmune sensorimotor neuropathy</td>
</tr>
<tr>
<td>559</td>
<td>Autoimmune sensorimotor neuropathy, neural autoantibody negative</td>
</tr>
<tr>
<td>560</td>
<td>Autoimmune sensorimotor neuropathy, neural autoantibody positive</td>
</tr>
<tr>
<td>561</td>
<td>Autoimmune autonomic neuropathy</td>
</tr>
<tr>
<td>562</td>
<td>autoimmune autonomic ganglionopathy</td>
</tr>
<tr>
<td>563</td>
<td>autoimmune pure autonomic failure</td>
</tr>
<tr>
<td>564</td>
<td>autoimmune dysautonomia</td>
</tr>
<tr>
<td>565</td>
<td>Pandysautonomia</td>
</tr>
<tr>
<td>566</td>
<td>Pandysautonomia neural autoantibody positive</td>
</tr>
<tr>
<td>567</td>
<td>Pandysautonomia neural autoantibody negative</td>
</tr>
<tr>
<td>568</td>
<td>Autoimmune autonomic neuropathy, ganglionic acetylcholine receptor antibody positive</td>
</tr>
<tr>
<td>569</td>
<td>Autoimmune autonomic neuropathy, other neural autoantibody positive</td>
</tr>
<tr>
<td>570</td>
<td>Autoimmune autonomic neuropathy, neural autoantibody negative</td>
</tr>
<tr>
<td>571</td>
<td>Limited autoimmune autonomic neuropathy</td>
</tr>
<tr>
<td>572</td>
<td>Limited autoimmune autonomic neuropathy, ganglionic acetylcholine receptor antibody positive</td>
</tr>
<tr>
<td>573</td>
<td>Limited autoimmune autonomic neuropathy, neural autoantibody positive</td>
</tr>
<tr>
<td>574</td>
<td>Limited autoimmune autonomic neuropathy, neural autoantibody negative</td>
</tr>
<tr>
<td>575</td>
<td>Paraneoplastic autonomic intussusception</td>
</tr>
<tr>
<td>576</td>
<td>Autoimmune acquired autonomic encephalomyelitis</td>
</tr>
<tr>
<td>577</td>
<td>Paraneoplastic sensory neuropathy</td>
</tr>
<tr>
<td>578</td>
<td>Denny Brown</td>
</tr>
<tr>
<td>579</td>
<td>Paraneoplastic sensory neuropathy, neural autoantibody negative</td>
</tr>
<tr>
<td>580</td>
<td>Paraneoplastic sensory neuropathy, neural autoantibody positive</td>
</tr>
<tr>
<td>581</td>
<td>Autoimmune sensory neuropathy</td>
</tr>
<tr>
<td>582</td>
<td>Autoimmune sensory neuropathy, neural autoantibody negative</td>
</tr>
<tr>
<td>583</td>
<td>Autoimmune sensory neuropathy, neural autoantibody positive</td>
</tr>
<tr>
<td>584</td>
<td>Paraneoplastic motor neuropathy</td>
</tr>
<tr>
<td>585</td>
<td>Paraneoplastic motor neuropathy, neural autoantibody&nbsp;negative</td>
</tr>
<tr>
<td>586</td>
<td>Autoimmune motor neuropathy</td>
</tr>
<tr>
<td>587</td>
<td>Autoimmune motor neuropathy, neural autoantibody negative</td>
</tr>
<tr>
<td>588</td>
<td>Autoimmune motor neuropathy, neural autoantibody positive</td>
</tr>
<tr>
<td>589</td>
<td>Monoclonal gammopathy of undetermined significance-associated neuropathies</td>
</tr>
<tr>
<td>590</td>
<td>MGUS - [monoclonal gammopathy of undetermined significance] associated neuropathies</td>
</tr>
<tr>
<td>591</td>
<td>Castleman disease with IgM-associated neuropathy</td>
</tr>
<tr>
<td>592</td>
<td>Myelin-associated glycoprotein</td>
</tr>
<tr>
<td>593</td>
<td>MAG - [Myelin-associated glycoprotein]</td>
</tr>
<tr>
<td>594</td>
<td>Distal acquired demyelinating neuropathy</td>
</tr>
<tr>
<td>595</td>
<td>DADS - [Distal acquired demyelinating neuropathy]</td>
</tr>
<tr>
<td>596</td>
<td>IgG, IgA or IgM-associated osteosclerotic myeloma with polyneuropathy organomegaly endocrinopathy M-spike and skin changes</td>
</tr>
<tr>
<td>597</td>
<td>Paraneoplastic neuromyopathy and neuropathy</td>
</tr>
<tr>
<td>598</td>
<td>Carcinomatous neuromyopathy</td>
</tr>
<tr>
<td>599</td>
<td>carcinomatous neuropathy</td>
</tr>
<tr>
<td>600</td>
<td>Sensorial paraneoplastic neuropathy [Denny Brown]</td>
</tr>
<tr>
<td>601</td>
<td>Paraneoplastic disorders of the spinal cord</td>
</tr>
<tr>
<td>602</td>
<td>Paraneoplastic autonomic neuropathy</td>
</tr>
<tr>
<td>603</td>
<td>Paraneoplastic neuropathy of unspecified site</td>
</tr>
<tr>
<td>1</td>
<td>Other specified syndromic genetic deafness</td>
</tr>
<tr>
<td>2</td>
<td>Albinism - black lock - cell migration disorder of the neurocytes of the gut - sensorineural deafness</td>
</tr>
<tr>
<td>3</td>
<td>ABCD - [Albinism - black lock - cell migration disorder of the neurocytes of the gut - sensorineural deafness] syndrome</td>
</tr>
<tr>
<td>4</td>
<td>Albinism-deafness syndrome</td>
</tr>
<tr>
<td>5</td>
<td>Alström syndrome</td>
</tr>
<tr>
<td>6</td>
<td>Ataxia - deafness - intellectual disability syndrome</td>
</tr>
<tr>
<td>7</td>
<td>Athabaskan brainstem dysgenesis syndrome</td>
</tr>
<tr>
<td>8</td>
<td>Atherosclerosis - deafness - diabetes - epilepsy - nephropathy</td>
</tr>
<tr>
<td>9</td>
<td>Bilateral microtia - deafness - cleft palate</td>
</tr>
<tr>
<td>10</td>
<td>Bosley-Salih-Alorainy syndrome</td>
</tr>
<tr>
<td>11</td>
<td>Brown-Vialetto-van Laere syndrome</td>
</tr>
<tr>
<td>12</td>
<td>Sensorineural hearing loss - pontobulbar palsy</td>
</tr>
<tr>
<td>13</td>
<td>Cataract - ataxia - deafness</td>
</tr>
<tr>
<td>14</td>
<td>Cataract - deafness - hypogonadism</td>
</tr>
<tr>
<td>15</td>
<td>Caudal appendage - deafness</td>
</tr>
<tr>
<td>16</td>
<td>Central nervous system calcification - deafness - tubular acidosis - anaemia</td>
</tr>
<tr>
<td>17</td>
<td>Choanal atresia - deafness - cardiac defects - dysmorphism</td>
</tr>
<tr>
<td>18</td>
<td>Choroideremia - deafness - obesity</td>
</tr>
<tr>
<td>19</td>
<td>Cleft lip or palate - deafness - sacral lipoma</td>
</tr>
<tr>
<td>20</td>
<td>Cochleosaccular degeneration - cataract</td>
</tr>
<tr>
<td>21</td>
<td>Corneal anaesthesia - deafness - intellectual disability</td>
</tr>
<tr>
<td>22</td>
<td>Corneal dystrophy - perceptive deafness</td>
</tr>
<tr>
<td>23</td>
<td>Craniofacial-deafness-hand syndrome</td>
</tr>
<tr>
<td>24</td>
<td>Deaf blind hypopigmentation syndrome, Yemenite type</td>
</tr>
<tr>
<td>25</td>
<td>Deafness - craniofacial syndrome</td>
</tr>
<tr>
<td>26</td>
<td>Deafness - epiphyseal dysplasia - short stature</td>
</tr>
<tr>
<td>27</td>
<td>Deafness - genital anomalies - metacarpal and metatarsal synostosis</td>
</tr>
<tr>
<td>28</td>
<td>Deafness - hypogonadism</td>
</tr>
<tr>
<td>29</td>
<td>Deafness - intellectual deficit syndrome, Martin-Probst type</td>
</tr>
<tr>
<td>30</td>
<td>Martin-Probst syndrome</td>
</tr>
<tr>
<td>31</td>
<td>Deafness - oligodontia</td>
</tr>
<tr>
<td>32</td>
<td>Deafness - peripheral neuropathy - arterial disease</td>
</tr>
<tr>
<td>33</td>
<td>Deafness - skeletal dysplasia - lip granuloma</td>
</tr>
<tr>
<td>34</td>
<td>Fountain syndrome</td>
</tr>
<tr>
<td>35</td>
<td>Deafness - small bowel diverticulosis - neuropathy</td>
</tr>
<tr>
<td>36</td>
<td>Deafness - vitiligo - achalasia</td>
</tr>
<tr>
<td>37</td>
<td>Deafness-infertility syndrome</td>
</tr>
<tr>
<td>38</td>
<td>15q15.3 deletion syndrome</td>
</tr>
<tr>
<td>39</td>
<td>Monosomy 15q15.3</td>
</tr>
<tr>
<td>40</td>
<td>15q15.3 deletion</td>
</tr>
<tr>
<td>41</td>
<td>Dentinogenesis imperfecta - short stature - hearing loss - intellectual deficit</td>
</tr>
<tr>
<td>42</td>
<td>Developmental delay - deafness, Hildebrand type</td>
</tr>
<tr>
<td>43</td>
<td>Developmental malformations - deafness - dystonia</td>
</tr>
<tr>
<td>44</td>
<td>Ermine phenotype</td>
</tr>
<tr>
<td>45</td>
<td>Gingival fibromatosis - progressive deafness</td>
</tr>
<tr>
<td>46</td>
<td>Hearing loss - familial salivary gland insensitivity to aldosterone</td>
</tr>
<tr>
<td>47</td>
<td>Hirschsprung disease - deafness - polydactyly</td>
</tr>
<tr>
<td>48</td>
<td>Hypospadias-hypertelorism-coloboma and deafness</td>
</tr>
<tr>
<td>49</td>
<td>Iris dysplasia - hypertelorism - deafness</td>
</tr>
<tr>
<td>50</td>
<td>Lethal ataxia with deafness and optic atrophy</td>
</tr>
<tr>
<td>51</td>
<td>Arts syndrome</td>
</tr>
<tr>
<td>52</td>
<td>Lipodystrophy - intellectual deficit - deafness</td>
</tr>
<tr>
<td>53</td>
<td>Lowe-Kohn-Cohen syndrome</td>
</tr>
<tr>
<td>54</td>
<td>Deafness - nephritis - anorectal malformation</td>
</tr>
<tr>
<td>55</td>
<td>Maternally inherited diabetes and deafness</td>
</tr>
<tr>
<td>56</td>
<td>Mitochondrial diabetes</td>
</tr>
<tr>
<td>57</td>
<td>Maxillonasal dysplasia</td>
</tr>
<tr>
<td>58</td>
<td>Intellectual disability – enteropathy – deafness – neuropathy – ichthyosis – keratoderma syndrome</td>
</tr>
<tr>
<td>59</td>
<td>Mental retardation – enteropathy – deafness – neuropathy – ichthyosis – keratoderma syndrome</td>
</tr>
<tr>
<td>60</td>
<td>MEDNIK - [Mental retardation – enteropathy – deafness – neuropathy – ichthyosis – keratoderma] syndrome</td>
</tr>
<tr>
<td>61</td>
<td>Microcephaly - deafness - intellectual disability</td>
</tr>
<tr>
<td>62</td>
<td>Microdontia - microtia type I - deafness</td>
</tr>
<tr>
<td>63</td>
<td>Deafness with labyrinthine aplasia, microtia, and microdontia</td>
</tr>
<tr>
<td>64</td>
<td>Mitral regurgitation - deafness - skeletal anomalies</td>
</tr>
<tr>
<td>65</td>
<td>Myoclonus - cerebellar ataxia - deafness</td>
</tr>
<tr>
<td>66</td>
<td>N syndrome</td>
</tr>
<tr>
<td>67</td>
<td>Nephropathy - deafness - hyperparathyroidism</td>
</tr>
<tr>
<td>68</td>
<td>Nephrosis - deafness - urinary tract - digital malformations</td>
</tr>
<tr>
<td>69</td>
<td>Neutropaenia - monocytopaenia - deafness</td>
</tr>
<tr>
<td>70</td>
<td>Olivopontocerebellar atrophy - deafness</td>
</tr>
<tr>
<td>71</td>
<td>Osteochondrodysplatic nanism - deafness - retinitis pigmentosa</td>
</tr>
<tr>
<td>72</td>
<td>Peripheral neuropathy, Fiskerstrand type</td>
</tr>
<tr>
<td>73</td>
<td>Perrault syndrome</td>
</tr>
<tr>
<td>74</td>
<td>Phocomelia - ectrodactyly - deafness - sinus arrhythmia</td>
</tr>
<tr>
<td>75</td>
<td>Hypertrophic cardiomyopathy due to Kearns–Sayre syndrome</td>
</tr>
<tr>
<td>76</td>
<td>progressive sensorineural hearing loss - hypertrophic cardiomyopathy</td>
</tr>
<tr>
<td>77</td>
<td>Hypertrophic cardiomyopathy associated with progressive sensorineural hearing loss</td>
</tr>
<tr>
<td>78</td>
<td>Retinitis pigmentosa - intellectual disability - deafness - hypogenitalism</td>
</tr>
<tr>
<td>79</td>
<td>Richards-Rundle syndrome</td>
</tr>
<tr>
<td>80</td>
<td>Schizophrenia - intellectual disability - deafness - retinitis</td>
</tr>
<tr>
<td>81</td>
<td>Sensorineural hearing loss - early greying - essential tremor</td>
</tr>
<tr>
<td>82</td>
<td>SeSAME syndrome</td>
</tr>
<tr>
<td>83</td>
<td>EAST syndrome</td>
</tr>
<tr>
<td>84</td>
<td>Short stature - deafness - neutrophil dysfunction - dysmorphism</td>
</tr>
<tr>
<td>85</td>
<td>Spastic paraparesis - deafness</td>
</tr>
<tr>
<td>86</td>
<td>Split hand - split foot - deafness</td>
</tr>
<tr>
<td>87</td>
<td>Thickened earlobes - conductive deafness</td>
</tr>
<tr>
<td>88</td>
<td>Deafness - optic atrophy syndrome</td>
</tr>
<tr>
<td>89</td>
<td>Optic atrophy, deafness, ophthalmoplegia, myopathy</td>
</tr>
<tr>
<td>90</td>
<td>Autosomal dominant optic atrophy and congenital deafness</td>
</tr>
<tr>
<td>91</td>
<td>Ocular albinism - late-onset sensorineural deafness</td>
</tr>
<tr>
<td>92</td>
<td>Spastic paraplegia - nephritis - deafness</td>
</tr>
<tr>
<td>93</td>
<td>Metaphyseal dysostosis - intellectual deficit - conductive deafness</td>
</tr>
<tr>
<td>94</td>
<td>Knuckle pads – leukonychia – sensorineural deafness</td>
</tr>
<tr>
<td>95</td>
<td>Bart-Pumphrey syndrome (MIM 149200)</td>
</tr>
<tr>
<td>96</td>
<td>Alport syndrome</td>
</tr>
<tr>
<td>97</td>
<td>Alport syndrome, autosomal dominant</td>
</tr>
<tr>
<td>98</td>
<td>Alport syndrome, autosomal recessive</td>
</tr>
<tr>
<td>99</td>
<td>Alport syndrome, X-linked</td>
</tr>
<tr>
<td>100</td>
<td>Alport syndrome, X-linked diffuse leiomyomatosis</td>
</tr>
<tr>
<td>101</td>
<td>Cardioauditory syndrome</td>
</tr>
<tr>
<td>102</td>
<td>Disorders of protein N-glycosylation</td>
</tr>
<tr>
<td>103</td>
<td>Phosphomannomutase 2 deficiency</td>
</tr>
<tr>
<td>104</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1A</td>
</tr>
<tr>
<td>105</td>
<td>Congenital disorder of glycosylation type 1A</td>
</tr>
<tr>
<td>106</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1A</td>
</tr>
<tr>
<td>107</td>
<td>Phosphomannose isomerase deficiency</td>
</tr>
<tr>
<td>108</td>
<td>Saguenay-Lac-Saint-Jean syndrome</td>
</tr>
<tr>
<td>109</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1B</td>
</tr>
<tr>
<td>110</td>
<td>Congenital disorder of glycosylation type 1B</td>
</tr>
<tr>
<td>111</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1B</td>
</tr>
<tr>
<td>112</td>
<td>SLSJ - [Saguenay-Lac-Saint-Jean] syndrome</td>
</tr>
<tr>
<td>113</td>
<td>Glucosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>114</td>
<td>Dol-P-Glc: Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>115</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1C</td>
</tr>
<tr>
<td>116</td>
<td>Congenital disorder of glycosylation type 1C</td>
</tr>
<tr>
<td>117</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1C</td>
</tr>
<tr>
<td>118</td>
<td>Mannosyltransferase 6 deficiency</td>
</tr>
<tr>
<td>119</td>
<td>Dol-P-Man: Man5-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>120</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1D</td>
</tr>
<tr>
<td>121</td>
<td>Congenital disorder of glycosylation type 1D</td>
</tr>
<tr>
<td>122</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1D</td>
</tr>
<tr>
<td>123</td>
<td>Mannosyltransferase 8 deficiency</td>
</tr>
<tr>
<td>124</td>
<td>Dol-P-Man: Man7-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>125</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1G</td>
</tr>
<tr>
<td>126</td>
<td>Congenital disorder of glycosylation type 1G</td>
</tr>
<tr>
<td>127</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1G</td>
</tr>
<tr>
<td>128</td>
<td>Glucosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>129</td>
<td>Dol-P-Glc: Glc1-Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>130</td>
<td>Carbohydrate deficient glycoprotein syndrome 1H</td>
</tr>
<tr>
<td>131</td>
<td>Congenital disorder of glycosylation type 1H</td>
</tr>
<tr>
<td>132</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1H</td>
</tr>
<tr>
<td>133</td>
<td>Mannosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>134</td>
<td>Dol-P-Man: Man1-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>135</td>
<td>Carbohydrate deficient glycoprotein syndrome 1I</td>
</tr>
<tr>
<td>136</td>
<td>Congenital disorder of glycosylation 1I</td>
</tr>
<tr>
<td>137</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1I</td>
</tr>
<tr>
<td>138</td>
<td>Dolichyl-phosphate N-acetylgalactosamine phosphotransferase deficiency</td>
</tr>
<tr>
<td>139</td>
<td>UDP-GlcNAc: Dol-P-GlcNac-P transferase deficiency</td>
</tr>
<tr>
<td>140</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1J</td>
</tr>
<tr>
<td>141</td>
<td>Congenital disorder of glycosylation type 1J</td>
</tr>
<tr>
<td>142</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1J</td>
</tr>
<tr>
<td>143</td>
<td>Mannosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>144</td>
<td>Dol-P-Man: GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>145</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1K</td>
</tr>
<tr>
<td>146</td>
<td>Congenital disorder of glycosylation type 1K</td>
</tr>
<tr>
<td>147</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1K</td>
</tr>
<tr>
<td>148</td>
<td>Mannosyltransferase 7-9 deficiency</td>
</tr>
<tr>
<td>149</td>
<td>Congenital disorder of glycosylation type 1L</td>
</tr>
<tr>
<td>150</td>
<td>Dol-P-Man: Man6 and Man8-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>151</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1L</td>
</tr>
<tr>
<td>152</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1L</td>
</tr>
<tr>
<td>153</td>
<td>M5-DLO flippase deficiency</td>
</tr>
<tr>
<td>154</td>
<td>Man5GlcNAc2-PP-Dol flippase deficiency</td>
</tr>
<tr>
<td>155</td>
<td>RTF1-CDG</td>
</tr>
<tr>
<td>156</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1N</td>
</tr>
<tr>
<td>157</td>
<td>N-acetylglucosaminyltransferase deficiency</td>
</tr>
<tr>
<td>158</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2A</td>
</tr>
<tr>
<td>159</td>
<td>Congenital disorder of glycosylation type 2A</td>
</tr>
<tr>
<td>160</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2A</td>
</tr>
<tr>
<td>161</td>
<td>Glucosidase 1 deficiency</td>
</tr>
<tr>
<td>162</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2B</td>
</tr>
<tr>
<td>163</td>
<td>Congenital disorder of glycosylation type 2B</td>
</tr>
<tr>
<td>164</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2B</td>
</tr>
<tr>
<td>165</td>
<td>TUSC3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>166</td>
<td>TUSC3-CDG</td>
</tr>
<tr>
<td>167</td>
<td>SRD5A3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>168</td>
<td>SRD5A3-CDG</td>
</tr>
<tr>
<td>169</td>
<td>Congenital disorder of glycosylation due to steroid 5-alpha-reductase type 3 deficiency</td>
</tr>
<tr>
<td>170</td>
<td>Intellectual deficit - cataract - coloboma - kyphosis</td>
</tr>
<tr>
<td>171</td>
<td>Kahrizi syndrome</td>
</tr>
<tr>
<td>172</td>
<td>Intellectual deficit, Kahrizi type</td>
</tr>
<tr>
<td>173</td>
<td>DPM3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>174</td>
<td>Congenital disorder of glycosylation type 1O</td>
</tr>
<tr>
<td>175</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1O</td>
</tr>
<tr>
<td>176</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1O</td>
</tr>
<tr>
<td>177</td>
<td>ALG11 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>178</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1P</td>
</tr>
<tr>
<td>179</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1P</td>
</tr>
<tr>
<td>180</td>
<td>Congenital disorder of glycosylation type 1P</td>
</tr>
<tr>
<td>181</td>
<td>Phosphoglucomutase-1 deficiency</td>
</tr>
<tr>
<td>182</td>
<td>PGM1-CDG - [Phosphoglucomutase-1 deficiency]</td>
</tr>
<tr>
<td>183</td>
<td>Congenital disorder of glycosylation type 1t</td>
</tr>
<tr>
<td>184</td>
<td>Compressive optic neuropathy</td>
</tr>
<tr>
<td>185</td>
<td>compression of optic nerve</td>
</tr>
<tr>
<td>186</td>
<td>n.opticus compression</td>
</tr>
<tr>
<td>187</td>
<td>Foster-Kennedy syndrome</td>
</tr>
<tr>
<td>188</td>
<td>Other specified mucopolysaccharidosis</td>
</tr>
<tr>
<td>189</td>
<td>Mucopolysaccharidosis type 3</td>
</tr>
<tr>
<td>190</td>
<td>Acetyl-CoA alpha-glucosaminide-N-acetyl transferase deficiency</td>
</tr>
<tr>
<td>191</td>
<td>N-acetyl-alpha-glucosaminidase sulfamidase deficiency</td>
</tr>
<tr>
<td>192</td>
<td>N-acetyl-glucosamine-6-sulfate sulfatase deficiency</td>
</tr>
<tr>
<td>193</td>
<td>Sanfilippo syndrome</td>
</tr>
<tr>
<td>194</td>
<td>Mucopolysaccharidosis type 3A</td>
</tr>
<tr>
<td>195</td>
<td>Sanfilippo syndrome type A</td>
</tr>
<tr>
<td>196</td>
<td>Heparan-N-sulfatase deficiency</td>
</tr>
<tr>
<td>197</td>
<td>Heparan sulfamidase deficiency</td>
</tr>
<tr>
<td>198</td>
<td>Heparan sulfate sulfatase deficiency</td>
</tr>
<tr>
<td>199</td>
<td>Mucopolysaccharidosis type 3B</td>
</tr>
<tr>
<td>200</td>
<td>Sanfilippo syndrome type B</td>
</tr>
<tr>
<td>201</td>
<td>Alpha-N-acetylglucosaminidase deficiency</td>
</tr>
<tr>
<td>202</td>
<td>N-acetyl-alpha-D-glucosaminidase deficiency</td>
</tr>
<tr>
<td>203</td>
<td>Mucopolysaccharidosis type 3C</td>
</tr>
<tr>
<td>204</td>
<td>Sanfilippo syndrome type C</td>
</tr>
<tr>
<td>205</td>
<td>Acetyl-CoA alpha-glucosaminide acetyltransferase deficiency</td>
</tr>
<tr>
<td>206</td>
<td>N-acetyl transferase deficiency</td>
</tr>
<tr>
<td>207</td>
<td>Mucopolysaccharidosis type 3D</td>
</tr>
<tr>
<td>208</td>
<td>Sanfilippo syndrome type D</td>
</tr>
<tr>
<td>209</td>
<td>N-acetylglucosamine-6-sulfate sulfatase deficiency</td>
</tr>
<tr>
<td>210</td>
<td>Mucopolysaccharidosis type 7</td>
</tr>
<tr>
<td>211</td>
<td>Beta-glucuronidase deficiency</td>
</tr>
<tr>
<td>212</td>
<td>Sly disease</td>
</tr>
<tr>
<td>213</td>
<td>Sly syndrome</td>
</tr>
<tr>
<td>214</td>
<td>Mucopolysaccharidosis type 9</td>
</tr>
<tr>
<td>215</td>
<td>Hyaluronidase deficiency</td>
</tr>
<tr>
<td>216</td>
<td>Natowicz syndrome</td>
</tr>
<tr>
<td>217</td>
<td>Injury of abducent nerve</td>
</tr>
<tr>
<td>218</td>
<td>abducens (6th) nerve injury</td>
</tr>
<tr>
<td>219</td>
<td>injury of sixth cranial nerve</td>
</tr>
<tr>
<td>220</td>
<td>injury to abducens nerve</td>
</tr>
<tr>
<td>221</td>
<td>traumatic injury of abducens nerve</td>
</tr>
<tr>
<td>222</td>
<td>traumatic injury of sixth cranial nerve</td>
</tr>
<tr>
<td>223</td>
<td>injury of n.abducens</td>
</tr>
<tr>
<td>224</td>
<td>Oligosaccharidosis</td>
</tr>
<tr>
<td>225</td>
<td>Aspartylglucosaminuria</td>
</tr>
<tr>
<td>226</td>
<td>Aspartylglucosaminidase deficiency</td>
</tr>
<tr>
<td>227</td>
<td>Alpha-mannosidosis</td>
</tr>
<tr>
<td>228</td>
<td>Lysosomal alpha-D-mannosidase deficiency</td>
</tr>
<tr>
<td>229</td>
<td>Infantile alpha-mannosidosis</td>
</tr>
<tr>
<td>230</td>
<td>Adult alpha-mannosidosis</td>
</tr>
<tr>
<td>231</td>
<td>Beta-mannosidosis</td>
</tr>
<tr>
<td>232</td>
<td>Lysosomal beta-mannosidase deficiency</td>
</tr>
<tr>
<td>233</td>
<td>Mannosidosis, not otherwise specified</td>
</tr>
<tr>
<td>234</td>
<td>mannosidase deficiency</td>
</tr>
<tr>
<td>235</td>
<td>Fucosidosis</td>
</tr>
<tr>
<td>236</td>
<td>Alpha-L-fucosidase deficiency</td>
</tr>
<tr>
<td>237</td>
<td>Sialidosis</td>
</tr>
<tr>
<td>238</td>
<td>Mucolipidosis type 1</td>
</tr>
<tr>
<td>239</td>
<td>Sialidosis type 1</td>
</tr>
<tr>
<td>240</td>
<td>Cherry-red-spot-myoclonus syndrome</td>
</tr>
<tr>
<td>241</td>
<td>Lipomucopolysaccharidosis</td>
</tr>
<tr>
<td>242</td>
<td>Normomorphic sialidosis</td>
</tr>
<tr>
<td>243</td>
<td>Sialidosis type 2</td>
</tr>
<tr>
<td>244</td>
<td>Infantile dysmorphic sialidosis</td>
</tr>
<tr>
<td>245</td>
<td>Congenital sialidosis type 2</td>
</tr>
<tr>
<td>246</td>
<td>Juvenile sialidosis type 2</td>
</tr>
<tr>
<td>247</td>
<td>Alpha-N-acetylgalactosaminidase deficiency</td>
</tr>
<tr>
<td>248</td>
<td>N-acetyl-alpha-D-galactosaminidase deficiency</td>
</tr>
<tr>
<td>249</td>
<td>NAGA - [Alpha-N-acetylgalactosaminidase] deficiency</td>
</tr>
<tr>
<td>250</td>
<td>Alpha-N-acetylgalactosaminidase deficiency type 1</td>
</tr>
<tr>
<td>251</td>
<td>Schindler disease type 1</td>
</tr>
<tr>
<td>252</td>
<td>Schindler disease</td>
</tr>
<tr>
<td>253</td>
<td>NAGA deficiency type 1 - [Alpha-N-acetylgalactosaminidase deficiency type 1]</td>
</tr>
<tr>
<td>254</td>
<td>Alpha-N-acetylgalactosaminidase deficiency type 2</td>
</tr>
<tr>
<td>255</td>
<td>Adult-onset Alpha-N-acetylgalactosaminidase deficiency</td>
</tr>
<tr>
<td>256</td>
<td>Schindler disease type 2</td>
</tr>
<tr>
<td>257</td>
<td>Kanzaki disease</td>
</tr>
<tr>
<td>258</td>
<td>NAGA deficiency type 2 - [Alpha-N-acetylgalactosaminidase deficiency type 2]</td>
</tr>
<tr>
<td>259</td>
<td>Alpha-N-acetylgalactosaminidase deficiency type 3</td>
</tr>
<tr>
<td>260</td>
<td>Schindler disease type 3</td>
</tr>
<tr>
<td>261</td>
<td>NAGA deficiency type 3 - [Alpha-N-acetylgalactosaminidase deficiency type 3]</td>
</tr>
<tr>
<td>262</td>
<td>Galactosialidosis</td>
</tr>
<tr>
<td>263</td>
<td>Neuraminidase deficiency with beta-galactosidase deficiency</td>
</tr>
<tr>
<td>264</td>
<td>Goldberg syndrome</td>
</tr>
<tr>
<td>265</td>
<td>Combined deficiency of neuraminidase and beta-galactosidase</td>
</tr>
<tr>
<td>266</td>
<td>Protective protein deficiency</td>
</tr>
<tr>
<td>267</td>
<td>Injury of axillary nerve</td>
</tr>
<tr>
<td>268</td>
<td>injury of n. axillaris</td>
</tr>
<tr>
<td>269</td>
<td>Injury of trigeminal nerve</td>
</tr>
<tr>
<td>270</td>
<td>injury of fifth cranial nerve</td>
</tr>
<tr>
<td>271</td>
<td>trigeminal (5th) nerve injury</td>
</tr>
<tr>
<td>272</td>
<td>injury of n.trigeminus</td>
</tr>
<tr>
<td>273</td>
<td>Injury of trigeminal ganglion</td>
</tr>
<tr>
<td>274</td>
<td>Injury of facial nerve</td>
</tr>
<tr>
<td>275</td>
<td>facial (7th) nerve injury</td>
</tr>
<tr>
<td>276</td>
<td>injury of seventh cranial nerve</td>
</tr>
<tr>
<td>277</td>
<td>traumatic facial neuropathy</td>
</tr>
<tr>
<td>278</td>
<td>injury of n.facialis</td>
</tr>
<tr>
<td>279</td>
<td>Injury of oculomotor nerve</td>
</tr>
<tr>
<td>280</td>
<td>injury of third cranial nerve</td>
</tr>
<tr>
<td>281</td>
<td>oculomotor (3rd) nerve injury</td>
</tr>
<tr>
<td>282</td>
<td>traumatic injury of third cranial nerve</td>
</tr>
<tr>
<td>283</td>
<td>injury of n.oculomotorius</td>
</tr>
<tr>
<td>284</td>
<td>Injury of trochlear nerve</td>
</tr>
<tr>
<td>285</td>
<td>injury of fourth cranial nerve</td>
</tr>
<tr>
<td>286</td>
<td>injury of n.trochlearis</td>
</tr>
<tr>
<td>287</td>
<td>Injury of accessory nerve</td>
</tr>
<tr>
<td>288</td>
<td>accessory (11th) nerve injury</td>
</tr>
<tr>
<td>289</td>
<td>injury of eleventh cranial nerve</td>
</tr>
<tr>
<td>290</td>
<td>Traumatic injury of spinal accessory nerve</td>
</tr>
<tr>
<td>291</td>
<td>injury of n.accessorius</td>
</tr>
<tr>
<td>292</td>
<td>Injury of musculocutaneous nerve</td>
</tr>
<tr>
<td>293</td>
<td>injury of n. musculocutaneus</td>
</tr>
<tr>
<td>294</td>
<td>Citrullinaemia</td>
</tr>
<tr>
<td>295</td>
<td>Argininosuccinate synthetase deficiency</td>
</tr>
<tr>
<td>296</td>
<td>Citrullinuria</td>
</tr>
<tr>
<td>297</td>
<td>ASA synthase deficiency</td>
</tr>
<tr>
<td>298</td>
<td>metabolic disorder of citrulline</td>
</tr>
<tr>
<td>299</td>
<td>deficiency of citrulline-aspartate ligase</td>
</tr>
<tr>
<td>300</td>
<td>Citrullinaemia type 1</td>
</tr>
<tr>
<td>301</td>
<td>Citrullinuria type 1</td>
</tr>
<tr>
<td>302</td>
<td>Citrullinaemia type 3</td>
</tr>
<tr>
<td>303</td>
<td>Citrullinuria type 3</td>
</tr>
<tr>
<td>304</td>
<td>Classic citrullinaemia</td>
</tr>
<tr>
<td>305</td>
<td>CTLN1 - [Citrullinaemia type 1]</td>
</tr>
<tr>
<td>306</td>
<td>Argininosuccinate synthase deficiency</td>
</tr>
<tr>
<td>307</td>
<td>Acute neonatal citrullinaemia type 1</td>
</tr>
<tr>
<td>308</td>
<td>Adult-onset citrullinaemia type 1</td>
</tr>
<tr>
<td>309</td>
<td>Citrin deficiency</td>
</tr>
<tr>
<td>310</td>
<td>Aspartate-glutamate carrier deficiency</td>
</tr>
<tr>
<td>311</td>
<td>Citrullinaemia type 2</td>
</tr>
<tr>
<td>312</td>
<td>Citrullinuria type 2</td>
</tr>
<tr>
<td>313</td>
<td>Adult-onset citrin deficiency</td>
</tr>
<tr>
<td>314</td>
<td>CTLN2 - [Citrullinaemia type 2]</td>
</tr>
<tr>
<td>315</td>
<td>N-acetylglutamate synthase deficiency</td>
</tr>
<tr>
<td>316</td>
<td>NAGS - [N-acetylglutamate synthase deficiency]</td>
</tr>
<tr>
<td>317</td>
<td>Neonatal intrahepatic cholestasis caused by citrin deficiency</td>
</tr>
<tr>
<td>318</td>
<td>NICCD - [Neonatal intrahepatic cholestasis caused by citrin deficiency]</td>
</tr>
<tr>
<td>319</td>
<td>Paralysis of vocal cords or larynx</td>
</tr>
<tr>
<td>320</td>
<td>complete paralysis of vocal cords and larynx of both sides</td>
</tr>
<tr>
<td>321</td>
<td>complete paralysis of vocal cords and larynx of one side</td>
</tr>
<tr>
<td>322</td>
<td>Laryngeal nerve paralysis</td>
</tr>
<tr>
<td>323</td>
<td>larynx nerve paralysis</td>
</tr>
<tr>
<td>324</td>
<td>paralysis of the N. laryngeus superior</td>
</tr>
<tr>
<td>325</td>
<td>superior paralysis of laryngeal nerve</td>
</tr>
<tr>
<td>326</td>
<td>Recurrent bilateral paralysis of laryngeal nerve</td>
</tr>
<tr>
<td>327</td>
<td>Recurrent unilateral paralysis of laryngeal nerve</td>
</tr>
<tr>
<td>328</td>
<td>recurrent laryngeal nerve palsy</td>
</tr>
<tr>
<td>329</td>
<td>recurrent laryngeal nerve paralysis</td>
</tr>
<tr>
<td>330</td>
<td>Paralysis of glottis</td>
</tr>
<tr>
<td>331</td>
<td>glottic paralysis</td>
</tr>
<tr>
<td>332</td>
<td>glottis paralysis</td>
</tr>
<tr>
<td>333</td>
<td>vocal fold palsy</td>
</tr>
<tr>
<td>334</td>
<td>Paralysis of vocal cords</td>
</tr>
<tr>
<td>335</td>
<td>VCP - [vocal cord palsy]</td>
</tr>
<tr>
<td>336</td>
<td>vocal cord palsy</td>
</tr>
<tr>
<td>337</td>
<td>vocal cord paralysis</td>
</tr>
<tr>
<td>338</td>
<td>Partial paralysis of vocal cord and larynx of one side</td>
</tr>
<tr>
<td>339</td>
<td>Partial paralysis of vocal cords and larynx of both sides</td>
</tr>
<tr>
<td>340</td>
<td>Laryngoplegia</td>
</tr>
<tr>
<td>341</td>
<td>laryngeal paralysis</td>
</tr>
<tr>
<td>342</td>
<td>paralysis of larynx</td>
</tr>
<tr>
<td>343</td>
<td>Other specified disorder of the optic nerve</td>
</tr>
<tr>
<td>344</td>
<td>Nutritional optic neuropathy</td>
</tr>
<tr>
<td>345</td>
<td>nutritional amblyopia</td>
</tr>
<tr>
<td>346</td>
<td>Toxic optic neuropathy</td>
</tr>
<tr>
<td>347</td>
<td>Haemorrhage in optic nerve sheath</td>
</tr>
<tr>
<td>348</td>
<td>n.opticus haemorrhage</td>
</tr>
<tr>
<td>349</td>
<td>optic nerve haemorrhage</td>
</tr>
<tr>
<td>350</td>
<td>Other disorders of optic disc</td>
</tr>
<tr>
<td>351</td>
<td>disorder of optic disc NOS</td>
</tr>
<tr>
<td>352</td>
<td>optic disc disorder NOS</td>
</tr>
<tr>
<td>353</td>
<td>optic disk disorder NOS</td>
</tr>
<tr>
<td>354</td>
<td>Crowded optic disc</td>
</tr>
<tr>
<td>355</td>
<td>Hyaline bodies of optic disc</td>
</tr>
<tr>
<td>356</td>
<td>Disorders of methionine cycle or sulphur amino acid metabolism</td>
</tr>
<tr>
<td>357</td>
<td>disorder of sulphur-bearing amino acid including those due to folate and b12 disturbance</td>
</tr>
<tr>
<td>358</td>
<td>disorder of sulphur-bearing amino acid metabolism</td>
</tr>
<tr>
<td>359</td>
<td>disorder of transsulfuration</td>
</tr>
<tr>
<td>360</td>
<td>disorder of transsulphuration</td>
</tr>
<tr>
<td>361</td>
<td>disturbances of sulphur-bearing amino-acid metabolism</td>
</tr>
<tr>
<td>362</td>
<td>sulphuraminoacidaemia</td>
</tr>
<tr>
<td>363</td>
<td>Disorders of sulphur-bearing amino-acid metabolism</td>
</tr>
<tr>
<td>364</td>
<td>Brain demyelination due to methionine adenosyltransferase deficiency</td>
</tr>
<tr>
<td>365</td>
<td>Methionine adenosyltransferase I/III deficiency</td>
</tr>
<tr>
<td>366</td>
<td>Isolated persistent hypermethioninaemia</td>
</tr>
<tr>
<td>367</td>
<td>MAT I/III - [Methionine adenosyltransferase I/III] deficiency</td>
</tr>
<tr>
<td>368</td>
<td>Glycine N-methyltransferase deficiency</td>
</tr>
<tr>
<td>369</td>
<td>GNMT - [Glycine N-methyltransferase] deficiency</td>
</tr>
<tr>
<td>370</td>
<td>Psychomotor retardation and myopathy due to S-adenosylhomocysteine hydrolase deficiency</td>
</tr>
<tr>
<td>371</td>
<td>Hypermethioninaemia due to S-adenosylhomocysteine hydrolase deficiency</td>
</tr>
<tr>
<td>372</td>
<td>Cystathioninuria</td>
</tr>
<tr>
<td>373</td>
<td>Gamma-cystathionase deficiency</td>
</tr>
<tr>
<td>374</td>
<td>Cystathione gamma-lyase deficiency</td>
</tr>
<tr>
<td>375</td>
<td>CTH - [cystathioninuria]</td>
</tr>
<tr>
<td>376</td>
<td>cystathionine metabolic disorder</td>
</tr>
<tr>
<td>377</td>
<td>Classical homocystinuria</td>
</tr>
<tr>
<td>378</td>
<td>Homocystinuria due to cystathionine beta-synthase deficiency</td>
</tr>
<tr>
<td>379</td>
<td>Cystathionine beta-synthase deficiency</td>
</tr>
<tr>
<td>380</td>
<td>CBS - [Cystathionine beta-synthase] deficiency</td>
</tr>
<tr>
<td>381</td>
<td>cystathionine synthase deficiency</td>
</tr>
<tr>
<td>382</td>
<td>homocystine metabolic disorder</td>
</tr>
<tr>
<td>383</td>
<td>Homocystinuria without methylmalonic aciduria</td>
</tr>
<tr>
<td>384</td>
<td>5-methyltetrahydrofolate-homocysteine s-methyltransferase deficiency</td>
</tr>
<tr>
<td>385</td>
<td>Methionine synthase deficiency</td>
</tr>
<tr>
<td>386</td>
<td>Methylcobalamin deficiency</td>
</tr>
<tr>
<td>387</td>
<td>N5-methylhomocysteine transferase deficiency</td>
</tr>
<tr>
<td>388</td>
<td>Methylcobalamin deficiency type cbl E</td>
</tr>
<tr>
<td>389</td>
<td>Homocystinuria due to defect in methylation type cbl E</td>
</tr>
<tr>
<td>390</td>
<td>Homocystinuria - megaloblastic anaemia due to defect in cobalamin metabolism, cbI E complementation type</td>
</tr>
<tr>
<td>391</td>
<td>Methylcobalamin deficiency type cbl G</td>
</tr>
<tr>
<td>392</td>
<td>Homocystinuria due to methionine synthase deficiency type Cbl G</td>
</tr>
<tr>
<td>393</td>
<td>Homocystinuria - megaloblastic anaemia due to defect in cobalamin metabolism, cbI G complementation type</td>
</tr>
<tr>
<td>394</td>
<td>Methylcobalamin deficiency type cbl Dv1</td>
</tr>
<tr>
<td>395</td>
<td>Encephalopathy due to sulfite oxidase deficiency</td>
</tr>
<tr>
<td>396</td>
<td>Isolated sulfite oxidase deficiency</td>
</tr>
<tr>
<td>397</td>
<td>ISOD - [Isolated sulfite oxidase deficiency]</td>
</tr>
<tr>
<td>398</td>
<td>Sulfite oxidase deficiency due to molybdenum cofactor deficiency</td>
</tr>
<tr>
<td>399</td>
<td>Combined deficiency of sulfite oxidase, xanthine dehydrogenase and aldehyde oxidase</td>
</tr>
<tr>
<td>400</td>
<td>Molybdenum cofactor deficiency, complementation group A</td>
</tr>
<tr>
<td>401</td>
<td>Molybdenum cofactor deficiency due to defects in MOCS1 gene</td>
</tr>
<tr>
<td>402</td>
<td>Molybdenum cofactor deficiency, complementation group B</td>
</tr>
<tr>
<td>403</td>
<td>Molybdenum cofactor deficiency due to defects in MOCS2 gene</td>
</tr>
<tr>
<td>404</td>
<td>Molybdenum cofactor deficiency, complementation group C</td>
</tr>
<tr>
<td>405</td>
<td>Hypermethioninaemia due to adenosine kinase deficiency</td>
</tr>
<tr>
<td>406</td>
<td>Other genetic defects of methionine cycle or sulfur amino acid metabolism</td>
</tr>
<tr>
<td>407</td>
<td>Secondary non-genetic disorders of methionine cycle or sulfur amino acid metabolism</td>
</tr>
<tr>
<td>408</td>
<td>Beery-baby syndrome</td>
</tr>
<tr>
<td>409</td>
<td>Cystathioninemia</td>
</tr>
<tr>
<td>410</td>
<td>Deficiency of cystathionase</td>
</tr>
<tr>
<td>411</td>
<td>Deficiency of cysteine desulfhydrase</td>
</tr>
<tr>
<td>412</td>
<td>deficiency of cysteine desulphydrase</td>
</tr>
<tr>
<td>413</td>
<td>deficiency of cystine desulfhydrase</td>
</tr>
<tr>
<td>414</td>
<td>deficiency of cystine desulphydrase</td>
</tr>
<tr>
<td>415</td>
<td>Deficiency of homoserine deaminase</td>
</tr>
<tr>
<td>416</td>
<td>Deficiency of methionine adenosyltransferase</td>
</tr>
<tr>
<td>417</td>
<td>Familial methionine malabsorption</td>
</tr>
<tr>
<td>418</td>
<td>Hepatic methionine adenosyltransferase deficiency</td>
</tr>
<tr>
<td>419</td>
<td>Homocystinaemia</td>
</tr>
<tr>
<td>420</td>
<td>Hypermethioninaemia</td>
</tr>
<tr>
<td>421</td>
<td>methionine metabolic disorder</td>
</tr>
<tr>
<td>422</td>
<td>Methionine malabsorption syndrome</td>
</tr>
<tr>
<td>423</td>
<td>oast-house disease</td>
</tr>
<tr>
<td>424</td>
<td>oast-house urine disease</td>
</tr>
<tr>
<td>425</td>
<td>oasthouse disease</td>
</tr>
<tr>
<td>426</td>
<td>oasthouse urine disease</td>
</tr>
<tr>
<td>427</td>
<td>Smith-Strang disease</td>
</tr>
<tr>
<td>428</td>
<td>Sulfite oxidase deficiency</td>
</tr>
<tr>
<td>429</td>
<td>sulfite oxidase deficiency syndrome</td>
</tr>
<tr>
<td>430</td>
<td>sulphite oxidase deficiency</td>
</tr>
<tr>
<td>431</td>
<td>sulfocysteinuria</td>
</tr>
<tr>
<td>432</td>
<td>sulphocysteinuria</td>
</tr>
<tr>
<td>433</td>
<td>Von Willebrand disease</td>
</tr>
<tr>
<td>434</td>
<td>Factor VIII deficiency with vascular defect</td>
</tr>
<tr>
<td>435</td>
<td>Vascular haemophilia</td>
</tr>
<tr>
<td>436</td>
<td>Willebrand Jurgen thrombopathy</td>
</tr>
<tr>
<td>437</td>
<td>pseudohaemophilia</td>
</tr>
<tr>
<td>438</td>
<td>Minot-von Willebrand-Jurgen disease</td>
</tr>
<tr>
<td>439</td>
<td>Angiohaemophilia</td>
</tr>
<tr>
<td>440</td>
<td>angiohaemophilia A</td>
</tr>
<tr>
<td>441</td>
<td>angiohaemophilia B</td>
</tr>
<tr>
<td>442</td>
<td>Von Willebrand disease type 1</td>
</tr>
<tr>
<td>443</td>
<td>Von Willebrand disease type 2</td>
</tr>
<tr>
<td>444</td>
<td>Von Willebrand disease type 2A</td>
</tr>
<tr>
<td>445</td>
<td>Von Willebrand disease type 2B</td>
</tr>
<tr>
<td>446</td>
<td>Von Willebrand disease type 2M</td>
</tr>
<tr>
<td>447</td>
<td>Von Willebrand disease type 2N</td>
</tr>
<tr>
<td>448</td>
<td>Von Willebrand disease type 3</td>
</tr>
<tr>
<td>449</td>
<td>Injury of lateral plantar nerve</td>
</tr>
<tr>
<td>450</td>
<td>injury of n.plantaris lateralis</td>
</tr>
<tr>
<td>451</td>
<td>Mucopolysaccharidosis type 6</td>
</tr>
<tr>
<td>452</td>
<td>N-acetylgalactosamine 4-sulfatase deficiency</td>
</tr>
<tr>
<td>453</td>
<td>Arylsulfatase B deficiency</td>
</tr>
<tr>
<td>454</td>
<td>Maroteaux-Lamy syndrome</td>
</tr>
<tr>
<td>455</td>
<td>ARSB - [Arylsulfatase B] deficiency</td>
</tr>
<tr>
<td>456</td>
<td>Injury of medial plantar nerve</td>
</tr>
<tr>
<td>457</td>
<td>injury of n.plantaris medialis</td>
</tr>
<tr>
<td>458</td>
<td>Disorders of protein O-glycosylation</td>
</tr>
<tr>
<td>459</td>
<td>Defects in O-xylosylglycan synthesis</td>
</tr>
<tr>
<td>460</td>
<td>Beta-1,4-galactosyltransferase 7 deficiency</td>
</tr>
<tr>
<td>461</td>
<td>Defects in O-N-acetylgalactosaminylglycan synthesis</td>
</tr>
<tr>
<td>462</td>
<td>Polypeptide N-acetylgalactosaminyl transferase deficiency</td>
</tr>
<tr>
<td>463</td>
<td>Hyperphosphataemic familial tumoural calcinosis</td>
</tr>
<tr>
<td>464</td>
<td>Defects in O-xylosyl/N-acetylgalactosaminylglycan synthesis</td>
</tr>
<tr>
<td>465</td>
<td>Defects in O-mannosylglycan synthesis</td>
</tr>
<tr>
<td>466</td>
<td>Protein-O-mannosyltransferase 1</td>
</tr>
<tr>
<td>467</td>
<td>Protein-O-mannosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>468</td>
<td>Protein-O-mannose beta-1,2-N-acetyglucosaminyltransferase deficiency</td>
</tr>
<tr>
<td>469</td>
<td>Fukutin deficiency</td>
</tr>
<tr>
<td>470</td>
<td>Fukutin-related protein deficiency</td>
</tr>
<tr>
<td>471</td>
<td>N-acetylglucosaminyltransferase-like protein deficiency</td>
</tr>
<tr>
<td>472</td>
<td>O-fucose-specific beta-1,3-N-acetylglucosaminyltransferase deficiency</td>
</tr>
<tr>
<td>473</td>
<td>O-fucose-specific beta-1,3-N-glucosyltransferase deficiency</td>
</tr>
<tr>
<td>474</td>
<td>Multiple osteochondromas</td>
</tr>
<tr>
<td>475</td>
<td>Multiple cartilaginous exostoses</td>
</tr>
<tr>
<td>476</td>
<td>Bessel-Hagen disease</td>
</tr>
<tr>
<td>477</td>
<td>Glucuronyltransferase/N-acetylglucosaminyltransferase deficiency</td>
</tr>
<tr>
<td>478</td>
<td>EXT1/EXT2-CDG</td>
</tr>
<tr>
<td>479</td>
<td>Diaphyseal aclasis</td>
</tr>
<tr>
<td>480</td>
<td>Multiple congenital exostoses</td>
</tr>
<tr>
<td>481</td>
<td>Mucolipidosis</td>
</tr>
<tr>
<td>482</td>
<td>Mucolipidosis type 3</td>
</tr>
<tr>
<td>483</td>
<td>Pseudo-Hurler polydystrophy</td>
</tr>
<tr>
<td>484</td>
<td>Pseudo-Hurler disease</td>
</tr>
<tr>
<td>485</td>
<td>Mucolipidosis type 2</td>
</tr>
<tr>
<td>486</td>
<td>N-acetyl-glucosamine 1-phosphotransferase deficiency</td>
</tr>
<tr>
<td>487</td>
<td>I-cell disease</td>
</tr>
<tr>
<td>488</td>
<td>Inclusion cell disease</td>
</tr>
<tr>
<td>489</td>
<td>Paraneoplastic or autoimmune disorders of the central nervous system, brain or spinal cord</td>
</tr>
<tr>
<td>490</td>
<td>Paraneoplastic encephalitis</td>
</tr>
<tr>
<td>491</td>
<td>Paraneoplastic encephalitis, neural autoantibody positive</td>
</tr>
<tr>
<td>492</td>
<td>Paraneoplastic encephalitis, neural autoantibody negative</td>
</tr>
<tr>
<td>493</td>
<td>Autoimmune encephalitis</td>
</tr>
<tr>
<td>494</td>
<td>Hashimoto encephalitis</td>
</tr>
<tr>
<td>495</td>
<td>non-vasculitic autoimmune meningoencephalitis</td>
</tr>
<tr>
<td>496</td>
<td>Autoimmune encephalitis, neural autoantibody positive</td>
</tr>
<tr>
<td>497</td>
<td>Autoimmune encephalitis, neural autoantibody negative</td>
</tr>
<tr>
<td>498</td>
<td>Paraneoplastic encephalopathy</td>
</tr>
<tr>
<td>499</td>
<td>Autoimmune encephalopathy</td>
</tr>
<tr>
<td>500</td>
<td>Hashimoto’s encephalopathy</td>
</tr>
<tr>
<td>501</td>
<td>immunotherapy responsive encephalopathy</td>
</tr>
<tr>
<td>502</td>
<td>autoimmune dementia</td>
</tr>
<tr>
<td>503</td>
<td>SREAT - [steroid-responsive-encephalopathy-associated with autoimmune thyroiditis]</td>
</tr>
<tr>
<td>504</td>
<td>Paraneoplastic limbic encephalitis</td>
</tr>
<tr>
<td>505</td>
<td>Paraneoplastic limbic encephalitis, neural autoantibody positive</td>
</tr>
<tr>
<td>506</td>
<td>Paraneoplastic limbic encephalitis, neural autoantibody negative</td>
</tr>
<tr>
<td>507</td>
<td>Autoimmune limbic encephalitis</td>
</tr>
<tr>
<td>508</td>
<td>Autoimmune limbic encephalitis, Neural autoantibody positive</td>
</tr>
<tr>
<td>509</td>
<td>Autoimmune limbic encephalitis, Neural autoantibody negative</td>
</tr>
<tr>
<td>510</td>
<td>Paraneoplastic brainstem encephalitis</td>
</tr>
<tr>
<td>511</td>
<td>Paraneoplastic rhomboencephalitis</td>
</tr>
<tr>
<td>512</td>
<td>paraneoplastic brain stem syndrome</td>
</tr>
<tr>
<td>513</td>
<td>Paraneoplastic brainstem encephalitis, neural autoantibody positive</td>
</tr>
<tr>
<td>514</td>
<td>Paraneoplastic brainstem encephalitis, neural autoantibody negative</td>
</tr>
<tr>
<td>515</td>
<td>Autoimmune brainstem encephalitis</td>
</tr>
<tr>
<td>516</td>
<td>autoimmune rhomboencephalitis</td>
</tr>
<tr>
<td>517</td>
<td>Autoimmune brainstem encephalitis, neural autoantibody positive</td>
</tr>
<tr>
<td>518</td>
<td>Autoimmune brainstem encephalitis, neural autoantibody negative</td>
</tr>
<tr>
<td>519</td>
<td>Paraneoplastic cerebellar degeneration</td>
</tr>
<tr>
<td>520</td>
<td>paraneoplastic ataxia</td>
</tr>
<tr>
<td>521</td>
<td>Paraneoplastic cerebellar degeneration, neural autoantibody positive</td>
</tr>
<tr>
<td>522</td>
<td>Paraneoplastic cerebellar degeneration, neural autoantibody negative</td>
</tr>
<tr>
<td>523</td>
<td>Autoimmune cerebellar degeneration or cerebellitis</td>
</tr>
<tr>
<td>524</td>
<td>autoimmune ataxia</td>
</tr>
<tr>
<td>525</td>
<td>Autoimmune cerebellar degeneration or cerebellitis, neural autoantibody positive</td>
</tr>
<tr>
<td>526</td>
<td>Autoimmune cerebellar degeneration or cerebellitis, neural autoantibody negative</td>
</tr>
<tr>
<td>527</td>
<td>Paraneoplastic encephalomyelitis</td>
</tr>
<tr>
<td>528</td>
<td>Paraneoplastic encephalomyelitis, neural autoantibody positive</td>
</tr>
<tr>
<td>529</td>
<td>Paraneoplastic encephalomyelitis, neural autoantibody negative</td>
</tr>
<tr>
<td>530</td>
<td>Paraneoplastic movement disorder</td>
</tr>
<tr>
<td>531</td>
<td>Paraneoplastic movement disorder, autoantibody positive</td>
</tr>
<tr>
<td>532</td>
<td>Paraneoplastic movement disorder, autoantibody negative</td>
</tr>
<tr>
<td>533</td>
<td>Paraneoplastic chorea</td>
</tr>
<tr>
<td>534</td>
<td>Paraneoplastic dyskinesia</td>
</tr>
<tr>
<td>535</td>
<td>Autoimmune movement disorder</td>
</tr>
<tr>
<td>536</td>
<td>paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections [PANDAS]</td>
</tr>
<tr>
<td>537</td>
<td>Autoimmune movement disorder, autoantibody positive</td>
</tr>
<tr>
<td>538</td>
<td>Autoimmune movement disorder, autoantibody negative</td>
</tr>
<tr>
<td>539</td>
<td>Autoimmune chorea</td>
</tr>
<tr>
<td>540</td>
<td>Autoimmune dyskinesia</td>
</tr>
<tr>
<td>541</td>
<td>Autoimmune dystonia</td>
</tr>
<tr>
<td>542</td>
<td>Autoimmune myoclonus</td>
</tr>
<tr>
<td>543</td>
<td>Paraneoplastic myelopathy</td>
</tr>
<tr>
<td>544</td>
<td>Paraneoplastic myelitis</td>
</tr>
<tr>
<td>545</td>
<td>Paraneoplastic myelopathy, neural autoantibody positive</td>
</tr>
<tr>
<td>546</td>
<td>Paraneoplastic myelopathy, neural autoantibody negative</td>
</tr>
<tr>
<td>547</td>
<td>Autoimmune myelopathy</td>
</tr>
<tr>
<td>548</td>
<td>autoimmune myelitis</td>
</tr>
<tr>
<td>549</td>
<td>Autoimmune myelopathy, neural autoantibody positive</td>
</tr>
<tr>
<td>550</td>
<td>Autoimmune myelopathy, neural autoantibody negative</td>
</tr>
<tr>
<td>551</td>
<td>Stiff person syndrome</td>
</tr>
<tr>
<td>552</td>
<td>stiff man syndrome</td>
</tr>
<tr>
<td>553</td>
<td>Moersch-Woltman syndrome</td>
</tr>
<tr>
<td>554</td>
<td>Stiff person syndrome classic form</td>
</tr>
<tr>
<td>555</td>
<td>Stiff person syndrome classic form, glutamic acid decarboxylase-autoantibody positive</td>
</tr>
<tr>
<td>556</td>
<td>Stiff person syndrome classic form, other neural autoantibody negative</td>
</tr>
<tr>
<td>557</td>
<td>Stiff person syndrome classic form, other neural autoantibody positive</td>
</tr>
<tr>
<td>558</td>
<td>Paraneoplastic stiff person syndrome classic form</td>
</tr>
<tr>
<td>559</td>
<td>Stiff person syndrome variant form</td>
</tr>
<tr>
<td>560</td>
<td>Stiff person syndrome variant form, glutamic acid decarboxylase autoantibody positive</td>
</tr>
<tr>
<td>561</td>
<td>Stiff person syndrome variant form, other neural antibody positive</td>
</tr>
<tr>
<td>562</td>
<td>Stiff person syndrome variant form, neural antibody negative</td>
</tr>
<tr>
<td>563</td>
<td>Paraneoplastic stiff person syndrome variant form</td>
</tr>
<tr>
<td>564</td>
<td>Neuromyelitis optica spectrum disorder</td>
</tr>
<tr>
<td>565</td>
<td>Certain specified neurological disorder aquaporin-4 antibody positive</td>
</tr>
<tr>
<td>566</td>
<td>Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids</td>
</tr>
<tr>
<td>567</td>
<td>CLIPPERS - [Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids]</td>
</tr>
<tr>
<td>568</td>
<td>Anti-NMDA receptor encephalitis</td>
</tr>
<tr>
<td>569</td>
<td>Post infectious encephalitis</td>
</tr>
<tr>
<td>570</td>
<td>Acute demyelinating encephalomyelopathy</td>
</tr>
<tr>
<td>571</td>
<td>Paraneoplastic dystonia</td>
</tr>
<tr>
<td>572</td>
<td>Recessive limb-girdle muscular dystrophy</td>
</tr>
<tr>
<td>573</td>
<td>LGMD2 - [Limb-girdle muscular dystrophy] 2</td>
</tr>
<tr>
<td>574</td>
<td>Limb-girdle muscular dystrophy 2A, calpain-3 deficiency</td>
</tr>
<tr>
<td>575</td>
<td>Limb-girdle muscular dystrophy 2B, dysferlin deficiency</td>
</tr>
<tr>
<td>576</td>
<td>Limb-girdle muscular dystrophy 2C, gamma-sarcoglycan deficiency</td>
</tr>
<tr>
<td>577</td>
<td>Limb-girdle muscular dystrophy 2D, alpha-sarcoglycan deficiency</td>
</tr>
<tr>
<td>578</td>
<td>Limb-girdle muscular dystrophy 2E, beta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>579</td>
<td>Limb-girdle muscular dystrophy 2F, delta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>580</td>
<td>Limb-girdle muscular dystrophy 2G, telethonin gene mutation</td>
</tr>
<tr>
<td>581</td>
<td>Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation</td>
</tr>
<tr>
<td>582</td>
<td>LGMD 2H - [Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation]</td>
</tr>
<tr>
<td>583</td>
<td>Limb-girdle muscular dystrophy 2I, fukutin related protein gene mutation</td>
</tr>
<tr>
<td>584</td>
<td>FKRP - [fukutin related protein gene mutation]</td>
</tr>
<tr>
<td>585</td>
<td>LGMD 2I - [Limb-girdle muscular dystrophy 2I]</td>
</tr>
<tr>
<td>586</td>
<td>Limb-girdle muscular dystrophy 2J, Titin gene mutation</td>
</tr>
<tr>
<td>587</td>
<td>LGMD 2J - [Limb-girdle muscular dystrophy 2J, Titin gene mutation]</td>
</tr>
<tr>
<td>588</td>
<td>Limb-girdle muscular dystrophy 2K, protein-O-mannosyltransferase 1 transferase</td>
</tr>
<tr>
<td>589</td>
<td>POMT1 - [protein-O-mannosyltransferase 1 transferase]</td>
</tr>
<tr>
<td>590</td>
<td>LGMD 2K - [Limb-girdle muscular dystrophy 2K]</td>
</tr>
<tr>
<td>591</td>
<td>Limb-girdle muscular dystrophy 2L, AN05 gene mutation</td>
</tr>
<tr>
<td>592</td>
<td>LGMD 2L - [Limb-girdle muscular dystrophy 2L]</td>
</tr>
<tr>
<td>593</td>
<td>Limb-girdle muscular dystrophy 2M, POMGnT1 gene mutation</td>
</tr>
<tr>
<td>594</td>
<td>LGMD2M - [limb-girdle muscular dystrophy 2M]</td>
</tr>
<tr>
<td>595</td>
<td>Limb-girdle muscular dystrophy 2N, POMT2 gene mutation</td>
</tr>
<tr>
<td>596</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C2)</td>
</tr>
<tr>
<td>597</td>
<td>MDDGC2</td>
</tr>
<tr>
<td>598</td>
<td>LGMD2N - limb-girdle muscular dystrophy 2N]</td>
</tr>
<tr>
<td>599</td>
<td>Limb-girdle muscular dystrophy 2O, POMGNT1 gene mutation</td>
</tr>
<tr>
<td>600</td>
<td>LGMD2O - [limb-girdle muscular dystrophy 2O]</td>
</tr>
<tr>
<td>601</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C3)</td>
</tr>
<tr>
<td>602</td>
<td>MDDGC3</td>
</tr>
<tr>
<td>603</td>
<td>Limb-girdle muscular dystrophy 2Q, plectin deficiency</td>
</tr>
<tr>
<td>604</td>
<td>LGMD2Q - [limb-girdle muscular dystrophy 2Q]</td>
</tr>
<tr>
<td>605</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy C7</td>
</tr>
<tr>
<td>606</td>
<td>MDDGC7</td>
</tr>
<tr>
<td>607</td>
<td>Other specified disorders of urea cycle metabolism</td>
</tr>
<tr>
<td>608</td>
<td>Ornithine carbamoyltransferase deficiency</td>
</tr>
<tr>
<td>609</td>
<td>Ornithine carbamyltransferase deficiency</td>
</tr>
<tr>
<td>610</td>
<td>Ornithine transcarbamoylase deficiency</td>
</tr>
<tr>
<td>611</td>
<td>Ornithine transcarbamylase deficiency</td>
</tr>
<tr>
<td>612</td>
<td>OCT - [Ornithine carbamyltransferase] deficiency</td>
</tr>
<tr>
<td>613</td>
<td>Hyperammonaemia due to N-acetylglutamate synthetase deficiency</td>
</tr>
<tr>
<td>614</td>
<td>NAGS - [Hyperammonaemia due to N-acetylglutamate synthetase] deficiency</td>
</tr>
<tr>
<td>615</td>
<td>Transient hyperammonaemia of the newborn</td>
</tr>
<tr>
<td>616</td>
<td>Transient neonatal hyperammonaemia</td>
</tr>
<tr>
<td>617</td>
<td>Transient hyperammonaemia of infancy</td>
</tr>
<tr>
<td>618</td>
<td>THAN - [Transient hyperammonaemia of the newborn]</td>
</tr>
<tr>
<td>619</td>
<td>Hyperornithinaemia-hyperammonaemia-homocitrullinuria</td>
</tr>
<tr>
<td>620</td>
<td>Triple H syndrome</td>
</tr>
<tr>
<td>621</td>
<td>HHH - [Hyperornithinaemia-hyperammonaemia-homocitrullinuria] syndrome</td>
</tr>
<tr>
<td>622</td>
<td>Hyperinsulinism-hyperammonaemia syndrome</td>
</tr>
<tr>
<td>623</td>
<td>Other disorders of the urea cycle</td>
</tr>
<tr>
<td>624</td>
<td>Unspecified hyperammonaemia</td>
</tr>
<tr>
<td>625</td>
<td>Congenital hyperammonaemia</td>
</tr>
<tr>
<td>626</td>
<td>Other specified disorders of glycine metabolism</td>
</tr>
<tr>
<td>627</td>
<td>D-glyceric acidaemia</td>
</tr>
<tr>
<td>628</td>
<td>D-glyceric aciduria</td>
</tr>
<tr>
<td>629</td>
<td>D-glycerate kinase deficiency</td>
</tr>
<tr>
<td>630</td>
<td>Sarcosinuria</td>
</tr>
<tr>
<td>631</td>
<td>Demethylation defect of N-methylglycine</td>
</tr>
<tr>
<td>632</td>
<td>Glucoglycinuria</td>
</tr>
<tr>
<td>633</td>
<td>Glycinaemia</td>
</tr>
<tr>
<td>634</td>
<td>Hyperglycinaemia</td>
</tr>
<tr>
<td>635</td>
<td>Immunodeficiencies with severe reduction in serum IgG or IgA with normal or elevated IgM and normal numbers of B-cells</td>
</tr>
<tr>
<td>636</td>
<td>Hyper IgM</td>
</tr>
<tr>
<td>637</td>
<td>Activation-induced cytidine deaminase deficiency</td>
</tr>
<tr>
<td>638</td>
<td>Hyper-IgM syndrome type 2</td>
</tr>
<tr>
<td>639</td>
<td>Hyper-IgM syndrome due to AID deficiency</td>
</tr>
<tr>
<td>640</td>
<td>Hyper-IgM syndrome due to AICDA deficiency</td>
</tr>
<tr>
<td>641</td>
<td>HIGM2 - [hyper-IgM syndrome type 2]</td>
</tr>
<tr>
<td>642</td>
<td>Hyper-IgM syndrome due to uracil N glycosylase</td>
</tr>
<tr>
<td>643</td>
<td>Hyper-IgM syndrome type 5</td>
</tr>
<tr>
<td>644</td>
<td>Hyper-IgM syndrome due to UNG - [uracil N glycosylase] deficiency</td>
</tr>
<tr>
<td>645</td>
<td>HIGM5 - [hyper-IgM syndrome type 5]</td>
</tr>
<tr>
<td>646</td>
<td>Charcot-Marie-Tooth disease 2 axonal</td>
</tr>
<tr>
<td>647</td>
<td>Charcot-Marie-Tooth disease 2 autosomal dominant</td>
</tr>
<tr>
<td>648</td>
<td>Recessive axonal Charcot-Marie-Tooth disease with acrodystrophy</td>
</tr>
<tr>
<td>649</td>
<td>Charcot-Marie-Tooth disease type 2A1</td>
</tr>
<tr>
<td>650</td>
<td>Charcot-Marie-Tooth disease type 2A2</td>
</tr>
<tr>
<td>651</td>
<td>Charcot-Marie-Tooth disease type 2B</td>
</tr>
<tr>
<td>652</td>
<td>Charcot-Marie-Tooth disease type 2C</td>
</tr>
<tr>
<td>653</td>
<td>Charcot-Marie-Tooth disease type 2D</td>
</tr>
<tr>
<td>654</td>
<td>Charcot-Marie-Tooth disease type 2E</td>
</tr>
<tr>
<td>655</td>
<td>Charcot-Marie-Tooth disease type 2F</td>
</tr>
<tr>
<td>656</td>
<td>Charcot-Marie-Tooth disease type 2G</td>
</tr>
<tr>
<td>657</td>
<td>Charcot-Marie-Tooth disease type 2I</td>
</tr>
<tr>
<td>658</td>
<td>Charcot-Marie-Tooth disease type 2J</td>
</tr>
<tr>
<td>659</td>
<td>Charcot-Marie-Tooth disease type 2K</td>
</tr>
<tr>
<td>660</td>
<td>Charcot-Marie-Tooth disease type 2L</td>
</tr>
<tr>
<td>661</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2M</td>
</tr>
<tr>
<td>662</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2N</td>
</tr>
<tr>
<td>663</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2O</td>
</tr>
<tr>
<td>664</td>
<td>Charcot-Marie-Tooth disease 2 autosomal recessive</td>
</tr>
<tr>
<td>665</td>
<td>Charcot-Marie-Tooth disease type 2B1</td>
</tr>
<tr>
<td>666</td>
<td>Charcot-Marie-Tooth disease type 2B2</td>
</tr>
<tr>
<td>667</td>
<td>Charcot-Marie-Tooth disease type 2B5</td>
</tr>
<tr>
<td>668</td>
<td>Charcot-Marie-Tooth disease type 2H</td>
</tr>
<tr>
<td>669</td>
<td>Autosomal recessive Charcot-Marie-Tooth disease with hoarseness</td>
</tr>
<tr>
<td>670</td>
<td>Hereditary motor and sensory neuropathy type 6</td>
</tr>
<tr>
<td>671</td>
<td>Charcot-Marie-Tooth type 6</td>
</tr>
<tr>
<td>672</td>
<td>HMSN6 - [Hereditary motor and sensory neuropathy type 6]</td>
</tr>
<tr>
<td>673</td>
<td>CMT6 - [Charcot-Marie-Tooth type 6]</td>
</tr>
<tr>
<td>674</td>
<td>Gangliosidosis</td>
</tr>
<tr>
<td>675</td>
<td>GM1 gangliosidosis</td>
</tr>
<tr>
<td>676</td>
<td>Landing disease</td>
</tr>
<tr>
<td>677</td>
<td>GM1 gangliosidosis type 1</td>
</tr>
<tr>
<td>678</td>
<td>Generalised gangliosidosis</td>
</tr>
<tr>
<td>679</td>
<td>Infantile GM1 gangliosidosis</td>
</tr>
<tr>
<td>680</td>
<td>GM1 gangliosidosis type 2</td>
</tr>
<tr>
<td>681</td>
<td>Juvenile GM1 gangliosidosis</td>
</tr>
<tr>
<td>682</td>
<td>GM1 gangliosidosis type 3</td>
</tr>
<tr>
<td>683</td>
<td>Adult GM1 gangliosidosis</td>
</tr>
<tr>
<td>684</td>
<td>GM2 gangliosidosis</td>
</tr>
<tr>
<td>685</td>
<td>deficiency of beta-n-acetylhexosaminidase isoenzymes</td>
</tr>
<tr>
<td>686</td>
<td>GM&lt;sub&gt;2&lt;/sub&gt; gangliosidosis</td>
</tr>
<tr>
<td>687</td>
<td>GM 2 gangliosidosis NOS</td>
</tr>
<tr>
<td>688</td>
<td>Retinal dystrophy in GM2 gangliosidosis</td>
</tr>
<tr>
<td>689</td>
<td>Sandhoff disease</td>
</tr>
<tr>
<td>690</td>
<td>GM2 gangliosidosis type 2</td>
</tr>
<tr>
<td>691</td>
<td>GM2 gangliosidosis 0 variant</td>
</tr>
<tr>
<td>692</td>
<td>Hexosaminidase A and B deficiency</td>
</tr>
<tr>
<td>693</td>
<td>Total hexosaminidase deficiency</td>
</tr>
<tr>
<td>694</td>
<td>GM&gt;2&lt; gangliosidosis, type 2</td>
</tr>
<tr>
<td>695</td>
<td>GM&lt;sub&gt;2&lt;/sub&gt; gangliosidosis, type 2</td>
</tr>
<tr>
<td>696</td>
<td>Infantile Sandhoff disease</td>
</tr>
<tr>
<td>697</td>
<td>Total hexosaminidase deficiency, infantile form</td>
</tr>
<tr>
<td>698</td>
<td>infantile GM2 gangliosidosis</td>
</tr>
<tr>
<td>699</td>
<td>infantile GM&lt;sub&gt;2&lt;/sub&gt; gangliosidosis</td>
</tr>
<tr>
<td>700</td>
<td>infantile GM&gt;2&lt; gangliosidosis</td>
</tr>
<tr>
<td>701</td>
<td>Juvenile Sandhoff disease</td>
</tr>
<tr>
<td>702</td>
<td>Total hexosaminidase deficiency, juvenile form</td>
</tr>
<tr>
<td>703</td>
<td>juvenile GM2 gangliosidosis</td>
</tr>
<tr>
<td>704</td>
<td>juvenile GM&lt;sub&gt;2&lt;/sub&gt; gangliosidosis</td>
</tr>
<tr>
<td>705</td>
<td>juvenile GM&gt;2&lt; gangliosidosis</td>
</tr>
<tr>
<td>706</td>
<td>Adult Sandhoff disease</td>
</tr>
<tr>
<td>707</td>
<td>Total hexosaminidase deficiency, adult form</td>
</tr>
<tr>
<td>708</td>
<td>adult GM2 gangliosidosis</td>
</tr>
<tr>
<td>709</td>
<td>Tay-Sachs disease</td>
</tr>
<tr>
<td>710</td>
<td>GM2-gangliosidosis, B, B1, AB variant</td>
</tr>
<tr>
<td>711</td>
<td>Hexosaminidase A deficiency</td>
</tr>
<tr>
<td>712</td>
<td>severe hexosaminidase a deficiency</td>
</tr>
<tr>
<td>713</td>
<td>B variant of hexosaminidase A deficiency</td>
</tr>
<tr>
<td>714</td>
<td>B variant of hexosaminidase A deficiency, infantile form</td>
</tr>
<tr>
<td>715</td>
<td>Classic infantile acute Tay-Sachs disease</td>
</tr>
<tr>
<td>716</td>
<td>GM2 gangliosidosis type 1</td>
</tr>
<tr>
<td>717</td>
<td>GM&lt;sub&gt;2&lt;/sub&gt; gangliosidosis, type 1</td>
</tr>
<tr>
<td>718</td>
<td>GM&gt;2&lt; gangliosidosis, type 1</td>
</tr>
<tr>
<td>719</td>
<td>B variant of hexosaminidase A deficiency, juvenile form</td>
</tr>
<tr>
<td>720</td>
<td>Juvenile subacute Tay-Sachs disease</td>
</tr>
<tr>
<td>721</td>
<td>GM2 gangliosidosis type 3</td>
</tr>
<tr>
<td>722</td>
<td>GM&lt;sub&gt;2&lt;/sub&gt; gangliosidosis, type 3</td>
</tr>
<tr>
<td>723</td>
<td>GM&gt;2&lt; gangliosidosis, type 3</td>
</tr>
<tr>
<td>724</td>
<td>B variant of hexosaminidase A deficiency, adult form</td>
</tr>
<tr>
<td>725</td>
<td>Adult Tay-Sachs disease</td>
</tr>
<tr>
<td>726</td>
<td>Chronic GM2 gangliosidosis</td>
</tr>
<tr>
<td>727</td>
<td>B1 variant of hexosaminidase A deficiency</td>
</tr>
<tr>
<td>728</td>
<td>Late infantile Tay-Sachs disease</td>
</tr>
<tr>
<td>729</td>
<td>Pseudo-AB variant of hexosaminidase deficiency</td>
</tr>
<tr>
<td>730</td>
<td>Hexosaminidase activator deficiency</td>
</tr>
<tr>
<td>731</td>
<td>GM2 activator deficiency</td>
</tr>
<tr>
<td>732</td>
<td>AB variant of hexosaminidase deficiency</td>
</tr>
<tr>
<td>733</td>
<td>Autoimmune disorders involving the autonomic nervous system</td>
</tr>
<tr>
<td>734</td>
<td>Autonomic disorder due to Multiple Sclerosis</td>
</tr>
<tr>
<td>735</td>
<td>Autonomic disorder due to Encephalitis</td>
</tr>
<tr>
<td>736</td>
<td>Autoimmune disorder due to encephalitis with NMDA receptor antibodies</td>
</tr>
<tr>
<td>737</td>
<td>Autonomic disorder due to Encephalitis with voltage gated potassium channel antibodies</td>
</tr>
<tr>
<td>738</td>
<td>Progressive encephalitis with rigidity or myoclonus</td>
</tr>
<tr>
<td>739</td>
<td>Autonomic disorder due to glutamic acid decarboxylase antibodies</td>
</tr>
<tr>
<td>1</td>
<td>Dystrophic epidermolysis bullosa</td>
</tr>
<tr>
<td>2</td>
<td>Epidermolysis bullosa dystrophica</td>
</tr>
<tr>
<td>3</td>
<td>Dystrophic EB - [epidermolysis bullosa]</td>
</tr>
<tr>
<td>4</td>
<td>Autosomal dominant dystrophic epidermolysis bullosa</td>
</tr>
<tr>
<td>5</td>
<td>Dominant dystrophic epidermolysis bullosa, generalised</td>
</tr>
<tr>
<td>6</td>
<td>DDEB-gen - [dominant dystrophic epidermolysis bullosa, generalised]</td>
</tr>
<tr>
<td>7</td>
<td>DDEB, generalised - [dominant dystrophic epidermolysis bullosa, generalised]</td>
</tr>
<tr>
<td>8</td>
<td>Dominant dystrophic epidermolysis bullosa, acral</td>
</tr>
<tr>
<td>9</td>
<td>Acral dystrophic epidermolysis bullosa</td>
</tr>
<tr>
<td>10</td>
<td>DDEB-acral - [dominant dystrophic epidermolysis bullosa, acral]</td>
</tr>
<tr>
<td>11</td>
<td>DDEB-ac - [dominant dystrophic epidermolysis bullosa, acral]</td>
</tr>
<tr>
<td>12</td>
<td>Dominant dystrophic epidermolysis bullosa, pretibial</td>
</tr>
<tr>
<td>13</td>
<td>DDEB-pretibial - [dominant dystrophic epidermolysis bullosa, pretibial]</td>
</tr>
<tr>
<td>14</td>
<td>DDEB-Pt - [dominant dystrophic epidermolysis bullosa, pretibial]</td>
</tr>
<tr>
<td>15</td>
<td>Dominant dystrophic epidermolysis bullosa pruriginosa</td>
</tr>
<tr>
<td>16</td>
<td>DDEB pruriginosa - [dominant dystrophic epidermolysis bullosa pruriginosa]</td>
</tr>
<tr>
<td>17</td>
<td>DDEB-Pr - [dominant dystrophic epidermolysis bullosa pruriginosa]</td>
</tr>
<tr>
<td>18</td>
<td>Dominant dystrophic epidermolysis bullosa, nails only</td>
</tr>
<tr>
<td>19</td>
<td>Dystrophic epidermolysis bullosa, nails only</td>
</tr>
<tr>
<td>20</td>
<td>DDEB, nails only - [dominant dystrophic epidermolysis bullosa, nails only]</td>
</tr>
<tr>
<td>21</td>
<td>DDEB-na - [dominant dystrophic epidermolysis bullosa, nails only]</td>
</tr>
<tr>
<td>22</td>
<td>Dominant bullous dermolysis of the newborn</td>
</tr>
<tr>
<td>23</td>
<td>DDEB-BDN - [dominant bullous dermolysis of the newborn]</td>
</tr>
<tr>
<td>24</td>
<td>Autosomal recessive dystrophic epidermolysis bullosa</td>
</tr>
<tr>
<td>25</td>
<td>Recessive dystrophic epidermolysis bullosa, generalised severe</td>
</tr>
<tr>
<td>26</td>
<td>RDEB Hallopeau-Siemens</td>
</tr>
<tr>
<td>27</td>
<td>RDEB-GS - [recessive dystrophic epidermolysis bullosa, generalised severe]</td>
</tr>
<tr>
<td>28</td>
<td>RDEB-gen sev - [recessive dystrophic epidermolysis bullosa, generalised severe]</td>
</tr>
<tr>
<td>29</td>
<td>Recessive dystrophic epidermolysis bullosa, generalised intermediate</td>
</tr>
<tr>
<td>30</td>
<td>RDEB-O - [recessive dystrophic epidermolysis bullosa, generalised other]</td>
</tr>
<tr>
<td>31</td>
<td>RDEB-gen intermed - [recessive dystrophic epidermolysis, generalised intermediate]</td>
</tr>
<tr>
<td>32</td>
<td>Recessive dystrophic epidermolysis bullosa inversa</td>
</tr>
<tr>
<td>33</td>
<td>RDEB - [recessive dystrophic epidermolysis bullosa] inversa</td>
</tr>
<tr>
<td>34</td>
<td>RDEB-I - [recessive dystrophic epidermolysis bullosa inversa]</td>
</tr>
<tr>
<td>35</td>
<td>RDEB-inv - [recessive dystrophic epidermolysis bullosa inversa]</td>
</tr>
<tr>
<td>36</td>
<td>Recessive dystrophic epidermolysis bullosa, pretibial</td>
</tr>
<tr>
<td>37</td>
<td>RDEB - [recessive dystrophic epidermolysis bullosa] pretibial</td>
</tr>
<tr>
<td>38</td>
<td>RDEB-Pt - [recessive dystrophic epidermolysis bullosa, pretibial]</td>
</tr>
<tr>
<td>39</td>
<td>Recessive dystrophic epidermolysis bullosa pruriginosa</td>
</tr>
<tr>
<td>40</td>
<td>RDEB - [recessive dystrophic epidermolysis bullosa] pruriginosa</td>
</tr>
<tr>
<td>41</td>
<td>RDEB-Pr - [recessive dystrophic epidermolysis bullosa pruriginosa]</td>
</tr>
<tr>
<td>42</td>
<td>Recessive dystrophic epidermolysis bullosa centripetalis</td>
</tr>
<tr>
<td>43</td>
<td>RDEB - [recessive dystrophic epidermolysis bullosa centripetalis] centripetalis</td>
</tr>
<tr>
<td>44</td>
<td>RDEB-Ce - [recessive dystrophic epidermolysis bullosa centripetalis]</td>
</tr>
<tr>
<td>45</td>
<td>Recessive bullous dermolysis of the newborn</td>
</tr>
<tr>
<td>46</td>
<td>Bullous dermolysis of the newborn (recessive)</td>
</tr>
<tr>
<td>47</td>
<td>Recessive transient bullous dermolysis of the newborn</td>
</tr>
<tr>
<td>48</td>
<td>RDEB-BDN - [recessive bullous dermolysis of the newborn]</td>
</tr>
<tr>
<td>49</td>
<td>Haemoglobin O disease</td>
</tr>
<tr>
<td>50</td>
<td>Arab disease</td>
</tr>
<tr>
<td>51</td>
<td>Disorders of protein N-glycosylation</td>
</tr>
<tr>
<td>52</td>
<td>Phosphomannomutase 2 deficiency</td>
</tr>
<tr>
<td>53</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1A</td>
</tr>
<tr>
<td>54</td>
<td>Congenital disorder of glycosylation type 1A</td>
</tr>
<tr>
<td>55</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1A</td>
</tr>
<tr>
<td>56</td>
<td>Phosphomannose isomerase deficiency</td>
</tr>
<tr>
<td>57</td>
<td>Saguenay-Lac-Saint-Jean syndrome</td>
</tr>
<tr>
<td>58</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1B</td>
</tr>
<tr>
<td>59</td>
<td>Congenital disorder of glycosylation type 1B</td>
</tr>
<tr>
<td>60</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1B</td>
</tr>
<tr>
<td>61</td>
<td>SLSJ - [Saguenay-Lac-Saint-Jean] syndrome</td>
</tr>
<tr>
<td>62</td>
<td>Glucosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>63</td>
<td>Dol-P-Glc: Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>64</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1C</td>
</tr>
<tr>
<td>65</td>
<td>Congenital disorder of glycosylation type 1C</td>
</tr>
<tr>
<td>66</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1C</td>
</tr>
<tr>
<td>67</td>
<td>Mannosyltransferase 6 deficiency</td>
</tr>
<tr>
<td>68</td>
<td>Dol-P-Man: Man5-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>69</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1D</td>
</tr>
<tr>
<td>70</td>
<td>Congenital disorder of glycosylation type 1D</td>
</tr>
<tr>
<td>71</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1D</td>
</tr>
<tr>
<td>72</td>
<td>Mannosyltransferase 8 deficiency</td>
</tr>
<tr>
<td>73</td>
<td>Dol-P-Man: Man7-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>74</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1G</td>
</tr>
<tr>
<td>75</td>
<td>Congenital disorder of glycosylation type 1G</td>
</tr>
<tr>
<td>76</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1G</td>
</tr>
<tr>
<td>77</td>
<td>Glucosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>78</td>
<td>Dol-P-Glc: Glc1-Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>79</td>
<td>Carbohydrate deficient glycoprotein syndrome 1H</td>
</tr>
<tr>
<td>80</td>
<td>Congenital disorder of glycosylation type 1H</td>
</tr>
<tr>
<td>81</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1H</td>
</tr>
<tr>
<td>82</td>
<td>Mannosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>83</td>
<td>Dol-P-Man: Man1-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>84</td>
<td>Carbohydrate deficient glycoprotein syndrome 1I</td>
</tr>
<tr>
<td>85</td>
<td>Congenital disorder of glycosylation 1I</td>
</tr>
<tr>
<td>86</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1I</td>
</tr>
<tr>
<td>87</td>
<td>Dolichyl-phosphate N-acetylgalactosamine phosphotransferase deficiency</td>
</tr>
<tr>
<td>88</td>
<td>UDP-GlcNAc: Dol-P-GlcNac-P transferase deficiency</td>
</tr>
<tr>
<td>89</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1J</td>
</tr>
<tr>
<td>90</td>
<td>Congenital disorder of glycosylation type 1J</td>
</tr>
<tr>
<td>91</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1J</td>
</tr>
<tr>
<td>92</td>
<td>Mannosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>93</td>
<td>Dol-P-Man: GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>94</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1K</td>
</tr>
<tr>
<td>95</td>
<td>Congenital disorder of glycosylation type 1K</td>
</tr>
<tr>
<td>96</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1K</td>
</tr>
<tr>
<td>97</td>
<td>Mannosyltransferase 7-9 deficiency</td>
</tr>
<tr>
<td>98</td>
<td>Congenital disorder of glycosylation type 1L</td>
</tr>
<tr>
<td>99</td>
<td>Dol-P-Man: Man6 and Man8-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>100</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1L</td>
</tr>
<tr>
<td>101</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1L</td>
</tr>
<tr>
<td>102</td>
<td>M5-DLO flippase deficiency</td>
</tr>
<tr>
<td>103</td>
<td>Man5GlcNAc2-PP-Dol flippase deficiency</td>
</tr>
<tr>
<td>104</td>
<td>RTF1-CDG</td>
</tr>
<tr>
<td>105</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1N</td>
</tr>
<tr>
<td>106</td>
<td>N-acetylglucosaminyltransferase deficiency</td>
</tr>
<tr>
<td>107</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2A</td>
</tr>
<tr>
<td>108</td>
<td>Congenital disorder of glycosylation type 2A</td>
</tr>
<tr>
<td>109</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2A</td>
</tr>
<tr>
<td>110</td>
<td>Glucosidase 1 deficiency</td>
</tr>
<tr>
<td>111</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2B</td>
</tr>
<tr>
<td>112</td>
<td>Congenital disorder of glycosylation type 2B</td>
</tr>
<tr>
<td>113</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2B</td>
</tr>
<tr>
<td>114</td>
<td>TUSC3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>115</td>
<td>TUSC3-CDG</td>
</tr>
<tr>
<td>116</td>
<td>SRD5A3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>117</td>
<td>SRD5A3-CDG</td>
</tr>
<tr>
<td>118</td>
<td>Congenital disorder of glycosylation due to steroid 5-alpha-reductase type 3 deficiency</td>
</tr>
<tr>
<td>119</td>
<td>Intellectual deficit - cataract - coloboma - kyphosis</td>
</tr>
<tr>
<td>120</td>
<td>Kahrizi syndrome</td>
</tr>
<tr>
<td>121</td>
<td>Intellectual deficit, Kahrizi type</td>
</tr>
<tr>
<td>122</td>
<td>DPM3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>123</td>
<td>Congenital disorder of glycosylation type 1O</td>
</tr>
<tr>
<td>124</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1O</td>
</tr>
<tr>
<td>125</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1O</td>
</tr>
<tr>
<td>126</td>
<td>ALG11 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>127</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1P</td>
</tr>
<tr>
<td>128</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1P</td>
</tr>
<tr>
<td>129</td>
<td>Congenital disorder of glycosylation type 1P</td>
</tr>
<tr>
<td>130</td>
<td>Phosphoglucomutase-1 deficiency</td>
</tr>
<tr>
<td>131</td>
<td>PGM1-CDG - [Phosphoglucomutase-1 deficiency]</td>
</tr>
<tr>
<td>132</td>
<td>Congenital disorder of glycosylation type 1t</td>
</tr>
<tr>
<td>133</td>
<td>Actinic elastosis</td>
</tr>
<tr>
<td>134</td>
<td>Solar elastosis</td>
</tr>
<tr>
<td>135</td>
<td>Elastosis senilis</td>
</tr>
<tr>
<td>136</td>
<td>Wrinkles secondary to chronic sun damage</td>
</tr>
<tr>
<td>137</td>
<td>Rhytides</td>
</tr>
<tr>
<td>138</td>
<td>Nodular actinic elastosis with cysts or comedones</td>
</tr>
<tr>
<td>139</td>
<td>Favre-Racouchot syndrome</td>
</tr>
<tr>
<td>140</td>
<td>Actinic comedonal plaque</td>
</tr>
<tr>
<td>141</td>
<td>Colloid milium</td>
</tr>
<tr>
<td>142</td>
<td>Colloid pseudomilium</td>
</tr>
<tr>
<td>143</td>
<td>Colloid degeneration of the skin</td>
</tr>
<tr>
<td>144</td>
<td>Adult colloid milium</td>
</tr>
<tr>
<td>145</td>
<td>Juvenile colloid milium</td>
</tr>
<tr>
<td>146</td>
<td>Cutis rhomboidalis nuchae</td>
</tr>
<tr>
<td>147</td>
<td>Actinic granuloma</td>
</tr>
<tr>
<td>148</td>
<td>O'Brien granuloma</td>
</tr>
<tr>
<td>149</td>
<td>Collagenous and elastotic marginal plaques of the hands</td>
</tr>
<tr>
<td>150</td>
<td>Degenerative collagenous plaques of the hands</td>
</tr>
<tr>
<td>151</td>
<td>Digital papular calcific elastosis</td>
</tr>
<tr>
<td>152</td>
<td>Keratoelastoidosis marginalis</td>
</tr>
<tr>
<td>153</td>
<td>Recessive limb-girdle muscular dystrophy</td>
</tr>
<tr>
<td>154</td>
<td>LGMD2 - [Limb-girdle muscular dystrophy] 2</td>
</tr>
<tr>
<td>155</td>
<td>Limb-girdle muscular dystrophy 2A, calpain-3 deficiency</td>
</tr>
<tr>
<td>156</td>
<td>Limb-girdle muscular dystrophy 2B, dysferlin deficiency</td>
</tr>
<tr>
<td>157</td>
<td>Limb-girdle muscular dystrophy 2C, gamma-sarcoglycan deficiency</td>
</tr>
<tr>
<td>158</td>
<td>Limb-girdle muscular dystrophy 2D, alpha-sarcoglycan deficiency</td>
</tr>
<tr>
<td>159</td>
<td>Limb-girdle muscular dystrophy 2E, beta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>160</td>
<td>Limb-girdle muscular dystrophy 2F, delta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>161</td>
<td>Limb-girdle muscular dystrophy 2G, telethonin gene mutation</td>
</tr>
<tr>
<td>162</td>
<td>Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation</td>
</tr>
<tr>
<td>163</td>
<td>LGMD 2H - [Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation]</td>
</tr>
<tr>
<td>164</td>
<td>Limb-girdle muscular dystrophy 2I, fukutin related protein gene mutation</td>
</tr>
<tr>
<td>165</td>
<td>FKRP - [fukutin related protein gene mutation]</td>
</tr>
<tr>
<td>166</td>
<td>LGMD 2I - [Limb-girdle muscular dystrophy 2I]</td>
</tr>
<tr>
<td>167</td>
<td>Limb-girdle muscular dystrophy 2J, Titin gene mutation</td>
</tr>
<tr>
<td>168</td>
<td>LGMD 2J - [Limb-girdle muscular dystrophy 2J, Titin gene mutation]</td>
</tr>
<tr>
<td>169</td>
<td>Limb-girdle muscular dystrophy 2K, protein-O-mannosyltransferase 1 transferase</td>
</tr>
<tr>
<td>170</td>
<td>POMT1 - [protein-O-mannosyltransferase 1 transferase]</td>
</tr>
<tr>
<td>171</td>
<td>LGMD 2K - [Limb-girdle muscular dystrophy 2K]</td>
</tr>
<tr>
<td>172</td>
<td>Limb-girdle muscular dystrophy 2L, AN05 gene mutation</td>
</tr>
<tr>
<td>173</td>
<td>LGMD 2L - [Limb-girdle muscular dystrophy 2L]</td>
</tr>
<tr>
<td>174</td>
<td>Limb-girdle muscular dystrophy 2M, POMGnT1 gene mutation</td>
</tr>
<tr>
<td>175</td>
<td>LGMD2M - [limb-girdle muscular dystrophy 2M]</td>
</tr>
<tr>
<td>176</td>
<td>Limb-girdle muscular dystrophy 2N, POMT2 gene mutation</td>
</tr>
<tr>
<td>177</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C2)</td>
</tr>
<tr>
<td>178</td>
<td>MDDGC2</td>
</tr>
<tr>
<td>179</td>
<td>LGMD2N - limb-girdle muscular dystrophy 2N]</td>
</tr>
<tr>
<td>180</td>
<td>Limb-girdle muscular dystrophy 2O, POMGNT1 gene mutation</td>
</tr>
<tr>
<td>181</td>
<td>LGMD2O - [limb-girdle muscular dystrophy 2O]</td>
</tr>
<tr>
<td>182</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C3)</td>
</tr>
<tr>
<td>183</td>
<td>MDDGC3</td>
</tr>
<tr>
<td>184</td>
<td>Limb-girdle muscular dystrophy 2Q, plectin deficiency</td>
</tr>
<tr>
<td>185</td>
<td>LGMD2Q - [limb-girdle muscular dystrophy 2Q]</td>
</tr>
<tr>
<td>186</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy C7</td>
</tr>
<tr>
<td>187</td>
<td>MDDGC7</td>
</tr>
<tr>
<td>188</td>
<td>Disorders of protein O-glycosylation</td>
</tr>
<tr>
<td>189</td>
<td>Defects in O-xylosylglycan synthesis</td>
</tr>
<tr>
<td>190</td>
<td>Beta-1,4-galactosyltransferase 7 deficiency</td>
</tr>
<tr>
<td>191</td>
<td>Defects in O-N-acetylgalactosaminylglycan synthesis</td>
</tr>
<tr>
<td>192</td>
<td>Polypeptide N-acetylgalactosaminyl transferase deficiency</td>
</tr>
<tr>
<td>193</td>
<td>Hyperphosphataemic familial tumoural calcinosis</td>
</tr>
<tr>
<td>194</td>
<td>Defects in O-xylosyl/N-acetylgalactosaminylglycan synthesis</td>
</tr>
<tr>
<td>195</td>
<td>Defects in O-mannosylglycan synthesis</td>
</tr>
<tr>
<td>196</td>
<td>Protein-O-mannosyltransferase 1</td>
</tr>
<tr>
<td>197</td>
<td>Protein-O-mannosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>198</td>
<td>Protein-O-mannose beta-1,2-N-acetyglucosaminyltransferase deficiency</td>
</tr>
<tr>
<td>199</td>
<td>Fukutin deficiency</td>
</tr>
<tr>
<td>200</td>
<td>Fukutin-related protein deficiency</td>
</tr>
<tr>
<td>201</td>
<td>N-acetylglucosaminyltransferase-like protein deficiency</td>
</tr>
<tr>
<td>202</td>
<td>O-fucose-specific beta-1,3-N-acetylglucosaminyltransferase deficiency</td>
</tr>
<tr>
<td>203</td>
<td>O-fucose-specific beta-1,3-N-glucosyltransferase deficiency</td>
</tr>
<tr>
<td>204</td>
<td>O'nyong-nyong fever</td>
</tr>
<tr>
<td>205</td>
<td>O'nyong-nyong mosquito-borne viral fever</td>
</tr>
<tr>
<td>206</td>
<td>O'nyong-nyong arthritis</td>
</tr>
<tr>
<td>207</td>
<td>ONN - [o'nyong-nyong fever]</td>
</tr>
<tr>
<td>208</td>
<td>Compound heterozygous sickling disorders without crisis</td>
</tr>
<tr>
<td>209</td>
<td>double heterozygous sickling disorder</td>
</tr>
<tr>
<td>210</td>
<td>Sickle cell Hb-C disease without crisis</td>
</tr>
<tr>
<td>211</td>
<td>Hb SC disease</td>
</tr>
<tr>
<td>212</td>
<td>Hb S Hb C disease</td>
</tr>
<tr>
<td>213</td>
<td>sickle-cell HbC disease</td>
</tr>
<tr>
<td>214</td>
<td>Sickle cell thalassaemia without crisis</td>
</tr>
<tr>
<td>215</td>
<td>sickle-cell thalassaemia</td>
</tr>
<tr>
<td>216</td>
<td>sickle-cell beta thalassaemia</td>
</tr>
<tr>
<td>217</td>
<td>haemoglobin s/beta thalassaemia</td>
</tr>
<tr>
<td>218</td>
<td>thalassaemia with haemoglobin S disease</td>
</tr>
<tr>
<td>219</td>
<td>microdrepanocytosis</td>
</tr>
<tr>
<td>220</td>
<td>double heterozygous for Hb S or beta thalassaemia</td>
</tr>
<tr>
<td>221</td>
<td>Compound HbS or HbC heterozygotes</td>
</tr>
<tr>
<td>222</td>
<td>Compound HbS, HbD-Punjab or Los Angeles heterozygotes</td>
</tr>
<tr>
<td>223</td>
<td>Hb-SD disease</td>
</tr>
<tr>
<td>224</td>
<td>Compound HbS or HbE heterozygotes</td>
</tr>
<tr>
<td>225</td>
<td>Hb SE disease</td>
</tr>
<tr>
<td>226</td>
<td>Compound HbS or O-Arab heterozygotes</td>
</tr>
<tr>
<td>227</td>
<td>Double heterozygous sickling disorders with retinopathy</td>
</tr>
<tr>
<td>228</td>
<td>Glomerular disorders in double heterozygous sickling disorders</td>
</tr>
<tr>
<td>229</td>
<td>Gouty arthropathy in double heterozygous sickling disorders</td>
</tr>
<tr>
<td>230</td>
<td>Compound HbS or beta thalassaemia heterozygotes</td>
</tr>
<tr>
<td>231</td>
<td>Compound HbS and beta thalassaemia heterozygotes including HbS/delta-beta-thal compounds</td>
</tr>
<tr>
<td>232</td>
<td>Hereditary persistence of fetal haemoglobin - sickle cell disease</td>
</tr>
<tr>
<td>233</td>
<td>Charcot-Marie-Tooth disease 2 axonal</td>
</tr>
<tr>
<td>234</td>
<td>Charcot-Marie-Tooth disease 2 autosomal dominant</td>
</tr>
<tr>
<td>235</td>
<td>Recessive axonal Charcot-Marie-Tooth disease with acrodystrophy</td>
</tr>
<tr>
<td>236</td>
<td>Charcot-Marie-Tooth disease type 2A1</td>
</tr>
<tr>
<td>237</td>
<td>Charcot-Marie-Tooth disease type 2A2</td>
</tr>
<tr>
<td>238</td>
<td>Charcot-Marie-Tooth disease type 2B</td>
</tr>
<tr>
<td>239</td>
<td>Charcot-Marie-Tooth disease type 2C</td>
</tr>
<tr>
<td>240</td>
<td>Charcot-Marie-Tooth disease type 2D</td>
</tr>
<tr>
<td>241</td>
<td>Charcot-Marie-Tooth disease type 2E</td>
</tr>
<tr>
<td>242</td>
<td>Charcot-Marie-Tooth disease type 2F</td>
</tr>
<tr>
<td>243</td>
<td>Charcot-Marie-Tooth disease type 2G</td>
</tr>
<tr>
<td>244</td>
<td>Charcot-Marie-Tooth disease type 2I</td>
</tr>
<tr>
<td>245</td>
<td>Charcot-Marie-Tooth disease type 2J</td>
</tr>
<tr>
<td>246</td>
<td>Charcot-Marie-Tooth disease type 2K</td>
</tr>
<tr>
<td>247</td>
<td>Charcot-Marie-Tooth disease type 2L</td>
</tr>
<tr>
<td>248</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2M</td>
</tr>
<tr>
<td>249</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2N</td>
</tr>
<tr>
<td>250</td>
<td>Autosomal dominant Charcot-Marie-Tooth disease type 2O</td>
</tr>
<tr>
<td>251</td>
<td>Charcot-Marie-Tooth disease 2 autosomal recessive</td>
</tr>
<tr>
<td>252</td>
<td>Charcot-Marie-Tooth disease type 2B1</td>
</tr>
<tr>
<td>253</td>
<td>Charcot-Marie-Tooth disease type 2B2</td>
</tr>
<tr>
<td>254</td>
<td>Charcot-Marie-Tooth disease type 2B5</td>
</tr>
<tr>
<td>255</td>
<td>Charcot-Marie-Tooth disease type 2H</td>
</tr>
<tr>
<td>256</td>
<td>Autosomal recessive Charcot-Marie-Tooth disease with hoarseness</td>
</tr>
<tr>
<td>257</td>
<td>Hereditary motor and sensory neuropathy type 6</td>
</tr>
<tr>
<td>258</td>
<td>Charcot-Marie-Tooth type 6</td>
</tr>
<tr>
<td>259</td>
<td>HMSN6 - [Hereditary motor and sensory neuropathy type 6]</td>
</tr>
<tr>
<td>260</td>
<td>CMT6 - [Charcot-Marie-Tooth type 6]</td>
</tr>
<tr>
<td>261</td>
<td>Cholera</td>
</tr>
<tr>
<td>262</td>
<td>cholera syndrome</td>
</tr>
<tr>
<td>263</td>
<td>asiatic cholera</td>
</tr>
<tr>
<td>264</td>
<td>epidemic cholera</td>
</tr>
<tr>
<td>265</td>
<td>Intestinal infection due to Vibrio cholerae</td>
</tr>
<tr>
<td>266</td>
<td>Enteritis due to cholera due to Vibrio cholerae, non-O1 strains</td>
</tr>
<tr>
<td>267</td>
<td>Cholera due to Vibrio cholerae O1, biovar cholerae</td>
</tr>
<tr>
<td>268</td>
<td>classical cholera</td>
</tr>
<tr>
<td>269</td>
<td>Enteritis due to Cholera due to Vibrio cholerae O1, biovar cholerae</td>
</tr>
<tr>
<td>270</td>
<td>Enteritis due to classical cholera</td>
</tr>
<tr>
<td>271</td>
<td>Cholera due to Vibrio cholerae O1, biovar eltor</td>
</tr>
<tr>
<td>272</td>
<td>cholera - vibrio cholerae 01 eltor biotype</td>
</tr>
<tr>
<td>273</td>
<td>cholera due to Vibrio cholerae 01, Cholera eltor</td>
</tr>
<tr>
<td>274</td>
<td>cholera due to Cholera eltor</td>
</tr>
<tr>
<td>275</td>
<td>Enteritis due to cholera due to Vibrio cholerae O1, biovar eltor</td>
</tr>
<tr>
<td>276</td>
<td>Enteritis due to cholera due to Cholera eltor</td>
</tr>
<tr>
<td>277</td>
<td>eltor enteritis</td>
</tr>
<tr>
<td>278</td>
<td>infectious enteritis due to vibrio cholerae 01, biovar eltor</td>
</tr>
<tr>
<td>279</td>
<td>Cholera due to Vibrio cholerae O139</td>
</tr>
<tr>
<td>1</td>
<td>Other specified undernutrition</td>
</tr>
<tr>
<td>2</td>
<td>Undernutrition based on anthropometric or clinical criteria</td>
</tr>
<tr>
<td>3</td>
<td>Undernutrition based on anthropometric or clinical criteria in infants, children or adolescents</td>
</tr>
<tr>
<td>4</td>
<td>thinness NOS in infants, children or adolescents</td>
</tr>
<tr>
<td>5</td>
<td>Undernutrition based on anthropometric or clinical criteria in adults</td>
</tr>
<tr>
<td>6</td>
<td>Undernutrition due to specific nutrient deficiencies</td>
</tr>
<tr>
<td>7</td>
<td>Vitamin deficiencies</td>
</tr>
<tr>
<td>8</td>
<td>vitamin deficiency</td>
</tr>
<tr>
<td>9</td>
<td>vitamins deprivation</td>
</tr>
<tr>
<td>10</td>
<td>vitamin absorption disorder</td>
</tr>
<tr>
<td>11</td>
<td>Deficiencies of B group vitamins</td>
</tr>
<tr>
<td>12</td>
<td>deficiency of vitamin B</td>
</tr>
<tr>
<td>13</td>
<td>deficiency of B-complex components</td>
</tr>
<tr>
<td>14</td>
<td>vitamin B-complex deficiency</td>
</tr>
<tr>
<td>15</td>
<td>group B vitamin deficiency</td>
</tr>
<tr>
<td>16</td>
<td>vitamin B deficiency NOS</td>
</tr>
<tr>
<td>17</td>
<td>Deficiency of certain specified B group vitamins</td>
</tr>
<tr>
<td>18</td>
<td>Dana-Putnam syndrome</td>
</tr>
<tr>
<td>19</td>
<td>Posterolateral sclerosis</td>
</tr>
<tr>
<td>20</td>
<td>Strachan syndrome</td>
</tr>
<tr>
<td>21</td>
<td>Vitamin P deficiency</td>
</tr>
<tr>
<td>22</td>
<td>Avitaminosis</td>
</tr>
<tr>
<td>23</td>
<td>multiple avitaminosis</td>
</tr>
<tr>
<td>24</td>
<td>Hypovitaminosis</td>
</tr>
<tr>
<td>25</td>
<td>Certain specified nutritional deficiencies</td>
</tr>
<tr>
<td>26</td>
<td>diet deficiency</td>
</tr>
<tr>
<td>27</td>
<td>dietary insufficiency</td>
</tr>
<tr>
<td>28</td>
<td>inadequate diet</td>
</tr>
<tr>
<td>29</td>
<td>Imbalance of constituents of food intake</td>
</tr>
<tr>
<td>30</td>
<td>disturbance of constituents of food intake</td>
</tr>
<tr>
<td>31</td>
<td>Nutritional polyneuritis</td>
</tr>
<tr>
<td>32</td>
<td>Nutritional growth failure</td>
</tr>
<tr>
<td>33</td>
<td>arrested development following protein-calorie malnutrition</td>
</tr>
<tr>
<td>34</td>
<td>nutritional development retardation</td>
</tr>
<tr>
<td>35</td>
<td>nutritional dwarfism</td>
</tr>
<tr>
<td>36</td>
<td>nutritional short stature</td>
</tr>
<tr>
<td>37</td>
<td>nutritional stunting</td>
</tr>
<tr>
<td>38</td>
<td>physical retardation due to malnutrition</td>
</tr>
<tr>
<td>39</td>
<td>Nutritional dystrophy</td>
</tr>
<tr>
<td>40</td>
<td>dystrophy due to malnutrition</td>
</tr>
<tr>
<td>41</td>
<td>Multiple system atrophy, Parkinsonism</td>
</tr>
<tr>
<td>42</td>
<td>MSA-P - [multiple system atrophy, Parkinsonian type]</td>
</tr>
<tr>
<td>43</td>
<td>Preterm premature rupture of membranes</td>
</tr>
<tr>
<td>44</td>
<td>PPROM - [preterm premature rupture of membranes]</td>
</tr>
<tr>
<td>45</td>
<td>preterm rupture of membranes</td>
</tr>
<tr>
<td>46</td>
<td>Deletions of the short arm of chromosome 5</td>
</tr>
<tr>
<td>47</td>
<td>5p partial deletion syndrome</td>
</tr>
<tr>
<td>48</td>
<td>5p partial monosomy syndrome</td>
</tr>
<tr>
<td>49</td>
<td>partial deletion of short arm of chromosome 5 syndrome</td>
</tr>
<tr>
<td>50</td>
<td>Cri-du-chat syndrome</td>
</tr>
<tr>
<td>51</td>
<td>5p minus syndrome</td>
</tr>
<tr>
<td>52</td>
<td>cat cry syndrome</td>
</tr>
<tr>
<td>53</td>
<td>Lejeune syndrome</td>
</tr>
<tr>
<td>54</td>
<td>5p deletion</td>
</tr>
<tr>
<td>55</td>
<td>Duplications of the short arm of chromosome 4</td>
</tr>
<tr>
<td>56</td>
<td>4p duplication</td>
</tr>
<tr>
<td>57</td>
<td>4p duplication syndrome</td>
</tr>
<tr>
<td>58</td>
<td>Short arm of chromosome 4 trisomy</td>
</tr>
<tr>
<td>59</td>
<td>4p16.3 duplication</td>
</tr>
<tr>
<td>60</td>
<td>Distal 4p duplication syndrome</td>
</tr>
<tr>
<td>61</td>
<td>Duplications of the short arm of chromosome 5</td>
</tr>
<tr>
<td>62</td>
<td>5p duplication</td>
</tr>
<tr>
<td>63</td>
<td>5p duplication syndrome</td>
</tr>
<tr>
<td>64</td>
<td>Short arm of chromosome 5 trisomy</td>
</tr>
<tr>
<td>65</td>
<td>Duplications of the short arm of chromosome 12</td>
</tr>
<tr>
<td>66</td>
<td>12p duplication</td>
</tr>
<tr>
<td>67</td>
<td>Duplications of the short arm of chromosome 10</td>
</tr>
<tr>
<td>68</td>
<td>10p duplication</td>
</tr>
<tr>
<td>69</td>
<td>Chromosome 10 short arm trisomy</td>
</tr>
<tr>
<td>70</td>
<td>10p duplication syndrome</td>
</tr>
<tr>
<td>71</td>
<td>Trisomy 10p</td>
</tr>
<tr>
<td>72</td>
<td>Duplications of the short arm of chromosome 7</td>
</tr>
<tr>
<td>73</td>
<td>7p duplication</td>
</tr>
<tr>
<td>74</td>
<td>Distal chromosome 7 short arm trisomy</td>
</tr>
<tr>
<td>75</td>
<td>Distal 7p duplication</td>
</tr>
<tr>
<td>76</td>
<td>Proximal duplications of the short arm of chromosome 7</td>
</tr>
<tr>
<td>77</td>
<td>7p11.2-p13 duplication</td>
</tr>
<tr>
<td>78</td>
<td>Distal duplications of the short arm of chromosome 7</td>
</tr>
<tr>
<td>79</td>
<td>Duplications of the short arm of chromosome 8</td>
</tr>
<tr>
<td>80</td>
<td>8p duplication</td>
</tr>
<tr>
<td>81</td>
<td>8p duplication syndrome</td>
</tr>
<tr>
<td>82</td>
<td>Chromosome 8 short arm trisomy</td>
</tr>
<tr>
<td>83</td>
<td>Proximal duplications of the short arm of chromosome 8</td>
</tr>
<tr>
<td>84</td>
<td>Distal duplications of the short arm of chromosome 8</td>
</tr>
<tr>
<td>85</td>
<td>8p23.1 duplication</td>
</tr>
<tr>
<td>86</td>
<td>8p23.1 duplication syndrome</td>
</tr>
<tr>
<td>87</td>
<td>Trisomy 8p23.1</td>
</tr>
<tr>
<td>88</td>
<td>Duplications of the short arm of chromosome 9</td>
</tr>
<tr>
<td>89</td>
<td>9p duplication</td>
</tr>
<tr>
<td>90</td>
<td>Chromosome 9 short arm trisomy</td>
</tr>
<tr>
<td>91</td>
<td>9p duplication syndrome</td>
</tr>
<tr>
<td>92</td>
<td>Proximal duplications of the short arm of chromosome 9</td>
</tr>
<tr>
<td>93</td>
<td>Distal duplications of the short arm of chromosome 9</td>
</tr>
<tr>
<td>94</td>
<td>Duplications of the short arm of chromosome 20</td>
</tr>
<tr>
<td>95</td>
<td>20p duplication</td>
</tr>
<tr>
<td>96</td>
<td>20p duplication syndrome</td>
</tr>
<tr>
<td>97</td>
<td>Trisomy 20p</td>
</tr>
<tr>
<td>98</td>
<td>Duplications of the short arm of chromosome 18</td>
</tr>
<tr>
<td>99</td>
<td>18p duplication</td>
</tr>
<tr>
<td>100</td>
<td>18p duplication syndrome</td>
</tr>
<tr>
<td>101</td>
<td>Duplications of the short arm of chromosome 17</td>
</tr>
<tr>
<td>102</td>
<td>17p duplication</td>
</tr>
<tr>
<td>103</td>
<td>17p duplication syndrome</td>
</tr>
<tr>
<td>104</td>
<td>17p13.3 duplication</td>
</tr>
<tr>
<td>105</td>
<td>17p13.3 duplication syndrome</td>
</tr>
<tr>
<td>106</td>
<td>Trisomy 17p13.3</td>
</tr>
<tr>
<td>107</td>
<td>Potocki-Lupski syndrome</td>
</tr>
<tr>
<td>108</td>
<td>Trisomy 17p11.2</td>
</tr>
<tr>
<td>109</td>
<td>17p11.2 duplication</td>
</tr>
<tr>
<td>110</td>
<td>Charcot-Marie-Tooth disease 1 autosomal dominant due to chromosome 17 duplication</td>
</tr>
<tr>
<td>111</td>
<td>Charcot-Marie-Tooth disease type 1A</td>
</tr>
<tr>
<td>112</td>
<td>Charcot Marie Tooth disease 1 autosomal dominant secondary to the chromosome 17 duplication</td>
</tr>
<tr>
<td>113</td>
<td>CMT1A - [Charcot-Marie-Tooth disease type 1A]</td>
</tr>
<tr>
<td>114</td>
<td>Deletions of the short arm of chromosome 9</td>
</tr>
<tr>
<td>115</td>
<td>Proximal deletions of the short arm of chromosome 9</td>
</tr>
<tr>
<td>116</td>
<td>Distal deletions of the short arm of chromosome 9</td>
</tr>
<tr>
<td>117</td>
<td>9p24.3 deletion</td>
</tr>
<tr>
<td>118</td>
<td>Distal 9p deletion syndrome</td>
</tr>
<tr>
<td>119</td>
<td>Alfi syndrome</td>
</tr>
<tr>
<td>120</td>
<td>9p deletion syndrome</td>
</tr>
<tr>
<td>121</td>
<td>9p22p24 deletion</td>
</tr>
<tr>
<td>122</td>
<td>Deletions of the short arm of chromosome 18</td>
</tr>
<tr>
<td>123</td>
<td>De Grouchy syndrome</td>
</tr>
<tr>
<td>124</td>
<td>18p deletion syndrome</td>
</tr>
<tr>
<td>125</td>
<td>Other specified chromosomal anomalies, excluding gene mutations</td>
</tr>
<tr>
<td>126</td>
<td>Tetrasomies of the autosomes</td>
</tr>
<tr>
<td>127</td>
<td>Tetrasomy 12p mosaicism</td>
</tr>
<tr>
<td>128</td>
<td>Pallister-Killian syndrome</td>
</tr>
<tr>
<td>129</td>
<td>Tetrasomy 15q</td>
</tr>
<tr>
<td>130</td>
<td>Tetrasomy 18p</td>
</tr>
<tr>
<td>131</td>
<td>Tetrasomy 21</td>
</tr>
<tr>
<td>132</td>
<td>Tetrasomy 5p mosaicism</td>
</tr>
<tr>
<td>133</td>
<td>Tetrasomy 9p</td>
</tr>
<tr>
<td>134</td>
<td>Mosaic variegated aneuploidy syndrome</td>
</tr>
<tr>
<td>135</td>
<td>Unbalanced translocations or structural rearrangements</td>
</tr>
<tr>
<td>136</td>
<td>Replacement of a chromosome with a dicentric, isochromosome, or isodicentric</td>
</tr>
<tr>
<td>137</td>
<td>Unbalanced reciprocal translocation</td>
</tr>
<tr>
<td>138</td>
<td>Unbalanced reciprocal translocation with 3:1 segregation (chromosome count = 45)</td>
</tr>
<tr>
<td>139</td>
<td>Unbalanced reciprocal translocation with 2:2 segregation (chromosome count = 46)</td>
</tr>
<tr>
<td>140</td>
<td>Unbalanced reciprocal translocation with 3:1 segregation (chromosome count = 47)</td>
</tr>
<tr>
<td>141</td>
<td>Unbalanced Robertsonian translocation</td>
</tr>
<tr>
<td>142</td>
<td>Chromosome replaced with ring or dicentric with normal number of chromosomes</td>
</tr>
<tr>
<td>143</td>
<td>Replaced chromosome by ring or dicentric</td>
</tr>
<tr>
<td>144</td>
<td>abnormal chromosome, ring replacement</td>
</tr>
<tr>
<td>145</td>
<td>Ring chromosome 1 with normal number of chromosomes</td>
</tr>
<tr>
<td>146</td>
<td>Ring chromosome 2 with normal number of chromosomes</td>
</tr>
<tr>
<td>147</td>
<td>Ring chromosome 3 with normal number of chromosomes</td>
</tr>
<tr>
<td>148</td>
<td>Ring chromosome 4 with normal number of chromosomes</td>
</tr>
<tr>
<td>149</td>
<td>Ring chromosome 5 with normal number of chromosomes</td>
</tr>
<tr>
<td>150</td>
<td>Ring chromosome 6 with normal number of chromosomes</td>
</tr>
<tr>
<td>151</td>
<td>Ring chromosome 7 with normal number of chromosomes</td>
</tr>
<tr>
<td>152</td>
<td>Ring chromosome 8 with normal number of chromosomes</td>
</tr>
<tr>
<td>153</td>
<td>Ring chromosome 9 with normal number of chromosomes</td>
</tr>
<tr>
<td>154</td>
<td>Ring chromosome 10 with normal number of chromosomes</td>
</tr>
<tr>
<td>155</td>
<td>Ring chromosome 11 with normal number of chromosomes</td>
</tr>
<tr>
<td>156</td>
<td>Ring chromosome 12 with normal number of chromosomes</td>
</tr>
<tr>
<td>157</td>
<td>Ring chromosome 13 with normal number of chromosomes</td>
</tr>
<tr>
<td>158</td>
<td>Ring chromosome 14 with normal number of chromosomes</td>
</tr>
<tr>
<td>159</td>
<td>Ring chromosome 15 with normal number of chromosomes</td>
</tr>
<tr>
<td>160</td>
<td>Ring chromosome 16 with normal number of chromosomes</td>
</tr>
<tr>
<td>161</td>
<td>Ring chromosome 17 with normal number of chromosomes</td>
</tr>
<tr>
<td>162</td>
<td>Ring chromosome 18 with normal number of chromosomes</td>
</tr>
<tr>
<td>163</td>
<td>Ring chromosome 19 with normal number of chromosomes</td>
</tr>
<tr>
<td>164</td>
<td>Ring chromosome 20 with normal number of chromosomes</td>
</tr>
<tr>
<td>165</td>
<td>Ring chromosome 20</td>
</tr>
<tr>
<td>166</td>
<td>Ring chromosome 21 with normal number of chromosomes</td>
</tr>
<tr>
<td>167</td>
<td>Ring chromosome 22 with normal number of chromosomes</td>
</tr>
<tr>
<td>168</td>
<td>Unbalanced dicentric chromosomes</td>
</tr>
<tr>
<td>169</td>
<td>Deletions of the short arm of chromosome 2</td>
</tr>
<tr>
<td>170</td>
<td>2p15p16.1 deletion</td>
</tr>
<tr>
<td>171</td>
<td>2p21 deletion</td>
</tr>
<tr>
<td>172</td>
<td>Other specified diseases of the skin</td>
</tr>
<tr>
<td>173</td>
<td>Adverse cutaneous effects of healthcare related interventions</td>
</tr>
<tr>
<td>174</td>
<td>Cutaneous complications of surgical, laser or other interventional procedures</td>
</tr>
<tr>
<td>175</td>
<td>Postprocedural cutaneous complications of surgical, laser or other interventions</td>
</tr>
<tr>
<td>176</td>
<td>Cutaneous complications of surgical procedures</td>
</tr>
<tr>
<td>177</td>
<td>Postprocedural cutaneous complications of surgical procedures</td>
</tr>
<tr>
<td>178</td>
<td>Surgical wound of skin</td>
</tr>
<tr>
<td>179</td>
<td>Delayed healing of surgical wound of skin</td>
</tr>
<tr>
<td>180</td>
<td>Complications of cutaneous flaps or grafts</td>
</tr>
<tr>
<td>181</td>
<td>Miscellaneous complications of cutaneous surgical procedures</td>
</tr>
<tr>
<td>182</td>
<td>Anatomical distortion of skin or soft tissues following cutaneous surgical procedure</td>
</tr>
<tr>
<td>183</td>
<td>Cicatricial contracture of skin or soft tissues following cutaneous surgical procedure</td>
</tr>
<tr>
<td>184</td>
<td>Temporary cutaneous sensory disturbance resulting from cutaneous surgical procedure</td>
</tr>
<tr>
<td>185</td>
<td>Permanent cutaneous sensory impairment resulting from cutaneous surgical procedure</td>
</tr>
<tr>
<td>186</td>
<td>Impairment of motor nerve function resulting from cutaneous surgical procedure</td>
</tr>
<tr>
<td>187</td>
<td>Cutaneous infection specified elsewhere resulting from surgical procedure</td>
</tr>
<tr>
<td>188</td>
<td>Cutaneous complications of laser surgery</td>
</tr>
<tr>
<td>189</td>
<td>Postprocedural cutaneous complications of laser surgery</td>
</tr>
<tr>
<td>190</td>
<td>Thermal burns resulting from cutaneous laser surgery</td>
</tr>
<tr>
<td>191</td>
<td>Infection specified elsewhere following cutaneous laser surgery</td>
</tr>
<tr>
<td>192</td>
<td>Dyspigmentation following cutaneous laser surgery</td>
</tr>
<tr>
<td>193</td>
<td>Cutaneous complications of stomas or fistulas</td>
</tr>
<tr>
<td>194</td>
<td>Skin problems resulting from tracheostomy</td>
</tr>
<tr>
<td>195</td>
<td>Skin problem resulting from external stoma of digestive organs</td>
</tr>
<tr>
<td>196</td>
<td>Skin problem resulting from gastrostomy</td>
</tr>
<tr>
<td>197</td>
<td>Skin problem resulting from ileostomy</td>
</tr>
<tr>
<td>198</td>
<td>Skin problem resulting from colostomy</td>
</tr>
<tr>
<td>199</td>
<td>Skin problem resulting from urinary diversion procedure</td>
</tr>
<tr>
<td>200</td>
<td>Skin problem resulting from cystostomy</td>
</tr>
<tr>
<td>201</td>
<td>Skin problem resulting from nephrostomy</td>
</tr>
<tr>
<td>202</td>
<td>Skin problem resulting from urethrostomy</td>
</tr>
<tr>
<td>203</td>
<td>Skin problem resulting from urostomy</td>
</tr>
<tr>
<td>204</td>
<td>Parastomal ulcer</td>
</tr>
<tr>
<td>205</td>
<td>Drug-induced parastomal ulceration</td>
</tr>
<tr>
<td>206</td>
<td>medicament-induced parastomal ulceration</td>
</tr>
<tr>
<td>207</td>
<td>Nicorandil-induced parastomal ulceration</td>
</tr>
<tr>
<td>208</td>
<td>Adverse effects of phototherapy</td>
</tr>
<tr>
<td>209</td>
<td>Adverse effects of UVB phototherapy</td>
</tr>
<tr>
<td>210</td>
<td>Phototherapy burn</td>
</tr>
<tr>
<td>211</td>
<td>Adverse effects of psoralen photochemotherapy</td>
</tr>
<tr>
<td>212</td>
<td>Adverse effects of PUVA</td>
</tr>
<tr>
<td>213</td>
<td>PUVA burn</td>
</tr>
<tr>
<td>214</td>
<td>PUVA-associated pseudoporphyria</td>
</tr>
<tr>
<td>215</td>
<td>PUVA lentiginosis</td>
</tr>
<tr>
<td>216</td>
<td>PUVA keratoses</td>
</tr>
<tr>
<td>217</td>
<td>PUVA-associated malignancy classified elsewhere</td>
</tr>
<tr>
<td>218</td>
<td>PUVA-associated pruritus</td>
</tr>
<tr>
<td>219</td>
<td>pruritus due to psoralen photochemotherapy</td>
</tr>
<tr>
<td>220</td>
<td>PUVA itch</td>
</tr>
<tr>
<td>221</td>
<td>Dermatoses associated with haemodialysis</td>
</tr>
<tr>
<td>222</td>
<td>Adverse cutaneous reactions to parenteral administration of proteins</td>
</tr>
<tr>
<td>223</td>
<td>Impairment of normal functioning resulting from skin disease</td>
</tr>
<tr>
<td>224</td>
<td>Absence of skin condition</td>
</tr>
<tr>
<td>225</td>
<td>No significant skin abnormality found</td>
</tr>
<tr>
<td>226</td>
<td>Skin condition resolved</td>
</tr>
<tr>
<td>227</td>
<td>Normal skin</td>
</tr>
<tr>
<td>228</td>
<td>Normal hair</td>
</tr>
<tr>
<td>229</td>
<td>Normal nails</td>
</tr>
<tr>
<td>230</td>
<td>Disorders of protein N-glycosylation</td>
</tr>
<tr>
<td>231</td>
<td>Phosphomannomutase 2 deficiency</td>
</tr>
<tr>
<td>232</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1A</td>
</tr>
<tr>
<td>233</td>
<td>Congenital disorder of glycosylation type 1A</td>
</tr>
<tr>
<td>234</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1A</td>
</tr>
<tr>
<td>235</td>
<td>Phosphomannose isomerase deficiency</td>
</tr>
<tr>
<td>236</td>
<td>Saguenay-Lac-Saint-Jean syndrome</td>
</tr>
<tr>
<td>237</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1B</td>
</tr>
<tr>
<td>238</td>
<td>Congenital disorder of glycosylation type 1B</td>
</tr>
<tr>
<td>239</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1B</td>
</tr>
<tr>
<td>240</td>
<td>SLSJ - [Saguenay-Lac-Saint-Jean] syndrome</td>
</tr>
<tr>
<td>241</td>
<td>Glucosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>242</td>
<td>Dol-P-Glc: Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>243</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1C</td>
</tr>
<tr>
<td>244</td>
<td>Congenital disorder of glycosylation type 1C</td>
</tr>
<tr>
<td>245</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1C</td>
</tr>
<tr>
<td>246</td>
<td>Mannosyltransferase 6 deficiency</td>
</tr>
<tr>
<td>247</td>
<td>Dol-P-Man: Man5-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>248</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1D</td>
</tr>
<tr>
<td>249</td>
<td>Congenital disorder of glycosylation type 1D</td>
</tr>
<tr>
<td>250</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1D</td>
</tr>
<tr>
<td>251</td>
<td>Mannosyltransferase 8 deficiency</td>
</tr>
<tr>
<td>252</td>
<td>Dol-P-Man: Man7-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>253</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1G</td>
</tr>
<tr>
<td>254</td>
<td>Congenital disorder of glycosylation type 1G</td>
</tr>
<tr>
<td>255</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1G</td>
</tr>
<tr>
<td>256</td>
<td>Glucosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>257</td>
<td>Dol-P-Glc: Glc1-Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>258</td>
<td>Carbohydrate deficient glycoprotein syndrome 1H</td>
</tr>
<tr>
<td>259</td>
<td>Congenital disorder of glycosylation type 1H</td>
</tr>
<tr>
<td>260</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1H</td>
</tr>
<tr>
<td>261</td>
<td>Mannosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>262</td>
<td>Dol-P-Man: Man1-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>263</td>
<td>Carbohydrate deficient glycoprotein syndrome 1I</td>
</tr>
<tr>
<td>264</td>
<td>Congenital disorder of glycosylation 1I</td>
</tr>
<tr>
<td>265</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1I</td>
</tr>
<tr>
<td>266</td>
<td>Dolichyl-phosphate N-acetylgalactosamine phosphotransferase deficiency</td>
</tr>
<tr>
<td>267</td>
<td>UDP-GlcNAc: Dol-P-GlcNac-P transferase deficiency</td>
</tr>
<tr>
<td>268</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1J</td>
</tr>
<tr>
<td>269</td>
<td>Congenital disorder of glycosylation type 1J</td>
</tr>
<tr>
<td>270</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1J</td>
</tr>
<tr>
<td>271</td>
<td>Mannosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>272</td>
<td>Dol-P-Man: GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>273</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1K</td>
</tr>
<tr>
<td>274</td>
<td>Congenital disorder of glycosylation type 1K</td>
</tr>
<tr>
<td>275</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1K</td>
</tr>
<tr>
<td>276</td>
<td>Mannosyltransferase 7-9 deficiency</td>
</tr>
<tr>
<td>277</td>
<td>Congenital disorder of glycosylation type 1L</td>
</tr>
<tr>
<td>278</td>
<td>Dol-P-Man: Man6 and Man8-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>279</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1L</td>
</tr>
<tr>
<td>280</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1L</td>
</tr>
<tr>
<td>281</td>
<td>M5-DLO flippase deficiency</td>
</tr>
<tr>
<td>282</td>
<td>Man5GlcNAc2-PP-Dol flippase deficiency</td>
</tr>
<tr>
<td>283</td>
<td>RTF1-CDG</td>
</tr>
<tr>
<td>284</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1N</td>
</tr>
<tr>
<td>285</td>
<td>N-acetylglucosaminyltransferase deficiency</td>
</tr>
<tr>
<td>286</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2A</td>
</tr>
<tr>
<td>287</td>
<td>Congenital disorder of glycosylation type 2A</td>
</tr>
<tr>
<td>288</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2A</td>
</tr>
<tr>
<td>289</td>
<td>Glucosidase 1 deficiency</td>
</tr>
<tr>
<td>290</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2B</td>
</tr>
<tr>
<td>291</td>
<td>Congenital disorder of glycosylation type 2B</td>
</tr>
<tr>
<td>292</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2B</td>
</tr>
<tr>
<td>293</td>
<td>TUSC3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>294</td>
<td>TUSC3-CDG</td>
</tr>
<tr>
<td>295</td>
<td>SRD5A3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>296</td>
<td>SRD5A3-CDG</td>
</tr>
<tr>
<td>297</td>
<td>Congenital disorder of glycosylation due to steroid 5-alpha-reductase type 3 deficiency</td>
</tr>
<tr>
<td>298</td>
<td>Intellectual deficit - cataract - coloboma - kyphosis</td>
</tr>
<tr>
<td>299</td>
<td>Kahrizi syndrome</td>
</tr>
<tr>
<td>300</td>
<td>Intellectual deficit, Kahrizi type</td>
</tr>
<tr>
<td>301</td>
<td>DPM3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>302</td>
<td>Congenital disorder of glycosylation type 1O</td>
</tr>
<tr>
<td>303</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1O</td>
</tr>
<tr>
<td>304</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1O</td>
</tr>
<tr>
<td>305</td>
<td>ALG11 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>306</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1P</td>
</tr>
<tr>
<td>307</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1P</td>
</tr>
<tr>
<td>308</td>
<td>Congenital disorder of glycosylation type 1P</td>
</tr>
<tr>
<td>309</td>
<td>Phosphoglucomutase-1 deficiency</td>
</tr>
<tr>
<td>310</td>
<td>PGM1-CDG - [Phosphoglucomutase-1 deficiency]</td>
</tr>
<tr>
<td>311</td>
<td>Congenital disorder of glycosylation type 1t</td>
</tr>
<tr>
<td>312</td>
<td>Deletions of the short arm of chromosome 4</td>
</tr>
<tr>
<td>313</td>
<td>4p partial monosomy syndrome</td>
</tr>
<tr>
<td>314</td>
<td>chromosome 4 short arm deletion syndrome</td>
</tr>
<tr>
<td>315</td>
<td>deletion of short arm of chromosome 4</td>
</tr>
<tr>
<td>316</td>
<td>chromosome 4 short arm deletion</td>
</tr>
<tr>
<td>317</td>
<td>Wolf-Hirschhorn syndrome</td>
</tr>
<tr>
<td>318</td>
<td>4p minus syndrome</td>
</tr>
<tr>
<td>319</td>
<td>4p16.3 deletion</td>
</tr>
<tr>
<td>320</td>
<td>Deletions of the short arm of chromosome 1</td>
</tr>
<tr>
<td>321</td>
<td>Proximal deletions of the short arm of chromosome 1</td>
</tr>
<tr>
<td>322</td>
<td>Medial deletions of the short arm of chromosome 1</td>
</tr>
<tr>
<td>323</td>
<td>1p21.3 deletion</td>
</tr>
<tr>
<td>324</td>
<td>1p21.3 microdeletion syndrome</td>
</tr>
<tr>
<td>325</td>
<td>Distal deletions of the short arm of chromosome 1</td>
</tr>
<tr>
<td>326</td>
<td>1p36 deletion</td>
</tr>
<tr>
<td>327</td>
<td>1p36 deletion syndrome</td>
</tr>
<tr>
<td>328</td>
<td>Duplications of the short arm of chromosome 6</td>
</tr>
<tr>
<td>329</td>
<td>Proximal duplications of the short arm of chromosome 6</td>
</tr>
<tr>
<td>330</td>
<td>Distal duplications of the short arm of chromosome 6</td>
</tr>
<tr>
<td>331</td>
<td>6p23pter duplication</td>
</tr>
<tr>
<td>332</td>
<td>Distal 6p duplication</td>
</tr>
<tr>
<td>333</td>
<td>Deletions of the short arm of chromosome 6</td>
</tr>
<tr>
<td>334</td>
<td>Proximal deletions of the short arm of chromosome 6</td>
</tr>
<tr>
<td>335</td>
<td>Distal deletions of the short arm of chromosome 6</td>
</tr>
<tr>
<td>336</td>
<td>6p22 deletion</td>
</tr>
<tr>
<td>337</td>
<td>6p22 deletion syndrome</td>
</tr>
<tr>
<td>338</td>
<td>Monosomy 6p22</td>
</tr>
<tr>
<td>339</td>
<td>6p24pter deletion</td>
</tr>
<tr>
<td>340</td>
<td>6p25 microdeletion syndrome</td>
</tr>
<tr>
<td>341</td>
<td>Monosomy 6p25</td>
</tr>
<tr>
<td>342</td>
<td>6p25 deletion syndrome</td>
</tr>
<tr>
<td>343</td>
<td>Deletions of the short arm of chromosome 11</td>
</tr>
<tr>
<td>344</td>
<td>11p15 deletion</td>
</tr>
<tr>
<td>345</td>
<td>Potocki-Shaffer syndrome</td>
</tr>
<tr>
<td>346</td>
<td>11p11.2 deletion syndrome</td>
</tr>
<tr>
<td>347</td>
<td>Duplications of the short arm of chromosome 2</td>
</tr>
<tr>
<td>348</td>
<td>Proximal duplications of the short arm of chromosome 2</td>
</tr>
<tr>
<td>349</td>
<td>Distal duplications of the short arm of chromosome 2</td>
</tr>
<tr>
<td>350</td>
<td>2p23pter duplication</td>
</tr>
<tr>
<td>351</td>
<td>Distal 2p duplication syndrome</td>
</tr>
<tr>
<td>352</td>
<td>Duplications of the short arm of chromosome 1</td>
</tr>
<tr>
<td>353</td>
<td>Proximal duplications of the short arm of chromosome 1</td>
</tr>
<tr>
<td>354</td>
<td>Medial duplications of the short arm of chromosome 1</td>
</tr>
<tr>
<td>355</td>
<td>Distal duplications of the short arm of chromosome 1</td>
</tr>
<tr>
<td>356</td>
<td>1p36 duplication</td>
</tr>
<tr>
<td>357</td>
<td>Distal 1p36 duplication syndrome</td>
</tr>
<tr>
<td>358</td>
<td>Other specified malformative disorders of sex development</td>
</tr>
<tr>
<td>359</td>
<td>45, X, 46, XY gonadal dysgenesis</td>
</tr>
<tr>
<td>360</td>
<td>Mixed gonadal dysgenesis</td>
</tr>
<tr>
<td>361</td>
<td>Streak testis</td>
</tr>
<tr>
<td>362</td>
<td>46, XX disorders of sex development</td>
</tr>
<tr>
<td>363</td>
<td>46, XX DSD</td>
</tr>
<tr>
<td>364</td>
<td>46,XX testicular disorder of sex development</td>
</tr>
<tr>
<td>365</td>
<td>46,XX testicular DSD</td>
</tr>
<tr>
<td>366</td>
<td>De la Chapelle syndrome</td>
</tr>
<tr>
<td>367</td>
<td>46, XY disorders of sex development</td>
</tr>
<tr>
<td>368</td>
<td>46,XY disorders of sex development due to a defect in testicular development</td>
</tr>
<tr>
<td>369</td>
<td>46,XY DSD due to a defect in testicular development</td>
</tr>
<tr>
<td>370</td>
<td>Dysgenetic 46,XY disorder of sex development</td>
</tr>
<tr>
<td>371</td>
<td>Dysgenetic 46,XY DSD</td>
</tr>
<tr>
<td>372</td>
<td>WAGR syndrome</td>
</tr>
<tr>
<td>373</td>
<td>Monosomy 11p13</td>
</tr>
<tr>
<td>374</td>
<td>11p13 microdeletion syndrome</td>
</tr>
<tr>
<td>375</td>
<td>11p13 deletion</td>
</tr>
<tr>
<td>376</td>
<td>WAGR - [Wilms tumour - aniridia - genitourinary anomalies - intellectual deficit] syndrome</td>
</tr>
<tr>
<td>377</td>
<td>Campomelic dysplasia</td>
</tr>
<tr>
<td>378</td>
<td>Campomelic dwarfism</td>
</tr>
<tr>
<td>379</td>
<td>Denys-Drash syndrome</td>
</tr>
<tr>
<td>380</td>
<td>Drash syndrome</td>
</tr>
<tr>
<td>381</td>
<td>Wilms tumour or pseudohermaphroditism</td>
</tr>
<tr>
<td>382</td>
<td>Frasier syndrome</td>
</tr>
<tr>
<td>383</td>
<td>Embryonic testicular regression syndrome</td>
</tr>
<tr>
<td>384</td>
<td>Testicular regression syndrome</td>
</tr>
<tr>
<td>385</td>
<td>Vanishing testes syndrome</td>
</tr>
<tr>
<td>386</td>
<td>Bilateral anorchidia</td>
</tr>
<tr>
<td>387</td>
<td>XY gonadal agenesis</td>
</tr>
<tr>
<td>388</td>
<td>TRS - [testicular regression syndrome]</td>
</tr>
<tr>
<td>389</td>
<td>Persistent Mullerian duct syndrome</td>
</tr>
<tr>
<td>390</td>
<td>Persistent Müllerian derivatives</td>
</tr>
<tr>
<td>391</td>
<td>Fuqua-Berkovitz syndrome</td>
</tr>
<tr>
<td>392</td>
<td>Ambiguous genitalia - normal Müllerian development</td>
</tr>
<tr>
<td>393</td>
<td>Congenital non genetic 46,XY disorder of sex development</td>
</tr>
<tr>
<td>394</td>
<td>46,XY disorder of sex development due to environmental chemical exposure</td>
</tr>
<tr>
<td>395</td>
<td>46,XY DSD due to environmental chemical exposure</td>
</tr>
<tr>
<td>396</td>
<td>46,XY disorder of sex development due to maternal ingestion of progestogen or estrogen</td>
</tr>
<tr>
<td>397</td>
<td>46,XY DSD due to maternal ingestion of progestogen and estrogen</td>
</tr>
<tr>
<td>398</td>
<td>Deletions of chromosome 5, unspecified</td>
</tr>
<tr>
<td>399</td>
<td>Deletions of chromosome 5</td>
</tr>
<tr>
<td>400</td>
<td>Partial monosomy 5</td>
</tr>
<tr>
<td>401</td>
<td>chromosome 5p deletion syndrome</td>
</tr>
<tr>
<td>402</td>
<td>Duplications of the short arm of chromosome 3</td>
</tr>
<tr>
<td>403</td>
<td>Proximal duplications of the short arm of chromosome 3</td>
</tr>
<tr>
<td>404</td>
<td>Distal duplications of the short arm of chromosome 3</td>
</tr>
<tr>
<td>405</td>
<td>3p25p26 duplication</td>
</tr>
<tr>
<td>406</td>
<td>Distal 3p duplication syndrome</td>
</tr>
<tr>
<td>407</td>
<td>Duplications of chromosome 11</td>
</tr>
<tr>
<td>408</td>
<td>Duplications of the long arm of chromosome 11</td>
</tr>
<tr>
<td>409</td>
<td>Proximal duplications of the long arm of chromosome 11</td>
</tr>
<tr>
<td>410</td>
<td>Distal duplications of the long arm of chromosome 11</td>
</tr>
<tr>
<td>411</td>
<td>11q23q25 duplication</td>
</tr>
<tr>
<td>412</td>
<td>Duplications of the short arm of chromosome 11</td>
</tr>
<tr>
<td>413</td>
<td>11p15 duplication</td>
</tr>
<tr>
<td>414</td>
<td>11p15.4 duplication</td>
</tr>
<tr>
<td>415</td>
<td>Deletions of the short arm of chromosome 10</td>
</tr>
<tr>
<td>416</td>
<td>10p11.21p12.31 deletion</td>
</tr>
<tr>
<td>417</td>
<td>10p14pter deletion</td>
</tr>
<tr>
<td>418</td>
<td>Distal 10p deletion syndrome</td>
</tr>
<tr>
<td>419</td>
<td>Deletions of the short arm of chromosome 7</td>
</tr>
<tr>
<td>420</td>
<td>Proximal deletions of the short arm of chromosome 7</td>
</tr>
<tr>
<td>421</td>
<td>7p12p14 deletion</td>
</tr>
<tr>
<td>422</td>
<td>Distal deletions of the short arm of chromosome 7</td>
</tr>
<tr>
<td>423</td>
<td>7p21.1 deletion</td>
</tr>
<tr>
<td>424</td>
<td>Distal 7p deletion syndrome</td>
</tr>
<tr>
<td>425</td>
<td>Deletions of the short arm of chromosome 20</td>
</tr>
<tr>
<td>426</td>
<td>20p12.2 deletion</td>
</tr>
<tr>
<td>427</td>
<td>20p12 deletion syndrome</td>
</tr>
<tr>
<td>428</td>
<td>20p12.3 deletion</td>
</tr>
<tr>
<td>429</td>
<td>20p12.3 deletion syndrome</td>
</tr>
<tr>
<td>430</td>
<td>Monosomy 20p12.3</td>
</tr>
<tr>
<td>431</td>
<td>Deletions of the short arm of chromosome 8</td>
</tr>
<tr>
<td>432</td>
<td>Proximal deletions of the short arm of chromosome 8</td>
</tr>
<tr>
<td>433</td>
<td>8p11.2 deletion</td>
</tr>
<tr>
<td>434</td>
<td>8p11.2 deletion syndrome</td>
</tr>
<tr>
<td>435</td>
<td>Monosomy 8p11.2</td>
</tr>
<tr>
<td>436</td>
<td>Distal deletions of the short arm of chromosome 8</td>
</tr>
<tr>
<td>437</td>
<td>8p23.1 deletion</td>
</tr>
<tr>
<td>438</td>
<td>8p23.1 deletion syndrome</td>
</tr>
<tr>
<td>439</td>
<td>Monosomy 8p23.1</td>
</tr>
<tr>
<td>440</td>
<td>8p23.1 microdeletion syndrome</td>
</tr>
<tr>
<td>441</td>
<td>Deletions of the short arm of chromosome 16</td>
</tr>
<tr>
<td>442</td>
<td>16p11.2 deletion</td>
</tr>
<tr>
<td>443</td>
<td>Monosomy 16p11.2</td>
</tr>
<tr>
<td>444</td>
<td>16p11.2 deletion syndrome</td>
</tr>
<tr>
<td>445</td>
<td>Proximal 16p11.2 microdeletion syndrome</td>
</tr>
<tr>
<td>446</td>
<td>16p11.2p12.2 deletion</td>
</tr>
<tr>
<td>447</td>
<td>16p11.2p12.2 deletion syndrome</td>
</tr>
<tr>
<td>448</td>
<td>Monosomy 16p11.2-p12.2</td>
</tr>
<tr>
<td>449</td>
<td>16p13.11 deletion</td>
</tr>
<tr>
<td>450</td>
<td>16p13.11 deletion syndrome</td>
</tr>
<tr>
<td>451</td>
<td>Monosomy 16p13.11</td>
</tr>
<tr>
<td>452</td>
<td>16p13.3 deletion</td>
</tr>
<tr>
<td>453</td>
<td>Monosomy 16p13.3</td>
</tr>
<tr>
<td>454</td>
<td>RSTS deletion syndrome</td>
</tr>
<tr>
<td>455</td>
<td>Rubinstein-Taybi deletion syndrome</td>
</tr>
<tr>
<td>456</td>
<td>Distal 16p11.2 deletion</td>
</tr>
<tr>
<td>457</td>
<td>Distal 16p11.2 deletion syndrome</td>
</tr>
<tr>
<td>458</td>
<td>Distal monosomy 16q11.2</td>
</tr>
<tr>
<td>459</td>
<td>Deletions of the short arm of chromosome 17</td>
</tr>
<tr>
<td>460</td>
<td>17p12-p11.2 deletion</td>
</tr>
<tr>
<td>461</td>
<td>Distal 17p13.3 deletion</td>
</tr>
<tr>
<td>462</td>
<td>Smith-Magenis syndrome</td>
</tr>
<tr>
<td>463</td>
<td>17p11.2 deletion syndrome</td>
</tr>
<tr>
<td>464</td>
<td>Monosomy 17p11.2</td>
</tr>
<tr>
<td>465</td>
<td>17p11.2 deletion</td>
</tr>
<tr>
<td>466</td>
<td>Duplications of the short arm of chromosome 16</td>
</tr>
<tr>
<td>467</td>
<td>16p11.2 duplication</td>
</tr>
<tr>
<td>468</td>
<td>16p11.2 duplication syndrome</td>
</tr>
<tr>
<td>469</td>
<td>Trisomy 16p11.2</td>
</tr>
<tr>
<td>470</td>
<td>16p13.11 duplication</td>
</tr>
<tr>
<td>471</td>
<td>16p13.11 trisomy</td>
</tr>
<tr>
<td>472</td>
<td>16p13.11 duplication syndrome</td>
</tr>
<tr>
<td>473</td>
<td>Deletions of the short arm of chromosome 19</td>
</tr>
<tr>
<td>474</td>
<td>19p13.12 deletion</td>
</tr>
<tr>
<td>475</td>
<td>19p13.12 deletion syndrome</td>
</tr>
<tr>
<td>476</td>
<td>Monosomy 19p13.12</td>
</tr>
<tr>
<td>477</td>
<td>19p13.3 deletion</td>
</tr>
<tr>
<td>478</td>
<td>19p13.3 deletion syndrome</td>
</tr>
<tr>
<td>479</td>
<td>Syndromes with lissencephaly as a major feature</td>
</tr>
<tr>
<td>480</td>
<td>Pachygyria</td>
</tr>
<tr>
<td>481</td>
<td>Agyria</td>
</tr>
<tr>
<td>482</td>
<td>Classic lissencephaly</td>
</tr>
<tr>
<td>483</td>
<td>Lissencephaly type 1</td>
</tr>
<tr>
<td>484</td>
<td>Lissencephaly type 1 due to doublecortin gene mutation</td>
</tr>
<tr>
<td>485</td>
<td>Subcortical band heterotopia</td>
</tr>
<tr>
<td>486</td>
<td>Miller-Dieker syndrome</td>
</tr>
<tr>
<td>487</td>
<td>Lissencephaly due to 17p13.3 deletion</td>
</tr>
<tr>
<td>488</td>
<td>17p13.3 microdeletion syndrome</td>
</tr>
<tr>
<td>489</td>
<td>Telomeric deletion 17p</td>
</tr>
<tr>
<td>490</td>
<td>Monosomy 17p13.3</td>
</tr>
<tr>
<td>491</td>
<td>17p13.3 deletion</td>
</tr>
<tr>
<td>492</td>
<td>Lissencephaly type 1 due to LIS1 gene mutation</td>
</tr>
<tr>
<td>493</td>
<td>Isolated lissencephaly type 1 without known genetic defects</td>
</tr>
<tr>
<td>494</td>
<td>Lissencephaly type 2</td>
</tr>
<tr>
<td>495</td>
<td>Lissencephaly type 3</td>
</tr>
<tr>
<td>496</td>
<td>Neu-Laxova syndrome</td>
</tr>
<tr>
<td>497</td>
<td>Lissencephaly type 3 - familial fetal akinesia sequence</td>
</tr>
<tr>
<td>498</td>
<td>Lissencephaly type 3 - metacarpal bone dysplasia</td>
</tr>
<tr>
<td>499</td>
<td>Lissencephaly with cerebellar hypoplasia</td>
</tr>
<tr>
<td>500</td>
<td>Lissencephaly with cerebellar hypoplasia type A</td>
</tr>
<tr>
<td>501</td>
<td>Lissencephaly with cerebellar hypoplasia type B</td>
</tr>
<tr>
<td>502</td>
<td>Lissencephaly with cerebellar hypoplasia type C</td>
</tr>
<tr>
<td>503</td>
<td>Lissencephaly with cerebellar hypoplasia type D</td>
</tr>
<tr>
<td>504</td>
<td>Lissencephaly with cerebellar hypoplasia type E</td>
</tr>
<tr>
<td>505</td>
<td>Lissencephaly with cerebellar hypoplasia type F</td>
</tr>
<tr>
<td>506</td>
<td>Microlissencephaly</td>
</tr>
<tr>
<td>507</td>
<td>Microlissencephaly type A</td>
</tr>
<tr>
<td>508</td>
<td>Lissencephaly syndrome, Norman-Roberts type</td>
</tr>
<tr>
<td>509</td>
<td>Microlissencephaly type B</td>
</tr>
<tr>
<td>510</td>
<td>Lissencephaly due to TUBA1A gene mutation</td>
</tr>
<tr>
<td>511</td>
<td>X-linked lissencephaly - agenesis of corpus callosum - genital anomalies</td>
</tr>
<tr>
<td>512</td>
<td>Craniotelencephalic dysplasia</td>
</tr>
<tr>
<td>513</td>
<td>Micro syndrome</td>
</tr>
<tr>
<td>514</td>
<td>Warburg Micro syndrome</td>
</tr>
<tr>
<td>515</td>
<td>WARBM1 - [Warburg Micro syndrome]</td>
</tr>
<tr>
<td>516</td>
<td>Iris coloboma with ptosis - intellectual deficit</td>
</tr>
<tr>
<td>517</td>
<td>Duplications with other complex rearrangements</td>
</tr>
<tr>
<td>518</td>
<td>15q11 duplication or inversion</td>
</tr>
<tr>
<td>519</td>
<td>8p inverted duplication or deletion</td>
</tr>
<tr>
<td>520</td>
<td>8p inverted duplication or deletion syndrome</td>
</tr>
<tr>
<td>521</td>
<td>Cat-eye syndrome</td>
</tr>
<tr>
<td>522</td>
<td>Ocular coloboma - imperforate anus</td>
</tr>
<tr>
<td>523</td>
<td>chromosome 22 inversion or duplication</td>
</tr>
<tr>
<td>524</td>
<td>Recombinant chromosome 8 syndrome</td>
</tr>
<tr>
<td>525</td>
<td>Duplication 8q/deletion 8p</td>
</tr>
<tr>
<td>526</td>
<td>Rec(8) syndrome</td>
</tr>
<tr>
<td>527</td>
<td>San Luis Valley syndrome</td>
</tr>
<tr>
<td>528</td>
<td>Recombinant 8 syndrome</td>
</tr>
<tr>
<td>529</td>
<td>Deletions of the short arm of chromosome 3</td>
</tr>
<tr>
<td>530</td>
<td>Proximal deletions of the short arm of chromosome 3</td>
</tr>
<tr>
<td>531</td>
<td>Distal deletions of the short arm of chromosome 3</td>
</tr>
<tr>
<td>532</td>
<td>3p25.3p26 deletion</td>
</tr>
<tr>
<td>533</td>
<td>Constitutional neutropaenia</td>
</tr>
<tr>
<td>534</td>
<td>congenital agranulocytosis and neutropaenia</td>
</tr>
<tr>
<td>535</td>
<td>congenital leukopaenia</td>
</tr>
<tr>
<td>536</td>
<td>Congenital neutropaenias</td>
</tr>
<tr>
<td>537</td>
<td>primary neutropaenia</td>
</tr>
<tr>
<td>538</td>
<td>Benign ethnic neutropaenia</td>
</tr>
<tr>
<td>539</td>
<td>Severe congenital neutropaenia</td>
</tr>
<tr>
<td>540</td>
<td>severe infantile genetic neutropaenia</td>
</tr>
<tr>
<td>541</td>
<td>Autosomal dominant severe congenital neutropaenia</td>
</tr>
<tr>
<td>542</td>
<td>Autosomal recessive severe congenital neutropaenia due to G6PC3 deficiency</td>
</tr>
<tr>
<td>543</td>
<td>Dursun syndrome</td>
</tr>
<tr>
<td>544</td>
<td>Pulmonary arterial hypertension - leukopenia - atrial septal defect</td>
</tr>
<tr>
<td>545</td>
<td>Autosomal recessive severe congenital neutropaenia due to JAGN1 deficiency</td>
</tr>
<tr>
<td>546</td>
<td>CSF3R-related severe congenital neutropaenia</td>
</tr>
<tr>
<td>547</td>
<td>Kostmann syndrome</td>
</tr>
<tr>
<td>548</td>
<td>Kostmann disease</td>
</tr>
<tr>
<td>549</td>
<td>X-linked severe congenital neutropaenia</td>
</tr>
<tr>
<td>550</td>
<td>Congenital neutropaenia with myelokathexis</td>
</tr>
<tr>
<td>551</td>
<td>Congenital neutropaenia with maturation arrest</td>
</tr>
<tr>
<td>552</td>
<td>Congenital neutropaenia associated with syndromal features</td>
</tr>
<tr>
<td>553</td>
<td>Cyclic neutropaenia</td>
</tr>
<tr>
<td>554</td>
<td>cyclic agranulocytosis</td>
</tr>
<tr>
<td>555</td>
<td>Cyclic haematopoiesis</td>
</tr>
<tr>
<td>556</td>
<td>Constitutional neutropaenia with extra-haematopoietic manifestations</td>
</tr>
<tr>
<td>557</td>
<td>Primary immunodeficiency syndrome due to p14 deficiency</td>
</tr>
<tr>
<td>558</td>
<td>Primary immunodeficiency syndrome with short stature</td>
</tr>
<tr>
<td>559</td>
<td>Infantile genetic agranulocytosis</td>
</tr>
<tr>
<td>560</td>
<td>severe infantile genetic agranulocytosis</td>
</tr>
<tr>
<td>561</td>
<td>Structural anomalies of chromosome X, excluding Turner syndrome</td>
</tr>
<tr>
<td>562</td>
<td>Small ring X chromosome</td>
</tr>
<tr>
<td>563</td>
<td>Xp11.22p11.23 duplication</td>
</tr>
<tr>
<td>564</td>
<td>Trisomy Xp11.22p11.23</td>
</tr>
<tr>
<td>565</td>
<td>Xp11.22p11.23 duplication syndrome</td>
</tr>
<tr>
<td>566</td>
<td>Xp11.3 deletion</td>
</tr>
<tr>
<td>567</td>
<td>Xp21 deletion</td>
</tr>
<tr>
<td>568</td>
<td>Xp21 deletion syndrome</td>
</tr>
<tr>
<td>569</td>
<td>Xp22.13p22.2 duplication</td>
</tr>
<tr>
<td>570</td>
<td>Xp22.33 deletion</td>
</tr>
<tr>
<td>571</td>
<td>Xq27.3q28 duplication</td>
</tr>
<tr>
<td>572</td>
<td>Xq28 deletion</td>
</tr>
<tr>
<td>573</td>
<td>Xq28 deletion syndrome</td>
</tr>
<tr>
<td>574</td>
<td>Distal monosomy Xq</td>
</tr>
<tr>
<td>575</td>
<td>Xq28 duplication</td>
</tr>
<tr>
<td>576</td>
<td>Xq28 duplication syndrome</td>
</tr>
<tr>
<td>577</td>
<td>Distal duplication Xq</td>
</tr>
<tr>
<td>578</td>
<td>Telomeric duplication Xq</td>
</tr>
<tr>
<td>579</td>
<td>Alpha thalassaemia related syndromes</td>
</tr>
<tr>
<td>580</td>
<td>Alpha thalassaemia related diseases</td>
</tr>
<tr>
<td>581</td>
<td>Alpha thalassaemia - X-linked intellectual deficit</td>
</tr>
<tr>
<td>582</td>
<td>X-linked alpha thalassaemia with mental retardation</td>
</tr>
<tr>
<td>583</td>
<td>Alpha thalassaemia - intellectual deficit syndrome</td>
</tr>
<tr>
<td>584</td>
<td>16pter-p13.3 deletion</td>
</tr>
<tr>
<td>585</td>
<td>Alpha-thalassaemia intellectual disability syndrome linked to chromosome 16</td>
</tr>
<tr>
<td>586</td>
<td>Genetic susceptibility to particular pathogens</td>
</tr>
<tr>
<td>587</td>
<td>Idiopathic CD4 lymphocytopenia</td>
</tr>
<tr>
<td>588</td>
<td>Immunodeficiency due to interleukin-1 receptor-associated kinase-4 deficiency</td>
</tr>
<tr>
<td>589</td>
<td>IRAK4 - [interleukin-1 receptor-associated kinase-4 deficiency]</td>
</tr>
<tr>
<td>590</td>
<td>Lung fibrosis - immunodeficiency - gonadal dysgenesis</td>
</tr>
<tr>
<td>591</td>
<td>Mendelian susceptibility to mycobacterial diseases</td>
</tr>
<tr>
<td>592</td>
<td>Idiopathic infection caused by BCG or atypical mycobacteria</td>
</tr>
<tr>
<td>593</td>
<td>MSMD - [Mendelian susceptibility to mycobacterial diseases]</td>
</tr>
<tr>
<td>594</td>
<td>Autosomal recessive mendelian susceptibility to mycobacterial diseases</td>
</tr>
<tr>
<td>595</td>
<td>AR MSMD - [autosomal recessive mendelian susceptibility to mycobacterial diseases]</td>
</tr>
<tr>
<td>596</td>
<td>Complete autosomal recessive interferon-gamma receptor 1 deficiency</td>
</tr>
<tr>
<td>597</td>
<td>Complete AR IFNGR1 - [autosomal recessive interferon-gamma receptor 1] deficiency</td>
</tr>
<tr>
<td>598</td>
<td>Partial autosomal recessive interferon-gamma receptor 1 deficiency</td>
</tr>
<tr>
<td>599</td>
<td>Partial AR IFNGR1- [autosomal recessive interferon-gamma receptor 1] deficiency</td>
</tr>
<tr>
<td>600</td>
<td>Complete autosomal recessive interferon-gamma receptor 2 deficiency</td>
</tr>
<tr>
<td>601</td>
<td>Complete AR IFNGR2 - [autosomal recessive interferon-gamma receptor 2] deficiency</td>
</tr>
<tr>
<td>602</td>
<td>Partial autosomal recessive interferon-gamma receptor 2 deficiency</td>
</tr>
<tr>
<td>603</td>
<td>Partial AR IFNGR2 - [autosomal recessive interferon-gamma receptor 2] deficiency</td>
</tr>
<tr>
<td>604</td>
<td>Autosomal recessive interleukin 12 receptor beta-1 chain deficiency</td>
</tr>
<tr>
<td>605</td>
<td>AR IL12RB1 - [Autosomal recessive interleukin 12 receptor beta-1 chain] deficiency</td>
</tr>
<tr>
<td>606</td>
<td>Autosomal recessive interleukin 12p40 deficiency</td>
</tr>
<tr>
<td>607</td>
<td>AR IL12B - [Autosomal recessive interleukin 12p40] deficiency</td>
</tr>
<tr>
<td>608</td>
<td>Autosomal recessive tyrosine kinase 2 deficiency</td>
</tr>
<tr>
<td>609</td>
<td>Autosomal recessive hyper-IgE syndrome with atypical mycobacteriosis</td>
</tr>
<tr>
<td>610</td>
<td>Autosomal dominant mendelian susceptibility to mycobacterial diseases</td>
</tr>
<tr>
<td>611</td>
<td>AD MSMD - [Autosomal dominant mendelian susceptibility to mycobacterial diseases]</td>
</tr>
<tr>
<td>612</td>
<td>Autosomal dominant interferon-gamma receptor 1 deficiency</td>
</tr>
<tr>
<td>613</td>
<td>AD IFNGR1 - [Autosomal dominant interferon-gamma receptor 1] deficiency</td>
</tr>
<tr>
<td>614</td>
<td>Autosomal dominant Stat1 deficiency</td>
</tr>
<tr>
<td>615</td>
<td>Mendelian susceptibility to mycobacterial diseases due to partial signal transducer and activator of transcription 1 deficiency</td>
</tr>
<tr>
<td>616</td>
<td>AD STAT1 - [Autosomal dominant Stat1] deficiency</td>
</tr>
<tr>
<td>617</td>
<td>X-linked recessive mendelian susceptibility to mycobacterial diseases</td>
</tr>
<tr>
<td>618</td>
<td>XR MSMD - [X-linked recessive mendelian susceptibility to mycobacterial diseases]</td>
</tr>
<tr>
<td>619</td>
<td>Monocytopenia with susceptibility to infections</td>
</tr>
<tr>
<td>620</td>
<td>MonoMAC syndrome</td>
</tr>
<tr>
<td>621</td>
<td>Pyogenic bacterial infections due to MyD88 deficiency</td>
</tr>
<tr>
<td>622</td>
<td>Disorders of multiple glycosylation or other pathways</td>
</tr>
<tr>
<td>623</td>
<td>Dolichol-phosphate-mannose synthase 1 deficiency</td>
</tr>
<tr>
<td>624</td>
<td>GDP-Man: Dol-P-mannosyltransferase deficiency</td>
</tr>
<tr>
<td>625</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1E</td>
</tr>
<tr>
<td>626</td>
<td>Congenital disorder of glycosylation type 1E</td>
</tr>
<tr>
<td>627</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1E</td>
</tr>
<tr>
<td>628</td>
<td>Mannose-P-dolichol utilisation defect 1</td>
</tr>
<tr>
<td>629</td>
<td>Lec35 deficiency</td>
</tr>
<tr>
<td>630</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1F</td>
</tr>
<tr>
<td>631</td>
<td>Congenital disorder of glycosylation type 1F</td>
</tr>
<tr>
<td>632</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1F</td>
</tr>
<tr>
<td>633</td>
<td>Beta-1,4-galactosyltransferase deficiency</td>
</tr>
<tr>
<td>634</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2D</td>
</tr>
<tr>
<td>635</td>
<td>Congenital disorder of glycosylation type 2D</td>
</tr>
<tr>
<td>636</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2D</td>
</tr>
<tr>
<td>637</td>
<td>CMP-sialic acid transporter deficiency</td>
</tr>
<tr>
<td>638</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2F</td>
</tr>
<tr>
<td>639</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2F</td>
</tr>
<tr>
<td>640</td>
<td>Congenital disorder of glycosylation type 2F</td>
</tr>
<tr>
<td>641</td>
<td>Leukocyte adhesion deficiency type 2</td>
</tr>
<tr>
<td>642</td>
<td>Rambam-Hasharon syndrome</td>
</tr>
<tr>
<td>643</td>
<td>GDP-fucose transporter deficiency</td>
</tr>
<tr>
<td>644</td>
<td>LAD-II - [Leukocyte adhesion deficiency type 2]</td>
</tr>
<tr>
<td>645</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2C</td>
</tr>
<tr>
<td>646</td>
<td>Dolichol kinase deficiency</td>
</tr>
<tr>
<td>647</td>
<td>Hypotonia or ichthyosis due to dolichol phosphate deficiency</td>
</tr>
<tr>
<td>648</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1M</td>
</tr>
<tr>
<td>649</td>
<td>Congenital disorder of glycosylation type 1M</td>
</tr>
<tr>
<td>650</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1M</td>
</tr>
<tr>
<td>651</td>
<td>Conserved oligomeric Golgi complex deficiencies</td>
</tr>
<tr>
<td>652</td>
<td>Component of conserved oligomeric Golgi complex 1 deficiency</td>
</tr>
<tr>
<td>653</td>
<td>CDG syndrome type 2G</td>
</tr>
<tr>
<td>654</td>
<td>Component of conserved oligomeric Golgi complex 4 deficiency</td>
</tr>
<tr>
<td>655</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2J</td>
</tr>
<tr>
<td>656</td>
<td>Congenital disorder of glycosylation type 2J</td>
</tr>
<tr>
<td>657</td>
<td>Component of conserved oligomeric Golgi complex 5 deficiency</td>
</tr>
<tr>
<td>658</td>
<td>Component of conserved oligomeric Golgi complex 7 deficiency</td>
</tr>
<tr>
<td>659</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2E</td>
</tr>
<tr>
<td>660</td>
<td>Congenital disorder of glycosylation type 2E</td>
</tr>
<tr>
<td>661</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2E</td>
</tr>
<tr>
<td>662</td>
<td>Component of conserved oligomeric Golgi complex 8 deficiency</td>
</tr>
<tr>
<td>663</td>
<td>Congenital disorder of glycosylation type 2h</td>
</tr>
<tr>
<td>664</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2H</td>
</tr>
<tr>
<td>665</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2H</td>
</tr>
<tr>
<td>666</td>
<td>V-ATPase deficiencies</td>
</tr>
<tr>
<td>667</td>
<td>Other specified pemphigoid</td>
</tr>
<tr>
<td>668</td>
<td>Bullous pemphigoid variants</td>
</tr>
<tr>
<td>669</td>
<td>Lichen planus pemphigoides</td>
</tr>
<tr>
<td>670</td>
<td>Localised bullous pemphigoid</td>
</tr>
<tr>
<td>671</td>
<td>Localised vulval pemphigoid</td>
</tr>
<tr>
<td>672</td>
<td>Pemphigoid nodularis</td>
</tr>
<tr>
<td>673</td>
<td>Anti-laminin-g1 pemphigoid</td>
</tr>
<tr>
<td>674</td>
<td>anti-p200 pemphigoid</td>
</tr>
<tr>
<td>675</td>
<td>Miscellaneous pemphigoid variants</td>
</tr>
<tr>
<td>676</td>
<td>Pretibial pemphigoid</td>
</tr>
<tr>
<td>677</td>
<td>Cicatricial pemphigoid, Brunsting-Perry type</td>
</tr>
<tr>
<td>678</td>
<td>Other specified qualitative platelet defects</td>
</tr>
<tr>
<td>679</td>
<td>Stormorken-Sjaastad-Langslet syndrome</td>
</tr>
<tr>
<td>680</td>
<td>Scott syndrome</td>
</tr>
<tr>
<td>681</td>
<td>ADP platelet receptor P2Y12 deficiency</td>
</tr>
<tr>
<td>682</td>
<td>Pseudo-Von Willebrand disease</td>
</tr>
<tr>
<td>683</td>
<td>Platelet-type Von Willebrand disease</td>
</tr>
<tr>
<td>684</td>
<td>Bleeding diathesis due to a collagen receptor defect</td>
</tr>
<tr>
<td>685</td>
<td>Bleeding diathesis due to glycoprotein VI deficiency</td>
</tr>
<tr>
<td>686</td>
<td>Bleeding diathesis due to integrin alpha2-beta1 deficiency</td>
</tr>
<tr>
<td>687</td>
<td>Secondary haemophagocytic lymphohistiocytosis</td>
</tr>
<tr>
<td>688</td>
<td>Reactive haemophagocytic syndrome</td>
</tr>
<tr>
<td>689</td>
<td>Haemophagocytic lymphohistiocytosis associated with a malignant disease</td>
</tr>
<tr>
<td>690</td>
<td>Familial Parkinson disease</td>
</tr>
<tr>
<td>691</td>
<td>Other genetic Parkinsonism</td>
</tr>
<tr>
<td>692</td>
<td>Autosomal dominant familial Parkinson disease</td>
</tr>
<tr>
<td>693</td>
<td>Parkinson disease LRRK2 gene mutation 12p11.23-q13.11</td>
</tr>
<tr>
<td>694</td>
<td>PARK8</td>
</tr>
<tr>
<td>695</td>
<td>Parkinson disease synuclein gene mutation 4q21.23</td>
</tr>
<tr>
<td>696</td>
<td>PARK1</td>
</tr>
<tr>
<td>697</td>
<td>Parkinson disease synduclein duplications or triplications</td>
</tr>
<tr>
<td>698</td>
<td>Parkinson disease UCHL-1 gene mutations 4p14</td>
</tr>
<tr>
<td>699</td>
<td>PARK5</td>
</tr>
<tr>
<td>700</td>
<td>Autosomal recessive familial Parkinson disease</td>
</tr>
<tr>
<td>701</td>
<td>Parkinson disease parkin mutations</td>
</tr>
<tr>
<td>702</td>
<td>PARK 2</td>
</tr>
<tr>
<td>703</td>
<td>Parkinson disease DJ-1 gene mutations 1p36</td>
</tr>
<tr>
<td>704</td>
<td>PARK 7</td>
</tr>
<tr>
<td>705</td>
<td>Parkinson disease PINK gene mutations</td>
</tr>
<tr>
<td>706</td>
<td>PARK 6</td>
</tr>
<tr>
<td>707</td>
<td>PINK 1</td>
</tr>
<tr>
<td>708</td>
<td>Parkinson disease ATP13A2 mutations</td>
</tr>
<tr>
<td>1</td>
<td>Myelodysplastic syndrome with isolated del(5q)</td>
</tr>
<tr>
<td>2</td>
<td>5 q- syndrome</td>
</tr>
<tr>
<td>3</td>
<td>Deletions of chromosome 21</td>
</tr>
<tr>
<td>4</td>
<td>Partial monosomy 21</td>
</tr>
<tr>
<td>5</td>
<td>21q deletion</td>
</tr>
<tr>
<td>6</td>
<td>Monosomy 21</td>
</tr>
<tr>
<td>7</td>
<td>Partial 21q monosomy</td>
</tr>
<tr>
<td>8</td>
<td>21q syndrome</td>
</tr>
<tr>
<td>9</td>
<td>Proximal deletions of chromosome 21</td>
</tr>
<tr>
<td>10</td>
<td>Distal deletions of chromosome 21</td>
</tr>
<tr>
<td>11</td>
<td>21q22.11q22.12 deletion</td>
</tr>
<tr>
<td>12</td>
<td>21q22 deletion syndrome</td>
</tr>
<tr>
<td>13</td>
<td>Monosomy 21q22</td>
</tr>
<tr>
<td>14</td>
<td>21q22.13q22.2 deletion</td>
</tr>
<tr>
<td>15</td>
<td>Deletions of the long arm of chromosome 18</td>
</tr>
<tr>
<td>16</td>
<td>18q deletion</td>
</tr>
<tr>
<td>17</td>
<td>18q deletion syndrome</td>
</tr>
<tr>
<td>18</td>
<td>Proximal deletions of the long arm of chromosome 18</td>
</tr>
<tr>
<td>19</td>
<td>Distal deletions of the long arm of chromosome 18</td>
</tr>
<tr>
<td>20</td>
<td>Duplications of the long arm of chromosome 8</td>
</tr>
<tr>
<td>21</td>
<td>8q duplication</td>
</tr>
<tr>
<td>22</td>
<td>8q duplication syndrome</td>
</tr>
<tr>
<td>23</td>
<td>Chromosome 8 long arm trisomy</td>
</tr>
<tr>
<td>24</td>
<td>Proximal duplications of the long arm of chromosome 8</td>
</tr>
<tr>
<td>25</td>
<td>8q12 duplication</td>
</tr>
<tr>
<td>26</td>
<td>8q12 microduplication syndrome</td>
</tr>
<tr>
<td>27</td>
<td>Trisomy 8q12</td>
</tr>
<tr>
<td>28</td>
<td>Distal duplications of the long arm of chromosome 8</td>
</tr>
<tr>
<td>29</td>
<td>8q24 duplication</td>
</tr>
<tr>
<td>30</td>
<td>Distal chromosome 8 long arm trisomy</td>
</tr>
<tr>
<td>31</td>
<td>Distal 8q duplication</td>
</tr>
<tr>
<td>32</td>
<td>Q fever</td>
</tr>
<tr>
<td>33</td>
<td>Nine Mile fever</td>
</tr>
<tr>
<td>34</td>
<td>Australian Q fever</td>
</tr>
<tr>
<td>35</td>
<td>Infection due to Coxiella burnetii</td>
</tr>
<tr>
<td>36</td>
<td>Quadrilateral fever</td>
</tr>
<tr>
<td>37</td>
<td>Balkan grippe</td>
</tr>
<tr>
<td>38</td>
<td>Pneumonia in Q fever</td>
</tr>
<tr>
<td>39</td>
<td>Q fever pneumonia</td>
</tr>
<tr>
<td>40</td>
<td>Cardiac Q fever</td>
</tr>
<tr>
<td>41</td>
<td>Q fever endocarditis</td>
</tr>
<tr>
<td>42</td>
<td>Deletions of the long arm of chromosome 2</td>
</tr>
<tr>
<td>43</td>
<td>Proximal deletions of the long arm of chromosome 2</td>
</tr>
<tr>
<td>44</td>
<td>Medial deletions of the long arm of chromosome 2</td>
</tr>
<tr>
<td>45</td>
<td>2q22 deletion</td>
</tr>
<tr>
<td>46</td>
<td>2q23.1 deletion</td>
</tr>
<tr>
<td>47</td>
<td>2q23.1 deletion syndrome</td>
</tr>
<tr>
<td>48</td>
<td>Monosomy 2q23.1</td>
</tr>
<tr>
<td>49</td>
<td>2q24 deletion</td>
</tr>
<tr>
<td>50</td>
<td>Monosomy 2q24</td>
</tr>
<tr>
<td>51</td>
<td>2q24 deletion syndrome</td>
</tr>
<tr>
<td>52</td>
<td>Distal deletions of the long arm of chromosome 2</td>
</tr>
<tr>
<td>53</td>
<td>2q31.1 deletion</td>
</tr>
<tr>
<td>54</td>
<td>2q31.1 microdeletion syndrome</td>
</tr>
<tr>
<td>55</td>
<td>Monosomy 2q31.1</td>
</tr>
<tr>
<td>56</td>
<td>2q32q33 deletion</td>
</tr>
<tr>
<td>57</td>
<td>2q31.2-q32.3 microdeletion syndrome</td>
</tr>
<tr>
<td>58</td>
<td>Monosomy 2q31.2-q32.3</td>
</tr>
<tr>
<td>59</td>
<td>Monosomy 2q32</td>
</tr>
<tr>
<td>60</td>
<td>2q32 microdeletion syndrome</td>
</tr>
<tr>
<td>61</td>
<td>2q33.1 deletion</td>
</tr>
<tr>
<td>62</td>
<td>2q33.1 microdeletion syndrome</td>
</tr>
<tr>
<td>63</td>
<td>Monosomy 2q33.1</td>
</tr>
<tr>
<td>64</td>
<td>2q37 deletion</td>
</tr>
<tr>
<td>65</td>
<td>Monosomy 2q37</td>
</tr>
<tr>
<td>66</td>
<td>2q37 deletion syndrome</td>
</tr>
<tr>
<td>67</td>
<td>Brachydactyly-intellectual deficit</td>
</tr>
<tr>
<td>68</td>
<td>Albright hereditary osteodystrophy 3</td>
</tr>
<tr>
<td>69</td>
<td>Albright hereditary osteodystrophy-like syndrome</td>
</tr>
<tr>
<td>70</td>
<td>Deletions of the long arm of chromosome 1</td>
</tr>
<tr>
<td>71</td>
<td>Proximal deletions of the long arm of chromosome 1</td>
</tr>
<tr>
<td>72</td>
<td>Medial deletions of the long arm of chromosome 1</td>
</tr>
<tr>
<td>73</td>
<td>1q21.1 deletion</td>
</tr>
<tr>
<td>74</td>
<td>1q21.1 deletion syndrome</td>
</tr>
<tr>
<td>75</td>
<td>Monosomy 1q21.1</td>
</tr>
<tr>
<td>76</td>
<td>Distal deletions of the long arm of chromosome 1</td>
</tr>
<tr>
<td>77</td>
<td>1q41q42 deletion</td>
</tr>
<tr>
<td>78</td>
<td>1q41q42 microdeletion syndrome</td>
</tr>
<tr>
<td>79</td>
<td>Monosomy 1q41q42</td>
</tr>
<tr>
<td>80</td>
<td>1q42qter deletion</td>
</tr>
<tr>
<td>81</td>
<td>Distal 1q deletion syndrome</td>
</tr>
<tr>
<td>82</td>
<td>Distal monosomy 1q</td>
</tr>
<tr>
<td>83</td>
<td>1q44 deletion</td>
</tr>
<tr>
<td>84</td>
<td>1q44 deletion syndrome</td>
</tr>
<tr>
<td>85</td>
<td>Monosomy 1q44</td>
</tr>
<tr>
<td>86</td>
<td>Other specified chromosomal anomalies, excluding gene mutations</td>
</tr>
<tr>
<td>87</td>
<td>Tetrasomies of the autosomes</td>
</tr>
<tr>
<td>88</td>
<td>Tetrasomy 12p mosaicism</td>
</tr>
<tr>
<td>89</td>
<td>Pallister-Killian syndrome</td>
</tr>
<tr>
<td>90</td>
<td>Tetrasomy 15q</td>
</tr>
<tr>
<td>91</td>
<td>Tetrasomy 18p</td>
</tr>
<tr>
<td>92</td>
<td>Tetrasomy 21</td>
</tr>
<tr>
<td>93</td>
<td>Tetrasomy 5p mosaicism</td>
</tr>
<tr>
<td>94</td>
<td>Tetrasomy 9p</td>
</tr>
<tr>
<td>95</td>
<td>Mosaic variegated aneuploidy syndrome</td>
</tr>
<tr>
<td>96</td>
<td>Unbalanced translocations or structural rearrangements</td>
</tr>
<tr>
<td>97</td>
<td>Replacement of a chromosome with a dicentric, isochromosome, or isodicentric</td>
</tr>
<tr>
<td>98</td>
<td>Unbalanced reciprocal translocation</td>
</tr>
<tr>
<td>99</td>
<td>Unbalanced reciprocal translocation with 3:1 segregation (chromosome count = 45)</td>
</tr>
<tr>
<td>100</td>
<td>Unbalanced reciprocal translocation with 2:2 segregation (chromosome count = 46)</td>
</tr>
<tr>
<td>101</td>
<td>Unbalanced reciprocal translocation with 3:1 segregation (chromosome count = 47)</td>
</tr>
<tr>
<td>102</td>
<td>Unbalanced Robertsonian translocation</td>
</tr>
<tr>
<td>103</td>
<td>Chromosome replaced with ring or dicentric with normal number of chromosomes</td>
</tr>
<tr>
<td>104</td>
<td>Replaced chromosome by ring or dicentric</td>
</tr>
<tr>
<td>105</td>
<td>abnormal chromosome, ring replacement</td>
</tr>
<tr>
<td>106</td>
<td>Ring chromosome 1 with normal number of chromosomes</td>
</tr>
<tr>
<td>107</td>
<td>Ring chromosome 2 with normal number of chromosomes</td>
</tr>
<tr>
<td>108</td>
<td>Ring chromosome 3 with normal number of chromosomes</td>
</tr>
<tr>
<td>109</td>
<td>Ring chromosome 4 with normal number of chromosomes</td>
</tr>
<tr>
<td>110</td>
<td>Ring chromosome 5 with normal number of chromosomes</td>
</tr>
<tr>
<td>111</td>
<td>Ring chromosome 6 with normal number of chromosomes</td>
</tr>
<tr>
<td>112</td>
<td>Ring chromosome 7 with normal number of chromosomes</td>
</tr>
<tr>
<td>113</td>
<td>Ring chromosome 8 with normal number of chromosomes</td>
</tr>
<tr>
<td>114</td>
<td>Ring chromosome 9 with normal number of chromosomes</td>
</tr>
<tr>
<td>115</td>
<td>Ring chromosome 10 with normal number of chromosomes</td>
</tr>
<tr>
<td>116</td>
<td>Ring chromosome 11 with normal number of chromosomes</td>
</tr>
<tr>
<td>117</td>
<td>Ring chromosome 12 with normal number of chromosomes</td>
</tr>
<tr>
<td>118</td>
<td>Ring chromosome 13 with normal number of chromosomes</td>
</tr>
<tr>
<td>119</td>
<td>Ring chromosome 14 with normal number of chromosomes</td>
</tr>
<tr>
<td>120</td>
<td>Ring chromosome 15 with normal number of chromosomes</td>
</tr>
<tr>
<td>121</td>
<td>Ring chromosome 16 with normal number of chromosomes</td>
</tr>
<tr>
<td>122</td>
<td>Ring chromosome 17 with normal number of chromosomes</td>
</tr>
<tr>
<td>123</td>
<td>Ring chromosome 18 with normal number of chromosomes</td>
</tr>
<tr>
<td>124</td>
<td>Ring chromosome 19 with normal number of chromosomes</td>
</tr>
<tr>
<td>125</td>
<td>Ring chromosome 20 with normal number of chromosomes</td>
</tr>
<tr>
<td>126</td>
<td>Ring chromosome 20</td>
</tr>
<tr>
<td>127</td>
<td>Ring chromosome 21 with normal number of chromosomes</td>
</tr>
<tr>
<td>128</td>
<td>Ring chromosome 22 with normal number of chromosomes</td>
</tr>
<tr>
<td>129</td>
<td>Unbalanced dicentric chromosomes</td>
</tr>
<tr>
<td>130</td>
<td>Other specified syndromic genetic deafness</td>
</tr>
<tr>
<td>131</td>
<td>Albinism - black lock - cell migration disorder of the neurocytes of the gut - sensorineural deafness</td>
</tr>
<tr>
<td>132</td>
<td>ABCD - [Albinism - black lock - cell migration disorder of the neurocytes of the gut - sensorineural deafness] syndrome</td>
</tr>
<tr>
<td>133</td>
<td>Albinism-deafness syndrome</td>
</tr>
<tr>
<td>134</td>
<td>Alström syndrome</td>
</tr>
<tr>
<td>135</td>
<td>Ataxia - deafness - intellectual disability syndrome</td>
</tr>
<tr>
<td>136</td>
<td>Athabaskan brainstem dysgenesis syndrome</td>
</tr>
<tr>
<td>137</td>
<td>Atherosclerosis - deafness - diabetes - epilepsy - nephropathy</td>
</tr>
<tr>
<td>138</td>
<td>Bilateral microtia - deafness - cleft palate</td>
</tr>
<tr>
<td>139</td>
<td>Bosley-Salih-Alorainy syndrome</td>
</tr>
<tr>
<td>140</td>
<td>Brown-Vialetto-van Laere syndrome</td>
</tr>
<tr>
<td>141</td>
<td>Sensorineural hearing loss - pontobulbar palsy</td>
</tr>
<tr>
<td>142</td>
<td>Cataract - ataxia - deafness</td>
</tr>
<tr>
<td>143</td>
<td>Cataract - deafness - hypogonadism</td>
</tr>
<tr>
<td>144</td>
<td>Caudal appendage - deafness</td>
</tr>
<tr>
<td>145</td>
<td>Central nervous system calcification - deafness - tubular acidosis - anaemia</td>
</tr>
<tr>
<td>146</td>
<td>Choanal atresia - deafness - cardiac defects - dysmorphism</td>
</tr>
<tr>
<td>147</td>
<td>Choroideremia - deafness - obesity</td>
</tr>
<tr>
<td>148</td>
<td>Cleft lip or palate - deafness - sacral lipoma</td>
</tr>
<tr>
<td>149</td>
<td>Cochleosaccular degeneration - cataract</td>
</tr>
<tr>
<td>150</td>
<td>Corneal anaesthesia - deafness - intellectual disability</td>
</tr>
<tr>
<td>151</td>
<td>Corneal dystrophy - perceptive deafness</td>
</tr>
<tr>
<td>152</td>
<td>Craniofacial-deafness-hand syndrome</td>
</tr>
<tr>
<td>153</td>
<td>Deaf blind hypopigmentation syndrome, Yemenite type</td>
</tr>
<tr>
<td>154</td>
<td>Deafness - craniofacial syndrome</td>
</tr>
<tr>
<td>155</td>
<td>Deafness - epiphyseal dysplasia - short stature</td>
</tr>
<tr>
<td>156</td>
<td>Deafness - genital anomalies - metacarpal and metatarsal synostosis</td>
</tr>
<tr>
<td>157</td>
<td>Deafness - hypogonadism</td>
</tr>
<tr>
<td>158</td>
<td>Deafness - intellectual deficit syndrome, Martin-Probst type</td>
</tr>
<tr>
<td>159</td>
<td>Martin-Probst syndrome</td>
</tr>
<tr>
<td>160</td>
<td>Deafness - oligodontia</td>
</tr>
<tr>
<td>161</td>
<td>Deafness - peripheral neuropathy - arterial disease</td>
</tr>
<tr>
<td>162</td>
<td>Deafness - skeletal dysplasia - lip granuloma</td>
</tr>
<tr>
<td>163</td>
<td>Fountain syndrome</td>
</tr>
<tr>
<td>164</td>
<td>Deafness - small bowel diverticulosis - neuropathy</td>
</tr>
<tr>
<td>165</td>
<td>Deafness - vitiligo - achalasia</td>
</tr>
<tr>
<td>166</td>
<td>Deafness-infertility syndrome</td>
</tr>
<tr>
<td>167</td>
<td>15q15.3 deletion syndrome</td>
</tr>
<tr>
<td>168</td>
<td>Monosomy 15q15.3</td>
</tr>
<tr>
<td>169</td>
<td>15q15.3 deletion</td>
</tr>
<tr>
<td>170</td>
<td>Dentinogenesis imperfecta - short stature - hearing loss - intellectual deficit</td>
</tr>
<tr>
<td>171</td>
<td>Developmental delay - deafness, Hildebrand type</td>
</tr>
<tr>
<td>172</td>
<td>Developmental malformations - deafness - dystonia</td>
</tr>
<tr>
<td>173</td>
<td>Ermine phenotype</td>
</tr>
<tr>
<td>174</td>
<td>Gingival fibromatosis - progressive deafness</td>
</tr>
<tr>
<td>175</td>
<td>Hearing loss - familial salivary gland insensitivity to aldosterone</td>
</tr>
<tr>
<td>176</td>
<td>Hirschsprung disease - deafness - polydactyly</td>
</tr>
<tr>
<td>177</td>
<td>Hypospadias-hypertelorism-coloboma and deafness</td>
</tr>
<tr>
<td>178</td>
<td>Iris dysplasia - hypertelorism - deafness</td>
</tr>
<tr>
<td>179</td>
<td>Lethal ataxia with deafness and optic atrophy</td>
</tr>
<tr>
<td>180</td>
<td>Arts syndrome</td>
</tr>
<tr>
<td>181</td>
<td>Lipodystrophy - intellectual deficit - deafness</td>
</tr>
<tr>
<td>182</td>
<td>Lowe-Kohn-Cohen syndrome</td>
</tr>
<tr>
<td>183</td>
<td>Deafness - nephritis - anorectal malformation</td>
</tr>
<tr>
<td>184</td>
<td>Maternally inherited diabetes and deafness</td>
</tr>
<tr>
<td>185</td>
<td>Mitochondrial diabetes</td>
</tr>
<tr>
<td>186</td>
<td>Maxillonasal dysplasia</td>
</tr>
<tr>
<td>187</td>
<td>Intellectual disability – enteropathy – deafness – neuropathy – ichthyosis – keratoderma syndrome</td>
</tr>
<tr>
<td>188</td>
<td>Mental retardation – enteropathy – deafness – neuropathy – ichthyosis – keratoderma syndrome</td>
</tr>
<tr>
<td>189</td>
<td>MEDNIK - [Mental retardation – enteropathy – deafness – neuropathy – ichthyosis – keratoderma] syndrome</td>
</tr>
<tr>
<td>190</td>
<td>Microcephaly - deafness - intellectual disability</td>
</tr>
<tr>
<td>191</td>
<td>Microdontia - microtia type I - deafness</td>
</tr>
<tr>
<td>192</td>
<td>Deafness with labyrinthine aplasia, microtia, and microdontia</td>
</tr>
<tr>
<td>193</td>
<td>Mitral regurgitation - deafness - skeletal anomalies</td>
</tr>
<tr>
<td>194</td>
<td>Myoclonus - cerebellar ataxia - deafness</td>
</tr>
<tr>
<td>195</td>
<td>N syndrome</td>
</tr>
<tr>
<td>196</td>
<td>Nephropathy - deafness - hyperparathyroidism</td>
</tr>
<tr>
<td>197</td>
<td>Nephrosis - deafness - urinary tract - digital malformations</td>
</tr>
<tr>
<td>198</td>
<td>Neutropaenia - monocytopaenia - deafness</td>
</tr>
<tr>
<td>199</td>
<td>Olivopontocerebellar atrophy - deafness</td>
</tr>
<tr>
<td>200</td>
<td>Osteochondrodysplatic nanism - deafness - retinitis pigmentosa</td>
</tr>
<tr>
<td>201</td>
<td>Peripheral neuropathy, Fiskerstrand type</td>
</tr>
<tr>
<td>202</td>
<td>Perrault syndrome</td>
</tr>
<tr>
<td>203</td>
<td>Phocomelia - ectrodactyly - deafness - sinus arrhythmia</td>
</tr>
<tr>
<td>204</td>
<td>Hypertrophic cardiomyopathy due to Kearns–Sayre syndrome</td>
</tr>
<tr>
<td>205</td>
<td>progressive sensorineural hearing loss - hypertrophic cardiomyopathy</td>
</tr>
<tr>
<td>206</td>
<td>Hypertrophic cardiomyopathy associated with progressive sensorineural hearing loss</td>
</tr>
<tr>
<td>207</td>
<td>Retinitis pigmentosa - intellectual disability - deafness - hypogenitalism</td>
</tr>
<tr>
<td>208</td>
<td>Richards-Rundle syndrome</td>
</tr>
<tr>
<td>209</td>
<td>Schizophrenia - intellectual disability - deafness - retinitis</td>
</tr>
<tr>
<td>210</td>
<td>Sensorineural hearing loss - early greying - essential tremor</td>
</tr>
<tr>
<td>211</td>
<td>SeSAME syndrome</td>
</tr>
<tr>
<td>212</td>
<td>EAST syndrome</td>
</tr>
<tr>
<td>213</td>
<td>Short stature - deafness - neutrophil dysfunction - dysmorphism</td>
</tr>
<tr>
<td>214</td>
<td>Spastic paraparesis - deafness</td>
</tr>
<tr>
<td>215</td>
<td>Split hand - split foot - deafness</td>
</tr>
<tr>
<td>216</td>
<td>Thickened earlobes - conductive deafness</td>
</tr>
<tr>
<td>217</td>
<td>Deafness - optic atrophy syndrome</td>
</tr>
<tr>
<td>218</td>
<td>Optic atrophy, deafness, ophthalmoplegia, myopathy</td>
</tr>
<tr>
<td>219</td>
<td>Autosomal dominant optic atrophy and congenital deafness</td>
</tr>
<tr>
<td>220</td>
<td>Ocular albinism - late-onset sensorineural deafness</td>
</tr>
<tr>
<td>221</td>
<td>Spastic paraplegia - nephritis - deafness</td>
</tr>
<tr>
<td>222</td>
<td>Metaphyseal dysostosis - intellectual deficit - conductive deafness</td>
</tr>
<tr>
<td>223</td>
<td>Knuckle pads – leukonychia – sensorineural deafness</td>
</tr>
<tr>
<td>224</td>
<td>Bart-Pumphrey syndrome (MIM 149200)</td>
</tr>
<tr>
<td>225</td>
<td>Alport syndrome</td>
</tr>
<tr>
<td>226</td>
<td>Alport syndrome, autosomal dominant</td>
</tr>
<tr>
<td>227</td>
<td>Alport syndrome, autosomal recessive</td>
</tr>
<tr>
<td>228</td>
<td>Alport syndrome, X-linked</td>
</tr>
<tr>
<td>229</td>
<td>Alport syndrome, X-linked diffuse leiomyomatosis</td>
</tr>
<tr>
<td>230</td>
<td>Cardioauditory syndrome</td>
</tr>
<tr>
<td>231</td>
<td>Deletions of the long arm of chromosome 3</td>
</tr>
<tr>
<td>232</td>
<td>Proximal deletions of the long arm of chromosome 3</td>
</tr>
<tr>
<td>233</td>
<td>3q13 deletion</td>
</tr>
<tr>
<td>234</td>
<td>3q13 deletion syndrome</td>
</tr>
<tr>
<td>235</td>
<td>Monosomy 3q13</td>
</tr>
<tr>
<td>236</td>
<td>Distal deletions of the long arm of chromosome 3</td>
</tr>
<tr>
<td>237</td>
<td>3q23 deletion</td>
</tr>
<tr>
<td>238</td>
<td>BPES syndrome due to 3q23 microdeletion</td>
</tr>
<tr>
<td>239</td>
<td>Blepharophimosis - epicanthus inversus - ptosis due to 3q23 microdeletion</td>
</tr>
<tr>
<td>240</td>
<td>3q29 deletion</td>
</tr>
<tr>
<td>241</td>
<td>3q29 deletion syndrome</td>
</tr>
<tr>
<td>242</td>
<td>Monosomy 3q29</td>
</tr>
<tr>
<td>243</td>
<td>Duplications of the long arm of chromosome 1</td>
</tr>
<tr>
<td>244</td>
<td>Mosaic 1q duplication</td>
</tr>
<tr>
<td>245</td>
<td>Proximal duplications of the long arm of chromosome 1</td>
</tr>
<tr>
<td>246</td>
<td>Medial duplications of the long arm of chromosome 1</td>
</tr>
<tr>
<td>247</td>
<td>Distal duplications of the long arm of chromosome 1</td>
</tr>
<tr>
<td>248</td>
<td>1q21.1 duplication</td>
</tr>
<tr>
<td>249</td>
<td>1q21.1 duplication syndrome</td>
</tr>
<tr>
<td>250</td>
<td>Trisomy 1q21.1</td>
</tr>
<tr>
<td>251</td>
<td>Deletions of the long arm of chromosome 4</td>
</tr>
<tr>
<td>252</td>
<td>Proximal deletions of the long arm of chromosome 4</td>
</tr>
<tr>
<td>253</td>
<td>Medial deletions of the long arm of chromosome 4</td>
</tr>
<tr>
<td>254</td>
<td>4q21 deletion</td>
</tr>
<tr>
<td>255</td>
<td>4q21 deletion syndrome</td>
</tr>
<tr>
<td>256</td>
<td>Monosomy 4q21</td>
</tr>
<tr>
<td>257</td>
<td>Distal deletions of the long arm of chromosome 4</td>
</tr>
<tr>
<td>258</td>
<td>Deletions of the long arm of chromosome 12</td>
</tr>
<tr>
<td>259</td>
<td>Proximal deletions of the long arm of chromosome 12</td>
</tr>
<tr>
<td>260</td>
<td>12q15 deletion</td>
</tr>
<tr>
<td>261</td>
<td>Distal deletions of the long arm of chromosome 12</td>
</tr>
<tr>
<td>262</td>
<td>12q24.31q24.32 deletion</td>
</tr>
<tr>
<td>263</td>
<td>12qter deletion</td>
</tr>
<tr>
<td>264</td>
<td>Distal 12q deletion syndrome</td>
</tr>
<tr>
<td>265</td>
<td>Deletions of the long arm of chromosome 17</td>
</tr>
<tr>
<td>266</td>
<td>Proximal deletions of the long arm of chromosome 17</td>
</tr>
<tr>
<td>267</td>
<td>17q11 deletion</td>
</tr>
<tr>
<td>268</td>
<td>17q11 microdeletion syndrome</td>
</tr>
<tr>
<td>269</td>
<td>Monosomy 17q11</td>
</tr>
<tr>
<td>270</td>
<td>Neurofibromatosis 1 microdeletion syndrome (MIM 613675)</td>
</tr>
<tr>
<td>271</td>
<td>17q12 deletion</td>
</tr>
<tr>
<td>272</td>
<td>17q12 deletion syndrome</td>
</tr>
<tr>
<td>273</td>
<td>Monosomy 17q12</td>
</tr>
<tr>
<td>274</td>
<td>Distal deletions of the long arm of chromosome 17</td>
</tr>
<tr>
<td>275</td>
<td>17q21.31 deletion</td>
</tr>
<tr>
<td>276</td>
<td>17q21.31 deletion syndrome</td>
</tr>
<tr>
<td>277</td>
<td>Monosomy 17q21.31</td>
</tr>
<tr>
<td>278</td>
<td>17q23.1q23.2 deletion</td>
</tr>
<tr>
<td>279</td>
<td>17q23.1q23.2 deletion syndrome</td>
</tr>
<tr>
<td>280</td>
<td>Monosomy 17q23.1q23.2</td>
</tr>
<tr>
<td>281</td>
<td>Distal 17q deletion</td>
</tr>
<tr>
<td>282</td>
<td>Distal 17q deletion syndrome</td>
</tr>
<tr>
<td>283</td>
<td>Other specified syndromes with multiple structural anomalies, not of environmental origin</td>
</tr>
<tr>
<td>284</td>
<td>46,XX disorder of sex development - anorectal anomalies</td>
</tr>
<tr>
<td>285</td>
<td>46,XX DSD - anorectal anomalies</td>
</tr>
<tr>
<td>286</td>
<td>Aarskog-Scott syndrome</td>
</tr>
<tr>
<td>287</td>
<td>Aarskog syndrome</td>
</tr>
<tr>
<td>288</td>
<td>Faciodigitogenital syndrome</td>
</tr>
<tr>
<td>289</td>
<td>Faciogenital dysplasia</td>
</tr>
<tr>
<td>290</td>
<td>Ablepharon-macrostomia syndrome</td>
</tr>
<tr>
<td>291</td>
<td>Acro-renal-mandibular syndrome</td>
</tr>
<tr>
<td>292</td>
<td>Acrocallosal syndrome</td>
</tr>
<tr>
<td>293</td>
<td>Acrocardiofacial syndrome</td>
</tr>
<tr>
<td>294</td>
<td>Acrocephalopolydactyly</td>
</tr>
<tr>
<td>295</td>
<td>Acrocephalopolydactylous dysplasia</td>
</tr>
<tr>
<td>296</td>
<td>Elejalde syndrome</td>
</tr>
<tr>
<td>297</td>
<td>Acrorenal syndrome</td>
</tr>
<tr>
<td>298</td>
<td>Adams-Oliver syndrome</td>
</tr>
<tr>
<td>299</td>
<td>Agonadism - dextrocardia - diaphragmatic hernia</td>
</tr>
<tr>
<td>300</td>
<td>Ankyloblepharon filiforme adnatum - cleft palate</td>
</tr>
<tr>
<td>301</td>
<td>Arthrogryposis multiplex congenita - lissencephaly</td>
</tr>
<tr>
<td>302</td>
<td>Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis</td>
</tr>
<tr>
<td>303</td>
<td>Tuberous sclerosis/polycystic kidney disease contiguous gene syndrome</td>
</tr>
<tr>
<td>304</td>
<td>Bifid nose - anorectal and renal anomalies</td>
</tr>
<tr>
<td>305</td>
<td>BNAR - [Bifid nose - anorectal and renal anomalies] syndrome</td>
</tr>
<tr>
<td>306</td>
<td>Blepharophimosis-intellectual deficit syndrome, Ohdo type</td>
</tr>
<tr>
<td>307</td>
<td>Boissel lethal polymalformative syndrome</td>
</tr>
<tr>
<td>308</td>
<td>Branchio-oculo-facial syndrome</td>
</tr>
<tr>
<td>309</td>
<td>Branchio-otic syndrome</td>
</tr>
<tr>
<td>310</td>
<td>Branchio-oto-renal syndrome</td>
</tr>
<tr>
<td>311</td>
<td>BOR - [Branchio-oto-renal] syndrome</td>
</tr>
<tr>
<td>312</td>
<td>Branchio-skeleto-genital syndrome</td>
</tr>
<tr>
<td>313</td>
<td>CAMFAK syndrome</td>
</tr>
<tr>
<td>314</td>
<td>Cataract - microcephaly - arthrogryposis - kyphosis</td>
</tr>
<tr>
<td>315</td>
<td>CAMAK - [Cataract - microcephaly - arthrogryposis - kyphosis] syndrome</td>
</tr>
<tr>
<td>316</td>
<td>Cataract - microcephaly - failure to thrive - kyphoscoliosis</td>
</tr>
<tr>
<td>317</td>
<td>Camptodactyly - tall stature - scoliosis - hearing loss</td>
</tr>
<tr>
<td>318</td>
<td>Cantrell pentalogy</td>
</tr>
<tr>
<td>319</td>
<td>Cantrell syndrome</td>
</tr>
<tr>
<td>320</td>
<td>Pentalogy of Cantrell</td>
</tr>
<tr>
<td>321</td>
<td>Capra-DeMarco syndrome</td>
</tr>
<tr>
<td>322</td>
<td>Craniosynostosis - hydrocephalus - Chiari I malformation - radio-ulnar synostosis</td>
</tr>
<tr>
<td>323</td>
<td>Berant syndrome</td>
</tr>
<tr>
<td>324</td>
<td>Familial scaphocephaly - radioulnar synostosis</td>
</tr>
<tr>
<td>325</td>
<td>Cardiocranial syndrome, Pfeiffer type</td>
</tr>
<tr>
<td>326</td>
<td>Cardioskeletal syndromes</td>
</tr>
<tr>
<td>327</td>
<td>Heart-hand syndromes</td>
</tr>
<tr>
<td>328</td>
<td>Brachydactyly - long thumb</td>
</tr>
<tr>
<td>329</td>
<td>Heart-hand syndrome type 1</td>
</tr>
<tr>
<td>330</td>
<td>Holt-Oram syndrome</td>
</tr>
<tr>
<td>331</td>
<td>Heart-hand syndrome type 2</td>
</tr>
<tr>
<td>332</td>
<td>Heart-hand syndrome type 3</td>
</tr>
<tr>
<td>333</td>
<td>Heart-hand syndrome, Spanish type</td>
</tr>
<tr>
<td>334</td>
<td>Heart-hand syndrome, Slovenian type</td>
</tr>
<tr>
<td>335</td>
<td>Microcephaly - facio-cardio-skeletal syndrome, Hadziselimovic type</td>
</tr>
<tr>
<td>336</td>
<td>Carey-Fineman-Ziter syndrome</td>
</tr>
<tr>
<td>337</td>
<td>Catel-Manzke syndrome</td>
</tr>
<tr>
<td>338</td>
<td>Caudal duplication</td>
</tr>
<tr>
<td>339</td>
<td>Caudal regression sequence</td>
</tr>
<tr>
<td>340</td>
<td>Sacral agenesis</td>
</tr>
<tr>
<td>341</td>
<td>Cavernous haemangiomas of face - supraumbilical midline raphe</td>
</tr>
<tr>
<td>342</td>
<td>Cloverleaf skull - multiple congenital anomalies</td>
</tr>
<tr>
<td>343</td>
<td>Coffin-Lowry syndrome</td>
</tr>
<tr>
<td>344</td>
<td>Coloboma of macula - brachydactyly type B</td>
</tr>
<tr>
<td>345</td>
<td>Congenital cataracts - facial dysmorphism - neuropathy</td>
</tr>
<tr>
<td>346</td>
<td>Cornelia de Lange syndrome</td>
</tr>
<tr>
<td>347</td>
<td>Costello syndrome</td>
</tr>
<tr>
<td>348</td>
<td>Cranio-facio-cardio-skeletal syndrome</td>
</tr>
<tr>
<td>349</td>
<td>Cantu syndrome</td>
</tr>
<tr>
<td>350</td>
<td>Craniosynostosis - anal anomalies - porokeratosis</td>
</tr>
<tr>
<td>351</td>
<td>Craniosynostosis - cataract</td>
</tr>
<tr>
<td>352</td>
<td>Craniosynostosis - Dandy-Walker malformation - hydrocephalus</td>
</tr>
<tr>
<td>353</td>
<td>Craniosynostosis - synostoses - hypertensive nephropathy</td>
</tr>
<tr>
<td>354</td>
<td>Currarino triad</td>
</tr>
<tr>
<td>355</td>
<td>Dandy Walker malformation - facial haemangioma</td>
</tr>
<tr>
<td>356</td>
<td>Deafness - ear malformation - facial palsy</td>
</tr>
<tr>
<td>357</td>
<td>Double uterus - hemivagina - renal agenesis</td>
</tr>
<tr>
<td>358</td>
<td>Ectrodactyly - cleft palate</td>
</tr>
<tr>
<td>359</td>
<td>Endocrine-cerebro-osteodysplasia syndrome</td>
</tr>
<tr>
<td>360</td>
<td>Endosteal sclerosis - cerebellar hypoplasia</td>
</tr>
<tr>
<td>361</td>
<td>Familial intestinal malrotation - facial anomalies</td>
</tr>
<tr>
<td>362</td>
<td>Femoral-facial syndrome</td>
</tr>
<tr>
<td>363</td>
<td>fetal akinesia sequence</td>
</tr>
<tr>
<td>364</td>
<td>FG syndrome</td>
</tr>
<tr>
<td>365</td>
<td>Keller syndrome</td>
</tr>
<tr>
<td>366</td>
<td>Opitz-Kaveggia syndrome</td>
</tr>
<tr>
<td>367</td>
<td>Filippi syndrome</td>
</tr>
<tr>
<td>368</td>
<td>Floating-Harbor syndrome</td>
</tr>
<tr>
<td>369</td>
<td>Fryns syndrome</td>
</tr>
<tr>
<td>370</td>
<td>Fuhrmann-Rieger-de Sousa syndrome</td>
</tr>
<tr>
<td>371</td>
<td>Fibular hypoplasia or aplasia - femoral bowing - oligodactyly</td>
</tr>
<tr>
<td>372</td>
<td>Fuhrmann syndrome</td>
</tr>
<tr>
<td>373</td>
<td>Genito-palato-cardiac syndrome</td>
</tr>
<tr>
<td>374</td>
<td>Genito-patellar syndrome</td>
</tr>
<tr>
<td>375</td>
<td>Goldberg-Shprintzen megacolon syndrome</td>
</tr>
<tr>
<td>376</td>
<td>Haddad syndrome</td>
</tr>
<tr>
<td>377</td>
<td>Hand-foot-uterus syndrome</td>
</tr>
<tr>
<td>378</td>
<td>Hand-foot-genital syndrome</td>
</tr>
<tr>
<td>379</td>
<td>HERNS syndrome</td>
</tr>
<tr>
<td>380</td>
<td>Holmes-Schepens syndrome</td>
</tr>
<tr>
<td>381</td>
<td>Donnai-Barrow syndrome</td>
</tr>
<tr>
<td>382</td>
<td>Hypopituitarism - micropenis - cleft lip or palate</td>
</tr>
<tr>
<td>383</td>
<td>Hypotelorism - cleft palate - hypospadias</td>
</tr>
<tr>
<td>384</td>
<td>Juberg-Hayward syndrome</td>
</tr>
<tr>
<td>385</td>
<td>Kabuki syndrome</td>
</tr>
<tr>
<td>386</td>
<td>KBG syndrome</td>
</tr>
<tr>
<td>387</td>
<td>Keutel syndrome</td>
</tr>
<tr>
<td>388</td>
<td>Kleefstra syndrome</td>
</tr>
<tr>
<td>389</td>
<td>Knobloch syndrome</td>
</tr>
<tr>
<td>390</td>
<td>Limb body wall complex</td>
</tr>
<tr>
<td>391</td>
<td>Lethal arthrogryposis - anterior horn cell disease</td>
</tr>
<tr>
<td>392</td>
<td>Vuopala disease</td>
</tr>
<tr>
<td>393</td>
<td>LAAHD - [Lethal arthrogryposis - anterior horn cell disease]</td>
</tr>
<tr>
<td>394</td>
<td>Lowry-MacLean syndrome</td>
</tr>
<tr>
<td>395</td>
<td>Malpuech syndrome</td>
</tr>
<tr>
<td>396</td>
<td>Marfanoid habitus - intellectual deficit, autosomal recessive</td>
</tr>
<tr>
<td>397</td>
<td>McDonough syndrome</td>
</tr>
<tr>
<td>398</td>
<td>Meacham syndrome</td>
</tr>
<tr>
<td>399</td>
<td>Megacystis - microcolon - intestinal hypoperistalsis - hydronephrosis</td>
</tr>
<tr>
<td>400</td>
<td>Berdon syndrome</td>
</tr>
<tr>
<td>401</td>
<td>MMIHS - [Megacystis - microcolon - intestinal hypoperistalsis - hydronephrosis]</td>
</tr>
<tr>
<td>402</td>
<td>Microgastria - limb reduction defect</td>
</tr>
<tr>
<td>403</td>
<td>Moebius syndrome</td>
</tr>
<tr>
<td>404</td>
<td>Mowat-Wilson syndrome</td>
</tr>
<tr>
<td>405</td>
<td>MULIBREY nanism</td>
</tr>
<tr>
<td>406</td>
<td>Perheentupa syndrome</td>
</tr>
<tr>
<td>407</td>
<td>Pericardial constriction - growth failure</td>
</tr>
<tr>
<td>408</td>
<td>MULIBREY dwarfism</td>
</tr>
<tr>
<td>409</td>
<td>Muscle-liver-brain-eye nanism</td>
</tr>
<tr>
<td>410</td>
<td>Mullerian duct anomalies - limb anomalies</td>
</tr>
<tr>
<td>411</td>
<td>Nance-Horan syndrome</td>
</tr>
<tr>
<td>412</td>
<td>Noonan syndrome or related disorders</td>
</tr>
<tr>
<td>413</td>
<td>Noonan-like syndrome with loose anagen hair</td>
</tr>
<tr>
<td>414</td>
<td>LEOPARD syndrome</td>
</tr>
<tr>
<td>415</td>
<td>Noonan with multiple lentigines syndrome</td>
</tr>
<tr>
<td>416</td>
<td>Neurofibromatosis-Noonan syndrome</td>
</tr>
<tr>
<td>417</td>
<td>Ochoa syndrome</td>
</tr>
<tr>
<td>418</td>
<td>Oculo-digito-oesophageal-duodenal syndrome</td>
</tr>
<tr>
<td>419</td>
<td>ODOD - [Oculo-digito-oesophageal-duodenal syndrome]</td>
</tr>
<tr>
<td>420</td>
<td>Oculopalatocerebral syndrome</td>
</tr>
<tr>
<td>421</td>
<td>Okihiro syndrome</td>
</tr>
<tr>
<td>422</td>
<td>Opitz BBB/G syndrome</td>
</tr>
<tr>
<td>423</td>
<td>Osteopathia striata - pigmentary dermopathy - white forelock</td>
</tr>
<tr>
<td>424</td>
<td>Osteopoikilosis - short stature - intellectual deficit</td>
</tr>
<tr>
<td>425</td>
<td>12q14 deletion</td>
</tr>
<tr>
<td>426</td>
<td>Osteosclerosis - developmental delay - craniosynostosis</td>
</tr>
<tr>
<td>427</td>
<td>Osteosclerosis - ichthyosis - premature ovarian failure</td>
</tr>
<tr>
<td>428</td>
<td>Osteosclerosis abnormalities of nervous system or meninges</td>
</tr>
<tr>
<td>429</td>
<td>Overgrowth - craniosynostosis - arthrogryposis</td>
</tr>
<tr>
<td>430</td>
<td>Pai syndrome</td>
</tr>
<tr>
<td>431</td>
<td>Pallister-Hall syndrome</td>
</tr>
<tr>
<td>432</td>
<td>PELVIS syndrome</td>
</tr>
<tr>
<td>433</td>
<td>PHACE syndrome</td>
</tr>
<tr>
<td>434</td>
<td>PHACE - [posterior fossa malformations – haemangiomas – arterial anomalies – cardiac defects – eye abnormalities – sternal cleft – supraumbilical raphe] syndrome</td>
</tr>
<tr>
<td>435</td>
<td>Phocomelia, Schinzel type</td>
</tr>
<tr>
<td>436</td>
<td>Pitt-Hopkins syndrome</td>
</tr>
<tr>
<td>437</td>
<td>Pitt-Rogers-Danks syndrome</td>
</tr>
<tr>
<td>438</td>
<td>RAPADILINO syndrome</td>
</tr>
<tr>
<td>439</td>
<td>Retinitis pigmentosa - hypopituitarism - nephronophthisis - skeletal dysplasia</td>
</tr>
<tr>
<td>440</td>
<td>RHYNS - [Retinitis pigmentosa - hypopituitarism - nephronophthisis - skeletal dysplasia] syndrome</td>
</tr>
<tr>
<td>441</td>
<td>Richieri Costa-Pereira syndrome</td>
</tr>
<tr>
<td>442</td>
<td>Roberts syndrome</td>
</tr>
<tr>
<td>443</td>
<td>/SC phocomelia</td>
</tr>
<tr>
<td>444</td>
<td>Shprintzen-Goldberg omphalocele syndrome</td>
</tr>
<tr>
<td>445</td>
<td>Silver-Russell syndrome</td>
</tr>
<tr>
<td>446</td>
<td>Silver-Russell dwarfism</td>
</tr>
<tr>
<td>447</td>
<td>Russell-Silver syndrome</td>
</tr>
<tr>
<td>448</td>
<td>Spondylocostal dysostosis - anal and genitourinary malformations</td>
</tr>
<tr>
<td>449</td>
<td>Stapes ankylosis with broad thumbs and toes</td>
</tr>
<tr>
<td>450</td>
<td>Stickler syndrome</td>
</tr>
<tr>
<td>451</td>
<td>Stickler syndrome type 1</td>
</tr>
<tr>
<td>452</td>
<td>Stickler syndrome type 2</td>
</tr>
<tr>
<td>453</td>
<td>Stickler syndrome type 3</td>
</tr>
<tr>
<td>454</td>
<td>Stickler syndrome type 4</td>
</tr>
<tr>
<td>455</td>
<td>Autosomal recessive Stickler syndrome</td>
</tr>
<tr>
<td>456</td>
<td>Syndactyly - telecanthus - anogenital and renal malformations</td>
</tr>
<tr>
<td>457</td>
<td>TARP - [Talipes equinovarus - atrial septal defect - Robin sequence - persistent left superior vena cava] syndrome</td>
</tr>
<tr>
<td>458</td>
<td>Talipes equinovarus - atrial septal defect - Pierre Robin sequence - persistence of the left superior vena cava</td>
</tr>
<tr>
<td>459</td>
<td>Tetraamelia - multiple malformations</td>
</tr>
<tr>
<td>460</td>
<td>Thoraco-abdominal enteric duplication</td>
</tr>
<tr>
<td>461</td>
<td>Toriello-Carey syndrome</td>
</tr>
<tr>
<td>462</td>
<td>Townes-Brocks syndrome</td>
</tr>
<tr>
<td>463</td>
<td>Transverse limb deficiency - haemangioma</td>
</tr>
<tr>
<td>464</td>
<td>Ulnar-mammary syndrome</td>
</tr>
<tr>
<td>465</td>
<td>Schinzel syndrome</td>
</tr>
<tr>
<td>466</td>
<td>Umbilical cord ulceration - intestinal atresia</td>
</tr>
<tr>
<td>467</td>
<td>Uveal coloboma - cleft lip and palate - intellectual deficit</td>
</tr>
<tr>
<td>468</td>
<td>VACTERL with hydrocephalus</td>
</tr>
<tr>
<td>469</td>
<td>Van Der Woude syndrome</td>
</tr>
<tr>
<td>470</td>
<td>Warsaw breakage syndrome</td>
</tr>
<tr>
<td>471</td>
<td>WABS - [Warsaw breakage syndrome]</td>
</tr>
<tr>
<td>472</td>
<td>X-linked intellectual deficit with marfanoid habitus</td>
</tr>
<tr>
<td>473</td>
<td>Zimmermann-Laband syndrome</td>
</tr>
<tr>
<td>474</td>
<td>Hydrolethalus</td>
</tr>
<tr>
<td>475</td>
<td>Rieger syndrome</td>
</tr>
<tr>
<td>476</td>
<td>Axenfeld-Rieger syndrome</td>
</tr>
<tr>
<td>477</td>
<td>Thrombocytopaenia - absent radius</td>
</tr>
<tr>
<td>478</td>
<td>TAR - [Thrombocytopaenia - absent radius] syndrome</td>
</tr>
<tr>
<td>479</td>
<td>Thrombocytopenia with absent radius syndrome</td>
</tr>
<tr>
<td>480</td>
<td>Macrocephaly - capillary malformation</td>
</tr>
<tr>
<td>481</td>
<td>Macrocephaly - cutis marmorata telangiectatica congenita (MIM 602501)</td>
</tr>
<tr>
<td>482</td>
<td>Rubinstein-Taybi syndrome</td>
</tr>
<tr>
<td>483</td>
<td>RSTS - [Rubinstein-Taybi syndrome]</td>
</tr>
<tr>
<td>484</td>
<td>Broad thumb syndrome</td>
</tr>
<tr>
<td>485</td>
<td>Broad thumb-hallux syndrome</td>
</tr>
<tr>
<td>486</td>
<td>Ramon syndrome</td>
</tr>
<tr>
<td>487</td>
<td>Cherubism – gingival fibromatosis – epilepsy – mental deficiency – hypertrichosis – stunted growth (Ramon) syndrome</td>
</tr>
<tr>
<td>488</td>
<td>Maffucci syndrome</td>
</tr>
<tr>
<td>489</td>
<td>Chondrodysplasia with haemangiomata</td>
</tr>
<tr>
<td>490</td>
<td>Dyschondroplasia with cavernous haemangiomata</td>
</tr>
<tr>
<td>491</td>
<td>Amniotic bands</td>
</tr>
<tr>
<td>492</td>
<td>3MC syndrome</td>
</tr>
<tr>
<td>493</td>
<td>Deletions of chromosome 14</td>
</tr>
<tr>
<td>494</td>
<td>Partial monosomy 14</td>
</tr>
<tr>
<td>495</td>
<td>Proximal deletions of chromosome 14</td>
</tr>
<tr>
<td>496</td>
<td>14q11.2 deletion</td>
</tr>
<tr>
<td>497</td>
<td>Monosomy 14q11.2</td>
</tr>
<tr>
<td>498</td>
<td>14q11.2 deletion syndrome</td>
</tr>
<tr>
<td>499</td>
<td>14q12 deletion</td>
</tr>
<tr>
<td>500</td>
<td>Monosomy 14q12</td>
</tr>
<tr>
<td>501</td>
<td>14q12 deletion syndrome</td>
</tr>
<tr>
<td>502</td>
<td>Medial deletions of chromosome 14</td>
</tr>
<tr>
<td>503</td>
<td>14q22q23 deletion</td>
</tr>
<tr>
<td>504</td>
<td>Monosomy 14q22q23</td>
</tr>
<tr>
<td>505</td>
<td>14q22q23 deletion syndrome</td>
</tr>
<tr>
<td>506</td>
<td>Distal deletions of chromosome 14</td>
</tr>
<tr>
<td>507</td>
<td>14q32 deletion</td>
</tr>
<tr>
<td>508</td>
<td>Maternal 14q32.2 deletion</td>
</tr>
<tr>
<td>509</td>
<td>Maternal 14q32.2 deletion syndrome</td>
</tr>
<tr>
<td>510</td>
<td>Paternal 14q32.2 deletion</td>
</tr>
<tr>
<td>511</td>
<td>Paternal 14q32.2 deletion syndrome</td>
</tr>
<tr>
<td>512</td>
<td>Acromesomelic dysplasias</td>
</tr>
<tr>
<td>513</td>
<td>Acromesomelic dysplasia, Maroteaux type</td>
</tr>
<tr>
<td>514</td>
<td>Acromesomelic dysplasia, Grebe type</td>
</tr>
<tr>
<td>515</td>
<td>Acromesomelic dysplasia, Hunter-Thomson type</td>
</tr>
<tr>
<td>516</td>
<td>Verloes-David syndrome</td>
</tr>
<tr>
<td>517</td>
<td>Mesomelia - synostoses</td>
</tr>
<tr>
<td>518</td>
<td>Monosomy 8q13</td>
</tr>
<tr>
<td>519</td>
<td>8q13 deletion</td>
</tr>
<tr>
<td>520</td>
<td>Mesomelia-synostoses syndrome</td>
</tr>
<tr>
<td>521</td>
<td>Deletions of the long arm of chromosome 6</td>
</tr>
<tr>
<td>522</td>
<td>Proximal deletions of the long arm of chromosome 6</td>
</tr>
<tr>
<td>523</td>
<td>Distal deletions of the long arm of chromosome 6</td>
</tr>
<tr>
<td>524</td>
<td>6q25 deletion</td>
</tr>
<tr>
<td>525</td>
<td>6q25 deletion syndrome</td>
</tr>
<tr>
<td>526</td>
<td>Monosomy 6q25</td>
</tr>
<tr>
<td>527</td>
<td>6q26qter deletion</td>
</tr>
<tr>
<td>528</td>
<td>Deletions of the long arm of chromosome 20</td>
</tr>
<tr>
<td>529</td>
<td>20q11.2q12 deletion</td>
</tr>
<tr>
<td>530</td>
<td>20q13 deletion</td>
</tr>
<tr>
<td>531</td>
<td>Okihiro syndrome caused by monosomy 20q13</td>
</tr>
<tr>
<td>532</td>
<td>20q13q33 deletion</td>
</tr>
<tr>
<td>533</td>
<td>Distal 20q deletion syndrome</td>
</tr>
<tr>
<td>534</td>
<td>Paternal 20q13.2q13.3 deletion</td>
</tr>
<tr>
<td>535</td>
<td>Monosomy 20q13q13.3 of paternal origin</td>
</tr>
<tr>
<td>536</td>
<td>Paternal 20q13q13.3 deletion syndrome</td>
</tr>
<tr>
<td>537</td>
<td>Recessive limb-girdle muscular dystrophy</td>
</tr>
<tr>
<td>538</td>
<td>LGMD2 - [Limb-girdle muscular dystrophy] 2</td>
</tr>
<tr>
<td>539</td>
<td>Limb-girdle muscular dystrophy 2A, calpain-3 deficiency</td>
</tr>
<tr>
<td>540</td>
<td>Limb-girdle muscular dystrophy 2B, dysferlin deficiency</td>
</tr>
<tr>
<td>541</td>
<td>Limb-girdle muscular dystrophy 2C, gamma-sarcoglycan deficiency</td>
</tr>
<tr>
<td>542</td>
<td>Limb-girdle muscular dystrophy 2D, alpha-sarcoglycan deficiency</td>
</tr>
<tr>
<td>543</td>
<td>Limb-girdle muscular dystrophy 2E, beta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>544</td>
<td>Limb-girdle muscular dystrophy 2F, delta-sarcoglycan deficiency</td>
</tr>
<tr>
<td>545</td>
<td>Limb-girdle muscular dystrophy 2G, telethonin gene mutation</td>
</tr>
<tr>
<td>546</td>
<td>Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation</td>
</tr>
<tr>
<td>547</td>
<td>LGMD 2H - [Limb-girdle muscular dystrophy 2H, TRIM32 gene mutation]</td>
</tr>
<tr>
<td>548</td>
<td>Limb-girdle muscular dystrophy 2I, fukutin related protein gene mutation</td>
</tr>
<tr>
<td>549</td>
<td>FKRP - [fukutin related protein gene mutation]</td>
</tr>
<tr>
<td>550</td>
<td>LGMD 2I - [Limb-girdle muscular dystrophy 2I]</td>
</tr>
<tr>
<td>551</td>
<td>Limb-girdle muscular dystrophy 2J, Titin gene mutation</td>
</tr>
<tr>
<td>552</td>
<td>LGMD 2J - [Limb-girdle muscular dystrophy 2J, Titin gene mutation]</td>
</tr>
<tr>
<td>553</td>
<td>Limb-girdle muscular dystrophy 2K, protein-O-mannosyltransferase 1 transferase</td>
</tr>
<tr>
<td>554</td>
<td>POMT1 - [protein-O-mannosyltransferase 1 transferase]</td>
</tr>
<tr>
<td>555</td>
<td>LGMD 2K - [Limb-girdle muscular dystrophy 2K]</td>
</tr>
<tr>
<td>556</td>
<td>Limb-girdle muscular dystrophy 2L, AN05 gene mutation</td>
</tr>
<tr>
<td>557</td>
<td>LGMD 2L - [Limb-girdle muscular dystrophy 2L]</td>
</tr>
<tr>
<td>558</td>
<td>Limb-girdle muscular dystrophy 2M, POMGnT1 gene mutation</td>
</tr>
<tr>
<td>559</td>
<td>LGMD2M - [limb-girdle muscular dystrophy 2M]</td>
</tr>
<tr>
<td>560</td>
<td>Limb-girdle muscular dystrophy 2N, POMT2 gene mutation</td>
</tr>
<tr>
<td>561</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C2)</td>
</tr>
<tr>
<td>562</td>
<td>MDDGC2</td>
</tr>
<tr>
<td>563</td>
<td>LGMD2N - limb-girdle muscular dystrophy 2N]</td>
</tr>
<tr>
<td>564</td>
<td>Limb-girdle muscular dystrophy 2O, POMGNT1 gene mutation</td>
</tr>
<tr>
<td>565</td>
<td>LGMD2O - [limb-girdle muscular dystrophy 2O]</td>
</tr>
<tr>
<td>566</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy (type C3)</td>
</tr>
<tr>
<td>567</td>
<td>MDDGC3</td>
</tr>
<tr>
<td>568</td>
<td>Limb-girdle muscular dystrophy 2Q, plectin deficiency</td>
</tr>
<tr>
<td>569</td>
<td>LGMD2Q - [limb-girdle muscular dystrophy 2Q]</td>
</tr>
<tr>
<td>570</td>
<td>Limb-girdle muscular dystrophy-dystroglycanopathy C7</td>
</tr>
<tr>
<td>571</td>
<td>MDDGC7</td>
</tr>
<tr>
<td>572</td>
<td>Deletions of the long arm of chromosome 5</td>
</tr>
<tr>
<td>573</td>
<td>Proximal deletions of the long arm of chromosome 5</td>
</tr>
<tr>
<td>574</td>
<td>5q14.3 deletion</td>
</tr>
<tr>
<td>575</td>
<td>5q14.3 deletion syndrome</td>
</tr>
<tr>
<td>576</td>
<td>Monosomy 5q14.3</td>
</tr>
<tr>
<td>577</td>
<td>Medial deletions of the long arm of chromosome 5</td>
</tr>
<tr>
<td>578</td>
<td>5q22.2 deletion</td>
</tr>
<tr>
<td>579</td>
<td>Distal deletions of the long arm of chromosome 5</td>
</tr>
<tr>
<td>580</td>
<td>5q35.3 deletion</td>
</tr>
<tr>
<td>581</td>
<td>Distal 5q deletion syndrome</td>
</tr>
<tr>
<td>582</td>
<td>Other specified deletions of chromosome 22</td>
</tr>
<tr>
<td>583</td>
<td>22q11.21 deletion</td>
</tr>
<tr>
<td>584</td>
<td>Distal 22q11.2 deletion syndrome</td>
</tr>
<tr>
<td>585</td>
<td>22q13 deletion</td>
</tr>
<tr>
<td>586</td>
<td>22q13 deletion syndrome</td>
</tr>
<tr>
<td>587</td>
<td>Phelan-McDermid syndrome</td>
</tr>
<tr>
<td>588</td>
<td>Duplications of the long arm of chromosome 5</td>
</tr>
<tr>
<td>589</td>
<td>Proximal duplications of the long arm of chromosome 5</td>
</tr>
<tr>
<td>590</td>
<td>Medial duplications of the long arm of chromosome 5</td>
</tr>
<tr>
<td>591</td>
<td>Distal duplications of the long arm of chromosome 5</td>
</tr>
<tr>
<td>592</td>
<td>5q35 duplication</td>
</tr>
<tr>
<td>593</td>
<td>5q35 duplication syndrome</td>
</tr>
<tr>
<td>594</td>
<td>Trisomy 5q35</td>
</tr>
<tr>
<td>595</td>
<td>Duplications of the long arm of chromosome 3</td>
</tr>
<tr>
<td>596</td>
<td>Proximal duplications of the long arm of chromosome 3</td>
</tr>
<tr>
<td>597</td>
<td>Distal duplications of the long arm of chromosome 3</td>
</tr>
<tr>
<td>598</td>
<td>3q29 duplication</td>
</tr>
<tr>
<td>599</td>
<td>3q29 duplication syndrome</td>
</tr>
<tr>
<td>600</td>
<td>Trisomy 3q29</td>
</tr>
<tr>
<td>601</td>
<td>Cornelia de Lange-like syndrome</td>
</tr>
<tr>
<td>602</td>
<td>Trisomy 3q26</td>
</tr>
<tr>
<td>603</td>
<td>3q26 duplication</td>
</tr>
<tr>
<td>604</td>
<td>Deletions of chromosome 15</td>
</tr>
<tr>
<td>605</td>
<td>Partial monosomy 15</td>
</tr>
<tr>
<td>606</td>
<td>Proximal deletions of chromosome 15</td>
</tr>
<tr>
<td>607</td>
<td>15q11.2 deletion</td>
</tr>
<tr>
<td>608</td>
<td>Monosomy 15q11.2</td>
</tr>
<tr>
<td>609</td>
<td>15q11.2 deletion syndrome</td>
</tr>
<tr>
<td>610</td>
<td>15q13.3 deletion</td>
</tr>
<tr>
<td>611</td>
<td>15q13.3 microdeletion syndrome</td>
</tr>
<tr>
<td>612</td>
<td>15q13.3 monosomy syndrome</td>
</tr>
<tr>
<td>613</td>
<td>15q14 deletion</td>
</tr>
<tr>
<td>614</td>
<td>15q14 microdeletion syndrome</td>
</tr>
<tr>
<td>615</td>
<td>Monosomy 15q14</td>
</tr>
<tr>
<td>616</td>
<td>Maternal 15q11q13 deletion</td>
</tr>
<tr>
<td>617</td>
<td>Paternal 15q11q13 deletion</td>
</tr>
<tr>
<td>618</td>
<td>Distal deletions of chromosome 15</td>
</tr>
<tr>
<td>619</td>
<td>15q24 deletion</td>
</tr>
<tr>
<td>620</td>
<td>15q24 deletion syndrome</td>
</tr>
<tr>
<td>621</td>
<td>Monosomy 15q24</td>
</tr>
<tr>
<td>622</td>
<td>Growth retardation - microcephaly - digital abnormalities - hypospadias</td>
</tr>
<tr>
<td>623</td>
<td>15q26.3 deletion</td>
</tr>
<tr>
<td>624</td>
<td>Monosomy 15q26</td>
</tr>
<tr>
<td>625</td>
<td>15q26 deletion syndrome</td>
</tr>
<tr>
<td>626</td>
<td>Distal 15q deletion syndrome</td>
</tr>
<tr>
<td>627</td>
<td>Duplications of the long arm of chromosome 17</td>
</tr>
<tr>
<td>628</td>
<td>Proximal duplications of the long arm of chromosome 17</td>
</tr>
<tr>
<td>629</td>
<td>17q11.2 duplication</td>
</tr>
<tr>
<td>630</td>
<td>Trisomy 17q11.2</td>
</tr>
<tr>
<td>631</td>
<td>17q11.2 duplication syndrome</td>
</tr>
<tr>
<td>632</td>
<td>Grisart-Destrée syndrome</td>
</tr>
<tr>
<td>633</td>
<td>17q12 duplication</td>
</tr>
<tr>
<td>634</td>
<td>17q12 duplication syndrome</td>
</tr>
<tr>
<td>635</td>
<td>Trisomy 17q12</td>
</tr>
<tr>
<td>636</td>
<td>Distal duplications of the long arm of chromosome 17</td>
</tr>
<tr>
<td>637</td>
<td>17q21.31 duplication</td>
</tr>
<tr>
<td>638</td>
<td>17q21.31 duplication syndrome</td>
</tr>
<tr>
<td>639</td>
<td>Trisomy 17q21.31</td>
</tr>
<tr>
<td>640</td>
<td>17q23.1q23.2 duplication</td>
</tr>
<tr>
<td>641</td>
<td>Hereditary isolated clubfoot due to 17q23.1-q23.2 microduplication</td>
</tr>
<tr>
<td>642</td>
<td>Familial isolated clubfoot due to 17q23.1-q23.2 microduplication</td>
</tr>
<tr>
<td>643</td>
<td>17q23.1-q23.2 duplication syndrome</td>
</tr>
<tr>
<td>644</td>
<td>Trisomy 17q23.1-q23.2</td>
</tr>
<tr>
<td>645</td>
<td>17q24qter duplication</td>
</tr>
<tr>
<td>646</td>
<td>Duplications of the long arm of chromosome 10</td>
</tr>
<tr>
<td>647</td>
<td>Proximal duplications of the long arm of chromosome 10</td>
</tr>
<tr>
<td>648</td>
<td>Distal duplications of the long arm of chromosome 10</td>
</tr>
<tr>
<td>649</td>
<td>10q21q24 duplication</td>
</tr>
<tr>
<td>650</td>
<td>non-distal 11q duplication syndrome</td>
</tr>
<tr>
<td>651</td>
<td>10q22.3q23.3 duplication</td>
</tr>
<tr>
<td>652</td>
<td>10q24qter duplication</td>
</tr>
<tr>
<td>653</td>
<td>Distal 11q duplication syndrome</td>
</tr>
<tr>
<td>654</td>
<td>Buttiens-Fryns syndrome</td>
</tr>
<tr>
<td>655</td>
<td>10q24 duplication syndrome</td>
</tr>
<tr>
<td>656</td>
<td>Trisomy 10q24</td>
</tr>
<tr>
<td>657</td>
<td>Distal limb deficiencies - micrognathia syndrome</td>
</tr>
<tr>
<td>658</td>
<td>10q24 duplication</td>
</tr>
<tr>
<td>659</td>
<td>Deletions of chromosome 13</td>
</tr>
<tr>
<td>660</td>
<td>Partial monosomy 13</td>
</tr>
<tr>
<td>661</td>
<td>Proximal deletions of chromosome 13</td>
</tr>
<tr>
<td>662</td>
<td>13q14 deletion</td>
</tr>
<tr>
<td>663</td>
<td>13q14 deletion syndrome</td>
</tr>
<tr>
<td>664</td>
<td>Medial deletions of chromosome 13</td>
</tr>
<tr>
<td>665</td>
<td>Distal deletions of chromosome 13</td>
</tr>
<tr>
<td>666</td>
<td>13q32 deletion</td>
</tr>
<tr>
<td>667</td>
<td>13q34 deletion</td>
</tr>
<tr>
<td>668</td>
<td>13q34 deletion syndrome</td>
</tr>
<tr>
<td>669</td>
<td>Duplications of the long arm of chromosome 19</td>
</tr>
<tr>
<td>670</td>
<td>19q13 duplication</td>
</tr>
<tr>
<td>671</td>
<td>Distal 19q duplication syndrome</td>
</tr>
<tr>
<td>672</td>
<td>Syndromes with obesity as a major feature</td>
</tr>
<tr>
<td>673</td>
<td>Börjeson-Forssman-Lehmann syndrome</td>
</tr>
<tr>
<td>674</td>
<td>MEHMO syndrome</td>
</tr>
<tr>
<td>675</td>
<td>X-linked intellectual deficit - epileptic seizures - hypogenitalism - microcephaly - obesity</td>
</tr>
<tr>
<td>676</td>
<td>Obesity due to 6q16 deletion</td>
</tr>
<tr>
<td>677</td>
<td>Prader-Willi-like syndrome due to deletion 6q16</td>
</tr>
<tr>
<td>678</td>
<td>6q16 deletion syndrome</td>
</tr>
<tr>
<td>679</td>
<td>Monosomy 6q16</td>
</tr>
<tr>
<td>680</td>
<td>Wilson-Turner syndrome</td>
</tr>
<tr>
<td>681</td>
<td>Duplications of the long arm of chromosome 4</td>
</tr>
<tr>
<td>682</td>
<td>Proximal duplications of the long arm of chromosome 4</td>
</tr>
<tr>
<td>683</td>
<td>Medial duplications of the long arm of chromosome 4</td>
</tr>
<tr>
<td>684</td>
<td>Distal duplications of the long arm of chromosome 4</td>
</tr>
<tr>
<td>685</td>
<td>4q25qter duplication</td>
</tr>
<tr>
<td>686</td>
<td>Distal 4q duplication syndrome</td>
</tr>
<tr>
<td>687</td>
<td>Deletions of the long arm of chromosome 10</td>
</tr>
<tr>
<td>688</td>
<td>Proximal deletions of the long arm of chromosome 10</td>
</tr>
<tr>
<td>689</td>
<td>10q11.2 deletion</td>
</tr>
<tr>
<td>690</td>
<td>Non-distal 10q deletion syndrome</td>
</tr>
<tr>
<td>691</td>
<td>Distal deletions of the long arm of chromosome 10</td>
</tr>
<tr>
<td>692</td>
<td>10q22.3q23.3 deletion</td>
</tr>
<tr>
<td>693</td>
<td>10q25qter deletion</td>
</tr>
<tr>
<td>694</td>
<td>Distal 10q deletion syndrome</td>
</tr>
<tr>
<td>695</td>
<td>Deletions of the long arm of chromosome 7</td>
</tr>
<tr>
<td>696</td>
<td>Proximal deletions of the long arm of chromosome 7</td>
</tr>
<tr>
<td>697</td>
<td>Distal 7q11.23 deletion</td>
</tr>
<tr>
<td>698</td>
<td>Distal 7q11.23 deletion syndrome</td>
</tr>
<tr>
<td>699</td>
<td>Distal monosomy 7q11.23</td>
</tr>
<tr>
<td>700</td>
<td>Williams-Beuren syndrome</td>
</tr>
<tr>
<td>701</td>
<td>Williams syndrome</td>
</tr>
<tr>
<td>702</td>
<td>Monosomy 7q11.23</td>
</tr>
<tr>
<td>703</td>
<td>7q11.23 deletion</td>
</tr>
<tr>
<td>704</td>
<td>Medial deletions of the long arm of chromosome 7</td>
</tr>
<tr>
<td>705</td>
<td>Distal deletions of the long arm of chromosome 7</td>
</tr>
<tr>
<td>706</td>
<td>7q31 deletion</td>
</tr>
<tr>
<td>707</td>
<td>7q31 deletion syndrome</td>
</tr>
<tr>
<td>708</td>
<td>Monosomy 7q31</td>
</tr>
<tr>
<td>709</td>
<td>7q36 deletion</td>
</tr>
<tr>
<td>710</td>
<td>7q36 deletion syndrome</td>
</tr>
<tr>
<td>711</td>
<td>CATCH 22 phenotype</td>
</tr>
<tr>
<td>712</td>
<td>Conotruncal anomalies face syndrome</td>
</tr>
<tr>
<td>713</td>
<td>Velocardiofacial syndrome</td>
</tr>
<tr>
<td>714</td>
<td>Shprintzen syndrome</td>
</tr>
<tr>
<td>715</td>
<td>Sedlackova syndrome</td>
</tr>
<tr>
<td>716</td>
<td>22q11 deletion syndrome</td>
</tr>
<tr>
<td>717</td>
<td>DiGeorge syndrome</td>
</tr>
<tr>
<td>718</td>
<td>DiGeorge sequence</td>
</tr>
<tr>
<td>719</td>
<td>CATCH 22</td>
</tr>
<tr>
<td>720</td>
<td>Monosomy 22q11</td>
</tr>
<tr>
<td>721</td>
<td>Pharyngeal pouch syndrome</td>
</tr>
<tr>
<td>722</td>
<td>agenesis of the parathyroid and thymus glands</td>
</tr>
<tr>
<td>723</td>
<td>branchial arch syndrome</td>
</tr>
<tr>
<td>724</td>
<td>third and fourth pharyngeal arch syndrome</td>
</tr>
<tr>
<td>725</td>
<td>third and fourth pharyngeal pouch syndrome</td>
</tr>
<tr>
<td>726</td>
<td>thymic hypoplasia syndrome</td>
</tr>
<tr>
<td>727</td>
<td>thymic-parathyroid aplasia</td>
</tr>
<tr>
<td>728</td>
<td>immunodeficient thymic aplasia</td>
</tr>
<tr>
<td>729</td>
<td>immunodeficient thymus aplasia</td>
</tr>
<tr>
<td>730</td>
<td>thymic alymphoplasia</td>
</tr>
<tr>
<td>731</td>
<td>thymic aplasia or hypoplasia with immunodeficiency</td>
</tr>
<tr>
<td>732</td>
<td>Deletions of the long arm of chromosome 9</td>
</tr>
<tr>
<td>733</td>
<td>9q22.3 deletion</td>
</tr>
<tr>
<td>734</td>
<td>9q22.3 microdeletion syndrome</td>
</tr>
<tr>
<td>735</td>
<td>Monosomy 9q22.3</td>
</tr>
<tr>
<td>736</td>
<td>Proximal deletions of the long arm of chromosome 9</td>
</tr>
<tr>
<td>737</td>
<td>Medial deletions of the long arm of chromosome 9</td>
</tr>
<tr>
<td>738</td>
<td>Distal deletions of the long arm of chromosome 9</td>
</tr>
<tr>
<td>739</td>
<td>9q34 deletion</td>
</tr>
<tr>
<td>740</td>
<td>9q34 deletion syndrome</td>
</tr>
<tr>
<td>741</td>
<td>Duplications of the long arm of chromosome 6</td>
</tr>
<tr>
<td>742</td>
<td>Proximal duplications of the long arm of chromosome 6</td>
</tr>
<tr>
<td>743</td>
<td>Distal duplications of the long arm of chromosome 6</td>
</tr>
<tr>
<td>744</td>
<td>6q23qter duplication</td>
</tr>
<tr>
<td>745</td>
<td>Distal chromosome 6 long arm trisomy</td>
</tr>
<tr>
<td>746</td>
<td>Distal 6q duplication syndrome</td>
</tr>
<tr>
<td>747</td>
<td>Duplications of the long arm of chromosome 9</td>
</tr>
<tr>
<td>748</td>
<td>9q11q33 duplication</td>
</tr>
<tr>
<td>749</td>
<td>Non-distal chromosome 9 long arm trisomy</td>
</tr>
<tr>
<td>750</td>
<td>Non-distal 9q duplication syndrome</td>
</tr>
<tr>
<td>751</td>
<td>Proximal duplications of the long arm of chromosome 9</td>
</tr>
<tr>
<td>752</td>
<td>Medial duplications of the long arm of chromosome 9</td>
</tr>
<tr>
<td>753</td>
<td>Distal duplications of the long arm of chromosome 9</td>
</tr>
<tr>
<td>754</td>
<td>9q33qter duplication</td>
</tr>
<tr>
<td>755</td>
<td>Distal chromosome 9 long arm trisomy</td>
</tr>
<tr>
<td>756</td>
<td>Distal 9q duplication syndrome</td>
</tr>
<tr>
<td>757</td>
<td>Duplications of the long arm of chromosome 20</td>
</tr>
<tr>
<td>758</td>
<td>20q13qter duplication</td>
</tr>
<tr>
<td>759</td>
<td>Distal 20q duplication syndrome</td>
</tr>
<tr>
<td>760</td>
<td>Duplications of chromosome 15</td>
</tr>
<tr>
<td>761</td>
<td>Proximal duplications of chromosome 15</td>
</tr>
<tr>
<td>762</td>
<td>15q11q13 duplication</td>
</tr>
<tr>
<td>763</td>
<td>15q11q13 duplication syndrome</td>
</tr>
<tr>
<td>764</td>
<td>Trisomy 15q11q13</td>
</tr>
<tr>
<td>765</td>
<td>Distal duplications of chromosome 15</td>
</tr>
<tr>
<td>766</td>
<td>15q25qter duplication</td>
</tr>
<tr>
<td>767</td>
<td>Distal 15q duplication syndrome</td>
</tr>
<tr>
<td>768</td>
<td>Duplications of chromosome 13</td>
</tr>
<tr>
<td>769</td>
<td>Proximal duplications of chromosome 13</td>
</tr>
<tr>
<td>770</td>
<td>Non-distal 13q duplication syndrome</td>
</tr>
<tr>
<td>771</td>
<td>Medial duplications of chromosome 13</td>
</tr>
<tr>
<td>772</td>
<td>Distal duplications of chromosome 13</td>
</tr>
<tr>
<td>773</td>
<td>Distal 13q duplication syndrome</td>
</tr>
<tr>
<td>774</td>
<td>Coenzyme Q10 deficiency</td>
</tr>
<tr>
<td>775</td>
<td>CoQ10 deficiency</td>
</tr>
<tr>
<td>776</td>
<td>Early-onset ataxia with oculomotor apraxia and hypoalbuminaemia</td>
</tr>
<tr>
<td>777</td>
<td>Ataxia - oculomotor apraxia type 1</td>
</tr>
<tr>
<td>778</td>
<td>Deafness - encephaloneuropathy - obesity - valvulopathy</td>
</tr>
<tr>
<td>779</td>
<td>Duplications of the long arm of chromosome 18</td>
</tr>
<tr>
<td>780</td>
<td>Proximal duplications of the long arm of chromosome 18</td>
</tr>
<tr>
<td>781</td>
<td>Distal duplications of the long arm of chromosome 18</td>
</tr>
<tr>
<td>782</td>
<td>18q21qter duplication</td>
</tr>
<tr>
<td>783</td>
<td>Distal 18q duplication syndrome</td>
</tr>
<tr>
<td>784</td>
<td>Duplications of the long arm of chromosome 16</td>
</tr>
<tr>
<td>785</td>
<td>Proximal duplications of the long arm of chromosome 16</td>
</tr>
<tr>
<td>786</td>
<td>Distal duplications of the long arm of chromosome 16</td>
</tr>
<tr>
<td>787</td>
<td>16q24qter duplication</td>
</tr>
<tr>
<td>788</td>
<td>Distal 16q duplication syndrome</td>
</tr>
<tr>
<td>789</td>
<td>Duplications of the long arm of chromosome 2</td>
</tr>
<tr>
<td>790</td>
<td>Proximal duplications of the long arm of chromosome 2</td>
</tr>
<tr>
<td>791</td>
<td>Medial duplications of the long arm of chromosome 2</td>
</tr>
<tr>
<td>792</td>
<td>Distal duplications of the long arm of chromosome 2</td>
</tr>
<tr>
<td>793</td>
<td>2q31.1 duplication</td>
</tr>
<tr>
<td>794</td>
<td>2q35q37 duplication</td>
</tr>
<tr>
<td>795</td>
<td>Duplications of chromosome 14</td>
</tr>
<tr>
<td>796</td>
<td>Proximal duplications of chromosome 14</td>
</tr>
<tr>
<td>797</td>
<td>14q11.2 duplication</td>
</tr>
<tr>
<td>798</td>
<td>14q11.2 duplication syndrome</td>
</tr>
<tr>
<td>799</td>
<td>Trisomy 14q11.2</td>
</tr>
<tr>
<td>800</td>
<td>Medial duplications of chromosome 14</td>
</tr>
<tr>
<td>801</td>
<td>Distal duplications of chromosome 14</td>
</tr>
<tr>
<td>802</td>
<td>14q32.2qter duplication</td>
</tr>
<tr>
<td>803</td>
<td>Distal 14q duplication syndrome</td>
</tr>
<tr>
<td>804</td>
<td>Deletions of the long arm of chromosome 8</td>
</tr>
<tr>
<td>805</td>
<td>Proximal deletions of the long arm of chromosome 8</td>
</tr>
<tr>
<td>806</td>
<td>Distal deletions of the long arm of chromosome 8</td>
</tr>
<tr>
<td>807</td>
<td>8q21.11 deletion</td>
</tr>
<tr>
<td>808</td>
<td>8q21.11 microdeletion syndrome</td>
</tr>
<tr>
<td>809</td>
<td>8q22.1 deletion</td>
</tr>
<tr>
<td>810</td>
<td>Trisomy 8q22.1</td>
</tr>
<tr>
<td>811</td>
<td>Nablus mask-like facial syndrome</td>
</tr>
<tr>
<td>812</td>
<td>8q22.1 deletion syndrome</td>
</tr>
<tr>
<td>813</td>
<td>Other specified syndromic craniosynostoses</td>
</tr>
<tr>
<td>814</td>
<td>Crouzon syndrome - acanthosis nigricans</td>
</tr>
<tr>
<td>815</td>
<td>Carpenter syndrome</td>
</tr>
<tr>
<td>816</td>
<td>Saethre-Chotzen syndrome</td>
</tr>
<tr>
<td>817</td>
<td>Robinow-Sorauf syndrome</td>
</tr>
<tr>
<td>818</td>
<td>Muenke syndrome</td>
</tr>
<tr>
<td>819</td>
<td>Antley-Bixler syndrome</td>
</tr>
<tr>
<td>820</td>
<td>Baller-Gerold syndrome</td>
</tr>
<tr>
<td>821</td>
<td>Craniosynostosis, Boston type</td>
</tr>
<tr>
<td>822</td>
<td>Craniosynostosis, Philadelphia type</td>
</tr>
<tr>
<td>823</td>
<td>C syndrome</td>
</tr>
<tr>
<td>824</td>
<td>Opitz trigonocephaly syndrome</td>
</tr>
<tr>
<td>825</td>
<td>Aurocephalosyndactyly</td>
</tr>
<tr>
<td>826</td>
<td>Craniomicromelic syndrome</td>
</tr>
<tr>
<td>827</td>
<td>Cloverleaf skull - asphyxiating thoracic dysplasia</td>
</tr>
<tr>
<td>828</td>
<td>Hunter-McAlpine craniosynostosis</td>
</tr>
<tr>
<td>829</td>
<td>5q35.2 duplication</td>
</tr>
<tr>
<td>830</td>
<td>Familial scaphocephaly syndrome, McGillivray type</td>
</tr>
<tr>
<td>831</td>
<td>Craniosynostosis, Herrmann-Opitz type</td>
</tr>
<tr>
<td>832</td>
<td>Pseudoaminopterin syndrome</td>
</tr>
<tr>
<td>833</td>
<td>Deletions of the long arm of chromosome 11</td>
</tr>
<tr>
<td>834</td>
<td>Proximal deletions of the long arm of chromosome 11</td>
</tr>
<tr>
<td>835</td>
<td>Distal deletions of the long arm of chromosome 11</td>
</tr>
<tr>
<td>836</td>
<td>Jacobsen syndrome</td>
</tr>
<tr>
<td>837</td>
<td>Monosomy 11q23.3</td>
</tr>
<tr>
<td>838</td>
<td>Telomeric deletion 11q</td>
</tr>
<tr>
<td>839</td>
<td>Monosomy 11qter</td>
</tr>
<tr>
<td>840</td>
<td>11q23.3 deletion syndrome</td>
</tr>
<tr>
<td>841</td>
<td>11q23.3 microdeletion syndrome</td>
</tr>
<tr>
<td>842</td>
<td>Duplications of chromosome 22</td>
</tr>
<tr>
<td>843</td>
<td>22q11.2 duplication syndrome</td>
</tr>
<tr>
<td>844</td>
<td>22q11.2 microduplication syndrome</td>
</tr>
<tr>
<td>845</td>
<td>Trisomy 22q11.2</td>
</tr>
<tr>
<td>846</td>
<td>22q11.2 duplication</td>
</tr>
<tr>
<td>847</td>
<td>Distal trisomy 22q11.2</td>
</tr>
<tr>
<td>848</td>
<td>Deletions of the long arm of chromosome 16</td>
</tr>
<tr>
<td>849</td>
<td>Proximal deletions of the long arm of chromosome 16</td>
</tr>
<tr>
<td>850</td>
<td>Distal deletions of the long arm of chromosome 16</td>
</tr>
<tr>
<td>851</td>
<td>16q24.3 deletion</td>
</tr>
<tr>
<td>852</td>
<td>16q24.3 deletion syndrome</td>
</tr>
<tr>
<td>853</td>
<td>Monosomy 16q24.3</td>
</tr>
<tr>
<td>1</td>
<td>Other specified periodontal disease</td>
</tr>
<tr>
<td>2</td>
<td>Chronic periodontitis</td>
</tr>
<tr>
<td>3</td>
<td>Adult periodontitis</td>
</tr>
<tr>
<td>4</td>
<td>adult-onset periodontitis</td>
</tr>
<tr>
<td>5</td>
<td>chronic pericementitis</td>
</tr>
<tr>
<td>6</td>
<td>Periodontitis NOS</td>
</tr>
<tr>
<td>7</td>
<td>parodontitis</td>
</tr>
<tr>
<td>8</td>
<td>pericementitis NOS</td>
</tr>
<tr>
<td>9</td>
<td>Localised chronic periodontitis</td>
</tr>
<tr>
<td>10</td>
<td>Adult periodontitis localised</td>
</tr>
<tr>
<td>11</td>
<td>Localised chronic pericoronitis</td>
</tr>
<tr>
<td>12</td>
<td>Localised periodontitis NOS</td>
</tr>
<tr>
<td>13</td>
<td>Generalised chronic periodontitis</td>
</tr>
<tr>
<td>14</td>
<td>Adult periodontitis generalised</td>
</tr>
<tr>
<td>15</td>
<td>Pyorrhoea alveolaris</td>
</tr>
<tr>
<td>16</td>
<td>pyorrhoea</td>
</tr>
<tr>
<td>17</td>
<td>Rigg disease</td>
</tr>
<tr>
<td>18</td>
<td>alveolar pyorrhoea</td>
</tr>
<tr>
<td>19</td>
<td>Fauchard disease</td>
</tr>
<tr>
<td>20</td>
<td>marginal periodontitis</td>
</tr>
<tr>
<td>21</td>
<td>Chronic periodontitis complex</td>
</tr>
<tr>
<td>22</td>
<td>periodontitis complex</td>
</tr>
<tr>
<td>23</td>
<td>Generalised periodontitis complex</td>
</tr>
<tr>
<td>24</td>
<td>Chronic periodontitis simplex</td>
</tr>
<tr>
<td>25</td>
<td>periodontitis simplex</td>
</tr>
<tr>
<td>26</td>
<td>Localised periodontitis simplex</td>
</tr>
<tr>
<td>27</td>
<td>Chronic suppurative pericementitis</td>
</tr>
<tr>
<td>28</td>
<td>Periodontitis as a manifestation of systemic diseases</td>
</tr>
<tr>
<td>29</td>
<td>Periodontal disease complications of diabetes mellitus</td>
</tr>
<tr>
<td>30</td>
<td>Periodontitis associated with endodontic lesions</td>
</tr>
<tr>
<td>31</td>
<td>Periodontal-endodontic combined lesions</td>
</tr>
<tr>
<td>32</td>
<td>Periodontal pocket</td>
</tr>
<tr>
<td>33</td>
<td>Other periodontal diseases</td>
</tr>
<tr>
<td>34</td>
<td>Periodontal traumatic occlusion</td>
</tr>
<tr>
<td>35</td>
<td>Traumatic occlusion</td>
</tr>
<tr>
<td>36</td>
<td>Periodontitis due to Campylobacter</td>
</tr>
<tr>
<td>37</td>
<td>Dental disease, not elsewhere classified</td>
</tr>
<tr>
<td>38</td>
<td>Disorders of cobalamin metabolism or transport</td>
</tr>
<tr>
<td>39</td>
<td>Haptocorrin deficiency</td>
</tr>
<tr>
<td>40</td>
<td>Transcobalamin I deficiency</td>
</tr>
<tr>
<td>41</td>
<td>Vitamin B12-binding protein 1 deficiency</td>
</tr>
<tr>
<td>42</td>
<td>Vitamin B12-binding alpha-globulin deficiency</td>
</tr>
<tr>
<td>43</td>
<td>Cobalophilin deficiency</td>
</tr>
<tr>
<td>44</td>
<td>Protein R deficiency</td>
</tr>
<tr>
<td>45</td>
<td>TCN1 - [Transcobalamin I] deficiency</td>
</tr>
<tr>
<td>46</td>
<td>Other genetic defects of cobalamine transport or metabolism</td>
</tr>
<tr>
<td>47</td>
<td>Secondary non-genetic disorders of cobalamin absorption, transport or metabolism</td>
</tr>
<tr>
<td>48</td>
<td>Unspecified disorders of cobalamin absorption, transport or metabolism</td>
</tr>
<tr>
<td>49</td>
<td>Other specified obesity</td>
</tr>
<tr>
<td>50</td>
<td>Leptin-related genetic obesity</td>
</tr>
<tr>
<td>51</td>
<td>Obesity due to congenital leptin deficiency</td>
</tr>
<tr>
<td>52</td>
<td>Obesity due to congenital leptin resistance</td>
</tr>
<tr>
<td>53</td>
<td>Obesity due to prohormone convertase-1 deficiency</td>
</tr>
<tr>
<td>54</td>
<td>PCI deficiency</td>
</tr>
<tr>
<td>55</td>
<td>Obesity due to leptin receptor gene deficiency</td>
</tr>
<tr>
<td>56</td>
<td>Obesity due to pro-opiomelanocortin deficiency</td>
</tr>
<tr>
<td>57</td>
<td>POMC - [ pro-opiomelanocortin] deficiency</td>
</tr>
<tr>
<td>58</td>
<td>Obesity due to melanocortin-4 receptor deficiency</td>
</tr>
<tr>
<td>59</td>
<td>MC4R - [melanocortin-4 receptor] deficiency</td>
</tr>
<tr>
<td>60</td>
<td>Obesity due to excess calories</td>
</tr>
<tr>
<td>61</td>
<td>alimentary obesity</td>
</tr>
<tr>
<td>62</td>
<td>exogenous obesity</td>
</tr>
<tr>
<td>63</td>
<td>nutritional obesity</td>
</tr>
<tr>
<td>64</td>
<td>overalimentation obesity</td>
</tr>
<tr>
<td>65</td>
<td>Obesity, not elsewhere classified, body mass index &gt;= 30 kg/m2 to &lt;= 34.99 kg/m2</td>
</tr>
<tr>
<td>66</td>
<td>Obesity, not elsewhere classified, body mass index &gt;= 40 kg/m²</td>
</tr>
<tr>
<td>67</td>
<td>Obesity, not elsewhere classified, body mass index &gt;= 35 kg/m² to &lt;= 39.99 kg/m²</td>
</tr>
<tr>
<td>68</td>
<td>Constitutional obesity</td>
</tr>
<tr>
<td>69</td>
<td>Endocrine obesity</td>
</tr>
<tr>
<td>70</td>
<td>obesity of endocrine origin</td>
</tr>
<tr>
<td>71</td>
<td>Extreme obesity, not elsewhere classified</td>
</tr>
<tr>
<td>72</td>
<td>Endogenous obesity</td>
</tr>
<tr>
<td>73</td>
<td>Familial obesity</td>
</tr>
<tr>
<td>74</td>
<td>Glandular obesity</td>
</tr>
<tr>
<td>75</td>
<td>Severe obesity</td>
</tr>
<tr>
<td>76</td>
<td>Constitutional neutrophilia</td>
</tr>
<tr>
<td>77</td>
<td>Congenital disorders with increased neutrophil counts</td>
</tr>
<tr>
<td>78</td>
<td>Congenital neutrophilias</td>
</tr>
<tr>
<td>79</td>
<td>Neutrophilia due to mutations in CSF3R</td>
</tr>
<tr>
<td>80</td>
<td>Hereditary chronic neutrophilia</td>
</tr>
<tr>
<td>81</td>
<td>Constitutional neutropaenia</td>
</tr>
<tr>
<td>82</td>
<td>congenital agranulocytosis and neutropaenia</td>
</tr>
<tr>
<td>83</td>
<td>congenital leukopaenia</td>
</tr>
<tr>
<td>84</td>
<td>Congenital neutropaenias</td>
</tr>
<tr>
<td>85</td>
<td>primary neutropaenia</td>
</tr>
<tr>
<td>86</td>
<td>Benign ethnic neutropaenia</td>
</tr>
<tr>
<td>87</td>
<td>Severe congenital neutropaenia</td>
</tr>
<tr>
<td>88</td>
<td>severe infantile genetic neutropaenia</td>
</tr>
<tr>
<td>89</td>
<td>Autosomal dominant severe congenital neutropaenia</td>
</tr>
<tr>
<td>90</td>
<td>Autosomal recessive severe congenital neutropaenia due to G6PC3 deficiency</td>
</tr>
<tr>
<td>91</td>
<td>Dursun syndrome</td>
</tr>
<tr>
<td>92</td>
<td>Pulmonary arterial hypertension - leukopenia - atrial septal defect</td>
</tr>
<tr>
<td>93</td>
<td>Autosomal recessive severe congenital neutropaenia due to JAGN1 deficiency</td>
</tr>
<tr>
<td>94</td>
<td>CSF3R-related severe congenital neutropaenia</td>
</tr>
<tr>
<td>95</td>
<td>Kostmann syndrome</td>
</tr>
<tr>
<td>96</td>
<td>Kostmann disease</td>
</tr>
<tr>
<td>97</td>
<td>X-linked severe congenital neutropaenia</td>
</tr>
<tr>
<td>98</td>
<td>Congenital neutropaenia with myelokathexis</td>
</tr>
<tr>
<td>99</td>
<td>Congenital neutropaenia with maturation arrest</td>
</tr>
<tr>
<td>100</td>
<td>Congenital neutropaenia associated with syndromal features</td>
</tr>
<tr>
<td>101</td>
<td>Cyclic neutropaenia</td>
</tr>
<tr>
<td>102</td>
<td>cyclic agranulocytosis</td>
</tr>
<tr>
<td>103</td>
<td>Cyclic haematopoiesis</td>
</tr>
<tr>
<td>104</td>
<td>Constitutional neutropaenia with extra-haematopoietic manifestations</td>
</tr>
<tr>
<td>105</td>
<td>Primary immunodeficiency syndrome due to p14 deficiency</td>
</tr>
<tr>
<td>106</td>
<td>Primary immunodeficiency syndrome with short stature</td>
</tr>
<tr>
<td>107</td>
<td>Infantile genetic agranulocytosis</td>
</tr>
<tr>
<td>108</td>
<td>severe infantile genetic agranulocytosis</td>
</tr>
<tr>
<td>109</td>
<td>Immunodeficiency with an early component of complement deficiency</td>
</tr>
<tr>
<td>110</td>
<td>Deficiency of complement initial pathway</td>
</tr>
<tr>
<td>111</td>
<td>Complement component C1q deficiency</td>
</tr>
<tr>
<td>112</td>
<td>Complement component C1r/C1s deficiency</td>
</tr>
<tr>
<td>113</td>
<td>Complement component C2 deficiency</td>
</tr>
<tr>
<td>114</td>
<td>Complement component C4 deficiency</td>
</tr>
<tr>
<td>115</td>
<td>Primary inherited erythrocytosis</td>
</tr>
<tr>
<td>116</td>
<td>Primary familial polycythaemia</td>
</tr>
<tr>
<td>117</td>
<td>Primary inherited polycythaemia</td>
</tr>
<tr>
<td>118</td>
<td>Polycythaemia due to HIF2A mutation</td>
</tr>
<tr>
<td>119</td>
<td>Polycythaemia due to PHD2 mutation</td>
</tr>
<tr>
<td>120</td>
<td>Polycythaemia due to VHL mutation</td>
</tr>
<tr>
<td>121</td>
<td>Chuvash polycythaemia</td>
</tr>
<tr>
<td>122</td>
<td>Von Hippel-Lindau-dependent polycythaemia</td>
</tr>
<tr>
<td>123</td>
<td>Chuvash erythrocytosis</td>
</tr>
<tr>
<td>124</td>
<td>Primary familial polycythaemia due to EPOR mutation</td>
</tr>
<tr>
<td>125</td>
<td>Primary familial polycythaemia due to other mutations</td>
</tr>
<tr>
<td>1</td>
<td>Adult T-cell lymphoma or leukaemia, human T-cell lymphotropic virus type 1-associated</td>
</tr>
<tr>
<td>2</td>
<td>adult t-cell lymphoma</td>
</tr>
<tr>
<td>3</td>
<td>adult t cell leukaemia lymphoma</td>
</tr>
<tr>
<td>4</td>
<td>adult t-cell leukaemia</td>
</tr>
<tr>
<td>5</td>
<td>cortical T ALL</td>
</tr>
<tr>
<td>6</td>
<td>pre-T ALL</td>
</tr>
<tr>
<td>7</td>
<td>precursor t-cell lymphoblastic leukaemia</td>
</tr>
<tr>
<td>8</td>
<td>pro-T ALL</td>
</tr>
<tr>
<td>9</td>
<td>t-cell acute lymphoblastic leukaemia</td>
</tr>
<tr>
<td>10</td>
<td>adult t-cell leukaemia or lymphoma HTLV-1 - [human t-cell lymphotropic virus type 1 positive]</td>
</tr>
<tr>
<td>11</td>
<td>adult T-cell lymphoma or leukaemia (HTLV-1-associated) without mention of remission</td>
</tr>
<tr>
<td>12</td>
<td>adult t-cell lymphoma or leukaemia (HTLV-1-associated), NOS</td>
</tr>
<tr>
<td>13</td>
<td>adult t-cell leukaemia or lymphoma (HTLV-1 positive)</td>
</tr>
<tr>
<td>14</td>
<td>Adult T-cell lymphoma or leukaemia, human T-cell lymphotropic virus type 1-associated in complete remission</td>
</tr>
<tr>
<td>15</td>
<td>Acute variant of adult T-cell lymphoma or leukaemia</td>
</tr>
<tr>
<td>16</td>
<td>Chronic variant of adult T-cell lymphoma or leukaemia</td>
</tr>
<tr>
<td>17</td>
<td>Lymphomatoid variant of adult T-cell lymphoma or leukaemia</td>
</tr>
<tr>
<td>18</td>
<td>Smouldering variant of adult T-cell lymphoma or leukaemia</td>
</tr>
<tr>
<td>19</td>
<td>Type 2 diabetes mellitus</td>
</tr>
<tr>
<td>20</td>
<td>adult onset diabetes</td>
</tr>
<tr>
<td>21</td>
<td>maturity onset diabetes</td>
</tr>
<tr>
<td>22</td>
<td>nonketotic diabetes</td>
</tr>
<tr>
<td>23</td>
<td>type 2 diabetes</td>
</tr>
<tr>
<td>24</td>
<td>diabetes mellitus Type 2</td>
</tr>
<tr>
<td>25</td>
<td>non-insulin dependent diabetes mellitus</td>
</tr>
<tr>
<td>26</td>
<td>T2DM - [Type 2 diabetes mellitus]</td>
</tr>
<tr>
<td>27</td>
<td>NIDDM - [non insulin dependent diabetes mellitus]</td>
</tr>
<tr>
<td>28</td>
<td>Type II diabetes mellitus</td>
</tr>
<tr>
<td>29</td>
<td>type II diabetes</td>
</tr>
<tr>
<td>30</td>
<td>DM2</td>
</tr>
<tr>
<td>31</td>
<td>DM type II</td>
</tr>
<tr>
<td>32</td>
<td>Diabetic type 2</td>
</tr>
<tr>
<td>33</td>
<td>insulin requiring type 2 diabetes</td>
</tr>
<tr>
<td>34</td>
<td>noninsulin dependent diabetes</td>
</tr>
<tr>
<td>35</td>
<td>maturity-onset diabetes mellitus</td>
</tr>
<tr>
<td>36</td>
<td>non-insulin-dependent diabetes mellitus without complications</td>
</tr>
<tr>
<td>37</td>
<td>diabetes due to insulin secretory defect</td>
</tr>
<tr>
<td>38</td>
<td>diabetes mellitus due to insulin secretory defect</td>
</tr>
<tr>
<td>39</td>
<td>non-insulin-dependent diabetes of the young</td>
</tr>
<tr>
<td>40</td>
<td>senile diabetes</td>
</tr>
<tr>
<td>41</td>
<td>nonketotic hyperglycaemia</td>
</tr>
<tr>
<td>42</td>
<td>stable diabetes</td>
</tr>
<tr>
<td>43</td>
<td>Ketosis-resistant diabetes mellitus</td>
</tr>
<tr>
<td>44</td>
<td>Insulin resistant diabetes mellitus</td>
</tr>
<tr>
<td>45</td>
<td>insulin resistant diabetes</td>
</tr>
<tr>
<td>46</td>
<td>Type 1 diabetes mellitus</td>
</tr>
<tr>
<td>47</td>
<td>T1DM - [type 1 diabetes mellitus]</td>
</tr>
<tr>
<td>48</td>
<td>type 1 diabetes</td>
</tr>
<tr>
<td>49</td>
<td>IDDM - [insulin dependent diabetes mellitus]</td>
</tr>
<tr>
<td>50</td>
<td>type 1 IDDM</td>
</tr>
<tr>
<td>51</td>
<td>juvenile diabetes mellitus without complications</td>
</tr>
<tr>
<td>52</td>
<td>idiopathic insulin-dependent diabetes mellitus without complications</td>
</tr>
<tr>
<td>53</td>
<td>juvenile-onset diabetes mellitus without complications</td>
</tr>
<tr>
<td>54</td>
<td>ketosis-prone diabetes mellitus without complications</td>
</tr>
<tr>
<td>55</td>
<td>juvenile-onset-type diabetes mellitus without complications</td>
</tr>
<tr>
<td>56</td>
<td>Idiopathic Type 1 diabetes mellitus</td>
</tr>
<tr>
<td>57</td>
<td>Fulminant type 1 diabetes mellitus</td>
</tr>
<tr>
<td>58</td>
<td>Immune-related Type 1 diabetes mellitus</td>
</tr>
<tr>
<td>59</td>
<td>Juvenile onset diabetes mellitus</td>
</tr>
<tr>
<td>60</td>
<td>Immune-mediated Type 1 diabetes mellitus</td>
</tr>
<tr>
<td>61</td>
<td>Latent autoimmune diabetes in adults</td>
</tr>
<tr>
<td>62</td>
<td>LADA - [Latent autoimmune diabetes in adults]</td>
</tr>
<tr>
<td>63</td>
<td>slowly progressive insulin-dependent diabetes mellitus</td>
</tr>
<tr>
<td>64</td>
<td>SPIDDM - [Slowly progressive insulin-dependent diabetes mellitus]</td>
</tr>
<tr>
<td>65</td>
<td>Sick-euthyroid syndrome</td>
</tr>
<tr>
<td>66</td>
<td>ESS - [euthyroid sick syndrome]</td>
</tr>
<tr>
<td>67</td>
<td>Low-T3 syndrome</td>
</tr>
<tr>
<td>68</td>
<td>NTIS - [non-thyroidal illness syndrome]</td>
</tr>
<tr>
<td>69</td>
<td>TSCITUS - [thyroid allostasis in critical illness, tumours, uraemia and starvation]</td>
</tr>
<tr>
<td>70</td>
<td>Abnormalities of size or form of teeth</td>
</tr>
<tr>
<td>71</td>
<td>Microdontia</td>
</tr>
<tr>
<td>72</td>
<td>Macrodontia</td>
</tr>
<tr>
<td>73</td>
<td>Fused mandibular incisors</td>
</tr>
<tr>
<td>74</td>
<td>synodontia</td>
</tr>
<tr>
<td>75</td>
<td>Fusion of teeth</td>
</tr>
<tr>
<td>76</td>
<td>Double teeth</td>
</tr>
<tr>
<td>77</td>
<td>schizodontia</td>
</tr>
<tr>
<td>78</td>
<td>Taurodontism</td>
</tr>
<tr>
<td>79</td>
<td>Dens evaginatus</td>
</tr>
<tr>
<td>80</td>
<td>evaginated odontoma for posterior teeth</td>
</tr>
<tr>
<td>81</td>
<td>Leong’s premolar</td>
</tr>
<tr>
<td>82</td>
<td>tuberculated premolar</td>
</tr>
<tr>
<td>83</td>
<td>tuberculum paramolare</td>
</tr>
<tr>
<td>84</td>
<td>Dens in dente</td>
</tr>
<tr>
<td>85</td>
<td>dens invaginatus</td>
</tr>
<tr>
<td>86</td>
<td>Talon cusp</td>
</tr>
<tr>
<td>87</td>
<td>talon for anterior teeth</td>
</tr>
<tr>
<td>88</td>
<td>t-shaped incisors</td>
</tr>
<tr>
<td>89</td>
<td>Abnormal cusps</td>
</tr>
<tr>
<td>90</td>
<td>Shovel teeth</td>
</tr>
<tr>
<td>91</td>
<td>shovel-shaped incisors</td>
</tr>
<tr>
<td>92</td>
<td>Conical teeth</td>
</tr>
<tr>
<td>93</td>
<td>Cone-shaped teeth</td>
</tr>
<tr>
<td>94</td>
<td>Peg-shaped teeth</td>
</tr>
<tr>
<td>95</td>
<td>Globodontia</td>
</tr>
<tr>
<td>96</td>
<td>Rounded globular teeth</td>
</tr>
<tr>
<td>97</td>
<td>Concrescence of teeth</td>
</tr>
<tr>
<td>98</td>
<td>concrescence</td>
</tr>
<tr>
<td>99</td>
<td>Dichotomy of teeth</td>
</tr>
<tr>
<td>100</td>
<td>Enamel pearls</td>
</tr>
<tr>
<td>101</td>
<td>Enameloma</td>
</tr>
<tr>
<td>102</td>
<td>Gemination of teeth</td>
</tr>
<tr>
<td>103</td>
<td>Molarization of premolars</td>
</tr>
<tr>
<td>104</td>
<td>Premolarization of cuspids</td>
</tr>
<tr>
<td>105</td>
<td>Disorders of protein N-glycosylation</td>
</tr>
<tr>
<td>106</td>
<td>Phosphomannomutase 2 deficiency</td>
</tr>
<tr>
<td>107</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1A</td>
</tr>
<tr>
<td>108</td>
<td>Congenital disorder of glycosylation type 1A</td>
</tr>
<tr>
<td>109</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1A</td>
</tr>
<tr>
<td>110</td>
<td>Phosphomannose isomerase deficiency</td>
</tr>
<tr>
<td>111</td>
<td>Saguenay-Lac-Saint-Jean syndrome</td>
</tr>
<tr>
<td>112</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1B</td>
</tr>
<tr>
<td>113</td>
<td>Congenital disorder of glycosylation type 1B</td>
</tr>
<tr>
<td>114</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1B</td>
</tr>
<tr>
<td>115</td>
<td>SLSJ - [Saguenay-Lac-Saint-Jean] syndrome</td>
</tr>
<tr>
<td>116</td>
<td>Glucosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>117</td>
<td>Dol-P-Glc: Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>118</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1C</td>
</tr>
<tr>
<td>119</td>
<td>Congenital disorder of glycosylation type 1C</td>
</tr>
<tr>
<td>120</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1C</td>
</tr>
<tr>
<td>121</td>
<td>Mannosyltransferase 6 deficiency</td>
</tr>
<tr>
<td>122</td>
<td>Dol-P-Man: Man5-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>123</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1D</td>
</tr>
<tr>
<td>124</td>
<td>Congenital disorder of glycosylation type 1D</td>
</tr>
<tr>
<td>125</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1D</td>
</tr>
<tr>
<td>126</td>
<td>Mannosyltransferase 8 deficiency</td>
</tr>
<tr>
<td>127</td>
<td>Dol-P-Man: Man7-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>128</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1G</td>
</tr>
<tr>
<td>129</td>
<td>Congenital disorder of glycosylation type 1G</td>
</tr>
<tr>
<td>130</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1G</td>
</tr>
<tr>
<td>131</td>
<td>Glucosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>132</td>
<td>Dol-P-Glc: Glc1-Man9-GlcNAc2-P-P-Dol glucosyltransferase deficiency</td>
</tr>
<tr>
<td>133</td>
<td>Carbohydrate deficient glycoprotein syndrome 1H</td>
</tr>
<tr>
<td>134</td>
<td>Congenital disorder of glycosylation type 1H</td>
</tr>
<tr>
<td>135</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1H</td>
</tr>
<tr>
<td>136</td>
<td>Mannosyltransferase 2 deficiency</td>
</tr>
<tr>
<td>137</td>
<td>Dol-P-Man: Man1-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>138</td>
<td>Carbohydrate deficient glycoprotein syndrome 1I</td>
</tr>
<tr>
<td>139</td>
<td>Congenital disorder of glycosylation 1I</td>
</tr>
<tr>
<td>140</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1I</td>
</tr>
<tr>
<td>141</td>
<td>Dolichyl-phosphate N-acetylgalactosamine phosphotransferase deficiency</td>
</tr>
<tr>
<td>142</td>
<td>UDP-GlcNAc: Dol-P-GlcNac-P transferase deficiency</td>
</tr>
<tr>
<td>143</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1J</td>
</tr>
<tr>
<td>144</td>
<td>Congenital disorder of glycosylation type 1J</td>
</tr>
<tr>
<td>145</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1J</td>
</tr>
<tr>
<td>146</td>
<td>Mannosyltransferase 1 deficiency</td>
</tr>
<tr>
<td>147</td>
<td>Dol-P-Man: GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>148</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1K</td>
</tr>
<tr>
<td>149</td>
<td>Congenital disorder of glycosylation type 1K</td>
</tr>
<tr>
<td>150</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1K</td>
</tr>
<tr>
<td>151</td>
<td>Mannosyltransferase 7-9 deficiency</td>
</tr>
<tr>
<td>152</td>
<td>Congenital disorder of glycosylation type 1L</td>
</tr>
<tr>
<td>153</td>
<td>Dol-P-Man: Man6 and Man8-GlcNAc2-P-P-Dol mannosyltransferase deficiency</td>
</tr>
<tr>
<td>154</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1L</td>
</tr>
<tr>
<td>155</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 1L</td>
</tr>
<tr>
<td>156</td>
<td>M5-DLO flippase deficiency</td>
</tr>
<tr>
<td>157</td>
<td>Man5GlcNAc2-PP-Dol flippase deficiency</td>
</tr>
<tr>
<td>158</td>
<td>RTF1-CDG</td>
</tr>
<tr>
<td>159</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1N</td>
</tr>
<tr>
<td>160</td>
<td>N-acetylglucosaminyltransferase deficiency</td>
</tr>
<tr>
<td>161</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2A</td>
</tr>
<tr>
<td>162</td>
<td>Congenital disorder of glycosylation type 2A</td>
</tr>
<tr>
<td>163</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2A</td>
</tr>
<tr>
<td>164</td>
<td>Glucosidase 1 deficiency</td>
</tr>
<tr>
<td>165</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2B</td>
</tr>
<tr>
<td>166</td>
<td>Congenital disorder of glycosylation type 2B</td>
</tr>
<tr>
<td>167</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2B</td>
</tr>
<tr>
<td>168</td>
<td>TUSC3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>169</td>
<td>TUSC3-CDG</td>
</tr>
<tr>
<td>170</td>
<td>SRD5A3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>171</td>
<td>SRD5A3-CDG</td>
</tr>
<tr>
<td>172</td>
<td>Congenital disorder of glycosylation due to steroid 5-alpha-reductase type 3 deficiency</td>
</tr>
<tr>
<td>173</td>
<td>Intellectual deficit - cataract - coloboma - kyphosis</td>
</tr>
<tr>
<td>174</td>
<td>Kahrizi syndrome</td>
</tr>
<tr>
<td>175</td>
<td>Intellectual deficit, Kahrizi type</td>
</tr>
<tr>
<td>176</td>
<td>DPM3 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>177</td>
<td>Congenital disorder of glycosylation type 1O</td>
</tr>
<tr>
<td>178</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1O</td>
</tr>
<tr>
<td>179</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1O</td>
</tr>
<tr>
<td>180</td>
<td>ALG11 congenital disorder of glycosylation</td>
</tr>
<tr>
<td>181</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1P</td>
</tr>
<tr>
<td>182</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1P</td>
</tr>
<tr>
<td>183</td>
<td>Congenital disorder of glycosylation type 1P</td>
</tr>
<tr>
<td>184</td>
<td>Phosphoglucomutase-1 deficiency</td>
</tr>
<tr>
<td>185</td>
<td>PGM1-CDG - [Phosphoglucomutase-1 deficiency]</td>
</tr>
<tr>
<td>186</td>
<td>Congenital disorder of glycosylation type 1t</td>
</tr>
<tr>
<td>187</td>
<td>Mature T-cell or NK-cell neoplasms, unspecified</td>
</tr>
<tr>
<td>188</td>
<td>Enteropathy associated T-cell lymphoma</td>
</tr>
<tr>
<td>189</td>
<td>Enteropathy type intestinal T-cell lymphoma</td>
</tr>
<tr>
<td>190</td>
<td>Intestinal T-cell lymphoma</td>
</tr>
<tr>
<td>191</td>
<td>Peripheral T-cell lymphoma, not otherwise specified</td>
</tr>
<tr>
<td>192</td>
<td>T-zone variant Peripheral T-cell lymphoma</td>
</tr>
<tr>
<td>193</td>
<td>Lymphoepithelioid lymphoma</td>
</tr>
<tr>
<td>194</td>
<td>mature t-cell lymphoma</td>
</tr>
<tr>
<td>195</td>
<td>peripheral t-cell lymphoma unspecified</td>
</tr>
<tr>
<td>196</td>
<td>peripheral t-cell lymphoma NOS</td>
</tr>
<tr>
<td>197</td>
<td>Follicular variant Peripheral T-cell lymphoma</td>
</tr>
<tr>
<td>198</td>
<td>Lennert lymphoma</td>
</tr>
<tr>
<td>199</td>
<td>peripheral t-cell lymphoma AILD - [angioimmunoblastic lymphadenopathy with dysproteinaemia]</td>
</tr>
<tr>
<td>200</td>
<td>peripheral t-cell lymphoma - pleomorphic small cell</td>
</tr>
<tr>
<td>201</td>
<td>peripheral t-cell lymphoma - pleomorphic medium and large cell</td>
</tr>
<tr>
<td>202</td>
<td>Other specified mature T-cell or NK-cell neoplasms</td>
</tr>
<tr>
<td>203</td>
<td>Severe combined immunodeficiencies</td>
</tr>
<tr>
<td>204</td>
<td>SCID - [Severe combined immunodeficiencies]</td>
</tr>
<tr>
<td>205</td>
<td>severe combined immunodeficiency disease</td>
</tr>
<tr>
<td>206</td>
<td>Severe combined immunodeficiency with reticular dysgenesis</td>
</tr>
<tr>
<td>207</td>
<td>Severe combined immunodeficiency with leukopenia</td>
</tr>
<tr>
<td>208</td>
<td>Congenital aleukocytosis</td>
</tr>
<tr>
<td>209</td>
<td>Reticular dysgenesis</td>
</tr>
<tr>
<td>210</td>
<td>De Vaal disease</td>
</tr>
<tr>
<td>211</td>
<td>SCID - [Severe combined immunodeficiencies] with reticular dysgenesis</td>
</tr>
<tr>
<td>212</td>
<td>generalised haematopoietic hypoplasia</td>
</tr>
<tr>
<td>213</td>
<td>Severe combined immunodeficiency with low T- and B-cell numbers</td>
</tr>
<tr>
<td>214</td>
<td>T- B- severe combined immunodeficiency</td>
</tr>
<tr>
<td>215</td>
<td>SCID - [Severe combined immunodeficiencies] with low t- and b-cell numbers</td>
</tr>
<tr>
<td>216</td>
<td>Severe combined immunodeficiency T- B- due to RAG1 deficiency</td>
</tr>
<tr>
<td>217</td>
<td>Severe combined immunodeficiency T- B- due to recombination activating gene 1deficiency</td>
</tr>
<tr>
<td>218</td>
<td>SCID - [severe combined immunodeficiency] T- B- due to RAG1 - [recombination-activating gene 1] deficiency</td>
</tr>
<tr>
<td>219</td>
<td>Severe combined immunodeficiency T- B- due to RAG2 deficiency</td>
</tr>
<tr>
<td>220</td>
<td>Severe combined immunodeficiency T- B- due to recombination activating gene 2 deficiency</td>
</tr>
<tr>
<td>221</td>
<td>SCID - [severe combined immunodeficiency] T- B- due to RAG2 - [recombination-activating gene 2] deficiency</td>
</tr>
<tr>
<td>222</td>
<td>Severe combined immunodeficiency with hypereosinophilia</td>
</tr>
<tr>
<td>223</td>
<td>Omenn syndrome</td>
</tr>
<tr>
<td>224</td>
<td>SCID - [severe combined immunodeficiency] with hypereosinophilia</td>
</tr>
<tr>
<td>225</td>
<td>SCID - [Severe combined immunodeficiency] due to DCLRE1C- [DNA cross-link repair 1C] deficiency</td>
</tr>
<tr>
<td>226</td>
<td>Agammaglobulinaemia, alymphocytotic type</td>
</tr>
<tr>
<td>227</td>
<td>SCID - [Severe combined immunodeficiency], Athabaskan type</td>
</tr>
<tr>
<td>228</td>
<td>SCID - [Severe combined immunodeficiency] due to DNA cross-link repair protein 1C deficiency</td>
</tr>
<tr>
<td>229</td>
<td>SCID - [Severe combined immunodeficiency] due to Artemis protein deficiency</td>
</tr>
<tr>
<td>230</td>
<td>Severe combined immunodeficiency [SCID], alymphocytotic type</td>
</tr>
<tr>
<td>231</td>
<td>Severe combined immunodeficiency due to LCK deficiency</td>
</tr>
<tr>
<td>232</td>
<td>SCID - [severe combined immunodeficiency due to LCK - [lymphocyte-specific protein tyrosine kinase] deficiency</td>
</tr>
<tr>
<td>233</td>
<td>SCID - [Severe combined immunodeficiency] due to DNA-PKcs deficiency</td>
</tr>
<tr>
<td>234</td>
<td>SCID - [Severe combined immunodeficiency] due to DNA-PKcs - [DNA-dependent protein kinase, catalytic subunit] deficiency</td>
</tr>
<tr>
<td>235</td>
<td>Severe combined immunodeficiency T- B- due to adenosine deaminase deficiency</td>
</tr>
<tr>
<td>236</td>
<td>Adenosine deaminase deficiency</td>
</tr>
<tr>
<td>237</td>
<td>ADA - [adenosine deaminase] deficiency</td>
</tr>
<tr>
<td>238</td>
<td>ADA - [adenosine aminohydrolase] deficiency</td>
</tr>
<tr>
<td>239</td>
<td>SCID - [severe combined immunodeficiency] T- B- due to adenosine deaminase deficiency</td>
</tr>
<tr>
<td>240</td>
<td>Short-limb skeletal dysplasia with severe combined immunodeficiency</td>
</tr>
<tr>
<td>241</td>
<td>Immunodeficiency with short limb dwarfism</td>
</tr>
<tr>
<td>242</td>
<td>immunodeficiency with short-limbed stature</td>
</tr>
<tr>
<td>243</td>
<td>severe combined immunodeficiency with short-limbed dwarfism</td>
</tr>
<tr>
<td>244</td>
<td>Achondroplasia - severe combined immunodeficiency</td>
</tr>
<tr>
<td>245</td>
<td>SCID - [severe combined immunodeficiency] with short-limbed dwarfism</td>
</tr>
<tr>
<td>246</td>
<td>short-limbed immunodeficiency</td>
</tr>
<tr>
<td>247</td>
<td>Achondroplasia or Swiss-type agammaglobulinaemia</td>
</tr>
<tr>
<td>248</td>
<td>lymphopenic agammaglobulinaemia - short-limbed dwarfism syndrome</td>
</tr>
<tr>
<td>249</td>
<td>Severe combined immunodeficiency with low or normal B-cell numbers</td>
</tr>
<tr>
<td>250</td>
<td>T- B+ severe combined immunodeficiency</td>
</tr>
<tr>
<td>251</td>
<td>SCID - [severe combined immunodeficiency] with low or normal b-cell numbers</td>
</tr>
<tr>
<td>252</td>
<td>Severe combined immunodeficiency T- B+ due to gamma chain deficiency</td>
</tr>
<tr>
<td>253</td>
<td>Severe combined immunodeficiency T- B+, X-linked</td>
</tr>
<tr>
<td>254</td>
<td>SCID - [severe combined immunodeficiency] T- B+ due to gamma chain deficiency</td>
</tr>
<tr>
<td>255</td>
<td>Severe combined immunodeficiency T- B+ due to JAK3 deficiency</td>
</tr>
<tr>
<td>256</td>
<td>SCID - [severe combined immunodeficiency] T- B+ due to JAK3- [Janus kinase 3] deficiency</td>
</tr>
<tr>
<td>257</td>
<td>Severe combined immunodeficiency T- B+ due to IL-7Ralpha deficiency</td>
</tr>
<tr>
<td>258</td>
<td>SCID - [severe combined immunodeficiency] T- B+ due to IL-7Ralpha - [Interleukin 7 receptor alpha] deficiency</td>
</tr>
<tr>
<td>259</td>
<td>Severe combined immunodeficiency T-B+ due to CD45 deficiency</td>
</tr>
<tr>
<td>260</td>
<td>SCID - [severe combined immunodeficiency] T- B+ due to CD45 deficiency</td>
</tr>
<tr>
<td>261</td>
<td>Severe combined immunodeficiency T- B+ due to CD3delta, CD3epsilon or CD3zeta</td>
</tr>
<tr>
<td>262</td>
<td>SCID - [severe combined immunodeficiency] T- B+ due to CD3delta/CD3epsilon/CD3zeta</td>
</tr>
<tr>
<td>263</td>
<td>Severe combined immunodeficiency due to CORO1A deficiency</td>
</tr>
<tr>
<td>264</td>
<td>SCID - [severe combined immunodeficiency] due to coronin-1A deficiency</td>
</tr>
<tr>
<td>265</td>
<td>Fracture of thoracic vertebra</td>
</tr>
<tr>
<td>266</td>
<td>fracture of thoracic spine</td>
</tr>
<tr>
<td>267</td>
<td>compression fracture of thoracic vertebra</td>
</tr>
<tr>
<td>268</td>
<td>dorsal vertebral fracture</td>
</tr>
<tr>
<td>269</td>
<td>fracture of pedicle of thoracic vertebra</td>
</tr>
<tr>
<td>270</td>
<td>Fracture of thoracic spine, NOS</td>
</tr>
<tr>
<td>271</td>
<td>fracture of thoracic spinous process</td>
</tr>
<tr>
<td>272</td>
<td>fracture of thoracic transverse process</td>
</tr>
<tr>
<td>273</td>
<td>thoracic vertebral fracture</td>
</tr>
<tr>
<td>274</td>
<td>thorax vertebral fracture</td>
</tr>
<tr>
<td>275</td>
<td>compression fracture of dorsal vertebra</td>
</tr>
<tr>
<td>276</td>
<td>compression fracture of vertebra of thorax</td>
</tr>
<tr>
<td>277</td>
<td>compression thoracic fracture</td>
</tr>
<tr>
<td>278</td>
<td>Fracture of first thoracic vertebra</td>
</tr>
<tr>
<td>279</td>
<td>Fracture of thoracic vertebra, T1</td>
</tr>
<tr>
<td>280</td>
<td>Fracture of second thoracic vertebra</td>
</tr>
<tr>
<td>281</td>
<td>Fracture of thoracic vertebra, T2</td>
</tr>
<tr>
<td>282</td>
<td>Fracture of third thoracic vertebra</td>
</tr>
<tr>
<td>283</td>
<td>Fracture of thoracic vertebra, T3</td>
</tr>
<tr>
<td>284</td>
<td>Fracture of fourth thoracic vertebra</td>
</tr>
<tr>
<td>285</td>
<td>Fracture of thoracic vertebra, T4</td>
</tr>
<tr>
<td>286</td>
<td>Fracture of fifth thoracic vertebra</td>
</tr>
<tr>
<td>287</td>
<td>Fracture of thoracic vertebra, T5</td>
</tr>
<tr>
<td>288</td>
<td>Fracture of sixth thoracic vertebra</td>
</tr>
<tr>
<td>289</td>
<td>Fracture of thoracic vertebra, T6</td>
</tr>
<tr>
<td>290</td>
<td>Fracture of seventh thoracic vertebra</td>
</tr>
<tr>
<td>291</td>
<td>Fracture of thoracic vertebra, T7</td>
</tr>
<tr>
<td>292</td>
<td>Fracture of eighth thoracic vertebra</td>
</tr>
<tr>
<td>293</td>
<td>Fracture of thoracic vertebra, T8</td>
</tr>
<tr>
<td>294</td>
<td>Fracture of ninth thoracic vertebra</td>
</tr>
<tr>
<td>295</td>
<td>Fracture of thoracic vertebra, T9</td>
</tr>
<tr>
<td>296</td>
<td>Fracture of tenth thoracic vertebra</td>
</tr>
<tr>
<td>297</td>
<td>Fracture of thoracic vertebra, T10</td>
</tr>
<tr>
<td>298</td>
<td>Fracture of eleventh thoracic vertebra</td>
</tr>
<tr>
<td>299</td>
<td>Fracture of thoracic vertebra, T11</td>
</tr>
<tr>
<td>300</td>
<td>Fracture of twelfth thoracic vertebra</td>
</tr>
<tr>
<td>301</td>
<td>Fracture of thoracic vertebra, T12</td>
</tr>
<tr>
<td>302</td>
<td>Precursor T-lymphoblastic neoplasms</td>
</tr>
<tr>
<td>303</td>
<td>T-precursor lymphoma</td>
</tr>
<tr>
<td>304</td>
<td>T-lymphoblastic neoplasms</td>
</tr>
<tr>
<td>305</td>
<td>Acquired neutropaenia</td>
</tr>
<tr>
<td>306</td>
<td>Immunologic neutropaenias</td>
</tr>
<tr>
<td>307</td>
<td>Acquired neutropaenia NOS</td>
</tr>
<tr>
<td>308</td>
<td>Adult idiopathic neutropaenia</td>
</tr>
<tr>
<td>309</td>
<td>Secondary agranulocytosis</td>
</tr>
<tr>
<td>310</td>
<td>Drug-induced secondary agranulocytosis</td>
</tr>
<tr>
<td>311</td>
<td>medicament-induced secondary agranulocytosis</td>
</tr>
<tr>
<td>312</td>
<td>drug-induced neutropaenia</td>
</tr>
<tr>
<td>313</td>
<td>Toxic secondary agranulocytosis</td>
</tr>
<tr>
<td>314</td>
<td>toxic neutropaenia</td>
</tr>
<tr>
<td>315</td>
<td>neutropaenia associated with T-cell large granular lymphocyte leukaemia</td>
</tr>
<tr>
<td>316</td>
<td>T-cell chronic lymphocytic leukaemia</td>
</tr>
<tr>
<td>317</td>
<td>T-cell LGL leukaemia</td>
</tr>
<tr>
<td>318</td>
<td>Combined immunodeficiencies, unspecified</td>
</tr>
<tr>
<td>319</td>
<td>Combined immunodeficiencies</td>
</tr>
<tr>
<td>320</td>
<td>Combined T and B cell immunodeficiency</td>
</tr>
<tr>
<td>321</td>
<td>combined immunity deficiency</td>
</tr>
<tr>
<td>322</td>
<td>combined immunodeficiency syndrome</td>
</tr>
<tr>
<td>323</td>
<td>combined t-cell and b-cell immunodeficiency</td>
</tr>
<tr>
<td>324</td>
<td>lymphopenic agammaglobulinaemia</td>
</tr>
<tr>
<td>325</td>
<td>Primary cutaneous CD30-positive T-cell lymphoproliferative disorders</td>
</tr>
<tr>
<td>326</td>
<td>primary cutaneous CD30+ T-cell proliferations</td>
</tr>
<tr>
<td>327</td>
<td>Primary cutaneous T-cell lymphoma of undetermined or unspecified type</td>
</tr>
<tr>
<td>328</td>
<td>Primary cutaneous peripheral T-cell lymphoma</td>
</tr>
<tr>
<td>329</td>
<td>Fracture of lower end of humerus, unspecified</td>
</tr>
<tr>
<td>330</td>
<td>Fracture of lower end of humerus</td>
</tr>
<tr>
<td>331</td>
<td>fracture of distal end of humerus</td>
</tr>
<tr>
<td>332</td>
<td>T-shaped fracture of distal humerus</td>
</tr>
<tr>
<td>333</td>
<td>fracture of articular process of humerus</td>
</tr>
<tr>
<td>334</td>
<td>Mycosis fungoides</td>
</tr>
<tr>
<td>335</td>
<td>Mycosis fungoides with limited patches or plaques</td>
</tr>
<tr>
<td>336</td>
<td>Mycosis fungoides stage T1</td>
</tr>
<tr>
<td>337</td>
<td>Mycosis fungoides with extensive patches or plaques</td>
</tr>
<tr>
<td>338</td>
<td>Mycosis fungoides stage T2</td>
</tr>
<tr>
<td>339</td>
<td>Patch or plaque stage mycosis fungoides</td>
</tr>
<tr>
<td>340</td>
<td>Mycosis fungoides, tumour stage</td>
</tr>
<tr>
<td>341</td>
<td>T3 stage mycosis fungoides</td>
</tr>
<tr>
<td>342</td>
<td>Tumour stage mycosis fungoides</td>
</tr>
<tr>
<td>343</td>
<td>Mycosis fungoides, erythrodermic</td>
</tr>
<tr>
<td>344</td>
<td>T4 stage mycosis fungoides</td>
</tr>
<tr>
<td>345</td>
<td>Mycosis fungoides variants</td>
</tr>
<tr>
<td>346</td>
<td>Folliculotropic mycosis fungoides</td>
</tr>
<tr>
<td>347</td>
<td>Syringotropic mycosis fungoides</td>
</tr>
<tr>
<td>348</td>
<td>syringotropic cutaneous T-cell lymphoma</td>
</tr>
<tr>
<td>349</td>
<td>Pagetoid reticulosis</td>
</tr>
<tr>
<td>350</td>
<td>Woringer-Kolopp disease</td>
</tr>
<tr>
<td>351</td>
<td>Granulomatous slack skin</td>
</tr>
<tr>
<td>352</td>
<td>Poikilodermatous mycosis fungoides</td>
</tr>
<tr>
<td>353</td>
<td>Paucibacillary leprosy</td>
</tr>
<tr>
<td>354</td>
<td>Hansen disease, paucibacillary</td>
</tr>
<tr>
<td>355</td>
<td>Indeterminate leprosy</td>
</tr>
<tr>
<td>356</td>
<td>Hansen disease, indeterminate</td>
</tr>
<tr>
<td>357</td>
<td>Indeterminate macular leprosy</td>
</tr>
<tr>
<td>358</td>
<td>Indeterminate neuritic leprosy</td>
</tr>
<tr>
<td>359</td>
<td>Tuberculoid leprosy</td>
</tr>
<tr>
<td>360</td>
<td>tuberculoid leprosy type T</td>
</tr>
<tr>
<td>361</td>
<td>Hansen disease, tuberculoid</td>
</tr>
<tr>
<td>362</td>
<td>Borderline tuberculoid leprosy</td>
</tr>
<tr>
<td>363</td>
<td>BT - [borderline tuberculoid] leprosy</td>
</tr>
<tr>
<td>364</td>
<td>T-cell prolymphocytic leukaemia</td>
</tr>
<tr>
<td>365</td>
<td>prolymphocytic leukaemia of T-cell type without mention of remission</td>
</tr>
<tr>
<td>366</td>
<td>T-cell prolymphocytic leukaemia in complete remission</td>
</tr>
<tr>
<td>367</td>
<td>prolymphocytic leukaemia of T-cell type in complete remission</td>
</tr>
<tr>
<td>368</td>
<td>Systemic Epstein-Barr Virus-positive T-cell lymphoma of childhood</td>
</tr>
<tr>
<td>369</td>
<td>Systemic EBV+ T-cell lymphoma of childhood</td>
</tr>
<tr>
<td>370</td>
<td>Dislocation of thoracic vertebra</td>
</tr>
<tr>
<td>371</td>
<td>dislocation of joint of thoracic spine</td>
</tr>
<tr>
<td>372</td>
<td>traumatic dislocation of joint of thoracic vertebra</td>
</tr>
<tr>
<td>373</td>
<td>dislocation of dorsal vertebra</td>
</tr>
<tr>
<td>374</td>
<td>vertebral dorsal dislocation</td>
</tr>
<tr>
<td>375</td>
<td>Dislocation of T1-T2 thoracic vertebra</td>
</tr>
<tr>
<td>376</td>
<td>Dislocation of T2-T3 thoracic vertebra</td>
</tr>
<tr>
<td>377</td>
<td>Dislocation of T3-T4 thoracic vertebra</td>
</tr>
<tr>
<td>378</td>
<td>Dislocation of T4-T5 thoracic vertebra</td>
</tr>
<tr>
<td>379</td>
<td>Dislocation of T5-T6 thoracic vertebra</td>
</tr>
<tr>
<td>380</td>
<td>Dislocation of T6-T7 thoracic vertebra</td>
</tr>
<tr>
<td>381</td>
<td>Dislocation of T7-T8 thoracic vertebra</td>
</tr>
<tr>
<td>382</td>
<td>Dislocation of T8-T9 thoracic vertebra</td>
</tr>
<tr>
<td>383</td>
<td>Dislocation of T9-T10 thoracic vertebra</td>
</tr>
<tr>
<td>384</td>
<td>Dislocation of T10-T11 thoracic vertebra</td>
</tr>
<tr>
<td>385</td>
<td>Dislocation of T11-T12 thoracic vertebra</td>
</tr>
<tr>
<td>386</td>
<td>Dislocation of T12-L1 thoracic vertebra</td>
</tr>
<tr>
<td>387</td>
<td>Mature T-cell lymphoma, specified types, nodal or systemic</td>
</tr>
<tr>
<td>1</td>
<td>Irritable bowel syndrome, unsubtyped</td>
</tr>
<tr>
<td>2</td>
<td>IBS-U - [Irritable bowel syndrome, unsubtyped]</td>
</tr>
<tr>
<td>1</td>
<td>DNA repair defects other than combined T-cell or B-cell immunodeficiencies</td>
</tr>
<tr>
<td>2</td>
<td>Nijmegen breakage syndrome</td>
</tr>
<tr>
<td>3</td>
<td>Autosomal recessive nonsyndromal microcephaly with normal intelligence</td>
</tr>
<tr>
<td>4</td>
<td>Immunodeficiency - microcephaly - chromosomal instability</td>
</tr>
<tr>
<td>5</td>
<td>Microcephaly - immunodeficiency - lymphoreticuloma</td>
</tr>
<tr>
<td>6</td>
<td>Ataxia-telangiectasia, variant 1</td>
</tr>
<tr>
<td>7</td>
<td>Seemanova syndrome type 2</td>
</tr>
<tr>
<td>8</td>
<td>Berlin breakage syndrome</td>
</tr>
<tr>
<td>9</td>
<td>NBS - [Nijmegen breakage syndrome]</td>
</tr>
<tr>
<td>10</td>
<td>AT V1- [Ataxia-telangiectasia, variant 1]</td>
</tr>
<tr>
<td>11</td>
<td>Nijmegen breakage syndrome-like disorder</td>
</tr>
<tr>
<td>12</td>
<td>NBS-like disorder</td>
</tr>
<tr>
<td>13</td>
<td>NBSLD - [Nijmegen breakage syndrome-like disorder]</td>
</tr>
<tr>
<td>14</td>
<td>Microcephaly or chromosomal instability without immunodeficiency</td>
</tr>
<tr>
<td>15</td>
<td>Bloom syndrome</td>
</tr>
<tr>
<td>16</td>
<td>Bloom-Torre-Machacek syndrome</td>
</tr>
<tr>
<td>17</td>
<td>Bloom Machacek syndrome</td>
</tr>
<tr>
<td>18</td>
<td>Ataxia-telangiectasia</td>
</tr>
<tr>
<td>19</td>
<td>Louis-Bar syndrome</td>
</tr>
<tr>
<td>20</td>
<td>Ataxia-telangiectasia-like disorder</td>
</tr>
<tr>
<td>21</td>
<td>ATLD - [Ataxia-telangiectasia-like disorder]</td>
</tr>
<tr>
<td>22</td>
<td>Other inherited coagulation factor deficiency with bleeding tendency, unspecified</td>
</tr>
<tr>
<td>23</td>
<td>Other inherited coagulation factor deficiency with bleeding tendency</td>
</tr>
<tr>
<td>24</td>
<td>Hereditary factor V deficiency</td>
</tr>
<tr>
<td>25</td>
<td>Proaccelerin deficiency</td>
</tr>
<tr>
<td>26</td>
<td>Owren disease</td>
</tr>
<tr>
<td>27</td>
<td>congenital factor V deficiency</td>
</tr>
<tr>
<td>28</td>
<td>Deficiency of factor V</td>
</tr>
<tr>
<td>29</td>
<td>Deficiency of factor V, labile</td>
</tr>
<tr>
<td>30</td>
<td>hereditary factor V deficiency disease</td>
</tr>
<tr>
<td>31</td>
<td>Parahaemophilia</td>
</tr>
<tr>
<td>32</td>
<td>Hereditary factor XIII deficiency</td>
</tr>
<tr>
<td>33</td>
<td>hereditary factor XIII deficiency disease</td>
</tr>
<tr>
<td>34</td>
<td>factor XIII deficiency disease</td>
</tr>
<tr>
<td>35</td>
<td>congenital factor XIII deficiency</td>
</tr>
<tr>
<td>36</td>
<td>deficiency of factor XIII</td>
</tr>
<tr>
<td>37</td>
<td>deficiency of stable factor</td>
</tr>
<tr>
<td>38</td>
<td>Combined deficiency of factor V and factor VIII</td>
</tr>
<tr>
<td>39</td>
<td>Familial multiple coagulation factor deficiency</td>
</tr>
<tr>
<td>40</td>
<td>FV - [factor 5] and FVIII - [factor 8] combined deficiency</td>
</tr>
<tr>
<td>41</td>
<td>Hereditary vitamin K-dependent coagulation factors deficiency</td>
</tr>
<tr>
<td>42</td>
<td>Hereditary factor II deficiency</td>
</tr>
<tr>
<td>43</td>
<td>Prothrombin deficiency</td>
</tr>
<tr>
<td>44</td>
<td>congenital factor II deficiency</td>
</tr>
<tr>
<td>45</td>
<td>deficiency of factor 2</td>
</tr>
<tr>
<td>46</td>
<td>hereditary factor II deficiency disease</td>
</tr>
<tr>
<td>47</td>
<td>Dysprothrombinaemia</td>
</tr>
<tr>
<td>48</td>
<td>constitutional dysprothrombinaemia</td>
</tr>
<tr>
<td>49</td>
<td>Hypoprothrombinaemia</td>
</tr>
<tr>
<td>50</td>
<td>idiopathic hypoprothrombinaemia</td>
</tr>
<tr>
<td>51</td>
<td>congenital hypoprothrombinaemia</td>
</tr>
<tr>
<td>52</td>
<td>Hereditary factor VII deficiency</td>
</tr>
<tr>
<td>53</td>
<td>Congenital proconvertin deficiency</td>
</tr>
<tr>
<td>54</td>
<td>proconvertin deficiency</td>
</tr>
<tr>
<td>55</td>
<td>Hypoproconvertinaemia</td>
</tr>
<tr>
<td>56</td>
<td>congenital factor VII deficiency</td>
</tr>
<tr>
<td>57</td>
<td>Deficiency of factor VII</td>
</tr>
<tr>
<td>58</td>
<td>factor VII deficiency</td>
</tr>
<tr>
<td>59</td>
<td>hereditary factor VII deficiency disease</td>
</tr>
<tr>
<td>60</td>
<td>hereditary factor VII deficiency syndrome</td>
</tr>
<tr>
<td>61</td>
<td>hereditary hypoproconvertinaemia</td>
</tr>
<tr>
<td>62</td>
<td>acquired deficiency of proconvertin</td>
</tr>
<tr>
<td>63</td>
<td>Acquired factor V deficiency</td>
</tr>
<tr>
<td>64</td>
<td>Chronic kidney disease, stage 5</td>
</tr>
<tr>
<td>65</td>
<td>chronic renal failure, stage 5</td>
</tr>
<tr>
<td>66</td>
<td>CKD - [chronic kidney disease] stage 5</td>
</tr>
<tr>
<td>67</td>
<td>end stage kidney failure</td>
</tr>
<tr>
<td>68</td>
<td>end stage renal failure</td>
</tr>
<tr>
<td>69</td>
<td>end stage kidney disease</td>
</tr>
<tr>
<td>70</td>
<td>end stage renal disease</td>
</tr>
<tr>
<td>71</td>
<td>end stage chronic renal failure</td>
</tr>
<tr>
<td>72</td>
<td>ESRF - [end stage renal failure]</td>
</tr>
<tr>
<td>73</td>
<td>ESRD - [end stage renal diseases]</td>
</tr>
<tr>
<td>74</td>
<td>eGFR - [estimated glomerular filtration rate] &lt; 15 ml/min/1.73m²</td>
</tr>
<tr>
<td>75</td>
<td>chronic renal disease, stage V</td>
</tr>
<tr>
<td>76</td>
<td>renal disease, stage 5</td>
</tr>
<tr>
<td>77</td>
<td>renal disease, stage V</td>
</tr>
<tr>
<td>78</td>
<td>kidney disease, stage 5</td>
</tr>
<tr>
<td>79</td>
<td>kidney disease, stage V</td>
</tr>
<tr>
<td>80</td>
<td>Chronic kidney disease, stage 5, not on dialysis</td>
</tr>
<tr>
<td>81</td>
<td>chronic renal failure, stage 5 not on dialysis</td>
</tr>
<tr>
<td>82</td>
<td>CKD- [chronic kidney disease] stage 5 not on dialysis</td>
</tr>
<tr>
<td>83</td>
<td>Chronic kidney disease, stage 5, on dialysis</td>
</tr>
<tr>
<td>84</td>
<td>chronic renal failure, stage 5 on dialysis</td>
</tr>
<tr>
<td>85</td>
<td>CKD - [chronic kidney disease] stage 5 on dialysis</td>
</tr>
<tr>
<td>86</td>
<td>end stage renal failure of dialysis</td>
</tr>
<tr>
<td>87</td>
<td>end stage renal failure on haemodialysis</td>
</tr>
<tr>
<td>88</td>
<td>Renal retinitis in chronic kidney disease, stage 5</td>
</tr>
<tr>
<td>89</td>
<td>Other specified haemorrhagic diseases due to acquired coagulation factor defects</td>
</tr>
<tr>
<td>90</td>
<td>Deficiency of coagulation factor due to vitamin K deficiency</td>
</tr>
<tr>
<td>91</td>
<td>Deficiency of coagulation factor due to nutritional vitamin K deficiency</td>
</tr>
<tr>
<td>92</td>
<td>Deficiency of coagulation factor due to other cause of vitamin K deficiency</td>
</tr>
<tr>
<td>93</td>
<td>Deficiency of coagulation factor due to other cause of vitamin K deficiency, coeliac disease included</td>
</tr>
<tr>
<td>94</td>
<td>Deficiency of coagulation factor due to vitamin K malabsorption in intestinal disease</td>
</tr>
<tr>
<td>95</td>
<td>Deficiency of coagulation factor due to vitamin K malabsorption in obstructive biliary disease</td>
</tr>
<tr>
<td>96</td>
<td>Deficiency of coagulation factor due to vitamin K malabsorption in obstructive biliary disease, congenital biliary atresia included</td>
</tr>
<tr>
<td>97</td>
<td>Other non-autoimmune acquired coagulation factor deficiencies</td>
</tr>
<tr>
<td>98</td>
<td>Acquired von Willebrand disease</td>
</tr>
<tr>
<td>99</td>
<td>Acquired von Willebrand syndrome</td>
</tr>
<tr>
<td>100</td>
<td>Acquired Von Willebrand disease due to myeloproliferative neoplasm or reactive thrombocytosis</td>
</tr>
<tr>
<td>101</td>
<td>Acquired Von Willebrand disease due to stenotic aortic valve or cardiac malformation</td>
</tr>
<tr>
<td>102</td>
<td>Heyde syndrome</td>
</tr>
<tr>
<td>103</td>
<td>Factor X deficiency associated with systemic amyloidosis</td>
</tr>
<tr>
<td>104</td>
<td>Acquired prothrombin complex deficiency</td>
</tr>
<tr>
<td>105</td>
<td>Acquired hypoprothrombinaemia</td>
</tr>
<tr>
<td>106</td>
<td>Deficiency of coagulation factor due to liver disease</td>
</tr>
<tr>
<td>107</td>
<td>Acquired factor II deficiency</td>
</tr>
<tr>
<td>108</td>
<td>Acquired factor V deficiency disease</td>
</tr>
<tr>
<td>109</td>
<td>acquired hypoproaccelerinaemia</td>
</tr>
<tr>
<td>110</td>
<td>acquired labile factor deficiency</td>
</tr>
<tr>
<td>111</td>
<td>acquired proaccelerin deficiency</td>
</tr>
<tr>
<td>112</td>
<td>Acquired factor VII deficiency disease</td>
</tr>
<tr>
<td>113</td>
<td>acquired hypoproconvertinaemia</td>
</tr>
<tr>
<td>114</td>
<td>Acquired fibrin stabilizing factor deficiency</td>
</tr>
<tr>
<td>115</td>
<td>acquired fibrinopenia</td>
</tr>
<tr>
<td>116</td>
<td>Acquired idiopathic hypoprothrombinaemia</td>
</tr>
<tr>
<td>117</td>
<td>Acquired stable factor deficiency</td>
</tr>
<tr>
<td>118</td>
<td>Alpha-granule diseases</td>
</tr>
<tr>
<td>119</td>
<td>Quebec platelet disorder</td>
</tr>
<tr>
<td>120</td>
<td>Factor V Quebec</td>
</tr>
<tr>
<td>121</td>
<td>Gray platelet syndrome</td>
</tr>
<tr>
<td>122</td>
<td>Other specified disorders of mitochondrial oxidative phosphorylation</td>
</tr>
<tr>
<td>123</td>
<td>Mitochondrial oxidative phosphorylation disorders due to mitochondrial DNA anomalies</td>
</tr>
<tr>
<td>124</td>
<td>Respiratory chain disorders caused by mutations of mtDNA</td>
</tr>
<tr>
<td>125</td>
<td>OXPHOS - [oxidative phosphorylation] diseases due to mtDNA anomalies</td>
</tr>
<tr>
<td>126</td>
<td>Proximal tubulopathy - diabetes mellitus - cerebellar ataxia</td>
</tr>
<tr>
<td>127</td>
<td>Large-scale single deletions of mitochondrial DNA</td>
</tr>
<tr>
<td>128</td>
<td>Duplications of mitochondrial DNA</td>
</tr>
<tr>
<td>129</td>
<td>Mitochondrial oxidative phosphorylation disorders due to nuclear DNA anomalies</td>
</tr>
<tr>
<td>130</td>
<td>Respiratory chain disorders caused by mutations of nuclear DNA</td>
</tr>
<tr>
<td>131</td>
<td>OXPHOS - [oxidative phosphorylation] diseases due to nDNA anomalies</td>
</tr>
<tr>
<td>132</td>
<td>GRACILE - [Growth delay - aminoaciduria - cholestasis - iron overload - lactic acidosis - early death] syndrome</td>
</tr>
<tr>
<td>133</td>
<td>Growth delay - aminoaciduria - cholestasis - iron overload - lactic acidosis - early death</td>
</tr>
<tr>
<td>134</td>
<td>Cardioencephalopathy with hyperammonaemia</td>
</tr>
<tr>
<td>135</td>
<td>Mitochondrial respiratory chain complex V deficiency</td>
</tr>
<tr>
<td>136</td>
<td>Mitochondrial encephalocardiomyopathy due to TMEM70 deficiency</td>
</tr>
<tr>
<td>137</td>
<td>ATP synthase deficiency caused by TMEM70 deficiency</td>
</tr>
<tr>
<td>138</td>
<td>F1Fo ATPase deficiency</td>
</tr>
<tr>
<td>139</td>
<td>ATP synthase deficiency, nuclear-encoded</td>
</tr>
<tr>
<td>140</td>
<td>Exercise intolerance with lactic acidosis</td>
</tr>
<tr>
<td>141</td>
<td>Isolated oxidative phosphorylation defects with variable phenotype, not elsewhere classified</td>
</tr>
<tr>
<td>142</td>
<td>Mitochondrial respiratory chain complex I structural subunit gene defect</td>
</tr>
<tr>
<td>143</td>
<td>Mitochondrial respiratory chain complex I assembly gene defect</td>
</tr>
<tr>
<td>144</td>
<td>Mitochondrial respiratory chain complex II structural subunit gene defect</td>
</tr>
<tr>
<td>145</td>
<td>Mitochondrial respiratory chain complex II assembly gene defect</td>
</tr>
<tr>
<td>146</td>
<td>Mitochondrial respiratory chain complex III structural subunit gene defect</td>
</tr>
<tr>
<td>147</td>
<td>Mitochondrial respiratory chain complex III assembly gene defect</td>
</tr>
<tr>
<td>148</td>
<td>Mitochondrial respiratory chain complex IV structural subunit gene defect</td>
</tr>
<tr>
<td>149</td>
<td>Mitochondrial respiratory chain complex IV assembly gene defect</td>
</tr>
<tr>
<td>150</td>
<td>ATP synthase structural subunit gene defect</td>
</tr>
<tr>
<td>151</td>
<td>Mitochondrial respiratory chain complex V structural subunit gene defect</td>
</tr>
<tr>
<td>152</td>
<td>ATP synthase assembly gene defect</td>
</tr>
<tr>
<td>153</td>
<td>Mitochondrial respiratory chain complex V assembly gene defect</td>
</tr>
<tr>
<td>154</td>
<td>Renal tubulopathy - encephalopathy - liver failure</td>
</tr>
<tr>
<td>155</td>
<td>Mitochondrial oxidative phosphorylation disorders with no known genetic basis</td>
</tr>
<tr>
<td>156</td>
<td>Respiratory chain deficiencies with no known genetic basis</td>
</tr>
<tr>
<td>157</td>
<td>OXPHOS - [oxidative phosphorylation] diseases due to unspecified DNA anomalies</td>
</tr>
<tr>
<td>158</td>
<td>Deafness - opticoacoustic nerve atrophy - dementia</td>
</tr>
<tr>
<td>159</td>
<td>Jensen syndrome</td>
</tr>
<tr>
<td>160</td>
<td>FASTKD2-related infantile mitochondrial encephalomyopathy</td>
</tr>
<tr>
<td>161</td>
<td>Succinic acidaemia</td>
</tr>
<tr>
<td>162</td>
<td>Zellweger-like syndrome without peroxisomal anomalies</td>
</tr>
<tr>
<td>163</td>
<td>Ahn-Lerman-Sagie syndrome</td>
</tr>
<tr>
<td>164</td>
<td>Isolated mitochondrial respiratory chain complex I deficiency</td>
</tr>
<tr>
<td>165</td>
<td>Nicotinamide-adenine-dinucleotide coenzyme Q reductase deficiency</td>
</tr>
<tr>
<td>166</td>
<td>Ubiquinone deficiency</td>
</tr>
<tr>
<td>167</td>
<td>NADH-CoQ - [Nicotinamide-adenine-dinucleotide coenzyme Q] reductase deficiency</td>
</tr>
<tr>
<td>168</td>
<td>Isolated mitochondrial respiratory chain complex II deficiency</td>
</tr>
<tr>
<td>169</td>
<td>Succinate coenzyme Q reductase deficiency</td>
</tr>
<tr>
<td>170</td>
<td>Succinate-CoQ reductase deficiency</td>
</tr>
<tr>
<td>171</td>
<td>Isolated mitochondrial respiratory chain complex III deficiency</td>
</tr>
<tr>
<td>172</td>
<td>Coenzyme Q cytochrome C reductase deficiency</td>
</tr>
<tr>
<td>173</td>
<td>Ubiquinone dehydrogenase deficiency</td>
</tr>
<tr>
<td>174</td>
<td>Isolated mitochondrial respiratory chain complex IV deficiency</td>
</tr>
<tr>
<td>175</td>
<td>Cytochrome C oxidase deficiency</td>
</tr>
<tr>
<td>176</td>
<td>Ataxia - leukodystrophy - tubulopathy, due to cytochrome C oxidase deficiency</td>
</tr>
<tr>
<td>177</td>
<td>Pancreatic insufficiency - anaemia - hyperostosis</td>
</tr>
<tr>
<td>178</td>
<td>Hereditary sensory and autonomic neuropathy type V</td>
</tr>
<tr>
<td>179</td>
<td>Congenital insensitivity to pain</td>
</tr>
<tr>
<td>180</td>
<td>HSAN5 - [Hereditary sensory and autonomic neuropathy type 5]</td>
</tr>
<tr>
<td>181</td>
<td>Disorders of multiple glycosylation or other pathways</td>
</tr>
<tr>
<td>182</td>
<td>Dolichol-phosphate-mannose synthase 1 deficiency</td>
</tr>
<tr>
<td>183</td>
<td>GDP-Man: Dol-P-mannosyltransferase deficiency</td>
</tr>
<tr>
<td>184</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1E</td>
</tr>
<tr>
<td>185</td>
<td>Congenital disorder of glycosylation type 1E</td>
</tr>
<tr>
<td>186</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1E</td>
</tr>
<tr>
<td>187</td>
<td>Mannose-P-dolichol utilisation defect 1</td>
</tr>
<tr>
<td>188</td>
<td>Lec35 deficiency</td>
</tr>
<tr>
<td>189</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1F</td>
</tr>
<tr>
<td>190</td>
<td>Congenital disorder of glycosylation type 1F</td>
</tr>
<tr>
<td>191</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1F</td>
</tr>
<tr>
<td>192</td>
<td>Beta-1,4-galactosyltransferase deficiency</td>
</tr>
<tr>
<td>193</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2D</td>
</tr>
<tr>
<td>194</td>
<td>Congenital disorder of glycosylation type 2D</td>
</tr>
<tr>
<td>195</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2D</td>
</tr>
<tr>
<td>196</td>
<td>CMP-sialic acid transporter deficiency</td>
</tr>
<tr>
<td>197</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2F</td>
</tr>
<tr>
<td>198</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2F</td>
</tr>
<tr>
<td>199</td>
<td>Congenital disorder of glycosylation type 2F</td>
</tr>
<tr>
<td>200</td>
<td>Leukocyte adhesion deficiency type 2</td>
</tr>
<tr>
<td>201</td>
<td>Rambam-Hasharon syndrome</td>
</tr>
<tr>
<td>202</td>
<td>GDP-fucose transporter deficiency</td>
</tr>
<tr>
<td>203</td>
<td>LAD-II - [Leukocyte adhesion deficiency type 2]</td>
</tr>
<tr>
<td>204</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2C</td>
</tr>
<tr>
<td>205</td>
<td>Dolichol kinase deficiency</td>
</tr>
<tr>
<td>206</td>
<td>Hypotonia or ichthyosis due to dolichol phosphate deficiency</td>
</tr>
<tr>
<td>207</td>
<td>Carbohydrate deficient glycoprotein syndrome type 1M</td>
</tr>
<tr>
<td>208</td>
<td>Congenital disorder of glycosylation type 1M</td>
</tr>
<tr>
<td>209</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 1M</td>
</tr>
<tr>
<td>210</td>
<td>Conserved oligomeric Golgi complex deficiencies</td>
</tr>
<tr>
<td>211</td>
<td>Component of conserved oligomeric Golgi complex 1 deficiency</td>
</tr>
<tr>
<td>212</td>
<td>CDG syndrome type 2G</td>
</tr>
<tr>
<td>213</td>
<td>Component of conserved oligomeric Golgi complex 4 deficiency</td>
</tr>
<tr>
<td>214</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2J</td>
</tr>
<tr>
<td>215</td>
<td>Congenital disorder of glycosylation type 2J</td>
</tr>
<tr>
<td>216</td>
<td>Component of conserved oligomeric Golgi complex 5 deficiency</td>
</tr>
<tr>
<td>217</td>
<td>Component of conserved oligomeric Golgi complex 7 deficiency</td>
</tr>
<tr>
<td>218</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2E</td>
</tr>
<tr>
<td>219</td>
<td>Congenital disorder of glycosylation type 2E</td>
</tr>
<tr>
<td>220</td>
<td>CDG - [Congenital disorder of glycosylation] syndrome type 2E</td>
</tr>
<tr>
<td>221</td>
<td>Component of conserved oligomeric Golgi complex 8 deficiency</td>
</tr>
<tr>
<td>222</td>
<td>Congenital disorder of glycosylation type 2h</td>
</tr>
<tr>
<td>223</td>
<td>Carbohydrate deficient glycoprotein syndrome type 2H</td>
</tr>
<tr>
<td>224</td>
<td>CDG - [[Congenital disorder of glycosylation] syndrome type 2H</td>
</tr>
<tr>
<td>225</td>
<td>V-ATPase deficiencies</td>
</tr>
<tr>
<td>226</td>
<td>Exotropia</td>
</tr>
<tr>
<td>227</td>
<td>Divergent concomitant strabismus</td>
</tr>
<tr>
<td>228</td>
<td>divergent squint</td>
</tr>
<tr>
<td>229</td>
<td>divergent strabismus</td>
</tr>
<tr>
<td>230</td>
<td>external strabismus</td>
</tr>
<tr>
<td>231</td>
<td>XT - [exotropia]</td>
</tr>
<tr>
<td>232</td>
<td>Monocular exotropia</td>
</tr>
<tr>
<td>233</td>
<td>Monocular exotropia with A pattern</td>
</tr>
<tr>
<td>234</td>
<td>Monocular exotropia with V pattern</td>
</tr>
<tr>
<td>235</td>
<td>Monocular exotropia with other noncomitancies</td>
</tr>
<tr>
<td>236</td>
<td>Alternating exotropia</td>
</tr>
<tr>
<td>237</td>
<td>Alternating exotropia with A pattern</td>
</tr>
<tr>
<td>238</td>
<td>Alternating exotropia with V pattern</td>
</tr>
<tr>
<td>239</td>
<td>Alternating exotropia with other noncomitancies</td>
</tr>
<tr>
<td>240</td>
<td>Esotropia</td>
</tr>
<tr>
<td>241</td>
<td>convergent concomitant strabismus</td>
</tr>
<tr>
<td>242</td>
<td>convergent squint</td>
</tr>
<tr>
<td>243</td>
<td>convergent strabismus</td>
</tr>
<tr>
<td>244</td>
<td>cross-eye</td>
</tr>
<tr>
<td>245</td>
<td>Monocular esotropia</td>
</tr>
<tr>
<td>246</td>
<td>Monocular esotropia with A pattern</td>
</tr>
<tr>
<td>247</td>
<td>Monocular esotropia with V pattern</td>
</tr>
<tr>
<td>248</td>
<td>Monocular esotropia with other noncomitancies</td>
</tr>
<tr>
<td>249</td>
<td>Alternating esotropia</td>
</tr>
<tr>
<td>250</td>
<td>Alternating esotropia with A pattern</td>
</tr>
<tr>
<td>251</td>
<td>Alternating esotropia with V pattern</td>
</tr>
<tr>
<td>252</td>
<td>Alternating esotropia with other noncomitancies</td>
</tr>
<tr>
<td>253</td>
<td>Accommodative esotropia</td>
</tr>
<tr>
<td>254</td>
<td>accommodative squint</td>
</tr>
<tr>
<td>255</td>
<td>accommodative strabismus</td>
</tr>
<tr>
<td>256</td>
<td>Monofixation syndrome</td>
</tr>
<tr>
<td>257</td>
<td>microtropia</td>
</tr>
<tr>
<td>258</td>
<td>microstrabismus</td>
</tr>
<tr>
<td>259</td>
<td>Pityriasis rubra pilaris</td>
</tr>
<tr>
<td>260</td>
<td>PRP - [pityriasis rubra pilaris]</td>
</tr>
<tr>
<td>261</td>
<td>Devergie's disease</td>
</tr>
<tr>
<td>262</td>
<td>Pityriasis rubra pilaris, adult</td>
</tr>
<tr>
<td>263</td>
<td>Pityriasis rubra pilaris type I, classical adult</td>
</tr>
<tr>
<td>264</td>
<td>Pityriasis rubra pilaris type II, atypical adult</td>
</tr>
<tr>
<td>265</td>
<td>Pityriasis rubra pilaris, juvenile</td>
</tr>
<tr>
<td>266</td>
<td>Pityriasis rubra pilaris type III, classical juvenile</td>
</tr>
<tr>
<td>267</td>
<td>Pityriasis rubra pilaris type IV, circumscribed juvenile</td>
</tr>
<tr>
<td>268</td>
<td>Pityriasis rubra pilaris type V, atypical juvenile</td>
</tr>
<tr>
<td>269</td>
<td>HIV-associated pityriasis rubra pilaris</td>
</tr>
<tr>
<td>270</td>
<td>Other specified hereditary thrombophilia</td>
</tr>
<tr>
<td>271</td>
<td>Hereditary thrombophilia due to activated protein C resistance</td>
</tr>
<tr>
<td>272</td>
<td>Hereditary thrombophilia due to activated protein C resistance, factor V Leiden</td>
</tr>
<tr>
<td>273</td>
<td>Hereditary thrombophilia due to other inherited factor V defects</td>
</tr>
<tr>
<td>274</td>
<td>Hereditary thrombophilia due to factor V Hong Kong defects</td>
</tr>
<tr>
<td>275</td>
<td>Hereditary thrombophilia due to factor V Cambridge defects</td>
</tr>
<tr>
<td>276</td>
<td>Hereditary thrombophilia due to congenital antithrombin deficiency</td>
</tr>
<tr>
<td>277</td>
<td>hereditary thrombophilia due to congenital antithrombin 3 deficiency</td>
</tr>
<tr>
<td>278</td>
<td>hereditary thrombophilia due to congenital antithrombin III deficiency</td>
</tr>
<tr>
<td>279</td>
<td>antithrombin deficiency NOS</td>
</tr>
<tr>
<td>280</td>
<td>Hereditary thrombophilia due to congenital protein S deficiency</td>
</tr>
<tr>
<td>281</td>
<td>Hereditary thrombophilia due to congenital protein C deficiency</td>
</tr>
<tr>
<td>282</td>
<td>Hereditary thrombophilia due to thrombomodulin deficiency</td>
</tr>
<tr>
<td>283</td>
<td>Hereditary thrombophilia due to prothrombin gene</td>
</tr>
<tr>
<td>284</td>
<td>hereditary thrombophilia due to prothrombin G20210A mutation</td>
</tr>
<tr>
<td>285</td>
<td>hereditary thrombophilia due to prothrombin gene mutation</td>
</tr>
<tr>
<td>286</td>
<td>Hereditary thrombophilia due to other prothrombotic prothrombin gene mutations</td>
</tr>
<tr>
<td>287</td>
<td>Prothrombin gene mutation</td>
</tr>
<tr>
<td>288</td>
<td>Hereditary thrombophilia due to congenital histidine-rich (poly-L) glycoprotein deficiency</td>
</tr>
<tr>
<td>289</td>
<td>Hereditary thrombophilia due to congenital HRG - [histidine-rich (poly-L) glycoprotein] deficiency</td>
</tr>
<tr>
<td>290</td>
<td>Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency</td>
</tr>
<tr>
<td>291</td>
<td>Heparin co-factor II deficiency</td>
</tr>
<tr>
<td>292</td>
<td>Choledochal cyst</td>
</tr>
<tr>
<td>293</td>
<td>Congenital bile duct dilatation</td>
</tr>
<tr>
<td>294</td>
<td>Type 1-C Fusiform dilatation of the entire extrahepatic bile duct</td>
</tr>
<tr>
<td>295</td>
<td>Type II Simple diverticula of the common bile duct</td>
</tr>
<tr>
<td>296</td>
<td>Type III Cyst or choledochocele distal intramural dilation of the common bile duct within the duodenal wall</td>
</tr>
<tr>
<td>297</td>
<td>Type IV A Combined intrahepatic and extrahepatic duct dilatation</td>
</tr>
<tr>
<td>298</td>
<td>Type IV B Multiple extrahepatic bile duct dilatations</td>
</tr>
<tr>
<td>299</td>
<td>Type V Caroli disease multiple intrahepatic bile duct dilatations</td>
</tr>
<tr>
<td>300</td>
<td>Acute leukaemias of ambiguous lineage</td>
</tr>
<tr>
<td>301</td>
<td>Mixed phenotype acute leukaemia with t(9;22) (q34;q11.2); BCR-ABL1</td>
</tr>
<tr>
<td>302</td>
<td>Mixed phenotype acute leukaemia with t(v;11q23); MLL rearranged</td>
</tr>
<tr>
<td>303</td>
<td>Mixed phenotype acute leukaemias, B and myeloid, not elsewhere classified</td>
</tr>
<tr>
<td>304</td>
<td>Mixed phenotype acute leukaemias, T and myeloid, not elsewhere classified</td>
</tr>
<tr>
<td>305</td>
<td>Other B-lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities</td>
</tr>
<tr>
<td>306</td>
<td>B lymphoblastic leukaemia or lymphoma with t(v;11q23); MLL rearranged</td>
</tr>
<tr>
<td>307</td>
<td>B lymphoblastic leukaemia or lymphoma with t(12;21) (p13;q22); TEL/AML1 (ETV6-RUNX1)</td>
</tr>
<tr>
<td>308</td>
<td>B lymphoblastic leukaemia or lymphoma with hyperdiploidy</td>
</tr>
<tr>
<td>309</td>
<td>B lymphoblastic leukaemia or lymphoma with hypodiploidy</td>
</tr>
<tr>
<td>310</td>
<td>Hypodiploid ALL</td>
</tr>
<tr>
<td>311</td>
<td>B lymphoblastic leukaemia or lymphoma with t(5;14)(q31;q32)(IL3-IGH)</td>
</tr>
<tr>
<td>312</td>
<td>B lymphoblastic leukaemia or lymphoma with t(1;19)(Q23;P13.3); (E2A-PBX1; TCF3/PBX1)</td>
</tr>
<tr>
<td>1</td>
<td>Turner syndrome</td>
</tr>
<tr>
<td>2</td>
<td>Monosomy X</td>
</tr>
<tr>
<td>3</td>
<td>Ullrich-Turner syndrome</td>
</tr>
<tr>
<td>4</td>
<td>X0 syndrome</td>
</tr>
<tr>
<td>5</td>
<td>Langerhans cell histiocytosis, unspecified</td>
</tr>
<tr>
<td>6</td>
<td>Langerhans cell histiocytosis</td>
</tr>
<tr>
<td>7</td>
<td>Langerhans-cell histiocytosis NOS</td>
</tr>
<tr>
<td>8</td>
<td>Histiocytosis X</td>
</tr>
<tr>
<td>9</td>
<td>Other specified conditions with disorders of intellectual development as a relevant clinical feature</td>
</tr>
<tr>
<td>10</td>
<td>Non-syndromic conditions with disorders of intellectual development as a relevant clinical feature</td>
</tr>
<tr>
<td>11</td>
<td>Autosomal dominant non-syndromic intellectual deficit</td>
</tr>
<tr>
<td>12</td>
<td>Autosomal recessive non-syndromic intellectual deficit</td>
</tr>
<tr>
<td>13</td>
<td>X-linked non-syndromic intellectual deficit</td>
</tr>
<tr>
<td>14</td>
<td>Syndromic conditions with disorders of intellectual development as a relevant clinical feature</td>
</tr>
<tr>
<td>15</td>
<td>ATR-X-related syndromes</td>
</tr>
<tr>
<td>16</td>
<td>X-linked intellectual deficit - hypotonic face</td>
</tr>
<tr>
<td>17</td>
<td>Carpenter-Waziri syndrome</td>
</tr>
<tr>
<td>18</td>
<td>Chudley-Lowry-Hoar syndrome</td>
</tr>
<tr>
<td>19</td>
<td>Holmes-Gang syndrome</td>
</tr>
<tr>
<td>20</td>
<td>Juberg-Marsidi syndrome</td>
</tr>
<tr>
<td>21</td>
<td>Renier-Gabreels-Jasper syndrome</td>
</tr>
<tr>
<td>22</td>
<td>Smith-Fineman-Myers syndrome</td>
</tr>
<tr>
<td>23</td>
<td>Axonal hereditary motor and sensory neuropathy, X-linked</td>
</tr>
<tr>
<td>24</td>
<td>X-linked Charcot-Marie-Tooth disease type 2</td>
</tr>
<tr>
<td>25</td>
<td>X-linked Charcot-Marie-Tooth disease type 3</td>
</tr>
<tr>
<td>26</td>
<td>X-linked Charcot-Marie-Tooth disease type 4</td>
</tr>
<tr>
<td>27</td>
<td>X-linked Charcot-Marie-Tooth disease type 5</td>
</tr>
<tr>
<td>28</td>
<td>Cohen syndrome</td>
</tr>
<tr>
<td>29</td>
<td>FRAXE intellectual deficit</td>
</tr>
<tr>
<td>30</td>
<td>Hereditary hyperekplexia</td>
</tr>
<tr>
<td>31</td>
<td>Congenital stiff man syndrome</td>
</tr>
<tr>
<td>32</td>
<td>Hereditary hyperexplexia</td>
</tr>
<tr>
<td>33</td>
<td>Familial Startle disease</td>
</tr>
<tr>
<td>34</td>
<td>Stiff baby syndrome</td>
</tr>
<tr>
<td>35</td>
<td>Hyperekplexia</td>
</tr>
<tr>
<td>36</td>
<td>Kok disease</td>
</tr>
<tr>
<td>37</td>
<td>Infantile bilateral striatal necrosis</td>
</tr>
<tr>
<td>38</td>
<td>Familial infantile bilateral striatal necrosis</td>
</tr>
<tr>
<td>39</td>
<td>Sporadic infantile bilateral striatal necrosis</td>
</tr>
<tr>
<td>40</td>
<td>Infantile onset spinocerebellar ataxia</td>
</tr>
<tr>
<td>41</td>
<td>Ophthalmoplegia - hypotonia - ataxia - hypoacusis - athetosis</td>
</tr>
<tr>
<td>42</td>
<td>IOSCA - [infantile onset spinocerebellar ataxia]</td>
</tr>
<tr>
<td>43</td>
<td>Ohaha - [Ophthalmoplegia - hypotonia - ataxia - hypoacusis - athetosis] syndrome</td>
</tr>
<tr>
<td>44</td>
<td>L1 syndrome</td>
</tr>
<tr>
<td>45</td>
<td>Laurence-Moon syndrome</td>
</tr>
<tr>
<td>46</td>
<td>PEHO syndrome</td>
</tr>
<tr>
<td>47</td>
<td>Progressive encephalopathy with oedema, hypsarrhythmia and optic atrophy</td>
</tr>
<tr>
<td>48</td>
<td>Renpenning syndrome</td>
</tr>
<tr>
<td>49</td>
<td>X-linked intellectual deficit, Renpenning type</td>
</tr>
<tr>
<td>50</td>
<td>Hamel cerebro-palato-cardiac syndrome</td>
</tr>
<tr>
<td>51</td>
<td>X-linked intellectual deficit, Fichera type</td>
</tr>
<tr>
<td>52</td>
<td>X-linked intellectual deficit, Golabi-Ito-Hall type</td>
</tr>
<tr>
<td>53</td>
<td>X-linked intellectual deficit, Porteous type</td>
</tr>
<tr>
<td>54</td>
<td>X-linked intellectual deficit, Sutherland-Haan type</td>
</tr>
<tr>
<td>55</td>
<td>X-linked intellectual deficit, Najm type</td>
</tr>
<tr>
<td>56</td>
<td>X-linked intellectual disability, Najm type</td>
</tr>
<tr>
<td>57</td>
<td>X-linked spastic paraplegia type 2</td>
</tr>
<tr>
<td>58</td>
<td>Demyelinating hereditary motor and sensory neuropathy, X-linked</td>
</tr>
<tr>
<td>59</td>
<td>X-linked Charcot-Marie-Tooth disease 1</td>
</tr>
<tr>
<td>60</td>
<td>CMT X - [X-linked Charcot-Marie-Tooth disease 1]</td>
</tr>
<tr>
<td>61</td>
<td>Cerebellar atrophy - ataxia - seizures</td>
</tr>
<tr>
<td>62</td>
<td>Autosomal recessive ataxia due to ubiquinone deficiency</td>
</tr>
<tr>
<td>63</td>
<td>Autosomal recessive ataxia due to coenzyme Q10 deficiency</td>
</tr>
<tr>
<td>64</td>
<td>Atypical Rett syndrome</td>
</tr>
<tr>
<td>65</td>
<td>De Sanctis-Cacchione syndrome</td>
</tr>
<tr>
<td>66</td>
<td>SYNGAP1 syndrome</td>
</tr>
<tr>
<td>67</td>
<td>synaptic Ras-GTPase-activating protein 1 syndrome</td>
</tr>
<tr>
<td>68</td>
<td>Alopecia – psychomotor epilepsy – periodontal pyorrhoea – intellectual disability syndrome</td>
</tr>
<tr>
<td>69</td>
<td>Shokeir syndrome</td>
</tr>
<tr>
<td>70</td>
<td>Karyotype 47,XXX</td>
</tr>
<tr>
<td>71</td>
<td>triple X female</td>
</tr>
<tr>
<td>72</td>
<td>trisomy x syndrome</td>
</tr>
<tr>
<td>73</td>
<td>xxx syndrome</td>
</tr>
<tr>
<td>74</td>
<td>female triple x syndrome</td>
</tr>
<tr>
<td>75</td>
<td>triple x syndrome</td>
</tr>
<tr>
<td>76</td>
<td>triple x</td>
</tr>
<tr>
<td>77</td>
<td>Hereditary factor X deficiency</td>
</tr>
<tr>
<td>78</td>
<td>Congenital Stuart factor deficiency</td>
</tr>
<tr>
<td>79</td>
<td>Stuart-Prower factor deficiency</td>
</tr>
<tr>
<td>80</td>
<td>Deficiency of factor X</td>
</tr>
<tr>
<td>81</td>
<td>congenital factor x deficiency</td>
</tr>
<tr>
<td>82</td>
<td>Stuart deficiency disease</td>
</tr>
<tr>
<td>83</td>
<td>Stuart Prower deficiency</td>
</tr>
<tr>
<td>84</td>
<td>Stuart-Prower disease</td>
</tr>
<tr>
<td>85</td>
<td>Other specified number anomalies of chromosome X</td>
</tr>
<tr>
<td>86</td>
<td>Female with more than three X chromosomes</td>
</tr>
<tr>
<td>87</td>
<td>abnormal female chromosomes, with more than three x chromosomes</td>
</tr>
<tr>
<td>88</td>
<td>Tetrasomy X</td>
</tr>
<tr>
<td>89</td>
<td>48 xxxx syndrome</td>
</tr>
<tr>
<td>90</td>
<td>female 48 xxxx syndrome</td>
</tr>
<tr>
<td>91</td>
<td>female xxxx syndrome</td>
</tr>
<tr>
<td>92</td>
<td>four x syndrome</td>
</tr>
<tr>
<td>93</td>
<td>xxxx syndrome</td>
</tr>
<tr>
<td>94</td>
<td>Carr-Barr-Plunkett syndrome</td>
</tr>
<tr>
<td>95</td>
<td>Pentasomy X</td>
</tr>
<tr>
<td>96</td>
<td>female xxxxx syndrome</td>
</tr>
<tr>
<td>97</td>
<td>five x syndrome</td>
</tr>
<tr>
<td>98</td>
<td>penta x syndrome</td>
</tr>
<tr>
<td>99</td>
<td>pentasomy x syndrome</td>
</tr>
<tr>
<td>100</td>
<td>xxxxx syndrome</td>
</tr>
<tr>
<td>101</td>
<td>Fragile X chromosome</td>
</tr>
<tr>
<td>102</td>
<td>Fragile X syndrome</td>
</tr>
<tr>
<td>103</td>
<td>FRAXA - fragile x syndrome</td>
</tr>
<tr>
<td>104</td>
<td>Martin-Bell syndrome</td>
</tr>
<tr>
<td>105</td>
<td>marker X syndrome</td>
</tr>
<tr>
<td>106</td>
<td>Murray Valley encephalitis</td>
</tr>
<tr>
<td>107</td>
<td>encephalitis australia</td>
</tr>
<tr>
<td>108</td>
<td>murray river encephalitis</td>
</tr>
<tr>
<td>109</td>
<td>Australian encephalitis</td>
</tr>
<tr>
<td>110</td>
<td>Australian arboencephalitis</td>
</tr>
<tr>
<td>111</td>
<td>Australian X disease</td>
</tr>
<tr>
<td>112</td>
<td>Australian x disorder</td>
</tr>
<tr>
<td>113</td>
<td>MVE - [murray valley encephalitis]</td>
</tr>
<tr>
<td>114</td>
<td>X-linked ichthyosis</td>
</tr>
<tr>
<td>115</td>
<td>Sex-linked ichthyosis</td>
</tr>
<tr>
<td>116</td>
<td>X-linked ichthyosis with steryl-sulfatase deficiency</td>
</tr>
<tr>
<td>117</td>
<td>X-linked recessive ichthyosis</td>
</tr>
<tr>
<td>118</td>
<td>Coronary microvascular disease</td>
</tr>
<tr>
<td>119</td>
<td>nonobstructive coronary heart disease</td>
</tr>
<tr>
<td>120</td>
<td>Microvascular angina</td>
</tr>
<tr>
<td>121</td>
<td>cardiac syndrome X</td>
</tr>
<tr>
<td>122</td>
<td>CMD -[coronary microvascular disease]</td>
</tr>
<tr>
<td>123</td>
<td>Erythropoietic porphyrias</td>
</tr>
<tr>
<td>124</td>
<td>Erythropoietic protoporphyria</td>
</tr>
<tr>
<td>125</td>
<td>Ferrochelatase deficiency</td>
</tr>
<tr>
<td>126</td>
<td>Heme synthetase deficiency</td>
</tr>
<tr>
<td>127</td>
<td>EPP - [erythropoietic protoporphyria]</td>
</tr>
<tr>
<td>128</td>
<td>Erythropoietic protoporphyria due to ferrochelatase deficiency</td>
</tr>
<tr>
<td>129</td>
<td>EPP due to ferrochelatase deficiency</td>
</tr>
<tr>
<td>130</td>
<td>FECH-deficient EPP</td>
</tr>
<tr>
<td>131</td>
<td>Erythropoietic protoporphyria due to gain of function of erythroid-specific aminolevulinic acid synthase 2</td>
</tr>
<tr>
<td>132</td>
<td>EPP due to gain of function of erythroid-specific aminolevulinic acid synthase 3</td>
</tr>
<tr>
<td>133</td>
<td>X-linked dominant protoporphyria</td>
</tr>
<tr>
<td>134</td>
<td>X-linked protoporphyria</td>
</tr>
<tr>
<td>135</td>
<td>XLDPP - [X-linked dominant protoporphyria]</td>
</tr>
<tr>
<td>136</td>
<td>XLP - [X-linked protoporphyria]</td>
</tr>
<tr>
<td>137</td>
<td>Congenital erythropoietic porphyria</td>
</tr>
<tr>
<td>138</td>
<td>Günther disease</td>
</tr>
<tr>
<td>139</td>
<td>Hereditary erythropoietic porphyria</td>
</tr>
<tr>
<td>140</td>
<td>Uroporphyrinogen III synthase deficiency</td>
</tr>
<tr>
<td>141</td>
<td>Syndromic ichthyosis</td>
</tr>
<tr>
<td>142</td>
<td>X-linked ichthyosis syndromes</td>
</tr>
<tr>
<td>143</td>
<td>Ichthyosis follicularis – atrichia – photophobia</td>
</tr>
<tr>
<td>144</td>
<td>IFAP - [Ichthyosis follicularis – atrichia – photophobia] syndrome</td>
</tr>
<tr>
<td>145</td>
<td>ichthyosis follicularis - alopecia - photophobia</td>
</tr>
<tr>
<td>146</td>
<td>Autosomal ichthyosis syndromes with hair abnormalities</td>
</tr>
<tr>
<td>147</td>
<td>Netherton syndrome</td>
</tr>
<tr>
<td>148</td>
<td>Comèl-Netherton syndrome</td>
</tr>
<tr>
<td>149</td>
<td>Netherton disease</td>
</tr>
<tr>
<td>150</td>
<td>Trichorrhexis invaginata</td>
</tr>
<tr>
<td>151</td>
<td>Bamboo hair</td>
</tr>
<tr>
<td>152</td>
<td>Ichthyosis – hypotrichosis syndrome</td>
</tr>
<tr>
<td>153</td>
<td>PIBIDS syndrome</td>
</tr>
<tr>
<td>154</td>
<td>Trichothiodystrophy - sun sensitivity</td>
</tr>
<tr>
<td>155</td>
<td>Trichothiodystrophy type F</td>
</tr>
<tr>
<td>156</td>
<td>SIBIDS syndrome</td>
</tr>
<tr>
<td>157</td>
<td>Trichothiodystrophy - osteosclerosis</td>
</tr>
<tr>
<td>158</td>
<td>Autosomal ichthyosis syndromes with neurological manifestations</td>
</tr>
<tr>
<td>159</td>
<td>Autosomal ichthyoses with fatal disease course</td>
</tr>
<tr>
<td>160</td>
<td>Cerebral dysgenesis – neuropathy – ichthyosis – keratoderma syndrome</td>
</tr>
<tr>
<td>161</td>
<td>CEDNIK - [Cerebral dysgenesis – neuropathy – ichthyosis – keratoderma syndrome] syndrome</td>
</tr>
<tr>
<td>162</td>
<td>Other autosomal ichthyosis syndromes</td>
</tr>
<tr>
<td>163</td>
<td>Ichthyosis - oral and digital anomalies</td>
</tr>
<tr>
<td>164</td>
<td>Clayton Smith-Donnai syndrome</td>
</tr>
<tr>
<td>165</td>
<td>Keratitis – ichthyosis – deafness syndrome</td>
</tr>
<tr>
<td>166</td>
<td>Keratitis - ichthyosis - deafness/Hystrix-like ichthyosis - deafness</td>
</tr>
<tr>
<td>167</td>
<td>Senter syndrome</td>
</tr>
<tr>
<td>168</td>
<td>Hystrix-like ichthyosis - deafness</td>
</tr>
<tr>
<td>169</td>
<td>KID - [Keratitis – ichthyosis – deafness syndrome] syndrome</td>
</tr>
<tr>
<td>170</td>
<td>KID/HID - [Keratitis - ichthyosis - deafness/Hystrix-like ichthyosis - deafness] syndrome</td>
</tr>
<tr>
<td>171</td>
<td>Ichthyosis – prematurity syndrome</td>
</tr>
<tr>
<td>172</td>
<td>Ichthyosis as component of other specified genetic syndrome</td>
</tr>
<tr>
<td>173</td>
<td>Number anomalies of chromosome X, unspecified</td>
</tr>
<tr>
<td>174</td>
<td>Number anomalies of chromosome X</td>
</tr>
<tr>
<td>175</td>
<td>Langerhans cell histiocytosis involving the skin</td>
</tr>
<tr>
<td>176</td>
<td>Class I histiocytosis involving the skin</td>
</tr>
<tr>
<td>177</td>
<td>Histiocytosis X involving the skin</td>
</tr>
<tr>
<td>178</td>
<td>Fabry disease</td>
</tr>
<tr>
<td>179</td>
<td>Anderson-Fabry disease</td>
</tr>
<tr>
<td>180</td>
<td>Ceramide trihexosidase deficiency</td>
</tr>
<tr>
<td>181</td>
<td>Alpha-galactosidase A deficiency</td>
</tr>
<tr>
<td>182</td>
<td>Fabry disease X-linked</td>
</tr>
<tr>
<td>183</td>
<td>X-linked dominant Fabry disease</td>
</tr>
<tr>
<td>184</td>
<td>X-linked recessive Fabry disease</td>
</tr>
<tr>
<td>185</td>
<td>Angiokeratoma corporis diffusum</td>
</tr>
<tr>
<td>186</td>
<td>Other specified syndromic genetic deafness</td>
</tr>
<tr>
<td>187</td>
<td>Albinism - black lock - cell migration disorder of the neurocytes of the gut - sensorineural deafness</td>
</tr>
<tr>
<td>188</td>
<td>ABCD - [Albinism - black lock - cell migration disorder of the neurocytes of the gut - sensorineural deafness] syndrome</td>
</tr>
<tr>
<td>189</td>
<td>Albinism-deafness syndrome</td>
</tr>
<tr>
<td>190</td>
<td>Alström syndrome</td>
</tr>
<tr>
<td>191</td>
<td>Ataxia - deafness - intellectual disability syndrome</td>
</tr>
<tr>
<td>192</td>
<td>Athabaskan brainstem dysgenesis syndrome</td>
</tr>
<tr>
<td>193</td>
<td>Atherosclerosis - deafness - diabetes - epilepsy - nephropathy</td>
</tr>
<tr>
<td>194</td>
<td>Bilateral microtia - deafness - cleft palate</td>
</tr>
<tr>
<td>195</td>
<td>Bosley-Salih-Alorainy syndrome</td>
</tr>
<tr>
<td>196</td>
<td>Brown-Vialetto-van Laere syndrome</td>
</tr>
<tr>
<td>197</td>
<td>Sensorineural hearing loss - pontobulbar palsy</td>
</tr>
<tr>
<td>198</td>
<td>Cataract - ataxia - deafness</td>
</tr>
<tr>
<td>199</td>
<td>Cataract - deafness - hypogonadism</td>
</tr>
<tr>
<td>200</td>
<td>Caudal appendage - deafness</td>
</tr>
<tr>
<td>201</td>
<td>Central nervous system calcification - deafness - tubular acidosis - anaemia</td>
</tr>
<tr>
<td>202</td>
<td>Choanal atresia - deafness - cardiac defects - dysmorphism</td>
</tr>
<tr>
<td>203</td>
<td>Choroideremia - deafness - obesity</td>
</tr>
<tr>
<td>204</td>
<td>Cleft lip or palate - deafness - sacral lipoma</td>
</tr>
<tr>
<td>205</td>
<td>Cochleosaccular degeneration - cataract</td>
</tr>
<tr>
<td>206</td>
<td>Corneal anaesthesia - deafness - intellectual disability</td>
</tr>
<tr>
<td>207</td>
<td>Corneal dystrophy - perceptive deafness</td>
</tr>
<tr>
<td>208</td>
<td>Craniofacial-deafness-hand syndrome</td>
</tr>
<tr>
<td>209</td>
<td>Deaf blind hypopigmentation syndrome, Yemenite type</td>
</tr>
<tr>
<td>210</td>
<td>Deafness - craniofacial syndrome</td>
</tr>
<tr>
<td>211</td>
<td>Deafness - epiphyseal dysplasia - short stature</td>
</tr>
<tr>
<td>212</td>
<td>Deafness - genital anomalies - metacarpal and metatarsal synostosis</td>
</tr>
<tr>
<td>213</td>
<td>Deafness - hypogonadism</td>
</tr>
<tr>
<td>214</td>
<td>Deafness - intellectual deficit syndrome, Martin-Probst type</td>
</tr>
<tr>
<td>215</td>
<td>Martin-Probst syndrome</td>
</tr>
<tr>
<td>216</td>
<td>Deafness - oligodontia</td>
</tr>
<tr>
<td>217</td>
<td>Deafness - peripheral neuropathy - arterial disease</td>
</tr>
<tr>
<td>218</td>
<td>Deafness - skeletal dysplasia - lip granuloma</td>
</tr>
<tr>
<td>219</td>
<td>Fountain syndrome</td>
</tr>
<tr>
<td>220</td>
<td>Deafness - small bowel diverticulosis - neuropathy</td>
</tr>
<tr>
<td>221</td>
<td>Deafness - vitiligo - achalasia</td>
</tr>
<tr>
<td>222</td>
<td>Deafness-infertility syndrome</td>
</tr>
<tr>
<td>223</td>
<td>15q15.3 deletion syndrome</td>
</tr>
<tr>
<td>224</td>
<td>Monosomy 15q15.3</td>
</tr>
<tr>
<td>225</td>
<td>15q15.3 deletion</td>
</tr>
<tr>
<td>226</td>
<td>Dentinogenesis imperfecta - short stature - hearing loss - intellectual deficit</td>
</tr>
<tr>
<td>227</td>
<td>Developmental delay - deafness, Hildebrand type</td>
</tr>
<tr>
<td>228</td>
<td>Developmental malformations - deafness - dystonia</td>
</tr>
<tr>
<td>229</td>
<td>Ermine phenotype</td>
</tr>
<tr>
<td>230</td>
<td>Gingival fibromatosis - progressive deafness</td>
</tr>
<tr>
<td>231</td>
<td>Hearing loss - familial salivary gland insensitivity to aldosterone</td>
</tr>
<tr>
<td>232</td>
<td>Hirschsprung disease - deafness - polydactyly</td>
</tr>
<tr>
<td>233</td>
<td>Hypospadias-hypertelorism-coloboma and deafness</td>
</tr>
<tr>
<td>234</td>
<td>Iris dysplasia - hypertelorism - deafness</td>
</tr>
<tr>
<td>235</td>
<td>Lethal ataxia with deafness and optic atrophy</td>
</tr>
<tr>
<td>236</td>
<td>Arts syndrome</td>
</tr>
<tr>
<td>237</td>
<td>Lipodystrophy - intellectual deficit - deafness</td>
</tr>
<tr>
<td>238</td>
<td>Lowe-Kohn-Cohen syndrome</td>
</tr>
<tr>
<td>239</td>
<td>Deafness - nephritis - anorectal malformation</td>
</tr>
<tr>
<td>240</td>
<td>Maternally inherited diabetes and deafness</td>
</tr>
<tr>
<td>241</td>
<td>Mitochondrial diabetes</td>
</tr>
<tr>
<td>242</td>
<td>Maxillonasal dysplasia</td>
</tr>
<tr>
<td>243</td>
<td>Intellectual disability – enteropathy – deafness – neuropathy – ichthyosis – keratoderma syndrome</td>
</tr>
<tr>
<td>244</td>
<td>Mental retardation – enteropathy – deafness – neuropathy – ichthyosis – keratoderma syndrome</td>
</tr>
<tr>
<td>245</td>
<td>MEDNIK - [Mental retardation – enteropathy – deafness – neuropathy – ichthyosis – keratoderma] syndrome</td>
</tr>
<tr>
<td>246</td>
<td>Microcephaly - deafness - intellectual disability</td>
</tr>
<tr>
<td>247</td>
<td>Microdontia - microtia type I - deafness</td>
</tr>
<tr>
<td>248</td>
<td>Deafness with labyrinthine aplasia, microtia, and microdontia</td>
</tr>
<tr>
<td>249</td>
<td>Mitral regurgitation - deafness - skeletal anomalies</td>
</tr>
<tr>
<td>250</td>
<td>Myoclonus - cerebellar ataxia - deafness</td>
</tr>
<tr>
<td>251</td>
<td>N syndrome</td>
</tr>
<tr>
<td>252</td>
<td>Nephropathy - deafness - hyperparathyroidism</td>
</tr>
<tr>
<td>253</td>
<td>Nephrosis - deafness - urinary tract - digital malformations</td>
</tr>
<tr>
<td>254</td>
<td>Neutropaenia - monocytopaenia - deafness</td>
</tr>
<tr>
<td>255</td>
<td>Olivopontocerebellar atrophy - deafness</td>
</tr>
<tr>
<td>256</td>
<td>Osteochondrodysplatic nanism - deafness - retinitis pigmentosa</td>
</tr>
<tr>
<td>257</td>
<td>Peripheral neuropathy, Fiskerstrand type</td>
</tr>
<tr>
<td>258</td>
<td>Perrault syndrome</td>
</tr>
<tr>
<td>259</td>
<td>Phocomelia - ectrodactyly - deafness - sinus arrhythmia</td>
</tr>
<tr>
<td>260</td>
<td>Hypertrophic cardiomyopathy due to Kearns–Sayre syndrome</td>
</tr>
<tr>
<td>261</td>
<td>progressive sensorineural hearing loss - hypertrophic cardiomyopathy</td>
</tr>
<tr>
<td>262</td>
<td>Hypertrophic cardiomyopathy associated with progressive sensorineural hearing loss</td>
</tr>
<tr>
<td>263</td>
<td>Retinitis pigmentosa - intellectual disability - deafness - hypogenitalism</td>
</tr>
<tr>
<td>264</td>
<td>Richards-Rundle syndrome</td>
</tr>
<tr>
<td>265</td>
<td>Schizophrenia - intellectual disability - deafness - retinitis</td>
</tr>
<tr>
<td>266</td>
<td>Sensorineural hearing loss - early greying - essential tremor</td>
</tr>
<tr>
<td>267</td>
<td>SeSAME syndrome</td>
</tr>
<tr>
<td>268</td>
<td>EAST syndrome</td>
</tr>
<tr>
<td>269</td>
<td>Short stature - deafness - neutrophil dysfunction - dysmorphism</td>
</tr>
<tr>
<td>270</td>
<td>Spastic paraparesis - deafness</td>
</tr>
<tr>
<td>271</td>
<td>Split hand - split foot - deafness</td>
</tr>
<tr>
<td>272</td>
<td>Thickened earlobes - conductive deafness</td>
</tr>
<tr>
<td>273</td>
<td>Deafness - optic atrophy syndrome</td>
</tr>
<tr>
<td>274</td>
<td>Optic atrophy, deafness, ophthalmoplegia, myopathy</td>
</tr>
<tr>
<td>275</td>
<td>Autosomal dominant optic atrophy and congenital deafness</td>
</tr>
<tr>
<td>276</td>
<td>Ocular albinism - late-onset sensorineural deafness</td>
</tr>
<tr>
<td>277</td>
<td>Spastic paraplegia - nephritis - deafness</td>
</tr>
<tr>
<td>278</td>
<td>Metaphyseal dysostosis - intellectual deficit - conductive deafness</td>
</tr>
<tr>
<td>279</td>
<td>Knuckle pads – leukonychia – sensorineural deafness</td>
</tr>
<tr>
<td>280</td>
<td>Bart-Pumphrey syndrome (MIM 149200)</td>
</tr>
<tr>
<td>281</td>
<td>Alport syndrome</td>
</tr>
<tr>
<td>282</td>
<td>Alport syndrome, autosomal dominant</td>
</tr>
<tr>
<td>283</td>
<td>Alport syndrome, autosomal recessive</td>
</tr>
<tr>
<td>284</td>
<td>Alport syndrome, X-linked</td>
</tr>
<tr>
<td>285</td>
<td>Alport syndrome, X-linked diffuse leiomyomatosis</td>
</tr>
<tr>
<td>286</td>
<td>Cardioauditory syndrome</td>
</tr>
<tr>
<td>287</td>
<td>Karyotype 45, X</td>
</tr>
<tr>
<td>288</td>
<td>Other specified immunodeficiencies with predominantly antibody defects</td>
</tr>
<tr>
<td>289</td>
<td>Common variable immunodeficiency</td>
</tr>
<tr>
<td>290</td>
<td>B-cell activating factor receptor deficiency</td>
</tr>
<tr>
<td>291</td>
<td>BAFF - [ B-cell activating factor] receptor deficiency</td>
</tr>
<tr>
<td>292</td>
<td>Cluster of differentiation 19 deficiency</td>
</tr>
<tr>
<td>293</td>
<td>CD19- [cluster of differentiation 19] deficiency</td>
</tr>
<tr>
<td>294</td>
<td>Cluster of differentiation 20 deficiency</td>
</tr>
<tr>
<td>295</td>
<td>CD20 - [cluster of differentiation 20] deficiency</td>
</tr>
<tr>
<td>296</td>
<td>Cluster of differentiation 81 deficiency</td>
</tr>
<tr>
<td>297</td>
<td>CD81 - [cluster of differentiation 81] deficiency</td>
</tr>
<tr>
<td>298</td>
<td>Inducible costimulator deficiency</td>
</tr>
<tr>
<td>299</td>
<td>ICOS - [inducible costimulator] deficiency</td>
</tr>
<tr>
<td>300</td>
<td>Transmembrane activator and calcium-modulating cyclophilin ligand interactor deficiency</td>
</tr>
<tr>
<td>301</td>
<td>TACI - [transmembrane activator and calcium-modulating cyclophilin ligand interactor] deficiency</td>
</tr>
<tr>
<td>302</td>
<td>Certain specified immunodeficiencies with predominantly antibody defects</td>
</tr>
<tr>
<td>303</td>
<td>Low birth weight - dwarfism - dysgammaglobulinaemia</td>
</tr>
<tr>
<td>304</td>
<td>Christian-Rosenberg syndrome</td>
</tr>
<tr>
<td>305</td>
<td>Osteopetrosis - hypogammaglobulinaemia</td>
</tr>
<tr>
<td>306</td>
<td>Autosomal recessive osteoclast-poor osteopetrosis with hypogammaglobulinaemia</td>
</tr>
<tr>
<td>307</td>
<td>Autosomal recessive osteopetrosis type 7</td>
</tr>
<tr>
<td>308</td>
<td>Microcephaly - hypogammaglobulinaemia - abnormal immunity</td>
</tr>
<tr>
<td>309</td>
<td>Say-Barber-Miller syndrome</td>
</tr>
<tr>
<td>310</td>
<td>Kappa light chain deficiency</td>
</tr>
<tr>
<td>311</td>
<td>Kappa light chain disease</td>
</tr>
<tr>
<td>312</td>
<td>Kappa light chain immunodeficiency</td>
</tr>
<tr>
<td>313</td>
<td>X-linked immunoneurologic disorder</td>
</tr>
<tr>
<td>314</td>
<td>Special screening examination for neoplasm of breast</td>
</tr>
<tr>
<td>315</td>
<td>breast neoplasm screening</td>
</tr>
<tr>
<td>316</td>
<td>breast x-ray for neoplasm</td>
</tr>
<tr>
<td>317</td>
<td>mammogram for breast neoplasm</td>
</tr>
<tr>
<td>318</td>
<td>mammography for breast neoplasm</td>
</tr>
<tr>
<td>319</td>
<td>Genetically-determined cutis laxa</td>
</tr>
<tr>
<td>320</td>
<td>Autosomal recessive cutis laxa</td>
</tr>
<tr>
<td>321</td>
<td>Autosomal recessive cutis laxa, type 1</td>
</tr>
<tr>
<td>322</td>
<td>Autosomal recessive cutis laxa with severe systemic involvement</td>
</tr>
<tr>
<td>323</td>
<td>Autosomal recessive cutis laxa, pulmonary emphysema type</td>
</tr>
<tr>
<td>324</td>
<td>ARCL-1 - [Autosomal recessive cutis laxa, type 1] (MIM 219100)</td>
</tr>
<tr>
<td>325</td>
<td>Autosomal recessive cutis laxa, type 2A</td>
</tr>
<tr>
<td>326</td>
<td>Autosomal recessive cutis laxa, Debré type</td>
</tr>
<tr>
<td>327</td>
<td>ARCL-2A - [Autosomal recessive cutis laxa, type 2A] (MIM 219200)</td>
</tr>
<tr>
<td>328</td>
<td>Autosomal recessive cutis laxa, type 2B</td>
</tr>
<tr>
<td>329</td>
<td>Cutis laxa with bone dystrophy</td>
</tr>
<tr>
<td>330</td>
<td>Cutis laxa with joint laxity and developmental delay</td>
</tr>
<tr>
<td>331</td>
<td>ARCL-2B - [Autosomal recessive cutis laxa, type 2B] (MIM 612940)</td>
</tr>
<tr>
<td>332</td>
<td>Autosomal recessive cutis laxa, type 3</td>
</tr>
<tr>
<td>333</td>
<td>Cutis laxa - corneal clouding - intellectual deficit</td>
</tr>
<tr>
<td>334</td>
<td>Progeroid syndrome, De Barsy type</td>
</tr>
<tr>
<td>335</td>
<td>De Barsy syndrome</td>
</tr>
<tr>
<td>336</td>
<td>ARCL-3 - [Autosomal recessive cutis laxa, type 3] (MIM 219150)</td>
</tr>
<tr>
<td>337</td>
<td>Autosomal dominant cutis laxa</td>
</tr>
<tr>
<td>338</td>
<td>ADCL - [Autosomal dominant cutis laxa] (MIM 123700)</td>
</tr>
<tr>
<td>339</td>
<td>Syndromic cutis laxa</td>
</tr>
<tr>
<td>340</td>
<td>Cutis laxa with severe pulmonary, gastrointestinal and urinary anomalies</td>
</tr>
<tr>
<td>341</td>
<td>Urban-Rifkin-Davis syndrome</td>
</tr>
<tr>
<td>342</td>
<td>URDS - [Urban-Rifkin-Davis syndrome] (MIM 613177)</td>
</tr>
<tr>
<td>343</td>
<td>X-linked cutis laxa</td>
</tr>
<tr>
<td>344</td>
<td>Ehlers-Danlos syndrome type IX</td>
</tr>
<tr>
<td>345</td>
<td>Occipital horn syndrome</td>
</tr>
<tr>
<td>346</td>
<td>OHS - [occipital horn syndrome]</td>
</tr>
<tr>
<td>347</td>
<td>Cutis laxa - Marfanoid syndrome</td>
</tr>
<tr>
<td>348</td>
<td>Macrocephaly – alopecia – cutis laxa – scoliosis syndrome</td>
</tr>
<tr>
<td>349</td>
<td>MACS syndrome (MIM 613075)</td>
</tr>
<tr>
<td>350</td>
<td>MACS - [Macrocephaly – alopecia – cutis laxa – scoliosis syndrome]</td>
</tr>
<tr>
<td>351</td>
<td>SCARF syndrome</td>
</tr>
<tr>
<td>352</td>
<td>Skeletal abnormalities – Cutis laxa – craniostenosis – Ambiguous genitalia – psychomotor Retardation and Facial abnormalities</td>
</tr>
<tr>
<td>353</td>
<td>Disorders of creatine metabolism</td>
</tr>
<tr>
<td>354</td>
<td>X-linked creatine transporter deficiency</td>
</tr>
<tr>
<td>355</td>
<td>X-linked intellectual deficit - seizures - short stature - midface hypoplasia</td>
</tr>
<tr>
<td>356</td>
<td>X-linked creatine deficiency syndrome</td>
</tr>
<tr>
<td>357</td>
<td>Guanidinoacetate methyltransferase deficiency</td>
</tr>
<tr>
<td>358</td>
<td>Cerebral creatine deficiency</td>
</tr>
<tr>
<td>359</td>
<td>GAMT - [guanidinoacetate methyltransferase] deficiency</td>
</tr>
<tr>
<td>360</td>
<td>Arginine glycine amidinotransferase deficiency</td>
</tr>
<tr>
<td>361</td>
<td>AGAT - [Arginine glycine amidinotransferase] deficiency</td>
</tr>
<tr>
<td>362</td>
<td>Localised spinal muscular atrophy</td>
</tr>
<tr>
<td>363</td>
<td>localised SMA - [spinal muscular atrophy]</td>
</tr>
<tr>
<td>364</td>
<td>Distal form of spinal muscular atrophy</td>
</tr>
<tr>
<td>365</td>
<td>Distal hereditary motor neuropathy</td>
</tr>
<tr>
<td>366</td>
<td>Distal HMN - [hereditary motor neuropathy]</td>
</tr>
<tr>
<td>367</td>
<td>Distal hereditary motor neuropathy, autosomal dominant</td>
</tr>
<tr>
<td>368</td>
<td>Distal spinal muscular atrophy, autosomal dominant</td>
</tr>
<tr>
<td>369</td>
<td>Distal HMN - [hereditary motor neuropathy] autosomal dominant</td>
</tr>
<tr>
<td>370</td>
<td>Autosomal dominant benign distal spinal muscular atrophy</td>
</tr>
<tr>
<td>371</td>
<td>Autosomal dominant congenital benign spinal muscular atrophy</td>
</tr>
<tr>
<td>372</td>
<td>Distal hereditary motor neuropathy type 1</td>
</tr>
<tr>
<td>373</td>
<td>DHMN1 - [Distal hereditary motor neuropathy type 1]</td>
</tr>
<tr>
<td>374</td>
<td>Distal hereditary motor neuropathy type 2</td>
</tr>
<tr>
<td>375</td>
<td>DHMN2 - [Distal hereditary motor neuropathy type 2]</td>
</tr>
<tr>
<td>376</td>
<td>Distal hereditary motor neuropathy type 5</td>
</tr>
<tr>
<td>377</td>
<td>DHMN5 - [Distal hereditary motor neuropathy type 5]</td>
</tr>
<tr>
<td>378</td>
<td>Distal hereditary motor neuropathy type 7</td>
</tr>
<tr>
<td>379</td>
<td>DHMN7 - [Distal hereditary motor neuropathy type 7]</td>
</tr>
<tr>
<td>380</td>
<td>Distal hereditary motor neuropathy, autosomal recessive</td>
</tr>
<tr>
<td>381</td>
<td>Distal spinal muscular atrophy, autosomal recessive</td>
</tr>
<tr>
<td>382</td>
<td>Distal HMN - [hereditary motor neuropathy] autosomal recessive</td>
</tr>
<tr>
<td>383</td>
<td>Autosomal recessive lower motor neuron disease with childhood onset</td>
</tr>
<tr>
<td>384</td>
<td>Autosomal recessive distal spinal muscular atrophy type 4</td>
</tr>
<tr>
<td>385</td>
<td>dSMA4 - [Autosomal recessive distal spinal muscular atrophy type 4]</td>
</tr>
<tr>
<td>386</td>
<td>Distal hereditary motor neuropathy type 3 and type 4</td>
</tr>
<tr>
<td>387</td>
<td>dSMA3 and dSMA4 - [Distal hereditary motor neuropathy type 3 and type 4]</td>
</tr>
<tr>
<td>388</td>
<td>Distal hereditary motor neuropathy, Jerash type</td>
</tr>
<tr>
<td>389</td>
<td>Distal spinal muscular atrophy type 2</td>
</tr>
<tr>
<td>390</td>
<td>Spinal muscular atrophy with respiratory distress</td>
</tr>
<tr>
<td>391</td>
<td>Distal hereditary motor neuronopathy type 6</td>
</tr>
<tr>
<td>392</td>
<td>Severe infantile axonal neuropathy with respiratory failure</td>
</tr>
<tr>
<td>393</td>
<td>SMARD - [Spinal muscular atrophy with respiratory distress]</td>
</tr>
<tr>
<td>394</td>
<td>Distal hereditary motor neuropathy, X-linked</td>
</tr>
<tr>
<td>395</td>
<td>Distal HMN, X-linked</td>
</tr>
<tr>
<td>396</td>
<td>Distal spinal muscular atrophy, X-linked</td>
</tr>
<tr>
<td>397</td>
<td>Scapuloperoneal form of spinal muscular atrophy</td>
</tr>
<tr>
<td>398</td>
<td>SPSMA - [Scapuloperoneal form of spinal muscular atrophy]</td>
</tr>
<tr>
<td>399</td>
<td>Facioscapulohumeral form of spinal muscular atrophy</td>
</tr>
<tr>
<td>400</td>
<td>FSHSMA - [Facioscapulohumeral form of spinal muscular atrophy]</td>
</tr>
<tr>
<td>401</td>
<td>Facioscapulohumeral form of spinal muscular atrophy with sensory loss</td>
</tr>
<tr>
<td>402</td>
<td>Davidenkow Disease</td>
</tr>
<tr>
<td>403</td>
<td>Scapulohumeral form of spinal muscular atrophy</td>
</tr>
<tr>
<td>404</td>
<td>Oculopharyngeal form of spinal muscular atrophy</td>
</tr>
<tr>
<td>405</td>
<td>Ryukyu type of spinal muscular atrophy</td>
</tr>
<tr>
<td>406</td>
<td>Bulbospinal muscular atrophy</td>
</tr>
<tr>
<td>407</td>
<td>Kennedy Disease</td>
</tr>
<tr>
<td>408</td>
<td>Spinal and bulbar muscular atrophy</td>
</tr>
<tr>
<td>409</td>
<td>Hypophosphataemic rickets</td>
</tr>
<tr>
<td>410</td>
<td>HPDR - [hypophosphatemic vitamin d-resistant rickets]</td>
</tr>
<tr>
<td>411</td>
<td>VDRR - [vitamin-D-resistant rickets]</td>
</tr>
<tr>
<td>412</td>
<td>Vitamin-D-resistant rickets</td>
</tr>
<tr>
<td>413</td>
<td>Autosomal dominant hypophosphataemic rickets</td>
</tr>
<tr>
<td>414</td>
<td>ADHR - [autosomal dominant hypophosphataemic rickets]</td>
</tr>
<tr>
<td>415</td>
<td>Autosomal dominant hypophosphataemia</td>
</tr>
<tr>
<td>416</td>
<td>Autosomal recessive hypophosphataemic rickets</td>
</tr>
<tr>
<td>417</td>
<td>Autosomal recessive hypophosphataemia</td>
</tr>
<tr>
<td>418</td>
<td>ARHR - [autosomal recessive hypophosphataemic rickets]</td>
</tr>
<tr>
<td>419</td>
<td>Hypophosphataemic rickets with hypercalciuria</td>
</tr>
<tr>
<td>420</td>
<td>X-linked hypophosphataemia</td>
</tr>
<tr>
<td>421</td>
<td>X-linked hypophosphatemic rickets</td>
</tr>
<tr>
<td>422</td>
<td>familial x-linked hypophosphatemic vitamin d refractory rickets</td>
</tr>
<tr>
<td>423</td>
<td>x-linked vitamin d-resistant rickets</td>
</tr>
<tr>
<td>424</td>
<td>X-linked hypophosphatemic osteomalacia</td>
</tr>
<tr>
<td>425</td>
<td>Familial hypophosphataemic rickets</td>
</tr>
<tr>
<td>426</td>
<td>familial vitamin d-resistant rickets</td>
</tr>
<tr>
<td>427</td>
<td>Other specified hereditary ataxia</td>
</tr>
<tr>
<td>428</td>
<td>Autosomal recessive ataxia</td>
</tr>
<tr>
<td>429</td>
<td>Autosomal recessive spastic ataxia of Charlevoix-Saguenay</td>
</tr>
<tr>
<td>430</td>
<td>Ataxia due to Marinesco-Sjögren syndrome</td>
</tr>
<tr>
<td>431</td>
<td>Autosomal recessive ataxias due to POLG mutations</td>
</tr>
<tr>
<td>432</td>
<td>Ataxia due to POLG mutations MIRAS</td>
</tr>
<tr>
<td>433</td>
<td>Autosomal recessive ataxias due to POLG mutations SANDO</td>
</tr>
<tr>
<td>434</td>
<td>Other autosomal recessive ataxia</td>
</tr>
<tr>
<td>435</td>
<td>Harding ataxia</td>
</tr>
<tr>
<td>436</td>
<td>Early onset cerebellar ataxia with retained tendon reflex</td>
</tr>
<tr>
<td>437</td>
<td>X-linked ataxia</td>
</tr>
<tr>
<td>438</td>
<td>X-linked intellectual deficit - ataxia - apraxia</td>
</tr>
<tr>
<td>439</td>
<td>X-linked intellectual deficit, South African type</td>
</tr>
<tr>
<td>440</td>
<td>X-linked intellectual deficit - craniofacial dysmorphism - epilepsy - ophthalmoplegia - cerebellar atrophy</td>
</tr>
<tr>
<td>441</td>
<td>Christianson syndrome</td>
</tr>
<tr>
<td>442</td>
<td>X-linked spinocerebellar ataxia type 1</td>
</tr>
<tr>
<td>443</td>
<td>X-linked spinocerebellar ataxia type 3</td>
</tr>
<tr>
<td>444</td>
<td>X-linked spinocerebellar ataxia type 4</td>
</tr>
<tr>
<td>445</td>
<td>Fragile X–associated tremor or ataxia syndrome</td>
</tr>
<tr>
<td>446</td>
<td>Autosomal dominant ataxia</td>
</tr>
<tr>
<td>447</td>
<td>Autosomal dominant cerebellar ataxia</td>
</tr>
<tr>
<td>448</td>
<td>Autosomal dominant spastic ataxia</td>
</tr>
<tr>
<td>449</td>
<td>Dominant ataxia with unknown mutation</td>
</tr>
<tr>
<td>450</td>
<td>Progressive Ataxia palatal tremor syndrome-GFAP gene mutation</td>
</tr>
<tr>
<td>451</td>
<td>Other specified congenital hypothyroidism</td>
</tr>
<tr>
<td>452</td>
<td>Permanent congenital hypothyroidism</td>
</tr>
<tr>
<td>453</td>
<td>Syndromic permanent congenital hypothyroidism</td>
</tr>
<tr>
<td>454</td>
<td>Young-Simpson syndrome</td>
</tr>
<tr>
<td>455</td>
<td>Hypothyroidism - dysmorphism - postaxial polydactyly - intellectual deficit</td>
</tr>
<tr>
<td>456</td>
<td>Bamforth-Lazarus syndrome</td>
</tr>
<tr>
<td>457</td>
<td>Hypothyroidism - cleft palate</td>
</tr>
<tr>
<td>458</td>
<td>Bamforth syndrome</td>
</tr>
<tr>
<td>459</td>
<td>Athydroidal hypothyroidism – spiky hair – cleft palate</td>
</tr>
<tr>
<td>460</td>
<td>Bamforth-Lazarus syndrome due to Forkhead box protein E1 [FOXE1] mutations</td>
</tr>
<tr>
<td>461</td>
<td>Kocher-Debre-Semelaigne syndrome</td>
</tr>
<tr>
<td>462</td>
<td>Muscular pseudohypertrophy - hypothyroidism</td>
</tr>
<tr>
<td>463</td>
<td>Choreoathetosis - hypothyroidism - neonatal respiratory distress</td>
</tr>
<tr>
<td>464</td>
<td>Choreoathetosis - hypothyroidism - neonatal respiratory distress due to NKX 2-1 mutations</td>
</tr>
<tr>
<td>465</td>
<td>Allan-Herndon-Dudley syndrome</td>
</tr>
<tr>
<td>466</td>
<td>X-linked intellectual deficit - hypotonia</td>
</tr>
<tr>
<td>467</td>
<td>AHDS - [Allan-Herndon-Dudley syndrome]</td>
</tr>
<tr>
<td>468</td>
<td>Congenital hypothyroidism with chromosome abnormalities</td>
</tr>
<tr>
<td>469</td>
<td>Benign chorea - hypothyroidism</td>
</tr>
<tr>
<td>470</td>
<td>Congenital idiopathic hypothyroidism</td>
</tr>
<tr>
<td>471</td>
<td>Other specified types of Ehlers-Danlos syndrome</td>
</tr>
<tr>
<td>472</td>
<td>Ehlers-Danlos syndrome, hypermobile type</td>
</tr>
<tr>
<td>473</td>
<td>Familial ligamentous laxity</td>
</tr>
<tr>
<td>474</td>
<td>Benign joint hypermobility syndrome</td>
</tr>
<tr>
<td>475</td>
<td>Ehlers-Danlos syndrome type 3</td>
</tr>
<tr>
<td>476</td>
<td>Ehlers-Danlos syndrome, vascular type</td>
</tr>
<tr>
<td>477</td>
<td>Sack-Barabas syndrome</td>
</tr>
<tr>
<td>478</td>
<td>Ehlers-Danlos syndrome type 4</td>
</tr>
<tr>
<td>479</td>
<td>Ehlers-Danlos syndrome, rare variants</td>
</tr>
<tr>
<td>480</td>
<td>Ehlers-Danlos syndrome, X-linked</td>
</tr>
<tr>
<td>481</td>
<td>Ehlers-Danlos syndrome type 5</td>
</tr>
<tr>
<td>482</td>
<td>Ehlers-Danlos syndrome, kyphoscoliotic type</td>
</tr>
<tr>
<td>483</td>
<td>Ehlers-Danlos syndrome type 6</td>
</tr>
<tr>
<td>484</td>
<td>Ehlers-Danlos syndrome type 6A</td>
</tr>
<tr>
<td>485</td>
<td>Ehlers-Danlos syndrome type 6B</td>
</tr>
<tr>
<td>486</td>
<td>Brittle cornea syndrome</td>
</tr>
<tr>
<td>487</td>
<td>Ehlers-Danlos syndrome, arthrochalasic type</td>
</tr>
<tr>
<td>488</td>
<td>Ehlers-Danlos syndrome type 7</td>
</tr>
<tr>
<td>489</td>
<td>Ehlers-Danlos syndrome type 7A</td>
</tr>
<tr>
<td>490</td>
<td>Ehlers-Danlos syndrome type 7B</td>
</tr>
<tr>
<td>491</td>
<td>Ehlers-Danlos syndrome, dermatosparaxis type</td>
</tr>
<tr>
<td>492</td>
<td>Ehlers-Danlos syndrome type 7C</td>
</tr>
<tr>
<td>493</td>
<td>Ehlers-Danlos syndrome, progeroid type</td>
</tr>
<tr>
<td>494</td>
<td>Galactosyltransferase I deficiency</td>
</tr>
<tr>
<td>495</td>
<td>Xylosylprotein 4-beta-galactosyltransferase deficiency</td>
</tr>
<tr>
<td>496</td>
<td>Defective biosynthesis of proteodermatan sulphate</td>
</tr>
<tr>
<td>497</td>
<td>Ehlers-Danlos syndrome, cardiac valvular type</td>
</tr>
<tr>
<td>498</td>
<td>Ehlers-Danlos syndrome, classic-like type</td>
</tr>
<tr>
<td>499</td>
<td>Ehlers-Danlos syndrome with periventricular heterotopia</td>
</tr>
<tr>
<td>500</td>
<td>Ehlers-Danlos-osteogenesis imperfecta syndrome</td>
</tr>
<tr>
<td>501</td>
<td>Ehlers-Danlos syndrome, spondylocheirodysplastic type</td>
</tr>
<tr>
<td>502</td>
<td>Ehlers-Danlos syndrome due to tenascin-X deficiency</td>
</tr>
<tr>
<td>503</td>
<td>Ehlers-Danlos syndrome, periodontitis type</td>
</tr>
<tr>
<td>504</td>
<td>Ehlers-Danlos syndrome type 8</td>
</tr>
<tr>
<td>505</td>
<td>Ehlers-Danlos syndrome, vascular-like type</td>
</tr>
<tr>
<td>506</td>
<td>Ehlers-Danlos syndrome, dysfibronectinaemic type</td>
</tr>
<tr>
<td>507</td>
<td>Ehlers-Danlos syndrome with platelet dysfunction from fibronectin abnormality</td>
</tr>
<tr>
<td>508</td>
<td>Ehlers-Danlos syndrome, fibronectin-deficient</td>
</tr>
<tr>
<td>509</td>
<td>Ehlers-Danlos syndrome type 10</td>
</tr>
<tr>
<td>510</td>
<td>Radiological examination</td>
</tr>
<tr>
<td>511</td>
<td>Routine chest X-ray</td>
</tr>
<tr>
<td>512</td>
<td>Nephrogenic diabetes insipidus</td>
</tr>
<tr>
<td>513</td>
<td>renal diabetes insipidus</td>
</tr>
<tr>
<td>514</td>
<td>familial nephrogenic diabetes</td>
</tr>
<tr>
<td>515</td>
<td>antidiuretic-hormone-resistant diabetes insipidus</td>
</tr>
<tr>
<td>516</td>
<td>adiuretin-resistant diabetes insipidus</td>
</tr>
<tr>
<td>517</td>
<td>NDI - [nephrogenic diabetes insipidus]</td>
</tr>
<tr>
<td>518</td>
<td>diabetes tenuifluus</td>
</tr>
<tr>
<td>519</td>
<td>ADH - [antidiuretic-hormone] resistant diabetes insipidus</td>
</tr>
<tr>
<td>520</td>
<td>congenital nephrogenic diabetes insipidus</td>
</tr>
<tr>
<td>521</td>
<td>hereditary nephrogenic diabetes insipidus</td>
</tr>
<tr>
<td>522</td>
<td>familial nephrogenic diabetes insipidus</td>
</tr>
<tr>
<td>523</td>
<td>primary nephrogenic diabetes insipidus</td>
</tr>
<tr>
<td>524</td>
<td>Nephrogenic diabetes insipidus - intracranial calcification</td>
</tr>
<tr>
<td>525</td>
<td>Nephrogenic Diabetes Insipidus associated with familial or genetic disorders elsewhere classified</td>
</tr>
<tr>
<td>526</td>
<td>AQP2 mutation</td>
</tr>
<tr>
<td>527</td>
<td>X-linked AVPR2 mutation</td>
</tr>
<tr>
<td>528</td>
<td>Acquired nephrogenic diabetes insipidus due to causes classified elsewhere</td>
</tr>
<tr>
<td>529</td>
<td>Vasopressin-resistant hyposthenuria</td>
</tr>
<tr>
<td>530</td>
<td>vasopressin-resistant diabetes insipidus</td>
</tr>
<tr>
<td>531</td>
<td>Vasopressin-unresponsiveness hyposthenuria</td>
</tr>
<tr>
<td>532</td>
<td>Dementia due to other specified diseases classified elsewhere</td>
</tr>
<tr>
<td>533</td>
<td>Dementia due to certain specified central nervous system degenerative diseases</td>
</tr>
<tr>
<td>534</td>
<td>Dementia due to corticobasal degeneration</td>
</tr>
<tr>
<td>535</td>
<td>Dementia due to progressive supranuclear palsy</td>
</tr>
<tr>
<td>536</td>
<td>Dementia due to neurofilament inclusion body disease</td>
</tr>
<tr>
<td>537</td>
<td>Dementia due to progressive subcortical gliosis</td>
</tr>
<tr>
<td>538</td>
<td>Dementia due to multiple system atrophy</td>
</tr>
<tr>
<td>539</td>
<td>Dementia due to spinocerebellar ataxia</td>
</tr>
<tr>
<td>540</td>
<td>Dementia due to neurodegeneration with brain iron accumulation</td>
</tr>
<tr>
<td>541</td>
<td>Dementia due to leukodystrophy</td>
</tr>
<tr>
<td>542</td>
<td>Dementia due to Parkinsonism-dementia complex of Guam</td>
</tr>
<tr>
<td>543</td>
<td>Dementia due to certain specified infectious diseases</td>
</tr>
<tr>
<td>544</td>
<td>Dementia due to neurosyphilis</td>
</tr>
<tr>
<td>545</td>
<td>syphilitic dementia paralytica</td>
</tr>
<tr>
<td>546</td>
<td>Dementia due to herpes encephalitis</td>
</tr>
<tr>
<td>547</td>
<td>Dementia due to trypanosomiasis</td>
</tr>
<tr>
<td>548</td>
<td>Dementia due to neurocysticercosis</td>
</tr>
<tr>
<td>549</td>
<td>Dementia due to Lyme disease</td>
</tr>
<tr>
<td>550</td>
<td>Dementia due to Whipple disease</td>
</tr>
<tr>
<td>551</td>
<td>Dementia due to progressive multifocal leukoencephalopathy</td>
</tr>
<tr>
<td>552</td>
<td>Certain specified primary degenerative dementias</td>
</tr>
<tr>
<td>553</td>
<td>Neurofibrillary tangle dementia</td>
</tr>
<tr>
<td>554</td>
<td>Familial multiple system tauopathy</td>
</tr>
<tr>
<td>555</td>
<td>Argyrophilic grain disease</td>
</tr>
<tr>
<td>556</td>
<td>Dementia due to certain specified disorders of the central nervous system</td>
</tr>
<tr>
<td>557</td>
<td>Dementia due to acute demyelinating encephalomyelitis</td>
</tr>
<tr>
<td>558</td>
<td>Dementia due to subacute sclerosing panencephalitis</td>
</tr>
<tr>
<td>559</td>
<td>Dementia due to Hashimoto encephalopathy</td>
</tr>
<tr>
<td>560</td>
<td>Dementia due to paraneoplastic encephalitis</td>
</tr>
<tr>
<td>561</td>
<td>Dementia due to autoimmune encephalitis</td>
</tr>
<tr>
<td>562</td>
<td>Dementia due to primary central nervous system neoplasm</td>
</tr>
<tr>
<td>563</td>
<td>Dementia due to metastatic brain tumour</td>
</tr>
<tr>
<td>564</td>
<td>Dementia due to epilepsy</td>
</tr>
<tr>
<td>565</td>
<td>Dementia due to metabolic disorders involving the brain</td>
</tr>
<tr>
<td>566</td>
<td>Dementia due to chronic subdural haematoma</td>
</tr>
<tr>
<td>567</td>
<td>Dementia due to obstructive hydrocephalus</td>
</tr>
<tr>
<td>568</td>
<td>Dementia due to nutritional deficiency</td>
</tr>
<tr>
<td>569</td>
<td>Dementia due to vitamin B12 deficiency</td>
</tr>
<tr>
<td>570</td>
<td>Dementia due to vitamin E deficiency</td>
</tr>
<tr>
<td>571</td>
<td>Dementia due to iron deficiency</td>
</tr>
<tr>
<td>572</td>
<td>Dementia due to other nutritional deficiency</td>
</tr>
<tr>
<td>573</td>
<td>Dementia due to metabolic abnormalities</td>
</tr>
<tr>
<td>574</td>
<td>Dementia due to hypercalcaemia</td>
</tr>
<tr>
<td>575</td>
<td>Dementia due to acquired hypothyroidism</td>
</tr>
<tr>
<td>576</td>
<td>Dementia due to Wilson disease</td>
</tr>
<tr>
<td>577</td>
<td>Dementia due to dialysis</td>
</tr>
<tr>
<td>578</td>
<td>Dementia due to hepatic failure</td>
</tr>
<tr>
<td>579</td>
<td>Dementia due to renal failure</td>
</tr>
<tr>
<td>580</td>
<td>Dementia due to chromosomal anomalies</td>
</tr>
<tr>
<td>581</td>
<td>Dementia due to Fragile X Syndrome</td>
</tr>
<tr>
<td>582</td>
<td>Dementia due to rheumatological diseases</td>
</tr>
<tr>
<td>583</td>
<td>Dementia due to polyarteritis nodosa</td>
</tr>
<tr>
<td>584</td>
<td>Dementia due to systemic lupus erythematosus</td>
</tr>
<tr>
<td>585</td>
<td>Dementia due to Behcet disease</td>
</tr>
<tr>
<td>586</td>
<td>Dementia due to certain specified cause</td>
</tr>
<tr>
<td>587</td>
<td>Uniparental disomies of maternal origin</td>
</tr>
<tr>
<td>588</td>
<td>Maternal uniparental disomy of chromosome 1</td>
</tr>
<tr>
<td>589</td>
<td>Maternal uniparental disomy of chromosome 2</td>
</tr>
<tr>
<td>590</td>
<td>Maternal uniparental disomy of chromosome 4</td>
</tr>
<tr>
<td>591</td>
<td>Maternal uniparental disomy of chromosome 6</td>
</tr>
<tr>
<td>592</td>
<td>Maternal uniparental disomy of chromosome 7</td>
</tr>
<tr>
<td>593</td>
<td>Maternal uniparental disomy of chromosome 9</td>
</tr>
<tr>
<td>594</td>
<td>Maternal uniparental disomy of chromosome 11</td>
</tr>
<tr>
<td>595</td>
<td>Maternal uniparental disomy of chromosome 13</td>
</tr>
<tr>
<td>596</td>
<td>Maternal uniparental disomy of chromosome 14</td>
</tr>
<tr>
<td>597</td>
<td>Maternal uniparental disomy of chromosome 15</td>
</tr>
<tr>
<td>598</td>
<td>Maternal uniparental disomy of chromosome 16</td>
</tr>
<tr>
<td>599</td>
<td>Maternal uniparental disomy of chromosome 20</td>
</tr>
<tr>
<td>600</td>
<td>Maternal uniparental disomy of chromosome 21</td>
</tr>
<tr>
<td>601</td>
<td>Maternal uniparental disomy of chromosome 22</td>
</tr>
<tr>
<td>602</td>
<td>Maternal uniparental disomy of chromosome X</td>
</tr>
<tr>
<td>603</td>
<td>Harmful effects of drugs, medicaments or biological substances, not elsewhere classified</td>
</tr>
<tr>
<td>604</td>
<td>drugs, medicaments or biological substances, toxicity not elsewhere classified</td>
</tr>
<tr>
<td>605</td>
<td>adverse drug effects</td>
</tr>
<tr>
<td>606</td>
<td>drug reaction NOS</td>
</tr>
<tr>
<td>607</td>
<td>drug allergy NOS</td>
</tr>
<tr>
<td>608</td>
<td>drug toxicity NOS</td>
</tr>
<tr>
<td>609</td>
<td>drug ingestion NOS</td>
</tr>
<tr>
<td>610</td>
<td>toxic effects of drugs NOS</td>
</tr>
<tr>
<td>611</td>
<td>acute drug intoxication</td>
</tr>
<tr>
<td>612</td>
<td>toxic use of drugs</td>
</tr>
<tr>
<td>613</td>
<td>intake of a toxic substance</td>
</tr>
<tr>
<td>614</td>
<td>Harmful effects of opioids or related analgesics</td>
</tr>
<tr>
<td>615</td>
<td>Harmful effects of opium</td>
</tr>
<tr>
<td>616</td>
<td>Harmful effects of morphine</td>
</tr>
<tr>
<td>617</td>
<td>Harmful effects of oxycodone</td>
</tr>
<tr>
<td>618</td>
<td>oxycodone toxicity</td>
</tr>
<tr>
<td>619</td>
<td>Harmful effects of codeine</td>
</tr>
<tr>
<td>620</td>
<td>Harmful effects of heroin</td>
</tr>
<tr>
<td>621</td>
<td>poisoning by diacetylmorphine</td>
</tr>
<tr>
<td>622</td>
<td>poisoning by heroin</td>
</tr>
<tr>
<td>623</td>
<td>poisoning by heroin NOS</td>
</tr>
<tr>
<td>624</td>
<td>acute heroin intoxication</td>
</tr>
<tr>
<td>625</td>
<td>acute heroin toxicity</td>
</tr>
<tr>
<td>626</td>
<td>toxic effects of heroin</td>
</tr>
<tr>
<td>627</td>
<td>Harmful effects of methadone</td>
</tr>
<tr>
<td>628</td>
<td>poisoning by methadone</td>
</tr>
<tr>
<td>629</td>
<td>poisoning by methadone NOS</td>
</tr>
<tr>
<td>630</td>
<td>methadone toxicity</td>
</tr>
<tr>
<td>631</td>
<td>Harmful effects of pethidine</td>
</tr>
<tr>
<td>632</td>
<td>pethidine poisoning</td>
</tr>
<tr>
<td>633</td>
<td>Harmful effects of fentanyl</td>
</tr>
<tr>
<td>634</td>
<td>fentanyl poisoning</td>
</tr>
<tr>
<td>635</td>
<td>fentanyl toxicity</td>
</tr>
<tr>
<td>636</td>
<td>toxic effects of fentanyl</td>
</tr>
<tr>
<td>637</td>
<td>fentanyl toxication</td>
</tr>
<tr>
<td>638</td>
<td>acute fentanyl toxicity</td>
</tr>
<tr>
<td>639</td>
<td>Harmful effects of phenoperidine</td>
</tr>
<tr>
<td>640</td>
<td>phenoperidine poisoning</td>
</tr>
<tr>
<td>641</td>
<td>Fentanyl and heroin toxicity</td>
</tr>
<tr>
<td>642</td>
<td>Harmful effects of sedative hypnotic drugs or other CNS depressants</td>
</tr>
<tr>
<td>643</td>
<td>Harmful effects of sedative-hypnotic drugs</td>
</tr>
<tr>
<td>644</td>
<td>hypnotic poisoning</td>
</tr>
<tr>
<td>645</td>
<td>sleeping draught NOS poisoning</td>
</tr>
<tr>
<td>646</td>
<td>sleeping drug NOS poisoning</td>
</tr>
<tr>
<td>647</td>
<td>sleeping tablet NOS poisoning</td>
</tr>
<tr>
<td>648</td>
<td>Harmful effects of barbiturates</td>
</tr>
<tr>
<td>649</td>
<td>Harmful effects of benzodiazepines</td>
</tr>
<tr>
<td>650</td>
<td>Harmful effects of chlordiazepoxide</td>
</tr>
<tr>
<td>651</td>
<td>chlordiazepoxide poisoning</td>
</tr>
<tr>
<td>652</td>
<td>Harmful effects of clozapine</td>
</tr>
<tr>
<td>653</td>
<td>clozapine poisoning</td>
</tr>
<tr>
<td>654</td>
<td>Harmful effects of cloral derivatives</td>
</tr>
<tr>
<td>655</td>
<td>Harmful effects of paraldehyde</td>
</tr>
<tr>
<td>656</td>
<td>Harmful effects of bromine compounds</td>
</tr>
<tr>
<td>657</td>
<td>Harmful effects of mixed sedatives or hypnotics, not elsewhere classified</td>
</tr>
<tr>
<td>658</td>
<td>Harmful effects of anaesthetics or therapeutic gases</td>
</tr>
<tr>
<td>659</td>
<td>Harmful effects of anaesthetics or therapeutic gases, nitrous oxide</td>
</tr>
<tr>
<td>660</td>
<td>Harmful effects of anaesthetics or therapeutic gases, other inhaled anaesthetics</td>
</tr>
<tr>
<td>661</td>
<td>Harmful effects of anaesthetics or therapeutic gases, intravenous anaesthetics</td>
</tr>
<tr>
<td>662</td>
<td>Harmful effects of anaesthetics or therapeutic gases, unspecified general anaesthetics</td>
</tr>
<tr>
<td>663</td>
<td>Harmful effects of anaesthetics or therapeutic gases, gamma hydroxybutyrate</td>
</tr>
<tr>
<td>664</td>
<td>Harmful effects of anaesthetics or therapeutic gases, ketamine</td>
</tr>
<tr>
<td>665</td>
<td>ketamine poisoning</td>
</tr>
<tr>
<td>666</td>
<td>Harmful effects of anaesthetics or therapeutic gases, other specified general anaesthetic</td>
</tr>
<tr>
<td>667</td>
<td>Harmful effects of anaesthetics or therapeutic gases, local anaesthetics</td>
</tr>
<tr>
<td>668</td>
<td>Harmful effects of cinchocaine</td>
</tr>
<tr>
<td>669</td>
<td>cinchocaine poisoning</td>
</tr>
<tr>
<td>670</td>
<td>Harmful effects of oxybuprocaine</td>
</tr>
<tr>
<td>671</td>
<td>oxybuprocaine poisoning</td>
</tr>
<tr>
<td>672</td>
<td>Harmful effects of psychostimulants</td>
</tr>
<tr>
<td>673</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Central nervous system stimulants, not elsewhere classified</td>
</tr>
<tr>
<td>674</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Analeptics</td>
</tr>
<tr>
<td>675</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Opioid receptor antagonists</td>
</tr>
<tr>
<td>676</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Caffeine</td>
</tr>
<tr>
<td>677</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Amphetamine</td>
</tr>
<tr>
<td>678</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Methylamphetamine</td>
</tr>
<tr>
<td>679</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Methylenedioxy methamphetamine</td>
</tr>
<tr>
<td>680</td>
<td>methamphetamine toxicity</td>
</tr>
<tr>
<td>681</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Other specified amphetamines</td>
</tr>
<tr>
<td>682</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Cocaine</td>
</tr>
<tr>
<td>683</td>
<td>poisoning by cocaine NOS</td>
</tr>
<tr>
<td>684</td>
<td>cocaine toxicity</td>
</tr>
<tr>
<td>685</td>
<td>acute cocaine toxicity</td>
</tr>
<tr>
<td>686</td>
<td>toxic effects of cocaine</td>
</tr>
<tr>
<td>687</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Methylphenidate</td>
</tr>
<tr>
<td>688</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Cathinone</td>
</tr>
<tr>
<td>689</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Psychostimulants, Cathinone derivatives</td>
</tr>
<tr>
<td>690</td>
<td>Harmful effects of Cannabinoids or hallucinogens</td>
</tr>
<tr>
<td>691</td>
<td>Harmful effects of Cannabis</td>
</tr>
<tr>
<td>692</td>
<td>cannabis poisoning</td>
</tr>
<tr>
<td>693</td>
<td>poisoning by cannabis derivative</td>
</tr>
<tr>
<td>694</td>
<td>poisoning by marijuana</td>
</tr>
<tr>
<td>695</td>
<td>poisoning by marijuana derivative</td>
</tr>
<tr>
<td>696</td>
<td>Harmful effects of synthetic cannabinoids</td>
</tr>
<tr>
<td>697</td>
<td>Harmful effects of Lysergide</td>
</tr>
<tr>
<td>698</td>
<td>Harmful effects of unspecified psychodysleptics</td>
</tr>
<tr>
<td>699</td>
<td>harmful effect of unspecified hallucinogens</td>
</tr>
<tr>
<td>700</td>
<td>Harmful effects of other psychodysleptics</td>
</tr>
<tr>
<td>701</td>
<td>Other hallucinogens</td>
</tr>
<tr>
<td>702</td>
<td>Harmful effects of analgesics, antipyretics or anti-inflammatory drugs</td>
</tr>
<tr>
<td>703</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, analgesics, antipyretics or anti-inflammatory drugs, Aspirin</td>
</tr>
<tr>
<td>704</td>
<td>aspirin poisoning</td>
</tr>
<tr>
<td>705</td>
<td>Harmful effects of other salicylates</td>
</tr>
<tr>
<td>706</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, analgesics, antipyretics or anti-inflammatory drugs, Paracetamol</td>
</tr>
<tr>
<td>707</td>
<td>paracetamol poisoning</td>
</tr>
<tr>
<td>708</td>
<td>Harmful effects of 4-Aminophenol derivatives</td>
</tr>
<tr>
<td>709</td>
<td>Harmful effects of Pyrazolone derivatives</td>
</tr>
<tr>
<td>710</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, analgesics, antipyretics or anti-inflammatory drugs, Ibuprofen</td>
</tr>
<tr>
<td>711</td>
<td>ibuprofen poisoning</td>
</tr>
<tr>
<td>712</td>
<td>Harmful effects of other propionic acid derivatives</td>
</tr>
<tr>
<td>713</td>
<td>Harmful effects of Indomethacin</td>
</tr>
<tr>
<td>714</td>
<td>indometacin poisoning</td>
</tr>
<tr>
<td>715</td>
<td>indomethacin poisoning</td>
</tr>
<tr>
<td>716</td>
<td>Harmful effects of other nonsteroidal anti-inflammatory drugs</td>
</tr>
<tr>
<td>717</td>
<td>poisoning by NSAID - [nonsteroidal anti-inflammatory drugs]</td>
</tr>
<tr>
<td>718</td>
<td>Harmful effects of etodolac</td>
</tr>
<tr>
<td>719</td>
<td>etodolac poisoning</td>
</tr>
<tr>
<td>720</td>
<td>Harmful effects of antirheumatics, not elsewhere classified</td>
</tr>
<tr>
<td>721</td>
<td>Harmful effects of antidepressants</td>
</tr>
<tr>
<td>722</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Tricyclic antidepressants</td>
</tr>
<tr>
<td>723</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Tetracyclic antidepressants</td>
</tr>
<tr>
<td>724</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Monoamine-oxidase-inhibitor antidepressants</td>
</tr>
<tr>
<td>725</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Selective serotonin or norepinephrine reuptake inhibitors</td>
</tr>
<tr>
<td>726</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Antidepressants, Selective serotonin reuptake inhibitors</td>
</tr>
<tr>
<td>727</td>
<td>Harmful effects of antipsychotics</td>
</tr>
<tr>
<td>728</td>
<td>Harmful effects of phenothiazine antipsychotics or neuroleptics</td>
</tr>
<tr>
<td>729</td>
<td>Harmful effects of promazine</td>
</tr>
<tr>
<td>730</td>
<td>promazine poisoning</td>
</tr>
<tr>
<td>731</td>
<td>Harmful effects of butyrophenone or thiothixene neuroleptics</td>
</tr>
<tr>
<td>732</td>
<td>Harmful effects of typical, second-generation antipsychotics</td>
</tr>
<tr>
<td>733</td>
<td>Harmful effects of lithium carbonate</td>
</tr>
<tr>
<td>734</td>
<td>Harmful effects of antiepileptics or antiparkinsonism drugs</td>
</tr>
<tr>
<td>735</td>
<td>Harmful effects of hydantoin derivatives</td>
</tr>
<tr>
<td>736</td>
<td>Harmful effects of iminostilbenes</td>
</tr>
<tr>
<td>737</td>
<td>Harmful effects of deoxybarbiturates</td>
</tr>
<tr>
<td>738</td>
<td>Harmful effects of succinimides</td>
</tr>
<tr>
<td>739</td>
<td>Harmful effects of oxazolidinediones</td>
</tr>
<tr>
<td>740</td>
<td>Harmful effects of mixed antiepileptics, not elsewhere classified</td>
</tr>
<tr>
<td>741</td>
<td>Harmful effects of Amantadine</td>
</tr>
<tr>
<td>742</td>
<td>Harmful effects of Valproic acid</td>
</tr>
<tr>
<td>743</td>
<td>Harmful effects of L-DOPA</td>
</tr>
<tr>
<td>744</td>
<td>Harmful effects of Antiparkinsonism drugs or other central muscle-tone depressants, not elsewhere classified</td>
</tr>
<tr>
<td>745</td>
<td>Harmful effects of antispasticity drugs</td>
</tr>
<tr>
<td>746</td>
<td>Harmful effects of substances, drugs, medicaments or biological substance, Other or unspecified drugs, medicaments or biological substances</td>
</tr>
<tr>
<td>747</td>
<td>Harmful effects of systemic antibiotics</td>
</tr>
<tr>
<td>748</td>
<td>Harmful effects of Penicillins</td>
</tr>
<tr>
<td>749</td>
<td>poisoning by penicillin</td>
</tr>
<tr>
<td>750</td>
<td>poisoning by penicillins nos</td>
</tr>
<tr>
<td>751</td>
<td>Harmful effects of cephalosporins and other beta-lactam antibiotics</td>
</tr>
<tr>
<td>752</td>
<td>Harmful effects of cefotaxime</td>
</tr>
<tr>
<td>753</td>
<td>cefotaxime poisoning</td>
</tr>
<tr>
<td>754</td>
<td>Harmful effects of chloramphenicol group</td>
</tr>
<tr>
<td>755</td>
<td>chloramphenicol poisoning</td>
</tr>
<tr>
<td>756</td>
<td>Harmful effects of macrolides</td>
</tr>
<tr>
<td>757</td>
<td>Harmful effects of tetracyclines</td>
</tr>
<tr>
<td>758</td>
<td>poisoning by tetracyclines</td>
</tr>
<tr>
<td>759</td>
<td>poisoning by tetracyclines nos</td>
</tr>
<tr>
<td>760</td>
<td>Harmful effects of aminoglycosides</td>
</tr>
<tr>
<td>761</td>
<td>Harmful effects of rifampicin</td>
</tr>
<tr>
<td>762</td>
<td>rifampicin poisoning</td>
</tr>
<tr>
<td>763</td>
<td>Harmful effects of antifungal antibiotics, systemically used</td>
</tr>
<tr>
<td>764</td>
<td>Harmful effects of co-trimoxazole</td>
</tr>
<tr>
<td>765</td>
<td>co-trimoxazole poisoning</td>
</tr>
<tr>
<td>766</td>
<td>Harmful effects of fusidic acid</td>
</tr>
<tr>
<td>767</td>
<td>fusidic acid poisoning</td>
</tr>
<tr>
<td>768</td>
<td>Harmful effects of sodium fusidate</td>
</tr>
<tr>
<td>769</td>
<td>sodium fusidate poisoning</td>
</tr>
<tr>
<td>770</td>
<td>Harmful effects of vancomycin</td>
</tr>
<tr>
<td>771</td>
<td>vancomycin poisoning</td>
</tr>
<tr>
<td>772</td>
<td>Harmful effects of other systemic anti-infectives or antiparasitics</td>
</tr>
<tr>
<td>773</td>
<td>Harmful effects of Sulfonamides</td>
</tr>
<tr>
<td>774</td>
<td>Harmful effects of antimycobacterial drugs</td>
</tr>
<tr>
<td>775</td>
<td>Harmful effects of antimalarials or drugs acting on other blood protozoa</td>
</tr>
<tr>
<td>776</td>
<td>Harmful effects of other antiprotozoal drugs</td>
</tr>
<tr>
<td>777</td>
<td>Harmful effects of anthelminthics</td>
</tr>
<tr>
<td>778</td>
<td>Harmful effects of antiviral drugs</td>
</tr>
<tr>
<td>779</td>
<td>Harmful effects of chiniofon</td>
</tr>
<tr>
<td>780</td>
<td>chiniofon poisoning</td>
</tr>
<tr>
<td>781</td>
<td>Harmful effects of diiodohydroxyquinoline</td>
</tr>
<tr>
<td>782</td>
<td>diiodohydroxyquinoline poisoning</td>
</tr>
<tr>
<td>783</td>
<td>Harmful effects of flucytosine</td>
</tr>
<tr>
<td>784</td>
<td>flucytosine poisoning</td>
</tr>
<tr>
<td>785</td>
<td>Harmful effects of hydroxyquinoline derivatives</td>
</tr>
<tr>
<td>786</td>
<td>hydroxyquinoline derivatives poisoning</td>
</tr>
<tr>
<td>787</td>
<td>Harmful effects of trimethoprim</td>
</tr>
<tr>
<td>788</td>
<td>trimethoprim poisoning</td>
</tr>
<tr>
<td>789</td>
<td>Harmful effects of hormones or their synthetic substitutes or antagonists, not elsewhere classified</td>
</tr>
<tr>
<td>790</td>
<td>Harmful effects of Glucocorticoids or synthetic analogues</td>
</tr>
<tr>
<td>791</td>
<td>Harmful effects of thyroid hormones or substitutes</td>
</tr>
<tr>
<td>792</td>
<td>Harmful effects of antithyroid drugs</td>
</tr>
<tr>
<td>793</td>
<td>Harmful effects of insulin or oral hypoglycaemic drugs</td>
</tr>
<tr>
<td>794</td>
<td>Harmful effects of oral contraceptives</td>
</tr>
<tr>
<td>795</td>
<td>poisoning by oral contraceptive</td>
</tr>
<tr>
<td>796</td>
<td>poisoning by oral contraceptives nos</td>
</tr>
<tr>
<td>797</td>
<td>Harmful effects of other estrogens or progestogens</td>
</tr>
<tr>
<td>798</td>
<td>oestrogen poisoning</td>
</tr>
<tr>
<td>799</td>
<td>Harmful effects of antigonadotropins, antiestrogens, antiandrogens, not elsewhere classified</td>
</tr>
<tr>
<td>800</td>
<td>Harmful effects of androgens or anabolic congeners</td>
</tr>
<tr>
<td>801</td>
<td>androgen poisoning</td>
</tr>
<tr>
<td>802</td>
<td>Harmful effects of unspecified hormones or synthetic substitutes</td>
</tr>
<tr>
<td>803</td>
<td>Harmful effects of anterior pituitary hormones</td>
</tr>
<tr>
<td>804</td>
<td>Harmful effects of other hormones or synthetic substitutes</td>
</tr>
<tr>
<td>805</td>
<td>Harmful effects of unspecified hormone antagonists</td>
</tr>
<tr>
<td>806</td>
<td>Harmful effects of other hormone antagonists</td>
</tr>
<tr>
<td>807</td>
<td>Harmful effects of trilostane</td>
</tr>
<tr>
<td>808</td>
<td>Harmful effects of drugs primarily affecting the autonomic nervous system</td>
</tr>
<tr>
<td>809</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Anticholinesterase agents</td>
</tr>
<tr>
<td>810</td>
<td>anticholinesterase poisoning</td>
</tr>
<tr>
<td>811</td>
<td>poisoning by anticholinesterase agents nos</td>
</tr>
<tr>
<td>812</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Other parasympathomimetics</td>
</tr>
<tr>
<td>813</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Ganglionic blocking drugs</td>
</tr>
<tr>
<td>814</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Other parasympatholytics or spasmolytics</td>
</tr>
<tr>
<td>815</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Predominantly alpha-adrenoreceptor agonists</td>
</tr>
<tr>
<td>816</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Predominantly beta-adrenoreceptor agonists</td>
</tr>
<tr>
<td>817</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Alpha-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>818</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Beta-adrenoreceptor antagonists</td>
</tr>
<tr>
<td>819</td>
<td>Harmful effects of substances, Drugs, medicaments or biological substances, Drugs primarily affecting the autonomic nervous system, Centrally-acting or adrenergic-neuron-blocking agents</td>
</tr>
<tr>
<td>820</td>
<td>Harmful effects of agents primarily affecting blood constituents</td>
</tr>
<tr>
<td>821</td>
<td>haematological agent poisoning</td>
</tr>
<tr>
<td>822</td>
<td>Harmful effects of Diphenhydramine</td>
</tr>
<tr>
<td>823</td>
<td>diphenhydramine toxicity</td>
</tr>
<tr>
<td>824</td>
<td>Harmful effects of other H1-receptor antagonists</td>
</tr>
<tr>
<td>825</td>
<td>Harmful effects of antiallergic or antiemetic drugs</td>
</tr>
<tr>
<td>826</td>
<td>Harmful effects of antineoplastic antimetabolites</td>
</tr>
<tr>
<td>827</td>
<td>Harmful effects of antineoplastic natural products</td>
</tr>
<tr>
<td>828</td>
<td>Harmful effects of other antineoplastic drugs</td>
</tr>
<tr>
<td>829</td>
<td>Harmful effects of immunosuppressive agents</td>
</tr>
<tr>
<td>830</td>
<td>Harmful effects of Vitamin B12, folic acid or other anti-megaloblastic-anaemia preparations</td>
</tr>
<tr>
<td>831</td>
<td>Harmful effects of enzymes</td>
</tr>
<tr>
<td>832</td>
<td>Harmful effects of iron or its compounds</td>
</tr>
<tr>
<td>833</td>
<td>Harmful effects of anticoagulants</td>
</tr>
<tr>
<td>834</td>
<td>Harmful effects of antithrombotic drugs</td>
</tr>
<tr>
<td>835</td>
<td>harmful effect of platelet aggregation inhibitors</td>
</tr>
<tr>
<td>836</td>
<td>Harmful effects of thrombolytic drug</td>
</tr>
<tr>
<td>837</td>
<td>Harmful effects of anticoagulant antagonists, vitamin K or other coagulants</td>
</tr>
<tr>
<td>838</td>
<td>Harmful effects of other fibrinolysis-affecting drugs</td>
</tr>
<tr>
<td>839</td>
<td>fibrinolytic drug poisoning</td>
</tr>
<tr>
<td>840</td>
<td>poisoning by fibrinolysis-affecting drug nos</td>
</tr>
<tr>
<td>841</td>
<td>Harmful effects of natural blood or blood products</td>
</tr>
<tr>
<td>842</td>
<td>Harmful effects of acidifying or alkalising agents</td>
</tr>
<tr>
<td>843</td>
<td>Harmful effects of other primarily systemic agents, not elsewhere classified</td>
</tr>
<tr>
<td>844</td>
<td>Blood poisoning, not elsewhere classified</td>
</tr>
<tr>
<td>845</td>
<td>whole blood poisoning</td>
</tr>
<tr>
<td>846</td>
<td>Harmful effects of heavy metal poisoning antidote</td>
</tr>
<tr>
<td>847</td>
<td>Harmful effects of plasma substitutes</td>
</tr>
<tr>
<td>848</td>
<td>Harmful effects of agents primarily affecting the cardiovascular system</td>
</tr>
<tr>
<td>849</td>
<td>Harmful effects of cardiac-stimulant glycosides or drugs of similar action</td>
</tr>
<tr>
<td>850</td>
<td>Harmful effects of calcium-channel blockers</td>
</tr>
<tr>
<td>851</td>
<td>poisoning by calcium-channel blockers NOS</td>
</tr>
<tr>
<td>852</td>
<td>Harmful effects of other antidysrhythmic drugs</td>
</tr>
<tr>
<td>853</td>
<td>Harmful effects of Nitroglycerin, nitroglycerol, medicinal</td>
</tr>
<tr>
<td>854</td>
<td>Harmful effects of other coronary vasodilators</td>
</tr>
<tr>
<td>855</td>
<td>Harmful effects of Angiotensin-converting-enzyme inhibitors</td>
</tr>
<tr>
<td>856</td>
<td>Harmful effects of other antihypertensive drugs</td>
</tr>
<tr>
<td>857</td>
<td>Harmful effects of antihyperlipidemic or antiarteriosclerotic drugs</td>
</tr>
<tr>
<td>858</td>
<td>Harmful effects of peripheral vasodilators</td>
</tr>
<tr>
<td>859</td>
<td>Harmful effects of antivaricose drugs, including sclerosing agents</td>
</tr>
<tr>
<td>860</td>
<td>antivaricose drug poisoning</td>
</tr>
<tr>
<td>861</td>
<td>Harmful effects of agents primarily affecting the gastrointestinal system</td>
</tr>
<tr>
<td>862</td>
<td>Harmful effects of Histamine H2-receptor blockers</td>
</tr>
<tr>
<td>863</td>
<td>poisoning by histamine h 2 -receptor antagonists</td>
</tr>
<tr>
<td>864</td>
<td>Harmful effects of other antacids or anti-gastric-secretion drugs</td>
</tr>
<tr>
<td>865</td>
<td>Harmful effects of stimulant laxatives</td>
</tr>
<tr>
<td>866</td>
<td>Harmful effects of saline or osmotic laxatives</td>
</tr>
<tr>
<td>867</td>
<td>Harmful effects of other laxatives</td>
</tr>
<tr>
<td>868</td>
<td>Harmful effects of digestants</td>
</tr>
<tr>
<td>869</td>
<td>Harmful effects of antidiarrhoeal drugs</td>
</tr>
<tr>
<td>870</td>
<td>Harmful effects of or exposure to emetics</td>
</tr>
<tr>
<td>871</td>
<td>Harmful effects of agents primarily acting on smooth or skeletal muscles or the respiratory system</td>
</tr>
<tr>
<td>872</td>
<td>Harmful effects of Oxytocic drugs</td>
</tr>
<tr>
<td>873</td>
<td>oxytocin poisoning</td>
</tr>
<tr>
<td>874</td>
<td>Harmful effects of skeletal muscle relaxants</td>
</tr>
<tr>
<td>875</td>
<td>harmful effect of neuromuscular blocking agents</td>
</tr>
<tr>
<td>876</td>
<td>Harmful effects of other drugs acting on muscles</td>
</tr>
<tr>
<td>877</td>
<td>Harmful effects of unspecified drugs acting on muscles</td>
</tr>
<tr>
<td>878</td>
<td>Harmful effects of antitussives</td>
</tr>
<tr>
<td>879</td>
<td>Harmful effects of expectorants</td>
</tr>
<tr>
<td>880</td>
<td>Harmful effects of other anti-common-cold drugs</td>
</tr>
<tr>
<td>881</td>
<td>Harmful effects of Salbutamol</td>
</tr>
<tr>
<td>882</td>
<td>salbutamol poisoning</td>
</tr>
<tr>
<td>883</td>
<td>Harmful effects of Aminophylline, theophylline</td>
</tr>
<tr>
<td>884</td>
<td>theophylline poisoning</td>
</tr>
<tr>
<td>885</td>
<td>aminophylline poisoning</td>
</tr>
<tr>
<td>886</td>
<td>Harmful effects of Terbutaline</td>
</tr>
<tr>
<td>887</td>
<td>Harmful effects of antiasthmatics, not elsewhere classified</td>
</tr>
<tr>
<td>888</td>
<td>Harmful effects of topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs</td>
</tr>
<tr>
<td>889</td>
<td>Harmful effects of topical corticosteroid preparations</td>
</tr>
<tr>
<td>890</td>
<td>Harmful effects of Iodine, antiseptic</td>
</tr>
<tr>
<td>891</td>
<td>Harmful effects of silver nitrate</td>
</tr>
<tr>
<td>892</td>
<td>Harmful effects of other local antifungal, anti-infective or anti-inflammatory drugs</td>
</tr>
<tr>
<td>893</td>
<td>Harmful effects of antipruritics</td>
</tr>
<tr>
<td>894</td>
<td>Harmful effects of Methyl salicylate</td>
</tr>
<tr>
<td>895</td>
<td>Harmful effects of other local astringents or local detergents</td>
</tr>
<tr>
<td>896</td>
<td>Tannic acid poisoning</td>
</tr>
<tr>
<td>897</td>
<td>Harmful effects of emollients, demulcents or protectants</td>
</tr>
<tr>
<td>898</td>
<td>Harmful effects of Podophyllin</td>
</tr>
<tr>
<td>899</td>
<td>Harmful effects of keratolytics, keratoplastics, or other hair treatment drugs or preparations</td>
</tr>
<tr>
<td>900</td>
<td>Harmful effects of ophthalmological drugs or preparations</td>
</tr>
<tr>
<td>901</td>
<td>Harmful effects of otorhinolaryngological drugs or preparations</td>
</tr>
<tr>
<td>902</td>
<td>Harmful effects of ear, nose or throat anti-infectives</td>
</tr>
<tr>
<td>903</td>
<td>Harmful effects of fluoride preparations</td>
</tr>
<tr>
<td>904</td>
<td>Harmful effects of other dental drugs, topically applied</td>
</tr>
<tr>
<td>905</td>
<td>Harmful effects of Camphor</td>
</tr>
<tr>
<td>906</td>
<td>Harmful effects of agents primarily affecting water-balance or mineral or uric acid metabolism</td>
</tr>
<tr>
<td>907</td>
<td>Harmful effects of Mineralocorticoids</td>
</tr>
<tr>
<td>908</td>
<td>Harmful effects of Mineralocorticoids antagonists</td>
</tr>
<tr>
<td>909</td>
<td>Harmful effects of Loop diuretics</td>
</tr>
<tr>
<td>910</td>
<td>Harmful effect of high-ceiling diuretics</td>
</tr>
<tr>
<td>911</td>
<td>Frusemide poisoning</td>
</tr>
<tr>
<td>912</td>
<td>furosemide poisoning</td>
</tr>
<tr>
<td>913</td>
<td>Etacrynic acid poisoning</td>
</tr>
<tr>
<td>914</td>
<td>ethacrynic acid poisoning</td>
</tr>
<tr>
<td>915</td>
<td>Harmful effects of Carbonic-anhydrase inhibitors</td>
</tr>
<tr>
<td>916</td>
<td>Acetazolamide poisoning</td>
</tr>
<tr>
<td>917</td>
<td>Bendroflumethiazide poisoning</td>
</tr>
<tr>
<td>918</td>
<td>Chlormerodrin poisoning</td>
</tr>
<tr>
<td>919</td>
<td>Chlorothiazide poisoning</td>
</tr>
<tr>
<td>920</td>
<td>Mercaptomerin poisoning</td>
</tr>
<tr>
<td>921</td>
<td>Mersalyl poisoning</td>
</tr>
<tr>
<td>922</td>
<td>Harmful effects of Benzothiadiazine derivatives</td>
</tr>
<tr>
<td>923</td>
<td>harmful effect of thiazides</td>
</tr>
<tr>
<td>924</td>
<td>Harmful effects of other diuretics</td>
</tr>
<tr>
<td>925</td>
<td>Harmful effects of electrolytic, caloric or water-balance agents</td>
</tr>
<tr>
<td>926</td>
<td>Harmful effect of oral rehydration salts</td>
</tr>
<tr>
<td>927</td>
<td>Sodium chloride poisoning</td>
</tr>
<tr>
<td>928</td>
<td>Harmful effects of mineral salts, not elsewhere classified</td>
</tr>
<tr>
<td>929</td>
<td>Harmful effects of drugs affecting uric acid metabolism</td>
</tr>
<tr>
<td>930</td>
<td>Allopurinol poisoning</td>
</tr>
<tr>
<td>931</td>
<td>Colchicine poisoning</td>
</tr>
<tr>
<td>932</td>
<td>Probenecid poisoning</td>
</tr>
<tr>
<td>933</td>
<td>Harmful effects of agents primarily affecting water-balance and mineral or uric acid metabolism, Vitamin D and derivatives</td>
</tr>
<tr>
<td>934</td>
<td>Harmful effects of Bisphosphonates</td>
</tr>
<tr>
<td>935</td>
<td>Harmful effects of appetite depressants</td>
</tr>
<tr>
<td>936</td>
<td>Harmful effects of antidotes or chelating agents, not elsewhere classified</td>
</tr>
<tr>
<td>937</td>
<td>Harmful effects of Disulfiram</td>
</tr>
<tr>
<td>938</td>
<td>disulfiram poisoning</td>
</tr>
<tr>
<td>939</td>
<td>Harmful effects of alcohol deterrents, not elsewhere classified</td>
</tr>
<tr>
<td>940</td>
<td>harmful effect of alcohol deterrents</td>
</tr>
<tr>
<td>941</td>
<td>Toxic effect of alcohol deterrents</td>
</tr>
<tr>
<td>942</td>
<td>Harmful effects of X-ray contrast media</td>
</tr>
<tr>
<td>943</td>
<td>Harmful effects of MRI contrast agents</td>
</tr>
<tr>
<td>944</td>
<td>Harmful effects of agents used for other scanning techniques</td>
</tr>
<tr>
<td>945</td>
<td>Harmful effects of other diagnostic agents</td>
</tr>
<tr>
<td>946</td>
<td>Harmful effects of Lipotropic drugs</td>
</tr>
<tr>
<td>947</td>
<td>Harmful effects of vitamins, not elsewhere classified, Pharmaceutical excipients</td>
</tr>
<tr>
<td>948</td>
<td>Harmful effects of herbal preparations or formulas</td>
</tr>
<tr>
<td>949</td>
<td>Harmful effects of dietary supplements, vitamins or minerals</td>
</tr>
<tr>
<td>950</td>
<td>Harmful effects of complementary or Traditional Medicines, not elsewhere classified</td>
</tr>
<tr>
<td>951</td>
<td>Harmful effects of complementary or Traditional Medicines, unspecified</td>
</tr>
<tr>
<td>952</td>
<td>Harmful effects of vaccines, immunoglobulins or other biological substances</td>
</tr>
<tr>
<td>953</td>
<td>Harmful effects of BCG vaccine</td>
</tr>
<tr>
<td>954</td>
<td>Harmful effects of Typhoid or paratyphoid vaccine</td>
</tr>
<tr>
<td>955</td>
<td>Harmful effects of Cholera vaccine</td>
</tr>
<tr>
<td>956</td>
<td>Harmful effects of Plague vaccine</td>
</tr>
<tr>
<td>957</td>
<td>Harmful effects of Tetanus vaccine</td>
</tr>
<tr>
<td>958</td>
<td>Harmful effects of Diphtheria vaccine</td>
</tr>
<tr>
<td>959</td>
<td>Harmful effects of Haemophilus influenzae type B vaccines</td>
</tr>
<tr>
<td>960</td>
<td>Harmful effects of Pertussis vaccine, including combinations with a pertussis component</td>
</tr>
<tr>
<td>961</td>
<td>Harmful effects of mixed bacterial vaccines without a pertussis component</td>
</tr>
<tr>
<td>962</td>
<td>Harmful effects of other or unspecified bacterial vaccines</td>
</tr>
<tr>
<td>963</td>
<td>Harmful effects of Smallpox vaccines</td>
</tr>
<tr>
<td>964</td>
<td>Harmful effects of Measles vaccines</td>
</tr>
<tr>
<td>965</td>
<td>Harmful effects of Mumps vaccines</td>
</tr>
<tr>
<td>966</td>
<td>Harmful effects of Rubella vaccines</td>
</tr>
<tr>
<td>967</td>
<td>Harmful effects of Polio vaccines</td>
</tr>
<tr>
<td>968</td>
<td>Harmful effects of Yellow fever vaccines</td>
</tr>
<tr>
<td>969</td>
<td>Harmful effects of Hepatitis A vaccines</td>
</tr>
<tr>
<td>970</td>
<td>Harmful effects of Hepatitis B vaccines</td>
</tr>
<tr>
<td>971</td>
<td>Harmful effects of Influenza vaccines</td>
</tr>
<tr>
<td>972</td>
<td>Harmful effects of Rotavirus vaccines</td>
</tr>
<tr>
<td>973</td>
<td>Harmful effects of Human papillomavirus vaccines</td>
</tr>
<tr>
<td>974</td>
<td>Harmful effects of other viral vaccines</td>
</tr>
<tr>
<td>975</td>
<td>Harmful effects of Rickettsial vaccines</td>
</tr>
<tr>
<td>976</td>
<td>Harmful effects of Protozoal vaccines</td>
</tr>
<tr>
<td>977</td>
<td>Harmful effects of Hepatitis B immune globulin</td>
</tr>
<tr>
<td>978</td>
<td>Harmful effects of antivenin, antivenom</td>
</tr>
<tr>
<td>979</td>
<td>Harmful effects of immunoglobulin, not elsewhere classified</td>
</tr>
<tr>
<td>980</td>
<td>Harmful effects of other specified vaccines</td>
</tr>
<tr>
<td>981</td>
<td>Harmful effects of unspecified vaccines</td>
</tr>
<tr>
<td>982</td>
<td>Multiple drug toxicity</td>
</tr>
<tr>
<td>983</td>
<td>Catatonia due to medication or substance</td>
</tr>
<tr>
<td>984</td>
<td>Overdose of drug, not otherwise specified</td>
</tr>
<tr>
<td>985</td>
<td>overdose NOS</td>
</tr>
<tr>
<td>986</td>
<td>Harmful effects of ketorolac</td>
</tr>
<tr>
<td>987</td>
<td>ketorolac poisoning</td>
</tr>
<tr>
<td>988</td>
<td>Harmful effects of meptazinol</td>
</tr>
<tr>
<td>989</td>
<td>meptazinol poisoning</td>
</tr>
<tr>
<td>990</td>
<td>Harmful effects of nefopam</td>
</tr>
<tr>
<td>991</td>
<td>nefopam poisoning</td>
</tr>
<tr>
<td>992</td>
<td>Harmful effects of oxygen</td>
</tr>
<tr>
<td>993</td>
<td>oxygen poisoning</td>
</tr>
<tr>
<td>994</td>
<td>Harmful effects of ethosuximide</td>
</tr>
<tr>
<td>995</td>
<td>ethosuximide poisoning</td>
</tr>
<tr>
<td>996</td>
<td>Harmful effects of paramethadione</td>
</tr>
<tr>
<td>997</td>
<td>paramethadione poisoning</td>
</tr>
<tr>
<td>998</td>
<td>Harmful effects of trimethadione</td>
</tr>
<tr>
<td>999</td>
<td>trimethadione poisoning</td>
</tr>
<tr>
<td>1000</td>
<td>Harmful effects of phensuximide</td>
</tr>
<tr>
<td>1001</td>
<td>phensuximide poisoning</td>
</tr>
<tr>
<td>1002</td>
<td>Adverse effect medical agent</td>
</tr>
<tr>
<td>1003</td>
<td>side effect</td>
</tr>
<tr>
<td>1004</td>
<td>side effect of medical agent</td>
</tr>
<tr>
<td>1005</td>
<td>Cocaine and fentanyl toxicity</td>
</tr>
<tr>
<td>1006</td>
<td>Methamphetamine and fentanyl toxicity</td>
</tr>
<tr>
<td>1007</td>
<td>Immune dysregulation syndromes presenting primarily with lymphoproliferation</td>
</tr>
<tr>
<td>1008</td>
<td>Autosomal recessive lymphoproliferative disease</td>
</tr>
<tr>
<td>1009</td>
<td>Autoimmune lymphoproliferative syndrome</td>
</tr>
<tr>
<td>1010</td>
<td>autoimmune lymphoproliferative syndrome with recurrent infections</td>
</tr>
<tr>
<td>1011</td>
<td>Canale-Smith syndrome</td>
</tr>
<tr>
<td>1012</td>
<td>FAS deficiency</td>
</tr>
<tr>
<td>1013</td>
<td>FAS deficiency (ALPS-FAS)(ALPS1a)</td>
</tr>
<tr>
<td>1014</td>
<td>Caspase 8 defect (ALPS2b)</td>
</tr>
<tr>
<td>1015</td>
<td>ALPS-NRAS</td>
</tr>
<tr>
<td>1016</td>
<td>ALPS-KRAS</td>
</tr>
<tr>
<td>1017</td>
<td>ALPS-FASLG (ALPS1b)</td>
</tr>
<tr>
<td>1018</td>
<td>ALPS-CASP10 (ALPS2a)</td>
</tr>
<tr>
<td>1019</td>
<td>X-linked lymphoproliferative disease</td>
</tr>
<tr>
<td>1020</td>
<td>Purtilo syndrome</td>
</tr>
<tr>
<td>1021</td>
<td>Immunodeficiency following hereditary defective response to Epstein-Barr virus</td>
</tr>
<tr>
<td>1022</td>
<td>immunodeficient hereditary defective response to Epstein Barr virus</td>
</tr>
<tr>
<td>1023</td>
<td>x-linked lymphoproliferation disease</td>
</tr>
<tr>
<td>1024</td>
<td>x-linked lymphoproliferative disease or disorder</td>
</tr>
<tr>
<td>1025</td>
<td>x-linked lymphoproliferative syndrome</td>
</tr>
<tr>
<td>1026</td>
<td>XLPS - [x-linked lymphoproliferative syndrome]</td>
</tr>
<tr>
<td>1027</td>
<td>Fatal Epstein Barr virus syndrome</td>
</tr>
<tr>
<td>1028</td>
<td>XIAP deficiency (XLP2)</td>
</tr>
<tr>
<td>1029</td>
<td>SH2D1A deficiency (XLP1)</td>
</tr>
<tr>
<td>1030</td>
<td>Other specified combined immunodeficiencies</td>
</tr>
<tr>
<td>1031</td>
<td>Combined immunodeficiency due to ORAI1 deficiency</td>
</tr>
<tr>
<td>1032</td>
<td>Combined immunodeficiency due to STIM1 deficiency</td>
</tr>
<tr>
<td>1033</td>
<td>Combined immunodeficiency T+ B+ due to partial RAG1 deficiency</td>
</tr>
<tr>
<td>1034</td>
<td>Immunodeficiency due to purine nucleoside phosphorylase deficiency</td>
</tr>
<tr>
<td>1035</td>
<td>Nucleoside phosphorylase deficiency</td>
</tr>
<tr>
<td>1036</td>
<td>deficiency of inosine phosphorylase</td>
</tr>
<tr>
<td>1037</td>
<td>deficiency of purine-nucleoside phosphorylase</td>
</tr>
<tr>
<td>1038</td>
<td>NP - [nucleoside phosphorylase] deficiency</td>
</tr>
<tr>
<td>1039</td>
<td>PNP - [purine nucleoside phosphorylase] deficiency</td>
</tr>
<tr>
<td>1040</td>
<td>Severe combined immunodeficiency - microcephaly - growth retardation - sensitivity to ionizing radiation</td>
</tr>
<tr>
<td>1041</td>
<td>Combined immunodeficiency due to Cernunnos protein deficiency</td>
</tr>
<tr>
<td>1042</td>
<td>NHEJ1 - [non-homologous end joining factor] syndrome</td>
</tr>
<tr>
<td>1043</td>
<td>DNA-ligase IV deficiency</td>
</tr>
<tr>
<td>1044</td>
<td>Ligase 4 syndrome</td>
</tr>
<tr>
<td>1045</td>
<td>LIG4 deficiency</td>
</tr>
<tr>
<td>1046</td>
<td>Combined immunodeficiency due to CRAC channel dysfunction</td>
</tr>
<tr>
<td>1047</td>
<td>Immune dysfunction due to T-cell inactivation due to calcium entry defect</td>
</tr>
<tr>
<td>1048</td>
<td>Combined immunodeficiency due to ZAP70 deficiency</td>
</tr>
<tr>
<td>1049</td>
<td>Zeta-associated-protein 70 deficiency</td>
</tr>
<tr>
<td>1050</td>
<td>Severe T-cell immunodeficiency - congenital alopecia - nail dystrophy</td>
</tr>
<tr>
<td>1051</td>
<td>SCID - [Severe combined immunodeficiency] due to winged helix deficiency</td>
</tr>
<tr>
<td>1052</td>
<td>Combined immunodeficiency due to CD3 gamma deficiency</td>
</tr>
<tr>
<td>1053</td>
<td>Familial CD8 deficiency</td>
</tr>
<tr>
<td>1054</td>
<td>Susceptibility to respiratory infections associated with CD8 alpha chain mutation</td>
</tr>
<tr>
<td>1055</td>
<td>Primary immunodeficiency with skin granulomas</td>
</tr>
<tr>
<td>1056</td>
<td>Combined cellular and humoral deficiencies and multiple granulomas</td>
</tr>
<tr>
<td>1057</td>
<td>Combined immunodeficiency due to DOCK8 deficiency</td>
</tr>
<tr>
<td>1058</td>
<td>CID - [combined immunodeficiency] due to DOCK8 - [dedicator of cytokinesis 8 protein] deficiency</td>
</tr>
<tr>
<td>1059</td>
<td>Pancytopenia due to IKZF1 mutations</td>
</tr>
<tr>
<td>1060</td>
<td>CID - [combined immunodeficiency] due to Ikaros deficiency</td>
</tr>
<tr>
<td>1061</td>
<td>X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection or neoplasia</td>
</tr>
<tr>
<td>1062</td>
<td>Combined immunodeficiency due to MAGT1 deficiency</td>
</tr>
<tr>
<td>1063</td>
<td>CID - [combined immunodeficiency] due to MAGT1 deficiency</td>
</tr>
<tr>
<td>1064</td>
<td>Hyper-IgM syndrome due to CD40 ligand deficiency</td>
</tr>
<tr>
<td>1065</td>
<td>Hyper-IgM syndrome type 1</td>
</tr>
<tr>
<td>1066</td>
<td>Hyper-IgM syndrome due to CD40L deficiency</td>
</tr>
<tr>
<td>1067</td>
<td>X-linked hyper-IgM syndrome</td>
</tr>
<tr>
<td>1068</td>
<td>HIGM1 - [hyper-IgM syndrome type 1]</td>
</tr>
<tr>
<td>1069</td>
<td>Hyper-IgM syndrome due to CD40 deficiency</td>
</tr>
<tr>
<td>1070</td>
<td>Hyper-IgM syndrome type 3</td>
</tr>
<tr>
<td>1071</td>
<td>HIGM3 - [hyper-IgM syndrome type 3]</td>
</tr>
<tr>
<td>1072</td>
<td>Combined immunodeficiency with facio-oculo-skeletal anomalies</td>
</tr>
<tr>
<td>1073</td>
<td>Corpus callosum agenesis – cataract – immunodeficiency</td>
</tr>
<tr>
<td>1074</td>
<td>Dionisi-Vici-Sabetta-Gambarara syndrome</td>
</tr>
<tr>
<td>1075</td>
<td>Vici syndrome</td>
</tr>
<tr>
<td>1076</td>
<td>Absent thumb - short stature - immune deficiency</td>
</tr>
<tr>
<td>1077</td>
<td>Hyper-IgM syndrome with susceptibility to opportunistic infections</td>
</tr>
<tr>
<td>1078</td>
<td>Hyper-IgM syndrome without susceptibility to opportunistic infections</td>
</tr>
<tr>
<td>1079</td>
<td>Hypohidrotic ectodermal dysplasia</td>
</tr>
<tr>
<td>1080</td>
<td>Anhidrotic ectodermal dysplasia</td>
</tr>
<tr>
<td>1081</td>
<td>Autosomal dominant hypohidrotic ectodermal dysplasia</td>
</tr>
<tr>
<td>1082</td>
<td>Autosomal recessive hypohidrotic ectodermal dysplasia</td>
</tr>
<tr>
<td>1083</td>
<td>X-linked hypohidrotic ectodermal dysplasia</td>
</tr>
<tr>
<td>1084</td>
<td>Christ-Siemens-Touraine syndrome</td>
</tr>
<tr>
<td>1085</td>
<td>EDA-ID syndrome</td>
</tr>
<tr>
<td>1086</td>
<td>EDA-ID syndrome (MIM 300291)</td>
</tr>
<tr>
<td>1087</td>
<td>Hypohidrotic ectodermal dysplasia with immunodeficiency</td>
</tr>
<tr>
<td>1088</td>
<td>Hypohidrotic ectodermal dysplasia - hypothyroidism - ciliary dyskinesia</td>
</tr>
<tr>
<td>1089</td>
<td>ANOTHER syndrome</td>
</tr>
<tr>
<td>1090</td>
<td>Arthrogryposis multiplex congenita</td>
</tr>
<tr>
<td>1091</td>
<td>congenital multiplex arthrogryposis</td>
</tr>
<tr>
<td>1092</td>
<td>amyoplasia congenita</td>
</tr>
<tr>
<td>1093</td>
<td>congenital multiple arthrogryposis</td>
</tr>
<tr>
<td>1094</td>
<td>congenital amyoplasia</td>
</tr>
<tr>
<td>1095</td>
<td>AMC - [arthrogryposis multiplex congenita]</td>
</tr>
<tr>
<td>1096</td>
<td>Neurogenic arthrogryposis multiplex congenita</td>
</tr>
<tr>
<td>1097</td>
<td>X-linked distal arthrogryposis multiplex congenita</td>
</tr>
<tr>
<td>1098</td>
<td>Arthrogryposis multiplex congenita with whistling face</td>
</tr>
<tr>
<td>1099</td>
<td>Crisponi syndrome</td>
</tr>
<tr>
<td>1100</td>
<td>Marden-Walker syndrome</td>
</tr>
<tr>
<td>1101</td>
<td>Van den Ende-Gupta syndrome</td>
</tr>
<tr>
<td>1102</td>
<td>Marden-Walker like syndrome</td>
</tr>
<tr>
<td>1103</td>
<td>Acrofacial dysostoses</td>
</tr>
<tr>
<td>1104</td>
<td>Acrofacial dysostosis, Nager type</td>
</tr>
<tr>
<td>1105</td>
<td>Postaxial acrofacial dysostosis</td>
</tr>
<tr>
<td>1106</td>
<td>Acrofacial dysostosis, Weyers type</td>
</tr>
<tr>
<td>1107</td>
<td>Acrofacial dysostosis, Catania type</td>
</tr>
<tr>
<td>1108</td>
<td>Acrofacial dysostosis, Rodriguez type</td>
</tr>
<tr>
<td>1109</td>
<td>Acrofacial dysostosis, Palagonia type</td>
</tr>
<tr>
<td>1110</td>
<td>Autosomal recessive acrofacial dysostosis</td>
</tr>
<tr>
<td>1111</td>
<td>X-linked mandibulofacial dysostosis</td>
</tr>
<tr>
<td>1112</td>
<td>Uniparental disomies of paternal origin</td>
</tr>
<tr>
<td>1113</td>
<td>Paternal uniparental disomy of chromosome 1</td>
</tr>
<tr>
<td>1114</td>
<td>Paternal uniparental disomy of chromosome 4</td>
</tr>
<tr>
<td>1115</td>
<td>Paternal uniparental disomy of chromosome 5</td>
</tr>
<tr>
<td>1116</td>
<td>Paternal uniparental disomy of chromosome 6</td>
</tr>
<tr>
<td>1117</td>
<td>Paternal uniparental disomy of chromosome 7</td>
</tr>
<tr>
<td>1118</td>
<td>Paternal uniparental disomy of chromosome 11</td>
</tr>
<tr>
<td>1119</td>
<td>Paternal uniparental disomy of chromosome 13</td>
</tr>
<tr>
<td>1120</td>
<td>Paternal uniparental disomy of chromosome 14</td>
</tr>
<tr>
<td>1121</td>
<td>Paternal uniparental disomy of chromosome 15</td>
</tr>
<tr>
<td>1122</td>
<td>Paternal uniparental disomy of chromosome 20</td>
</tr>
<tr>
<td>1123</td>
<td>Paternal uniparental disomy of chromosome 21</td>
</tr>
<tr>
<td>1124</td>
<td>Paternal uniparental disomy of chromosome X</td>
</tr>
<tr>
<td>1125</td>
<td>Mosaicism, 45, X, 46, XX or XY</td>
</tr>
<tr>
<td>1126</td>
<td>Mosaicism 45, x; 46, xx</td>
</tr>
<tr>
<td>1127</td>
<td>Mosaicism 45, x; 46, xy</td>
</tr>
<tr>
<td>1128</td>
<td>45, x/46, xy mosaicism</td>
</tr>
<tr>
<td>1129</td>
<td>Mosaicism, lines with various numbers of X chromosomes</td>
</tr>
<tr>
<td>1130</td>
<td>Sex chromosome mosaics, lines with various numbers of X chromosomes</td>
</tr>
<tr>
<td>1131</td>
<td>Congenital adrenal hypoplasia</td>
</tr>
<tr>
<td>1132</td>
<td>congenital adrenal gland hypoplasia</td>
</tr>
<tr>
<td>1133</td>
<td>Congenital small adrenal gland</td>
</tr>
<tr>
<td>1134</td>
<td>adrenal hypoplasia</td>
</tr>
<tr>
<td>1135</td>
<td>CAH - [congenital adrenal hypoplasia]</td>
</tr>
<tr>
<td>1136</td>
<td>Autosomal recessive congenital adrenal hypoplasia</td>
</tr>
<tr>
<td>1137</td>
<td>X-linked congenital adrenal hypoplasia</td>
</tr>
<tr>
<td>1138</td>
<td>Cytomegalic congenital adrenal hypoplasia</td>
</tr>
<tr>
<td>1139</td>
<td>Congenital adrenal hypoplasia due to DAX1 mutations</td>
</tr>
<tr>
<td>1140</td>
<td>Congenital absence of adrenal gland</td>
</tr>
<tr>
<td>1141</td>
<td>Agenesis of adrenal gland</td>
</tr>
<tr>
<td>1142</td>
<td>Congenital adrenal glandular absence</td>
</tr>
<tr>
<td>1143</td>
<td>Aplasia of adrenal gland</td>
</tr>
<tr>
<td>1144</td>
<td>Congenital thrombocytosis</td>
</tr>
<tr>
<td>1145</td>
<td>Familial thrombocythaemia</td>
</tr>
<tr>
<td>1146</td>
<td>Hereditary thrombocythaemia</td>
</tr>
<tr>
<td>1147</td>
<td>Hereditary thrombocytosis</td>
</tr>
<tr>
<td>1148</td>
<td>Autosomal dominant thrombocytosis</td>
</tr>
<tr>
<td>1149</td>
<td>X-linked thrombocytosis</td>
</tr>
<tr>
<td>1150</td>
<td>Other specified syndromes with central nervous system anomalies as a major feature</td>
</tr>
<tr>
<td>1151</td>
<td>Aicardi syndrome</td>
</tr>
<tr>
<td>1152</td>
<td>Cerebro-oculo-nasal syndrome</td>
</tr>
<tr>
<td>1153</td>
<td>Oculo-cerebro-cutaneous syndrome</td>
</tr>
<tr>
<td>1154</td>
<td>Delleman-Oorthuys syndrome</td>
</tr>
<tr>
<td>1155</td>
<td>Leichtman-Wood-Rohn syndrome</td>
</tr>
<tr>
<td>1156</td>
<td>Orbital cyst with cerebral and focal dermal malformations</td>
</tr>
<tr>
<td>1157</td>
<td>Delleman syndrome</td>
</tr>
<tr>
<td>1158</td>
<td>Pachygyria - epilepsy - intellectual deficit - dysmorphism</td>
</tr>
<tr>
<td>1159</td>
<td>X-linked complicated corpus callosum dysgenesis</td>
</tr>
<tr>
<td>1160</td>
<td>Corpus callosum agenesis - neuronopathy</td>
</tr>
<tr>
<td>1161</td>
<td>Andermann syndrome</td>
</tr>
<tr>
<td>1162</td>
<td>Charlevoix disease</td>
</tr>
<tr>
<td>1163</td>
<td>Dystonia associated with heredodegenerative disorders</td>
</tr>
<tr>
<td>1164</td>
<td>Dystonia due to autosomal dominant disorders</td>
</tr>
<tr>
<td>1165</td>
<td>Rapid-onset dystonia-parkinsonism</td>
</tr>
<tr>
<td>1166</td>
<td>Dystonia due to dentatorubropallidoluysian atrophy</td>
</tr>
<tr>
<td>1167</td>
<td>Dystonia due to Huntington disease</td>
</tr>
<tr>
<td>1168</td>
<td>Dystonia due to autosomal recessive disorders</td>
</tr>
<tr>
<td>1169</td>
<td>Dystonia due to Wilson disease</td>
</tr>
<tr>
<td>1170</td>
<td>Dystonia due to Niemann-Pick disease type C</td>
</tr>
<tr>
<td>1171</td>
<td>Dystonia due to other autosomal recessive metabolic disorders</td>
</tr>
<tr>
<td>1172</td>
<td>Dystonia due to GM2 gangliosidosis</td>
</tr>
<tr>
<td>1173</td>
<td>Dystonia due to Metachromatic leukodystrophy</td>
</tr>
<tr>
<td>1174</td>
<td>Dystonia due to homocystinuria</td>
</tr>
<tr>
<td>1175</td>
<td>Dystonia due to glutaric acidaemia</td>
</tr>
<tr>
<td>1176</td>
<td>Dystonia due to Hartnup disease</td>
</tr>
<tr>
<td>1177</td>
<td>Dystonia due to ataxia-telangiectasia</td>
</tr>
<tr>
<td>1178</td>
<td>Dystonia in neurodegeneration with brain iron accumulation type 1</td>
</tr>
<tr>
<td>1179</td>
<td>NBIA 2 PLA2G6 mutation</td>
</tr>
<tr>
<td>1180</td>
<td>PANK gene mutation</td>
</tr>
<tr>
<td>1181</td>
<td>Dystonia due to Juvenile Parkinson Disease including Parkin mutation</td>
</tr>
<tr>
<td>1182</td>
<td>Probable autosomal recessive dystonia</td>
</tr>
<tr>
<td>1183</td>
<td>Progressive pallidal degeneration</td>
</tr>
<tr>
<td>1184</td>
<td>Dystonia due to X-linked dominant disorders</td>
</tr>
<tr>
<td>1185</td>
<td>Dystonia due to Rett syndrome</td>
</tr>
<tr>
<td>1186</td>
<td>Dystonia due to X-linked recessive disorders</td>
</tr>
<tr>
<td>1187</td>
<td>Deafness-dystonia optic atrophy syndrome</td>
</tr>
<tr>
<td>1188</td>
<td>Mohr-Tranebjærg syndrome</td>
</tr>
<tr>
<td>1189</td>
<td>Dystonia due to Pelizaeus-Merzbacher disease</td>
</tr>
<tr>
<td>1190</td>
<td>Dystonia due to Lesch-Nyhan syndrome</td>
</tr>
<tr>
<td>1191</td>
<td>Dystonia due to mitochondrial cytopathies</td>
</tr>
<tr>
<td>1192</td>
<td>Dystonia due to Leber's disease</td>
</tr>
<tr>
<td>1193</td>
<td>Dystonia due to other mitochondrial cytopathies</td>
</tr>
<tr>
<td>1194</td>
<td>Dystonia of variable inheritance</td>
</tr>
<tr>
<td>1195</td>
<td>Dystonia due to Familial basal ganglia calcifications</td>
</tr>
<tr>
<td>1196</td>
<td>Dystonia due to certain specified inherited disorders</td>
</tr>
<tr>
<td>1197</td>
<td>Dystonia associated with familial basal ganglia calcifications</td>
</tr>
<tr>
<td>1198</td>
<td>Dystonia due to isolated hereditary vitamin E deficiency</td>
</tr>
<tr>
<td>1199</td>
<td>Dystonia due to hereditary spastic paraplegia</td>
</tr>
<tr>
<td>1200</td>
<td>Dystonia 16</td>
</tr>
<tr>
<td>1201</td>
<td>Infantile dystonia-parkinsonism</td>
</tr>
<tr>
<td>1202</td>
<td>Lesch-Nyhan syndrome</td>
</tr>
<tr>
<td>1203</td>
<td>choreoathetosis self-mutilation syndrome</td>
</tr>
<tr>
<td>1204</td>
<td>deficiency of imp pyrophosphorylase</td>
</tr>
<tr>
<td>1205</td>
<td>x-linked hyperuricemia</td>
</tr>
<tr>
<td>1206</td>
<td>Lesch-Nyhan disease</td>
</tr>
<tr>
<td>1207</td>
<td>complete hypoxanthine-guanine phosphoribosyltransferase deficiency</td>
</tr>
<tr>
<td>1208</td>
<td>HPRT - [ hypoxanthine-guanine phosphoribosyltransferase] complete deficiency</td>
</tr>
<tr>
<td>1209</td>
<td>total HGPRT - [hypoxanthine-guanine phosphoribosyltransferase] deficiency</td>
</tr>
<tr>
<td>1210</td>
<td>Other specified hypoparathyroidism due to impaired parathyroid hormone secretion</td>
</tr>
<tr>
<td>1211</td>
<td>Transient neonatal hypoparathyroidism due to maternal hyperparathyroidism</td>
</tr>
<tr>
<td>1212</td>
<td>Syndrome with hypoparathyroidism</td>
</tr>
<tr>
<td>1213</td>
<td>Familial isolated hypoparathyroidism</td>
</tr>
<tr>
<td>1214</td>
<td>Hereditary isolated hypoparathyroidism</td>
</tr>
<tr>
<td>1215</td>
<td>Autosomal dominant hypocalcaemia</td>
</tr>
<tr>
<td>1216</td>
<td>Familial isolated hypoparathyroidism due to agenesis of parathyroid gland</td>
</tr>
<tr>
<td>1217</td>
<td>Hereditary isolated hypoparathyroidism due to agenesis of parathyroid gland</td>
</tr>
<tr>
<td>1218</td>
<td>X-linked recessive hypoparathyroidism</td>
</tr>
<tr>
<td>1219</td>
<td>XLHPT - [X-linked recessive hypoparathyroidism]</td>
</tr>
<tr>
<td>1220</td>
<td>Hypoparathyroidism by glial cells missing B mutations</td>
</tr>
<tr>
<td>1221</td>
<td>Hypothyroidism by GCMB - [glial cells missing B] mutations</td>
</tr>
<tr>
<td>1222</td>
<td>Familial isolated hypoparathyroidism due to impaired parathormone secretion</td>
</tr>
<tr>
<td>1223</td>
<td>Hereditary isolated hypoparathyroidism due to impaired parathormone secretion</td>
</tr>
<tr>
<td>1224</td>
<td>Familial isolated hypoparathyroidism due to impaired PTH - [parathyroid hormone] secretion</td>
</tr>
<tr>
<td>1225</td>
<td>Hereditary isolated hypoparathyroidism due to impaired PTH - [parathyroid hormone] secretion</td>
</tr>
<tr>
<td>1226</td>
<td>Emery-Dreifuss muscular dystrophy</td>
</tr>
<tr>
<td>1227</td>
<td>EMD - [Emery-Dreifuss muscular dystrophy]</td>
</tr>
<tr>
<td>1228</td>
<td>Emery-Dreifuss muscular dystrophy, X-linked</td>
</tr>
<tr>
<td>1229</td>
<td>Muscular dystrophy, tardive, Dreifuss-Emery type, with contractures</td>
</tr>
<tr>
<td>1230</td>
<td>EMD1 - [Emery-Dreifuss muscular dystrophy 1]</td>
</tr>
<tr>
<td>1231</td>
<td>Emery-Dreifuss muscular dystrophy, autosomal dominant</td>
</tr>
<tr>
<td>1232</td>
<td>Emery-Dreifuss muscular dystrophy, autosomal recessive</td>
</tr>
<tr>
<td>1233</td>
<td>Juvenile retinoschisis</td>
</tr>
<tr>
<td>1234</td>
<td>X-linked retinoschisis</td>
</tr>
<tr>
<td>1235</td>
<td>XLRS - [X-linked retinoschisis]</td>
</tr>
<tr>
<td>1236</td>
<td>Klinefelter syndrome, male with more than two X chromosomes</td>
</tr>
<tr>
<td>1237</td>
<td>male Klinefelter with more than two x chromosomes</td>
</tr>
<tr>
<td>1238</td>
<td>male Klinefelter karyotype with more than two x chromosomes</td>
</tr>
<tr>
<td>1239</td>
<td>xxxxy syndrome</td>
</tr>
<tr>
<td>1240</td>
<td>Structural anomalies of chromosome X, excluding Turner syndrome</td>
</tr>
<tr>
<td>1241</td>
<td>Small ring X chromosome</td>
</tr>
<tr>
<td>1242</td>
<td>Xp11.22p11.23 duplication</td>
</tr>
<tr>
<td>1243</td>
<td>Trisomy Xp11.22p11.23</td>
</tr>
<tr>
<td>1244</td>
<td>Xp11.22p11.23 duplication syndrome</td>
</tr>
<tr>
<td>1245</td>
<td>Xp11.3 deletion</td>
</tr>
<tr>
<td>1246</td>
<td>Xp21 deletion</td>
</tr>
<tr>
<td>1247</td>
<td>Xp21 deletion syndrome</td>
</tr>
<tr>
<td>1248</td>
<td>Xp22.13p22.2 duplication</td>
</tr>
<tr>
<td>1249</td>
<td>Xp22.33 deletion</td>
</tr>
<tr>
<td>1250</td>
<td>Xq27.3q28 duplication</td>
</tr>
<tr>
<td>1251</td>
<td>Xq28 deletion</td>
</tr>
<tr>
<td>1252</td>
<td>Xq28 deletion syndrome</td>
</tr>
<tr>
<td>1253</td>
<td>Distal monosomy Xq</td>
</tr>
<tr>
<td>1254</td>
<td>Xq28 duplication</td>
</tr>
<tr>
<td>1255</td>
<td>Xq28 duplication syndrome</td>
</tr>
<tr>
<td>1256</td>
<td>Distal duplication Xq</td>
</tr>
<tr>
<td>1257</td>
<td>Telomeric duplication Xq</td>
</tr>
<tr>
<td>1258</td>
<td>Centronuclear myopathy</td>
</tr>
<tr>
<td>1259</td>
<td>Autosomal recessive centronuclear myopathy</td>
</tr>
<tr>
<td>1260</td>
<td>Centronuclear myopathy with type I fibre hypotrophy</td>
</tr>
<tr>
<td>1261</td>
<td>Autosomal dominant centronuclear myopathy</td>
</tr>
<tr>
<td>1262</td>
<td>Severe infantile myotubular myopathy</td>
</tr>
<tr>
<td>1263</td>
<td>Myotubular myopathy</td>
</tr>
<tr>
<td>1264</td>
<td>severe x-linked myotubular myopathy</td>
</tr>
<tr>
<td>1265</td>
<td>x-linked centronuclear myopathy</td>
</tr>
<tr>
<td>1266</td>
<td>myotubular centronuclear myopathy</td>
</tr>
<tr>
<td>1</td>
<td>Male with double or multiple Y</td>
</tr>
<tr>
<td>2</td>
<td>Karyotype 47,XYY</td>
</tr>
<tr>
<td>3</td>
<td>double y syndrome</td>
</tr>
<tr>
<td>4</td>
<td>xyy syndrome</td>
</tr>
<tr>
<td>5</td>
<td>Karyotype 47,XYY, regular</td>
</tr>
<tr>
<td>6</td>
<td>Karyotype 47,XYY, mosaicism</td>
</tr>
<tr>
<td>7</td>
<td>Male with more than two Y chromosomes</td>
</tr>
<tr>
<td>8</td>
<td>Structural anomalies of chromosome Y</td>
</tr>
<tr>
<td>9</td>
<td>male with structurally abnormal sex chromosome</td>
</tr>
<tr>
<td>10</td>
<td>Chromosome Y duplication</td>
</tr>
<tr>
<td>11</td>
<td>Inv dup del Y</td>
</tr>
<tr>
<td>12</td>
<td>Isochromosome Y</td>
</tr>
<tr>
<td>13</td>
<td>Isochromosome Yp</td>
</tr>
<tr>
<td>14</td>
<td>Isochromosome Yq</td>
</tr>
<tr>
<td>15</td>
<td>Ring chromosome Y</td>
</tr>
<tr>
<td>16</td>
<td>Testicular hypofunction</td>
</tr>
<tr>
<td>17</td>
<td>hypofunction testicle</td>
</tr>
<tr>
<td>18</td>
<td>gonadal insufficiency of testis</td>
</tr>
<tr>
<td>19</td>
<td>Testicular hypogonadism NOS</td>
</tr>
<tr>
<td>20</td>
<td>undeveloped testis</td>
</tr>
<tr>
<td>21</td>
<td>testicular hypogonadism</td>
</tr>
<tr>
<td>22</td>
<td>male hypogonadism</td>
</tr>
<tr>
<td>23</td>
<td>prepuberal castrate syndrome</td>
</tr>
<tr>
<td>24</td>
<td>eunuchoidism</td>
</tr>
<tr>
<td>25</td>
<td>deficiency of testicular hormone</td>
</tr>
<tr>
<td>26</td>
<td>androgen deficiency</td>
</tr>
<tr>
<td>27</td>
<td>5-alpha-reductase deficiency with male pseudohermaphroditism</td>
</tr>
<tr>
<td>28</td>
<td>defect of testicular androgen synthesis</td>
</tr>
<tr>
<td>29</td>
<td>5-alpha-reductase deficiency</td>
</tr>
<tr>
<td>30</td>
<td>Male infertility due to a systemic disease</td>
</tr>
<tr>
<td>31</td>
<td>Male infertility with normal virilization due to a systemic disease</td>
</tr>
<tr>
<td>32</td>
<td>Male infertility with normal virilization due to acquired testicular defects</td>
</tr>
<tr>
<td>33</td>
<td>Defective biosynthesis of testosterone in aged men</td>
</tr>
<tr>
<td>34</td>
<td>Testicular hypogonadism in aged men</td>
</tr>
<tr>
<td>35</td>
<td>defective biosynthesis of testicular androgen</td>
</tr>
<tr>
<td>36</td>
<td>Defective biosynthesis of testicular androgen NOS</td>
</tr>
<tr>
<td>37</td>
<td>deficiency of testosterone biosynthesis</td>
</tr>
<tr>
<td>38</td>
<td>Male infertility associated with autoimmunity</td>
</tr>
<tr>
<td>39</td>
<td>Male infertility with normal virilisation due to acquired testicular defect associated with autoimmunity</td>
</tr>
<tr>
<td>40</td>
<td>Male infertility associated with drug</td>
</tr>
<tr>
<td>41</td>
<td>Male infertility with normal virilisation due to acquired testicular defect associated with drug</td>
</tr>
<tr>
<td>42</td>
<td>Drug induced testicular hypofunction</td>
</tr>
<tr>
<td>43</td>
<td>Male infertility associated with environmental toxin</td>
</tr>
<tr>
<td>44</td>
<td>Male infertility with normal virilisation due to acquired testicular defect associated with environmental toxin</td>
</tr>
<tr>
<td>45</td>
<td>Male infertility associated with mycoplasma infection</td>
</tr>
<tr>
<td>46</td>
<td>Male infertility associated with radiation</td>
</tr>
<tr>
<td>47</td>
<td>Male infertility with normal virilisation due to acquired testicular defect associated with radiation</td>
</tr>
<tr>
<td>48</td>
<td>Male infertility associated with spinal cord injury</td>
</tr>
<tr>
<td>49</td>
<td>Male infertility with normal virilisation due to testicular defect associated with spinal cord injury</td>
</tr>
<tr>
<td>50</td>
<td>Male infertility with normal virilization due to developmental or structural testicular defects</td>
</tr>
<tr>
<td>51</td>
<td>Chromosome Y deletion</td>
</tr>
<tr>
<td>52</td>
<td>Male sterility due to chromosome Y deletion</td>
</tr>
<tr>
<td>53</td>
<td>Partial chromosome Y deletion</td>
</tr>
<tr>
<td>54</td>
<td>Male infertility associated with cryptorchidism</td>
</tr>
<tr>
<td>55</td>
<td>Male infertility with normal virilisation due to developmental or structural testicular defect associated with cryptorchidism</td>
</tr>
<tr>
<td>56</td>
<td>Male infertility associated with varicocele</td>
</tr>
<tr>
<td>57</td>
<td>Male infertility with normal virilisation due to a developmental or structural testicular defect associated with varicocele</td>
</tr>
<tr>
<td>58</td>
<td>Sertoli cell only syndrome</td>
</tr>
<tr>
<td>59</td>
<td>Number anomalies of chromosome Y, unspecified</td>
</tr>
<tr>
<td>60</td>
<td>Number anomalies of chromosome Y</td>
</tr>
<tr>
<td>61</td>
<td>Other specified number anomalies of chromosome Y</td>
</tr>
<tr>
<td>62</td>
<td>Congenital cataract</td>
</tr>
<tr>
<td>63</td>
<td>congenita cataracta</td>
</tr>
<tr>
<td>64</td>
<td>congenital cortical cataract</td>
</tr>
<tr>
<td>65</td>
<td>crystalline cataract</td>
</tr>
<tr>
<td>66</td>
<td>Volkmann-type congenital cataract</td>
</tr>
<tr>
<td>67</td>
<td>Pulverulent cataract</td>
</tr>
<tr>
<td>68</td>
<td>Dusty cataract</td>
</tr>
<tr>
<td>69</td>
<td>Cataract with Y-shaped suture opacities</td>
</tr>
<tr>
<td>70</td>
<td>Coppock-like cataract</td>
</tr>
<tr>
<td>71</td>
<td>Hutterite-type cataract</td>
</tr>
<tr>
<td>72</td>
<td>Anterior polar cataract</td>
</tr>
<tr>
<td>73</td>
<td>Anterior subcapsular cataract</td>
</tr>
<tr>
<td>74</td>
<td>Cerulean cataract</td>
</tr>
<tr>
<td>75</td>
<td>Blue-dot cataract</td>
</tr>
<tr>
<td>76</td>
<td>Cerulea cataracta</td>
</tr>
<tr>
<td>77</td>
<td>Cataracta cerulea</td>
</tr>
<tr>
<td>78</td>
<td>Coralliform cataract</td>
</tr>
<tr>
<td>79</td>
<td>Coralliformis cataracta</td>
</tr>
<tr>
<td>80</td>
<td>Cataracta coralliformis</td>
</tr>
<tr>
<td>81</td>
<td>Nuclear cataract</td>
</tr>
<tr>
<td>82</td>
<td>Partial congenital cataract</td>
</tr>
<tr>
<td>83</td>
<td>Posterior polar cataract</td>
</tr>
<tr>
<td>84</td>
<td>Total congenital cataract</td>
</tr>
<tr>
<td>85</td>
<td>Zonular cataract</td>
</tr>
<tr>
<td>86</td>
<td>Lamellar cataract</td>
</tr>
<tr>
<td>87</td>
<td>Coronary cataract</td>
</tr>
<tr>
<td>88</td>
<td>coronaria cataracta</td>
</tr>
<tr>
<td>89</td>
<td>Anterior pyramidal cataract</td>
</tr>
<tr>
<td>90</td>
<td>Central cataract</td>
</tr>
<tr>
<td>91</td>
<td>Centralis pulverulenta cataracta</td>
</tr>
<tr>
<td>92</td>
<td>Anterior and posterior axial embryonal cataract</td>
</tr>
<tr>
<td>93</td>
<td>Iron overload diseases</td>
</tr>
<tr>
<td>94</td>
<td>idiopathic haemosiderosis</td>
</tr>
<tr>
<td>95</td>
<td>hemosiderosis</td>
</tr>
<tr>
<td>96</td>
<td>Hereditary haemochromatosis</td>
</tr>
<tr>
<td>97</td>
<td>HFE-related hereditary haemochromatosis, Type 1</td>
</tr>
<tr>
<td>98</td>
<td>C282Y/C282Y haemochromatosis</td>
</tr>
<tr>
<td>99</td>
<td>Classic haemochromatosis</td>
</tr>
<tr>
<td>100</td>
<td>Arthropathy in haemochromatosis</td>
</tr>
<tr>
<td>101</td>
<td>Juvenile hereditary haemochromatosis, Type 2</td>
</tr>
<tr>
<td>102</td>
<td>Juvenile hereditary haemochromatosis, Type 2A</td>
</tr>
<tr>
<td>103</td>
<td>Hemojuvelin-related haemochromatosis</td>
</tr>
<tr>
<td>104</td>
<td>Juvenile hereditary haemochromatosis, Type 2B</td>
</tr>
<tr>
<td>105</td>
<td>Hepcidin-related haemochromatosis</td>
</tr>
<tr>
<td>106</td>
<td>Non-HFE-related hereditary haemochromatosis, Type 3</td>
</tr>
<tr>
<td>107</td>
<td>TFR2-related haemochromatosis</td>
</tr>
<tr>
<td>108</td>
<td>Non-HFE-related hereditary haemochromatosis, Type 4</td>
</tr>
<tr>
<td>109</td>
<td>Autosomal dominant hereditary haemochromatosis</td>
</tr>
<tr>
<td>110</td>
<td>Haemochromatosis due to defect in ferroportin</td>
</tr>
<tr>
<td>111</td>
<td>Ferroportin disease</td>
</tr>
<tr>
<td>112</td>
<td>Secondary iron overload</td>
</tr>
<tr>
<td>113</td>
<td>African iron overload</td>
</tr>
<tr>
<td>114</td>
<td>Bantu haemosiderosis</td>
</tr>
<tr>
<td>115</td>
<td>Iron overload in sub-Saharan Africa</td>
</tr>
<tr>
<td>116</td>
<td>Dietary haemosiderosis</td>
</tr>
<tr>
<td>117</td>
<td>Neurodegeneration with brain iron accumulation</td>
</tr>
<tr>
<td>118</td>
<td>Hallervorden-Spatz disease (deprecated)</td>
</tr>
<tr>
<td>119</td>
<td>Pigmentary pallidal degeneration</td>
</tr>
<tr>
<td>120</td>
<td>pigmentary pallidal atrophy</td>
</tr>
<tr>
<td>121</td>
<td>pigmentary; degeneration, pallidal (progressive)</td>
</tr>
<tr>
<td>122</td>
<td>NBIA - [Neurodegeneration with brain iron accumulation]</td>
</tr>
<tr>
<td>123</td>
<td>Infantile neuroaxonal dystrophy</td>
</tr>
<tr>
<td>124</td>
<td>Seitelberger disease</td>
</tr>
<tr>
<td>125</td>
<td>INAD - [Infantile neuroaxonal dystrophy]</td>
</tr>
<tr>
<td>126</td>
<td>Neurodegeneration with brain iron accumulation due to C19orf12 mutation</td>
</tr>
<tr>
<td>127</td>
<td>Pantothenate-kinase-associated neurodegeneration</td>
</tr>
<tr>
<td>128</td>
<td>Neurodegeneration with brain iron accumulation type 1</td>
</tr>
<tr>
<td>129</td>
<td>NBIA1 - [Neurodegeneration with brain iron accumulation type 1]</td>
</tr>
<tr>
<td>130</td>
<td>PKAN - [Pantothenate-kinase-associated neurodegeneration]</td>
</tr>
<tr>
<td>131</td>
<td>HARP - [hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration]</td>
</tr>
<tr>
<td>132</td>
<td>HSS - [Hallervorden-Spatz-Syndrome] (deprecated)</td>
</tr>
<tr>
<td>133</td>
<td>Atypical pantothenate kinase associated neurodegeneration</td>
</tr>
<tr>
<td>134</td>
<td>Neurodegeneration with brain iron accumulation type 1, atypical form</td>
</tr>
<tr>
<td>135</td>
<td>NBIA1 - [Neurodegeneration with brain iron accumulation type 1] atypical form</td>
</tr>
<tr>
<td>136</td>
<td>PKAN - [Pantothenate-kinase-associated neurodegeneration] atypical form</td>
</tr>
<tr>
<td>137</td>
<td>Classic pantothenate kinase associated neurodegeneration</td>
</tr>
<tr>
<td>138</td>
<td>Neurodegeneration with brain iron accumulation type 1, classic form</td>
</tr>
<tr>
<td>139</td>
<td>NBIA1 - [Neurodegeneration with brain iron accumulation type 1] classic form</td>
</tr>
<tr>
<td>140</td>
<td>PKAN - [Pantothenate-kinase-associated neurodegeneration] classic form</td>
</tr>
<tr>
<td>141</td>
<td>Acquired hemochromatosis</td>
</tr>
<tr>
<td>142</td>
<td>Acquired iron overload</td>
</tr>
<tr>
<td>143</td>
<td>Neonatal haemochromatosis</td>
</tr>
<tr>
<td>144</td>
<td>Other specified qualitative platelet defects</td>
</tr>
<tr>
<td>145</td>
<td>Stormorken-Sjaastad-Langslet syndrome</td>
</tr>
<tr>
<td>146</td>
<td>Scott syndrome</td>
</tr>
<tr>
<td>147</td>
<td>ADP platelet receptor P2Y12 deficiency</td>
</tr>
<tr>
<td>148</td>
<td>Pseudo-Von Willebrand disease</td>
</tr>
<tr>
<td>149</td>
<td>Platelet-type Von Willebrand disease</td>
</tr>
<tr>
<td>150</td>
<td>Bleeding diathesis due to a collagen receptor defect</td>
</tr>
<tr>
<td>151</td>
<td>Bleeding diathesis due to glycoprotein VI deficiency</td>
</tr>
<tr>
<td>152</td>
<td>Bleeding diathesis due to integrin alpha2-beta1 deficiency</td>
</tr>
<tr>
<td>153</td>
<td>Secondary haemophagocytic lymphohistiocytosis</td>
</tr>
<tr>
<td>154</td>
<td>Reactive haemophagocytic syndrome</td>
</tr>
<tr>
<td>155</td>
<td>Haemophagocytic lymphohistiocytosis associated with a malignant disease</td>
</tr>
<tr>
<td>1</td>
<td>Noncompaction cardiomyopathy</td>
</tr>
<tr>
<td>2</td>
<td>Left ventricular noncompaction</td>
</tr>
<tr>
<td>3</td>
<td>Familial-genetic noncompaction cardiomyopathy</td>
</tr>
<tr>
<td>4</td>
<td>Sarcomeric noncompaction cardiomyopathy</td>
</tr>
<tr>
<td>5</td>
<td>X-linked noncompaction cardiomyopathy</td>
</tr>
<tr>
<td>6</td>
<td>Noncompaction cardiomyopathy due to Barth syndrome</td>
</tr>
<tr>
<td>7</td>
<td>Noncompaction cardiomyopathy due to laminopathy</td>
</tr>
<tr>
<td>8</td>
<td>Noncompaction cardiomyopathy due to Z-line protein/Cypher mutation</td>
</tr>
<tr>
<td>9</td>
<td>Noncompaction cardiomyopathy due to Z-line protein/Cypher mutation (Zaspopathy)</td>
</tr>
<tr>
<td>10</td>
<td>Left ventricular noncompaction cardiomyopathy</td>
</tr>
<tr>
<td>11</td>
<td>Right ventricular noncompaction cardiomyopathy</td>
</tr>
<tr>
<td>12</td>
<td>Biventricular noncompaction cardiomyopathy</td>
</tr>
<tr>
<td>13</td>
<td>Noncompaction cardiomyopathy associated with congenital heart disease</td>
</tr>
<tr>
<td>14</td>
<td>Myofibrillar myopathy</td>
</tr>
<tr>
<td>15</td>
<td>MFM - [myofibrillar myopathy]</td>
</tr>
<tr>
<td>16</td>
<td>Desmin myopathy</td>
</tr>
<tr>
<td>17</td>
<td>Desmin aggregate myopathy</td>
</tr>
<tr>
<td>18</td>
<td>Desmin protein surplus myopathy</td>
</tr>
<tr>
<td>19</td>
<td>Myotilin myopathy</td>
</tr>
<tr>
<td>20</td>
<td>Myotilinopathy</td>
</tr>
<tr>
<td>21</td>
<td>Alpha B crystalline myopathy</td>
</tr>
<tr>
<td>22</td>
<td>Fatal infantile hypertonic myofibrillar myopathy</td>
</tr>
<tr>
<td>23</td>
<td>Filamin C myopathy</td>
</tr>
<tr>
<td>24</td>
<td>Filaminopathy</td>
</tr>
<tr>
<td>25</td>
<td>Z-band alternatively spliced PDZ motif containing-protein myopathy</td>
</tr>
<tr>
<td>26</td>
<td>ZASP - [Z-band alternatively spliced PDZ motif containing-protein myopathy]</td>
</tr>
<tr>
<td>27</td>
<td>Zaspopathy</td>
</tr>
<tr>
<td>28</td>
<td>Certain specified myofibrillar myopathy</td>
</tr>
<tr>
<td>29</td>
<td>Selcen muscular dystrophy</td>
</tr>
</tbody></table>



</body></html>